PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Flotho, A; Simpson, DM; Qi, MS; Elion, EA				Flotho, A; Simpson, DM; Qi, MS; Elion, EA			Localized feedback phosphorylation of Ste5p scaffold by associated MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; KINASE CASCADE; SIGNAL-TRANSDUCTION; MEMBRANE RECRUITMENT; PROTEIN-KINASES; PLASMA-MEMBRANE; CELL-CYCLE; G-BETA; YEAST; ACTIVATION	Scaffold proteins play pivotal roles during signal transduction. In Saccharomyces cerevisiae, the Ste5p scaffold protein is required for activation of the mating MAPK cascade in response to mating pheromone and assembles a G protein-MAPK cascade complex at the plasma membrane. To serve this function, Ste5p undergoes a regulated localization event involving nuclear shuttling and recruitment to the cell cortex. Here, we show that Ste5p is also subject to two types of phosphorylation and increases in abundance as a result of MAPK activation. During vegetative growth, Ste5p is basally phosphorylated through a process regulated by the CDK Cdc28p. During mating pheromone signaling, Ste5p undergoes increased phosphorylation by the mating MAPK cascade. Multiple kinases of the mating MAPK cascade contribute to pheromone-induced phosphorylation of Ste5p, with the mating MAPKs contributing the most. Pheromone induction or overexpression of the Ste4p Gbeta subunit increases the abundance of Ste5p at a post-translational step, as long as the mating MAPKs are present. Increasing the level of MAPK activation increases the amount of Ste5p at the cell cortex. Analysis of Ste5p localization mutants reveals a strict requirement for Ste5p recruitment to the plasma membrane for the pheromone-induced phosphorylation. These results suggest that the pool of Ste5p that is recruited to the plasma membrane selectively undergoes feedback phosphorylation by the associated MAPKs, leading to an increased pool of Ste5p at the site of polarized growth. These findings provide evidence of a spatially regulated mechanism for post-activation control of a signaling scaffold that potentiates pathway activation.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	elaine_elion@hms.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM46962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER R, 1991, NUCLEIC ACIDS RES, V19, P1945, DOI 10.1093/nar/19.8.1945; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Brennan JA, 2002, J BIOL CHEM, V277, P5369, DOI 10.1074/jbc.M109875200; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cherkasova VA, 2003, CURR BIOL, V13, P1220, DOI 10.1016/S0960-9822(03)00490-1; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Elion EA, 2001, J CELL SCI, V114, P3967; Elion EA, 2000, CURR OPIN MICROBIOL, V3, P573, DOI 10.1016/S1369-5274(00)00143-0; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Farley FW, 1999, GENETICS, V151, P1425; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Friesen H, 2003, MOL BIOL CELL, V14, P3027, DOI 10.1091/mbc.E02-09-0613; HASSON MS, 1992, THESIS U CALIFORNIA; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; RAABE T, 2002, SCI STKE; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; SADEGHI H, 1999, DETECTION POSSIBLE D; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Siekhaus DE, 2003, NAT CELL BIOL, V5, P231, DOI 10.1038/ncb941; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; van Drogen F, 2001, NAT CELL BIOL, V3, P1051, DOI 10.1038/ncb1201-1051; Wang YM, 2003, MOL BIOL CELL, V14, P2543, DOI 10.1091/mbc.E02-10-0699; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Zhou Pengbo, 2004, Methods Mol Biol, V284, P67	45	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47391	47401		10.1074/jbc.M405681200	http://dx.doi.org/10.1074/jbc.M405681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322134	hybrid			2022-12-25	WOS:000224832400128
J	Friedman, JS; Khanna, H; Swain, PK; DeNicola, R; Cheng, H; Mitton, KP; Weber, CH; Hicks, D; Swaroop, A				Friedman, JS; Khanna, H; Swain, PK; DeNicola, R; Cheng, H; Mitton, KP; Weber, CH; Hicks, D; Swaroop, A			The minimal transactivation domain of the basic motif-leucine zipper transcription factor NRL interacts with TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN PROMOTER; GLUCOCORTICOID-RECEPTOR; SUBUNIT GENE; PHOTORECEPTOR; ACTIVATORS; MECHANISMS; CRX; IDENTIFICATION; TRANSFORMATION; HOMEODOMAIN	The basic motif-leucine zipper ( bZIP) transcription factor NRL controls the expression of rhodopsin and other phototransduction genes and is a key mediator of photoreceptor differentiation. To delineate the molecular mechanisms underlying transcriptional initiation of rod-specific genes, we characterized different regions of the NRL protein using yeast-based autoactivation assays. We identified 35 amino acid residues in the proline- and serine-rich N-terminal region ( called minimal transactivation domain, MTD), which, when combined with LexA or Gal4 DNA binding domains, exhibited activation of target promoters. Because this domain is conserved in all proteins of the large Maf family, we hypothesized that NRL-MTD played an important role in assembling the transcription initiation complex. Our studies showed that the NRL protein, including the MTD, interacted with full-length or the C-terminal domain of TATA-binding protein (TBP) in vitro. NRL and TBP could be co-immunoprecipitated from bovine retinal nuclear extract. TBP was also part of c-Maf and MafA ( two other large Maf proteins)- containing complex( es) in vivo. Our data suggest that the function of NRL-MTD is to activate transcription by recruiting or stabilizing TBP ( and consequently other components of the general transcription complex) at the promoter of target genes, and a similar function may be attributed to other bZIP proteins of the large Maf family.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Neurosci, Ann Arbor, MI 48105 USA; Univ Michigan, WK Kellogg Eye Ctr, Dept Human Genet, Ann Arbor, MI 48105 USA; Ctr Hosp Univ Reg, Clin Med A, INSERM, U592,Lab Physiopathol Cellulaire & Mol Retine, F-67091 Strasbourg, France; SBI Sci, Ann Arbor, MI 48103 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu	Weber, Christian/AAW-2153-2020; mitton, kenneth/Y-1974-2019	Weber, Christian/0000-0003-4610-8714; mitton, kenneth/0000-0002-4751-7440; Swaroop, Anand/0000-0002-1975-1141	NEI NIH HHS [EY07003, EY11115] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011115] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DeAngelis MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P369; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Hermann S, 2001, J BIOL CHEM, V276, P40127, DOI 10.1074/jbc.M103793200; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; Juo ZS, 2003, NATURE, V422, P534, DOI 10.1038/nature01534; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kinkl N, 2001, J BIOL CHEM, V276, P43871, DOI 10.1074/jbc.M105256200; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; LATCHMAN DS, 1993, INT J EXP PATHOL, V74, P417; Latchman DS, 2001, TRENDS BIOCHEM SCI, V26, P211, DOI 10.1016/S0968-0004(01)01812-6; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Mani SS, 2001, J BIOL CHEM, V276, P36557, DOI 10.1074/jbc.M101685200; Martinez-Gimeno M, 2001, Hum Mutat, V17, P520, DOI 10.1002/humu.1135; May LA, 2003, CLIN EXP OPHTHALMOL, V31, P445, DOI 10.1046/j.1442-9071.2003.00694.x; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Mitton KP, 2003, HUM MOL GENET, V12, P365, DOI 10.1093/hmg/ddg035; Montano M M, 2001, Methods Mol Biol, V177, P99; Motohashi H, 2002, GENE, V294, P1, DOI 10.1016/S0378-1119(02)00788-6; Nishizawa M, 2003, ONCOGENE, V22, P7931, DOI 10.1038/sj.onc.1206527; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pacione LR, 2003, ANNU REV NEUROSCI, V26, P657, DOI 10.1146/annurev.neuro.26.041002.131416; Pittler SJ, 2004, J BIOL CHEM, V279, P19800, DOI 10.1074/jbc.M401864200; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rattner A, 1999, ANNU REV GENET, V33, P89, DOI 10.1146/annurev.genet.33.1.89; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Roeder RG, 2003, NAT MED, V9, P1239, DOI 10.1038/nm938; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; STRUHL K, 1996, BIOCHIM BIOPHYS ACTA, V1288, P15; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Tan E, 2001, INVEST OPHTH VIS SCI, V42, P589; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Warnmark A, 2000, J BIOL CHEM, V275, P15014, DOI 10.1074/jbc.M001007200; Williams DS, 2002, VISION RES, V42, P455, DOI 10.1016/S0042-6989(01)00228-0; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	60	30	31	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47233	47241		10.1074/jbc.M408298200	http://dx.doi.org/10.1074/jbc.M408298200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328344	hybrid			2022-12-25	WOS:000224832400111
J	Li, XY; Sakashita, G; Matsuzaki, H; Sugimoto, K; Kimura, K; Hanaoka, F; Taniguchi, H; Furukawa, K; Urano, T				Li, XY; Sakashita, G; Matsuzaki, H; Sugimoto, K; Kimura, K; Hanaoka, F; Taniguchi, H; Furukawa, K; Urano, T			Direct association with inner centromere protein (INCENP) activates the novel chromosomal passenger protein, Aurora-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H3; CELL-CYCLE; MITOTIC CHROMOSOME; A KINASE; CLEAVAGE FURROW; GENE-EXPRESSION; HUMAN CONDENSIN; BUDDING YEAST; PHOSPHORYLATION; MITOSIS	A family of serine/threonine kinase Aurora constitutes a key regulator in the orchestration of mitotic events. The human Aurora paralogues Aurora-A, Aurora-B, and Aurora-C have a highly conserved catalytic domain. Extensive studies on the role of Aurora-A and Aurora-B have revealed distinct localizations and functions in regulating mitotic processes, whereas little is known about Aurora-C. The present study shows that human Aurora-C is a chromosomal passenger protein that forms complexes with Aurora-B and inner centromere protein ( INCENP), which are known passenger proteins. We show that INCENP binds and activates Aurora-C in vivo and in vitro. Furthermore, Aurora-C co-expressed with INCENP elicits the phosphorylation of endogenous histone H3 in mammalian cells, even though this phosphorylation is not sufficient to establish chromosome condensation in interphase cells. We therefore suggest that Aurora-C is a novel chromosomal passenger protein that cooperates with Aurora-B to regulate mitotic chromosome dynamics in mammalian cells.	Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4668550, Japan; RIKEN, Spring8, Harima Inst,Membrane Dynam Project, Synchrotron Radiat Res Network, Sayo, Hyogo 6795148, Japan; Osaka Prefecture Univ, Grad Sch Agr & Biol Sci, Div Appl Biochem, Osaka 5998531, Japan; RIKEN, Discovery Res Inst, Cellular Physiol Lab, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	Nagoya University; Japan Synchrotron Radiation Research Institute; RIKEN; Osaka Metropolitan University; RIKEN; Osaka University	Urano, T (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	turano@med.nagoya-u.ac.jp	Taniguchi, Hisaaki/I-9171-2012	Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2001, CHROMOSOMA, V110, P65, DOI 10.1007/s004120100130; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Ban R, 2004, J BIOL CHEM, V279, P16394, DOI 10.1074/jbc.M313257200; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Bishop JD, 2002, J BIOL CHEM, V277, P27577, DOI 10.1074/jbc.C200307200; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kufer TA, 2003, CHROMOSOMA, V112, P159, DOI 10.1007/s00412-003-0265-1; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2002, CURR BIOL, V12, P894, DOI 10.1016/S0960-9822(02)00848-5; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Romano A, 2003, J CELL BIOL, V161, P229, DOI 10.1083/jcb.200207117; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; Shannon KB, 2002, CURR BIOL, V12, pR458, DOI 10.1016/S0960-9822(02)00945-4; Sugimoto K, 2000, CELL STRUCT FUNCT, V25, P253, DOI 10.1247/csf.25.253; Sugimoto K, 2002, CELL STRUCT FUNCT, V27, P457, DOI 10.1247/csf.27.457; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Takemoto A, 2004, J BIOL CHEM, V279, P4551, DOI 10.1074/jbc.M310925200; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; URANO T, 1993, ONCOGENE, V8, P1371; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200	65	127	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47201	47211		10.1074/jbc.M403029200	http://dx.doi.org/10.1074/jbc.M403029200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316025	hybrid			2022-12-25	WOS:000224832400108
J	Saric, T; Graef, CI; Goldberg, AL				Saric, T; Graef, CI; Goldberg, AL			Pathway for degradation of peptides generated by proteasomes - A key role for thimet oligopeptidase and other metallopeptidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; SENSITIVE NEUTRAL ENDOPEPTIDASE; BESTATIN-INDUCED PEPTIDES; 20 S PROTEASOMES; ANTIGEN PRESENTATION; PROTEIN-DEGRADATION; RABBIT BRAIN; PROCESSING PATHWAY; PRESENTED PEPTIDES; EC 3.4.24.15	The degradation of cellular proteins by proteasomes generates peptides 2-24 residues long, which are hydrolyzed rapidly to amino acids. To define the final steps in this pathway and the responsible peptidases, we fractionated by size the peptides generated by proteasomes from beta-[C-14] casein and studied in HeLa cell extracts the degradation of the 9-17 residue fraction and also of synthetic deca-and dodecapeptide libraries, because peptides of this size serve as precursors to MHC class I antigenic peptides. Their hydrolysis was followed by measuring the generation of smaller peptides or of new amino groups using fluorescamine. The C-14-labeled peptides released by 20 S proteasomes could not be degraded further by proteasomes. However, their degradation in the extracts and that of the peptide libraries was completely blocked by o-phenanthroline and thus required metallopeptidases. One such endopeptidase, thimet oligopeptidase (TOP), which was recently shown to degrade many antigenic precursors in the cytosol, was found to play a major role in degrading proteasome products. Inhibition or immunodepletion of TOP decreased their degradation and that of the peptide libraries by 30-50%. Pure TOP failed to degrade proteasome products 18-24 residues long but degraded the 9-17 residue fraction to peptides of 6-9 residues. When aminopeptidases in the cell extract were inhibited with bestatin, the 9-17 residue proteasome products were also converted to peptides of 6-9 residues, instead of smaller products. Accordingly, the cytosolic aminopeptidase, leucine aminopeptidase, could not degrade the 9-17 residue fraction but hydrolyzed the peptides generated by TOP to smaller products, recapitulating the process in cell extracts. Inactivation of both TOP and aminopeptidases blocked the degradation of proteasome products and peptide libraries nearly completely. Thus, degradation of most 9-17 residue proteasome products is initiated by endoproteolytic cleavages, primarily by TOP, and the resulting 6-9 residue fragments are further digested to amino acids by aminopeptidases.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu	Saric, Tomo/B-3415-2015	Saric, Tomo/0000-0001-8344-1095				Authier F, 1996, CLIN INVEST MED, V19, P149; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BOTBOL V, 1979, P NATL ACAD SCI USA, V76, P710, DOI 10.1073/pnas.76.2.710; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; Botbol V, 1985, Prog Clin Biol Res, V180, P573; Botbol V, 1997, AM J PHYSIOL-ENDOC M, V273, pE1149, DOI 10.1152/ajpendo.1997.273.6.E1149; BOTBOL V, 1989, J BIOL CHEM, V264, P13504; BOTBOL V, 1979, J BIOL CHEM, V254, P1254; BOTBOL V, 1991, J BIOL CHEM, V266, P2151; BUCHLER M, 1994, EUR J BIOCHEM, V219, P627, DOI 10.1111/j.1432-1033.1994.tb19978.x; Camargo ACM, 1997, BIOCHEM J, V324, P517, DOI 10.1042/bj3240517; CAMARGO ACM, 1973, BIOCHEMISTRY-US, V12, P1838, DOI 10.1021/bi00733a028; CARVALHO KM, 1981, BIOCHEMISTRY-US, V20, P7082, DOI 10.1021/bi00528a005; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; CHECLER F, 1995, METHOD ENZYMOL, V248, P593; CHESNEAU V, 1994, J BIOL CHEM, V269, P2056; CONLIN CA, 1995, METHOD ENZYMOL, V248, P567; Crack PJ, 1999, BRAIN RES, V835, P113, DOI 10.1016/S0006-8993(99)01494-8; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DESAUTELS M, 1982, P NATL ACAD SCI-BIOL, V79, P1869, DOI 10.1073/pnas.79.6.1869; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; Emmerich NPN, 2000, J BIOL CHEM, V275, P21140, DOI 10.1074/jbc.M000740200; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Hayashi MAF, 2000, BIOCHEM BIOPH RES CO, V269, P7, DOI 10.1006/bbrc.2000.2243; Hughes E, 2000, J BIOL CHEM, V275, P25109, DOI 10.1074/jbc.M003554200; Kato A, 1997, J BIOL CHEM, V272, P15313, DOI 10.1074/jbc.272.24.15313; Kim SI, 2003, BIOCHEM J, V375, P111, DOI 10.1042/BJ20030490; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Massarelli EE, 1999, BRAIN RES, V851, P261, DOI 10.1016/S0006-8993(99)02135-6; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; Oliveira V, 2003, FEBS LETT, V541, P89, DOI 10.1016/S0014-5793(03)00310-7; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Portaro FCV, 1999, BIOCHEM BIOPH RES CO, V255, P596, DOI 10.1006/bbrc.1999.0251; RAY K, 2004, J BIOL CHEM; Reits E, 2004, IMMUNITY, V20, P495, DOI 10.1016/S1074-7613(04)00074-3; Reits E, 2003, IMMUNITY, V18, P97, DOI 10.1016/S1074-7613(02)00511-3; Rioli V, 2003, J BIOL CHEM, V278, P8547, DOI 10.1074/jbc.M212030200; Rioli V, 1998, BIOCHEM BIOPH RES CO, V250, P5, DOI 10.1006/bbrc.1998.8941; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; SERIZAWA A, 1995, J BIOL CHEM, V270, P2092, DOI 10.1074/jbc.270.5.2092; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Silva CL, 1999, BIOCHEM BIOPH RES CO, V255, P591, DOI 10.1006/bbrc.1999.0250; Stoltze L, 2000, NAT IMMUNOL, V1, P413, DOI 10.1038/80852; Tamura N, 1998, CELL, V95, P637, DOI 10.1016/S0092-8674(00)81634-7; Tenidis K, 2000, J MOL BIOL, V295, P1055, DOI 10.1006/jmbi.1999.3422; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X; York IA, 2002, NAT IMMUNOL, V3, P1177, DOI 10.1038/ni860; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	65	143	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46723	46732		10.1074/jbc.M406537200	http://dx.doi.org/10.1074/jbc.M406537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328361	hybrid			2022-12-25	WOS:000224832400050
J	Shishodia, S; Aggarwal, BB				Shishodia, S; Aggarwal, BB			Guggulsterone inhibits NF-kappa B and I kappa B alpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR; CONSTITUTIVE ACTIVATION; DEPENDENT INDUCTION; ENDOTHELIAL-CELLS; COMMIPHORA MUKUL; NATURAL PRODUCT; TNF-ALPHA; CYCLIN D1	Guggulsterone, derived from Commiphora mukul and used to treat obesity, diabetes, hyperlipidemia, atherosclerosis, and osteoarthritis, has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile acid-activated genes. Because activation of NF-kappaB has been closely linked with inflammatory diseases affected by guggulsterone, we postulated that it must modulate NF-kappaB activation. In the present study, we tested this hypothesis by investigating the effect of this steroid on the activation of NF-kappaB induced by inflammatory agents and carcinogens. Guggulsterone suppressed DNA binding of NF-kappaB induced by tumor necrosis factor (TNF), phorbol ester, okadaic acid, cigarette smoke condensate, hydrogen peroxide, and interleukin-1. NF-kappaB activation was not cell type-specific, because both epithelial and leukemia cells were inhibited. Guggulsterone also suppressed constitutive NF-kappaB activation expressed in most tumor cells. Through inhibition of IkappaB kinase activation, this steroid blocked IkappaBalpha phosphorylation and degradation, thus suppressing p65 phosphorylation and nuclear translocation. NF-kappaB-dependent reporter gene transcription induced by TNF, TNFR1, TRADD, TRAF2, NIK, and IKK was also blocked by guggulsterone but without affecting p65-mediated gene transcription. In addition, guggulsterone decreased the expression of gene products involved in anti-apoptosis (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP, and survivin), proliferation ( cyclin D1 and c-Myc), and metastasis (MMP-9, COX-2, and VEGF); this correlated with enhancement of apoptosis induced by TNF and chemotherapeutic agents. Overall, our results indicate that guggulsterone suppresses NF-kappaB and NF-kappaB-regulated gene products, which may explain its anti-inflammatory activities.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal Bharat B., 2004, Indian Journal of Experimental Biology, V42, P341; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Craig WJ, 1997, J AM DIET ASSOC, V97, pS199, DOI 10.1016/S0002-8223(97)00765-7; Craig WJ, 1999, AM J CLIN NUTR, V70, p491S, DOI 10.1093/ajcn/70.3.491s; Cui J, 2003, J BIOL CHEM, V278, P10214, DOI 10.1074/jbc.M209323200; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Estrov Z, 1999, BLOOD, V94, P2844, DOI 10.1182/blood.V94.8.2844.420k43_2844_2853; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUJRAL M L, 1960, Indian J Physiol Pharmacol, V4, P267; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang S, 2000, CANCER RES, V60, P5334; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; MAHON TM, 1995, J BIOL CHEM, V270, P28557, DOI 10.1074/jbc.270.48.28557; Majumdar S, 2001, J IMMUNOL, V167, P2911, DOI 10.4049/jimmunol.167.5.2911; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Meselhy MR, 2003, PHYTOCHEMISTRY, V62, P213, DOI 10.1016/S0031-9422(02)00388-6; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SHARMA JN, 1977, ARZNEIMITTEL-FORSCH, V27, P1455; Shishodia S, 2003, CANCER RES, V63, P4375; SHYAMALA G, 1992, P NATL ACAD SCI USA, V89, P10628, DOI 10.1073/pnas.89.22.10628; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sinal CJ, 2002, TRENDS ENDOCRIN MET, V13, P275, DOI 10.1016/S1043-2760(02)00640-9; Singh BB, 2003, ALTERN THER HEALTH M, V9, P74; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Thurberg BL, 1998, CURR OPIN LIPIDOL, V9, P387, DOI 10.1097/00041433-199810000-00002; Urizar NL, 2003, ANNU REV NUTR, V23, P303, DOI 10.1146/annurev.nutr.23.011702.073102; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wittekindt NE, 2000, NUCLEIC ACIDS RES, V28, P800, DOI 10.1093/nar/28.3.800; Wu J, 2002, MOL ENDOCRINOL, V16, P1590, DOI 10.1210/me.16.7.1590; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Yumi, 2001, Current Molecular Medicine (Hilversum), V1, P287; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	61	192	203	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47148	47158		10.1074/jbc.M408093200	http://dx.doi.org/10.1074/jbc.M408093200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322087	hybrid			2022-12-25	WOS:000224832400102
J	Tsuda, M; Makino, Y; Iwahara, T; Nishihara, H; Sawa, H; Nagashima, K; Hanafusa, H; Tanaka, S				Tsuda, M; Makino, Y; Iwahara, T; Nishihara, H; Sawa, H; Nagashima, K; Hanafusa, H; Tanaka, S			Crk associates with ERM proteins and promotes cell motility toward hyaluronic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; CD44 CLEAVAGE; RHO FAMILY; ACTIVATION; ADHESION; KINASE; TRANSFORMATION; MIGRATION; PATHWAY; ONCOPROTEIN	Cell migration is a well organized process regulated by the extracellular matrix-mediated cytoskeletal reorganization. The signaling adaptor protein Crk has been shown to regulate cell motility, but its precise role is still under investigation. Herein, we report that Crk associates with ERM family proteins ( including ezrin, radixin, and moesin), activates RhoA, and promotes cell motility toward hyaluronic acid. The binding of Crk with ERMs was demonstrated both by transient and stable protein expression systems in 293T cells and 3Y1 cells, and it was shown that v-Crk translocated the phosphorylated form of ERMs to microvilli in 3Y1 cells by immunofluorescence and immunoelectron microscopy. This v-Crk-dependent formation of microvilli was suppressed by inhibitors of Rho-associated kinase, and the activity of RhoA was elevated by coexpression of c-Crk-II and ERMs in 3Y1 cells. In concert with the activation of RhoA by Crk, Crk was found to associate with Rho-GDI, which has been shown to bind to ERMs. Furthermore, upon hyaluronic acid treatment, coexpression of c-Crk-II and ERMs enhanced cell motility, whereas the sole expression of c-Crk-II or either of the ERMs decreased the motility of 3Y1 cells. These results suggest that Crk may be involved in regulation of cell motility by a hyaluronic acid-dependent mechanism through an association with ERMs.	Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Osaka Biosci Inst, Osaka 5650874, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Japan Science & Technology Agency (JST)	Tanaka, S (corresponding author), Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, N15 W7, Sapporo, Hokkaido 0608638, Japan.	tanaka@med.hokudai.ac.jp	Tanaka, Shinya/D-3586-2011; Sawa, Hirofumi/AAW-8816-2021; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755				Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Brugge JS, 1998, NAT GENET, V19, P309, DOI 10.1038/1189; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kawano Y, 2000, J BIOL CHEM, V275, P29628, DOI 10.1074/jbc.M002440200; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu EB, 2000, CANCER RES, V60, P2361; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Nishihara H, 2002, BIOCHEM BIOPH RES CO, V296, P716, DOI 10.1016/S0006-291X(02)00931-2; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Takino T, 2003, CANCER RES, V63, P2335; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsuda M, 2002, CELL GROWTH DIFFER, V13, P131; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391	30	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46843	46850		10.1074/jbc.M401476200	http://dx.doi.org/10.1074/jbc.M401476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326184	hybrid			2022-12-25	WOS:000224832400065
J	Bieganowski, P; Shilinski, K; Tsichlis, PN; Brenner, C				Bieganowski, P; Shilinski, K; Tsichlis, PN; Brenner, C			Cdc123 and checkpoint forkhead associated with RING proteins control the cell cycle by controlling eIF2 gamma abundance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC STRESS CHECKPOINT; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; FHA DOMAIN; EPIGENETIC INACTIVATION; NEGATIVE REGULATOR; ACTIVATING KINASE; ADENYLATE-CYCLASE; ESCHERICHIA-COLI; STRUCTURAL GENE	Eukaryotic initiation factor 2 (eIF2) is a central regulator of translational initiation in times of growth and times of stress. Here we discovered three new conserved regulators of eIF2 in Saccharomyces cerevisiae. cdc123, homolog of mammalian D123, is a new cell division cycle mutant with a G(2) delay at permissive temperature and a terminal, mating-proficient G(1) arrest point. Cdc123 protein is regulated by nutrient availability. CHF1 and CHF2, homologs of mammalian checkpoint forkhead associated with RING genes, are required for G2 delay and G(1) arrest of cdc123-4 and promote G(1) delay when overexpressed. Cell cycle delaying activity and the natural instability of Chf1 and Chf2 depend on the integrity of both domains and association with Cdc123. Genetic analysis maps the Chf1 forkhead associated domain-binding site to the conserved Thr-274 of Cdc123, suggesting that mammalian D123 is a key target of Chfr. Gcd11, the gamma subunit of eIF2, is an additional Cdc123-interacting protein that is an essential target of the Cdc123 cell cycle promoting and Chf cell cycle arresting activity whose abundance is regulated by Cdc123, Chf1, and Chf2. Loss of cdc123 activity promotes Chf1 and Chf2 accumulation and Gcd11 depletion, accounting for the essentiality of Cdc123. The data establish the Cdc123-Chf-Gcd11 axis as an essential pathway for nutritional control of START that runs parallel to the Tor-Gcn2-Sui2 system of translational control.	Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Dept Biochem, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Tufts New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA	Dartmouth College; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Tufts Medical Center	Brenner, C (corresponding author), Dartmouth Coll Sch Med, Dept Genet, Lebanon, NH 03756 USA.	charles.brenner@dartmouth.edu	Brenner, Charles/D-6339-2014; Bieganowski, Pawel/ABC-8554-2021	Brenner, Charles/0000-0002-4955-3226; Bieganowski, Pawel/0000-0002-1169-4517	NATIONAL CANCER INSTITUTE [P01CA077738] Funding Source: NIH RePORTER; NCI NIH HHS [CA77738] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; Bai C, 1996, METHOD ENZYMOL, V273, P331; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Chaturvedi P, 2002, CANCER RES, V62, P1797; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; FORTUNA M, 2000, CURRENT PROTOCOLS CY; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Gross A, 1999, BIOCHEMISTRY-US, V38, P13252, DOI 10.1021/bi9909849; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HARASHIMA S, 1986, MOL CELL BIOL, V6, P3990, DOI 10.1128/MCB.6.11.3990; Hartwell LH, 2002, BIOSCIENCE REP, V22, P373, DOI 10.1023/A:1020918107706; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaiser C., 1994, METHODS YEAST GENETI; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Laurino JP, 1999, MOL CELL BIOL, V19, P173; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Li J, 2000, J CELL SCI, V113, P4143; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mariatos G, 2003, CANCER RES, V63, P7185; MATSUMOTO K, 1984, J BACTERIOL, V157, P277, DOI 10.1128/JB.157.1.277-282.1984; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Okuda A, 1996, EXP CELL RES, V223, P242, DOI 10.1006/excr.1996.0078; Okuda A, 1999, CELL STRUCT FUNCT, V24, P443, DOI 10.1247/csf.24.443; Okuda A, 2001, CELL STRUCT FUNCT, V26, P205, DOI 10.1247/csf.26.205; Onisto M, 1998, EXP CELL RES, V242, P451, DOI 10.1006/excr.1998.4074; REED SI, 1980, GENETICS, V95, P561; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; Roll-Mecak A, 2001, TRENDS BIOCHEM SCI, V26, P705, DOI 10.1016/S0968-0004(01)02024-2; Satoh A, 2003, CANCER RES, V63, P8606; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; UNO I, 1985, P NATL ACAD SCI USA, V82, P7855, DOI 10.1073/pnas.82.23.7855; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832	56	36	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44656	44666		10.1074/jbc.M406151200	http://dx.doi.org/10.1074/jbc.M406151200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15319434	hybrid			2022-12-25	WOS:000224505600052
J	Doerrler, WT; Gibbons, HS; Raetz, CRH				Doerrler, WT; Gibbons, HS; Raetz, CRH			MsbA-dependent translocation of lipids across the inner membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT SALMONELLA-TYPHIMURIUM; RAPID TRANSMEMBRANE MOVEMENT; RETRACTED ARTICLE. SEE; ABC TRANSPORTERS; PHOSPHOLIPID TRANSLOCATION; PLASMA-MEMBRANE; GENE; 4-AMINO-4-DEOXY-L-ARABINOSE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOETHANOLAMINE	MsbA is an essential ABC transporter in Escherichia coli required for exporting newly synthesized lipids from the inner to the outer membrane. It remains uncertain whether or not MsbA catalyzes trans-bilayer lipid movement (i.e. flip-flop) within the inner membrane. We now show that newly synthesized lipid A accumulates on the cytoplasmic side of the inner membrane after shifting an E. coli msbA missense mutant to the non-permissive temperature. This conclusion is based on the selective inhibition of periplasmic, but not cytoplasmic, covalent modifications of lipid A that occur in polymyxin-resistant strains of E. coli. The accessibility of newly synthesized phosphatidylethanolamine to membrane impermeable reagents, like 2,4,6-trinitrobenzene sulfonic acid, is also reduced severalfold. Our data showed that MsbA facilitates the rapid translocation of some lipids from the cytoplasmic to the periplasmic side of the inner membrane in living cells.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Gibbons, Henry/0000-0002-5603-8679	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310] Funding Source: NIH RePORTER; NIAID NIH HHS [1 F32 AI-10613-01] Funding Source: Medline; NIGMS NIH HHS [GM-51310, GM-07184] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen C, 2000, EMBO REP, V1, P313, DOI 10.1093/embo-reports/kvd075; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Boon JM, 2002, MED RES REV, V22, P251, DOI 10.1002/med.10009; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Bos MP, 2004, P NATL ACAD SCI USA, V101, P9417, DOI 10.1073/pnas.0402340101; Buchaklian AH, 2004, BIOCHEMISTRY-US, V43, P8600, DOI 10.1021/bi0497751; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Clements JM, 2002, ANTIMICROB AGENTS CH, V46, P1793, DOI 10.1128/AAC.46.6.1793-1799.2002; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; CLEMENTZ T, 1995, FASEB J, V9, pA1311; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; ELFERINK RPJO, 1995, J CLIN INVEST, V95, P31, DOI 10.1172/JCI117658; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; Gibbons HS, 2000, J BIOL CHEM, V275, P32940, DOI 10.1074/jbc.M005779200; Hrafnsdottir S, 2000, J BACTERIOL, V182, P4198, DOI 10.1128/JB.182.15.4198-4206.2000; Huijbregts RPH, 1998, J BIOL CHEM, V273, P18936, DOI 10.1074/jbc.273.30.18936; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Kol MA, 2002, SEMIN CELL DEV BIOL, V13, P163, DOI 10.1016/S1084-9521(02)00044-7; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; Kol MA, 2001, BIOCHEMISTRY-US, V40, P10500, DOI 10.1021/bi010627+; KORNBERG RD, 1971, BIOCHEMISTRY-US, V10, P1111; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LANGLEY KE, 1979, P NATL ACAD SCI USA, V76, P6245, DOI 10.1073/pnas.76.12.6245; Lee H, 2004, J BACTERIOL, V186, P4124, DOI 10.1128/JB.186.13.4124-4133.2004; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; MARINETTI GV, 1982, J BIOL CHEM, V257, P245; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Muller W A, 1994, Methods Mol Biol, V27, P31; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Pomorski T, 2003, MOL BIOL CELL, V14, P1240, DOI 10.1091/mbc.E02-08-0501; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; Raetz CRH, 2001, J ENDOTOXIN RES, V7, P73; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; ROTHMAN JE, 1977, J MOL BIOL, V110, P603, DOI 10.1016/S0022-2836(77)80114-9; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; WU G, 1993, BIOCHEMISTRY-US, V32, P879, DOI 10.1021/bi00054a020; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	58	187	193	2	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45102	45109		10.1074/jbc.M408106200	http://dx.doi.org/10.1074/jbc.M408106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304478	hybrid, Green Published			2022-12-25	WOS:000224505600103
J	Narayanan, K; Srinivas, R; Peterson, MC; Ramachandran, A; Hao, JJ; Thimmapaya, B; Scherer, PE; George, A				Narayanan, K; Srinivas, R; Peterson, MC; Ramachandran, A; Hao, JJ; Thimmapaya, B; Scherer, PE; George, A			Transcriptional regulation of dentin matrix protein 1 by JunB and p300 during osteoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; HISTONE ACETYLTRANSFERASE; MICE LACKING; CELL-CYCLE; MOUSE DEVELOPMENT; COACTIVATOR P300; BONE-FORMATION; NULL MUTATION; AP-1 COMPLEX; ACETYLATION	Dentin matrix protein 1 (DMP1) is an acidic noncollagenous protein localized specifically in the mineralized matrix of bone and dentin. Expression analyses demonstrate that DMP1 is differentially regulated in osteoblasts and odontoblasts. Earlier we have reported on the transcriptional regulation of DMP1 by c-Fos and c-Jun (AP-1) transcription factors. Results from earlier study indicate that c-Fos and c-Jun play an important role in early osteoblast differentiation, whereas they do not have a significant effect on the terminally differentiated osteoblasts. In this paper, we demonstrate a regulatory mechanism by which JunB transcriptionally controls the expression of DMP1 during osteoblast differentiation. The cooperative interaction of JunB with p300 has been shown to dramatically modulate the DMP1 promoter activity during mineralization. Immunoprecipitation and chromatin immunoprecipitation analysis demonstrate the interaction of JunB and p300 in vivo. Further, phosphorylation of JunB at Ser-79 was found to be essential for its interaction with p300. Intrinsic histone acetyltransferase activity of p300 also plays a critical role in regulating DMP1 gene expression.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA; Childrens Mem Hosp, Chicago, IL 60614 USA; Northwestern Univ, Evanston, IL 60208 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Yeshiva University; Albert Einstein College of Medicine	George, A (corresponding author), Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.	anneg@uic.edu	Narayanan, Karthikeyan/D-1957-2010; Scherer, Philipp E/K-7819-2012	Narayanan, Karthikeyan/0000-0001-5136-2296; Scherer, Philipp E/0000-0003-0680-3392; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE 11657, DE 13836] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; Chan HM, 2001, J CELL SCI, V114, P2363; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DUNGY LJ, 1991, AM J OBSTET GYNECOL, V165, P1853, DOI 10.1016/0002-9378(91)90045-S; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LUO W, 1997, CELL GROWTH DIFFER, V11, P1225; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Narayanan K, 2002, CONNECT TISSUE RES, V43, P365, DOI 10.1080/03008200290000592; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; O'Connor MJ, 1999, J VIROL, V73, P3574; OGRYZKO VV, 1996, CELL, V87, P1107; Ornaghi P, 1999, J MOL BIOL, V287, P1, DOI 10.1006/jmbi.1999.2577; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Stanton LA, 2004, BIOCHEM J, V378, P53, DOI 10.1042/BJ20030874; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Thotakura SR, 2000, J BIOL CHEM, V275, P10272, DOI 10.1074/jbc.275.14.10272; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XAVIER F, 1991, BIOL CELL, V73, P27, DOI 10.1016/0248-4900(91)90005-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Ye L, 2004, J BIOL CHEM, V279, P19141, DOI 10.1074/jbc.M400490200; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	68	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44294	44302		10.1074/jbc.M403511200	http://dx.doi.org/10.1074/jbc.M403511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308641	hybrid			2022-12-25	WOS:000224505600010
J	Xia, XF; Roundtree, M; Merikhi, A; Lu, XH; Shentu, S; LeSage, G				Xia, XF; Roundtree, M; Merikhi, A; Lu, XH; Shentu, S; LeSage, G			Degradation of the apical sodium-dependent bile acid transporter by the ubiquitin-proteasome pathway in cholangiocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; ORGANIC ANION TRANSPORTERS; TOXIC LIVER-INJURY; RAT CHOLANGIOCYTES; PROINFLAMMATORY CYTOKINES; SALT TRANSPORTERS; DOWN-REGULATION; QUALITY-CONTROL; FACTOR RECEPTOR; PROTEIN	To attenuate injury during cholestasis, adaptive changes in bile acid transporter expression in the liver provide alternative bile acid excretory pathways. Apical sodium-dependent bile acid transporter ( ASBT) (SLC10A2), only expressed in the liver on the cholangiocyte apical membrane, is rapidly regulated in response to inflammation and bile acids. Here, we studied the mechanisms controlling ASBT protein levels in cholangiocytes to determine whether ASBT expression is regulated by ubiquitination and disposal through the proteasome. Protein turnover assays demonstrated that ASBT is an unstable and short-lived protein. Treatment with MG-132, a proteasome inhibitor, causes time-dependent increased ASBT levels and increased intracellular accumulation of ASBT. In cells cotransfected with green fluorescent protein-tagged ASBT and hemagglutinin-tagged ubiquitin, we demonstrated coimmunoprecipitation and colocalization of ASBT and ubiquitin. Interleukin-1beta( IL-1beta) induced down-regulation of ASBT is abrogated by a JNK inhibitor and is accompanied by an increase in ASBT polyubiquitin conjugates and a reduced ASBT half-life. In phosphorylation-deficient S335A and T339A mutants, the ASBT half-life is markedly prolonged, IL-1beta-induced ASBT ubiquitination is significantly reduced, and IL-1beta fails to increase ASBT turnover. These results indicate that ASBT undergoes ubiquitin-proteasome degradation under basal conditions and that ASBT proteasome disposal is increased by IL-1beta due to JNK-regulated serine/threonine phosphorylation of ASBT protein at both Ser-335 and Thr-339. These studies are the first report of regulation of a bile acid transporter expression by the ubiquitin-proteasome pathway.	Univ Texas, Sch Med, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA	University of Texas System	LeSage, G (corresponding author), Univ Texas, Sch Med, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, 6431 Fannin,MSB 4-234, Houston, TX 77030 USA.	Gene.LeSage@uth.tmc.edu			NIDDK NIH HHS [R01 DK 54208] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054208] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Alpini G, 1997, GASTROENTEROLOGY, V113, P1734, DOI 10.1053/gast.1997.v113.pm9352879; Alpini G, 2003, AM J PHYSIOL-GASTR L, V284, pG1066, DOI 10.1152/ajpgi.00260.2002; Alpini G, 2002, GASTROENTEROLOGY, V123, P1226, DOI 10.1053/gast.2002.36055; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; Chen F, 2002, GASTROENTEROLOGY, V123, P2005, DOI 10.1053/gast.2002.37055; Cook LB, 2003, MOL ENDOCRINOL, V17, P1777, DOI 10.1210/me.2003-0073; Dawson PA, 2003, J BIOL CHEM, V278, P33920, DOI 10.1074/jbc.M306370200; Dupre DJ, 2003, J BIOL CHEM, V278, P48228, DOI 10.1074/jbc.M304082200; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1996, ONCOGENE, V13, P1531; Geier A, 2003, HEPATOLOGY, V38, P345, DOI 10.1053/jhep.2003.50317; Geier A, 2002, J HEPATOL, V37, P198, DOI 10.1016/S0168-8278(02)00108-3; Harada M, 2001, GASTROENTEROLOGY, V120, P967, DOI 10.1053/gast.2001.22543; Hatakeyama S, 2003, J BIOCHEM, V134, P1, DOI 10.1093/jb/mvg106; HIANO K, 2003, AM J PATHOL, V163, P111; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOMANN AF, 1989, DIGEST DIS SCI, V34, pS16; Horak J, 2003, BBA-BIOMEMBRANES, V1614, P139, DOI 10.1016/S0005-2736(03)00195-0; Imai J, 2003, CELL CYCLE, V2, P585, DOI 10.4161/cc.2.6.586; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Keitel V, 2003, AM J PHYSIOL-GASTR L, V284, pG165, DOI 10.1152/ajpgi.00362.2002; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Lazaridis KN, 1997, J CLIN INVEST, V100, P2714, DOI 10.1172/JCI119816; Lee J, 2001, GASTROENTEROLOGY, V121, P1473, DOI 10.1053/gast.2001.29608; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Li D, 2002, J BIOL CHEM, V277, P31416, DOI 10.1074/jbc.M204818200; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Mitchell BS, 2003, NEW ENGL J MED, V348, P2597, DOI 10.1056/NEJMp030092; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shneider BL, 2001, J PEDIATR GASTR NUTR, V32, P407, DOI 10.1097/00005176-200104000-00002; Shneider BL, 1997, HEPATOLOGY, V25, P1176, DOI 10.1002/hep.510250521; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Skach WR, 2000, KIDNEY INT, V57, P825, DOI 10.1046/j.1523-1755.2000.00921.x; Spirli C, 2001, GASTROENTEROLOGY, V121, P156, DOI 10.1053/gast.2001.25516; Strous GJ, 2002, MOL CELL ENDOCRINOL, V197, P143, DOI 10.1016/S0303-7207(02)00258-7; Sun AQ, 2003, J BIOL CHEM, V278, P4000, DOI 10.1074/jbc.M207163200; Trauner M, 1999, J GASTROEN HEPATOL, V14, P946, DOI 10.1046/j.1440-1746.1999.01982.x; Tsirigotis M, 2001, J BIOL CHEM, V276, P46073, DOI 10.1074/jbc.M109023200; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316; Wang L, 2002, J CLIN INVEST, V110, P965, DOI 10.1172/JCI200215968; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zhang F, 2003, EXP CELL RES, V291, P275, DOI 10.1016/j.yexcr.2003.07.007	51	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44931	44937		10.1074/jbc.M400969200	http://dx.doi.org/10.1074/jbc.M400969200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304498	hybrid			2022-12-25	WOS:000224505600084
J	Marsee, DK; Venkateswaran, A; Tao, HY; Vadysirisack, D; Zhang, ZX; Vandre, DD; Jhiang, SM				Marsee, DK; Venkateswaran, A; Tao, HY; Vadysirisack, D; Zhang, ZX; Vandre, DD; Jhiang, SM			Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM/IODIDE SYMPORTER; TRANSFORMING ACTIVITY; RET PROTOONCOGENE; CRYSTAL-STRUCTURE; ANTITUMOR AGENT; HSP90 CHAPERONE; CANCER; COMPLEX; KINASE; EXPRESSION	RET/PTC1 is a rearranged form of the RET tyrosine kinase commonly seen in papillary thyroid carcinomas. It has been shown that RET/PTC1 decreases expression of the sodium/iodide symporter (NIS), the molecule that mediates radioiodide therapy for thyroid cancer. Using proteomic analysis, we identify hsp90 and its co-chaperone p50(cdc37) as novel proteins associated with RET/PTC1. Inhibition of hsp90 function with 17-allylamino-17-demothoxygeldanamycin (17-AAG) reduces RET/PTC1 protein levels. Furthermore, 17-AAG increases radioiodide accumulation in thyroid cells, mediated in part through a protein kinase A-independent mechanism. We show that 17-AAG does not increase the total amount of NIS protein or cell surface NIS localization. Instead, 17-AAG increases radioiodide accumulation by decreasing iodide efflux. Finally, the ability of 17-AAG to increase radioiodide accumulation is not restricted to thyroid cells expressing RET/PTC1. These findings suggest that 17-AAG may be useful as a chemotherapeutic agent, not only to inhibit proliferation but also to increase the efficacy of radioiodide therapy in patients with thyroid cancer.	Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Med Sci Program, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Biochem Program, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Jhiang, SM (corresponding author), Ohio State Univ, Coll Med, Dept Physiol & Cell Biol, 304 Hamilton Hall, Columbus, OH 43210 USA.	jhiang.1@osu.edu			NATIONAL CANCER INSTITUTE [R01CA060074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE014320] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60074] Funding Source: Medline; NIDCR NIH HHS [T32DE14320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBESIIMPIOMBAT.FS, 1982, COLD SPRING HARBOR C, V9, P483; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Braga-Basaria M, 2004, J CLIN ENDOCR METAB, V89, P2982, DOI 10.1210/jc.2003-031767; Buzzoni R, 2003, TUMORI, V89, P544, DOI 10.1177/030089160308900518; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Cho JY, 1999, ONCOGENE, V18, P3659, DOI 10.1038/sj.onc.1202709; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Furuya F, 2004, ENDOCRINOLOGY, V145, P2865, DOI 10.1210/en.2003-1258; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GERARD C, 1994, MOL CELL ENDOCRINOL, V106, P195, DOI 10.1016/0303-7207(94)90203-8; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Gruning T, 2003, EUR J ENDOCRINOL, V148, P395, DOI 10.1530/eje.0.1480395; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Iwashita T, 1996, ONCOGENE, V12, P481; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Knauf JA, 2003, ONCOGENE, V22, P6830, DOI 10.1038/sj.onc.1206829; Knauf JA, 2003, ONCOGENE, V22, P4406, DOI 10.1038/sj.onc.1206602; Lin XQ, 2004, J CLIN ENDOCR METAB, V89, P2344, DOI 10.1210/jc.2003-031963; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Nikiforov YE, 1997, CANCER RES, V57, P1690; PANG XP, 1989, ENDOCRINOLOGY, V125, P1783, DOI 10.1210/endo-125-4-1783; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Park JW, 2003, J CLIN ENDOCR METAB, V88, P3346, DOI 10.1210/jc.2002-020340; PICKER E, 2003, CIRC RES, V92, pE87; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Riedel C, 2001, J BIOL CHEM, V276, P21458, DOI 10.1074/jbc.M100561200; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; Segev DL, 2003, SURG ONCOL, V12, P69, DOI 10.1016/S0960-7404(03)00037-9; SMALLRIDGE RC, 1994, AM J PHYSIOL, V267, pE323, DOI 10.1152/ajpendo.1994.267.2.E323; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Trapasso F, 1999, EUR J ENDOCRINOL, V140, P447, DOI 10.1530/eje.0.1400447; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Xing S, 1998, J BIOL CHEM, V273, P4909, DOI 10.1074/jbc.273.9.4909; Xu WP, 2002, CELL STRESS CHAPERON, V7, P91, DOI 10.1379/1466-1268(2002)007<0091:HNGRTI>2.0.CO;2; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009	46	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43990	43997		10.1074/jbc.M407503200	http://dx.doi.org/10.1074/jbc.M407503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302866	hybrid			2022-12-25	WOS:000224383100077
J	Casanovas, O; Jaumot, M; Paules, AB; Agell, N; Bachs, O				Casanovas, O; Jaumot, M; Paules, AB; Agell, N; Bachs, O			P38(SAPK2) phosphorylates cyclin D3 at Thr-283 and targets it for proteasomal degradation	ONCOGENE			English	Article						cell cycle; cyclin D3; p38(SAPK); proteasome; cancer	ACTIVATED PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; CELL CARCINOMA; D GENES; D1; EXPRESSION; COMPLEXES; PROLIFERATION; LOCALIZATION	Cyclin D3 plays a critical role in maturation of precursor T cells and their levels are tightly regulated during this process. Alteration of cyclin D3 levels has been proposed to be important in the development of different human cancers, including malignancies of the lymphoid system. Thus, we have analysed the mechanisms involved in the regulation of cyclin D3 levels. Our results indicate that cyclin D3 is degraded via proteasome and that Thr-283 is essential for its degradation. Wild-type cyclin D3 but not the Thr-283A mutant accumulated ubiquitylated forms after treatment with proteasome inhibitors. We also observed that different type of stresses promote the Thr-283-dependent in vivo degradation of cyclin D3. The analysis of the kinases involved in Thr-283 phosphorylation indicates that all the members of the p38(SAPK) family of serine - threonine kinases are able to phosphorylate cyclin D3 at this specific site. Moreover, we found that the overexpression of p38alpha(SAPK2) induce the decrease of cyclin D3 in vivo. These results indicate that p38(SAPK) might be involved in the regulation of cyclin D3 levels and suggest that this mechanism is involved in the maturation of precursor T-cells. Alterations of this mechanism might be important for oncogenesis.	Univ Barcelona, IDIBAPS, Fac Med, Dept Biol Cellular & Anat Patol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bachs, O (corresponding author), Univ Barcelona, IDIBAPS, Fac Med, Dept Biol Cellular & Anat Patol, Casanova 143, E-08036 Barcelona, Spain.	obachs@.ub.edu	Jaumot, Montserrat/F-2640-2016; Agell, Neus/E-9640-2016; Casanovas, Oriol/L-5210-2014	Agell, Neus/0000-0002-1205-6074; Casanovas, Oriol/0000-0002-4298-3995; Jaumot, Montserrat/0000-0003-2864-357X				Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buschges R, 1999, BRAIN PATHOL, V9, P435; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Diehl NL, 2000, J EXP MED, V191, P321, DOI 10.1084/jem.191.2.321; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Filipits M, 2002, CLIN CANCER RES, V8, P729; Florenes VA, 2000, CLIN CANCER RES, V6, P3614; GRANA X, 1995, ONCOGENE, V11, P211; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gutzkow KB, 2003, CELL SIGNAL, V15, P871, DOI 10.1016/S0898-6568(03)00038-X; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Ito Y, 2001, ANTICANCER RES, V21, P1043; Iyoda K, 2003, CANCER-AM CANCER SOC, V97, P3017, DOI 10.1002/cncr.11425; Jaumot M, 1999, HEPATOLOGY, V29, P385, DOI 10.1002/hep.510290226; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; MATSUSHIME H, 1991, COLD SH Q B, V56, P69; MAYOL X, 1995, ONCOGENE, V11, P801; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morin CI, 2004, CANCER RES, V64, P1893, DOI 10.1158/0008-5472.CAN-03-3448; NEET K, 1995, MOL CELL BIOL, V15, P4908; Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007; Pirkmaier A, 2003, ONCOGENE, V22, P4425, DOI 10.1038/sj.onc.1206488; Rickheim DG, 2002, HEPATOLOGY, V36, P30, DOI 10.1053/jhep.2002.33996; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Sen J, 1996, J IMMUNOL, V156, P4535; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Tao GZ, 2002, J BIOL CHEM, V277, P19295, DOI 10.1074/jbc.M109654200; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E	44	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7537	7544		10.1038/sj.onc.1208040	http://dx.doi.org/10.1038/sj.onc.1208040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326477				2022-12-25	WOS:000224176500010
J	Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE				Miron, MJ; Gallouzi, IE; Lavoie, JN; Branton, PE			Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death	ONCOGENE			English	Article						adenovirus; E4orf4; cell death; nuclear localization signal; nucleus; nucleolus; arginine-rich motif	REV TRANS-ACTIVATOR; NUCLEOLAR-LOCALIZATION; P53-INDEPENDENT APOPTOSIS; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TAT PROTEIN; B-ALPHA; VIRUS; HIV-1; SEQUENCE	The adenovirus E4orf4 protein induces p53-independent death of human cancer cells by a mechanism requiring interactions with the Balpha subunit of protein phosphatase 2A. When expressed alone E4orf4 localizes predominantly in the nucleus, although significant levels are also present in the cytoplasm. While tyrosine phosphorylation of E4orf4 and recruitment of Src have been linked with E4orf4 cytoplasmic cell death functions, little is known about the functions of E4orf4 in the nucleus. In this study, we identified an arginine-rich motif (E4ARM; residues 66-75) that is necessary and sufficient for nuclear and nucleolar localization. This motif, which is highly homologous to the arginine-rich nuclear and nucleolar localization motif of some lentiviral proteins, was shown to target heterologous proteins to the nucleus and to nucleoli, functions found to be dependent on the overall charge of the motif rather than on specific residues. Furthermore, mutation of arginine residues to alanines but not to lysines in E4ARM was shown to block such targeting activity and, when introduced into full-length E4orf4, to decrease induction of cell death. Finally, coexpression of the ARM motifs of E4orf4, HIV-1 Tat or Rev along with full-length E4orf4 was seen to decrease E4orf4-dependent cell killing. Thus it appears that targeting of E4orf4 to the nucleus and cell nucleoli by E4ARM is an important component of E4orf4-induced cell death.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Laval, Hotel Dieu Quebec, CHUQ, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Laval University; McGill University; McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Promenade Sir William Osle, Montreal, PQ H3G 1Y6, Canada.	philip.branton@mcgill.ca		Lavoie, Josee N/0000-0001-6912-1132				Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Branton PE, 2001, ONCOGENE, V20, P7855, DOI 10.1038/sj.onc.1204862; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CASTIGLIA CL, 1983, MOL CELL BIOL, V3, P662, DOI 10.1128/MCB.3.4.662; Catez F, 2002, MOL CELL BIOL, V22, P1126, DOI 10.1128/MCB.22.4.1126-1139.2002; Champagne C, 2004, J BIOL CHEM, V279, P25905, DOI 10.1074/jbc.M400933200; DANG CV, 1989, J BIOL CHEM, V264, P18019; DUNDR M, 1995, J CELL SCI, V108, P2811; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gingras MC, 2002, MOL CELL BIOL, V22, P41, DOI 10.1128/MCB.22.1.41-56.2002; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Hiscox JA, 2002, ARCH VIROL, V147, P1077, DOI 10.1007/s00705-001-0792-0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Lavoie JN, 2000, J CELL BIOL, V150, P1037, DOI 10.1083/jcb.150.5.1037; LEDINKO N, 1972, VIROLOGY, V49, P79, DOI 10.1016/S0042-6822(72)80008-4; Lee TWR, 2003, J GEN VIROL, V84, P3423, DOI 10.1099/vir.0.19546-0; Lee TWR, 2004, J GEN VIROL, V85, P185, DOI 10.1099/vir.0.19352-0; Leung AKL, 2003, BIOCHEM J, V376, P553, DOI 10.1042/BJ20031169; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Livne A, 2001, J VIROL, V75, P789, DOI 10.1128/JVI.75.2.789-798.2001; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lutz P, 1996, J VIROL, V70, P3449, DOI 10.1128/JVI.70.6.3449-3460.1996; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MARASCO WA, 1994, ARCH VIROL, V139, P133, DOI 10.1007/BF01309460; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Matthews DA, 2001, J VIROL, V75, P1031, DOI 10.1128/JVI.75.2.1031-1038.2001; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PUVIONDUTILLEUL F, 1993, EUR J CELL BIOL, V61, P168; RASKAS HJ, 1970, VIROLOGY, V40, P893, DOI 10.1016/0042-6822(70)90135-2; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Robert A, 2002, J CELL BIOL, V158, P519, DOI 10.1083/jcb.200201106; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; RUBEN S, 1989, J VIROL, V63, P1; Scheer U, 1999, CURR OPIN CELL BIOL, V11, P385, DOI 10.1016/S0955-0674(99)80054-4; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Strom AC, 2001, GENOME BIOL, V2; Truant R, 1999, MOL CELL BIOL, V19, P1210; WALTON TH, 1989, J VIROL, V63, P3651, DOI 10.1128/JVI.63.9.3651-3660.1989	63	30	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7458	7468		10.1038/sj.onc.1207919	http://dx.doi.org/10.1038/sj.onc.1207919			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334069				2022-12-25	WOS:000224176500002
J	Peltier, JB; Ytterberg, AJ; Sun, Q; van Wijk, KJ				Peltier, JB; Ytterberg, AJ; Sun, Q; van Wijk, KJ			New functions of the thylakoid membrane proteome of Arabidopsis thaliana revealed by a simple, fast, and versatile fractionation strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-PROTOCHLOROPHYLLIDE OXIDOREDUCTASE; SODIUM DODECYL-SULFATE; LARGE-SCALE ANALYSIS; LIQUID-CHROMATOGRAPHY; CHLOROPLAST ENVELOPE; SUBCELLULAR-LOCALIZATION; HYDROPHOBIC PROTEINS; MASS-SPECTROMETRY; NUCLEAR GENE; IDENTIFICATION	Identification of membrane proteomes remains challenging. Here, we present a simple, fast, and scalable off-line procedure based on three-phase partitioning with butanol to fractionate membrane proteomes in combination with both in-gel and in-solution digestions and mass spectrometry. This should help to further accelerate the field of membrane proteomics. Using this new strategy, we analyzed the salt-stripped thylakoid membrane of chloroplasts of Arabidopsis thaliana. 242 proteins were identified, at least 40% of which are integral membrane proteins. The functions of 86 proteins are unknown; these include proteins with TPR, PPR, rhodanese, and DnaJ domains. These proteins were combined with all known thylakoid proteins and chloroplast (associated) envelope proteins, collected from primary literature, resulting in 714 non-redundant proteins. They were assigned to functional categories using a classification developed for MapMan (Thimm, O., Blasing, O., Gibon, Y., Nagel, A., Meyer, S., Kruger, P., Selbig, J., Muller, L. A., Rhee, S. Y., and Stitt, M. (2004) Plant J. 37, 914-939), updated with information from primary literature. The analysis elucidated the likely location of many membrane proteins, including 190 proteins of unknown function, holding the key to better understanding the two membrane systems. The three-phase partitioning procedure added a new level of dynamic resolution to the known thylakoid proteome. An automated strategy was developed to track possible ambiguous identifications to more than one gene model or family member. Mass spectrometry search results, ambiguities, and functional classifications can be searched via the Plastid Proteome Database.	Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA; Cornell Univ, Computat Biol Serv Unit, Ithaca, NY 14853 USA	Cornell University; Cornell University	van Wijk, KJ (corresponding author), Cornell Univ, Dept Plant Pathol, Emerson Hall,Rm 332,Tower Rd, Ithaca, NY 14853 USA.	kv35@Cornell.edu	Ytterberg, Anders/E-1773-2016	Ytterberg, Anders/0000-0002-1485-2314; Peltier, Jean-Benoit/0000-0001-6656-6072				Adamska I, 2001, ADV PHOTOSYNTH, V11, P487; Aronsson H, 2001, FEBS LETT, V502, P11, DOI 10.1016/S0014-5793(01)02595-9; Bae MS, 2003, PLANT J, V36, P652, DOI 10.1046/j.1365-313X.2003.01907.x; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beisson F, 2003, PLANT PHYSIOL, V132, P681, DOI 10.1104/pp.103.022988; Blonder J, 2004, ELECTROPHORESIS, V25, P1307, DOI 10.1002/elps.200405891; Blonder J, 2004, PROTEOMICS, V4, P31, DOI 10.1002/pmic.200300543; Blonder J, 2002, J PROTEOME RES, V1, P351, DOI 10.1021/pr0255248; Borderies G, 2003, ELECTROPHORESIS, V24, P3421, DOI 10.1002/elps.200305608; Brugiere S, 2004, PHYTOCHEMISTRY, V65, P1693, DOI 10.1016/j.phytochem.2004.03.028; Carlberg I, 2003, P NATL ACAD SCI USA, V100, P757, DOI 10.1073/pnas.0235452100; Chou ML, 2003, EMBO J, V22, P2970, DOI 10.1093/emboj/cdg281; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; DAHLIN C, 1995, PLANT MOL BIOL, V29, P317, DOI 10.1007/BF00043655; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; Dennison C, 1997, PROTEIN EXPRES PURIF, V11, P149, DOI 10.1006/prep.1997.0779; Dietz KJ, 2003, ANNU REV PLANT BIOL, V54, P93, DOI 10.1146/annurev.arplant.54.031902.134934; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Ferro M, 2000, ELECTROPHORESIS, V21, P3517; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Froehlich JE, 2003, J PROTEOME RES, V2, P413, DOI 10.1021/pr034025j; Fukao Y, 2002, PLANT CELL PHYSIOL, V43, P689, DOI 10.1093/pcp/pcf101; Giege P, 2003, PLANT CELL, V15, P2140, DOI 10.1105/tpc.012500; Gomez SM, 2002, MOL CELL PROTEOMICS, V1, P46, DOI 10.1074/mcp.M100007-MCP200; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Heller M, 2003, J AM SOC MASS SPECTR, V14, P704, DOI 10.1016/S1044-0305(03)00207-1; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jarvis P, 2002, BBA-MOL CELL RES, V1590, P177, DOI 10.1016/S0167-4889(02)00176-3; Jeong SY, 2003, NUCLEIC ACIDS RES, V31, P5175, DOI 10.1093/nar/gkg693; Joyard J, 1998, PLANT PHYSIOL, V118, P715, DOI 10.1104/pp.118.3.715; Karakaya HC, 2002, AM J BOT, V89, P559, DOI 10.3732/ajb.89.4.559; Kelly AA, 2004, CURR OPIN PLANT BIOL, V7, P262, DOI 10.1016/j.pbi.2004.03.009; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Lew S, 1997, ANAL BIOCHEM, V251, P113, DOI 10.1006/abio.1997.2232; Marmagne A, 2004, MOL CELL PROTEOMICS, V3, P675, DOI 10.1074/mcp.M400001-MCP200; Meierhoff K, 2003, PLANT CELL, V15, P1480, DOI 10.1105/tpc.010397; Meskauskiene R, 2001, P NATL ACAD SCI USA, V98, P12826, DOI 10.1073/pnas.221252798; Miras S, 2002, J BIOL CHEM, V277, P47770, DOI 10.1074/jbc.M207477200; Molloy MP, 1999, ELECTROPHORESIS, V20, P701, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<701::AID-ELPS701>3.0.CO;2-5; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; Nuhse TS, 2003, MOL CELL PROTEOMICS, V2, P1234, DOI 10.1074/mcp.T300006-MCP200; Pastori GM, 2002, PLANT PHYSIOL, V129, P460, DOI 10.1104/pp.011021; Peltier JB, 2004, J BIOL CHEM, V279, P4768, DOI 10.1074/jbc.M309212200; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; PENN N, 1958, BIOCHIM BIOPHYS ACTA, V27, P539, DOI 10.1016/0006-3002(58)90383-4; PENNA TCV, 2002, BMC BIOTECHNOL; PIKE R, 1989, PREP BIOCHEM, V19, P231, DOI 10.1080/10826068908544913; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Puchades M, 1999, RAPID COMMUN MASS SP, V13, P344; RABILLOUD T, 1994, CELL MOL BIOL, V40, P57; Rey P, 2000, PLANT J, V21, P483, DOI 10.1046/j.1365-313x.2000.00699.x; Roy I, 2002, ANAL BIOCHEM, V300, P11, DOI 10.1006/abio.2001.5367; Sakamoto W, 2003, PLANT CELL, V15, P2843, DOI 10.1105/tpc.017319; SALOMON M, 1990, P NATL ACAD SCI USA, V87, P5778, DOI 10.1073/pnas.87.15.5778; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Seigneurin-Berny D, 1999, PLANT J, V19, P217, DOI 10.1046/j.1365-313X.1999.00511.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimamura M, 2004, PLANT CELL, V16, P45, DOI 10.1105/tpc.016501; Shimaoka T, 2004, PLANT CELL PHYSIOL, V45, P672, DOI 10.1093/pcp/pch099; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stenzel I, 2003, PLANT MOL BIOL, V51, P895, DOI 10.1023/A:1023049319723; Sun Q, 2004, PLANT PHYSIOL, V135, P723, DOI 10.1104/pp.104.040717; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Szponarski W, 2004, PROTEOMICS, V4, P397, DOI 10.1002/pmic.200300607; TARR GE, 1983, ANAL BIOCHEM, V131, P99, DOI 10.1016/0003-2697(83)90140-9; Thimm O, 2004, PLANT J, V37, P914, DOI 10.1111/j.1365-313X.2004.02016.x; Tottey S, 2003, P NATL ACAD SCI USA, V100, P16119, DOI 10.1073/pnas.2136793100; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weber APM, 2004, CURR OPIN PLANT BIOL, V7, P247, DOI 10.1016/j.pbi.2004.03.008; Whitelegge JP, 2003, ADV PROTEIN CHEM, V65, P271; Williams PM, 2003, PLANT J, V36, P675, DOI 10.1046/j.1365-313X.2003.01915.x; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Wu CC, 2003, NAT BIOTECHNOL, V21, P262, DOI 10.1038/nbt0303-262; Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819; Yakhnin AV, 1998, PROTEIN EXPRES PURIF, V14, P382, DOI 10.1006/prep.1998.0981; Yamazaki H, 2004, PLANT J, V38, P152, DOI 10.1111/j.1365-313X.2004.02035.x; Yu F, 2004, PLANT J, V37, P864, DOI 10.1111/j.1365-313X.2003.02014.x; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	89	207	224	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49367	49383		10.1074/jbc.M406763200	http://dx.doi.org/10.1074/jbc.M406763200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15322131	hybrid			2022-12-25	WOS:000225098100106
J	Matsumoto, M; Kogawa, M; Wada, S; Takayanagi, H; Tsujimoto, M; Katayama, S; Hisatake, K; Nogi, Y				Matsumoto, M; Kogawa, M; Wada, S; Takayanagi, H; Tsujimoto, M; Katayama, S; Hisatake, K; Nogi, Y			Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROPHTHALMIA TRANSCRIPTION FACTOR; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ACID-PHOSPHATASE GENE; RECEPTOR ACTIVATOR; NUCLEAR-FACTOR; MAP KINASES; T-CELLS; TERMINAL DIFFERENTIATION; BONE-RESORPTION	The receptor activator of NF-kappaB ligand (RANKL) induces various osteoclast-specific marker genes during osteoclast differentiation mediated by mitogen-activated protein ( MAP) kinase cascades. However, the results of transcriptional programming of an osteoclast-specific cathepsin K gene are inconclusive. Here we report the regulatory mechanisms of RANKL-induced cathepsin K gene expression during osteoclastogenesis in a p38 MAP kinase-dependent manner. The reporter gene analysis with sequential 5'-deletion constructs of the cathepsin K gene promoter indicates that limited sets of the transcription factors such as NFATc1, PU.1, and microphthalmia transcription factor indeed enhance synergistically the gene expression when overexpressed in RAW264 cells. In addition, the activation of p38 MAP kinase is required for the maximum enhancement of the gene expression. RANKL-induced NFATc1 forms a complex with PU. 1 in nuclei of osteoclasts following the nuclear accumulation of NFATc1 phosphorylated by the activated p38 MAP kinase. These results suggest that the RANKL-induced cathepsin K gene expression is cooperatively regulated by the combination of the transcription factors and p38 MAP kinase in a gradual manner.	Saitama Med Sch, Dept Mol Biol, Iruma, Saitama 3500495, Japan; Saitama Med Sch, Dept Internal Med 4, Iruma, Saitama 3500495, Japan; Tokyo Med Dent Univ, Dept Cellular Physiol Chem, Tokyo 1138549, Japan; RIKEN, Dept Cellular Biochem, Saitama 3510198, Japan	Saitama Medical University; Saitama Medical University; Tokyo Medical & Dental University (TMDU); RIKEN	Matsumoto, M (corresponding author), Saitama Med Sch, Dept Mol Biol, 38 Morohongo, Iruma, Saitama 3500495, Japan.	masam@saitama-med.ac.jp	Matsumoto, Masahito/AGS-0755-2022	Hisatake, Koji/0000-0002-5795-3115				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Boissy P, 1998, J CELL SCI, V111, P2563; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chuvpilo S, 2002, IMMUNITY, V16, P881, DOI 10.1016/S1074-7613(02)00329-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006-291X(03)00695-8; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014-5793(00)02231-6; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsumoto M, 2001, J BIOL CHEM, V276, P33086, DOI 10.1074/jbc.M104299200; Matsumoto M, 1999, BIOL CHEM, V380, P699, DOI 10.1515/BC.1999.087; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915; Rood JA, 1997, GENOMICS, V41, P169, DOI 10.1006/geno.1997.4614; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; So H, 2003, J BIOL CHEM, V278, P24209, DOI 10.1074/jbc.M302940200; Steingrimsson E, 2002, P NATL ACAD SCI USA, V99, P4477, DOI 10.1073/pnas.072071099; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhou B, 2002, J BIOL CHEM, V277, P10704, DOI 10.1074/jbc.M107068200	63	328	336	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45969	45979		10.1074/jbc.M408795200	http://dx.doi.org/10.1074/jbc.M408795200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15304486	hybrid			2022-12-25	WOS:000224694900082
J	Narayanan, K; Ramachandran, A; Peterson, MC; Hao, JJ; Kolsto, AB; Friedman, AD; George, A				Narayanan, K; Ramachandran, A; Peterson, MC; Hao, JJ; Kolsto, AB; Friedman, AD; George, A			The CCAAT enhancer-binding protein (c/EBP)beta and Nrf1 interact to regulate dentin sialophosphoprotein (DSPP) gene expression during odontoblast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BZIP TRANSCRIPTION FACTOR; MATRIX PROTEIN-1; FACTOR TCF11; IN-VIVO; MYC REPRESSES; ACTIVATION; PROMOTER; ELEMENT; REGION; C/EBP	Terminal differentiation of odontoblasts, the principal cells in dentin formation, proceeds by synthesis of type I collagen and noncollagenous proteins. DSP and DPP are specific markers for terminally differentiated odontoblasts and are encoded by a single gene DSPP ( dentin sialophosphoprotein). In an attempt to understand the molecular mechanisms required for tissue-specific expression of the DSPP gene, we have identified a novel interaction between two bZIP transcription factors, Nrf1 and the CCAAT enhancer-binding protein (C/EBP)beta. This interaction was confirmed by both immunoprecipitation and chromatin immunoprecipitation assays. In undifferentiated odontoblasts, Nrf1 and C/EBPbeta repress DSPP promoter activity individually and synergistically by cooperatively interacting with each other. This mutual interaction is facilitated by the bZIP domains in both the proteins. The repression domain in both Nrf1 and C/EBPbeta was determined, and deletion of this domain abolished transcriptional repression. In fully differentiated odontoblasts, the loss of interaction between Nrf1 and C/EBPbeta results in an increased DSPP transcription. Further, this interaction was found to be dependent on phosphorylation at Ser(599) of Nrf1. Thus, the physical interaction between Nrf1 and C/EBPbeta provide a novel mechanism for the transcriptional regulation of DSPP in odontoblasts.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA; Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway; Johns Hopkins Univ, Sch Med, Dept Pediat Oncol, Baltimore, MD 21287 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Oslo; Johns Hopkins University	George, A (corresponding author), Univ Illinois, Dept Oral Biol, M-C 690, Chicago, IL 60612 USA.	anneg@uic.edu	Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE 13836, DE 11657] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Butler WT, 2002, CONNECT TISSUE RES, V43, P301, DOI 10.1080/03008200290000682; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; Farmer SC, 1997, GENE DEV, V11, P786, DOI 10.1101/gad.11.6.786; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; George A, 1999, CONNECT TISSUE RES, V40, P49, DOI 10.3109/03008209909005277; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hao JJ, 2002, J BIOL CHEM, V277, P19976, DOI 10.1074/jbc.M112223200; Harrison JR, 2001, J BONE MINER RES, V16, pS162; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Husberg C, 2003, BBA-MOL CELL RES, V1640, P143, DOI 10.1016/S0167-4889(03)00041-7; Husberg C, 2001, J BIOL CHEM, V276, P17641, DOI 10.1074/jbc.M007951200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUNA L, 1995, GENOMICS, V27, P237, DOI 10.1006/geno.1995.1037; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; MacDougall M, 1997, CYTOGENET CELL GENET, V79, P121, DOI 10.1159/000134697; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Murphy P, 2000, MECH DEVELOP, V97, P141, DOI 10.1016/S0925-4773(00)00413-5; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Narayanan K, 2002, CONNECT TISSUE RES, V43, P365, DOI 10.1080/03008200290000592; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Novotny V, 1998, NUCLEIC ACIDS RES, V26, P5480, DOI 10.1093/nar/26.23.5480; Papagerakis P, 2002, CONNECT TISSUE RES, V43, P372, DOI [10.1080/713713533, 10.1080/03008200290000655]; Rajpar MH, 2002, HUM MOL GENET, V11, P2559, DOI 10.1093/hmg/11.21.2559; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Roberts SGE, 2000, CELL MOL LIFE SCI, V57, P1149, DOI 10.1007/PL00000755; Sreenath T, 2003, J BIOL CHEM, V278, P24874, DOI 10.1074/jbc.M303908200; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Veis A, 1985, CHEM BIOL MINERALIZE, P170; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Xiao SX, 2001, NAT GENET, V27, P201, DOI 10.1038/84848; Zhang XH, 2001, NAT GENET, V27, P151, DOI 10.1038/84765	38	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45423	45432		10.1074/jbc.M405031200	http://dx.doi.org/10.1074/jbc.M405031200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308669	hybrid			2022-12-25	WOS:000224694900018
J	Riviere, L; van Weelden, SWH; Glass, P; Vegh, P; Coustou, V; Biran, M; van Hellemond, JJ; Bringaud, F; Tielens, AGM; Boshart, M				Riviere, L; van Weelden, SWH; Glass, P; Vegh, P; Coustou, V; Biran, M; van Hellemond, JJ; Bringaud, F; Tielens, AGM; Boshart, M			Acetyl : succinate CoA-transferase in procyclic Trypanosoma brucei - Gene identification and role in carbohydrate metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; ENERGY-METABOLISM; HYDROGENOSOMES; PROTEIN; COMPARTMENTATION; MITOCHONDRION; RESISTANCE; PYRUVATE; GLUCOSE; ENZYME	Acetyl: succinate CoA-transferase (ASCT) is an acetate-producing enzyme shared by hydrogenosomes, mitochondria of trypanosomatids, and anaerobically functioning mitochondria. The gene encoding ASCT in the protozoan parasite Trypanosoma brucei was identified as a new member of the CoA transferase family. Its assignment to ASCT activity was confirmed by 1) a quantitative correlation of protein expression and activity upon RNA interference-mediated repression, 2) the absence of activity in homozygous Deltaasct/Deltaasct knock out cells, 3) mitochondrial colocalization of protein and activity, 4) increased activity and acetate excretion upon transgenic overexpression, and 5) depletion of ASCT activity from lysates upon immunoprecipitation. Genetic ablation of ASCT produced a severe growth phenotype, increased glucose consumption, and excretion of beta-hydroxybutyrate and pyruvate, indicating accumulation of acetyl-CoA. Analysis of the excreted end products of C-13-enriched and C-14-labeled glucose metabolism showed that acetate excretion was only slightly reduced. Adaptation to ASCT deficiency, however, was an infrequent event at the population level, indicating the importance of this enzyme. These studies show that ASCT is indeed involved in acetate production, but is not essential, as apparently it is not the only enzyme that produces acetate in T. brucei.	Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Funct Trypanosomatides, F-33076 Bordeaux, France; Univ Utrecht, Fac Med Vet, Dept Biochem & Cell Biol, NL-3584 CM Utrecht, Netherlands; Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Univ Bordeaux 2, CNRS, UMR 5536, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Utrecht University; University of Munich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Bringaud, F (corresponding author), Univ Bordeaux 2, CNRS, UMR 5162, Lab Genom Funct Trypanosomatides, F-33076 Bordeaux, France.	bringaud@u-bordeaux2.fr; a.g.m.tielens@vet.uu.nl; boshart@lmu.de	Boshart, Michael/A-2700-2011; van Hellemond, Jaap/T-7555-2019	Boshart, Michael/0000-0002-5070-2663; van Hellemond, Jaap/0000-0003-4862-7796; Tielens, Aloysius/0000-0002-5485-1105				Bateman KS, 2002, BIOCHEMISTRY-US, V41, P14455, DOI 10.1021/bi020568f; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Bergmeyer H. U., 1970, METHODEN ENZYMATISCH, P1163; Besteiro S, 2002, J BIOL CHEM, V277, P38001, DOI 10.1074/jbc.M201759200; BLUM JJ, 1993, PARASITOL TODAY, V9, P118, DOI 10.1016/0169-4758(93)90168-F; Bringaud F, 1995, MOL BIOCHEM PARASIT, V74, P119, DOI 10.1016/0166-6851(95)02486-7; Bringaud F, 2000, MOL BIOCHEM PARASIT, V111, P283, DOI 10.1016/S0166-6851(00)00319-4; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; BRUN R, 1979, ACTA TROP, V36, P289; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; CavalierSmith T, 1996, J MOL EVOL, V43, P551, DOI 10.1007/BF02202103; CAZZULO JJ, 1992, FASEB J, V6, P3153, DOI 10.1096/fasebj.6.13.1397837; Clayton CE, 1996, PARASITOL TODAY, V12, P465, DOI 10.1016/S0169-4758(96)10073-9; Coustou V, 2003, J BIOL CHEM, V278, P49625, DOI 10.1074/jbc.M307872200; DELAUW MF, 1985, EMBO J, V4, P989, DOI 10.1002/j.1460-2075.1985.tb03728.x; EMBLEY TM, 1995, P ROY SOC B-BIOL SCI, V262, P87, DOI 10.1098/rspb.1995.0180; Fairlamb A. H., 1986, Carbohydrate metabolism in cultured cells., P183; FREEMAN R, 1981, J MAGN RESON, V42, P341, DOI 10.1016/0022-2364(81)90227-4; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Hannaert Veronique, 2003, Kinetoplastid Biology and Disease, V2, pUnpaginated; Harlow E., 1988, ANTIBODIES LAB MANUA; Heider J, 2001, FEBS LETT, V509, P345, DOI 10.1016/S0014-5793(01)03178-7; HOREMANS AMC, 1991, PARASITOLOGY, V102, P259, DOI 10.1017/S0031182000062570; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Martin W, 1998, NATURE, V392, P37, DOI 10.1038/32096; MARVINSIKKEMA FD, 1993, ARCH MICROBIOL, V160, P388; McCulloch Richard, 2004, Methods Mol Biol, V262, P53; MCLAUGHLIN GL, 1986, COMP BIOCHEM PHYS B, V83, P523, DOI 10.1016/0305-0491(86)90290-7; OPPERDOES FR, 1994, J BIOENERG BIOMEMBR, V26, P145, DOI 10.1007/BF00763062; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; Opperdoes Fred R., 1995, P19, DOI 10.1016/B978-012473345-9/50003-9; PANDE SV, 1976, ANAL BIOCHEM, V74, P25, DOI 10.1016/0003-2697(76)90306-7; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; ROTHMAN DL, 1985, P NATL ACAD SCI USA, V82, P1633, DOI 10.1073/pnas.82.6.1633; Saas J, 2000, J BIOL CHEM, V275, P2745, DOI 10.1074/jbc.275.4.2745; Saz HJ, 1996, J PARASITOL, V82, P694, DOI 10.2307/3283876; STEINBUCHEL A, 1986, MOL BIOCHEM PARASIT, V20, P57, DOI 10.1016/0166-6851(86)90142-8; Sveshnikova N, 2000, BIOL CHEM, V381, P687, DOI 10.1515/BC.2000.089; TIELENS AGM, 1981, MOL BIOCHEM PARASIT, V3, P205, DOI 10.1016/0166-6851(81)90052-9; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; van Hoek AHAM, 2000, MOL BIOL EVOL, V17, P202, DOI 10.1093/oxfordjournals.molbev.a026234; van Weelden SWH, 2003, J BIOL CHEM, V278, P12854, DOI 10.1074/jbc.M213190200; VanHellemond JJ, 1997, PARASITOLOGY, V114, P351, DOI 10.1017/S0031182096008591; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P91, DOI 10.1016/0166-6851(96)02727-2; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7	48	74	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45337	45346		10.1074/jbc.M407513200	http://dx.doi.org/10.1074/jbc.M407513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326192	hybrid			2022-12-25	WOS:000224694900008
J	Takahashi, H; Hattori, S; Iwamatsu, A; Takizawa, H; Shibuya, M				Takahashi, H; Hattori, S; Iwamatsu, A; Takizawa, H; Shibuya, M			A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLT TYROSINE KINASE; PLC-GAMMA; AUTOPHOSPHORYLATION SITE; CRYSTAL-STRUCTURE; CELLS SECRETE; DNA-SYNTHESIS; BINDING-SITE; TUMOR-CELLS; ORF VIRUS; ANGIOGENESIS	Vascular endothelial growth factor (VEGF)/vascular permeability factor induces both angiogenesis and vascular permeability mainly through VEGF receptor (VEGFR)-2 activation. VEGF binds VEGFR-1 as well, but the importance of VEGFR-1 signaling in vascular permeability has been largely neglected. Here, we report the purification and characterization of a novel VEGF-like protein from Trimeresurus flavoviridis Habu snake venom. The Habu snake has a venom-specific VEGF-like molecule, T. flavoviridis snake venom VEGF (TfsvVEGF), in addition to VEGF-A. TfsvVEGF has almost 10-fold less mitotic activity than VEGF(165), a predominant isoform of human VEGF-A, but a similar effect on vascular permeability. TfsvVEGF bound VEGFR-1 and induced its autophosphorylation to almost the same extent as VEGF(165), but bound VEGFR-2 weakly and induced its autophosphorylation almost 10-fold less effectively than VEGF(165). This unique binding affinity for VEGFR-1 and VEGFR-2 leads to the vascular permeability-dominant activity of TfsvVEGF. These results suggest that Habu snakes have acquired a highly purposive molecule for a toxin, which enhances the toxicity in envenomation without inducing effective angiogenesis and the following regeneration of damaged tissues, taking advantage of the difference in signaling properties involving VEGFR-1 and VEGFR-2 between vascular permeability and angiogenesis. TfsvVEGF is thus a potent inducing factor selective for vascular permeability through preferential signaling via VEGFR-1. These data strongly indicate the importance of VEGFR-1 signaling in vascular permeability.	Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, Inst Med Sci, Amami Lab Injurious Anim, Kagoshima 8941531, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Kirin Brewery Company Limited	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	shibuya@ims.u-tokyo.ac.jp						Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Curnis F, 2002, J CLIN INVEST, V110, P475, DOI 10.1172/JCI200215223; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gasmi A, 2002, J BIOL CHEM, V277, P29992, DOI 10.1074/jbc.M202202200; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Junqueira de Azevedo ILM, 2001, J BIOL CHEM, V276, P39836; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kiba A, 2003, J BIOL CHEM, V278, P13453, DOI 10.1074/jbc.M210931200; Kiba A, 2003, BIOCHEM BIOPH RES CO, V301, P371, DOI 10.1016/S0006-291X(02)03033-4; Kobayashi M, 2003, ONCOGENE, V22, P1294, DOI 10.1038/sj.onc.1206256; Komori Y, 1999, BIOCHEMISTRY-US, V38, P11796, DOI 10.1021/bi990562z; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PARK JE, 1994, J BIOL CHEM, V269, P25646; Robinson CJ, 2001, J CELL SCI, V114, P853; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2003, CANCER SCI, V94, P751, DOI 10.1111/j.1349-7006.2003.tb01514.x; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; YAMANE A, 1994, ONCOGENE, V9, P2683; Yamazaki Y, 2003, J BIOL CHEM, V278, P51985, DOI 10.1074/jbc.C300454200; Yu Y, 2001, BIOCHEM J, V358, P465, DOI 10.1042/0264-6021:3580465	46	65	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46304	46314		10.1074/jbc.M403687200	http://dx.doi.org/10.1074/jbc.M403687200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15328352	hybrid			2022-12-25	WOS:000224694900118
J	Barak, O; Lazzaro, MA; Cooch, NS; Picketts, DJ; Shiekhattar, R				Barak, O; Lazzaro, MA; Cooch, NS; Picketts, DJ; Shiekhattar, R			A tissue-specific, naturally occurring human SNF2L variant inactivates chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; SPLICE VARIANT; COMPLEX; ISWI; EXPRESSION; RECEPTOR; GENE; FAC1; REPLICATION; REGULATOR	Mammalian genomes encode two imitation switch family chromatin remodeling proteins, SNF2H and SNF2L. In the mouse, SNF2H is expressed ubiquitously, whereas SNF2L expression is limited to the brain and gonadal tissue. This pattern of SNF2L expression suggests a critical role for SNF2L in neuronal physiology. Indeed, SNF2L was shown to promote neurite outgrowth as well as regulate the human engrailed homeotic genes, important regulators of brain development. Here we identify a novel splice variant of human SNF2L we call SNF2L+13, which contains a nonconserved in-frame exon within the conserved catalytic core domain of SNF2L. SNF2L+13 retains the ability to incorporate into multiprotein complexes; however, it is devoid of enzymatic activity. Most interestingly, unlike mouse SNF2L, human SNF2L is expressed ubiquitously, and regulation is mediated by isoform variation. The human SNF2L+13 null variant is predominant in nonneuronal tissue, whereas the human wild type active SNF2L isoform is expressed in neurons. Thus, like the mouse, active human SNF2L is limited to neurons and a few other tissues.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1H 8M5, Canada	The Wistar Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wisatar.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061204] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171-28] Funding Source: Medline; NIGMS NIH HHS [GM61204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aalfs JD, 2001, J BIOL CHEM, V276, P34270, DOI 10.1074/jbc.M104163200; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Barak O, 2003, EMBO J, V22, P6089, DOI 10.1093/emboj/cdg582; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; BERGET SM, 1977, BROOKHAVEN SYM BIOL, V29, P332; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; BOWSER R, 1995, DEV NEUROSCI-BASEL, V17, P20, DOI 10.1159/000111270; Bozhenok L, 2002, EMBO J, V21, P2231, DOI 10.1093/emboj/21.9.2231; Collins N, 2002, NAT GENET, V32, P627, DOI 10.1038/ng1046; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; HARLOW E, 1988, ANTIBODIES LAB MANUA, P285; Havas K, 2001, CELL MOL LIFE SCI, V58, P673, DOI 10.1007/PL00000891; Jensen LE, 2001, J BIOL CHEM, V276, P29037, DOI 10.1074/jbc.M103815200; Jiang DW, 2003, J BIOL CHEM, V278, P4763, DOI 10.1074/jbc.M210410200; Jones MH, 2000, GENOMICS, V63, P35, DOI 10.1006/geno.1999.6070; Jordan-Sciutto K, 1998, NEUROPATH APPL NEURO, V24, P359; Kuemerle B, 1997, J NEUROSCI, V17, P7881; Lastowska M, 2001, MED PEDIATR ONCOL, V36, P20, DOI 10.1002/1096-911X(20010101)36:1<20::AID-MPO1006>3.0.CO;2-E; Lazzaro MA, 2001, J NEUROCHEM, V77, P1145, DOI 10.1046/j.1471-4159.2001.00324.x; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Loyola A, 2003, MOL CELL BIOL, V23, P6759, DOI 10.1128/MCB.23.19.6759-6768.2003; Mu XJ, 1997, EXP NEUROL, V146, P17, DOI 10.1006/exnr.1997.6508; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Strohner R, 2001, EMBO J, V20, P4892, DOI 10.1093/emboj/20.17.4892; Thanaraj TA, 2001, NUCLEIC ACIDS RES, V29, P2581, DOI 10.1093/nar/29.12.2581; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	35	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45130	45138		10.1074/jbc.M406212200	http://dx.doi.org/10.1074/jbc.M406212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310751	hybrid			2022-12-25	WOS:000224505600106
J	Gande, R; Gibson, KJC; Brown, AK; Krumbach, K; Dover, LG; Sahm, H; Shioyama, S; Oikawa, T; Besra, GS; Eggeling, L				Gande, R; Gibson, KJC; Brown, AK; Krumbach, K; Dover, LG; Sahm, H; Shioyama, S; Oikawa, T; Besra, GS; Eggeling, L			Acyl-CoA carboxylases (accD2 and accD3), together with a unique polyketide synthase (Cg-pks), are key to mycolic acid biosynthesis in corynebacterianeae such as Corynebacterium glutamicum and Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; CELL-FREE SYSTEM; BACTERIONEMA-MATRUCHOTII; CONDENSATION STEP; FATTY-ACIDS; IDENTIFICATION; DIPHTHERIAE; ENVELOPE; GENES; ATCC-13032	The Corynebacterianeae such as Corynebacterium glutamicum and Mycobacterium tuberculosis possess several unique and structurally diverse lipids, including the genus-specific mycolic acids. Although the function of a number of genes involved in fatty acid and mycolic acid biosynthesis is known, information relevant to the initial steps within these biosynthetic pathways is relatively sparse. Interestingly, the genomes of Corynebacterianeae possess a high number of accD genes, whose gene products resemble the beta-subunit of the acetyl-CoA carboxylase of Escherichia coli, providing the activated intermediate for fatty acid synthesis. We present here our studies on four putative accD genes found in C. glutamicum. Although growth of the accD4 mutant remained unchanged, growth of the accD1 mutant was strongly impaired and partially recovered by the addition of exogenous oleic acid. Overexpression of accD1 and accBC, encoding the carboxylase alpha-subunit, resulted in an 8-fold increase in malonyl-CoA formation from acetyl-CoA in cell lysates, providing evidence that accD1 encodes a carboxyltransferase involved in the biosynthesis of malonyl-CoA. Interestingly, fatty acid profiles remained unchanged in both our accD2 and accD3 mutants, but a complete loss of mycolic acids, either as organic extractable trehalose and glucose mycolates or as cell wall-bound mycolates, was observed. These two carboxyltransferases are also retained in all Corynebacterianeae, including Mycobacterium leprae, constituting two distinct groups of orthologs. Furthermore, carboxyl fixation assays, as well as a study of a Cg-pks deletion mutant, led us to conclude that accD2 and accD3 are key to mycolic acid biosynthesis, thus providing a carboxylated intermediate during condensation of the mero-chain and alpha-branch directed by the pks-encoded polyketide synthase. This study illustrates that the high number of accD paralogs have evolved to represent specific variations on the well known basic theme of providing carboxylated intermediates in lipid biosynthesis.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Forschungszentrum Julich, Inst Biotechnol, D-52425 Julich, Germany; Kansai Univ, High Technol Res Ctr, Suita, Osaka 5648680, Japan	University of Birmingham; Helmholtz Association; Research Center Julich; Kansai University	Besra, GS (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	g.besra@bham.ac.uk	Dover, Lynn George/Q-6778-2019; Dover, Lynn G/F-3021-2010	Dover, Lynn George/0000-0002-4776-2665; Dover, Lynn G/0000-0002-4776-2665; Brown, Alistair/0000-0003-0479-8294; Besra, Gurdyal/0000-0002-5605-0395				AHIBOCOFFY A, 1978, CHEM PHYS LIPIDS, V22, P185, DOI 10.1016/0009-3084(78)90025-7; Baulard AR, 2003, J BIOL CHEM, V278, P2242, DOI 10.1074/jbc.M207922200; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Brand S, 2003, ARCH MICROBIOL, V180, P33, DOI 10.1007/s00203-003-0556-1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cerdeno-Tarraga AM, 2003, NUCLEIC ACIDS RES, V31, P6516, DOI 10.1093/nar/gkg874; Choi KH, 2000, J BIOL CHEM, V275, P28201; CHURCHES SS, 2002, BIOCHEM J, V365, P441; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; De Sousa-D'Auria C, 2003, FEMS MICROBIOL LETT, V224, P35, DOI 10.1016/S0378-1097(03)00396-3; Eggeling L., 2001, BASIC BIOTECHNOLOGY, P281; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Gibson KJC, 2003, J BIOL CHEM, V278, P40842, DOI 10.1074/jbc.M307988200; Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7; HAASE FC, 1982, J BIOL CHEM, V257, P1994; Hall PR, 2003, EMBO J, V22, P2334, DOI 10.1093/emboj/cdg244; Kacem R, 2004, MICROBIOL-SGM, V150, P73, DOI 10.1099/mic.0.26583-0; Kalinowski J, 2003, J BIOTECHNOL, V104, P5, DOI 10.1016/S0168-1656(03)00154-8; KEILHAUER C, 1993, J BACTERIOL, V175, P5595, DOI 10.1128/JB.175.17.5595-5603.1993; Kimura E, 1997, BIOCHEM BIOPH RES CO, V234, P157, DOI 10.1006/bbrc.1997.6613; Kremer L, 2002, EXPERT OPIN INV DRUG, V11, P1033; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; Kremer L, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P173; Lee RE, 1997, BBA-LIPID LIPID MET, V1346, P275, DOI 10.1016/S0005-2760(97)00051-9; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Nakamura Y, 2003, GENE, V317, P149, DOI 10.1016/S0378-1119(03)00653-X; Nishio Y, 2003, GENOME RES, V13, P1572, DOI 10.1101/gr.1285603; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; Puech V, 2000, MOL MICROBIOL, V35, P1026, DOI 10.1046/j.1365-2958.2000.01738.x; RAINWATER DL, 1982, J BACTERIOL, V151, P905, DOI 10.1128/JB.151.2.905-911.1982; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SHIMAKATA T, 1985, ARCH BIOCHEM BIOPHYS, V238, P497, DOI 10.1016/0003-9861(85)90193-6; SHIMAKATA T, 1984, ARCH BIOCHEM BIOPHYS, V229, P329, DOI 10.1016/0003-9861(84)90159-0; Stackebrandt E, 1997, INT J SYST BACTERIOL, V47, P479, DOI 10.1099/00207713-47-2-479; Trivedi OA, 2004, NATURE, V428, P441, DOI 10.1038/nature02384; WALKER RW, 1973, BIOCHIM BIOPHYS ACTA, V326, P52, DOI 10.1016/0005-2760(73)90027-1	41	134	138	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44847	44857		10.1074/jbc.M408648200	http://dx.doi.org/10.1074/jbc.M408648200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308633	Green Published, hybrid			2022-12-25	WOS:000224505600075
J	Kahlina, K; Goren, I; Pfeilschifter, J; Frank, S				Kahlina, K; Goren, I; Pfeilschifter, J; Frank, S			p68 DEAD box RNA helicase expression in keratinocytes - Regulation, nucleolar localization, and functional connection to proliferation and vascular endothelial growth factor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTANEOUS WOUND REPAIR; NITRIC-OXIDE; MESSENGER-RNA; CULTURED KERATINOCYTES; PROTEIN; TRANSLATION; DIFFERENTIATION; IDENTIFICATION; DISRUPTION; INDUCTION	Nitric oxide (NO) represents a short lived mediator that pivotally drives keratinocyte movements during cutaneous wound healing. In this study, we have identified p68 DEAD box RNA helicase (p68) from an NO-induced differential keratinocyte cDNA library. Subsequently, we have analyzed regulation of p68 by wound-associated mediators in human and murine keratinocytes. NO, serum, growth factors, and pro-inflammatory cytokines were potent inducers of p68 expression in the cells. p68 was constitutively expressed in the epithelial compartment of murine skin. Upon injury, we found a transient down-regulation of overall p68 protein in wound tissue. However, p68 did not completely disappear during early wound repair, as we found an expression of p68 protein in isolated wound margin tissue 24 h after wounding. Moreover, immunohistochemistry and cell fractionation analysis revealed a restricted localization of p68 in keratinocyte nuclei of the developing epithelium. Accordingly, cultured keratinocytes also showed a nuclear localization of the helicase. Moreover, confocal microscopy revealed a strong localization of p68 protein within the nucleoli of the cells. Functional analyses demonstrated that p68 strongly participated in keratinocyte proliferation and gene expression. Keratinocytes that constitutively overexpressed p68 protein were characterized by a marked increase in serum-induced proliferation and vascular endothelial growth factor expression, whereas down-regulation of endogenous p68 using small interfering RNA markedly attenuated serum-induced proliferation and vascular endothelial growth factor expression. Altogether, our results suggest a tightly controlled expression and nucleolar localization of p68 in keratinocytes in vitro and during skin repair in vivo that functionally contributes to keratinocyte proliferation and gene expression.	Univ Frankfurt Klinikum, Inst Allgemeine Pharmakol & Toxikol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Frank, S (corresponding author), Univ Frankfurt Klinikum, Inst Allgemeine Pharmakol & Toxikol, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	S.Frank@em.uni-frankfurt.de						Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; BARTA I, 1995, EMBO J, V14, P3800, DOI 10.1002/j.1460-2075.1995.tb00049.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Bruch-Gerharz D, 1998, ARCH DERMATOL RES, V290, P643, DOI 10.1007/s004030050367; BUGLER B, 1982, EUR J BIOCHEM, V128, P475; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Frank S, 2000, BIOCHEM J, V347, P265, DOI 10.1042/0264-6021:3470265; Frank S, 1999, FASEB J, V13, P2002, DOI 10.1096/fasebj.13.14.2002; Frank S, 2000, BIOCHEM J, V346, P719, DOI 10.1042/0264-6021:3460719; Frank S, 2002, KIDNEY INT, V61, P882, DOI 10.1046/j.1523-1755.2002.00237.x; Frank S, 1998, J INVEST DERMATOL, V111, P1058, DOI 10.1046/j.1523-1747.1998.00434.x; Frank S, 1998, J INVEST DERMATOL, V111, P1065, DOI 10.1046/j.1523-1747.1998.00433.x; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Kampfer H, 1999, J INVEST DERMATOL, V113, P369, DOI 10.1046/j.1523-1747.1999.00704.x; Krischel V, 1998, J INVEST DERMATOL, V111, P286, DOI 10.1046/j.1523-1747.1998.00268.x; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Lamm GM, 1996, NUCLEIC ACIDS RES, V24, P3739, DOI 10.1093/nar/24.19.3739; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LEMAIRE L, 1993, LIFE SCI, V52, P917, DOI 10.1016/0024-3205(93)90526-9; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Linder P, 2001, TRENDS BIOCHEM SCI, V26, P339, DOI 10.1016/S0968-0004(01)01870-9; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cb.11.110195.000521; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stallmeyer B, 1999, J INVEST DERMATOL, V113, P1090, DOI 10.1046/j.1523-1747.1999.00784.x; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Svitkin YV, 2001, RNA, V7, P1743; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; Weller R, 1999, CLIN EXP DERMATOL, V24, P388; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wetzler C, 2000, BIOCHEM BIOPH RES CO, V274, P689, DOI 10.1006/bbrc.2000.3170; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067	47	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44872	44882		10.1074/jbc.M402467200	http://dx.doi.org/10.1074/jbc.M402467200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304501	hybrid			2022-12-25	WOS:000224505600077
J	Schmidt, A; Su, YH; Kunze, R; Warner, S; Hewitt, M; Slocum, RD; Ludewig, U; Frommer, WB; Desimone, M				Schmidt, A; Su, YH; Kunze, R; Warner, S; Hewitt, M; Slocum, RD; Ludewig, U; Frommer, WB; Desimone, M			UPS1 and UPS2 from Arabidopsis mediate high affinity transport of uracil and 5-fluorouracil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRANSPORTERS; SACCHAROMYCES-CEREVISIAE; PURINE; FAMILY; EXPRESSION; ALLANTOIN; GENE; TRANSFORMATION; SPECIFICITY; DERIVATIVES	Salvage pathways play an important role in providing nucleobases to cells, which are unable to synthesize sufficient amounts for their needs. Cellular uptake systems for pyrimidines have been described, but in higher eukaryotes, transporters for thymine and uracil have not been identified. Two plant transporters, AtUPS1 and PvUPS1, were recently identified as transporters for allantoin in Arabidopsis and French bean, respectively. However, Arabidopsis, in contrast to tropical legumes, uses mainly amino acids for long distance transport. Allantoin transport has not been described in the Brassicaceae. Thus, the physiological substrates of ureide permease (UPS) transporters in Arabidopsis may be compounds structurally related to allantoin. A detailed analysis of the substrate specificities of two members of the AtUPS family shows that AtUPS1 and AtUPS2 mediate high affinity uracil and 5-fluorouracil (a toxic uracil analogue) transport when expressed in yeast and Xenopus oocytes. Consistent with a function during germination and early seedling development, AtUPS1 expression is transiently induced during the early stages of seedling development followed by up-regulation of AtUPS2 expression. Arabidopsis ups2 insertion mutants and ups1 lines, in which transcript levels were reduced by post-transcriptional gene silencing, are more tolerant to 5-fluorouracil as compared with wild type plants. The results suggest that in Arabidopsis UPS transporters are the main transporters for uracil and potentially other nucleobases, whereas during evolution legumes may have taken advantage of the low selectivity of UPS proteins for long distance transport of allantoin.	ZMBP, Plant Physiol, D-72076 Tubingen, Germany; Univ Cologne, Bot Inst 2, D-50931 Cologne, Germany; Goucher Coll, Dept Biol Sci, Baltimore, MD 21204 USA; Carnegie Inst Sci, Stanford, CA 94305 USA	University of Cologne; Carnegie Institution for Science	Desimone, M (corresponding author), ZMBP, Plant Physiol, Morgenstelle 1, D-72076 Tubingen, Germany.	marcelo.desimone@zmbp.uni-tuebingen.de	Schmidt, Anja/AAS-5288-2021; Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Schmidt, Anja/0000-0002-3276-3243; Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Kunze, Reinhard/0000-0002-3304-5550				Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Amillis S, 2001, J MOL BIOL, V313, P765, DOI 10.1006/jmbi.2001.5087; ANDERSEN PS, 1995, J BACTERIOL, V177, P2008, DOI 10.1128/jb.177.8.2008-2013.1995; Argyrou E, 2001, PLANT CELL, V13, P953, DOI 10.1105/tpc.13.4.953; Bassett EV, 2003, PLANT PHYSIOL BIOCH, V41, P695, DOI 10.1016/S0981-9428(03)00094-9; Boyes DC, 2001, PLANT CELL, V13, P1499, DOI 10.1105/tpc.13.7.1499; Burkle L, 2003, PLANT J, V34, P13, DOI 10.1046/j.1365-313X.2003.01700.x; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; Chang S. J., 1993, Plant Molecular Biology Reporter, V11, P113, DOI 10.1007/BF02670468; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; De Montigny J, 1998, YEAST, V14, P1051, DOI 10.1002/(SICI)1097-0061(199808)14:11<1051::AID-YEA287>3.0.CO;2-1; Desimone M, 2002, PLANT CELL, V14, P847, DOI 10.1105/tpc.010458; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; Gillissen B, 2000, PLANT CELL, V12, P291, DOI 10.1105/tpc.12.2.291; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KOMBRINK E, 1983, PLANT PHYSIOL, V73, P370, DOI 10.1104/pp.73.2.370; Li GY, 2003, J BIOL CHEM, V278, P35732, DOI 10.1074/jbc.M304768200; Ludewig U, 2002, J BIOL CHEM, V277, P13548, DOI 10.1074/jbc.M200739200; Luo MZ, 1997, PLANT MOL BIOL, V33, P709, DOI 10.1023/A:1005798207693; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; Meintanis C, 2000, MOL MEMBR BIOL, V17, P47; Moffatt Barbara A, 2002, Arabidopsis Book, V1, pe0018, DOI 10.1199/tab.0018; Mohlmann T, 2001, FEBS LETT, V509, P370, DOI 10.1016/S0014-5793(01)03195-7; Pelissier HC, 2004, PLANT PHYSIOL, V134, P664, DOI 10.1104/pp.103.033365; Pinsoni B, 1999, BIOCHEM J, V339, P37, DOI 10.1042/0264-6021:3390037; RENTSCH D, 1995, FEBS LETT, V370, P264, DOI 10.1016/0014-5793(95)00853-2; STASOLLA C, 2003, J PLANT PHYSL, V160, P1; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; van der Graaff E, 2004, FRONT BIOSCI-LANDMRK, V9, P1803, DOI 10.2741/1344; WAGNER KG, 1992, INT REV CYTOL, V134, P1, DOI 10.1016/S0074-7696(08)62027-6; WORMIT A, 2004, IN PRESS BIOCH J; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593; YOO HS, 1992, YEAST, V8, P997, DOI 10.1002/yea.320081202	38	49	55	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44817	44824		10.1074/jbc.M405433200	http://dx.doi.org/10.1074/jbc.M405433200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308648	hybrid			2022-12-25	WOS:000224505600071
J	Krautwald, S; Ziegler, E; Tiede, K; Pust, R; Kunzendorf, U				Krautwald, S; Ziegler, E; Tiede, K; Pust, R; Kunzendorf, U			Transduction of the TAT-FLIP fusion protein results in transient resistance to Fas-induced apoptosis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC BRAIN INJURY; MEDIATED APOPTOSIS; CELL-DEATH; MAMMALIAN-CELLS; BCL-2 FAMILY; DELIVERY; ACTIVATION; CASPASE-8; INHIBITION; HYPERRESPONSIVENESS	Although tightly regulated programmed cell death (apoptosis) possesses great importance for tissue homeostasis, several pathologic processes are associated with organ failure due to adversely activated cell apoptosis. Transient increase in apoptosis has been shown to cause organ damage during fulminant hepatitis B, autoimmune diseases, ischemia-reperfusion injury, sepsis, or allograft rejection. A defined and temporary inhibition of cell apoptosis may therefore be of high clinical relevance. Activation of death receptors results in caspase-8 recruitment to the death-inducing signaling complex, which initiates the apoptotic process through cleavage of caspase-8 and downstream substrates. This initial step may be inhibited by the caspase-8 inhibitor FLIP (FLICE inhibitory protein). To specifically inhibit the initiation of death receptor-mediated apoptosis we constructed a fusion protein containing FLIP fused N-terminally to the human immunodeficiency virus TAT domain. This TAT domain allows the fusion protein to cross the cell membrane and thus makes the FLIP domain able to interfere with the death-inducing signaling complex inside of the cell. We observed that incubation of lymphocytic Jurkat or BJAB cells with TAT-FLIPS proteins significantly inhibits Fas-induced activation of procaspase-8 and downstream caspases, preventing cells from undergoing apoptosis. Systemic application of TAT-FLIPS prolongs survival and reduces multi-organ failure due to Fas-receptor-mediated lethal apoptosis in mice. Therefore, application of cellular FLIPS in the form of a TAT fusion protein may open a promising, easily applicable new tool for providing protection against transient, pathologically increased apoptosis in various diseases.	Univ Schleswig Holstein, Dept Hypertens & Nephrol, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Kunzendorf, U (corresponding author), Univ Schleswig Holstein, Dept Hypertens & Nephrol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	kunzendorf@nephro.uni-kiel.de	Kunzendorf, Ulrich/A-8257-2010; Krautwald, Stefan/J-9984-2016	Krautwald, Stefan/0000-0001-7768-2132				Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299; Barka T, 2000, J HISTOCHEM CYTOCHEM, V48, P1453, DOI 10.1177/002215540004801102; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Cao GD, 2002, J NEUROSCI, V22, P5423; Chung CS, 2001, SURGERY, V130, P339, DOI 10.1067/msy.2001.116540; Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Garvey TL, 2002, J VIROL, V76, P697, DOI 10.1128/JVI.76.2.697-706.2002; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeremias I, 2000, CIRCULATION, V102, P915; Kilic U, 2003, STROKE, V34, P1304, DOI 10.1161/01.STR.0000066869.45310.50; Krautwald S, 1998, J IMMUNOL, V160, P5874; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Lorenz HM, 2001, SCAND J CLIN LAB INV, V61, P16, DOI 10.1080/003655101753352004; McGregor A, 2003, HUM EXP TOXICOL, V22, P221, DOI 10.1191/0960327103ht325oa; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Myou S, 2003, J IMMUNOL, V171, P4379, DOI 10.4049/jimmunol.171.8.4379; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nogae S, 1998, J AM SOC NEPHROL, V9, P620; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Ryo K, 2000, AM J GASTROENTEROL, V95, P2047; Schattner EJ, 2002, AUTOIMMUNITY, V35, P283, DOI 10.1080/0891693021000002072; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Snyder EL, 2001, CURR OPIN MOL THER, V3, P147; Tagami A, 2003, HEPATO-GASTROENTEROL, V50, P443; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508; Vocero-Akbani A, 2001, METHOD ENZYMOL, V332, P36; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Yang J, 2003, J BIOL CHEM, V278, P15185, DOI 10.1074/jbc.M211707200; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	44	20	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44005	44011		10.1074/jbc.M401327200	http://dx.doi.org/10.1074/jbc.M401327200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304499	hybrid			2022-12-25	WOS:000224383100079
J	Kalaitzidis, D; Ok, J; Sulak, L; Starczynowski, DT; Gilmore, TD				Kalaitzidis, D; Ok, J; Sulak, L; Starczynowski, DT; Gilmore, TD			Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; estrogen receptor; ER fusion; malignant transformation	NF-KAPPA-B; INTERLEUKIN-6 GENE-EXPRESSION; TRANSCRIPTION FACTOR; DNA-BINDING; V-REL; HODGKINS-DISEASE; LINE RC-K8; TRANSACTIVATION; ACTIVATION; DOMAINS	Overexpression of the human REL transcription factor can malignantly transform chicken spleen cells in vitro. In this report, we have created and characterized a cDNA encoding a chimeric protein (RELDelta424 - 490- ER) in which sequences of a highly transforming REL mutant ( RELD424 - 490) are fused to the ligand-binding domain of the human estrogen receptor ( ER). Surprisingly, RELDelta424 - 490- ER is constitutively nuclear in A293 cells, and RELDelta424 - 490- ER activates transcription in the absence, but not in the presence, of estrogen in kappaB-site reporter gene assays. Furthermore, RELDelta424 - 490- ER transforms chicken spleen cells in the absence of estrogen, but the addition of estrogen blocks the ability of RELDelta424 - 490- ER-transformed cells to form colonies in soft agar, even though estrogen induces increased nuclear translocation of RELDelta424 - 490- ER in these cells. ERalpha can also inhibit REL-dependent transactivation in trans in an estrogen-dependent manner, and ERalpha can interact with REL in vitro. Thus, the RELDelta424 - 490- ER fusion protein shows an unusual, reverse hormone regulation, in that its most prominent biological activities ( transformation and transactivation) are inhibited by estrogen, probably due to an estrogen-induced interaction between the ER sequences and sequences in the Rel homology domain. Nevertheless, these results indicate that the continual activity of REL is required to sustain the transformed state of chicken spleen cells in culture, suggesting that direct and specific inhibitors of REL may have therapeutic efficacy in certain human lymphoid cancers.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HORIGOME T, 1988, ENDOCRINOLOGY, V123, P2540, DOI 10.1210/endo-123-5-2540; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Maia DM, 2000, LEUKEMIA LYMPHOMA, V39, P365, DOI 10.3109/10428190009065836; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; RAY A, 1994, J BIOL CHEM, V269, P12940; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sharma RV, 2001, J APPL PHYSIOL, V91, P2400, DOI 10.1152/jappl.2001.91.5.2400; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARK JJ, 1981, ANN INTERN MED, V95, P186, DOI 10.7326/0003-4819-95-2-186; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tzagarakis-Foster C, 2002, J BIOL CHEM, V277, P44772, DOI 10.1074/jbc.M205355200; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200; VANGOOL A, 2002, KEYSTONE S NF KB BEN; Walker AK, 1996, ONCOGENE, V12, P2515; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	30	8	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7580	7587		10.1038/sj.onc.1207912	http://dx.doi.org/10.1038/sj.onc.1207912			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326488				2022-12-25	WOS:000224176500015
J	Feng, H; Xiang, H; Mao, YW; Wang, J; Liu, JP; Huang, XQ; Liu, Y; Liu, SJ; Luo, C; Zhang, XJ; Liu, Y; Li, DWC				Feng, H; Xiang, H; Mao, YW; Wang, J; Liu, JP; Huang, XQ; Liu, Y; Liu, SJ; Luo, C; Zhang, XJ; Liu, Y; Li, DWC			Human Bcl-2 activates ERK signaling pathway to regulate activating protein-1, lens epithelium-derived growth factor and downstream genes	ONCOGENE			English	Article						Bcl-2; ERK1/2; c-jun; c-fos; AP-1; LEDGF; lens	NF-KAPPA-B; PROGRAMMED CELL-DEATH; STRESS-RELATED GENES; C-JUN; DEPENDENT PATHWAY; OXIDATIVE STRESS; DOWN-REGULATION; MESSENGER-RNA; MAP KINASE; EXPRESSION	The proto-oncogene, bcl-2, has various functions besides its role in protecting cells from apoptosis. One of the functions is to regulate expression of other genes. Previous studies have demonstrated that Bcl-2 regulates activities of several important transcription factors including NF-kappaB and p53, and also their downstream genes. In our recent studies, we reported that Bcl-2 substantially downregulates expression of the endogenous alphaB-crystallin gene through modulating the transcriptional activity of lens epithelium-derived growth factor ( LEDGF). In the present communication, we report that human Bcl-2 can positively regulate expression of the proto-oncogenes c-jun and c-fos. Moreover, it enhances the DNA binding activity and transactivity of the activating protein-1 (AP-1). Furthermore, we present evidence to show that Bcl-2 can also activate both ERK1 and ERK2 MAP kinases. Inhibition of the activities of these kinases or the upstream activating kinases by pharmacological inhibitors or dominant-negative mutants abolishes the Bcl-2-mediated regulation of AP-1, LEDGF and their downstream genes. Together, our results demonstrate that through activation of the ERK kinase signaling pathway, Bcl-2 regulates the transcriptional activities of multiple transcription factors, and hence modulates the expression of their downstream genes. Thus, our results provide a mechanism to explain how Bcl-2 may regulate expression of other genes.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Hunan Normal Univ, Coll Life Sci, Changsha, Hunan, Peoples R China; Univ Med & Dent New Jersey, Dept Mol Biol, Stratford, NJ USA	University of Minnesota System; Hunan Normal University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Li, DWC (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	dwli1688@hotmail.com	Li, David/AAN-9205-2021	xiang, hua/0000-0003-0369-1225; Mao, Yingwei/0000-0001-7339-1565	PHS HHS [NEI 11372] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011372] Funding Source: NIH RePORTER	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Casalino L, 2003, MOL CELL BIOL, V23, P4401, DOI 10.1128/MCB.23.12.4401-4415.2003; Chen DB, 2003, MOL CELL ENDOCRINOL, V200, P141, DOI 10.1016/S0303-7207(02)00379-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Feng LX, 1999, J CELL BIOCHEM, V74, P576, DOI 10.1002/(SICI)1097-4644(19990915)74:4<576::AID-JCB7>3.0.CO;2-N; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GRUDA MC, 1994, ONCOGENE, V9, P2537; Hilton M, 1997, CURR BIOL, V7, P798, DOI 10.1016/S0960-9822(06)00339-3; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KORSMEYER SJ, 1992, BLOOD, V80, P879; Kubo E, 2002, J MOL BIOL, V320, P1053, DOI 10.1016/S0022-2836(02)00551-X; Kukushkin AN, 2002, ONCOGENE, V21, P719, DOI 10.1038/sj.onc.1205118; Kumar NV, 2001, J BIOL CHEM, V276, P32362, DOI 10.1074/jbc.M103677200; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li DWC, 1998, EUR J BIOCHEM, V257, P351, DOI 10.1046/j.1432-1327.1998.2570351.x; Li DWC, 2003, INVEST OPHTH VIS SCI, V44, P5277, DOI 10.1167/iovs.03-0348; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Li DWC, 2001, INVEST OPHTH VIS SCI, V42, P2603; Li DWC, 2001, EXP CELL RES, V266, P279, DOI 10.1006/excr.2001.5223; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; LI WC, 1994, EXP EYE RES, V59, P179, DOI 10.1006/exer.1994.1096; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; McDermott JB, 1997, INVEST OPHTH VIS SCI, V38, P951; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; NIESON DA, 1983, P NATL ACAD SCI USA, V80, P5198; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rosenberger SF, 1999, J BIOL CHEM, V274, P1124, DOI 10.1074/jbc.274.2.1124; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Schwarz CS, 2002, NEUROREPORT, V13, P2439, DOI 10.1097/00001756-200212200-00013; Shinohara T, 2002, PROG RETIN EYE RES, V21, P341, DOI 10.1016/S1350-9462(02)00007-1; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310	64	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7310	7321		10.1038/sj.onc.1208041	http://dx.doi.org/10.1038/sj.onc.1208041			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326476				2022-12-25	WOS:000224021400002
J	Nakagawa, H; Liyanarachchi, S; Davuluri, RV; Auer, H; Martin, EW; de la Chapelle, A; Frankel, WL				Nakagawa, H; Liyanarachchi, S; Davuluri, RV; Auer, H; Martin, EW; de la Chapelle, A; Frankel, WL			Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles	ONCOGENE			English	Article						colon cancer; cancer-associated stroma; cancer microenvironment; COX2	GROWTH-FACTOR; TUMOR-GROWTH; CELLS; TUMORIGENICITY; ACCELERATION; SUPPRESSION; INHIBITION; PROSTATE; MICE	The cancer microenvironment and interaction between cancer and stromal cells play critical roles in tumor development and progression. The molecular features of cancer stroma are less well understood than those of cancer cells. Cancer-associated stromal fibroblasts are the predominant component of stroma associated with colon cancer and its functions remain unclear. Fibroblast cell cultures were established from metastatic colon cancer in liver, liver away from the metastatic lesions, and skin from three patients with metastatic colorectal cancer. We generated expression profiles of cancer-associated fibroblasts using oligochip arrays and compared them to those of uninvolved fibroblasts. The conditioned media from the cancer-associated fibroblast cultures enhanced proliferation of colon cancer cell line HCT116 to a greater extent than cultures from uninvolved fibroblasts. In microarray expression analysis, cancer-associated fibroblasts clustered tightly into one group and skin fibroblasts into another. Approximately 170 of 22 000 genes were upregulated in cancer-associated fibroblasts ( fold change >2, P<0.05) as compared to skin fibroblasts, including many genes encoding cell adhesion molecules, growth factors, and COX2. By immunohistochemistry in-vivo, we confirmed COX2 and TGFB2 expression in cancer-associated fibroblasts in metastatic colon cancer. The distinct molecular expression profiles of cancer-associated fibroblasts in colon cancer metastasis support the notion that these fibroblasts form a favorable microenvironment for cancer cells.	Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Surg Oncol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Frankel, WL (corresponding author), Ohio State Univ, Dept Pathol, 410 W 10th Ave,401 E Doan Hall, Columbus, OH 43210 USA.	frankel-1@medctr.osu.edu	Davuluri, Ramana/D-7348-2011; Thomson, Axel/A-7893-2013; Martin Jr, Edward/E-3604-2011	Frankel, Wendy/0000-0003-1658-1009	NCI NIH HHS [CA16058, CA67941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058, U01CA067941, R01CA067941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1993, J CLIN INVEST, V92, P2569, DOI 10.1172/JCI116871; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bartholin L, 2002, ONCOGENE, V21, P2227, DOI 10.1038/sj.onc.1205294; BRATTAIN MG, 1982, J NATL CANCER I, V69, P767; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Conze D, 2001, CANCER RES, V61, P8851; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DIGNASS AU, 1994, GASTROENTEROLOGY, V106, P1254, DOI 10.1016/0016-5085(94)90017-5; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; Gho YS, 2001, CANCER RES, V61, P4253; GLEAVE M, 1991, CANCER RES, V51, P3753; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hill DP, 2002, GENOME RES, V12, P1982, DOI 10.1101/gr.580102; Holen I, 2002, CANCER RES, V62, P1619; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Matrisian LM, 2001, CANCER RES, V61, P3844; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Paget S, 1889, LANCET, V133, P571, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; PICARD O, 1986, CANCER RES, V46, P3290; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; Studeny M, 2002, CANCER RES, V62, P3603; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Virtaneva K, 2001, P NATL ACAD SCI USA, V98, P1124, DOI 10.1073/pnas.98.3.1124; WESTERMARK B, 1991, CANCER RES, V51, P5087; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	37	182	191	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7366	7377		10.1038/sj.onc.1208013	http://dx.doi.org/10.1038/sj.onc.1208013			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326482				2022-12-25	WOS:000224021400007
J	Zhang, AJ; Wang, JL; Zheng, BY; Fang, XL; Angstrom, T; Liu, C; Li, XD; Erlandsson, F; Bjorkholm, M; Nordenskjord, M; Gruber, A; Wallin, KL; Xu, DW				Zhang, AJ; Wang, JL; Zheng, BY; Fang, XL; Angstrom, T; Liu, C; Li, XD; Erlandsson, F; Bjorkholm, M; Nordenskjord, M; Gruber, A; Wallin, KL; Xu, DW			Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix	ONCOGENE			English	Article						cervical cancer; HPV; genomic instability; telomere erosion; telomerase	SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-PAPILLOMAVIRUS TYPE-16; COMPARATIVE GENOMIC HYBRIDIZATION; REVERSE-TRANSCRIPTASE GENE; HTERT GENE; CHROMOSOME INSTABILITY; HUMAN CANCER; AMPLIFICATION; DYSFUNCTION; ACTIVATION	Although human papillomavirus (HPV) has been defined as the pathogen for cervical carcinomas, molecular events underlying the oncogenic process are unclear. As telomere dysfunction-mediated chromosomal instability and telomerase activation have been suggested as key events in carcinogenesis, we dissected the dynamic changes in telomere length, checkpoint response, and temporal pro. le of telomerase expression during the evolution from precursor lesions ( cervical intraepithelial neoplasia, CINs) to invasive cancers of the uterine cervix in sequential samples from 16 patients. Telomeres were significantly shortened in all CIN samples and no further substantial attritions occurred in most cases with the acquisition of malignant phenotype. Very short telomeres were coupled with constitutive activation of the DNA damage response pathway (Chk2 phosphorylation) and increased cellular proliferation in those cervical specimens. Telomerase reverse transcriptase ( hTERT) expression was preferably induced at advanced CINs or invasive cancers. The present finding demonstrates that excessive telomere shortening predominantly occurs in the early carcinogenesis of the uterine cervix largely prior to telomerase activation. Widespread over-erosion of telomeres or telomere dysfunction in very early stages of cervical tumorigenesis might fuel transformation processes by driving chromosomal instability.	Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, CMM, SE-17176 Stockholm, Sweden; Univ Umea Hosp, Cytol Lab, SE-90187 Umea, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Med, Div Hematol, SE-17176 Stockholm, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Peking Univ, Peoples Hosp, Dept Gynecol, Beijing 100083, Peoples R China; Shandong Univ, Qilu Hosp, Dept Urol, Jinan 250108, Peoples R China; Karolinska Univ Hosp, Karolinska Inst, Dept Urol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Umea University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Peking University; Shandong University; Karolinska Institutet; Karolinska University Hospital	Wallin, KL (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med, CMM, SE-17176 Stockholm, Sweden.	Keng-Ling.Wallin@cmm.ki.se; Dawei.Xu@cmm.ki.se		Xu, Dawei/0000-0003-3141-4524; Wang, Jianliu/0000-0003-0338-0427				Anderson S, 1997, AM J PATHOL, V151, P25; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Aubele M, 1998, CANCER CYTOPATHOL, V84, P375, DOI 10.1002/(SICI)1097-0142(19981225)84:6<375::AID-CNCR10>3.0.CO;2-1; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Chang S, 2001, SEMIN CANCER BIOL, V11, P227, DOI 10.1006/scbi.2000.0374; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Evans MF, 1998, ONCOGENE, V16, P2557, DOI 10.1038/sj.onc.1202039; FAGAGNA FF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; Giannoudis A, 2000, BRIT J CANCER, V82, P424, DOI 10.1054/bjoc.1999.0937; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hahn WC, 2003, J CLIN ONCOL, V21, P2034, DOI 10.1200/JCO.2003.06.018; Heselmeyer-Haddad K, 2003, AM J PATHOL, V163, P1405, DOI 10.1016/S0002-9440(10)63498-0; Jarboe EA, 2002, ONCOGENE, V21, P664, DOI 10.1038/sj.onc.1205073; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kyo S, 1997, CANCER RES, V57, P1863; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Meeker AK, 2002, CANCER RES, V62, P6405; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Oh H, 2003, P NATL ACAD SCI USA, V100, P5378, DOI 10.1073/pnas.0836098100; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pihan GA, 2003, CANCER RES, V63, P1398; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Shay JW, 2001, HUM MOL GENET, V10, P677, DOI 10.1093/hmg/10.7.677; Snijders PJF, 1998, CANCER RES, V58, P3812; Southern SA, 1997, CANCER RES, V57, P4210; Takakura M, 1998, CANCER RES, V58, P1558; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Veldman T, 2001, J VIROL, V75, P4467, DOI 10.1128/JVI.75.9.4467-4472.2001; Vukovic B, 2003, ONCOGENE, V22, P1978, DOI 10.1038/sj.onc.1206227; Zhang AJ, 2002, GENE CHROMOSOME CANC, V34, P269, DOI 10.1002/gcc.10071; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	40	45	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7441	7447		10.1038/sj.onc.1207527	http://dx.doi.org/10.1038/sj.onc.1207527			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15318175				2022-12-25	WOS:000224021400015
J	Gragasin, FS; Michelakis, ED; Hogan, A; Moudgil, R; Hashimoto, K; Wu, XC; Bonnet, S; Haromy, A; Archer, SL				Gragasin, FS; Michelakis, ED; Hogan, A; Moudgil, R; Hashimoto, K; Wu, XC; Bonnet, S; Haromy, A; Archer, SL			The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels	FASEB JOURNAL			English	Article						laser capture microdissection; protein kinase G; electrical field stimulation; sildenafil; phosphodiesterase 5; nitric oxide electrode	FEMALE SEXUAL DYSFUNCTION; CAVERNOSUM SMOOTH-MUSCLE; DEPENDENT PROTEIN-KINASE; GENE-TRANSFER; CORPUS CAVERNOSUM; BLOOD-FLOW; TYPE-5 PHOSPHODIESTERASE; PULMONARY-HYPERTENSION; CORPORA CAVERNOSA; DUCTUS-ARTERIOSUS	Female sexual function is under-studied, and mechanisms of clitoral engorgement-relaxation are incompletely understood. Penile erection results from nitric oxide (NO)-induced cyclic guanosine monophosphate (cGMP) accumulation. cGMP-dependent protein kinase (PKG) activates large-conductance, calcium- activated potassium channels (BKCa), thereby hyperpolarizing and relaxing vascular and trabecular smooth muscle cells, allowing engorgement. We hypothesize rat clitorises relax by a similar mechanism. Rat clitorises express components of the proposed pathway: neuronal and endothelial NO synthases, soluble guanylyl cyclase (sGC), type 5 phosphodiesterase (PDE-5), and BKCa channels. The NO donor diethylamine NONOate ( DEANO), the PKG activator 8-pCPT-cGMP, and the PDE-5 inhibitor sildenafil, cause dose-dependent clitoral relaxation that is inhibited by antagonists of PKG (Rp-8-Br-cGMPS) or BKCa channels (iberiotoxin). Electrical field stimulation induces tetrodotoxin- sensitive NO release and relaxation that is inhibited by the Na+ channel blocker tetrodotoxin or sGC inhibitor H-1-(1,2,4) oxadiozolo(4,3-a) quinoxalin-1-one. Human BKCa channels, transferred to Chinese hamster ovary cells via an adenoviral vector, and endogenous rat clitoral smooth muscle K+ current are activated by this PKG-dependent mechanism. Laser confocal microscopy reveals protein expression of BKCa channels on clitoral smooth muscle cells; these cells exhibit BKCa channel activity that is activated by both DEANO and sildenafil. We conclude that neurovascular derived NO causes clitoral relaxation via a PKG-dependent activation of BKCa channels. The BKCa channel is an appealing target for drug therapy of female erectile dysfunction.	Univ Alberta, Div Cardiol, Dept Med, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Vasc Biol Grp, Edmonton, AB T6G 2B7, Canada	University of Alberta; University of Alberta	Archer, SL (corresponding author), Univ Alberta, Div Cardiol, Dept Med, WMC 2C-36,8440 112th St, Edmonton, AB T6G 2B7, Canada.	sarcher@cha.ab.ca	Archer, Stephen L/C-3621-2013		NHLBI NIH HHS [R01-HL071115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angulo J, 2003, INT J IMPOT RES, V15, P137, DOI 10.1038/sj.ijir.3900985; Archer SL, 2003, CIRCULATION, V107, P769, DOI 10.1161/01.CIR.0000047278.28407.C2; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; Avis N E, 2000, J Gend Specif Med, V3, P37; Bechara AJ, 2003, INT J IMPOT RES, V15, P166, DOI 10.1038/sj.ijir.3900982; Berman JR, 2001, J SEX MARITAL THER, V27, P411, DOI 10.1080/713846815; Berman JR, 1999, INT J IMPOT RES, V11, pS31, DOI 10.1038/sj.ijir.3900468; Bivalacqua TJ, 2000, INT J IMPOT RES, V12, pS8, DOI 10.1038/sj.ijir.3900556; Bivalacqua TJ, 2003, J UROLOGY, V169, P1911, DOI 10.1097/01.ju.0000051881.14239.4a; Bivalacqua TJ, 2003, AM J PHYSIOL-HEART C, V284, pH1408, DOI 10.1152/ajpheart.00770.2002; Burchardt T, 2000, J UROLOGY, V164, P1807, DOI 10.1016/S0022-5347(05)67111-X; Burnett AL, 1997, J UROLOGY, V158, P75, DOI 10.1097/00005392-199707000-00020; CANDIA S, 1992, BIOPHYS J, V63, P583, DOI 10.1016/S0006-3495(92)81630-2; Cellek S, 1998, BRIT J PHARMACOL, V125, P1627, DOI 10.1038/sj.bjp.0702278; Champion HC, 1999, P NATL ACAD SCI USA, V96, P11648, DOI 10.1073/pnas.96.20.11648; Christ GJ, 1998, AM J PHYSIOL-HEART C, V275, pH600, DOI 10.1152/ajpheart.1998.275.2.H600; D'amati G, 2002, UROLOGY, V60, P191, DOI 10.1016/S0090-4295(02)01663-1; GILLAN P, 1979, PSYCHOPHYSIOLOGY, V16, P471, DOI 10.1111/j.1469-8986.1979.tb01507.x; Gragasin FS, 2003, ARTERIOSCL THROM VAS, V23, P38, DOI 10.1161/01.ATV.0000047868.93732.B7; Haas CA, 1998, UROLOGY, V51, P516, DOI 10.1016/S0090-4295(97)00715-2; Hampl V, 1996, CARDIOVASC RES, V31, P55, DOI 10.1016/0008-6363(95)00172-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hedlund P, 2000, P NATL ACAD SCI USA, V97, P2349, DOI 10.1073/pnas.030419997; Holdiman AJ, 2002, MOL CELL ENDOCRINOL, V192, P1, DOI 10.1016/S0303-7207(02)00136-3; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; Kim Young Chan, 1994, Yonsei Medical Journal, V35, P308; LEVIN RJ, 1980, CLIN OBSTET GYNAECOL, V7, P213; Lin JSN, 2001, UROLOGY, V57, P837, DOI 10.1016/S0090-4295(00)01097-9; MacRitchie AN, 1997, CIRC RES, V81, P355, DOI 10.1161/01.RES.81.3.355; Michelakis ED, 2002, CIRC RES, V90, P1307, DOI 10.1161/01.RES.0000024689.07590.C2; Michelakis ED, 2002, CIRC RES, V91, P478, DOI 10.1161/01.RES.0000035057.63303.D1; MORLEY D, 1993, J CARDIOVASC PHARM, V22, pS3, DOI 10.1097/00005344-199306227-00003; Munarriz R, 2003, J UROLOGY, V170, pS40, DOI 10.1097/01.ju.0000075352.03144.15; NAKAZAWA M, 1994, EUR J PHARMACOL, V253, P179; Node K, 1997, FASEB J, V11, P793, DOI 10.1096/fasebj.11.10.9271364; Park JK, 2002, EXP BIOL MED, V227, P1022, DOI 10.1177/153537020222701111; Park K, 2000, INT J IMPOT RES, V12, P111, DOI 10.1038/sj.ijir.3900514; Park K, 1997, INT J IMPOT RES, V9, P27, DOI 10.1038/sj.ijir.3900258; Park K, 2002, J UROLOGY, V168, P1269, DOI 10.1016/S0022-5347(05)64638-1; Park K, 1998, BIOCHEM BIOPH RES CO, V249, P612, DOI 10.1006/bbrc.1998.9206; Park K, 2001, INT J IMPOT RES, V13, P116, DOI 10.1038/sj.ijir.3900655; Pozeg ZI, 2003, CIRCULATION, V107, P2037, DOI 10.1161/01.CIR.0000062688.76508.B3; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; Rosenfeld CR, 2002, VASC PHARMACOL, V38, P115, DOI 10.1016/S0306-3623(02)00135-0; Seftel AD, 1997, UROLOGY, V50, P1016, DOI 10.1016/S0090-4295(97)00512-8; Shen WW, 1999, J REPROD MED, V44, P535; Sipski ML, 2000, UROLOGY, V55, P812, DOI 10.1016/S0090-4295(00)00493-3; Thebaud B, 2002, PEDIATR RES, V52, P19, DOI 10.1203/00006450-200207000-00006; Tristani-Firouzi M, 1998, J LAB CLIN MED, V131, P281, DOI 10.1016/S0022-2143(98)90101-9; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; Vachon P, 2000, INT J IMPOT RES, V12, P53, DOI 10.1038/sj.ijir.3900480; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Vemulapalli S, 2000, LIFE SCI, V67, P23, DOI 10.1016/S0024-3205(00)00596-8; WAGNER G, 1992, SEMIN NEUROL, V12, P87, DOI 10.1055/s-2008-1041161; Wallis RM, 1999, AM J CARDIOL, V83, p3C; Wei JY, 1998, J MOL NEUROSCI, V10, P53, DOI 10.1007/BF02737085	57	67	70	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1382	1391		10.1096/fj.04-1978com	http://dx.doi.org/10.1096/fj.04-1978com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333581				2022-12-25	WOS:000224243200057
J	Manuel, RC; Hitomi, K; Arvai, AS; House, PG; Kurtz, AJ; Dodson, ML; McCullough, AK; Tainer, JA; Lloyd, RS				Manuel, RC; Hitomi, K; Arvai, AS; House, PG; Kurtz, AJ; Dodson, ML; McCullough, AK; Tainer, JA; Lloyd, RS			Reaction intermediates in the catalytic mechanism of Escherichia coli MutY DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; MEDIATED CHARGE-TRANSPORT; T4 ENDONUCLEASE-V; C-TERMINAL DOMAIN; ADENINE GLYCOSYLASE; STRUCTURAL BASIS; SUBSTRATE RECOGNITION; FLIPPING MECHANISM; PYRIMIDINE DIMER; DAMAGED DNA	The Escherichia coli adenine DNA glycosylase, MutY, plays an important role in the maintenance of genomic stability by catalyzing the removal of adenine opposite 8-oxo-7,8-dihydroguanine or guanine in duplex DNA. Although the x-ray crystal structure of the catalytic domain of MutY revealed a mechanism for catalysis of the glycosyl bond, it appeared that several opportunistically positioned lysine side chains could participate in a secondary beta-elimination reaction. In this investigation, it is established via site-directed mutagenesis and the determination of a 1.35-Angstrom structure of MutY in complex with adenine that the abasic site (apurinic/apyrimidinic) lyase activity is alternatively regulated by two lysines, Lys(142) and Lys(20). Analyses of the crystallographic structure also suggest a role for Glu(161) in the apurinic/apyrimidinic lyase chemistry. The beta-elimination reaction is structurally and chemically uncoupled from the initial glycosyl bond scission, indicating that this reaction occurs as a consequence of active site plasticity and slow dissociation of the product complex. MutY with either the K142A or K20A mutation still catalyzes beta and beta-delta elimination reactions, and both mutants can be trapped as covalent enzyme-DNA intermediates by chemical reduction. The trapping was observed to occur both pre- and post-phosphodiester bond scission, establishing that both of these intermediates have significant half-lives. Thus, the final spectrum of DNA products generated reflects the outcome of a delicate balance of closely related equilibrium constants.	Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Oregon Health & Science University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Scripps Research Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Lloyd, RS (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	lloydst@ohsu.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059237, R01GM046312] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 06766] Funding Source: Medline; NIGMS NIH HHS [GM46312, GM59237] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernards AS, 2002, J BIOL CHEM, V277, P20960, DOI 10.1074/jbc.C200181200; Boon EM, 2003, P NATL ACAD SCI USA, V100, P12543, DOI 10.1073/pnas.2035257100; Boon EM, 2002, BIOCHEMISTRY-US, V41, P8464, DOI 10.1021/bi012068c; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chmiel NH, 2001, NUCLEIC ACIDS RES, V29, P553, DOI 10.1093/nar/29.2.553; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Dodson ML, 2002, METHOD ENZYMOL, V354, P202; Dodson ML, 2002, FREE RADICAL BIO MED, V32, P678, DOI 10.1016/S0891-5849(02)00767-0; Francis AW, 2003, J AM CHEM SOC, V125, P16235, DOI 10.1021/ja0374426; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; House PG, 2001, PROG NUCLEIC ACID RE, V68, P349; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Kurtz AJ, 2002, BIOCHEMISTRY-US, V41, P7054, DOI 10.1021/bi020026y; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Lu AL, 1996, J BIOL CHEM, V271, P24138, DOI 10.1074/jbc.271.39.24138; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MORIKAWA K, 1992, SCIENCE, V256, P523, DOI 10.1126/science.1575827; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pope MA, 2002, J BIOL CHEM, V277, P22605, DOI 10.1074/jbc.M203037200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P6465, DOI 10.1021/bi972433t; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Volk DE, 2000, BIOCHEMISTRY-US, V39, P7331, DOI 10.1021/bi000416p; Wiederhold L, 2004, MOL CELL, V15, P209, DOI 10.1016/j.molcel.2004.06.003; Williams SD, 1998, NUCLEIC ACIDS RES, V26, P5123, DOI 10.1093/nar/26.22.5123; Williams SD, 1999, BIOCHEMISTRY-US, V38, P15417, DOI 10.1021/bi992013z; Williams SD, 2000, BIOCHEMISTRY-US, V39, P10098, DOI 10.1021/bi0004652; Wright PM, 1999, J BIOL CHEM, V274, P29011, DOI 10.1074/jbc.274.41.29011; Zharkov DO, 1998, BIOCHEMISTRY-US, V37, P12384, DOI 10.1021/bi981066y; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335; Zharkov DO, 2000, BIOCHEMISTRY-US, V39, P14768, DOI 10.1021/bi001538k	42	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46930	46939		10.1074/jbc.M403944200	http://dx.doi.org/10.1074/jbc.M403944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326180	hybrid			2022-12-25	WOS:000224832400076
J	Strand, KR; Karlsen, S; Kolberg, M; Rohr, AK; Gorbitz, CH; Andersson, KK				Strand, KR; Karlsen, S; Kolberg, M; Rohr, AK; Gorbitz, CH; Andersson, KK			Crystal structural studies of changes in the native dinuclear iron center of ribonucleotide reductase protein R2 from mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX-VIRUS; HIGH-FREQUENCY EPR; METHANE MONOOXYGENASE HYDROXYLASE; SMALL INORGANIC MODELS; HIGH-FIELD EPR; MU-OXO BRIDGE; ESCHERICHIA-COLI; OXYGEN ACTIVATION; ACTIVE-SITE; 3-DIMENSIONAL STRUCTURE	Class I ribonucleotide reductase (RNR) catalyzes the de novo synthesis of deoxyribonucleotides in mammals and many other organisms. The RNR subunit R2 contains a dinuclear iron center, which in its diferrous form spontaneously reacts with O-2, forming a mu-oxo-bridged diferric cluster and a stable tyrosyl radical. Here, we present the first crystal structures of R2 from mouse with its native dinuclear iron center, both under reducing and oxidizing conditions. In one structure obtained under reducing conditions, the iron-bridging ligand Glu-267 adopts the mu-(eta(1),eta(2)) coordination mode, which has previously been related to O-2 activation, and an acetate ion from the soaking solution is observed where O2 has been proposed to bind the iron. The structure of mouse R2 under oxidizing conditions resembles the non-radical diferric R2 from Escherichia coli, with the exception of the coordination of water and Asp-139 to Fe1. There are also additional water molecules near the tyrosyl radical site, as suggested by previous spectroscopic studies. Since no crystal structure of the active radical form has been reported, we propose models for the movement of waters and/or tyrosyl radical site when diferric R2 is oxidized to the radical form, in agreement with our previous ENDOR study. Compared with E. coli R2, two conserved phenylalanine residues in the hydrophobic environment around the diiron center have opposing rotameric conformations, and the carboxylate ligands of the diiron center in mouse R2 appear more flexible. Together, this might contribute to the lower affinity and cooperative binding of iron in mouse R2.	Univ Oslo, Dept Mol Biosci, NO-0316 Oslo, Norway; Univ Oslo, Dept Chem, NO-0315 Oslo, Norway	University of Oslo; University of Oslo	Andersson, KK (corresponding author), Univ Oslo, Dept Mol Biosci, POB 1041 Blindern, NO-0316 Oslo, Norway.	k.k.andersson@biokjemi.uio.no	Kjendseth, Åsmund Røhr/O-2543-2016; Kolberg, Matthias/G-2784-2011; Kolberg, Matthias/AAY-3478-2021; Andersson, K Kristoffer/F-9624-2010	Kjendseth, Åsmund Røhr/0000-0002-4956-4865; Kolberg, Matthias/0000-0001-8288-5364; 				Allard P, 1996, J AM CHEM SOC, V118, P895, DOI 10.1021/ja9529192; Andersson K. K., 1995, ADV INORG CHEM, V43, P359; Andersson KK, 2003, J BIOL INORG CHEM, V8, P235, DOI 10.1007/s00775-002-0429-0; Andersson KK, 2002, SPECTROCHIM ACTA A, V58, P1101, DOI 10.1016/S1386-1425(01)00700-4; Andersson ME, 1999, J AM CHEM SOC, V121, P2346, DOI 10.1021/ja982280c; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Barra AL, 2004, BIO MAGN RE, V22, P145; Bollinger JM, 1997, J AM CHEM SOC, V119, P5976, DOI 10.1021/ja970319s; Bruger AT, 1998, ACTA CRYSTALLOGR D, V54, P905; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; DeLano W, 2002, PYMOL 0 99; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eriksson M, 1998, BIOCHEMISTRY-US, V37, P13359, DOI 10.1021/bi981380s; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GALLI C, 1995, J AM CHEM SOC, V117, P740, DOI 10.1021/ja00107a017; Graff P, 2004, CELL PROLIFERAT, V37, P367, DOI 10.1111/j.1365-2184.2004.00319.x; GREFEN GS, 1993, J AM CHEM SOC, V115, P6420; Hanson MA, 1999, J AM CHEM SOC, V121, P6755, DOI 10.1021/ja990995p; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Hogbom M, 2002, BIOCHEMISTRY-US, V41, P1381, DOI 10.1021/bi011429l; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Kashlan OB, 2003, BIOCHEMISTRY-US, V42, P1696, DOI 10.1021/bi020634d; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LING JS, 1994, J BIOL CHEM, V269, P5595; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P24; Liu A, 1998, BIOCHEMISTRY-US, V37, P16369, DOI 10.1021/bi981471p; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Moche M, 2003, J BIOL CHEM, V278, P25072, DOI 10.1074/jbc.M301662200; NIELSEN BB, 1995, FEBS LETT, V373, P310, DOI 10.1016/0014-5793(95)01067-O; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NYHOLM S, 1993, BIOCHEMISTRY-US, V32, P11569, DOI 10.1021/bi00094a013; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Strand KR, 2003, BIOCHEMISTRY-US, V42, P12223, DOI 10.1021/bi035248q; Strand KR, 2002, J BIOL CHEM, V277, P34229, DOI 10.1074/jbc.M203358200; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; Tong W, 1998, BIOCHEMISTRY-US, V37, P5840, DOI 10.1021/bi9728811; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; Voegtli WC, 2003, J AM CHEM SOC, V125, P15822, DOI 10.1021/ja0370387; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Whittington DA, 2001, J AM CHEM SOC, V123, P827, DOI 10.1021/ja003240n; Yang YS, 2000, J AM CHEM SOC, V122, P8495, DOI 10.1021/ja994406r; Zlateva T, 2004, J BIOL CHEM, V279, P18742, DOI 10.1074/jbc.M311355200	60	51	51	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46794	46801		10.1074/jbc.M407346200	http://dx.doi.org/10.1074/jbc.M407346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322079	hybrid			2022-12-25	WOS:000224832400059
J	Wilke, MS; Hills, TL; Zhang, HZ; Chambers, HF; Strynadka, NCJ				Wilke, MS; Hills, TL; Zhang, HZ; Chambers, HF; Strynadka, NCJ			Crystal structures of the apo and penicillin- acylated forms of the BlaR1 beta-lactam sensor of Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAHIGH-RESOLUTION STRUCTURE; METHICILLIN-RESISTANT; CLASS-A; BACILLUS-LICHENIFORMIS; TRANSCRIPTIONAL REGULATION; SIGNALING PATHWAY; BINDING PROTEIN; MECHANISM; RECEPTOR; PROGRAM	Staphylococcus aureus is among the most prevalent and antibiotic-resistant of pathogenic bacteria. The resistance of S. aureus to prototypal beta-lactam antibiotics is conferred by two mechanisms: (i) secretion of hydrolytic beta-lactamase enzymes and (ii) production of beta-lactam-insensitive penicillin-binding proteins (PBP2a). Despite their distinct modes of resistance, expression of these proteins is controlled by similar regulation systems, including a repressor (BlaI/MecI) and a multidomain transmembrane receptor (BlaR1/MecR1). Resistance is triggered in response to a covalent binding event between a beta-lactam antibiotic and the extracellular sensor domain of BlaR1/MecR1 by transduction of the binding signal to an intracellular protease domain capable of repressor inactivation. This study describes the first crystal structures of the sensor domain of BlaR1 (BlaR(S)) from S. aureus in both the apo and penicillin-acylated forms. The structures show that the sensor domain resembles the beta-lactam-hydrolyzing class D beta-lactamases, but is rendered a penicillin-binding protein due to the formation of a very stable acyl-enzyme. Surprisingly, conformational changes upon penicillin binding were not observed in our structures, supporting the hypothesis that transduction of the antibiotic-binding signal into the cytosol is mediated by additional intramolecular interactions of the sensor domain with an adjacent extracellular loop in BlaR1.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA	University of British Columbia; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; CHAMBERS HF, 1985, J CLIN INVEST, V76, P325, DOI 10.1172/JCI111965; COHEN S, 1968, J BACTERIOL, V95, P1368, DOI 10.1128/JB.95.4.1368-1374.1968; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476; Davies C, 2001, J BIOL CHEM, V276, P616, DOI 10.1074/jbc.M004471200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Duval V, 2003, MOL MICROBIOL, V48, P1553, DOI 10.1046/j.1365-2958.2003.03520.x; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Garcia-Castellanos R, 2004, J BIOL CHEM, V279, P17888, DOI 10.1074/jbc.M313123200; Garcia-Castellanos R, 2003, J BIOL CHEM, V278, P39897, DOI 10.1074/jbc.M307199200; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; Golemi-Kotra D, 2004, J BIOL CHEM, V279, P34665, DOI 10.1074/jbc.M313143200; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HACKBARTH CJ, 1993, ANTIMICROB AGENTS CH, V37, P1144, DOI 10.1128/AAC.37.5.1144; Hanique S, 2004, J BIOL CHEM, V279, P14264, DOI 10.1074/jbc.M313488200; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Katayama Y, 2003, J BACTERIOL, V185, P5465, DOI 10.1128/JB.185.18.5465-5472.2003; Kerff F, 2003, BIOCHEMISTRY-US, V42, P12835, DOI 10.1021/bi034976a; KERNODLE DS, 1990, ANTIMICROB AGENTS CH, V34, P420, DOI 10.1128/AAC.34.3.420; Kim SH, 2003, CLIN INFECT DIS, V37, P794, DOI 10.1086/377540; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMOTTEBRASSEUR J, 1991, BIOCHEM J, V279, P213, DOI 10.1042/bj2790213; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis RA, 2000, J ANTIMICROB CHEMOTH, V45, P139, DOI 10.1093/jac/45.2.139; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Maveyraud L, 2002, J AM CHEM SOC, V124, P2461, DOI 10.1021/ja016736t; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Nukaga M, 2003, J MOL BIOL, V328, P289, DOI 10.1016/S0022-2836(03)00210-9; OEFNER C, 1990, NATURE, V343, P284, DOI 10.1038/343284a0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Paetzel M, 2000, NAT STRUCT BIOL, V7, P918; Pernot L, 2001, J MOL BIOL, V310, P859, DOI 10.1006/jmbi.2001.4805; Rhazi N, 2003, BIOCHEMISTRY-US, V42, P2895, DOI 10.1021/bi027256x; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Sun T, 2003, PROTEIN SCI, V12, P82, DOI 10.1110/ps.0224303; SUZUKI E, 1993, ANTIMICROB AGENTS CH, V37, P1219, DOI 10.1128/AAC.37.6.1219; SWAREN P, 1995, STRUCTURE, V3, P603, DOI 10.1016/S0969-2126(01)00194-0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Van Melckebeke H, 2003, J MOL BIOL, V333, P711, DOI 10.1016/j/jmb.2003.09.005; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144	55	53	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47278	47287		10.1074/jbc.M407054200	http://dx.doi.org/10.1074/jbc.M407054200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322076	hybrid			2022-12-25	WOS:000224832400116
J	Botzki, A; Rigden, DJ; Braun, S; Nukui, M; Salmen, S; Hoechstetter, J; Bernhardt, G; Dove, S; Jedrzejas, MJ; Buschauer, A				Botzki, A; Rigden, DJ; Braun, S; Nukui, M; Salmen, S; Hoechstetter, J; Bernhardt, G; Dove, S; Jedrzejas, MJ; Buschauer, A			L-ascorbic acid 6-hexadecanoate, a potent hyaluronidase inhibitor - X-ray structure and molecular modeling of enzyme-inhibitor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE FACTORS; DEGRADATION; MECHANISM; LYASE; PH-20; PURIFICATION; DOCKING; BINDING; MAPS	Hyaluronidases are enzymes that degrade hyaluronan, an important component of the extracellular matrix. The mammalian hyaluronidases are considered to be involved in many (patho) physiological processes like fertilization, tumor growth, and metastasis. Bacterial hyaluronidases, also termed hyaluronate lyases, contribute to the spreading of microorganisms in tissues. Such roles for hyaluronidases suggest that inhibitors could be useful pharmacological tools. Potent and selective inhibitors are not known to date, although L-ascorbic acid has been reported to be a weak inhibitor of Streptococcus pneumoniae hyaluronate lyase (SpnHL). The x-ray structure of SpnHL complexed with L-ascorbic acid has been elucidated suggesting that additional hydrophobic interactions might increase inhibitory activity. Here we show that L-ascorbic acid 6-hexadecanoate (Vcpal) is a potent inhibitor of both streptococcal and bovine testicular hyaluronidase (BTH). Vcpal showed strong inhibition of Streptococcus agalactiae hyaluronate lyase with an IC50 of 4 muM and weaker inhibition of SpnHL and BTH with IC50 values of 100 and 56 muM, respectively. To date, Vcpal has proved to be one of the most potent inhibitors of hyaluronidase. We also determined the x-ray structure of the SpnHL-Vcpal complex and confirmed the hypothesis that additional hydrophobic interactions with Phe-343, His-399, and Thr-400 in the active site led to increased inhibition. A homology structural model of BTH was also generated to suggest binding modes of Vcpal to this hyaluronidase. The long alkyl chain seemed to interact with an extended, hydrophobic channel formed by mostly conserved amino acids Ala-84, Leu-91, Tyr-93, Tyr-220, and Leu-344 in BTH.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Univ Regensburg, Inst Pharm, D-93040 Regensburg, Germany; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Regensburg; University of Liverpool	Jedrzejas, MJ (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	mjedrzejas@chori.org; armin.buschauer@chemie.uni-regensburg.de	Buschauer, Armin/D-2861-2009	Botzki, Alexander/0000-0001-6691-4233; Rigden, Daniel/0000-0002-7565-8937	NIAID NIH HHS [AI44079] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044079] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arming S, 1997, EUR J BIOCHEM, V247, P810, DOI 10.1111/j.1432-1033.1997.t01-1-00810.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brameld KA, 1998, J MOL BIOL, V280, P913, DOI 10.1006/jmbi.1998.1890; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cherr GN, 2001, MATRIX BIOL, V20, P515, DOI 10.1016/S0945-053X(01)00171-8; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Csoka TB, 1997, FEBS LETT, V417, P307, DOI 10.1016/S0014-5793(97)01309-4; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DELANO WL, 2003, PYMOL VERSION 0 97; DIFERRANTE N, 1956, J BIOL CHEM, V220, P303; GEHLHAAR DK, 1995, CHEM BIOL, V2, P317, DOI 10.1016/1074-5521(95)90050-0; Hynes WL, 2000, FEMS MICROBIOL LETT, V183, P201, DOI 10.1111/j.1574-6968.2000.tb08958.x; Jedrzejas MJ, 2000, CRIT REV BIOCHEM MOL, V35, P221, DOI 10.1080/10409230091169195; Jedrzejas MJ, 1998, J STRUCT BIOL, V121, P73, DOI 10.1006/jsbi.1998.3963; Jedrzejas MJ, 1998, PROTEIN EXPRES PURIF, V13, P83, DOI 10.1006/prep.1997.0864; Jedrzejas MJ, 2004, FRONT BIOSCI-LANDMRK, V9, P891, DOI 10.2741/1299; Jedrzejas MJ, 2002, J BIOL CHEM, V277, P28287, DOI 10.1074/jbc.M112009200; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; JEDRZEJAS MJ, 2002, SCI HYALURONAN TODAY; JEDRZEJAS MJ, 2002, RRD BIO BIO, V2, P197; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SJ, 2001, GLYCOBIOLOGY, V11, P297, DOI 10.1093/glycob/11.4.297; Klein E, 2001, J AGR FOOD CHEM, V49, P1224, DOI 10.1021/jf000725m; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KREIL G, 1995, PROTEIN SCI, V4, P1666, DOI 10.1002/pro.5560040902; KUPPUSAMY UR, 1990, BIOCHEM PHARMACOL, V40, P397, DOI 10.1016/0006-2952(90)90709-T; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Li SL, 2001, J BIOL CHEM, V276, P15125, DOI 10.1074/jbc.M011102200; Li SL, 2001, J BIOL CHEM, V276, P41407, DOI 10.1074/jbc.M106634200; Lin G, 2001, CANCER LETT, V163, P95, DOI 10.1016/S0304-3835(00)00669-8; Markovic-Housley Z, 2002, ROY SOC CH, P19; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; McPherson A., 1999, CRYSTALLIZATION BIOL; MEYER K, 1971, ENZYMES, V3, P307; Meyer MF, 1997, FEBS LETT, V413, P385, DOI 10.1016/S0014-5793(97)00936-8; Mio K, 2002, MATRIX BIOL, V21, P31, DOI 10.1016/S0945-053X(01)00185-8; MITRA A, 1992, TOXICOL LETT, V60, P281, DOI 10.1016/0378-4274(92)90286-S; NISHIBATA Y, 1991, TETRAHEDRON, V47, P8985, DOI 10.1016/S0040-4020(01)86503-0; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; QUIOCHO FA, 1999, BIOORGANIC CHEM CARB, P441; Rarey M, 1999, PROTEINS, V34, P17, DOI 10.1002/(SICI)1097-0134(19990101)34:1<17::AID-PROT3>3.0.CO;2-1; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 2000, METH MOL B, V143, P97; SCOTT JE, 1989, CIBA F SYMP, V143, P6; Simpson GLW, 2000, BBA-MOL BASIS DIS, V1501, P12, DOI 10.1016/S0925-4439(00)00009-0; Stahl M, 2001, J MED CHEM, V44, P1035, DOI 10.1021/jm0003992; Suzuki A, 2001, GLYCOBIOLOGY, V11, P57, DOI 10.1093/glycob/11.1.57; Suzuki K, 2002, J ENZYM INHIB MED CH, V17, P183, DOI 10.1080/14756360290032930; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toida T, 1999, ARCH BIOCHEM BIOPHYS, V370, P176, DOI 10.1006/abbi.1999.1395; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WOLF RA, 1984, AM J CARDIOL, V53, P941, DOI 10.1016/0002-9149(84)90529-0	60	104	110	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45990	45997		10.1074/jbc.M406146200	http://dx.doi.org/10.1074/jbc.M406146200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322107	hybrid			2022-12-25	WOS:000224694900084
J	Chen, H; McCaig, BC; Melotto, M; He, SY; Howe, GA				Chen, H; McCaig, BC; Melotto, M; He, SY; Howe, GA			Regulation of plant arginase by wounding, jasmonate, and the phytotoxin coronatine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE PRODUCTION; RAT-LIVER ARGINASE; HYDROXY-L-ARGININE; METHYL JASMONATE; ORNITHINE-DECARBOXYLASE; PSEUDOMONAS-SYRINGAE; IN-VITRO; CONJUGATED POLYAMINES; MACROPHAGE ARGINASE; SIGNALING PATHWAY	In mammalian cells, induced expression of arginase in response to wound trauma and pathogen infection plays an important role in regulating the metabolism of L-arginine to either polyamines or nitric oxide ( NO). In higher plants, which also utilize arginine for the production of polyamines and NO, the potential role of arginase as a control point for arginine homeostasis has not been investigated. Here, we report the characterization of two genes (LeARG1 and LeARG2) from Lycopersicon esculentum ( tomato) that encode arginase. Phylogenic analysis showed that LeARG1 and -2, like all other plant arginases, are more similar to agmatinase than to arginases from vertebrates, fungi, and bacteria. Nevertheless, recombinant LeARG1 and -2 exhibited specificity for L-arginine over agmatine and related guanidino substrates. The plant enzymes, like mammalian arginases, were inhibited (K-i similar to 14 similar to muM) by the NO precursor N-G-hydroxy-L-arginine. These results indicate that plant arginases define a distinct group of ureohydrolases that function as authentic L-arginases. LeARG1 and LeARG2 transcripts accumulated to their highest levels in reproductive tissues. In leaves, LeARG2 expression and arginase activity were induced in response to wounding and treatment with jasmonic acid (JA), a potent signal for plant defense responses. Wound- and JA-induced expression of LeARG2 was not observed in the tomato jasmonic acid-insensitive1 mutant, indicating that this response is strictly dependent on an intact JA signal transduction pathway. Infection of wild-type plants with a virulent strain of Pseudomonas syringae pv. tomato also up-regulated LeARG2 expression and arginase activity. This response was mediated by the bacterial phytotoxin coronatine, which exerts its virulence effects by co-opting the host JA signaling pathway. These results highlight striking similarities in the regulation of arginase in plants and animals and suggest that stress-induced arginase may perform similar roles in diverse biological systems.	Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Howe, GA (corresponding author), Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA.	howeg@msu.edu	Howe, Gregg A/N-1887-2014; Chen, Hui/C-1490-2011	Howe, Gregg A/0000-0002-9218-979X; He, Sheng Yang/0000-0003-1308-498X; Melotto, Maeli/0000-0001-6021-9803				Alabadi D, 1996, PLANT PHYSIOL, V112, P1237, DOI 10.1104/pp.112.3.1237; Alabadi D, 1998, PLANT PHYSIOL, V118, P323, DOI 10.1104/pp.118.1.323; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bender CL, 1999, MICROBIOL MOL BIOL R, V63, P266, DOI 10.1128/MMBR.63.2.266-292.1999; Bewley MC, 1999, STRUCT FOLD DES, V7, P435, DOI 10.1016/S0969-2126(99)80056-2; Biondi S, 2000, PLANT CELL REP, V19, P691, DOI 10.1007/s002999900178; Biondi S, 2001, J EXP BOT, V52, P231, DOI 10.1093/jexbot/52.355.231; BOUCHER JL, 1994, BIOCHEM BIOPH RES CO, V203, P1614, DOI 10.1006/bbrc.1994.2371; Bouchereau A, 1999, PLANT SCI, V140, P103, DOI 10.1016/S0168-9452(98)00218-0; BOUTIN JP, 1982, EUR J BIOCHEM, V127, P237, DOI 10.1111/j.1432-1033.1982.tb06861.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bronte V, 2003, TRENDS IMMUNOL, V24, P302, DOI 10.1016/S1471-4906(03)00132-7; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Carvajal N, 1996, PHYTOCHEMISTRY, V41, P373, DOI 10.1016/0031-9422(95)00538-2; Cederbaum SD, 2004, MOL GENET METAB, V81, pS38, DOI 10.1016/j.ymgme.2003.10.012; Chandok MR, 2004, P NATL ACAD SCI USA, V101, P8239, DOI 10.1073/pnas.0402344101; Chandok MR, 2003, CELL, V113, P469, DOI 10.1016/S0092-8674(03)00350-7; Chang CI, 2001, CANCER RES, V61, P1100; CHEN CT, 1994, J PLANT PHYSIOL, V143, P119, DOI 10.1016/S0176-1617(11)82107-3; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; Duleu S, 2004, J IMMUNOL, V172, P6298, DOI 10.4049/jimmunol.172.10.6298; Durner J, 1999, CURR OPIN PLANT BIOL, V2, P369, DOI 10.1016/S1369-5266(99)00007-2; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Goldraij A, 1999, PLANT PHYSIOL, V119, P297, DOI 10.1104/pp.119.1.297; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Hallemeesch MM, 2002, CLIN NUTR, V21, P273, DOI 10.1054/clnu.2002.0571; Hanfrey C, 2001, PLANT J, V27, P551, DOI 10.1046/j.1365-313X.2001.01100.x; HEIMER YM, 1979, FEBS LETT, V104, P146, DOI 10.1016/0014-5793(79)81102-3; Howe GA, 2000, PLANT PHYSIOL, V123, P711, DOI 10.1104/pp.123.2.711; Hwang HJ, 2001, PHYTOCHEMISTRY, V58, P1015, DOI 10.1016/S0031-9422(01)00392-2; Imanishi S, 1998, PLANT MOL BIOL, V38, P1101, DOI 10.1023/A:1006058700949; Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Kampfer H, 2003, J INVEST DERMATOL, V121, P1544, DOI 10.1046/j.1523-1747.2003.12610.x; KANG JH, 1990, PLANT PHYSIOL, V93, P1230, DOI 10.1104/pp.93.3.1230; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; Keinanen M, 2001, J AGR FOOD CHEM, V49, P3553, DOI 10.1021/jf010200+; KOLLOFFEL C, 1975, PLANT PHYSIOL, V55, P507, DOI 10.1104/pp.55.3.507; KRUMPELMAN PM, 1995, PLANT PHYSIOL, V107, P1479, DOI 10.1104/pp.107.4.1479; Lee J, 1997, PHYTOCHEMISTRY, V44, P589, DOI 10.1016/S0031-9422(96)00562-6; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; Lee TM, 1996, PLANT CELL ENVIRON, V19, P65, DOI 10.1111/j.1365-3040.1996.tb00227.x; Li L, 2004, PLANT CELL, V16, P126, DOI 10.1105/tpc.017954; Li L, 2002, P NATL ACAD SCI USA, V99, P6416, DOI 10.1073/pnas.072072599; Li L, 2001, PLANT PHYSIOL, V127, P1414, DOI 10.1104/pp.010705; Li L, 2001, PLANT MOL BIOL, V46, P409, DOI 10.1023/A:1010645330275; Mader JC, 1999, J PLANT PHYSIOL, V154, P79, DOI 10.1016/S0176-1617(99)80321-6; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; Merkouropoulos G, 1999, PLANTA, V208, P212, DOI 10.1007/s004250050552; Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547; Ogura Y, 2001, Z NATURFORSCH C, V56, P193; Pauleau AL, 2004, J IMMUNOL, V172, P7565, DOI 10.4049/jimmunol.172.12.7565; Perez-Amador MA, 2002, PLANT PHYSIOL, V130, P1454, DOI 10.1104/pp.009951; Perozich J, 1998, BBA-PROTEIN STRUCT M, V1382, P23, DOI 10.1016/S0167-4838(97)00131-3; POLACCO JC, 1993, INT REV CYTOL, V145, P65, DOI 10.1016/S0074-7696(08)60425-8; RECZKOWSKI RS, 1994, ARCH BIOCHEM BIOPHYS, V312, P31, DOI 10.1006/abbi.1994.1276; Ryan CA, 2000, BBA-PROTEIN STRUCT M, V1477, P112, DOI 10.1016/S0167-4838(99)00269-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satriano J, 2003, ANN NY ACAD SCI, V1009, P34, DOI 10.1196/annals.1304.004; Sekowska A, 2000, MICROBIOL-SGM, V146, P1815, DOI 10.1099/00221287-146-8-1815; SPLITTST.WE, 1969, PHYTOCHEMISTRY, V8, P753, DOI 10.1016/S0031-9422(00)85847-1; Swofford D. L., 2000, PAUP PHYLOENETIC ANA; TEITEL DC, 1985, PLANT GROWTH REGUL, V3, P309, DOI 10.1007/BF00117588; Todd CD, 2001, PLANT MOL BIOL, V45, P555, DOI 10.1023/A:1010645616920; Todd CD, 2002, PLANTA, V215, P110, DOI 10.1007/s00425-001-0720-2; Vincendeau P, 2003, TRENDS PARASITOL, V19, P9, DOI 10.1016/S1471-4922(02)00010-7; Walters D, 2002, J EXP BOT, V53, P747, DOI 10.1093/jexbot/53.369.747; Walters DR, 2003, PHYTOCHEMISTRY, V64, P97, DOI 10.1016/S0031-9422(03)00329-7; WANG CY, 1994, ENVIRON EXP BOT, V34, P427, DOI 10.1016/0098-8472(94)90025-6; Wendehenne D, 2001, TRENDS PLANT SCI, V6, P177, DOI 10.1016/S1360-1385(01)01893-3; WRIGHT LC, 1981, PHYTOCHEMISTRY, V20, P2641, DOI 10.1016/0031-9422(81)85259-4; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xie DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/science.280.5366.1091; Zhao YF, 2003, PLANT J, V36, P485, DOI 10.1046/j.1365-313X.2003.01895.x; ZHOU J, 1992, PLANT MOL BIOL, V20, P5, DOI 10.1007/BF00029144; ZONIA LE, 1995, PLANT PHYSIOL, V107, P1097, DOI 10.1104/pp.107.4.1097	76	115	131	3	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45998	46007		10.1074/jbc.M407151200	http://dx.doi.org/10.1074/jbc.M407151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322128	hybrid			2022-12-25	WOS:000224694900085
J	Raghavan, SC; Houston, S; Hegde, BG; Langen, R; Haworth, IS; Lieber, MR				Raghavan, SC; Houston, S; Hegde, BG; Langen, R; Haworth, IS; Lieber, MR			Stability and strand asymmetry in the non-B DNA structure at the bcl-2 major breakpoint region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTRICHA TELOMERIC DNA; DOT-TTC REPEATS; FOLLICULAR LYMPHOMA; CHROMOSOMAL TRANSLOCATIONS; V(D)J RECOMBINATION; S1 NUCLEASE; STICKY DNA; SEQUENCE; ASSOCIATION; POLYMERASE	The t(14;18) translocation involving the Ig heavy chain locus and the BCL-2 gene is the single most common chromosomal translocation in human cancer. Recently we reported in vitro and in vivo chemical probing data indicating that the 150-bp major breakpoint region (Mbr), which contains three breakage subregions (hotspots) (known as peaks I, II, and III), has single-stranded character and hence a non-B DNA conformation. Although we could document the non-B DNA structure formation at the bcl-2 Mbr, the structural studies were limited to chemical probing. Therefore, in the present study, we used multiple methods including circular dichroism to detect the non-B DNA at the bcl-2 Mbr. We established a new gel shift method to detect the altered structure at neutral pH on shorter DNA fragments containing the bcl-2 Mbr and analyzed the fine structural features. We found that the single-stranded region in the non-B DNA structure observed is stable for days and is asymmetric with respect to the Watson and Crick strands. It could be detected by oligomer probing, a bisulfite modification assay, or a P1 nuclease assay. We provide evidence that two different non-B conformations exist at peak I in addition to the single one observed at peak III. Finally we used mutagenesis and base analogue incorporation to show that the non-B DNA structure formation requires Hoogsteen pairing. These findings place major constraints on the location and nature of the non-B conformations assumed at peaks I and III of the bcl-2 Mbr.	Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biol Sci, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pharmaceut Sci, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Zilka Neurogenet Inst, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Rm 5428,1441 Eastlake Ave,MC9176, Los Angeles, CA 90033 USA.	lieber@usc.edu	Hegde, Balachandra/GPS-6028-2022	Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				Albinger-Hegyi A, 2002, AM J PATHOL, V160, P823, DOI 10.1016/S0002-9440(10)64905-X; AUSUBEL FM, 1906, CURRENT PROTOCOLS MO; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BEERMAN TA, 1973, J MOL BIOL, V79, P451, DOI 10.1016/0022-2836(73)90398-7; Buchonnet G, 2002, LEUKEMIA, V16, P1852, DOI 10.1038/sj.leu.2402568; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER F, 1990, BLOOD, V76, P131; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; Dornberger U, 1999, J BIOL CHEM, V274, P6957, DOI 10.1074/jbc.274.11.6957; GOUGH GW, 1986, EMBO J, V5, P191, DOI 10.1002/j.1460-2075.1986.tb04195.x; HENTSCHEL CC, 1982, NATURE, V295, P714, DOI 10.1038/295714a0; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; Kirsch IR, 1993, CAUSES CONSEQUENCES; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kramer PR, 1997, BIOCHEMISTRY-US, V36, P3151, DOI 10.1021/bi962396q; LETAI AG, 1988, BIOCHEMISTRY-US, V27, P9108, DOI 10.1021/bi00426a007; Lewis SM, 1997, MOL CELL BIOL, V17, P3125, DOI 10.1128/MCB.17.6.3125; Lieber MR., 1993, CAUSES CONSEQUENCES, P239; MACE HAF, 1983, NATURE, V304, P555, DOI 10.1038/304555a0; Marculescu R, 2002, J EXP MED, V195, P85, DOI 10.1084/jem.20011578; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; MORGAN AR, 1970, NATURE, V227, P1310, DOI 10.1038/2271310a0; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; Potaman VN, 2004, NUCLEIC ACIDS RES, V32, P1224, DOI 10.1093/nar/gkh274; Raghavan SC, 2004, CELL CYCLE, V3, P762; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEELA F, 1982, NUCLEIC ACIDS RES, V10, P1389, DOI 10.1093/nar/10.4.1389; SHEFLIN LG, 1984, NUCLEIC ACIDS RES, V12, P7087, DOI 10.1093/nar/12.18.7087; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; SINDEN RR, 1984, J BIOL CHEM, V259, P6593; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919	47	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46213	46225		10.1074/jbc.M406280200	http://dx.doi.org/10.1074/jbc.M406280200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15328356	hybrid			2022-12-25	WOS:000224694900108
J	Xu, GY; Kane, DJ; Faller, LD; Farley, RA				Xu, GY; Kane, DJ; Faller, LD; Farley, RA			The role of loop 6/7 in folding and functional performance of Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; SITE-DIRECTED MUTAGENESIS; TRANSMEMBRANE SEGMENTS 6; CYTOPLASMIC LOOP; ALPHA-SUBUNIT; RENAL NA,K-ATPASE; COORDINATING RESIDUES; GASTRIC H+,K+-ATPASE; CATION OCCLUSION; CA2+ BINDING	Alanine substitutions were made for 15 amino acids in the cytoplasmic loop between transmembrane helices 6 and 7 (L6/7) of the human alpha(1)-subunit of Na,K-ATPase. Most mutations reduced Na,K-ATPase activity by less than 50%; however, the mutations R834A, R837A, and R848A reduced Na,K-ATPase activity by 75, 89, and 66%, respectively. Steady-state phosphoenzyme formation from ATP was reduced in mutants R834A, R837A, and R848A, and R837A also had a faster E2P-->E-2 dephosphorylation rate compared with the wild-type enzyme. Effects of L6/7 mutations on the phosphorylation domain of the protein were also demonstrated by O-18 exchange, which showed that intrinsic rate constants for P-i binding and/or reaction with the protein were altered. Although most L6/7 mutations had no effect on the interaction of Na+ or K+ with Na,K-ATPase, the E825A, E828A, R834A, and R837A mutations reduced the apparent affinity of the enzyme for both Na+ and K+ by 1.5-3-fold. 1-Bromo-2,4,6-tris(methylisothiouronium) benzene (Br-TITU3+), a competitive antagonist of Rb+ and Na+ occlusion (Hoving, S., Bar-Shimon, M., Tijmes, J.J., Goldschleger, R., Tal, D. M., and Karlish, S.J.D. (1995) J. Biol. Chem. 270, 29788-29793), was used to test whether charged residues in L6/7 are involved in binding monovalent cations and cation antagonists. Br-TITU3+ inhibited ouabain binding to wild type Na, K-ATPase with an IC50 of 30 muM. Ouabain binding to the E825A, E828A, R834A, or R837A mutants was still inhibited by Br-TITU3+, indicating that Br-TITU3+ does not bind to charged residues in L6/7. This observation makes it unlikely that L6/7 functions as a cytoplasmic cation binding site in Na,K-ATPase, and together with the effects of L6/7 mutations on phosphate interactions with the enzyme suggests that L6/7 is important in stabilizing the phosphorylation domain and its relationship to the ion binding sites of the protein.	Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, CURE, Digest Dis Res Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA	University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Farley, RA (corresponding author), Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, 1333 San Pablo St,MMR 250, Los Angeles, CA 90033 USA.	rfarley@usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028673] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52802] Funding Source: Medline; NIGMS NIH HHS [GM28673] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; DAVID P, 1992, J BIOL CHEM, V267, P1141; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FAGAN MJ, 1994, J MOL EVOL, V38, P57; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; Farley RA, 2001, BIOCHEMISTRY-US, V40, P6361, DOI 10.1021/bi010270+; HOVING S, 1995, J BIOL CHEM, V270, P29788; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Jorgensen PL, 2001, J BIOENERG BIOMEMBR, V33, P367, DOI 10.1023/A:1010611322024; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; Koenderink JB, 2000, P NATL ACAD SCI USA, V97, P11209, DOI 10.1073/pnas.200109597; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lingrel JB, 1997, ANN NY ACAD SCI, V834, P194, DOI 10.1111/j.1749-6632.1997.tb52251.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Menguy T, 2002, J BIOL CHEM, V277, P13016, DOI 10.1074/jbc.M108899200; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Muller-Ehmsen J, 2001, AM J PHYSIOL-CELL PH, V281, pC1355, DOI 10.1152/ajpcell.2001.281.4.C1355; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; OR E, 1993, J BIOL CHEM, V268, P16929; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Toustrup-Jensen M, 2003, J BIOL CHEM, V278, P11402, DOI 10.1074/jbc.M212136200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; WEBER K, 1969, J BIOL CHEM, V244, P4406; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	37	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45594	45602		10.1074/jbc.M408147200	http://dx.doi.org/10.1074/jbc.M408147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322120	hybrid			2022-12-25	WOS:000224694900038
J	DellaVecchia, MJ; Croteau, DL; Skorvaga, M; Dezhurov, SV; Lavrik, OI; Van Houten, B				DellaVecchia, MJ; Croteau, DL; Skorvaga, M; Dezhurov, SV; Lavrik, OI; Van Houten, B			Analyzing the handoff of DNA from UvrA to UvrB utilizing DNA-protein photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; DAMAGE RECOGNITION; (A)BC EXCINUCLEASE; CROSS-LINKING; ACTIVE-SITE; 5 INCISION; COMPLEX; NUCLEASE; BINDING	To better define the molecular architecture of nucleotide excision repair intermediates it is necessary to identify the specific domains of UvrA, UvrB, and UvrC that are in close proximity to DNA damage during the repair process. One key step of nucleotide excision repair that is poorly understood is the transfer of damaged DNA from UvrA to UvrB, prior to incision by UvrC. To study this transfer, we have utilized two types of arylazido-modified photoaffinity reagents that probe residues in the Uvr proteins that are closest to either the damaged or non-damaged strands. The damaged strand probes consisted of dNTP analogs linked to a terminal arylazido moiety. These analogs were incorporated into double-stranded DNA using DNA polymerase beta and functioned as both the damage site and the cross-linking reagent. The non-damaged strand probe contained an arylazido moiety coupled to a phosphorothioate-modified backbone of an oligonucleotide opposite the damaged strand, which contained an internal fluorescein adduct. Six site-directed mutants of Bacillus caldotenax UvrB located in different domains within the protein (Y96A, E99A, R123A, R183E, F249A, and D510A), and two domain deletions (Delta2 and Deltabeta-hairpin), were assayed. Data gleaned from these mutants suggest that the hand-off of damaged DNA from UvrA to UvrB proceeds in a three-step process: 1) UvrA and UvrB bind to the damaged site, with UvrA in direct contact; 2) a transfer reaction with UvrB contacting mostly the non-damaged DNA strand; 3) lesion engagement by the damage recognition pocket of UvrB with concomitant release of UvrA.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; Slovak Acad Sci, Canc Res Inst, Dept Mol Genet, Bratislava 83391, Slovakia; Russian Acad Sci, Novosibirsk Inst Chem Biol & Fundamental Med, Siberian Branch, Novosibirsk 630090, Russia	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Slovak Academy of Sciences; Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences	Van Houten, B (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	vanhout1@niehs.nih.gov	Croteau, Deb/AAP-5933-2020; Van Houten, Bennett/K-2284-2019; Skorvaga, Milan/AAO-2360-2021; Lavrik, Olga I/G-4641-2013	Croteau, Deborah/0000-0002-6094-4084	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES061060] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; Bienstock RJ, 2003, J BIOL CHEM, V278, P5309, DOI 10.1074/jbc.M210159200; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Delagoutte E, 2002, J MOL BIOL, V320, P73, DOI 10.1016/S0022-2836(02)00401-1; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goosen N, 2001, RES MICROBIOL, V152, P401, DOI 10.1016/S0923-2508(01)01211-6; GROSSMAN L, 1990, MUTAT RES, V236, P213, DOI 10.1016/0921-8777(90)90006-Q; Hoare S, 2000, BIOCHEMISTRY-US, V39, P12252, DOI 10.1021/bi0013187; Knorre DG, 1998, FEBS LETT, V433, P9, DOI 10.1016/S0014-5793(98)00860-6; Lavrik OI, 1998, FEBS LETT, V441, P186, DOI 10.1016/S0014-5793(98)01544-0; Lavrik OI, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf073; Lavrik OI, 2003, NATO SCI SER II MATH, V129, P193; Lavrik OI, 1998, NUCLEIC ACIDS RES, V26, P602, DOI 10.1093/nar/26.2.602; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; LIN JJ, 1992, J BIOL CHEM, V267, P17693; LIN JJ, 1992, J BIOL CHEM, V267, P17688; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; Moolenaar GF, 2000, J BIOL CHEM, V275, P8044, DOI 10.1074/jbc.275.11.8044; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; ORREN DK, 1992, J BIOL CHEM, V267, P780; ORREN DK, 1990, J BIOL CHEM, V265, P15796; Persinger J, 1999, MOL CELL BIOL, V19, P5218; Reardon JT, 2002, MOL CELL BIOL, V22, P5938, DOI 10.1128/MCB.22.16.5938-5945.2002; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SHI Q, 1992, J MOL BIOL, V226, P425, DOI 10.1016/0022-2836(92)90957-L; Skorvaga M, 2002, J BIOL CHEM, V277, P1553, DOI 10.1074/jbc.M108847200; Tate JJ, 1998, NUCLEIC ACIDS RES, V26, P1421, DOI 10.1093/nar/26.6.1421; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; Truglio JJ, 2004, EMBO J, V23, P2498, DOI 10.1038/sj.emboj.7600263; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Verhoeven EEA, 2000, J BIOL CHEM, V275, P5120, DOI 10.1074/jbc.275.7.5120; Verhoeven EEA, 2002, EMBO J, V21, P4196, DOI 10.1093/emboj/cdf396; Verhoeven EEA, 2001, EMBO J, V20, P601, DOI 10.1093/emboj/20.3.601; VISSE R, 1994, BIOCHEMISTRY-US, V33, P9881, DOI 10.1021/bi00199a009; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; YANG SW, 1994, P NATL ACAD SCI USA, V91, P12183, DOI 10.1073/pnas.91.25.12183; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889; ZOU Y, 1995, BIOCHEMISTRY-US, V34, P13582, DOI 10.1021/bi00041a038; Zou Y, 2004, BIOCHEMISTRY-US, V43, P4196, DOI 10.1021/bi035992a	44	55	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45245	45256		10.1074/jbc.M408659200	http://dx.doi.org/10.1074/jbc.M408659200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308661	hybrid			2022-12-25	WOS:000224505600118
J	Mark, L; Lee, WH; Spiller, OB; Proctor, D; Blackbourn, DJ; Villoutreix, BO; Blom, AM				Mark, L; Lee, WH; Spiller, OB; Proctor, D; Blackbourn, DJ; Villoutreix, BO; Blom, AM			The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; CHARGED AMINO-ACIDS; I COFACTOR FUNCTION; VACCINIA VIRUS; ALPHA-CHAIN; C4B-BINDING PROTEIN; DNA-SEQUENCES; ENHANCED NEUTRALIZATION; ACTIVE-SITES; BINDING	Kaposi's sarcoma-associated human herpesvirus (KSHV) is thought to cause Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Previously, we reported that the KSHV complement control protein (KCP) encoded within the viral genome is a potent regulator of the complement system; it acts both as a cofactor for factor I and accelerates decay of the C3 convertases (Spiller, O.B., Blackbourn, D.J., Mark, L., Proctor, D. G., and Blom, A. M. (2003) J. Biol. Chem. 278, 9283-9289). KCP is a homologue to human complement regulators, being comprised of four complement control protein (CCP) domains. In this, the first study to identify the functional sites of a viral homologue at the amino acid level, we created a three-dimensional homology-based model followed by site-directed mutagenesis to locate complement regulatory sites. Classical pathway regulation, both through decay acceleration and factor I cleavage of C4b, required a cluster of positively charged amino acids in CCP1 stretching into CCP2 (Arg-20, Arg-33, Arg-35, Lys-64, Lys-65, and Lys-88) as well as positively (Lys-131, Lys-133, and His-135) and negatively (Glu-99, Glu-152, and Asp-155) charged areas at opposing faces of the border region between CCPs 2 and 3. The regulation of the alternative pathway (via factor I-mediated C3b cleavage) was found to both overlap with classical pathway regulatory sites (Lys-64, Lys-65, Lys-88 and Lys-131, Lys-133, His-135) as well as require unique, more C-terminal residues in CCPs 3 and 4 (His-158, His-171, and His-213) and CCP 4 (Phe-195, Phe-207, and Leu-209). We show here that KCP has evolved to maintain the spatial structure of its functional sites, especially the positively charged patches, compared with host complement regulators.	Lund Univ, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Paris 05, INSERM, U428, F-75006 Paris, France; Univ Wales Coll Med, Dept Biochem Med, Virus Receptor & Immune Evas Grp, Cardiff CF14 4XX, S Glam, Wales; Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland	Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Cardiff University; University of Glasgow	Blom, AM (corresponding author), Wallenberg Inst & Labs, Entrance 46,6th Floor, S-20502 Malmo, Sweden.	anna.blom@klkemi.mas.lu.se	Lee, Wen Hwa/GZA-8183-2022; Villoutreix, Bruno/I-4565-2015; Blom, Anna/B-9607-2009; Lee, Wen Hwa/G-1250-2013; Spiller, Owen Brad/AAC-2474-2020; Blom, Anna/AFS-7369-2022	Lee, Wen Hwa/0000-0002-4098-5225; Villoutreix, Bruno/0000-0002-6456-7730; Blom, Anna/0000-0002-1348-1734; Lee, Wen Hwa/0000-0002-4098-5225; Spiller, Owen Brad/0000-0002-9117-6911; Blackbourn, David/0000-0002-6703-4497				ADAMS EM, 1991, J IMMUNOL, V147, P3005; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Blom AM, 2003, J BIOL CHEM, V278, P43437, DOI 10.1074/jbc.M306620200; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Blue CE, 2004, VIROLOGY, V319, P176, DOI 10.1016/j.virol.2003.11.029; Brodbeck WG, 2000, IMMUNOLOGY, V101, P104, DOI 10.1046/j.1365-2567.2000.00086.x; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; FRIES LF, 1986, J IMMUNOL, V137, P1636; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x; ISAACS SN, 1992, P NATL ACAD SCI USA, V89, P628, DOI 10.1073/pnas.89.2.628; Isaacs SN, 2003, J VIROL, V77, P8256, DOI 10.1128/JVI.77.15.8256-8262.2003; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Kapadia SB, 2002, IMMUNITY, V17, P143, DOI 10.1016/S1074-7613(02)00369-2; Kirkitadze MD, 1999, BIOCHEM J, V344, P167, DOI 10.1042/0264-6021:3440167; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; Kuttner-Kondo LA, 2003, J BIOL CHEM, V278, P52386, DOI 10.1074/jbc.M304620200; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; Lubinski J, 1999, J EXP MED, V190, P1637, DOI 10.1084/jem.190.11.1637; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; Mossakowska D, 1999, EUR J IMMUNOL, V29, P1955, DOI 10.1002/(SICI)1521-4141(199906)29:06<1955::AID-IMMU1955>3.3.CO;2-F; Mullick J, 2003, J VIROL, V77, P3878, DOI 10.1128/JVI.77.6.3878-3881.2003; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Smith SA, 2003, BBA-PROTEINS PROTEOM, V1650, P30, DOI 10.1016/S1570-9639(03)00189-4; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spiller OB, 2003, J BIOL CHEM, V278, P9283, DOI 10.1074/jbc.M211579200; Spiller OB, 2003, J VIROL, V77, P592, DOI 10.1128/JVI.77.1.592-599.2003; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; Williams P, 2003, J BIOL CHEM, V278, P10691, DOI 10.1074/jbc.M212561200	45	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45093	45101		10.1074/jbc.M407558200	http://dx.doi.org/10.1074/jbc.M407558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304516	hybrid			2022-12-25	WOS:000224505600102
J	Muller, EA; Danner, DJ				Muller, EA; Danner, DJ			Tissue-specific translation of murine branched-chain alpha-ketoacid dehydrogenase kinase mRNA is dependent upon an upstream open reading frame in the 5 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-OXO ACID DEHYDROGENASE; SECONDARY STRUCTURE; GENE-EXPRESSION; ACTIVITY STATE; COMPLEX; PROMOTER; TRANSCRIPTION; IDENTIFICATION; METABOLISM; CLONING	The committed step in the pathway for leucine, isoleucine, and valine catabolism is catalyzed by branched-chain alpha-ketoacid dehydrogenase (BCKD). This multienzyme complex is itself regulated through reversible subunit phosphorylation by a specific kinase (BCKD-kinase). Although BCKD is present in the mitochondria of all mammalian cells, BCKD-kinase has a tissue-specific pattern of expression. Various experimental, nutritional, and hormonal conditions have been used to alter the expression of BCKD-kinase, yet little is known regarding the regulation of basal BCKD-kinase expression under normal conditions including the mechanism of its tissue specificity in any organism. Here we use tissue-derived cultured cells to explore the mechanisms used to control BCKD-kinase expression. Whereas the amount of BCKD-kinase protein is significantly higher in mitochondria from C2C12 myotubes than in BNL Cl. 2 liver cells, gene transcription and stability of BCKD-kinase mRNA share similar properties in these two cell types. Our results show that the amount of protein synthesized is regulated at the level of translation of BCKD-kinase mRNA and that an upstream open reading frame in the 5'- untranslated region of this transcript controls its translation. The location and putative 19-residue peptide are conserved in the mouse, rat, chimpanzee, and human genes. Likewise, gene structure of mouse, chimpanzee, and human BCKD-kinase is conserved, whereas the rat gene has lost intron 9.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Danner, DJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St,Rm 305C, Atlanta, GA 30322 USA.	ddanner@genetics.emory.edu			NIGMS NIH HHS [T32 GM008169, 5T32GM-08490, 5T32GM-08169, T32 GM008490] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490, T32GM008169] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ammanamanchi S, 2003, J BIOL CHEM, V278, P35775, DOI 10.1074/jbc.M305961200; Borchert A, 2003, J BIOL CHEM, V278, P2571, DOI 10.1074/jbc.M209064200; CHUANG DT, 1981, BIOCHEM J, V200, P59, DOI 10.1042/bj2000059; CHUANG DT, 1995, METABOLIC MOL BASES, P1239; DANCIS J, 1960, BIOCHIM BIOPHYS ACTA, V43, P342, DOI 10.1016/0006-3002(60)90448-0; Danner DJ, 2000, METHOD ENZYMOL, V324, P336; DANNER DJ, 1988, METHOD ENZYMOL, V166, P108; Denson LA, 2001, J CLIN INVEST, V107, P1451, DOI 10.1172/JCI10994; Ding Y, 2003, NUCLEIC ACIDS RES, V31, P7280, DOI 10.1093/nar/gkg938; Ding Y, 2001, NUCLEIC ACIDS RES, V29, P1034, DOI 10.1093/nar/29.5.1034; Doering CB, 1998, GENE, V212, P213, DOI 10.1016/S0378-1119(98)00182-6; Doering CB, 2000, METAB ENG, V2, P349, DOI 10.1006/mben.2000.0164; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; GIBSON R, 1993, ARCH BIOCHEM BIOPHYS, V306, P22, DOI 10.1006/abbi.1993.1475; GILLIM SE, 1983, BIOCHEM BIOPH RES CO, V111, P74, DOI 10.1016/S0006-291X(83)80119-3; HARRIS RA, 1988, METHOD ENZYMOL, V166, P114; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang YS, 2000, METHOD ENZYMOL, V324, P498; Huang YS, 1998, BIOCHEM J, V334, P713, DOI 10.1042/bj3340713; Huang YS, 1996, BIOCHEM J, V313, P603, DOI 10.1042/bj3130603; Kasinski A, 2004, MOL BRAIN RES, V122, P180, DOI 10.1016/j.molbrainres.2003.08.023; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kobayashi R, 2000, ARCH BIOCHEM BIOPHYS, V375, P55, DOI 10.1006/abbi.1999.1635; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Laviano A, 1996, NUTRITION, V12, P358, DOI 10.1016/S0899-9007(96)80061-X; Lee J, 2002, NUCLEIC ACIDS RES, V30, P5110, DOI 10.1093/nar/gkf664; Martin KM, 2000, BIOCHEM J, V345, P529, DOI 10.1042/0264-6021:3450529; McConnell BB, 1996, J CELL BIOCHEM, V61, P118, DOI 10.1002/(SICI)1097-4644(19960401)61:1<118::AID-JCB13>3.0.CO;2-K; Meijer HA, 2003, NUCLEIC ACIDS RES, V31, P3174, DOI 10.1093/nar/gkg429; MENKES JH, 1959, PEDIATRICS, V23, P348; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nellis MM, 2002, AM J PHYSIOL-ENDOC M, V283, pE853, DOI 10.1152/ajpendo.00133.2002; ODESSEY R, 1982, BIOCHEM J, V204, P353, DOI 10.1042/bj2040353; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; POPOV KM, 1995, ARCH BIOCHEM BIOPHYS, V316, P148, DOI 10.1006/abbi.1995.1022; Raney A, 2000, J BIOL CHEM, V275, P24444, DOI 10.1074/jbc.M003364200; Sitler TL, 1998, BBA-MOL CELL RES, V1404, P385, DOI 10.1016/S0167-4889(98)00086-X; Tarumi T, 2002, J BIOL CHEM, V277, P18510, DOI 10.1074/jbc.M201886200; Vilela C, 2003, MOL MICROBIOL, V49, P859, DOI 10.1046/j.1365-2958.2003.03622.x; WAGENMAKERS AJM, 1984, BIOCHEM J, V220, P273, DOI 10.1042/bj2200273; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; Wu Z, 2003, ENDOCRINOLOGY, V144, P3251, DOI 10.1210/en.2003-0015	45	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44645	44655		10.1074/jbc.M406550200	http://dx.doi.org/10.1074/jbc.M406550200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302860	hybrid			2022-12-25	WOS:000224505600051
J	Zhang, HF; Zhang, R; Luo, Y; D'Alessio, A; Pober, JS; Min, W				Zhang, HF; Zhang, R; Luo, Y; D'Alessio, A; Pober, JS; Min, W			AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; KAPPA-B ACTIVATION; REGULATING KINASE 1; TNF RECEPTOR 1; SIGNAL-TRANSDUCTION; CELL-DEATH; RING FINGER; APOPTOSIS; TRAF2; INHIBITOR	Previously we have shown that ASK-interacting protein 1 (AIP1, also known as DAB2IP), a novel member of the Ras-GAP protein family, mediates TNF-induced activation of ASK1-JNK signaling pathway. However, the mechanism by which TNF signaling is coupled to AIP1 is not known. Here we show that AIP1 is localized on the plasma membrane in resting endothelial cells (EC) in a complex with TNFR1. TNF binding induces release of AIP1 from TNFR1, resulting in cytoplasmic translocation and concomitant formation of an intracellular signaling complex comprised of TRADD, RIP1, TRAF2, and AIPl. A proline-rich region ( amino acids 796 - 807) is critical for maintaining AIP1 in a closed form, which associates with a region of TNFR1 distinct from the death domain, the site of TNFR1 association with TRADD. An AIP1 mutant with deletion of this proline-rich region constitutively binds to TRAF2 and ASK1. A PERIOD-like domain ( amino acids 591 - 719) of AIP1 binds to the intact RING finger of TRAF2, and specifically enhances TRAF2-induced ASK1 activation. At the same time, the binding of AIP1 to TRAF2 inhibits TNF-induced IKK-NF-kappaB signaling. Taken together, our data suggest that AIP1 is a novel transducer in TNF-induced TRAF2-dependent activation of ASK1 that mediates a balance between JNK versus NF-kappaB signaling.	Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, Boyer Ctr Mol Med,Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Immunol & Dermatol, New Haven, CT 06510 USA; Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China	Yale University; Yale University; Sun Yat Sen University	Min, W (corresponding author), Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, Boyer Ctr Mol Med,Dept Pathol, BCMM 454,295 Congress Ave, New Haven, CT 06510 USA.	wang.min@yale.edu	D'Alessio, Alessio/F-3778-2010	D'Alessio, Alessio/0000-0002-3340-2634	NHLBI NIH HHS [HL-36003, HV28286, HL-65978] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065978, R37HL036003, R01HL036003] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brink R, 1998, J BIOL CHEM, V273, P4129, DOI 10.1074/jbc.273.7.4129; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Dadgostar H, 1998, J BIOL CHEM, V273, P24775, DOI 10.1074/jbc.273.38.24775; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guicciardi ME, 2003, J CLIN INVEST, V111, P1813, DOI 10.1172/JCI200318911; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jones SJ, 1999, J IMMUNOL, V162, P1042; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Min W, 1998, J IMMUNOL, V161, P319; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang R, 2003, J CLIN INVEST, V111, P1933, DOI 10.1172/JCI200317790	40	111	129	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44955	44965		10.1074/jbc.M407617200	http://dx.doi.org/10.1074/jbc.M407617200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310755	hybrid			2022-12-25	WOS:000224505600087
J	Dufour, G; Demers, MJ; Gagne, D; Dydensborg, AB; Teller, IC; Bouchard, V; Degongre, I; Beaulieu, JF; Cheng, JQ; Fujita, N; Tsuruo, T; Vallee, K; Vachon, PH				Dufour, G; Demers, MJ; Gagne, D; Dydensborg, AB; Teller, IC; Bouchard, V; Degongre, I; Beaulieu, JF; Cheng, JQ; Fujita, N; Tsuruo, T; Vallee, K; Vachon, PH			Human intestinal epithelial cell survival and anoikis - Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TRANSIENT MOSAIC PATTERNS; INDUCED APOPTOSIS-ANOIKIS; CRYPT-VILLUS AXIS; PHOSPHATIDYLINOSITOL 3-KINASE; BCL-2 HOMOLOGS; MICE LACKING; ENTEROCYTIC DIFFERENTIATION; COMPLEX MODULATIONS; SIGNAL-TRANSDUCTION	We have shown previously that human intestinal epithelial cell survival and anoikis are distinctively regulated according to the state of differentiation. Here we analyzed the roles of protein kinase B/Akt isoforms in such differentiation state distinctions. Anoikis was induced in undifferentiated and differentiated enterocytes by inhibition of focal adhesion kinase (Fak; pharmacologic inhibition or overexpression of dominant-negative mutants) or beta(1) integrins (antibody blocking) or by maintaining cells in suspension. Expression/ activation parameters of Akt isoforms (Akt-1, Akt-2, and Akt-3) and Fak were analyzed. Activity of Akt isoforms was also blocked by inhibition of phosphatidylinositol 3-kinase or by overexpression of dominant-negative mutants. Here we report the following. 1) The expression/activation levels of Akt-1 increase overall during enterocytic differentiation, and those of Akt-2 decrease, whereas Akt-3 is not expressed. 2) Akt-1 activation is dependent on beta(1) integrins/Fak signaling, regardless of the differentiation state. 3) Akt-2 activation is dependent on beta(1) integrins/Fak signaling in undifferentiated cells only. 4) Activation of Akt-1 is phosphatidylinositol 3-kinase-dependent, whereas that of Akt-2 is not. 5) Akt-2 does not promote survival or apoptosis/anoikis. 6) Akt-1 is essential for survival. 7) Akt-2 cannot substitute for Akt-1 in the suppression of anoikis. Hence, the expression and regulation of Akt isoforms show differentiation state-specific distinctions that ultimately reflect upon their selective implication in the mediation of human intestinal epithelial cell survival. These data provide new insights into the synchronized regulation of cell survival/death that is required in the dynamic renewal process of tissues such as the intestinal epithelium.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; CHU Sherbrooke, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Tokyo; University of Sherbrooke	Vachon, PH (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Canadian Inst Hlth Res Grp Funct Dev & Physiopath, Sherbrooke, PQ J1H 5N4, Canada.	Pierre.H.Vachon@USherbrooke.ca	Teller, Inga/AAW-1093-2020; Beaulieu, Jean-Francois/D-2054-2010	Teller, Inga/0000-0002-1708-8702; Fujita, Naoya/0000-0002-9631-9264				Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200; Basora N, 1999, J BIOL CHEM, V274, P29819, DOI 10.1074/jbc.274.42.29819; Basora N, 1997, GASTROENTEROLOGY, V113, P1510, DOI 10.1053/gast.1997.v113.pm9352853; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BEAULIEU JF, 1992, J CELL SCI, V102, P427; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1999, METH MOL B, V129, P251; Fujio Y, 2001, CELL DEATH DIFFER, V8, P1207, DOI 10.1038/sj.cdd.4400919; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Gauthier R, 2001, AM J PHYSIOL-CELL PH, V280, pC1540, DOI 10.1152/ajpcell.2001.280.6.C1540; Gauthier R, 2001, J CELL BIOCHEM, V82, P339, DOI 10.1002/jcb.1172; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grossmann J, 2002, AM J GASTROENTEROL, V97, P1421, DOI 10.1016/S0002-9270(02)04143-6; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Harnois C, 2004, J CELL PHYSIOL, V198, P209, DOI 10.1002/jcp.10399; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Laprise P, 2003, J CELL BIOCHEM, V89, P1115, DOI 10.1002/jcb.10581; Laprise P, 2002, J CELL PHYSIOL, V191, P69, DOI 10.1002/jcp.10075; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Levy P, 2003, J CELL PHYSIOL, V197, P336, DOI 10.1002/jcp.10345; Levy P, 1998, J CELL PHYSIOL, V177, P618, DOI 10.1002/(SICI)1097-4652(199812)177:4<618::AID-JCP12>3.0.CO;2-R; Liu AX, 1998, CANCER RES, V58, P2973; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nolan K, 1999, MOL CELL BIOL, V19, P6120; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Rane MJ, 2003, J BIOL CHEM, V278, P27828, DOI 10.1074/jbc.M303417200; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Ringel MD, 2001, CANCER RES, V61, P6105; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Sumitani S, 2002, ENDOCRINOLOGY, V143, P820, DOI 10.1210/en.143.3.820; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Thomson ABR, 2003, DIGEST DIS SCI, V48, P1546, DOI 10.1023/A:1024719925058; Thomson ABR, 2003, DIGEST DIS SCI, V48, P1565, DOI 10.1023/A:1024724109128; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716; Vachon PH, 1996, J CELL PHYSIOL, V166, P198, DOI 10.1002/(SICI)1097-4652(199601)166:1<198::AID-JCP21>3.0.CO;2-A; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Vachon PH, 2001, HISTOL HISTOPATHOL, V16, P497, DOI 10.14670/HH-16.497; Vachon PH, 2000, INT J DEV BIOL, V44, P891; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wary KK, 1999, METH MOL B, V129, P35; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zinda MJ, 2001, CLIN CANCER RES, V7, P2475	74	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44113	44122		10.1074/jbc.M405323200	http://dx.doi.org/10.1074/jbc.M405323200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299029	hybrid			2022-12-25	WOS:000224383100091
J	Zhang, Z; Lapolla, SM; Annis, MG; Truscott, M; Roberts, GJ; Miao, YW; Shao, YL; Tan, CB; Peng, J; Johnson, AE; Zhang, XJC; Andrews, DW; Lin, JL				Zhang, Z; Lapolla, SM; Annis, MG; Truscott, M; Roberts, GJ; Miao, YW; Shao, YL; Tan, CB; Peng, J; Johnson, AE; Zhang, XJC; Andrews, DW; Lin, JL			Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; PHOTO-CROSS-LINKING; FAMILY-MEMBERS; SIGNAL SEQUENCE; BH4 DOMAIN; BIOPHYSICAL CHARACTERIZATION; INDEPENDENT MECHANISMS; ENDOPLASMIC-RETICULUM; APOPTOTIC ACTIVITY; PROTEIN BCL-2	The homo- and heterodimerization of Bcl-2 family proteins is important for transduction and integration of apoptotic signals and control of the permeability of mitochondria and endoplasmic reticulum membranes. Here we mapped the interface of the Bcl-2 homodimer in a cell-free system using site-specific photocross-linking. Bcl-2 homodimer-specific photoadducts were detected from 11 of 17 sites studied. When modeled into the structure of Bcl-2 core, the interface is composed of two distinct surfaces: an acceptor surface that includes the hydrophobic groove made by helices 2 and 8 and the loop connecting helices 4 and 5 and a donor surface that is made by helices 1-4 and the loop connecting helices 2 and 3. The two binding surfaces are on separate faces of the three-dimensional structure, explaining the formation of Bcl-2 homodimers, homo- oligomers, and Bcl-2/Bax hetero-oligomers. We show that in vitro the Bcl-2 dimer can still interact with activated Bax as a larger oligomer. However, formation of a Bax/Bcl-2 heterodimer is favored, since this interaction inhibits Bcl-2 homodimerization. Our data support a simple model mechanism by which Bcl-2 interacts with activated Bax during apoptosis in an effective manner to neutralize the proapoptotic activity of Bax.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Oklahoma Med Res Fdn, Crystallog Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; McMaster University; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Oklahoma Medical Research Foundation	Lin, JL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd,BMSB 935,POB 26901, Oklahoma City, OK 73190 USA.	jialing-lin@ouhsc.edu	Johnson, Arthur E/G-3457-2012	Andrews, David/0000-0002-9266-7157; Truscott, Mary/0000-0002-2324-6383; Annis, Matthew/0000-0002-8776-004X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062964] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM062964, R01 GM062964] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annis MG, 2004, BBA-MOL CELL RES, V1644, P115, DOI 10.1016/j.bbamcr.2003.07.001; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Denisov AY, 2003, J BIOL CHEM, V278, P21124, DOI 10.1074/jbc.M301798200; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; HACKER G, 1995, CURR BIOL, V5, P622, DOI 10.1016/S0960-9822(95)00126-6; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Kim KM, 2001, BIOCHEMISTRY-US, V40, P4911, DOI 10.1021/bi002368e; Kim PK, 2004, MOL CELL, V14, P523, DOI 10.1016/S1097-2765(04)00263-1; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; Li LY, 2001, J BIOL CHEM, V276, P27354, DOI 10.1074/jbc.M103821200; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Liu XQ, 2003, IMMUNITY, V19, P341, DOI 10.1016/S1074-7613(03)00234-6; Mathura VS, 2003, J MOL MODEL, V9, P298, DOI 10.1007/s00894-003-0152-y; McCallum CD, 2000, J CELL BIOL, V149, P591, DOI 10.1083/jcb.149.3.591; McCormick PJ, 2003, MOL CELL, V12, P329, DOI 10.1016/S1097-2765(03)00304-6; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shirane M, 2003, NAT CELL BIOL, V5, P28, DOI 10.1038/ncb894; StClair EG, 1997, J BIOL CHEM, V272, P29347; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wei MC, 2000, GENE DEV, V14, P2060; Woo JS, 2003, CELL DEATH DIFFER, V10, P1310, DOI 10.1038/sj.cdd.4401303; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yethon JA, 2003, J BIOL CHEM, V278, P48935, DOI 10.1074/jbc.M306289200; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999	60	61	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43920	43928		10.1074/jbc.M406412200	http://dx.doi.org/10.1074/jbc.M406412200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302859	hybrid, Green Accepted			2022-12-25	WOS:000224383100070
J	Jez, JM; Cahoon, RE				Jez, JM; Cahoon, RE			Kinetic mechanism of glutathione synthetase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-B; INITIAL VELOCITY; FLEXIBLE LOOP; SUBSTRATE; LIGASE; IDENTIFICATION; BIOSYNTHESIS; MUTATIONS; PHOSPHATE; BINDING	Glutathione synthetase (GS) catalyzes the ATP-dependent formation of the ubiquitous peptide glutathione from gamma-glutamylcysteine and glycine. The bacterial and eukaryotic GS form two distinct families lacking amino acid sequence homology. Moreover, the detailed kinetic mechanism of the bacterial and the eukaryotic GS remains unclear. Here we have overexpressed Arabidopsis thaliana GS (AtGS) in an Escherichia coli expression system and purified the recombinant enzyme for biochemical characterization. AtGS is functional as a homodimeric protein with steady-state kinetic properties similar to those of other eukaryotic GS. The kinetic mechanism of AtGS was investigated using initial velocity methods and product inhibition studies. The best fit of the observed data was to the equation for a random Ter-reactant mechanism in which dependencies between the binding of some substrate pairs were preferred. The binding of either ATP or gamma-glutamylcysteine increased the binding affinity of AtGS for the other substrate by 10-fold. Likewise, the binding of ATP or glycine increased binding affinity for the other ligand by 3.5-fold. In contrast, binding of either glycine or gamma-glutamylcysteine causes a 6.7-fold decrease in binding affinity for the second molecule. Product inhibition studies suggest that ADP is the last product released from the enzyme. Overall, these observations are consistent with a random Ter-reactant mechanism for the eukaryotic GS in which the binding order of certain substrates is kinetically preferred for catalysis.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA	Donald Danforth Plant Science Center	Jez, JM (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	jjez@danforthcenter.org						AINSLIE GR, 1972, J BIOL CHEM, V247, P946; Anderson MS, 1996, BIOCHEMISTRY-US, V35, P16264, DOI 10.1021/bi961872+; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; COOPER BF, 1995, METHOD ENZYMOL, V249, P188; Copley SD, 2002, GENOME BIOL, V3; DANENBERG KD, 1975, BIOCHEMISTRY-US, V14, P28, DOI 10.1021/bi00672a006; Dinescu A, 2004, J BIOL CHEM, V279, P22412, DOI 10.1074/jbc.M401334200; DODDMOOZ E, 1967, BIOCHEMISTRY-US, V6, P1722; Emanuele JJ, 1997, BIOCHEMISTRY-US, V36, P7264, DOI 10.1021/bi970266r; Gali RR, 1997, BIOCHEM J, V321, P207, DOI 10.1042/bj3210207; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; HELL R, 1988, PHYSIOL PLANTARUM, V72, P70, DOI 10.1111/j.1399-3054.1988.tb06624.x; Jez JM, 2004, J BIOL CHEM, V279, P33463, DOI 10.1074/jbc.M405127200; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; JOYCE BK, 1966, J BIOL CHEM, V241, P5725; KATO H, 1987, J BIOCHEM, V101, P207, DOI 10.1093/oxfordjournals.jbchem.a121893; May MJ, 1998, J EXP BOT, V49, P649, DOI 10.1093/jexbot/49.321.649; MEEK TD, 1980, BIOCHEMISTRY-US, V19, P5513, DOI 10.1021/bi00565a008; Meierjohann S, 2002, BIOCHEM J, V363, P833, DOI 10.1042/0264-6021:3630833; MEISTER A, 1976, ANNU REV BIOCHEM, V45, P559, DOI 10.1146/annurev.bi.45.070176.003015; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULLINS LS, 1990, J BIOL CHEM, V265, P8993; NISHIMURA JS, 1964, J BIOL CHEM, V239, P2553; Njalsson R, 2000, BIOCHEM J, V349, P275, DOI 10.1042/0264-6021:3490275; Njalsson R, 2001, BIOCHEM BIOPH RES CO, V289, P80, DOI 10.1006/bbrc.2001.5961; Noctor G, 1998, J EXP BOT, V49, P623, DOI 10.1093/jexbot/49.321.623; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; Segel IH, 1975, ENZYME KINETICS BEHA; TANAKA T, 1992, BIOCHEMISTRY-US, V31, P2259, DOI 10.1021/bi00123a007; TANAKA T, 1993, BIOCHEMISTRY-US, V32, P12398, DOI 10.1021/bi00097a018; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; VIOLA RE, 1982, METHOD ENZYMOL, V87, P353; Wang CL, 1997, BIOCHEM J, V322, P241, DOI 10.1042/bj3220241; Wang CL, 1997, BIOCHEM J, V326, P563, DOI 10.1042/bj3260563; Wang CL, 1996, PLANT MOL BIOL, V31, P1093, DOI 10.1007/BF00040827; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; Zenk MH, 1996, GENE, V179, P21, DOI 10.1016/S0378-1119(96)00422-2	39	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42726	42731		10.1074/jbc.M407961200	http://dx.doi.org/10.1074/jbc.M407961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302873	hybrid			2022-12-25	WOS:000224226400047
J	Shinohara, S; Rothstein, JL				Shinohara, S; Rothstein, JL			Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells	ONCOGENE			English	Article						inflammation; interleukin 24; Mda7; RET/PTC; thyroid	DIFFERENTIATION-ASSOCIATED GENE; PAPILLARY THYROID-CARCINOMA; HUMAN-MELANOMA DIFFERENTIATION; LYMPHOCYTIC THYROIDITIS; TYROSINE KINASE; SUPPRESSOR GENE; BRAF MUTATIONS; IN-VITRO; CANCER; EXPRESSION	Thyroid cancers, like hematological malignancies, are commonly associated with chromosomal translocations leading to the formation of fusion proteins. Through altered signaling by fusion proteins, cell death and survival pathways are disrupted and the physiological balance of cell - cell communication may be lost. A consequence of this disruption is the release of factors by stressed cells that alert the host. One type of host response is leukocytic infiltration that may develop into chronic inflammation or autoimmune disease. Although inflammation can be associated with neoplastic tissue, the mechanism driving this process is largely unknown. Therefore, to address the mechanism of cancer inflammation we investigated the effects of an oncogene in a murine model system. A comprehensive genetic analysis revealed several soluble factors that were induced by RET/papillary thyroid carcinoma (PTC) 3 gene expression including several proinflammatory cytokines, chemokines and immunologically relevant costimulatory molecules. Following a large genetic screen using RP3-expressing thyroid cells, we identified a highly abundant transcript and later identified it as interleukin 24 (Il24), a cytokine with diverse tumor suppressor and inflammatory activities. We show that RET/PTC3 induces Il24 expression in rat thyrocytes and that this expression is dependent on the signaling properties of its tyrosine kinase. Likewise, RET/PTC3 induces large amounts of Il24 following expression in murine thyrocytes, but its expression is dramatically reduced in poorly differentiated carcinomas, a finding that parallels the loss of RET/PTC3 expression. Consistent with its behavior as a tumor suppressor, the loss of Il24 coincided with the loss of RET/PTC3 in poorly differentiated mouse tumors. A functional role of Il24 in the autocrine growth/survival of RET/PTC3-expressing thyroid cells was identified helping to support its role in cellular transformation. These data suggest that the induction of Il24 by oncogenes may support tumor growth at the early stages of cancer.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.	jay.rothstein@jefferson.edu	Shinohara, Shogo/H-8976-2019	Shinohara, Shogo/0000-0002-1794-2091	NCI NIH HHS [CA-76259, T32-CA09678] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, T32CA009678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aust G, 1996, EXP CLIN ENDOCR DIAB, V104, P64, DOI 10.1055/s-0029-1211705; Basolo F, 1998, CLIN CANCER RES, V4, P381; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; DAILEY ME, 1955, AMA ARCH SURG, V70, P271; Ekmekcioglu S, 2001, INT J CANCER, V94, P54, DOI 10.1002/ijc.1437; ENOMOTO T, 1990, CANCER, V65, P1971, DOI 10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUSCO A, 1995, J ENDOCRINOL INVEST, V18, P127, DOI 10.1007/BF03349720; JHIANG SM, 1992, ONCOGENE, V7, P1331; Jiang HP, 1995, ONCOGENE, V11, P2477; KAYSER L, 1995, AUTOIMMUNITY, V20, P75, DOI 10.3109/08916939509001930; Kimura ET, 2003, CANCER RES, V63, P1454; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Loh KC, 1999, J CLIN ENDOCR METAB, V84, P458, DOI 10.1210/jc.84.2.458; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mechler C, 2001, BRIT J CANCER, V85, P1831, DOI 10.1054/bjoc.2001.2187; Nakada T, 1996, INTERNAL MED, V35, P815, DOI 10.2169/internalmedicine.35.815; OTT RA, 1987, AM SURGEON, V53, P442; PASQUALE D, 2001, HUM PATHOL, V32, P24; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Powell DJ, 1998, CANCER RES, V58, P5523; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Ramesh R, 2003, CANCER RES, V63, P5105; Rasmussen AK, 2000, DAN MED BULL, V47, P94; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Russell JP, 2004, J IMMUNOL, V172, P4059, DOI 10.4049/jimmunol.172.7.4059; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Sarkar D, 2002, BIOTECHNIQUES, P30; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Soo C, 1999, J CELL BIOCHEM, V74, P1; Stassi G, 2003, CANCER RES, V63, P6784; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Sugg SL, 1996, J CLIN ENDOCR METAB, V81, P3360, DOI 10.1210/jc.81.9.3360; TAKAHASHI K, 1995, PATHOL INT, V45, P366, DOI 10.1111/j.1440-1827.1995.tb03470.x; Tamimi DM, 2002, INT J SURG PATHOL, V10, P141, DOI 10.1177/106689690201000207; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Winterrowd GE, 1999, J IMMUNOL METHODS, V226, P105, DOI 10.1016/S0022-1759(99)00049-6; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623; YOSHIDA M, 1992, CANCER RES, V52, P464; Zhang R, 2000, J BIOL CHEM, V275, P24436, DOI 10.1074/jbc.M001958200	52	29	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7571	7579		10.1038/sj.onc.1207964	http://dx.doi.org/10.1038/sj.onc.1207964			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326486				2022-12-25	WOS:000224176500014
J	Ayub, K; Hallett, MB				Ayub, K; Hallett, MB			The mitochondrial ADPR link between Ca2+ store release and Ca2+ influx channel opening in immune cells	FASEB JOURNAL			English	Article						non-voltage-operated Ca2+; mitochondrial Ca2+; Ca2+ influx channels	ENDOPLASMIC-RETICULUM; T-LYMPHOCYTES; CALCIUM; ENTRY; DEPLETION; EXPRESSION; TRANSPORT; MESSENGER; NAD(+)	The regulation of non-voltage-operated Ca2+ channels in the plasma membrane remains unclear (1-3). However, there is often a link between the physiological release of Ca2+ from intracellular stores and opening of Ca2+ influx channels on the plasma membrane. This route has been referred to variously as store-operated Ca2+ entry (SOC), capacitative Ca2+ entry, and Ca2+ release-activated channel opening (CRAC), and often underlies the large changes in cytosolic free Ca2+ that accompany many stimuli in a wide variety of cell types (1-3). The linkage between Ca2+ store release and opening of Ca2+ channels on the plasma membrane has remained elusive for a number of years, perhaps in part because different mechanisms exist for this linkage, and are used to differing extents by different cells. We suggest here that one of the mechanisms that may operate in cells of the immune system, but that may be important elsewhere, involves the release of mitochondrial adenosine diphosphate ribose (ADPR) or nicotinamide adenine dinucleotide (NAD(+)). There is accumulating evidence to support each of the steps necessary for a complete description of this "Ca2+ store release to plasma membrane channel opening" link, but to our knowledge they have not been connected before to make a coherent model.	Cardiff Univ, Seutrophil Signalling Grp, Dept Surg, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Hallett, MB (corresponding author), Cardiff Univ, Seutrophil Signalling Grp, Dept Surg, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	hallettmb@cardiff.ac.uk	Hallett, Maurice/I-6866-2012	Hallett, Maurice/0000-0001-8197-834X				ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Conde M, 1996, J LEUKOCYTE BIOL, V60, P278, DOI 10.1002/jlb.60.2.278; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; DAVIES EV, 1995, BIOCHEM BIOPH RES CO, V206, P348, DOI 10.1006/bbrc.1995.1048; Davies-Cox EV, 2001, BIOCHEM J, V355, P139, DOI 10.1042/bj3550139; Di Lisa F, 2001, J BIOL CHEM, V276, P2571, DOI 10.1074/jbc.M006825200; Di Lisa F, 2001, FEBS LETT, V492, P4, DOI 10.1016/S0014-5793(01)02198-6; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FILIPPIN L, 2003, J BIOL CHEM, V31, P31; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GUNTER KK, 1994, J BIOENERG BIOMEMBR, V26, P471, DOI 10.1007/BF00762732; Haak LL, 2002, J NEUROCHEM, V80, P405, DOI 10.1046/j.0022-3042.2001.00727.x; Heiner I, 2003, CELL CALCIUM, V33, P533, DOI 10.1016/S0143-4160(03)00058-7; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Scott SR, 1998, PFLUG ARCH EUR J PHY, V436, P928, DOI 10.1007/s004240050725; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	41	16	17	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1335	1338		10.1096/fj.04-1888hyp	http://dx.doi.org/10.1096/fj.04-1888hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333576				2022-12-25	WOS:000224243200052
J	Block, ML; Wu, X; Pei, Z; Li, G; Wang, T; Qin, L; Wilson, B; Yang, J; Hong, JS; Veronesi, B				Block, ML; Wu, X; Pei, Z; Li, G; Wang, T; Qin, L; Wilson, B; Yang, J; Hong, JS; Veronesi, B			Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase	FASEB JOURNAL			English	Article						dopaminergic neurotoxicity; oxidative stress; Parkinson's disease	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; ROTENONE-INDUCED DEGENERATION; IN-VITRO; PULMONARY INFLAMMATION; TETRAZOLIUM SALT; ACTIVATION; BRAIN; PARTICULATE; MECHANISMS; INHIBITION	The contributing role of environmental factors to the development of Parkinson's disease has become increasingly evident. We report that mesencephalic neuron-glia cultures treated with diesel exhaust particles (DEP; 0.22 muM) ( 5 - 50 mug/ml) resulted in a dose-dependent decrease in dopaminergic (DA) neurons, as determined by DA-uptake assay and tyrosine-hydroxylase immunocytochemistry (ICC). The selective toxicity of DEP for DA neurons was demonstrated by the lack of DEP effect on both GABA uptake and Neu-N immunoreactive cell number. The critical role of microglia was demonstrated by the failure of neuron-enriched cultures to exhibit DEP-induced DA neurotoxicity, where DEP-induced DA neuron death was reinstated with the addition of microglia to neuron-enriched cultures. OX-42 ICC staining of DEP treated neuronglia cultures revealed changes in microglia morphology indicative of activation. Intracellular reactive oxygen species and superoxide were produced from enriched-microglia cultures in response to DEP. Neuron-glia cultures from NADPH oxidase deficient (PHOX-/-) mice were insensitive to DEP neurotoxicity when compared with control mice (PHOX+/+). Cytochalasin D inhibited DEP-induced superoxide production in enriched-microglia cultures, implying that DEP must be phagocytized by microglia to produce superoxide. Together, these in vitro data indicate that DEP selectively damages DA neurons through the phagocytic activation of microglial NADPH oxidase and consequent oxidative insult.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA; NIEHS, Div Neurotoxicol, Off Res & Dev, US EPA, Res Triangle Pk, NC 27709 USA; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); United States Environmental Protection Agency; Dalian Medical University	Block, ML (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, MD F1-01,POB 12233, Res Triangle Pk, NC 27709 USA.	Block@niehs.nih.gov	Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401; Block, Michelle/0000-0001-8303-7914				Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604, DOI 10.1152/ajplung.1999.276.4.L604; Calderon-Garciduenas L, 2003, TOXICOL PATHOL, V31, P524, DOI 10.1080/01926230390226645; Calderon-Garciduenas L, 2002, TOXICOL PATHOL, V30, P373, DOI 10.1080/01926230252929954; Canudas AM, 2000, NEUROBIOL DIS, V7, P343, DOI 10.1006/nbdi.2000.0308; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cho BP, 2003, CELL MOL NEUROBIOL, V23, P551, DOI 10.1023/A:1025024129946; Finch GL, 2002, INHAL TOXICOL, V14, P1017, DOI 10.1080/08958370290084764; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; JEFFREY M, 1994, NEUROPATH APPL NEURO, V20, P535, DOI 10.1111/j.1365-2990.1994.tb01007.x; JENSEN L K, 1989, Ugeskrift for Laeger, V151, P2255; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; KUMAGAI Y, 1995, FREE RADICAL BIO MED, V18, P365, DOI 10.1016/0891-5849(94)00125-4; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2003, METH MOLEC MED, V79, P387; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2001, J PHARMACOL EXP THER, V298, P1133; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; LOEFFLER DA, 1994, CLIN NEUROPHARMACOL, V17, P370, DOI 10.1097/00002826-199408000-00009; Ma JYC, 2002, J ENVIRON SCI HEAL C, V20, P117, DOI 10.1081/GNC-120016202; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Mitrasinovic OM, 2003, NEUROBIOL AGING, V24, P807, DOI 10.1016/S0197-4580(02)00237-3; Mitrasinovic OM, 2003, NEUROSCI LETT, V344, P185, DOI 10.1016/S0304-3940(03)00474-9; Nemmar A, 2003, TOXICOL APPL PHARM, V186, P38, DOI 10.1016/S0041-008X(02)00024-8; Oberdorster G, 1996, PARTICLE OVERLOAD IN THE RAT LUNG AND LUNG CANCER, P73; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Qin LY, 2002, J NEUROCHEM, V83, P973, DOI 10.1046/j.1471-4159.2002.01210.x; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Sherer TB, 2003, NEUROSCI LETT, V341, P87, DOI 10.1016/S0304-3940(03)00172-1; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Sugama S, 2003, NEUROSCIENCE, V116, P925, DOI 10.1016/S0306-4522(02)00572-9; Takenaka S, 2001, ENVIRON HEALTH PERSP, V109, P547, DOI 10.2307/3454667; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Tao F, 2003, FREE RADICAL BIO MED, V35, P327, DOI 10.1016/S0891-5849(03)00280-6; Veronesi B, 2003, NEUROTOXICOLOGY, V24, P463, DOI 10.1016/S0161-813X(03)00022-6; Veronesi B, 2002, TOXICOL APPL PHARM, V178, P144, DOI 10.1006/taap.2001.9341; von Baumgarten F, 1980, Cell Tissue Res, V212, P279; WU X, IN PRESS ANTIOXID RE	45	269	280	1	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1618	+		10.1096/fj.04-1945fje	http://dx.doi.org/10.1096/fj.04-1945fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319363				2022-12-25	WOS:000223554900004
J	Casanova, ML; Bravo, A; Martinez-Palacio, J; Fernandez-Acenero, MJ; Villanueva, C; Larcher, F; Conti, CJ; Jorcano, JL				Casanova, ML; Bravo, A; Martinez-Palacio, J; Fernandez-Acenero, MJ; Villanueva, C; Larcher, F; Conti, CJ; Jorcano, JL			Epidermal abnormalities and increased malignancy of skin tumors in human epidermal keratin 8-expressing transgenic mice	FASEB JOURNAL			English	Article						cutaneous cancer; epithelial dysplastic changes; ectopic keratin expression; neoplastic diseases	GROWTH-FACTOR RECEPTOR; SIMPLE EPITHELIAL KERATIN-8; INTERMEDIATE-FILAMENTS; CELL-PROLIFERATION; FACTOR-ALPHA; EXPRESSION; GENE; CYTOKERATINS; PROGRESSION; PAPILLOMAS	Keratins K8 and K18 are the major components of the intermediate filament cytoskeleton of simple epithelia. Increased levels of these keratins have been associated with invasive growth and progression to malignancy in different types of human and murine epithelial tumors ( including skin tumors), and even in tumors from nonepithelial origin. However, it has not yet clarified whether K8/K18 expression in tumors is cause or consequence of malignancy. Given the increasing incidence of epidermal cancer in humans (40% of all tumors diagnosed), we generated a mouse model to examine the role of simple epithelium keratins in the establishment and progression of human skin cancer. Transgenic mice expressing human K8 in the epidermis showed severe epidermal and hair follicle dysplasia with concomitant alteration in epidermal differentiation markers. The severity of the skin phenotype of these transgenic mice increases with age, leading to areas of preneoplastic transformation. Skin carcinogenesis assays showed a dramatic increase in the progression of papillomas toward malignancy in transgenic animals. These results support the idea that K8 alters the epidermal cell differentiation, favors the neoplastic transformation of cells, and is ultimately responsible of the invasive behavior of transformed epidermal cells leading of conversion of benign to malignant tumors.	CIEMAT, Epithelial Damage Repair & Tissue Engn, E-28040 Madrid, Spain; Univ Santiago de Compostela, Fac Vet, Dept Anim Pathol, Lugo, Spain; Univ Texas, MD Anderson Canc Ctr, Smithville, TX USA; Hosp Gen Mostoles, Madrid, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela; University of Texas System; UTMD Anderson Cancer Center	Casanova, ML (corresponding author), CIEMAT, Epithelial Damage Repair & Tissue Engn, Ave Complutense 22, E-28040 Madrid, Spain.	llanos.casanova@ciemat.es	Martinez, Jesus/M-3791-2014; Larcher, Fernando/J-1527-2016; Aceñero, M Jesús Fernández/ABC-5904-2020; Moral, Ana María Bravo/AAD-3339-2021	Martinez, Jesus/0000-0002-9521-8744; Larcher, Fernando/0000-0002-6771-3561; Aceñero, M Jesús Fernández/0000-0002-2439-3553; Moral, Ana María Bravo/0000-0002-5282-8921; Casanova, M. Llanos/0000-0001-7742-8265				ABE M, 1990, J CELL BIOL, V111, P1197, DOI 10.1083/jcb.111.3.1197; Ameen NA, 2001, J CELL SCI, V114, P563; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; BARIBAULT H, 1993, GENE DEV, V7, P1191, DOI 10.1101/gad.7.7a.1191; Bottinger EP, 1997, EMBO J, V16, P2621, DOI 10.1093/emboj/16.10.2621; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; CASANOVA L, 1995, J CELL SCI, V108, P811; Casanova ML, 2002, CANCER RES, V62, P3402; Casanova ML, 1999, J CLIN INVEST, V103, P1587, DOI 10.1172/JCI5343; CAULIN C, 1993, EXP CELL RES, V204, P11, DOI 10.1006/excr.1993.1003; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; CHENG C, 1990, MOL CARCINOGEN, V3, P363, DOI 10.1002/mc.2940030608; DIAZGUERRA M, 1992, CANCER RES, V52, P680; DLUGOSZ AA, 1994, CELL GROWTH DIFFER, V5, P1283; DuBowski A, 1998, CARCINOGENESIS, V19, P1141, DOI 10.1093/carcin/19.6.1141; EINARSSON R, 1995, SCAND J CLIN LAB INV, V55, P113, DOI 10.3109/00365519509090574; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HASHIDO K, 1991, EXP CELL RES, V192, P203, DOI 10.1016/0014-4827(91)90177-V; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; HUNTS J, 1985, JPN J CANCER RES, V76, P663; Hutton E, 1998, J CELL BIOL, V143, P487, DOI 10.1083/jcb.143.2.487; Jaquemar D, 2003, J CELL BIOL, V161, P749, DOI 10.1083/jcb.200210004; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 1996, J CLIN INVEST, V98, P1034, DOI 10.1172/JCI118864; KU NO, 1995, J CELL BIOL, V131, P1303, DOI 10.1083/jcb.131.5.1303; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lasota J, 1996, AM J SURG PATHOL, V20, P346, DOI 10.1097/00000478-199603000-00012; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Limmer B L, 2001, Tex Med, V97, P56; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; MARKEY AC, 1991, J INVEST DERMATOL, V97, P763, DOI 10.1111/1523-1747.ep12486607; McGowan K, 1998, Subcell Biochem, V31, P173; Moll I, 1996, J INVEST DERMATOL, V106, P281, DOI 10.1111/1523-1747.ep12340714; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; OGDEN GR, 1994, ORAL ONCOL, V30B, P405, DOI 10.1016/0964-1955(94)90020-5; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Porter RM, 2003, TRENDS GENET, V19, P278, DOI 10.1016/S0168-9525(03)00071-4; Relchelt J, 2002, J CELL SCI, V115, P2639; RHO OY, 1994, MOL CARCINOGEN, V11, P19, DOI 10.1002/mc.2940110105; Santos M, 2002, J BIOL CHEM, V277, P19122, DOI 10.1074/jbc.M201001200; SCHAAFSMA HE, 1990, AM J PATHOL, V136, P329; SCHERMER A, 1989, DIFFERENTIATION, V42, P103, DOI 10.1111/j.1432-0436.1989.tb00611.x; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Toivola DM, 2001, HEPATOLOGY, V34, P1174, DOI 10.1053/jhep.2001.29374; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x	53	45	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1556	+		10.1096/fj.04-1683fje	http://dx.doi.org/10.1096/fj.04-1683fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319370				2022-12-25	WOS:000223554900015
J	Zhang, HJ; Doctrow, SR; Xu, LJ; Oberley, LW; Beecher, B; Morrison, J; Oberley, TD; Kregel, KC				Zhang, HJ; Doctrow, SR; Xu, LJ; Oberley, LW; Beecher, B; Morrison, J; Oberley, TD; Kregel, KC			Redox modulation of the liver with chronic antioxidant enzyme mimetic treatment prevents age-related oxidative damage associated with environmental stress	FASEB JOURNAL			English	Article						free radicals; ROS; hyperthermia; lipid peroxidation; AP-1	SYNTHETIC SUPEROXIDE-DISMUTASE; GLUTATHIONE-S-TRANSFERASE; SALEN-MANGANESE COMPLEXES; CALORIC RESTRICTION; CATALASE MIMETICS; HEAT-WAVE; LIFE-SPAN; AP-1; EXTENSION; RESPONSES	A reduction in stress tolerance is a hallmark of the aging process, and the lowered functional capacity observed in aged organisms is associated with an increased rate of oxidative stress and a greater susceptibility of aged tissues to oxidative injury. In this report, we show that chronic systemic administration of a superoxide dismutase (SOD)/catalase mimetic (EUK-189), delivered over a 1 month period via osmotic pump, prevents heat stress-induced liver injury by dramatically decreasing oxidative damage in aged animals. Widespread liver injury was present in old but not young vehicle-treated rats in response to a 2 day heating protocol. However, SOD/catalase mimetic treatment markedly decreased the hyperthermia-induced liver injury associated in old animals. The reversal of damage with EUK-189 was associated with an improvement in intracellular redox status and a striking reduction in hepatocellular lipid peroxidation. EUK-189 treatment also blocked the activation of activator protein-1 (AP-1), which is a redox-sensitive early response transcription factor involved in the regulation of cellular stress responses. These results demonstrate that oxidative stress plays a unique role in age-related hyperthermic injury and suggest that therapeutic strategies aimed at improving redox potential, such as chronic SOD/catalase mimetic treatment, can prevent the oxidative-mediated damage associated with environmental stress.	Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; Eukarion Inc, Bedford, MA 01730 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53705 USA	University of Iowa; University of Iowa; University of Wisconsin System; University of Wisconsin Madison	Kregel, KC (corresponding author), Univ Iowa, Integrat Physiol Lab, Dept Exercise Sci, 532 FH, Iowa City, IA 52242 USA.	kevin-kregel@uiowa.edu		Doctrow, Susan/0000-0003-0628-9960	NHLBI NIH HHS [HL-61389] Funding Source: Medline; NIA NIH HHS [AG-14687, AG-12350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG012350, R01AG012350, R01AG014687] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Baker K, 1998, J PHARMACOL EXP THER, V284, P215; BAUDRY M, 1993, BIOCHEM BIOPH RES CO, V192, P964, DOI 10.1006/bbrc.1993.1509; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; Doctrow S R, 1997, Adv Pharmacol, V38, P247; Doctrow SR, 2002, J MED CHEM, V45, P4549, DOI 10.1021/jm020207y; Dorozynski A, 2003, BRIT MED J, V327, P411, DOI 10.1136/bmj.327.7412.411; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; Hall DM, 2000, J APPL PHYSIOL, V89, P749, DOI 10.1152/jappl.2000.89.2.749; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Jones DP, 2002, METHOD ENZYMOL, V348, P93, DOI 10.1016/S0076-6879(02)48630-2; Jung CW, 2001, NEUROSCI LETT, V304, P157, DOI 10.1016/S0304-3940(01)01784-0; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEW M, 1970, AM J MED, V49, P192, DOI 10.1016/S0002-9343(70)80075-4; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Malfroy B, 1997, CELL IMMUNOL, V177, P62, DOI 10.1006/cimm.1997.1091; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; OBERLEY TD, 1991, AM J PATHOL, V139, P355; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Pong K, 2000, BRAIN RES, V881, P182, DOI 10.1016/S0006-8993(00)02841-9; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Rong YQ, 1999, P NATL ACAD SCI USA, V96, P9897, DOI 10.1073/pnas.96.17.9897; RYAN AJ, 1995, J APPL PHYSIOL, V78, P38, DOI 10.1152/jappl.1995.78.1.38; Schar C, 2004, NATURE, V427, P332, DOI 10.1038/nature02300; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Van Remmen H, 2003, EXERC SPORT SCI REV, V31, P149, DOI 10.1097/00003677-200307000-00009; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7; Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje; Zhang HJ, 2002, J VIROL, V76, P355, DOI 10.1128/JVI.76.1.355-363.2002	39	55	55	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1547	+		10.1096/fj.04-1629fje	http://dx.doi.org/10.1096/fj.04-1629fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319374				2022-12-25	WOS:000223554900009
J	Kallen, J; Schlaeppi, JM; Bitsch, F; Filipuzzi, I; Schilb, A; Riou, V; Graham, A; Strauss, A; Geiser, M; Fournier, B				Kallen, J; Schlaeppi, JM; Bitsch, F; Filipuzzi, I; Schilb, A; Riou, V; Graham, A; Strauss, A; Geiser, M; Fournier, B			Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERR alpha) - Crystal structure of ERR alpha ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; GAMMA; GENE; 4-HYDROXYTAMOXIFEN; DIETHYLSTILBESTROL; DIFFERENTIATION; IDENTIFICATION; PGC-1-ALPHA; EXPRESSION	The crystal structure of the ligand binding domain (LBD) of the estrogen-related receptor alpha(ERRalpha, NR3B1) complexed with a coactivator peptide from peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) reveals a transcriptionally active conformation in the absence of a ligand. This is the first x-ray structure of ERRalpha LBD, solved to a resolution of 2.5 Angstrom, and the first structure of a PGC-1alpha complex. The putative ligand binding pocket (LBP) of ERRalpha is almost completely occupied by side chains, in particular with the bulky side chain of Phe(328) (corresponding to Ala(272) in ERRgamma and Ala(350) in estrogen receptor alpha). Therefore, a ligand of a size equivalent to more than similar to4 carbon atoms could only bind in the LBP, if ERRalpha would undergo a major conformational change (in particular the ligand would displace H12 from its agonist position). The x-ray structure thus provides strong evidence for ligand-independent transcriptional activation by ERRalpha. The interactions of PGC-1alpha with ERRalpha also reveal for the first time the atomic details of how a coactivator peptide containing an inverted LXXLL motif (namely a LLXYL motif) binds to a LBD. In addition, we show that a PGC-1alpha peptide containing this nuclear box motif from the L3 site binds ERRalpha LBD with a higher affinity than a peptide containing a steroid receptor coactivator-1 motif and that the affinity is further enhanced when all three leucine-rich regions of PGC-1alpha are present.	Novartis Inst Biomed Res, Prot Struct Unit, CH-4002 Basel, Switzerland; Novartis Inst Biomed Res, Biomol Prod Unit, CH-4002 Basel, Switzerland; Novartis Inst Biomed Res, Dept Analyt & Imaging Sci, CH-4002 Basel, Switzerland; Novartis Inst Biomed Res, Dept Global Screening Operat, CH-4002 Basel, Switzerland; Novartis Inst Biomed Res, Dept Bone Metab, CH-4002 Basel, Switzerland	Novartis; Novartis; Novartis; Novartis; Novartis	Kallen, J (corresponding author), Novartis Inst Biomed Res, Prot Struct Unit, CH-4002 Basel, Switzerland.	joerg.kallen@pharma.novartis.com; brigitte.fournier@pharma.novartis.com	Riou, Virginie/K-7874-2016	Riou, Virginie/0000-0002-6549-385X				Ariazi EA, 2002, CANCER RES, V62, P6510; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Greschik H, 2004, J BIOL CHEM, V279, P33639, DOI 10.1074/jbc.M402195200; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P320; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu DS, 2001, CANCER RES, V61, P6755; Luo JM, 2003, MOL CELL BIOL, V23, P7947, DOI 10.1128/MCB.23.22.7947-7956.2003; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; SCHILB A, 2004, IN PRESS J BIOMOL SC; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Strauss A, 2003, J BIOMOL NMR, V26, P367, DOI 10.1023/A:1024013111478; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yang C, 1999, CANCER RES, V59, P4519; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	41	171	177	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49330	49337		10.1074/jbc.M407999200	http://dx.doi.org/10.1074/jbc.M407999200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15337744	hybrid, Green Published			2022-12-25	WOS:000225098100102
J	Bachmann, M; Hennemann, H; Xing, PX; Hoffmann, I; Moroy, T				Bachmann, M; Hennemann, H; Xing, PX; Hoffmann, I; Moroy, T			The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1) - A novel role for Pim-1 at the G(2)/M cell cycle checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; C-MYC; RECRUITMENT SYSTEM; TRANSGENIC MICE; PROTEIN-KINASE; GENE-PRODUCT; HUMAN CDC25C; IN-VIVO; EXPRESSION; APOPTOSIS	The Pim-1 oncogene encodes a serine-threonine kinase that relays signals from cytokine receptors and contributes to the formation of lymphoid tumors when expressed at high levels. Here we show that the protein kinase Cdc25 C-associated kinase 1 (C-TAK1) is a binding partner and a substrate of Pim-1. A physical interaction of Pim-1 and C-TAK1 could be shown biochemically and in yeast two-hybrid assays. Immunofluorescence experiments suggested that Pim-1.C-TAK1 complexes are predominantly cytoplasmic. When transiently transfected, Pim-1 was also found in the nucleus and could recruit C-TAK1 to this compartment. Both Pim-1 and C-TAK1 underwent autophosphorylation, but only Pim-1 was able to phosphorylate C-TAK1 but not vice versa. Mass spectrometry analysis of C-TAK1 suggested that the sites of autophosphorylation and Pim-1-mediated phosphorylation are distinct and not overlapping. Phosphorylation by Pim-1 decreased C-TAK1 kinase activity significantly, in particular its ability to phosphorylate and inactivate Cdc25C, a protein that actively promotes cell cycle progression at the G(2)/M phase. Hence our findings directly suggest a novel role for Pim-1 as a positive regulator at the G(2)/M transition of the cell cycle.	Univ Klinikum Essen, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany; Austin Res Inst, Canc Immunotherapy Lab, Heidelberg, Vic 3084, Australia; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	University of Duisburg Essen; Austin Research Institute; Helmholtz Association; German Cancer Research Center (DKFZ)	Moroy, T (corresponding author), Univ Klinikum Essen, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.	moeroey@uni-essen.de	Moroy, Tarik/D-9923-2011					Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Aronheim A, 1997, NUCLEIC ACIDS RES, V25, P3373, DOI 10.1093/nar/25.16.3373; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Borg KE, 1999, ENDOCRINOLOGY, V140, P5659, DOI 10.1210/en.140.12.5659; Brideau AD, 1998, J VIROL, V72, P4560, DOI 10.1128/JVI.72.6.4560-4570.1998; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; CUYPERS HT, 1984, CELL, V37, P141; DOMEN J, 1993, LEUKEMIA, V7, pS108; Eichmann A, 2000, ONCOGENE, V19, P1215, DOI 10.1038/sj.onc.1203355; FRIEDMANN M, 1992, ARCH BIOCHEM BIOPHYS, V298, P594, DOI 10.1016/0003-9861(92)90454-5; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hennemann H, 2003, J BIOL CHEM, V278, P28799, DOI 10.1074/jbc.M207196200; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Ionov Y, 2003, ANTICANCER RES, V23, P167; Ishibashi Y, 2001, FEBS LETT, V506, P33, DOI 10.1016/S0014-5793(01)02881-2; Jaster R, 1999, CELL SIGNAL, V11, P769, DOI 10.1016/S0898-6568(99)00050-9; Jaster R, 1999, CELL SIGNAL, V11, P331, DOI 10.1016/S0898-6568(98)00049-7; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; Maita H, 2000, EUR J BIOCHEM, V267, P5168, DOI 10.1046/j.1432-1327.2000.01585.x; Margolis SS, 2003, EMBO J, V22, P5734, DOI 10.1093/emboj/cdg545; Matikainen S, 1999, BLOOD, V93, P1980, DOI 10.1182/blood.V93.6.1980.406k20_1980_1991; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PADMA R, 1991, CANCER RES, V51, P2486; Palaty CK, 1997, J BIOL CHEM, V272, P10514; Palaty CK, 1997, BIOCHEM CELL BIOL, V75, P153, DOI 10.1139/bcb-75-2-153; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Pircher TJ, 2000, ONCOGENE, V19, P3684, DOI 10.1038/sj.onc.1203684; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Rainio EM, 2002, J IMMUNOL, V168, P1524, DOI 10.4049/jimmunol.168.4.1524; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Wang ZP, 2002, BBA-MOL CELL RES, V1593, P45, DOI 10.1016/S0167-4889(02)00347-6; Wang ZP, 2001, ARCH BIOCHEM BIOPHYS, V390, P9, DOI 10.1006/abbi.2001.2370	56	114	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48319	48328		10.1074/jbc.M404440200	http://dx.doi.org/10.1074/jbc.M404440200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15319445	hybrid			2022-12-25	WOS:000224957000107
J	Khvotchev, M; Sudhof, TC				Khvotchev, M; Sudhof, TC			Proteolytic processing of amyloid-beta precursor protein by secretases does not require cell surface transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; NEUROTRANSMITTER RELEASE; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; CLEAVAGE; APP; PRESENILIN-1; COMPARTMENTS; PATHWAY	Cleavage of amyloid-beta precursor protein (APP) by alpha-, beta-, and gamma-secretases releases an extracellular fragment called APPS, small Abeta peptides, and a short APP intracellular domain that may provide a transcriptional signal analogous to the Notch intracellular domain. Notch cleavage is activated by extracellular ligands on the cell surface, but the cellular localization of APP cleavage remains unclear. We now show that in transfected cultured cells, the plasma membrane SNARE protein syntaxin 1A, when expressed as a full-length protein, disrupts the Golgi apparatus and blocks trans-Golgi traffic and exocytosis. In contrast, truncated syntaxin 1A(1-243) selectively abolishes exocytosis but has no apparent effect on trans-Golgi traffic or Golgi structure, whereas further truncated syntaxins 1A(1-236) and 1A(1-230\) have no effect on either exocytosis or Golgi traffic. Using these syntaxin 1A fragments, we demonstrated that blocking trans-Golgi traffic greatly impairs APP cleavage and AICD-dependent nuclear signaling, whereas blocking exocytosis alone does not affect either process, even though secretion of APPS and Abeta40 peptide is abolished. Our data suggest that, different from Notch, cleavage of APP is independent of cell surface regulation by extracellular ligands but may be controlled by intracellular signaling.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, 6000 Harry Hines Blvd NA4-118, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu	Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549				AMARATUNGA A, 1995, J BIOL CHEM, V270, P17268, DOI 10.1074/jbc.270.29.17268; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Biederer T, 2002, J NEUROSCI, V22, P7340; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hartmann D, 2001, J MOL NEUROSCI, V17, P171, DOI 10.1385/JMN:17:2:171; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ikin AF, 1996, J BIOL CHEM, V271, P31783, DOI 10.1074/jbc.271.50.31783; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Khvotchev MV, 2003, J NEUROSCI, V23, P10531; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lazarov O, 2002, J NEUROSCI, V22, P9785; LeBlanc AC, 1999, J NEUROCHEM, V72, P1832, DOI 10.1046/j.1471-4159.1999.0721832.x; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Piccini A, 2004, NEUROBIOL DIS, V15, P380, DOI 10.1016/j.nbd.2003.11.013; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; REFOLO LM, 1995, J NEUROSCI RES, V40, P694, DOI 10.1002/jnr.490400515; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Rowe J, 1999, J CELL SCI, V112, P1865; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schluter OM, 2002, J BIOL CHEM, V277, P40919, DOI 10.1074/jbc.M203704200; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sheng JG, 2002, J NEUROSCI, V22, P9794; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	67	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47101	47108		10.1074/jbc.M408474200	http://dx.doi.org/10.1074/jbc.M408474200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316009	hybrid			2022-12-25	WOS:000224832400096
J	Vathipadiekal, V; Rao, M				Vathipadiekal, V; Rao, M			Inhibition of 1,4-beta-D-xylan xylanohydrolase by the specific aspartic protease inhibitor pepstatin - Probing the two-step inhibition mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING-INHIBITION; SLOW-BINDING; ACTIVE-SITE; CRYSTAL-STRUCTURE; BIOTECHNOLOGICAL ASPECTS; IRREVERSIBLE INHIBITORS; THERMOSTABLE XYLANASE; THERMOMONOSPORA SP; RENIN; GLYCOSIDASES	This is the first report that describes the inhibition mechanism of xylanase from Thermomonospora sp. by pepstatin A, a specific inhibitor toward aspartic proteases. The kinetic analysis revealed competitive inhibition of xylanase by pepstatin A with an IC50 value 3.6 +/- 0.5 muM. The progress curves were time-depended, consistent with a two-step slow tight binding inhibition. The inhibition followed a rapid equilibrium step to form a reversible enzyme-inhibitor complex (EI), which isomerizes to the second enzyme-inhibitor complex (EI*), which dissociated at a very slow rate. The rate constants determined for the isomerization of EI to EI* and the dissociation of EI* were 15 +/- 1 x 10(-5) and 3.0 +/- 1 x 10(-8) s(-1), respectively. The K-i value for the formation of EI complex was 1.5 +/- 0.5 muM, whereas the overall inhibition constant K-i* was 28.0 +/- 1 nM. The conformational changes induced in Xyl I by pepstatin A were monitored by fluorescence spectroscopy, and the rate constants derived were in agreement with the kinetic data. Thus, the conformational alterations were correlated to the isomerization of EI to EI*. Pepstatin A binds to the active site of the enzyme and disturbs the native interaction between the histidine and lysine, as demonstrated by the abolished isoindole fluorescence of o-phthalaldehyde-labeled xylanase. Our results revealed that the inactivation of xylanase is due to the interference in the electronic microenvironment and disruption of the hydrogen-bonding network between the essential histidine and other residues involved in catalysis, and a model depicting the probable interaction between pepstatin A with xylanase has been proposed.	Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL)	Rao, M (corresponding author), Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India.	malarao@dalton.ncl.res.in		/0000-0002-8181-6890				BARRETT AJ, 1972, BIOCHEM J, V127, P439, DOI 10.1042/bj1270439; BEITH JG, 1995, METHOD ENZYMOL, V248, P59; BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARVOL P, 1973, FEBS LETT, V34, P189; Cheung H.C., 1991, TOPICS FLUORESCENCE, P127; Cleland W W, 1979, Methods Enzymol, V63, P103; Dash C, 2002, J BIOL CHEM, V277, P17978, DOI 10.1074/jbc.M111250200; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DORLING PR, 1980, BIOCHEM J, V191, P649, DOI 10.1042/bj1910649; ELBEIN AD, 1984, ARCH BIOCHEM BIOPHYS, V235, P579, DOI 10.1016/0003-9861(84)90232-7; Fenton RJ, 1999, ANTIMICROB AGENTS CH, V43, P2642, DOI 10.1128/AAC.43.11.2642; FUJINAGA M, 1995, PROTEIN SCI, V4, P960; George SP, 2001, BIOCHEM BIOPH RES CO, V282, P48, DOI 10.1006/bbrc.2001.4543; George SP, 2001, EUR J BIOCHEM, V268, P2881, DOI 10.1046/j.1432-1327.2001.02174.x; George SP, 2001, BIORESOURCE TECHNOL, V77, P171, DOI 10.1016/S0960-8524(00)00150-4; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HOHENSCHUTZ LD, 1981, PHYTOCHEMISTRY, V20, P811, DOI 10.1016/0031-9422(81)85181-3; Houtzager V, 1996, BIOCHEMISTRY-US, V35, P10974, DOI 10.1021/bi960053m; Kati WM, 1998, BIOCHEM BIOPH RES CO, V244, P408, DOI 10.1006/bbrc.1998.8282; KNIGHT CG, 1976, BIOCHEM J, V155, P117, DOI 10.1042/bj1550117; Kulkarni N, 1999, FEMS MICROBIOL REV, V23, P411, DOI 10.1111/j.1574-6976.1999.tb00407.x; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P180; LAZAR J, 1972, N-S ARCH PHARMACOL, V275, P114, DOI 10.1007/BF00505072; LEGER G, 1968, HOPPESEYLER Z PHYSL, V349, P767; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; Leroy E, 1999, ORG LETT, V1, P775, DOI 10.1021/ol990754m; LY HD, 1999, ANNU REV BIOCHEM, V316, P695; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7088; MARSHALL PJ, 1981, J CHEM SOC PERK T 1, P366, DOI 10.1039/p19810000366; MCKOWN MM, 1974, J BIOL CHEM, V249, P7770; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; MILLER RP, 1972, BIOCHEM PHARMACOL, V21, P2941, DOI 10.1016/0006-2952(72)90221-3; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; MURAKAMI K, 1973, BIOCHEM BIOPH RES CO, V54, P482, DOI 10.1016/0006-291X(73)91446-0; MURAO S, 1980, AGR BIOL CHEM TOKYO, V44, P219, DOI 10.1080/00021369.1980.10863929; Natesh R, 1999, J MOL BIOL, V288, P999, DOI 10.1006/jmbi.1999.2727; PALCZEWSKI K, 1983, EUR J BIOCHEM, V137, P429, DOI 10.1111/j.1432-1033.1983.tb07846.x; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; PAWAGI AB, 1990, BIOCHEMISTRY-US, V29, P950, DOI 10.1021/bi00456a015; PEGG MS, 1994, BIOCHEM MOL BIOL INT, V32, P851; Ploux O, 1999, EUR J BIOCHEM, V259, P63, DOI 10.1046/j.1432-1327.1999.00006.x; Rao MB, 1998, MICROBIOL MOL BIOL R, V62, P597, DOI 10.1128/MMBR.62.3.597-635.1998; ROYER JC, 1989, ENZYME MICROB TECH, V11, P405, DOI 10.1016/0141-0229(89)90134-8; SACHDEV GP, 1973, J BIOL CHEM, V248, P6292; Sculley MJ, 1996, BBA-PROTEIN STRUCT M, V1298, P78, DOI 10.1016/S0167-4838(96)00118-5; SIMONS SS, 1979, BIOCHEMISTRY-US, V18, P4915, DOI 10.1021/bi00589a020; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Stutz AE, 1999, IMMUNOSUGARS GLYCOSI, P95; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; TRUSCHEIT E, 1981, ANGEW CHEM INT EDIT, V20, P744, DOI 10.1002/anie.198107441; UMEZAWA H, 1970, J ANTIBIOT, V23, P259, DOI 10.7164/antibiotics.23.259; UMEZAWA H, 1972, ENZYME INHIBITORS MI, P31; VONDERHELM K, 1989, FEBS LETT, V247, P349, DOI 10.1016/0014-5793(89)81368-7; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Williams J W, 1979, Methods Enzymol, V63, P437; WITHERS SG, 1995, PROTEIN SCI, V4, P361; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415; Yiallouros I, 1998, BIOCHEM J, V331, P375, DOI 10.1042/bj3310375	65	4	4	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47024	47033		10.1074/jbc.M407866200	http://dx.doi.org/10.1074/jbc.M407866200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15317808	hybrid			2022-12-25	WOS:000224832400087
J	Hollingshead, BD; Petrulis, JR; Perdew, GH				Hollingshead, BD; Petrulis, JR; Perdew, GH			The aryl hydrocarbon (Ah) receptor transcriptional regulator hepatitis B virus X-associated protein 2 antagonizes p23 binding to Ah receptor-Hsp90 complexes and is dispensable for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CO-CHAPERONE P23; DIOXIN RECEPTOR; SUBCELLULAR-LOCALIZATION; GLUCOCORTICOID-RECEPTOR; DNA-BINDING; HSP90; XAP2; FKBP52; ARA9	To further understand the role that the hepatitis B virus X-associated protein 2 (XAP2) plays in regulating aryl hydrocarbon receptor (AhR) function, a point mutation was introduced at tyrosine 408 of the AhR, changing the residue to an alanine or lysine. These mutations resulted in the loss of AhR binding to endogenous XAP2 in COS-1 cells and reduced binding of exogenously expressed XAP2. Cellular localization of the mutant AhR-yellow fluorescent protein fusion proteins remained nuclear when XAP2 was co-expressed, while the non-mutant receptor was redistributed to the cytoplasm. XAP2 expression caused an overall repression of constitutive and ligand-induced AhR transcriptional activity. However, increased expression of XAP2 had no effect on the AhRY408A mutant transcriptional activity. Additionally the XAP2 binding-deficient AhR mutants showed overall higher transcriptional activity when compared with the non-mutant receptor. Interestingly reduced incorporation of the Hsp90 associated co-chaperone p23 in the unliganded AhR complex was observed with increasing XAP2 expression. The displacement of p23 from Hsp90 did not occur when increasing levels of XAP2 were introduced in COS-1 cells in the absence of the AhR; thus this displacement event occurs specifically within an AhR complex. Finally XAP2 itself was capable of existing in multimeric complexes, and these complexes did not require Hsp90 or AhR to form. However, it is not yet clear whether XAP2 can exist within the AhR complex in more than one copy.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Grad Program Biochem Microbiol & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Perdew, GH (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA.	ghp2@psu.edu			NIEHS NIH HHS [ES04869] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES004869, R01ES004869] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Cox MB, 2002, TOXICOL LETT, V129, P13, DOI 10.1016/S0378-4274(01)00465-9; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Freeman BC, 2000, GENE DEV, V14, P422; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Kazlauskas A, 2002, J BIOL CHEM, V277, P11795, DOI 10.1074/jbc.M200053200; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 2002, TOXICOLOGY, V181, P143, DOI 10.1016/S0300-483X(02)00270-6; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nebert DW, 2000, BIOCHEM PHARMACOL, V59, P65, DOI 10.1016/S0006-2952(99)00310-X; Panda S, 2002, NATURE, V417, P329, DOI 10.1038/417329a; PERDEW GH, 1995, HYBRIDOMA, V14, P279, DOI 10.1089/hyb.1995.14.279; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Pirkl F, 2001, J MOL BIOL, V308, P795, DOI 10.1006/jmbi.2001.4595; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Ramadoss P, 2004, MOL PHARMACOL, V66, P129, DOI 10.1124/mol.66.1.129; Ramadoss P, 2004, BIOCHEMISTRY-US, V43, P700, DOI 10.1021/bi035827v; Shetty PV, 2003, BIOCHEM PHARMACOL, V65, P941, DOI 10.1016/S0006-2952(02)01650-7; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Sumanasekera WK, 2003, BIOCHEMISTRY-US, V42, P10726, DOI 10.1021/bi0347353; Sumanasekera WK, 2003, J BIOL CHEM, V278, P4467, DOI 10.1074/jbc.M211261200; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930	47	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45652	45661		10.1074/jbc.M407840200	http://dx.doi.org/10.1074/jbc.M407840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322122	hybrid			2022-12-25	WOS:000224694900045
J	Jorgensen, R; Yates, SP; Teal, DJ; Nilsson, J; Prentice, GA; Merrill, AR; Andersen, GR				Jorgensen, R; Yates, SP; Teal, DJ; Nilsson, J; Prentice, GA; Merrill, AR; Andersen, GR			Crystal structure of ADP-ribosylated ribosomal translocase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; PSEUDOMONAS-AERUGINOSA EXOTOXIN; TOXIN-RESISTANT MUTANTS; COLI 70S RIBOSOME; DIPHTHERIA-TOXIN; GLUTAMIC ACID-553; DOMAIN-III; DIPHTHAMIDE; RNA; HYDROLYSIS	The crystal structure of ADP-ribosylated yeast elongation factor 2 in the presence of sordarin and GDP has been determined at 2.6 Angstrom resolution. The diphthamide at the tip of domain IV, which is the target for diphtheria toxin and Pseudomonas aeruginosa exotoxin A, contains a covalently attached ADP-ribose that functions as a very potent inhibitor of the factor. We have obtained an electron density map of ADP-ribosylated translation factor 2 revealing both the ADP-ribosylation and the diphthamide. This is the first structure showing the conformation of an ADP-ribosylated residue and confirms the inversion of configuration at the glycosidic linkage. Binding experiments show that the ADP-ribosylation has limited effect on nucleotide binding affinity, on ribosome binding, and on association with exotoxin A. These results provide insight to the inhibitory mechanism and suggest that inhibition may be caused by erroneous interaction of the translation factor with the codon-anticodon area in the P-site of the ribosome.	Univ Guelph, Dept Microbiol, Biochem Grp, Guelph, ON N1G 2W1, Canada; Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark	University of Guelph; Aarhus University	Merrill, AR (corresponding author), Univ Guelph, Dept Microbiol, Biochem Grp, Guelph, ON N1G 2W1, Canada.	rmerrill@uoguelph.ca; grand@bioxray.dk	Merrill, Rod/M-8313-2014; Jørgensen, René/P-5619-2014	Jørgensen, René/0000-0003-0672-466X; Nilsson, Jakob/0000-0003-4100-1125; Andersen, Gregers Rom/0000-0001-6292-3319				AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Al-Karadaghi S, 1996, STRUCTURE, V4, P555, DOI 10.1016/S0969-2126(96)00061-5; ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; Armstrong S, 2002, J BIOL CHEM, V277, P46669, DOI 10.1074/jbc.M206916200; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNS G, 1986, FEBS LETT, V208, P217, DOI 10.1016/0014-5793(86)81021-3; CARROLL SF, 1987, J BIOL CHEM, V262, P8707; CHEN JYC, 1985, MOL CELL BIOL, V5, P3357, DOI 10.1128/MCB.5.12.3357; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DAVYDOVA EK, 1990, FEBS LETT, V261, P350, DOI 10.1016/0014-5793(90)80589-B; Diekema DJ, 1999, CLIN INFECT DIS, V29, P595, DOI 10.1086/598640; Dominguez JM, 1998, ANTIMICROB AGENTS CH, V42, P2279, DOI 10.1128/AAC.42.9.2279; DOUGLAS CM, 1987, J BACTERIOL, V169, P4967, DOI 10.1128/jb.169.11.4967-4971.1987; DUNLOP PC, 1983, J BIOL CHEM, V258, P4754; FENDRICK JL, 1992, EUR J BIOCHEM, V205, P25, DOI 10.1111/j.1432-1033.1992.tb16748.x; FENDRICK JL, 1989, P NATL ACAD SCI USA, V86, P554, DOI 10.1073/pnas.86.2.554; FOLEY BT, 1995, J BIOL CHEM, V270, P23218, DOI 10.1074/jbc.270.39.23218; Han S, 2002, INT J MED MICROBIOL, V291, P523; Iglewski B H, 1979, Methods Enzymol, V60, P780; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; IGLEWSKI WJ, 1994, MOL CELL BIOCHEM, V138, P131, DOI 10.1007/BF00928454; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen R, 2003, NAT STRUCT BIOL, V10, P379, DOI 10.1038/nsb923; Jorgensen R, 2002, ACTA CRYSTALLOGR D, V58, P712, DOI 10.1107/S0907444902003001; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MOEHRING JM, 1979, SOMAT CELL GENET, V5, P453, DOI 10.1007/BF01538880; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MOEHRING JM, 1980, P NATL ACAD SCI-BIOL, V77, P1010, DOI 10.1073/pnas.77.2.1010; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; NURTEN R, 1980, EUR J BIOCHEM, V103, P551, DOI 10.1111/j.1432-1033.1980.tb05979.x; NYGARD O, 1985, BIOCHIM BIOPHYS ACTA, V824, P152, DOI 10.1016/0167-4781(85)90092-2; NYGARD O, 1990, J BIOL CHEM, V265, P6030; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Parikh SL, 2004, BIOCHEMISTRY-US, V43, P1204, DOI 10.1021/bi035907z; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; Richards MJ, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.4.e39; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; SITIKOV AS, 1984, FEBS LETT, V176, P406, DOI 10.1016/0014-5793(84)81207-7; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Tang S, 2001, MOL CELL BIOCHEM, V223, P117, DOI 10.1023/A:1017914413081; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VANNESS BG, 1980, J BIOL CHEM, V255, P710; VANNESS BG, 1980, J BIOL CHEM, V255, P717; Yates SP, 2001, J BIOL CHEM, V276, P35029, DOI 10.1074/jbc.M105002200	56	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45919	45925		10.1074/jbc.M406218200	http://dx.doi.org/10.1074/jbc.M406218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15316019	hybrid			2022-12-25	WOS:000224694900076
J	Wagner, LE; Li, WH; Joseph, SK; Yule, DI				Wagner, LE; Li, WH; Joseph, SK; Yule, DI			Functional consequences of phosphomimetic mutations at key cAMP-dependent protein kinase phosphorylation sites in the type 1 inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; TRISPHOSPHATE RECEPTORS; (1,4,5)-TRISPHOSPHATE RECEPTOR; RAT HEPATOCYTES; SPLICE VARIANTS; IP3 RECEPTOR; CA2+; EXPRESSION; CELLS; OLIGOMERIZATION	Regulation of Ca2+ release through inositol 1,4,5-trisphosphate receptors (InsP(3)R) has important consequences for defining the particular spatio-temporal properties of intracellular Ca2+ signals. In this study, regulation of Ca2+ release by phosphorylation of type 1 InsP(3)R (InsP(3)R-1) was investigated by constructing "phosphomimetic" charge mutations in the functionally important phosphorylation sites of both the S2+ and S2- InsP(3)R-1 splice variants. Ca2+ release was investigated following expression in Dt-40 3ko cells devoid of endogenous InsP(3)R. In cells expressing either the S1755E S2+ or S1589E/S1755E S2- InsP(3)R-1, InsP(3)-induced Ca2+ release was markedly enhanced compared with nonphosphorylatable S2+ S1755A and S2- S1589A/S1755A mutants. Ca2+ release through the S2- S1589E/S1755E InsP(3)R-1 was enhanced similar to8-fold over wild type and similar to50-fold when compared with the nonphosphorylatable S2- S1589A/S1755A mutant. In cells expressing S2- InsP(3)R-1 with single mutations in either S1589E or S1755E, the sensitivity of Ca2+ release was enhanced similar to3-fold; sensitivity was midway between the wild type and the double glutamate mutation. Paradoxically, forskolin treatment of cells expressing either single Ser/Glu mutation failed to further enhance Ca2+ release. The sensitivity of Ca2+ release in cells expressing S2+ S1755E InsP(3)R-1 was comparable with the sensitivity of S2- S1589E/S1755E InsP(3)R-1. In contrast, mutation of S2+ S1589E InsP(3)R-1 resulted in a receptor with comparable sensitivity to wild type cells. Expression of S2- S1589E/S1755E InsP(3)R-1 resulted in robust Ca2+ oscillations when cells were stimulated with concentrations of alpha-IgM antibody that were threshold for stimulation in S2- wild type InsP(3)R-1-expressing cells. However, at higher concentrations of alpha-IgM antibody, Ca2+ oscillations of a similar period and magnitude were initiated in cells expressing either wild type or S2- phosphomimetic mutations. Thus, regulation by phosphorylation of the functional sensitivity of InsP(3)R-1 appears to define the threshold at which oscillations are initiated but not the frequency or amplitude of the signal when established.	Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	University of Rochester; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Jefferson University	Yule, DI (corresponding author), Univ Rochester, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.	david_yule@urmc.rochester.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804, R01DK054568] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE13539, R01-DE14756] Funding Source: Medline; NIDDK NIH HHS [R01-DK34804, R01-DK54568] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ando H, 2003, J BIOL CHEM, V278, P10602, DOI 10.1074/jbc.M210119200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Chatton JY, 1998, BIOCHEM J, V330, P1411, DOI 10.1042/bj3301411; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Galvan DL, 2002, J BIOL CHEM, V277, P48248, DOI 10.1074/jbc.M209990200; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kubista H, 1998, BBA-MOL CELL RES, V1448, P299, DOI 10.1016/S0167-4889(98)00132-3; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Lin C, 2000, J BIOL CHEM, V275, P2305, DOI 10.1074/jbc.275.4.2305; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; Maximov A, 2003, MOL CELL NEUROSCI, V22, P271, DOI 10.1016/S1044-7431(02)00027-1; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKAGAWA T, 1991, J NEUROCHEM, V57, P1807, DOI 10.1111/j.1471-4159.1991.tb06385.x; Parker AKT, 2004, J BIOL CHEM, V279, P23797, DOI 10.1074/jbc.M402098200; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; Reiken S, 2003, J CELL BIOL, V160, P919, DOI 10.1083/jcb.200211012; Sneyd J, 2004, P NATL ACAD SCI USA, V101, P1392, DOI 10.1073/pnas.0303472101; Soulsby MD, 2004, FEBS LETT, V557, P181, DOI 10.1016/S0014-5793(03)01487-X; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tang TS, 2003, J NEUROSCI, V23, P403, DOI 10.1523/JNEUROSCI.23-02-00403.2003; Tateyama M, 2003, J BIOL CHEM, V278, P46718, DOI 10.1074/jbc.M308977200; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 2002, CELL CALCIUM, V32, P321, DOI 10.1016/S0143416002001859; Tu HP, 2004, J BIOL CHEM, V279, P19375, DOI 10.1074/jbc.M313476200; Tu HP, 2002, BIOPHYS J, V82, P1995, DOI 10.1016/S0006-3495(02)75548-3; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	45	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46242	46252		10.1074/jbc.M405849200	http://dx.doi.org/10.1074/jbc.M405849200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308649	hybrid			2022-12-25	WOS:000224694900111
J	Wohlschlegel, JA; Johnson, ES; Reed, SI; Yates, JR				Wohlschlegel, JA; Johnson, ES; Reed, SI; Yates, JR			Global analysis of protein sumoylation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-RELATED PROTEIN; MASS-SPECTRAL DATA; CONJUGATING ENZYME; IDENTIFICATION TECHNOLOGY; SUMO-1 MODIFICATION; BUDDING YEAST; SMT4; DNA; LOCALIZATION; ISOPEPTIDASE	Although the modification of cellular factors by SUMO is an essential process in Saccharomyces cerevisiae, the identities of the substrates remain largely unknown. Using a mass spectrometry-based approach, we have identified 271 new SUMO targets. These substrates play roles in a diverse set of biological processes and greatly expand the scope of SUMO regulation in eukaryotic cells. Transcription appears to be the most prevalent process associated with sumoylation with novel SUMO substrates found in basal transcription machinery for RNA polymerases I, II, and III, pol II transcriptional elongation complexes, and a variety of chromatin remodeling, chromatin modifying, and chromatin silencing complexes. Additionally, our global analysis has revealed a number of interesting biological patterns in the list of SUMO targets including a clustering of sumoylation targets within macromolecular complexes.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Jefferson University; Scripps Research Institute	Yates, JR (corresponding author), Scripps Res Inst, Dept Cell Biol, Mail Drop SR11,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jyates@scripps.edu			NATIONAL CANCER INSTITUTE [R01CA085487] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES012021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062268] Funding Source: NIH RePORTER; NCI NIH HHS [CA85487] Funding Source: Medline; NCRR NIH HHS [RR11823-08] Funding Source: Medline; NIEHS NIH HHS [ES012021-02] Funding Source: Medline; NIGMS NIH HHS [GM62268-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gao J, 2003, J PROTEOME RES, V2, P643, DOI 10.1021/pr034038x; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Panse VG, 2004, J BIOL CHEM, V279, P41346, DOI 10.1074/jbc.M407950200; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Sadygov RG, 2003, ANAL CHEM, V75, P3792, DOI 10.1021/ac034157w; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Stead K, 2003, J CELL BIOL, V163, P729, DOI 10.1083/jcb.200305080; Strunnikov AV, 2001, GENETICS, V158, P95; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	38	254	262	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45662	45668		10.1074/jbc.M409203200	http://dx.doi.org/10.1074/jbc.M409203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326169	hybrid			2022-12-25	WOS:000224694900046
J	Kim, J; Ghosh, S; Liu, HJ; Tateyama, M; Kass, RS; Pitt, GS				Kim, J; Ghosh, S; Liu, HJ; Tateyama, M; Kass, RS; Pitt, GS			Calmodulin mediates Ca2+ sensitivity of sodium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; LONG-QT SYNDROME; CARDIAC NA+ CHANNEL; CA2+-DEPENDENT INACTIVATION; CALCIUM-CHANNELS; SECONDARY STRUCTURE; C-TERMINUS; EF-HAND; MECHANISMS; SEQUENCE	Ca2+ has been proposed to regulate Na+ channels through the action of calmodulin (CaM) bound to an IQ motif or through direct binding to a paired EF hand motif in the Na(v)1 C terminus. Mutations within these sites cause cardiac arrhythmias or autism, but details about how Ca2+ confers sensitivity are poorly understood. Studies on the homologous Ca(v)1.2 channel revealed non-canonical CaM interactions, providing a framework for exploring Na+ channels. In contrast to previous reports, we found that Ca2+ does not bind directly to Na+ channel C termini. Rather, Ca2+ sensitivity appears to be mediated by CaM bound to the C termini in a manner that differs significantly from CaM regulation of Ca(v)1.2. In Na(v)1.2 or Na(v)1.5, CaM bound to a localized region containing the IQ motif and did not support the large Ca2+-dependent conformational change seen in the Ca(v)1.2 . CaM complex. Furthermore, CaM binding to Na(v)1 C termini lowered Ca2+ binding affinity and cooperativity among the CaM-binding sites compared with CaM alone. Nonetheless, we found suggestive evidence for Ca2+/CaM-dependent effects upon Na(v)1 channels. The R1902C autism mutation conferred a Ca2+-dependent conformational change in Na(v)1.2 C terminus . CaM complex that was absent in the wild-type complex. In Na(v)1.5, CaM modulates the C-terminal interaction with the III-IV linker, which has been suggested as necessary to stabilize the inactivation gate, to minimize sustained channel activity during depolarization, and to prevent cardiac arrhythmias that lead to sudden death. Together, these data offer new biochemical evidence for Ca2+/CaM modulation of Na+ channel function.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, Div Cardiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Cardiol, New York, NY 10032 USA	Columbia University; Columbia University	Pitt, GS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, Div Cardiol, 630 W 168th St,PH7W318, New York, NY 10032 USA.	gp2004@columbia.edu	Pitt, Geoffrey/L-4927-2019	Pitt, Geoffrey/0000-0003-2246-0289	NHLBI NIH HHS [R01 HL071165, R01 HL071165-02, R01 HL071165-01, R01 HL071165-03, HL-67849, HL-56810, HL-71165] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067849, R01HL056810, R01HL071165] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; Bond CT, 1999, ANN NY ACAD SCI, V868, P370, DOI 10.1111/j.1749-6632.1999.tb11298.x; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Clancy CE, 2004, BIOPHYS J, V86, P2606, DOI 10.1016/S0006-3495(04)74315-5; Clancy CE, 2003, CIRCULATION, V107, P2233, DOI 10.1161/01.CIR.0000069273.51375.BD; Cormier JW, 2002, J BIOL CHEM, V277, P9233, DOI 10.1074/jbc.M110204200; Deschenes I, 2002, CIRC RES, V90, pE49, DOI 10.1161/01.RES.0000012502.92751.E6; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Herzog RI, 2003, J NEUROSCI, V23, P8261; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; Kass RS, 2003, J CLIN INVEST, V112, P810, DOI 10.1172/JCI200319844; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Kim J, 2004, NEURON, V41, P745, DOI 10.1016/S0896-6273(04)00081-9; KINCAID RL, 1982, J BIOL CHEM, V257, P638; Makita N, 2002, CIRCULATION, V106, P1269, DOI 10.1161/01.CIR.0000027139.42087.B6; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; Motoike HK, 2004, J GEN PHYSIOL, V123, P155, DOI 10.1085/jgp.200308929; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Rivolta I, 2001, J BIOL CHEM, V276, P30623, DOI 10.1074/jbc.M104471200; Rook MB, 1999, CARDIOVASC RES, V44, P507, DOI 10.1016/S0008-6363(99)00350-8; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Tan HL, 2002, NATURE, V415, P442, DOI 10.1038/415442a; Tateyama M, 2004, BIOPHYS J, V86, P1843, DOI 10.1016/S0006-3495(04)74251-4; WALLACE RW, 1982, J BIOL CHEM, V257, P1845; Weiss LA, 2003, MOL PSYCHIATR, V8, P186, DOI 10.1038/sj.mp.4001241; Wingo TL, 2004, NAT STRUCT MOL BIOL, V11, P219, DOI 10.1038/nsmb737; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	41	130	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45004	45012		10.1074/jbc.M407286200	http://dx.doi.org/10.1074/jbc.M407286200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316014	hybrid			2022-12-25	WOS:000224505600092
J	Xue, M; Vines, CM; Buranda, T; Cimino, DF; Bennett, TA; Prossnitz, ER				Xue, M; Vines, CM; Buranda, T; Cimino, DF; Bennett, TA; Prossnitz, ER			N-formyl peptide receptors cluster in an active raft-associated state prior to phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; LIPID RAFTS; BETA-ARRESTINS; SIGNAL-TRANSDUCTION; CAVEOLAE; ACTIVATION; INTERNALIZATION; DESENSITIZATION; CHEMOTAXIS; BINDING	In response to ligand binding, G protein-coupled receptors undergo phosphorylation and activate cellular internalization machinery. An important component of this process is the concentration of receptors into clusters on the plasma membrane. Aside from organizing the receptor in anticipation of internalization, little is known of the function of ligand-mediated G protein-coupled receptor clustering, which has traditionally been thought of as being a phosphorylation-dependent event prior to receptor internalization. We now report that following receptor activation, the N-formyl peptide receptor (FPR) forms distinct membrane clusters prior to its association with arrestin. To determine whether this clustering is dependent upon receptor phosphorylation, we used a mutant form of the FPR, DeltaST-FPR, which lacks all phosphorylation sites in the carboxyl-terminal domain. We found that activation of the signaling-competent DeltaST-FPR resulted in rapid receptor clustering on the plasma membrane independent of G(i) protein activation. This clustering required receptor activation since the D71A mutant receptor, which binds ligand but is incapable of transitioning to an active state, failed to induce receptor clustering. Furthermore we demonstrated that FPR-mediated clustering and signaling were cholesterol-dependent processes, suggesting that translocation of the active receptor to lipid rafts may be required for maximal signaling activity. Finally we showed that FPR stimulation in the absence of receptor phosphorylation resulted in translocation of FPR to GM1-rich clusters. Our results demonstrate for the first time that formation of a clustered activated receptor state precedes receptor phosphorylation, arrestin binding, and internalization.	Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Univ New Mexico Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Prossnitz, ER (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA.	eprossnitz@salud.umn.edu	Prossnitz, Eric/I-4599-2019; Prossnitz, Eric R./B-4543-2008	Prossnitz, Eric/0000-0001-9190-8302; 	NATIONAL CANCER INSTITUTE [R24CA088339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014668, P20RR011830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K25AI060036, R29AI036357, T32AI007538, R01AI036357] Funding Source: NIH RePORTER; NCI NIH HHS [R24 CA88339] Funding Source: Medline; NCRR NIH HHS [P20 RR11830, 1 S10 RR14668] Funding Source: Medline; NIAID NIH HHS [AI36357, K25AI60036, K25 AI060036, T32 AI007538] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Haasemann M, 1998, J CELL SCI, V111, P917; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Key TA, 2001, J BIOL CHEM, V276, P49204, DOI 10.1074/jbc.M109475200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li N, 2003, PROTEOMICS, V3, P536, DOI 10.1002/pmic.200390067; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1991, BIOCHEM BIOPH RES CO, V179, P471, DOI 10.1016/0006-291X(91)91394-R; Prossnitz ER, 1999, BIOCHEMISTRY-US, V38, P2240, DOI 10.1021/bi982274t; Revankar CM, 2004, J BIOL CHEM, V279, P24578, DOI 10.1074/jbc.M402121200; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sabourin T, 2002, MOL PHARMACOL, V61, P546, DOI 10.1124/mol.61.3.546; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; Santini F, 2002, J CELL BIOL, V156, P665, DOI 10.1083/jcb.200110132; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Slaughter N, 2003, CLIN IMMUNOL, V108, P138, DOI 10.1016/S1521-6616(03)00097-4; SPIEGEL S, 1982, BIOCHIM BIOPHYS ACTA, V687, P27, DOI 10.1016/0005-2736(82)90166-3; VanCompernolle SE, 2003, J IMMUNOL, V171, P2050, DOI 10.4049/jimmunol.171.4.2050; Vilven JC, 1998, J RECEPT SIGNAL TR R, V18, P187, DOI 10.3109/10799899809047744; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Vines CM, 2002, J IMMUNOL, V169, P6760, DOI 10.4049/jimmunol.169.12.6760	44	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45175	45184		10.1074/jbc.M407053200	http://dx.doi.org/10.1074/jbc.M407053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302864	hybrid			2022-12-25	WOS:000224505600111
J	Subramanian, S; West, RB; Corless, CL; Ou, WB; Rubin, BP; Chu, KM; Leung, SY; Yuen, ST; Zhu, S; Hernandez-Boussard, T; Montgomery, K; Nielsen, TO; Patel, RM; Goldblum, JR; Heinrich, MC; Fletcher, JA; van de Rijn, M				Subramanian, S; West, RB; Corless, CL; Ou, WB; Rubin, BP; Chu, KM; Leung, SY; Yuen, ST; Zhu, S; Hernandez-Boussard, T; Montgomery, K; Nielsen, TO; Patel, RM; Goldblum, JR; Heinrich, MC; Fletcher, JA; van de Rijn, M			Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles	ONCOGENE			English	Article						GIST; KIT; PDGFRA; mutations; microarray; gene expression	OF-FUNCTION MUTATIONS; SIGNAL-TRANSDUCTION; C-KIT; ERM PROTEINS; CANCER; IMATINIB; SITE; MICROARRAYS; MODULATION; APOPTOSIS	Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates with both tumor biology and imatinib response. For example, GISTs with KIT exon 11 mutations are typically gastric and have excellent imatinib response, whereas those with KIT exon 9 mutations generally arise in the small bowel and are less responsive to imatinib. To identify genes that might contribute to these biological differences, we carried out gene expression profiling of 26 GISTs with known KIT and PDGFRA mutational status. Expression differences were then evaluated further by RNA in situ hybridization, immunohistochemistry, and immunoblotting. Unsupervised hierarchical clustering grouped tumors with similar mutations together, but the distinction between the different groups was not absolute. Differentially expressed genes included ezrin, p70S6K, and PKCs, which are known to have key roles in KIT or PDGFRA signaling, and which might therefore contribute to the distinctive clinicopathological features in GISTs with different mutation types. These gene products could serve as highly selective therapeutic targets in GISTs containing the KIT or PDGFRA mutational types with which they are associated.	Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Pathol, Portland, OR 97201 USA; Portland VA Med Ctr, Portland, OR USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Med Ctr, Dept Anat Pathol, Seattle, WA 98195 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Vancouver, BC, Canada; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Oregon Hlth & Sci Univ, OHSU Canc Inst, Dept Med, Portland, OR 97201 USA	Stanford University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; University of Hong Kong; University of Hong Kong; Stanford University; University of British Columbia; University of British Columbia; Cleveland Clinic Foundation; Oregon Health & Science University	van de Rijn, M (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, L-235,300 Pasteur Dr, Stanford, CA 94305 USA.	mrijn@stanford.edu	Leung, Suet Yi/C-4340-2009; Ou, Wen-Bin/J-1142-2019; Chu, Kent/C-4251-2009; Heinrich, Michael/AAC-6745-2019; PATEL, Rajiv Michael/AAI-9424-2021; Yuen, Siu/K-6311-2014; Leung, Suet Yi/T-9620-2019	PATEL, Rajiv Michael/0000-0002-1521-4947; West, Robert/0000-0002-8330-8283; Subramanian, Subbaya/0000-0002-2544-480X; , Wenbin/0000-0002-6311-9442; Heinrich, Michael/0000-0003-3790-0478; Leung, Suet Yi/0000-0001-8614-4619; van de Rijn, Matt/0000-0002-1909-9739	NCI NIH HHS [CA85129] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA085129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonescu CR, 2003, CLIN CANCER RES, V9, P3329; Antonescu CR, 2004, CLIN CANCER RES, V10, P3282, DOI 10.1158/1078-0432.CCR-03-0715; BESMER P, 1997, MOL CELL BIOL, P369; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1994, J BIOL CHEM, V269, P21793; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Breiner JA, 2000, CANCER GENET CYTOGEN, V120, P111, DOI 10.1016/S0165-4608(00)00212-0; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Corless CL, 2002, AM J PATHOL, V160, P1567, DOI 10.1016/S0002-9440(10)61103-0; Debiec-Rychter M, 2004, J PATHOL, V202, P430, DOI 10.1002/path.1546; Debiec-Rychter M, 2004, EUR J CANCER, V40, P689, DOI 10.1016/j.ejca.2003.11.025; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gunawan B, 2004, J PATHOL, V202, P421, DOI 10.1002/path.1537; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirota S, 2001, J PATHOL, V193, P505, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kinoshita K, 2003, J GASTROEN HEPATOL, V18, P147, DOI 10.1046/j.1440-1746.2003.02911.x; Kohno T, 1999, CANCER RES, V59, P4170; Koon N, 2004, GUT, V53, P235, DOI 10.1136/gut.2003.021238; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Lux ML, 2000, AM J PATHOL, V156, P791, DOI 10.1016/S0002-9440(10)64946-2; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Plo I, 2001, ONCOGENE, V20, P6752, DOI 10.1038/sj.onc.1204877; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Rubin BP, 2001, CANCER RES, V61, P8118; Sanders KM, 1999, NEUROGASTROENT MOTIL, V11, P311; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; West RB, 2004, AM J PATHOL, V165, P107, DOI 10.1016/S0002-9440(10)63279-8; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966	47	113	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7780	7790		10.1038/sj.onc.1208056	http://dx.doi.org/10.1038/sj.onc.1208056			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15326474				2022-12-25	WOS:000224331600004
J	Rausa, FM; Hughes, DE; Costa, RH				Rausa, FM; Hughes, DE; Costa, RH			Stability of the hepatocyte nuclear factor 6 transcription factor requires acetylation by the CREB-binding protein coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIFFERENTIATION; MAMMALIAN MEMBER; ONECUT CLASS; GENE FAMILY; DNA-BINDING; LIVER; CBP; EXPRESSION; HOMEODOMAIN; ACTIVATION	We previously demonstrated that the formation of complexes between the DNA binding domains of the hepatocyte nuclear factor 6 (HNF6) and Forkhead Box a2 (Foxa2) transcription factors resulted in synergistic transcriptional activation of a Foxa2 target promoter. This Foxa2.HNF6 transcriptional synergy was mediated by the recruitment of CREB-binding protein (CBP) coactivator through the HNF6 Cut-Homeodomain sequences. Although the HNF6 DNA binding domain sequences are sufficient to recruit CBP coactivator for HNF6.Foxa2 transcriptional synergy, paradoxically these HNF6 Cut-Homeodomain sequences were unable to stimulate the transcription of an HNF6-dependent reporter gene. Here, we investigated whether the CBP coactivator protein played a different role in regulating HNF6 transcriptional activity. We showed that acetylation of the HNF6 protein by CBP increased both HNF6 protein stability and its ability to stimulate transcription of the glucose transporter 2 promoter. Mutation of the HNF6 Cut domain lysine 339 residue to an arginine residue abrogated CBP acetylation, which is required for HNF6 protein stability. Furthermore, the HNF6 K339R mutant protein, which failed to accumulate detected protein levels, was transcriptionally inactive and could not be stabilized by inhibiting the ubiquitin proteasome pathway. Finally, increased HNF6 protein levels stabilized the Foxa2 protein, presumably through the formation of the Foxa2.HNF6 complex. These studies show for the first time that HNF6 protein stability is controlled by CBP acetylation and provides a novel mechanism by which the activity of the CBP coactivator may regulate steady levels of two distinct liver-enriched transcription factors.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Costa, RH (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet MC 669, 900 S Ashland Ave,Rm 2220 MBRB, Chicago, IL 60607 USA.	Robcosta@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043241] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM43241-15] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, J CELL SCI, V114, P2363; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clotman F, 2002, DEVELOPMENT, V129, P1819; Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Giandomenico V, 2003, MOL CELL BIOL, V23, P2587, DOI 10.1128/MCB.23.7.2587-2599.2003; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jacquemin P, 1999, J BIOL CHEM, V274, P2665, DOI 10.1074/jbc.274.5.2665; Kaestner KH, 2000, GENE DEV, V14, P142; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; Landry C, 1997, DEV BIOL, V192, P247, DOI 10.1006/dbio.1997.8757; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Lannoy VJ, 2000, J BIOL CHEM, V275, P22098, DOI 10.1074/jbc.M000855200; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sambrook J, 2001, MOL CLONING LAB MANU; Sheng WY, 2004, J BIOL CHEM, V279, P33928, DOI 10.1074/jbc.M403805200; Shim EY, 1998, GENE DEV, V12, P5, DOI 10.1101/gad.12.1.5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; Tan YJ, 2002, HEPATOLOGY, V35, P790, DOI 10.1053/jhep.2002.32482; Tan YJ, 2001, GENE EXPRESSION, V9, P237, DOI 10.3727/000000001783992542; Vanhorenbeeck V, 2002, BIOCHEM BIOPH RES CO, V292, P848, DOI 10.1006/bbrc.2002.6760; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	53	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43070	43076		10.1074/jbc.M407472200	http://dx.doi.org/10.1074/jbc.M407472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15304484	hybrid			2022-12-25	WOS:000224226400090
J	Califice, S; Castronovo, V; Bracke, M; van den Brule, F				Califice, S; Castronovo, V; Bracke, M; van den Brule, F			Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3	ONCOGENE			English	Article						galectin-3; prostate cancer; nucleus; cytoplasm	HUMAN BREAST-CARCINOMA; IGE-BINDING-PROTEIN; CELL-CYCLE ARREST; INDUCED APOPTOSIS; OVEREXPRESSION PROTECTS; SURFACE EXPRESSION; EPITHELIAL-CELLS; 3T3 FIBROBLASTS; NITRIC-OXIDE; LINE LNCAP	Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.	Univ Liege, Expt Canc Res Ctr, Metastasis Res Lab, B-4000 Liege 1, Belgium; State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Liege, Dept Gynecol, Liege, Belgium	University of Liege; Ghent University; Ghent University Hospital; University of Liege	van den Brule, F (corresponding author), Univ Liege, Expt Canc Res Ctr, Metastasis Res Lab, B-4000 Liege 1, Belgium.	f.vandenbrule@ulg.ac.be						Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Akahani S, 1997, CANCER RES, V57, P5272; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bowen C, 2000, CANCER RES, V60, P6111; Bracke M E, 2001, Methods Mol Med, V58, P91, DOI 10.1385/1-59259-137-X:091; CALIFICE S, IN PRESS INT J ONCOL; COWLES EA, 1990, J BIOL CHEM, V265, P17706; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Davidson PJ, 2002, GLYCOBIOLOGY, V12, P329, DOI 10.1093/glycob/12.5.329; Ellerhorst JA, 2002, PROSTATE, V50, P64, DOI 10.1002/pros.10033; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Gaudin JC, 2000, BIOL CELL, V92, P49, DOI 10.1016/S0248-4900(00)88763-8; Gelmann EP, 2003, PROSTATE, V55, P111, DOI 10.1002/pros.10210; GILLES C, 1993, INT J CANCER, V53, P872, DOI 10.1002/ijc.2910530527; GRITZMACHER CA, 1988, J IMMUNOL, V141, P2801; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HO MK, 1982, J IMMUNOL, V128, P1221; Honjo Y, 2001, CLIN CANCER RES, V7, P661; Honjo Y, 2000, CLIN CANCER RES, V6, P4635; Hughes RC, 2001, BIOCHIMIE, V83, P667; Kim HRC, 1999, CANCER RES, V59, P4148; Kim MJ, 2002, CANCER RES, V62, P2999; Kleeff J, 2000, INT J CANCER, V86, P399, DOI 10.1002/(SICI)1097-0215(20000501)86:3<399::AID-IJC15>3.0.CO;2-G; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Korkmaz KS, 2000, GENE, V260, P25, DOI 10.1016/S0378-1119(00)00453-4; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; LeMarer N, 1996, ANTICANCER RES, V16, P2767; Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820; Locigno R, 2002, INT J ONCOL, V20, P69; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; NANGIAMAKKER P, 1995, INT J ONCOL, V7, P1079; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paron I, 2003, BIOCHEM BIOPH RES CO, V302, P545, DOI 10.1016/S0006-291X(03)00151-7; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sanjuan X, 1997, GASTROENTEROLOGY, V113, P1906, DOI 10.1016/S0016-5085(97)70010-6; SATO S, 1994, J BIOL CHEM, V269, P4424; Song YK, 2002, AM J PATHOL, V160, P1069, DOI 10.1016/S0002-9440(10)64927-9; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Tsay YG, 1999, EXP CELL RES, V252, P250, DOI 10.1006/excr.1999.4643; van den Brule FA, 2000, INT J CANCER, V89, P361, DOI 10.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.3.CO;2-L; VANDENBRULE F, 2000, LECT PATHOLOGY; VandenBrule FA, 1997, INT J ONCOL, V11, P261; VANDENBRULE FA, 1995, BIOCHEM BIOPH RES CO, V209, P760, DOI 10.1006/bbrc.1995.1564; VandenBrule FA, 1996, HUM PATHOL, V27, P1185, DOI 10.1016/S0046-8177(96)90313-5; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Warfield PR, 1997, INVAS METAST, V17, P101; WIERDER R, 1999, CELL GROWTH DIFFER, P1; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Yoshii T, 2001, INT J ONCOL, V18, P787; Yu F, 2002, J BIOL CHEM, V277, P15819, DOI 10.1074/jbc.M200154200	70	135	138	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7527	7536		10.1038/sj.onc.1207997	http://dx.doi.org/10.1038/sj.onc.1207997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326483				2022-12-25	WOS:000224176500009
J	Gaggero, A; De Ambrosis, A; Mezzanzanica, D; Piazza, T; Rubartelli, A; Figini, M; Canevari, S; Ferrini, S				Gaggero, A; De Ambrosis, A; Mezzanzanica, D; Piazza, T; Rubartelli, A; Figini, M; Canevari, S; Ferrini, S			A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and-4 processing	ONCOGENE			English	Article						IL-18 isoform; alternative splicing; caspase-1; caspase-4	GAMMA-INDUCING FACTOR; ENDOTHELIAL GROWTH-FACTOR; MESSENGER-RNA ISOFORMS; NECROSIS-FACTOR-ALPHA; CANCER CELL-LINES; 2 IL-15 ISOFORMS; INTERFERON-GAMMA; HUMAN INTERLEUKIN-18; FIBRONECTIN ISOFORM; EPITHELIAL-CELLS	Interleukin-18 (IL-18) is a proinflammatory cytokine synthesized as a 24 kDa inactive precursor (pro-IL-18) by several cell types, and is processed to a bioactive molecule of 18 kDa by the proteinases caspase-1 or caspase-4. All ovarian carcinoma cell lines express pro-IL-18, only in some instances coexpress caspase-1, and always express caspase-4; in any case, they display a defective processing of IL-18. We analysed whether pro-IL-18, present in two ovarian carcinoma cell lysates, could be processed 'in vitro' by recombinant active caspase-1. While most of pro-IL-18 could be cleaved by caspase-1, a residual of pro-IL-18 appeared to be resistant. Cloning and sequence analysis of the whole pro-IL-18 open reading frame demonstrated the existence of an alternatively spliced mRNA variant, which lacked exon-3 (Delta3pro-IL-18). The 12 bp exon-3 encodes for the AEDD amino-acid sequence, which is N-terminal with respect to the cleavage site of caspase-1. Both pro-IL-18 and D3pro-IL-18 mRNA isoforms were detected in all ovarian cancer cell lines analysed, while Delta3pro-IL-18 mRNA was undetectable in normal ovarian epithelial cells. The Delta3pro-IL-18 cDNA induced synthesis of an alternative Delta3pro-IL-18 protein upon transfection into a murine cell line. The Delta3pro-IL-18 protein was resistant to proteolytic activation by caspase-1 and -4, although it was capable to bind caspase-1. Aternative splicing of pro-IL-18 exon-3 may represent a novel mechanism of regulation of bioactive IL-18 production in human ovarian tumors.	Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, I-16132 Genoa, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Genoa; IRCCS AOU San Martino IST; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ferrini, S (corresponding author), Ist Nazl Ric Canc, Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.	silvano.ferrini@istge.it	Mezzanzanica, Delia/C-2607-2017; Figini, Mariangela/K-8753-2016; Rubartelli, Anna/AAA-1259-2021	Mezzanzanica, Delia/0000-0002-9664-6871; Figini, Mariangela/0000-0001-9001-8754; Ferrini, Silvano/0000-0001-7254-2616				Akita K, 1997, J BIOL CHEM, V272, P26595, DOI 10.1074/jbc.272.42.26595; Bufler P, 2002, P NATL ACAD SCI USA, V99, P13723, DOI 10.1073/pnas.212519099; Cameron LA, 1999, EUR RESPIR J, V14, P553, DOI 10.1034/j.1399-3003.1999.14c12.x; Carnemolla B, 1996, J BIOL CHEM, V271, P8157, DOI 10.1074/jbc.271.14.8157; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; Coughlin CM, 1998, J CLIN INVEST, V101, P1441, DOI 10.1172/JCI1555; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; FANTUZZI G, 1999, EUR CYTOKIN E NETW, V9; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Galmozzi E, 2001, FEBS LETT, V502, P31, DOI 10.1016/S0014-5793(01)02659-X; Gardella S, 1999, J LEUKOCYTE BIOL, V66, P237, DOI 10.1002/jlb.66.2.237; Gardella S, 2000, FEBS LETT, V481, P245, DOI 10.1016/S0014-5793(00)02015-9; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hartenbach EM, 1997, CANCER LETT, V121, P169, DOI 10.1016/S0304-3835(97)00350-9; Kalina U, 2002, EUR J IMMUNOL, V32, P2635, DOI 10.1002/1521-4141(200209)32:9<2635::AID-IMMU2635>3.0.CO;2-N; Kalina U, 2000, SCAND J IMMUNOL, V52, P525, DOI 10.1046/j.1365-3083.2000.00836.x; Kim SH, 2000, P NATL ACAD SCI USA, V97, P1190, DOI 10.1073/pnas.97.3.1190; Kohno K, 1997, J IMMUNOL, V158, P1541; Kost ER, 1999, GYNECOL ONCOL, V72, P392, DOI 10.1006/gyno.1998.5257; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Lu H, 2000, J IMMUNOL, V165, P1463, DOI 10.4049/jimmunol.165.3.1463; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 2000, INT J CANCER, V87, P574, DOI 10.1002/1097-0215(20000815)87:4<574::AID-IJC18>3.3.CO;2-K; Meazza R, 1996, ONCOGENE, V12, P2187; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Naik SM, 1999, J INVEST DERMATOL, V113, P766, DOI 10.1046/j.1523-1747.1999.00750.x; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nash MA, 1998, CLIN EXP IMMUNOL, V112, P172; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Onu A, 1997, J IMMUNOL, V158, P255; Osaki T, 1999, GENE THER, V6, P808, DOI 10.1038/sj.gt.3300908; Pages F, 1999, INT J CANCER, V84, P326, DOI 10.1002/(SICI)1097-0215(19990621)84:3<326::AID-IJC22>3.0.CO;2-K; Stoll S, 1997, J IMMUNOL, V159, P298; Sugawara S, 2001, J IMMUNOL, V167, P6568, DOI 10.4049/jimmunol.167.11.6568; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Tatsumi T, 2002, CANCER RES, V62, P5853; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; USHIO S, 1996, J IMMUNOL, V156, P4272; Wang ZY, 2002, INT J CANCER, V98, P873, DOI 10.1002/ijc.10268; Windbichler GH, 2000, BRIT J CANCER, V82, P1138; WU S, 1993, CANCER RES, V53, P1939; Xiang Y, 2001, J VIROL, V75, P9947, DOI 10.1128/JVI.75.20.9947-9954.2001; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535	49	23	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7552	7560		10.1038/sj.onc.1208036	http://dx.doi.org/10.1038/sj.onc.1208036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326478				2022-12-25	WOS:000224176500012
J	Kinnear, NP; Boittin, FX; Thomas, JM; Galione, A; Evans, AM				Kinnear, NP; Boittin, FX; Thomas, JM; Galione, A; Evans, AM			Lysosome-sarcoplasmic reticulum junctions - A trigger zone for calcium signaling by nicotinic acid adenine dinucleotide phosphate and endothelin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ARTERIAL SMOOTH-MUSCLE; PANCREATIC BETA-CELLS; NAADP MOBILIZES CA2+; INTRACELLULAR CALCIUM; RYANODINE RECEPTORS; 2-POOL MECHANISM; GENE-EXPRESSION; RELEASE; CADPR	Previous studies on pulmonary arterial smooth muscle cells have shown that nicotinic acid adenine dinucleotide phosphate ( NAADP) evokes highly localized intracellular Ca2+ signals by mobilizing thapsigarginin-sensitive stores. Such localized Ca2+ signals may initiate global Ca2+ waves and contraction of the myocytes through the recruitment of ryanodine receptors on the sarcoplasmic reticulum via Ca2+-induced Ca2+ release. Here we show that NAADP evokes localized Ca2+ signals by mobilizing a bafilomycin A1-sensitive, lysosome-related Ca2+ store. These lysosomal stores facilitate this process by co-localizing with a portion of the sarcoplasmic reticulum expressing ryanodine receptors to comprise a highly specialized trigger zone for NAADP-dependent Ca2+ signaling by the vasoconstrictor hormone, endothelin-1. These findings further advance our understanding of how the spatial organization of discrete, organellar Ca2+ stores may underpin the generation of differential Ca2+ signaling patterns by different Ca2+-mobilizing messengers.	Univ St Andrews, Sch Biol, Div Biomed Sci, St Andrews KY16 9TS, Fife, Scotland; Univ Oxford, Univ Dept Pharmacol, Oxford OX1 3QT, England	University of St Andrews; University of Oxford	Evans, AM (corresponding author), Univ St Andrews, Sch Biol, Div Biomed Sci, Bute Bldg, St Andrews KY16 9TS, Fife, Scotland.	ame3@st-and.ac.uk	Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646				BERG TO, 1994, BIOCHEM J, V300, P229, DOI 10.1042/bj3000229; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boittin FX, 2003, J BIOL CHEM, V278, P9602, DOI 10.1074/jbc.M204891200; Boittin FX, 2002, CIRC RES, V91, P1168, DOI 10.1161/01.RES.0000047507.22487.85; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Christensen KA, 2002, J CELL SCI, V115, P599; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Gerasimenko JV, 2003, J CELL BIOL, V163, P271, DOI 10.1083/jcb.200306134; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; Hohenegger M, 2002, BIOCHEM J, V367, P423, DOI 10.1042/BJ20020584; ITO M, 1989, INT J IMMUNOPHARMACO, V11, P185, DOI 10.1016/0192-0561(89)90070-2; Kannan MS, 1996, AM J PHYSIOL-HEART C, V270, pH801, DOI 10.1152/ajpheart.1996.270.2.H801; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LANGTON PD, 1993, J PHYSIOL-LONDON, V471, P1; Lee HC, 2000, J CELL SCI, V113, P4413; Li PL, 2003, ACTA PHYSIOL SCAND, V179, P339, DOI 10.1046/j.0001-6772.2003.01216.x; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Masgrau R, 2003, CURR BIOL, V13, P247, DOI 10.1016/S0960-9822(03)00041-1; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; SUGAYA E, 1978, SCIENCE, V202, P1195, DOI 10.1126/science.725594; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; Tang WX, 2002, AM J PHYSIOL-HEART C, V282, pH1304, DOI 10.1152/ajpheart.00843.2001; Wang YX, 2004, AM J PHYSIOL-CELL PH, V286, pC538, DOI 10.1152/ajpcell.00106.2003; Wilson Heather L., 1998, British Journal of Pharmacology, V124, p30P; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Yamasaki M, 2004, J BIOL CHEM, V279, P7234, DOI 10.1074/jbc.M311088200; Yusufi ANK, 2002, EXP BIOL MED, V227, P36, DOI 10.1177/153537020222700107	34	162	163	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54319	54326		10.1074/jbc.M406132200	http://dx.doi.org/10.1074/jbc.M406132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15331591	hybrid			2022-12-25	WOS:000225793600053
J	Vickers, TJ; Wyllie, S; Fairlamb, AH				Vickers, TJ; Wyllie, S; Fairlamb, AH			Leishmania major elongation factor 1B complex has trypanothione S-transferase and peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-CRUZI; MOLECULAR-CLONING; PROTEIN-SYNTHESIS; OXIDATIVE STRESS; GLUTATHIONE; HYDROPEROXIDE; MITOCHONDRIAL; ENZYME; LOCALIZATION; SPECIFICITY	In the Trypanosomatidae, trypanothione has subsumed many of the roles of glutathione in defense against chemical and oxidant stress. Crithidia fasciculata lacks glutathione S-transferase, but contains an unusual trypanothione S-transferase activity that is associated with eukaryotic translation elongation factor 1B (eEF1B). Here we describe the cloning, expression, and reconstitution of the purified alpha, beta, and gamma subunits of eEF1B from Leishmania major. Individual subunits lacked trypanothione S-transferase activity. Only eEF1B, formed by reconstitution or co-expression of the three subunits, was able to conjugate a variety of electrophilic substrates to trypanothione or glutathionylspermidine, but not glutathione. In contrast to the C. fasciculata eEF1B, the L. major enzyme also displayed peroxidase activity against a variety of organic hydroperoxides. The enzyme showed no activity with hydrogen peroxide and greatest activity with linoleic acid hydroperoxide (1 unit mg(-1)). Kinetic studies suggest a ternary complex mechanism, with Km values of 140 muM for trypanothione and 7.4 mM for cumene hydroperoxide and k(cat) = 25 s(-1). Immunofluorescence studies indicate that the enzyme may be localized to the surface of the endoplasmic reticulum. These results suggest that, in addition to its role in protein synthesis, the Leishmania eEF1B may help protect the parasite from lipid peroxidation.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Mol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Fairlamb, AH (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Mol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	a.h.fairlamb@dundee.ac.uk	Fairlamb, Alan/A-5272-2009; Wyllie, Susan/AAI-4430-2021	Fairlamb, Alan/0000-0001-5134-0329; Wyllie, Susan/0000-0001-8810-5605	Wellcome Trust [079838] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Ariyanayagam MR, 2001, MOL BIOCHEM PARASIT, V115, P189, DOI 10.1016/S0166-6851(01)00285-7; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; BANGS JD, 1993, J CELL SCI, V105, P1101; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BillautMulot O, 1997, GENE, V198, P259, DOI 10.1016/S0378-1119(97)00323-5; BORGES A, 1995, EUR J BIOCHEM, V228, P745, DOI 10.1111/j.1432-1033.1995.tb20319.x; Castro H, 2002, FREE RADICAL BIO MED, V33, P1563, DOI 10.1016/S0891-5849(02)01088-2; Castro H, 2002, FREE RADICAL BIO MED, V33, P1552, DOI 10.1016/S0891-5849(02)01089-4; COLLIER HB, 1973, ANAL BIOCHEM, V56, P310, DOI 10.1016/0003-2697(73)90196-6; COOPER C, 1995, OSTEOARTHR CARTILAGE, V3, P1; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb AH, 2003, TRENDS PARASITOL, V19, P488, DOI 10.1016/j.pt.2003.09.002; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; GRACEFFA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P46, DOI 10.1016/0003-9861(92)90639-E; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Habig W H, 1981, Methods Enzymol, V77, P398; HAHN BS, 1976, J ORG CHEM, V41, P567, DOI 10.1021/jo00865a039; Han J, 1996, ANAL BIOCHEM, V234, P107, DOI 10.1006/abio.1996.0059; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Hurst R, 1998, BIOCHEM J, V332, P97, DOI 10.1042/bj3320097; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Irsch T, 2004, J BIOL CHEM, V279, P22209, DOI 10.1074/jbc.M401240200; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; Ketterer B., 1988, P73; KEZDY FJ, 1962, BIOCHEMISTRY-US, V1, P1097, DOI 10.1021/bi00912a021; Kobayashi S, 2001, BIOCHEM BIOPH RES CO, V288, P509, DOI 10.1006/bbrc.2001.5799; KOSOWER NS, 1971, BIOCHEM BIOPH RES CO, V45, P816, DOI 10.1016/0006-291X(71)90490-6; Levick MP, 1998, MOL BIOCHEM PARASIT, V96, P125, DOI 10.1016/S0166-6851(98)00122-4; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Minella O, 1996, CELL MOL BIOL, V42, P805; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Negrutskii BS, 1999, J BIOL CHEM, V274, P4545, DOI 10.1074/jbc.274.8.4545; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Ong LL, 2003, J BIOL CHEM, V278, P32115, DOI 10.1074/jbc.M210917200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanders J, 1996, J CELL SCI, V109, P1113; SANG LJ, 2002, BIOCHEM BIOPH RES CO, V291, P158; Sheu GT, 1997, J BIOL CHEM, V272, P33290, DOI 10.1074/jbc.272.52.33290; Sun QA, 1996, BIOCHEM MOL BIOL INT, V39, P343; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Tetaud E, 2001, MOL BIOCHEM PARASIT, V116, P171, DOI 10.1016/S0166-6851(01)00320-6; Tovar J, 1998, MOL MICROBIOL, V29, P653, DOI 10.1046/j.1365-2958.1998.00968.x; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; vanderAar EM, 1996, XENOBIOTICA, V26, P143, DOI 10.3109/00498259609046696; Vickers TJ, 2004, P NATL ACAD SCI USA, V101, P13186, DOI 10.1073/pnas.0402918101; Vickers TJ, 2004, J BIOL CHEM, V279, P27246, DOI 10.1074/jbc.M311039200; Wilkinson SM, 2002, J BIOL CHEM, V277, P17062, DOI 10.1074/jbc.M111126200; Wilkinson SR, 2000, J BIOL CHEM, V275, P8220, DOI 10.1074/jbc.275.11.8220; Wilkinson SR, 2002, BIOCHEM J, V364, P787, DOI 10.1042/BJ20020038; Wilkinson SR, 2000, BIOCHEM J, V352, P755, DOI 10.1042/0264-6021:3520755; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405	62	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49003	49009		10.1074/jbc.M407958200	http://dx.doi.org/10.1074/jbc.M407958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15322082	hybrid			2022-12-25	WOS:000225098100063
J	Yegneswaran, S; Mesters, RM; Fernandez, JA; Griffin, JH				Yegneswaran, S; Mesters, RM; Fernandez, JA; Griffin, JH			Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; PHOSPHOLIPID SURFACE; CRYSTAL-STRUCTURE; ACTIVE-SITE; CONFORMATIONAL SENSITIVITY; PROTEIN; DOMAIN; SEQUENCE; MEIZOTHROMBIN; FLUORESCENCE	To identify sequences in prothrombin (fII) involved in prothrombinase complex (fXa . fVa . fII . phospholipids) assembly, synthetic peptides based on fII sequences were prepared and screened for their ability to inhibit factor Xa (fXa)-induced clotting of normal plasma. The fII peptide (PT473 - 487, homologous to chymotrypsin residues 149D-163) potently inhibited plasma clotting assays and prothrombinase activity, with 50% inhibition of 12 and 10 muM peptide, respectively. Prothrombinase inhibition by PT473 - 487 was factor Va (fVa)-dependent and sequence-specific, because the peptide did not inhibit fII activation in the absence of fVa, and a scrambled sequence peptide, PT473 - 487SCR, was not inhibitory. Peptide PT473 - 487 did not inhibit the amidolytic activities of fXa and thrombin, suggesting that the peptide did not alter the integrity of their active sites. To determine whether PT473 - 487 interacted directly with fVa, fluorescein-labeled fVa (Fl-fVa) was prepared. When PT473 - 487 was titrated into samples containing phospholipid-bound Fl-fVa, the peptide increased fluorescein anisotropy (EC50 at 3 muM peptide), whereas the control peptide PT473 - 487SCR did not alter the anisotropy, suggesting a direct binding interaction between PT473 487 and Fl-fVa. These functional and spectroscopic data suggest that fII residues 473 - 487 provide fVa-binding sites and mediate interactions between fVa and fII in the prothrombinase complex.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Griffin, JH (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM 180,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jgriffin@scripps.edu	Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021544, R37HL052246, P01HL031950, R01HL052246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31950, HL21544, HL52246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2004, P NATL ACAD SCI USA, V101, P8918, DOI 10.1073/pnas.0403072101; Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; Blostein MD, 2000, J BIOL CHEM, V275, P38120, DOI 10.1074/jbc.M007174200; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE B, 1982, J BIOL CHEM, V257, P3875; Gale AJ, 2000, BLOOD, V96, P585; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; Grimm DR, 2001, CELL MOL LIFE SCI, V58, P148, DOI 10.1007/PL00000775; Heeb MJ, 1999, EUR J BIOCHEM, V260, P64, DOI 10.1046/j.1432-1327.1999.00137.x; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P3823; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, V9, P258; LEYTUS SP, 1984, P NATL ACAD SCI-BIOL, V81, P3699, DOI 10.1073/pnas.81.12.3699; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MAGNUSSON S, 1975, PROTEASES BIOL CONTR; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; MESTERS RM, 1993, PROTEIN SCI, V2, P1482, DOI 10.1002/pro.5560020912; MESTERS RM, 1991, J BIOL CHEM, V266, P24514; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; Monteiro RQ, 2002, THROMB HAEMOSTASIS, V87, P288; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Pellequer JL, 2000, THROMB HAEMOSTASIS, V84, P849, DOI 10.1055/s-0037-1614127; ROSING J, 1986, J BIOL CHEM, V261, P4224; ROSING J, 1980, J BIOL CHEM, V255, P274; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; TANEDA H, 1994, J BIOCHEM-TOKYO, V116, P589, DOI 10.1093/oxfordjournals.jbchem.a124565; YE J, 1991, J BIOL CHEM, V266, P23016; Yegneswaran S, 2002, CHEM BIOL, V9, P485, DOI 10.1016/S1074-5521(02)00132-1; Yegneswaran S, 2003, J BIOL CHEM, V278, P33312, DOI 10.1074/jbc.M305906200	48	24	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49019	49025		10.1074/jbc.M406645200	http://dx.doi.org/10.1074/jbc.M406645200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15331602	hybrid			2022-12-25	WOS:000225098100065
J	Fujimoto, T; Yamazaki, S; Eto-Kimura, A; Takeshige, K; Muta, T				Fujimoto, T; Yamazaki, S; Eto-Kimura, A; Takeshige, K; Muta, T			The amino-terminal region of Toll-like receptor 4 is essential for binding to MD-2 and receptor translocation to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; LIGAND-SPECIFIC RECOGNITION; LEUCINE-RICH REPEATS; INNATE IMMUNITY; SIGNAL-TRANSDUCTION; BACTERIAL LIPOPOLYSACCHARIDE; DROSOPHILA EMBRYO; ACTIVATION SIGNAL; CRYSTAL-STRUCTURE; HORSESHOE-CRAB	Toll-like receptor 4 (TLR4) and MD-2 are pivotal components that elicit inflammatory responses to lipopolysaccharide (LPS). They have been shown to form a physical complex on the cell surface that responds directly to LPS. However, the functional region of TLR4 required for association with MD-2 and LPS responsiveness is poorly understood. To identify the region of TLR4, we created a series of mutants with deletions in the extracellular domain and examined their activities in human embryonic kidney 293 cells. A mutant with a 317-amino acid deletion from the membrane proximal region of TLR4 was capable of associating with MD-2, while only a 9-amino acid truncation of the N terminus severely impaired the interaction. The association between the two molecules was well correlated with TLR4 maturation into an endoglycosidase H-resistant form and the cell surface expression. Mouse MD-2 bound to human TLR4, but its activity to facilitate the cell surface expression of TLR4 and confer LPS responsiveness was much weaker than that of human MD-2, indicating species specificity. A chimeric receptor composed of the N-terminal region of human TLR4 and the adjacent region of mouse TLR4 showed preference for human MD-2 in its transport to the cell surface and responsiveness to LPS. Taken together, the N-terminal region of TLR4 is essential for association with MD-2, which is required for the cell surface expression and hence the responsiveness to LPS.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Host & Def, Saitama 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan.	tmuta@mailserver.med.kyushu-u.ac.jp		Yamazaki, Soh/0000-0001-5038-1567				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; ALLEN JN, 1993, J LAB CLIN MED, V122, P374; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; KAWANO K, 1990, J BIOL CHEM, V265, P15365; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kawasaki K, 2001, J IMMUNOL, V166, P11, DOI 10.4049/jimmunol.166.1.11; Kennedy MN, 2004, J BIOL CHEM, V279, P34698, DOI 10.1074/jbc.M405444200; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lee LF, 1996, CANCER RES, V56, P1303; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; Miura Y, 1998, BLOOD, V92, P2815, DOI 10.1182/blood.V92.8.2815.420k09_2815_2822; Miyake K, 1998, J IMMUNOL, V161, P1348; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Nagai Y, 2002, BLOOD, V99, P1699, DOI 10.1182/blood.V99.5.1699; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; SEVERINSSON L, 1984, J CELL BIOL, V99, P226, DOI 10.1083/jcb.99.1.226; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; WINANS KA, 1995, MOL BIOL CELL, V6, P587, DOI 10.1091/mbc.6.5.587; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5	51	31	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47431	47437		10.1074/jbc.M408724200	http://dx.doi.org/10.1074/jbc.M408724200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337750	hybrid			2022-12-25	WOS:000224957000004
J	Liang, Y; Fotiadis, D; Maeda, T; Maeda, A; Modzelewska, A; Filipek, S; Saperstein, DA; Engel, A; Palczewski, K				Liang, Y; Fotiadis, D; Maeda, T; Maeda, A; Modzelewska, A; Filipek, S; Saperstein, DA; Engel, A; Palczewski, K			Rhodopsin signaling and organization in heterozygote rhodopsin knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 3-DIMENSIONAL STRUCTURE; CA2+-BINDING PROTEINS; TARGETED DISRUPTION; CRYSTAL-STRUCTURE; VISUAL PIGMENT; MOUSE RETINA; DIMERIZATION; ACTIVATION; BOVINE	Rhodopsin ( Rho) resides within internal membrane structures called disc membranes that are found in the rod outer segments (ROS) of photoreceptors in the retina. Rho expression is essential for formation of ROS, which are absent in knockout Rho-/- mice. ROS of mice heterozygous for the Rho gene deletion (Rho+/-) may have a lower Rho density than wild type (WT) membranes, or the ROS structure may be reduced in size due to lower Rho expression. Here, we present evidence that the smaller volume of ROS from heterozygous mice is most likely responsible for observed electrophysiological response differences. In Rho-/- mice as compared with age-matched WT mice, the length of ROS was shorter by 30-40%, and the average diameter of ROS was reduced by similar to20%, as demonstrated by transmission and scanning electron microscopy. Together, the reduction of the volume of ROS was similar to60% in Rho+/- mice. Rho content in the eyes was reduced by similar to43% and 11-cis-retinal content in the eye was reduced by similar to38%, as determined by UV-visible spectroscopy and retinoid analysis, respectively. Transmission electron microscopy of negatively stained disc membranes from Rho+/- mice indicated a typical morphology apart from the reduced size of disc diameter. Power spectra calculated from disc membrane regions on such electron micrographs displayed a diffuse ring at similar to4.5 nm(-1), indicating paracrystallinity of Rho. Atomic force microscopy of WT and Rho+/- disc membranes revealed, in both cases, Rho organized in paracrystalline and raftlike structures. From these data, we conclude that the differences in physiological responses measured in WT and Rho+/- mice are due to structural changes of the whole ROS and not due to a lower density of Rho.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Basel, ME Muller Inst Microscopy, Biozentrum, CH-4056 Basel, Switzerland; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Basel; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R01EY008061, P30EY001730, R29EY008061] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bai M, 2004, CELL SIGNAL, V16, P175, DOI 10.1016/S0898-6568(03)00128-1; Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; CARRILLO JJ, 2004, IN PRESS MOL PHARM; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; Chabre M, 2003, NATURE, V426, P30, DOI 10.1038/426030b; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Filizola M, 2002, PROTEIN ENG, V15, P881, DOI 10.1093/protein/15.11.881; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fotiadis D, 2003, NATURE, V426, P31, DOI 10.1038/426031a; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; Hernanz-Falcon P, 2004, NAT IMMUNOL, V5, P216, DOI 10.1038/ni1027; Howes KA, 2002, EMBO J, V21, P1545, DOI 10.1093/emboj/21.7.1545; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; JAVITCH JA, 2004, IN PRESS MOL PHARM; Krebs A, 2003, J BIOL CHEM, V278, P50217, DOI 10.1074/jbc.M307995200; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mendez A, 2001, P NATL ACAD SCI USA, V98, P9948, DOI 10.1073/pnas.171308998; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Muller DJ, 1997, J STRUCT BIOL, V119, P172, DOI 10.1006/jsbi.1997.3875; OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/pnas.90.8.3241; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2000, J STRUCT BIOL, V130, P73, DOI 10.1006/jsbi.1999.4209; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Ridge KD, 2003, TRENDS BIOCHEM SCI, V28, P479, DOI 10.1016/S0968-0004(03)00172-5; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; SCHLEGEL W, 1979, J BIOL CHEM, V254, P5168; Soyer OS, 2003, BIOCHEMISTRY-US, V42, P14522, DOI 10.1021/bi035097r; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Terrillon S, 2004, EMBO REP, V5, P30, DOI 10.1038/sj.embor.7400052; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Vogel R, 2004, J MOL BIOL, V338, P597, DOI 10.1016/j.jmb.2004.03.006	52	108	111	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48189	48196		10.1074/jbc.M408362200	http://dx.doi.org/10.1074/jbc.M408362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337746	Green Accepted, hybrid			2022-12-25	WOS:000224957000093
J	Rzepecki, P; Nagel-Steger, L; Feuerstein, S; Linne, U; Molt, O; Zadmard, R; Aschermann, K; Wehner, M; Schrader, T; Riesner, D				Rzepecki, P; Nagel-Steger, L; Feuerstein, S; Linne, U; Molt, O; Zadmard, R; Aschermann, K; Wehner, M; Schrader, T; Riesner, D			Prevention of Alzheimer's disease-associated A beta aggregation by rationally designed nonpeptidic beta-sheet ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; CENTRAL-NERVOUS-SYSTEM; AMYLOID PEPTIDE; FIBRIL FORMATION; AQUEOUS-SOLUTION; GAS-PHASE; PROTEIN; FIBRILLOGENESIS; INHIBITORS; MODEL	A new concept is introduced for the rational design of beta-sheet ligands, which prevent protein aggregation. Oligomeric acylated aminopyrazoles with a donor-acceptor-donor ( DAD) hydrogen bond pattern complementary to that of a beta-sheet efficiently block the solvent-exposed beta-sheet portions in Abeta-(1-40) and thereby prevent formation of insoluble protein aggregates. Density gradient centrifugation revealed that in the initial phase, the size of Abeta aggregates was efficiently kept between the trimeric and 15-meric state, whereas after 5 days an additional high molecular weight fraction appeared. With fluorescence correlation spectroscopy (FCS) exactly those two, i.e. a dimeric aminopyrazole with an oxalyl spacer and a trimeric head-to-tail connected aminopyrazole, of nine similar aminopyrazole ligands were identified as efficient aggregation retardants whose minimum energy conformations showed a perfect complementarity to a beta-sheet. The concentration dependence of the inhibitory effect of a trimeric aminopyrazole derivative allowed an estimation of the dissociation constant in the range of 10(-5) M. Finally, electrospray ionization mass spectrometry (ESI-MS) was used to determine the aggregation kinetics of Abeta-(1-40) in the absence and in the presence of the ligands. From the comparable decrease in Abeta monomer concentration, we conclude that these beta-sheet ligands do not prevent the initial oligomerization of monomeric Abeta but rather block further aggregation of spontaneously formed small oligomers. Together with the results from density gradient centrifugation and fluorescence correlation spectroscopy it is now possible to restrict the approximate size of soluble Abeta aggregates formed in the presence of both inhibitors from 3- to 15-mers.	Univ Marburg, Dept Chem, D-35032 Marburg, Germany; Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Biol Med Res Ctr, D-40225 Dusseldorf, Germany	Philipps University Marburg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Schrader, T (corresponding author), Univ Marburg, Dept Chem, Hans Meerwein Str, D-35032 Marburg, Germany.	schradet@mailer.uni-marburg.de	Nagel-Steger, Luitgard/H-6415-2013	Nagel-Steger, Luitgard/0000-0001-5232-2149; Feuerstein, Sophie/0000-0003-2258-912X				Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Chen XG, 1997, FASEB J, V11, P817, DOI 10.1096/fasebj.11.10.9271367; Chitnumsub P, 1999, BIOORGAN MED CHEM, V7, P39, DOI 10.1016/S0968-0896(98)00222-3; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Gordon DJ, 2003, BIOCHEMISTRY-US, V42, P475, DOI 10.1021/bi0259857; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Harrington BJ, 2002, LAB MED, V33, P609; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; Kirsten CN, 1997, J AM CHEM SOC, V119, P12061, DOI 10.1021/ja972158y; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1996, ACCOUNTS CHEM RES, V29, P317, DOI 10.1021/ar950159u; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lowe TL, 2001, BIOCHEMISTRY-US, V40, P7882, DOI 10.1021/bi002734u; Nowick JS, 1999, ACCOUNTS CHEM RES, V32, P287, DOI 10.1021/ar970204t; Ono K, 2002, J NEUROCHEM, V81, P434, DOI 10.1046/j.1471-4159.2002.00904.x; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Reixach N, 2000, J STRUCT BIOL, V130, P247, DOI 10.1006/jsbi.2000.4245; RIBEIRO AA, 1979, INT J PEPT PROT RES, V14, P414; Rzepecki P, 2003, SYNTHESIS-STUTTGART, P1815, DOI 10.1055/s-2003-41031; Sacchettini JC, 2002, NAT REV DRUG DISCOV, V1, P267, DOI 10.1038/nrd769; Saweczko P, 2001, INORG CHEM, V40, P4409, DOI 10.1021/ic010145m; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schenck HL, 1998, J AM CHEM SOC, V120, P4869, DOI 10.1021/ja973984+; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHRADER T, 1996, J CHEM SOC CHEM COMM, P2089; Schroder M, 2002, NERVENHEILKUNDE, V21, P7; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Skribanek Z, 2001, J MASS SPECTROM, V36, P1226, DOI 10.1002/jms.243; SMITH AB, 1994, J MED CHEM, V37, P215, DOI 10.1021/jm00028a001; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tsai JH, 1999, BIOORGAN MED CHEM, V7, P29, DOI 10.1016/S0968-0896(98)00225-9; Unterberg C, 2003, J CHEM PHYS, V118, P8296, DOI 10.1063/1.1565110; Unterberg C, 2002, EUR PHYS J D, V20, P543, DOI 10.1140/epjd/e2002-00152-9; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; Watanabe K, 2002, BIOCHEM BIOPH RES CO, V290, P121, DOI 10.1006/bbrc.2001.6191; Weiner WS, 1998, BIOORG MED CHEM LETT, V8, P681, DOI 10.1016/S0960-894X(98)00099-7; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Wisniewski T, 1998, AMYLOID, V5, P212; Yamada K, 1999, JPN J PHARMACOL, V80, P9, DOI 10.1254/jjp.80.9	51	53	73	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47497	47505		10.1074/jbc.M405914200	http://dx.doi.org/10.1074/jbc.M405914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15322133	hybrid			2022-12-25	WOS:000224957000012
J	Dutton, JL; Renda, RF; Waine, C; Clark, RJ; Daly, NL; Jennings, CV; Anderson, MA; Craik, DJ				Dutton, JL; Renda, RF; Waine, C; Clark, RJ; Daly, NL; Jennings, CV; Anderson, MA; Craik, DJ			Conserved structural and sequence elements implicated in the processing of gene-encoded circular proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT CYCLOTIDES; MACROCYCLIC POLYPEPTIDES; KNOTTED PROTEINS; PEPTIDE; PROGRAM; MODEL; PROPEPTIDE; MEMBRANES; BINDING; NMR	The cyclotides are the largest family of naturally occurring circular proteins. The mechanism by which the termini of these gene-encoded proteins are linked seamlessly with a peptide bond to form a circular backbone is unknown. Here we report cyclotide-encoding cDNA sequences from the plant Viola odorata and compare them with those from an evolutionarily distinct species, Oldenlandia affinis. Individual members of this multigene family encode one to three mature cyclotide domains. These domains are preceded by N-terminal repeat regions (NTRs) that are conserved within a plant species but not between species. We have structurally characterized peptides corresponding to these NTRs and show that, despite them having no sequence homology, they form a structurally conserved alpha-helical motif. This structural conservation suggests a vital role for the NTR in the in vivo folding, processing, or detoxification of cyclotide domains from the precursor protein.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia	University of Queensland; La Trobe University	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Anderson, Marilyn A/A-4259-2012; Clark, Richard J/G-8848-2012; Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013	Anderson, Marilyn A/0000-0002-8257-5128; Clark, Richard J/0000-0002-6807-5426; Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Dutton, Julie/0000-0002-9798-1284				Bokesch HR, 2001, J NAT PROD, V64, P249, DOI 10.1021/np000372l; Braun P, 1998, TRENDS MICROBIOL, V6, P6, DOI 10.1016/S0966-842X(97)01188-8; Broussalis AM, 2001, PHYTOCHEMISTRY, V58, P47, DOI 10.1016/S0031-9422(01)00173-X; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; BRUNGER AT, 1992, XPLOR VERSION 3 1A S; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Buczek O, 2004, BIOCHEMISTRY-US, V43, P1093, DOI 10.1021/bi0354233; Claeson P, 1998, J NAT PROD, V61, P77, DOI 10.1021/np970342r; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P1809, DOI 10.1016/S0041-0101(01)00129-5; Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512; Craik DJ, 2001, LETT PEPT SCI, V8, P119, DOI 10.1007/BF02446507; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Goransson U, 2003, ANAL BIOCHEM, V318, P107, DOI 10.1016/S0003-2697(03)00114-3; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; GRAN L, 1973, ACTA PHARMACOL TOX, V33, P400; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Gustafson KR, 2000, J NAT PROD, V63, P176, DOI 10.1021/np990432r; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; Kliemannel M, 2004, FEBS LETT, V566, P207, DOI 10.1016/j.febslet.2004.04.034; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; Mouchantaf R, 2001, J BIOL CHEM, V276, P26308, DOI 10.1074/jbc.M102514200; Nielsen KJ, 1996, BIOCHEMISTRY-US, V35, P369, DOI 10.1021/bi952228i; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; Olson S A, 1994, Methods Mol Biol, V25, P195; Rosengren KJ, 2003, J AM CHEM SOC, V125, P12464, DOI 10.1021/JA0367703; Roy RS, 1998, CHEM BIOL, V5, P217, DOI 10.1016/S1074-5521(98)90635-4; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schoepke T., 1993, SCI PHARM, V61, P145; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sheldon PS, 1996, BIOCHEM J, V320, P865, DOI 10.1042/bj3200865; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; Svangard E, 2004, J NAT PROD, V67, P144, DOI 10.1021/np030101l; Svangard E, 2003, PHYTOCHEMISTRY, V64, P135, DOI 10.1016/S0031-9422(03)00218-8; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002	45	113	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46858	46867		10.1074/jbc.M407421200	http://dx.doi.org/10.1074/jbc.M407421200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328347	hybrid			2022-12-25	WOS:000224832400067
J	Gehrmann, ML; Douglas, JT; Banyai, L; Tordai, H; Patthy, L; Llinas, M				Gehrmann, ML; Douglas, JT; Banyai, L; Tordai, H; Patthy, L; Llinas, M			Modular autonomy, ligand specificity, and functional cooperativity of the three in-tandem fibronectin type II repeats from human matrix metalloproteinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATIN-BINDING SITE; HUMAN MATRIX METALLOPROTEINASE-2; CIRCULAR-DICHROISM SPECTRA; HIGH-AFFINITY BINDING; IV COLLAGENASE; HUMAN PLASMINOGEN; N-15 NMR; DOMAIN; PROTEINS; SPECTROSCOPY	Matrix metalloproteinase 2 (MMP-2) contains three fibronectin type II (col) modules that contribute to its collagen specificity. We observed that the CD spectra of the separate col modules account for the CD and temperature profiles of the in-tandem col-123 construct. Thus, to the extent of not significantly perturbing the secondary structure and thermal stability characteristics of the neighboring units, the domains within col-123 do not interact. Via NMR, we investigated ligand binding properties of the three repeats within col-123: col-123/1 (the col-1 domain within col-123), col-123/2, and col-123/3. Interactions of col-123 with the collagen mimic peptide (Pro-Pro-Gly)(6) (PPG6) and propeptide segment PIIKFPGDVA (p33-42) were studied. While col-123/1 and col-123/2 bound PPG6, they interacted more weakly with p33-42. In contrast, col-123/3 exhibited a higher affinity for p33-42 than for PPG6. Thus, despite their structural homology, the col repeats of MMP-2 differ in substrate specificity. Furthermore the binding affinities toward the three in-tandem col repeats were close to those determined for the individual isolated domains or for col-12/1, indicating that vis-a-vis these ligands each module interacts essentially as an autonomous unit. Interestingly the domains within col-123 exhibited enhanced affinities for Hel3, a construct that contains ((Gly-Pro-Pro)(12)3) in triple helical configuration. Nevertheless the affinities were significantly higher for col-123/1 and col123/2 relative to col-123/3 in line with their behaviors toward PPG6. This hints at a cooperative participation toward Hel3, which is a closer mimic of collagen, a hypothesis that is supported by the detected lower affinities of col-12/1, col-12/2, col-2, col-23/2, col-3, and col-23/3 for Hel3.	Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary	Carnegie Mellon University; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Llinas, M (corresponding author), Carnegie Mellon Univ, Dept Chem, 4400 5th Ave, Pittsburgh, PA 15213 USA.	llinas@andrew.cmu.edu	Patthy, Laszlo/A-2353-2013; Patthy, Laszlo/Q-6058-2019	Tordai, Hedvig/0000-0002-0875-5569	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029409] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29409] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; An SSA, 1998, PROTEIN SCI, V7, P1947, DOI 10.1002/pro.5560070910; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; Bocquier AA, 1999, STRUCT FOLD DES, V7, P1451, DOI 10.1016/S0969-2126(00)88336-7; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Briknarova K, 1999, STRUCTURE, V7, P1235, DOI 10.1016/S0969-2126(00)80057-X; Briknarova K, 2001, J BIOL CHEM, V276, P27613, DOI 10.1074/jbc.M101105200; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CONSTANTINE KL, 1992, J MOL BIOL, V223, P281, DOI 10.1016/0022-2836(92)90731-X; DEMARCO A, 1977, J MAGN RESON, V26, P527, DOI 10.1016/0022-2364(77)90104-4; Ferry G, 1997, MOL DIVERS, V2, P135, DOI 10.1007/BF01682201; FRIEDRICHS MS, 1995, J BIOMOL NMR, V5, P147, DOI 10.1007/BF00208805; Gehrmann M, 2002, BIOL CHEM, V383, P137, DOI 10.1515/BC.2002.014; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Krittanai C, 1997, ANAL BIOCHEM, V253, P57, DOI 10.1006/abio.1997.2366; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; MACKAY AR, 1990, J BIOL CHEM, V265, P21929; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; Marti DN, 1997, BIOCHEMISTRY-US, V36, P11591, DOI 10.1021/bi971316v; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MULLER L, 1979, J AM CHEM SOC, V101, P4481; MURPHY G, 1994, J BIOL CHEM, V269, P6632; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Shipley JM, 1996, J BIOL CHEM, V271, P4335; Sreerama N, 1999, PROTEIN SCI, V8, P370; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Sticht H, 1998, J MOL BIOL, V276, P177, DOI 10.1006/jmbi.1997.1528; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Tordai H, 1999, EUR J BIOCHEM, V259, P513, DOI 10.1046/j.1432-1327.1999.00070.x; Trexler M, 2003, J BIOL CHEM, V278, P12241, DOI 10.1074/jbc.M210116200; Yadav S, 2000, ANAL BIOCHEM, V283, P207, DOI 10.1006/abio.2000.4641; Yu AE, 1998, BIOL EXTRAC, P85; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	41	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46921	46929		10.1074/jbc.M408859200	http://dx.doi.org/10.1074/jbc.M408859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15317806	hybrid			2022-12-25	WOS:000224832400075
J	Hung, JH; Su, IJ; Lei, HY; Wang, HC; Lin, WC; Chang, WT; Huang, WY; Chang, WC; Chang, YS; Chen, CC; Lai, MD				Hung, JH; Su, IJ; Lei, HY; Wang, HC; Lin, WC; Chang, WT; Huang, WY; Chang, WC; Chang, YS; Chen, CC; Lai, MD			Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappa B and pp38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; RECEPTOR-ASSOCIATED FACTOR-2; SIGNAL-TRANSDUCTION PATHWAY; NECROSIS-FACTOR-ALPHA; PRE-S MUTANTS; MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; ER STRESS; TRANSLATIONAL CONTROL	Expression of mutant proteins or viral infection may interfere with proper protein folding activity in the endoplasmic reticulum (ER). Several pathways that maintain cellular homeostasis were activated in response to these ER disturbances. Here we investigated which of these ER stress-activated pathways induce COX-2 and potentially oncogenesis. Tunicamycin and brefeldin A, two ER stress inducers, increased the expression of COX-2 in ML-1 or MCF-7 cells. Nuclear translocation of NF-kappaB and activation of pp38 MAPK were observed during ER stress. IkappaBalpha kinase inhibitor Bay 11-7082 or IkappaBalpha kinase dominant negative mutant significantly inhibited the induction of COX-2. pp38 MAPK inhibitor SB203580 or eIF2alpha phosphorylation inhibitor 2-aminopurine attenuated the nuclear NF-kappaB DNA binding activity and COX-2 induction. Expression of mutant hepatitis B virus (HBV) large surface proteins, inducers of ER stress, enhanced the expression of COX-2 in ML-1 and HuH-7 cells. Transgenic mice showed higher expression of COX-2 protein in liver and kidney tissue expressing mutant HBV large surface protein in vivo. Similarly, increased expression of COX-2 mRNA was observed in human hepatocellular carcinoma tissue expressing mutant HBV large surface proteins. In ML-1 cells expressing mutant HBV large surface protein, anchorage-independent growth was enhanced, and the enhancement was abolished by the addition of specific COX-2 inhibitors. Thus, ER stress due either to expression of viral surface proteins or drugs can stimulate the expression of COX-2 through the NF-kappaB and pp38 kinase pathways. Our results provide important insights into cellular carcinogenesis associated with latent endoplasmic reticulum stress.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan; Natl Hlth Res Inst, Div Clin Res, Tainan 701, Taiwan; Natl Taiwan Univ, Dept Pharmacol, Coll Med, Taipei 100, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Health Research Institutes - Taiwan; National Taiwan University	Lai, MD (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan.	a1211207@mail.ncku.edu.tw	Lai, Ming-Derg/M-8028-2014; Su, Ih-Jen/B-2655-2010; Huang, Wenya/G-9115-2011	Hung, Jui-Hsiang/0000-0002-7649-4823; CHEN, CHING-CHOW/0000-0002-7810-0939				Araki E, 2003, INTERNAL MED, V42, P7, DOI 10.2169/internalmedicine.42.7; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Cavin LG, 2003, HEPATOLOGY, V38, P1540, DOI 10.1016/j.hep.2003.09.019; Charalambous MP, 2003, BRIT J CANCER, V88, P1598, DOI 10.1038/sj.bjc.6600927; Chen CC, 2001, MOL PHARMACOL, V59, P493, DOI 10.1124/mol.59.3.493; Cheng JD, 2002, INT J CANCER, V99, P755, DOI 10.1002/ijc.10409; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; Chiao PJ, 2002, CANCER, V95, P1696, DOI 10.1002/cncr.10829; Davies G, 2003, CLIN CANCER RES, V9, P2651; Einspahr JG, 2003, CANCER RES, V63, P3891; Fan YF, 2001, HEPATOLOGY, V33, P277, DOI 10.1053/jhep.2001.21163; Faour WH, 2003, J BIOL CHEM, V278, P26897, DOI 10.1074/jbc.M212790200; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hsieh YH, 2004, CARCINOGENESIS, V25, P2023, DOI 10.1093/carcin/bgh207; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Jiang HY, 2003, MOL CELL BIOL, V23, P5651, DOI 10.1128/MCB.23.16.5651-5663.2003; Kaneko M, 2003, BIOL PHARM BULL, V26, P931, DOI 10.1248/bpb.26.931; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kern MA, 2002, HEPATOLOGY, V36, P885, DOI 10.1053/jhep.2002.36125; Koga H, 2003, CANCER-AM CANCER SOC, V98, P661, DOI 10.1002/cncr.11576; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Ledoux S, 2003, CANCER RES, V63, P7284; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Leonardi A, 2002, ENDOCRINOLOGY, V143, P2169, DOI 10.1210/en.143.6.2169; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Liu P, 2002, J HEPATOL, V37, P63, DOI 10.1016/S0168-8278(02)00064-8; Liu WV, 2003, CANCER RES, V63, P3632; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Mao JT, 2003, CLIN CANCER RES, V9, P5835; Marjon PL, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-4; Matskevich AA, 2003, GENE THER, V10, P1861, DOI 10.1038/sj.gt.3302091; Matsuyama W, 2004, J IMMUNOL, V172, P2332, DOI 10.4049/jimmunol.172.4.2332; Mestre JR, 2001, J BIOL CHEM, V276, P3977, DOI 10.1074/jbc.M005077200; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; PAHL HL, 1995, EMBO J, V14, P2580, DOI 10.1002/j.1460-2075.1995.tb07256.x; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rahman MA, 2001, CLIN CANCER RES, V7, P1325; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Shariat SF, 2003, J UROLOGY, V170, P985, DOI 10.1097/01.ju.0000080401.85145.ee; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shi YG, 2003, ENDOCR REV, V24, P91, DOI 10.1210/er.2002-0018; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Shishodia S, 2003, CANCER RES, V63, P4375; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Wang HC, 2003, AM J PATHOL, V163, P2441, DOI 10.1016/S0002-9440(10)63599-7; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Watanabe T, 2004, P NATL ACAD SCI USA, V101, P3563, DOI 10.1073/pnas.0400557101; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Wong BCY, 2003, ONCOGENE, V22, P1189, DOI 10.1038/sj.onc.1206234; Wu DY, 2003, J BIOL CHEM, V278, P10983, DOI 10.1074/jbc.M207470200; Xu ZC, 1997, J VIROL, V71, P7387, DOI 10.1128/JVI.71.10.7387-7392.1997; Yamamoto H, 2003, GASTROENTEROLOGY, V125, P556, DOI 10.1016/S0016-5085(03)00904-1; Yeo SJ, 2003, J BIOL CHEM, V278, P22563, DOI 10.1074/jbc.M302076200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	74	205	208	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46384	46392		10.1074/jbc.M403568200	http://dx.doi.org/10.1074/jbc.M403568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15319438	hybrid			2022-12-25	WOS:000224832400007
J	Jacobs, RL; Devlin, C; Tabas, I; Vance, DE				Jacobs, RL; Devlin, C; Tabas, I; Vance, DE			Targeted deletion of hepatic CTP : phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; CDP-CHOLINE PATHWAY; RAT-LIVER; SCAVENGER RECEPTOR; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ENDOPLASMIC-RETICULUM; CELL-CYCLE; PARTIAL-HEPATECTOMY; NEURITE OUTGROWTH; S-PHASE	CTP: phosphocholine cytidylyltransferase (CT) is the key regulatory enzyme in the CDP-choline pathway for the biosynthesis of phosphatidylcholine. Hepatic cells express both an alpha and a beta2 isoform of CT and can also synthesize phosphatidylcholine via the sequential methylation of phosphatidylethanolamine catalyzed by phosphatidylethanolamine N-methyltransferase. To ascertain the functional importance of CTalpha, we created a mouse in which the hepatic CTalpha gene was specifically inactivated by the Cre/LoxP procedure. In CTalpha knockout mice, hepatic CT activity ( due to residual CTbeta2 activity as well as activity in nonhepatic cells) was 15% of normal, whereas phosphatidylethanolamine N-methyltransferase activity was elevated 2-fold compared with controls. Lipid analyses of the liver indicated that female knockout mice had reduced phosphatidylcholine levels and accumulated triacylglycerols. The plasma phosphatidylcholine concentration was reduced in the CTalpha knockout ( independent of gender), as were levels of high density lipoproteins ( cholesterol and apoAI) and very low density lipoproteins ( triacylglycerols and apoB100). Experiments in which mice were injected with Triton WR1339 indicated that apoB secretion was decreased in hepatic-specific CTalpha knockout mice compared with controls. These results suggest an important role for hepatic CTalpha in regulating both hepatic and systemic lipid and lipoprotein metabolism.	Univ Alberta, Canadian Inst Hlth Res, Grp Mol & Cell Biol Lipids, Edmonton, AB, Canada; Univ Alberta, Dept Biochem, Edmonton, AB, Canada; Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA	Institute for Work & Health; University of Alberta; University of Alberta; Columbia University; Columbia University; Columbia University	Vance, DE (corresponding author), Univ Alberta, Canadian Inst Hlth Res, Grp Mol & Cell Biol Lipids, Edmonton, AB, Canada.	dennis.vance@ualberta.ca		Jacobs, Rene/0000-0002-5525-1355				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Banchio C, 2003, J BIOL CHEM, V278, P32457, DOI 10.1074/jbc.M304810200; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Best CH, 1932, J PHYSIOL-LONDON, V75, P405, DOI 10.1113/jphysiol.1932.sp002899; Carter JM, 2003, J BIOL CHEM, V278, P44988, DOI 10.1074/jbc.M307336200; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; CUI Z, 1993, J BIOL CHEM, V268, P16655; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fisher MC, 2002, FASEB J, V16, P619, DOI 10.1096/fj.01-0564fje; FOLCH J, 1957, J BIOL CHEM, V226, P497; Food and Nutrition Board - Institute of Medicine, 1998, DIET REF INT THIAM R; Glomset J A, 1980, Adv Intern Med, V25, P91; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAYASHI H, 1981, J BIOCHEM, V89, P573, DOI 10.1093/oxfordjournals.jbchem.a133233; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JOHNSON JE, 1992, BIOCHEM J, V285, P815, DOI 10.1042/bj2850815; Karim M, 2003, BBA-MOL CELL BIOL L, V1633, P1, DOI 10.1016/S1388-1981(03)00067-2; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KULINSKI A, 2004, J BIOL CHEM, P76200; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; Noga AA, 2003, J BIOL CHEM, V278, P21851, DOI 10.1074/jbc.M301982200; Noga AA, 2002, J BIOL CHEM, V277, P42358, DOI 10.1074/jbc.M204542200; PORTAL I, 1993, AM J PHYSIOL, V264, pG1052, DOI 10.1152/ajpgi.1993.264.6.G1052; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; SCHNEIDER WJ, 1978, EUR J BIOCHEM, V85, P181, DOI 10.1111/j.1432-1033.1978.tb12226.x; SUNDLER R, 1975, BIOCHEM J, V146, P309, DOI 10.1042/bj1460309; TABAS I, 2002, BIOCH LIPIDS LIPOPRO, P573; TERCE F, 1994, J LIPID RES, V35, P2130; Torchia EC, 2001, ANAL BIOCHEM, V298, P293, DOI 10.1006/abio.2001.5379; Van Eck M, 2003, J BIOL CHEM, V278, P23699, DOI 10.1074/jbc.M211233200; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; Vermeulen PS, 1997, J LIPID RES, V38, P447; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Waite KA, 2000, J BIOL CHEM, V275, P21197, DOI 10.1074/jbc.M003539200; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Watkins SM, 2003, J NUTR, V133, P3386, DOI 10.1093/jn/133.11.3386; Wellington CL, 2003, J LIPID RES, V44, P1470, DOI 10.1194/jlr.M300110-JLR200; YAO Z, 1990, BIOCHEM CELL BIOL, V68, P552, DOI 10.1139/o90-079; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; YAO ZM, 1990, J BIOL CHEM, V265, P4326; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200	61	137	138	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47402	47410		10.1074/jbc.M404027200	http://dx.doi.org/10.1074/jbc.M404027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331603	hybrid			2022-12-25	WOS:000224832400129
J	Lopez-Llano, J; Maldonado, S; Jain, S; Lostao, A; Godoy-Ruiz, R; Sanchez-Ruiz, JM; Cortijo, M; Fernandez-Recio, J; Sancho, J				Lopez-Llano, J; Maldonado, S; Jain, S; Lostao, A; Godoy-Ruiz, R; Sanchez-Ruiz, JM; Cortijo, M; Fernandez-Recio, J; Sancho, J			The long and short flavodoxins - II. The role of the differentiating loop in apoflavodoxin stability and folding mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-DESULFURICANS FLAVODOXIN; HYDROGEN-EXCHANGE; TRANSITION-STATE; MOLTEN GLOBULE; PROTEIN; STABILIZATION; INTERMEDIATE; RESOLUTION; TOPOLOGY; PATHWAY	Flavodoxins are classified in two groups according to the presence or absence of a similar to20-residue loop of unknown function. In the accompanying paper (36), we have shown that the differentiating loop from the long-chain Anabaena PCC 7119 flavodoxin is a peripheral structural element that can be removed without preventing the proper folding of the apoprotein. Here we investigate the role played by the loop in the stability and folding mechanism of flavodoxin by comparing the equilibrium and kinetic behavior of the full-length protein with that of loop-lacking, shortened variants. We show that, when the loop is removed, the three-state equilibrium thermal unfolding of apoflavodoxin becomes two-state. Thus, the loop is responsible for the complexity shown by long-chain apoflavodoxins toward thermal denaturation. As for the folding reaction, both shortened and wild type apoflavodoxins display three-state behavior but their folding mechanisms clearly differ. Whereas the full-length protein populates an essentially off-pathway transient intermediate, the additional state observed in the folding of the shortened variant analyzed seems to be simply an alternative native conformation. This finding suggests that the long loop may also be responsible for the accumulation of the kinetic intermediate observed in the full-length protein. Most revealing, however, is that the influence of the loop on the overall conformational stability of apoflavodoxin is quite low and the natively folded shortened variant Delta( 120 - 139) is almost as stable as the wild type protein. The fact that the loop, which is not required for a proper folding of the polypeptide, does not even play a significant role in increasing the conformational stability of the protein supports our proposal ( 36) that the differentiating loop of long-chain flavodoxins may be related to a recognition function, rather than serving a structural purpose.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Zaragoza, Biocomputat & Complex Syst Phys Inst, Zaragoza, Spain; Univ Complutense Madrid, Inst Estudios Biofunc, Madrid, Spain; Univ Granada, Dept Quim Fis, Fac Ciencias, E-18071 Granada, Spain	University of Zaragoza; University of Zaragoza; Complutense University of Madrid; University of Granada	Sancho, J (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	jsancho@unizar.es	Lostao, Anabel/P-8693-2015; Sanchez-Ruiz, Jose/H-2849-2015; Godoy Ruiz, Raquel/GOH-1617-2022; Sancho, javier/AAA-1225-2019	Lostao, Anabel/0000-0001-7460-5916; Sanchez-Ruiz, Jose/0000-0002-9056-3928; Sancho, javier/0000-0002-2879-9200; Fernandez-Recio, Juan/0000-0002-3986-7686; GODOY-RUIZ, RAQUEL/0000-0003-4569-0781				Apiyo D, 2002, PROTEIN SCI, V11, P1129, DOI 10.1110/ps.3840102; Apiyo D, 2000, BBA-PROTEIN STRUCT M, V1479, P214, DOI 10.1016/S0167-4838(00)00032-7; Beldarrain A, 1999, BIOCHEMISTRY-US, V38, P7865, DOI 10.1021/bi990287g; DELPINO IMP, 1995, BIOCHEMISTRY-US, V34, P8621, DOI 10.1021/bi00027a011; Fernandez-Recio J, 1999, J MOL BIOL, V290, P319, DOI 10.1006/jmbi.1999.2863; Fernandez-Recio J, 2001, BIOCHEMISTRY-US, V40, P15234, DOI 10.1021/bi010216t; Fersht AR, 2000, P NATL ACAD SCI USA, V97, P1525, DOI 10.1073/pnas.97.4.1525; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; Irun MP, 2001, J MOL BIOL, V306, P877, DOI 10.1006/jmbi.2001.4436; Irun MP, 2001, PROTEIN ENG, V14, P173, DOI 10.1093/protein/14.3.173; Ladurner AG, 1997, J MOL BIOL, V273, P330, DOI 10.1006/jmbi.1997.1304; Langdon GM, 2001, PROTEINS, V43, P476, DOI 10.1002/prot.1059; Li L, 2001, J MOL BIOL, V306, P121, DOI 10.1006/jmbi.2000.4375; Lindberg M, 2002, NAT STRUCT BIOL, V9, P818, DOI 10.1038/nsb847; Lopez-Llano J, 2004, J BIOL CHEM, V279, P47177, DOI 10.1074/jbc.M405792200; LUDWIG ML, 1969, J BIOL CHEM, V244, P6047; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; Maldonado S, 2002, PROTEIN SCI, V11, P1260, DOI 10.1110/ps.2980102; Maldonado S, 1998, BIOCHIMIE, V80, P813, DOI 10.1016/S0300-9084(00)88876-8; Maldonado S, 1998, BIOCHEMISTRY-US, V37, P10589, DOI 10.1021/bi980368x; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; Nagi AD, 1999, J MOL BIOL, V286, P257, DOI 10.1006/jmbi.1998.2474; Nuallain BO, 2002, EUR J BIOCHEM, V269, P212, DOI 10.1046/j.0014-2956.2002.02637.x; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Privalov P L, 1986, Methods Enzymol, V131, P4; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; Steensma E, 1998, PROTEIN SCI, V7, P306; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; van Mierlo CPM, 2000, J BIOTECHNOL, V79, P281, DOI 10.1016/S0168-1656(00)00244-3; Van Mierlo CPM, 2000, PROTEIN SCI, V9, P145; Van Mierlo CPM, 1998, PROTEIN SCI, V7, P2331, DOI 10.1002/pro.5560071110; Viguera AR, 1997, NAT STRUCT BIOL, V4, P939, DOI 10.1038/nsb1197-939; WATENPAUGH KD, 1972, P NATL ACAD SCI USA, V69, P3185, DOI 10.1073/pnas.69.11.3185	36	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47184	47191		10.1074/jbc.M405791200	http://dx.doi.org/10.1074/jbc.M405791200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15317817	hybrid			2022-12-25	WOS:000224832400106
J	Vyhlidal, CA; Rogan, PK; Leeder, JS				Vyhlidal, CA; Rogan, PK; Leeder, JS			Development and refinement of pregnane X receptor (PXR) DNA binding site model using information theory - Insights into PXR-mediated gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROSTANE-RECEPTOR; CYP2B6 GENE; NUCLEAR; INDUCTION; DEFINES; RECOGNITION; EXPRESSION; PREDICTION; MUTATIONS; EVOLUTION	The pregnane X receptor (PXR) acts as a receptor to induce gene expression in response to structurally diverse xenobiotics through binding as a heterodimer with the 9-cis retinoic acid receptor (RXR) to enhancers in target gene promoters. We identified and estimated the affinities of novel PXR/RXR binding sites in regulated genes and additional genomic targets of PXR with an information theory-based model of the PXR/RXR binding site. Our initial PXR/RXR model, the result of the alignment of 15 previously characterized binding sites, was used to scan the promoters of known PXR target genes. Sites from these genes, with information contents of >8 bits bound by PXR/RXR in vitro, were used to revise the information weight matrix; this procedure was repeated by screening for progressively weaker binding sites. After three iterations of refinement, the model was based on 48 validated PXR/RXR binding sites and has an average information content (R-sequence) of 14.43 +/- 3.21 bits. A scan of the human genome predicted novel PXR/RXR binding sites in the promoters of UGT1A3 (19.78 bits at -8040 and 16.37 bits at -6930) and UGT1A6 (12.74 bits at -9216), both of which were identified previously as targets for PXR. These sites were subsequently demonstrated to specifically bind PXR/RXR in competition electrophoretic mobility shift assays. A strong PXR site was also predicted upstream of the CASP10 gene (18.69 bits at -7872) and was validated by binding studies and reporter assays as a PXR responsive element. This suggests that the PXR-mediated response extends beyond genes involved in drug biotransformation and transport.	Childrens Mercy Hosp & Clin, Div Pediat Clin Pharmacol & Med Toxicol, Sect Dev Pharmacol & Expt Therapeut, Kansas City, MO 64108 USA; Childrens Mercy Hosp & Clin, Lab Human Mol Genet, Kansas City, MO 64108 USA	Children's Mercy Hospital; Children's Mercy Hospital	Leeder, JS (corresponding author), Childrens Mercy Hosp & Clin, Div Pediat Clin Pharmacol & Med Toxicol, Sect Dev Pharmacol & Expt Therapeut, 2401 Gillham Rd, Kansas City, MO 64108 USA.	sleeder@cmh.edu	Rogan, Peter/B-9845-2017; Leeder, James Steven/ABD-5438-2021	Rogan, Peter/0000-0003-2070-5254; Leeder, James Steven/0000-0001-6688-0504	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010855] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES10855-04] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; BI CP, 2004, RECOMB 2004, P453; Bussey KJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r27; Gadiraju S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-38; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; HENNIGHAUSEN L, 1985, NATURE, V314, P289, DOI 10.1038/314289a0; Ijpenberg A, 1997, J BIOL CHEM, V272, P20108, DOI 10.1074/jbc.272.32.20108; Kim JT, 2003, J THEOR BIOL, V220, P529, DOI 10.1006/jtbi.2003.3153; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Masuyama H, 2000, MOL ENDOCRINOL, V14, P421, DOI 10.1210/me.14.3.421; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Qiu P, 2003, BIOCHEM BIOPH RES CO, V309, P495, DOI 10.1016/j.bbrc.2003.08.052; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rae JM, 2001, J PHARMACOL EXP THER, V299, P849; Rikhof B, 2003, CANCER BIOL THER, V2, P707; Rogan PK, 2003, PHARMACOGENETICS, V13, P207, DOI 10.1097/00008571-200304000-00005; Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO;2-O; ROGAN PK, 1995, HUM MUTAT, V6, P74, DOI 10.1002/humu.1380060114; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Schneider TD, 1997, J THEOR BIOL, V189, P427, DOI 10.1006/jtbi.1997.0540; SCHNEIDER TD, 1986, J MOL BIOL, V188, P415, DOI 10.1016/0022-2836(86)90165-8; Schneider TD, 1997, NUCLEIC ACIDS RES, V25, P4408, DOI 10.1093/nar/25.21.4408; Schneider TD, 1996, DISCRETE APPL MATH, V71, P259, DOI 10.1016/S0166-218X(96)00068-6; SCHNEIDER TD, 1991, J THEOR BIOL, V148, P125, DOI 10.1016/S0022-5193(05)80467-9; Schneider Thomas D, 2002, Appl Bioinformatics, V1, P111; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Shultzaberger RK, 1999, NUCLEIC ACIDS RES, V27, P882, DOI 10.1093/nar/27.3.882; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Udalova IA, 2002, P NATL ACAD SCI USA, V99, P8167, DOI 10.1073/pnas.102674699; von Hippel P. H, 1979, BIOL REGULATION DEV, V1, P279; von Kodolitsch Y, 1999, CIRCULATION, V100, P693, DOI 10.1161/01.CIR.100.7.693; Wang HY, 2003, J BIOL CHEM, V278, P31547, DOI 10.1074/jbc.M212532200; Yang ZY, 1998, J BIOL CHEM, V273, P891, DOI 10.1074/jbc.273.2.891; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28; [No title captured]	49	36	39	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46779	46786		10.1074/jbc.M408395200	http://dx.doi.org/10.1074/jbc.M408395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316010	hybrid			2022-12-25	WOS:000224832400057
J	Corton, JC; Apte, U; Anderson, SP; Limaye, P; Yoon, L; Latendresse, J; Dunn, C; Everitt, JI; Voss, KA; Swanson, C; Kimbrough, C; Wong, JS; Gill, SS; Chandraratna, RAS; Kwak, MK; Kensler, TW; Stulnig, TM; Steffensen, KR; Gustafsson, JA; Mehendale, HM				Corton, JC; Apte, U; Anderson, SP; Limaye, P; Yoon, L; Latendresse, J; Dunn, C; Everitt, JI; Voss, KA; Swanson, C; Kimbrough, C; Wong, JS; Gill, SS; Chandraratna, RAS; Kwak, MK; Kensler, TW; Stulnig, TM; Steffensen, KR; Gustafsson, JA; Mehendale, HM			Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-NULL MICE; PEROXISOME-PROLIFERATOR; GENE-EXPRESSION; ACETAMINOPHEN HEPATOTOXICITY; TISSUE-REPAIR; DIABETIC MICE; MOUSE-LIVER; PPAR-ALPHA; FATTY-ACID; DISEASE	The obesity epidemic in industrialized countries is associated with increases in cardiovascular disease (CVD) and certain types of cancer. In animal models, caloric restriction (CR) suppresses these diseases as well as chemical-induced tissue damage. These beneficial effects of CR overlap with those altered by agonists of nuclear receptors (NR) under control of the fasting-responsive transcriptional co-activator, peroxisome proliferator-activated co-activator 1alpha (PGC-1alpha). In a screen for compounds that mimic CR effects in the liver, we found statistically significant overlaps between the CR transcript profile in wild-type mice and the profiles altered by agonists of lipid-activated NR, including peroxisome proliferator-activated receptor alpha (PPARalpha), liver X receptor, and their obligate heterodimer partner, retinoid X receptor. The overlapping genes included those involved in CVD (lipid metabolism and inflammation) and cancer (cell fate). Based on this overlap, we hypothesized that some effects of CR are mediated by PPARalpha. As determined by transcript profiling, 19% of all gene expression changes in wild-type mice were dependent on PPARalpha, including Cyp4a10 and Cyp4a14, involved in fatty acid omega-oxidation, acute phase response genes, and epidermal growth factor receptor but not increases in PGC-1alpha. CR protected the livers of wild-type mice from damage induced by thioacetamide, a liver toxicant and hepatocarcinogen. CR protection was lost in PPARalpha-null mice due to inadequate tissue repair. These results demonstrate that PPARalpha mediates some of the effects of CR and indicate that a pharmacological approach to mimicking many of the beneficial effects of CR may be possible.	ToxicoGenomics, Chapel Hill, NC 27514 USA; NE Louisiana Univ, Coll Pharm, Dept Toxicol, Monroe, LA 71209 USA; GlaxoSmithKline, Res & Dev, Dept Safety Assessment, Res Triangle Pk, NC 27709 USA; Natl Ctr Toxicol Res, Pathol Associates Int, Jefferson, AR 72079 USA; CIIT Ctr Hlth Res, Res Triangle Pk, NC 27709 USA; ARS, Toxicol & Mycotoxin Res Unit, USDA, Athens, GA 30604 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Environm Toxicol Grad Program, Riverside, CA 92521 USA; Allergan Pharmaceut Inc, Dept Biol & Chem, Irvine, CA 92612 USA; Allergan Pharmaceut Inc, Dept Reginoid Res, Irvine, CA 92612 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Karolinska Inst, Novum, Dept Biosci, S-14186 Huddinge, Sweden; Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden	University of Louisiana System; University of Louisiana Monroe; GlaxoSmithKline; US Food & Drug Administration (FDA); United States Department of Agriculture (USDA); University of California System; University of California Riverside; AbbVie; Allergan; AbbVie; Allergan; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Karolinska Institutet; Karolinska Institutet	Corton, JC (corresponding author), ToxicoGenomics, 209 Silver Creek Tr, Chapel Hill, NC 27514 USA.	ccorton@msn.com; mehendale@ulm.edu	Kensler, Thomas W/D-8686-2014	Kensler, Thomas W/0000-0002-6676-261X; Steffensen, Knut/0000-0001-6093-2801; Everitt, Jeffrey/0000-0003-0273-6284; Stulnig, Thomas/0000-0003-3300-6161	NIEHS NIH HHS [ES-09870] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009870] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Aghi M, 1999, J NATL CANCER I, V91, P1233, DOI 10.1093/jnci/91.14.1233; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Apte UM, 2003, TOXICOL SCI, V72, P272, DOI 10.1093/toxsci/kfg021; Baldi A, 2003, EXP DERMATOL, V12, P213, DOI 10.1034/j.1600-0625.2003.00026.x; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BARTLES JR, 1990, CANCER RES, V50, P669; Bauer M, 2004, PHYSIOL GENOMICS, V17, P230, DOI 10.1152/physiolgenomics.00203.2003; Bernard DJ, 2001, RECENT PROG HORM RES, V56, P417, DOI 10.1210/rp.56.1.417; Bugni JM, 2001, CARCINOGENESIS, V22, P1853, DOI 10.1093/carcin/22.11.1853; Chen C, 2000, TOXICOL SCI, V57, P338, DOI 10.1093/toxsci/57.2.338; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Dhawan P, 2002, J LEUKOCYTE BIOL, V72, P9; Edwards PA, 2002, VASC PHARMACOL, V38, P249, DOI 10.1016/S1537-1891(02)00175-1; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Rifai W, 2002, CANCER RES, V62, P6823; FAN LQ, 1908, BIOCHEM PHARMACOL, V65, P949; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Frame LT, 1998, ENVIRON HEALTH PERSP, V106, P313; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; Guan JZ, 2003, TOHOKU J EXP MED, V201, P251, DOI 10.1620/tjem.201.251; Hart RW, 1997, ENVIRON HEALTH PERSP, V105, P989, DOI 10.2307/3433316; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; James WPT, 1998, EXP CLIN ENDOCR DIAB, V106, P1; Kari C, 2003, CANCER RES, V63, P1; Keenan KP, 1998, J TOXICOL ENV HEAL B, V1, P135, DOI 10.1080/10937409809524548; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kirkland JL, 2002, CLIN GERIATR MED, V18, P383, DOI 10.1016/S0749-0690(02)00023-X; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Maglich JM, 2004, J BIOL CHEM, V279, P19832, DOI 10.1074/jbc.M313601200; McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291; Mehendale HM, 2000, TOXICOL SCI, V57, P187, DOI 10.1093/toxsci/57.2.187; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Miller RT, 2001, TOXICOL PATHOL, V29, P149, DOI 10.1080/019262301301418964; Murakami S, 2003, FASEB J, V17, P1565, DOI 10.1096/fj.02-1092fje; Nakamura Y, 2000, LEUKEMIA LYMPHOMA, V38, P505, DOI 10.3109/10428190009059269; Oberkofler H, 2003, BIOCHEM J, V371, P89, DOI 10.1042/BJ20021665; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ramaiah SK, 1998, TOXICOL SCI, V45, P233, DOI 10.1006/toxs.1998.2511; Shankar K, 2003, FASEB J, V17, P1748, DOI 10.1096/fj.02-1186fje; Shankar K, 2003, TOXICOL SCI, V73, P220, DOI 10.1093/toxsci/kfg059; Shankar K, 2003, TOXICOL APPL PHARM, V188, P122, DOI 10.1016/S0041-008X(02)00037-6; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Standeven AM, 1997, BIOCHEM PHARMACOL, V54, P517, DOI 10.1016/S0006-2952(97)00209-8; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tobin KAR, 2000, MOL ENDOCRINOL, V14, P741, DOI 10.1210/me.14.5.741; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; Weindruch R, 2001, J GERONTOL A-BIOL, V56, P20, DOI 10.1093/gerona/56.suppl_1.20; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WEINDRUCH R, 1988, RETARDATION AGING DI, P73; Wong JS, 2002, TOXICOL APPL PHARM, V185, P180, DOI 10.1006/taap.2002.9540; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zhang LB, 2004, J BIOL CHEM, V279, P2053, DOI 10.1074/jbc.M310357200	65	91	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46204	46212		10.1074/jbc.M406739200	http://dx.doi.org/10.1074/jbc.M406739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302862	hybrid			2022-12-25	WOS:000224694900107
J	Daniel, R; Ramcharan, J; Rogakou, E; Taganov, KD; Greger, JG; Bonner, W; Nussenzweig, A; Katz, RA; Skalka, AM				Daniel, R; Ramcharan, J; Rogakou, E; Taganov, KD; Greger, JG; Bonner, W; Nussenzweig, A; Katz, RA; Skalka, AM			Histone H2AX is phosphorylated at sites of retroviral DNA integration but is dispensable for postintegration repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; V(D)J RECOMBINATION; IONIZING-RADIATION; DAMAGE; CELLS; TRANSDUCTION; CHECKPOINT; VIRUS; GAMMA-H2AX	The histone variant H2AX is rapidly phosphorylated (denoted gammaH2AX) in large chromatin domains ( foci) flanking double strand DNA ( dsDNA) breaks that are produced by ionizing radiation or genotoxic agents and during V(D)J recombination. H2AX-deficient cells and mice demonstrate increased sensitivity to dsDNA break damage, indicating an active role for gammaH2AX in DNA repair; however, gammaH2AX formation is not required for V(D)J recombination. The latter finding has suggested a greater dependence on gammaH2AX for anchoring free broken ends versus ends that are held together during programmed breakage-joining reactions. Retroviral DNA integration produces a unique intermediate in which a dsDNA break in host DNA is held together by the intervening viral DNA, and such a reaction provides a useful model to distinguish gammaH2AX functions. We found that integration promotes transient formation of gammaH2AX at retroviral integration sites as detected by both immunocytological and chromatin immunoprecipitation methods. These results provide the first direct evidence for the association of newly integrated viral DNA with a protein species that is an established marker for the onset of a DNA damage response. We also show that H2AX is not required for repair of the retroviral integration intermediate as determined by stable transduction. These observations provide independent support for an anchoring model for the function of gammaH2AX in chromatin repair.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Skalka, AM (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 333 Cottman Ave, Philadelphia, PA 19111 USA.	AM_skalka@fccc.edu		Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [CA06927, CA98090, CA71515] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, ZIABC010283, K01CA098090, R01CA071515, Z01BC010283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bassing CH, 2004, CELL CYCLE, V3, P149; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Craig NL, 1996, SCIENCE, V271, P1512, DOI 10.1126/science.271.5255.1512; Daniel R, 2004, J VIROL, V78, P8573, DOI 10.1128/JVI.78.16.8573-8581.2004; Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100; Daniel R, 2001, MOL CELL BIOL, V21, P1164, DOI 10.1128/MCB.21.4.1164-1172.2001; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Fernandez-Capetillo O, 2003, DEV CELL, V4, P497, DOI 10.1016/S1534-5807(03)00093-5; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Jones JM, 2003, P NATL ACAD SCI USA, V100, P15446, DOI 10.1073/pnas.2637012100; Katz RA, 2003, J VIROL, V77, P13412, DOI 10.1128/JVI.77.24.13412-13417.2003; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Katz RA, 2002, J VIROL, V76, P5422, DOI 10.1128/JVI.76.11.5422-5434.2002; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Vandegraaff N, 2001, J VIROL, V75, P11253, DOI 10.1128/JVI.75.22.11253-11260.2001; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200	35	48	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45810	45814		10.1074/jbc.M407886200	http://dx.doi.org/10.1074/jbc.M407886200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308627	hybrid, Green Accepted			2022-12-25	WOS:000224694900065
J	Gonsalvez, GB; Little, JL; Long, RM				Gonsalvez, GB; Little, JL; Long, RM			ASH1 mRNA anchoring requires reorganization of the Myo4p-She3p-She2p transport complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUDDING YEAST DEPENDS; BINDING PROTEIN; ASYMMETRIC LOCALIZATION; STRUCTURAL ELEMENTS; MYOSIN MYO4P; DNA-BINDING; EXPRESSION; MOTOR; TRANSLATION; DETERMINANT	One mechanism by which cells post-transcriptionally regulate gene expression is via intercellular and intracellular sorting of mRNA. In Saccharomyces cerevisiae, the localization of ASH1 mRNA to the distal tip of budding cells results in the asymmetric sorting of Ash1p to daughter cell nuclei. Efficient localization of ASH1 mRNA depends upon the activity of four cis-acting localization elements and also upon the activity of trans-factors She2p, She3p, and Myo4p. She2p, She3p, and Myo4p have been proposed to form an ASH1 mRNA localization particle. She2p directly and specifically binds each of the four ASH1 cis-acting localization elements, whereas She3p has been hypothesized to function as an adaptor by recruiting the She2p-mRNA complex to Myo4p, a type V myosin. The Myo4p-She3p-She2p heterotrimeric protein complex has been proposed to localize mRNA to daughter cells using polarized actin cables. Here we demonstrate that whereas the predicted Myo4p-She3p-She2p heterotrimeric complex forms in vivo, it represents a relatively minor species compared with the Myo4p-She3p complex. Furthermore, contrary to a prediction of the heterotrimeric complex model for ASH1 mRNA localization, ASH1 mRNA artificially tethered to She2p is not localized. Upon closer examination, we found that mRNA tightly associated with She2p is transported to daughter cells but is not properly anchored at the bud tip. These results are consistent with a model whereby anchoring of ASH1 mRNA requires molecular remodeling of the Myo4p-She3p-She2p heterotrimeric complex, a process that is apparently altered when mRNA is artificially tethered to She2p.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Long, RM (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.	rlong@mcw.edu			NIGMS NIH HHS [GM60392] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060392] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; Arn EA, 2003, DEV CELL, V4, P41, DOI 10.1016/S1534-5807(02)00397-0; Aronov S, 2004, J BIOL CHEM, V279, P36962, DOI 10.1074/jbc.M402068200; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; Beach DL, 2001, MOL BIOL CELL, V12, P2567, DOI 10.1091/mbc.12.9.2567; Beach DL, 1999, CURR BIOL, V9, P569, DOI 10.1016/S0960-9822(99)80260-7; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; Chartrand P, 2000, METHOD ENZYMOL, V318, P493; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; Chartrand P, 2002, MOL CELL, V10, P1319, DOI 10.1016/S1097-2765(02)00694-9; Darzacq X, 2003, CURR OPIN MICROBIOL, V6, P614, DOI 10.1016/j.mib.2003.10.005; Estrada P, 2003, J CELL BIOL, V163, P1255, DOI 10.1083/jcb.200304030; GARZINO V, 1992, EMBO J, V11, P4471, DOI 10.1002/j.1460-2075.1992.tb05548.x; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gonsalvez GB, 2003, RNA, V9, P1383, DOI 10.1261/rna.5120803; Gonzalez I, 1999, CURR BIOL, V9, P337, DOI 10.1016/S0960-9822(99)80145-6; Gu W, 2004, GENE DEV, V18, P1452, DOI 10.1101/gad.1189004; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hachet O, 2004, NATURE, V428, P959, DOI 10.1038/nature02521; Irie K, 2002, EMBO J, V21, P1158, DOI 10.1093/emboj/21.5.1158; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Kress TL, 2004, J CELL BIOL, V165, P203, DOI 10.1083/jcb.200309145; Kruse C, 2002, J CELL BIOL, V159, P971, DOI 10.1083/jcb.200207101; Lie YS, 1999, DEVELOPMENT, V126, P4989; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Long RM, 2001, J CELL BIOL, V153, P307, DOI 10.1083/jcb.153.2.307; Long RM, 2000, EMBO J, V19, P6592, DOI 10.1093/emboj/19.23.6592; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maxon ME, 2001, P NATL ACAD SCI USA, V98, P1495, DOI 10.1073/pnas.98.4.1495; Munchow S, 1999, J CELL SCI, V112, P1511; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; SUGIYAMA T, 1970, J MOL BIOL, V48, P349, DOI 10.1016/0022-2836(70)90166-X; Takizawa PA, 2000, P NATL ACAD SCI USA, V97, P5273, DOI 10.1073/pnas.080585897; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015	43	16	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46286	46294		10.1074/jbc.M406086200	http://dx.doi.org/10.1074/jbc.M406086200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15328357	hybrid			2022-12-25	WOS:000224694900116
J	Lavrrar, JL; Farnham, PJ				Lavrrar, JL; Farnham, PJ			The use of transient chromatin Immunoprecipitation assays to test models for E2F1-specific transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E2F PROTEINS; CELL-CYCLE; IDENTIFICATION; INDUCTION; BINDING; SPECIFICITY; SUBUNIT; TARGETS; GENES; SITES	The E2F family of transcription factors regulates the expression of genes involved in cell cycle progression, DNA synthesis, repair, and recombination, and a variety of other cellular processes. Although E2F proteins are often redundant in function, specificity of binding and activity can occur. For example, E2F1, but not other E2F family members, was shown previously to bind the murine carboxylesterase promoter in chromatin immunoprecipitation studies (Wells, J., Graveel, C. R., Bartley, S. M., Madore, S. J., and Farnham, P. J. (2002) Proc. Natl. Acad. Sci. U.S.A. 99, 3890-3895). This promoter region lacks a consensus E2F binding site, suggesting that E2F1 may be recruited to the DNA in a unique fashion. To further investigate this E2F1-specific binding, we have employed a "transient chromatin immunoprecipitation" approach. Using various deletions and mutations of the promoter region, we localized the E2F1-specific binding site and demonstrated that it was required for E2F1-mediated transcription of the carboxylesterase promoter. The identified site was similar to the 8-bp consensus E2F site but differed from the consensus at a crucial position. To address whether E2F1 directly bound to this non-consensus site, we demonstrated that the DNA binding domain of E2F1 is necessary for E2F1-mediated activation of the carboxylesterase promoter. Interestingly, a "UP" mutation of the site, making it more similar to the consensus element, did not improve the ability of E2F1 to bind the promoter. Rather, E2F1 could no longer bind to the carboxylesterase promoter that contained the consensus E2F site. We propose a model in which E2F1-specific regulation of the carboxylesterase promoter requires both E2F1/DNA interactions and protein-protein interaction between E2F1 and a factor that binds adjacent to the non-consensus site.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Calif Davis, Genome Ctr, 1 Shields Ave, Davis, CA 95616 USA.	pjfarnham@ucdavis.edu		Farnham, Peggy/0000-0003-4469-7914				de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SCJ, 2001, ONCOGENE, V20, P7073, DOI 10.1038/sj.onc.1204932; Lin WC, 2001, GENE DEV, V15, P1833; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; SATOH T, 1998, ANN REV PHARM TOXICO, V28, P257; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Yamada M, 2002, J BIOL CHEM, V277, P27668, DOI 10.1074/jbc.M202884200; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	28	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46343	46349		10.1074/jbc.M402692200	http://dx.doi.org/10.1074/jbc.M402692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15328355	hybrid			2022-12-25	WOS:000224694900122
J	Noda, M; Kawahara, Y; Ichikawa, A; Matoba, Y; Matsuo, H; Lee, DG; Kumagai, T; Sugiyama, M				Noda, M; Kawahara, Y; Ichikawa, A; Matoba, Y; Matsuo, H; Lee, DG; Kumagai, T; Sugiyama, M			Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae - Gene cloning, characterization, and kinetics of its alanine racemase and D-alanyl-D-alanine ligase, which are target enzymes of D-cycloserine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROCOCCUS-FAECALIS V583; COMPLETE GENOME SEQUENCE; CELL-WALL BIOSYNTHESIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; VANCOMYCIN RESISTANCE; BACILLUS-STEAROTHERMOPHILUS; MYCOBACTERIUM-SMEGMATIS; SUBSTRATE-SPECIFICITY; DDLA GENE	An antibiotic, D-cycloserine (DCS), inhibits the catalytic activities of alanine racemase (ALR) and D-alanyl-D-alanine ligase (DDL), which are necessary for the biosynthesis of the bacterial cell wall. In this study, we cloned both genes encoding ALR and DDL, designated alrS and ddlS, respectively, from DCS-producing Streptomyces lavendulae ATCC25233. Each gene product was purified to homogeneity and characterized. Escherichia coli, transformed with a pET vector carrying alrS or ddlS, displays higher resistance to DCS than the same host carrying the E. coli ALR- or DDL-encoded gene inserted into the pET vector. Although the S. lavendulae DDL was competitively inhibited by DCS, the K-i value (920 muM) was obviously higher (40similar to100-fold) than those for E. coli DdlA (9 muM) or DdlB (27 muM). The high K-i value of the S. lavendulae DDL suggests that the enzyme may be a self-resistance determinant in the DCS-producing microorganism. Kinetic studies for the S. lavendulae ALR suggest that the time-dependent inactivation rate of the enzyme by DCS is absolutely slower than that of the E. coli ALR. We conclude that ALR from DCS-producing S. lavendulae is also one of the self-resistance determinants.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Biotechnol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp	Matsuo, Hiroaki/B-4290-2008	Matsuo, Hiroaki/0000-0002-8730-5389				Andersen JM, 2002, BEHAV BRAIN RES, V129, P211, DOI 10.1016/S0166-4328(01)00318-7; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BIBB MJ, 1984, GENE, V30, P157, DOI 10.1016/0378-1119(84)90116-1; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briggs GE, 1925, BIOCHEM J, V19, P338, DOI 10.1042/bj0190338; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; Caceres NE, 1997, J BACTERIOL, V179, P5046, DOI 10.1128/jb.179.16.5046-5055.1997; DAUB E, 1988, BIOCHEMISTRY-US, V27, P3701, DOI 10.1021/bi00410a027; DUTKAMALEN S, 1990, MOL GEN GENET, V224, P364, DOI 10.1007/BF00262430; DUTKAMALEN S, 1992, GENE, V112, P53, DOI 10.1016/0378-1119(92)90302-6; ESAKI N, 1986, BIOCHEMISTRY-US, V25, P3261, DOI 10.1021/bi00359a027; EVERS S, 1994, GENE, V140, P97, DOI 10.1016/0378-1119(94)90737-4; Evers S, 1996, J MOL EVOL, V42, P706, DOI 10.1007/BF02338803; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Feng ZY, 2003, ANTIMICROB AGENTS CH, V47, P283, DOI 10.1128/AAC.47.1.283-291.2003; Fenn TD, 2003, BIOCHEMISTRY-US, V42, P5775, DOI 10.1021/bi027022d; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; HEIFETS LB, 1991, AM REV RESPIR DIS, V144, P1; Hopwood D. A., 1985, GENETIC MANIPULATION; Ikeda K, 1996, J BIOCHEM-TOKYO, V120, P1141; Johannesen TS, 2002, EUR J PHARMACOL, V437, P73, DOI 10.1016/S0014-2999(02)01282-7; LAMBERT MP, 1972, J BACTERIOL, V110, P978, DOI 10.1128/JB.110.3.978-987.1972; LILLEY PE, 1993, GENE, V129, P9; Matsuo H, 2003, J ANTIBIOT, V56, P762, DOI 10.7164/antibiotics.56.762; MEZIANECHERIF D, 1994, FEBS LETT, V354, P140, DOI 10.1016/0014-5793(94)01096-X; NEUHAUS FC, 1962, J BIOL CHEM, V237, P778; NEUHAUS FC, 1981, PHARMACOL THERAPEUT, V14, P265, DOI 10.1016/0163-7258(81)90030-9; NEUHAUS FC, 1969, BIOCHEMISTRY-US, V8, P5119, DOI 10.1021/bi00840a066; Noda M, 2004, J BIOL CHEM, V279, P46153, DOI 10.1074/jbc.M404605200; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Park IS, 1997, P NATL ACAD SCI USA, V94, P10040, DOI 10.1073/pnas.94.19.10040; Park IS, 1996, BIOCHEMISTRY-US, V35, P10464, DOI 10.1021/bi9603128; Peisach D, 1998, J AM CHEM SOC, V120, P2268, DOI 10.1021/ja973353f; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sammon AM, 1999, POSTGRAD MED J, V75, P129, DOI 10.1136/pgmj.75.881.129; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Strych U, 2001, FEMS MICROBIOL LETT, V196, P93, DOI 10.1016/S0378-1097(01)00045-3; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189; Watanabe A, 1999, J BIOCHEM-TOKYO, V125, P987, DOI 10.1093/oxfordjournals.jbchem.a022406; Yokoigawa K, 2003, FEMS MICROBIOL LETT, V221, P263, DOI 10.1016/S0378-1097(03)00216-7; ZAWADZKE LE, 1991, BIOCHEMISTRY-US, V30, P1673, DOI 10.1021/bi00220a033	47	43	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46143	46152		10.1074/jbc.M404603200	http://dx.doi.org/10.1074/jbc.M404603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302885	hybrid			2022-12-25	WOS:000224694900101
J	Yoshida, M; Kashiwagi, K; Shigemasa, A; Taniguchi, S; Yamamoto, K; Makinoshima, H; Ishihama, A; Igarashi, K				Yoshida, M; Kashiwagi, K; Shigemasa, A; Taniguchi, S; Yamamoto, K; Makinoshima, H; Ishihama, A; Igarashi, K			A unifying model for the role of polyamines in bacterial cell growth, the polyamine modulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ORNITHINE-DECARBOXYLASE; BOVINE LYMPHOCYTES; PROTEIN-SYNTHESIS; GENE-EXPRESSION; MESSENGER-RNA; FIS PROTEIN; BINDING; STIMULATION; TRANSPORT	We reported previously that the synthesis of specific proteins such as OppA, Cya, and RpoS (sigma(38)), which are important for cell growth and viability, is stimulated by polyamines at the level of translation. In this study we found that the synthesis of FecI and Fis was also stimulated by polyamines at the level of translation. The FecI and Fis proteins enhance the expression of mRNAs that are involved in iron uptake and energy metabolism and the expression of rRNA and some tRNAs. The Shine-Dalgarno (SD) sequence of their mRNAs was not obvious or was not located at the usual position. When the SD sequences were created at the normal position on these mRNAs, protein synthesis was no longer influenced by polyamines. Thus, the common characteristic of these mRNAs was to have a weak or ineffective SD sequence. We propose that a group of genes whose expression is enhanced by polyamines at the level of translation be referred to as a "polyamine modulon." By DNA microarray, we found that 309 of 2,742 mRNA species were up-regulated by polyamines. Among the 309 up-regulated genes, transcriptional enhancement of at least 58 genes might be attributable to increased levels of the transcription factors Cya, RpoS, FecI, and Fis, which are all organized in the polyamine modulon. This unifying molecular mechanism is proposed to underlie the physiological role of polyamines in controlling the growth of Escherichia coli.	Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, Chiba 2608675, Japan; Kinki Univ, Grad Sch Agr, Nara 6318505, Japan; Nippon Inst Biol Sci, Div Mol Biol, Tokyo 1980024, Japan	Chiba University; Kindai University (Kinki University)	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.	iga16077@p.chiba-u.ac.jp		Igarashi, Kazuei/0000-0003-3751-3187				Antognoni F, 1999, J BIOL CHEM, V274, P1942, DOI 10.1074/jbc.274.4.1942; ATKINS JF, 1975, J BIOL CHEM, V250, P5688; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; Gowrishankar J, 2003, J BACTERIOL, V185, P2673, DOI 10.1128/JB.185.8.2673-2679.2003; Hirvonen CA, 2001, J BACTERIOL, V183, P6305, DOI 10.1128/JB.183.21.6305-6314.2001; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IGARASHI K, 1984, CANCER RES, V44, P5332; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; Igarashi K, 1999, BIOCHEM J, V344, P633, DOI 10.1042/0264-6021:3440633; IGARASHI K, 1979, BIOCHEM BIOPH RES CO, V91, P440, DOI 10.1016/0006-291X(79)91541-9; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; ITO K, 1990, J BIOL CHEM, V265, P13036; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jishage M, 1998, P NATL ACAD SCI USA, V95, P4953, DOI 10.1073/pnas.95.9.4953; KASAHARA M, 1991, J BACTERIOL, V173, P549, DOI 10.1128/jb.173.2.549-558.1991; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1994, BIOCHEM BIOPH RES CO, V200, P591, DOI 10.1006/bbrc.1994.1489; Kingston R.E., 1987, CURRENT PROTOCOLS MO; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maeda H, 2000, J BACTERIOL, V182, P1181, DOI 10.1128/JB.182.4.1181-1184.2000; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7390; MIYAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63, DOI 10.1006/abbi.1993.1009; Oshima T, 2002, MOL MICROBIOL, V45, P673, DOI 10.1046/j.1365-2958.2002.03037.x; PEGG AE, 1988, CANCER RES, V48, P759; PENG ZH, 1990, ARCH BIOCHEM BIOPHYS, V279, P138, DOI 10.1016/0003-9861(90)90473-C; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; Sambrook J, 2001, MOL CLONING LAB MANU; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SHAPIRA SK, 1983, GENE, V25, P71, DOI 10.1016/0378-1119(83)90169-5; Shin D, 2003, J BIOL CHEM, V278, P14776, DOI 10.1074/jbc.M213248200; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; VALENTINHANSEN P, 1989, MOL MICROBIOL, V3, P1385, DOI 10.1111/j.1365-2958.1989.tb00120.x; Visca P, 2002, MOL MICROBIOL, V45, P1177, DOI 10.1046/j.1365-2958.2002.03088.x; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; WATANABE S, 1991, J BIOL CHEM, V266, P20803; Yoshida M, 2002, J BIOL CHEM, V277, P37139, DOI 10.1074/jbc.M206668200; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723	47	123	124	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46008	46013		10.1074/jbc.M404393200	http://dx.doi.org/10.1074/jbc.M404393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326188	hybrid			2022-12-25	WOS:000224694900086
J	Bernard, MP; Lin, W; Cao, DH; Myers, RV; Xing, YN; Moyle, WR				Bernard, MP; Lin, W; Cao, DH; Myers, RV; Xing, YN; Moyle, WR			Only a portion of the small seatbelt loop in human choriogonadotropin appears capable of contacting the lutropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; COMMON ALPHA-SUBUNIT; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; ENDOPLASMIC-RETICULUM; BIOLOGICAL-ACTIVITY; BINDING; SPECIFICITY; PROTEIN; DOMAIN	Twenty residues of the human choriogonadotropin (hCG) beta-subunit that are wrapped around alpha-subunit loop 2 like a "seatbelt" stabilize the heterodimer and enable the hormone to distinguish lutropin (LHR), follitropin, and thyrotropin receptors. The N-terminal portion of the seatbelt contains a small disulfide-stabilized loop needed for heterodimer assembly and is thought to mediate hCG-LHR interactions. To test the latter notion, we compared the LHR binding and signal transduction activities of hCG analogs in which the alpha-subunit C terminus (alphaCT) was cross-linked to residues in the small seatbelt loop. Analogs having an intersubunit disulfide between a cysteine in place of alphaCT residue alphaSer-92 and cysteines substituted for loop residues betaArg-94, betaArg-95, or betaSer-96 had high activities in LHR binding and signaling assays despite the fact that both portions of the hormone are thought to be essential for hCG activity. Use of a larger probe blocked hormone activity when the alphaCT was crosslinked to cysteines in place of residues betaArg-95 and betaAsp-99, but not to cysteines in place of residues betaArg-94, betaSer-96, or betaThr-97. This suggested that the side chains of residues betaArg-95 and betaAsp-99, which face in the same outward direction from the heterodimer, are nearer than the others to the LHR interface. The finding that residue 95 can be cross-linked to small alphaCT probes without eliminating hormone activity indicates its side chain does not participate in essential LHR contacts. We suggest that contacts between the small seatbelt loop and the LHR, if any, involve its backbone atoms and possibly the side chain of residue betaAsp-99.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept OB GYN, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept OB GYN, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014907, R01HD014907] Funding Source: NIH RePORTER; NICHD NIH HHS [HD14907, HD28547] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard MP, 1998, BIOCHEM J, V335, P611, DOI 10.1042/bj3350611; Bernard MP, 2004, ANAL BIOCHEM, V327, P278, DOI 10.1016/j.ab.2003.12.029; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P19357; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Marichatou H, 2000, EUR J ENDOCRINOL, V142, P402, DOI 10.1530/eje.0.1420402; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; Moyle WR, 2004, J BIOL CHEM, V279, P44442, DOI 10.1074/jbc.M406948200; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; Xing YN, 2004, J BIOL CHEM, V279, P44427, DOI 10.1074/jbc.M406931200; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35458, DOI 10.1074/jbc.M403055200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200	27	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44438	44441		10.1074/jbc.M406932200	http://dx.doi.org/10.1074/jbc.M406932200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304512	hybrid			2022-12-25	WOS:000224505600027
J	Enserink, JM; Price, LS; Methi, T; Mahic, M; Sonnenberg, A; Bos, JL; Tasken, K				Enserink, JM; Price, LS; Methi, T; Mahic, M; Sonnenberg, A; Bos, JL; Tasken, K			The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha(3)beta(1) integrin but not the alpha(6 beta 4) integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAP1; ALPHA-6-BETA-4 INTEGRIN; PROTEIN-KINASE; CYCLIC-AMP; ACTIVATION; EPAC; MIGRATION; HEMIDESMOSOMES; FAMILY; RAC	Laminin-5 is an important constituent of the basal lamina. The receptors for laminin-5, the integrins alpha(3)beta(1) and alpha(6)beta(4), have been associated with epithelial wound migration and carcinoma invasion. The signal transduction mechanisms that regulate these integrins are not well understood. We report here that the small GTPase Rap1 regulates the adhesion of a number of cell lines to various extracellular matrix proteins including laminin-5. cAMP also mediates cell adhesion and spreading on laminin-5, a process that is independent of protein kinase A but rather dependent on Epac1, a cAMP-dependent exchange factor for Rap. Interestingly, although both alpha(3)beta(1) and alpha(6)beta(4) mediate adhesion to laminin-5, only alpha(3)beta(1)-dependent adhesion is dependent on Rap1. These results provide evidence for a function of the cAMP-Epac-Rap1 pathway in cell adhesion and spreading on different extracellular matrix proteins. They also define different roles for the laminin-binding integrins in regulated cell adhesion and subsequent cell spreading.	Univ Oslo, Ctr Biotechnol, N-0317 Oslo, Norway; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Netherlands	University of Oslo; Utrecht University; Utrecht University; Netherlands Cancer Institute	Tasken, K (corresponding author), Univ Oslo, Ctr Biotechnol, POB 1125, N-0317 Oslo, Norway.	kjetil.tasken@biotek.uio.no	Enserink, Jorrit/E-5383-2010	Enserink, Jorrit/0000-0002-2394-5387; Tasken, Kjetil/0000-0003-2841-4697				Baker SE, 1996, J CELL SCI, V109, P2509; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Koster J, 2003, J CELL SCI, V116, P387, DOI 10.1242/jcs.00241; Kreidberg JA, 2000, CURR OPIN CELL BIOL, V12, P548, DOI 10.1016/S0955-0674(00)00130-7; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; LANGHOFER M, 1993, J CELL SCI, V105, P753; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; McLeod SJ, 2004, J BIOL CHEM, V279, P12009, DOI 10.1074/jbc.M313098200; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Price LS, 2004, J BIOL CHEM, V279, P35127, DOI 10.1074/jbc.M404917200; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ruegg C, 2004, BBA-REV CANCER, V1654, P51, DOI 10.1016/j.bbcan.2003.09.003; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Su L, 2003, J BIOL CHEM, V278, P15232, DOI 10.1074/jbc.M211888200; Tiwari S, 2004, BLOOD, V103, P2661, DOI 10.1182/blood-2003-06-2154; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Tsygankova OM, 2004, J BIOL CHEM, V279, P5501, DOI 10.1074/jbc.M305824200; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Van Triest M, 2001, METHOD ENZYMOL, V333, P343	55	105	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44889	44896		10.1074/jbc.M404599200	http://dx.doi.org/10.1074/jbc.M404599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302884	hybrid			2022-12-25	WOS:000224505600079
J	Frey, MR; Golovin, A; Polk, DB				Frey, MR; Golovin, A; Polk, DB			Epidermal growth factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR RECEPTOR; EGF RECEPTOR; SUSTAINED ACTIVATION; CHLORIDE SECRETION; FACTOR PROMOTES; DOWN-REGULATION; TNF-ALPHA; RESTITUTION; PATHWAY	Members of the epidermal growth factor (EGF) family of ligands and their receptors regulate migration and growth of intestinal epithelial cells. However, our understanding of the signal transduction pathways determining these responses is incomplete. In this study we tested the hypothesis that p38 is required for EGF-stimulated intestinal epithelial monolayer restitution. EGF-stimulated migration in a wound closure model required continuous presence of ligand for several hours for maximal response, suggesting a requirement for sustained signal transduction pathway activation. In this regard, prolonged exposure of cells to EGF activated p38 for up to 5 h. Furthermore genetic or pharmacological blockade of p38 signaling inhibited the ability of EGF to accelerate wound closure. Interestingly p38 inhibition was associated with increased EGF-stimulated ERK1/ ERK2 phosphorylation and cell proliferation, suggesting that p38 regulates the balance of proliferation/migration signaling in response to EGF receptor activity. Activation of p38 in intestinal epithelial cells through EGF receptor was abolished by blockade of Src family tyrosine kinase signaling but not inhibition of phosphatidylinositol 3-kinase or protein kinase C. Taken together, these data suggest that Src family kinase-dependent p38 activation is a key component of a signaling switch routing EGF-stimulated responses to epithelial cell migration/restitution rather than proliferation during wound closure.	Vanderbilt Univ, Sch Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Polk, DB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, 221 Kirkland Hall, Nashville, TN 37232 USA.	d-brent.polk@vanderbilt.edu	Frey, Mark/G-3691-2015; Frey, Mark/M-1739-2019	Frey, Mark/0000-0002-2561-5402; Frey, Mark/0000-0002-2561-5402	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK054993, T32DK007673] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07673, DK54993, DK58404] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad SR, 2003, IMMUNOLOGY, V110, P258, DOI 10.1046/j.1365-2567.2003.01733.x; ARGENZIO RA, 1988, AM J PHYSIOL, V255, pG62, DOI 10.1152/ajpgi.1988.255.1.G62; Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Bedrin MS, 1997, J CELL PHYSIOL, V172, P126, DOI 10.1002/(SICI)1097-4652(199707)172:1<126::AID-JCP14>3.3.CO;2-N; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CARPENTER G, 1981, EGF RECEPTOR INTERAC, V13, P43; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Chou J, 2002, INT J BIOCHEM CELL B, V34, P776, DOI 10.1016/S1357-2725(01)00177-7; Chow JYC, 2003, GASTROENTEROLOGY, V125, P1114, DOI 10.1016/S0016-5085(03)01211-3; Chun KS, 2004, CARCINOGENESIS, V25, P713, DOI 10.1093/carcin/bgh076; CIACCI C, 1993, GASTROENTEROLOGY, V105, P93, DOI 10.1016/0016-5085(93)90014-4; Corredor J, 2003, AM J PHYSIOL-CELL PH, V284, pC953, DOI 10.1152/ajpcell.00309.2002; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dieckgraefe BK, 1997, BIOCHEM BIOPH RES CO, V233, P389, DOI 10.1006/bbrc.1997.6469; Egan LJ, 2003, AM J PHYSIOL-CELL PH, V285, pC1028, DOI 10.1152/ajpcell.00167.2003; FEIL W, 1989, GASTROENTEROLOGY, V97, P685, DOI 10.1016/0016-5085(89)90640-9; FEIL W, 1987, GASTROENTEROLOGY, V92, P1973, DOI 10.1016/0016-5085(87)90632-9; Goke M, 1996, AM J PHYSIOL-GASTR L, V271, pG729, DOI 10.1152/ajpgi.1996.271.5.G729; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hofmann M, 2004, BIOCHEM BIOPH RES CO, V316, P673, DOI 10.1016/j.bbrc.2004.02.101; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Imayasu M, 2003, CURR EYE RES, V27, P133, DOI 10.1076/ceyr.27.3.133.16055; Jeohn GH, 2002, NEUROSCIENCE, V114, P689, DOI 10.1016/S0306-4522(02)00356-1; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Kanda Y, 2001, BRIT J PHARMACOL, V132, P1657, DOI 10.1038/sj.bjp.0703952; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Karayiannakis AJ, 1998, J PATHOL, V185, P413; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; Kim MS, 2003, CANCER RES, V63, P5454; LACY ER, 1988, J CLIN GASTROENTEROL, V10, pS72, DOI 10.1097/00004836-198812001-00012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; MOORE R, 1989, LAB INVEST, V60, P237; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nijhout HF, 2003, EVOL DEV, V5, P281, DOI 10.1046/j.1525-142X.2003.03035.x; O'Dwyer PJ, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.35643; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; PARK JS, 1993, ONCOGENE, V8, P2627; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; POLK DB, 1995, GASTROENTEROLOGY, V109, P1845; Polk DB, 1999, AM J PHYSIOL-CELL PH, V277, pC1149, DOI 10.1152/ajpcell.1999.277.6.C1149; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Riegler M, 1996, GASTROENTEROLOGY, V111, P28, DOI 10.1053/gast.1996.v111.pm8698221; Riegler M, 1997, SCAND J GASTROENTERO, V32, P925, DOI 10.3109/00365529709011204; Saika S, 2004, INVEST OPHTH VIS SCI, V45, P100, DOI 10.1167/iovs.03-0700; SAWYER ST, 1981, BIOCHEMISTRY-US, V20, P6280, DOI 10.1021/bi00524a057; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Sinha A, 2003, NEW ENGL J MED, V349, P350, DOI 10.1056/NEJMoa013136; Sizemore N, 1999, GASTROENTEROLOGY, V117, P567, DOI 10.1016/S0016-5085(99)70449-X; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tanimura S, 2002, J BIOL CHEM, V277, P28256, DOI 10.1074/jbc.M202866200; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tikhomirov O, 2004, J BIOL CHEM, V279, P12988, DOI 10.1074/jbc.M311655200; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Wilson AJ, 1999, EXP CELL RES, V250, P187, DOI 10.1006/excr.1999.4496; Wilson AJ, 1997, CLIN SCI, V93, P97, DOI 10.1042/cs0930097; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yan F, 2001, CANCER RES, V61, P8668; Yan F, 2002, J BIOL CHEM, V277, P50959, DOI 10.1074/jbc.M207050200; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	77	104	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44513	44521		10.1074/jbc.M406253200	http://dx.doi.org/10.1074/jbc.M406253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316018	hybrid			2022-12-25	WOS:000224505600036
J	Greenbaum, S; Lazorchak, AS; Zhuang, Y				Greenbaum, S; Lazorchak, AS; Zhuang, Y			Differential functions for the transcription factor E2A in positive and negative gene regulation in pre-B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; HEAVY-CHAIN; CELL FACTOR; DNA-BINDING; EXPRESSION; ENHANCER; SURVIVAL; EBF; IDENTIFICATION; PROGENITORS	The transcription factors encoded by the E2A gene have been shown to play essential roles in the initiation and progression of lymphocyte development. However, there is still a lack of comprehensive understanding of E2A downstream genes in B-cell development. We previously developed a gene tagging-based chromatin immunoprecipitation (ChIP) system to directly evaluate E2A target genes in B-cell development. Here, we have improved this ChIP strategy and used it in conjunction with microarray analysis on E2A-deficient pre-B-cell lines to determine E2A target genes in lymphocyte development. Both microarray data and ChIP studies confirmed that E2A directly controls IgH gene expression. The microarray assay also revealed genes that were significantly up-regulated after E2A disruption. ChIP analysis showed that E2A was most likely to be directly involved in repression of some of these target genes such as Nfil3 and FGFR2. An inducible E2A reconstitution system further demonstrated that E2A-mediated repression of Nfil3 and FGFR2 was reversible. Collectively, these findings indicate that E2A is a positive regulator for one set of genes and a negative regulator for another set of genes in developing B lymphocytes.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Zhuang, Y (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Box 3010,328 Jones Bldg,Res Dr, Durham, NC 27710 USA.	yzhuang@acpub.duke.edu		zhuang, yuan/0000-0002-2964-3654	NCI NIH HHS [R01 CA072433-07, R01 CA072433, R01 CA072433-08, R01 CA72433] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072433] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLOUCHE M, 1995, LEUKEMIA, V9, P77; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; BERARDI AC, 1995, BLOOD, V86, P2123, DOI 10.1182/blood.V86.6.2123.bloodjournal8662123; Chauveau C, 1998, EUR J IMMUNOL, V28, P3048, DOI 10.1002/(SICI)1521-4141(199810)28:10<3048::AID-IMMU3048>3.0.CO;2-V; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Dudoit S, 2003, BIOTECHNIQUES, P45; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; FERNEX C, 1995, MOL CELL BIOL, V15, P3217; GENOT E, 1989, CELL IMMUNOL, V122, P424, DOI 10.1016/0008-8749(89)90089-0; GIANNINI SL, 1993, J IMMUNOL, V150, P1772; Greenbaum S, 2002, SEMIN IMMUNOL, V14, P405, DOI 10.1016/S1044532302000751; Greenbaum S, 2002, P NATL ACAD SCI USA, V99, P15030, DOI 10.1073/pnas.232299999; Ikawa T, 2004, IMMUNITY, V20, P349, DOI 10.1016/S1074-7613(04)00049-4; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; O'Riordan M, 1999, IMMUNITY, V11, P21, DOI 10.1016/S1074-7613(00)80078-3; Pan LH, 2002, J IMMUNOL, V168, P3923, DOI 10.4049/jimmunol.168.8.3923; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; Sigvardsson M, 2002, MOL CELL BIOL, V22, P8539, DOI 10.1128/MCB.22.24.8539-8551.2002; Sigvardsson M, 2000, MOL CELL BIOL, V20, P3640, DOI 10.1128/MCB.20.10.3640-3654.2000; Tsai CA, 2003, BIOMETRICS, V59, P1071, DOI 10.1111/j.0006-341X.2003.00123.x; Ulgiati D, 2001, J IMMUNOL, V167, P6912, DOI 10.4049/jimmunol.167.12.6912; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; XIN XQ, 1993, J IMMUNOL, V151, P5398; Yu YL, 2002, J BIOL CHEM, V277, P27144, DOI 10.1074/jbc.M200924200; Zhao F, 2001, MOL CELL BIOL, V21, P6346, DOI 10.1128/MCB.21.18.6346-6357.2001; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zhuang YA, 2004, MOL IMMUNOL, V40, P1165, DOI 10.1016/j.molimm.2003.11.031	37	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45028	45035		10.1074/jbc.M400061200	http://dx.doi.org/10.1074/jbc.M400061200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310760	Green Accepted, hybrid			2022-12-25	WOS:000224505600095
J	Klinkert, B; Ossenbuhl, F; Sikorski, M; Berry, S; Eichacker, L; Nickelsen, J				Klinkert, B; Ossenbuhl, F; Sikorski, M; Berry, S; Eichacker, L; Nickelsen, J			PratA, a periplasmic tetratricopeptide repeat protein involved in biogenesis of photosystem II in Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPTIMAL PHOTOSYNTHETIC PERFORMANCE; TERMINAL PROCESSING PROTEASE; PRECURSOR D1 PROTEIN; STRAIN PCC 6803; CHLAMYDOMONAS-REINHARDTII; CHLOROPLAST; GENE; ACCUMULATION; PHOSPHATASE; EXPRESSION	The light reactions of oxygenic photosynthesis are mediated by multisubunit pigment-protein complexes situated within the specialized thylakoid membrane system. The biogenesis of these complexes is regulated by transacting factors that affect the expression of the respective subunit genes and/or the assembly of their products. Here we report on the analysis of the PratA gene from the cyanobacterium Synechocystis sp. PCC 6803 that encodes a periplasmic tetratricopeptide repeat protein of formerly unknown function. Targeted inactivation of PratA resulted in drastically reduced photosystem II (PSII) content. Protein pulse labeling experiments of PSII subunits indicated that the C-terminal processing of the precursor of the reaction center protein D1 is compromised in the pratA mutant. Moreover, a direct interaction of PratA and precursor D1 was demonstrated by applying yeast two-hybrid analyses. This suggests that PratA represents a factor facilitating D1 maturation via the endoprotease CtpA. The periplasmic localization of PratA supports a model that predicts the initial steps of PSII biogenesis to occur at the plasma membrane of cyanobacterial cells.	Ruhr Univ Bochum, D-44780 Bochum, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany	Ruhr University Bochum; University of Munich	Nickelsen, J (corresponding author), Ruhr Univ Bochum, D-44780 Bochum, Germany.	joerg.nickelsen@ruhr-uni-bochum.de	Nickelsen, Jörg/J-8896-2014	Nickelsen, Joerg/0000-0003-4184-4560				ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; Baena-Gonzalez E, 2002, PHILOS T R SOC B, V357, P1451, DOI 10.1098/rstb.2002.1141; Barkan A, 2000, BIOCHIMIE, V82, P559, DOI 10.1016/S0300-9084(00)00602-7; Berry S, 2002, BIOCHEMISTRY-US, V41, P3422, DOI 10.1021/bi011683d; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Boudreau E, 2000, EMBO J, V19, P3366, DOI 10.1093/emboj/19.13.3366; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; BOWYER JR, 1992, J BIOL CHEM, V267, P5424; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Felder S, 2001, PLANT CELL, V13, P2127, DOI 10.1105/tpc.13.9.2127; Fulda S, 1999, ARCH MICROBIOL, V171, P214, DOI 10.1007/s002030050702; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hartweck LM, 2002, GENETICS, V161, P1279; Herranen M, 2004, PLANT PHYSIOL, V134, P470, DOI 10.1104/pp.103.032326; Inagaki N, 2001, FEBS LETT, V509, P197, DOI 10.1016/S0014-5793(01)03180-5; Ivleva NB, 2000, PLANT PHYSIOL, V124, P1403, DOI 10.1104/pp.124.3.1403; Kong RQ, 2003, FEMS MICROBIOL LETT, V219, P75, DOI 10.1016/S0378-1097(02)01205-3; Kroll D, 2001, P NATL ACAD SCI USA, V98, P4238, DOI 10.1073/pnas.061500998; LERS A, 1992, J BIOL CHEM, V267, P17494; Nickelsen J, 2003, PROG BOT, V64, P53; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Ruf S, 1997, J CELL BIOL, V139, P95, DOI 10.1083/jcb.139.1.95; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Thaminy Safia, 2004, Methods Mol Biol, V261, P297; Vaistij FE, 2000, P NATL ACAD SCI USA, V97, P14813, DOI 10.1073/pnas.97.26.14813; Wellburn AR, 1984, ADV PHOTOSYNTHESIS R, VII, P9; Westphal S, 2001, P NATL ACAD SCI USA, V98, P4243, DOI 10.1073/pnas.061501198; Wilde A, 2001, BIOCHEM J, V357, P211, DOI 10.1042/0264-6021:3570211; Yamamoto Y, 2001, J BIOL CHEM, V276, P7518, DOI 10.1074/jbc.M008877200; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101; Zhang LX, 2002, FEBS LETT, V512, P13, DOI 10.1016/S0014-5793(02)02218-4; Zinchenko VV, 1999, RUSS J GENET+, V35, P228	36	66	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44639	44644		10.1074/jbc.M405393200	http://dx.doi.org/10.1074/jbc.M405393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15328351	hybrid			2022-12-25	WOS:000224505600050
J	Hlaing, M; Spitz, P; Padmanabhan, K; Cabezas, B; Barker, CS; Bernstein, HS				Hlaing, M; Spitz, P; Padmanabhan, K; Cabezas, B; Barker, CS; Bernstein, HS			E2F-1 regulates the expression of a subset of target genes during skeletal myoblast hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; REPRESS TRANSCRIPTION; HISTONE DEACETYLASE; SIGNALING PATHWAYS; PROTEIN-SYNTHESIS; CARDIAC MYOCYTES; RESPONSIVE GENES; DNA-REPLICATION; GROWTH-FACTORS; FAMILY-MEMBER	Cellular hypertrophy, or growth without division, is an adaptive response to various physiological and pathological stimuli in postmitotic muscle. We demonstrated previously that angiotensin II stimulates hypertrophy in C2C12 myoblasts by transient activation of the cyclin-dependent kinase 4 complex, subsequent phosphorylation of retinoblastoma protein, release of histone deacetylase 1 from the retinoblastoma protein inhibitory complex, and partial activation of the transcription factor E2F-1. These observations led us to propose a model in which partial inactivation of the retinoblastoma protein complex leads to the derepression of a subset of E2F-1 targets necessary for cell growth without division during hypertrophy. We now present data that support this model and suggest the mechanism by which E2F-1 regulates hypertrophy. We examined expression profiles of angiotensin II-stimulated myoblasts and identified a subset of E2F-1 target genes that are specifically regulated during the hypertrophic response. We showed that the expression of E2F-1 targets involved in G(1)/S transit, DNA replication, and mitosis is not altered during the hypertrophic response, while the expression of E2F-1-regulated genes controlling early G(1) progression, cytoskeletal organization, protein synthesis, mitochondrial function, and programmed cell death is up-regulated. Furthermore, we demonstrated that activation of cytochrome c oxidase genes occurs during the development of hypertrophy and that cytochrome c oxidase IV is a direct transcriptional target of E2F-1. These studies demonstrated that E2F-1 activity at specific promoters is dependent on physiological circumstances and that E2F-1 should be considered a potential target in the treatment of pathologic hypertrophy.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; J David Gladstone Inst, Geneom Lab, San Francisco, CA 94103 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Bernstein, HS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 505 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.	hsbernstein@pedcard.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL072571, R01HL062174, R01HL072301] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62174, HL72301, F32 HL 72571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Akli S, 1999, CIRC RES, V85, P319, DOI 10.1161/01.RES.85.4.319; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; Callow MJ, 2000, GENOME RES, V10, P2022, DOI 10.1101/gr.10.12.2022; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CARTER RS, 1991, ARCH BIOCHEM BIOPHYS, V288, P97, DOI 10.1016/0003-9861(91)90169-J; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Diffee GM, 2003, AM J PHYSIOL-HEART C, V284, pH830, DOI 10.1152/ajpheart.00761.2002; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Everett AD, 2001, AM J PHYSIOL-HEART C, V281, pH161, DOI 10.1152/ajpheart.2001.281.1.H161; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hlaing M, 2002, J BIOL CHEM, V277, P23794, DOI 10.1074/jbc.M201980200; Iemitsu M, 2001, AM J PHYSIOL-REG I, V281, pR2029, DOI 10.1152/ajpregu.2001.281.6.R2029; Iglesias A, 2004, J CLIN INVEST, V113, P1398, DOI 10.1172/JCI200418879; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; ITO H, 1993, CIRCULATION, V87, P1715, DOI 10.1161/01.CIR.87.5.1715; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jun D, 1998, MOL CELLS, V8, P731; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kaddoura S, 1996, CIRCULATION, V93, P2068, DOI 10.1161/01.CIR.93.11.2068; Kim S, 2000, P NATL ACAD SCI USA, V97, P11198, DOI 10.1073/pnas.200372597; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Lei XH, 2000, J CELL SCI, V113, P4523; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagatomo Y, 1999, AM J PHYSIOL-HEART C, V277, pH2176; Nebigil CG, 2003, CIRCULATION, V107, P3223, DOI 10.1161/01.CIR.0000074224.57016.01; Nishikawa NS, 2000, NUCLEIC ACIDS RES, V28, P1525, DOI 10.1093/nar/28.7.1525; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Philip-Couderc P, 2003, HYPERTENSION, V41, P414, DOI 10.1161/01.HYP.0000057573.32425.95; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Storre J, 2002, EMBO REP, V3, P695, DOI 10.1093/embo-reports/kvf141; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Taanman JW, 1997, J BIOENERG BIOMEMBR, V29, P151, DOI 10.1023/A:1022638013825; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vara D, 2003, J BIOL CHEM, V278, P21388, DOI 10.1074/jbc.M212612200; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Wang ZM, 1998, P NATL ACAD SCI USA, V95, P15583, DOI 10.1073/pnas.95.26.15583; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200	77	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43625	43633		10.1074/jbc.M408391200	http://dx.doi.org/10.1074/jbc.M408391200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304485	hybrid			2022-12-25	WOS:000224383100035
J	Schwegmann-Wessels, C; Al-Falah, M; Escors, D; Wang, Z; Zimmer, G; Deng, HK; Enjuanes, L; Naim, HY; Herrler, G				Schwegmann-Wessels, C; Al-Falah, M; Escors, D; Wang, Z; Zimmer, G; Deng, HK; Enjuanes, L; Naim, HY; Herrler, G			A novel sorting signal for intracellular localization is present in the S protein of a porcine coronavirus but absent from severe acute respiratory syndrome-associated coronavirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATITIS-VIRUS; GOLGI-COMPLEX; CYTOPLASMIC TAIL; ENDOPLASMIC-RETICULUM; AVIAN CORONAVIRUS; ENVELOPE PROTEIN; EPITHELIAL-CELLS; SYNCYTIAL VIRUS; SPIKE PROTEINS; GLYCOPROTEIN	Coronaviruses (CoV) mature by a budding process at intracellular membranes. Here we showed that the major surface protein S of a porcine CoV ( transmissible gastroenteritis virus) is not transported to the cell surface but is retained intracellularly. Site-directed mutagenesis indicated that a tyrosine-dependent signal (YXXI) in the cytoplasmic tail is essential for intracellular localization of the S protein. Surface expression of mutant proteins was evident by immunofluorescence analysis and surface biotinylation. Intracellularly retained S proteins only contained endoglycosidase H-sensitive N-glycans, whereas mutant proteins that migrated to the plasma membrane acquired N-linked oligosaccharides of the complex type. Corresponding tyrosine residues are present in the cytoplasmic tails of the S proteins of other animal CoV but not in the tail portion of the S protein of severe acute respiratory syndrome (SARS)-CoV. Changing the SEPV tetrapeptide in the cytoplasmic tail to YEPI resulted in intracellular retention of the S protein of SARS-CoV. As the S proteins of CoV have receptor binding and fusion activities and are the main target of neutralizing antibodies, the differences in the transport behavior of the S proteins suggest different strategies in the virus host interactions between SARS-CoV and other coronaviruses.	Tierarztlichen Hsch Hannover, Inst Virol, D-30559 Hannover, Germany; CSIC, Ctr Nacl Biotecnol, Dept Mol & Cell Biol, Madrid 28049, Spain; Peking Univ, Dept Cell Biol & Genet, Coll Life Sci, Beijing 100871, Peoples R China	University of Veterinary Medicine Hannover, Foundation; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Peking University	Herrler, G (corresponding author), Tierarztlichen Hsch Hannover, Inst Virol, Bunteweg 17, D-30559 Hannover, Germany.	Georg.Herrler@tiho-hannover.de	Escors, David/C-1549-2008; Enjuanes, Luis/F-7845-2016; Al Falah, Dr. Marwan/C-6281-2011; Escors-Murugarren, David/ABG-1930-2020	Escors, David/0000-0003-2828-4458; Escors-Murugarren, David/0000-0003-2828-4458; Enjuanes, Luis/0000-0002-0854-0226; Zimmer, Gert/0000-0002-2708-2507				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Borroto A, 1999, J IMMUNOL, V163, P25; COMPANS RW, 1999, MUCOSAL IMMUNOLOGY, P671; Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000; Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002; Escors D, 2001, J VIROL, V75, P1312, DOI 10.1128/JVI.75.3.1312-1324.2001; Escors D, 2001, J VIROL, V75, P12228, DOI 10.1128/JVI.75.24.12228-12240.2001; Fauquet C.M., 2000, VIRUS TAXONOMY CLASS, P835; GEBAUER F, 1991, VIROLOGY, V183, P225, DOI 10.1016/0042-6822(91)90135-X; GODET M, 1991, VIROLOGY, V185, P732, DOI 10.1016/0042-6822(91)90544-L; Hauri HP, 2000, J CELL SCI, V113, P587; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; Kohl W, 2004, J GEN VIROL, V85, P1101, DOI 10.1099/vir.0.19740-0; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; Kunkel F, 1996, ARCH VIROL, V141, P1123, DOI 10.1007/BF01718615; Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; Lontok E, 2004, J VIROL, V78, P5913, DOI 10.1128/JVI.78.11.5913-5922.2004; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; Maisner A, 1998, J VIROL, V72, P5276, DOI 10.1128/JVI.72.6.5276-5278.1998; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Penzes Z, 2001, VIRUS GENES, V23, P105, DOI 10.1023/A:1011147832586; PULFORD DJ, 1991, VIROLOGY, V182, P765, DOI 10.1016/0042-6822(91)90617-K; Risco C, 1998, J VIROL, V72, P4022, DOI 10.1128/JVI.72.5.4022-4031.1998; Sanger C, 2001, J VIROL, V75, P1274, DOI 10.1128/JVI.75.3.1274-1283.2001; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TOOZE J, 1984, EUR J CELL BIOL, V33, P281; Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x; VENNEMA H, 1990, J VIROL, V64, P339, DOI 10.1128/JVI.64.1.339-346.1990; Zimmer G, 2001, J BIOL CHEM, V276, P31642, DOI 10.1074/jbc.M102633200; Zimmer G, 2001, J VIROL, V75, P4744, DOI 10.1128/JVI.75.10.4744-4751.2001	38	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43661	43666		10.1074/jbc.M407233200	http://dx.doi.org/10.1074/jbc.M407233200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304515	Green Published, hybrid			2022-12-25	WOS:000224383100039
J	Dudognon, C; Pendino, F; Hillion, J; Saumet, A; Lanotte, M; Segal-Bendirdjian, E				Dudognon, C; Pendino, F; Hillion, J; Saumet, A; Lanotte, M; Segal-Bendirdjian, E			Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance	ONCOGENE			English	Article						telomerase; TRAIL; apoptosis; ATRA; APL	LEUKEMIA-CELL LINE; CATALYTIC SUBUNIT; CANCER-CELLS; EXPRESSION; LENGTH; SENESCENCE; INHIBITION; MATURATION; RESISTANCE; MECHANISM	Human telomerase has been implicated in cell immortalization and cancer. Recent works suggest that telomerase confers additional function required for tumorigenesis that does not depend on its ability to maintain telomeres. This new action may influence tumor therapy outcomes by yet unraveled mechanisms. Here, we show that overexpression of the catalytic subunit of telomerase (hTERT) protects a maturation-resistant acute promyelocytic leukemia (APL) cell line from apoptosis induced by the tumor necrosis factor (TNF) or TNF-related apoptosis- inducing ligand (TRAIL) and not from apoptosis induced by chemotherapeutic drugs such as etoposide or cisplatin. Conversely, in these cells, TRAIL-induced cell death is magnified by all-trans retinoic acid ( ATRA) treatment, independently of telomerase activity on telomeres. Of note, this response is subordinated neither to maturation nor to telomere shortening. This work underlines that retinoids and death receptor signaling cross-talks offer new perspectives for antitumor therapy.	Hop St Louis, Inst Hematol, INSERM, U496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Segal-Bendirdjian, E (corresponding author), Hop St Louis, Inst Hematol, INSERM, U496, 1 Ave Claude Vellefaux, F-75010 Paris, France.	Evelyne.Segal-Bendirdjian@stlouis.inserm.fr	PENDINO, Frederic/G-6630-2017	Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Folini M, 2000, EUR J CANCER, V36, P2137, DOI 10.1016/S0959-8049(00)00295-1; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; LANOTTE M, 1991, BLOOD, V77, P1080; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Ludwig A, 2001, CANCER RES, V61, P3053; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; RUBIO MA, 2004, IN PRESS EXP CELL RE; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Yuan Zhang, 2002, Hematol J, V3, P201, DOI 10.1038/sj.thj.6200177	32	65	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7469	7474		10.1038/sj.onc.1208029	http://dx.doi.org/10.1038/sj.onc.1208029			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326479				2022-12-25	WOS:000224176500003
J	Shaw, WJ; Campbell, AA; Paine, ML; Snead, ML				Shaw, WJ; Campbell, AA; Paine, ML; Snead, ML			The COOH terminus of the amelogenin, LRAP, is oriented next to the hydroxyapatite surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; DYNAMIC LIGHT-SCATTERING; DOUBLE-RESONANCE NMR; ENAMEL-MATRIX; RECOMBINANT AMELOGENIN; ROTATIONAL-ECHO; PEPTIDE; PROTEINS; BIOMINERALIZATION; CONFORMATION	The organic matrix in forming enamel consists largely of the amelogenin protein self-assembled into nanospheres that are necessary to guide the formation of the unusually long and highly ordered hydroxyapatite (HAP) crystallites that constitute enamel. Despite its ability to direct crystal growth, the interaction of the amelogenin protein with HAP is unknown. However, the demonstration of growth restricted to the c-axis suggests a specific protein-crystal interaction, and the charged COOH terminus is often implicated in this function. To elucidate whether the COOH terminus is important in the binding and orientation of amelogenin onto HAP, we have used solid state NMR to determine the orientation of the COOH terminus of an amelogenin splice variant, LRAP (leucine-rich amelogenin protein), which contains the charged COOH terminus of the full protein, on the HAP surface. These experiments demonstrate that the methyl (13)C-labeled side chain of Ala(46) is 8.0 Angstrom from the HAP surface under hydrated conditions, for the protein with and without phosphorylation. The experimental results provide direct evidence orienting the charged COOH-terminal region of the amelogenin protein on the HAP surface, optimized to exert control on developing enamel crystals.	Pacific NW Natl Lab, Richland, WA 99352 USA; Univ So Calif, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Southern California	Shaw, WJ (corresponding author), Pacific NW Natl Lab, MS K2-57,POB 999, Richland, WA 99352 USA.	wendy.shaw@pnl.gov		Shaw, Wendy/0000-0002-4696-7415	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013045, R01DE015347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE013045, R01DE013404] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE015347, DE13404, R01 DE015347-01A2, DE13045] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOBA T, 1987, CALCIFIED TISSUE INT, V41, P281, DOI 10.1007/BF02555230; Bak M, 2000, J MAGN RESON, V147, P296, DOI 10.1006/jmre.2000.2179; BENNETT AE, 1995, J CHEM PHYS, V103, P6951, DOI 10.1063/1.470372; Burkett SL, 2001, LANGMUIR, V17, P5059, DOI 10.1021/la010156s; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1994, J STRUCT BIOL, V112, P103, DOI 10.1006/jsbi.1994.1011; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; FINCHAM AG, 1992, INT CONGR SER, V1002, P187; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; GIBSON CW, 1991, BIOCHEM BIOPH RES CO, V174, P1306, DOI 10.1016/0006-291X(91)91564-S; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Gougeon RD, 2002, LANGMUIR, V18, P3396, DOI 10.1021/la0115381; GULLION T, 1989, J MAGN RESON, V81, P196, DOI 10.1016/0022-2364(89)90280-1; GULLION T, 1991, J MAGN RESON, V92, P439, DOI 10.1016/0022-2364(91)90286-3; Hunter GK, 1996, CURR OPIN SOLID ST M, V1, P430, DOI 10.1016/S1359-0286(96)80036-2; Hunter GK, 1999, CALCIFIED TISSUE INT, V65, P226, DOI 10.1007/s002239900688; Long JR, 2001, BIOCHEMISTRY-US, V40, P15451, DOI 10.1021/bi010864c; Long JR, 1998, P NATL ACAD SCI USA, V95, P12083, DOI 10.1073/pnas.95.21.12083; Moradian-Oldak J, 1998, J STRUCT BIOL, V122, P320, DOI 10.1006/jsbi.1998.4008; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; Moradian-Oldak J, 1998, BIOPOLYMERS, V46, P225, DOI 10.1002/(SICI)1097-0282(19981005)46:4<225::AID-BIP4>3.0.CO;2-R; Moradian-Oldak J, 2002, MATRIX BIOL, V21, P197, DOI 10.1016/S0945-053X(01)00190-1; Moradian-Oldak J, 2001, MATRIX BIOL, V20, P293, DOI 10.1016/S0945-053X(01)00154-8; Paine ML, 2001, MATRIX BIOL, V20, P273, DOI 10.1016/S0945-053X(01)00153-6; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; Shaw WJ, 2000, J AM CHEM SOC, V122, P1709, DOI 10.1021/ja9842823; Shaw WJ, 2000, J AM CHEM SOC, V122, P7118, DOI 10.1021/ja000878q; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SIMMER JP, 1995, CRIT REV ORAL BIOL M, V6, P84, DOI 10.1177/10454411950060020701; Viswanathan HL, 2003, J PERIODONTOL, V74, P1423, DOI 10.1902/jop.2003.74.10.1423	31	121	126	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40263	40266		10.1074/jbc.C400322200	http://dx.doi.org/10.1074/jbc.C400322200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15299015	hybrid			2022-12-25	WOS:000223916800005
J	Mori, S; Matsuzaki, K; Yoshida, K; Furukawa, F; Tahashi, Y; Yamagata, H; Sekimoto, G; Seki, T; Matsui, H; Nishizawa, M; Fujisawa, JI; Okazaki, K				Mori, S; Matsuzaki, K; Yoshida, K; Furukawa, F; Tahashi, Y; Yamagata, H; Sekimoto, G; Seki, T; Matsui, H; Nishizawa, M; Fujisawa, JI; Okazaki, K			TGF-beta and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions	ONCOGENE			English	Article						TGF-beta; HGF; JNK; MAPK; Smad; PAI-1	TRANSFORMING-GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR; FUNCTIONAL-CHARACTERIZATION; IDENTIFICATION; INHIBITOR; RECEPTOR; P15(INK4B); MECHANISM; PATHWAYS; PROMOTER	Although hepatocyte growth factor (HGF) can act synergistically or antagonistically with transforming growth factor-beta (TGF-beta) signaling, molecular mechanism of their crosstalk remains unknown. Using antibodies which selectively distinguished receptor-regulated Smads (R-Smads) phosphorylated at linker regions from those at C-terminal regions, we herein showed that either HGF or TGF-beta treatment of normal stomach-origin cells activated the JNK pathway, thereafter inducing endogenous R-Smads phosphorylation at linker regions. However, the phosphorylation at their C-terminal regions was not induced by HGF treatment. The activated JNK could directly phosphorylate R-Smads in vitro at the same sites that were phosphorylated in response to TGF-beta or HGF in vivo. Thus, the linker regions of R-Smads were the common phosphorylation sites for HGF and TGF-beta signaling pathways. The phosphorylation induced by simultaneous treatment with HGF and TGF-beta allowed R-Smads to associate with Smad4 and to translocate into the nucleus. JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals. Moreover, a combined treatment with HGF and TGF-beta led to a potent increase in plasminogen activator inhibitor type 1 transcriptional activity through Smad3 phosphorylation at the linker region. In contrast, HGF treatment reduced TGF-beta-dependent activation of p15(INK4B) promoter, in which Smad3 phosphorylation at the C-terminal region was involved. In conclusion, HGF and TGF-beta transmit the signals through JNK-mediated R-Smads phosphorylation at linker regions.	Kansai Med Univ, Dept Internal Med 3, Osaka 5708507, Japan; Univ Tsukuba, Inst Clin Med, Div Gastroenterol, Tsukuba, Ibaraki 3058576, Japan; Inst Chem & Phys RIKEN, RIKEN Cell Bank, Tsukuba, Ibaraki 3050074, Japan; Kansai Med Univ, Dept Med Chem, Osaka 5708507, Japan; Kansai Med Univ, Dept Microbiol, Osaka 5708507, Japan	Kansai Medical University; University of Tsukuba; RIKEN; Kansai Medical University; Kansai Medical University	Matsuzaki, K (corresponding author), Kansai Med Univ, Dept Internal Med 3, 10-15 Fumizonocho, Osaka 5708507, Japan.	matsuzak@takii.kmu.ac.jp						Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Furukawa F, 2003, HEPATOLOGY, V38, P879, DOI 10.1053/jhep.2003.50384; Gutierrez LS, 2000, CANCER RES, V60, P5839; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Kobayashi I, 1996, IN VITRO CELL DEV-AN, V32, P259; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, CANCER RES, V60, P1394; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; WRANA JL, 2000, SCI STKE, pRE1; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	37	162	174	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7416	7429		10.1038/sj.onc.1207981	http://dx.doi.org/10.1038/sj.onc.1207981			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326485				2022-12-25	WOS:000224021400012
J	Khanim, FL; Gommersall, LM; Wood, VHJ; Smith, KL; Montalvo, L; O'Neill, LP; Xu, Y; Peehl, DM; Stewart, PM; Turner, BM; Campbell, MJ				Khanim, FL; Gommersall, LM; Wood, VHJ; Smith, KL; Montalvo, L; O'Neill, LP; Xu, Y; Peehl, DM; Stewart, PM; Turner, BM; Campbell, MJ			Altered SMRT levels disrupt vitamin D-3 receptor signalling in prostate cancer cells	ONCOGENE			English	Article						histone deacetylation inhibitors; 1 alpha,25-dihydroxyvitamin D-3; prostate cancer; SMRT; GADD45 alpha	HISTONE DEACETYLASE INHIBITOR; TRANSCRIPTION FACTORS OCT-1; 1,25-DIHYDROXYVITAMIN D-3; RETINOIC ACID; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PRIMARY CULTURES; GENE-EXPRESSION; P53-INDEPENDENT INDUCTION; 24-HYDROXYLASE ACTIVITY; PROMYELOCYTIC LEUKEMIA	We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity. To explore this possibility, we examined nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often associated with reduced sensitivity to 1alpha,25-dihydroxyvitamin D-3 (1alpha, 25(OH)(2)D-3). For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (P<0.05). Similarly, 10/15 primary tumour cultures ( including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated. Corepressor proteins often have associated histone deacetylases (HDAC) and reflectively the antiproliferative action of 1 alpha, 25(OH)(2)D-3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines. To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1 alpha, 25(OH)(2)D-3 plus TSA after 6 h. Examination of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1 alpha, 25(OH)(2)D-3 plus TSA cooperatively upregulated eight (outof1176) genes, including MAPK-APK2 and GADD45 alpha. MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation. Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA ( siRNA) approach and found that GADD45 alpha induction by 1 alpha, 25(OH)(2)D-3 alone became very significantly enhanced. The same distortion of gene responsiveness, with repressed induction of GADD45 alpha was found in primary tumour cultures compared and to matched peripheral zone ( normal) cultures from the same donor. These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes associated with antiproliferative action and apparent 1 alpha,25(OH)(2)D-3-insensitivity. This can be targeted therapeutically by combination treatments with HDAC inhibitors.	Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Sch Med, Inst Biomed Res, Div Immun & Infect, Birmingham B15 2TH, W Midlands, England; Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA	University of Birmingham; University of Birmingham; Stanford University	Campbell, MJ (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, 2nd Floor, Birmingham B15 2TT, W Midlands, England.	m.j.campbell@bham.ac.uk	Campbell, Moray/ABF-1264-2021; Campbell, Moray J/A-1311-2013	Campbell, Moray/0000-0002-3355-0928; 				Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Beer TM, 2003, J CLIN ONCOL, V21, P123, DOI 10.1200/jco.2003.05.117; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Blutt SE, 2000, CANCER RES, V60, P779; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Campbell MJ, 1998, ENDOCRINOLOGY, V139, P1972, DOI 10.1210/en.139.4.1972; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; Chen TC, 2003, TRENDS ENDOCRIN MET, V14, P423, DOI 10.1016/j.tem.2003.09.004; Cohen LA, 2002, ANTICANCER RES, V22, P1497; Danielsson C, 1997, J CELL BIOCHEM, V66, P552, DOI 10.1002/(SICI)1097-4644(19970915)66:4<552::AID-JCB14>3.0.CO;2-D; DeFouw LM, 2000, TISSUE CELL, V32, P238, DOI 10.1054/tice.2000.0111; Dwivedi PP, 2002, J BIOL CHEM, V277, P29643, DOI 10.1074/jbc.M204561200; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Gnanapragasam VJ, 2001, BRIT J CANCER, V85, P1928, DOI 10.1054/bjoc.2001.2179; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; HANCHETTE CL, 1992, CANCER, V70, P2861, DOI 10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Hudelist G, 2003, BREAST CANCER RES TR, V78, P193, DOI 10.1023/A:1022930710850; Ingles SA, 1998, CANCER RES, V58, P1620; Jiang F, 2003, J BIOL CHEM, V278, P48030, DOI 10.1074/jbc.M308430200; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Jin SQ, 2003, ONCOGENE, V22, P8536, DOI 10.1038/sj.onc.1206907; Kawashima H, 2003, BIOCHEM J, V369, P163, DOI 10.1042/BJ20020743; Kollara A, 2001, BREAST CANCER RES TR, V67, P245, DOI 10.1023/A:1017938608460; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krishnan AV, 2003, RECENT RESULTS CANC, V164, P205; Kubota T, 1998, CANCER RES, V58, P3370; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Ly LH, 1999, ENDOCRINOLOGY, V140, P2071, DOI 10.1210/en.140.5.2071; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miller CW, 1997, MOL CARCINOGEN, V19, P254, DOI 10.1002/(SICI)1098-2744(199708)19:4<254::AID-MC6>3.0.CO;2-C; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Oda Y, 2003, MOL ENDOCRINOL, V17, P2329, DOI 10.1210/me.2003-0063; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Peehl DM, 2004, J CELL BIOCHEM, V91, P185, DOI 10.1002/jcb.10691; Peehl DM, 2003, ENDOCR-RELAT CANCER, V10, P131, DOI 10.1677/erc.0.0100131; PEEHL DM, 1994, CANCER RES, V54, P805; Planas-Silva MD, 2001, CANCER RES, V61, P3858; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Polly P, 2000, FASEB J, V14, P1455, DOI 10.1096/fj.14.10.1455; Quack M, 1999, MOL PHARMACOL, V55, P1077, DOI 10.1124/mol.55.6.1077; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Rashid SF, 2001, ONCOGENE, V20, P1860, DOI 10.1038/sj.onc.1204269; Rashid SF, 2001, STEROIDS, V66, P433, DOI 10.1016/S0039-128X(00)00203-8; Ratnam AV, 1996, J INVEST DERMATOL, V106, P522, DOI 10.1111/1523-1747.ep12343898; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; SCHMID HP, 1992, AM J SURG PATHOL, V16, P184, DOI 10.1097/00000478-199202000-00012; Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727; SOMMERVILLE J, 1993, J CELL BIOL, V120, P277, DOI 10.1083/jcb.120.2.277; Tong WM, 1998, INT J CANCER, V75, P467, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;467::AID-IJC22&gt;3.0.CO;2-4; Wang DF, 2004, BIOORG MED CHEM LETT, V14, P707, DOI 10.1016/j.bmcl.2003.11.062; Wang XN, 2000, EXP CELL RES, V258, P425, DOI 10.1006/excr.2000.4939; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yu JJ, 2003, EMBO J, V22, P3403, DOI 10.1093/emboj/cdg326; Zhang C, 2001, J BIOL CHEM, V276, P40614, DOI 10.1074/jbc.M106263200; Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440; Zhuang SH, 1997, MOL CELL ENDOCRINOL, V126, P83, DOI 10.1016/S0303-7207(96)03974-3; Zierold C, 2002, ARCH BIOCHEM BIOPHYS, V404, P18, DOI 10.1016/S0003-9861(02)00238-2; Zinser G, 2002, DEVELOPMENT, V129, P3067	72	108	110	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6712	6725		10.1038/sj.onc.1207772	http://dx.doi.org/10.1038/sj.onc.1207772			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15300237	Green Submitted			2022-12-25	WOS:000223653600003
J	Maurice, P; Legrand, C; Fauvel-Lafeve, F				Maurice, P; Legrand, C; Fauvel-Lafeve, F			Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen	FASEB JOURNAL			English	Article						platelet aggregation; glycoprotein; platelet-collagen interaction	RECEPTOR-GAMMA-CHAIN; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN IB-ALPHA; C-TERMINAL PEPTIDE; TYROSINE PHOSPHORYLATION; INTEGRIN ALPHA(2)BETA(1); FLOW CONDITIONS; IMMUNOGLOBULIN SUPERFAMILY; INCLUDING PLC-GAMMA-2; VI	Platelet adhesion to vascular collagens is an essential step in the initiation of hemostasis and thrombosis. Several platelet receptors interact with type I and type III collagens, including GP Ia/IIa and GP VI. We recently described a new platelet receptor (TIIICBP) specific for a type III collagen-related primary binding sequence, the KOGEOGPK octapeptide. Here, we characterize platelet adhesion to the immobilized octapeptide and demonstrate that this adhesion 1) is Ca2+ and Mg2+ independent, suggesting a noninvolvement of GP Ia/IIa; 2) is not inhibited by an antibody against GP VI; and 3) triggers platelet protein tyrosine phosphorylation. Whereas TXA(2) has minimal effects, released ADP via only P2Y(12) potentiates platelet adhesion to the octapeptide. Octapeptide-induced platelet adhesion triggers platelet signaling through tyrosine phosphorylation of the 68 kDa subunit of TIIICBP, Syk, PLCgamma2, and FAK. Tyrosine phosphorylation of the FcR gamma-chain and LAT is also observed but to a lesser extent than with type III collagen, suggesting the requirement of GP VI for full tyrosine phosphorylation of FcR gamma-chain and LAT. The present study provides evidence for a critical role for the type III collagen-related KOGEOGPK octapeptide in mediating platelet adhesion and signaling, and consequently in platelet-collagen interactions.	Univ Paris 07, Hop St Louis, U553,INSERM, Inst Hematol,IFR St Louis, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fauvel-Lafeve, F (corresponding author), Hop St Louis, INSERM, U553, 1 Ave Calude Vellefaux, F-75475 Paris 10, France.	f.lafeve@chu-stlouis.fr	Maurice, Pascal/AAM-9126-2021	MAURICE, Pascal/0000-0003-2167-4808				Arderiu G, 2002, BIOCHEM J, V364, P65, DOI 10.1042/bj3640065; Atkinson BT, 2001, EUR J BIOCHEM, V268, P5242, DOI 10.1046/j.0014-2956.2001.02448.x; Barnes MJ, 1996, BIOPOLYMERS, V40, P383, DOI 10.1002/(SICI)1097-0282(1996)40:4<383::AID-BIP4>3.0.CO;2-S; BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; FAUVEL F, 1979, THROMB RES, V16, P269, DOI 10.1016/0049-3848(79)90289-5; FAUVELLAFEVE F, 1993, THROMB RES, V71, P193, DOI 10.1016/0049-3848(93)90094-5; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V354, P255, DOI 10.1006/abbi.1998.0637; Francischetti IMB, 1998, ARCH BIOCHEM BIOPHYS, V353, P239, DOI 10.1006/abbi.1998.0598; FUJII T, 1975, H-S Z PHYSIOL CHEM, V356, P1793, DOI 10.1515/bchm2.1975.356.2.1793; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Guidetti GF, 2003, BBA-MOL CELL RES, V1640, P43, DOI 10.1016/S0167-4889(02)00401-9; Hers I, 2000, EUR J BIOCHEM, V267, P2088, DOI 10.1046/j.1432-1327.2000.01214.x; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jarvis GE, 2002, BRIT J PHARMACOL, V137, P107, DOI 10.1038/sj.bjp.0704834; Judd BA, 2002, J EXP MED, V195, P705, DOI 10.1084/jem.20011583; Kamiguti AS, 2000, ARCH BIOCHEM BIOPHYS, V374, P356, DOI 10.1006/abbi.1999.1627; Kanaji S, 2003, J BIOL CHEM, V278, P39452, DOI 10.1074/jbc.M300199200; KARNIGUIAN A, 1983, THROMB RES, V32, P593, DOI 10.1016/0049-3848(83)90061-0; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Kunapuli SP, 2003, CURR OPIN PHARMACOL, V3, P175, DOI 10.1016/S1471-4892(03)00007-9; Lecut C, 2003, J THROMB HAEMOST, V1, P2653, DOI 10.1111/j.1538-7836.2003.00495.x; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; Marshall SJ, 2002, BIOCHEM J, V361, P297, DOI 10.1042/0264-6021:3610297; Miura Y, 2000, THROMB RES, V98, P301, DOI 10.1016/S0049-3848(00)00182-1; Monnet E, 2000, J BIOL CHEM, V275, P10912, DOI 10.1074/jbc.275.15.10912; Monnet E, 2001, THROMB HAEMOSTASIS, V86, P694, DOI 10.1055/s-0037-1616106; Monnet E, 2000, THROMB RES, V98, P423, DOI 10.1016/S0049-3848(00)00199-7; MOROI M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P1, DOI 10.1016/0167-4889(92)90092-P; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; Nakamura T, 1999, J BIOL CHEM, V274, P11897, DOI 10.1074/jbc.274.17.11897; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Rauterberg J, 1993, Curr Top Pathol, V87, P163; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; Staatz WD, 1997, BIOCHEM MOL BIOL INT, V42, P577; SUGIYAMA T, 1987, BLOOD, V69, P1712; Trumel C, 2003, J THROMB HAEMOST, V1, P320, DOI 10.1046/j.1538-7836.2003.00068.x; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Tulasne D, 2001, BLOOD, V98, P3346, DOI 10.1182/blood.V98.12.3346; Verkleij MW, 1998, BLOOD, V91, P3808; Verkleij MW, 1999, THROMB HAEMOSTASIS, V82, P1137; Vuori K, 1998, J MEMBRANE BIOL, V165, P191, DOI 10.1007/s002329900433; Wu CC, 1996, BIOCHEM BIOPH RES CO, V220, P388, DOI 10.1006/bbrc.1996.0415	53	17	17	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1339	1347		10.1096/fj.03-1151com	http://dx.doi.org/10.1096/fj.03-1151com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333577				2022-12-25	WOS:000224243200053
J	Horibata, Y; Sakaguchi, K; Okino, N; Iida, H; Inagaki, M; Fujisawa, T; Hama, Y; Ito, M				Horibata, Y; Sakaguchi, K; Okino, N; Iida, H; Inagaki, M; Fujisawa, T; Hama, Y; Ito, M			Unique catabolic pathway of Glycosphingolipids in a hydrozoan, Hydra magnipapillata, involving endoglycoceramidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERAMIDE-GLYCANASE; MOLECULAR-CLONING; RHODOCOCCUS SP; PURIFICATION; GENE; EXPRESSION; STRAIN; CARBOHYDRATE; PROTEINS; FAMILY	Endoglycoceramidase (EGCase; EC 3.2.1.123) is an enzyme capable of cleaving the glycosidic linkage between oligosaccharides and ceramides of various glycosphingolipids. We detected strong EGCase activity in animals belonging to Cnidaria, Mollusca, and Annelida and cloned the enzyme from a hydra, Hydra magnipapillata. The hydra EGCase, consisting of 517 amino acid residues, showed 19.2% and 50.2% identity to the Rhodococcus and jellyfish EGCases, respectively. The recombinant hydra enzyme, expressed in CHOP ( Chinese hamster ovary cells expressing polyoma LT antigen) cells, hydrolyzed [C-14] GM1a to produce [C-14] ceramide with a pH optimum at 3.0 - 3.5. Whole mount in situ hybridization and immunocytochemical analysis revealed that EGCase was widely expressed in the endodermal layer, especially in digestive cells. GM1a injected into the gastric cavity was incorporated and then directly catabolized by EGCase to produce GM1a-oligosaccharide and ceramide, which were further degraded by exoglycosidases and ceramidase, respectively. However, hydra exoglycosidases did not hydrolyze GM1a directly. These results indicate that the EGCase is indispensable for the catabolic processing of dietary glycosphingolipids in hydra, demonstrating the unique catabolic pathway for glycosphingolipids in the animal.	Kyushu Univ, Dept Biosci & Biotechnol, Grad Sch Bioresource & Bioenvironm Sci, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Dept Appl Genet & Pest Management, Grad Sch Bioresource & Bioenvironm Sci, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Fac Pharmaceut Sci, Higashi Ku, Grad Sch, Fukuoka 8128582, Japan; Natl Inst Genet, Dept Dev Genet, Shizuoka 4118540, Japan; Saga Univ, Dept Appl Biol Sci, Fac Agr, Saga 8408502, Japan	Kyushu University; Kyushu University; Kyushu University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Saga University	Ito, M (corresponding author), Kyushu Univ, Dept Biosci & Biotechnol, Grad Sch Bioresource & Bioenvironm Sci, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818				ASHIDA H, 1992, EUR J BIOCHEM, V205, P729, DOI 10.1111/j.1432-1033.1992.tb16836.x; BASU SS, 1994, ANAL BIOCHEM, V222, P270, DOI 10.1006/abio.1994.1484; BURNETT AL, 1973, BIOL HYDRA FEEDING D, P43; DAVID CN, 1973, ROUX ARCH DEV BIOL, V171, P259, DOI 10.1007/BF00577724; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fukano Y, 1997, APPL ENVIRON MICROB, V63, P1861, DOI 10.1128/AEM.63.5.1861-1865.1997; GIERER A, 1974, SCI AM, V231, P44, DOI 10.1038/scientificamerican1274-44; Grens A, 1995, DEVELOPMENT, V121, P4027; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HORI T, 1983, J BIOL CHEM, V258, P2239; Horibata Y, 2000, J BIOL CHEM, V275, P31297, DOI 10.1074/jbc.M003575200; ITO M, 1989, J BIOL CHEM, V264, P9510; Ito M, 1996, J BIOL CHEM, V271, P12655, DOI 10.1074/jbc.271.21.12655; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; Kolter T, 1999, ANGEW CHEM INT EDIT, V38, P1532, DOI 10.1002/(SICI)1521-3773(19990601)38:11<1532::AID-ANIE1532>3.0.CO;2-U; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUBO H, 1992, J BIOCHEM-TOKYO, V111, P726, DOI 10.1093/oxfordjournals.jbchem.a123826; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LI YT, 1987, BIOCHEM BIOPH RES CO, V149, P167, DOI 10.1016/0006-291X(87)91619-6; MATSUBARA T, 1981, J BIOCHEM-TOKYO, V89, P645, DOI 10.1093/oxfordjournals.jbchem.a133241; Mitsutake S, 1998, J BIOCHEM-TOKYO, V123, P859; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V187, P113, DOI 10.1016/0005-2760(69)90138-6; Sakaguchi K, 2000, J BIOCHEM-TOKYO, V128, P145, DOI 10.1093/oxfordjournals.jbchem.a022725; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P881, DOI 10.1093/oxfordjournals.jbchem.a134002; SUGIYAMA T, 1977, DEV GROWTH DIFFER, V19, P187; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG QP, 1993, J BIOL CHEM, V268, P14096; YAMAKAWA T, 1964, JPN J EXP MED, V34, P37; YAMAKAWA T, 1964, JPN J EXP MED, V34, P361; ZHOU B, 1989, J BIOL CHEM, V264, P12272	39	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 6	2004	279	32					33379	33389		10.1074/jbc.M401460200	http://dx.doi.org/10.1074/jbc.M401460200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	842YD	15320336	hybrid			2022-12-25	WOS:000223039700045
J	Ilani, T; Strous, RD; Fuchs, S				Ilani, T; Strous, RD; Fuchs, S			Dopaminergic regulation of immune cells via D-3 dopamine receptor: a pathway mediated by activated T cells	FASEB JOURNAL			English	Article						blood brain barrier; CNS; cytokines; neurotransmitter; schizophrenia	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CD4+AND CD8+T CELLS; IN-VITRO; SCHIZOPHRENIC-PATIENTS; LYMPHOCYTE FUNCTION; PARKINSONS-DISEASE; CYTOKINE PROFILES; BLOOD-LYMPHOCYTES; MESSENGER-RNA	Neuro-immune interactions enable mutual regulation of the nervous and immune systems. To date, evidence exists for manipulations of immune cells by neurotransmitters in the periphery. In this study, we suggest the existence of a pathway by which the brain affects immune cells. The pathway we describe here is mediated by dopamine receptors expressed on activated T cells, termed blasts. Blasts can cross the blood brain barrier regardless of antigen specificity and can therefore encounter neurotransmitters in the brain. We show that blasts have a unique response to dopaminergic activation, which has no counterpart in resting T cells. Dopaminergic activation of blasts induces a Th1 bias in their cytokine profile and causes changes in surface marker expression. We further suggest that these changes can subsequently be transferred to peripheral T cells. We have tested this pathway in two in vivo systems: in rats exogenously administered with L-dopa, and in schizophrenia, which is characterized by a central nervous system-restricted increase in dopamine. In both models, peripheral T cells exhibit similar features to those of dopaminergically activated blasts. The existence of such a pathway by which the brain can regulate immune cells opens a conceptually new direction in neuro-immune interactions.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Fac Med, Beer Yaakov Mental Hlth Ctr, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il		Ilani, Tal/0000-0003-2806-4455				Aloisi F, 2001, ANN MED, V33, P510, DOI 10.3109/07853890108995960; Amenta F, 2002, CELL MOL BIOL, V48, P415; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Basu S, 2000, J NEUROIMMUNOL, V102, P113, DOI 10.1016/S0165-5728(99)00176-9; BERGQUIST J, 1994, P NATL ACAD SCI USA, V91, P12912, DOI 10.1073/pnas.91.26.12912; Carlsson A, 1999, BIOL PSYCHIAT, V46, P1388, DOI 10.1016/S0006-3223(99)00117-1; Cazzullo CL, 2002, PROG NEURO-PSYCHOPH, V26, P33, DOI 10.1016/S0278-5846(01)00221-4; Cazzullo CL, 2001, SCHIZOPHR RES, V47, P293, DOI 10.1016/S0920-9964(00)00046-3; COOKMILLS JM, 1995, IMMUNOLOGY, V85, P544; CUCHE JL, 1990, J LAB CLIN MED, V116, P681; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Ghosh MC, 2003, INT IMMUNOPHARMACOL, V3, P1019, DOI 10.1016/S1567-5769(03)00100-0; Goldstein DS, 2003, J PHARMACOL EXP THER, V305, P800, DOI 10.1124/jpet.103.049270; GUY W, 1976, US DHEW PUBLICATION, V76, P338; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Ilani T, 2002, CELL MOL NEUROBIOL, V22, P47, DOI 10.1023/A:1015341712166; Kivisakk P, 2002, CLIN EXP IMMUNOL, V129, P510, DOI 10.1046/j.1365-2249.2002.01947.x; KOPIN IJ, 1985, PHARMACOL REV, V37, P333; Krakowski ML, 1997, EUR J IMMUNOL, V27, P2840, DOI 10.1002/eji.1830271115; Krakowski ML, 2000, EUR J IMMUNOL, V30, P1002, DOI 10.1002/(SICI)1521-4141(200004)30:4<1002::AID-IMMU1002>3.0.CO;2-2; Lehmann PV, 1998, AM J PATHOL, V153, P677, DOI 10.1016/S0002-9440(10)65609-X; Levine D, 2001, Top Magn Reson Imaging, V12, P25, DOI 10.1097/00002142-200102000-00004; Levite M, 2001, EUR J IMMUNOL, V31, P3504, DOI 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F; Levite M, 2000, ANN NY ACAD SCI, V917, P307; Mizruchin A, 1999, J NEUROIMMUNOL, V101, P201, DOI 10.1016/S0165-5728(99)00144-7; MORIKAWA K, 1994, CLIN EXP IMMUNOL, V95, P514; Nagai Y, 1996, NEUROLOGY, V46, P791, DOI 10.1212/WNL.46.3.791; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Owens T, 1998, RES IMMUNOL, V149, P781, DOI 10.1016/S0923-2494(99)80005-4; Picconi B, 2002, BRAIN, V125, P2635, DOI 10.1093/brain/awf269; Ricci A, 1998, J NEUROIMMUNOL, V92, P191, DOI 10.1016/S0165-5728(98)00207-0; Ricci A, 1999, J NEUROIMMUNOL, V96, P234, DOI 10.1016/S0165-5728(99)00042-9; Saha B, 2001, INT IMMUNOPHARMACOL, V1, P1363, DOI 10.1016/S1567-5769(01)00068-6; Saha B, 2001, NEUROIMMUNOMODULAT, V9, P23, DOI 10.1159/000049004; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHMIED M, 1993, AM J PATHOL, V143, P446; Steinman L, 1996, P NATL ACAD SCI USA, V93, P2253, DOI 10.1073/pnas.93.6.2253; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Theodoropoulou S, 2001, SCHIZOPHR RES, V47, P13, DOI 10.1016/S0920-9964(00)00007-4; Vajkoczy P, 2001, J CLIN INVEST, V108, P557; Wandinger KP, 1999, J NEUROIMMUNOL, V98, P214, DOI 10.1016/S0165-5728(99)00093-4; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; Zangen A, 2001, PSYCHOPHARMACOLOGY, V155, P434, DOI 10.1007/s002130100746	46	76	85	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11								10.1096/fj.04-1652fje	http://dx.doi.org/10.1096/fj.04-1652fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319371				2022-12-25	WOS:000223554900006
J	Townsend, PA; Scarabelli, TM; Pasini, E; Gitti, G; Menegazzi, M; Suzuki, H; Knight, RA; Latchman, DS; Stephanou, A				Townsend, PA; Scarabelli, TM; Pasini, E; Gitti, G; Menegazzi, M; Suzuki, H; Knight, RA; Latchman, DS; Stephanou, A			Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis	FASEB JOURNAL			English	Article						myocardial infarction; cardioprotection; transcription factor; heart	ENDOTHELIAL-CELLS; ISCHEMIA; TRANSCRIPTION; KINASE; EXPRESSION; INDUCTION	We have previously demonstrated that STAT-1 plays a critical role in promoting apoptotic cell death in cardiac myocytes following ischemia/reperfusion (I/R) injury. Epigallocatechin-3-gallate ( EGCG), the major constituent of green tea, has recently been reported to inhibit STAT-1 activity in noncardiac cells. In the present study, we have assessed the protective effects of EGCG and green tea extract (GTE) infusion on both cultures of cardiac myocytes and the isolated rat heart. EGCG reduced STAT-1 phosphorylation and protected cardiac myocytes against I/R-induced apoptotic cell death. Moreover, EGCG reduced the expression of a known STAT-1 pro-apoptotic target gene, Fas receptor. More interestingly, oral administration of GTE as well as EGCG infusion limited the extent of infarct size and attenuated the magnitude of myocyte apoptosis in the isolated rat heart exposed to I/R injury. This reduction cell death was associated with improved hemodynamic recovery and ventricular function in the ischemic/reperfused rat heart. This is the first report to show that consumption of green tea is able to mediate cardioprotection and enhance cardiac function during I/R injury. Because GTE-mediated cardioprotection is achieved, at least in part, through inhibition of STAT-1 activity, we may postulate that a similar action can be implemented in the clinical setting to minimize STAT-1 activation levels in patients with acute coronary artery disease (CAD).	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; St John Hosp & Med Ctr, Div Cardiol, Detroit, MI USA; Univ Verona, Dept Neurosci, Biochem Sect, I-37134 Verona, Italy	University of London; University College London; St. John Hospital & Medical Center; University of Verona	Townsend, PA (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.stephanou@ich.ucl.ac.uk	Pasini, Evasio/AAC-1798-2020; Menegazzi, Marta/AAE-7079-2019; Townsend, Paul/AAF-8234-2020	Pasini, Evasio/0000-0003-2836-4490; Menegazzi, Marta/0000-0003-1310-9227; Townsend, Paul/0000-0001-8956-9508				Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Jeremias I, 2000, CIRCULATION, V102, P915; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LEE S, 2002, NEUROSCI LETT, V287, P191; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Menegazzi M, 2001, FASEB J, V15, P1309, DOI 10.1096/fj.00-0519fje; Nagai K, 2002, BRAIN RES, V956, P319, DOI 10.1016/S0006-8993(02)03564-3; Roth E, 1998, Curr Opin Clin Nutr Metab Care, V1, P97; Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com; Scarabelli T, 2001, CIRCULATION, V104, P253, DOI 10.1161/01.CIR.104.3.253; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 2002, EUR CYTOKINE NETW, V13, P401; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2001, CELL DEATH DIFFER, V8, P434, DOI 10.1038/sj.cdd.4400846; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Takagi Y, 2002, J CEREBR BLOOD F MET, V22, P1311, DOI 10.1097/01.WCB.0000034148.72481.F4; Uchida S., 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS302, DOI 10.1111/j.1440-1681.1995.tb02928.x	22	147	160	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1612	+		10.1096/fj.04-1716fje	http://dx.doi.org/10.1096/fj.04-1716fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319365				2022-12-25	WOS:000223554900010
J	Krarup, A; Thiel, S; Hansen, A; Fujita, T; Jensenius, JC				Krarup, A; Thiel, S; Hansen, A; Fujita, T; Jensenius, JC			L-ficolin is a pattern recognition molecule specific for acetyl groups	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNAN-BINDING LECTIN; FIBRINOGEN-LIKE DOMAIN; HORSESHOE-CRAB LECTIN; HAKATA ANTIGEN; AEROCOCCUS-VIRIDANS; COMPLEMENT PATHWAY; SERINE-PROTEASE; INNATE IMMUNITY; BACTERIAL LIPOPOLYSACCHARIDES; RECURRENT MISCARRIAGE	L-ficolin and H-ficolin are molecules of the innate immune system. Upon recognition of a suitable target they activate the complement system. The ligand recognition structure of ficolins is contained within a fibrinogen-like domain. We examined the selectivity of the ficolins through inhibiting the binding to bacteria or to beads coupled with N-acetylglucosamine. The binding of L-ficolin to Streptococcus pneumoniae 11F and the beads was inhibited by N-acetylated sugars and not by non-acetylated sugars. However, it was also inhibited by other acetylated compounds. Based on this selectivity L-ficolin is not easily defined as a lectin. The binding of H-ficolin to Aerococcus viridans was not inhibited by any of the sugars or other compounds examined. Based on the selectivity of L-ficolin we developed a new purification procedure involving affinity chromatography on N-acetylcysteine-derivatized Sepharose. The column was loaded in the presence of EDTA and high salt, and L-ficolin was eluted by decreasing the salt concentration. Further purification was achieved by ion exchange chromatography.	Aarhus Univ, Inst Med Microbiol & Immunol, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark; Fukushima Med Univ, Fukushima 9601250, Japan	Aarhus University; Fukushima Medical University	Thiel, S (corresponding author), Aarhus Univ, Inst Med Microbiol & Immunol, Dept Med Microbiol & Immunol, Bartholin Bldg, DK-8000 Aarhus, Denmark.	st@microbiology.au.dk		Thiel, Steffen/0000-0002-4817-155X				Akaiwa M, 1999, J HISTOCHEM CYTOCHEM, V47, P777, DOI 10.1177/002215549904700607; Christiansen OB, 1999, SCAND J IMMUNOL, V49, P193; Cseh S, 2002, J IMMUNOL, V169, P5735, DOI 10.4049/jimmunol.169.10.5735; Dagnaes-Hansen F, 2004, LAB ANIM-UK, V38, P321, DOI 10.1258/002367704323133718; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Endo Y, 1996, GENOMICS, V36, P515, DOI 10.1006/geno.1996.0497; Gaboriaud C, 2004, MOL IMMUNOL, V41, P231; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; HAURUM JS, 1993, BIOCHEM J, V293, P873, DOI 10.1042/bj2930873; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; Inamori K, 1999, J BIOL CHEM, V274, P3272, DOI 10.1074/jbc.274.6.3272; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kawabata S, 2002, BBA-GEN SUBJECTS, V1572, P414, DOI 10.1016/S0304-4165(02)00322-7; Kilpatrick DC, 1999, IMMUNOL LETT, V67, P109, DOI 10.1016/S0165-2478(98)00147-3; Le Y, 1998, FEBS LETT, V425, P367, DOI 10.1016/S0014-5793(98)00267-1; Le Y, 1997, J IMMUNOL METHODS, V204, P43, DOI 10.1016/S0022-1759(97)00029-X; Lu JH, 1998, IMMUNOBIOLOGY, V199, P190, DOI 10.1016/S0171-2985(98)80026-0; Lynch NJ, 2004, J IMMUNOL, V172, P1198, DOI 10.4049/jimmunol.172.2.1198; Ma YG, 2004, J BIOL CHEM, V279, P25307, DOI 10.1074/jbc.M400701200; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; Matsushita M, 2001, INT IMMUNOPHARMACOL, V1, P359, DOI 10.1016/S1567-5769(00)00045-X; Matsushita M, 2000, J IMMUNOL, V164, P2281, DOI 10.4049/jimmunol.164.5.2281; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 2002, J IMMUNOL, V168, P3502, DOI 10.4049/jimmunol.168.7.3502; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Moller-Kristensen M, 2003, J IMMUNOL METHODS, V282, P159, DOI 10.1016/j.jim.2003.08.012; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Okino N, 1995, J BIOL CHEM, V270, P31008, DOI 10.1074/jbc.270.52.31008; Pineda AO, 2004, J BIOL CHEM, V279, P31842, DOI 10.1074/jbc.M401756200; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; SAITO T, 1995, J BIOL CHEM, V270, P14493, DOI 10.1074/jbc.270.24.14493; Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721; Taira S, 2000, Fukushima J Med Sci, V46, P13; Taylor ME, 2003, METHOD ENZYMOL, V363, P3; Terai I, 1997, CLIN EXP IMMUNOL, V110, P317; Thiel S, 2000, J IMMUNOL, V165, P878, DOI 10.4049/jimmunol.165.2.878; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; Tsujimura M, 2002, CLIN CHIM ACTA, V325, P139, DOI 10.1016/S0009-8981(02)00274-7; Tsujimura M, 2001, CLIN DIAGN LAB IMMUN, V8, P454, DOI 10.1128/CDLI.8.2.454-459.2001; Vorup-Jensen T, 2001, INT IMMUNOPHARMACOL, V1, P677, DOI 10.1016/S1567-5769(00)00052-7; WILLIAMS DF, 1992, J ENTOMOL SCI, V27, P29, DOI 10.18474/0749-8004-27.1.29; YAE Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P369, DOI 10.1016/0167-4838(91)90158-V	42	152	163	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47513	47519		10.1074/jbc.M407161200	http://dx.doi.org/10.1074/jbc.M407161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15331601	hybrid			2022-12-25	WOS:000224957000014
J	Kristelly, R; Gao, G; Tesmer, JJG				Kristelly, R; Gao, G; Tesmer, JJG			Structural determinants of RhoA binding and nucleotide exchange in leukemia-associated Rho guanine-nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; EF-TS COMPLEX; CRYSTAL-STRUCTURE; P115 RHOGEF; DH/PH DOMAINS; PRODUCT P21; PH DOMAINS; G-PROTEINS; ACTIVATION; DBL	Rho guanine-nucleotide exchange factors (RhoGEFs) activate Rho GTPases, and thereby regulate cytoskeletal structure, gene transcription, and cell migration. Leukemia-associated RhoGEF ( LARG) belongs to a small subfamily of RhoGEFs that are RhoA-selective and directly activated by the Galpha(12/13) family of heterotrimeric G proteins. Herein we describe the atomic structures of the catalytic Dbl homology (DH) and pleckstrin homology (PH) domains of LARG alone and in complex with RhoA. These structures demonstrate that the DH/PH domains of LARG can undergo a dramatic conformational change upon binding RhoA, wherein both the DH and PH domains directly engage RhoA. Through mutational analysis we show that full nucleotide exchange activity requires a novel N-terminal extension on the DH domain that is predicted to exist in a broader family of RhoGEFs that includes p115-RhoGEF, Lbc, Lfc, Net1, and Xpln, and identify regions within the LARG PH domain that contribute to its ability to facilitate nucleotide exchange in vitro. In crystals of the DH/PH-RhoA complex, the active site of RhoA adopts two distinct GDP-excluding conformations among the four unique complexes in the asymmetric unit. Similar changes were previously observed in structures of nucleotide-free Ras and Ef-Tu. A potential protein-docking site on the LARG PH domain is also evident and appears to be conserved throughout the Lbc subfamily of RhoGEFs.	Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Tesmer, JJG (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Dept Chem & Biochem, 1 Univ Stn A5300, Austin, TX 78712 USA.	tesmer@mail.utexas.edu		Tesmer, John/0000-0003-1125-3727	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Bellanger JM, 2003, BIOL CELL, V95, P625, DOI 10.1016/j.biolcel.2003.10.002; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fuentes EJ, 2003, J BIOL CHEM, V278, P21188, DOI 10.1074/jbc.M211792200; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hayashi I, 2003, J BIOL CHEM, V278, P36430, DOI 10.1074/jbc.M305773200; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karnoub AE, 2001, NAT STRUCT BIOL, V8, P1037, DOI 10.1038/nsb719; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kristelly R, 2003, ACTA CRYSTALLOGR D, V59, P1859, DOI 10.1107/S0907444903018067; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Pruitt WM, 2003, BBA-MOL CELL RES, V1640, P61, DOI 10.1016/S0167-4889(03)00002-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2003, J BIOL CHEM, V278, P18393, DOI 10.1074/jbc.M300127200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; Skowronek KR, 2004, J BIOL CHEM, V279, P37895, DOI 10.1074/jbc.M312677200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Suzuki N, 2003, P NATL ACAD SCI USA, V100, P733, DOI 10.1073/pnas.0234057100; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Whitehead IP, 2001, ONCOGENE, V20, P1547, DOI 10.1038/sj.onc.1204188; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Worthylake DK, 2004, STRUCTURE, V12, P1079, DOI 10.1016/j.str.2004.03.021; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	53	110	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47352	47362		10.1074/jbc.M406056200	http://dx.doi.org/10.1074/jbc.M406056200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331592	hybrid			2022-12-25	WOS:000224832400124
J	Liang, W; Fishman, PH				Liang, W; Fishman, PH			Resistance of the human beta(1)-adrenergic receptor to agonist-induced ubiquitination - A mechanism for impaired receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA-ADRENERGIC-RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; DOWN-REGULATION; PROMOTED UBIQUITINATION; MEMBRANE TRAFFICKING; OPIOID RECEPTORS; ARRESTIN; INTERNALIZATION	Down-regulation is a classic response of most G protein-coupled receptors to prolonged agonist stimulation. We recently showed that when expressed in baby hamster kidney cells, the human beta(1)-but not the beta(2)-adrenergic receptor (AR) is totally resistant to agonist-mediated down-regulation, whereas both have similar rates of basal degradation (Liang, W., Austin, S., Hoang, Q., and Fishman, P. H. (2003) J. Biol. Chem. 278, 39773-39781). To identify the underlying mechanism(s) for this resistance, we investigated the role of proteasomes, lysosomes, and ubiquitination in the degradation of beta(1)AR expressed in baby hamster kidney and human embryonic kidney 293 cells. Both lysosomal and proteasomal inhibitors reduced beta(1)AR degradation in agonist-stimulated cells but were less effective on basal degradation. To determine whether beta(1)AR trafficked to lysosomes we used confocal fluorescence microscopy. We observed some colocalization of beta(1)AR and lysosomal markers in agonist-treated cells but much less than that of beta(2)AR even in cells co-transfected with arrestin-2, which increases beta(1)AR internalization. Ubiquitination of beta(2)AR readily occurred in agonist-stimulated cells, whereas ubiquitination of beta(1)AR was not detectable even under conditions optimal for that of beta(2)AR. Moreover, in cells expressing betaAR chimeras in which the C termini have been switched, the chimeric beta(1)AR with beta(2)AR C-tail underwent ubiquitination and down-regulation, but the chimeric beta(2)AR with beta(1)AR C-tail did not. Our results demonstrate for the first time that beta(1)AR and beta(2)AR differ in the ability to be ubiquitinated. Because ubiquitin serves as a signal for sorting membrane receptors to lysosomes, the lack of agonist-mediated ubiquitination of beta(1)AR may prevent its extensive trafficking to lysosomes and, thus, account for its resistance to down-regulation.	NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Fishman, PH (corresponding author), NINDS, Membrane Biochem Sect, Mol & Cellular Neurobiol Lab, NIH, Bldg 49,Rm 2A28,49 Convent Dr,MSC4440, Bethesda, MD 20892 USA.	fishmanp@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002366] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; Donati RJ, 2003, LIFE SCI, V73, P1, DOI 10.1016/S0024-3205(03)00249-2; Dunigan CD, 2000, METH MOL B, V136, P329; Dunigan CD, 2002, BIOCHEMISTRY-US, V41, P8019, DOI 10.1021/bi025538r; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Liang W, 2004, J CELL SCI, V117, P723, DOI 10.1242/jcs.00878; Liang W, 2003, J BIOL CHEM, V278, P39773, DOI 10.1074/jbc.M304482200; MAHAN LC, 1987, ANNU REV PHARMACOL, V27, P215; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Martin NP, 2003, J BIOL CHEM, V278, P45954, DOI 10.1074/jbc.M308285200; McLean AJ, 2000, BRIT J PHARMACOL, V130, P1825, DOI 10.1038/sj.bjp.0703506; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Port JD, 2001, J MOL CELL CARDIOL, V33, P887, DOI 10.1006/jmcc.2001.1358; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tanowitz M, 2003, J BIOL CHEM, V278, P45978, DOI 10.1074/jbc.M304504200; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; von Zastrow M, 2003, LIFE SCI, V74, P217, DOI 10.1016/j.lfs.2003.09.008; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; ZHOU XM, 1995, CELL SIGNAL, V7, P207, DOI 10.1016/0898-6568(94)00091-O	41	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46882	46889		10.1074/jbc.M406501200	http://dx.doi.org/10.1074/jbc.M406501200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331590	hybrid			2022-12-25	WOS:000224832400070
J	Mittal, V; Linder, ME				Mittal, V; Linder, ME			The RGS14 GoLoco domain discriminates among G alpha(i) isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; DISSOCIATION INHIBITOR ACTIVITY; GTPASE-ACTIVATING PROTEINS; GUANINE-NUCLEOTIDE BINDING; HETEROTRIMERIC G-PROTEINS; GI-ALPHA; SIGNALING PATHWAYS; MOLECULAR-CLONING; ESCHERICHIA-COLI; EXCHANGE FACTOR	Regulators of G protein signaling (RGS) modulate G protein activity by functioning as GTPase-activating proteins (GAPs) for alpha-subunits of heterotrimeric G proteins. RGS14 regulates G protein nucleotide exchange and hydrolysis by acting as a GAP through its RGS domain and as a guanine nucleotide dissociation inhibitor (GDI) through its GoLoco motif. RGS14 exerts GDI activity on Galpha(i1), but not Galpha(0). Selective interactions are mediated by contacts between the alphaA and alphaB helices of the Galpha(i1) helical domain and the GoLoco C terminus (Kimple, R. J., Kimple, M. E., Betts, L., Sondek, J., and Siderovski, D. P. (2002) Nature 416, 878-881). Three isoforms of Galpha(i) exist in mammalian cells. In this study, we tested whether all three isoforms were subject to RGS14 GDI activity. We found that RGS14 inhibits guanine nucleotide exchange on Galpha(i1) and Galpha(i3), but not Galpha(i2). Galpha(i2) could be rendered sensitive to RGS14 GDI activity by replacement of residues within the alpha-helical domain. In addition to the contact residues in the alphaA and alphaB helices previously identified, we found that the alphaA/alphaB and alphaB/alphaC loops are important determinants of Galpha(i) selectivity. The striking selectivity observed for RGS14 GDI activity in vitro points to Galpha(i1) and Galpha(i3) as the likely targets of RGS14-GoLoco regulation in vivo.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Linder, ME (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave,Campus Box 8228, St Louis, MO 63110 USA.		Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712				Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bowers MS, 2004, NEURON, V42, P269, DOI 10.1016/S0896-6273(04)00159-X; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Granderath S, 1999, DEVELOPMENT, V126, P1781; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Ivanina T, 2004, J BIOL CHEM, V279, P17260, DOI 10.1074/jbc.M313425200; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kimple RJ, 2004, BIOCHEM J, V378, P801, DOI 10.1042/BJ20031686; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Ma HZ, 2003, BIOCHEMISTRY-US, V42, P8085, DOI 10.1021/bi034561p; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Pineda VV, 2004, NEURON, V41, P153, DOI 10.1016/S0896-6273(03)00813-4; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Remmers AE, 1999, BIOCHEMISTRY-US, V38, P13795, DOI 10.1021/bi990887f; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sambrook J., 2002, MOL CLONING LAB MANU; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Skiba NP, 1999, J BIOL CHEM, V274, P8770, DOI 10.1074/jbc.274.13.8770; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Traver S, 2004, BIOCHEM J, V379, P627, DOI 10.1042/BJ20031889; Wettschureck N, 2004, PHARMACOL THERAPEUT, V101, P75, DOI 10.1016/j.pharmthera.2003.10.005; Willard FS, 2004, ANNU REV BIOCHEM, V73, P925, DOI 10.1146/annurev.biochem.73.011303.073756; Yu FW, 2002, MOL CELL BIOL, V22, P4230, DOI 10.1128/MCB.22.12.4230-4240.2002	46	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46772	46778		10.1074/jbc.M407409200	http://dx.doi.org/10.1074/jbc.M407409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337739	hybrid			2022-12-25	WOS:000224832400056
J	Ambasta, RK; Kumar, P; Griendling, KK; Schmidt, HHHW; Busse, R; Brandes, RP				Ambasta, RK; Kumar, P; Griendling, KK; Schmidt, HHHW; Busse, R; Brandes, RP			Direct interaction of the novel nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; RESONANCE ENERGY-TRANSFER; NAD(P)H OXIDASE; FLAVOCYTOCHROME B(558); IN-VITRO; CYTOCHROME B(558); MAGNETIC FORCE; GENE DELIVERY; SUPEROXIDE; ACTIVATION	Nox1 and Nox4, homologues of the leukocyte NADPH oxidase subunit Nox2 (gp91phox) mediate superoxide anion formation in various cell types. However, their interactions with other components of the NADPH oxidase are poorly defined. We determined whether a direct interaction of Nox1 and Nox4 with the p22phox subunit of the NADPH oxidase occurs. Using confocal microscopy, co-localization of p22phox with Nox1, Nox2, and Nox4 was observed in transiently transfected vascular smooth muscle cells (VSMC) and HEK293 cells. Plasmids coding for fluorescent fusion proteins of p22phox and the Nox proteins with cyan- and yellow-fluorescent protein (cfp and yfp, respectively) were constructed and expressed in VSMC and HEK293 cells. The cfp-tagged p22phox expression level increased upon co-transfection with Nox1 or Nox4. Protein-protein interaction between the fluorescent fusion proteins of p22phox and the Nox partners was observed using the fluorescence resonance energy transfer technique. Immunoprecipitation of native Nox1 from human VSMC revealed co-precipitation of p22phox. Immunoprecipitation from transfected HEK293 cells revealed co-precipitation of native p22phox with yfp-tagged Nox1, Nox2, and Nox4. Following mutation of a histidine (corresponding to the position 115 in human Nox2) to leucine, this interaction was abolished. Transfection of rat p22phox ( but not Noxo1 and Noxa1) increased the radical generation in cells expressing Nox4. We provide evidence that p22phox directly interacts with Nox1 and Nox4, to form an superoxide-generating NADPH oxidase and demonstrate that mutation of the potential heme binding site in the Nox proteins disrupts the complex formation of Nox1 and Nox4 with p22phox.	Univ Frankfurt Klinikum, Inst Kardiovaskulare Physiol, D-60596 Frankfurt, Germany; Emory Univ, Div Cardiol, Atlanta, GA 30322 USA; Univ Giessen, Rudolf Buchheim Inst Pharmakol, D-35392 Giessen, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Emory University; Justus Liebig University Giessen	Brandes, RP (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovaskulare Physiol, Theodor Stern Kai 7, D-60596 Frankfurt, Germany.	r.brandes@em.uni-frankfurt.de	Kumar, Pravir/AAR-1207-2020; Kumar, Pravir/B-2164-2015; Brandes, Ralf P/L-3058-2017; Ambasta, Rashmi/K-8611-2019; Schmidt, Harald HHW/B-1549-2008	Kumar, Pravir/0000-0001-7444-2344; Brandes, Ralf P/0000-0002-8035-0048; Schmidt, Harald HHW/0000-0003-0419-5549; Griendling, Kathy/0000-0002-9456-8582				Ago T, 2004, CIRCULATION, V109, P227, DOI 10.1161/01.CIR.0000105680.92873.70; Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Badorff C, 2000, J BIOL CHEM, V275, P11191, DOI 10.1074/jbc.275.15.11191; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; Burritt JB, 2001, J BIOL CHEM, V276, P2053, DOI 10.1074/jbc.M006236200; Cheng GJ, 2004, J BIOL CHEM, V279, P4737, DOI 10.1074/jbc.M305968200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorin Y, 2003, AM J PHYSIOL-RENAL, V285, pF219, DOI 10.1152/ajprenal.00414.2002; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; Lassegue B, 2003, AM J PHYSIOL-REG I, V285, pR277, DOI 10.1152/ajpregu.00758.2002; Mahadev K, 2004, MOL CELL BIOL, V24, P1844, DOI 10.1128/MCB.24.5.1844-1854.2004; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Paclet MH, 2000, BIOCHEMISTRY-US, V39, P9302, DOI 10.1021/bi000483j; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Plank C, 2003, BIOL CHEM, V384, P737, DOI 10.1515/BC.2003.082; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj.gt.3301624; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Vignais PV, 2002, CELL MOL LIFE SCI, V59, P1428, DOI 10.1007/s00018-002-8520-9; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Wingler M, 2001, FREE RADICAL BIO MED, V31, P1456, DOI 10.1016/S0891-5849(01)00727-4; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; Yamauchi A, 2001, MICROBIOL IMMUNOL, V45, P249, DOI 10.1111/j.1348-0421.2001.tb02614.x; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	37	425	433	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45935	45941		10.1074/jbc.M406486200	http://dx.doi.org/10.1074/jbc.M406486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322091	hybrid			2022-12-25	WOS:000224694900078
J	Demma, MJ; Wong, S; Maxwell, E; Dasmahapatra, B				Demma, MJ; Wong, S; Maxwell, E; Dasmahapatra, B			CP-31398 restores DNA-binding activity to mutant p53 in vitro but does not affect p53 homologs p63 and p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION ACTIVATION FUNCTION; CORE DOMAIN; WILD-TYPE; CRYSTAL-STRUCTURE; CANCER-CELLS; RESCUE; APOPTOSIS; PEPTIDE; DRUG; CONFORMATION	The p53 protein plays a major role in the maintenance of genome stability in mammalian cells. Mutations of p53 occur in over 50% of all cancers and are indicative of highly aggressive cancers that are hard to treat. Recently, there has been a high degree of interest in therapeutic approaches to restore growth suppression functions to mutant p53. Several compounds have been reported to restore wild type function to mutant p53. One such compound, CP-31398, has been shown effective in vivo, but questions have arisen to whether it actually affects p53. Here we show that mutant p53, isolated from cells treated with CP-31398, is capable of binding to p53 response elements in vitro. We also show the compound restores DNA-binding activity to mutant p53 in cells as determined by a chromatin immunoprecipitation assay. In addition, using purified p53 core domain from two different hotspot mutants (R273H and R249S), we show that CP-31398 can restore DNA-binding activity in a dose-dependent manner. Using a quantitative DNA binding assay, we also show that CP-31398 increases significantly the amount of mutant p53 that binds to cognate DNA (B-max) and its affinity (K-d) for DNA. The compound, however, does not affect the affinity (K-d value) of wild type p53 for DNA and only increases Bmax slightly. In a similar assay PRIMA1 does not have any effect on p53 core DNA-binding activity. We also show that CP-31398 had no effect on the DNA-binding activity of p53 homologs p63 and p73.	Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Dasmahapatra, B (corresponding author), Schering Plough Corp, Res Inst, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	bimalendu.dasmahapatra@spcorp.com						ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Friedler A, 2003, J BIOL CHEM, V278, P24108, DOI 10.1074/jbc.M302458200; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Joerger AC, 2004, J BIOL CHEM, V279, P1291, DOI 10.1074/jbc.M309732200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lane DR, 2003, DRUG DISCOV TODAY, V8, P347, DOI 10.1016/S1359-6446(03)02669-2; Luu Y, 2002, EXP CELL RES, V276, P214, DOI 10.1006/excr.2002.5526; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; SIEGAL IH, 1993, ENZYME KINETICS, P125; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Willis A. C., 2002, Current Molecular Medicine (Hilversum), V2, P329, DOI 10.2174/1566524023362474; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8348	38	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45887	45896		10.1074/jbc.M401854200	http://dx.doi.org/10.1074/jbc.M401854200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308639	hybrid			2022-12-25	WOS:000224694900073
J	Harper, CV; Barratt, CLR; Publicover, SJ				Harper, CV; Barratt, CLR; Publicover, SJ			Stimulation of human spermatozoa with progesterone gradients to simulate approach to the oocyte - Induction of [Ca2+](i) oscillations and cyclical transitions in flagellar beating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM STORE; INDUCED ACROSOME REACTION; HUMAN-SPERM; ZONA-PELLUCIDA; CA2+ ENTRY; HYPERACTIVATED MOTILITY; HAMSTER SPERM; CUMULUS CELLS; CHANNELS; INFLUX	Progesterone is present at micromolar concentrations in the cumulus matrix, which surrounds mammalian oocytes. Exposure of human spermatozoa to a concentration gradient of progesterone (0-3 muM) to simulate approach to the oocyte induced a slowly developing increase in [Ca2+](i) upon which, in many cells, slow oscillations were superimposed. [Ca2+](i) oscillations often started at very low progesterone (<10 nM), and their frequency did not change during the subsequent rise in concentration. Oscillations also occurred, but in a much smaller proportion of cells, in response to stepped application of progesterone (3 mu M). When progesterone was removed, [Ca2+](i) oscillations often persisted or quickly resumed. Superfusion with low-Ca2+ bathing medium (no added Ca2+) did not prevent [Ca2+](i) oscillations, but they could be abolished by addition of EGTA or La3+. Inhibitors of sarcoplasmic/endoplasmic reticulum Ca2+-ATPases or inositol trisphosphate signaling had no effect on [Ca2+](i) oscillations, but pharmacological manipulation of ryanodine receptors affected both their frequency and amplitude. Staining of live spermatozoa with BODIPY FL-X ryanodine showed localization of ryanodine binding primarily to the caudal part of the head and mid-piece. [Ca2+](i) oscillations did not induce acrosome reaction, but in cells generating oscillations, the flagellar beat mode alternated in synchrony with the oscillation cycle. Flagellar bending and lateral movement of the sperm head during [Ca2+](i) peaks were markedly increased compared with during [Ca2+](i) troughs. This alternating pattern of activity is likely to facilitate zona penetration. These observations show that progesterone initiates unusual and complex store-mediated [Ca2+](i) signaling in human spermatozoa and identify a previously unrecognized effect of progesterone in regulating sperm "behavior" during fertilization.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Reprod Biol & Genet Res Grp, Birmingham B15 2TT, W Midlands, England; Birmingham Maternity Hosp, Assisted Concept Unit, Birmingham B15 2TG, W Midlands, England	University of Birmingham; University of Birmingham	Publicover, SJ (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	s.j.publicover@bham.ac.uk	Publicover, Steve J/E-7970-2018	harper, claire/0000-0001-6228-4078; Barratt, christopher/0000-0003-0062-9979				BAILEY JL, 1994, MOL REPROD DEV, V39, P297, DOI 10.1002/mrd.1080390307; BALDI E, 1991, J ANDROL, V12, P323; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKMORE PF, 1990, J BIOL CHEM, V265, P1376; Buffone MG, 2004, HUM REPROD, V19, P139, DOI 10.1093/humrep/deh040; Carlson AE, 2003, P NATL ACAD SCI USA, V100, P14864, DOI 10.1073/pnas.2536658100; CHIOU CY, 1975, BRIT J PHARMACOL, V53, P279, DOI 10.1111/j.1476-5381.1975.tb07359.x; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; DROBNIS EZ, 1988, DEV BIOL, V130, P311, DOI 10.1016/0012-1606(88)90437-X; FLORMAN HM, 1994, DEV BIOL, V165, P152, DOI 10.1006/dbio.1994.1242; Gregory RB, 2003, BIOCHEM J, V370, P695, DOI 10.1042/BJ20021671; GUERRERO A, 1989, J BIOL CHEM, V264, P19593; Guzman-Grenfell AM, 2004, J ANDROL, V25, P117; Harper CV, 2003, BIOCHEM J, V372, P407, DOI 10.1042/BJ20021560; Hirohashi N, 2003, BIOCHEM BIOPH RES CO, V304, P285, DOI 10.1016/S0006-291X(03)00587-4; Ho HC, 2003, BIOL REPROD, V68, P1590, DOI 10.1095/biolreprod.102.011320; Ho HC, 2002, DEV BIOL, V250, P208, DOI 10.1006/dbio.2002.0797; Ho HC, 2001, BIOL REPROD, V65, P1606, DOI 10.1095/biolreprod65.5.1606; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; JOHNSON LL, 1981, GAMETE RES, V4, P275, DOI 10.1002/mrd.1120040403; Kaupp UB, 2003, NAT CELL BIOL, V5, P109, DOI 10.1038/ncb915; KERR JB, 1991, J ELECTRON MICR TECH, V19, P215, DOI 10.1002/jemt.1060190208; Kirkman-Brown JC, 2000, DEV BIOL, V222, P326, DOI 10.1006/dbio.2000.9729; Kirkman-Brown JC, 2004, BIOCHEM J, V378, P827, DOI 10.1042/BJ20031368; Krausz C, 1996, HUM REPROD, V11, P1661; Kuroda Y, 1999, LIFE SCI, V65, P135, DOI 10.1016/S0024-3205(99)00230-1; Meizel S, 1997, DEV BIOL, V182, P67, DOI 10.1006/dbio.1997.8477; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Mingoti GZ, 2002, ANIM REPROD SCI, V69, P175, DOI 10.1016/S0378-4320(01)00187-7; MORALES P, 1988, J REPROD FERTIL, V83, P119; Mortimer ST, 1995, HUM REPROD, V10, P3178, DOI 10.1093/oxfordjournals.humrep.a135882; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; OSMAN RA, 1989, BIOCHEM BIOPH RES CO, V160, P828, DOI 10.1016/0006-291X(89)92508-4; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; PLANT A, 1995, FERTIL STERIL, V64, P1213, DOI 10.1016/S0015-0282(16)57989-8; Publicover SJ, 1999, HUM REPROD, V14, P873, DOI 10.1093/humrep/14.4.873; Quill TA, 2003, P NATL ACAD SCI USA, V100, P14869, DOI 10.1073/pnas.2136654100; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Rossato M, 2001, MOL HUM REPROD, V7, P119, DOI 10.1093/molehr/7.2.119; Shuttleworth TJ, 2003, BIOCHEM SOC T, V31, P916; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; SUAREZ SS, 1993, P NATL ACAD SCI USA, V90, P4660, DOI 10.1073/pnas.90.10.4660; Suarez SS, 2003, REPROD DOMEST ANIM, V38, P119, DOI 10.1046/j.1439-0531.2003.00397.x; THOMAS P, 1989, BIOCHEM J, V264, P539, DOI 10.1042/bj2640539; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Trevino CL, 1998, ZYGOTE, V6, P159, DOI 10.1017/S0967199498000094; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Westbrook VA, 2001, BIOL REPROD, V64, P345; Williams KM, 2003, INT J ANDROL, V26, P366, DOI 10.1111/j.1365-2605.2003.00438.x; Wood CD, 2003, J CELL BIOL, V161, P89, DOI 10.1083/jcb.200212053; Wuytack F, 2003, PFLUG ARCH EUR J PHY, V446, P148, DOI 10.1007/s00424-003-1011-5; Yamashita Y, 2003, BIOL REPROD, V68, P1193, DOI 10.1095/biolreprod.102.010934	56	146	149	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46315	46325		10.1074/jbc.M401194200	http://dx.doi.org/10.1074/jbc.M401194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322137	hybrid			2022-12-25	WOS:000224694900119
J	Jakel, H; Nowak, M; Moitrot, M; Dehondt, H; Hum, DW; Pennacchio, LA; Fruchart-Najib, J; Fruchart, JC				Jakel, H; Nowak, M; Moitrot, M; Dehondt, H; Hum, DW; Pennacchio, LA; Fruchart-Najib, J; Fruchart, JC			The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PLASMA TRIGLYCERIDE LEVELS; BOUND TRANSCRIPTION FACTOR; APOLIPOPROTEIN A-V; FATTY-ACID; RESPONSE ELEMENT; CULTURED-CELLS; MICE; PROMOTER	Alterations in the expression of the recently discovered apolipoprotein A5 gene strongly affect plasma triglyceride levels. In this study, we investigated the contribution of APOA5 to the liver X receptor (LXR) ligand-mediated effect on plasma triglyceride levels. Following treatment with the LXR ligand T0901317, we found that APOA5 mRNA levels were decreased in hepatoma cell lines. The observation that no down-regulation of APOA5 promoter activity was obtained by LXR-retinoid X receptor (RXR) co-transfection prompted us to explore the possible involvement of the known LXR target gene SREBP-1c (sterol regulatory element-binding protein 1c). In fact, we found that co-transfection with the active form of SREBP-1c down-regulated APOA5 promoter activity in a dose-dependent manner. We then scanned the human APOA5 promoter sequence and identified two putative E-box elements that were able to bind specifically SREBP-1c in gel-shift assays and were shown to be functional by mutation analysis. Subsequent suppression of SREBP-1 mRNA through small interfering RNA interference abolished the decrease of APOA5 mRNA in response to T0901317. Finally, administration of T0901317 to hAPOA5 transgenic mice revealed a significant decrease of APOA5 mRNA in liver tissue and circulating apolipoprotein AV protein in plasma, confirming that the described down-regulation also occurs in vivo. Taken together, our results demonstrate that APOA5 gene expression is regulated by the LXR ligand T0901317 in a negative manner through SREBP-1c. These findings may provide a new mechanism responsible for the elevation of plasma triglyceride levels by LXR ligands and support the development of selective LXR agonists, not affecting SREBP-1c, as beneficial modulators of lipid metabolism.	Inst Pasteur, INSERM, UR545, Dept Atherosclerose, F-59019 Lille, France; Fac Pharm Lille, F-59019 Lille, France; Genfit SA, F-59120 Loos, France; Univ Calif Berkeley, Lawrence Berkeley Lab, Joint Genome Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; United States Department of Energy (DOE); Joint Genome Institute - JGI; Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Fruchart-Najib, J (corresponding author), Inst Pasteur, INSERM, UR545, Dept Atherosclerose, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.	Jamila.Fruchart@genfit.com		Dehondt, Helene/0000-0003-2900-4673; Pennacchio, Len/0000-0002-8748-3732	NHLBI NIH HHS [HL66681, HL071954A] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066681, T32HL007195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Austin MA, 1998, AM J CARDIOL, V81, p7B, DOI 10.1016/S0002-9149(98)00031-9; Barber MC, 2003, BIOCHEM J, V375, P489, DOI 10.1042/BJ20030480; Baum L, 2003, CLIN GENET, V63, P377, DOI 10.1034/j.1399-0004.2003.00063.x; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chakravarty K, 2004, J BIOL CHEM, V279, P15385, DOI 10.1074/jbc.M309905200; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; del Castill-Olivares A, 2002, J BIOL CHEM, V277, P6750, DOI 10.1074/jbc.M106785200; Eichenbaum-Voline S, 2004, ARTERIOSCL THROM VAS, V24, P167, DOI 10.1161/01.ATV.0000099881.83261.D4; Endo K, 2002, HUM GENET, V111, P570, DOI 10.1007/s00439-002-0825-0; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fruchart-Najib J, 2004, BIOCHEM BIOPH RES CO, V319, P397, DOI 10.1016/j.bbrc.2004.05.003; Grefhorst A, 2002, J BIOL CHEM, V277, P34182, DOI 10.1074/jbc.M204887200; Haim M, 1999, CIRCULATION, V100, P475, DOI 10.1161/01.CIR.100.5.475; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kan HY, 1999, NUCLEIC ACIDS RES, V27, P1104, DOI 10.1093/nar/27.4.1104; KARDASSIS D, 1992, J BIOL CHEM, V267, P7956; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Nara TY, 2002, BIOCHEM BIOPH RES CO, V296, P111, DOI 10.1016/S0006-291X(02)00851-3; Norlin M, 2004, BIOCHEM BIOPH RES CO, V316, P158, DOI 10.1016/j.bbrc.2004.02.029; OGAMI K, 1990, J BIOL CHEM, V265, P9808; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Prieur X, 2003, J BIOL CHEM, V278, P25468, DOI 10.1074/jbc.M301302200; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Tobin KAR, 2002, J BIOL CHEM, V277, P10691, DOI 10.1074/jbc.M109771200; Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 2003, J BIOL CHEM, V278, P17982, DOI 10.1074/jbc.M212191200; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YAMAMOTO T, 2004, J BIOL CHEM; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001	54	76	89	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45462	45469		10.1074/jbc.M404744200	http://dx.doi.org/10.1074/jbc.M404744200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15317819	hybrid			2022-12-25	WOS:000224694900023
J	Berchner-Pfannschmidt, U; Petrat, F; Doege, K; Trinidad, B; Freitag, P; Metzen, E; de Groot, H; Fandrey, J				Berchner-Pfannschmidt, U; Petrat, F; Doege, K; Trinidad, B; Freitag, P; Metzen, E; de Groot, H; Fandrey, J			Chelation of cellular calcium modulates hypoxia-inducible gene expression through activation of hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CHELATABLE IRON POOL; UBIQUITIN-PROTEASOME PATHWAY; ENDOTHELIAL-CELLS; FACTOR 1-ALPHA; FACTOR-I; TRANSCRIPTION FACTORS; TYROSINE-HYDROXYLASE; LIVING CELLS; HIF-ALPHA	Hypoxia-Inducible Factor-1 ( HIF-1) is the key transcription factor in control of the expression of hypoxia-inducible genes needed by cells to adapt to decreased oxygen availability. Herein, we investigated the HIF-1alpha-mediated gene expression of carbonic anhydrase 9 (CA9) in response to hypoxia and changes of intracellular calcium levels in the neuroblastoma cell line SH-SY5Y. Decreasing the intracellular calcium level by BAPTA (1,2-bis( 2-aminophenoxy) ethane-N,N,N', N'-tetraacetic acid) induced HIF-1alpha nuclear accumulation and enhanced HIF-1 DNA binding within 1 h of incubation. Like hypoxia, BAPTA stimulated HIF-1-dependent transcription by increasing the activity of the C-terminal transactivation domain of HIF-1alpha and greatly enhanced expression of the HIF-1 target gene CA9. Detailed analysis of HIF-1alpha accumulation revealed that BAPTA attenuated the interaction of HIF-1alpha with von-Hippel-Lindau protein thus decreasing proteasomal degradation of HIF-1alpha. Knock down of HIF-1alpha mRNA and protein by small interference RNA for HIF-1alpha revealed that both hypoxia and the BAPTA-induced gene expression of CA9 were strictly dependent on HIF-1alpha. In contrast, elevation of cytosolic calcium level by thapsigargin reduced the BAPTA-mediated effects. Measurements of intracellular calcium under hypoxia revealed a change in the cellular calcium distribution. BAPTA-dependent induction of HIF-1 activity was not caused by its in vitro capability to chelate iron. Instead, effective chelation of cellular calcium caused the accumulation of HIF-1alpha protein through inhibition of HIF-prolyl hydroxylases and activated HIF-1-dependent gene expression under normoxic conditions.	Univ Duisburg Essen, Inst Physiol, D-45122 Essen, Germany; Univ Duisburg Essen, Inst Physiol Chem, D-45122 Essen, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Lubeck	Fandrey, J (corresponding author), Univ Duisburg Essen, Inst Physiol, Hufelandstr 55, D-45122 Essen, Germany.	joachim.fandrey@uni-essen.de	Fandrey, Joachim/AAA-3524-2021	Fandrey, Joachim/0000-0001-9585-0531				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; ARNOULD T, 1992, J CELL PHYSIOL, V152, P215, DOI 10.1002/jcp.1041520127; Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y; Britigan BE, 1998, BIOCHEM PHARMACOL, V55, P287, DOI 10.1016/S0006-2952(97)00463-2; CHABEREK S, 1959, ORGANIC SEQUESTERING, P511; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; Gu YZ, 1998, GENE EXPRESSION, V7, P205; HAMPL V, 1995, EUR RESPIR J, V8, P515; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kirsch M, 2000, CHEM RES TOXICOL, V13, P451, DOI 10.1021/tx990138z; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; MARTELL AE, 1998, NIST STANDARD REFERE; Masson N, 2003, J CELL SCI, V116, P3041, DOI 10.1242/jcs.00655; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 1999, J PHYSIOL-LONDON, V517, P651, DOI 10.1111/j.1469-7793.1999.0651s.x; Metzen E, 2003, MOL BIOL CELL, V14, P3470, DOI 10.1091/mbc.e02-12-0791; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Millhorn DE, 2000, ADV EXP MED BIOL, V475, P131; Millhorn DE, 1997, KIDNEY INT, V51, P527, DOI 10.1038/ki.1997.73; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; O'sullivan W., 1969, DATA BIOCH RES, P430; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; PENTZ S, 1992, J MICROSC-OXFORD, V167, P97, DOI 10.1111/j.1365-2818.1992.tb03222.x; Petrat F, 1999, HEPATOLOGY, V29, P1171, DOI 10.1002/hep.510290435; Petrat F, 2000, ARCH BIOCHEM BIOPHYS, V376, P74, DOI 10.1006/abbi.2000.1711; Petrat F, 2002, BIOL CHEM, V383, P489, DOI 10.1515/BC.2002.051; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; Pisani A, 2000, J CEREBR BLOOD F MET, V20, P839, DOI 10.1097/00004647-200005000-00011; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Wykoff CC, 2000, CANCER RES, V60, P7075	56	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44976	44986		10.1074/jbc.M313995200	http://dx.doi.org/10.1074/jbc.M313995200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322093	hybrid			2022-12-25	WOS:000224505600089
J	Dai, MS; Lu, H				Dai, MS; Lu, H			Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOPROTEIN MDM2; ACTIVATION DOMAIN; NUCLEAR EXPORT; CELL-CYCLE; PHOSPHORYLATION; UBIQUITYLATION; ACETYLATION; PROMOTES; PATHWAY; SIGNALS	The oncoprotein MDM2 associates with ribosomal proteins L5, L11, and L23. Both L11 and L23 have been shown to activate p53 by inhibiting MDM2-mediated p53 suppression. Here we have shown that L5 also activates p53. Overexpression of L5 stabilized ectopic p53 in H1299 cells and endogenous p53 in U2OS cells. Consequently, L5 enhanced p53 transcriptional activity and induced p53-dependent G(1) cell cycle arrest. Furthermore, like L11 and L23, L5 also remarkably inhibited MDM2-mediated p53 ubiquitination. The interaction of L5 with MDM2 was also enhanced by treatment with a low dose of actinomycin D. Actinomycin D-induced p53 was inhibited by small interference RNA against L5. By reciprocal co-immunoprecipitation, we further showed that there were at least two MDM2-ribosomal protein complexes in cells: MDM2-L5-L11-L23 and p53-MDM2-L5-L11- L23. We propose that the MDM2-L5-L11-L23 complex functions to inhibit MDM2-mediated p53 ubiquitination and thus activates p53.	Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth & Sci Univ, Sch Med, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	luh@ohsu.edu			NCI NIH HHS [CA93614, CA095441, CA079721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095441, R01CA093614, R01CA079721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Claussen M, 1999, J BIOL CHEM, V274, P33951, DOI 10.1074/jbc.274.48.33951; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Matsson H, 2004, MOL CELL BIOL, V24, P4032, DOI 10.1128/MCB.24.9.4032-4037.2004; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Rosorius O, 2000, J BIOL CHEM, V275, P12061, DOI 10.1074/jbc.275.16.12061; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	31	418	426	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44475	44482		10.1074/jbc.M403722200	http://dx.doi.org/10.1074/jbc.M403722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308643	hybrid			2022-12-25	WOS:000224505600031
J	Kurogochi, M; Nishimura, SI; Lee, YC				Kurogochi, M; Nishimura, SI; Lee, YC			Mechanism-based fluorescent labeling of beta-galactosidases - An efficient method in proteomics for glycoside hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; MASS-SPECTROMETRY; PROTEIN IDENTIFICATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DRUG DESIGN; CLASSIFICATION; NEURAMINIDASE; PURIFICATION; NUCLEOPHILE	(4-N-5-Dimethylaminonaphthalene-1-sulfonyl-2-difluoromethylphenyl)-beta-D-galactopyranoside was synthesized and successfully tested on beta-galactosidases from Xanthomonas manihotis (Wong-Madden, S. T., and Landry, D. Glycobiology (1995) 5, 19-28 and Taron, C. H., Benner, J. S., Hornstra, L. J., and Guthrie, E. P. (1995) Glycobiology 5, 603-610), Escherichia coli (Jacobson, R. H., Zhang, X. J., DuBose, R. F., and Matthews, B. W. (1994) Nature 369, 761-766), and Bacillus circulans (Fujimoto, H., Miyasato, M., Ito, Y., Sasaki, T., and Ajisaka, K. (1988) Glycoconj. J. 15, 155-160) for the rapid identification of the catalytic site. Reaction of the irreversible inhibitor with enzymes proceeded to afford a fluorescence-labeled protein suitable for further high throughput characterization by using antidansyl antibody and matrix-assisted laser desorption ionization time-off-light/time-of-flight (MALDI-TOF/TOF). Specific probing by a fluorescent aglycon greatly facilitated identification of the labeled peptide fragments from beta-galactosidases. It was demonstrated by using X. manihotis beta-galactosidase that the Arg-58 residue, which is located within a sequence of (IP)-I-56 (R) under bar AYWKD(63), was labeled by nucleophilic attack of the guanidinyl group. This sequence including Arg-58 (Leu-46 to Tyr-194) was similar to that (Met-1 to Tyr-151) of Thermus thermophilus A4, which is the first known structure of glycoside hydrolases family 42 (Hidaka, M., Fushinobu, S., Ohtsu, N., Motoshima, H., Matsuzawa, H., Shoun, H., and Wakagi, T. (2002) J. Mol. Biol. 322, 79-91). A catalytic glutamic acid (Glu-537) of E. coli beta-galactosidase was proved to be labeled by the same procedure, suggesting that the modification site with this irreversible substrate might depend both on the nucleophilicity of the amino acids and their spatial arrangement in the individual catalytic cavity. Similarly, a Glu-259 in (TL)-T-257 (E) under barE(260) was selectively labeled using B. circulans beta-galactosidase, indicating that Glu-259 is one of the nucleophiles in the active site. The present method can be readily extended to other glycosidases and should greatly aid the high throughput proteomics of many glycoside hydrolases showing both retaining- and inverting-type mechanisms.	Hokkaido Univ, Frontier Res Ctr Postgenom Sci & Technol, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0010021, Japan; Natl Inst Adv Ind Sci & Technol, Sapporo, Hokkaido 0628517, Japan; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Hokkaido University; National Institute of Advanced Industrial Science & Technology (AIST); Johns Hopkins University	Nishimura, SI (corresponding author), Hokkaido Univ, Frontier Res Ctr Postgenom Sci & Technol, Grad Sch Sci, Div Biol Sci, N21,W11, Sapporo, Hokkaido 0010021, Japan.	shin@glyco.sci.hokudai.ac.jp; yclee@jhu.edu	Nishimura, Shinichiro/F-5277-2011					Aguilar CF, 1997, J MOL BIOL, V271, P789, DOI 10.1006/jmbi.1997.1215; Akama TO, 2002, SCIENCE, V295, P124, DOI 10.1126/science.1065570; Babu YS, 2000, J MED CHEM, V43, P3482, DOI 10.1021/jm0002679; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Callahan JW, 1999, BBA-MOL BASIS DIS, V1455, P85, DOI 10.1016/S0925-4439(99)00075-7; Cesaro-Tadic S, 2003, NAT BIOTECHNOL, V21, P679, DOI 10.1038/nbt828; CHEETHAM PSJ, 1976, BIOCHEM J, V157, P189, DOI 10.1042/bj1570189; Dan S, 2000, J BIOL CHEM, V275, P4973, DOI 10.1074/jbc.275.7.4973; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; Fujimoto H, 1998, GLYCOCONJUGATE J, V15, P155, DOI 10.1023/A:1006916222187; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HALAZY S, 1990, BIOORG CHEM, V18, P330, DOI 10.1016/0045-2068(90)90007-R; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Henzel WJ, 2003, J AM SOC MASS SPECTR, V14, P931, DOI 10.1016/S1044-0305(03)00214-9; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Hidaka M, 2002, J MOL BIOL, V322, P79, DOI 10.1016/S0022-2836(02)00746-5; Ichikawa M, 2001, BIOORG MED CHEM LETT, V11, P1769, DOI 10.1016/S0960-894X(01)00300-6; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Janda KD, 1997, SCIENCE, V275, P945, DOI 10.1126/science.275.5302.945; Keough T, 2000, ELECTROPHORESIS, V21, P2252, DOI 10.1002/1522-2683(20000601)21:11<2252::AID-ELPS2252>3.0.CO;2-O; KOBAYASHI T, 1979, J NEUROL, V221, P137, DOI 10.1007/BF00313045; Kurogochi M, 2004, ANGEW CHEM INT EDIT, V43, P4071, DOI 10.1002/anie.200460020; Lapierre L, 2002, J BACTERIOL, V184, P928, DOI 10.1128/jb.184.4.928-935.2002; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; McCarter JD, 1997, J BIOL CHEM, V272, P396; MONTGOMERY RK, 1991, FASEB J, V5, P2824, DOI 10.1096/fasebj.5.13.1916106; MUELLER OT, 1982, HUM GENET, V60, P158, DOI 10.1007/BF00569704; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; Roth J, 2002, HISTOCHEM CELL BIOL, V117, P159, DOI 10.1007/s00418-001-0365-z; Ryttersgaard C, 2002, BIOCHEMISTRY-US, V41, P15135, DOI 10.1021/bi026238c; Schnaible V, 2002, ANAL CHEM, V74, P4980, DOI 10.1021/ac025807j; Sears P, 1998, CELL MOL LIFE SCI, V54, P223, DOI 10.1007/s000180050146; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; TARON CH, 1995, GLYCOBIOLOGY, V5, P603, DOI 10.1093/glycob/5.6.603; TAYLOR G, 1993, NATURE, V363, P401, DOI 10.1038/363401a0; TIPTON KF, 1996, ENZYMOLOGY LABFAX, P151; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WONGMADDEN ST, 1995, GLYCOBIOLOGY, V5, P19, DOI 10.1093/glycob/5.1.19; ZIEGLER Z, 2001, ANAL CHEM, V73, P4063	45	51	52	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44704	44712		10.1074/jbc.M401718200	http://dx.doi.org/10.1074/jbc.M401718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308675	hybrid			2022-12-25	WOS:000224505600058
J	Moyle, WR; Xing, YN; Lin, W; Cao, DH; Myers, RV; Kerrigan, JE; Bernard, MP				Moyle, WR; Xing, YN; Lin, W; Cao, DH; Myers, RV; Kerrigan, JE; Bernard, MP			Model of glycoprotein hormone receptor ligand binding and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LEUCINE-RICH REPEATS; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTOR; CELL-SURFACE RECEPTOR; LUTEINIZING-HORMONE; EXTRACELLULAR DOMAIN; BETA-SUBUNIT; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT	Studies described here were initiated to develop a model of glycoprotein hormone receptor structure and function. We found that the region that links the lutropin receptor leucine-rich repeat domain (LRD) to its transmembrane domain (TMD) has substantial roles in ligand binding and signaling, hence we term it the signaling specificity domain (SSD). Theoretical considerations indicated the short SSDs in marmoset lutropin and salmon follitropin receptors have KH domain folds. We assembled models of lutropin, follitropin, and thyrotropin receptors by aligning models of their LRD, TMD, and shortened SSD in a manner that explains how substitutions in follitropin and thyrotropin receptors distant from their apparent ligand binding sites enable them to recognize lutropins. In these models, the SSD is parallel to the concave surface of the LRD and makes extensive contacts with TMD outer loops 1 and 2. The LRD appears to contact TMD outer loop 3 and a few residues in helices 1, 5, 6, and 7. We propose that signaling results from contacts of the ligands with the SSD and LRD that alter the LRD, which then moves TMD helices 6 and 7. The positions of the LRD and SSD support the notion that the receptor can be activated by hormones that dock with these domains in either of two different orientations. This would account for the abilities of some ligands and ligand chimeras to bind multiple receptors and for some receptors to bind multiple ligands. This property of the receptor may have contributed significantly to ligand-receptor co-evolution.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept OB GYN, Piscataway, NJ 08854 USA; Rutgers State Univ, Robert Wood Johnson Med Sch, Acad Comp Serv, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept OB GYN, 675 Hoes Lane, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			NICHD NIH HHS [HD38547, HD14907] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD014907, R37HD014907, R01HD038547] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abell A, 1996, J BIOL CHEM, V271, P4518; Angelova K, 2002, J BIOL CHEM, V277, P32202, DOI 10.1074/jbc.M203272200; Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Bernard MP, 1998, BIOCHEM J, V335, P611, DOI 10.1042/bj3350611; Bernard MP, 2004, J BIOL CHEM, V279, P44438, DOI 10.1074/jbc.M406932200; Bernard MP, 2004, ANAL BIOCHEM, V327, P278, DOI 10.1016/j.ab.2003.12.029; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; Campbell RK, 1997, NAT BIOTECHNOL, V15, P439, DOI 10.1038/nbt0597-439; Chazenbalk GD, 1997, J BIOL CHEM, V272, P18959, DOI 10.1074/jbc.272.30.18959; Chazenbalk GD, 2002, J CLIN INVEST, V110, P209, DOI 10.1172/JCI200215745; Chazenbalk GD, 1999, ENDOCRINOLOGY, V140, P4516, DOI 10.1210/en.140.10.4516; Chen CR, 2003, ENDOCRINOLOGY, V144, P1324, DOI 10.1210/en.2002-0005; Chen CR, 2003, ENDOCRINOLOGY, V144, P3821, DOI 10.1210/en.2003-0430; CHEN F, 1991, J BIOL CHEM, V266, P19357; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DIAS JA, 1994, J BIOL CHEM, V269, P25289; Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Gromoll J, 2003, BIOL REPROD, V69, P75, DOI 10.1095/biolreprod.102.014902; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; HUANG JN, 1993, J BIOL CHEM, V268, P9311; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JI IH, 1991, J BIOL CHEM, V266, P14953; JI IH, 1995, J BIOL CHEM, V270, P15970, DOI 10.1074/jbc.270.27.15970; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Kishi M, 2000, MOL ENDOCRINOL, V14, P926, DOI 10.1210/me.14.6.926; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee C, 2001, IBM SYST J, V40, P592, DOI 10.1147/sj.402.0592; Licht P, 1976, Recent Prog Horm Res, V33, P169; Liu ZH, 2001, SCIENCE, V294, P1098, DOI 10.1126/science.1064719; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; METTITT EA, 1997, METHOD ENZYMOL, V277, P505; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; Muller T, 2003, J CLIN ENDOCR METAB, V88, P2242, DOI 10.1210/jc.2002-021946; MURPHY BD, 1991, ENDOCR REV, V12, P27, DOI 10.1210/edrv-12-1-27; Myers RV, 2000, BBA-GEN SUBJECTS, V1475, P390, DOI 10.1016/S0304-4165(00)00097-0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Oba Y, 1999, BIOCHEM BIOPH RES CO, V265, P366, DOI 10.1006/bbrc.1999.1700; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; REBOIS RV, 1984, J BIOL CHEM, V259, P8087; REBOIS RV, 1987, J BIOL CHEM, V262, P3891; Remy JJ, 1996, MOL CELL ENDOCRINOL, V125, P79, DOI 10.1016/S0303-7207(96)03955-X; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Sangkuhl K, 2002, J BIOL CHEM, V277, P47748, DOI 10.1074/jbc.M203491200; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Tanaka K, 1999, J BIOL CHEM, V274, P33979, DOI 10.1074/jbc.274.48.33979; Tegoni M, 1999, J MOL BIOL, V289, P1375, DOI 10.1006/jmbi.1999.2845; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vu-Hai MT, 2000, BIOCHEMISTRY-US, V39, P5509, DOI 10.1021/bi992913f; Wang YH, 2000, MOL CELL ENDOCRINOL, V170, P67, DOI 10.1016/S0303-7207(00)00331-2; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Xing YN, 2004, J BIOL CHEM, V279, P44427, DOI 10.1074/jbc.M406931200; Xing YN, 2003, BIOCHEM BIOPH RES CO, V303, P201, DOI 10.1016/S0006-291X(03)00322-X; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; YAN LG, 1992, BIOL REPROD, V47, P418, DOI 10.1095/biolreprod47.3.418; Zhang FP, 1997, ENDOCRINOLOGY, V138, P2481, DOI 10.1210/en.138.6.2481; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	76	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44442	44459		10.1074/jbc.M406948200	http://dx.doi.org/10.1074/jbc.M406948200			18	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304493	hybrid			2022-12-25	WOS:000224505600028
J	Tan, MGK; Ooi, LLPJ; Aw, SE; Hui, KM				Tan, MGK; Ooi, LLPJ; Aw, SE; Hui, KM			Cloning and identification of hepatocellular carcinoma down-regulated mitochondrial carrier protein, a novel liver-specific uncoupling protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE-PHOSPHORYLATION; PERMEABILITY TRANSITION; PROTON LEAK; CELL-DEATH; RHODAMINE-123; MEMBRANE; APOPTOSIS; BIOENERGETICS; RETENTION; MECHANISM	We report the identification of a novel cDNA fragment that shows significantly reduced expression in cancerous tissue compared with paired non-cancerous liver tissue in patients with hepatocellular carcinoma (HCC). The full-length transcript of 1733 bp encodes a protein of 308 amino acids that has all the hallmark features of mitochondrial carrier proteins. We designate the novel protein as HDMCP ((H) under bar CC- (d) under bar own-regulated (m) under bar itochondrial (c) under bar arrier (p) under bar rotein). The HDMCP orthologs in human, mouse, and rat are found to exhibit close similarity in protein sequence and gene organization, as well as exclusive expression in the liver. Moreover, conserved syntenic regions have been demonstrated at the HDMCP gene locus in the human, mouse, and rat genome. Taken together, we suggest that HDMCP might have a conserved and unique biological function in the liver. Overexpression of HDMCP in transiently transfected cancer cells results in the loss of staining by MitoTracker dye, indicating that HDMCP could induce the dissipation of mitochondrial membrane potential (DeltaPsi(m)). However, HDMCP-mediated disruption of DeltaPsi(m) is not related to mitochondrial permeability transition or apoptosis. In addition, we further demonstrate that the dissipation of DeltaPsi(m) is accompanied by significant reduction of cellular ATP in 293T cells overexpressing HDMCP or uncoupling protein 2 (UCP2). Our present findings suggest that HDMCP might be one of the long postulated uncoupling proteins that catalyze the physiological "proton leak" in the liver. The down-regulation of HDMCP in HCC cancer cells might result in the elevation of DeltaPsi(m), a common phenomenon found in cancer cells.	Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore; Natl Canc Ctr, Dept Surg Oncol, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Clin Res, Singapore 0316, Singapore	National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS); Singapore General Hospital	Hui, KM (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhkm@nccs.com	Hui, Kam/C-6186-2011; Tan, Michelle/AAQ-7275-2021; Ooi, London Lucien/AGK-1395-2022; LIU, JIANG Jimmy/AHB-8921-2022	Hui, Kam/0000-0003-1820-1399; Tan, Michelle/0000-0002-3202-2023; LIU, JIANG Jimmy/0000-0001-6281-6505				ALBERTS B, 1994, MOL BIOL CELL, P653; AQUILA H, 1987, FEBS LETT, V212, P1, DOI 10.1016/0014-5793(87)81546-6; BERNAL SD, 1983, SCIENCE, V222, P169, DOI 10.1126/science.6623064; BERNAL SD, 1982, SCIENCE, V218, P1117, DOI 10.1126/science.7146897; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; Capuano F, 1997, J BIOENERG BIOMEMBR, V29, P379, DOI 10.1023/A:1022402915431; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Fukuda H, 2002, CARCINOGENESIS, V23, P2019, DOI 10.1093/carcin/23.12.2019; HEYTLER PG, 1980, PHARMACOL THERAPEUT, V10, P461, DOI 10.1016/0163-7258(80)90027-3; Jaeschke H, 2000, J GASTROEN HEPATOL, V15, P718, DOI 10.1046/j.1440-1746.2000.02207.x; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; KOHNKE D, 1993, FEBS LETT, V336, P90, DOI 10.1016/0014-5793(93)81616-8; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUAN J, 1993, CRIT REV BIOCHEM MOL, V28, P209, DOI 10.3109/10409239309086795; LAMPIDIS TJ, 1983, CANCER RES, V43, P716; Loguercio C, 2003, FREE RADICAL BIO MED, V34, P1, DOI 10.1016/S0891-5849(02)01167-X; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mills EM, 2002, J BIOL CHEM, V277, P27385, DOI 10.1074/jbc.M111860200; MITCHELL P, 1965, NATURE, V208, P147, DOI 10.1038/208147a0; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; MODICANAPOLITAN.JS, 2002, EXP REV MOL MED; MODICANAPOLITANO JS, 1987, CANCER RES, V47, P4361; MODICANAPOLITANO JS, 1990, CANCER RES, V50, P7876; Morgan J, 2001, ADV DRUG DELIVER REV, V49, P71, DOI 10.1016/S0169-409X(01)00126-0; NADAKAVUKAREN KK, 1985, CANCER RES, V45, P6093; Ng A, 2003, INT J CANCER, V104, P179, DOI 10.1002/ijc.10926; NOBES CD, 1990, J BIOL CHEM, V265, P12903; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PARLO RA, 1984, J BIOL CHEM, V259, P9997; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rolfe DFS, 1997, BIOSCIENCE REP, V17, P9, DOI 10.1023/A:1027327015957; Scorrano L, 1999, J BIOL CHEM, V274, P24657, DOI 10.1074/jbc.274.35.24657; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stuart JA, 1999, J BIOENERG BIOMEMBR, V31, P517, DOI 10.1023/A:1005456725549; SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292; TERADA H, 1990, ENVIRON HEALTH PERSP, V87, P213, DOI 10.2307/3431027; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	46	34	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45235	45244		10.1074/jbc.M403683200	http://dx.doi.org/10.1074/jbc.M403683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322095	hybrid			2022-12-25	WOS:000224505600117
J	Yang, XP; Albrecht, U; Zakowski, V; Sobota, RM; Haussinger, D; Heinrich, PC; Ludwig, S; Bode, JG; Schaper, F				Yang, XP; Albrecht, U; Zakowski, V; Sobota, RM; Haussinger, D; Heinrich, PC; Ludwig, S; Bode, JG; Schaper, F			Dual function of interleukin-1 beta for the regulation of interleukin-6-induced suppressor of cytokine signaling 3 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN INTERLEUKIN-6; ACUTE-PHASE PROTEINS; NF-KAPPA-B; GENE-EXPRESSION; TRANSCRIPTION FACTORS; HUMAN HEPATOCYTES; MESSENGER-RNA; IL-6; SOCS3; PHOSPHORYLATION	Interleukin-6 (IL-6) exerts pro- as well as anti-inflammatory activities in response to infection, injury, or other stimuli that affect the homeostasis of the organism. IL-6-induced expression of acute-phase protein genes in the liver is tightly regulated through both IL-6-induced feedback inhibitors and the activity of proinflammatory cytokines such as tumor necrosis factor alpha and interleukin-1beta. In previous studies mechanisms for how IL-1beta counteracts IL-6-dependent acute-phase protein gene induction have been proposed. Herein we analyzed IL-1beta-mediated regulation of IL-6-induced expression of the feedback inhibitor SOCS3. In hepatocytes IL-1beta alone does not induce SOCS3 expression, but it counteracts SOCS3-promoter activation in long term studies. Surprisingly, short term stimulation revealed IL-1beta to be a potent enhancer of SOCS3 expression in concert with IL-6. This activity of IL-1beta does not depend on IL-1beta-dependent STAT1-serine phosphorylation but on NF-kappaB-dependent gene induction. Such a regulatory network allows IL-1beta to counteract IL-6-dependent expression of acute-phase protein genes without inhibiting IL-6-induced SOCS3 expression and provides a reasonable mechanism for the IL-1beta-dependent inhibition of acute-phase gene induction, because reduced SOCS3 expression would lead to enhanced IL-6 activity.	Rhein Westfal TH Aachen, Sch Med, Dept Biochem, D-52074 Aachen, Germany; Univ Dusseldorf, Dept Mol Med, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany	RWTH Aachen University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Schaper, F (corresponding author), Rhein Westfal TH Aachen, Sch Med, Dept Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	schaper@rwth-aachen.de	Yang, Xiangping/B-4833-2011; Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414; Yang, Xiang-Ping/0000-0001-9003-1772; Ludwig, Stephan/0000-0003-4490-3052				Ahmed ST, 2000, J IMMUNOL, V165, P5227, DOI 10.4049/jimmunol.165.9.5227; Ahmed ST, 2002, J LEUKOCYTE BIOL, V72, P154; ANDUS T, 1988, EUR J IMMUNOL, V18, P739, DOI 10.1002/eji.1830180513; Anhuf D, 2000, J IMMUNOL, V165, P2535, DOI 10.4049/jimmunol.165.5.2535; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Bode JG, 2003, J IMMUNOL, V171, P257, DOI 10.4049/jimmunol.171.1.257; Bode JG, 2001, J IMMUNOL, V167, P1469, DOI 10.4049/jimmunol.167.3.1469; Bode JG, 2001, BIOL CHEM, V382, P1447, DOI 10.1515/BC.2001.178; Bode JG, 1999, FEBS LETT, V463, P365, DOI 10.1016/S0014-5793(99)01662-2; Bode JG, 2001, LIVER BIOL PATHOBIOL, P565; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Inagaki-Ohara K, 2003, CURR OPIN PHARMACOL, V3, P435, DOI 10.1016/S1471-4892(03)00070-5; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Leung KC, 2003, P NATL ACAD SCI USA, V100, P1016, DOI 10.1073/pnas.0337600100; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Nguyen H, 2003, J INTERF CYTOK RES, V23, P183, DOI 10.1089/107999003765027384; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; Ruminy P, 2001, INFLAMM RES, V50, P383, DOI 10.1007/PL00000260; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Stoiber D, 1999, J IMMUNOL, V163, P2640; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang ZX, 2000, BLOOD, V96, P3466, DOI 10.1182/blood.V96.10.3466.h8003466_3466_3472; Zhang ZX, 1997, BIOCHEM BIOPH RES CO, V237, P90, DOI 10.1006/bbrc.1997.7082	39	21	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45279	45289		10.1074/jbc.M313072200	http://dx.doi.org/10.1074/jbc.M313072200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308667	hybrid			2022-12-25	WOS:000224505600121
J	Cheng, PL; Chang, MH; Chao, CH; Lee, YHW				Cheng, PL; Chang, MH; Chao, CH; Lee, YHW			Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation	ONCOGENE			English	Article						HCV; core protein; NS3 protein; TGF-beta; Smad3; hepatocarcinogenesis	GROWTH-FACTOR-BETA; VIRUS CORE PROTEIN; INDUCED APOPTOSIS; GENE-EXPRESSION; PROMOTER; RECEPTOR; BINDING; REPLICATION; SUPPRESSION; CELLS	Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine implicated as a pathogenic mediator in various liver diseases. Enhanced TGF-beta production and lack of TGF-beta responses are often observed during hepatitis C virus (HCV) infection. In this study, we demonstrate that TGF-beta-mediated transactivation is decreased in cells exogenously expressing the intact HCV polyprotein. Among 16 viral products of HCV, only core and nonstructural protein 3 (NS3) physically interact with the MH1 (Mad homology 1) region of the Smad3 and block TGF-beta/Smad3-mediated transcriptional activation through interference with the DNA-binding ability of Smad3, not the nuclear translocation. However, the interactive domain of NS3 extends to the MH2 (Mad homology 2) region of Smad3 and a distinction is found between effects mediated, respectively, by these two viral proteins. HCV core, in the presence or absence of TGF-beta, has a stronger suppressive effect on the DNA-binding and transactivation ability of Smad3 than NS3. Although HCV core, NS3, and the HCV subgenomic replicon all attenuate TGF-beta/Smad3-mediated apoptosis, only HCV core represses TGF-beta-induced G1 phase arrest through downregulation of the TGF-beta-induced p21 promoter activation. Along with this, HCV core, rather than NS3, exhibits a significant inhibitory effect on the binding of Smad3/Sp1 complex to the proximal p21 promoter in response to TGF-beta. In conclusion, HCV viral proteins interact with the TGF-beta signaling mediator Smad3 and differentially impair TGF-beta/Smad3-mediated transactivation and growth inhibition. This functional counteraction of TGF-beta responses provides insights into possible mechanisms, whereby the HCV oncogenic proteins antagonize the host defenses during hepatocarcinogenesis.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Cheng, Pei-Lin/ABB-2255-2021	Cheng, Pei-Lin/0000-0002-0090-8153; Lee Wu, Yan-Hwa/0000-0001-7299-7354; Chao, Chi-Hong/0000-0001-9890-4902				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Chen SY, 2003, J BIOL CHEM, V278, P591, DOI 10.1074/jbc.M204241200; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dey A, 1997, VIROLOGY, V228, P190, DOI 10.1006/viro.1996.8363; Dubourdeau M, 2002, J HEPATOL, V37, P486, DOI 10.1016/S0168-8278(02)00241-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fujita T, 1996, BIOCHEM BIOPH RES CO, V229, P825, DOI 10.1006/bbrc.1996.1887; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; ITO N, 1991, CANCER RES, V51, P4080; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Kim DH, 1997, J BIOL CHEM, V272, P688; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kwong AD, 2000, CURR TOP MICROBIOL, V242, P171; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Lee MN, 2002, J GEN VIROL, V83, P2145, DOI 10.1099/0022-1317-83-9-2145; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matsuzaki K, 2000, CANCER RES, V60, P1394; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Prokova V, 2002, J BIOL CHEM, V277, P9342, DOI 10.1074/jbc.M109099200; Ray RB, 1998, GENE, V208, P331, DOI 10.1016/S0378-1119(98)00030-4; Ray S, 2003, J GASTROEN HEPATOL, V18, P393, DOI 10.1046/j.1440-1746.2003.02985.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zemel R, 2001, J VIRAL HEPATITIS, V8, P96, DOI 10.1046/j.1365-2893.2001.00283.x; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	48	55	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7821	7838		10.1038/sj.onc.1208066	http://dx.doi.org/10.1038/sj.onc.1208066			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334054				2022-12-25	WOS:000224331600008
J	Rippo, MR; Moretti, S; Vescovi, S; Tomasetti, M; Orecchia, S; Amici, G; Catalano, A; Procopio, A				Rippo, MR; Moretti, S; Vescovi, S; Tomasetti, M; Orecchia, S; Amici, G; Catalano, A; Procopio, A			FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells	ONCOGENE			English	Article						malignant mesothelioma; Fas; TRAIL; FLIP; caspase-8; apoptosis	LIGAND-INDUCED APOPTOSIS; TUMOR IMMUNE ESCAPE; PLEURAL MESOTHELIOMA; MEDIATED APOPTOSIS; FAS-LIGAND; EXPRESSION; TRAIL; PROTEIN; GROWTH; LINES	Tumors have developed several forms of resistance to receptor-induced cell death. Here, we show that malignant mesothelial (MM) cell lines as well as primary MM cells and normal mesothelial (NM) cells express Fas and TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5. We found that, although Fas expression levels are comparable, only MM cells are resistant to cell death. Furthermore, MM cells show resistance to TRAIL-induced apoptosis. Caspase-8 (FLICE) is not activated by death receptors triggering in malignant cells whereas it is well activated by nonreceptor stimuli, such as UV radiation. We found that FLIP (FLICE-Inhibitory Protein) is constitutively expressed in all MM cell lines and is more expressed in primary MM cells than in NM cells. Knockdown of FLIP expression in MM cell lines, by a FLIPsiRNA, re-established the normal response to apoptosis induced by Fas or DR4/DR5, which was blocked by pretreatment with the caspase-8 inhibitor z-IETD-fmk. These results indicate that MM cells develop an intrinsic resistance to apoptosis induced by death receptors upregulating the expression of the antiapoptotic protein c-FLIP.	Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy; Italian Natl Res Ctr Aging, Lab Cytol, I-860124 Ancona, Italy; S Antonio & Biagio Hosp, Dept Anat Pathol, I-15100 Alessandria, Italy; Pediat Hosp G Salesi, I-60100 Ancona, Italy	Marche Polytechnic University; IRCCS INRCA; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo	Rippo, MR (corresponding author), Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60100 Ancona, Italy.	m.r.rippo@univpm.it	Procopio, Antonio Domenico/AAB-2451-2021	Procopio, Antonio Domenico/0000-0001-6897-8724; RIPPO, Maria Rita/0000-0003-3024-3495				Attanoos RL, 1997, HISTOPATHOLOGY, V30, P403, DOI 10.1046/j.1365-2559.1997.5460776.x; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bradley M, 1998, BLOOD, V92, P4248, DOI 10.1182/blood.V92.11.4248.423k20_4248_4255; CARBONE M, 1994, ONCOGENE, V9, P1781; Catalan MP, 2003, KIDNEY INT, V64, P321, DOI 10.1046/j.1523-1755.2003.00062.x; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; French LE, 2002, SEMIN CANCER BIOL, V12, P51, DOI 10.1006/scbi.2001.0405; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Frost P, 1997, CELL IMMUNOL, V180, P70, DOI 10.1006/cimm.1997.1169; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Jaklitsch MT, 2001, WORLD J SURG, V25, P210, DOI 10.1007/s002680020021; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; LEW F, 1986, J CLIN IMMUNOL, V6, P225, DOI 10.1007/BF00918702; Liu WH, 2001, AM J RESP CELL MOL, V25, P111, DOI 10.1165/ajrcmb.25.1.4472; MANNING LS, 1991, CLIN EXP IMMUNOL, V83, P85; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Mutsaers SE, 2002, RESPIROLOGY, V7, P171, DOI 10.1046/j.1440-1843.2002.00404.x; Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459; Narasimhan SR, 1998, AM J PHYSIOL-LUNG C, V275, pL165, DOI 10.1152/ajplung.1998.275.1.L165; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Plasilova M, 2002, LEUKEMIA, V16, P67, DOI 10.1038/sj.leu.2402338; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Roth W, 2001, CANCER RES, V61, P2759; Screpanti V, 2001, J IMMUNOL, V167, P2068, DOI 10.4049/jimmunol.167.4.2068; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Stewart JH, 2002, J THORAC CARDIOV SUR, V123, P295, DOI 10.1067/mtc.2002.119882; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Tomasetti M, 2004, BRIT J CANCER, V90, P1644, DOI 10.1038/sj.bjc.6601707; Tomek S, 2003, BRIT J CANCER, V88, P167, DOI 10.1038/sj.bjc.6600673; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wall NR, 2003, LANCET, V362, P1401, DOI 10.1016/S0140-6736(03)14637-5; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Zang DY, 2001, BLOOD, V98, P3058, DOI 10.1182/blood.V98.10.3058	38	75	79	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	2004	23	47					7753	7760		10.1038/sj.onc.1208051	http://dx.doi.org/10.1038/sj.onc.1208051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334061				2022-12-25	WOS:000224331600001
J	Bitomsky, N; Bohm, M; Klempnauer, KH				Bitomsky, N; Bohm, M; Klempnauer, KH			Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun	ONCOGENE			English	Article						Pdcd4; c-Jun; phosphorylation; JNK-signaling; p300	INITIATION-FACTOR 4A; NF-KAPPA-B; ACTIVATION DOMAIN; C/EBP-BETA; HA-RAS; V-MYB; AP-1 TRANSACTIVATION; DELTA-DOMAIN; MIM-1 GENE; IN-VIVO	The transformation suppressor gene Pdcd4 ( programmed cell death gene 4) inhibits the tumor-promoter mediated transformation of mouse keratinocytes and has recently been implicated as a potential tumor suppressor gene in the development of human lung cancer. Biochemical analysis has suggested that the Pdcd4 protein is involved in protein translation as well as in nuclear events. Recent work has shown that Pdcd4 suppresses the transactivation of AP-1 responsive promoters by c-Jun, suggesting that the transformation-suppressor activity of Pdcd4 might be due, at least in part, to the inhibition of c-Jun activity. Here, we have addressed how Pdcd4 inhibits c-Jun. We show that Pdcd4 interferes with the phosphorylation of c-Jun by Jun N-terminal kinase (JNK). The inhibition of c-Jun phosphorylation by Pdcd4 appears not to be due to a general suppression of JNK activity, our data rather suggest that Pdcd4 interacts with c-Jun and thereby blocks phosphorylation of c-Jun. In addition to affecting c-Jun phosphorylation, Pdcd4 blocks the recruitment of the coactivator p300 by c-Jun. Taken together, our results strongly suggest that Pdcd4 is directly involved in the regulation of c-Jun activity.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Bannister AJ, 1995, ONCOGENE, V11, P2509; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DAI TN, 1995, ONCOGENE, V10, P849; David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Goke A, 2002, BIOCHEM BIOPH RES CO, V297, P78, DOI 10.1016/S0006-291X(02)02129-0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6	37	116	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7484	7493		10.1038/sj.onc.1208064	http://dx.doi.org/10.1038/sj.onc.1208064			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334056				2022-12-25	WOS:000224176500005
J	Pozo, D; Delgado, M				Pozo, D; Delgado, M			The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?	FASEB JOURNAL			English	Article						immune response; autoimmunity; Th cells; vasoactive intestinal peptide	VASOACTIVE-INTESTINAL-PEPTIDE; ACTIVATING POLYPEPTIDE PACAP; IN-VIVO; TRANSGENIC MICE; CELL EXPRESSION; VPAC2 RECEPTOR; CUTTING EDGE; AUTOIMMUNE; ARTHRITIS; DISEASE	Neuroimmunomodulation has experienced an explosive growth not only in basic research, but expanding to the point that prospective clinical research could be now a reality. A crucial factor for the functioning of this intimate bidirectional network was the demonstration that the immune and neuroendocrine systems speak a mutual biochemical language. This implies 1) production of neuroendocrine hormones and neuropeptides by immune cells and of cytokines by neuroendocrine cells; 2) evidence for shared receptors on cells of the immune and neuroendocrine systems; 3) effect of neuroendocrine mediators on immune functions; and 4) effect of cytokines on the neuroendocrine system. This reduces traditional differences between neurotransmitters, hormones, and immune mediators and raises the following question: what can we now regard as immune or neuroendocrine? Vasoactive intestinal peptide (VIP) is one example of this paradigm. VIP has traditionally been classified as a neuropeptide/neurotransmitter based in its capacity to mediate and regulate neuronal functions. Recent work has demonstrated that VIP is produced by T cells, especially Th2 cells, and that through specific receptors it exerts immunological functions typically ascribed to Th2 cytokines in nervous and immune systems. Here, we postulate that instead of a neuropeptide, VIP could be fully considered a type 2 cytokine with a key role in neuroimmunology.	CSIC, Inst Parasitol & Biomed, Granada, Spain; Univ Seville, Dept Med Biochem & Mol Biol, Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); University of Sevilla	Delgado, M (corresponding author), CSIC, Inst Parasitol & Biomed, Granada, Spain.	mdelgado@ipb.csic.es	Delgado, Mario/P-1524-2016; Pozo, David/C-2149-2017	Delgado, Mario/0000-0003-1893-5982; Pozo, David/0000-0002-3732-4960				Abad C, 2003, GASTROENTEROLOGY, V124, P961, DOI 10.1053/gast.2003.50141; Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Colwell CS, 2003, AM J PHYSIOL-REG I, V285, pR939, DOI 10.1152/ajpregu.00200.2003; de Wied D, 1974, EXCERPTA MED INT C S, V359, P653; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 2004, J LEUKOCYTE BIOL, V75, P1122, DOI 10.1189/jlb.1203626; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Delgado M, 2003, FASEB J, V17, P944, DOI 10.1096/fj.02-0799fje; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Delgado M, 2001, J IMMUNOL, V166, P2907, DOI 10.4049/jimmunol.166.5.2907; Delgado M, 2003, TRENDS IMMUNOL, V24, P221, DOI 10.1016/S1471-4906(03)00069-3; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Delgado M, 1999, J IMMUNOL, V163, P3629; Delgado M, 2001, J IMMUNOL, V167, P966, DOI 10.4049/jimmunol.167.2.966; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gomariz R, 2000, ANN NY ACAD SCI, V921, P284; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Gozes I, 2003, CURR PHARM DESIGN, V9, P483, DOI 10.2174/1381612033391667; Grimm MC, 2003, J IMMUNOL, V171, P4990, DOI 10.4049/jimmunol.171.10.4990; GUERRERO JM, 1981, MOL CELL ENDOCRINOL, V21, P151, DOI 10.1016/0303-7207(81)90052-6; Henning RJ, 2001, CARDIOVASC RES, V49, P27, DOI 10.1016/S0008-6363(00)00229-7; Iversen L, 1999, TRENDS NEUROSCI, V22, P482, DOI DOI 10.1016/S0166-2236(99)01429-0; Kastin AJ, 2000, TRENDS NEUROSCI, V23, P113, DOI 10.1016/S0166-2236(99)01525-8; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; McCulloch DA, 2002, BIOCHEM SOC T, V30, P441, DOI 10.1042/bst0300441; Netea MG, 2003, TRENDS IMMUNOL, V24, P254, DOI 10.1016/S1471-4906(03)00079-6; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Petkov V, 2003, J CLIN INVEST, V111, P1339, DOI 10.1172/JCI200317500; PIPER PJ, 1970, NATURE, V225, P1144, DOI 10.1038/2251144a0; Pozo D, 1997, BBA-MOL CELL RES, V1359, P250, DOI 10.1016/S0167-4889(97)00104-3; Pozo D, 2003, TRENDS MOL MED, V9, P211, DOI 10.1016/S1471-4914(03)00049-2; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; Strand FL, 1999, NEUROPEPTIDES REGULA; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Tuncel N, 2000, PEPTIDES, V21, P81, DOI 10.1016/S0196-9781(99)00177-1; VANRAMPELBERGH J, 1997, BIOCHIM BIOPHYS ACTA, V135, P249; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; Williams RO, 2002, ARTHRITIS RHEUM, V46, P271, DOI 10.1002/1529-0131(200201)46:1<271::AID-ART10039>3.0.CO;2-C; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yung SL, 2003, J BIOL CHEM, V278, P10273, DOI 10.1074/jbc.M211945200	45	72	75	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1325	1334		10.1096/fj.03-1440hyp	http://dx.doi.org/10.1096/fj.03-1440hyp			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333575	Green Submitted			2022-12-25	WOS:000224243200051
J	Serban, A; Legname, G; Hansen, K; Kovaleva, N; Prusiner, SB				Serban, A; Legname, G; Hansen, K; Kovaleva, N; Prusiner, SB			Immunoglobulins in urine of hamsters with scrapie	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; CHRONIC WASTING DISEASE; PRION PROTEIN ISOFORM; BLOOD-TRANSFUSION; LIGHT-CHAINS; TRANSMISSION; ANTIBODIES; EPITOPE; HUMANS	In the prion diseases, a prolonged, asymptomatic incubation period precedes the onset of neurologic dysfunction. At present, a noninvasive test is not available for the presymptomatic diagnosis of prion disease, and thus the report of a test for prions using urine has been of great interest (Shaked, G. M., Shaked, Y., Kariv-Inbal, Z., Halimi, M., Avraham, I., and Gabizon, R. (2001) J. Biol. Chem. 276, 31479-31482). Using Western immunoblots with the anti-prion protein (PrP) 3F4 monoclonal antibody and an anti-mouse IgG secondary antibody, a protease-resistant PrP was reported in the urine of Syrian hamsters and humans with prion disease. Here we have demonstrated that this purportedly "protease-resistant PrP" band in the urine of diseased hamsters is detectable using the anti-mouse IgG secondary antibody in the absence of the 3F4 monoclonal antibody. Mass spectrometric analysis identified an immunoglobulin light chain in the band but found no PrP peptides. No similar band was found in the urine of uninfected hamsters or in brain homogenates from normal or prion-infected hamsters. Moreover, the band in the urine of infected hamsters was not detected using two chimeric human-mouse recombinant anti-PrP antibody fragments followed by an anti-human IgG secondary antibody. Our results indicate that the band detected under previously published conditions is due to the cross-reactivity of the anti-mouse IgG antibody with IgG light chains and possibly heavy chain fragments in urine, but not with PrP.	Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Prusiner, SB (corresponding author), Univ Calif San Francisco, Inst Neurodegenerat Dis, Box 0518, San Francisco, CA 94143 USA.	stanley@ind.ucsf.edu	Legname, Giuseppe/C-1723-2012	Legname, Giuseppe/0000-0003-0716-4393	NIA NIH HHS [AG010770, AG02132] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG002132, P01AG010770] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bosque PJ, 2002, P NATL ACAD SCI USA, V99, P3812, DOI 10.1073/pnas.052707499; Bourne PC, 2002, ACTA CRYSTALLOGR D, V58, P815, DOI 10.1107/S0907444902004183; Echebarria LEH, 2000, NEUROLOGY, V54, P1539, DOI 10.1212/WNL.54.7.1539; FURUKAWA H, 2003, 15 INT C NEUR TUR IT, pT343; Geschwind MD, 2003, ARCH NEUROL-CHICAGO, V60, P813, DOI 10.1001/archneur.60.6.813; Glatzel M, 2003, NEW ENGL J MED, V349, P1812, DOI 10.1056/NEJMoa030351; Graziani MS, 2001, CLIN CHEM, V47, P2069; Hunter N, 2002, J GEN VIROL, V83, P2897, DOI 10.1099/0022-1317-83-11-2897; Kanyo ZF, 1999, J MOL BIOL, V293, P855, DOI 10.1006/jmbi.1999.3193; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Miller MW, 2000, J WILDLIFE DIS, V36, P676, DOI 10.7589/0090-3558-36.4.676; Miyazawa K, 2002, ANN NEUROL, V52, pS54; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; PRUSINER SB, 2001, Patent No. 6221614; PRUSINER SB, 1999, PRION BIOL DIS; Prusiner Stanley B., 2004, VVolume 41, P545; ROGERS M, 1991, J IMMUNOL, V147, P3568; Safar JG, 2002, NAT BIOTECHNOL, V20, P1147, DOI 10.1038/nbt748; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Shaked GM, 2001, J BIOL CHEM, V276, P31479, DOI 10.1074/jbc.C100278200; SOLOMON A, 1976, NEW ENGL J MED, V294, P17, DOI 10.1056/NEJM197601012940105; Thomzig A, 2003, EMBO REP, V4, P530, DOI 10.1038/sj.embor.embor827; Will RG, 1999, LANCET, V353, P979, DOI 10.1016/S0140-6736(99)01160-5; Will Robert G., 2004, VVolume 41, P629; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998	26	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48817	48820		10.1074/jbc.M409107200	http://dx.doi.org/10.1074/jbc.M409107200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15310752	hybrid			2022-12-25	WOS:000225098100042
J	Du, XM; Pham, YH; Brown, AJ				Du, XM; Pham, YH; Brown, AJ			Effects of 25-hydroxycholesterol on cholesterol esterification and sterol regulatory element-binding protein processing are dissociable - Implications for cholesterol movement to the regulatory pool in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; HUMAN FIBROBLASTS; PLASMA-MEMBRANE; ACYL-COA; O-ACYLTRANSFERASE; ESTER FORMATION; ER MEMBRANES; RAT-LIVER; CELLS; SCAP	The regulatory pool of cholesterol is located in the endoplasmic reticulum (ER) and is key to how mammalian cells sense and respond to changes in cellular cholesterol levels. The extent of cholesterol esterification by the ER-resident protein, acyl-coenzyme A:cholesterol acyl-transferase (ACAT), has become the standard method for monitoring cholesterol transport to the ER and is assumed to reflect the regulatory pool of ER cholesterol. The oxysterol, 25-hydroxycholesterol (25HC), is thought to trigger intracellular cholesterol transport to the ER. In support of this contention, we confirmed previous reports that 25HC activates cholesterol esterification and is a potent suppressor of the sterol regulatory element-binding protein (SREBP) pathway. Processing of the ER membrane-bound SREBP into a soluble transcription factor is controlled by cholesterol levels in the ER. In this study, we addressed whether or not cholesterol esterification necessarily reflects cholesterol movement to the cholesterol homeostatic machinery in the ER as determined by SREBP processing. We found that three agents that inhibited the ability of 25HC to induce cholesterol esterification (progesterone, nigericin, and monensin) did not have a corresponding effect on 25HC suppression of SREBP processing. Moreover, ACAT inhibition did not alter the sensitivity of SREBP processing to 25HC. Therefore, cholesterol esterification by the ER-resident protein ACAT is dissociable from cholesterol transport to the cholesterol homeostatic machinery in the ER. In light of our results, we question the security of previous work that has inferred cholesterol transport to the ER regulatory pool based solely on cholesterol esterification.	Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Brown, AJ (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Biol Sci Bldg D26, Sydney, NSW 2052, Australia.	aj.brown@unsw.edu.au						Adams CM, 2003, P NATL ACAD SCI USA, V100, P10647, DOI 10.1073/pnas.1534833100; Anderson RGW, 2003, TRENDS CELL BIOL, V13, P534, DOI 10.1016/j.tcb.2003.08.007; BALASUBRAMANIAM S, 1978, BIOCHEM J, V174, P863, DOI 10.1042/bj1740863; BILLHEIMER JT, 1981, ANAL BIOCHEM, V111, P331, DOI 10.1016/0003-2697(81)90570-4; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Cusinato F, 2002, LIPIDS, V37, P53, DOI 10.1007/s11745-002-0863-9; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; Espenshade PJ, 2002, P NATL ACAD SCI USA, V99, P11694, DOI 10.1073/pnas.182412799; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; FIELD FJ, 1983, J LIPID RES, V24, P1049; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1978, P NATL ACAD SCI USA, V75, P1877, DOI 10.1073/pnas.75.4.1877; Hall E, 2001, AM J PHYSIOL-GASTR L, V281, pG293, DOI 10.1152/ajpgi.2001.281.1.G293; HASHIMOTO S, 1980, J BIOL CHEM, V255, P8678; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Janowski BA, 2001, J BIOL CHEM, V276, P45408, DOI 10.1074/jbc.M108348200; Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Khelef N, 2000, ARTERIOSCL THROM VAS, V20, P1769; LANGE Y, 1995, J LIPID RES, V36, P1092; Lange Y, 2002, BIOCHEM BIOPH RES CO, V290, P488, DOI 10.1006/bbrc.2001.6156; LANGE Y, 1994, J BIOL CHEM, V269, P3411; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LIN HS, 1995, J MED CHEM, V38, P277, DOI 10.1021/jm00002a010; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; MAZZONE T, 1995, J LIPID RES, V36, P544; MILLER SC, 1984, J LIPID RES, V25, P991; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rowe AH, 2003, CIRC RES, V93, P717, DOI 10.1161/01.RES.0000097606.43659.F4; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Scheidt HA, 2003, J BIOL CHEM, V278, P45563, DOI 10.1074/jbc.M303567200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Steck TL, 2002, DEV CELL, V3, P306, DOI 10.1016/S1534-5807(02)00263-0; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Wiegand V, 2003, FASEB J, V17, P782, DOI 10.1096/fj.02-0818fje; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhang J, 1999, J STEROID BIOCHEM, V70, P123, DOI 10.1016/S0960-0760(99)00107-7	50	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47010	47016		10.1074/jbc.M408690200	http://dx.doi.org/10.1074/jbc.M408690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15317807	hybrid			2022-12-25	WOS:000224832400085
J	Gaumont-Leclerc, MF; Mukhopadhyay, UK; Goumard, S; Ferbeyre, G				Gaumont-Leclerc, MF; Mukhopadhyay, UK; Goumard, S; Ferbeyre, G			PEA-15 is inhibited by adenovirus E1A and plays a role in ERK nuclear export and Ras-induced senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; ONCOGENIC RAS; CELL-CYCLE; GENE-EXPRESSION; P53; PML; TRANSLOCATION; BINDING; PHOSPHORYLATION	Oncogenic ras activates multiple signaling pathways to enforce cell proliferation in tumor cells. The ERK1/2 mitogen-activated protein kinase pathway is required for the transforming effects of ras, and its activation is often sufficient to convey mitogenic stimulation. However, in some settings oncogenic ras triggers a permanent cell cycle arrest with features of cellular senescence. How the Ras/ERK1/2 pathway activates different cellular programs is not well understood. Here we show that ERK1/2 localize predominantly in the cytoplasm during ras-induced senescence. This cytoplasmic localization seems to be dependent on an active nuclear export mechanism and can be rescued by the viral oncoprotein E1A. Consistent with this hypothesis, we showed that E1A dramatically down-regulated the expression of the ERK1/2 nuclear export factor PEA-15. Also, RNA interference against PEA-15 restored the nuclear localization of phospho-ERK1/2 in Ras-expressing primary murine embryo fibroblasts and stimulated their escape from senescence. Because senescence prevents the transforming effect of oncogenic ras, our results suggest a tumor suppressor function for PEA-15 that operates by means of controlling the localization of phospho-ERK1/2.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Ferbeyre, G (corresponding author), Univ Montreal, Dept Biochim, E-515,CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	g.ferbeyre@umontreal.ca	Ferbeyre, Gerardo/A-1569-2010					Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fischer RS, 1998, J VIROL, V72, P2815, DOI 10.1128/JVI.72.4.2815-2824.1998; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAYNE PS, 1995, CURR OPIN GENET DEV, V5, P38, DOI 10.1016/S0959-437X(95)90051-9; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lim IK, 2000, MECH AGEING DEV, V119, P113, DOI 10.1016/S0047-6374(00)00167-6; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Meyyappan M, 1996, BIOL SIGNAL, V5, P130; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; SPECOTR DL, 1998, CELLS LAB MANUAL; STACEY DW, 1988, COLD SPRING HARB SYM, V53, P871, DOI 10.1101/SQB.1988.053.01.100; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Torres C, 2003, EXP CELL RES, V290, P195, DOI 10.1016/S0014-4827(03)00309-4; Tresini M, 2001, EXP CELL RES, V269, P287, DOI 10.1006/excr.2001.5334; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZHU J, 1998, GENE DEV, V12, P3008	44	46	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46802	46809		10.1074/jbc.M403893200	http://dx.doi.org/10.1074/jbc.M403893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331596	hybrid			2022-12-25	WOS:000224832400060
J	Leconte, L; Lecoin, L; Martin, P; Saule, S				Leconte, L; Lecoin, L; Martin, P; Saule, S			Pax6 interacts with cVax and Tbx5 to establish the dorsoventral boundary of the developing eye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX GENES TBX2-TBX5; DORSAL-VENTRAL AXIS; DNA-BINDING; T-BOX; EXPRESSION; PATTERNS; DOMAINS; RETINA	Dorsoventral pattern formation of the optic cup is essential for vertebrate eye morphogenesis and retinotectal topographic mapping. Dorsal and ventral aspects of the eye are distinct at early stages of development; cVax homeodomain protein expression is confined to the ventral optic cup, whereas Tbx5 (T-box transcription factor) expression domain becomes restricted to the dorsal region. Misexpression of cVax or Tbx5 induces profound defects in eye morphology and abnormal visual projections. In the Pax6-/- mutant Tbx5 fails to be expressed, and Vax1 and - 2 are abnormally present in the entire optic vesicle. During eye development Pax6 becomes expressed in a gradient at the optic cup stage due to the specific activation of a highly conserved intronic alpha enhancer in the Pax6 locus. We observed that the highest level of Pax6 in the optic cup corresponds to the boundary between non-overlapping cVax and Tbx5 territories. To further investigate how these transcription factors control the patterning of the eye, we overexpressed Pax6 in the chick optic cup (E2) using in ovo electroporation. We observed that overexpression of Pax6 extends the Tbx5 and Bmp4 domains but reduces the cVax expression domains in the E3 chick eye. This results in an abnormal eye phenotype at E4. In addition, we showed that cVax and Tbx5 interact with Pax6 and modulate in an opposite manner the activity of the Pax6 alpha enhancer. Moreover, the Pax6/cVax interaction inhibits the transactivation properties of Pax6. These results demonstrate that Pax6 together with cVax and Tbx5 mediate dorsoventral patterning of the eye.	Ctr Univ Orsay, Sect Rech, Inst Curie, CNRS,UMR 146, F-91405 Orsay, France; Univ Nice, CNRS, UMR6548, F-06108 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Saule, S (corresponding author), Ctr Univ Orsay, Sect Rech, Inst Curie, CNRS,UMR 146, Batiment 110, F-91405 Orsay, France.	Simon.Saule@curie.u-psud.fr		LECOIN, Laure/0000-0001-5259-4339				Barbieri AM, 2002, DEVELOPMENT, V129, P805; Barbieri AM, 1999, P NATL ACAD SCI USA, V96, P10729, DOI 10.1073/pnas.96.19.10729; Baumer N, 2002, DEVELOPMENT, V129, P4535; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Chow RL, 1999, DEVELOPMENT, V126, P4213; Dutting D, 1995, INT J DEV BIOL, V39, P921; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Gibson-Brown JJ, 1998, MECH DEVELOP, V74, P165, DOI 10.1016/S0925-4773(98)00056-2; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GRINDLEY JC, 1995, DEVELOPMENT, V121, P1433; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Jun S, 1996, DEVELOPMENT, V122, P2639; Kioussi C, 1999, P NATL ACAD SCI USA, V96, P14378, DOI 10.1073/pnas.96.25.14378; Koshiba-Takeuchi K, 2000, SCIENCE, V287, P134, DOI 10.1126/science.287.5450.134; Lecoin L, 2004, GENE EXPR PATTERNS, V4, P35, DOI 10.1016/S1567-133X(03)00152-2; Logan M, 1998, DEVELOPMENT, V125, P2825; MARTIN P, 1992, ONCOGENE, V7, P1721; Monsoro-Burq AH, 2001, MOL CELL, V7, P789, DOI 10.1016/S1097-2765(01)00223-4; Mui SH, 2002, DEVELOPMENT, V129, P797; Peters MA, 2002, DEV BIOL, V251, P59, DOI 10.1006/dbio.2002.0791; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; PLAZA S, 1995, MOL CELL BIOL, V15, P892; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sasagawa S, 2002, GENESIS, V33, P86, DOI 10.1002/gene.10095; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; Schulte D, 1999, NEURON, V24, P541, DOI 10.1016/S0896-6273(00)81111-3; Simpson TI, 2002, BIOESSAYS, V24, P1041, DOI 10.1002/bies.10174; Sivak B, 2000, Results Probl Cell Differ, V31, P1; Stoykova A, 2000, J NEUROSCI, V20, P8042; Uemonsa T, 2002, DEV BIOL, V248, P319, DOI 10.1006/dbio.2002.0737; Zhang XM, 2001, DEV BIOL, V233, P271, DOI 10.1006/dbio.2000.0195; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	35	34	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47272	47277		10.1074/jbc.M406624200	http://dx.doi.org/10.1074/jbc.M406624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322073	hybrid			2022-12-25	WOS:000224832400115
J	Amzallag, N; Passer, BJ; Allanic, D; Segura, E; Thery, C; Goud, B; Amson, R; Telerman, A				Amzallag, N; Passer, BJ; Allanic, D; Segura, E; Thery, C; Goud, B; Amson, R; Telerman, A			TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DERIVED EXOSOMES; BINDING CASSETTE TRANSPORTER; CONTROLLED PROTEIN P23; EHRLICH ASCITES TUMOR; GROWTH-FACTOR-I; MOLECULAR-IDENTIFICATION; PROSTATE-CANCER; MESSENGER-RNA; APOPTOSIS; CLONING	Translationally controlled tumor protein ( TCTP) is cytoplasmic and structurally related to guanine-nucleotide free chaperones. TCTP ( also called histamine-releasing factor) has been described previously as a secreted protein that participates in inflammatory responses by promoting the release of histamine. How TCTP is eventually exported out of the cell to promote such activities is unknown. Here we show that TCTP secretion was insensitive to either brefeldin A or monensin, suggesting that it proceeds via an endoplasmic reticulum/Golgi-independent or nonclassical pathway. Moreover, our analyses also suggest that secreted TCTP originates from pre-existing pools. TSAP6, a p53-inducible 5-6 transmembrane protein, was found to interact with TCTP in a yeast two-hybrid hunt. GST pull down assays confirmed their direct interaction, and immunofluorescence analysis revealed their partial co-distribution to vesicular-like structures at the plasma membrane and around the nucleus. Functionally, the overexpression of TSAP6 consistently leads to enhanced secretion of both endogenously and exogenously expressed TCTP. Finally, we found TCTP in preparations of small secreted vesicles called exosomes, which have been suggested as a possible pathway for nonclassical secretion. Overexpression of TSAP6 also increased TCTP levels in exosome preparations. Altogether, these data identify a novel role for TSAP6 in the export of TCTP and indicate that this multipass membrane protein could have a general role in the regulation of vesicular trafficking and secretion.	Mol Engines Labs, F-75011 Paris, France; Inst Curie, INSERM, U365, F-75005 Paris, France; CNRS, UMR 144, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Telerman, A (corresponding author), Mol Engines Labs, 20 Rue Bouvier, F-75011 Paris, France.	atelerman@molecular-engines.com	Goud, Bruno/GWC-4807-2022; Segura, Elodie/K-7614-2017; thery, clotilde/F-6373-2013	Segura, Elodie/0000-0003-1795-1921; thery, clotilde/0000-0001-8294-6884				Amson RB, 1996, P NATL ACAD SCI USA, V93, P3953, DOI 10.1073/pnas.93.9.3953; BOHM H, 1991, BIOMED BIOCHIM ACTA, V50, P1193; BOHM H, 1989, BIOCHEM INT, V19, P277; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; Gachet Y, 1997, BIOCHEM SOC T, V25, pS269, DOI 10.1042/bst025269s; Gachet Y, 1999, J CELL SCI, V112, P1257; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Hubert RS, 1999, P NATL ACAD SCI USA, V96, P14523, DOI 10.1073/pnas.96.25.14523; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; Kang HS, 2001, J IMMUNOL, V166, P6545, DOI 10.4049/jimmunol.166.11.6545; Korkmaz KS, 2002, J BIOL CHEM, V277, P36689, DOI 10.1074/jbc.M202414200; Landriscina M, 2001, J BIOL CHEM, V276, P22544, DOI 10.1074/jbc.M100546200; MacDonald SM, 1996, CURR OPIN IMMUNOL, V8, P778, DOI 10.1016/S0952-7915(96)80004-5; MACDONALD SM, 1995, SCIENCE, V269, P688, DOI 10.1126/science.7542803; MacDonald SM, 2001, P NATL ACAD SCI USA, V98, P10829, DOI 10.1073/pnas.201191498; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Moldes M, 2001, J BIOL CHEM, V276, P33938, DOI 10.1074/jbc.M105726200; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORCI L, 1991, CELL, V64, P1183; Passer BJ, 2003, P NATL ACAD SCI USA, V100, P2284, DOI 10.1073/pnas.0530298100; Rao KVN, 2002, J BIOL CHEM, V277, P31207, DOI 10.1074/jbc.M204114200; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Rinaldy A R, 2000, Gan To Kagaku Ryoho, V27 Suppl 2, P215; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Schroeder JT, 1996, J EXP MED, V183, P1265, DOI 10.1084/jem.183.3.1265; Shin JT, 1996, ARCH BIOCHEM BIOPHYS, V335, P32, DOI 10.1006/abbi.1996.0479; Steiner MS, 2000, CANCER RES, V60, P4419; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; Teshima S, 1998, J IMMUNOL, V161, P6356; Thaw P, 2001, NAT STRUCT BIOL, V8, P701, DOI 10.1038/90415; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Xu AM, 1999, BIOCHEM J, V342, P683, DOI 10.1042/0264-6021:3420683; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; YENOFSKY R, 1983, MOL CELL BIOL, V3, P1197, DOI 10.1128/MCB.3.7.1197; YILLA M, 1993, J BIOL CHEM, V268, P19092; Yoneda K, 2004, AM J PHYSIOL-LUNG C, V286, pL174, DOI 10.1152/ajplung.00118.2003; Zhou XQ, 2002, BIOCHEM BIOPH RES CO, V291, P598, DOI 10.1006/bbrc.2002.6473; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	49	151	158	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46104	46112		10.1074/jbc.M404850200	http://dx.doi.org/10.1074/jbc.M404850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319436	hybrid			2022-12-25	WOS:000224694900096
J	Chou, JL; Huang, CL; Lai, HL; Hung, AC; Chien, CL; Kao, YY; Chern, Y				Chou, JL; Huang, CL; Lai, HL; Hung, AC; Chien, CL; Kao, YY; Chern, Y			Regulation of type VI adenylyl cyclase by Snapin, a SNAP25-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE EXPRESSION; CYCLIC-AMP; N-TERMINUS; KINASE; PHOSPHORYLATION; DESENSITIZATION; IDENTIFICATION; TRAFFICKING; PKA; INTERACTS	In the present study, we used the N terminus (amino acids 1similar to160) of type VI adenylyl cyclase (ACVI) as bait to screen a mouse brain cDNA library and identified Snapin as a novel ACVI-interacting molecule. Snapin is a binding protein of SNAP25, a component of the SNARE complex. Co-immunoprecipitation analyses confirmed the interaction between Snapin and full-length ACVI. Mutational analysis revealed that the interaction domains of ACVI and Snapin were located within amino acids 1similar to86 of ACVI and 33-51 of Snapin, respectively. Co-localization of ACVI and Snapin was observed in primary hippocampal neurons. Moreover, expression of Snapin specifically eliminated protein kinase C (PKC)-mediated suppression of ACVI, but not that of cAMP-dependent protein kinase (PKA) or calcium. Mutation of the potential PKC and PKA phosphorylation sites of Snapin did not affect the ability of Snapin to reverse the PKC inhibitory effect on ACVI. Phosphorylation of Snapin by PKC or PKA therefore might not be crucial for Snapin action on ACVI. In contrast, Snapin(Delta33-51), which harbors an internal deletion of amino acids 33-51 did not affect PKC-mediated inhibition of ACVI, supporting that amino acids 33-51 of Snapin comprises the ACVI-interacting region. Consistently, Snapin exerted no effect on PKC-mediated inhibition of an ACVI mutant (ACVI-DeltaA87), which lacked the Snapin-interacting region (amino acids 1-86). Snapin thus reverses its action via direct interaction with the N terminus of ACVI. Collectively, we demonstrate herein that in addition to its association with the SNARE complex, Snapin also functions as a regulator of an important cAMP synthesis enzyme in the brain.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan; Yuanpei Univ Sci & Technol, Dept Med Technol, Hsinchu 300, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chern, Y (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.	bmychern@ibms.sinica.edu.tw	chern, yijuang/S-7013-2018	chern, yijuang/0000-0002-5842-5429; Hung, Chun-Tao/0000-0001-7572-8897				BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; Buxton P, 2003, BIOCHEM J, V375, P433, DOI 10.1042/BJ20030427; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; CHERN YJ, 1995, MOL PHARMACOL, V48, P1; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Chheda MG, 2001, NAT CELL BIOL, V3, P331, DOI 10.1038/35070000; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; COOPER DMF, 1994, BIOCHEM J, V297, P437, DOI 10.1042/bj2970437; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Evans GJO, 2003, BIOCHEM SOC T, V31, P824, DOI 10.1042/bst0310824; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Harlow E., 1988, ANTIBODIES LAB MANUA; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Hilfiker S, 1999, NAT NEUROSCI, V2, P104, DOI 10.1038/5659; Hunt RA, 2003, BIOCHEM BIOPH RES CO, V303, P594, DOI 10.1016/S0006-291X(03)00400-5; Ilardi JM, 1999, NAT NEUROSCI, V2, P119, DOI 10.1038/5673; Inoue A, 2003, CURR OPIN NEUROBIOL, V13, P332, DOI 10.1016/S0959-4388(03)00077-1; Jones MB, 1999, ANAL BIOCHEM, V268, P126, DOI 10.1006/abio.1998.3064; Kavalali ET, 2002, BIOESSAYS, V24, P926, DOI 10.1002/bies.10165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; Lee YC, 2003, EUR J NEUROSCI, V18, P1786, DOI 10.1046/j.1460-9568.2003.02907.x; Lin TH, 2002, J BIOL CHEM, V277, P15721, DOI 10.1074/jbc.M111537200; Liu FC, 1998, FEBS LETT, V436, P92, DOI 10.1016/S0014-5793(98)01098-9; Lu HC, 2003, NAT NEUROSCI, V6, P939, DOI 10.1038/nn1106; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Salim S, 2003, J BIOL CHEM, V278, P15842, DOI 10.1074/jbc.M210663200; Scholich K, 2001, J BIOL CHEM, V276, P47583, DOI 10.1074/jbc.M107816200; Shih YP, 2002, PROTEIN SCI, V11, P1714, DOI 10.1110/ps.0205202; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Starcevic M, 2004, J BIOL CHEM, V279, P28393, DOI 10.1074/jbc.M402513200; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Vites O, 2004, J BIOL CHEM, V279, P26251, DOI 10.1074/jbc.M404079200; Wang HB, 2003, J NEUROSCI, V23, P9710; Wang HB, 2002, J NEUROCHEM, V83, P946, DOI 10.1046/j.1471-4159.2002.01206.x; WONG YH, 1994, METHOD ENZYMOL, V238, P81; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200	43	38	39	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46271	46279		10.1074/jbc.M407206200	http://dx.doi.org/10.1074/jbc.M407206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319443	hybrid			2022-12-25	WOS:000224694900114
J	Doucet, N; De Wals, PY; Pelletier, JN				Doucet, N; De Wals, PY; Pelletier, JN			Site-saturation mutagenesis of Tyr-105 reveals its importance in substrate stabilization and discrimination in TEM-1 beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; STRUCTURE-BASED DESIGN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MOLECULAR-DYNAMICS; EXTENDED-SPECTRUM; RESOLUTION; ENZYME; MECHANISM; BENZYLPENICILLIN	The conserved Class A beta-lactamase active site residue Tyr-105 was substituted by saturation mutagenesis in TEM-1 alpha-lactamase from Escherichia coli in order to clarify its role in enzyme activity and in substrate stabilization and discrimination. Minimum inhibitory concentrations were calculated for E. coli cells harboring each Y105X mutant in the presence of various penicillin and cephalosporin antibiotics. We found that only aromatic residues as well as asparagine replacements conferred high in vivo survival rates for all substrates tested. At position 105, the small residues alanine and glycine provide weak substrate discrimination as evidenced by the difference in benzylpenicillin hydrolysis relative to cephalothin, two typical penicillin and cephalosporin antibiotics. Kinetic analyses of mutants of interest revealed that the Y105X replacements have a greater effect on K-m than k(cat), highlighting the importance of Tyr-105 in substrate recognition. Finally, by performing a short molecular dynamics study on a restricted set of Y105X mutants of TEM-1, we found that the strong aromatic bias observed at position 105 in Class A beta-lactamases is primarily defined by a structural requirement, selecting planar residues that form a stabilizing wall to the active site. The adopted conformation of residue 105 prevents detrimental steric interactions with the substrate molecule in the active site cavity and provides a rationalization for the strong aromatic bias found in nature at this position among Class A beta-lactamases.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Chim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Pelletier, JN (corresponding author), Univ Montreal, Dept Biochim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	joelle.pelletier@umontreal.ca						Abraham EP, 1940, NATURE, V146, P837, DOI 10.1038/146837a0; AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; Bouthors AT, 1998, BIOCHEM J, V330, P1443, DOI 10.1042/bj3301443; BULYCHEV A, 1995, J AM CHEM SOC, V117, P5938, DOI 10.1021/ja00127a005; Bush K, 1998, ADV EXP MED BIOL, V456, P71; Cantu C, 1996, J BIOL CHEM, V271, P22538, DOI 10.1074/jbc.271.37.22538; Castillo R, 2002, J AM CHEM SOC, V124, P1809, DOI 10.1021/ja017156z; Chen CCH, 2001, BIOCHEMISTRY-US, V40, P2351, DOI 10.1021/bi002277h; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; Diaz N, 2003, J AM CHEM SOC, V125, P672, DOI 10.1021/ja027704o; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; DiGleria K, 1997, FEBS LETT, V400, P155, DOI 10.1016/S0014-5793(96)01373-7; ESCOBAR WA, 1994, BIOCHEM J, V303, P555, DOI 10.1042/bj3030555; Guo FS, 1999, BBA-PROTEIN STRUCT M, V1431, P132, DOI 10.1016/S0167-4838(99)00048-5; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang WZ, 1996, J MOL BIOL, V258, P688, DOI 10.1006/jmbi.1996.0279; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; MATAGNE A, 1995, BBA-PROTEIN STRUCT M, V1246, P109, DOI 10.1016/0167-4838(94)00177-I; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Maveyraud L, 1998, J AM CHEM SOC, V120, P9748, DOI 10.1021/ja9818001; Maveyraud L, 1996, J AM CHEM SOC, V118, P7435, DOI 10.1021/ja9609718; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; Ness S, 2000, BIOCHEMISTRY-US, V39, P5312, DOI 10.1021/bi992505b; Orencia MC, 2001, NAT STRUCT BIOL, V8, P238, DOI 10.1038/84981; Page MGF, 2000, DRUG RESIST UPDATE, V3, P109, DOI 10.1054/drup.2000.0137; Shimamura T, 2002, J BIOL CHEM, V277, P46601, DOI 10.1074/jbc.M207884200; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P290, DOI 10.1038/nsb0396-290; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P688, DOI 10.1038/nsb0896-688; Swaren P, 1998, J BIOL CHEM, V273, P26714, DOI 10.1074/jbc.273.41.26714; TaibiTronche P, 1996, J AM CHEM SOC, V118, P7441, DOI 10.1021/ja9529753; Tranier S, 2000, J BIOL CHEM, V275, P28075; Wang XJ, 2003, BIOCHEMISTRY-US, V42, P8434, DOI 10.1021/bi034242y; WOLOZIN BL, 1982, BIOCHIM BIOPHYS ACTA, V701, P153, DOI 10.1016/0167-4838(82)90108-X; Yang YJ, 1999, PHARMACOL THERAPEUT, V83, P141, DOI 10.1016/S0163-7258(99)00027-3; ZAFARALLA G, 1992, BIOCHEMISTRY-US, V31, P3847, DOI 10.1021/bi00130a016	39	38	40	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46295	46303		10.1074/jbc.M407606200	http://dx.doi.org/10.1074/jbc.M407606200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326193	hybrid			2022-12-25	WOS:000224694900117
J	Roose, JL; Pakrasi, HB				Roose, JL; Pakrasi, HB			Evidence that D1 processing is required for manganese binding and extrinsic protein assembly into photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME STRUCTURE; LOW-FLUORESCENT MUTANTS; AMINO-ACID-RESIDUES; OXIDIZING SIDE; SCENEDESMUS-OBLIQUUS; CRYSTAL-STRUCTURE; CYANOBACTERIUM; SYNECHOCYSTIS; POLYPEPTIDE; CLUSTER	Photosystem II (PSII) is a large membrane protein complex that catalyzes oxidation of water to molecular oxygen. During its normal function, PSII is damaged and frequently turned over. The maturation of the D1 protein, a key component in PSII, is a critical step in PSII biogenesis. The precursor form of D1 (pD1) contains a C-terminal extension, which is removed by the protease CtpA to yield PSII complexes with oxygen evolution activity. To determine the temporal position of D1 processing in the PSII assembly pathway, PSII complexes containing only pD1 were isolated from a CtpA-deficient strain of the cyanobacterium Synechocystis 6803. Although membranes from the mutant cell had nearly 50% manganese, no manganese was detected in isolated DeltactpAHT3 PSII, indicating a severely decreased manganese affinity. However, chlorophyll fluorescence decay kinetics after a single saturating flash suggested that the donor Y-Z was accessible to exogenous Mn2+ ions. Furthermore, the extrinsic proteins PsbO, PsbU, and PsbV were not present in PSII isolated from this mutant. However, PsbO and PsbV were present in mutant membranes, but the amount of PsbV protein was consistently less in the mutant membranes compared with the control membranes. We conclude that D1 processing precedes manganese binding and assembly of the extrinsic proteins into PSII. Interestingly, the Psb27 protein was found to be more abundant in DeltactpAHT3 PSII than in HT3 PSII, suggesting a possible role of Psb27 as an assembly factor during PSII biogenesis.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pakrasi, HB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.	Pakrasi@wustl.edu						ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; Ananyev GM, 2001, BBA-BIOENERGETICS, V1503, P52, DOI 10.1016/S0005-2728(00)00215-2; ANBUDURAI PR, 1994, P NATL ACAD SCI USA, V91, P8082, DOI 10.1073/pnas.91.17.8082; Andersson B, 2001, ADV PHOTOSYNTH, V11, P377; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; Bricker TM, 1998, BBA-BIOENERGETICS, V1409, P50, DOI 10.1016/S0005-2728(98)00148-0; Chu HA, 2004, BIOCHEMISTRY-US, V43, P3152, DOI 10.1021/bi035915f; CHU HA, 1994, BIOCHEMISTRY-US, V33, P6150, DOI 10.1021/bi00186a014; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Debus RJ, 2001, BBA-BIOENERGETICS, V1503, P164, DOI 10.1016/S0005-2728(00)00221-8; Dennis C, 2000, NATURE, V408, P791; Diner BA, 1998, METHOD ENZYMOL, V297, P337; DINER BA, 1988, J BIOL CHEM, V263, P8972; Diner BA, 2001, BBA-BIOENERGETICS, V1503, P147, DOI 10.1016/S0005-2728(00)00220-6; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Goussias C, 2002, PHILOS T R SOC B, V357, P1369, DOI 10.1098/rstb.2002.1134; Ikeuchi M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P297; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; KAVELAKI K, 1991, PHOTOSYNTH RES, V29, P149, DOI 10.1007/BF00036218; Keren N, 1997, P NATL ACAD SCI USA, V94, P1579, DOI 10.1073/pnas.94.4.1579; Keren N, 2002, BIOCHEMISTRY-US, V41, P15085, DOI 10.1021/bi026892s; METZ J, 1980, BIOCHEM BIOPH RES CO, V94, P560, DOI 10.1016/0006-291X(80)91268-1; METZ JG, 1985, FEBS LETT, V185, P191, DOI 10.1016/0014-5793(85)80768-7; METZ JG, 1980, FEBS LETT, V114, P61, DOI 10.1016/0014-5793(80)80861-1; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; Nakamura Y, 2002, DNA RES, V9, P123, DOI 10.1093/dnares/9.4.123; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; Pakrasi HB, 1995, ANNU REV GENET, V29, P755; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Qian M, 1997, BIOCHEMISTRY-US, V36, P15244, DOI 10.1021/bi9713198; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; RUTHERFORD AW, 1988, BIOCHIM BIOPHYS ACTA, V932, P171, DOI 10.1016/0005-2728(88)90152-1; SHESTAKOV SV, 1994, J BIOL CHEM, V269, P19354; TAKAHASHI M, 1988, FEBS LETT, V240, P6, DOI 10.1016/0014-5793(88)80330-2; TAKAHASHI Y, 1990, PLANT CELL PHYSIOL, V31, P273; Thornton LE, 2004, PLANT CELL, V16, P2164, DOI 10.1105/tpc.104.023515; Trost JT, 1997, J BIOL CHEM, V272, P20348, DOI 10.1074/jbc.272.33.20348; Zak E, 1999, EUR J BIOCHEM, V261, P311, DOI 10.1046/j.1432-1327.1999.00281.x; Zhang LX, 2000, PLANT CELL, V12, P1769, DOI 10.1105/tpc.12.9.1769; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	46	93	96	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45417	45422		10.1074/jbc.M408458200	http://dx.doi.org/10.1074/jbc.M408458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308630	hybrid, Green Published			2022-12-25	WOS:000224694900017
J	Schultz, CJ; Ferguson, KL; Lahnstein, J; Bacic, A				Schultz, CJ; Ferguson, KL; Lahnstein, J; Bacic, A			Post-translational modifications of arabinogalactan-peptides of Arabidopsis thaliana - Endoplasmic reticulum and glycosylphosphatidylinositol-anchor signal cleavage sites and hydroxylation of proline	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUM-ARABIC GLYCOPROTEIN; MUCIN TANDEM REPEAT; LIPID ANCHOR; EXTRACELLULAR-MATRIX; TOMATO LEAGP-1; DRAFT SEQUENCE; PYRUS-COMMUNIS; OMEGA-SITE; PROTEINS; GLYCOSYLATION	We have developed a method for separating the deglycosylated protein/peptide backbones of the small arabinogalactan (AG)-peptides from the larger classical arabinogalactan-proteins (AGPs). AGPs are an important class of plant proteoglycans implicated in plant growth and development. Separation of AG-peptides enabled us to identify eight of 12 AG-peptides from Arabidopsis thaliana predicted from genomic sequences. Of the remaining four, two have low abundance based on expressed sequence tag databases and the other two are only present in pollen (At3g20865) or flowers (At3g57690) and therefore would not be detected in our analysis. Characterization of AG-peptides was performed using matrix-assisted laser desorption ionization-time of flight mass spectrometry and tandem mass spectrometry protein sequencing. These data provide (i) experimental evidence that AG-peptides are processed in vivo for the addition of a glycosylphosphatidylinositol (GPI) anchor, (ii) cleavage site information for both the endoplasmic reticulum secretion signal and the GPI-anchor signal for eight of the 12 AG-peptides, and (iii) experimental evidence that the Gly-Pro motif is hydroxylated in vivo. Furthermore, we show that AtAGP16 is GPI-anchored despite its unusually long hydrophobic C-terminal GPI-signal sequence. Prior to this work, the GPI-anchor cleavage site for only two plant proteins, NaAGP1 from Nicotiana alata and PcAGP1 from Pyrus communis, had been determined experimentally. Characterization of the post-translational modifications of AG-peptides contributes toward obtaining the complete primary structure of this class of biologically important plant proteoglycans and provides a greater understanding of post-translational modifications of plant proteins.	Univ Adelaide, Waite Agr Res Inst, Sch Agr & Wine, Glen Osmond, SA 5064, Australia; Univ Melbourne, Sch Bot, Australian Ctr Plant Funct Genom, Parkville, Vic 3010, Australia; Univ Melbourne, Sch Bot, Plant Cell Biol Res Ctr, Parkville, Vic 3010, Australia	University of Adelaide; University of Melbourne; University of Melbourne	Schultz, CJ (corresponding author), Univ Adelaide, Waite Agr Res Inst, Sch Agr & Wine, PMB1, Glen Osmond, SA 5064, Australia.	carolyn.schultz@adelaide.edu.au		Bacic, Tony/0000-0001-7483-8605				Borner GHH, 2003, PLANT PHYSIOL, V132, P568, DOI 10.1104/pp.103.021170; Borner GHH, 2002, PLANT PHYSIOL, V129, P486, DOI 10.1104/pp.010884; Chai L, 1999, EXP NEUROL, V160, P175, DOI 10.1006/exnr.1999.7195; Dalley JA, 2003, J BIOL CHEM, V278, P51749, DOI 10.1074/jbc.M303978200; Du H, 1996, TRENDS CELL BIOL, V6, P411, DOI 10.1016/S0962-8924(96)20036-4; Eisenhaber B, 2000, TRENDS BIOCHEM SCI, V25, P340, DOI 10.1016/S0968-0004(00)01601-7; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Eisenhaber B, 2003, PLANT PHYSIOL, V133, P1691, DOI 10.1104/pp.103.023580; Eisenhaber B, 2003, BIOESSAYS, V25, P367, DOI 10.1002/bies.10254; Eisenhaber B, 2001, PROTEIN ENG, V14, P17, DOI 10.1093/protein/14.1.17; FINCHER GB, 1974, BIOCHEM J, V139, P535, DOI 10.1042/bj1390535; Gaspar Y, 2001, PLANT MOL BIOL, V47, P161, DOI 10.1023/A:1010683432529; Gens JS, 2000, PROTOPLASMA, V212, P115, DOI 10.1007/BF01279353; Gerken TA, 2002, J BIOL CHEM, V277, P49850, DOI 10.1074/jbc.M205851200; Gerken TA, 2002, J BIOL CHEM, V277, P7736, DOI 10.1074/jbc.M111690200; Gobom J, 2002, ANAL CHEM, V74, P3915, DOI 10.1021/ac011203o; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Goodrum LJ, 2000, PHYTOCHEMISTRY, V54, P99, DOI 10.1016/S0031-9422(00)00043-1; Han C, 2004, DEVELOPMENT, V131, P601, DOI 10.1242/dev.00958; Hieta R, 2002, J BIOL CHEM, V277, P23965, DOI 10.1074/jbc.M201865200; Jacobsen R, 1998, J PEPT RES, V51, P173; JERMYN MA, 1978, AUST J PLANT PHYSIOL, V5, P697, DOI 10.1071/PP9780697; Johnson K., 2003, PLANT CELL WALL, V8, P111; Johnson KL, 2003, PLANT PHYSIOL, V133, P1911, DOI 10.1104/pp.103.031237; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kieliszewski MJ, 2001, CELL MOL LIFE SCI, V58, P1386, DOI 10.1007/PL00000783; KNOX JP, 1995, FASEB J, V9, P1004, DOI 10.1096/fasebj.9.11.7544308; Lalanne E, 2004, PLANT CELL, V16, P229, DOI 10.1105/tpc.014407; Majewska-Sawka A, 2000, PLANT PHYSIOL, V122, P3, DOI 10.1104/pp.122.1.3; MAU SL, 1995, PLANT J, V8, P269, DOI 10.1046/j.1365-313X.1995.08020269.x; Misawa H, 1996, PLANT PHYSIOL, V110, P665, DOI 10.1104/pp.110.2.665; MORT AJ, 1977, ANAL BIOCHEM, V82, P289, DOI 10.1016/0003-2697(77)90165-8; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nothnagel EA, 1997, INT REV CYTOL, V174, P195, DOI 10.1016/S0074-7696(08)62118-X; Oxley D, 1999, P NATL ACAD SCI USA, V96, P14246, DOI 10.1073/pnas.96.25.14246; Pallaghy PK, 2000, BIOCHEMISTRY-US, V39, P12845, DOI 10.1021/bi0010930; QI W, 1991, PLANT PHYSIOL, V96, P848, DOI 10.1104/pp.96.3.848; Schultz C, 1998, TRENDS PLANT SCI, V3, P426, DOI 10.1016/S1360-1385(98)01328-4; Schultz CJ, 1997, PLANT MOL BIOL, V35, P833, DOI 10.1023/A:1005816520060; Schultz CJ, 2002, PLANT PHYSIOL, V129, P1448, DOI 10.1104/pp.003459; Schultz CJ, 2000, PLANT CELL, V12, P1751, DOI 10.1105/tpc.12.9.1751; SERPE MD, 1994, PLANTA, V193, P542, DOI 10.1007/BF02411560; Sherrier DJ, 1999, ELECTROPHORESIS, V20, P2027, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2027::AID-ELPS2027>3.0.CO;2-A; Showalter AM, 2001, CELL MOL LIFE SCI, V58, P1399, DOI 10.1007/PL00000784; Shpak E, 2001, J BIOL CHEM, V276, P11272, DOI 10.1074/jbc.M011323200; Simpson RJ, 2003, PROTEINS PROTEOMICS; Sun WX, 2004, PHYSIOL PLANTARUM, V120, P319, DOI 10.1111/j.0031-9317.2004.0236.x; Svetek J, 1999, J BIOL CHEM, V274, P14724, DOI 10.1074/jbc.274.21.14724; Takos AM, 2000, PLANT J, V21, P43, DOI 10.1046/j.1365-313x.2000.00651.x; Tan L, 2003, PLANT PHYSIOL, V132, P1362, DOI 10.1104/pp.103.021766; Tan L, 2004, J BIOL CHEM, V279, P13156, DOI 10.1074/jbc.M311864200; UDENFRIEND S, 1995, METHOD ENZYMOL, V250, P571; Van den Bulck K, 2002, CEREAL CHEM, V79, P329, DOI 10.1094/CCHEM.2002.79.3.329; van Hengel AJ, 2002, PLANT J, V32, P105, DOI 10.1046/j.1365-313X.2002.01406.x; VANHOLST GJ, 1984, PLANT PHYSIOL, V75, P1163, DOI 10.1104/pp.75.4.1163; Wang JY, 1999, J MOL BIOL, V286, P1303, DOI 10.1006/jmbi.1999.2584; Wilkins MR, 1999, J MOL BIOL, V289, P645, DOI 10.1006/jmbi.1999.2794; Wilson IBH, 2002, CURR OPIN STRUC BIOL, V12, P569, DOI 10.1016/S0959-440X(02)00367-6; Yamada H, 2000, CELL AND DEVELOPMENTAL BIOLOGY OF ARABINOGALACTAN-PROTEINS, P221; Youl JJ, 1998, P NATL ACAD SCI USA, V95, P7921, DOI 10.1073/pnas.95.14.7921; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Zhao ZD, 2002, PLANT J, V31, P431, DOI 10.1046/j.1365-313X.2002.01365.x	63	64	80	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45503	45511		10.1074/jbc.M407594200	http://dx.doi.org/10.1074/jbc.M407594200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322080	hybrid			2022-12-25	WOS:000224694900028
J	Jaubert, M; Zappa, S; Fardoux, J; Adriano, JM; Hannibal, L; Elsen, S; Lavergne, J; Vermeglio, A; Giraud, E; Pignol, D				Jaubert, M; Zappa, S; Fardoux, J; Adriano, JM; Hannibal, L; Elsen, S; Lavergne, J; Vermeglio, A; Giraud, E; Pignol, D			Light and redox control of photosynthesis gene expression in Bradyrhizobium - Dual roles of two PpsR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR; BACTERIOCHLOROPHYLL; BACTERIOPHYTOCHROME; SEQUENCE; OXYGEN; APPA; CRTJ	The two closely related bacteria Bradyrhizobium and Rhodopseudomonas palustris show an unusual mechanism of regulation of photosystem formation by light thanks to a bacteriophytochrome that antirepresses the regulator PpsR. In these two bacteria, we found out, unexpectedly, that two ppsR genes are present. We show that the two Bradyrhizobium PpsR proteins exert antagonistic effects in the regulation of photosystem formation with a classical repressor role for PpsR2 and an unexpected activator role for PpsR1. DNase I footprint analysis show that both PpsR bind to the same DNA TGTN(12)ACA motif that is present in tandem in the bchC promoter and the crtED intergenic region. Interestingly, the cycA and aerR promoter regions that contain only one conserved palindrome are recognized by PpsR2, but not PpsR1. Further biochemical analyses indicate that PpsR1 only is redox sensitive through the formation of an intermolecular disulfide bond, which changes its oligomerization state from a tetramer to an octamer under oxidizing conditions. Moreover, PpsR1 presents a higher DNA affinity under its reduced form in contrast to what has been previously found for PpsR or its homolog CrtJ from the Rhodobacter species. These results suggest that regulation of photosystem synthesis in Bradyrhizobium involves two PpsR competing for the binding to the same photosynthesis genes and this competition might be modulated by two factors: light via the antagonistic action of a bacteriophytochrome on PpsR2 and redox potential via the switch of PpsR1 oligomerization state.	IRD, Lab Symbioses Trop & Mediterraneennes, UMR113,CIRAD, AGRO,INRA UM2, F-34398 Montpellier 5, France; Univ Mediterranee, CEA 1000, CEA,CNRS,UMR 6191,Lab Bioenerget Cellulaire, CEA,Cadarache DEVM, F-13108 St Paul Les Durance, France; Univ Grenoble 1, CEA Grenoble, CNRS, UMR 5092,Lab Biochim & Biophys Syst Integres, F-38054 Grenoble 9, France	CIRAD; INRAE; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Giraud, E (corresponding author), IRD, Lab Symbioses Trop & Mediterraneennes, UMR113,CIRAD, AGRO,INRA UM2, LSTM TA 10-J,Campus Baillarguet, F-34398 Montpellier 5, France.	Giraud@mpl.ird.fr	Giraud, Eric/GLS-1036-2022	PIGNOL, David/0000-0002-8070-0319; Elsen, Sylvie/0000-0003-4611-4719				Alberti M, 1995, ANOXYGENIC PHOTOSYNT, P1083; ANSARI AZ, 1995, NATURE, V374, P371; Bauer C, 2003, PHILOS T R SOC B, V358, P147, DOI 10.1098/rstb.2002.1189; Braatsch S, 2002, MOL MICROBIOL, V45, P827, DOI 10.1046/j.1365-2958.2002.03058.x; Choudhary M, 2000, NUCLEIC ACIDS RES, V28, P862, DOI 10.1093/nar/28.4.862; Dong C, 2002, J BACTERIOL, V184, P2805, DOI 10.1128/JB.184.10.2805-2814.2002; Elsen S, 1998, J BIOL CHEM, V273, P30762, DOI 10.1074/jbc.273.46.30762; Giraud E, 2004, PHOTOCH PHOTOBIO SCI, V3, P587, DOI 10.1039/b315770a; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Giraud E, 2000, P NATL ACAD SCI USA, V97, P14795, DOI 10.1073/pnas.250484097; Gomelsky L, 2003, MICROBIOL-SGM, V149, P377, DOI 10.1099/mic.0.25972-0; GOMELSKY M, 1995, J BACTERIOL, V177, P1634, DOI 10.1128/jb.177.6.1634-1637.1995; Gomelsky M, 2000, J BACTERIOL, V182, P2253, DOI 10.1128/JB.182.8.2253-2261.2000; Gregor J, 1999, FEMS MICROBIOL LETT, V179, P1; KOKOTEK W, 1989, GENE, V84, P67; Larimer FW, 2004, NAT BIOTECHNOL, V22, P55, DOI 10.1038/nbt923; Masuda S, 2002, CELL, V110, P613, DOI 10.1016/S0092-8674(02)00876-0; Masuda S, 2002, P NATL ACAD SCI USA, V99, P7078, DOI 10.1073/pnas.102013099; Oh JI, 2001, MOL MICROBIOL, V39, P1116, DOI 10.1046/j.1365-2958.2001.02299.x; Oh JI, 2000, EMBO J, V19, P4237, DOI 10.1093/emboj/19.16.4237; PENFOLD RJ, 1994, J BACTERIOL, V176, P2869, DOI 10.1128/JB.176.10.2869-2876.1994; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; Senear DF, 1998, METHODS, V16, P3, DOI 10.1006/meth.1998.0641; Steunou AS, 2004, J BACTERIOL, V186, P3133, DOI 10.1128/JB.186.10.3133-3142.2004; Zeilstra-Ryalls JH, 2004, CELL MOL LIFE SCI, V61, P417, DOI 10.1007/s00018-003-3242-1	27	42	48	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44407	44416		10.1074/jbc.M408039200	http://dx.doi.org/10.1074/jbc.M408039200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304477	hybrid			2022-12-25	WOS:000224505600024
J	Sluyter, R; Shemon, AN; Barden, JA; Wiley, JS				Sluyter, R; Shemon, AN; Barden, JA; Wiley, JS			Extracellular ATP increases cation fluxes in human erythrocytes by activation of the P2X(7) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALA POLYMORPHISM; ADENOSINE-TRIPHOSPHATASE; PURINERGIC RECEPTORS; HUMAN-LYMPHOCYTES; CUTTING EDGE; BINDING-SITE; BLOOD-CELLS; SODIUM; PERMEABILITY; CHANNELS	Canine erythrocytes are known to undergo a reversible increase in cation permeability when incubated with extracellular ATP. We have examined the expression and function of P2X receptors on human erythrocytes using confocal microscopy and a panel of anti-P2X(1-7) antibodies and have measured monovalent cation fluxes in the presence of various nucleotide agonists. Human erythrocytes expressed P2X(7) receptors on all cells examined from eight of eight subjects, as well as P2X(2) at a far lower staining intensity in six of eight subjects. ATP stimulated the efflux of Rb-86(+) (K+) from human erythrocytes in a dose-dependent fashion with an EC50 of similar to95 muM. Other nucleotides also induced an efflux of Rb-86(+) from erythrocytes with an order of agonist potency of 2'- and 3'-O(4-benzoylbenzoyl) ATP ( BzATP)>ATP>2-methylthio-ATP (2MeSATP)>adenosine 5'-O-(3-thiotriphosphate) (ATPgammaS), whereas ADP or UTP had no effect. ATP-induced efflux of Rb-86(+) from erythrocytes was inhibited by extracellular Na+ and oxidized ATP, as well as by KN-62, an antagonist specific for the human P2X(7) receptor. When erythrocytes were incubated in isotonic KCl medium, the addition of ATP stimulated an Rb-86(+) influx approximately equal in magnitude to ATP-stimulated Rb-86(+) efflux from the same cells. BzATP also stimulated the influx of Na-22(+) into erythrocytes incubated in isotonic NaCl medium. Both ATP-induced efflux and influx of Rb-86(+) and Na-22(+) were impaired in erythrocytes from subjects who had inherited loss-of-function polymorphisms in the P2X(7) receptor. These results suggest that the reversible permeabilization of erythrocytes by extracellular ATP is mediated by the P2X(7) receptor.	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2750, Australia; Nepean Hosp, Dept Pathol, Penrith, NSW 2750, Australia; Univ Sydney, Inst Biomed Res, Biosceptre Res Lab, Sydney, NSW 2006, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia	Nepean Hospital; University of Sydney; Nepean Hospital; University of Sydney; University of Sydney; University of Sydney	Wiley, JS (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Level 5 S Block, Penrith, NSW 2750, Australia.	wileyj@medicine.usyd.edu.au	Sluyter, Ronald/B-5798-2009	Sluyter, Ronald/0000-0003-4909-686X; Wiley, James/0000-0001-9421-4154				Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Boldt W, 2003, AM J PHYSIOL-CELL PH, V284, pC749, DOI 10.1152/ajpcell.00042.2002; BOYER JL, 1989, J BIOL CHEM, V264, P884; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Courageot MP, 2004, J BIOL CHEM, V279, P21815, DOI 10.1074/jbc.M401426200; Dao-Ung LP, 2004, BRIT J HAEMATOL, V125, P815, DOI 10.1111/j.1365-2141.2004.04976.x; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Ding SH, 1999, J GEN PHYSIOL, V113, P695, DOI 10.1085/jgp.113.5.695; Drabkin DL, 1935, J BIOL CHEM, V112, P51; DUNHAM ET, 1961, J PHYSIOL-LONDON, V156, P274, DOI 10.1113/jphysiol.1961.sp006675; Enderle T, 1997, P NATL ACAD SCI USA, V94, P520, DOI 10.1073/pnas.94.2.520; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081; Gargett CE, 1997, BRIT J PHARMACOL, V122, P911, DOI 10.1038/sj.bjp.0701447; Gibson JS, 2003, RED CELL MEMBRANE TR, P721; Gu BJ, 2004, J BIOL CHEM, V279, P31287, DOI 10.1074/jbc.M313902200; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Lang KS, 2003, N-S ARCH PHARMACOL, V367, P391, DOI 10.1007/s00210-003-0701-z; Lang KS, 2003, CELL DEATH DIFFER, V10, P249, DOI 10.1038/sj.cdd.4401144; Li GH, 2000, J BIOL CHEM, V275, P29107, DOI 10.1074/jbc.M910277199; Light DB, 2001, J MEMBRANE BIOL, V182, P193, DOI 10.1007/s0023201-0043-z; Light DB, 1999, AM J PHYSIOL-CELL PH, V277, pC480, DOI 10.1152/ajpcell.1999.277.3.C480; Lynch KJ, 1999, MOL PHARMACOL, V56, P1171, DOI 10.1124/mol.56.6.1171; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mandal D, 2002, FEBS LETT, V513, P184, DOI 10.1016/S0014-5793(02)02294-9; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; Moore KH, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-18-j0002.2001; Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02-04-0061; MURGIA M, 1993, J BIOL CHEM, V268, P8199; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; PARKER JC, 1977, J GEN PHYSIOL, V69, P417, DOI 10.1085/jgp.69.4.417; PARKER JC, 1972, AM J PHYSIOL, V223, P888, DOI 10.1152/ajplegacy.1972.223.4.888; Pfeiffer ZA, 2004, J LEUKOCYTE BIOL, V75, P1173, DOI 10.1189/jlb.1203648; POST RL, 1960, J BIOL CHEM, V235, P1796; ROMUALDEZ A, 1976, J CELL PHYSIOL, V87, P297, DOI 10.1002/jcp.1040870305; Saunders BM, 2003, J IMMUNOL, V171, P5442, DOI 10.4049/jimmunol.171.10.5442; Shemon AN, 2004, BRIT J PHARMACOL, V142, P1015, DOI 10.1038/sj.bjp.0705868; Sluyter R, 2004, GENES IMMUN, V5, P588, DOI 10.1038/sj.gene.6364127; Sluyter R, 2004, J IMMUNOL, V172, P3399, DOI 10.4049/jimmunol.172.6.3399; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Sluyter R, 2001, CELL TISSUE RES, V304, P231, DOI 10.1007/s004410100372; STEINBERG TH, 1987, J BIOL CHEM, V262, P3118; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Verhoef PA, 2003, J IMMUNOL, V170, P5728, DOI 10.4049/jimmunol.170.11.5728; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Wiley JS, 2003, J BIOL CHEM, V278, P17108, DOI 10.1074/jbc.M212759200; Wiley JS, 2002, LANCET, V359, P1114, DOI 10.1016/S0140-6736(02)08156-4; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T; WILEY JS, 1974, J CLIN INVEST, V53, P745, DOI 10.1172/JCI107613; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7	55	59	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44749	44755		10.1074/jbc.M405631200	http://dx.doi.org/10.1074/jbc.M405631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304508	hybrid			2022-12-25	WOS:000224505600063
J	Holmborn, K; Ledin, J; Smeds, E; Eriksson, I; Kusche-Gullberg, M; Kjellen, L				Holmborn, K; Ledin, J; Smeds, E; Eriksson, I; Kusche-Gullberg, M; Kjellen, L			Heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and NDST2 is 6-O-sulfated but contains no N-sulfate groups	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSAMINE RESIDUES; NEONATAL LETHALITY; AMINO-GROUPS; SULFOTRANSFERASE; MICE; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; SPECIFICITIES; DISRUPTION	Heparan sulfate structure differs significantly between various cell types and during different developmental stages. The diversity is created during biosynthesis by sulfotransferases, which add sulfate groups to the growing chain, and a C5-epimerase, which converts selected glucuronic acid residues to iduronic acid. All these modifications are believed to depend on initial glucosamine N-sulfation carried out by the enzyme glucosaminyl N-deacetylase/N-sulfotransferase (NDST). Here we report that heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and NDST2 completely lacks N-sulfation but still contains 6-O-sulfate groups, demonstrating that 6-O-sulfation can occur without prior N-sulfation. Reverse transcriptase-PCR analysis indicates that all three identified 6-O-sulfotransferases are expressed by the cells, 6-O-sulfotransferase-1 being the dominating form. The 6-O-sulfated polysaccharide lacking N-sulfate groups also contains N-unsubstituted glucosamine units, raising questions about how these units are generated.	BMC, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden		Kjellen, L (corresponding author), BMC, Dept Med Biochem & Microbiol, Box 582, SE-75123 Uppsala, Sweden.	lena.kjellen@imbim.uu.se	Kjellen, Lena/F-1362-2011; Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ledin, Johan/0000-0002-7319-7735				Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Bengtsson J, 2003, BIOCHEMISTRY-US, V42, P2110, DOI 10.1021/bi026928g; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; LEDIN J, 2004, J BIOL CHEM     0729; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; RIESENFELD J, 1982, J BIOL CHEM, V257, P421; RIESENFELD J, 1990, ANAL BIOCHEM, V188, P383, DOI 10.1016/0003-2697(90)90624-I; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; Staatz W D, 2001, Methods Mol Biol, V171, P41; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200	25	79	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42355	42358		10.1074/jbc.C400373200	http://dx.doi.org/10.1074/jbc.C400373200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15319440	hybrid			2022-12-25	WOS:000224226400003
J	Grinninger, C; Wang, WG; Oskoui, KB; Voice, JK; Goetzl, EJ				Grinninger, C; Wang, WG; Oskoui, KB; Voice, JK; Goetzl, EJ			A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; MODEL BASEMENT-MEMBRANE; T-CELL MIGRATION; EXPRESSION; SELECTIVITY; MICE; VIP1; GENE; PCR	The vasoactive intestinal peptide (VIP) and its G protein-coupled receptors VPAC(1) and VPAC(2) prominently mediate diverse physiological functions in the neural, endocrine, and immune systems. A deletion variant of mouse VPAC(2) has been identified in immune cells that lacks amino acids 367 - 380 at the carboxyl-terminal end of the seventh transmembrane domain. When expressed at equivalent levels in a human Jurkat T cell line, which has very low endogenous expression of human VPAC(1) and VPAC(2), wild-type and deletion-variant VPAC(2) bound the same amount of I-125-VIP with similar affinity. Unlike wild-type VPAC(2), however, deletion-variant VPAC(2) did not transduce VIP-elicited increases in intracellular concentration of cyclic AMP, chemotaxis, or suppression of generation of interleukin-2. Natural deletion of part of the last transmembrane domain of VPAC(2) thus abrogates signaling functions without apparent alterations of expression or ligand binding.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, Rm UB8B,UC Box 0711,533 Parnassus & 4th Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu			NIAID NIH HHS [AI29912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029912, R01AI029912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ajpru S, 2002, MOL BRAIN RES, V105, P29, DOI 10.1016/S0169-328X(02)00387-X; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Juarranz MG, 1999, MOL PHARMACOL, V56, P1280, DOI 10.1124/mol.56.6.1280; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; Lutz EM, 1999, FEBS LETT, V458, P197, DOI 10.1016/S0014-5793(99)01135-7; Nicole P, 1998, J PHARMACOL EXP THER, V284, P744; Park CG, 2000, J PHARMACOL EXP THER, V295, P682; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; SREEDHARAN SP, 1994, BIOCHEM BIOPH RES CO, V203, P141, DOI 10.1006/bbrc.1994.2160; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; Wang WG, 2004, FASEB J, V18, P1043, DOI 10.1096/fj.04-1555fje; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; Xia MH, 1996, J IMMUNOL, V156, P160; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zhou CJ, 2000, ANN NY ACAD SCI, V921, P373	20	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40259	40262		10.1074/jbc.C400332200	http://dx.doi.org/10.1074/jbc.C400332200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15302876	hybrid			2022-12-25	WOS:000223916800004
J	Huang, STJ; Vo, KCT; Lyell, DJ; Faessen, GH; Tulac, S; Tibshirani, R; Giaccia, AJ; Giudice, LC				Huang, STJ; Vo, KCT; Lyell, DJ; Faessen, GH; Tulac, S; Tibshirani, R; Giaccia, AJ; Giudice, LC			Developmental response to hypoxia	FASEB JOURNAL			English	Article						intrauterine growth restriction; fetal growth; hypoxic response	FACTOR-BINDING PROTEIN-1; GROWTH-FACTOR-I; EXCITATORY AMINO-ACIDS; FETAL-GROWTH; INTRAUTERINE GROWTH; GENE-EXPRESSION; BIRTH-WEIGHT; CARDIOVASCULAR-RESPONSES; BRAIN-INJURY; CORD SERUM	Molecular mechanisms underlying fetal growth restriction due to placental insufficiency and in utero hypoxia are not well understood. In the current study, time- dependent (3 h-11 days) changes in fetal tissue gene expression in a rat model of in utero hypoxia compared with normoxic controls were investigated as an initial approach to understand molecular events underlying fetal development in response to hypoxia. Under hypoxic conditions, litter size was reduced and IGFBP-1 was up-regulated in maternal serum and in fetal liver and heart. Tissue-specific, distinct regulatory patterns of gene expression were observed under acute vs. chronic hypoxic conditions. Induction of glycolytic enzymes was an early event in response to hypoxia during organ development; consistently, tissue-specific induction of calcium homeostasis-related genes and suppression of growth-related genes were observed, suggesting mechanisms underlying hypoxia-related fetal growth restriction. Furthermore, induction of inflammation-related genes in placentas exposed to long-term hypoxia (11 days) suggests a mechanism for placental dysfunction and impaired pregnancy outcome accompanying in utero hypoxia.	Stanford Univ, Dept Obstet & Gynecol, Med Ctr, Stanford, CA 94305 USA	Stanford University	Giudice, LC (corresponding author), Stanford Univ, Dept Obstet & Gynecol, Med Ctr, 300 Pasteur Dr,Room HH 333, Stanford, CA 94305 USA.	giudice@stanford.edu	Huang, Se-Te/F-6881-2013		NICHD NIH HHS [5 R01 HD36732] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036732] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTHABE O, 1985, PLACENTA, V6, P265, DOI 10.1016/S0143-4004(85)80056-4; BABAJKO S, 1993, ENDOCRINOLOGY, V132, P2586, DOI 10.1210/en.132.6.2586; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; Belkacemi L, 2002, ENDOCRINE, V19, P57, DOI 10.1385/ENDO:19:1:57; BODDY K, 1974, J PHYSIOL-LONDON, V243, P599, DOI 10.1113/jphysiol.1974.sp010768; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; CLARK GD, 1989, CLIN PERINATOL, V16, P459, DOI 10.1016/S0095-5108(18)30641-9; COHN HE, 1974, AM J OBSTET GYNECOL, V120, P817, DOI 10.1016/0002-9378(74)90587-0; DEGRAUW TJ, 1986, BIOL NEONATE, V49, P85, DOI 10.1159/000242515; FANT M, 1993, REGUL PEPTIDES, V48, P29, DOI 10.1016/0167-0115(93)90333-4; Gibson JM, 2001, MOL HUM REPROD, V7, P79, DOI 10.1093/molehr/7.1.79; GIUDICE LC, 1995, J CLIN ENDOCR METAB, V80, P1548, DOI 10.1210/jc.80.5.1548; Gluckman PD, 1997, ACTA PAEDIATR, V86, P153; GOPDA N, 2003, ANTIOXID REDOX SIGN, V5, P467; Hochachka PW, 1999, BRAZ J MED BIOL RES, V32, P661, DOI 10.1590/S0100-879X1999000600001; Holemans K, 2003, J SOC GYNECOL INVEST, V10, P392, DOI 10.1016/S1071-5576(03)00134-5; Ibanez L, 2000, ANN ENDOCRINOL-PARIS, V61, P141; IWAMOTO HS, 1992, AM J PHYSIOL, V263, pE1151; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; Kelley KM, 2002, J ENDOCRINOL, V175, P3, DOI 10.1677/joe.0.1750003; Kovacs CS, 2002, AM J PHYSIOL-ENDOC M, V282, pE721, DOI 10.1152/ajpendo.00369.2001; Langford K, 1998, HUM REPROD, V13, P1389, DOI 10.1093/humrep/13.5.1389; LANGFORD KS, 1993, EUR J CLIN INVEST, V23, P503, DOI 10.1111/j.1365-2362.1993.tb00958.x; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; Maulik D, 1999, BRAIN RES, V817, P117, DOI 10.1016/S0006-8993(98)01235-9; MCLELLAN KC, 1992, ENDOCRINOLOGY, V131, P1619, DOI 10.1210/en.131.4.1619; MORI A, 1993, MED BIOL ENG COMPU S, V31, pS49; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Odegard RA, 2000, OBSTET GYNECOL, V96, P950, DOI 10.1016/S0029-7844(00)01040-1; Ostlund E, 1997, HUM REPROD, V12, P840, DOI 10.1093/humrep/12.4.840; PukaSundvall M, 1997, BRAIN RES, V750, P325, DOI 10.1016/S0006-8993(97)00024-3; Redman C W, 2001, Gynecol Obstet Fertil, V29, P518, DOI 10.1016/S1297-9589(01)00180-1; Schulze A, 2001, NAT CELL BIOL, V3, pE190, DOI 10.1038/35087138; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SHEPPARD BL, 1976, BRIT J OBSTET GYNAEC, V83, P948, DOI 10.1111/j.1471-0528.1976.tb00781.x; SOOTHILL PW, 1994, ACTA PAEDIATR, V83, P55, DOI 10.1111/j.1651-2227.1994.tb13289.x; Tapanainen PJ, 1997, HORM RES, V48, P227, DOI 10.1159/000185520; TAPANAINEN PJ, 1994, PEDIATR RES, V36, P152, DOI 10.1203/00006450-199408000-00004; TIERNEY EP, 2003, PHYSL GENOMICS; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UNGER C, 1988, JAMA-J AM MED ASSOC, V259, P3427, DOI 10.1001/jama.259.23.3427; VERHAEGHE J, 1993, AM J OBSTET GYNECOL, V169, P89, DOI 10.1016/0002-9378(93)90137-8; Verhaeghe J, 2001, J ENDOCRINOL, V170, P585, DOI 10.1677/joe.0.1700585; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; WOODWORTH SH, 1994, J CLIN ENDOCR METAB, V78, P1225, DOI 10.1210/jc.78.5.1225; Yiu V, 1999, AM J KIDNEY DIS, V33, P253, DOI 10.1016/S0272-6386(99)70297-0; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388	51	56	61	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1348	1365		10.1096/fj.03-1377com	http://dx.doi.org/10.1096/fj.03-1377com			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333578				2022-12-25	WOS:000224243200054
J	Li, WJ; Hou, LF; Hua, ZW; Wang, X				Li, WJ; Hou, LF; Hua, ZW; Wang, X			Interleukin-1 induces beta-calcitonin gene-related peptide secretion in human type II alveolar epithelial cells	FASEB JOURNAL			English	Article						neuroimmunology; neuropeptide; inflammation; chemokine	PROTEIN-KINASE-C; AIRWAY HYPERRESPONSIVENESS; NEUROEPITHELIAL BODIES; RESPIRATORY-TRACT; SENSORY NEURONS; EXPRESSION; CGRP; RELEASE; LYMPHOCYTES; NEUROPEPTIDES	Calcitonin gene-related peptide ( CGRP) is a 37-amino acid neuropeptide mainly present in sensory nerve fibers, which is present in almost all organs, but it is also found in cultured rat type II alveolar epithelial cells (AEII). Our data have previously shown that CGRP may play an important role in inflammation as an immunomodulator. Proinflammatory factor IL-1 induces CGRP release from neuron-derived sources. However, whether IL-1 can induce CGRP secretion from a nonneural source, AEII cells, is not known. In the present study, we demonstrated that human AEII A549 cells expressed beta-CGRP, and IL-1beta (0.001- 50 ng/ml) directly increased CGRP secretion from these cells in a time- and concentration-dependent manner. The mRNA level of beta-CGRP was also elevated by IL-1beta ( 1 ng/ml). In addition, we found that IL-1beta-induced CGRP production was mediated through the PKC-p38 mitogen-activated protein (MAP) kinase-NF-kappaB signaling pathway. Furthermore, IL-1beta-induced chemokines MCP-1 and IL-8 were partially inhibited by exogenous hCGRP (0.1- 10 nM) and potentiated by hCGRP(8-37) ( 0.1- 10 nM), a CGRP(1)-receptor antagonist. In addition, the CGRP-inhibited chemokine effect was partially reduced by Rp-cAMP, a cAMP-PK inhibitor. These results suggest that AEII-derived CGRP may act in an autocrine/paracrine mode and play an important inhibitory role in the local area in lung inflammatory diseases.	Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100083, Peoples R China; Peking Univ, Hlth Sci Ctr, Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing 100083, Peoples R China; Peking Univ, Dept Physiol, Beijing 100083, Peoples R China	Peking University; Peking University; Peking University	Wang, X (corresponding author), Peking Univ, Hosp 3, Inst Vasc Med, Beijing 100083, Peoples R China.	xwang@bjmu.edu.cn						ADRIAENSEN D, 1991, HISTOCHEMISTRY, V95, P567, DOI 10.1007/BF00266743; Bellibas SE, 1996, PEPTIDES, V17, P563, DOI 10.1016/0196-9781(96)00027-7; Bracci-Laudiero L, 2002, J NEUROIMMUNOL, V123, P58, DOI 10.1016/S0165-5728(01)00475-1; Brouns I, 2003, AM J RESP CELL MOL, V28, P275, DOI 10.1165/rcmb.2002-0117OC; BUCKLEY TL, 1991, J IMMUNOL, V146, P3424; CADIEUX A, 1986, NEUROSCIENCE, V19, P605, DOI 10.1016/0306-4522(86)90285-X; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; CLEMENTI G, 1994, LIFE SCI, V54, pPL119, DOI 10.1016/0024-3205(94)90011-6; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/ajrccm.165.8.2109058; DAVIES D, 1992, ANN NY ACAD SCI, V657, P405, DOI 10.1111/j.1749-6632.1992.tb22786.x; Evans BN, 2000, J BIOL CHEM, V275, P31438, DOI 10.1074/jbc.M005604200; Fehrenbach H, 2001, RESP RES, V2, P33, DOI 10.1186/rr36; HASTINGS RH, 1995, AM J RESP CELL MOL, V13, P563, DOI 10.1165/ajrcmb.13.5.7576692; He Yanling, 2002, Zhonghua Yi Xue Za Zhi, V82, P131; Hou LF, 2003, J NEUROSCI RES, V73, P188, DOI 10.1002/jnr.10651; Hou LF, 2001, J NEUROSCI RES, V66, P592, DOI 10.1002/jnr.1249; Ichinose M, 1996, PEPTIDES, V17, P1405, DOI 10.1016/S0196-9781(96)00198-2; Kawase T, 2003, EUR J PHARMACOL, V470, P125, DOI 10.1016/S0014-2999(03)01763-1; Keith IM, 2000, PHYSIOL RES, V49, P519; KEITH IM, 1991, HISTOCHEMISTRY, V96, P311, DOI 10.1007/BF00271351; Levite M, 1998, J IMMUNOL, V160, P993; Lin CH, 2000, MOL PHARMACOL, V57, P36; LUNDBERG JM, 1985, EUR J PHARMACOL, V108, P315, DOI 10.1016/0014-2999(85)90456-X; Millet I, 2000, J BIOL CHEM, V275, P15114, DOI 10.1074/jbc.275.20.15114; Monton C, 1998, Monaldi Arch Chest Dis, V53, P56; Neri LM, 2002, HISTOL HISTOPATHOL, V17, P1311, DOI 10.14670/HH-17.1311; Nystedt JM, 2002, J NEUROCHEM, V82, P1330, DOI 10.1046/j.1471-4159.2002.01035.x; Opree A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000; REINSHAGEN M, 1994, GASTROENTEROLOGY, V106, P1208, DOI 10.1016/0016-5085(94)90011-6; Reinshagen M, 1998, J PHARMACOL EXP THER, V286, P657; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Shirai Y, 2002, J BIOCHEM, V132, P663, DOI 10.1093/oxfordjournals.jbchem.a003271; SINGARAM C, 1991, GASTROENTEROLOGY, V100, P560, DOI 10.1016/0016-5085(91)90231-9; Springer J, 2003, PULM PHARMACOL THER, V16, P121, DOI 10.1016/S1094-5539(03)00049-X; STANDIFORD TJ, 1991, J BIOL CHEM, V266, P9912; STANDIFORD TJ, 1990, J CLIN INVEST, V86, P1945, DOI 10.1172/JCI114928; Stankiewicz W, 2002, MEDIAT INFLAMM, V11, P307, DOI 10.1080/09629350210000015719; STEENBERGH PH, 1985, FEBS LETT, V183, P408, DOI 10.1016/0014-5793(85)80820-6; Strieter RM, 2003, CURR OPIN INFECT DIS, V16, P193, DOI 10.1097/00001432-200306000-00002; Sun W, 2003, EUR J IMMUNOL, V33, P233, DOI 10.1002/immu.200390026; Tonnel AB, 2001, INT ARCH ALLERGY IMM, V124, P267, DOI 10.1159/000053729; Townley RG, 2003, CLIN REV ALLERG IMMU, V24, P85, DOI 10.1385/CRIAI:24:1:85; Tran MT, 2000, J IMMUNOL, V164, P4307, DOI 10.4049/jimmunol.164.8.4307; VASKO MR, 1994, J NEUROSCI, V14, P4987; Wang HC, 2002, J NEUROIMMUNOL, V130, P155, DOI 10.1016/S0165-5728(02)00221-7; Wang Shengxian, 2001, Zhonghua Jiehe He Huxi Zazhi, V24, P725; Wang X, 1999, J NEUROIMMUNOL, V94, P95, DOI 10.1016/S0165-5728(98)00230-6; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Xing LY, 2002, BRAIN BEHAV IMMUN, V16, P17, DOI 10.1006/brbi.2000.0601; Xing LY, 2000, J IMMUNOL, V165, P4359, DOI 10.4049/jimmunol.165.8.4359; XU H, 1999, NATL MED J CHINA, V79, P385; Xu Hui, 1999, Zhonghua Jiehe He Huxi Zazhi, V22, P558	55	35	40	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1603	+		10.1096/fj.04-1737fje	http://dx.doi.org/10.1096/fj.04-1737fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319367				2022-12-25	WOS:000223554900012
J	Schiefner, A; Holtmann, G; Diederichs, K; Welte, W; Bremer, E				Schiefner, A; Holtmann, G; Diederichs, K; Welte, W; Bremer, E			Structural basis for the binding of compatible solutes by ProX from the hyperthermophilic archaeon Archaeoglobus fulgidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; GLYCINE BETAINE; ESCHERICHIA-COLI; HYDROGEN-BONDS; CRYSTALLOGRAPHIC EVIDENCE; PERIPLASMIC RECEPTORS; PATTERN-RECOGNITION; ACTIVE-TRANSPORT; DIFFRACTION DATA; LIGAND-BINDING	Compatible solutes such as glycine betaine and proline betaine serve as protein stabilizers because of their preferential exclusion from protein surfaces. To use extracellular sources of this class of compounds as osmo-, cryo-, or thermoprotectants, Bacteria and Archaea have developed high affinity uptake systems of the ATP-binding cassette type. These transport systems require periplasmic- or extracellular-binding proteins that are able to bind the transported substance with high affinity. Therefore, binding proteins that bind compatible solutes have to avoid the exclusion of their ligands within the binding pocket. In the present study we addressed the question to how compatible solutes can be effectively bound by a protein at temperatures around 83 C as this is done by the ligand-binding protein ProX from the hyperthermophilic archaeon Archaeoglobus fulgidus. We solved the structures of ProX without ligand and in complex with both of its natural ligands glycine betaine and proline betaine, as well as in complex with the artificial ligand trimethylammonium. Cation-pi interactions and non-classical hydrogen bonds between four tyrosine residues, a main chain carbonyl oxygen, and the ligand have been identified to be the key determinants in binding the quaternary amines of the three investigated ligands. The comparison of the ligand binding sites of ProX from A. fulgidus and the recently solved structure of ProX from Escherichia coli revealed a very similar solution for the problem of compatible solute binding, although both proteins share only a low degree of sequence identity. The residues involved in ligand binding are functionally equivalent but not conserved in the primary sequence.	Univ Konstanz, Fachbereich Biol, D-78457 Constance, Germany; Univ Marburg, Mikrobiol Lab, Fachbereich Biol, D-35032 Marburg, Germany	University of Konstanz; Philipps University Marburg	Schiefner, A (corresponding author), Univ Konstanz, Fachbereich Biol, Univ Str 10, D-78457 Constance, Germany.	andre.schiefner@uni-konstanz.de	Holtmann, Gerald/S-4065-2019; Holtmann, Gerald/I-5341-2014	Schiefner, Andre/0000-0001-5215-4122; Holtmann, Gerald/0000-0002-0206-2358				Altschul SF, 1996, METHOD ENZYMOL, V266, P460; ARAKAWA T, 1985, BIOPHYS J, V47, P411, DOI 10.1016/S0006-3495(85)83932-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; Booth IR, 1999, CURR OPIN MICROBIOL, V2, P166, DOI 10.1016/S1369-5274(99)80029-0; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; Brandl M, 2001, J MOL BIOL, V307, P357, DOI 10.1006/jmbi.2000.4473; Bremer E, 2000, BACTERIAL STRESS RESPONSES, P79; Brigulla M, 2003, J BACTERIOL, V185, P4305, DOI 10.1128/JB.185.15.4305-4314.2003; BROWN AD, 1976, BACTERIOL REV, V40, P803, DOI 10.1128/MMBR.40.4.803-846.1976; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Caldas T, 1999, MICROBIOL-SGM, V145, P2543, DOI 10.1099/00221287-145-9-2543; Canovas D, 1999, APPL ENVIRON MICROB, V65, P3774; Canovas D, 2001, J BACTERIOL, V183, P3365, DOI 10.1128/JB.183.11.3365-3371.2001; Courtenay ES, 2000, BIOCHEMISTRY-US, V39, P4455, DOI 10.1021/bi992887l; CSONKA LN, 1996, ESCHERICHIA COLI SAL, V1, P1210; da Costa M. S., 1998, V61, P117; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DULANEY EUGENE L., 1968, DEVELOP IND MICROBIOL, V9, P260; GALINSKI EA, 1994, FEMS MICROBIOL REV, V15, P95, DOI 10.1111/j.1574-6976.1994.tb00128.x; GERSTEIN M, 1993, J MOL BIOL, V234, P357, DOI 10.1006/jmbi.1993.1592; GHOUL M, 1990, APPL ENVIRON MICROB, V56, P551, DOI 10.1128/AEM.56.2.551-554.1990; GOWRISHANKAR J, 1989, J BACTERIOL, V171, P1923, DOI 10.1128/jb.171.4.1923-1931.1989; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hohmann S, 2002, INT REV CYTOL, V215, P149; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kempf B, 1998, ARCH MICROBIOL, V170, P319, DOI 10.1007/s002030050649; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEHMANN MS, 1984, BIOCHEMISTRY-US, V23, P1939, DOI 10.1021/bi00304a008; LERUDULIER D, 1984, SCIENCE, V224, P1064, DOI 10.1126/science.224.4653.1064; Li AJ, 1998, PROTEINS, V32, P111, DOI 10.1002/(SICI)1097-0134(19980701)32:1<111::AID-PROT12>3.0.CO;2-H; LIPPERT K, 1992, APPL MICROBIOL BIOT, V37, P61; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; Magnusson U, 2002, J BIOL CHEM, V277, P14077, DOI 10.1074/jbc.M200514200; MAO B, 1982, J BIOL CHEM, V257, P1131; Martin DD, 1999, APPL ENVIRON MICROB, V65, P1815; McNeil SD, 1999, PLANT PHYSIOL, V120, P945, DOI 10.1104/pp.120.4.945; Mendum ML, 2002, APPL ENVIRON MICROB, V68, P813, DOI 10.1128/AEM.68.2.813-819.2002; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J. H., 1992, LAB MANUAL HDB ESCHE; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OH BH, 1993, J BIOL CHEM, V268, P11348; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RHODES D, 1993, ANNU REV PLANT PHYS, V44, P357, DOI 10.1146/annurev.pp.44.060193.002041; Roessler M, 2001, ENVIRON MICROBIOL, V3, P743, DOI 10.1046/j.1462-2920.2001.00252.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Santos H, 2002, ENVIRON MICROBIOL, V4, P501, DOI 10.1046/j.1462-2920.2002.00335.x; Scheiner S, 2001, J BIOL CHEM, V276, P9832, DOI 10.1074/jbc.M010770200; Schiefner A, 2004, J BIOL CHEM, V279, P5588, DOI 10.1074/jbc.M309771200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; Sleator RD, 2002, FEMS MICROBIOL REV, V26, P49, DOI 10.1111/j.1574-6976.2002.tb00598.x; Steiner T, 2001, J MOL BIOL, V305, P535, DOI 10.1006/jmbi.2000.4301; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Ventosa A, 1998, MICROBIOL MOL BIOL R, V62, P504, DOI 10.1128/MMBR.62.2.504-544.1998; Weiss MS, 1997, J APPL CRYSTALLOGR, V30, P203, DOI 10.1107/S0021889897003907; Weiss MS, 2001, TRENDS BIOCHEM SCI, V26, P521, DOI 10.1016/S0968-0004(01)01935-1; Welsh DT, 2000, FEMS MICROBIOL REV, V24, P263, DOI 10.1111/j.1574-6976.2000.tb00542.x; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yancey P.H., 1994, CELLULAR MOL PHYSL C, P81	85	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48270	48281		10.1074/jbc.M403540200	http://dx.doi.org/10.1074/jbc.M403540200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15308642	Green Published, hybrid			2022-12-25	WOS:000224957000103
J	Amberg, GC; Rossow, CF; Navedo, MF; Santana, LF				Amberg, GC; Rossow, CF; Navedo, MF; Santana, LF			NFATc3 regulates Kv2.1 expression in arterial smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; ANGIOTENSIN-II; CEREBRAL-ARTERIES; TRANSCRIPTION FACTORS; POTASSIUM CHANNELS; VASCULAR MYOCYTES; LARGE-CONDUCTANCE; CA2+ ENTRY; RAT; CELLS	Voltage-gated K+ (Kv) channels control the excitability of arterial smooth muscle. However, the molecular mechanisms regulating Kv channel function in smooth muscle remain unclear. We examined the hypothesis that the vasoactive peptide angiotensin II (Ang II) regulates arterial smooth muscle Kv channel function via calcineurin-dependent activation of the transcription factor NFAT. We found that sustained administration of Ang II decreased Kv currents (I-Kv) by reducing the expression of Kv2.1 K+ channel subunits. This effect of Ang II was independent of pressure but required Ca2+ influx through L-type Ca2+ channels. Consistent with our hypothesis, we found that calcineurin and NFATc3 are obligatory components of the signaling cascade mediating reduced IKv by Ang II. We conclude that sustained Ang II exposure increases smooth muscle Ca2+, which leads to activation of calcineurin and NFATc3, culminating in decreased Kv2.1 expression and reduced IKv function. These results support the novel concept that NFATc3 controls the excitability of arterial smooth muscle by regulating Kv2.1 expression.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Santana, LF (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357290, Seattle, WA 98195 USA.	santana@u.washington.edu	Santana, Luis/AAF-9298-2019	Santana, Luis/0000-0002-4297-8029; Amberg, Gregory/0000-0001-6094-1185	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077115] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07312, HL77115] Funding Source: Medline; NINDS NIH HHS [NS34905] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albarwani S, 2003, J PHYSIOL-LONDON, V551, P751, DOI 10.1113/jphysiol.2003.040014; ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Archer SL, 2000, ADV EXP MED BIOL, V475, P219; Arnaudeau S, 1996, BIOCHEM BIOPH RES CO, V222, P809, DOI 10.1006/bbrc.1996.0808; Belevych AE, 2002, CARDIOVASC RES, V54, P152, DOI 10.1016/S0008-6363(02)00227-4; BOCHKOV V, 1992, BIOCHEM BIOPH RES CO, V188, P1295, DOI 10.1016/0006-291X(92)91372-W; BOLTON TB, 1985, EXPERIENTIA, V41, P887, DOI 10.1007/BF01970006; Bonev AD, 1997, AM J PHYSIOL-CELL PH, V273, pC2090, DOI 10.1152/ajpcell.1997.273.6.C2090; Chen JT, 2003, J IMMUNOL, V170, P3109, DOI 10.4049/jimmunol.170.6.3109; Cox DH, 2000, J GEN PHYSIOL, V116, P411, DOI 10.1085/jgp.116.3.411; Cox RH, 2001, HYPERTENSION, V37, P1315, DOI 10.1161/01.HYP.37.5.1315; Cox RH, 2001, AM J HYPERTENS, V14, P897, DOI 10.1016/S0895-7061(01)02145-8; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Gomez MF, 2003, J BIOL CHEM, V278, P46847, DOI 10.1074/jbc.M304765200; Hayabuchi Y, 2001, AM J PHYSIOL-HEART C, V281, pH2480, DOI 10.1152/ajpheart.2001.281.6.H2480; HILLE B, 2001, IONIC CHANNELS EXCIT, P29; Kleppisch T, 1996, AM J PHYSIOL-HEART C, V271, pH2462, DOI 10.1152/ajpheart.1996.271.6.H2462; KNOT HJ, 1995, AM J PHYSIOL-HEART C, V269, pH348, DOI 10.1152/ajpheart.1995.269.1.H348; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Kramer JW, 1998, AM J PHYSIOL-CELL PH, V274, pC1501, DOI 10.1152/ajpcell.1998.274.6.C1501; LESH RE, 1995, CIRC RES, V77, P220, DOI 10.1161/01.RES.77.2.220; Liang HY, 1999, J BIOL CHEM, V274, P19846, DOI 10.1074/jbc.274.28.19846; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; Lu Y, 2002, LIFE SCI, V71, P1465, DOI 10.1016/S0024-3205(02)01922-7; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Meera P, 1996, FEBS LETT, V385, P127; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morel JL, 1996, BRIT J PHARMACOL, V118, P73, DOI 10.1111/j.1476-5381.1996.tb15368.x; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rossow CF, 2004, CIRC RES, V94, P1340, DOI 10.1161/01.RES.0000128406.08418.34; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Suzuki E, 2002, CIRC RES, V90, P1004, DOI 10.1161/01.RES.0000017629.70769.CC; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; Wellman GC, 2001, AM J PHYSIOL-HEART C, V281, pH2559, DOI 10.1152/ajpheart.2001.281.6.H2559; Wiener J, 1996, J VASC RES, V33, P195, DOI 10.1159/000159148; Xu CL, 2000, LIFE SCI, V66, P2023, DOI 10.1016/S0024-3205(00)00529-4	43	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47326	47334		10.1074/jbc.M408789200	http://dx.doi.org/10.1074/jbc.M408789200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322114	hybrid			2022-12-25	WOS:000224832400121
J	Aono, S; Tokita, Y; Shuo, T; Yamauchi, S; Matsui, F; Nakanishi, K; Hirano, K; Sano, M; Oohira, A				Aono, S; Tokita, Y; Shuo, T; Yamauchi, S; Matsui, F; Nakanishi, K; Hirano, K; Sano, M; Oohira, A			Glycosylation site for chondroitin sulfate on the neural part-time proteoglycan, neuroglycan C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-INTERACTIONS; BRAIN; GROWTH; EXPRESSION; NEUROCAN; SEQUENCE; RECEPTOR; BINDING; DOMAIN; CALEB	Neuroglycan C (NGC) is a membrane-spanning chondroitin sulfate (CS) proteoglycan that is expressed predominantly in the central nervous system (CNS). NGC dramatically changed its structure from a proteoglycan to a nonproteoglycan form with cerebellar development, whereas a small portion of NGC molecules existed in a nonproteoglycan form in the other areas of the mature CNS, suggesting that the CS glycosylation of NGC is developmentally regulated in the whole CNS. As primary cultured neurons and astrocytes from cerebral cortices expressed NGC in a proteoglycan form and in a nonproteoglycan form, respectively, CS glycosylation seems to be regulated differently depending on cell type. To investigate the glycosylation process, cell lines expressing a proteoglycan form of NGC would be favorable experimental models. When a mouse NGC cDNA was transfected into COS 1, PC12D, and Neuro 2a cells, only Neuro 2a cells, a mouse neuroblastoma cell line, expressed NGC bearing CS chains. In PC12D cells, although three intrinsic CS proteoglycans were detected, exogenously expressed NGC did not bear any short CS chains just like NGC in the mature cerebellum. This suggests that the addition of CS chains to the NGC core protein is regulated in a manner different from that of other CS proteoglycans. As the first step in investigating the CS glycosylation mechanism using Neuro 2a cells, we determined the CS attachment site as Ser-123 on the NGC core protein by site-directed mutagenesis. The CS glycosylation was not necessary for intracellular trafficking of NGC to the cell surface at least in Neuro 2a cells.	Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, Aichi 4800392, Japan; Kyoto Prefectural Univ Med, Dept Biol, Kyoto 6038334, Japan	Kyoto Prefectural University of Medicine	Aono, S (corresponding author), Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, Aichi 4800392, Japan.	saono@inst-hsc.jp						ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; Aono S., 2000, CONNECT TISSUE, V32, P45; Asher RA, 2000, J NEUROSCI, V20, P2427; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Cai B, 1998, J CELL PHYSIOL, V177, P282, DOI 10.1002/(SICI)1097-4652(199811)177:2<282::AID-JCP10>3.0.CO;2-C; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; Esko JD, 1996, CURR OPIN STRUC BIOL, V6, P663, DOI 10.1016/S0959-440X(96)80034-0; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; KATOHSEMBA R, 1992, J NEUROCHEM, V59, P282, DOI 10.1111/j.1471-4159.1992.tb08902.x; MANN DM, 1990, J BIOL CHEM, V265, P5317; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MATSUI F, 1994, NEUROCHEM INT, V25, P425, DOI 10.1016/0197-0186(94)90018-3; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nakanishi K, 1999, BRAIN RES PROTOC, V4, P105, DOI 10.1016/S1385-299X(99)00003-3; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; OOHIRA A, 1988, J BIOL CHEM, V263, P10240; OOHIRA A, 1994, NEUROSCI RES, V20, P195, DOI 10.1016/0168-0102(94)90088-4; OOHIRA A, 1998, CONNECT TISSUE, V30, P49; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; Prydz K, 2000, J CELL SCI, V113, P193; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANO M, 1988, BRAIN RES, V459, P404, DOI 10.1016/0006-8993(88)90660-9; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; Shuo T, 2003, GLYCOCONJUGATE J, V20, P267, DOI 10.1023/B:GLYC.0000025821.22618.33; Small DH, 1996, J NEUROCHEM, V67, P889; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Winzen U, 2003, J BIOL CHEM, V278, P30106, DOI 10.1074/jbc.M212676200; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200; YAMAUCHI S, 2003, CONNECT TISSUE, V35, P31; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4	36	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46536	46541		10.1074/jbc.M403263200	http://dx.doi.org/10.1074/jbc.M403263200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331613	hybrid			2022-12-25	WOS:000224832400025
J	Avery, AM; Willetts, SA; Avery, SV				Avery, AM; Willetts, SA; Avery, SV			Genetic dissection of the phospholipid hydroperoxidase activity of yeast Gpx3 reveals its functional importance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; METABOLIC PATHWAY; PLASMA-MEMBRANE; CADMIUM; RESPIRATION; EVOLUTION; YAP1; H2O2	Saccharomyces cerevisiae expresses multiple phospholipid hydroperoxide glutathione peroxidase (PHGPx)-like proteins in the absence of a classical glutathione peroxidase (cGPx), providing a unique system for dissecting the roles of these enzymes in vivo. The Gpx3 (Orp1/PHGpx3) protein transduces the hydroperoxide signal to the transcription factor Yap1, a function that could account for most GPX-dependent phenotypes. To test this hypothesis and ascertain what functions of Gpx3 can be shared by cGPx-like enzymes, we constructed a novel cGPx-like yeast enzyme, cGpx3. We confirmed that the "gap" sequences conserved among cGPxs but absent from aligned PHGPx sequences are the principal cause of the structural and functional differences of these enzymes. Peroxidase activity against a cGPx substrate was high in the cGpx3 construct, which was multimeric and had a peroxidase catalytic mechanism distinct from Gpx3; but cGpx3 was defective for phospholipid hydroperoxidase and signaling activities. cGpx3 did not complement the sensitivity to lipid peroxidation of a gpxDelta mutant, and the resistance to lipid peroxidation conferred by Gpx3 was independent of Yap1, establishing a functional role for Gpx3 phospholipid hydroperoxidase activity. Using the comparison between cGpx3 and Gpx3 in conjunction with other constructs to probe lipid peroxidation as a toxicity mechanism, we also ascertained that lipid peroxidation-dependent processes are a principal cause of cellular cadmium toxicity. The results demonstrate that phospholipid hydroperoxidase and Yap1-mediated signaling activities of Gpx3 have independent functional roles, although both functions depend on the absence of cGPx-like subunit interaction sites, and the results resolve more clearly the potential drivers of the differential selective evolution of GPx-like enzymes.	Univ Nottingham, Sch Biol, Inst Genet, Nottingham NG7 2RD, England	University of Nottingham	Avery, SV (corresponding author), Univ Nottingham, Sch Biol, Inst Genet, Univ Pk, Nottingham NG7 2RD, England.	Simon.Avery@nottingham.ac.uk	Avery, Simon/U-5816-2019; Avery, Simon/AAS-5291-2021	Avery, Simon/0000-0002-2102-2255	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057945] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM57945] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 2004, CURRENT PROTOCOLS MO; Assmann S, 1996, ARCH MICROBIOL, V165, P279, DOI 10.1007/s002030050327; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Avery SV, 2001, ADV APPL MICROBIOL, V49, P111, DOI 10.1016/S0065-2164(01)49011-3; Azevedo D, 2003, FREE RADICAL BIO MED, V35, P889, DOI 10.1016/S0891-5849(03)00434-9; Basu U, 2004, MOL GENET GENOMICS, V271, P627, DOI 10.1007/s00438-004-1015-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; Brigelius-Flohe R, 2003, BIOFACTORS, V17, P93, DOI 10.1002/biof.5520170110; Brigelius-Flohe R, 1999, FREE RADICAL BIO MED, V27, P951, DOI 10.1016/S0891-5849(99)00173-2; Brigelius-Flohe R, 2002, METHOD ENZYMOL, V347, P101; BRIGELIUSFLOHE R, 2001, HDB ANTIOXIDANTS, P633; Collinson EJ, 2002, J BIOL CHEM, V277, P16712, DOI 10.1074/jbc.M111686200; DAWES IW, 1999, METABOLISM MOL PHYSL, P277; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Georgiou G, 2002, CELL, V111, P607, DOI 10.1016/S0092-8674(02)01165-0; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Herbette S, 2002, EUR J BIOCHEM, V269, P2414, DOI 10.1046/j.1432-1033.2002.02905.x; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Howlett NG, 1997, APPL ENVIRON MICROB, V63, P2971, DOI 10.1128/AEM.63.8.2971-2976.1997; Infante JJ, 2003, GENETICS, V165, P1745; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Jin YH, 2003, NAT GENET, V34, P326, DOI 10.1038/ng1172; Karaffa L, 2001, FREE RADICAL RES, V34, P405, DOI 10.1080/10715760100300341; Nagai T, 2002, Z NATURFORSCH C, V57, P172; Ryu JH, 2003, J BIOCHEM, V134, P137, DOI 10.1093/jb/mvg121; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STYBLO M, 1992, BIOL TRACE ELEM RES, V34, P11, DOI 10.1007/BF02783893; Tsuzi D, 2004, FEBS LETT, V569, P301, DOI 10.1016/j.febslet.2004.05.077; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Veal EA, 2003, J BIOL CHEM, V278, P30896, DOI 10.1074/jbc.M303542200; Veiga A, 2003, FEMS YEAST RES, V3, P239, DOI 10.1016/S1567-1356(03)00036-9; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405	37	59	63	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46652	46658		10.1074/jbc.M408340200	http://dx.doi.org/10.1074/jbc.M408340200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337745	hybrid			2022-12-25	WOS:000224832400040
J	Caramelo, JJ; Castro, OA; de Prat-Gay, G; Parodi, AJ				Caramelo, JJ; Castro, OA; de Prat-Gay, G; Parodi, AJ			The endoplasmic reticulum glucosyltransferase recognizes nearly native glycoprotein folding intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCOSE-GLYCOPROTEIN; CHYMOTRYPSIN INHIBITOR-2; MOLECULAR CHAPERONES; SECRETORY PATHWAY; PROTEIN; CALNEXIN; BIP; CALRETICULIN; MECHANISM; SUBSTRATE	The UDP-Glc:glycoprotein glucosyltransferase (GT), a key player in the endoplasmic reticulum (ER) quality control of glycoprotein folding, only glucosylates glycoproteins displaying non-native conformations. To determine whether GT recognizes folding intermediates or irreparably misfolded species with nearly native structures, we generated and tested as GT substrates neoglycoprotein fragments derived from chymotrypsin inhibitor 2 (GCI2) bearing from 53 to 64 (full-length) amino acids. Fragment conformations mimicked the last stagefolding structures adopted by a glycoprotein entering the ER lumen. GT catalytic efficiency (V-max/K-m) remained constant from GCI2-(1-53) to GCI2-(1-58) and then steadily declined to reach a minimal value with GCI2-(1-64). The same parameter showed a direct hyperbolic relationship with solvent accessibility of the single Trp residue but only in fragments exposing hydrophobic amino acid patches. Mutations introduced (GCI2-(1-63) V63S and GCI2-(1-64) V63S) produced slight structural destabilizations but increased GT catalytic efficiency. This parameter presented an inverse exponential relationship with the free energy of unfolding of canonical and mutant fragments. Moreover, the catalytic efficiency showed a linear relationship with the fraction of unfolded species in water. It was concluded that the GT-derived quality control may be operative with nearly native conformers and that no alternative ER-retaining mechanisms are required when glycoproteins approach their proper folding.	Fdn Inst Leloir, Buenos Aires, DF, Argentina	Leloir Institute	Parodi, AJ (corresponding author), Fdn Inst Leloir, Avda Patricias Argentinas 435,C1405BWE, Buenos Aires, DF, Argentina.	aparodi@leloir.org.ar		Prat Gay, Gonzalo/0000-0001-5748-6863	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044500] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM44500/13] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold SM, 2003, J BIOL CHEM, V278, P43320, DOI 10.1074/jbc.M305800200; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; CLACKSON T, 1991, PCR PRACTICAL APPROA, P202; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; GAY GD, 1995, J MOL BIOL, V254, P968, DOI 10.1006/jmbi.1995.0669; Guerin M, 2003, J BIOL CHEM, V278, P20540, DOI 10.1074/jbc.M300891200; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; MCPHALEN CA, 1987, BIOCHEMISTRY-US, V26, P261, DOI 10.1021/bi00375a036; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; Petrescu AJ, 2004, GLYCOBIOLOGY, V14, P103, DOI 10.1093/glycob/cwh008; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Taylor SC, 2004, NAT STRUCT MOL BIOL, V11, P128, DOI 10.1038/nsmb715; Taylor SC, 2003, EMBO REP, V4, P405, DOI 10.1038/sj.embor.embor797; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Tomita Y, 1999, J BIOCHEM-TOKYO, V126, P1090, DOI 10.1093/oxfordjournals.jbchem.a022554; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; Yamada S, 2003, EUR J BIOCHEM, V270, P146, DOI 10.1046/j.1432-1033.2003.03375.x	24	94	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46280	46285		10.1074/jbc.M408404200	http://dx.doi.org/10.1074/jbc.M408404200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319428	hybrid, Green Published			2022-12-25	WOS:000224694900115
J	Petrini, EM; Marchionni, I; Zacchi, P; Sieghart, W; Cherubini, E				Petrini, EM; Marchionni, I; Zacchi, P; Sieghart, W; Cherubini, E			Clustering of extrasynaptic GABA(A) receptors modulates tonic inhibition in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTORS; CEREBELLAR GRANULE CELLS; CA1 PYRAMIDAL NEURONS; ADULT-RAT BRAIN; SUBUNIT COMPOSITION; KINETIC-PROPERTIES; QUANTITATIVE IMPORTANCE; PERSISTENT ACTIVATION; SYNAPTIC INHIBITION; CHANNEL PROPERTIES	Tonic inhibition plays a crucial role in regulating neuronal excitability because it sets the threshold for action potential generation and integrates excitatory signals. Tonic currents are known to be largely mediated by extrasynaptic gamma-aminobutyric acid type A (GABA(A)) receptors that are persistently activated by submicromolar concentrations of ambient GABA. We recently reported that, in cultured hippocampal neurons, the clustering of synaptic GABA(A) receptors significantly affects synaptic transmission (Petrini, E. M., Zacchi, P., Barberis, A., Mozrzymas, J. W., and Cherubini, E. ( 2003) J. Biol. Chem. 278, 16271-16279). In this work, we demonstrated that the clustering of extrasynaptic GABA(A) receptors modulated tonic inhibition. Depolymerization of the cytoskeleton with nocodazole promoted the disassembly of extrasynaptic clusters of delta and gamma(2) subunit-containing GABA(A) receptors. This effect was associated with a reduction in the amplitude of tonic currents and diminished shunting inhibition. Moreover, diffuse GABA(A) receptors were less sensitive to the GAT-1 inhibitor NO-711 and to flurazepam. Quantitative analysis of GABA-evoked currents after prolonged exposure to submicromolar concentrations of GABA and model simulations suggest that clustering affects the gating properties of extrasynaptic GABA(A) receptors. In particular, a larger occupancy of the singly and doubly bound desensitized states can account for the modulation of tonic inhibition recorded after nocodazole treatment. Moreover, comparison of tonic currents recorded during spontaneous activity and those elicited by exogenously applied low agonist concentrations allows estimation of the concentration of ambient GABA. In conclusion, receptor clustering appears to be an additional regulating factor for tonic inhibition.	Scuola Int Super Studi Avanzati, Neurosci Programme, I-34014 Trieste, Italy; Univ Vienna, Psychiat Clin, Sect Biochem Psychiat, A-1090 Vienna, Austria	International School for Advanced Studies (SISSA); University of Vienna	Cherubini, E (corresponding author), Scuola Int Super Studi Avanzati, Neurosci Programme, Via Beirut 2-4, I-34014 Trieste, Italy.	cher@sissa.it	Sieghart, Werner/A-4877-2013	Sieghart, Werner/0000-0002-0443-0302				Andjus PR, 1997, J PHYSIOL-LONDON, V504, P103, DOI 10.1111/j.1469-7793.1997.103bf.x; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bai DL, 2001, MOL PHARMACOL, V59, P814, DOI 10.1124/mol.59.4.814; Banks MI, 2000, J NEUROSCI, V20, P937, DOI 10.1523/JNEUROSCI.20-03-00937.2000; Berger T, 1998, J NEUROSCI, V18, P2437; Bianchi MT, 2002, NEUROPHARMACOLOGY, V43, P492, DOI 10.1016/S0028-3908(02)00163-6; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; Birnir B, 2000, J MEMBRANE BIOL, V174, P21, DOI 10.1007/s002320001028; Birnir B, 2001, J MEMBRANE BIOL, V181, P171, DOI 10.1007/s00232-001-0021-5; BORDEN LA, 1994, EUR J PHARM-MOLEC PH, V269, P219, DOI 10.1016/0922-4106(94)90089-2; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; Brickley SG, 1999, J NEUROSCI, V19, P2960; Brickley SG, 2001, NATURE, V409, P88, DOI 10.1038/35051086; Bueno OF, 1998, NEUROPHARMACOLOGY, V37, P383, DOI 10.1016/S0028-3908(98)00020-3; Burgard EC, 1999, MOL BRAIN RES, V73, P28, DOI 10.1016/S0169-328X(99)00230-2; Caraiscos VB, 2004, P NATL ACAD SCI USA, V101, P3662, DOI 10.1073/pnas.0307231101; CELENTANO JJ, 1994, BIOPHYS J, V66, P1039, DOI 10.1016/S0006-3495(94)80885-9; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cherubini E, 2001, TRENDS NEUROSCI, V24, P155, DOI 10.1016/S0166-2236(00)01724-0; Christie SB, 2002, NEUROREPORT, V13, P2355, DOI 10.1097/00001756-200212030-00037; Christie SB, 2002, PROG BRAIN RES, V136, P157; Coyle JE, 2003, NEUROSCIENTIST, V9, P205, DOI 10.1177/1073858403009003013; Crestani F, 2002, P NATL ACAD SCI USA, V99, P8980, DOI 10.1073/pnas.142288699; Danglot L, 2003, MOL CELL NEUROSCI, V23, P264, DOI 10.1016/S1044-7431(03)00069-1; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; De Schutter E, 2002, CURR BIOL, V12, pR363, DOI 10.1016/S0960-9822(02)00861-8; Ebert V, 1999, NEUROCHEM INT, V34, P453, DOI 10.1016/S0197-0186(99)00039-X; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; GABBIANI F, 1994, J NEUROPHYSIOL, V72, P999, DOI 10.1152/jn.1994.72.2.999; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Haas KF, 1999, J PHYSIOL-LONDON, V514, P27, DOI 10.1111/j.1469-7793.1999.027af.x; Hamann M, 2002, NEURON, V33, P625, DOI 10.1016/S0896-6273(02)00593-7; Hausser M, 1997, NEURON, V19, P665, DOI 10.1016/S0896-6273(00)80379-7; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jensen K, 2003, J NEUROPHYSIOL, V90, P2690, DOI 10.1152/jn.00240.2003; Jonas Peter, 1995, P231; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Kannenberg K, 1999, EUR J NEUROSCI, V11, P1256, DOI 10.1046/j.1460-9568.1999.00533.x; Leao RM, 2000, NEUROPHARMACOLOGY, V39, P990, DOI 10.1016/S0028-3908(99)00177-X; Liu QY, 2000, J NEUROPHYSIOL, V84, P1392, DOI 10.1152/jn.2000.84.3.1392; LUDDENS H, 1995, NEUROPHARMACOLOGY, V34, P245, DOI 10.1016/0028-3908(94)00158-O; MacDonald R L, 1992, Ion Channels, V3, P315; MACDONALD RL, 1989, J PHYSIOL-LONDON, V410, P479, DOI 10.1113/jphysiol.1989.sp017545; Machu TK, 1998, NEUROPHARMACOLOGY, V37, P391, DOI 10.1016/S0028-3908(98)00021-5; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; MERTENS S, 1993, J BIOL CHEM, V268, P5965; Mitchell SJ, 2000, J NEUROSCI, V20, P8651; Mody I, 2001, NEUROCHEM RES, V26, P907, DOI 10.1023/A:1012376215967; Mozrzymas JW, 2003, J NEUROPHYSIOL, V89, P871, DOI 10.1152/jn.00951.2002; Nusser Z, 1998, J NEUROSCI, V18, P1693; NUSSER Z, 1995, J NEUROSCI, V15, P2948; Nusser Z, 2002, J NEUROPHYSIOL, V87, P2624, DOI 10.1152/jn.2002.87.5.2624; OTIS TS, 1991, BRAIN RES, V545, P142, DOI 10.1016/0006-8993(91)91280-E; Overstreet LS, 2000, J NEUROSCI, V20, P7914; Peng Z, 2002, J COMP NEUROL, V446, P179, DOI 10.1002/cne.10210; Petrini EM, 2003, J BIOL CHEM, V278, P16271, DOI 10.1074/jbc.M213081200; Poltl A, 2003, J NEUROCHEM, V87, P1444, DOI 10.1046/j.1471-4159.2003.02135.x; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Rossi DJ, 1998, NEURON, V20, P783, DOI 10.1016/S0896-6273(00)81016-8; Ruiz M, 1997, NATURE, V389, P389, DOI 10.1038/38744; SAXENA NC, 1994, J NEUROSCI, V14, P7077; Schousboe A, 2003, NEUROCHEM RES, V28, P347, DOI 10.1023/A:1022397704922; Scotti AL, 2001, P NATL ACAD SCI USA, V98, P3489, DOI 10.1073/pnas.061028798; Semyanov A, 2003, NAT NEUROSCI, V6, P484, DOI 10.1038/nn1043; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Smith TC, 2000, NAT NEUROSCI, V3, P992, DOI 10.1038/79931; Sperk G, 1997, NEUROSCIENCE, V80, P987, DOI 10.1016/S0306-4522(97)00146-2; STALEY KJ, 1992, J NEUROPHYSIOL, V68, P197, DOI 10.1152/jn.1992.68.1.197; Stell BM, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0003.2002; Stell BM, 2003, P NATL ACAD SCI USA, V100, P14439, DOI 10.1073/pnas.2435457100; Strecker GJ, 1999, J NEUROPHYSIOL, V81, P184, DOI 10.1152/jn.1999.81.1.184; Sur C, 1998, MOL PHARMACOL, V54, P928, DOI 10.1124/mol.54.5.928; VALEYEV AY, 1993, NEUROSCI LETT, V155, P199, DOI 10.1016/0304-3940(93)90707-R; Vautrin J, 2000, SYNAPSE, V37, P38, DOI 10.1002/(SICI)1098-2396(200007)37:1<38::AID-SYN5>3.0.CO;2-C; Wall MJ, 1997, EUR J NEUROSCI, V9, P533, DOI 10.1111/j.1460-9568.1997.tb01630.x; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wei WZ, 2003, J NEUROSCI, V23, P10650; Wingrove PB, 1997, MOL PHARMACOL, V52, P874, DOI 10.1124/mol.52.5.874; Wisden W, 2002, NEUROPHARMACOLOGY, V43, P530, DOI 10.1016/S0028-3908(02)00151-X; Wu YM, 2001, J NEUROSCI, V21, P2630, DOI 10.1523/JNEUROSCI.21-08-02630.2001; Yeung JYT, 2003, MOL PHARMACOL, V63, P2, DOI 10.1124/mol.63.1.2	85	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45833	45843		10.1074/jbc.M407229200	http://dx.doi.org/10.1074/jbc.M407229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15317810	Green Published, hybrid			2022-12-25	WOS:000224694900068
J	Sidera, K; Samiotaki, M; Yfanti, E; Panayotou, G; Patsavoudi, E				Sidera, K; Samiotaki, M; Yfanti, E; Panayotou, G; Patsavoudi, E			Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ADHESION MOLECULES; NEURONAL MIGRATION; 4C5 ANTIGEN; FUNCTIONAL-CHARACTERIZATION; MORPHOLOGICAL EVOLUTION; SIGNAL-TRANSDUCTION; SUBVENTRICULAR ZONE; NEURAL DEVELOPMENT; SCHWANN-CELLS; HEAT-SHOCK	Heat shock protein HSP90 plays important roles in cellular regulation, primarily as a chaperone for a number of key intracellular proteins. We report here that the two HSP90 isoforms, alpha and beta, also localize on the surface of cells in the nervous system and are involved in their migration. A 94-kDa surface antigen, the 4C5 antigen, which was previously shown to be involved in migration processes during development of the nervous system, is shown to be identical to HSP90alpha using mass spectrometry analysis. This identity is further confirmed by immunoprecipitation experiments and by induction of 4C5 antigen expression in heat shock-treated embryonic rat brain cultures. Moreover, immunocytochemistry on live cerebellar rat cells reveals cell surface localization of both HSP90alpha and -beta. Cell migration from cerebellar and sciatic nerve explants is inhibited by anti-HSP90alpha and anti-HSP90beta antibodies, similarly to the inhibition observed with monoclonal antibody 4C5. Moreover, immunostaining with rhodamine-phalloidin of migrating Schwann cells cultured in the presence of antibodies against both alpha and beta isoforms of HSP90 reveals that HSP90 activity is associated with actin cytoskeletal organization, necessary for lamellipodia formation.	Hellenic Pasteur Inst, Dept Biochem, Athens 11521, Greece; Biomed Sci Res Ctr, Prot Chem Lab, Athens 16672, Greece; Inst Athens, Dept Biomed Instrumentat Technol, Athens 12210, Greece		Patsavoudi, E (corresponding author), Hellenic Pasteur Inst, Dept Biochem, 127 Vas Sofias, Athens 11521, Greece.	epatsavoudi@pasteur.gr	Samiotaki, Martina/B-3851-2018	Samiotaki, Martina/0000-0001-9952-0636; YFANTI, ELENI/0000-0002-8211-2692				Anton ES, 1996, J NEUROSCI, V16, P2283; ANTON ES, 1995, J NEUROSCI, V15, P584; ANTONICEK H, 1987, J CELL BIOL, V104, P1587, DOI 10.1083/jcb.104.6.1587; Becker B, 2004, EXP DERMATOL, V13, P27, DOI 10.1111/j.0906-6705.2004.00114.x; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BROCKES JP, 1980, J NEUROCYTOL, V9, P67, DOI 10.1007/BF01205227; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burt ET, 2003, ANN CLIN LAB SCI, V33, P86; CHUONG CM, 1987, J CELL BIOL, V104, P331, DOI 10.1083/jcb.104.2.331; CHUONG CM, 1990, EXPERIENTIA, V46, P892, DOI 10.1007/BF01939381; Cid C, 2003, FASEB J, V17, P409, DOI 10.1096/fj.03-0606fje; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; FISHMAN RB, 1993, J NEUROSCI, V13, P3485; GALILEO DS, 1992, NEURON, V9, P1117, DOI 10.1016/0896-6273(92)90070-T; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; KEYNES RJ, 1987, TRENDS NEUROSCI, V10, P137, DOI 10.1016/0166-2236(87)90037-3; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Loones MT, 2000, CELL STRESS CHAPERON, V5, P291, DOI 10.1379/1466-1268(2000)005<0291:TDOHSP>2.0.CO;2; LUSKIN MB, 1994, GLIA, V11, P211, DOI 10.1002/glia.440110302; MAMALAKI A, 1995, J BIOL CHEM, V270, P14201, DOI 10.1074/jbc.270.23.14201; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; MIRSKY R, 1990, SEMINARS NEUROSCIENC, V2, P423; Misson JP, 1991, CEREB CORTEX, V1, P221, DOI 10.1093/cercor/1.3.221; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; PATSAVOUDI E, 1989, NEUROSCIENCE, V30, P463, DOI 10.1016/0306-4522(89)90266-2; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Previtali SC, 2001, PROG NEUROBIOL, V64, P35, DOI 10.1016/S0301-0082(00)00045-9; QUELTSCH C, 2002, NATURE, V417, P618; RAKIC P, 1995, J NEUROBIOL, V26, P299, DOI 10.1002/neu.480260303; Rakic Pasko, 1994, Current Opinion in Neurobiology, V4, P63, DOI 10.1016/0959-4388(94)90033-7; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMAIDOU D, 1995, J NEUROCHEM, V64, P1937; THOMAIDOU D, 1993, NEUROSCIENCE, V53, P813, DOI 10.1016/0306-4522(93)90626-Q; Thomaidou D, 1996, J NEUROSCI RES, V46, P24; Walsh D, 1997, CELL MOL LIFE SCI, V53, P198, DOI 10.1007/PL00000592; Walsh FS, 1996, CURR OPIN CELL BIOL, V8, P707, DOI 10.1016/S0955-0674(96)80113-X; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Yamauchi J, 2003, P NATL ACAD SCI USA, V100, P14421, DOI 10.1073/pnas.2336152100; Yfanti E, 1998, J NEUROCHEM, V71, P1381; Yfanti E, 2004, GLIA, V45, P39, DOI 10.1002/glia.10307; Zhou FQ, 2003, CELL, V113, P814, DOI 10.1016/S0092-8674(03)00467-7	53	99	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45379	45388		10.1074/jbc.M405486200	http://dx.doi.org/10.1074/jbc.M405486200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302889	hybrid			2022-12-25	WOS:000224694900013
J	Bozic, D; Sciandra, F; Lamba, D; Brancaccio, A				Bozic, D; Sciandra, F; Lamba, D; Brancaccio, A			The structure of the N-terminal region of murine skeletal muscle alpha-dystroglycan discloses a modular architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MOLECULAR-BASIS; PROTEIN; BINDING; IDENTIFICATION; RECEPTOR; DYSTROPHIN; DOMAIN	Dystroglycan (DG) is a cell surface receptor consisting of two subunits: alpha-dystroglycan, extracellular and highly glycosylated, and beta-dystroglycan, spanning the cell membrane. It is a pivotal member of the dystrophin-glycoprotein complex and is involved in a wide variety of important cellular processes such as the stabilization of the muscle fiber sarcolemma or the clustering of acetylcholine receptors. We report the 2.3-Angstrom resolution crystal structure of the murine skeletal muscle N-terminal alpha-DG region, which confirms the presence of two autonomous domains; the first finally identified as an Ig-like and the second resembling ribosomal RNA-binding proteins. Solid-phase laminin binding assays show the occurrence of protein-protein type of interactions involving the Ig-like domain of alpha-DG.	Univ Zurich, Inst Biochem, CH-8044 Zurich, Switzerland; Univ Cattolica Sacro Cuore, Ist Biochim & Biochim Clin, Ist Chim Riconoscimento Mol, CNR, I-00168 Rome, Italy; CNR, Ist Cristallog, Unita Staccata Trieste, I-34012 Trieste, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	University of Zurich; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto Di Cristallografia (IC-CNR); International Center for Genetic Engineering & Biotechnology (ICGEB)	Bozic, D (corresponding author), ETH, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.	bozic@mat.ethz.ch	Sciandra, Francesca/AAY-4650-2020; Lamba, Doriano/L-9808-2018; Brancaccio, Andrea/C-5876-2009; Lamba, Doriano/B-2961-2011	Sciandra, Francesca/0000-0002-2123-1516; Lamba, Doriano/0000-0001-6859-7868; Brancaccio, Andrea/0000-0003-4690-8826; Lamba, Doriano/0000-0001-6859-7868				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bozic D, 1998, MATRIX BIOL, V17, P495, DOI 10.1016/S0945-053X(98)90097-X; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dickens NJ, 2002, CURR BIOL, V12, pR197, DOI 10.1016/S0960-9822(02)00748-0; Fong S, 1996, J MOL BIOL, V264, P624, DOI 10.1006/jmbi.1996.0665; Hall H, 2003, MOL CELL NEUROSCI, V24, P1062, DOI 10.1016/j.mcn.2003.08.007; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Holt KH, 2000, FEBS LETT, V468, P79, DOI 10.1016/S0014-5793(00)01195-9; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kanagawa M, 2004, CELL, V117, P953, DOI 10.1016/j.cell.2004.06.003; Kunz S, 2001, J CELL BIOL, V155, P301, DOI 10.1083/jcb.200104103; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Sciandra F, 2001, EUR J BIOCHEM, V268, P4590, DOI 10.1046/j.1432-1327.2001.02386.x; SMALHEISER NR, 1987, P NATL ACAD SCI USA, V84, P6457, DOI 10.1073/pnas.84.18.6457; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TURK D, 1992, MAIN; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; Winder SJ, 2001, TRENDS BIOCHEM SCI, V26, P118, DOI 10.1016/S0968-0004(00)01731-X; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	31	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44812	44816		10.1074/jbc.C400353200	http://dx.doi.org/10.1074/jbc.C400353200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15326183	hybrid			2022-12-25	WOS:000224505600070
J	Gopal, E; Fei, YJ; Sugawara, M; Miyauchi, S; Zhuang, L; Martin, P; Smith, SB; Prasad, PD; Ganapathy, V				Gopal, E; Fei, YJ; Sugawara, M; Miyauchi, S; Zhuang, L; Martin, P; Smith, SB; Prasad, PD; Ganapathy, V			Expression of slc5a8 in kidney and its role in Na+-coupled transport of lactate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; BORDER MEMBRANE-VESICLES; FUNCTIONAL-CHARACTERIZATION; GENOMIC ORGANIZATION; IODIDE TRANSPORTER; SODIUM; COTRANSPORT; FAMILY; IDENTIFICATION; RECEPTORS	We report here on the expression of slc5a8 in kidney and its relevance to Na+-coupled reabsorption of lactate. slc5a8 is the murine ortholog of SLC5A8, a candidate tumor suppressor gene, which we recently cloned from human intestine and demonstrated its functional identity as a Na+-coupled transporter for short-chain fatty acids and lactate. The slc5a8 cDNA, cloned from mouse kidney, codes for a protein consisting of 611 amino acids. When expressed heterologously in mammalian cells or Xenopus oocytes, slc5a8 mediates Na+-coupled electrogenic transport of lactate/pyruvate as well as short-chain fatty acids ( e. g. acetate, propionate, and butyrate). The Na+/fatty acid stoichiometry varies depending on the fatty acid substrate ( 2: 1 for lactate and 4: 1 for propionate). This phenomenon of variable Na+/ substrate stoichiometry depending on the fatty acid substrate is also demonstrable with human SLC5A8. In situ hybridization with sagittal sections of mouse kidney demonstrates abundant expression of the transcripts in the cortex as well as the medulla. Brush border membrane vesicles prepared from rabbit kidney are able to transport lactate in a Na+-coupled manner. The transport process exhibits the overshoot phenomenon, indicating uphill lactate transport in response to the transmembrane Na+ gradient. The Na+-coupled lactate transport in these membrane vesicles is inhibitable by short-chain fatty acids. We conclude that slc5a8 is expressed abundantly in the kidney and that it plays a role in the active reabsorption of lactate. slc5a8 is the first transporter known to be expressed in mammalian kidney that has the ability to mediate the Na+-coupled reabsorption of lactate.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mail.mcg.edu	Sugawara, Mitsuru/A-5274-2012	Sugawara, Mitsuru/0000-0001-5350-2950	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD044404] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049849] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64196] Funding Source: Medline; NIAID NIH HHS [AI49849] Funding Source: Medline; NICHD NIH HHS [HD44404] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARACNIETO M, 1980, AM J PHYSIOL, V239, pF496, DOI 10.1152/ajprenal.1980.239.5.F496; BARBARAT B, 1988, J BIOL CHEM, V263, P12190; Blottiere HM, 2003, P NUTR SOC, V62, P101, DOI 10.1079/PNS2002215; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Chen JS, 2003, CURR CANCER DRUG TAR, V3, P219, DOI 10.2174/1568009033481994; CRAIG FN, 1946, AM J PHYSIOL, V146, P146, DOI 10.1152/ajplegacy.1946.146.1.146; Friesema ECH, 2003, J BIOL CHEM, V278, P40128, DOI 10.1074/jbc.M300909200; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; HOHMANN B, 1974, KIDNEY INT, V5, P261, DOI 10.1038/ki.1974.35; Inoue K, 2004, BIOCHEM J, V378, P949, DOI 10.1042/BJ20031261; Inoue K, 2002, J BIOL CHEM, V277, P39469, DOI 10.1074/jbc.M207072200; JORGENSEN KE, 1984, BIOCHEM J, V223, P803, DOI 10.1042/bj2230803; Knauf F, 2002, P NATL ACAD SCI USA, V99, P14315, DOI 10.1073/pnas.222531899; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; Lacroix L, 2004, J CLIN ENDOCR METAB, V89, P1423, DOI 10.1210/jc.2003-030542; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; MENGUAL R, 1990, J BIOL CHEM, V265, P292; MENGUAL R, 1989, J MEMBRANE BIOL, V108, P197, DOI 10.1007/BF01871734; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Mortensen PB, 1996, SCAND J GASTROENTERO, V31, P132, DOI 10.3109/00365529609094568; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pouillart PR, 1998, LIFE SCI, V63, P1739, DOI 10.1016/S0024-3205(98)00279-3; Rodriguez AM, 2002, J CLIN ENDOCR METAB, V87, P3500, DOI 10.1210/jc.87.7.3500; Saemann MD, 2002, WIEN KLIN WOCHENSCHR, V114, P289; Seth P, 2001, BBA-MOL CELL RES, V1540, P59, DOI 10.1016/S0167-4889(01)00117-3; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; TIRUPPATHI C, 1990, J BIOL CHEM, V265, P14870; TIRUPPATHI C, 1990, BIOCHEM J, V268, P27, DOI 10.1042/bj2680027; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wachtershauser A, 2000, EUR J NUTR, V39, P164, DOI 10.1007/s003940070020; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Wolever TMS, 1997, METABOLISM, V46, P805, DOI 10.1016/S0026-0495(97)90127-X; Wright EM, 2004, PFLUG ARCH EUR J PHY, V447, P510, DOI 10.1007/s00424-003-1063-6; Xiong YM, 2004, P NATL ACAD SCI USA, V101, P1045, DOI 10.1073/pnas.2637002100	39	113	118	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44522	44532		10.1074/jbc.M405365200	http://dx.doi.org/10.1074/jbc.M405365200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322102	hybrid			2022-12-25	WOS:000224505600037
J	Toh, WH; Siddique, MM; Boominathan, L; Lin, KW; Sabapathy, K				Toh, WH; Siddique, MM; Boominathan, L; Lin, KW; Sabapathy, K			c-Jun regulates the stability and activity of the p53 homologue, p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PHYSICAL INTERACTION; P53-RELATED PROTEIN; MODULATION; INDUCTION; APOPTOSIS; PHOSPHORYLATION; MDM2; AP-1; ABL	Chemotherapeutic drugs and stress signals activate p73, the structural and functional homologue of p53, both by transcriptional activation and post-translational modifications. However, cisplatin, a DNA damage-inducing chemotherapeutic agent, is thought to regulate p73 only by affecting its stability through mechanisms involving the MLH-1/c-Abl signaling cascade. Here we show that c-Jun, a component of the AP-1 family of transcription factors, contributes to p73 induction by cisplatin. c-jun(-/-) cells are defective in p73 induction, and ectopic c-Jun expression augments p73 levels. c-Jun-mediated accumulation of p73 requires the transactivation activity of c-Jun and occurs in a c-Abl- and Mdm2-independent manner. c-Jun expression increases p73 half-life by preventing it from proteasome-mediated degradation, resulting in the potentiation of p73-mediated transcriptional activity. Moreover, mouse fibroblasts lacking c-Jun are resistant to cisplatin-induced apoptosis, and reintroduction of c-Jun restores p73 activation and sensitivity to cisplatin. Furthermore, p73-mediated apoptosis is abrogated in c-jun(-/-) cells. Together, these findings demonstrate a possible role for c-Jun in regulating p73 function and highlight the importance of the cooperativity between transcription factors in potentiating apoptosis.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 119260, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Carcinogenesis Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg	Lakshamanane, Boominathan/AAW-5331-2020					Agami R, 1999, NATURE, V399, P809; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gong JG, 1999, NATURE, V399, P806; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LIN KW, 2004, IN PRESS NEOPLASIA, V6; Manson MM, 2000, BIOCHEM SOC T, V28, P7, DOI 10.1042/bst0280007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Ohtsuka T, 2003, ONCOGENE, V22, P1678, DOI 10.1038/sj.onc.1206306; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shimodaira H, 2003, P NATL ACAD SCI USA, V100, P2420, DOI 10.1073/pnas.0438031100; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Tsai KKC, 2003, CANCER RES, V63, P3418; Watanabe K, 2002, J BIOL CHEM, V277, P15113, DOI 10.1074/jbc.M111281200; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	39	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44713	44722		10.1074/jbc.M407672200	http://dx.doi.org/10.1074/jbc.M407672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302867	hybrid			2022-12-25	WOS:000224505600059
J	Vetrivel, KS; Cheng, HP; Lin, W; Sakurai, T; Li, T; Nukina, N; Wong, PC; Xu, HX; Thinakaran, G				Vetrivel, KS; Cheng, HP; Lin, W; Sakurai, T; Li, T; Nukina, N; Wong, PC; Xu, HX; Thinakaran, G			Association of gamma-secretase with lipid rafts in post-golgi and endosome membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR CHOLESTEROL TRANSPORT; NETWORK VESICLE TRAFFICKING; LOW-BUOYANT DENSITY; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; BETA-SECRETASE; IN-VIVO; INTRAMEMBRANE PROTEOLYSIS; ENDOPLASMIC-RETICULUM	Alzheimer's disease-associated beta-amyloid peptides (Abeta) are generated by the sequential proteolytic processing of amyloid precursor protein (APP) by beta- and gamma-secretases. There is growing evidence that cholesterol- and sphingolipid-rich membrane microdomains are involved in regulating trafficking and processing of APP. BACE1, the major beta-secretase in neurons is a palmitoylated transmembrane protein that resides in lipid rafts. A subset of APP is subject to amyloidogenic processing by BACE1 in lipid rafts, and this process depends on the integrity of lipid rafts. Here we describe the association of all four components of the gamma-secretase complex, namely presenilin 1 (PS1)-derived fragments, mature nicastrin, APH-1, and PEN-2, with cholesterol- rich detergent insoluble membrane (DIM) domains of non-neuronal cells and neurons that fulfill the criteria of lipid rafts. In PS1(-/-)/PS2(-/-) and NCT-/- fibroblasts, gamma-secretase components that still remain fail to become detergent-resistant, suggesting that raft association requires gamma-secretase complex assembly. Biochemical evidence shows that subunits of the gamma-secretase complex and three TGN/endosome-resident SNAREs cofractionate in sucrose density gradients, and show similar solubility or insolubility characteristics in distinct non-ionic and zwitterionic detergents, indicative of their co-residence in membrane microdomains with similar protein-lipid composition. This notion is confirmed using magnetic immunoisolation of PS1- or syntaxin 6-positive membrane patches from a mixture of membranes with similar buoyant densities following Lubrol WX extraction or sonication, and gradient centrifugation. These findings are consistent with the localization of gamma-secretase in lipid raft microdomains of post-Golgi and endosomes, organelles previously implicated in amyloidogenic processing of APP.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; RIKEN, Brain Sci Inst, Lab Neurodegenerat Signal, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Lab Struct Neuropathol, Saitama 3510198, Japan; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA	University of Chicago; University of Chicago; RIKEN; RIKEN; Johns Hopkins University; Sanford Burnham Prebys Medical Discovery Institute	Thinakaran, G (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA.	gopal@uchicago.edu	Xu, Huaxi/AAV-7177-2021; Nukina, Nobuyuki/GPP-6265-2022		NIA NIH HHS [R01 AG021495, AG 19070, R01 AG019070, AG21495] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019070, R01AG021495] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; Baulac S, 2003, NEUROBIOL DIS, V14, P194, DOI 10.1016/S0969-9961(03)00123-2; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200; Burns M, 2003, J NEUROSCI, V23, P5645; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Chamberlain LH, 2002, J BIOL CHEM, V277, P49750, DOI 10.1074/jbc.M206936200; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cordy JM, 2003, P NATL ACAD SCI USA, V100, P11735, DOI 10.1073/pnas.1635130100; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HASHIMOTO K, 1992, ACTA NEUROPATHOL, V83, P613, DOI 10.1007/BF00299410; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Iwatsubo T, 2004, CURR OPIN NEUROBIOL, V14, P379, DOI 10.1016/j.conb.2004.05.010; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kim SH, 2000, NEUROBIOL DIS, V7, P99, DOI 10.1006/nbdi.1999.0280; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Lah JJ, 1997, J NEUROSCI, V17, P1971; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li T, 2003, J NEUROSCI, V23, P3272; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Radeva G, 2004, BIOCHEM J, V380, P219, DOI 10.1042/BJ20031348; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Rechards M, 2003, TRAFFIC, V4, P553, DOI 10.1034/j.1600-0854.2003.t01-1-00114.x; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Thinakaran G, 2004, PHARMACOL RES, V50, P411, DOI 10.1016/j.phrs.2003.12.026; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Torp R, 2003, NEUROSCIENCE, V120, P291, DOI 10.1016/S0306-4522(03)00320-8; Vassar R, 2004, J MOL NEUROSCI, V23, P105, DOI 10.1385/JMN:23:1-2:105; Wada S, 2003, BIOCHEMISTRY-US, V42, P13977, DOI 10.1021/bi034904j; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Wolozin B, 2004, NEURON, V41, P7, DOI 10.1016/S0896-6273(03)00840-7; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748	76	342	353	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44945	44954		10.1074/jbc.M407986200	http://dx.doi.org/10.1074/jbc.M407986200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322084	hybrid, Green Accepted			2022-12-25	WOS:000224505600086
J	Quelo, I; Gauthier, C; Hannigan, GE; Dedhar, S; St-Arnaud, R				Quelo, I; Gauthier, C; Hannigan, GE; Dedhar, S; St-Arnaud, R			Integrin-linked kinase regulates the nuclear entry of the c-Jun coactivator alpha-NAC and its coactivation potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-ASSOCIATED COMPLEX; GLYCOGEN-SYNTHASE KINASE; AP-1 TRANSCRIPTION FACTORS; BETA-CATENIN; PROTEIN-KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; BONE-FORMATION; IN-VITRO	Overexpression of the integrin-linked kinase (ILK) was shown to increase c-Jun-dependent transcription. We now show that this effect of ILK involves the c-Jun transcriptional coactivator, (n) under bar ascent polypeptide-associated complex (a) under bar nd (c) under bar oactivator alpha (alpha-NAC). ILK phosphorylated alpha-NAC on residue Ser-43 upon adhesion of cells to fibronectin. Co-expression of constitutively active ILK with alpha-NAC led to the nuclear accumulation of the coactivator. Conversely, alpha-NAC remained in the cytoplasm of cells transfected with a dominant-negative ILK mutant, and a mutated alpha-NAC at phosphoacceptor position Ser-43 (S43A) also localized outside of the nucleus. The S43A alpha-NAC mutant could not potentiate the effect of ILK on c-Jun-dependent transcription. We conclude that ILK-dependent phosphorylation of alpha-NAC induced the nuclear accumulation of the coactivator and that phosphorylation of alpha-NAC by ILK is required for the potentiation of c-Jun-mediated responses by the kinase. The results represent one of the rare examples of a transcriptional coactivator shuttling between the cytosol and the nucleus.	Shriners Hosp Children, Genet Unit, Montreal, PQ H3G 1A6, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2T5, Canada	McGill University; University of Toronto; British Columbia Cancer Agency; University of British Columbia; University of British Columbia; McGill University; McGill University; McGill University	St-Arnaud, R (corresponding author), Shriners Hosp Children, Genet Unit, 1529 Cedar Ave, Montreal, PQ H3G 1A6, Canada.	rst-arnaud@shriners.mcgill.ca	Hannigan, Greg/A-5092-2009	Dedhar, Shoukat/0000-0003-4355-1657				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; Bannister AJ, 1995, ONCOGENE, V11, P2509; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; CARTER NA, 1997, CURRENT PROTOCOLS MO, V4; Cheng SL, 2001, J BONE MINER RES, V16, P277, DOI 10.1359/jbmr.2001.16.2.277; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cowles EA, 2000, J BIOMED MATER RES, V52, P725, DOI 10.1002/1097-4636(20001215)52:4<725::AID-JBM18>3.3.CO;2-F; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danen EHJ, 2003, J PATHOL, V200, P471, DOI 10.1002/path.1416; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; Franke J, 2001, J CELL SCI, V114, P2641; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; HURTUBISE M, 2003, THESIS MCGILL U MONT; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; LIAN JB, 1991, J CELL BIOCHEM, V45, P9, DOI 10.1002/jcb.240450106; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; MONDAL K, 1995, BIOCHEM SOC T, V23, P460, DOI 10.1042/bst0230460; Moreau A, 1998, MOL CELL BIOL, V18, P1312, DOI 10.1128/MCB.18.3.1312; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Quelo I, 2004, BIOCHEMISTRY-US, V43, P2906, DOI 10.1021/bi036256+; Quelo I, 2002, GENE EXPRESSION, V10, P255, DOI 10.3727/000000002783992433; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303; Yotov WV, 1996, GENE DEV, V10, P1763, DOI 10.1101/gad.10.14.1763	56	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43893	43899		10.1074/jbc.M406310200	http://dx.doi.org/10.1074/jbc.M406310200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299025	hybrid			2022-12-25	WOS:000224383100067
J	Shao, YA; Yang, C; Elly, C; Liu, YC				Shao, YA; Yang, C; Elly, C; Liu, YC			Differential regulation of the B cell receptor-mediated signaling by the E3 ubiquitin ligase Cbl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; LYN-DEFICIENT MICE; ANTIGEN RECEPTOR; LYMPHOCYTE DEVELOPMENT; NEGATIVE REGULATION; POSITIVE SELECTION; C-CBL; ACTIVATION; CD19; TRANSDUCTION	The E3 ubiquitin ligase Cbl has been implicated in intracellular signaling pathways induced by the engagement of the B cell antigen receptor (BCR) as a negative regulator. Here we showed that Cbl deficiency results in a reduction of B cell proliferation. Cbl(-/-) B cells show impaired tyrosine phosphorylation, reduced Erk activation, and attenuated calcium mobilization in response to BCR engagement. The phosphorylation of Syk and Btk is also down-modulated. Interestingly, Cbl(-/-) B cells display enhanced BCR-induced phosphorylation of CD19 and its association with phosphatidylinositol 3-kinase. Importantly, Lyn kinase activity is up-regulated in Cbl(-/-) B cells, which correlates inversely with the Cbl-mediated ubiquitination of Lyn. Because Lyn has both negative and positive roles in B cells, our results suggested that Cbl differentially modulates the BCR-mediated signaling pathways through targeting Lyn ubiquitination, which affects B cell development and activation.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	yuncail@liai.org		LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK-56558] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; DeFranco AL, 1998, SEMIN IMMUNOL, V10, P299, DOI 10.1006/smim.1998.0122; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; Fujimoto M, 2000, IMMUNITY, V13, P47, DOI 10.1016/S1074-7613(00)00007-8; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Inabe K, 2002, BLOOD, V99, P584, DOI 10.1182/blood.V99.2.584; Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801; Kyo S, 2003, GENES CELLS, V8, P825, DOI 10.1046/j.1365-2443.2003.00679.x; Martin F, 2002, NAT REV IMMUNOL, V2, P323, DOI 10.1038/nri799; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Otero DC, 2001, J BIOL CHEM, V276, P1474, DOI 10.1074/jbc.M003918200; Pillai S, 2004, IMMUNOL REV, V197, P206, DOI 10.1111/j.0105-2896.2003.097.x; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; Roberts T, 1999, J IMMUNOL, V162, P4377; Shao Y, 2003, EMBO REP, V4, P425, DOI 10.1038/sj.embor.embor813; Sohn HW, 2003, J EXP MED, V197, P1511, DOI 10.1084/jem.20021686; Tezuka T, 1996, J EXP MED, V183, P675, DOI 10.1084/jem.183.2.675; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Wang Y, 2002, IMMUNITY, V17, P501, DOI 10.1016/S1074-7613(02)00426-0; Xu YK, 2002, J IMMUNOL, V169, P6910, DOI 10.4049/jimmunol.169.12.6910; Yasuda T, 2000, J EXP MED, V191, P641, DOI 10.1084/jem.191.4.641; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068	30	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43646	43653		10.1074/jbc.M404082200	http://dx.doi.org/10.1074/jbc.M404082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304502	hybrid			2022-12-25	WOS:000224383100037
J	Hood, JL; Brooks, WH; Thomas, LR				Hood, JL; Brooks, WH; Thomas, LR			Differential compartmentalization of the calpain/calpastatin network with the endoplasmic reticulum and Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-CALPAIN; SIGNAL SEQUENCE; CRYSTAL-STRUCTURE; PROTEASE CALPAIN; CA2+ SENSITIVITY; T-CELLS; CALCIUM; SYSTEM; DOMAIN; LOCALIZATION	Calpain, a calcium-activated cysteine protease, is involved in modulating a variety of cell activities such as shape change, mobility, and apoptosis. The two ubiquitous isoforms of this protease, calpain I and II, are considered to be cytosolic proteins that can translocate to various sites in the cell. The activity of calpain is modulated by two regulatory proteins, calpastatin, the specific endogenous inhibitor of calpain, and the 28-kDa regulatory subunit. Using velocity gradient centrifugation, the results of this study confirm and greatly expand upon our previous finding that the calpain/calpastatin network is associated with the endoplasmic reticulum and Golgi apparatus in cells. Moreover, confocal microscopy demonstrates that calpain II colocalizes with specific proteins found in these organelles. Additional experiments reveal that hydrophobic rather than electrostatic interactions are responsible for the association of the calpain/calpastatin network with these organelles. Treatment of the organelles with Na2CO3 or deoxycholate reveal that calpain I, 78-kDa calpain II, and the regulatory subunit are "embedded" within the organelle membranes similar to integral membrane proteins. Proteinase K treatment of the organelles shows that calpain I and II, calpastatin, and the regulatory subunit localize to the cytosolic surface of the organelle membranes, and a subset of calpain II and the regulatory subunit are also found within the lumen of these organelles. These results provide a new and novel explanation for how the calpain/calpastatin network is organized in the cell.	Univ Kentucky, Med Ctr, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA	University of Kentucky	Thomas, LR (corresponding author), Chandler Med Ctr MN 415, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA.	tlrosz00@uky.edu	Hood, Joshua L./I-9797-2019	Hood, Joshua L./0000-0003-3998-4118				Beaudoin F, 2002, PLANTA, V215, P293, DOI 10.1007/s00425-002-0737-1; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Blaustein MR, 2001, TRENDS NEUROSCI, V24, P602, DOI 10.1016/S0166-2236(00)01891-9; Chakrabarti AK, 1996, J NEUROSCI RES, V44, P374; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Dourdin N, 1997, EXP CELL RES, V235, P385, DOI 10.1006/excr.1997.3684; Evans JH, 2004, MOL BIOL CELL, V15, P371, DOI 10.1091/mbc.e03-05-0338; FOX JEB, 1993, J CELL BIOL, V120, P1051; Fu J, 2000, EUR J CELL BIOL, V79, P219, DOI 10.1078/S0171-9335(04)70025-4; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; GOLL D E, 1986, Ciencia Biologica Molecular and Cellular Biology, V11, P75; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Hood JL, 2003, BIOCHEM BIOPH RES CO, V310, P1200, DOI 10.1016/j.bbrc.2003.09.142; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; Kawasaki H, 1996, MOL MEMBR BIOL, V13, P217, DOI 10.3109/09687689609160599; Kjer-Nielsen L, 1999, J CELL SCI, V112, P1645; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; Melloni E, 2000, BIOCHEM BIOPH RES CO, V272, P472, DOI 10.1006/bbrc.2000.2796; Melloni E, 1998, BIOCHEM BIOPH RES CO, V249, P583, DOI 10.1006/bbrc.1998.9200; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Moremen KW, 2002, BBA-GEN SUBJECTS, V1573, P225, DOI 10.1016/S0304-4165(02)00388-4; Morford LA, 2002, BIOCHEM BIOPH RES CO, V295, P540, DOI 10.1016/S0006-291X(02)00676-9; Murachi T. M., 1983, CALCIUM CELL FUNCTIO, V4, P377; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Rock MT, 1997, J BIOL CHEM, V272, P33377, DOI 10.1074/jbc.272.52.33377; Rock MT, 2000, EXP CELL RES, V261, P260, DOI 10.1006/excr.2000.5048; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; SIMON J, 1996, BIOCHIM BIOPHYS ACTA, V1293, P201; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAM LY, 1994, J BIOL CHEM, V269, P32542; Tekirian TL, 2001, MOL BRAIN RES, V96, P14, DOI 10.1016/S0169-328X(01)00250-9; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; Xie XL, 2001, PROTEIN SCI, V10, P2419, DOI 10.1110/ps.ps.36701	49	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43126	43135		10.1074/jbc.M408100200	http://dx.doi.org/10.1074/jbc.M408100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302874	hybrid			2022-12-25	WOS:000224226400097
J	Beyne-Rauzy, O; Recher, C; Dastugue, N; Demur, C; Pottier, G; Laurent, G; Sabatier, L; Mansat-De Mas, V				Beyne-Rauzy, O; Recher, C; Dastugue, N; Demur, C; Pottier, G; Laurent, G; Sabatier, L; Mansat-De Mas, V			Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells	ONCOGENE			English	Article						TNF alpha; senescence; AML cells; genetic instability	COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; OXIDATIVE DNA-DAMAGE; INDUCED APOPTOSIS; TELOMERASE ACTIVITY; ULCERATIVE-COLITIS; TNF-ALPHA; CERAMIDE; EXPRESSION; LINES	Previous studies have documented that Tumor necrosis factor alpha (TNFalpha) is a potent negative regulator of normal hematopoiesis. However, the mechanism by which TNFalpha acts at the cellular level is not totally understood. Although apoptotic cell killing appears to be the most common cellular effect of TNFalpha, other studies suggest that this cytokine may elicit other cellular responses such as prolonged growth inhibition. In this context, we have investigated whether TNFalpha may induce senescence in hematopoietic cells, which display intrinsic defect in the apoptotic machinery. The present study described that, in the leukemic KG1 cells, TNFalpha induced no apoptosis but a senescence state characterized by prolonged growth arrest, increased beta-galactosidase activity, p21(WAF-1) induction, decreased telomerase activity, telomeric disturbances ( shortening, losses, fusions), and additional chromosomal aberrations. Telomerase inhibition correlated with reduced levels of hTERT transcripts. GM-CSF prevented TNFalpha effects and allowed leukemic cells to recover growth capacity. Finally, our study shows for the first time that, at least in some hematopoietic cells, TNFalpha may induce senescence with important functional consequences, including sustained growth inhibition and genetic instability, and that this cellular response is efficiently regulated by hematopoietic growth factors.	Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31059 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France; CHU Purpan, Hematol Lab, F-31059 Toulouse, France; CEA, DSV, DRR, LRO, F-92265 Fontenay Aux Roses, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU de Toulouse; CEA	Mansat-De Mas, V (corresponding author), Hop Purpan, Hematol Lab, Pavillon Caubet,Pl Dr Baylac, F-31059 Toulouse, France.	demas.v@chu-toulouse.fr	De Mas, Véronique/P-2414-2014; Beyne-Rauzy, Odile OBR/G-6560-2013; Beyne-Rauzy, Odile/AAN-1873-2020	Beyne-Rauzy, Odile/0000-0003-0321-6029; Sabatier, Laure/0000-0003-0552-6549				Akiyama M, 2002, CANCER RES, V62, P3876; BALOCH Z, 1990, J IMMUNOL, V145, P2908; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, J ANAT, V197, P529, DOI 10.1046/j.1469-7580.2000.19740529.x; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kitagawa M, 1997, LEUKEMIA, V11, P2049, DOI 10.1038/sj.leu.2400844; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mathieu N, 2004, CELL MOL LIFE SCI, V61, P641, DOI 10.1007/s00018-003-3296-0; MURASE T, 1987, BLOOD, V69, P467; Nathan I, 2000, CYTOKINE, V12, P881, DOI 10.1006/cyto.1999.0638; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186; Park YM, 1998, J CELL PHYSIOL, V174, P27, DOI 10.1002/(SICI)1097-4652(199801)174:1<27::AID-JCP4>3.0.CO;2-I; Quentmeier H, 2000, EXP HEMATOL, V28, P1008, DOI 10.1016/S0301-472X(00)00516-6; QuilletMary A, 1996, LEUKEMIA, V10, P417; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TOBLER A, 1987, BLOOD, V70, P200; Tsukada Y, 2002, AM J GASTROENTEROL, V97, P2820; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Young NS, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90026-X; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	31	58	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7507	7516		10.1038/sj.onc.1208024	http://dx.doi.org/10.1038/sj.onc.1208024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326480				2022-12-25	WOS:000224176500007
J	Joseph, J; Mudduluru, G; Antony, S; Vashistha, S; Ajitkumar, P; Somasundaram, K				Joseph, J; Mudduluru, G; Antony, S; Vashistha, S; Ajitkumar, P; Somasundaram, K			Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB	ONCOGENE			English	Article						sodium butyrate; histone deacetyalse inhibitor; chromatin remodeling; microarray; expression profiling; cytokine signaling; metastasis	HISTONE DEACETYLASE INHIBITOR; KAPPA-B ACTIVATION; CHAIN FATTY-ACIDS; INTERFERON-GAMMA; PROSTATE-CANCER; IFN-GAMMA; IN-VITRO; GROWTH-INHIBITION; EPITHELIAL-CELLS; CROHNS-DISEASE	Histone deacetylase (HDAC) inhibitors induce growth arrest and apoptosis in a variety of human cancer cells. Sodium butyrate (NaB), a short chain fatty acid, is a HDAC inhibitor and is produced in the colonic lumen as a consequence of microbial degradation of dietary fibers. In order to dissect out the mechanism of NaB-induced growth inhibition of cancer cells, we carried out expression pro. ling of a human lung carcinoma cell line (H460) treated with NaB using a cDNA microarray. Of the total 1728 genes analysed, there were 32 genes with a mean expression value of 2.0-fold and higher and 66 genes with a mean expression value 3.0-fold and lower in NaB-treated cells. For a few selected genes, we demonstrate that their expression pattern by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis is matching with the results obtained by microarray analysis. Closer view at the expression pro. le of NaB-treated cells revealed the downregulation of a total of 16 genes associated with cytokine signaling, in particular, interferon gamma (IFNgamma) pathway. In good correlation, NaB-pretreated cells failed to induce interferon regulatory factor 1, an INFgamma target gene, efficiently upon IFNgamma addition. These results suggest that NaB inhibits proinflammatory cytokine signaling pathway, thus providing proof of mechanism for its anti-inflammatory activity. We also found that NaB induced three genes, which are known metastatic suppressors, and downregulated 11 genes, which have been shown to promote metastasis. Upregulation of metastatic suppressor Kangai 1 (KAI1) by NaB in a time-dependent manner was confirmed by RT-PCR analysis. The differential regulation of metastasis-associated genes by NaB provides explanation for the anti-invasive properties of NaB. Therefore, our study presents new evidence for pathways regulated by NaB, thus providing evidence for the mechanism behind anti-inflammatory and antimetastatic activities of NaB.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in						Ailenberg M, 2002, BIOCHEM BIOPH RES CO, V298, P110, DOI 10.1016/S0006-291X(02)02420-8; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70, DOI 10.1177/014860719902300518; BREESE E, 1993, IMMUNOLOGY, V78, P127; BUGAUT M, 1993, ANNU REV NUTR, V13, P217, DOI 10.1146/annurev.nu.13.070193.001245; Butler LM, 2000, CANCER RES, V60, P5165; Chai F, 2000, CARCINOGENESIS, V21, P7, DOI 10.1093/carcin/21.1.7; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CHAROLLAIS RH, 1990, J CELL PHYSIOL, V145, P46, DOI 10.1002/jcp.1041450108; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clarke KO, 2001, CANCER LETT, V171, P57, DOI 10.1016/S0304-3835(01)00574-2; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Das S, 2003, ONCOGENE, V22, P8394, DOI 10.1038/sj.onc.1206908; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; DeRisi J, 1996, NAT GENET, V14, P457; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FAIS S, 1991, GUT, V32, P403, DOI 10.1136/gut.32.4.403; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Iacomino G, 2001, BIOCHEM BIOPH RES CO, V285, P1280, DOI 10.1006/bbrc.2001.5323; Inan MS, 2000, GASTROENTEROLOGY, V118, P724, DOI 10.1016/S0016-5085(00)70142-9; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KAWAMATA H, 1995, INT J CANCER, V63, P680, DOI 10.1002/ijc.2910630513; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kim MS, 2000, CANCER LETT, V157, P23, DOI 10.1016/S0304-3835(00)00465-1; Klampfer L, 2003, MOL CANCER RES, V1, P855; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; Lehninger A., 1993, PRINCIPLES BIOCH; Liu LT, 2003, CANCER RES, V63, P3069; Luhrs H, 2002, SCAND J GASTROENTERO, V37, P458, DOI 10.1080/003655202317316105; Luhrs H, 2002, ANTICANCER RES, V22, P1561; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Masuda T, 2000, IN VITRO CELL DEV-AN, V36, P387; McIntosh GH, 1996, J GASTROEN HEPATOL, V11, P113, DOI 10.1111/j.1440-1746.1996.tb00046.x; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; Medina V, 1997, CANCER RES, V57, P3697; Miele ME, 1997, CLIN EXP METASTAS, V15, P259, DOI 10.1023/A:1018473415458; MORITA A, 1982, CANCER RES, V42, P4540; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Phillips KK, 1998, MOL CARCINOGEN, V21, P111, DOI 10.1002/(SICI)1098-2744(199802)21:2<111::AID-MC5>3.0.CO;2-Q; Ranganna K, 2000, MOL CELL BIOCHEM, V205, P149, DOI 10.1023/A:1007078200482; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Saemann MD, 2000, FASEB J, V14, P2380; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Segain JP, 2000, GUT, V47, P397, DOI 10.1136/gut.47.3.397; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Tabuchi Y, 2000, CELL STRUCT FUNCT, V25, P297, DOI 10.1247/csf.25.297; TSAO D, 1982, CANCER RES, V42, P1052; Urnov FD, 2003, J CELL BIOCHEM, V88, P684, DOI 10.1002/jcb.10397; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; Wang JX, 1999, CANCER RES, V59, P2766; Weidle UH, 2000, ANTICANCER RES, V20, P1471; Whiteley LO, 1996, DIGEST DIS SCI, V41, P1458, DOI 10.1007/BF02088573; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yim JH, 2003, J INTERF CYTOK RES, V23, P501, DOI 10.1089/10799900360708623; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200	71	107	113	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6304	6315		10.1038/sj.onc.1207852	http://dx.doi.org/10.1038/sj.onc.1207852			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15318170	Green Accepted			2022-12-25	WOS:000223399000015
J	Cooper, TM; Mockett, RJ; Sohal, BH; Sohal, RS; Orr, WC				Cooper, TM; Mockett, RJ; Sohal, BH; Sohal, RS; Orr, WC			Effect of caloric restriction on life span of the housefly, Musca domestica	FASEB JOURNAL			English	Article						aging; metabolic rate; insect nutrition; oxygen; fertility	DIETARY RESTRICTION; EXTENSION; LONGEVITY; GROWTH	Caloric restriction (CR) has been found to extend the life spans of a wide variety of species, transcending phylogenetic boundaries. The objective of this study was to test the generality of this phenomenon, using the male housefly as an insect model in which food intake can be quantified precisely. Sucrose was found to promote a longer life span than diets additionally containing proteins and lipids. Flies were fed sucrose or a more complex diet ad libitum (AL), or in amounts ranging from 50% to 100% of the average amount consumed by young flies. CR shortened rather than prolonged the life span of houseflies, particularly flies fed sucrose only. The rate of oxygen consumption was not affected by caloric restriction or by the exclusion of proteins and lipids from the diet, and the reproductive activity of male flies remained unchanged by sucrose feeding. Thus, it is unlikely that the life-shortening effects of CR can be explained either in terms of an adaptive response in metabolic rate or use of a suboptimal food source. Results of this study contradict the widely held view that CR has a life-extending effect in all species.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	Southern Methodist University; University of Southern California	Orr, WC (corresponding author), So Methodist Univ, Dept Biol Sci, Dedman Life Sci Bldg,6501 Airline Rd, Dallas, TX 75275 USA.	borr@mail.smu.edu			NATIONAL INSTITUTE ON AGING [R01AG007657] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG7657] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AUSTAD SN, 1989, EXP GERONTOL, V24, P83, DOI 10.1016/0531-5565(89)90037-5; BOURG L, 1991, AGE NUTR, V2, P90; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; COMFORT A, 1963, GERONTOLOGY, V8, P150, DOI 10.1159/000211216; FANESTIL DD, 1965, J GERONTOL, V20, P462; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Good TP, 2001, J INSECT PHYSIOL, V47, P1467, DOI 10.1016/S0022-1910(01)00138-X; Jiang JC, 2000, FASEB J, V14, P2135; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; MASORO E, 2002, CALORIE RESTRICTION; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; RAGLAND SS, 1973, EXP GERONTOL, V8, P135, DOI 10.1016/0531-5565(73)90003-X; RAGLAND SS, 1984, THESIS SO METHODIST; RUDZINSKA MA, 1952, J GERONTOL, V7, P544; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; WEST L, 1951, HOUSEFLY ITS NATURAL	22	80	83	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1591	+		10.1096/fj.03-1464fje	http://dx.doi.org/10.1096/fj.03-1464fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319362				2022-12-25	WOS:000223554900003
J	Tomassini, B; Malisan, F; Franchi, L; Nicolo, C; Brea-Calvo, G; Saito, T; Testi, R				Tomassini, B; Malisan, F; Franchi, L; Nicolo, C; Brea-Calvo, G; Saito, T; Testi, R			Calnexin suppresses GD3 synthase-induced apoptosis	FASEB JOURNAL			English	Article						ceramide-mediated stress response; sialyltransferase; mitochondrial damage	MITOCHONDRIAL PERMEABILITY TRANSITION; CHO-K1 CELLS; MOLECULAR CHAPERONE; GANGLIOSIDE GD3; N-GLYCOSYLATION; EXPRESSION; GLYCOSYLTRANSFERASES; DEFICIENT; ALPHA; MICE	An accelerated activity of the GD3 synthase (ST8), with consequent GD3 accumulation, is part of the response to environmental stressors in different cell types. Depending on specific, yet largely undefined, cellular settings, this can be followed by adaptation or apoptosis, the latter mostly due to GD3-induced mitochondrial damage. Here we show that subcellular localization of ST8 could significantly affect the biological outcome of GD3 accumulation. Binding to the molecular chaperone calnexin causes the retention of ST8 within the endoplasmic reticulum ( ER) and prevents its relocalization to the Golgi. Calnexin-dependent ER retention does not affect the activity of ST8; yet the de novo synthesized GD3 largely fails to reach the mitochondria. Accordingly, overexpression of calnexin suppresses the pro-apoptotic activity of ST8, while the loss of calnexin sensitizes the cells to ST8-induced apoptosis. Reconstitution of calnexin confers protection to deficient cells. Thus, calnexin controls the biological outcome of GD3 accumulation and reveals a novel role in the stress response.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Immunol & Signal Transduct, I-00133 Rome, Italy; Chiba Univ, Grad Sch Med, Dept Mol Genet, Chiba, Japan; RIKEN Ctr Allergy & Immunol, Lab Cell Signaling, Yokohama, Kanagawa, Japan	University of Rome Tor Vergata; Chiba University; RIKEN	Testi, R (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Immunol & Signal Transduct, Via Montpellier 1, I-00133 Rome, Italy.	roberto.testi@flashnet.it	Saito, Takashi/C-9684-2009; Brea-Calvo, Gloria/N-4728-2014	Saito, Takashi/0000-0001-9495-3547; Brea-Calvo, Gloria/0000-0001-5536-6868; MALISAN, FLORENCE/0000-0002-0213-9407				Bieberich E, 2000, J NEUROCHEM, V74, P2359, DOI 10.1046/j.1471-4159.2000.0742359.x; Bieberich E, 2002, BIOCHEMISTRY-US, V41, P11479, DOI 10.1021/bi0259958; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; Daniotti JL, 2002, NEUROCHEM RES, V27, P1421, DOI 10.1023/A:1021684018665; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; Giraudo CG, 2003, J BIOL CHEM, V278, P40262, DOI 10.1074/jbc.M305455200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Li F, 2001, BIOCHEM BIOPH RES CO, V289, P725, DOI 10.1006/bbrc.2001.6001; Malisan F, 2002, BBA-MOL CELL BIOL L, V1585, P179, DOI 10.1016/S1388-1981(02)00339-6; Malisan F, 2002, J EXP MED, V196, P1535, DOI 10.1084/jem.20020960; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Rippo MR, 2000, EUR CYTOKINE NETW, V11, P487; Schrag JD, 2001, MOL CELL, V8, P633, DOI 10.1016/S1097-2765(01)00318-5; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SCOTT JE, 1995, J IMMUNOL, V155, P143	25	29	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1553	+		10.1096/fj.04-1675fje	http://dx.doi.org/10.1096/fj.04-1675fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319364				2022-12-25	WOS:000223554900005
J	Gentile, MT; Vecchione, C; Maffei, A; Aretini, A; Marino, G; Poulet, R; Capobianco, L; Selvetella, G; Lembo, G				Gentile, MT; Vecchione, C; Maffei, A; Aretini, A; Marino, G; Poulet, R; Capobianco, L; Selvetella, G; Lembo, G			Mechanisms of soluble beta-amyloid impairment of endothelial function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAPID CELLULAR DEGENERATION; BLOOD-BRAIN-BARRIER; PROTEIN-KINASE-C; PEPTIDE; PHOSPHORYLATION; MODULATION; ACTIVATION; RESISTANCE; VESSELS	Alzheimer's disease ( AD) has been recently associated with vascular risk factors. beta-amyloid peptides (AbetaP), the main component of senile plaques typical of AD, circulate in soluble globular form in bloodstream. Interestingly, AbetaP is able to induce endothelial dysfunction, and this effect may represent the link between vascular and neuronal pathophysiological factors involved in AD. We aimed to clarify the molecular mechanisms underlying globular AbetaP-induced vascular toxicity. Using several methodological approaches, we have observed that in vascular tissues globular AbetaP is unable to induce oxidative stress, one of the mechanisms hypothesized involved in beta-amyloid toxicity. More important, we have demonstrated that globular AbetaP is able to localize on vascular endothelium, where it inhibits eNOS enzymatic activity. In particular, AbetaP enhances eNOS phosphorylation on threonine 495 and serine 116 and reduces acetylcholine-induced phosphorylation on serine 1177. Such an effect depends on a PKC signaling pathway, as suggested by its phosphorylation on serine 660. In fact, selective inhibition of the calcium-dependent group of PKC is able to rescue beta-amyloid-induced alteration of eNOS phosphorylation, NO production, and endothelial vasorelaxation. The activation of these Ca2+-dependent pathways is probably due to the ability of AbetaP to evoke Ca2+ leakage from inositol 1,4,5-triphosphate receptors on endoplasmic reticulum. Our data demonstrate that globular AbetaP-induced endothelial NO dysfunction can be attributed to an alteration of intracellular Ca2+ homeostasis, which could lead to the activation of calcium-dependent group of PKC with a consequent change of the eNOS phosphorylation pattern. These mechanisms could contribute to shed further light on the toxic effect of beta-amyloid in vascular tissues.	IRCCS Neuromed, Dept Angiocardioneurol, I-86077 Pozzilli, IS, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-86077 Rome, Italy; Univ Naples 2, Excellence Ctr Cardiovasc Dis, I-80100 Naples, Italy	IRCCS Neuromed; Sapienza University Rome; Universita della Campania Vanvitelli	Lembo, G (corresponding author), IRCCS Neuromed, Dept Angiocardioneurol, Localita Camerelle, I-86077 Pozzilli, IS, Italy.	lembo@neuromed.it	Vecchione, Carmine/K-2175-2018; Lembo, Giuseppe/AAE-8096-2020; Selvetella, Giulio/J-4342-2012; maffei, angelo/AAC-2219-2020; CAPOBIANCO, LOREDANA/L-9047-2015	Lembo, Giuseppe/0000-0002-3510-223X; GENTILE, Maria Teresa/0000-0003-4239-5330; maffei, angelo/0000-0002-7491-0344; Vecchione, Carmine/0000-0002-2473-4565				Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Casabona G, 1997, PROG NEURO-PSYCHOPH, V21, P407, DOI 10.1016/S0278-5846(97)00011-0; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Kalaria RN, 1996, PHARMACOL THERAPEUT, V72, P193, DOI 10.1016/S0163-7258(96)00116-7; Kisilevsky R, 1998, NAT MED, V4, P772, DOI 10.1038/nm0798-772; KORSGAARD N, 1988, HYPERTENSION, V12, P162, DOI 10.1161/01.HYP.12.2.162; Kuperstein F, 2001, J NEUROCHEM, V76, P758, DOI 10.1046/j.1471-4159.2001.00037.x; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Luo Y, 1997, BRAIN RES, V769, P287, DOI 10.1016/S0006-8993(97)00718-X; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; MITCHELL BJ, 2001, J BIOL CHEM, V276, P17625; Niwa K, 2000, P NATL ACAD SCI USA, V97, P9735, DOI 10.1073/pnas.97.17.9735; Pitschke M, 1998, NAT MED, V4, P832, DOI 10.1038/nm0798-832; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; Sowers JR, 2002, NEW ENGL J MED, V346, P1999, DOI 10.1056/NEJMe020054; Stewart R, 1998, J NEUROL NEUROSUR PS, V65, P143, DOI 10.1136/jnnp.65.2.143; Su GC, 1999, BRAIN RES, V818, P105, DOI 10.1016/S0006-8993(98)01143-3; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vecchione C, 2002, DIABETES, V51, P168, DOI 10.2337/diabetes.51.1.168; Venturini G, 2002, FASEB J, V16, P1970, DOI 10.1096/fj.02-0186fje; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	35	79	89	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48135	48142		10.1074/jbc.M407358200	http://dx.doi.org/10.1074/jbc.M407358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15319431	Green Published, hybrid			2022-12-25	WOS:000224957000087
J	Ritter, E; Zimmermann, K; Heck, M; Hofmann, KP; Bartl, FJ				Ritter, E; Zimmermann, K; Heck, M; Hofmann, KP; Bartl, FJ			Transition of rhodopsin into the active metarhodopsin II state opens a new light-induced pathway linked to Schiff base isomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED-RECEPTOR; SIGNALING STATES; RETINAL CHROMOPHORE; FTIR SPECTROSCOPY; CRYSTAL-STRUCTURE; GAMMA-SUBUNITS; GROUND-STATE; META-III; ACTIVATION; BACTERIORHODOPSIN	Rhodopsin bears 11-cis-retinal covalently bound by a protonated Schiff base linkage. 11-cis/all-trans isomerization, induced by absorption of green light, leads to active metarhodopsin II, in which the Schiff base is intact but deprotonated. The subsequent metabolic retinoid cycle starts with Schiff base hydrolysis and release of photolyzed all-trans-retinal from the active site and ends with the uptake of fresh 11-cis-retinal. To probe chromophore-protein interaction in the active state, we have studied the effects of blue light absorption on metarhodopsin II using infrared and time-resolved UV-visible spectroscopy. A light-induced shortcut of the retinoid cycle, as it occurs in other retinal proteins, is not observed. The predominantly formed illumination product contains all-trans-retinal, although the spectra reflect Schiff base reprotonation and protein deactivation. By its kinetics of formation and decay, its low temperature photointermediates, and its interaction with transducin, this illumination product is identified as metarhodopsin III. This species is known to bind all-trans-retinal via a reprotonated Schiff base and forms normally in parallel to retinal release. We find that its generation by light absorption is only achieved when starting from active metarhodopsin II and is not found with any of its precursors, including metarhodopsin I. Based on the finding of others that metarhodopsin III binds retinal in all-trans-C-15-syn configuration, we can now conclude that light-induced formation of metarhodopsin III operates by Schiff base isomerization ("second switch"). Our reaction model assumes steric hindrance of the retinal polyene chain in the active conformation, thus preventing central double bond isomerization.	Charite Univ Med Berlin, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Humboldt Univ, Zentrum Biophys & Bioinformat, D-10015 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Bartl, FJ (corresponding author), Charite Univ Med Berlin, Inst Med Phys & Biophys, Campus Charite Mitte,Schumannstr 20-21, D-10098 Berlin, Germany.	franz.bartl@charite.de						ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; BENTROP J, 1986, EUR J BIOCHEM, V161, P61, DOI 10.1111/j.1432-1033.1986.tb10124.x; BIRGE RR, 1995, BIOPHYS CHEM, V55, P115, DOI 10.1016/0301-4622(94)00145-A; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; DeGrip W. J., 2000, HDB BIOL PHYS, P1, DOI 10.1016/s1383- 8121(00)80004- 4; DeLange F, 1998, BIOCHEMISTRY-US, V37, P1411, DOI 10.1021/bi972397y; DRUCKMANN S, 1992, PHOTOCHEM PHOTOBIOL, V56, P1041, DOI 10.1111/j.1751-1097.1992.tb09727.x; Ernst OP, 2002, CHEMBIOCHEM, V3, P968, DOI 10.1002/1439-7633(20021004)3:10<968::AID-CBIC968>3.0.CO;2-Q; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fan GB, 2002, J BIOL CHEM, V277, P40229, DOI 10.1074/jbc.M205033200; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hofmann K. P., 2000, HDB BIOL PHYSICS, P91, DOI 10.1016/s1383-8121(00)80006-8; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Kandori H, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1197, DOI 10.1023/A:1013123016803; Kolesnikov AV, 2003, VISUAL NEUROSCI, V20, P249, DOI 10.1017/S0952523803203047; Kuksa V, 2002, J BIOL CHEM, V277, P42315, DOI 10.1074/jbc.M206014200; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Patzelt H, 2002, P NATL ACAD SCI USA, V99, P9765, DOI 10.1073/pnas.132253899; Reme CE, 2000, NEWS PHYSIOL SCI, V15, P120, DOI 10.1152/physiologyonline.2000.15.3.120; Sachs K, 2000, METHOD ENZYMOL, V315, P238; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Siebert F, 1995, ISRAEL J CHEM, V35, P309; SIEBERT F, 1983, EUR J BIOCHEM, V136, P119, DOI 10.1111/j.1432-1033.1983.tb07714.x; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u; Vogel R, 2004, BIOCHEMISTRY-US, V43, P10255, DOI 10.1021/bi049182q; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; WILLIAMS TP, 1968, VISION RES, V8, P1457, DOI 10.1016/0042-6989(68)90120-X; Xu D, 1996, BIOPHYS J, V70, P453, DOI 10.1016/S0006-3495(96)79588-7; Yan ECY, 2003, P NATL ACAD SCI USA, V100, P9262, DOI 10.1073/pnas.1531970100; ZIMMERMANN K, J BIOL CHEM, V279, P48112	44	36	36	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48102	48111		10.1074/jbc.M406857200	http://dx.doi.org/10.1074/jbc.M406857200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15322129	hybrid			2022-12-25	WOS:000224957000083
J	Seifert, JP; Wing, MR; Snyder, JT; Gershburg, S; Sondek, J; Harden, TK				Seifert, JP; Wing, MR; Snyder, JT; Gershburg, S; Sondek, J; Harden, TK			RhoA activates purified phospholipase C-epsilon by a guanine nucleotide-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; TURKEY ERYTHROCYTES; ALPHA-SUBUNITS; P115 RHOGEF; G-PROTEINS; STIMULATION; RECEPTOR; EFFECTOR; PURIFICATION; C-BETA(2)	Phospholipase C-epsilon (PLC-epsilon) is a recently identified PLC isoform activated by subunits of heterotrimeric G proteins (Galpha(12), Galpha(13), and Gbetagamma) as well as by the low molecular weight GTPases, Rho and Ras. To define the enzymatic activity and substrate specificity of PLC-epsilon as well as its potential direct activation by Rho family GTPases, a major fragment of PLC-epsilon encompassing the catalytic core (EF-hand repeats through the tandem Ras-associating domains; similar to118 kDa) was purified to near homogeneity and assayed after reconstitution under various conditions. Similar to the enzymatic profiles of previously purified PLC-beta isozymes, the purified fragment of PLC-epsilon maximally hydrolyzed phosphatidylinositol 4-phosphate at a rate of similar to10 mumol/mg of protein/min, exhibited phospholipase activity dependent on the concentration of free calcium, and favored phosphatidylinositol 4,5-bisphosphate as substrate relative to other phosphoinositides. Furthermore, in mixed detergent phospholipid micelles, RhoA stimulated the phospholipase activity of the PLC-epsilon fragment in both a concentration-dependent and guanosine 5'-O-(3-thiotriphosphate)-dependent manner. This activation was abolished by the deletion of a unique similar to65 amino acid-insert within the catalytic core of PLC-epsilon. Although Rac1 activated purified PLC-beta2 in a guanine nucleotide-dependent manner, Rac1 failed to promote guanine nucleotide-dependent activation of purified PLC-epsilon. These results indicate that PLC-epsilon is a direct downstream effector for RhoA and that RhoA-dependent activation of PLC-epsilon depends on a unique insert within the catalytic core of the phospholipase.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365, Chapel Hill, NC 27599 USA.	tkh@med.unc.edu		Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM065533, R01GM057391] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57391, GM65533, GM29316] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Houssa B, 1999, J BIOL CHEM, V274, P6820, DOI 10.1074/jbc.274.11.6820; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wing MR, 2003, J BIOL CHEM, V278, P41253, DOI 10.1074/jbc.M306904200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Yoda A, 2004, DEV BIOL, V268, P245, DOI 10.1016/j.ydbio.2003.12.028	37	46	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47992	47997		10.1074/jbc.M407111200	http://dx.doi.org/10.1074/jbc.M407111200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15322077	hybrid, Green Published			2022-12-25	WOS:000224957000070
J	Zhang, Y; Lu, H; Dazin, P; Kapila, Y				Zhang, Y; Lu, H; Dazin, P; Kapila, Y			Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis - Fibronectin and integrin alpha(v) mediate survival signals through focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; HEPARIN-BINDING DOMAIN; EPITHELIAL-CELLS; TYROSINE KINASE; V-REGION; APOPTOSIS; P53; MODULATION; INTEGRINS; OVEREXPRESSION	Resistance to anoikis, or apoptosis triggered by detachment from the extracellular matrix (ECM), lengthens the survival of malignant cells, facilitating reattachment and colonization of secondary sites. To examine the molecular mechanisms underlying resistance to anoikis in human oral squamous cell carcinoma (SCC) cells, we cultured human squamous carcinoma (HSC-3) cells in suspension on plates coated with poly-2-hydroxyethyl methacrylate, which blocks access to the ECM. Cells in suspension that formed multicellular aggregates had significantly lower levels of apoptosis than single cells. Aggregates, but not single cells, had high levels of fibronectin. Preincubation with a cyclic arginine-glycine-aspartic acid peptide or fibronectin-blocking antibody significantly increased anoikis. Single cells had markedly lower expression of the integrin alpha(v) receptor than aggregates. Blocking alpha(v) function with a blocking antibody or by transfection with an antisense oligonucleotide increased apoptosis and inhibited aggregation. In single cells but not aggregates, phosphorylation of the integrin-associated focal adhesion kinase (FAK) at tyrosine 397 was reduced, and p53 levels were increased. Apoptosis was increased by blocking FAK with an antisense oligonucleotide and reduced by blocking p53. These findings show that SCC cells escape suspension-induced anoikis by forming multicellular aggregates that avail themselves of fibronectin survival signals mediated by integrin alpha(v). Single cells in suspension that do not form aggregates undergo anoikis because of decreased FAK phosphorylation and increased p53 levels. Thus, SCC cells appear to use neighboring cells and the ECM molecule FN to promote the metastatic phenotype.	Univ Calif San Francisco, Sch Dent, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Dent, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Kapila, Y (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevnet Geriatr, 1011 N Univ Ave,Rm 5213, Ann Arbor, MI 48109 USA.	ykapila@umich.edu	Kapila, Yvonne/AAG-5418-2021	Lu, Hai/0000-0002-4212-3282	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014429, P01DE013904] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE14429, P01 DE13904] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; Alberts B., 2002, MOL BIOL CELL, P1065; AUMAILLEY M, 1991, FEBS LETT, V291, P50, DOI 10.1016/0014-5793(91)81101-D; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; Diaz-Montero CM, 2003, EUR J CANCER, V39, P2395, DOI 10.1016/S0959-8049(03)00575-6; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Fukai F, 1998, EXP CELL RES, V242, P92, DOI 10.1006/excr.1998.4076; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Green LJ, 1998, INT J BIOCHEM CELL B, V30, P179, DOI 10.1016/S1357-2725(97)00107-6; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hamel W, 1996, CYTOMETRY, V25, P173, DOI 10.1002/(SICI)1097-0320(19961001)25:2<173::AID-CYTO6>3.0.CO;2-I; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hauck CR, 2001, CANCER RES, V61, P7079; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1990, FIBRONECTINS, P8; Ilic D, 1998, J CELL BIOL, V143, P547; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kapila YL, 2002, J BIOL CHEM, V277, P8482, DOI 10.1074/jbc.M108932200; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Marco RAW, 2003, J CELL BIOCHEM, V88, P1038, DOI 10.1002/jcb.10465; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; Miyazaki T, 2003, BRIT J CANCER, V89, P140, DOI 10.1038/sj.bjc.6601050; Nikiforov MA, 1996, ONCOGENE, V13, P1709; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Ramos DM, 1997, INT J CANCER, V72, P369, DOI 10.1002/(SICI)1097-0215(19970717)72:2<369::AID-IJC28>3.3.CO;2-7; Rezaee M, 2002, AM J PHYSIOL-HEART C, V282, pH1924, DOI 10.1152/ajpheart.00921.2001; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; SILVERMAN S, 1998, ORAL CANC, pR11; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Thomas GJ, 1997, ORAL ONCOL, V33, P381, DOI 10.1016/S0964-1955(97)00021-3; Townsend PA, 2000, EUR J CANCER, V36, P397, DOI 10.1016/S0959-8049(99)00275-0; Vitale M, 1999, FEBS LETT, V462, P57, DOI 10.1016/S0014-5793(99)01512-4; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Wei L, 2001, CANCER RES, V61, P2439; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zeng QH, 2002, J BIOL CHEM, V277, P50137, DOI 10.1074/jbc.M208952200	49	107	114	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48342	48349		10.1074/jbc.M407953200	http://dx.doi.org/10.1074/jbc.M407953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15331608	hybrid			2022-12-25	WOS:000224957000109
J	Banfi, B; Malgrange, B; Knisz, J; Steger, K; Dubois-Dauphin, M; Krause, KH				Banfi, B; Malgrange, B; Knisz, J; Steger, K; Dubois-Dauphin, M; Krause, KH			NOX3, a superoxide-generating NADPH oxidase of the inner ear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H OXIDASE; NITRIC-OXIDE; GUINEA-PIG; COCHLEAR; EXPRESSION; PROTEINS; OTOTOXICITY; INHIBITORS; HOMOLOG; CLONING	Reactive oxygen species (ROS) play a major role in drug-, noise-, and age-dependent hearing loss, but the source of ROS in the inner ear remains largely unknown. Herein, we demonstrate that NADPH oxidase (NOX) 3, a member of the NOX/dual domain oxidase family of NADPH oxidases, is highly expressed in specific portions of the inner ear. As assessed by real-time PCR, NOX3 mRNA expression in the inner ear is at least 50-fold higher than in any other tissues where its expression has been observed ( e. g. fetal kidney, brain, skull). Microdissection and in situ hybridization studies demonstrated that NOX3 is localized to the vestibular and cochlear sensory epithelia and to the spiral ganglions. Transfection of human embryonic kidney 293 cells with NOX3 revealed that it generates low levels of ROS on its own but produces high levels of ROS upon co-expression with cytoplasmic NOX subunits. NOX3-dependent superoxide production required a stimulus in the absence of subunits and upon co-expression with phagocyte NADPH oxidase subunits p47(phox) and p67(phox), but it was stimulus-independent upon co-expression with colon NADPH oxidase subunits NOX organizer 1 and NOX activator 1. Pre-incubation of NOX3-transfected human embryonic kidney 293 cells with the ototoxic drug cisplatin markedly enhanced superoxide production, in both the presence and the absence of subunits. Our data suggest that NOX3 is a relevant source of ROS generation in the cochlear and vestibular systems and that NOX3-dependent ROS generation might contribute to hearing loss and balance problems in response to ototoxic drugs.	Univ Iowa, Dept Anat & Cell Biol, Coralville, IA 52241 USA; Univ Iowa, Inflammat Program, Coralville, IA 52241 USA; Univ Iowa, Dept Internal Med, Coralville, IA 52241 USA; Univ Liege, Ctr Cellular & Mol Neurosci, B-4020 Liege, Belgium; Inst Vet Anat, D-35392 Giessen, Germany; Univ Hosp Geneva, Dept Geriatr, Biol Ageing Lab, CH-1225 Geneva, Switzerland	University of Iowa; University of Iowa; University of Iowa; University of Liege; University of Geneva	Banfi, B (corresponding author), Univ Iowa, Dept Anat & Cell Biol, D186 MTF,2501 Crosspk Rd, Coralville, IA 52241 USA.	botond-banfi@uiowa.edu	Krause, Karl-Heinz/E-8030-2011; malgrange, brigitte/A-4887-2019; Malgrange, Brigitte/F-8384-2010; Knisz, Judit/HDN-2414-2022	Krause, Karl-Heinz/0000-0002-9033-6768; malgrange, brigitte/0000-0002-8957-2528; Banfi, Botond/0000-0001-9273-1318	NIAID NIH HHS [AI20866-18, R01 AI020866] Funding Source: Medline; NIA NIH HHS [R01 AG019519, AG19519-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020866, R01AI020866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Babior BM, 2002, ARCH BIOCHEM BIOPHYS, V397, P342, DOI 10.1006/abbi.2001.2642; Banfi B, 2004, J BIOL CHEM, V279, P18583, DOI 10.1074/jbc.M310268200; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Caillou B, 2001, J CLIN ENDOCR METAB, V86, P3351, DOI 10.1210/jc.86.7.3351; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Clerici WJ, 1996, HEARING RES, V98, P116, DOI 10.1016/0378-5955(96)00075-5; Darlington Cynthia L, 2003, Curr Opin Investig Drugs, V4, P841; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Fekete DM, 2002, CURR OPIN NEUROBIOL, V12, P35, DOI 10.1016/S0959-4388(02)00287-8; Fritzsch B., 1998, DEV AUDITORY SYSTEM, P80; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Henderson D, 1999, ANN NY ACAD SCI, V884, P368, DOI 10.1111/j.1749-6632.1999.tb08655.x; Jones GEG, 2003, EXP BRAIN RES, V152, P293, DOI 10.1007/s00221-003-1531-4; Kikuchi H, 2000, GENE, V254, P237, DOI 10.1016/S0378-1119(00)00258-4; Kopke R, 1999, ANN NY ACAD SCI, V884, P171, DOI 10.1111/j.1749-6632.1999.tb08641.x; Kopke RD, 1997, AM J OTOL, V18, P559; Lalucque H, 2003, TRENDS MICROBIOL, V11, P9, DOI 10.1016/S0966-842X(02)00007-0; Lambeth JD, 2002, CURR OPIN HEMATOL, V9, P11, DOI 10.1097/00062752-200201000-00003; Liochev SI, 1998, FREE RADICAL BIO MED, V25, P926, DOI 10.1016/S0891-5849(98)00121-X; Malgrange B, 1998, NEUROCHEM RES, V23, P1133, DOI 10.1023/A:1020724506337; McFadden SL, 1999, J COMP NEUROL, V413, P101; Mocsai A, 1997, BIOCHEM PHARMACOL, V54, P781, DOI 10.1016/S0006-2952(97)00245-1; Ohinata Y, 2000, BRAIN RES, V878, P163, DOI 10.1016/S0006-8993(00)02733-5; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P229, DOI 10.1159/000013846; Paffenholz R, 2004, GENE DEV, V18, P486, DOI 10.1101/gad.1172504; Sergi B, 2003, HEARING RES, V182, P56, DOI 10.1016/S0378-5955(03)00142-4; Sha SH, 1999, FREE RADICAL BIO MED, V26, P341, DOI 10.1016/S0891-5849(98)00207-X; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; Takumida M, 2003, ACTA OTO-LARYNGOL, V123, P8, DOI 10.1080/0036554021000028078; Takumida M, 2002, ORL J OTO-RHINO-LARY, V64, P143, DOI 10.1159/000057794; Van Campen LE, 2002, HEARING RES, V164, P29, DOI 10.1016/S0378-5955(01)00391-4; Yanai T, 2001, J BONE MINER METAB, V19, P345, DOI 10.1007/s007740170003; Zhang M, 2003, NEUROSCIENCE, V120, P191, DOI 10.1016/S0306-4522(03)00286-0	40	315	344	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46065	46072		10.1074/jbc.M403046200	http://dx.doi.org/10.1074/jbc.M403046200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326186	hybrid			2022-12-25	WOS:000224694900092
J	Beller, TC; Maekawa, A; Friend, DS; Austen, KF; Kanaoka, Y				Beller, TC; Maekawa, A; Friend, DS; Austen, KF; Kanaoka, Y			Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MAST-CELLS; ACUTE INFLAMMATORY RESPONSE; SLOW-REACTING SUBSTANCE; VEIN ENDOTHELIAL-CELLS; MOLECULAR-CLONING; C-4 SYNTHASE; CYSLT(2) RECEPTOR; TISSUE DISTRIBUTION; IN-VIVO; EXPRESSION	The cysteinyl leukotrienes (cys-LTs) mediate both acute and chronic inflammatory responses in mice, as demonstrated by the attenuation of the IgE/antigen-mediated increase in microvascular permeability and of bleomycin-induced pulmonary fibrosis, respectively, in a strain with targeted disruption of leukotriene C-4 synthase to prevent cys-LT synthesis. Our earlier finding that the acute, but not the chronic, injury was attenuated in a strain with targeted disruption of the cysteinyl leukotriene 1 (CysLT(1)) receptor suggested that the chronic injury might be mediated through the CysLT(2) receptor. Thus, we generated CysLT(2) receptor-deficient mice by targeted gene disruption. These mice developed normally and were fertile. The increased vascular permeability associated with IgE-dependent passive cutaneous anaphylaxis was significantly reduced in CysLT(2) receptor-null mice as compared with wild-type mice, whereas plasma protein extravasation in response to zymosan A-induced peritoneal inflammation was not altered. Alveolar septal thickening after intratracheal injection of bleomycin, characterized by interstitial infiltration with macrophages and fibroblasts and the accumulation of collagen fibers, was significantly reduced in CysLT(2) receptor-null mice as compared with the wild-type mice. The amounts of cys-LTs in bronchoalveolar lavage fluid after bleomycin injection were similar in the CysLT(2) receptor-null mice and the wildtype mice. Thus, in response to a particular pathobiologic event the CysLT(2) receptor can mediate an increase in vascular permeability in some tissues or promote chronic pulmonary inflammation with fibrosis.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Kanaoka, Y (corresponding author), Brigham & Womens Hosp, Dept Pathol, Smith Bldg,Rm 626C,1 Jimmy Fund Way, Boston, MA 02115 USA.	ykanaoka@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031599, U19AI031599] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-31599, AI-07306] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ME, 1982, P NATL ACAD SCI-BIOL, V79, P1088, DOI 10.1073/pnas.79.4.1088; BAUD L, 1987, J IMMUNOL, V138, P1190; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DAMON M, 1983, BIOCHEM BIOPH RES CO, V111, P518, DOI 10.1016/0006-291X(83)90337-6; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; DOHERTY NS, 1985, PROSTAGLANDINS, V30, P769, DOI 10.1016/0090-6980(85)90006-1; Evans JF, 2003, PROSTAG LEUKOTR ESS, V69, P117, DOI 10.1016/S0952-3278(03)00072-3; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; LAM BK, 1989, J BIOL CHEM, V264, P12885; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2001, P NATL ACAD SCI USA, V98, P2256, DOI 10.1073/pnas.041624398; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Mita H, 2001, CLIN EXP ALLERGY, V31, P1714, DOI 10.1046/j.1365-2222.2001.01184.x; Mollerup J, 2001, BBA-GENE STRUCT EXPR, V1517, P455, DOI 10.1016/S0167-4781(00)00271-2; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Ogasawara H, 2002, J BIOL CHEM, V277, P18763, DOI 10.1074/jbc.M109447200; ORANGE RP, 1980, J IMMUNOL, V124, P2264; PHAN SH, 1988, BIOCHEMISTRY-US, V27, P2846, DOI 10.1021/bi00408a028; Raghu G, 2004, NEW ENGL J MED, V350, P125, DOI 10.1056/NEJMoa030511; RAO TS, 1994, J PHARMACOL EXP THER, V269, P917; ROUZER CA, 1982, J EXP MED, V155, P720, DOI 10.1084/jem.155.3.720; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sheehan D.C., 1980, THEORY PRACTICE HIST; Shi ZZ, 2001, MOL CELL BIOL, V21, P5389, DOI 10.1128/MCB.21.16.5389-5395.2001; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Sjostrom M, 2002, BBA-MOL CELL BIOL L, V1583, P53, DOI 10.1016/S1388-1981(02)00160-9; Sjostrom M, 2001, EUR J BIOCHEM, V268, P2578, DOI 10.1046/j.1432-1327.2001.02142.x; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; YOSHIMOTO T, 1988, J CLIN INVEST, V81, P866, DOI 10.1172/JCI113396	52	124	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46129	46134		10.1074/jbc.M407057200	http://dx.doi.org/10.1074/jbc.M407057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15328359	hybrid			2022-12-25	WOS:000224694900099
J	DeVries, TA; Kalkofen, RL; Matassa, AA; Reyland, ME				DeVries, TA; Kalkofen, RL; Matassa, AA; Reyland, ME			Protein kinase C delta regulates apoptosis via activation of STAT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NUCLEAR IMPORT; PKC-DELTA; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; CELL APOPTOSIS; ALPHA; EXPRESSION; INACTIVATION; ACCUMULATION	Protein kinase Cdelta(PKCdelta) is required for mitochondria-dependent apoptosis; however, little is known about downstream effectors of PKCdelta in apoptotic cells. Here we show that activation of STAT1 is an early response to DNA damage and that STAT1 activation requires PKCdelta. Treatment of HeLa cells with etoposide results in phosphorylation of STAT1 on Ser(727) and the association of STAT1 with PKCdelta. Etoposide increases transcription from STAT1-dependent reporter constructs. Increased transcription, as well as STAT1 Ser(727) phosphorylation, can be blocked by inhibition or depletion of PKCdelta. To ask if STAT1 is required for PKCdelta-mediated apoptosis, we utilized U3A STAT1-deficient cells. Induction of apoptosis by PKCdelta is suppressed in U3A cells but can be rescued by co-transfection with STAT1alpha but not STAT1 mutated at Ser(727). Nuclear accumulation of STAT1, phospho-Ser(727) STAT1, and PKCdelta are detectable 30-60 min after treatment with etoposide. Nuclear localization is necessary for apoptosis, since a nuclear localization mutant of PKCdelta does not induce apoptosis in U3A cells reconstituted with STAT1alpha, and a nuclear localization mutant of STAT1 does not support PKCdelta-induced apoptosis in U3A cells. Our data identify STAT1 as a downstream target of PKCdelta and suggest that PKCdelta may regulate apoptosis by activation of STAT1 target genes.	Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Sch Dent, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Reyland, ME (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Craniofacial Biol, Sch Dent, Biomed Res Bldg 133,Box C286,4200 E 9th Ave, Denver, CO 80262 USA.	Mary.Reyland@UCHSC.edu			NIDCR NIH HHS [DE12798, DE015648] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012798] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Deb DK, 2003, J IMMUNOL, V171, P267, DOI 10.4049/jimmunol.171.1.267; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Janjua S, 2002, CELL DEATH DIFFER, V9, P1140, DOI 10.1038/sj.cdd.4401082; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li LW, 1999, MOL CELL BIOL, V19, P8547; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; MCBRIDE K, 2003, SCI STKE; McBride KM, 2002, EMBO J, V21, P1754, DOI 10.1093/emboj/21.7.1754; Meyer T, 2004, J BIOL CHEM, V279, P18998, DOI 10.1074/jbc.M400766200; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Quissell DO, 1998, IN VITRO CELL DEV-AN, V34, P58; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1998, AM J PHYSIOL-CELL PH, V275, pC780, DOI 10.1152/ajpcell.1998.275.3.C780; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Sironi JJ, 2004, J BIOL CHEM, V279, P4066, DOI 10.1074/jbc.M307774200; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	57	42	46	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45603	45612		10.1074/jbc.M407448200	http://dx.doi.org/10.1074/jbc.M407448200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322115	hybrid			2022-12-25	WOS:000224694900039
J	Lall, S; Friedman, CC; Jankowska-Anyszka, M; Stepinski, J; Darzynkiewicz, E; Davis, RE				Lall, S; Friedman, CC; Jankowska-Anyszka, M; Stepinski, J; Darzynkiewicz, E; Davis, RE			Contribution of trans-splicing, 5 '-leader length, cap-poly(A) synergism, and initiation factors to nematode translation in an Ascaris suum embryo cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-SPLICED LEADER; MESSENGER-RNA CAP; CAENORHABDITIS-ELEGANS; C-ELEGANS; FACTOR 4E; TRIMETHYLGUANOSINE CAP; SCHISTOSOMA-MANSONI; POLY(A) TAIL; 5' TERMINI; IN-VIVO	Trans-splicing introduces a common 5' 22-nucleotide sequence with an N-2,2,7-trimethylguanosine cap (m(3) (2,2,7)GpppG or TMG-cap) to more than 70% of transcripts in the nematodes Caenorhabditis elegans and Ascaris suum. Using an Ascaris embryo cell-free translation system, we found that the TMG-cap and spliced leader sequence synergistically collaborate to promote efficient translation, whereas addition of either a TMG-cap or spliced leader sequence alone decreased reporter activity. We cloned an A. suum embryo eIF4E homolog and demonstrate that this recombinant protein can bind m(7)G- and TMG-capped mRNAs in cross-linking assays and that binding is enhanced by eIF4G. Both the cap structure and the spliced leader (SL) sequence affect levels of A. suum eIF4E cross-linking to mRNA. Furthermore, the differential binding of eIF4E to a TMG-cap and to trans-spliced and non-trans-spliced RNAs is commensurate with the translational activity of reporter RNAs observed in the cell-free extract. Together, these binding data and translation assays with competitor cap analogs suggest that A. suum eIF4E-3 activity may be sufficient to mediate translation of both trans-spliced and non-trans-spliced mRNAs. Bioinformatic analyses demonstrate the SL sequence tends to trans-splice close to the start codon in a diversity of nematodes. This evolutionary conservation is functionally reflected in the optimal SL to AUG distance for reporter mRNA translation in the cell-free system. Therefore, trans-splicing of the SL1 leader sequence may serve at least two functions in nematodes, generation of an optimal 5'-untranslated region length and a specific sequence context (SL1) for optimal translation of trimethylguanosine capped transcripts.	CUNY Coll Staten Isl, Dept Biol, Grad Ctr, Staten Isl, NY 10314 USA; Warsaw Univ, Dept Chem, PL-02093 Warsaw, Poland; Warsaw Univ, Dept Biophys, PL-02093 Warsaw, Poland	City University of New York (CUNY) System; College of Staten Island (CUNY); University of Warsaw; University of Warsaw	Davis, RE (corresponding author), UCHSC Fitzsimons, Dept Biochem & Mol Genet, Mail Stop 8101,POB 6511,12801 E 17th Ave, Aurora, CO 80045 USA.	richard.davis@uchsc.edu			NIAID NIH HHS [AI49558, AI043300, AI039714, R01 AI049558] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R15AI043300, R15AI039714, R01AI049558] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blumenthal T, 2003, NAT REV GENET, V4, P110, DOI 10.1038/nrg995; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; Cohen LS, 2004, RNA, V10, P1609, DOI 10.1261/rna.7690504; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; Davis RE, 1997, MOL BIOCHEM PARASIT, V89, P25, DOI 10.1016/S0166-6851(97)00097-2; DAVIS RE, 1995, J BIOL CHEM, V270, P21813, DOI 10.1074/jbc.270.37.21813; Davis RE, 1996, PARASITOL TODAY, V12, P33, DOI 10.1016/0169-4758(96)80643-0; Denker JA, 1996, RNA, V2, P746; Denker JA, 2002, NATURE, V417, P667, DOI 10.1038/nature00783; Evans D, 1997, P NATL ACAD SCI USA, V94, P9751, DOI 10.1073/pnas.94.18.9751; Ferguson KC, 1999, MOL CELL BIOL, V19, P1892; FROMONTRACINE M, 1993, NUCLEIC ACIDS RES, V21, P1683, DOI 10.1093/nar/21.7.1683; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Gebauer F, 1999, EMBO J, V18, P6146, DOI 10.1093/emboj/18.21.6146; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HUANG XY, 1989, P NATL ACAD SCI USA, V86, P8640, DOI 10.1073/pnas.86.22.8640; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Keiper BD, 2000, J BIOL CHEM, V275, P10590, DOI 10.1074/jbc.275.14.10590; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; Lee KZ, 2003, MOL BIOL EVOL, V20, P2097, DOI 10.1093/molbev/msg225; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; MADER S, 1995, MOL CELL BIOL, V15, P4990; MARAYUMA K, 1994, GENE, V138, P171; MARONEY PA, 1989, MOL BIOCHEM PARASIT, V35, P277, DOI 10.1016/0166-6851(89)90214-4; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MARONEY PA, 1995, RNA N Y, V1, P715; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; Miyoshi H, 2002, EMBO J, V21, P4680, DOI 10.1093/emboj/cdf473; Nei M., 2000, MOL EVALUATION PHYLO; Nilsen TW, 2001, TRENDS GENET, V17, P678, DOI 10.1016/S0168-9525(01)02499-4; Pasquinelli AE, 1995, RNA, V1, P957; Peri S, 2001, TRENDS GENET, V17, P685, DOI 10.1016/S0168-9525(01)02493-3; Redmond DL, 2001, MOL BIOCHEM PARASIT, V117, P107, DOI 10.1016/S0166-6851(01)00331-0; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SALLIE R, 1993, PCR METH APPL, V3, P54; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stover NA, 2001, P NATL ACAD SCI USA, V98, P5693, DOI 10.1073/pnas.101049998; Svitkin Yuri V., 2004, V257, P155; SWOFFORD DL, 1996, MOL SYSTEMATICS; Thoma Christian, 2004, Methods Mol Biol, V257, P171, DOI 10.1385/1-59259-750-5:171; THOMAS JD, 1988, CELL, V54, P533, DOI 10.1016/0092-8674(88)90075-X; Tomoo K, 2003, J MOL BIOL, V328, P365, DOI 10.1016/S0022-2836(03)00314-0; Tomoo K, 2002, BIOCHEM J, V362, P539, DOI 10.1042/0264-6021:3620539; ULLU E, 1996, MOL BIOL PARASITIC P, P115; Vandenberghe AE, 2001, GENE DEV, V15, P294, DOI 10.1101/gad.865401; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; VOLLOCH V, 1994, NUCLEIC ACIDS RES, V22, P2507, DOI 10.1093/nar/22.13.2507; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Xie HY, 1998, P NATL ACAD SCI USA, V95, P4235, DOI 10.1073/pnas.95.8.4235; Zeiner GM, 2003, J BIOL CHEM, V278, P38269, DOI 10.1074/jbc.M304295200; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	63	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45573	45585		10.1074/jbc.M407475200	http://dx.doi.org/10.1074/jbc.M407475200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322127	hybrid			2022-12-25	WOS:000224694900036
J	Vinals, F; Ventura, F				Vinals, F; Ventura, F			Myogenin protein stability is decreased by BMP-2 through a mechanism implicating Id1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; LOOP-HELIX PROTEINS; MUSCLE DIFFERENTIATION PROGRAM; FIBROBLAST GROWTH-FACTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; OSTEOBLAST DIFFERENTIATION; RETINOBLASTOMA PROTEIN; MEDIATED DEGRADATION; FACTOR BETA-1	Bone morphogenetic protein-2 (BMP-2) induces a switch in differentiation of mesenchymal cells from the myogenic to the osteogenic lineage. Here we describe that in C2C12 cells, BMP-2 decreases myogenin expression induced by des-(1,3) insulin-like growth factor-1 (des-(1,3) IGF-1) or ectopically expressed from a constitutive promoter, even in conditions where myogenin mRNA levels were unaffected. Addition of BMP-2 decreases myogenin protein half-life to 50%, whereas proteasome inhibitors abolish these effects. Forced expression of Id1, either by transient transfection or under the control of an inducible system, causes degradation of myogenin in the absence of BMP-2. In contrast, E47 overexpression blocks the inhibitory effect of BMP-2 on myogenin levels. Finally, expression of E47 in 293 cells stabilizes myogenin, an effect that is dependent on the heterodimerization mediated by their helix-loop-helix. Our findings indicate that induction of Id1 not only blocks transcriptional activity but also induces myogenin degradation by blocking formation of myogenin-E47 protein complexes.	Univ Barcelona, Dept Ciencies Fisiol 2, Unitat Bioquim, E-08907 Lhospitalet De Llobregat, Spain	University of Barcelona	Ventura, F (corresponding author), Univ Barcelona, Dept Ciencies Fisiol 2, Unitat Bioquim, Campus Bellvitge,C Feixa Llarga S-N, E-08907 Lhospitalet De Llobregat, Spain.	fvinals@ub.edu; fventura@ub.edu	Vinals, Francesc/P-6278-2019; Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014; Viñals, Francesc/F-5928-2016	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Viñals, Francesc/0000-0002-9918-6751				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Blagden CS, 2004, MOL CELL BIOL, V24, P1983, DOI 10.1128/MCB.24.5.1983-1989.2004; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chambard JC, 1998, NUCLEIC ACIDS RES, V26, P3443, DOI 10.1093/nar/26.14.3443; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Floyd ZE, 2001, J BIOL CHEM, V276, P22468, DOI 10.1074/jbc.M009388200; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HARDY S, 1993, MOL CELL BIOL, V13, P5943, DOI 10.1128/MCB.13.10.5943; Hatoum Ossama Abu, 1998, Molecular and Cellular Biology, V18, P5670; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092-8674(01)00622-5; Norton JD, 2000, J CELL SCI, V113, P3897; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tang HB, 2004, CELL SIGNAL, V16, P551, DOI 10.1016/j.cellsig.2003.09.006; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Tintignac LA, 2000, EXP CELL RES, V259, P300, DOI 10.1006/excr.2000.4973; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; Vinals F, 2002, FEBS LETT, V510, P99, DOI 10.1016/S0014-5793(01)03236-7; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Wada MR, 2002, DEVELOPMENT, V129, P2987; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	66	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45766	45772		10.1074/jbc.M408059200	http://dx.doi.org/10.1074/jbc.M408059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322112	hybrid, Green Published			2022-12-25	WOS:000224694900060
J	Jiang, PH; Ji, QZ; Liu, Z; Snyder, LA; Benard, LMJ; Margolskee, RF; Max, M				Jiang, PH; Ji, QZ; Liu, Z; Snyder, LA; Benard, LMJ; Margolskee, RF; Max, M			The cysteine-rich region of T1R3 determines responses to intensely sweet proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDATE TASTE RECEPTOR; UMAMI TASTE; MAMMALIAN SWEET; CHORDA TYMPANI; GENE; IDENTIFICATION; MONELLIN; BRAZZEIN; FAMILY; LOCUS	A wide variety of chemically diverse compounds taste sweet, including natural sugars such as glucose, fructose, sucrose, and sugar alcohols, small molecule artificial sweeteners such as saccharin and acesulfame K, and proteins such as monellin and thaumatin. Brazzein, like monellin and thaumatin, is a naturally occurring plant protein that humans, apes, and Old World monkeys perceive as tasting sweet but that is not perceived as sweet by other species including New World monkeys, mouse, and rat. It has been shown that heterologous expression of T1R2 plus T1R3 together yields a receptor responsive to many of the above-mentioned sweet tasting ligands. We have determined that the molecular basis for species-specific sensitivity to brazzein sweetness depends on a site within the cysteine-rich region of human T1R3. Other mutations in this region of T1R3 affected receptor activity toward monellin, and in some cases, overall efficacy to multiple sweet compounds, implicating this region as a previously unrecognized important determinant of sweet receptor function.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Howard Hughes Med Inst, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Howard Hughes Medical Institute; Icahn School of Medicine at Mount Sinai	Max, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	max@inka.mssm.edu		Margolskee, Robert/0000-0002-9572-2887	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003155, R01DC003055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER; NIDA NIH HHS [T32DA007135-22] Funding Source: Medline; NIDCD NIH HHS [DC003155, DC003055] Funding Source: Medline; NIMH NIH HHS [MH58811] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Caldwell JE, 1998, NAT STRUCT BIOL, V5, P427, DOI 10.1038/nsb0698-427; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Damak S, 2003, SCIENCE, V301, P850, DOI 10.1126/science.1087155; Danilova V, 2002, J NEUROPHYSIOL, V88, P579, DOI 10.1152/jn.2002.88.2.579; Danilova V, 1998, J NEUROPHYSIOL, V80, P2102, DOI 10.1152/jn.1998.80.4.2102; Faus I, 2000, APPL MICROBIOL BIOT, V53, P145, DOI 10.1007/s002530050001; Hellekant G, 1997, PHYSIOL BEHAV, V61, P829, DOI 10.1016/S0031-9384(96)00562-8; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Kitagawa M, 2001, BIOCHEM BIOPH RES CO, V283, P236, DOI 10.1006/bbrc.2001.4760; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Li XD, 2002, P NATL ACAD SCI USA, V99, P4692, DOI 10.1073/pnas.072090199; Max M, 2001, NAT GENET, V28, P58, DOI 10.1038/88270; Montmayeur JP, 2001, NAT NEUROSCI, V4, P492, DOI 10.1038/87440; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Sainz E, 2001, J NEUROCHEM, V77, P896, DOI 10.1046/j.1471-4159.2001.00292.x; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; Temussi PA, 2002, FEBS LETT, V526, P1, DOI 10.1016/S0014-5793(02)03155-1; Zhao GQ, 2003, CELL, V115, P255, DOI 10.1016/S0092-8674(03)00844-4	21	222	232	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45068	45075		10.1074/jbc.M406779200	http://dx.doi.org/10.1074/jbc.M406779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299024	hybrid			2022-12-25	WOS:000224505600099
J	Legube, G; Linares, LK; Tyteca, S; Caron, C; Scheffner, M; Chevillard-Briet, M; Trouche, D				Legube, G; Linares, LK; Tyteca, S; Caron, C; Scheffner, M; Chevillard-Briet, M; Trouche, D			Role of the histone acetyl transferase Tip60 in the p53 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLTRANSFERASE ACTIVITY; ONCOPROTEIN MDM2; PROTEIN; COMPLEX; DEGRADATION; TRANSCRIPTION; CHROMATIN; COACTIVATOR; RECRUITMENT; EXPRESSION	The histone acetyl transferase Tip60 (HTATIP) shares many properties with the tumor suppressor p53 (TP53). Both proteins are involved in the cellular response to DNA damage, are subjected to proteasomal digestion following Mdm2-mediated ubiquitination, and accumulate after UV irradiation. We found here that knock-down of Tip60 affects the p53-dependent response following actinomycin D treatment, most likely because it inhibits p21 (CDKN1A) accumulation. Moreover, Tip60 is required for p53 to activate the endogenous p21 promoter, suggesting that it functions as a p53 co-activator. However, we also found that knock-down of Tip60 increases the turnover rate of p53 under normal growth conditions. Tip60 interferes with Mdm2-mediated degradation of p53, probably because it affects its subcellular localization. Taken together, our results suggest that Tip60 plays a double role in the p53 pathway: under normal growth conditions, Tip60 contributes to maintain a basal pool of p53 by interfering with its degradation; following DNA damage, Tip60 functions as p53 co-activator. That these two distinct roles are linked during the p53-dependent response is an attractive hypothesis.	Univ Toulouse 3, CNRS, UMR 5099, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Univ Toulouse 3, IEFG, IFR 109, F-31062 Toulouse, France; Univ Cologne, Fak Med, Zentrum Biochem, D-50931 Cologne, Germany; Inst Albert Bonniot, INSERM, U309, F-38706 La Tronche, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Cologne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Trouche, D (corresponding author), Univ Toulouse 3, CNRS, UMR 5099, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.	trouche@ibcg.biotoul.fr	Scheffner, Martin/K-2940-2012; Trouche, Didier/B-2854-2008; Linares, Laetitia LKL/F-9901-2018; LEGUBE, Gaelle/AAX-9772-2021	Scheffner, Martin/0000-0003-2229-0128; Linares, Laetitia LKL/0000-0003-1661-2119; Trouche, Didier/0000-0003-1398-6481				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Gottifredi V, 2001, SCIENCE, V292, P1851, DOI 10.1126/science.1062238; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nicolas E, 2000, J BIOL CHEM, V275, P9797, DOI 10.1074/jbc.275.13.9797; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595	33	110	113	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44825	44833		10.1074/jbc.M407478200	http://dx.doi.org/10.1074/jbc.M407478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310756	hybrid			2022-12-25	WOS:000224505600072
J	Wang, YR; Inoue, T; Forgac, M				Wang, YR; Inoue, T; Forgac, M			TM2 but not TM4 of subunit c '' interacts with TM7 of subunit a of the yeast V-ATPase as defined by disulfide-mediated cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; COATED VESICLE (H+)-ATPASE; SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; LUMINAL ACIDIFICATION; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; NEUROSPORA-CRASSA; 100-KDA SUBUNIT	The vacuolar (H+)-ATPase ( or V-ATPase) is an ATP-dependent proton pump which couples the energy released upon ATP hydrolysis to rotational movement of a ring of proteolipid subunits (c, c', and c") relative to the integral subunit a. The proteolipid subunits each contain a single buried acidic residue that is essential for proton transport, with this residue located in TM4 of subunits c and c' and TM2 of subunit c". Subunit c" contains an additional buried acidic residue in TM4 that is not required for proton transport. The buried acidic residues of the proteolipid subunits are believed to interact with an essential arginine residue (Arg(735)) in TM7 of subunit a during proton translocation. We have previously shown that the helical face of TM7 of subunit a containing Arg735 interacts with the helical face of TM4 of subunit c' bordered by Glu(145) and Leu(147) ( Kawasaki-Nishi et al. ( 2003) J. Biol. Chem. 278, 41908 - 41913). We have now analyzed interaction of subunits a and c" using disulfide-mediated cross-linking. The results indicate that the helical face of TM7 of subunit a containing Arg735 interacts with the helical face of TM2 of subunit c" centered on Ile(105), with the essential glutamic acid residue (Glu(108)) located near the opposite border of this face compared with TM4 of subunit c'. By contrast, TM4 of subunit c" does not form strong cross-links with TM7 of subunit a, suggesting that these transmembrane segments are not normally in close proximity. These results are discussed in terms of a model involving rotation of interacting helices in subunit a and the proteolipid subunits relative to each other.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [R37 GM034478, R01 GM034478, GM34478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angevine CM, 2003, P NATL ACAD SCI USA, V100, P13179, DOI 10.1073/pnas.2234364100; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; Bowman EJ, 2004, J BIOL CHEM, V279, P33131, DOI 10.1074/jbc.M404638200; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 2002, BBA-BIOENERGETICS, V1555, P29, DOI 10.1016/S0005-2728(02)00250-5; Flannery AR, 2004, J BIOL CHEM, V279, P39856, DOI 10.1074/jbc.M406767200; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; Graham LA, 2000, J EXP BIOL, V203, P61; Harrison M, 2000, BIOCHEMISTRY-US, V39, P7531, DOI 10.1021/bi000159o; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2003, J BIOL CHEM, V278, P23714, DOI 10.1074/jbc.M302756200; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Kane PM, 2000, J EXP BIOL, V203, P81; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawasaki-Nishi S, 2003, J BIOL CHEM, V278, P41908, DOI 10.1074/jbc.M308026200; Kawasaki-Nishi S, 2001, P NATL ACAD SCI USA, V98, P12397, DOI 10.1073/pnas.221291798; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; MacLeod KJ, 1998, J BIOL CHEM, V273, P150, DOI 10.1074/jbc.273.1.150; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; Wieczorek H, 2000, J EXP BIOL, V203, P127; Yokoyama K, 2003, J BIOL CHEM, V278, P24255, DOI 10.1074/jbc.M303104200; ZHANG JM, 1992, J BIOL CHEM, V267, P9773	54	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44628	44638		10.1074/jbc.M407345200	http://dx.doi.org/10.1074/jbc.M407345200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322078	hybrid			2022-12-25	WOS:000224505600049
J	Benke, D; Fakitsas, P; Roggenmoser, C; Michel, C; Rudolph, U; Mohler, H				Benke, D; Fakitsas, P; Roggenmoser, C; Michel, C; Rudolph, U; Mohler, H			Analysis of the presence and abundance of GABA(A) receptors containing two different types of alpha subunits in murine brain using point-mutated alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTORS; A-RECEPTORS; BINDING; PHARMACOLOGY; SUBTYPES; PREVALENCE; HETEROGENEITY; ARCHITECTURE; COMBINATIONS; POPULATIONS	gamma-Aminobutyric acid, type A (GABA(A)) receptors are pentameric proteins of which the majority is composed of two alpha subunits, two beta subunits and one gamma subunit. It is well documented that two different types of alpha subunits can exist in a singles GABA(A) receptor complex. However, information on the abundance of such GABA(A) receptors is rather limited. Here we tested whether mice containing the His to Arg point mutation in the alpha1, alpha2, or alpha3 subunit at positions 101, 101, and 126, respectively, which render the respective subunits insensitive to diazepam, would be suitable to analyze this issue. Immunodepletion studies indicated that the His to Arg point mutation solely rendered those GABA(A) receptors totally insensitive to diazepam binding that contain two mutated alpha subunits in the receptor complex, whereas receptors containing one mutated and one heterologous alpha subunit not carrying the mutation remained sensitive to diazepam binding. This feature permitted a quantitative analysis of native GABA(A) receptors containing heterologous alpha subunits by comparing the diazepam-insensitive binding sites in mutant mouse lines containing one mutated alpha subunit with those present in mouse lines containing two different mutated alpha subunits. The data indicate that the alpha1alpha1-containing receptors with 61% is the most abundant receptor subtype in brain, whereas the alpha1alpha2 (13%), alpha1alpha3 (15%), alpha2alpha2 (12%), alpha2alpha3 (2%), and alpha3alpha3 combinations (4%) are considerably less expressed. Only within the alpha1-containing receptor population does the combination of equal alpha subunits (84% alpha1alpha1, 7% alpha1alpha2,and 8% alpha1alpha3) prevail, whereas in the alpha2-containing receptor population (46% alpha2alpha2, 36% alpha2alpha1, and 19% alpha2alpha3) and particularly in the alpha3-containing receptor population (27% alpha3alpha3, 56% alpha3alpha1, and 19% alpha3alpha2), the receptors with two different types of alpha subunits predominate. This experimental approach provides the basis for a detailed analysis of the abundance of GABA(A) receptors containing heterologous alpha subunits on a brain regional level.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Fed Inst Technol, Dept Chem & Appl Biosci, CH-8057 Zurich, Switzerland	University of Zurich	Benke, D (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	benke@pharma.unizh.ch						Araujo F, 1996, J BIOL CHEM, V271, P27902, DOI 10.1074/jbc.271.44.27902; Araujo F, 1999, J PHARMACOL EXP THER, V290, P989; Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2003, J NEUROSCI, V23, P11158; Baumann SW, 2002, J BIOL CHEM, V277, P46020, DOI 10.1074/jbc.M207663200; BENKE D, 1991, J RECEPTOR RES, V11, P407, DOI 10.3109/10799899109066418; Benke D, 1997, J NEUROCHEM, V69, P806; Benke D, 1996, NEUROPHARMACOLOGY, V35, P1413, DOI 10.1016/S0028-3908(96)00068-8; BENKE D, 1991, Molecular Neuropharmacology, V1, P103; Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; del Rio JC, 2001, J NEUROCHEM, V79, P183; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; EBERT B, 1994, MOL PHARMACOL, V46, P957; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Khan ZU, 1996, J NEUROCHEM, V66, P685; Low K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131; MARKSITZER R, 1993, J RECEPTOR RES, V13, P467, DOI 10.3109/10799899309073673; MERTENS S, 1993, J BIOL CHEM, V268, P5965; Minier F, 2004, P NATL ACAD SCI USA, V101, P7769, DOI 10.1073/pnas.0400220101; Mohler H, 2000, GABA IN THE NERVOUS SYSTEM: THE VIEW AT FIFTY YEARS, P97; Mohler H, 1996, Ion Channels, V4, P89; POLLARD S, 1993, J BIOL CHEM, V268, P3753; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Sigel E, 2000, J NEUROCHEM, V74, P2590, DOI 10.1046/j.1471-4159.2000.0742590.x; Tia S, 1996, NEUROPHARMACOLOGY, V35, P1375, DOI 10.1016/S0028-3908(96)00018-4; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; WIELAND HA, 1992, J BIOL CHEM, V267, P1426	28	55	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43654	43660		10.1074/jbc.M407154200	http://dx.doi.org/10.1074/jbc.M407154200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304513	Green Accepted, hybrid			2022-12-25	WOS:000224383100038
J	Constantinescu, A; Wu, M; Asher, O; Diamond, I				Constantinescu, A; Wu, M; Asher, O; Diamond, I			cAMP-dependent protein kinase type I regulates ethanol-induced cAMP response element-mediated gene expression via activation of CREB-binding protein and inhibition of MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CYCLIC-AMP; B-RAF; TRANSCRIPTIONAL REGULATION; NUCLEAR TRANSLOCATION; SYNAPTIC PLASTICITY; SIGNALING PATHWAY; NG108-15 CELLS; CROSS-TALK; PC12 CELLS	We have shown that the two types of cAMP-dependent protein kinase (PKA) in NG108-15 cells differentially mediate forskolin-nand ethanol-induced cAMP response element (CRE)-binding protein (CREB) phosphorylation and CRE-mediated gene transcription. Activated type II PKA is translocated into the nucleus where it phosphorylates CREB. By contrast, activated type I PKA does not translocate to the nucleus but is required for CRE-mediated gene transcription by inducing the activation of other transcription cofactors such as CREB-binding protein (CBP). We show here that CBP is required for forskolin- and ethanol-induced CRE-mediated gene expression. Forskolin- and ethanol-induced CBP phosphorylation, demonstrable at 10 min, persists up to 24 h. CBP phosphorylation requires type I PKA but not type II PKA. In NG108-15 cells, ethanol and forskolin activation of type I PKA also inhibits several components of the MAPK pathway including B-Raf kinase, ERK1/2, and p90RSK phosphorylation. As a result, unphosphorylated p90RSK no longer binds to nor inhibits CBP. Moreover, MEK inhibition by PD98059 induces a significant increase of CRE-mediated gene activation. Taken together, our findings suggest that inhibition of the MAPK pathway enhances cAMP-dependent gene activation during exposure of NG108-15 cells to ethanol. This mechanism appears to involve type I PKA-dependent phosphorylation of CBP and inhibition of MEK-dependent phosphorylation of p90RSK. Under these conditions p90RSK is no longer bound to CBP, thereby promoting CBP-dependent CREB-mediated gene expression.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Grad Program Neurosci, Emeryville, CA 94608 USA; Univ Calif San Francisco, Ctr Neurobiol Addict, Emeryville, CA 94608 USA; Magen David Adom Natl Blood Serv Ctr, IL-52621 Ramat Gan, Israel	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Constantinescu, A (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	anconst@itsa.ucsf.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA010030] Funding Source: NIH RePORTER; NIAAA NIH HHS [R37 AA10030] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams JP, 2000, ACTA NEUROBIOL EXP, V60, P377; Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Brockmann D, 2003, CURR TOP MICROBIOL, V272, P97; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Constantinescu A, 2002, J BIOL CHEM, V277, P18810, DOI 10.1074/jbc.M112107200; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Davis MI, 1999, NEUROSCI LETT, V272, P95, DOI 10.1016/S0304-3940(99)00572-8; Deisseroth K, 2002, NEURON, V34, P179, DOI 10.1016/S0896-6273(02)00664-5; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hendrickson RJ, 1998, EUR J PHARMACOL, V362, P251, DOI 10.1016/S0014-2999(98)00771-7; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kalluri HSG, 2002, EUR J PHARMACOL, V439, P53, DOI 10.1016/S0014-2999(01)01599-0; Kapoor GS, 2003, J LIPID RES, V44, P584, DOI 10.1194/jlr.M200302-JLR200; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Licata SC, 2003, J NEUROCHEM, V85, P14, DOI 10.1046/j.1471-4159.2003.01662.x; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Medina DL, 2000, J BIOL CHEM, V275, P15549, DOI 10.1074/jbc.275.20.15549; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Rimondini R, 2002, FASEB J, V16, P27, DOI 10.1096/fj.01-0593com; Roberto M, 2003, EUR J NEUROSCI, V17, P1646, DOI 10.1046/j.1460-9568.2003.02614.x; Roberto M, 2002, J NEUROPHYSIOL, V87, P2385, DOI 10.1152/jn.2002.87.5.2385; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sanna PP, 2002, BRAIN RES, V948, P186, DOI 10.1016/S0006-8993(02)03191-8; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; WEISS F, 1992, ANN NY ACAD SCI, V654, P220, DOI 10.1111/j.1749-6632.1992.tb25970.x; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, J PHARMACOL EXP THER, V278, P338; Yao LN, 2002, CELL, V109, P733, DOI 10.1016/S0092-8674(02)00763-8; Zanassi P, 2001, J BIOL CHEM, V276, P11487, DOI 10.1074/jbc.M007631200	69	24	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43321	43329		10.1074/jbc.M406994200	http://dx.doi.org/10.1074/jbc.M406994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299023	hybrid			2022-12-25	WOS:000224226400116
J	Kiss-Toth, E; Bagstaff, SM; Sung, HY; Jozsa, V; Dempsey, C; Caunt, JC; Oxley, KM; Wyllie, DH; Polgar, T; Harte, M; O'Neill, LAJ; Qwarnstrom, EE; Dower, SK				Kiss-Toth, E; Bagstaff, SM; Sung, HY; Jozsa, V; Dempsey, C; Caunt, JC; Oxley, KM; Wyllie, DH; Polgar, T; Harte, M; O'Neill, LAJ; Qwarnstrom, EE; Dower, SK			Human tribbles, a protein family controlling mitogen-activated protein kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; SCAFFOLD PROTEINS; P38 KINASE; KAPPA-B; DROSOPHILA; IDENTIFICATION; MORPHOGENESIS; PATHWAYS; CHECKPOINT; EXPRESSION	Control of mitogen-activated protein kinase ( MAPK) cascades is central to regulation of many cellular responses. We describe here human tribbles homologues (Htrbs) that control MAPK activity. MAPK kinases interact with Trbs and regulate their steady state levels. Further, Trbs selectively regulate the activation of extracellular signal-regulated kinases, c-Jun NH2-terminal kinases, and p38 MAPK with different relative levels of activity for the three classes of MAPK observed depending on the level of Trb expression. These results suggest that Trbs control both the extent and the specificity of MAPK kinase activation of MAPK.	Univ Sheffield, No Gen Hosp, Div Clin Sci N, Cardiovasc Res Unit, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Royal Hallamshire Hosp, Cell Biol & Funct Genom Grp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; Inst Biochem, H-6726 Szeged, Hungary; Trinity Coll Dublin, Dept Biochem, Dublin 2, Ireland	Northern General Hospital; University of Sheffield; University of Sheffield; Trinity College Dublin	Kiss-Toth, E (corresponding author), Univ Sheffield, No Gen Hosp, Div Clin Sci N, Cardiovasc Res Unit, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.	E.Kiss-Toth@sheffield.ac.uk	Kiss-Toth, Endre/A-8596-2014; Polgár, Tímea/A-2089-2013; Kiss-Toth, Endre/AAC-4252-2020	Kiss-Toth, Endre/0000-0003-4406-4017; Polgár, Tímea/0000-0002-1367-6128; Kiss-Toth, Endre/0000-0003-4406-4017; dower, steve/0000-0002-4675-4225; Qwarnstrom, Eva/0000-0003-4417-8663; O'Neill, Luke/0000-0002-4333-2748				Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; DOWER SK, 2002, CURR GENOMICS, V3, P131; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kiss-Toth E, 2000, J IMMUNOL METHODS, V239, P125, DOI 10.1016/S0022-1759(00)00151-4; Kiss-Toth E, 2001, ANAL BIOCHEM, V288, P230, DOI 10.1006/abio.2000.4858; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Mayumi-Matsuda K, 1999, BIOCHEM BIOPH RES CO, V258, P260, DOI 10.1006/bbrc.1999.0576; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; PERRELL JE, 2000, SCIENCE; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rorth P, 2000, MOL CELL, V6, P23; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Seher TC, 2000, CURR BIOL, V10, P623, DOI 10.1016/S0960-9822(00)00502-9; Sveiczer A, 2000, P NATL ACAD SCI USA, V97, P7865, DOI 10.1073/pnas.97.14.7865; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wilkin F, 1997, EUR J BIOCHEM, V248, P660, DOI 10.1111/j.1432-1033.1997.t01-1-00660.x; Wilkin F, 1996, J BIOL CHEM, V271, P28451, DOI 10.1074/jbc.271.45.28451; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	35	245	258	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42703	42708		10.1074/jbc.M407732200	http://dx.doi.org/10.1074/jbc.M407732200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299019	hybrid			2022-12-25	WOS:000224226400044
J	Shen, JS; Prywes, R				Shen, JS; Prywes, R			Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR ATF6; ER STRESS; INTRAMEMBRANE PROTEOLYSIS; PROTEINS; GOLGI; SREBP; REQUIREMENTS; TRANSPORT; RELEASE	ATF6 is an endoplasmic reticulum (ER) membrane-anchored transcription factor activated by regulated intramembrane proteolysis in the ER stress response. The release of the cytosolic transcription factor domain of ATF6 requires the sequential processing by the Golgi site-1 and site-2 proteases (S1P and S2P). It has been unclear why S2P proteolysis relies on previous site-1 cleavage. One possibility is that S2P localizes to a different cellular compartment than S1P; however, here we show that S2P localizes to the same compartment as S1P, the cis/medial-Golgi. In addition, we have re-localized S1P and S2P to the ER with brefeldin A and find that the sequential cleavage of ATF6 is reconstituted in the ER. The mapping of the region of ATF6 required for sequential S1P and S2P cleavage showed that short luminal domains resulted in S1P-independent S2P cleavage. The addition of artificial domains onto these short ATF6 luminal domains restored the S1P dependence of S2P cleavage, suggesting that it is the size rather than specific sequences in the luminal domain that determines the S1P dependence of S2P cleavage. These results suggest that the bulky ATF6 luminal domain blocks S2P cleavage and that the role of S1P is to reduce the size of the luminal domain to prepare ATF6 to be an optimal S2P substrate.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,MC 2420,1212 Amsterdam Ave, New York, NY 10027 USA.	mrp6@columbia.edu		SHEN, JINGSHI/0000-0001-9595-1148	NCI NIH HHS [CA50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; GOLDE TE, 2003, SCI STKE; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kanehara K, 2003, EMBO J, V22, P6389, DOI 10.1093/emboj/cdg602; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Okada T, 2003, J BIOL CHEM, V278, P31024, DOI 10.1074/jbc.M300923200; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973	26	91	97	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43046	43051		10.1074/jbc.M408466200	http://dx.doi.org/10.1074/jbc.M408466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299016	hybrid			2022-12-25	WOS:000224226400087
J	Iwai, A; Marusawa, H; Matsuzawa, S; Fukushima, T; Hijikata, M; Reed, JC; Shimotohno, K; Chiba, T				Iwai, A; Marusawa, H; Matsuzawa, S; Fukushima, T; Hijikata, M; Reed, JC; Shimotohno, K; Chiba, T			Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner	ONCOGENE			English	Article						beta-catenin; Siah-1; Siah-1L; p53; hepatocellular carcinoma	HUMAN HEPATOCELLULAR CARCINOMAS; CANCER-CELLS; P53; MUTATIONS; IDENTIFICATION; SUPPRESSION; APOPTOSIS; HOMOLOGS; PATHWAY; GENE	beta-Catenin is a potent oncogenic protein whose cytoplasmic accumulation is a frequent event in cancer cells. The level of beta-catenin is regulated by two mechanisms: the adenomatous polyposis coli/Axin/glycogen synthase kinase 3beta-dependent degradation pathway and the Siah-1/ Siah interacting protein/Ebi-mediated degradation pathway. In this study, we have investigated the functional significance of p53-inducible human Siah-family protein expression in the regulation of beta-catenin activity. We show here by reverse-transcriptase polymerase chain reaction that two mRNA transcripts, designated human Siah-1 and Siah-1L, are generated from the human Siah-1 locus. Interestingly, the expression of Siah-1L was upregulated by p53, whereas human Siah-1 expression was constant. Furthermore, introduction of exogenous Siah-1L protein downregulated beta-catenin protein and promoted apoptosis induced by anticancer drugs in cancer cells that lack endogenous p53. Thus, Siah-1L represents a new member of the human Siah family that is induced in response to p53 and plays an important role in the regulation of beta-catenin activity in tumor cells. These findings also suggest new strategies for restoring tumor suppressive pathways lost in cancer cells that have suffered p53 inactivation.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Med, Div Gastroenterol & Hepatol, Kyoto, Japan; Burnham Inst, La Jolla, CA 92037 USA	Kyoto University; Kyoto University; Sanford Burnham Prebys Medical Discovery Institute	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Human Tumor Viruses,Sakyo Ku, 53 Kawara Cho, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp		Marusawa, Hiroyuki/0000-0002-4286-2712				Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DELLA NG, 1993, DEVELOPMENT, V117, P1333; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hu G, 1997, GENOMICS, V46, P103, DOI 10.1006/geno.1997.4997; Hu G, 1997, GENE DEV, V11, P2701, DOI 10.1101/gad.11.20.2701; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Lee TKW, 2002, CANCER CHEMOTH PHARM, V49, P78, DOI 10.1007/s00280-001-0376-4; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Maeda A, 2002, FEBS LETT, V512, P223, DOI 10.1016/S0014-5793(02)02265-2; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Park WS, 2001, J PATHOL, V193, P483; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Relaix F, 2000, P NATL ACAD SCI USA, V97, P2105, DOI 10.1073/pnas.040378897; Roperch JP, 1999, P NATL ACAD SCI USA, V96, P8070, DOI 10.1073/pnas.96.14.8070; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	28	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7593	7600		10.1038/sj.onc.1208016	http://dx.doi.org/10.1038/sj.onc.1208016			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326481	Green Submitted			2022-12-25	WOS:000224176500017
J	Xiong, JP; Stehle, T; Goodman, SL; Arnaout, MA				Xiong, JP; Stehle, T; Goodman, SL; Arnaout, MA			A novel adaptation of the integrin PSI domain revealed from its crystal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR SEGMENT; RISK-FACTOR; POLYMORPHISM; SUBUNIT; COMPLEX; GPIIIA; LIGAND; ALPHA-V-BETA-3; ACTIVATION; RECEPTOR	Integrin beta-subunits contain an N-terminal PSI (for plexin-semaphorin-integrin) domain that contributes to integrin activation and harbors the PI(A) alloantigen associated with immune thrombocytopenias and susceptibility to sudden cardiac death. Here we report the crystal structure of PSI in the context of the crystallized alpha(V)beta(3) ectodomain. The integrin PSI forms a two-stranded antiparallel beta-sheet flanked by two short helices; its long interstrand loop houses Pl(A) and may face the EGF2 domain. The integrin PSI contains four cysteine pairs connected in a 1-4, 2-8, 3-6, 5-7 pattern. An unexpected feature of the structure is that the final, eighth cysteine is located C-terminal to the Ig-like hybrid domain and is thus separated by the hybrid domain from the other seven cysteines of PSI. This architecture may be relevant to the evolution of integrins and should help refine the current models of integrin activation.	Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Struct Biol Program, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Lab Dev Immunol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Merck KGaA, Oncol Res, D-64271 Darmstadt, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Merck KGaA	Arnaout, MA (corresponding author), Massachusetts Gen Hosp, Renal Unit, Leukocyte Biol & Inflammat Program, Struct Biol Program, 149 13th St, Charlestown, MA 02129 USA.	arnaout@receptor.mgh.harvard.edu		Goodman, Simon L./0000-0002-3480-1346	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048549] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70219] Funding Source: Medline; NIDDK NIH HHS [DK48549] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Brunger AT, 2002, ACCOUNTS CHEM RES, V35, P404, DOI 10.1021/ar010034r; Bussel James B., 2000, Hematology Am Soc Hematol Educ Program, P222; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; Love CA, 2003, NAT STRUCT BIOL, V10, P843, DOI 10.1038/nsb977; Peterson JA, 2003, BLOOD, V101, P937, DOI 10.1182/blood-2002-07-2336; Salido E, 1999, J AM SOC NEPHROL, V10, P2599; Stamos J, 2004, EMBO J, V23, P2325, DOI 10.1038/sj.emboj.7600243; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Undas A, 2001, CIRCULATION, V104, P2666, DOI 10.1161/hc4701.099787; Weiss EJ, 1996, NEW ENGL J MED, V334, P1090, DOI 10.1056/NEJM199604253341703; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zang Q, 2001, J BIOL CHEM, V276, P6922, DOI 10.1074/jbc.M005868200	21	79	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40252	40254		10.1074/jbc.C400362200	http://dx.doi.org/10.1074/jbc.C400362200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15299032	hybrid			2022-12-25	WOS:000223916800002
J	Sun, YH; Tran, S; Norstrom, EA; Dahlback, B				Sun, YH; Tran, S; Norstrom, EA; Dahlback, B			Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by Gla domain-mutated human-activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-BOND CLEAVAGES; MOLECULAR-MECHANISMS; FACTOR VA(R506Q); BINDING-SITE; FACTOR XA; INACTIVATION; COFACTOR; EXPRESSION; RESISTANCE; MUTAGENESIS	A Gla domain-mutated protein C variant, QGNSEDY, modified at positions 10-12, 23, 32-33, and 44, having enhanced affinity for negatively charged phospholipid and increased anticoagulant potential, was used to elucidate the importance of the interaction between the Gla domain and the phospholipid for the ability of activated protein C (APC) to inactivate factor Va (FVa). FVa degradation by wild type (WT)-APC and QGNSEDY-APC yielded similar fragments on Western blotting; QGNSEDY-APC was, however, considerably more efficient. The kinetic parameters for individual APC-mediated cleavages in FVa, i.e. at Arg-306 and Arg-506, were investigated at high and low phospholipid concentrations in the presence and absence of protein S. FVa variants 306Q679Q and 506Q679Q, which can only be cleaved at Arg-506 and Arg-306, respectively, were used. In the absence of protein S, QGNSEDY-APC was 17.8- and 4-fold more efficient than WT-APC in cleaving at Arg-306 and Arg-506, respectively, at high phospholipid. Similar values were obtained at low phospholipid. In the presence of protein S, QGNSEDY-APC was 6.8- and 3.2-fold more active than WT-APC in cleaving at Arg-306 and Arg-506, respectively, at high phospholipid. At low phospholipid, the corresponding values were 14- and 6.5-fold. In conclusion, the modification of the Gla domain in QGNSEDY-APC yielded increased rates of cleavage at both sites in FVa, the increase being particularly pronounced for the Arg-306 site in the absence of protein S. The results obtained with QGNSEDY-APC provide insights into the importance of the APC-phospholipid interaction for the APC-mediated cleavages at Arg-306 and Arg-506 in FVa.	Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med,Div Clin Chem, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med,Div Clin Chem, SE-20502 Malmo, Sweden.	bjorn.dahlback@klkemi.mas.lu.se		Dahlback, Bjorn/0000-0003-1546-0328				Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1992, BIOCHEMISTRY-US, V31, P12769, DOI 10.1021/bi00166a009; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; Dahlback B, 1997, SEMIN HEMATOL, V34, P217; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Dahlback B, 2001, MOL BASIS BLOOD DIS, P614; Esmon CT, 1999, HAEMATOLOGICA, V84, P363; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gale AJ, 2002, PROTEIN SCI, V11, P2091, DOI 10.1110/ps.0210002; HEEB MJ, 1995, BLOOD, V85, P3405, DOI 10.1182/blood.V85.12.3405.bloodjournal85123405; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; Kolfschoten MV, 2004, J BIOL CHEM, V279, P6567, DOI 10.1074/jbc.M308574200; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MANN KG, 1990, BLOOD, V76, P1; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; Nelsestuen GL, 1999, TRENDS CARDIOVAS MED, V9, P162, DOI 10.1016/S1050-1738(99)00024-9; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Nicolaes GAF, 2002, ARTERIOSCL THROM VAS, V22, P530, DOI 10.1161/01.ATV.0000012665.51263.B7; Norstrom E, 2002, BLOOD, V100, P524, DOI 10.1182/blood-2002-02-0343; Norstrom EA, 2003, J BIOL CHEM, V278, P24904, DOI 10.1074/jbc.M303829200; ROSING J, 1995, J BIOL CHEM, V270, P27852, DOI 10.1074/jbc.270.46.27852; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; SHEN L, 1994, J BIOL CHEM, V269, P18735; Shen L, 1998, J BIOL CHEM, V273, P31086, DOI 10.1074/jbc.273.47.31086; Sun YH, 2003, BLOOD, V101, P2277, DOI 10.1182/blood-2002-06-1691; ten Cate H, 2001, CRIT CARE MED, V29, pS51; Varadi K, 1996, THROMB HAEMOSTASIS, V76, P208; WALKER FJ, 1981, J BIOL CHEM, V256, P1128; Yegneswaran S, 1999, J BIOL CHEM, V274, P5462, DOI 10.1074/jbc.274.9.5462; Yegneswaran S, 1997, J BIOL CHEM, V272, P25013, DOI 10.1074/jbc.272.40.25013	39	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47528	47535		10.1074/jbc.M407366200	http://dx.doi.org/10.1074/jbc.M407366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337738	hybrid			2022-12-25	WOS:000224957000016
J	Hasegawa, H; Sanjo, N; Chen, FS; Gu, YJ; Shier, C; Petit, A; Kawarai, T; Katayama, T; Schmidt, SD; Mathews, PM; Schmitt-Ulms, G; Fraser, PE; St George-Hyslop, P				Hasegawa, H; Sanjo, N; Chen, FS; Gu, YJ; Shier, C; Petit, A; Kawarai, T; Katayama, T; Schmidt, SD; Mathews, PM; Schmitt-Ulms, G; Fraser, PE; St George-Hyslop, P			Both the sequence and length of the C terminus of PEN-2 are critical for intermolecular interactions and function of presenilin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE COMPLEX; FAMILIAL ALZHEIMERS-DISEASE; MISSENSE MUTATIONS; SORTING SIGNALS; BETA-APP; APH-1; NICASTRIN; PROTEIN; NOTCH; COMPONENT	Presenilin 1 or presenilin 2, nicastrin, APH-1, and PEN-2 form high molecular weight complexes that play a pivotal role in the cleavage of various Type I transmembrane proteins, including the beta-amyloid precursor protein. The specific function of PEN-2 is unclear. To explore its function and intermolecular interactions, we conducted deletion and mutagenesis studies on a series of conserved residues at the C terminus of PEN-2. These studies suggest that: 1) both the presence and amino acid sequence of the conserved DYLSF domain at the C terminus of PEN-2 (residues 90-94) is critical for binding PEN-2 to other components in the presenilin complex and 2) the overall length of the exposed C terminus is critical for functional gamma-secretase activity.	Univ Toronto, Dept Med Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; NYU, Med Ctr, Nathan Kline Inst, Orangeburg, NY 10962 USA; Univ Toronto, Toronto Western Hosp, Dept Med, Div Neurol,Univ Hlth Network, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; Nathan Kline Institute for Psychiatric Research; New York University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Dept Med Med Biophys, 100 Coll St, Toronto, ON M5S 3H2, Canada.		Schmidt, Stephen/AAC-6967-2019; Schmidt, Stephen/B-5398-2012	Sanjo, Nobuo/0000-0002-1226-2425; Petit-Paitel, Agnes/0000-0003-1138-9966; St George-Hyslop, Peter/0000-0003-0796-7209; Mathews, Paul/0000-0003-1742-7687				Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Boll W, 2002, TRAFFIC, V3, P590, DOI 10.1034/j.1600-0854.2002.30808.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; Crystal AS, 2003, J BIOL CHEM, V278, P20117, DOI 10.1074/jbc.M213107200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dell'Angelica EC, 2001, CELL, V106, P395, DOI 10.1016/S0092-8674(01)00470-6; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2004, J BIOL CHEM, V279, P31329, DOI 10.1074/jbc.M401548200; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Kim SH, 2003, J BIOL CHEM, V278, P33992, DOI 10.1074/jbc.M305834200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PROKOP S, 2004, J BIOL CHEM, V23, P23; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	29	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46455	46463		10.1074/jbc.M406289200	http://dx.doi.org/10.1074/jbc.M406289200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322109	hybrid			2022-12-25	WOS:000224832400016
J	Hruska-Hageman, AM; Benson, CJ; Leonard, AS; Price, MP; Welsh, MJ				Hruska-Hageman, AM; Benson, CJ; Leonard, AS; Price, MP; Welsh, MJ			PSD-95 and Lin-7b interact with acid-sensing ion channel-3 and have opposite effects on H+-gated current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTORS; DEPENDENT PROTEIN-KINASE; SODIUM-CHANNEL; MOLECULAR-CLONING; SENSORY NEURONS; CELL-ADHESION; CONTRIBUTES; ASSOCIATION; SUBUNITS; BINDING	The acid-sensing ion channel-3 (ASIC3) is a degenerin/epithelial sodium channel expressed in the peripheral nervous system. Previous studies indicate that it participates in the response to mechanical and painful stimuli, perhaps contributing to mechanoreceptor and/or H+-gated nociceptor function. ASIC3 subunits contain intracellular N and C termini that may control channel localization and function. We found that a PDZ-binding motif at the ASIC3 C terminus interacts with four different proteins that contain PDZ domains: PSD-95, Lin-7b, MAGI-1b, and PIST. ASIC3 and these interacting proteins were expressed in dorsal root ganglia and spinal cord, and PSD-95 co-precipitated ASIC3 from spinal cord. When expressed in heterologous cells, PSD-95 reduced the amplitude of ASIC3 acid-evoked currents, whereas Lin-7b increased current amplitude. PSD-95 and Lin-7b altered current density by decreasing or increasing, respectively, the amount of ASIC3 on the cell surface. The finding that multiple PDZ-containing proteins bind ASIC3 and can influence its presence in the plasma membrane suggests that they may play an important role in the contribution of ASIC3 to nociception and mechanosensation.	Univ Iowa, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa	Welsh, MJ (corresponding author), Univ Iowa, Howard Hughes Med Inst, Roy J & Lucille A Carver Coll Med, 500 EMRB, Iowa City, IA 52242 USA.	michael-welsh@uiowa.edu		Benson, Christopher/0000-0001-6600-8193; Welsh, Michael/0000-0002-1646-6206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK054759] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54759] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Benos DJ, 1999, J PHYSIOL-LONDON, V520, P631, DOI 10.1111/j.1469-7793.1999.00631.x; Benson CJ, 1999, CIRC RES, V84, P921; Benson CJ, 2002, P NATL ACAD SCI USA, V99, P2338, DOI 10.1073/pnas.032678399; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de la Rosa DA, 2002, P NATL ACAD SCI USA, V99, P2326, DOI 10.1073/pnas.042688199; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Garry EM, 2003, CURR BIOL, V13, P321, DOI 10.1016/S0960-9822(03)00084-8; Hanley JG, 2002, NEURON, V34, P53, DOI 10.1016/S0896-6273(02)00638-4; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kosari F, 1999, CURR TOP MEMBR, V47, P37; Laura RP, 2002, EXP CELL RES, V275, P155, DOI 10.1006/excr.2002.5475; Leonard AS, 2003, P NATL ACAD SCI USA, V100, P2029, DOI 10.1073/pnas.252782799; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Sans N, 2000, J NEUROSCI, V20, P1260, DOI 10.1523/JNEUROSCI.20-03-01260.2000; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Tao F, 2003, NEUROSCIENCE, V117, P731, DOI 10.1016/S0306-4522(02)00801-1; Tao YX, 2000, NEUROSCIENCE, V98, P201, DOI 10.1016/S0306-4522(00)00193-7; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Welsh MJ, 2002, J BIOL CHEM, V277, P2369, DOI 10.1074/jbc.R100060200; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Xie JH, 2002, J NEUROPHYSIOL, V87, P2835, DOI 10.1152/jn.2002.87.6.2835; Zuckerman JB, 1999, J BIOL CHEM, V274, P23286, DOI 10.1074/jbc.274.33.23286	47	46	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46962	46968		10.1074/jbc.M405874200	http://dx.doi.org/10.1074/jbc.M405874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15317815	hybrid			2022-12-25	WOS:000224832400080
J	Stockton, RA; Schaefer, E; Schwartz, MA				Stockton, RA; Schaefer, E; Schwartz, MA			p21-activated kinase regulates endothelial permeability through modulation of contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; SMALL GTPASE RAC; MYOSIN-II; BARRIER FUNCTION; MDCK CELLS; GAMMA-PAK; RHO; INHIBITION; ACTIVATION; AUTOPHOSPHORYLATION	Endothelial cells lining the vasculature have close cell-cell associations that maintain separation of the blood fluid compartment from surrounding tissues. Permeability is regulated by a variety of growth factors and cytokines and plays a role in numerous physiological and pathological processes. We examined a potential role for the p21-activated kinase (PAK) in the regulation of vascular permeability. In both bovine aortic and human umbilical vein endothelial cells, PAK is phosphorylated on Ser(141) during the activation downstream of Rac, and the phosphorylated subfraction translocates to endothelial cell-cell junctions in response to serum, VEGF, bFGF, TNFalpha, histamine, and thrombin. Blocking PAK activation or translocation prevents the increase in permeability across the cell monolayer in response to these factors. Permeability correlates with myosin phosphorylation, formation of actin stress fibers, and the appearance of paracellular pores. Inhibition of myosin phosphorylation blocks the increase in permeability. These data suggest that PAK is a central regulator of endothelial permeability induced by multiple growth factors and cytokines via an effect on cell contractility. PAK may therefore be a suitable drug target for the treatment of pathological conditions where vascular leak is a contributing factor, such as ischemia and inflammation.	Univ Virginia Hlth Syst, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Biosource Int, Hopkinton, MA 01748 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Schwartz, MA (corresponding author), Univ Virginia Hlth Syst, Cardiovasc Res Ctr, 415 Lane Rd,MR5 Rm G-111, Charlottesville, VA 22908 USA.	maschwartz@virginia.edu		schwartz, martin/0000-0002-2071-1243	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047214] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL-007284-27] Funding Source: Medline; NIGMS NIH HHS [R01-GM47214] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerongen GPV, 2002, VASC PHARMACOL, V39, P257, DOI 10.1016/S1537-1891(03)00014-4; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Becker PM, 2001, AM J PHYSIOL-LUNG C, V281, pL1500, DOI 10.1152/ajplung.2001.281.6.L1500; Birukov KG, 2002, AM J RESP CELL MOL, V26, P453, DOI 10.1165/ajrcmb.26.4.4725; Bisson N, 2003, DEV BIOL, V263, P264, DOI 10.1016/j.ydbio.2003.07.002; Bogatcheva NV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P75, DOI 10.1023/A:1013904231324; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Eriksson A, 2003, CIRCULATION, V107, P1532, DOI 10.1161/01.CIR.0000055324.34758.32; Esser S, 1998, J CELL SCI, V111, P1853; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; Groeneveld ABJ, 2002, VASC PHARMACOL, V39, P247, DOI 10.1016/S1537-1891(03)00013-2; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Lee TYJ, 2003, MICROSC RES TECHNIQ, V60, P115, DOI 10.1002/jemt.10250; Lush CW, 2000, MICROCIRCULATION, V7, P83, DOI 10.1038/sj.mn.7300096; Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rudrabhatla RS, 2003, INFECT IMMUN, V71, P2787, DOI 10.1128/IAI.71.5.2787-2797.2003; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419; Suzuki Y, 2003, INT J BIOCHEM CELL B, V35, P881, DOI 10.1016/S1357-2725(02)00271-6; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Valeski JE, 2003, MICROCIRCULATION, V10, P411, DOI 10.1038/sj.mn.7800202; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; Watanabe H, 1998, FASEB J, V12, P341, DOI 10.1096/fasebj.12.3.341; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Wirth A, 2003, J PHYSIOL-LONDON, V549, P489, DOI 10.1113/jphysiol.2002.033167; Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9; Yuan SY, 2002, CIRC RES, V90, P1214, DOI 10.1161/01.RES.0000020402.73609.F1; Zeng Q, 2000, J CELL SCI, V113, P471; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	49	121	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46621	46630		10.1074/jbc.M408877200	http://dx.doi.org/10.1074/jbc.M408877200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15333633	hybrid			2022-12-25	WOS:000224832400036
J	Ma, ZD; Chang, MJ; Shah, R; Adamski, J; Zhao, XY; Benveniste, EN				Ma, ZD; Chang, MJ; Shah, R; Adamski, J; Zhao, XY; Benveniste, EN			Brg-1 is required for maximal transcription of the human matrix metalloproteinase-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEXES; MAMMALIAN SWI/SNF COMPLEXES; CELL-CYCLE ARREST; HISTONE MODIFICATIONS; SP3 REPRESSES; EXPRESSION; PROMOTER; CANCER; ACTIVATION; COMPONENT	Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases whose aberrant expression are correlated with tumor invasion and angiogenesis. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive expression of MMP-2 in tumor cells; however, the regulatory mechanisms of MMP-2 expression are not well understood. We investigated the involvement of Brg-1, the ATPase subunit of the SWI/SNF complex, in human MMP-2 gene transcription. Reconstitution of Brg-1 enhances MMP-2 transcription in Brg-1-deficient SW-13 cells. Chromatin immunoprecipitation assay demonstrates that Brg-1 is required for recruitment of Sp1, AP-2, and polymerase II to the MMP-2 promoter, whereas the binding of Sp3 to the MMP-2 promoter is decreased upon Brg-1 reconstitution. Furthermore, Sp1 interacts with Brg-1 in vivo. Restriction enzyme accessibility assays indicate that accessibility of the MMP-2 promoter region is not changed in the absence or presence of Brg-1. These results illustrate the connection between the SWI/SNF complex and optimal expression of MMP-2 and highlight the critical function of Brg-1 in regulating the recruitment of Sp1, Sp3, AP-2, and polymerase II to the MMP-2 promoter.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, McCallum Basic Sci Bldg 395, Birmingham, AL 35294 USA.	tika@uab.edu			NCI NIH HHS [CA-97247] Funding Source: Medline; NIAMS NIH HHS [T32 AR-07450] Funding Source: Medline; NIMH NIH HHS [MH-63650] Funding Source: Medline; NINDS NIH HHS [NS-39954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Chadjichristos C, 2003, J BIOL CHEM, V278, P39762, DOI 10.1074/jbc.M303541200; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Huang M, 2002, NAT CELL BIOL, V4, P774, DOI 10.1038/ncb855; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Liu H, 2002, MOL CELL BIOL, V22, P6471, DOI 10.1128/MCB.22.18.6471-6479.2002; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Mudhasani R, 2002, MOL CELL BIOL, V22, P5019, DOI 10.1128/MCB.22.14.5019-5026.2002; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pattenden SG, 2002, EMBO J, V21, P1978, DOI 10.1093/emboj/21.8.1978; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Reisman DN, 2003, CANCER RES, V63, P560; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Sentani K, 2001, PATHOBIOLOGY, V69, P315, DOI 10.1159/000064638; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; van der Vlag J, 2000, J BIOL CHEM, V275, P697, DOI 10.1074/jbc.275.1.697; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wolffe AP, 2001, ESSAYS BIOCHEM, V37, P45, DOI 10.1042/bse0370045; Wong AKC, 2000, CANCER RES, V60, P6171; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46326	46334		10.1074/jbc.M405438200	http://dx.doi.org/10.1074/jbc.M405438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15317818	hybrid			2022-12-25	WOS:000224694900120
J	Snyder, PM; Olson, DR; Kabra, R; Zhou, RF; Steines, JC				Snyder, PM; Olson, DR; Kabra, R; Zhou, RF; Steines, JC			cAMP and serum and glucocorticoid-inducible kinase (SGK) regulate the epithelial Na+ channel through convergent phosphorylation of Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; CELL-SURFACE; LIDDLES-SYNDROME; COLLECTING DUCT; BETA-SUBUNIT; MEDIATED REGULATION; MISSENSE MUTATION; ENAC REGULATION; A6 CELLS; ALDOSTERONE	The epithelial Na+ channel (ENaC) functions as a pathway for epithelial Na+ transport, contributing to Na+ homeostasis and blood pressure control. Vasopressin increases ENaC expression at the cell surface through a pathway that includes cAMP and cAMP-dependent protein kinase (PKA), but the mechanisms that link PKA to ENaC are unknown. Here we found that cAMP regulates Na+ transport in part by inhibiting the function of Nedd4-2, an E3 ubiquitin-protein ligase that targets ENaC for degradation. Consistent with this model, we found that cAMP inhibited Nedd4-2 by decreasing its binding to ENaC. Moreover, decreased Nedd4-2 expression ( RNA interference) or overexpression of a dominant negative Nedd4-2 construct disrupted ENaC regulation by cAMP. Nedd4-2 was a substrate for phosphorylation by PKA in vitro and in cells; three Nedd4-2 residues were phosphorylated by PKA and were required for cAMP to inhibit Nedd4-2 ( relative functional importance Ser-327 > Ser-221 > Thr-246). Previous work found that these residues are also phosphorylated by serum and glucocorticoid-inducible kinase (SGK), a downstream mediator by which aldosterone regulates epithelial Na+ transport. Consistent with a functional interaction between these pathways, overexpression of SGK blunted ENaC stimulation by cAMP, whereas inhibition of SGK increased stimulation. Conversely, cAMP agonists decreased ENaC stimulation by SGK. The data suggest that cAMP regulates ENaC in part by phosphorylation and inhibition of Nedd4-2. Moreover, Nedd4-2 is a central convergence point for kinase regulation of Na+ transport.	Univ Iowa, Coll Med, Dept Internal Med, EMRB 371, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, EMRB 371, Iowa City, IA 52242 USA.	psnyder@blue.weeg.uiowa.edu			NHLBI NIH HHS [HL55006, HL58812, HL72256] Funding Source: Medline; NIDDK NIH HHS [DK52617] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058812, P50HL055006, R01HL072256, R01HL058812] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK052617] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfaidy N, 1997, J CLIN INVEST, V100, P2437, DOI 10.1172/JCI119785; Benos DJ, 1997, NEWS PHYSIOL SCI, V12, P55; BINDELS RJM, 1988, BIOCHIM BIOPHYS ACTA, V972, P320, DOI 10.1016/0167-4889(88)90208-X; Blazer-Yost BL, 2001, AM J PHYSIOL-CELL PH, V281, pC624, DOI 10.1152/ajpcell.2001.281.2.C624; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Brickley DR, 2002, J BIOL CHEM, V277, P43064, DOI 10.1074/jbc.M207604200; Butterworth MB, 2001, AM J PHYSIOL-CELL PH, V280, pC752, DOI 10.1152/ajpcell.2001.280.4.C752; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; De la Rosa DA, 2003, AM J PHYSIOL-CELL PH, V284, pC404, DOI 10.1152/ajpcell.00398.2002; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Ecelbarger CA, 2000, AM J PHYSIOL-RENAL, V279, pF46, DOI 10.1152/ajprenal.2000.279.1.F46; Fouladkou F, 2004, AM J PHYSIOL-RENAL, V287, pF550, DOI 10.1152/ajprenal.00353.2003; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; Kamynina E, 2002, AM J PHYSIOL-RENAL, V283, pF377, DOI 10.1152/ajprenal.00143.2002; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; Massaad C, 1999, MOL ENDOCRINOL, V13, P57, DOI 10.1210/me.13.1.57; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; Snyder PM, 2004, J BIOL CHEM, V279, P5042, DOI 10.1074/jbc.M312477200; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Stokes JB, 1998, AM J PHYSIOL-CELL PH, V274, pC1699, DOI 10.1152/ajpcell.1998.274.6.C1699; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Uehara Y, 1998, J HYPERTENS, V16, P1131, DOI 10.1097/00004872-199816080-00008	40	176	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45753	45758		10.1074/jbc.M407858200	http://dx.doi.org/10.1074/jbc.M407858200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15328345	hybrid			2022-12-25	WOS:000224694900058
J	Wenk, J; Schuller, J; Hinrichs, C; Syrovets, T; Azoitei, N; Podda, M; Wlaschek, M; Brenneisen, P; Schneider, LA; Sabiwalsky, A; Peters, T; Sulyok, S; Dissemond, J; Schauen, M; Krieg, T; Wirth, T; Simmet, T; Scharffetter-Kochanek, K				Wenk, J; Schuller, J; Hinrichs, C; Syrovets, T; Azoitei, N; Podda, M; Wlaschek, M; Brenneisen, P; Schneider, LA; Sabiwalsky, A; Peters, T; Sulyok, S; Dissemond, J; Schauen, M; Krieg, T; Wirth, T; Simmet, T; Scharffetter-Kochanek, K			Overexpression of phospholipid-hydroperoxide glutathione peroxidase in human dermal fibroblasts abrogates UVA irradiation-induced expression of interstitial collagenase/matrix metalloproteinase-1 by suppression of phosphatidylcholine hydroperoxide-mediated NF kappa B activation and interleukin-6 release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED AUTOCRINE STIMULATION; MESSENGER-RNA LEVELS; DNA-BINDING PROTEIN; SUPEROXIDE-DISMUTASE; MATRIX-METALLOPROTEINASES; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; TRANSCRIPTIONAL ACTIVITY; ULTRAVIOLET-RADIATION; LIPID HYDROPEROXIDES	Phospholipid-hydroperoxide glutathione peroxidase (PHGPx) exhibits high specific activity in reducing phosphatidylcholine hydroperoxides (PCOOHs) and thus may play a central role in protecting the skin against UV irradiation-triggered detrimental long term effects like cancer formation and premature skin aging. Here we addressed the role of PHGPx in the protection against UV irradiation-induced expression of matrix metalloproteinase-1 (MMP-1). For this purpose, we created human dermal fibroblast cell lines overexpressing human PHGPx. Overexpression led to a significant increase in PHGPx activity. In contrast to a maximal 4.5-fold induction of specific MMP-1 mRNA levels in vector-transfected cells at 24 h after UVA irradiation, no MMP-1 induction occurred at any studied time point after UVA treatment of PHGPx-overexpressing fibroblasts. As interleukin-6 (IL-6) was earlier shown to mediate the UVA induction of MMP-1, we studied whether PHGPx overexpression might interfere with the NFkappaB-mediated IL-6 induction and downstream signaling. Using transient transfections of IL-6 promoter constructs containing NFkappaB binding sites, we observed a high induction of the reporter gene luciferase in vector-transfected control cells and a significantly lower induction in PHGPx-overexpressing fibroblasts following UVA irradiation. Consistently both UVA irradiation and treatment of fibroblasts with PCOOHs led to phosphorylation and nuclear translocation of the p65 subunit, whereas cells overexpressing PHGPx exhibited impaired NFkappaB activation, p65 phosphorylation, and nuclear translocation. In line with this, the PHGPx-overexpressing fibroblasts showed a reduced constitutive and UVA irradiation-induced IL-6 release. After incubating PHGPx-overexpressing cells with PCOOHs a reduced induction of IL-6 was observed. This together with the suppression of UVA irradiation-induced IL-6 release in the presence of Trolox, a chain breaker of PCOOH-initiated lipid peroxidation, indicates that UVA irradiation-induced PCOOHs and subsequent lipid peroxides initiate the NFkappaB-mediated induction of IL-6, which mediates the induction of MMP-1. Our finding is particularly relevant in light of the already available small molecule mimetics of PHGPx.	Univ Ulm, Dept Dermatol & Allergol, D-89081 Ulm, Germany; Univ Cologne, Dept Dermatol, D-50924 Cologne, Germany; Univ Ulm, Dept Pharm & Nat Med, D-89081 Ulm, Germany; Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany; Goethe Univ Frankfurt, Dept Dermatol, D-60590 Frankfurt, Germany; Univ Essen Gesamthsch, Dept Dermatol, D-45122 Essen, Germany	Ulm University; University of Cologne; Ulm University; Ulm University; Heinrich Heine University Dusseldorf; Goethe University Frankfurt; University of Duisburg Essen	Scharffetter-Kochanek, K (corresponding author), Univ Ulm, Dept Dermatol & Allergol, Maienweg 12, D-89081 Ulm, Germany.	Scharffetter-Kochanek@medizin.uni-ulm.de	Syrovets, Tatiana/J-4594-2019; Wirth, Thomas/X-7172-2019; Dissemond, Joachim/AFG-0691-2022	Syrovets, Tatiana/0000-0002-6751-2233; Scharffetter-Kochanek, Karin/0000-0002-9655-685X; Brenneisen, Peter/0000-0003-3405-0287				AEBI H, 1984, METHOD ENZYMOL, V105, P121; AMES BN, 1993, DNA FREE RADICALS; ANGEL P, 1985, J CELL BIOCHEM, V29, P351, DOI 10.1002/jcb.240290408; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennan M, 2003, PHOTOCHEM PHOTOBIOL, V78, P43, DOI 10.1562/0031-8655(2003)078<0043:MMITMC>2.0.CO;2; Brenneisen P, 1999, FEBS LETT, V449, P36, DOI 10.1016/S0014-5793(99)00402-0; Brenneisen P, 1996, PHOTOCHEM PHOTOBIOL, V64, P649, DOI 10.1111/j.1751-1097.1996.tb03119.x; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; Brenneisen P, 1998, J BIOL CHEM, V273, P5279, DOI 10.1074/jbc.273.9.5279; Brigelius-Flohe R, 2000, ATHEROSCLEROSIS, V152, P307, DOI 10.1016/S0021-9150(99)00486-4; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Burysek L, 2002, J BIOL CHEM, V277, P33509, DOI 10.1074/jbc.M201941200; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CEBALLOS I, 1991, FREE RADICAL RES COM, V12-3, P581; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHEATLE T, 1991, BRIT J DERMATOL, V124, P508, DOI 10.1111/j.1365-2133.1991.tb00641.x; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; ESWORTHY RS, 1994, GENE, V144, P317, DOI 10.1016/0378-1119(94)90400-6; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Foresta C, 2002, BIOL REPROD, V67, P967, DOI 10.1095/biolreprod.102.003822; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; Halliwell B, 1999, FREE RADICAL BIO MED, P284; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HENRIKSEN T, 1990, PHOTOCHEM PHOTOBIOL, V51, P579, DOI 10.1111/j.1751-1097.1990.tb01968.x; Herrmann G, 1998, J CELL SCI, V111, P759; Herrmann G, 1993, Exp Dermatol, V2, P92, DOI 10.1111/j.1600-0625.1993.tb00015.x; Imai H, 2003, BIOCHEM BIOPH RES CO, V305, P278, DOI 10.1016/S0006-291X(03)00734-4; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MAIORINO M, 1991, J BIOL CHEM, V266, P7728; MAJMUDAR G, 1994, MOL CARCINOGEN, V9, P17, DOI 10.1002/mc.2940090105; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Moulton PJ, 1996, BRIT J BIOMED SCI, V53, P317; MUTZHAS MF, 1981, J INVEST DERMATOL, V76, P42, DOI 10.1111/1523-1747.ep12524813; OBERLEY LW, 1979, CANCER RES, V39, P1141; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; Schnurr K, 1996, J BIOL CHEM, V271, P4653; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIES H, 1986, ANGEW CHEM INT EDIT, V25, P1058, DOI 10.1002/anie.198610581; Sies H., 1991, OXIDATIVE STRESS OXI; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URBACH F, 1989, PHOTOCHEM PHOTOBIOL, V50, P507, DOI 10.1111/j.1751-1097.1989.tb05556.x; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WLASCHEK M, 1993, J INVEST DERMATOL, V101, P164, DOI 10.1111/1523-1747.ep12363644; WLASCHEK M, 1995, J INVEST DERMATOL, V104, P194, DOI 10.1111/1523-1747.ep12612751; WLASCHEK M, 1994, PHOTOCHEM PHOTOBIOL, V59, P550, DOI 10.1111/j.1751-1097.1994.tb02982.x; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; YAMAMOTO Y, 1990, METHOD ENZYMOL, V186, P371; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	80	62	68	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45634	45642		10.1074/jbc.M408893200	http://dx.doi.org/10.1074/jbc.M408893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308634	hybrid			2022-12-25	WOS:000224694900043
J	Chi, YL; Zhou, B; Wang, WQ; Chung, SK; Kwon, YU; Ahn, YH; Chang, YT; Tsujishita, Y; Hurley, JH; Zhang, ZY				Chi, YL; Zhou, B; Wang, WQ; Chung, SK; Kwon, YU; Ahn, YH; Chang, YT; Tsujishita, Y; Hurley, JH; Zhang, ZY			Comparative mechanistic and substrate specificity study of inositol polyphosphate 5-phosphatase Schizosaccharomyces pombe synaptojanin and SHIP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSSIBLE REGIOISOMERS; PROTEIN; PHOSPHATE; DEPHOSPHORYLATION; MOBILIZATION; MODULATION; FAMILY; PTEN	Inositol-5-phosphatases are important enzymes involved in the regulation of diverse cellular processes from synaptic vesicle recycling to insulin signaling. We describe a comparative study of two representative inositol-5-phosphatases, Schizosaccharomyces pombe synaptojanin (SPsynaptojanin) and human SH2 domain-containing inositol-5-phosphatase SHIP2. We show that in addition to Mg2+, transition metals such as Mn2+, Co2+, and Ni2+ are also effective activators of SPsynaptojanin. In contrast, Ca2+ and Cu2+ are inhibitory. We provide evidence that Mg2+ binds the same site occupied by Ca2+ observed in the crystal structure of SPsynaptojanin complexed with inositol 1,4-bisphosphate (Ins(1,4)P-2). Ionizations important for substrate binding and catalysis are defined for the SPsynaptojanin-catalyzed Ins(1,4,5) P-3 reaction. Kinetic analysis with four phosphatidylinositol lipids bearing a 5-phosphate and 54 water-soluble inositol phosphates reveals that SPsynaptojanin and SHIP2 possess much broader substrate specificity than previously appreciated. The rank order for SPsynaptojanin is Ins(2,4,5) P-3 > phosphatidylinositol-4,5- bisphosphate (PtdIns(4,5) P-2) approximate to Ins(4,5) P-2 approximate to Ins(1,4,5) P-3 approximate to Ins(4,5,6) P-3 > PtdIns(3,5) P-2 approximate to PtdIns(3,4,5) P-3 approximate to Ins(1,2,4,5) P-4 approximate to Ins(1,3,4,5) P-4 approximate to Ins( 2,4,5,6) P-4 approximate to Ins(1,2,4,5,6) P-5. The rank order for SHIP2 is Ins(1,2,3,4,5) P-5 > Ins(1,3,4,5) P-4 > PtdIns(3,4,5) P-4 approximate to PtdIns(3,5) P-2 approximate to Ins(1,4,5,6) P-4 approximate to Ins(2,4,5,6) P-4. Because inositol phosphate isomers elicit different biological activities, the extended substrate specificity for SPsynaptojanin and SHIP2 suggest that these enzymes likely have multiple roles in cell signaling and may regulate distinct pathways. The unique substrate specificity profiles and the importance of 2-position phosphate in binding also have important implications for the design of potent and selective SPsynaptojanin and SHIP2 inhibitors for pharmacological investigation.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, South Korea; NYU, Dept Chem, New York, NY 10003 USA; NIDDK, Mol Biol Lab, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; Pohang University of Science & Technology (POSTECH); New York University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu	Chang, Young-Tae/B-2780-2010	Chang, Young-Tae/0000-0002-1927-3688	NCI NIH HHS [CA69202, 5T32-CA09475] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009475, R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; CERDAN S, 1986, J BIOL CHEM, V261, P4676; Chung S. K., 1996, KOR J MED CHEM, V6, P162; CHUNG SK, 1995, J CHEM SOC CHEM COMM, P11, DOI 10.1039/c39950000011; Chung SK, 1998, BIOORG MED CHEM LETT, V8, P1503, DOI 10.1016/S0960-894X(98)00245-5; Chung SK, 1998, J CARBOHYD CHEM, V17, P369, DOI 10.1080/07328309808002898; Chung SK, 1996, BIOORG MED CHEM LETT, V6, P2039, DOI 10.1016/0960-894X(96)00371-X; Chung SK, 2002, J ORG CHEM, V67, P5626, DOI 10.1021/jo0257694; Chung SK, 1996, CHEM COMMUN, P163, DOI 10.1039/cc9960000163; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; Lin T, 1997, AM J HUM GENET, V60, P1384, DOI 10.1086/515471; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Marchant JS, 1997, BIOCHEM J, V321, P573, DOI 10.1042/bj3210573; McCain DF, 2002, METHOD ENZYMOL, V345, P507; Norris FA, 1997, J BIOL CHEM, V272, P23859, DOI 10.1074/jbc.272.38.23859; Orchiston EA, 2004, J BIOL CHEM, V279, P1116, DOI 10.1074/jbc.M310933200; Pattni K, 2004, CELL SIGNAL, V16, P643, DOI 10.1016/j.cellsig.2003.10.009; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Tsujishita Y, 2001, CELL, V105, P379, DOI 10.1016/S0092-8674(01)00326-9; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; YORK JD, 1995, P NATL ACAD SCI USA, V92, P5149, DOI 10.1073/pnas.92.11.5149; Zhang ZY, 2003, PROG NUCLEIC ACID RE, V73, P171, DOI 10.1016/S0079-6603(03)01006-7; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	33	41	42	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44987	44995		10.1074/jbc.M406416200	http://dx.doi.org/10.1074/jbc.M406416200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316017	hybrid			2022-12-25	WOS:000224505600090
J	Cline, GW; LePine, RL; Papas, KK; Kibbey, RG; Shulman, GI				Cline, GW; LePine, RL; Papas, KK; Kibbey, RG; Shulman, GI			C-13 NMR isotopomer analysis of anaplerotic pathways in INS-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; PANCREATIC-ISLETS; LACTATE-DEHYDROGENASE; GLUCOSE-METABOLISM; MALONYL-COA; L-LEUCINE; GLUTAMATE; PYRUVATE; TRANSPORTER; EXPRESSION	Anaplerotic flux into the Kreb's cycle is crucial for glucose-stimulated insulin secretion from pancreatic beta-cells. However, the regulation of flux through various anaplerotic pathways in response to combinations of physiologically relevant substrates and its impact on glucose-stimulated insulin secretion is unclear. Because different pathways of anaplerosis generate distinct products, they may differentially modulate the insulin secretory response. To examine this question, we applied C-13-isotopomer analysis to quantify flux through three anaplerotic pathways: 1) pyruvate carboxylase of pyruvate derived from glycolytic sources; 2) pyruvate carboxylase of pyruvate derived from nonglycolytic sources; and 3) glutamate dehydrogenase (GDH). At sub-stimulatory glucose, anaplerotic flux rate in the clonal INS-1 832/13 cells was similar to40% of Kreb's cycle flux, with similar contributions from each pathway. Increasing glucose to 15 mM stimulated insulin secretion similar to4-fold, and was associated with a similar to4-fold increase in anaplerotic flux that could mostly be attributed to an increase in PC flux. In contrast, the addition of glutamine to the perfusion media stimulated GDH flux similar to6-fold at both glucose concentrations without affecting insulin secretion rates. In conclusion, these data support the hypothesis that a signal generated by anaplerosis from increased pyruvate carboxylase flux is essential for glucose-stimulated insulin secretion in beta-cells and that anaplerosis through GDH does not play a major role in this process.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of Minnesota System; University of Minnesota Twin Cities	Cline, GW (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Fitkin 1,POB 208020, New Haven, CT 06520 USA.	gary.cline@yale.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NIDDK NIH HHS [R01 DK040936, P30 DK-45735, R01 DK-40936, U24 DK-59635] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK040936, U24DK059635] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alcazar O, 2000, BIOCHEM J, V352, P373, DOI 10.1042/0264-6021:3520373; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Fahien LA, 2002, DIABETES, V51, P2669, DOI 10.2337/diabetes.51.9.2669; Giroix MH, 1999, DIABETOLOGIA, V42, P965; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Jucker BM, 1997, J BIOL CHEM, V272, P10464, DOI 10.1074/jbc.272.16.10464; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; Li CH, 2003, J BIOL CHEM, V278, P2853, DOI 10.1074/jbc.M210577200; Liu YJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE380, DOI 10.1152/ajpendo.00008.2003; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MacDonald MJ, 2000, J BIOL CHEM, V275, P34025, DOI 10.1074/jbc.C000411200; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Nadi AB, 2000, MOL CELL BIOCHEM, V210, P167; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; SENER A, 1981, P NATL ACAD SCI-BIOL, V78, P5460, DOI 10.1073/pnas.78.9.5460; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; Zhao C, 2001, DIABETES, V50, P361, DOI 10.2337/diabetes.50.2.361	24	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44370	44375		10.1074/jbc.M311842200	http://dx.doi.org/10.1074/jbc.M311842200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304488	hybrid			2022-12-25	WOS:000224505600019
J	Esposito, EA; Martin, CT				Esposito, EA; Martin, CT			Cross-linking of promoter DNA to T7 RNA polymerase does not prevent formation of a stable elongation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; TRANSCRIPTION INITIATION; STRUCTURAL BASIS; CLEARANCE; SEQUENCE; GENE; FLUORESCENCE; MECHANISM; STABILITY; SLIPPAGE	T7 RNA polymerase recognizes a small promoter, binds DNA, and begins the process of transcription by synthesizing short RNA products without releasing promoter contacts. To determine whether the promoter contact must be released to make longer RNA products and at what position the promoter must be released, a mutant RNA polymerase was designed that allows cross-linking to a modified promoter via a covalent disulfide bond. The modifications individually have no measurable effect on transcription. Under oxidizing conditions that produce the protein-DNA cross-link, the complex is able to synthesize short RNA products, strongly supporting a model in which promoter contacts are not lost on translocation through at least position +6. However, cross-linked complexes are impaired in promoter escape in that only about one in four can escape to make full-length RNA. The remainder release 12- and 13-mer RNA transcripts, suggesting an increased energetic barrier in the transition from an initial transcribing complex to a fully competent elongation complex. The results are discussed in the context of a model in which promoter release helps drive initial collapse of the upstream edge of the bubble, which, in turn, drives initial displacement of the 5'-end of the RNA.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 710 N Pleasant St,LGRT 701, Amherst, MA 01003 USA.	cmartin@chem.umass.edu	Martin, Craig T/L-3596-2013	Martin, Craig T/0000-0003-1029-5239	NIGMS NIH HHS [T32 GM08515, 1R01 GM55002] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055002, T32GM008515] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DIETZ A, 1990, MOL GEN GENET, V221, P283, DOI 10.1007/BF00261733; Dvir A, 2001, CURR OPIN GENET DEV, V11, P209, DOI 10.1016/S0959-437X(00)00181-7; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; Hsu LM, 2002, BBA-GENE STRUCT EXPR, V1577, P191, DOI 10.1016/S0167-4781(02)00452-9; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2000, BIOCHEMISTRY-US, V39, P10419, DOI 10.1021/bi000365w; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; Kuzmine I, 2001, NUCLEIC ACIDS RES, V29, P2601, DOI 10.1093/nar/29.12.2601; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCGRAW NJ, 1985, NUCLEIC ACIDS RES, V13, P6753, DOI 10.1093/nar/13.18.6753; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SCHONEICH C, 1995, METHOD ENZYMOL, V251, P45, DOI 10.1016/0076-6879(95)51109-1; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Ujvari A, 2000, J MOL BIOL, V295, P1173, DOI 10.1006/jmbi.1999.3418; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	35	17	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44270	44276		10.1074/jbc.M407688200	http://dx.doi.org/10.1074/jbc.M407688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304497	hybrid			2022-12-25	WOS:000224505600007
J	Oloo, EO; Tieleman, DP				Oloo, EO; Tieleman, DP			Conformational transitions induced by the binding of MgATP to the vitamin B-12 ATP-binding cassette (ABC) transporter BtuCD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATION; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURES; SULFOLOBUS-SOLFATARICUS; CATALYTIC CYCLE; NUCLEOTIDE; MECHANISM; PROTEIN	ATP-binding cassette transporters use the free energy of ATP hydrolysis to transport structurally diverse molecules across prokaryotic and eukaryotic membranes. Computer simulation studies of the "real-time" dynamics of the ATP binding process in BtuCD, the vitamin B-12 importer from Escherichia coli, demonstrate that the docking of ATP to the catalytic pockets progressively draws the two cytoplasmic nucleotide-binding cassettes toward each other. Movement of the cassettes into closer opposition in turn induces conformational rearrangement of alpha-helices in the transmembrane domain. The shape of the translocation pathway consequently changes in a manner that could aid the vectorial movement of vitamin B-12. These results suggest that ATP binding may indeed represent the power stroke in the catalytic mechanism. Moreover, occlusion of ATP at one catalytic site is mechanically coupled to opening of the nucleotide-binding pocket at the second site. We propose that this asymmetry in nucleotide binding behavior at the two catalytic pockets may form the structural basis by which the transporter is able to alternate ATP hydrolysis from one site to the other.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Calgary	Tieleman, DP (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	tieleman@ucalgary.ca	Tieleman, D. Peter/A-4790-2011	Tieleman, D. Peter/0000-0001-5507-0688				Antes I, 2003, BIOPHYS J, V85, P695, DOI 10.1016/S0006-3495(03)74513-5; ARMSTRONG S, 1998, PEDIAT PULMONOL, V17, P91; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berendsen HJC, 2001, SCIENCE, V294, P2304, DOI 10.1126/science.1067546; Bockmann RA, 2002, NAT STRUCT BIOL, V9, P198, DOI 10.1038/nsb760; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Borths EL, 2002, P NATL ACAD SCI USA, V99, P16642, DOI 10.1073/pnas.262659699; Campbell JD, 2004, J BIOL CHEM, V279, P463, DOI 10.1074/jbc.M310711200; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Faraldo-Gomez JD, 2002, EUR BIOPHYS J BIOPHY, V31, P217, DOI 10.1007/s00249-002-0207-5; FERENCI T, 1977, EUR J BIOCHEM, V75, P187, DOI 10.1111/j.1432-1033.1977.tb11516.x; Gao YQ, 2003, P NATL ACAD SCI USA, V100, P11339, DOI 10.1073/pnas.1334188100; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Jones PM, 2002, P NATL ACAD SCI USA, V99, P12639, DOI 10.1073/pnas.152439599; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Karpowich NK, 2003, J BIOL CHEM, V278, P8429, DOI 10.1074/jbc.M212239200; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Patzlaff JS, 2003, J BIOL CHEM, V278, P29546, DOI 10.1074/jbc.M304796200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1345, DOI 10.1021/bi0267745; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SMART OS, 1993, BIOPHYS J, V65, P2455, DOI 10.1016/S0006-3495(93)81293-1; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stenham DR, 2003, FASEB J, V17, P2287, DOI 10.1096/fj.03-0107fje; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang W, 2003, P NATL ACAD SCI USA, V100, P874, DOI 10.1073/pnas.0337432100	56	83	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45013	45019		10.1074/jbc.M405084200	http://dx.doi.org/10.1074/jbc.M405084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308647	hybrid			2022-12-25	WOS:000224505600093
J	Togo, T				Togo, T			Long-term potentiation of wound-induced exocytosis and plasma membrane repair is dependant on cAMP-response element-mediated transcription via a protein kinase C- and p38 MAPK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-REGULATED EXOCYTOSIS; REGULATED EXOCYTOSIS; STRESS; CREB; ACTIVATION; DISRUPTION; FIBROBLASTS; INHIBITION; EXPRESSION; MECHANISM	Ca2+-regulated exocytosis is required for rapid resealing of disrupted plasma membranes. It has been previously demonstrated that repeated membrane disruptions reseal more quickly than the initial wound and that this facilitated response requires the transcription factor cAMP-response element-binding protein ( CREB). This study examines the signaling pathway between membrane disruption and CREB-dependent gene expression in 3T3 fibroblasts. A reporter gene assay using pCRE-d2EGFP revealed that membrane disruption induced CRE-mediated transcription. Immunofluorescence observations suggested that membrane disruption activated CREB, p38 mitogen-activated protein kinase ( p38 MAPK), and MAPK kinase3/6, the kinase responsible for activation of p38 MAPK. CREB phosphorylation upon membrane disruption was inhibited by a specific p38 MAPK inhibitor, SB203580. Both CRE-mediated transcription and long-term potentiation of membrane resealing and wound-induced exocytosis were suppressed when cells were wounded in the presence of either SB203580 or Go-6976, a specific protein kinase C (PKC) inhibitor. Furthermore, activation of MAPK kinase3/6 was impaired by PKC inhibition during membrane disruption. These results suggest that PKC mediates the stimulation of CREB-dependent gene expression through a p38 MAPK pathway upon membrane disruption.	Univ Tokyo, Misaki Marine Biol Stn, Kanagawa 2380225, Japan	University of Tokyo	Togo, T (corresponding author), Univ Tokyo, Misaki Marine Biol Stn, 1024 Ko Ajiro, Kanagawa 2380225, Japan.	togot@mmbs.s.u-tokyo.ac.jp	Togo, Tatsuru/D-5365-2011	Togo, Tatsuru/0000-0003-3015-6367				Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Grembowicz KP, 1999, MOL BIOL CELL, V10, P1247, DOI 10.1091/mbc.10.4.1247; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Meredith GD, 2000, NAT BIOTECHNOL, V18, P309, DOI 10.1038/73760; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; SWANSON JA, 1987, SCIENCE, V238, P548, DOI 10.1126/science.2443981; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Togo T, 2004, MOL BIOL CELL, V15, P688, DOI 10.1091/mbc.E03-06-0430; Togo T, 2003, MOL BIOL CELL, V14, P93, DOI 10.1091/mbc.E02-01-0056; Togo T, 1999, J CELL SCI, V112, P719; Togo T, 2000, MOL BIOL CELL, V11, P4339, DOI 10.1091/mbc.11.12.4339; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	29	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44996	45003		10.1074/jbc.M406327200	http://dx.doi.org/10.1074/jbc.M406327200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15317814	hybrid			2022-12-25	WOS:000224505600091
J	Yamamura, H; Ugawa, S; Ueda, T; Nagao, M; Shimada, S				Yamamura, H; Ugawa, S; Ueda, T; Nagao, M; Shimada, S			Capsazepine is a novel activator of the delta subunit of the human epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VANILLOID CAPSAICIN RECEPTORS; SODIUM-CHANNEL; 2-AMINOETHOXYDIPHENYL BORATE; ION CHANNELS; EXPRESSION; RAT; CLONING; ENAC; SENSITIVITY; ANTAGONIST	The amiloride-sensitive epithelial Na+ channel (ENaC) regulates Na+ homeostasis into cells and across epithelia. So far, four homologous subunits of mammalian ENaC have been isolated and are denoted as alpha, beta, gamma, and delta. The chemical agents acting on ENaC are, however, largely unknown, except for amiloride and benzamil as ENaC inhibitors. In particular, there are no agonists currently known that are selective for ENaC delta, which is mainly expressed in the brain. Here we demonstrate that capsazepine, a competitive antagonist for transient receptor potential vanilloid subfamily 1, potentiates the activity of human ENaC deltabetagamma (hENaCdeltabetagamma) heteromultimer expressed in Xenopus oocytes. The inward currents at a holding potential of - 60 mV in hENaCdeltabetagamma-expressing oocytes were markedly enhanced by the application of capsazepine (greater than or equal to 1 muM), and the capsazepine-induced current was mostly abolished by the addition of 100 muM amiloride. The stimulatory effects of capsazepine on the inward current were concentration-dependent with an EC50 value of 8 muM. Neither the application of other vanilloid compounds ( capsaicin, resiniferatoxin, and olvanil) nor a structurally related compound ( dopamine) modulated the inward current. Although hENaCdelta homomer was also significantly activated by capsazepine, unexpectedly, capsazepine had no effect on hENaCalpha and caused a slight decrease on the hENaCalphabetagamma current. In conclusion, capsazepine acts on ENaCdelta and acts together with protons. Other vanilloids tested do not have any effect. These findings identify capsazepine as the first known chemical activator of ENaCdelta.	Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Forens Med Sci, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University	Yamamura, H (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Mol Morphol, Mizuho Ku, 1 Kawasumi Mizuhocho, Nagoya, Aichi 4678601, Japan.	yamamura@med.nagoya-cu.ac.jp						Behrendt HJ, 2004, BRIT J PHARMACOL, V141, P737, DOI 10.1038/sj.bjp.0705652; BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Biasio W, 2004, J BIOL CHEM, V279, P5429, DOI 10.1074/jbc.M311155200; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Carattino MD, 2003, J BIOL CHEM, V278, P36202, DOI 10.1074/jbc.M300312200; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; Condliffe SB, 2004, J BIOL CHEM, V279, P10085, DOI 10.1074/jbc.M313592200; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Docherty RJ, 1997, BRIT J PHARMACOL, V121, P1461, DOI 10.1038/sj.bjp.0701272; Gavva NR, 2004, J BIOL CHEM, V279, P20283, DOI 10.1074/jbc.M312577200; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Ji HL, 2004, J BIOL CHEM, V279, P26939, DOI 10.1074/jbc.M401143200; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kuenzi FM, 1996, BRIT J PHARMACOL, V119, P81, DOI 10.1111/j.1476-5381.1996.tb15680.x; Liu L, 1997, NEUROSCI LETT, V228, P29, DOI 10.1016/S0304-3940(97)00358-3; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Ray AM, 2003, J NEUROSCI, V23, P10146; Segal A, 2002, FEBS LETT, V515, P177, DOI 10.1016/S0014-5793(02)02464-X; Szallasi A, 1999, PHARMACOL REV, V51, P159; SZALLASI A, 1993, J PHARMACOL EXP THER, V267, P728; Ugawa S, 1998, NATURE, V395, P555, DOI 10.1038/26882; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Waldmann R, 1996, GENOMICS, V34, P262, DOI 10.1006/geno.1996.0282; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Welsh MJ, 2002, J BIOL CHEM, V277, P2369, DOI 10.1074/jbc.R100060200; Yamamura H, 2004, J BIOL CHEM, V279, P12529, DOI 10.1074/jbc.M400274200	33	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44483	44489		10.1074/jbc.M408929200	http://dx.doi.org/10.1074/jbc.M408929200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308635	hybrid			2022-12-25	WOS:000224505600032
J	Huang, D; Liu, XH; Plymate, SR; Idowu, M; Grimes, M; Best, AM; McKinney, JL; Ware, JL				Huang, D; Liu, XH; Plymate, SR; Idowu, M; Grimes, M; Best, AM; McKinney, JL; Ware, JL			Proteomic identification of 14-3-3 sigma as a common component of the androgen receptor and the epidermal growth factor receptor signaling pathways of the human prostate epithelial cell line M12	ONCOGENE			English	Article						proteomics; 14-3-3 sigma; androgen receptor; epidermal growth factor receptor; prostate	GLUCOCORTICOID-RECEPTOR; CANCER; ASSOCIATION; PROTEINS	The epidermal growth factor receptor and androgen receptor (AR) bot h play major roles in the control of prostate growth. Our hypothesis is that shared downstream components of these two signaling pathways are significant participants in androgen-independent growth. Our first objective was to identify proteins whose activation and/or expression in AR-positive prostate epithelial cells are induced by both epidermal growth factor (EGF) and dihydrotestosterone (DHT). AR expression was induced in a tumorigenic, metastatic subline of the SV40 large T-antigen immortalized human prostate epithelial subline M12 by stable transfection with human wild-type AR cDNA. These M12AR (+) cells with functional AR were treated in parallel with EGF (10 ng/ml) or DHT (10(-8) M) for 24 h before 2D gel electrophoresis and Western immunoblotting with antiphosphotyrosine monoclonal antibody. Coomassie blue-stained spots on a 2D gel run in parallel were aligned with the phosphoproteins on the Western immunoblot, and identified by matrix-assisted laser desorption ionization/time-of-flight mass spectroscopy. The most interesting of the seven proteins that appeared to be phosphorylated by these criteria was 14-3-3 protein sigma. Protein extracted after either EGF or DHT treatment, immunoprecipitated with antiphosphotyrosine monoclonal antibody, and immunoblotted by anti-14-3-3 sigma confirmed phosphorylation of 14-3-3 sigma. Addition of either DHT or EGF to the M12AR(+) cells induced subcellular migration of 14-3-3 sigma and activated a 14-3-3 sigma reporter construct. Immunohistochemical analysis revealed nuclear localization of 14-3-3 sigma in higher Gleason grade prostate cancers relative to benign glands. These findings implicate 14-3-3 sigma in the development of human prostate cancer cells and could provide a new target for intervention in prostate cancer.	Virginia Commonwealth Univ, Med Ctr, Dept Pathol, Richmond, VA 23298 USA; Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA; Virginia Commonwealth Univ, Med Ctr, Dept Biostat, Richmond, VA 23298 USA	Virginia Commonwealth University; University of Washington; University of Washington Seattle; Virginia Commonwealth University	Ware, JL (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Pathol, 1101 E Marshall St,Sanger Hall Rm 5-014,POB 98066, Richmond, VA 23298 USA.	jlware@vcu.edu	Best, Al/F-6425-2012	Idowu, Michael/0000-0002-7416-5444; Best, Al/0000-0002-6300-3925; Ketchum, Jessica/0000-0002-5566-3691	NIDDK NIH HHS [R01 DK52683] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052683] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CULIG Z, 1994, CANCER RES, V54, P5474; El Sheikh SS, 2003, NEOPLASIA, V5, P99, DOI 10.1016/S1476-5586(03)80001-5; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Haendler B, 2001, MOL CELL ENDOCRINOL, V173, P63, DOI 10.1016/S0303-7207(00)00434-2; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Liu XH, 2003, ELECTROPHORESIS, V24, P3445, DOI 10.1002/elps.200305574; Martel CL, 2003, CANCER TREAT REV, V29, P171, DOI 10.1016/S0305-7372(02)00090-7; Myers RB, 1999, INT J CANCER, V82, P424, DOI 10.1002/(SICI)1097-0215(19990730)82:3<424::AID-IJC16>3.0.CO;2-B; Orio F, 2002, MOL CELL ENDOCRINOL, V198, P105, DOI 10.1016/S0303-7207(02)00374-X; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; PLYMATE SR, 2004, IN PRESS PROSTATE; Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376; Torring N, 2003, PROSTATE, V56, P142, DOI 10.1002/pros.10245; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vercoutter-Edouart AS, 2001, CANCER RES, V61, P76; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/me.15.4.501	28	14	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6881	6889		10.1038/sj.onc.1207788	http://dx.doi.org/10.1038/sj.onc.1207788			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15300238				2022-12-25	WOS:000223750700005
J	Campopiano, DJ; Clarke, DJ; Polfer, NC; Barran, PE; Langley, RJ; Govan, JRW; Maxwell, A; Dorin, JR				Campopiano, DJ; Clarke, DJ; Polfer, NC; Barran, PE; Langley, RJ; Govan, JRW; Maxwell, A; Dorin, JR			Structure-activity relationships in defensin dimers - A novel link between beta-defensin tertiary structure and antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-CAPTURE DISSOCIATION; DISULFIDE; PEPTIDE; BETA-DEFENSIN-2; PROTEINS; CONSERVATION; DIVERGENCE; ACTIVATION; REVEALS; BNBD-12	Defensins are cationic antimicrobial peptides that have a characteristic six-cysteine motif and are important components of the innate immune system. We recently described a beta-defensin-related peptide (Defr1) that had potent antimicrobial activity despite having only five cysteines. Here we report a relationship between the structure and activity of Defr1 through a comparative study with its six cysteine-containing analogue (Defr1 Y5C). Against a panel of pathogens, we found that oxidized Defr1 had significantly higher activity than its reduced form and the oxidized and reduced forms of Defr1 Y5C. Furthermore, Defr1 displayed activity against Pseudomonas aeruginosa in the presence of 150 mM NaCl, whereas Defr1 Y5C was inactive. By using nondenaturing gel electrophoresis and Fourier transform ion cyclotron resonance mass spectrometry, we observed Defr1 and Defr1 Y5C dimers. Two complementary fragmentation techniques (collision-induced dissociation and electron capture dissociation) revealed that Defr1 Y5C dimers form by noncovalent, weak association of monomers that contain three intramolecular disulfide bonds. In contrast, Defr1 dimers are resistant to collision-induced dissociation and are only dissociated into monomers by reduction using electron capture. This is indicative of Defr1 dimerization being mediated by an intermolecular disulfide bond. Proteolysis and peptide mass mapping revealed that Defr1 Y5C monomers have beta-defensin disulfide bond connectivity, whereas oxidized Defr1 is a complex mixture of dimeric isoforms with as yet unknown inter- and intramolecular connectivities. Each isoform contains one intermolecular and four intramolecular disulfide bonds, but because we were unable to resolve the isoforms by reverse phase chromatography, we could not assign each isoform with a specific antimicrobial activity. We conclude that the enhanced activity and stability of this mixture of Defr1 dimeric isoforms are due to the presence of an intermolecular disulfide bond. This first description of a covalently cross-linked member of the defensin family provides further evidence that the antimicrobial activity of a defensin is linked to its ability to form stable higher order structures.	Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; Univ Edinburgh, Univ Med Sch, Dept Med Microbiol, Edinburgh EH8 9AG, Midlothian, Scotland; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; University of Edinburgh	Campopiano, DJ (corresponding author), Univ Edinburgh, Sch Chem, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Dominic.Campopiano@ed.ac.uk; Perdita.Barran@ed.ac.uk	Barran, Perdita/AAY-6303-2021	Clarke, David/0000-0002-3741-2952; Campopiano, Dominic/0000-0001-8573-6735				Bauer F, 2001, PROTEIN SCI, V10, P2470, DOI 10.1110/ps.ps.24401; BEAN MF, 1992, ANAL BIOCHEM, V201, P216, DOI 10.1016/0003-2697(92)90331-Z; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Hancock REW, 1999, ANTIMICROB AGENTS CH, V43, P1317, DOI 10.1128/AAC.43.6.1317; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; He F, 2000, J AM SOC MASS SPECTR, V11, P120, DOI 10.1016/S1044-0305(99)00132-4; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Hoover DM, 2003, ANTIMICROB AGENTS CH, V47, P2804, DOI 10.1128/AAC.47.9.2804-2809.2003; Horn DM, 2000, ANAL CHEM, V72, P4778, DOI 10.1021/ac000494i; Krishnakumari V, 2003, BIOCHEMISTRY-US, V42, P9307, DOI 10.1021/bi034403y; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Mandal M, 2002, PEPTIDES, V23, P413, DOI 10.1016/S0196-9781(01)00628-3; Maxwell AI, 2003, MOL IMMUNOL, V40, P413, DOI 10.1016/S0161-5890(03)00160-3; Morrison GM, 2003, MOL BIOL EVOL, V20, P460, DOI 10.1093/molbev/msg060; Morrison GM, 2002, MAMM GENOME, V13, P445, DOI 10.1007/s00335-002-3014-5; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Salzman NH, 2003, NATURE, V422, P522, DOI 10.1038/nature01520; Sawai MV, 2001, BIOCHEMISTRY-US, V40, P3810, DOI 10.1021/bi002519d; Schibli DJ, 2002, J BIOL CHEM, V277, P8279, DOI 10.1074/jbc.M108830200; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; SEMPLE CA, 2003, GENOME BIOL, V4, P4; SENKO MW, 1994, ANAL CHEM, V66, P2801, DOI 10.1021/ac00090a003; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; SMITH RD, 1992, ORG MASS SPECTROM, V27, P811, DOI 10.1002/oms.1210270709; TANG YQ, 1993, J BIOL CHEM, V268, P6649; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zubarev RA, 1999, J AM CHEM SOC, V121, P2857, DOI 10.1021/ja981948k; Zubarev RA, 1998, J AM CHEM SOC, V120, P3265, DOI 10.1021/ja973478k	37	79	84	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48671	48679		10.1074/jbc.M404690200	http://dx.doi.org/10.1074/jbc.M404690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15317821	hybrid			2022-12-25	WOS:000225098100024
J	Marrington, R; Small, E; Rodger, A; Dafforn, TR; Addinall, SG				Marrington, R; Small, E; Rodger, A; Dafforn, TR; Addinall, SG			FtsZ fiber bundling is triggered by a conformational change in bound GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION PROTEIN; ESCHERICHIA-COLI; LINEAR DICHROISM; ASSEMBLY DYNAMICS; Z RING; TUBULIN; POLYMERIZATION; HYDROLYSIS; ORIENTATION; FLUORESCENCE	Polymer formation by the essential FtsZ protein plays a crucial role in the cytokinesis of most prokaryotes. Lateral associations between these FtsZ polymers to form bundles or sheets are widely predicted to be extremely important for FtsZ function in vivo. We have carried out a study in vitro of FtsZ polymer formation and bundling using linear dichroism (LD) to assess structural properties of the polymers. We demonstrate proof-of-principle experiments to show that LD can be used as a technique to follow FtsZ polymerization, and we present the LD spectra of FtsZ polymers. Our subsequent examination of FtsZ polymer bundling induced by calcium reveals a substantial increase in the LD signal indicative of increased polymer length and rigidity. We also detect a specific conformational change in the guanine moiety associated with bundling, whereas the conformation and configuration of the FtsZ monomers within the polymer remain largely unchanged. We demonstrate that other divalent cations can induce this conformational change in FtsZ-bound GTP coincident with polymer bundling. Therefore, we present "flipping" of the guanine moiety in FtsZ-bound GTP as a mechanism that explains the link between reduced GTPase activity, increased polymer stability, and polymer bundling.	Univ Birmingham, Dept Biosci, Birmingham B15 2TT, W Midlands, England; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Birmingham; University of Warwick; University of Manchester	Dafforn, TR (corresponding author), Univ Birmingham, Dept Biosci, Birmingham B15 2TT, W Midlands, England.	T.R.Dafforn@bham.ac.uk	Rodger, Alison/A-1063-2009; Dafforn, Tim/A-9072-2015	Rodger, Alison/0000-0002-7111-3024; Dafforn, Tim/0000-0003-2257-6679				Addinall SG, 1997, J BACTERIOL, V179, P4277, DOI 10.1128/jb.179.13.4277-4284.1997; Addinall SG, 2002, J MOL BIOL, V318, P219, DOI 10.1016/S0022-2836(02)00024-4; Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; Beuria TK, 2003, J BIOL CHEM, V278, P3735, DOI 10.1074/jbc.M205760200; Chen JC, 2001, MOL MICROBIOL, V42, P395, DOI 10.1046/j.1365-2958.2001.02640.x; CLARK LB, 1977, J AM CHEM SOC, V99, P3934, DOI 10.1021/ja00454a006; Dafforn TR, 2004, BIOPHYS J, V86, P404, DOI 10.1016/S0006-3495(04)74116-8; Diaz JF, 2001, J BIOL CHEM, V276, P17307, DOI 10.1074/jbc.M010920200; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Erickson HP, 1998, TRENDS CELL BIOL, V8, P133, DOI 10.1016/S0962-8924(98)01237-9; Gilson PR, 2003, EUKARYOT CELL, V2, P1315, DOI 10.1128/EC.2.6.1315-1326.2003; Glockner FO, 2003, P NATL ACAD SCI USA, V100, P8298, DOI 10.1073/pnas.1431443100; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Gueiros FJ, 2002, GENE DEV, V16, P2544, DOI 10.1101/gad.1014102; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hale CA, 2000, J BACTERIOL, V182, P5153, DOI 10.1128/JB.182.18.5153-5166.2000; Hale CA, 2002, J BACTERIOL, V184, P2552, DOI 10.1128/JB.184.9.2552-2556.2002; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Lockhart A, 1998, FEBS LETT, V430, P278, DOI 10.1016/S0014-5793(98)00677-2; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lowe J, 2000, BIOL CHEM, V381, P993, DOI 10.1515/BC.2000.122; Lu C, 2001, BMC Microbiol, V1, P7, DOI 10.1186/1471-2180-1-7; Lu CL, 1998, CELL MOTIL CYTOSKEL, V40, P71, DOI 10.1002/(SICI)1097-0169(1998)40:1<71::AID-CM7>3.3.CO;2-Z; Lu CL, 1998, METHOD ENZYMOL, V298, P305, DOI 10.1016/S0076-6879(98)98027-2; Lu CL, 2000, J BACTERIOL, V182, P164, DOI 10.1128/JB.182.1.164-170.2000; Lutkenhaus J, 1997, ANNU REV BIOCHEM, V66, P93, DOI 10.1146/annurev.biochem.66.1.93; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 2000, FEMS MICROBIOL REV, V24, P531, DOI 10.1016/S0168-6445(00)00038-3; Marrington R, 2004, BIOPHYS J, V87, P2002, DOI 10.1529/biophysj.103.035022; MIKI M, 1976, BIOPHYS CHEM, V6, P101, DOI 10.1016/0301-4622(76)80066-X; Miyagishima SY, 2003, TRENDS PLANT SCI, V8, P432, DOI 10.1016/S1360-1385(03)00193-6; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; Mukherjee A, 1998, P NATL ACAD SCI USA, V95, P2885, DOI 10.1073/pnas.95.6.2885; Mukherjee A, 1998, METHOD ENZYMOL, V298, P296, DOI 10.1016/S0076-6879(98)98026-0; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; NORDH J, 1986, EUR BIOPHYS J BIOPHY, V14, P113, DOI 10.1007/BF00263068; Oliva MA, 2003, J BIOL CHEM, V278, P33562, DOI 10.1074/jbc.M303798200; Osteryoung KW, 2003, SCIENCE, V302, P1698, DOI 10.1126/science.1082192; Pandya MJ, 2000, BIOCHEMISTRY-US, V39, P8728, DOI 10.1021/bi000246g; Rivas G, 2001, P NATL ACAD SCI USA, V98, P3150, DOI 10.1073/pnas.051634398; Rodger A, 2002, ROY SOC CH, P3, DOI 10.1039/9781847550255-00003; Rodger A, 2002, PHYS CHEM CHEM PHYS, V4, P4051, DOI 10.1039/b205080n; RODGER A, 1987, CIRCULAR LINEAR DICH; Romberg L, 2003, ANNU REV MICROBIOL, V57, P125, DOI 10.1146/annurev.micro.57.012903.074300; Romberg L, 2001, J BIOL CHEM, V276, P11743, DOI 10.1074/jbc.M009033200; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Santra MK, 2004, J BIOL CHEM, V279, P25959, DOI 10.1074/jbc.M312473200; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Scheffers DJ, 2000, MOL MICROBIOL, V35, P1211, DOI 10.1046/j.1365-2958.2000.01791.x; Sigel H, 2001, CHEM-EUR J, V7, P3729, DOI 10.1002/1521-3765(20010903)7:17<3729::AID-CHEM3729>3.0.CO;2-E; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Small E, 2003, MICROBIOL-SGM, V149, P2235, DOI 10.1099/mic.0.26126-0; Sossong TM, 1999, BIOCHEMISTRY-US, V38, P14843, DOI 10.1021/bi990917e; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Trusca D, 1998, J BACTERIOL, V180, P3946, DOI 10.1128/JB.180.15.3946-3953.1998; Vaughan S, 2004, J MOL EVOL, V58, P19, DOI 10.1007/s00239-003-2523-5; White EL, 2000, J BACTERIOL, V182, P4028, DOI 10.1128/JB.182.14.4028-4034.2000; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; ZALOUDEK F, 1985, J AM CHEM SOC, V107, P7344, DOI 10.1021/ja00311a022	60	42	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48821	48829		10.1074/jbc.M404944200	http://dx.doi.org/10.1074/jbc.M404944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15328358	hybrid			2022-12-25	WOS:000225098100043
J	Arnesano, F; Banci, L; Bertini, I; Martinelli, M; Furukawa, Y; O'Halloran, TV				Arnesano, F; Banci, L; Bertini, I; Martinelli, M; Furukawa, Y; O'Halloran, TV			The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; AMYOTROPHIC-LATERAL-SCLEROSIS; COPPER CHAPERONE; CIRCULAR-DICHROISM; PROTEIN; MECHANISM; STABILITY; REDUCTION; DYNAMICS; MUTANTS	The eukaryotic copper, zinc superoxide dismutases are remarkably stable dimeric proteins that maintain an intrasubunit disulfide bond in the reducing environment of the cytosol and are active under a variety of stringent denaturing conditions. The structural interplay of conserved disulfide bond and metal-site occupancy in human copper, zinc superoxide dismutase (hSOD1) is of increasing interest as these post-translational modifications are known to dramatically alter the catalytic chemistry, the subcellular localization, and the susceptibility of the protein to aggregation. Using biophysical methods, we find no significant change in the gross secondary or tertiary structure of the demetallated form upon reduction of the disulfide. Interestingly, reduction does lead to a dramatic change in the quaternary structure, decreasing the monomer-to-dimer equilibrium constant by at least four orders of magnitude. This reduced form of hSOD1 is monomeric, even at concentrations well above the physiological range. Either the addition of Zn(II) or the formation of the disulfide leads to a shift in equilibrium that favors the dimeric species, even at low protein concentrations (i.e. micromolar range). We conclude that only the most immature form of hSOD1, i.e. one without any post-translational modifications, favors the monomeric state under physiological conditions. This finding provides a basis for understanding the selectivity of mitochondrial SOD1 import and may be relevant to the toxic properties of mutant forms of hSOD1 that can cause the familial form of amyotrophic lateral sclerosis.	Univ Florence, Magnet Resonance Ctr CERM, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; Northwestern Univ, Dept Chem & Biochem, Evanston, IL 60208 USA; Northwestern Univ, Dept Mol Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Cell Biol, Evanston, IL 60208 USA	University of Florence; University of Florence; Northwestern University; Northwestern University; Northwestern University	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr CERM, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.	bertini@cerm.unifi.it; t-ohalloran@northwestern.edu	Furukawa, Yoshiaki/F-2871-2014; Arnesano, Fabio/C-3066-2016; O'Halloran, Thomas/ABE-6125-2021	Furukawa, Yoshiaki/0000-0002-1918-372X; Arnesano, Fabio/0000-0002-8399-0964; O'Halloran, Thomas/0000-0001-8732-5059; BANCI, LUCIA/0000-0003-0562-5774; martinelli, manuele/0000-0002-9371-076X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54111, R01 GM054111] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; Banci L, 2000, BIOCHEMISTRY-US, V39, P9108, DOI 10.1021/bi000067z; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; Banci L, 2002, PROTEIN SCI, V11, P2479, DOI 10.1110/ps.0210802; BEEM KM, 1974, J BIOL CHEM, V249, P7298; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Carroll MC, 2004, P NATL ACAD SCI USA, V101, P5964, DOI 10.1073/pnas.0308298101; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Einstein A, 1956, INVESTIGATIONS THEOR; Eisses JF, 2000, BIOCHEMISTRY-US, V39, P7337, DOI 10.1021/bi000690j; Field LS, 2003, J BIOL CHEM, V278, P28052, DOI 10.1074/jbc.M304296200; FISHER CL, 1994, PROTEINS, V19, P24, DOI 10.1002/prot.340190105; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Lindberg MJ, 2002, P NATL ACAD SCI USA, V99, P16607, DOI 10.1073/pnas.262527099; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rae TD, 2001, J BIOL CHEM, V276, P5166, DOI 10.1074/jbc.M008005200; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017; Tiwari A, 2003, J BIOL CHEM, V278, P5984, DOI 10.1074/jbc.M210419200	36	207	211	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47998	48003		10.1074/jbc.M406021200	http://dx.doi.org/10.1074/jbc.M406021200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15326189	hybrid			2022-12-25	WOS:000224957000071
J	Campbell, GR; Pesquier, E; Watkins, J; Bourgarel-Rey, V; Peyrot, V; Esquieu, D; Barbier, P; de Mareuil, J; Braguer, D; Kaleebu, P; Yirrell, DL; Loret, EP				Campbell, GR; Pesquier, E; Watkins, J; Bourgarel-Rey, V; Peyrot, V; Esquieu, D; Barbier, P; de Mareuil, J; Braguer, D; Kaleebu, P; Yirrell, DL; Loret, EP			The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CIRCULAR-DICHROISM; STRUCTURAL CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; BLOOD-LYMPHOCYTES; RAPID PROGRESSION; KAPOSIS-SARCOMA; AIDS PATIENTS; JURKAT CELLS; CYTOCHROME-C	Human immunodeficiency virus (HIV) infection and the progression to AIDS are characterized by the depletion of CD4(+) T-cells. HIV-1 infection leads to apoptosis of uninfected bystander cells and the direct killing of HIV-infected cells. This is mediated, in part, by the HIV-1 Tat protein, which is secreted by virally infected cells and taken up by uninfected cells. We chemically synthesized two 86-residue subtype D Tat proteins, Ug05RP and Ug11LTS, from two Ugandan patients who were clinically categorized as either rapid progressor or long-term survivor, with non-conservative mutations located essentially in the glutamine-rich region. Structural heterogeneities were revealed by CD, which translate into differing trans-activational and apoptotic effects. CD data analysis and molecular modeling indicated that the short alpha-helix observed in subtype D Tat proteins from rapid progressor patients such as Tat Mal and Tat Ug05RP is not present in Ug11LTS. We show that Tat Ug05RP is more efficient than Tat Ug11LTS in its trans-activational role and in inducing apoptosis in binding tubulin via the mitochondrial pathway. The glutamine-rich region of Tat appears to be involved in the Tat-mediated apoptosis of T-cells.	Univ Mediterranee, Fac Pharm, CNRS Format Rech Evolut 2737, F-13385 Marseille, France; Uganda Virus Res Inst, MRC United Kingdom Programme AIDS Uganda, Entebbe, Uganda; Gartnavel Royal Hosp, W Scotland Specialist Virol Ctr, Glasgow G12 0ZA, Lanark, Scotland	UDICE-French Research Universities; Aix-Marseille Universite; Uganda Virus Research Institute; Gartnavel Royal Hospital	Loret, EP (corresponding author), Univ Mediterranee, Fac Pharm, CNRS Format Rech Evolut 2737, 27 Blvd Jean Moulin, F-13385 Marseille, France.	erwann.loret@pharmacie.univ-mrs.fr	Pasquier, Eddy/A-8112-2018; Barbier, Pascale/AAE-1781-2019; peyrot, vincent/B-6365-2015; Campbell, Grant/C-9018-2011	Pasquier, Eddy/0000-0003-2824-5002; Campbell, Grant/0000-0003-3927-1994; Bourgarel-Rey, Veronique/0000-0002-7044-3910				ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; ANDREU JM, 1984, BIOCHEMISTRY-US, V23, P1742, DOI 10.1021/bi00303a025; ANZALA OA, 1995, J INFECT DIS, V171, P686, DOI 10.1093/infdis/171.3.686; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; Barbier P, 1995, BIOCHEMISTRY-US, V34, P16821, DOI 10.1021/bi00051a033; Bartz SR, 1999, J VIROL, V73, P1956, DOI 10.1128/JVI.73.3.1956-1963.1999; Brand SR, 1997, J BIOL CHEM, V272, P8388, DOI 10.1074/jbc.272.13.8388; Carre M, 2002, BIOCHEM PHARMACOL, V63, P1831, DOI 10.1016/S0006-2952(02)00922-X; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chen D, 2002, EMBO J, V21, P6801, DOI 10.1093/emboj/cdf683; Cohen SS, 1999, P NATL ACAD SCI USA, V96, P10842, DOI 10.1073/pnas.96.19.10842; Conti L, 1998, J EXP MED, V187, P403, DOI 10.1084/jem.187.3.403; Dockrell DH, 1998, J CLIN INVEST, V101, P2394, DOI 10.1172/JCI1171; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; French N, 1999, J ACQ IMMUN DEF SYND, V22, P509; FURLINI MCRG, 1995, J ACQ IMMUN DEF SYND, V10, P408, DOI 10.1097/00042560-199512000-00003; Gatignol A, 2000, Adv Pharmacol, V48, P209; GIBELLINI D, 1995, BRIT J HAEMATOL, V89, P24, DOI 10.1111/j.1365-2141.1995.tb08915.x; Gregoire C, 2001, BIOPOLYMERS, V62, P324, DOI 10.1002/bip.10000; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lawn SD, 2004, J INFECTION, V48, P1, DOI 10.1016/j.jinf.2003.09.001; LEE JC, 1973, J BIOL CHEM, V248, P7253; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liang Chen, 2002, AIDS Reviews, V4, P41; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; MANAVALAN P, 1985, ANAL BIOCHEM, V167, P76; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; McCloskey TW, 1997, J IMMUNOL, V158, P1014; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Moretti S, 2000, CLIN EXP IMMUNOL, V122, P364, DOI 10.1046/j.1365-2249.2000.01375.x; Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011; Morgan D, 2002, BRIT MED J, V324, P193, DOI 10.1136/bmj.324.7331.193; Moy P, 1996, MOL BIOTECHNOL, V6, P105, DOI 10.1007/BF02740767; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NARDELLI B, 1995, P NATL ACAD SCI USA, V92, P7312, DOI 10.1073/pnas.92.16.7312; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Peloponese JM, 1999, J BIOL CHEM, V274, P11473, DOI 10.1074/jbc.274.17.11473; Peloponese JM, 2000, CR ACAD SCI III-VIE, V323, P883, DOI 10.1016/S0764-4469(00)01228-2; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; Quinones-Mateu ME, 1998, VIRUS RES, V57, P11, DOI 10.1016/S0168-1702(98)00082-3; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Rubartelli A, 1998, IMMUNOL TODAY, V19, P543, DOI 10.1016/S0167-5699(98)01351-6; Secchiero P, 1999, J IMMUNOL, V162, P2427; Smith SM, 2003, J BIOL CHEM, V278, P44816, DOI 10.1074/jbc.M307546200; Towbin H, 1992, Biotechnology, V24, P145; Vendeville A, 2004, MOL BIOL CELL, V15, P2347, DOI 10.1091/mbc.E03-12-0921; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WHITTLE H, 1992, AIDS, V6, P685, DOI 10.1097/00002030-199207000-00011; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Wu YT, 2003, J VIROL, V77, P10376, DOI 10.1128/JVI.77.19.10376-10382.2003; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Yen-Moore A, 2000, VIROLOGY, V267, P247, DOI 10.1006/viro.1999.0125; Zagury J F, 1998, J Hum Virol, V1, P282; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	71	67	74	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48197	48204		10.1074/jbc.M406195200	http://dx.doi.org/10.1074/jbc.M406195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15331610	hybrid			2022-12-25	WOS:000224957000094
J	Skill, NJ; Johnson, TS; Coutts, IGC; Saint, RE; Fisher, M; Huang, LH; El Nahas, AM; Collighan, RJ; Griffin, M				Skill, NJ; Johnson, TS; Coutts, IGC; Saint, RE; Fisher, M; Huang, LH; El Nahas, AM; Collighan, RJ; Griffin, M			Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TISSUE TRANSGLUTAMINASE; TRANSFORMING GROWTH-FACTOR-BETA-1; LIVER TRANSGLUTAMINASE; DIABETIC NEPHROPATHY; GENE-EXPRESSION; CROSS-LINKING; COLLAGEN; BINDING; FIBRONECTIN	Diabetic nephropathy affects 30-40% of diabetics leading to end-stage kidney failure through progressive scarring and fibrosis. Previous evidence suggests that tissue transglutaminase (tTg) and its protein cross-link product epsilon(gamma-glutamyl) lysine contribute to the expanding renal tubulointerstitial and glomerular basement membranes in this disease. Using an in vitro cell culture model of renal proximal tubular epithelial cells we determined the link between elevated glucose levels with changes in expression and activity of tTg and then, by using a highly specific site directed inhibitor of tTg (1,3-dimethyl- 2[(oxopropyl) thio] imidazolium), determined the contribution of tTg to glucose-induced matrix accumulation. Exposure of cells to 36 mM glucose over 96 h caused an mRNA-dependent increase in tTg activity with a 25% increase in extracellular matrix (ECM)-associated tTg and a 150% increase in ECM epsilon(gamma-glutamyl) lysine cross-linking. This was paralleled by an elevation in total deposited ECM resulting from higher levels of deposited collagen and fibronectin. These were associated with raised mRNA for collagens III, IV, and fibronectin. The specific site-directed inhibitor of tTg normalized both tTg activity and ECM-associated epsilon(gamma-glutamyl) lysine. Levels of ECM per cell returned to near control levels with non-transcriptional reductions in deposited collagen and fibronectin. No changes in transforming growth factor beta1 (expression or biological activity) occurred that could account for our observations, whereas incubation of tTg with collagen III indicated that cross-linking could directly increase the rate of collagen fibril/gel formation. We conclude that Tg inhibition reduces glucose-induced deposition of ECM proteins independently of changes in ECM and transforming growth factor beta1 synthesis thus opening up its possible application in the treatment other fibrotic and scarring diseases where tTg has been implicated.	Nottingham Trent Univ, Sch Sci, Nottingham NG11 8NS, England; No Gen Hosp, Sheffield Kidney Inst, Sheffield S5 7AU, S Yorkshire, England	Nottingham Trent University; Northern General Hospital	Griffin, M (corresponding author), Nottingham Trent Univ, Sch Sci, Clifton Lane, Nottingham NG11 8NS, England.	martin.griffin@ntu.ac.uk		Griffin, Martin/0000-0003-3824-306X; Skill, Nicholas/0000-0003-0965-3836				ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Amos A.F., 1997, DIABET MED S5, V14, P1; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CAMPA JS, 1990, ANAL BIOCHEM, V186, P257, DOI 10.1016/0003-2697(90)90076-L; Chiarelli F, 2003, PANMINERVA MED, V45, P23; Collighan RJ, 2004, J AM LEATHER CHEM AS, V99, P293; Fraser D, 2003, AM J PATHOL, V163, P2565, DOI 10.1016/S0002-9440(10)63611-5; FREUND KF, 1994, BIOCHEMISTRY-US, V33, P10109, DOI 10.1021/bi00199a039; Gaster B, 1998, ARCH INTERN MED, V158, P134, DOI 10.1001/archinte.158.2.134; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; GENTILE V, 1991, J BIOL CHEM, V266, P478; GEORGE MD, 1990, J BIOL CHEM, V265, P11098; Gilbert RE, 1999, KIDNEY INT, V56, P1627, DOI 10.1046/j.1523-1755.1999.00721.x; GRIFFIN M, 1984, MOL CELL BIOCHEM, V58, P37, DOI 10.1007/BF00240603; GRIFFIN M, 1979, BRIT J EXP PATHOL, V60, P653; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Gross SR, 2003, J INVEST DERMATOL, V121, P412, DOI 10.1046/j.1523-1747.2003.12353.x; Gstraunthaler G, 1999, CELL PHYSIOL BIOCHEM, V9, P150, DOI 10.1159/000016312; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; Johnson TS, 1997, J CLIN INVEST, V99, P2950, DOI 10.1172/JCI119490; Johnson TS, 2003, J AM SOC NEPHROL, V14, P2052, DOI 10.1097/01.ASN.0000079614.63463.DD; Johnson TS, 1999, J AM SOC NEPHROL, V10, P2146; KLEMAN JP, 1995, BIOCHEMISTRY-US, V34, P13768, DOI 10.1021/bi00042a007; KURKINEN M, 1987, J BIOL CHEM, V262, P8496; Laurent G J, 1983, Curr Probl Clin Biochem, V13, P124; MAYS PK, 1991, BIOCHEM J, V276, P307, DOI 10.1042/bj2760307; MILLAN FA, 1991, DEVELOPMENT, V111, P131; Mirza A, 1997, AM J PHYSIOL-GASTR L, V272, pG281, DOI 10.1152/ajpgi.1997.272.2.G281; NOMURA Y, 1989, AGR BIOL CHEM TOKYO, V53, P1614; Nosadini R, 2004, J AM SOC NEPHROL, V15, pS1, DOI 10.1097/01.ASN.0000093372.84929.BA; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Phillips AO, 2002, HISTOL HISTOPATHOL, V17, P247, DOI 10.14670/HH-17.247; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; Skill NJ, 2001, LAB INVEST, V81, P705, DOI 10.1038/labinvest.3780279; Small K, 1999, J BIOL CHEM, V274, P21291, DOI 10.1074/jbc.274.30.21291; SYKES B, 1977, NEW ENGL J MED, V296, P1200, DOI 10.1056/NEJM197705262962104; SYKES B, 1976, BIOCHEM BIOPH RES CO, V72, P1472, DOI 10.1016/S0006-291X(76)80180-5; Syntex, 1990, US Patent, Patent No. [4, 912, 120, 4912120]; Tam VK, 1998, ENDOCRINOLOGY, V139, P3072, DOI 10.1210/en.139.7.3072; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; VIROLAINEN P, 1995, CLIN ORTHOP RELAT R, P263; Welge-Lussen U, 2000, INVEST OPHTH VIS SCI, V41, P2229; Zhang SL, 1999, KIDNEY INT, V55, P454, DOI 10.1046/j.1523-1755.1999.00271.x	45	73	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47754	47762		10.1074/jbc.M402698200	http://dx.doi.org/10.1074/jbc.M402698200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15326185	Green Accepted, hybrid			2022-12-25	WOS:000224957000043
J	Di Giusto, DA; King, GC				Di Giusto, DA; King, GC			Construction, stability, and activity of multivalent circular anticoagulant aptamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNPAIRED THYMIDINE BASES; IN-VITRO; SYSTEMATIC EVOLUTION; STRUCTURAL FEATURES; NICK RECOGNITION; HUMAN THROMBIN; RNA APTAMER; DNA-LIGASE; OLIGONUCLEOTIDES; SELECTION	Here we describe the design and construction of multivalent circular DNA aptamers. Four aptameric binding motifs directed at blood-borne targets are used as a model set from which larger, multidomain aptamers are constructed in a straightforward manner. Intra- or intermolecular ligation of precursor oligonucleotides provides a stabilizing mechanism against degradation by the predominant exonuclease activity of blood products without the need for post-selection chemical modification. In many cases, circular DNA aptamer half-lives are extended beyond 10 h in serum and plasma, making such constructs viable for therapeutic and diagnostic applications. Duplexes and three-way junctions are used as scaffold architectures around which two, three, or four aptameric motifs can be arranged in a structurally defined manner, giving rise to improved binding characteristics through stability and avidity gains. Circular aptamers targeted against thrombin display improved anticoagulant potency with EC50 values 2-3-fold better than those of the canonical GS-522 thrombin DNA aptamer. Intrinsic duplex regions provide an opportunity to incorporate additional transcription factor binding motifs, whereas ancillary loops can be used to provide further functionality. These anticoagulant aptamers provide a starting point for merging the principles of DNA nanotechnology with aptameric functions.	Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia	University of New South Wales Sydney	King, GC (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.	garry@kinglab.unsw.edu.au						Ahn JD, 2003, BIOCHEM BIOPH RES CO, V310, P1048, DOI 10.1016/j.bbrc.2003.09.124; AKHTAR S, 1991, LIFE SCI, V49, P1793, DOI 10.1016/0024-3205(91)90480-Y; Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730; Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5; Burgstaller P, 2002, CURR OPIN DRUG DISC, V5, P690; Charlton J, 1997, CHEM BIOL, V4, P809, DOI 10.1016/S1074-5521(97)90114-9; CHEN JH, 1991, NATURE, V350, P631, DOI 10.1038/350631a0; Cherepanov AV, 2002, EUR J BIOCHEM, V269, P5993, DOI 10.1046/j.1432-1033.2002.03309.x; Cho-Chung YS, 1999, CURR OPIN MOL THER, V1, P386; Cogoi S, 2004, BIOCHEMISTRY-US, V43, P2512, DOI 10.1021/bi035754f; Cox JC, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf107; Doherty AJ, 2000, J MOL BIOL, V296, P43, DOI 10.1006/jmbi.1999.3423; Dougan H, 2000, NUCL MED BIOL, V27, P289, DOI 10.1016/S0969-8051(99)00103-1; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Famulok M, 1998, CURR OPIN CHEM BIOL, V2, P320, DOI 10.1016/S1367-5931(98)80004-5; Fredriksson S, 2002, NAT BIOTECHNOL, V20, P473, DOI 10.1038/nbt0502-473; Gewirtz AM, 1999, CURR OPIN MOL THER, V1, P297; Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092; Hwang BH, 2003, FEBS LETT, V548, P85, DOI 10.1016/S0014-5793(03)00745-2; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Kurreck J, 2003, EUR J BIOCHEM, V270, P1628, DOI 10.1046/j.1432-1033.2003.03555.x; Levin AA, 1999, BBA-GENE STRUCT EXPR, V1489, P69, DOI 10.1016/S0167-4781(99)00140-2; MACAYA RF, 1995, BIOCHEMISTRY-US, V34, P4478, DOI 10.1021/bi00013a041; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Norman KE, 2003, BLOOD, V101, P921, DOI 10.1182/blood-2001-12-0190; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Osborne SE, 1997, CURR OPIN CHEM BIOL, V1, P5, DOI 10.1016/S1367-5931(97)80102-0; Overmars FJJ, 1996, J MOL BIOL, V255, P702, DOI 10.1006/jmbi.1996.0057; Pietras K, 2002, CANCER RES, V62, P5476; ROSEN MA, 1993, BIOCHEMISTRY-US, V32, P6576, DOI 10.1021/bi00077a011; Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556; Seeman NC, 1998, ANGEW CHEM INT EDIT, V37, P3220, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3220::AID-ANIE3220>3.0.CO;2-C; Shaw JP, 1995, PHARMACEUT RES, V12, P1937, DOI 10.1023/A:1016243923195; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; Tavitian B, 2003, GUT, V52, P40; Tomita N, 2003, CURR DRUG TARGETS, V4, P603, DOI 10.2174/1389450033490803; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; van Buuren BNM, 2000, J MOL BIOL, V304, P371, DOI 10.1006/jmbi.2000.4224; vanDongen MJP, 1997, NUCLEIC ACIDS RES, V25, P1537, DOI 10.1093/nar/25.8.1537; Vater A, 2003, CURR OPIN DRUG DI DE, V6, P253; Verthelyi D, 2003, CLIN IMMUNOL, V109, P64, DOI 10.1016/S1521-6616(03)00202-X; White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100; WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7; Winfree E, 1998, NATURE, V394, P539, DOI 10.1038/28998; Wooldridge James E., 2003, Current Opinion in Oncology, V15, P440, DOI 10.1097/00001622-200311000-00006; Zacharski LR, 2002, CANCER LETT, V186, P1, DOI 10.1016/S0304-3835(02)00258-6	49	66	81	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46483	46489		10.1074/jbc.M408037200	http://dx.doi.org/10.1074/jbc.M408037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322086	hybrid			2022-12-25	WOS:000224832400019
J	Nickols, HH; Shah, VN; Chazin, WJ; Limbird, LE				Nickols, HH; Shah, VN; Chazin, WJ; Limbird, LE			Calmodulin interacts with the V2 vasopressin receptor - Elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; PROTEIN-KINASE-C; COLLECTING DUCT; COUPLING SELECTIVITY; CARBOXYL-TERMINUS; MOLECULAR-BASIS; V-2 RECEPTOR; PHOSPHORYLATION; AQUAPORIN-2; SEQUENCE	To identify molecules that might contribute to V2 vasopressin receptor (V2R) trafficking or signaling, we searched for novel interacting proteins with this receptor. Preliminary data, using the V2R C terminus as bait in a yeast two-hybrid screen, revealed calmodulin as a binding partner. Because calmodulin interacts with other G protein-coupled receptors, we explored this interaction and its possible functional relevance in greater detail. A Ca2+-dependent interaction occurs between calmodulin-linked agarose and the holo-V2R as well as the V2R C terminus. Truncation and site-directed mutagenesis of the V2R C terminus revealed an involvement of an RGR sequence in this interaction. NMR studies showed that a peptide fragment of the V2R C terminus containing the RGR sequence binds to calmodulin in a Ca2+-dependent manner with a K-d less than or equal to1.5 muM; concentration-dependent binding of the V2R C terminus to calmodulin-agarose was used to estimate a Kd value of similar to200 nM for this entire C-terminal sequence as expressed in mammalian cells. Madin-Darby canine kidney II cells stably expressing either wild type or a mutant V2R, in which the RGR C-terminal sequence was mutated to alanines ( AAA V2R), revealed that the steady-state localization and agonist-induced internalization of the AAA V2R resembled that of the wild type V2R in polarized Madin-Darby canine kidney II cells. V2R binding of agonist similarly was unchanged in the AAA V2R, as was the concentration response for arginine vasopressin (AVP)-stimulated cAMP accumulation. Most interestingly, AVP-induced increases in intracellular Ca2+ observed for the wild type V2R were virtually eliminated for the AAA V2R. Taken together, the data suggest that a C-terminal region of the V2R important for calmodulin interaction is also important in modulation of V2R elevation of intracellular Ca2+, a prerequisite for AVP-induced fusion of aquaporin-containing vesicles with the apical surface of renal epithelial cells.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Struct Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Robinson Res Bldg,Rm 464, Nashville, TN 37232 USA.	lee.limbird@vanderbilt.edu		O'Reilly-Shah, Vikas/0000-0003-0741-0291	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120, R29GM040120] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43879] Funding Source: Medline; NIGMS NIH HHS [GM40120] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; CHAMPIGNEULLE A, 1993, AM J PHYSIOL, V265, pF35, DOI 10.1152/ajprenal.1993.265.1.F35; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; El Far O, 2001, J BIOL CHEM, V276, P30662, DOI 10.1074/jbc.M102573200; Erlenbach I, 1998, J BIOL CHEM, V273, P26549, DOI 10.1074/jbc.273.41.26549; Innamorati G, 1997, J BIOL CHEM, V272, P2486; Innamorati G, 1998, P NATL ACAD SCI USA, V95, P2222, DOI 10.1073/pnas.95.5.2222; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Jan CR, 2000, TOXICOL APPL PHARM, V162, P142, DOI 10.1006/taap.1999.8844; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; LEVINE SD, 1981, J CLIN INVEST, V67, P662, DOI 10.1172/JCI110081; LIMBIRD LE, 1998, HDB PHYSL, P49; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Schulein R, 2001, J BIOL CHEM, V276, P8384, DOI 10.1074/jbc.M007045200; Sorensen SD, 2002, MOL PHARMACOL, V61, P1303, DOI 10.1124/mol.61.6.1303; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; Thomas WG, 1999, FEBS LETT, V455, P367, DOI 10.1016/S0014-5793(99)00904-7; Turner JH, 2004, J BIOL CHEM, V279, P17027, DOI 10.1074/jbc.M313919200; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; VOGEL HJ, 1983, FEBS LETT, V157, P241, DOI 10.1016/0014-5793(83)80554-7; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; Yip KP, 2002, J PHYSIOL-LONDON, V538, P891, DOI 10.1113/jphysiol.2001.012606	35	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46969	46980		10.1074/jbc.M407351200	http://dx.doi.org/10.1074/jbc.M407351200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15319442	hybrid			2022-12-25	WOS:000224832400081
J	Csitkovits, VC; Dermic, D; Zechner, EL				Csitkovits, VC; Dermic, D; Zechner, EL			Concomitant reconstitution of TraI-catalyzed DNA transesterase and DNA helicase activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-PLASMID ORIT; STRAND-SPECIFIC NICKING; GENE-PRODUCT; BACTERIAL CONJUGATION; TRANSFER ORIGIN; SEX FACTOR; PROTEIN; BINDING; INTEGRATION; MECHANISMS	TraI protein of plasmid R1 possesses two activities, a DNA transesterase and a highly processive 5'-3' DNA helicase, which are essential for bacterial conjugation. Regulation of the functional domains of the enzyme is poorly understood. TraI cleaves supercoiled oriT DNA with site and strand specificity in vitro but fails to initiate unwinding from this site (nic). The helicase requires an extended region of adjacent single-stranded DNA to enter the duplex, yet interaction of purified TraI with oriT DNA alone or as an integral part of the IncF relaxosome does not melt sufficient duplex to load the helicase. This study aims to gain insights into the controlled initiation of both TraI-catalyzed activities. Linear double-stranded DNA substrates with a central region of sequence heterogeneity were used to trap defined lengths of R1 oriT sequence in unwound conformation. Concomitant reconstitution of TraI DNA transesterase and helicase activities was observed. Efficient helicase activity was measured on substrates containing 60 bases of open duplex but not on substrates containing less than or equal to30 bases in open conformation. The additional presence of auxiliary DNA-binding proteins TraY and Escherichia coli integration host factor did not stimulate TraI activities on these substrates. This model system offers a novel approach to investigate factors controlling helicase loading and the directionality of DNA unwinding from nic.	Karl Franzens Univ Graz, Inst Mol Biowissensch, A-8010 Graz, Austria; Rudjer Boskovic Inst, Dept Mol Biol, Zagreb 10002, Croatia	University of Graz; Rudjer Boskovic Institute	Zechner, EL (corresponding author), Karl Franzens Univ Graz, Inst Mol Biowissensch, Univ Pl 2, A-8010 Graz, Austria.	ellen.zechner@uni-graz.at		Zechner, Ellen L./0000-0003-2035-1898; Dermic, Damir/0000-0002-5263-2750				ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; ABDELMONEM M, 1983, P NATL ACAD SCI-BIOL, V80, P4659, DOI 10.1073/pnas.80.15.4659; Byrd DR, 1997, MOL MICROBIOL, V25, P1011, DOI 10.1046/j.1365-2958.1997.5241885.x; Byrd DR, 2002, J BIOL CHEM, V277, P42645, DOI 10.1074/jbc.M205984200; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Csitkovits VC, 2003, J BIOL CHEM, V278, P48696, DOI 10.1074/jbc.M310025200; Delagoutte E, 2003, Q REV BIOPHYS, V36, P1, DOI 10.1017/S0033583502003864; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; EVERETT R, 1980, J MOL BIOL, V136, P129, DOI 10.1016/0022-2836(80)90309-5; FURSTE JP, 1987, MECH DNA REPLICATION, P553; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GILBERT W, 1968, COLD SPRING HARB SYM, V33, P473, DOI 10.1101/SQB.1968.033.01.055; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; GRANDOSO G, 1994, EUR J BIOCHEM, V226, P403, DOI 10.1111/j.1432-1033.1994.tb20065.x; GRAUS H, 1990, NUCLEIC ACIDS RES, V18, P1046, DOI 10.1093/nar/18.4.1046; Guasch A, 2003, NAT STRUCT BIOL, V10, P1002, DOI 10.1038/nsb1017; HOWARD MT, 1995, J BIOL CHEM, V270, P28381; INAMOTO S, 1994, J BIOCHEM-TOKYO, V116, P838, DOI 10.1093/oxfordjournals.jbchem.a124604; Karl W, 2001, J BACTERIOL, V183, P909, DOI 10.1128/JB.183.3.909-914.2001; KUHN B, 1979, J BIOL CHEM, V254, P1343; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; LAHUE EE, 1988, J BIOL CHEM, V263, P3208; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; Llosa M, 2003, P NATL ACAD SCI USA, V100, P10465, DOI 10.1073/pnas.1830264100; Llosa M, 1996, J MOL BIOL, V264, P56, DOI 10.1006/jmbi.1996.0623; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; MATSON SW, 1991, J BIOL CHEM, V266, P16232; Matson SW, 2001, J BIOL CHEM, V276, P2372, DOI 10.1074/jbc.M008728200; Miller J. H., 1972, EXPT MOL GENETICS, P433; NELSON WC, 1995, J BIOL CHEM, V270, P28374; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; Sastre JI, 1998, J BACTERIOL, V180, P6039, DOI 10.1128/JB.180.22.6039-6042.1998; Schroder G, 2002, J BACTERIOL, V184, P2767, DOI 10.1128/JB.184.10.2767-2779.2002; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; Stern JC, 2001, BIOCHEMISTRY-US, V40, P11586, DOI 10.1021/bi010877q; Street LM, 2003, BBA-PROTEINS PROTEOM, V1646, P86, DOI 10.1016/S1570-9639(02)00553-8; TRAXLER BA, 1988, J MOL BIOL, V204, P205, DOI 10.1016/0022-2836(88)90609-2; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; Verdino P, 1999, J BIOL CHEM, V274, P37421, DOI 10.1074/jbc.274.52.37421; von Hippel PH, 2003, BIOESSAYS, V25, P1168, DOI 10.1002/bies.10369; WILKINS BM, 1974, MOL GEN GENET, V134, P143, DOI 10.1007/BF00268416; Zechner E. L., 2000, HORIZONTAL GENE POOL, P87	44	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45477	45484		10.1074/jbc.M407970200	http://dx.doi.org/10.1074/jbc.M407970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322083	hybrid			2022-12-25	WOS:000224694900025
J	Eastmond, PJ				Eastmond, PJ			Cloning and characterization of the acid lipase from castor beans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID ACYL-HYDROLASE; OIL-BODIES; GLYOXYSOMAL LIPASE; NEUTRAL LIPASE; POTATO-TUBERS; PURIFICATION; PROTEIN; OLEOSINS; SEEDS; PLANTS	Castor bean endosperm contains a well known acid lipase activity that is associated with the oil body membrane. In order to identify this enzyme, proteomic analysis was performed on purified oil bodies. A similar to60-kDa protein was identified (RcOBL1), which shares homology with a lipase from the filamentous fungus Rhizomucor miehei. RcOBL1 contains features that are characteristic of an alpha/beta-hydrolase, such as a putative catalytic triad ((S) under bar DH) and a conserved pentapeptide ( GX (S) under bar XG) surrounding the nucleophilic serine residue. RcOBL1 was expressed heterologously in Escherichia coli and shown to hydrolyze triolein at an acid pH (optima similar to4.5). RcOBL1 can hydrolyze a range of triacylglycerols but is not active on phospholipids. The activity is sensitive to the serine reagent diethyl p-nitrophenyl phosphate, indicating that RcOBL1 is a serine esterase. Antibodies raised against RcOBL1 were used to show that the protein is restricted to the endosperm where it is associated with the surface of oil bodies. This is the first evidence for the molecular identity of an oil body-associated lipase from plants. Sequence comparisons reveal that families of OBL1-like proteins are present in many species, and it is likely that they play an important role in regulating lipolysis.	Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Eastmond, PJ (corresponding author), Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England.	pje4@york.ac.uk		Eastmond, Peter/0000-0003-4526-5136	Biotechnology and Biological Sciences Research Council [JF16985] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abell BM, 1997, PLANT CELL, V9, P1481, DOI 10.1105/tpc.9.8.1481; Altaf A, 1997, J PLANT BIOCHEM BIOT, V6, P13, DOI 10.1007/BF03263002; Beaudoin F, 2000, PLANT J, V23, P159, DOI 10.1046/j.1365-313x.2000.00769.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FOLCH P, 1957, J BIOL CHEM, V226, P449; Fuchs C, 1996, J PLANT PHYSIOL, V149, P23, DOI 10.1016/S0176-1617(96)80168-4; Graham IA, 2002, PROG LIPID RES, V41, P156, DOI 10.1016/S0163-7827(01)00022-4; Green J. R., 1890, P ROY SOC LONDON, V48, P370, DOI 10.1098/rspl.1890.0044; Hayashi Y, 2001, PROTOPLASMA, V218, P83, DOI 10.1007/BF01288364; HILLS MJ, 1987, PLANT PHYSIOL, V85, P1084, DOI 10.1104/pp.85.4.1084; HILLS MJ, 1987, PLANT PHYSIOL, V84, P272, DOI 10.1104/pp.84.2.272; HILLS MJ, 1989, PLANT PHYSIOL, V89, P1006, DOI 10.1104/pp.89.3.1006; HIRAYAMA O, 1975, BIOCHIM BIOPHYS ACTA, V384, P127, DOI 10.1016/0005-2744(75)90102-3; Hong YW, 2000, P NATL ACAD SCI USA, V97, P8717, DOI 10.1073/pnas.140213697; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Huang A.H.C., 1983, LIPASES, P419; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; Ishiguro S, 2001, PLANT CELL, V13, P2191, DOI 10.1105/tpc.13.10.2191; Jolivet P, 2004, PLANT PHYSIOL BIOCH, V42, P501, DOI 10.1016/j.plaphy.2004.04.006; Lacey DJ, 1998, BIOCHEM J, V334, P469, DOI 10.1042/bj3340469; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Li M, 2002, J BIOL CHEM, V277, P37888, DOI 10.1074/jbc.M202721200; LIN YH, 1984, PLANT PHYSIOL, V76, P719, DOI 10.1104/pp.76.3.719; MAESHIMA M, 1985, PLANT PHYSIOL, V79, P489, DOI 10.1104/pp.79.2.489; Millichip M, 1996, BIOCHEM J, V314, P333, DOI 10.1042/bj3140333; MURPHY DJ, 1993, PROG LIPID RES, V32, P247, DOI 10.1016/0163-7827(93)90009-L; NCUBE I, 1995, BBA-LIPID LIPID MET, V1257, P149, DOI 10.1016/0005-2760(95)00067-M; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; ORY RL, 1969, LIPIDS, V4, P261, DOI 10.1007/BF02533183; ORY RL, 1962, J LIPID RES, V3, P99; ORY RL, 1969, LIPIDS, V4, P177, DOI 10.1007/BF02532626; ORY RL, 1968, ARCH BIOCHEM BIOPHYS, V123, P255, DOI 10.1016/0003-9861(68)90132-X; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Sambrook J, 1989, MOL CLONING LAB MANU, P1860; Schmid M, 1999, P NATL ACAD SCI USA, V96, P14159, DOI 10.1073/pnas.96.24.14159; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRICKLAND JA, 1995, PLANT PHYSIOL, V109, P667, DOI 10.1104/pp.109.2.667; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TZEN JTC, 1992, J CELL BIOL, V117, P327, DOI 10.1083/jcb.117.2.327; Verger R, 1997, TRENDS BIOTECHNOL, V15, P32, DOI 10.1016/S0167-7799(96)10064-0; WANNER G, 1978, PLANTA, V140, P163, DOI 10.1007/BF00384916; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200	43	101	107	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45540	45545		10.1074/jbc.M408686200	http://dx.doi.org/10.1074/jbc.M408686200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322116	hybrid			2022-12-25	WOS:000224694900032
J	Gonzalez-Navarro, H; Nong, ZX; Amar, MJA; Shamburek, RD; Najib-Fruchart, J; Paigen, BJ; Brewer, HB; Santamarina-Fojo, S				Gonzalez-Navarro, H; Nong, ZX; Amar, MJA; Shamburek, RD; Najib-Fruchart, J; Paigen, BJ; Brewer, HB; Santamarina-Fojo, S			The ligand-binding function of hepatic lipase modulates the development of atherosclerosis in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; IN-VIVO EVIDENCE; HUMAN APO-B; LDL RECEPTOR; CHYLOMICRON REMNANTS; APOLIPOPROTEIN-B; SELECTIVE UPTAKE; TRIGLYCERIDE LIPASE; CHOLESTERYL ESTERS	To investigate the separate contributions of the lipolytic versus ligand-binding function of hepatic lipase (HL) to plasma lipoprotein metabolism and atherosclerosis, we compared mice expressing catalytically active wild-type HL (HL-WT) and inactive HL (HL-S145G) with no endogenous expression of mouse apoE or HL (E-KO x HL-KO, where KO is knockout). HL-WT and HL-S145G reduced plasma cholesterol ( by 40 and 57%, respectively), non-high density lipoprotein cholesterol ( by 48 and 61%, respectively), and apoB (by 36 and 44%, respectively) (p < 0.01), but only HL-WT decreased high density lipoprotein cholesterol (by 67%) and apoA-I (by 54%). Compared with E-KO x HL-KO mice, both active and inactive HL lowered the pro-atherogenic lipoproteins by enhancing the catabolism of autologous I-125-apoB very low density/intermediate density lipoprotein (VLDL/IDL) ( fractional catabolic rates of 2.87 +/- 0.04/day for E-KO x HL-KO, 3.77 +/- 0.03/day for E-KO x HL-WT, and 3.63 +/- 0.09/day for E-KO x HL-S145G mice) and I-125-apoB-48 low density lipoprotein (LDL) ( fractional catabolic rates of 5.67 +/- 0.34/day for E-KO x HL-KO, 18.88 +/- 1.72/day for E-KO x HL-WT, and 9.01 +/- 0.14/day for E-KO x HL-S145G mice). In contrast, the catabolism of apoE-free, I-131-apoB-100 LDL was not increased by either HL-WT or HL-S145G. Infusion of the receptor-associated protein ( RAP), which blocks LDL receptor-related protein function, decreased plasma clearance and hepatic uptake of I-131-apoB-48 LDL induced by HL-S145G. Despite their similar effects on lowering proatherogenic apoB-containing lipoproteins, HL-WT enhanced atherosclerosis by up to 50%, whereas HL-S145G markedly reduced aortic atherosclerosis by up to 96% (p < 0.02) in both male and female E-KO x HL-KO mice. These data identify a major receptor pathway ( LDL receptor-related protein) by which the ligand-binding function of HL alters remnant lipoprotein uptake in vivo and delineate the separate contributions of the lipolytic versus ligand-binding function of HL to plasma lipoprotein size and metabolism, identifying an anti-atherogenic role of the ligand-binding function of HL in vivo.	NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Inst Pasteur, F-59019 Lille, France	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Jackson Laboratory; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Santamarina-Fojo, S (corresponding author), NHLBI, Mol Dis Branch, NIH, Bldg 10,Rm 7N115,10 Ctr Dr,MSC 1666, Bethesda, MD 20892 USA.	silvia@mdb.nhlbi.nih.gov	Amar, Marcelo/AAD-5599-2019	Gonzalez-Navarro, Herminia/0000-0001-6883-3808	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002058, Z01HL002064, Z01HL002058] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amar MJA, 1998, J LIPID RES, V39, P2436; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; Barbagallo CM, 1999, ARTERIOSCL THROM VAS, V19, P625, DOI 10.1161/01.ATV.19.3.625; Beisiegel U, 1996, ATHEROSCLEROSIS, V124, P1, DOI 10.1016/0021-9150(95)05792-7; Bergeron N, 1998, P NATL ACAD SCI USA, V95, P15647, DOI 10.1073/pnas.95.26.15647; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CAMPOS H, 1995, J LIPID RES, V36, P462; CHENG CF, 1985, J BIOL CHEM, V260, P720; CHOI SSY, 1994, J LIPID RES, V35, P848; CISAR LA, 1985, J LIPID RES, V26, P380; Cohen JC, 1999, CURR OPIN LIPIDOL, V10, P259, DOI 10.1097/00041433-199906000-00008; Connelly PW, 1998, CRIT REV CL LAB SCI, V35, P547, DOI 10.1080/10408369891234273; Connelly PW, 1999, CLIN CHIM ACTA, V286, P243, DOI 10.1016/S0009-8981(99)00105-9; Couture P, 2000, ARTERIOSCL THROM VAS, V20, P815, DOI 10.1161/01.ATV.20.3.815; Deeb SS, 2003, J LIPID RES, V44, P1279, DOI 10.1194/jlr.R200017-JLR200; deFaria E, 1996, J LIPID RES, V37, P197; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; Dichek HL, 2004, J LIPID RES, V45, P551, DOI 10.1194/jlr.M300459-JLR200; Dichek HL, 2001, J LIPID RES, V42, P201; Dichek HL, 1998, J BIOL CHEM, V273, P1896, DOI 10.1074/jbc.273.4.1896; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; Dugi KA, 2001, CIRCULATION, V104, P3057, DOI 10.1161/hc5001.100795; Dugi KA, 2000, ARTERIOSCL THROM VAS, V20, P793, DOI 10.1161/01.ATV.20.3.793; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; Flood C, 2004, ARTERIOSCL THROM VAS, V24, P564, DOI 10.1161/01.ATV.0000117174.19078.85; Gonzalez-Navarro H, 2002, J LIPID RES, V43, P671; Greif P, 1998, ADV EXP MED BIOL, V445, P3; HERZ J, 1995, P NATL ACAD SCI USA, V92, P4611, DOI 10.1073/pnas.92.10.4611; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; Jansen H, 2002, J LIPID RES, V43, P1352, DOI 10.1194/jlr.R200008-JLR200; JI ZS, 1994, J BIOL CHEM, V269, P13429; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; KATZEL LI, 1992, ARTERIOSCLER THROMB, V12, P814, DOI 10.1161/01.ATV.12.7.814; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; Krapp A, 1996, J LIPID RES, V37, P926; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; Lambert G, 1999, J LIPID RES, V40, P1294; MARCEL YL, 1988, ARTERIOSCLEROSIS, V8, P832, DOI 10.1161/01.ATV.8.6.832; MARQUESVIDAL P, 1994, J LIPID RES, V35, P373; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; Mezdour H, 1997, J BIOL CHEM, V272, P13570, DOI 10.1074/jbc.272.21.13570; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; Nong ZX, 2003, J CLIN INVEST, V112, P367, DOI 10.1172/JCI200316484; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; Perret B, 2002, J LIPID RES, V43, P1163, DOI 10.1194/jlr.R100020-JLR200; Qiu SQ, 1998, J LIPID RES, V39, P1661; Rizzo M, 2004, ARTERIOSCL THROM VAS, V24, P141, DOI 10.1161/01.ATV.0000107027.73816.ce; Sanan DA, 1997, J LIPID RES, V38, P1002; Santamarina-Fojo S, 1998, CURR OPIN LIPIDOL, V9, P211, DOI 10.1097/00041433-199806000-00005; SHAFI S, 1994, J LIPID RES, V35, P709; Shohet RV, 1999, ARTERIOSCL THROM VAS, V19, P1975, DOI 10.1161/01.ATV.19.8.1975; Thuren T, 2000, CURR OPIN LIPIDOL, V11, P277, DOI 10.1097/00041433-200006000-00008; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; Verges M, 2004, J BIOL CHEM, V279, P9030, DOI 10.1074/jbc.M312908200; Zambon A, 1999, CIRCULATION, V99, P1959, DOI 10.1161/01.CIR.99.15.1959; Zambon A, 2003, CURR OPIN LIPIDOL, V14, P179, DOI 10.1097/00041433-200304000-00010; Zambon A, 2000, J LIPID RES, V41, P2094; Zambon A, 2001, CIRCULATION, V103, P792, DOI 10.1161/01.CIR.103.6.792; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	63	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45312	45321		10.1074/jbc.M406495200	http://dx.doi.org/10.1074/jbc.M406495200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15304509	hybrid			2022-12-25	WOS:000224694900005
J	Jakopitsch, C; Ivancich, A; Schmuckenschlager, F; Wanasinghe, A; Poltl, G; Furtmuller, PG; Ruker, F; Obinger, C				Jakopitsch, C; Ivancich, A; Schmuckenschlager, F; Wanasinghe, A; Poltl, G; Furtmuller, PG; Ruker, F; Obinger, C			Influence of the unusual covalent adduct on the kinetics and formation of radical intermediates in Synechocystis catalase peroxidase - A stopped-flow and EPR characterization of the MET275, TYR249, and Arg(349) variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; DISTAL SIDE TRYPTOPHAN; COMPOUND I; BURKHOLDERIA-PSEUDOMALLEI; ESCHERICHIA-COLI; HEME IRON; KATG; SITE; TYROSINE; PURIFICATION	Catalase-peroxidases (KatGs) are heme peroxidases with a catalatic activity comparable to monofunctional catalases. They contain an unusual covalent distal side adduct with the side chains of Trp(122), Tyr(249), and Met(275) (Synechocysis KatG numbering). The known crystal structures suggest that Tyr(249) and Met(275) could be within hydrogen-bonding distance to Arg(439). To investigate the role of this peculiar adduct, the variants Y249F, M275I, R439A, and R439N were investigated by electronic absorption, steady-state and transient-state kinetic techniques and EPR spectroscopy combined with deuterium labeling. Exchange of these conserved residues exhibited dramatic consequences on the bifunctional activity of this peroxidase. The turnover numbers of catalase activity of M275I, Y249F, R439A, and R439N are 0.6, 0.17, 4.9, and 3.14% of wild-type activity, respectively. By contrast, the peroxidase activity was unaffected or even enhanced, in particular for the M275I variant. As shown by mass spectrometry and EPR spectra, the KatG typical adduct is intact in both Arg(439) variants, as is the case of the wild-type enzyme, whereas in the M275I variant the covalent link exists only between Tyr(249) and Trp(122). In the Y249F variant, the link is absent. EPR studies showed that the radical species formed upon reaction of the Y249F and R439A/N variants with peroxoacetic acid are the oxoferrylporphyrin radical, the tryptophanyl and the tyrosyl radicals, as in the wild-type enzyme. The dramatic loss in catalase activity of the Y249F variant allowed the comparison of the radical species formed with hydrogen peroxide and peroxoacetic acid. The EPR data strongly suggest that the sequence of intermediates formed in the absence of a one electron donor substrate, is por(.+) --> Trp(.) (or Trp(.+)) --> Tyr(.). The M275I variant did not form the Trp(.) species because of the dramatic changes on the heme distal side, most probably induced by the repositioning of the remaining Trp(122)-Tyr(249) adduct. The results are discussed with respect to the bifunctional activity of catalase-peroxidases.	BOKU Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem, A-1190 Vienna, Austria; BOKU Univ Nat Resources & Appl Life Sci, Dept Biotechnol, A-1190 Vienna, Austria; CEA Saclay, CNRS,URA 2096, Dept Biol Joliot Curie, Serv Bioenerget, F-91191 Gif Sur Yvette, France	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Obinger, C (corresponding author), BOKU Univ Nat Resources & Appl Life Sci, Dept Chem, Div Biochem, Muthgasse 18, A-1190 Vienna, Austria.	christian.obinger@boku.ac.at	Furtmüller, Paul G./Y-5819-2018; Obinger, Christian/AAV-3173-2021	Furtmüller, Paul G./0000-0002-1199-2469; Jakopitsch, Christa/0000-0002-5855-2057; Rueker, Florian/0000-0001-7639-2686; Ivancich, Anabella/0000-0002-4275-0980; Obinger, Christian/0000-0002-7133-3430				Blodig W, 1999, ARCH BIOCHEM BIOPHYS, V370, P86, DOI 10.1006/abbi.1999.1365; Carpena X, 2003, J MOL BIOL, V327, P475, DOI 10.1016/S0022-2836(03)00122-0; CHELIKANI P, 2003, CMLS CELL MOL LIFE S, V60, P1; Donald LJ, 2003, J BIOL CHEM, V278, P35687, DOI 10.1074/jbc.M304053200; Dunford H. B., 1999, HEME PEROXIDASES, P58; DUNFORD HB, 1999, HEME PEROXIDASES, P435; Fraaije MW, 1996, EUR J BIOCHEM, V235, P192, DOI 10.1111/j.1432-1033.1996.00192.x; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heering HA, 2002, BIOCHEMISTRY-US, V41, P9237, DOI 10.1021/bi025740u; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HO PS, 1983, J BIOL CHEM, V258, P4356; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 2003, J AM CHEM SOC, V125, P14093, DOI 10.1021/ja035582+; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Jakopitsch C, 2003, FEBS LETT, V552, P135, DOI 10.1016/S0014-5793(03)00901-3; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; Jakopitsch C, 2001, BIOCHEM BIOPH RES CO, V287, P682, DOI 10.1006/bbrc.2001.5616; Jakopitsch C, 2003, J BIOL CHEM, V278, P20185, DOI 10.1074/jbc.M211625200; LEVY E, 1992, ARCH BIOCHEM BIOPHYS, V296, P321, DOI 10.1016/0003-9861(92)90579-L; LOEWEN PC, 1997, OXIDATIVE STRESS MOL, P273; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Santoni E, 2004, BIOPOLYMERS, V74, P46, DOI 10.1002/bip.20041; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Switala J, 2002, ARCH BIOCHEM BIOPHYS, V401, P145, DOI 10.1016/S0003-9861(02)00049-8; Un S, 2001, APPL MAGN RESON, V21, P341, DOI 10.1007/BF03162413; Wariishi H, 2000, J BIOL CHEM, V275, P32919, DOI 10.1074/jbc.M004223200; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; Wengenack NL, 2000, BIOCHEMISTRY-US, V39, P11508, DOI 10.1021/bi001239v; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; YAMAGUCHI K, 1993, J AM CHEM SOC, V115, P4058, DOI 10.1021/ja00063a026; Yu SW, 2003, J BIOL CHEM, V278, P44121, DOI 10.1074/jbc.M304757200; Zhao XB, 2004, J BIOL CHEM, V279, P7606, DOI 10.1074/jbc.M311884200	32	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46082	46095		10.1074/jbc.M408399200	http://dx.doi.org/10.1074/jbc.M408399200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326163	hybrid			2022-12-25	WOS:000224694900094
J	Jeong, JS; Rouault, TA; Levine, RL				Jeong, JS; Rouault, TA; Levine, RL			Identification of a heme-sensing domain in iron regulatory protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; OXIDIZED PROTEINS; MICROSOMAL CYTOCHROME-P-450; OXIDATIVE MODIFICATION; DEPENDENT DEGRADATION; HIF-ALPHA; PROTEASOME; BINDING; IRP2; METABOLISM	Iron regulatory protein 2 coordinates the cellular regulation of iron metabolism by binding to iron-responsive elements in mRNA. The protein is synthesized constitutively but is rapidly degraded when iron stores are replete. The mechanisms that prevent degradation during iron deficiency or promote degradation during iron sufficiency are not delineated. Iron regulatory protein 2 contains a domain not present in the closely related iron regulatory protein 1, and we found that this domain binds heme with high affinity. A cysteine within the domain is axially liganded to the heme, as occurs in cytochrome P450. The protein-bound heme reacts with molecular oxygen to mediate the oxidation of cysteine, including beta-elimination of the sulfur to yield alanine. This covalent modification may thus mark the protein molecule for degradation by the proteasome system, providing another mechanism by which heme can regulate the level of iron regulatory protein 2.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levine, RL (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 50,Rm 2351, Bethesda, MD 20892 USA.	rlevine@nih.gov	Levine, Rodney L/D-9885-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000225, ZIAHL000225] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bourdon E, 2003, BLOOD CELL MOL DIS, V31, P247, DOI 10.1016/S1079-9796(03)00161-X; CHANG CK, 1976, P NATL ACAD SCI USA, V73, P3338, DOI 10.1073/pnas.73.10.3338; COLLMAN JP, 1976, P NATL ACAD SCI USA, V73, P6, DOI 10.1073/pnas.73.1.6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DRABKIN DL, 1951, PHYSIOL REV, V31, P345, DOI 10.1152/physrev.1951.31.4.345; GARDNER LC, 1991, J BIOL CHEM, V266, P22010; Goessling LS, 1998, J BIOL CHEM, V273, P12555, DOI 10.1074/jbc.273.20.12555; Gouterman M., 1978, PORPHYRINS, P1, DOI DOI 10.1016/B978-0-12-220103-5.50008-8; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X; GUENGERICH FP, 1977, J BIOL CHEM, V252, P3970; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hanson ES, 2003, J BIOL CHEM, V278, P40337, DOI 10.1074/jbc.M302798200; HANSON LK, 1976, J AM CHEM SOC, V98, P2672, DOI 10.1021/ja00425a050; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; INADA Y, 1962, BIOCHEM BIOPH RES CO, V9, P323, DOI 10.1016/0006-291X(62)90048-7; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kang DK, 2003, J BIOL CHEM, V278, P14857, DOI 10.1074/jbc.M300616200; Kim S, 2004, MOL CELL BIOL, V24, P330, DOI 10.1128/MCB.24.1.330-337.2004; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; MANSUY D, 1974, H-S Z PHYSIOL CHEM, V355, P1341, DOI 10.1515/bchm2.1974.355.2.1341; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; RIVETT AJ, 1986, CURR TOP CELL REGUL, V28, P291; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; RIVETT AJ, 1985, ARCH BIOCHEM BIOPHYS, V243, P624, DOI 10.1016/0003-9861(85)90540-5; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; RUF HH, 1977, J AM CHEM SOC, V99, P5499, DOI 10.1021/ja00458a054; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; SLIGAR SG, 1974, BIOCHEM BIOPH RES CO, V61, P290, DOI 10.1016/0006-291X(74)90565-8; SONO M, 1982, J BIOL CHEM, V257, P8308; SONO M, 1984, J BIOL CHEM, V259, P13209; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Wang J, 2004, MOL CELL BIOL, V24, P954, DOI 10.1128/MCB.24.3.954-965.2004; WIJERS HE, 1969, RECL TRAV CHIM PAY-B, V88, P519; WILLIAMS VP, 1978, J BIOL CHEM, V253, P202; Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	46	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45450	45454		10.1074/jbc.M407562200	http://dx.doi.org/10.1074/jbc.M407562200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15316013	hybrid			2022-12-25	WOS:000224694900021
J	Ji, H; Zhang, YH; Zheng, W; Wu, Z; Lee, SH; Sandberg, K				Ji, H; Zhang, YH; Zheng, W; Wu, Z; Lee, SH; Sandberg, K			Translational regulation of angiotensin type 1a receptor expression and signaling by upstream AUGs in the 5 ' leader sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; OPEN READING FRAMES; AT(1) RECEPTOR; MESSENGER-RNA; INITIATION; IDENTIFICATION; ANTAGONISTS; MUTATION; BINDING; REGION	Rat angiotensin type 1a receptor (AT(1a)R) is regulated by four upstream AUGs present in the 5' leader sequence (5'-LS). Disruption of all four upstream AUGs (QM) results in 2-3- fold higher levels of angiotensin type 1 receptor (AT(1)R) densities in transiently transfected rat aortic smooth muscle cells (A10 cells) and stably transfected Chinese hamster ovary cells. Cells expressing QM have 5-fold higher levels of angiotensin II-induced inositol phosphate production than wild type (WT). Polysome analysis showed that QM mRNA is present in heavier fractions than the WT transcript, and 5.7-fold more AT(1)R protein is produced by in vitro translation from QM transcripts compared with WT transcripts. The AT(1a)R comprises 3 exons. Exon 3 (E3) encodes the entire open reading frame and 3'-untranslated region. Exons 1 and 2 (E1 and E2) and 52 nucleotides of E3 encode the 5'-LS. The AUGs in both exons contribute to the inhibitory effect on AT1R expression but not to the same degree. Disruption of the AUGs in exon 2 (DM2) relieves half of the inhibition, whereas disruption of the AUGs in exon 1 (DM1) is without effect. Disruption of the AUGs in exon 2 results in levels of receptor expression and translation that are indistinguishable from the alternative splice variant E1,3, which we previously showed was more efficiently translated than the E1,2,3 transcript. Individual mutations revealed that only the fourth AUG increased AT(1)R translation. In conclusion, all four AUGs present in the 5'-LS function cumulatively to suppress AT(1a)R expression and signaling by inhibiting translation. These data also show that both AUGs in E2 contribute to the inhibitory cis element present in this alternatively spliced exon.	Georgetown Univ, Ctr Study Sex Differences Hlth Aging & Dis, Washington, DC 20057 USA; Georgetown Univ, Dept Physiol & Biophys, Washington, DC 20057 USA; Georgetown Univ, Dept Med, Washington, DC 20057 USA	Georgetown University; Georgetown University; Georgetown University	Ji, H (corresponding author), Rm 235B,Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20057 USA.	jih@georgetown.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; Davies E, 1995, METHOD CELL BIOL, V50, P209, DOI 10.1016/S0091-679X(08)61032-8; JI H, 1994, J BIOL CHEM, V269, P16533; Ji H, 2001, METH MOLEC MED, V51, P171, DOI 10.1385/1-59259-087-X:171; KOZAK M, 1991, GENE EXPRESSION, V1, P111; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; Liu L, 1999, NAT GENET, V21, P128, DOI 10.1038/5082; Martin MM, 2003, MOL CELL ENDOCRINOL, V212, P51, DOI 10.1016/j.mce.2003.09.017; Martin MM, 2001, MOL CELL ENDOCRINOL, V183, P81, DOI 10.1016/S0303-7207(01)00595-0; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Sandberg K, 2000, SEMIN NEPHROL, V20, P402; Thekkumkara TJ, 1998, BIOCHEM J, V329, P255; Thomas WG, 1999, REGUL PEPTIDES, V79, P9, DOI 10.1016/S0167-0115(98)00140-2; Tian Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE831, DOI 10.1152/ajpendo.1996.270.5.E831; Vanderheyden PML, 1999, BRIT J PHARMACOL, V126, P1057, DOI 10.1038/sj.bjp.0702398; Wiestner A, 1998, NAT GENET, V18, P49, DOI 10.1038/ng0198-49; Wu Z, 2003, ENDOCRINOLOGY, V144, P3251, DOI 10.1210/en.2003-0015; Xu KM, 2000, J BIOL CHEM, V275, P7604, DOI 10.1074/jbc.275.11.7604; Zhang YH, 2004, GENE, V341, P93, DOI 10.1016/j.gene.2004.07.017	22	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45322	45328		10.1074/jbc.M407261200	http://dx.doi.org/10.1074/jbc.M407261200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319432	hybrid			2022-12-25	WOS:000224694900006
J	Li, Y; Langlais, P; Gamper, N; Liu, F; Shapiro, MS				Li, Y; Langlais, P; Gamper, N; Liu, F; Shapiro, MS			Dual phosphorylations underlie modulation of unitary KCNQ K+ channels by Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KCNQ2/KCNQ3 POTASSIUM CHANNELS; CYSTEINE-MODIFYING REAGENT; L CALCIUM-CHANNELS; MUSCARINIC MODULATION; SYMPATHETIC NEURONS; M-CURRENTS; G-PROTEIN; RECEPTOR; SUBUNIT; DOMAIN	Src tyrosine kinase suppresses KCNQ (M-type) K+ channels in a subunit-specific manner representing a mode of modulation distinct from that involving G protein-coupled receptors. We probed the molecular and biophysical mechanisms of this modulation using mutagenesis, biochemistry, and both whole-cell and single channel modes of patch clamp recording. Immunoprecipitation assays showed that Src associates with KCNQ2-5 subunits but phosphorylates only KCNQ3-5. Using KCNQ3 as a background, we found that mutation of a tyrosine in the amino terminus (Tyr-67) or one in the carboxyl terminus (Tyr-349) abolished Src-dependent modulation of heterologously expressed KCNQ2/3 heteromultimers. The tyrosine phosphorylation was much weaker for either the KCNQ3-Y67F or KCNQ3-Y349F mutants and wholly absent in the KCNQ3-Y67F/Y349F double mutant. Biotinylation assays showed that Src activity does not alter the membrane abundance of channels in the plasma membrane. In recordings from cell-attached patches containing a single KCNQ2/3 channel, we found that Src inhibits the open probability of the channels. Kinetic analysis was consistent with the channels having two discrete open times and three closed times. Src activity reduced the durations of the longest open time and lengthened the longest closed time of the channels. The implications for the mechanisms of channel regulation by the dual phosphorylations on both channel termini are discussed.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Shapiro, MS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	shapirom@uthscsa.edu		Gamper, Nikita/0000-0001-5806-0207	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043394] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52933] Funding Source: Medline; NINDS NIH HHS [R01 NS43394] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Blair LAC, 1997, NEURON, V19, P421, DOI 10.1016/S0896-6273(00)80950-2; CONSTANTI A, 1981, NEUROSCI LETT, V24, P289, DOI 10.1016/0304-3940(81)90173-7; Cook KK, 2002, J BIOL CHEM, V277, P13268, DOI 10.1074/jbc.M108898200; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Gamper N, 2003, J GEN PHYSIOL, V122, P17, DOI 10.1085/jgp.200208783; Gamper N, 2003, J NEUROSCI, V23, P84; Gutman GA, 2003, PHARMACOL REV, V55, P583, DOI 10.1124/pr.55.4.9; Hadley JK, 2000, BRIT J PHARMACOL, V129, P413, DOI 10.1038/sj.bjp.0703086; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Hoshi N, 2003, NAT NEUROSCI, V6, P564, DOI 10.1038/nn1062; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Li Y, 2004, J NEUROSCI, V24, P5079, DOI 10.1523/JNEUROSCI.0882-04.2004; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Maljevic S, 2003, J PHYSIOL-LONDON, V548, P353, DOI 10.1113/jphysiol.2003.040980; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Mayer BJ, 2001, J CELL SCI, V114, P1253; Miller WE, 2000, J BIOL CHEM, V275, P11312, DOI 10.1074/jbc.275.15.11312; Nitabach MN, 2002, J NEUROSCI, V22, P7913; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Prole DL, 2003, J GEN PHYSIOL, V122, P775, DOI 10.1085/jgp.200308897; Roche JP, 2002, BRIT J PHARMACOL, V137, P1173, DOI 10.1038/sj.bjp.0704989; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; Selyanko AA, 2001, J PHYSIOL-LONDON, V534, P15, DOI 10.1111/j.1469-7793.2001.00015.x; Selyanko AA, 1996, NEURON, V16, P151, DOI 10.1016/S0896-6273(00)80032-X; Shah MM, 2002, J PHYSIOL-LONDON, V544, P29, DOI 10.1113/jphysiol.2002.028571; Shapiro MS, 2000, J NEUROSCI, V20, P1710; Suh BC, 2004, J GEN PHYSIOL, V123, P663, DOI 10.1085/jgp.200409029; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Tatulian L, 2003, J PHYSIOL-LONDON, V549, P57, DOI 10.1113/jphysiol.2003.039842; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Wen H, 2002, J NEUROSCI, V22, P7991, DOI 10.1523/jneurosci.22-18-07991.2002; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	43	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45399	45407		10.1074/jbc.M408410200	http://dx.doi.org/10.1074/jbc.M408410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15304482	hybrid			2022-12-25	WOS:000224694900015
J	Moers, A; Wettschureck, N; Gruner, S; Nieswandt, B; Offermanns, S				Moers, A; Wettschureck, N; Gruner, S; Nieswandt, B; Offermanns, S			Unresponsiveness of platelets lacking both G alpha q and G alpha 13 - Implications for collagen-induced platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAPE CHANGE; SIGNALING PATHWAYS; THROMBUS FORMATION; COUPLED RECEPTORS; G-PROTEINS; RHO; AGGREGATION; INTEGRIN; KINASE; PHOSPHORYLATION	The diffusible platelet stimuli ADP and thromboxane A(2) activate multiple G protein-mediated signaling pathways and function as important secondary mediators of platelet activation as they are released from activated platelets. Because they can also increase their own formation and release, their effects are amplified; eventually, all major G protein-mediated signaling pathways are activated. The multiple positive feedback mechanisms operating during platelet activation have obscured the exact analysis of the roles individual G protein-mediated signaling pathways play during the platelet activation process. In this report, we show that platelets lacking G(q) and G(13) are completely unresponsive to diffusible stimuli such as ADP, thromboxane A(2), or thrombin, even when applied at very high concentrations in combination, whereas all stimuli are able to induce platelet aggregation, shape change, and RhoA activation in platelets lacking only one Galpha subunit. This shows that G(q) or G(13) is required to induce some platelet activation, whereas the activation of G(i)-mediated signaling alone is not sufficient to induce activation of mouse platelets. In addition, platelets lacking Galpha(q) and Galpha(13) adhered normally to collagen under high shear but did not aggregate any more in response to collagen, indicating that collagen-induced platelet activation but not platelet adhesion requires intact G protein-mediated signaling pathways.	Univ Heidelberg, Inst Pharmakol, D-69120 Heidelberg, Germany; Rudolf Virchow Zentrum Expt Biomed, D-97078 Wurzburg, Germany	Ruprecht Karls University Heidelberg; University of Wurzburg	Offermanns, S (corresponding author), Univ Heidelberg, Inst Pharmakol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	stefan.offermanns@urz.uni-heidelberg.de	Wettschureck, Nina/L-3651-2017; Offermanns, Stefan/L-3313-2017	Wettschureck, Nina/0000-0001-6858-1460; Offermanns, Stefan/0000-0001-8676-6805				ABRAMS CS, 2001, HEMOSTASIS THROMBOSI, P541; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bergmeier W, 2002, CYTOMETRY, V48, P80, DOI 10.1002/cyto.10114; Cho MJ, 2003, BLOOD, V101, P2646, DOI 10.1182/blood-2002-05-1363; Coughlin Sr, 2002, COLD SPRING HARB SYM, V67, P197, DOI 10.1101/sqb.2002.67.197; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; Gachet C, 2001, THROMB HAEMOSTASIS, V86, P222; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Jackson SP, 2003, J THROMB HAEMOST, V1, P1602, DOI 10.1046/j.1538-7836.2003.00267.x; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Kunapuli SP, 2003, CURR OPIN PHARMACOL, V3, P175, DOI 10.1016/S1471-4892(03)00007-9; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nieswandt B, 2003, BLOOD, V102, P449, DOI 10.1182/blood-2002-12-3882; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; WOULFE D, 2002, PLATELETS, P197; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; Yang J, 2002, J BIOL CHEM, V277, P46035, DOI 10.1074/jbc.M208519200	32	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45354	45359		10.1074/jbc.M408962200	http://dx.doi.org/10.1074/jbc.M408962200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326177	hybrid			2022-12-25	WOS:000224694900010
J	Neeli, I; Liu, ZM; Dronadula, N; Ma, ZA; Rao, GN				Neeli, I; Liu, ZM; Dronadula, N; Ma, ZA; Rao, GN			An essential role of the Jak-2/STAT-3/cytosolic phospholipase A(2) axis in platelet-derived growth factor BB-induced vascular smooth muscle cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ARACHIDONIC-ACID; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; PHOSPHORYLATION; INHIBITION; METABOLITES; MIGRATION; GENE	Platelet-derived growth factor-BB (PDGF-BB) is a potent motogen for vascular smooth muscle cells (VSMCs). To understand its motogenic signaling events, we have studied the role of the Janus-activated kinase/signal transducers and activators of transcription (Jak/STAT) pathway and cytosolic phospholipase A(2) (cPLA(2)). PDGF-BB stimulated tyrosine phosphorylation of Jak-2 and STAT-3 in a time-dependent manner in VSMCs. In addition, AG490 and Jak-2KEpRK5, a selective pharmacological inhibitor and a dominant negative mutant, respectively, of Jak-2, attenuated PDGF-BB-induced STAT-3 tyrosine phosphorylation and its DNA binding and reporter gene activities. PDGF-BB induced VSMC motility in a dose-dependent manner with a maximum effect at 10 ng/ml. Dominant negative mutant-dependent suppression of Jak-2 and STAT-3 blocked PDGF-BB-induced VSMC motility. PDGF-BB induced the expression of cPLA(2) in a Jak-2/STAT-3-dependent manner, and pharmacological inhibitors of cPLA(2) prevented PDGF-BB-induced VSMC motility. Furthermore, either exogenous addition of arachidonic acid or forced expression of cPLA(2) rescued PDGF-BB-induced VSMC motility from inhibition by blockade of Jak-2 and STAT-3 activation. Together, these results for the first time show that PDGF-BB-induced VSMC motility requires activation of the Jak-2/STAT-3/cPLA(2) signaling axis.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Mt Sinai Sch Med, Div Expt Diabet & Aging, New York, NY 10029 USA	University of Tennessee System; University of Tennessee Health Science Center; Icahn School of Medicine at Mount Sinai	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physiol.utmem.edu			NHLBI NIH HHS [HL2RO1064165-06] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Berk BC, 2001, PHYSIOL REV, V81, P999, DOI 10.1152/physrev.2001.81.3.999; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; Duan C, 2000, CIRC RES, V86, P15, DOI 10.1161/01.RES.86.1.15; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Maddox JF, 1998, FASEB J, V12, P487, DOI 10.1096/fasebj.12.6.487; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Mezentsev A, 2002, J BIOL CHEM, V277, P18670, DOI 10.1074/jbc.M201143200; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Stockton RA, 2001, MOL BIOL CELL, V12, P1937, DOI 10.1091/mbc.12.7.1937; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; TAY A, 1994, BBA-GENE STRUCT EXPR, V1217, P345, DOI 10.1016/0167-4781(94)90299-2; TSAI MH, 1991, MOL CELL BIOL, V11, P2785, DOI 10.1128/MCB.11.5.2785; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; WU T, 1994, NUCLEIC ACIDS RES, V22, P5093, DOI 10.1093/nar/22.23.5093; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Yahata Y, 2003, J BIOL CHEM, V278, P40026, DOI 10.1074/jbc.M301866200; Yellaturu CR, 2003, J BIOL CHEM, V278, P9986, DOI 10.1074/jbc.M211276200; Zhuang DM, 2004, AM J PHYSIOL-HEART C, V286, pH2103, DOI 10.1152/ajpheart.01118.2003	60	45	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46122	46128		10.1074/jbc.M406922200	http://dx.doi.org/10.1074/jbc.M406922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322111	hybrid			2022-12-25	WOS:000224694900098
J	Zhang, J; Das, SC; Kotalik, C; Pattnaik, AK; Zhang, LW				Zhang, J; Das, SC; Kotalik, C; Pattnaik, AK; Zhang, LW			The latent membrane protein 1 of Epstein-Barr virus establishes an antiviral state via induction of interferon-stimulated genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CATALYTIC SUBUNIT; BURKITT-LYMPHOMA CELLS; HERPES-SIMPLEX-VIRUS; MEMBRANE-PROTEIN LMP1; REGULATORY FACTOR-7; HUMAN CYTOMEGALOVIRUS; RAJI CELLS; EBV SUPERINFECTION; ACCESSORY SUBUNIT; NORMAL-BUTYRATE	Epstein-Barr virus (EBV) infection is associated with several human cancers. Latent membrane protein 1 (LMP-1) is one of the key viral proteins required for transformation of primary B cells in vitro and establishment of EBV latency. In this report, we show that LMP-1 is able to induce the expression of several interferon (IFN)-stimulated genes (ISGs) with antiviral properties such as 2'-5' oligoadenylate synthetase (OAS), stimulated trans-acting factor of 50 kDa (STAF-50), and ISG-15. LMP-1 inhibits vesicular stomatitis virus (VSV) replication at low multiplicity of infection (0.1 pfu/cell). The antiviral effect of LMP-1 is associated with the ability of LMP-1 to induce ISGs; an LMP-1 mutant that cannot induce ISGs fails to induce an antiviral state. High levels of ISGs are expressed in EBV latency cells in which LMP-1 is expressed. EBV latency cells have antiviral activity that inhibits replication of superinfecting VSV. The antiviral activity of LMP-1 is apparently not related to IFN production in our experimental systems. In addition, EBV latency is responsive to viral superinfection: LMP-1 is induced and EBV latency is disrupted by EBV lytic replication during VSV superinfection of EBV latency cells. These data suggest that LMP-1 has antiviral effect, which may be an intrinsic part of EBV latency program to assist the establishment and/or maintenance of EBV latency.	Univ Nebraska, Nebraska Ctr Virol, Beadle Ctr E141, Lincoln, NE 68588 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Zhang, LW (corresponding author), Univ Nebraska, Nebraska Ctr Virol, Beadle Ctr E141, 1901 Vine St, Lincoln, NE 68588 USA.	lzhang2@unlnotes.unl.edu	Pattnaik, Asit K./X-1531-2019	Pattnaik, Asit K./0000-0002-9581-6787	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034956, R01AI034956] Funding Source: NIH RePORTER; NCRR NIH HHS [RR15635] Funding Source: Medline; NIAID NIH HHS [AI34956] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Accola MA, 2002, J BIOL CHEM, V277, P21829, DOI 10.1074/jbc.M201641200; ADLDINGER HK, 1985, VIROLOGY, V141, P221, DOI 10.1016/0042-6822(85)90253-3; Adler B, 2002, P NATL ACAD SCI USA, V99, P437, DOI 10.1073/pnas.221439999; Ankel H, 1998, VIROLOGY, V251, P317, DOI 10.1006/viro.1998.9432; Arcenas RC, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-20; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BOOS H, 1987, VIROLOGY, V159, P161, DOI 10.1016/0042-6822(87)90360-6; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Browne EP, 2003, P NATL ACAD SCI USA, V100, P11439, DOI 10.1073/pnas.1534570100; Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; Carter KL, 2002, J VIROL, V76, P10427, DOI 10.1128/JVI.76.20.10427-10436.2002; Chang YJE, 2000, J VIROL, V74, P4174, DOI 10.1128/JVI.74.9.4174-4182.2000; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chee AV, 2004, J VIROL, V78, P4185, DOI 10.1128/JVI.78.8.4185-4196.2004; Chee AV, 2003, J VIROL, V77, P7101, DOI 10.1128/JVI.77.12.7101-7105.2003; CONTRERASSALAZAR B, 1990, J VIROL, V64, P5441, DOI 10.1128/JVI.64.11.5441-5447.1990; Cuomo L, 1998, J MED VIROL, V55, P219, DOI 10.1002/(SICI)1096-9071(199807)55:3<219::AID-JMV7>3.0.CO;2-4; CUOMO L, 1995, AIDS RES HUM RETROV, V11, P1241, DOI 10.1089/aid.1995.11.1241; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EVANS TJ, 1995, VIROLOGY, V206, P866, DOI 10.1006/viro.1995.1009; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; FLAMAND L, 1993, J VIROL, V67, P6768, DOI 10.1128/JVI.67.11.6768-6777.1993; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Fujii K, 2000, J VIROL, V74, P2550, DOI 10.1128/JVI.74.6.2550-2557.2000; Gershburg E, 2002, J VIROL, V76, P998, DOI 10.1128/JVI.76.3.998-1003.2002; Ghosh A, 2000, VIROLOGY, V266, P319, DOI 10.1006/viro.1999.0085; GHOSH D, 1990, J VIROL, V64, P1855, DOI 10.1128/JVI.64.4.1855-1858.1990; GIRES O, 1997, EMBO J, V16; IMPROTA T, 1992, J INTERFERON RES, V12, P87, DOI 10.1089/jir.1992.12.87; KANDA K, 1992, MOL CELL BIOL, V12, P4930, DOI 10.1128/MCB.12.11.4930; Kieff E, 1996, VIROLOGY, P2343; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Kunzi MS, 1996, J INTERF CYTOK RES, V16, P919, DOI 10.1089/jir.1996.16.919; Lam N, 2004, J VIROL, V78, P1657, DOI 10.1128/JVI.78.4.1657-1664.2004; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIN JC, 1985, J VIROL, V53, P793, DOI 10.1128/JVI.53.3.793-799.1985; LIN JC, 1987, J VIROL, V61, P1985, DOI 10.1128/JVI.61.6.1985-1991.1987; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MILLER WE, 1995, J VIROL, V69, P4390, DOI 10.1128/JVI.69.7.4390-4398.1995; Mossman KL, 2002, J VIROL, V76, P1995, DOI 10.1128/JVI.76.4.1995-1998.2002; Ning S, 2003, J VIROL, V77, P9359, DOI 10.1128/JVI.77.17.9359-9368.2003; Nonkwelo C, 1996, J VIROL, V70, P623, DOI 10.1128/JVI.70.1.623-627.1996; Prince S, 2003, J VIROL, V77, P5000, DOI 10.1128/JVI.77.8.5000-5007.2003; RAGONA G, 1980, VIROLOGY, V101, P553, DOI 10.1016/0042-6822(80)90473-0; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rickinson AB, 1996, VIROLOGY, P2397; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SATO H, 1988, J VIROL, V62, P3288, DOI 10.1128/JVI.62.9.3288-3294.1988; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Simmen KA, 2001, P NATL ACAD SCI USA, V98, P7140, DOI 10.1073/pnas.121177598; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; TSANG SF, 1991, J VIROL, V65, P6765, DOI 10.1128/JVI.65.12.6765-6771.1991; TSURUMI T, 1994, J VIROL, V68, P3354, DOI 10.1128/JVI.68.5.3354-3363.1994; TSURUMI T, 1993, J VIROL, V67, P4651, DOI 10.1128/JVI.67.8.4651-4658.1993; TSURUMI T, 1993, J VIROL, V67, P7648, DOI 10.1128/JVI.67.12.7648-7653.1993; VANHEUVEL M, 1988, J CELL BIOCHEM, V38, P269, DOI 10.1002/jcb.240380406; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; YAJIMA Y, 1978, P NATL ACAD SCI USA, V75, P2008, DOI 10.1073/pnas.75.4.2008; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; Zacny VL, 1999, J VIROL, V73, P7271, DOI 10.1128/JVI.73.9.7271-7277.1999; ZHANG L, 2000, J VIROL, V74, P5748; ZHANG L, 2004, IN PRESS J VIROL; Zhang LW, 2004, VIROLOGY, V323, P141, DOI 10.1016/j.virol.2004.03.007; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700; Zhang LW, 2001, J VIROL, V75, P12393, DOI 10.1128/JVI.75.24.12393-12401.2001; Zhang LW, 2001, J VIROL, V75, P341, DOI 10.1128/JVI.75.1.341-350.2001; Zhu FX, 2002, P NATL ACAD SCI USA, V99, P5573, DOI 10.1073/pnas.082420599; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	79	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46335	46342		10.1074/jbc.M403966200	http://dx.doi.org/10.1074/jbc.M403966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322136	hybrid, Green Published			2022-12-25	WOS:000224694900121
J	Ferrer, JL; Ravanel, S; Robert, M; Dumas, R				Ferrer, JL; Ravanel, S; Robert, M; Dumas, R			Crystal structures of cobalamin-independent methionine synthase complexed with zinc, homocysteine, and methyltetrahydrofolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; METHYLTRANSFERASE; EXPRESSION; TRANSMETHYLASE; IDENTIFICATION; SUBSTRATE; BINDING; METE; GENE	Cobalamin-independent methionine synthase (MetE) catalyzes the synthesis of methionine by a direct transfer of the methyl group of N-5-methyltetrahydrofolate (CH3-H(4)PteGlu(n)) to the sulfur atom of homocysteine (Hcy). We report here the first crystal structure of this metalloenzyme under different forms, free or complexed with the Hcy and folate substrates. The Arabidopsis thaliana MetE (AtMetE) crystals reveal a monomeric structure built by two (betaalpha)(8) barrels making a deep groove at their interface. The active site is located at the surface of the C-terminal domain, facing the large inter-domain cleft. Inside the active site, His(647), Cys(649), and Cys(733) are involved in zinc coordination, whereas Asp(605), Ile(437), and Ser(439) interact with Hcy. Opposite the zinc/Hcy binding site, a cationic loop (residues 507-529) belonging to the C-terminal domain anchors the first glutamyl residue of CH3-H(4)PteGlu(5). The pterin moiety of CH3-H(4)PteGlu(5) is stacked with Trp(567), enabling the N-5-methyl group to protrude in the direction of the zinc atom. These data suggest a structural role of the N-terminal domain of AtMetE in the stabilization of loop 507-529 and in the interaction with the poly-glutamate chain of CH3-H(4)PteGlu(n). Comparison of AtMetE structures reveals that the addition of Hcy does not lead to a direct coordination of the sulfur atom with zinc but to a reorganization of the zinc binding site with a stronger coordination to Cys(649), Cys(733), and a water molecule.	Inst Biol Struct JP Ebel, Lab Cristallogenese & Cristallog Prot, F-38027 Grenoble 1, France; CEA Grenoble, Physiol Cellulaire Vegetale Lab, F-38054 Grenoble 9, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Ferrer, JL (corresponding author), Inst Biol Struct JP Ebel, Lab Cristallogenese & Cristallog Prot, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	jean-luc.ferrer@ibs.fr; rdumas@cea.fr	Dumas, Renaud/E-1835-2011	Ravanel, Stephane/0000-0001-9475-4222				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Eckermann C, 2000, BIOL CHEM, V381, P695, DOI 10.1515/BC.2000.090; Evans JC, 2004, P NATL ACAD SCI USA, V101, P3729, DOI 10.1073/pnas.0308082100; Evans JC, 2002, STRUCTURE, V10, P1159, DOI 10.1016/S0969-2126(02)00796-7; Fu TF, 2003, J BIOL CHEM, V278, P2645, DOI 10.1074/jbc.M210649200; Gonzalez B, 2004, J MOL BIOL, V338, P771, DOI 10.1016/j.jmb.2004.03.005; GONZALEZ JC, 1992, BIOCHEMISTRY-US, V31, P6045, DOI 10.1021/bi00141a013; Incharoensakdi A, 2000, CURR MICROBIOL, V41, P227, DOI 10.1007/s002840010125; JONES TA, 1993, ACTA CRYSTALLOGR D, V49, P148; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kacprzak MM, 2003, BIOCHEM J, V376, P517, DOI 10.1042/BJ20030747; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Matthews RG, 1997, CURR OPIN CHEM BIOL, V1, P332, DOI 10.1016/S1367-5931(97)80070-1; Matthews RG, 2001, ACCOUNTS CHEM RES, V34, P681, DOI 10.1021/ar0000051; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; Peariso K, 2001, BIOCHEMISTRY-US, V40, P987, DOI 10.1021/bi001711c; Ranocha P, 2000, J BIOL CHEM, V275, P15962, DOI 10.1074/jbc.M001116200; Ravanel S, 2004, J BIOL CHEM, V279, P22548, DOI 10.1074/jbc.M313250200; Roth M, 2002, ACTA CRYSTALLOGR D, V58, P805, DOI 10.1107/S0907444902003943; Schroder I, 1999, EUR J BIOCHEM, V263, P789, DOI 10.1046/j.1432-1327.1999.00559.x; Sunden SLF, 1997, ARCH BIOCHEM BIOPHYS, V345, P171, DOI 10.1006/abbi.1997.0246; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WHITFIELD CD, 1970, J BIOL CHEM, V245, P390; WHITFIELD CD, 1970, J BIOL CHEM, V245, P402; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b	27	45	49	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44235	44238		10.1074/jbc.C400325200	http://dx.doi.org/10.1074/jbc.C400325200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15326182	Green Published, hybrid			2022-12-25	WOS:000224505600002
J	Horn, R; Paulsen, H				Horn, R; Paulsen, H			Early steps in the assembly of light-harvesting chlorophyll a/b complex - Time-resolved fluorescence measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; LESS BARLEY MUTANT; HIGHER-PLANTS; ARABIDOPSIS-THALIANA; BINDING PROTEIN; IN-VITRO; PIGMENT-BINDING; PHOTOSYSTEM-II; B-LESS; THYLAKOID MEMBRANES	The light-harvesting chlorophyll a/b complex (LHCIIb) spontaneously assembles from its pigment and protein components in detergent solution. The formation of functional LHCIIb can be detected in time-resolved experiments by monitoring the establishment of excitation energy transfer from protein-bound chlorophyll b to chlorophyll a. To detect the possible initial steps of chlorophyll binding that may not yet give rise to chlorophyll b-to-a energy transfer, we have monitored LHCIIb assembly by measuring excitation energy transfer from a fluorescent dye, covalently bound to the protein, to the chlorophylls. In order to exclude interference of the dye with protein folding or pigment binding, the experiments were repeated with the dye bound to four different positions in the protein. Initial chlorophyll binding occurs at roughly the same rate as the establishment of chlorophyll b-to-a energy transfer, in the range of 10 s. However, under limiting chlorophyll concentrations, the binding of chlorophyll a clearly precedes that of chlorophyll b. The complex containing the apoprotein, carotenoids, and chlorophyll a but no chlorophyll b is biochemically unstable and therefore cannot be isolated. However, chlorophyll a binding into this weak complex is specific, as it does not occur with a C-terminal deletion mutant of Lhcb1 which still contains most chlorophyll-ligating amino acids but is unable to fold and assemble into functional LHCIIb. As a scenario for LHCIIb assembly in the thylakoid, we propose the initial formation of a labile Lhcb1-chlorophyll a-carotenoid complex that then becomes stabilized by the binding (or formation in situ) of chlorophyll b.	Univ Mainz, Inst Allgemeine Bot, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Paulsen, H (corresponding author), Univ Mainz, Inst Allgemeine Bot, Mullerweg 6, D-55099 Mainz, Germany.	rhorn@mail.uni-mainz.de; paulsen@mail.uni-mainz.de	Paulsen, Harald/D-3742-2011					Adamska I, 2001, J BIOL CHEM, V276, P8582, DOI 10.1074/jbc.M010447200; Booth PJ, 1996, BIOCHEMISTRY-US, V35, P5103, DOI 10.1021/bi953053f; CAMMARATA KV, 1992, BIOCHEMISTRY-US, V31, P2779, DOI 10.1021/bi00125a019; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; Eggink L L, 2001, BMC Plant Biol, V1, P2, DOI 10.1186/1471-2229-1-2; Eggink Laura L., 2004, BMC Plant Biology, V4, P5, DOI 10.1186/1471-2229-4-5; Espineda CE, 1999, P NATL ACAD SCI USA, V96, P10507, DOI 10.1073/pnas.96.18.10507; HARRISON MA, 1993, PHOTOSYNTH RES, V38, P141, DOI 10.1007/BF00146413; Hobe S, 2000, EUR J BIOCHEM, V267, P616, DOI 10.1046/j.1432-1327.2000.01060.x; Hobe S, 2003, J BIOL CHEM, V278, P5912, DOI 10.1074/jbc.M211145200; HOBE S, 1994, EMBO J, V13, P3423, DOI 10.1002/j.1460-2075.1994.tb06647.x; Hoober JK, 1999, PHOTOSYNTH RES, V61, P197; Horn R, 2002, J MOL BIOL, V318, P547, DOI 10.1016/S0022-2836(02)00115-8; Jansson S, 2000, PLANT MOL BIOL, V42, P345, DOI 10.1023/A:1006365213954; KROL M, 1995, PLANT PHYSIOL, V107, P873, DOI 10.1104/pp.107.3.873; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUTTKAT A, 1995, PLANT PHYSIOL, V109, P1267, DOI 10.1104/pp.109.4.1267; Kuttkat A, 1997, J BIOL CHEM, V272, P20451, DOI 10.1074/jbc.272.33.20451; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Mick V, 2004, BIOCHEMISTRY-US, V43, P5467, DOI 10.1021/bi036198s; Nagata N, 2004, PLANTA, V218, P1019, DOI 10.1007/s00425-003-1181-6; Oster U, 2000, PLANT J, V21, P305, DOI 10.1046/j.1365-313x.2000.00672.x; PAULSEN H, 1992, EUR J BIOCHEM, V205, P71, DOI 10.1111/j.1432-1033.1992.tb16752.x; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Paulsen H, 1997, PHYSIOL PLANTARUM, V100, P760, DOI 10.1034/j.1399-3054.1997.1000403.x; Phillip D, 2002, J BIOL CHEM, V277, P25160, DOI 10.1074/jbc.M202002200; PLUMLEY FG, 1995, PLANT CELL, V7, P689, DOI 10.2307/3870172; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; PORRA RJ, 1994, EUR J BIOCHEM, V219, P671, DOI 10.1111/j.1432-1033.1994.tb19983.x; PREISS S, 1995, PLANT PHYSIOL, V107, P709, DOI 10.1104/pp.107.3.709; Reinsberg D, 2000, BIOCHEMISTRY-US, V39, P14305, DOI 10.1021/bi001365z; Reinsberg D, 2001, J MOL BIOL, V308, P59, DOI 10.1006/jmbi.2001.4573; Schmid VHR, 2001, FEBS LETT, V499, P27, DOI 10.1016/S0014-5793(01)02509-1; SCHMIDT GW, 1981, J CELL BIOL, V91, P468, DOI 10.1083/jcb.91.2.468; Schmidt K, 2003, BIOCHEMISTRY-US, V42, P7427, DOI 10.1021/bi034207r; Schunemann D, 2004, CURR GENET, V44, P295, DOI 10.1007/s00294-003-0450-z; SHIMADA Y, 1990, PLANT CELL PHYSIOL, V31, P639; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; Tanaka R, 2001, PLANT J, V26, P365, DOI 10.1046/j.1365-313X.2001.2641034.x; Xu H, 2001, P NATL ACAD SCI USA, V98, P14168, DOI 10.1073/pnas.251530298	41	40	43	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44400	44406		10.1074/jbc.M407188200	http://dx.doi.org/10.1074/jbc.M407188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304514	hybrid			2022-12-25	WOS:000224505600023
J	Jia, WY; El Zoeiby, A; Petruzziello, TN; Jayabalasingham, B; Seyedirashti, S; Bishop, RE				Jia, WY; El Zoeiby, A; Petruzziello, TN; Jayabalasingham, B; Seyedirashti, S; Bishop, RE			Lipid trafficking controls endotoxin acylation in outer membranes of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; VIRULENCE GENE-EXPRESSION; ACID-DEFICIENT MUTANT; SALMONELLA-TYPHIMURIUM; PHOSPHOLIPASE-A; EDTA TREATMENT; CLONING VECTORS; MOLECULAR-BASIS; ENZYME PAGP; PHOP-PHOQ	The biogenesis of biological membranes hinges on the coordinated trafficking of membrane lipids between distinct cellular compartments. The bacterial outer membrane enzyme PagP confers resistance to host immune defenses by transferring a palmitate chain from a phospholipid to the lipid A ( endotoxin) component of lipopolysaccharide. PagP is an eight-stranded antiparallel beta-barrel, preceded by an N-terminal amphipathic alpha-helix. The active site is localized inside the beta-barrel and is aligned with the lipopolysaccharide-containing outer leaflet, but the phospholipid substrates are normally restricted to the inner leaflet of the asymmetric outer membrane. We examined the possibility that PagP activity in vivo depends on the aberrant migration of phospholipids into the outer leaflet. We find that brief addition to Escherichia coli cultures of millimolar EDTA, which is reported to replace a fraction of lipopolysaccharide with phospholipids, rapidly induces palmitoylation of lipid A. Although expression of the E. coli pagP gene is induced during Mg2+ limitation by the phoPQ two-component signal transduction pathway, EDTA-induced lipid A palmitoylation occurs more rapidly than pagP induction and is independent of de novo protein synthesis. EDTA-induced lipid A palmitoylation requires functional MsbA, an essential ATP-binding cassette transporter needed for lipid transport to the outer membrane. A potential role for the PagP alpha-helix in phospholipid translocation to the outer leaflet was excluded by showing that alpha-helix deletions are active in vivo. Neither EDTA nor Mg2+-EDTA stimulate PagP activity in vitro. These findings suggest that PagP remains dormant in outer membranes until Mg2+ limitation promotes the migration of phospholipids into the outer leaflet.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Bishop, RE (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 6213 Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	russell.bishop@utoronto.ca						Achleitner G, 1999, EUR J BIOCHEM, V264, P545, DOI 10.1046/j.1432-1327.1999.00658.x; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahn VE, 2004, EMBO J, V23, P2931, DOI 10.1038/sj.emboj.7600320; Bader MW, 2003, MOL MICROBIOL, V50, P219, DOI 10.1046/j.1365-2958.2003.03675.x; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Bishop RE, 1998, J MOL BIOL, V280, P583, DOI 10.1006/jmbi.1998.1894; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Clements JM, 2002, ANTIMICROB AGENTS CH, V46, P1793, DOI 10.1128/AAC.46.6.1793-1799.2002; COUGHLIN RT, 1983, BIOCHEMISTRY-US, V22, P2002, DOI 10.1021/bi00277a041; CRONAN JE, 1969, VIROLOGY, V38, P241, DOI 10.1016/0042-6822(69)90365-1; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; Dekker N, 2000, MOL MICROBIOL, V35, P711, DOI 10.1046/j.1365-2958.2000.01775.x; Derzelle S, 2004, J BACTERIOL, V186, P1270, DOI 10.1128/JB.186.5.1270-1279.2004; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; Eguchi Y, 2004, J BACTERIOL, V186, P3006, DOI 10.1128/JB.186.10.3006-3014.2004; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4; Fukuoka S, 2001, BBA-BIOMEMBRANES, V1510, P185, DOI 10.1016/S0005-2736(00)00347-3; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GMEINER J, 1980, ARCH MICROBIOL, V124, P69, DOI 10.1007/BF00407030; GROISMAN EA, 1992, J BACTERIOL, V174, P486, DOI 10.1128/jb.174.2.486-491.1992; Groisman EA, 1998, BIOESSAYS, V20, P96, DOI 10.1002/(SICI)1521-1878(199801)20:1<96::AID-BIES13>3.0.CO;2-3; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hand NJ, 2000, METHOD ENZYMOL, V326, P11; HORREVOETS AJG, 1989, BIOCHEMISTRY-US, V28, P1139, DOI 10.1021/bi00429a031; Horstman AL, 2000, J BIOL CHEM, V275, P12489, DOI 10.1074/jbc.275.17.12489; Hu KH, 1996, GENETICS, V143, P1521; Huijbregts RPH, 2000, BBA-REV BIOMEMBRANES, V1469, P43, DOI 10.1016/S0304-4157(99)00014-3; Hwang PM, 2004, P NATL ACAD SCI USA, V101, P9618, DOI 10.1073/pnas.0402324101; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; JONES NC, 1977, J BIOL CHEM, V252, P7405; KAMIO Y, 1976, BIOCHEMISTRY-US, V15, P2561, DOI 10.1021/bi00657a012; Kawasaki K, 2004, J BIOL CHEM, V279, P20044, DOI 10.1074/jbc.M401275200; Kol MA, 2002, SEMIN CELL DEV BIOL, V13, P163, DOI 10.1016/S1084-9521(02)00044-7; Kol MA, 2003, J BIOL CHEM, V278, P24586, DOI 10.1074/jbc.M301875200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEIVE L, 1968, J BIOL CHEM, V243, P6384; LEIVE L, 1967, BIOCHEM BIOPH RES CO, V28, P229, DOI 10.1016/0006-291X(67)90434-2; LEIVE L, 1965, BIOCHEM BIOPH RES CO, V21, P290, DOI 10.1016/0006-291X(65)90191-9; LEIVE L, 1968, J BIOL CHEM, V243, P2373; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; NELSON DL, 1971, J BIOL CHEM, V246, P3042; Nickel W, 2002, J CELL SCI, V115, P3235; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Pilione MR, 2004, INFECT IMMUN, V72, P2837, DOI 10.1128/IAI.72.5.2837-2842.2004; POWELL BS, 1994, NUCLEIC ACIDS RES, V22, P5765, DOI 10.1093/nar/22.25.5765; Preston A, 2003, MOL MICROBIOL, V48, P725, DOI 10.1046/j.1365-2958.2003.03484.x; PUGSLEY AP, 1984, EMBO J, V3, P2393, DOI 10.1002/j.1460-2075.1984.tb02145.x; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Rebeil R, 2004, MOL MICROBIOL, V52, P1363, DOI 10.1111/j.1365-2958.2004.04059.x; Robey M, 2001, INFECT IMMUN, V69, P4276, DOI 10.1128/IAI.69.7.4276-4286.2001; ROSNER MR, 1979, J BIOL CHEM, V254, P5906; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHINDLER M, 1979, BIOCHEMISTRY-US, V18, P4425, DOI 10.1021/bi00587a024; Schulz GE, 2002, BBA-BIOMEMBRANES, V1565, P308, DOI 10.1016/S0005-2736(02)00577-1; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Silhavy T.J., 1984, EXPT GENE FUSIONS; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; Snijder HJ, 1999, NATURE, V401, P717, DOI 10.1038/44890; STRAIN SM, 1985, J BIOL CHEM, V260, P6089; Tanamoto K, 2000, J IMMUNOL, V164, P3149, DOI 10.4049/jimmunol.164.6.3149; TESH VL, 1986, J IMMUNOL, V137, P1329; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WEISS J, 1994, J BIOL CHEM, V269, P26331; Xu YF, 1999, BIOTECHNIQUES, V26, P639, DOI 10.2144/99264bm10; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	83	82	86	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44966	44975		10.1074/jbc.M404963200	http://dx.doi.org/10.1074/jbc.M404963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15319435	hybrid			2022-12-25	WOS:000224505600088
J	Sloan, EK; Stanley, KL; Anderson, RL				Sloan, EK; Stanley, KL; Anderson, RL			Caveolin-1 inhibits breast cancer growth and metastasis	ONCOGENE			English	Article						caveolin-1; breast cancer; invasion; metastasis; bone metastases	TUMOR-SUPPRESSOR GENE; ENDOPLASMIC-RETICULUM; PROSTATE-CANCER; NULL MICE; EXPRESSION; CHOLESTEROL; D7S522; REGION; 7Q31.1	Caveolin-1 was identified in a screen for genes involved in breast cancer progression. Caveolin-1 is the major protein component of caveolae, flask-shaped invaginations found in a number of different cell types. Using an orthotopic model of spontaneous breast cancer metastasis, caveolin-1 was found to be expressed in low and non-metastatic primary tumors, but at much lower levels in highly metastatic 4T1.2 and 4T1.13 tumors. Exogenous expression of caveolin-1 at moderate levels in 4T1.2 cells was sufficient to suppress primary tumor growth after inoculation of cells into the mammary gland. Expression of high levels of caveolin-1 also inhibited subsequent metastasis to distant organs. Cells expressing high levels of caveolin-1 showed reduced capacity to invade Matrigel, diminished response to laminin-1 stimulation and decreased metastasis to lung and bone. This study provides the first functional evidence that caveolin-1 regulates primary breast tumor growth and spontaneous metastasis of breast cancer.	Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Anderson, RL (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	robin.anderson@petermac.org	Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Anderson, Robin/S-1005-2017	Sloan, Erica/0000-0002-2355-1433; Anderson, Robin/0000-0002-6841-7422	NCI NIH HHS [R01 CA 90291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bender FC, 2000, CANCER RES, V60, P5870; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hayashi K, 2001, CANCER RES, V61, P2361; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Li LK, 2001, CANCER RES, V61, P4386; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Parker BS, 2004, CAN META BIO TREAT, V6, P1; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Razani B, 2001, J BIOL CHEM, V276, P38121; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Tester AM, 2002, CLIN EXP METASTAS, V19, P377, DOI 10.1023/A:1016381416463; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	35	131	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7893	7897		10.1038/sj.onc.1208062	http://dx.doi.org/10.1038/sj.onc.1208062			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334058				2022-12-25	WOS:000224331600015
J	Tomoda, K; Yoneda-Kato, N; Fukumoto, A; Yamanaka, S; Kato, Y				Tomoda, K; Yoneda-Kato, N; Fukumoto, A; Yamanaka, S; Kato, Y			Multiple functions of Jab1 are required for early embryonic development and growth potential in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-1 EXPRESSION; COP9 SIGNALOSOME; CELL-CYCLE; FISSION YEAST; COP9/SIGNALOSOME SUBUNITS; INHIBITOR P27(KIP1); INVERSE EXPRESSION; POOR-PROGNOSIS; LIGHT CONTROL; COMPLEX	Jab1 interacts with a variety of signaling molecules and regulates their stability in mammalian cells. As the fifth component of the COP9 signalosome (CSN) complex, Jab1 (CSN5) plays a central role in the deneddylation of the cullin subunit of the Skp1-Cullin- F box protein ubiquitin ligase complex. In addition, a CSN-independent function of Jab1 is suggested but is less well characterized. To elucidate the function of Jab1, we targeted the Jab1 locus by homologous recombination in mouse embryonic stem cells. Jab1-null embryos died soon after implantation. Jab1-/- embryonic cells, which lacked other CSN components, expressed higher levels of p27, p53, and cyclin E, resulting in impaired proliferation and accelerated apoptosis. Jab1 heterozygous mice were healthy and fertile but smaller than their wild-type littermates. Jab1-/- mouse embryonic fibroblast cells, in which the amount of Jab1-containing small subcomplex, but not that of CSN, was selectively reduced, proliferated poorly, showed an inefficient down-regulation of p27 during G(1), and was delayed in the progression from G(0) to S phase by 3 h compared with the wild-type cells. Most interestingly, in Jab1-/- mouse embryonic fibroblasts, the levels of cyclin E and deneddylated Cul1 were unchanged, and p53 was not induced. Thus, Jab1 controls cell cycle progression and cell survival by regulating multiple cell cycle signaling pathways.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Nara Med Univ, Dept Surg 1, Kashihara, Nara 634, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Nara 6300101, Japan	Nara Institute of Science & Technology; Nara Medical University; Nara Institute of Science & Technology	Kato, Y (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	jkata@bs.naist.jp						Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Bemis L, 2004, GENE DEV, V18, P739, DOI 10.1101/gad.1180104; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Doronkin S, 2002, DEVELOPMENT, V129, P5053; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Esteva FJ, 2003, CLIN CANCER RES, V9, P5652; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Fukumoto A, 2004, ONCOL REP, V11, P277; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Ito Y, 2003, ANTICANCER RES, V23, P4121; Ito Y, 2003, CANCER LETT, V196, P87, DOI 10.1016/S0304-3835(03)00129-0; Ivan D, 2004, MODERN PATHOL, V17, P811, DOI 10.1038/modpathol.3800123; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Kwok SF, 1998, PLANT CELL, V10, P1779, DOI 10.1105/tpc.10.11.1779; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Maytal-Kivity V, 2002, EMBO REP, V3, P1215, DOI 10.1093/embo-reports/kvf235; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nielsen O, 2003, CURR BIOL, V13, pR565, DOI 10.1016/S0960-9822(03)00475-5; Oron E, 2002, DEVELOPMENT, V129, P4399; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Seeger M, 2001, CURR BIOL, V11, pR643, DOI 10.1016/S0960-9822(01)00382-7; Serino G, 2003, ANNU REV PLANT BIOL, V54, P165, DOI 10.1146/annurev.arplant.54.031902.134847; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shintani S, 2003, ONCOLOGY-BASEL, V65, P355, DOI 10.1159/000074649; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smith P, 2002, DEV BIOL, V251, P333, DOI 10.1006/dbio.2002.0832; Sui L, 2001, CLIN CANCER RES, V7, P4130; Sun Y, 2002, J BIOL CHEM, V277, P45759, DOI 10.1074/jbc.M208709200; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsuchida R, 2002, JPN J CANCER RES, V93, P1000, DOI 10.1111/j.1349-7006.2002.tb02476.x; Uhle S, 2003, EMBO J, V22, P1302, DOI 10.1093/emboj/cdg127; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Wang XP, 2002, MOL BIOL CELL, V13, P646, DOI 10.1091/mbc.01-08-0427; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; Wee S, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-15; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003; Yang XM, 2002, CURR BIOL, V12, P667, DOI 10.1016/S0960-9822(02)00791-1; Zhou CS, 2003, MOL CELL, V11, P927, DOI 10.1016/S1097-2765(03)00136-9	67	131	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43013	43018		10.1074/jbc.M406559200	http://dx.doi.org/10.1074/jbc.M406559200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299027	hybrid			2022-12-25	WOS:000224226400083
J	Klose, RJ; Bird, AP				Klose, RJ; Bird, AP			MeCP2 behaves as an elongated monomer that does not stably associate with the Sin3a chromatin remodeling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG-BINDING-PROTEIN; DNA METHYLATION; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSOR; RETT-SYNDROME; METHYLTRANSFERASE; IDENTIFICATION; FAMILY; DOMAIN; MBD1	MeCP2 is a transcription factor that recognizes and binds symmetrically methylated CpG dinucleotides to repress transcription. MeCP2 can associate with the Sin3a/histone deacetylase corepressor complex and mediate repression in a histone deacetylase-dependent manner. In extracts from rodent tissues, cultured cells, and Xenopus laevis oocytes, we find that only a small amount of mammalian MeCP2 interacts with Sin3a and that this interaction is not stable. Purification of rat brain MeCP2 (53 kDa) indicates no associated proteins despite an apparent molecular mass by size exclusion chromatography of 400-500 kDa. Biophysical analysis demonstrated that the large apparent size was not because of homo-multimerization, as MeCP2 consistently behaves as a monomeric protein that has an elongated shape. Our findings indicate the MeCP2 is not an obligate component of the Sin3a corepressor complex and may therefore engage a more diverse range of cofactors for repressive function.	Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh	Bird, AP (corresponding author), Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Michael Swann Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk		Bird, Adrian/0000-0002-8600-0372				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; Feng Q, 2001, GENE DEV, V15, P827; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; George RA, 2002, PROTEIN ENG, V15, P871, DOI 10.1093/protein/15.11.871; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Jones P.L., 2001, METH MOL B, V181, P297, DOI 10.1385/1-59259-211-2:297; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klose R, 2003, SCIENCE, V302, P793, DOI 10.1126/science.1091762; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kolb SJ, 1998, J BIOL CHEM, V273, P31555, DOI 10.1074/jbc.273.47.31555; Kriaucionis S, 2003, HUM MOL GENET, V12, pR221, DOI 10.1093/hmg/ddg286; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Ryan J, 1999, J CELL SCI, V112, P2441; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SOBER HA, 1973, HDB BIOCH, pC10; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	36	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46490	46496		10.1074/jbc.M408284200	http://dx.doi.org/10.1074/jbc.M408284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322089	hybrid			2022-12-25	WOS:000224832400020
J	Merkley, N; Shaw, GS				Merkley, N; Shaw, GS			Solution structure of the flexible class II ubiquitin-conjugating enzyme Ubc1 provides insights for polyubiquitin chain assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; RESONANCE ASSIGNMENTS; C-13-LABELED PROTEINS; ANGSTROM RESOLUTION; BACKBONE DYNAMICS; SELF-ASSOCIATION; BINDING DOMAIN; YEAST UBC4	E2 conjugating enzymes form a thiol ester intermediate with ubiquitin, which is subsequently transferred to a substrate protein targeted for degradation. While all E2 proteins comprise a catalytic domain where the thiol ester is formed, several E2s ( class II) have C-terminal extensions proposed to control substrate recognition, dimerization, or polyubiquitin chain formation. Here we present the novel solution structure of the class II E2 conjugating enzyme Ubc1 from Saccharomyces cerevisiae. The structure shows the N-terminal catalytic domain adopts an alpha/beta fold typical of other E2 proteins. This domain is physically separated from its C-terminal domain by a 22-residue flexible tether. The C-terminal domain adopts a three-helix bundle that we have identified as an ubiquitin-associated domain (UBA). NMR chemical shift perturbation experiments show this UBA domain interacts in a regioselective manner with ubiquitin. This two-domain structure of Ubc1 was used to identify other UBA-containing class II E2 proteins, including human E2-25K, that likely have a similar architecture and to determine the role of the UBA domain in facilitating polyubiquitin chain formation.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Shaw, GS (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	gshaw1@uwo.ca	Shaw, Gary S./C-7656-2009	Shaw, Gary S./0000-0002-4685-9625				BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; Chim N, 2004, PROTEINS, V54, P784, DOI 10.1002/prot.10636; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gardner KH, 1998, ANNU REV BIOPH BIOM, V27, P357, DOI 10.1146/annurev.biophys.27.1.357; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; GOSINK MM, 1995, P NATL ACAD SCI USA, V92, P9117, DOI 10.1073/pnas.92.20.9117; Goto NK, 1999, J BIOMOL NMR, V13, P369, DOI 10.1023/A:1008393201236; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GWOZD CS, 1995, BIOCHEMISTRY-US, V34, P6296, DOI 10.1021/bi00019a006; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hamilton KS, 2000, J BIOMOL NMR, V18, P319, DOI 10.1023/A:1026773008237; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hodgins R, 1996, J BIOL CHEM, V271, P28766, DOI 10.1074/jbc.271.46.28766; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Leggett DS, 1997, BIOCHEM J, V327, P357; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; MARSDEN BJ, 1988, BIOCHEMISTRY-US, V27, P4198, DOI 10.1021/bi00411a043; McKenna S, 2003, BIOCHEMISTRY-US, V42, P7922, DOI 10.1021/bi034480t; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; Merkley N, 2003, J BIOMOL NMR, V26, P147, DOI 10.1023/A:1023571703783; Miura T, 2002, J BIOMOL NMR, V22, P89, DOI 10.1023/A:1013807519703; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; Mueller TD, 2004, J BIOL CHEM, V279, P11926, DOI 10.1074/jbc.M312865200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Passmore LA, 2004, BIOCHEM J, V379, P513, DOI 10.1042/BJ20040198; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PTAK C, 1994, J BIOL CHEM, V269, P26539; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Slupsky CM, 2001, J BIOL CHEM, V276, P5943, DOI 10.1074/jbc.M008716200; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Wu PY, 2003, EMBO J, V22, P5241, DOI 10.1093/emboj/cdg501; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X; Zwahlen C, 1998, J AM CHEM SOC, V120, P7617, DOI 10.1021/ja981205z	68	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47139	47147		10.1074/jbc.M409576200	http://dx.doi.org/10.1074/jbc.M409576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328341	hybrid			2022-12-25	WOS:000224832400101
J	Nagato, H; Matsuo, N; Sumiyoshi, H; Sakata-Takatani, K; Nasu, M; Yoshioka, H				Nagato, H; Matsuo, N; Sumiyoshi, H; Sakata-Takatani, K; Nasu, M; Yoshioka, H			The transcription factor CCAAT-binding factor CBF/NF-Y and two Repressors regulate the core promoter of the human Pro-alpha 3(V) collagen gene (COL5A3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ACTING ELEMENTS; V COLLAGEN; I COLLAGEN; CELLS SYNTHESIZE; DNA-BINDING; YEAST HAP2; MOUSE; EXPRESSION; CHAINS; PROTEINS	To elucidate the mechanisms underlining alpha3(V) collagen chain expression, we performed an initial analysis of the structure and function of the core promoter of the human COL5A3 gene. The core promoter, which lacks a typical TATA motif and has a high GC content, was defined within the -129 bp immediately upstream from the major transcription start site by transient transfection experiments. In this region, we identified four DNA-protein complexes, named A, B, C, and D, by a combination of DNase I footprinting and electrophoretic mobility shift assays. Electrophoretic mobility shift assays using mutant oligonucleotide revealed that the complexes A, B, C, and D bind to -122 to -117, the -101 to -96, the -83 to -78, and the -68 to -57 bp, respectively. The competition assays using consensus oligonucleotides and supershift assays with specific antibodies showed that complex A consists of CBF/NF-Y. In a chromatin immunoprecipitation assay, CBF/NF-Y protein directly bound to this region, in vivo. Functional analysis showed that CBF/NF-Y activated the gene, whereas the proteins of complexes B and C repressed its activity. Furthermore, overexpression of a mutant form of the CBF-B/NF-YA subunit, which forms CBF/NF-Y with CBF-A/NF-YB and CBF-C/NF-YC subunits, inhibited promoter activity.	Oita Univ, Fac Med, Dept Anat Biol & Med, Oita 8795593, Japan; Oita Univ, Fac Med, Dept Immunol & Allergy, Oita 8795593, Japan	Oita University; Oita University	Yoshioka, H (corresponding author), Oita Univ, Fac Med, Dept Anat Biol & Med, 1-1 Hasama Machi, Oita 8795593, Japan.	hidey@med.oita-u.ac.jp						ABEDIN MZ, 1982, BIOSCIENCE REP, V2, P493, DOI 10.1007/BF01115247; ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; BARSKY SH, 1982, AM J PATHOL, V108, P276; BROWM JC, 1995, INT ARCH ALLERGY IMM, V107, P484, DOI 10.1159/000237090; BROWN RA, 1978, BIOCHEM BIOPH RES CO, V71, P1167; BURGESON RE, 1976, P NATL ACAD SCI USA, V73, P2579, DOI 10.1073/pnas.73.8.2579; Chernousov MA, 2000, J BIOL CHEM, V275, P28208; Chernousov MA, 2001, J NEUROSCI, V21, P6125, DOI 10.1523/JNEUROSCI.21-16-06125.2001; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; Galera P, 1996, J BIOL CHEM, V271, P21331, DOI 10.1074/jbc.271.35.21331; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KIM CG, 1990, J BIOL CHEM, V265, P13362; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEE SB, 1995, BIOCHEM J, V310, P15, DOI 10.1042/bj3100015; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; Luchetti MM, 2003, J BIOL CHEM, V278, P1533, DOI 10.1074/jbc.M204392200; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Matsuo N, 2003, J BIOL CHEM, V278, P32763, DOI 10.1074/jbc.M305599200; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; NARAYANAN AS, 1983, COLLAGEN REL RES, V3, P323; OOSHIMA A, 1981, SCIENCE, V213, P666, DOI 10.1126/science.7256267; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; RAMIREZ F, 1990, FASEB J, V4, P16116; RHODES RK, 1981, COLLAGEN REL RES, V1, P337; Rippe RA, 1997, J BIOL CHEM, V272, P1753, DOI 10.1074/jbc.272.3.1753; RUTESHOUSER EC, 1989, J BIOL CHEM, V264, P13740; SAGE H, 1979, BIOCHEMISTRY-US, V18, P3815, DOI 10.1021/bi00584a027; Sakata-Takatani K, 2004, MATRIX BIOL, V23, P87, DOI 10.1016/j.matbio.2004.03.003; Seki K, 2003, J BIOL CHEM, V278, P41862, DOI 10.1074/jbc.M308336200; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; Terraz C, 2002, J BIOL CHEM, V277, P19019, DOI 10.1074/jbc.M200125200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; Wu YL, 1998, BBA-GENE STRUCT EXPR, V1397, P275, DOI 10.1016/S0167-4781(98)00016-5	57	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46373	46383		10.1074/jbc.M406069200	http://dx.doi.org/10.1074/jbc.M406069200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316020	hybrid			2022-12-25	WOS:000224832400006
J	Yu, ZY; Kone, BC				Yu, ZY; Kone, BC			Hypermethylation of the inducible nitric-oxide synthase gene promoter inhibits its transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RAT MESANGIAL CELLS; DNA-METHYLATION; MURINE MACROPHAGES; CPG METHYLATION; INOS GENE; EXPRESSION; BINDING; GLOMERULONEPHRITIS; INTERLEUKIN-1-BETA	Exuberant generation of nitric oxide (NO) by inducible nitric-oxide synthase (iNOS) can cause unintended injury to host cells during glomerulonephritis and other inflammatory diseases. Although much is known about the mechanisms of iNOS induction, few transcriptional repression mechanisms have been found. We explored the role of cytosine methylation in the regulation of iNOS transcription. Treatment of mesangial cells with DNA methylation inhibitors augmented cytokine induction of endogenous NO production and iNOS protein levels, as well as iNOS promoter activity. In a corresponding manner, in vitro methylation of the murine iNOS promoter was sufficient to silence its activity in mesangial cells. In contrast, antisense knockdown of DNA methyltransferase-3b expression and activity increased iNOS promoter activity and nitrite production. Bisulfite treatment and sequencing analysis of the iNOS promoter identified methylation of cytosines framing an enhancer element at -879/-871. In vitro methylation inhibited binding of NFkappaB p50 to this element, and deletion of the element resulted in relief of transcriptional repression. These results provide evidence for a unique molecular mechanism involved in transcriptional regulation of iNOS gene expression.	Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol Pharmacol & Physiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Nephrol Sect, Houston, TX 77030 USA; Brown Fdn Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System; UTMD Anderson Cancer Center	Kone, BC (corresponding author), Univ Texas, Sch Med, Dept Internal Med, 6431 Fannin,MSB 1-150, Houston, TX 77030 USA.	Bruce.C.Kone@uth.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM038529] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK50745] Funding Source: Medline; NIGMS NIH HHS [P50 GM38529] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1991, J BIOCHEM BIOPH METH, V22, P19, DOI 10.1016/0165-022X(91)90077-A; Beck KF, 1996, FEBS LETT, V394, P263, DOI 10.1016/0014-5793(96)00966-0; BEDNARIK DP, 1991, NEW BIOL, V3, P969; Deng WG, 2003, J IMMUNOL, V171, P6581, DOI 10.4049/jimmunol.171.12.6581; DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697; Eberhardt W, 1998, J IMMUNOL, V160, P4961; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Furusu A, 1998, KIDNEY INT, V53, P1760, DOI 10.1046/j.1523-1755.1998.00907.x; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; Geiman TM, 2002, J CELL BIOCHEM, V87, P117, DOI 10.1002/jcb.10286; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Gupta AK, 2002, AM J PHYSIOL-CELL PH, V283, pC1065, DOI 10.1152/ajpcell.00100.2002; Gupta AK, 1999, AM J PHYSIOL-RENAL, V276, pF599, DOI 10.1152/ajprenal.1999.276.4.F599; Hansen RS, 1999, P NATL ACAD SCI USA, V96, P14412, DOI 10.1073/pnas.96.25.14412; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Kone BC, 1997, AM J PHYSIOL-RENAL, V272, pF561, DOI 10.1152/ajprenal.1997.272.5.F561; Kuncewicz T, 2001, AM J PHYSIOL-RENAL, V281, pF326, DOI 10.1152/ajprenal.2001.281.2.F326; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; NARITA I, 1995, LAB INVEST, V72, P17; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Perrella MA, 1999, J BIOL CHEM, V274, P9045, DOI 10.1074/jbc.274.13.9045; PFEILSCHIFTER J, 1991, BIOCHEM BIOPH RES CO, V175, P372, DOI 10.1016/0006-291X(91)91574-V; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Saura M, 1996, BIOCHEM J, V313, P641, DOI 10.1042/bj3130641; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; Shi HD, 2003, CANCER RES, V63, P2164; SMITH GM, 1993, BIOCHEM BIOPH RES CO, V194, P215, DOI 10.1006/bbrc.1993.1806; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8; Yu ZY, 2004, J AM SOC NEPHROL, V15, P585, DOI 10.1097/01.ASN.0000114556.19556.F9; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588	31	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46954	46961		10.1074/jbc.M407192200	http://dx.doi.org/10.1074/jbc.M407192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15308624	hybrid			2022-12-25	WOS:000224832400079
J	Noda, M; Matoba, Y; Kumagai, T; Sugiyama, M				Noda, M; Matoba, Y; Kumagai, T; Sugiyama, M			Structural evidence that alanine racemase from a D-cycloserine-producing microorganism exhibits resistance to its own product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; SALMONELLA-TYPHIMURIUM; FACTOR REFINEMENT; SEQUENCE; PURIFICATION; MECHANISM; DNA; ENZYMES; CLONING; LIGASE	Alanine racemase (ALR), an enzyme that catalyzes the interconversion of Ala enantiomers, is essential for the synthesis of the bacterial cell wall. We have shown that it is harder to inhibit the catalytic activity of ALR from D-cycloserine (DCS)-producing Streptomyces lavendulae than that from Escherichia coli by DCS. To obtain structural evidence for the fact that Streptomyces ALR displays resistance to DCS, we determined the precise nature of the x-ray crystal structures of the cycloserine-free and cycloserine enantiomer-bound forms of Streptomyces ALR at high resolutions. Streptomyces ALR takes a dimer structure, which is formed by interactions between the N-terminal domain of one monomer with the C-terminal domain of its partner. Each of the two active sites of ALR, which is generated as a result of the formation of the dimer structure, is composed of pyridoxal 5'-phosphate (PLP), the PLP-binding residue Lys(38), and the amino acids in the immediate environment of the pyridoxal cofactor. The current model suggests that each active site of Streptomyces ALR maintains a larger space and takes a more rigid conformation than that of Bacillus stearothermophilus ALR determined previously. Furthermore, we show that Streptomyces ALR results in a slow conversion to a final form of a pyridoxal derivative arising from either isomer of cycloserine, which inhibits the catalytic activity noncompetitively. In fact, the slow conversion is confirmed by the fact that each enzyme-bound cycloserine derivative, which is bound to PLP, takes an asymmetric structure.	Hiroshima Univ, Dept Mol Microbiol & Biotechnol, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan	Hiroshima University	Sugiyama, M (corresponding author), Hiroshima Univ, Dept Mol Microbiol & Biotechnol, Grad Sch Biomed Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	sugi@hiroshima-u.ac.jp						BADET B, 1985, BIOCHEMISTRY-US, V24, P1333, DOI 10.1021/bi00327a010; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER A, 1993, X PLOR VERSION 3 1 M; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Caceres NE, 1997, J BACTERIOL, V179, P5046, DOI 10.1128/jb.179.16.5046-5055.1997; DAVID HL, 1969, AM REV RESPIR DIS, V100, P579; DIVEN WF, 1964, BIOCHIM BIOPHYS ACTA, V85, P322, DOI 10.1016/0926-6569(64)90253-6; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Feng ZY, 2003, ANTIMICROB AGENTS CH, V47, P283, DOI 10.1128/AAC.47.1.283-291.2003; Fenn TD, 2003, BIOCHEMISTRY-US, V42, P5775, DOI 10.1021/bi027022d; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; JANSKI AM, 1981, BIOCHEM J, V194, P1027, DOI 10.1042/bj1941027; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LAMBERT MP, 1972, J BACTERIOL, V110, P978, DOI 10.1128/JB.110.3.978-987.1972; LILLEY PE, 1993, GENE, V129, P9; LOBOCKA M, 1994, J BACTERIOL, V176, P1500, DOI 10.1128/jb.176.5.1500-1510.1994; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Morollo AA, 1999, BIOCHEMISTRY-US, V38, P3293, DOI 10.1021/bi9822729; Neuhaus F. C., 1967, ANTIBIOTICS-BASEL, V1, P40; Noda M, 2004, J BIOL CHEM, V279, P46143, DOI 10.1074/jbc.M404603200; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; *RIG MOL STRUCT CO, 2001, CRYSTALCLEAR; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015; Watanabe A, 2002, J BIOL CHEM, V277, P19166, DOI 10.1074/jbc.M201615200; YEW WW, 1993, CLIN INFECT DIS, V17, P288, DOI 10.1093/clinids/17.2.288	34	36	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46153	46161		10.1074/jbc.M404605200	http://dx.doi.org/10.1074/jbc.M404605200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302886	hybrid			2022-12-25	WOS:000224694900102
J	Yang, L; Lee, O; Chen, J; Chen, J; Chang, CCY; Zhou, P; Wang, ZZ; Ma, HH; Sha, HF; Feng, JX; Wang, Y; Yang, XY; Wang, L; Dong, RH; Ornvold, K; Li, BL; Chang, TY				Yang, L; Lee, O; Chen, J; Chen, J; Chang, CCY; Zhou, P; Wang, ZZ; Ma, HH; Sha, HF; Feng, JX; Wang, Y; Yang, XY; Wang, L; Dong, RH; Ornvold, K; Li, BL; Chang, TY			Human acyl-coenzyme A : cholesterol acyltransferase 1 (acat1) sequences located in two different chromosomes (7 and 1) are required to produce a novel ACAT1 isoenzyme with additional sequence at the N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; HUMAN LIVER; GENE; COA; MACROPHAGES; PROTEIN; LOCALIZATION; ORGANIZATION	A rare form of human ACAT1 mRNA, containing the optional long 5'-untranslated region, is produced as a 4.3-kelonucleotide chimeric mRNA through a novel interchromosomal trans-splicing of two discontinuous RNAs transcribed from chromosomes 1 and 7 (Li, B. L., Li, X. L., Duan, Z.J., Lee, O., Lin, S., Ma, Z. M., Chang, C. C., Yang, X.Y., Park, J. P., Mohandas, T. K., Noll, W., Chan, L., and Chang, T. Y. (1999) J. Biol. Chem. 274, 11060-11071). To investigate its function, we express the chimeric ACAT1 mRNA in Chinese hamster ovary cells and show that it can produce a larger ACAT1 protein, with an apparent molecular mass of 56 kDa on SDS-PAGE, in addition to the normal, 50-kDa ACAT1 protein, which is produced from the ACAT1 mRNAs without the optional long 5'-untranslated repeat. To produce the 56-kDa ACAT1, acat1 sequences located at both chromosomes 7 and 1 are required. The 56-kDa ACAT1 can be recognized by specific antibodies prepared against the predicted additional amino acid sequence located upstream of the N-terminal of the ACAT1(ORF). The translation initiation codon for the 56-kDa protein is GGC, which encodes for glycine, as deduced by mutation analysis and mass spectrometry. Similar to the 50-kDa protein, when expressed alone, the 56-kDa ACAT1 is located in the endoplasmic reticulum and is enzymatically active. The 56-kDa ACAT1 is present in native human cells, including human monocyte-derived macrophages. Our current results show that the function of the chimeric ACAT1 mRNA is to increase the ACAT enzyme diversity by producing a novel isoenzyme. To our knowledge, our result provides the first mammalian example that a trans-spliced mRNA produces a functional protein.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Shanghai Chest Hosp, Shanghai Inst Thorac Tumor, Shanghai 200030, Peoples R China; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA	Dartmouth College; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Dartmouth College	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 304 Vail, Hanover, NH 03755 USA.	Ta.Yuan.Chang@dartmouth.edu		Chang, Ta-Yuan/0000-0002-3249-0468; li, bo liang/0000-0002-7123-5638	NHLBI NIH HHS [HL60306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buhman KF, 2000, BBA-MOL CELL BIOL L, V1529, P142, DOI 10.1016/S1388-1981(00)00144-X; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; Chang CCY, 2000, J BIOL CHEM, V275, P28083; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; Chang TY, 2001, J LIPID RES, V42, P1933; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; Chang TY, 2001, CURR OPIN LIPIDOL, V12, P289, DOI 10.1097/00041433-200106000-00008; CHENG WL, 1995, AM J PHYSIOL-ENDOC M, V269, pE642, DOI 10.1152/ajpendo.1995.269.4.E642; Dorn R, 2001, P NATL ACAD SCI USA, V98, P9724, DOI 10.1073/pnas.151268698; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Lee O, 1998, J LIPID RES, V39, P1722; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Lin S, 2003, MOL BIOL CELL, V14, P2447, DOI 10.1091/mbc.E02-11-0725; Liu JW, 1997, J LIPID RES, V38, P2035; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; OHNO K, 1988, J BIOL CHEM, V263, P19764; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Sakashita N, 2003, LAB INVEST, V83, P1569, DOI 10.1097/01.LAB.0000095687.17383.39; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Song BL, 2001, BIOCHEM BIOPH RES CO, V282, P580, DOI 10.1006/bbrc.2001.4612; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Wang HX, 1996, ARTERIOSCL THROM VAS, V16, P809, DOI 10.1161/01.ATV.16.6.809; Yang JB, 2001, J BIOL CHEM, V276, P20989, DOI 10.1074/jbc.M011488200; Yang L, 2004, ACTA BIOCH BIOPH SIN, V36, P259, DOI 10.1093/abbs/36.4.259; Yu CJ, 2002, BIOCHEMISTRY-US, V41, P3762, DOI 10.1021/bi0120188; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	34	27	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46253	46262		10.1074/jbc.M408155200	http://dx.doi.org/10.1074/jbc.M408155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319423	hybrid			2022-12-25	WOS:000224694900112
J	Kerchner, KR; Clay, RL; McCleery, G; Watson, N; McIntire, WE; Myung, CS; Garrison, JC				Kerchner, KR; Clay, RL; McCleery, G; Watson, N; McIntire, WE; Myung, CS; Garrison, JC			Differential sensitivity of phosphatidylinositol 3-kinase p110 gamma to isoforms of G protein beta gamma dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; PHOSPHOLIPASE C-BETA; HETEROTRIMERIC G-PROTEINS; RECOMBINANT G-PROTEINS; PHOSPHOINOSITIDE 3-KINASE; ADENOSINE RECEPTORS; COUPLED RECEPTORS; ADENYLYL-CYCLASE; CHEMOATTRACTANT RECEPTOR; NEUTROPHIL CHEMOTAXIS	The ability of G protein alpha and betagamma subunits to activate the p110gamma isoform of phosphatidylinositol 3-kinase ( PtdIns 3-kinase) was examined using pure, recombinant G proteins and the p101/p110gamma form of PtdIns 3-kinase reconstituted into synthetic lipid vesicles. GTP-activated G(s), G(i), G(q), or G(o) alpha subunits were unable to activate PtdIns 3-kinase. Dimers containing Gbeta(1-4) complexed with gamma(2)-stimulated PtdIns 3-kinase activity about 26-fold with EC50 values ranging from 4 to 7 nM. Gbeta(5)gamma(2) was not able to stimulate PtdIns 3-kinase despite producing a 10-fold activation of avian phospholipase Cbeta. A series of dimers with beta subunits containing point mutations in the amino acids that undergo a conformational change upon interaction of betagamma with phosducin (beta1H311Agamma2, beta1R314Agamma2, and beta1W332Agamma2) was tested, and only beta1W332Agamma2 inhibited the ability of the dimer to stimulate PtdIns 3-kinase. Dimers containing the beta(1) subunit complexed with a panel of different Ggamma subunits displayed variation in their ability to stimulate PtdIns 3-kinase. The beta(1)gamma(2), beta(1)gamma(10), beta(1)gamma(12), and beta(1)gamma(13) dimers all activated PtdIns 3-kinase about 26-fold with 4 - 25 nM EC50 values. The beta(1)gamma(11) dimer, which contains the farnesyl isoprenoid group and is highly expressed in tissues containing the p101/p110gamma form of PtdIns 3-kinase, was ineffective. The role of the prenyl group on the gamma subunit in determining the activation of PtdIns 3-kinase was examined using gamma subunits with altered CAAX boxes directing the addition of farnesyl to the gamma(2) subunit and geranylgeranyl to the gamma(1) and gamma(11) subunits. Replacement of the geranylgeranyl group of the gamma(2) subunit with farnesyl inhibited the activity of beta(1)gamma(2) on PtdIns 3-kinase. Conversely, replacement of the farnesyl group on the gamma(1) and gamma(11) subunit with geranylgeranyl restored almost full activity. These findings suggest that all beta subunits, with the exception of beta(5), interact equally well with PtdIns 3-kinase. In contrast, the composition of the gamma subunit and its prenyl group markedly affects the ability of the betagamma dimer to stimulate PtdIns 3-kinase.	Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Garrison, JC (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735, Charlottesville, VA 22908 USA.	jcg8w@virginia.edu		Myung, Chang-Seon/0000-0002-6292-2911	NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; Akgoz M, 2002, J BIOL CHEM, V277, P19573, DOI 10.1074/jbc.M201546200; Albert PR, 2002, CELL SIGNAL, V14, P407, DOI 10.1016/S0898-6568(01)00259-5; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; BOYER JL, 1994, J BIOL CHEM, V269, P2814; Brass LF, 1999, J CLIN INVEST, V104, P1663, DOI 10.1172/JCI8944; Braun MC, 2001, MICROBES INFECT, V3, P99, DOI 10.1016/S1286-4579(00)01357-5; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Coggeshall KM, 2002, MOL IMMUNOL, V39, P519, DOI 10.1016/S0161-5890(02)00208-0; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Downes GB, 1999, GENOMICS, V62, P544, DOI 10.1006/geno.1999.5992; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FLORIO VA, 1985, J BIOL CHEM, V260, P3477; Fogg VC, 2001, J BIOL CHEM, V276, P41797, DOI 10.1074/jbc.M107661200; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fruman DA, 2002, SEMIN IMMUNOL, V14, P7, DOI 10.1006/smim.2001.0337; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Giembycz MA, 2000, PULM PHARMACOL THER, V13, P195, DOI 10.1006/pupt.2000.0250; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Hildebrandt JD, 1997, BIOCHEM PHARMACOL, V54, P325, DOI 10.1016/S0006-2952(97)00269-4; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Hwang JI, 2004, P NATL ACAD SCI USA, V101, P488, DOI 10.1073/pnas.0307549100; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lim WK, 2001, BIOCHEMISTRY-US, V40, P10532, DOI 10.1021/bi010950c; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Lukov GL, 2004, BIOCHEMISTRY-US, V43, P5651, DOI 10.1021/bi035903u; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; March ME, 2002, SEMIN IMMUNOL, V14, P37, DOI 10.1006/smim.2001.0340; McIntire WE, 2002, METHOD ENZYMOL, V343, P372; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; Morishita R, 1998, FEBS LETT, V428, P85, DOI 10.1016/S0014-5793(98)00498-0; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Myung CS, 1999, ANAL BIOCHEM, V270, P303, DOI 10.1006/abio.1999.4086; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Myung CS, 1999, J BIOL CHEM, V274, P16595, DOI 10.1074/jbc.274.23.16595; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Rohrschneider LR, 2000, GENE DEV, V14, P505; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sasaki T, 2002, J BIOCHEM, V131, P495, DOI 10.1093/oxfordjournals.jbchem.a003126; Schwindinger WF, 2003, J BIOL CHEM, V278, P6575, DOI 10.1074/jbc.M211132200; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wolfe JT, 2003, NATURE, V424, P209, DOI 10.1038/nature01772; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588	88	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44554	44562		10.1074/jbc.M406071200	http://dx.doi.org/10.1074/jbc.M406071200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322106	hybrid			2022-12-25	WOS:000224505600040
J	Liu, JJ; Farmer, SR				Liu, JJ; Farmer, SR			Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis - A glycogen synthase kinase 3 beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; TRANSCRIPTION FACTOR LEF-1; PPAR-GAMMA; ANDROGEN RECEPTOR; C/EBP-ALPHA; DOWN-REGULATION; CYCLIN D1; WNT PATHWAY; IN-VITRO; DEGRADATION	The differentiation of preadipocytes into adipocytes requires the suppression of canonical Wnt signaling, which appears to involve a peroxisome proliferator-activated receptor gamma (PPARgamma)-associated targeting of beta-catenin to the proteasome. In fact, sustained activation of beta-catenin by expression of Wnt1 or Wnt 10b in preadipocytes blocks adipogenesis by inhibiting PPARgamma-associated gene expression. In this report, we investigated the mechanisms regulating the balance between beta-catenin and PPARgamma signaling that determines whether mouse fibroblasts differentiate into adipocytes. Specifically, we show that activation of PPARgamma by exposure of Swiss mouse fibroblasts to troglitazone stimulates the degradation of beta-catenin, which depends on glycogen synthase kinase (GSK) 3beta activity. Mutation of serine 37 ( a target of GSK3beta) to an alanine renders beta-catenin resistant to the degradatory action of PPARgamma. Ectopic expression of the GSK3beta phosphorylation-defective S37A-beta-catenin in Swiss mouse fibroblasts expressing PPARgamma stimulates the canonical Wnt signaling pathway without blocking their troglitazone-dependent differentiation into lipid-laden cells. Analysis of protein expression in these cells, however, shows that S37A-beta-catenin inhibits a select set of adipogenic genes because adiponectin expression is completely blocked, but FABP4/aP2 expression is unaffected. Furthermore, the mutant beta-catenin appears to have no affect on the ability of PPARgamma to bind to or transactivate a PPAR response element. The S37A-beta-catenin-associated inhibition of adiponectin expression coincides with an extensive decrease in the abundance of C/EBPalpha in the nuclei of the differentiated mouse fibroblasts. Taken together, these data suggest that GSKbeta is a key regulator of the balance between beta-catenin and PPARgamma activity and that activation of canonical Wnt signaling downstream of PPARgamma blocks expression of a select subset of adipogenic genes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu		Farmer, Stephen/0000-0003-2483-2795	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058825, R01DK051586, R56DK058825, R56DK051586] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51586, DK58825] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Dixon TM, 2001, J BIOL CHEM, V276, P722, DOI 10.1074/jbc.M008440200; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Girnun GD, 2003, GASTROENTEROLOGY, V124, P564, DOI 10.1053/gast.2003.50070; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Goodwin A. M., 2002, Angiogenesis, V5, P1, DOI 10.1023/A:1021563510866; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu JJ, 2003, J IMMUNOL, V170, P4489, DOI 10.4049/jimmunol.170.9.4489; Longo KA, 2004, J BIOL CHEM, V279, P35503, DOI 10.1074/jbc.M402937200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Truica CI, 2000, CANCER RES, V60, P4709; Walczak R, 2002, J LIPID RES, V43, P177; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	55	57	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45020	45027		10.1074/jbc.M407050200	http://dx.doi.org/10.1074/jbc.M407050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308623	hybrid			2022-12-25	WOS:000224505600094
J	Venkatesha, RT; Ahamed, J; Nuesch, C; Zaidi, AK; Ali, H				Venkatesha, RT; Ahamed, J; Nuesch, C; Zaidi, AK; Ali, H			Platelet-activating factor-induced chemokine gene expression requires NF-kappa B activation and Ca2+/calcineurin signaling pathways - Inhibition by receptor phosphorylation and beta-arrestin recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; AGONIST-INDUCED INTERNALIZATION; MU-OPIOID RECEPTOR; PHOSPHOLIPASE-C; AIRWAY HYPERRESPONSIVENESS; DIFFERENTIAL REGULATION; DESENSITIZATION; CELLS; BETA-ARRESTIN-2; KINASE	Previously, we reported that platelet-activating factor (PAF) stimulates higher G protein activation and a more robust Ca2+ mobilization in RBL-2H3 cells expressing carboxyl terminus deletion, phosphorylation-deficient mutant of PAF receptor (mPAFR) when compared with the wild-type receptor (PAFR). However, PAF did not provide sufficient signal for CC chemokine receptor ligand 2 (CCL2) production in cells expressing mPAFR. Based on these findings, we hypothesized that receptor phosphorylation provides a G protein-independent signal that synergizes with Ca2+ mobilization to induce CCL2 production. Here, we show that a mutant of PAFR (D289A), which does not couple to G proteins, was resistant to agonist-induced receptor phosphorylation. Unexpectedly, we found that when this mutant was coexpressed with mPAFR, it restored NF-kappaB activation and CCL2 production. PAF caused translocation of beta-arrestin from the cytoplasm to the membrane in cells expressing PAFR but not a phosphorylation-deficient mutant in which all Ser/Thr residues were replaced with Ala (DeltaST-PAFR). Interestingly, PAF induced significantly higher NF-kappaB and nuclear factor of activated T cells ( NFAT)luciferase activity as well as CCL2 production in cells expressing DeltaST-PAFR than those expressing PAFR. Furthermore, a Ca2+/calcineurin inhibitor completely inhibited PAF-induced NFAT activation and CCL2 production but not NF-kappaB activation. These findings suggest that the carboxyl terminus of PAFR provides a G protein-independent signal for NF-kappaB activation, which synergizes with G protein-mediated Ca2+/calcineurin activation to induce CCL2 production. However, receptor phosphorylation and beta-arrestin recruitment inhibit CCL2 production by blocking both NF-kappaB activation and Ca2+/calcineurin-dependent signaling pathways.	Univ Penn, Sch Dent Med, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania	Ali, H (corresponding author), Univ Penn, Sch Dent Med, Dept Pathol, 240 S 40th St,346 Levy Bldg, Philadelphia, PA 19104 USA.	ali@path.dental.upenn.edu			NHLBI NIH HHS [HL-63372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063372] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahamed J, 2002, J BIOL CHEM, V277, P22685, DOI 10.1074/jbc.M110210200; Ahamed J, 2001, J IMMUNOL, V167, P3559, DOI 10.4049/jimmunol.167.7.3559; Ali H, 1998, J BIOL CHEM, V273, P11012, DOI 10.1074/jbc.273.18.11012; Ali H, 1997, J BIOL CHEM, V272, P11706, DOI 10.1074/jbc.272.18.11706; ALI H, 1994, J BIOL CHEM, V269, P24557; ALI H, 1993, J BIOL CHEM, V268, P24247; Beaudeux JL, 2004, CLIN CHIM ACTA, V344, P163, DOI 10.1016/j.cccn.2004.02.030; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; BRAQUET P, 1987, PHARMACOL REV, V39, P97; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Henning SW, 1998, CURR OPIN IMMUNOL, V10, P322, DOI 10.1016/S0952-7915(98)80171-4; Hernandez PA, 2003, NAT GENET, V34, P70, DOI 10.1038/ng1149; Hikiji H, 2004, J CLIN INVEST, V114, P85, DOI 10.1172/JC1200420504; Ishii S, 2004, J IMMUNOL, V172, P7095, DOI 10.4049/jimmunol.172.11.7095; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Jocks T, 1998, NEPHROL DIAL TRANSPL, V13, P37, DOI 10.1093/ndt/13.1.37; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KRAVCHENKO VV, 1995, J BIOL CHEM, V270, P14928, DOI 10.1074/jbc.270.25.14928; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Lukashova V, 2001, J BIOL CHEM, V276, P24113, DOI 10.1074/jbc.M100720200; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Maruoka S, 2000, AM J RESP CRIT CARE, V161, P922, DOI 10.1164/ajrccm.161.3.9906059; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Nasu K, 1999, MOL HUM REPROD, V5, P548, DOI 10.1093/molehr/5.6.548; Oda T, 2002, J IMMUNOL, V169, P3329, DOI 10.4049/jimmunol.169.6.3329; Ohsawa M, 2003, NEUROSCI LETT, V346, P13, DOI 10.1016/S0304-3940(03)00591-3; Perron A, 2003, J BIOL CHEM, V278, P27956, DOI 10.1074/jbc.M212302200; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Richardson RM, 1996, J BIOL CHEM, V271, P28717, DOI 10.1074/jbc.271.45.28717; Rijneveld AW, 2004, J INFECT DIS, V189, P711, DOI 10.1086/381392; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; Satonaka H, 2004, CIRC RES, V94, P693, DOI 10.1161/01.RES.0000118250.67032.5E; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Sromek SM, 1998, MOL PHARMACOL, V54, P485, DOI 10.1124/mol.54.3.485; Syrbu SI, 1999, J IMMUNOL, V162, P2334; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VENABLE ME, 1993, J LIPID RES, V34, P691; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; Walker JKL, 2003, J CLIN INVEST, V112, P566, DOI 10.1172/JCI200317265; Wang P, 2003, J BIOL CHEM, V278, P6363, DOI 10.1074/jbc.M210350200; WITHEROW DS, 2004, P NATL ACAD SCI US; Ye RD, 1996, ADV EXP MED BIOL, V416, P143	53	36	41	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44606	44612		10.1074/jbc.M408035200	http://dx.doi.org/10.1074/jbc.M408035200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308653	hybrid			2022-12-25	WOS:000224505600046
J	Leyland, ML; Dart, C				Leyland, ML; Dart, C			An alternatively spliced isoform of PSD-93/chapsyn 110 binds to the inwardly rectifying potassium channel, Kir2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY; K+ CHANNELS; CLUSTERING INTERACTIONS; SIGNALING PATHWAYS; ANCHORING PROTEIN; GUANYLATE KINASES; PERSISTENT PAIN; MESSENGER-RNAS; PDZ PROTEINS; PSD-95	Inwardly rectifying potassium (Kir) channels are prime determinants of resting membrane potential in neurons. Their subcellular distribution and surface density thus help shape neuronal excitability, yet mechanisms governing the membrane targeting and localization of Kir channels are poorly understood. Here we report a direct interaction between the strong inward rectifier, Kir2.1, and a recently identified splice variant of postsynaptic density-93 (PSD-93), a protein involved the subcellular targeting of ion channels and glutamate receptors at excitatory synapses. Yeast two-hybrid screening of a human brain cDNA library using the carboxyl terminus of Kir2.1 as bait yielded cDNA encoding the first two PDZ domains of PSD-93, but with an extended N-terminal region that diverged from other PSD-93 isoforms. This clone represented the human homologue of the mouse PSD-93 splice variant, PSD-93delta. Reverse transcription-polymerase chain reaction analysis showed diffuse low level PSD-93delta expression throughout the brain, with significantly higher levels in spinal cord. In vitro binding studies revealed that a type I PDZ recognition motif at the extreme C terminus of the Kir2.1 mediates interaction with all three PDZ domains of PSD-93delta, and association between Kir2 channels and PSD-93delta was confirmed further by the ability of anti-Kir2.1 antibodies to coimmunoprecipitate PSD-93delta from rat spinal cord lysates. Functionally, coexpression of Kir2.1 and PSD-93delta had no discernible effect upon channel kinetics but resulted in cell surface Kir2.1 clustering and suppression of channel internalization. We conclude that PSD-93delta is potentially an important regulator of the spatial and temporal distribution of Kir2 channels within neuronal membranes of the central nervous system.	Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Leyland, ML (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	ml27@le.ac.uk		Dart, Caroline/0000-0002-3509-8349				Brenman JE, 1996, J NEUROSCI, V16, P7407; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dart C, 2001, J BIOL CHEM, V276, P20499, DOI 10.1074/jbc.M101425200; Dart C, 1998, J PHYSIOL-LONDON, V511, P15, DOI 10.1111/j.1469-7793.1998.015bi.x; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; Firestein BL, 2000, NEUROREPORT, V11, P3479, DOI 10.1097/00001756-200011090-00016; Harris BZ, 2001, J CELL SCI, V114, P3219; Horio Y, 1996, FEBS LETT, V379, P239, DOI 10.1016/0014-5793(95)01519-1; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Inanobe A, 2002, AM J PHYSIOL-CELL PH, V282, pC1396, DOI 10.1152/ajpcell.00615.2001; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Karschin C, 1996, J NEUROSCI, V16, P3559; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Leonoudakis D, 2004, J BIOL CHEM, V279, P22331, DOI 10.1074/jbc.M400285200; Leonoudakis D, 2004, J BIOL CHEM, V279, P19051, DOI 10.1074/jbc.M400284200; Leonoudakis D, 2001, J CELL SCI, V114, P987; Leyland ML, 1999, PFLUG ARCH EUR J PHY, V438, P778, DOI 10.1007/s004240051106; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Parker MJ, 2004, J NEUROSCI, V24, P378, DOI 10.1523/JNEUROSCI.3865-03.2004; Roche KW, 1999, J NEUROSCI, V19, P3926; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; SAMPSON LJ, 2002, J PHYSL LOND P, V544, pS236; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; SHENG M, 2003, ANNU REV NEUROSCI, V24, P1; Stanfield PR, 2002, REV PHYSIOL BIOCH P, V145, P47, DOI 10.1007/BFb0116431; Tao YX, 2003, J NEUROSCI, V23, P6703; Topert C, 1998, J NEUROSCI, V18, P4096; Wong W, 2002, J BIOL CHEM, V277, P20423, DOI 10.1074/jbc.M109412200; Zhang BS, 2003, PAIN, V106, P187, DOI 10.1016/j.pain.2003.08.003; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	43	27	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43427	43436		10.1074/jbc.M407575200	http://dx.doi.org/10.1074/jbc.M407575200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304517	hybrid			2022-12-25	WOS:000224383100012
J	Bennett, RL; Blalock, WL; May, WS				Bennett, RL; Blalock, WL; May, WS			Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PKR; CELLULAR ACTIVATOR; RNA; PACT; INTERFERON; INTERLEUKIN-3; SURVIVAL; BINDING; SITES; CELLS	It is now apparent that the double-stranded (ds) RNA-dependent protein kinase, PKR, is a regulator of diverse cellular responses to stress. Recently, the murine dsRNA-binding protein RAX and its human ortholog PACT were identified as cellular activators of PKR. Previous reports demonstrate that following stress, RAX/ PACT associates with and activates PKR resulting in eIF2alpha phosphorylation, consequent translation inhibition, and cell death via apoptosis. Although RAX/ PACT is phosphorylated during stress, any regulatory role for this post-translational modification has been uncertain. Now we have discovered that RAX is phosphorylated on serine 18 in both human and mouse cells. The non-phosphorylatable form of RAX, RAX(S18A), although still able to bind dsRNA and associate with PKR, fails to activate PKR following stress. Furthermore, stable expression of RAX( S18A) results in a dominant-negative effect characterized by deficiency of eukaryotic initiation factor 2 alpha subunit phosphorylation, delay of translation inhibition, and failure to undergo rapid apoptosis following removal of interleukin-3. We propose that the ability of RAX to activate PKR is regulated by a sequential mechanism featuring RAX association with PKR, RAX phosphorylation at serine 18, and activation of PKR.	Univ Florida, Coll Dent, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	May, WS (corresponding author), 1600 SW Archer Rd,POB 100232, Gainesville, FL 32610 USA.	smay@ufscc.ufl.edu	Bennett, Richard/ABF-9211-2021; Blalock, William L/C-6959-2019	Blalock, William L/0000-0002-8045-4840; Bennett, Richard/0000-0002-0243-2443	NCI NIH HHS [CA09126-27] Funding Source: Medline; NHLBI NIH HHS [5R01HL054083-8, R01 HL054083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009126] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Gunnery S, 1998, METHODS, V15, P189, DOI 10.1006/meth.1998.0623; HAPEL AJ, 1985, BLOOD, V65, P1453, DOI 10.1182/blood.V65.6.1453.bloodjournal6561453; Huang X, 2002, BIOCHEM J, V366, P175, DOI 10.1042/BJ20020204; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KELVIN DJ, 1986, J CELL PHYSIOL, V127, P403, DOI 10.1002/jcp.1041270308; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Li SD, 2003, J INTERF CYTOK RES, V23, P689, DOI 10.1089/107999003772084806; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; May W S Jr, 1997, Adv Pharmacol, V41, P219; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Yang ML, 2003, J BIOL CHEM, V278, P38325, DOI 10.1074/jbc.M303420200; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	33	52	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42687	42693		10.1074/jbc.M403321200	http://dx.doi.org/10.1074/jbc.M403321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299031	hybrid			2022-12-25	WOS:000224226400042
J	Reinhardt, TA; Lippolis, JD; Shull, GE; Horst, RL				Reinhardt, TA; Lippolis, JD; Shull, GE; Horst, RL			Null mutation in the gene encoding plasma membrane Ca2+-ATPase isoform 2 impairs calcium transport into milk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP; SPERM MOTILITY; MAMMARY-GLAND; EXPRESSION; SECRETION; PMCA; ATPASE; 2A	The means by which calcium is transported into the milk produced by mammary glands is a poorly understood process. One hypothesis is that it occurs during exocytosis of secretory products via the Golgi pathway, consistent with the observation that the SPCA1 Ca2+-ATPase, which is expressed in the Golgi, is induced in lactating mammary tissue. However, massive up-regulation of the PMCA2bw plasma membrane Ca2+-ATPase also occurs during lactation and is more strongly correlated with increases in milk calcium, suggesting that calcium may be secreted directly via this pump. To examine the physiological role of PMCA2bw in lactation we compared lactating PMCA2-null mice to heterozygous and wild-type mice. Relative expression levels of individual milk proteins were unaffected by genotype. However, milk from PMCA2-null mice had 60% less calcium than milk from heterozygous and wild-type mice, the total milk protein concentration was lower, and an indirect measure of milk production ( litter weights) suggested that the PMCA2-null mice produce significantly less milk. In contrast, lactose was higher in milk from PMCA2-null mice during early lactation, but by day 12 of lactation there were no differences in milk lactose between the three genotypes. These data demonstrate that the activity of PMCA2bw is required for secretion of much of the calcium in milk. This major secretory function represents a novel biological role for the plasma membrane Ca2+-ATPases, which are generally regarded as premier regulators of intracellular Ca2+.	USDA ARS, Periparturient Dis Cattle Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	United States Department of Agriculture (USDA); University System of Ohio; University of Cincinnati	Reinhardt, TA (corresponding author), USDA ARS, Periparturient Dis Cattle Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA.	treinhar@nadc.ars.usda.gov	Reinhardt, Timothy/A-7536-2009	Reinhardt, Timothy/0000-0001-5552-2509; Lippolis, John/0000-0003-2314-4384	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061974] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61974] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; BAUMRUCKER CR, 1978, LACTATION, V4, P463; Brini M, 2003, J BIOL CHEM, V278, P24500, DOI 10.1074/jbc.M300784200; Burgoyne RD, 1998, J MAMMARY GLAND BIOL, V3, P275, DOI 10.1023/A:1018763427108; Burgoyne RD, 1998, BIOCHEM SOC SYMP, P91; CAMERON IL, 1980, CYTOBIOS, V27, P89; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; Chicka MC, 2003, J BIOL CHEM, V278, P18464, DOI 10.1074/jbc.M301482200; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Duncan JS, 1996, BIOCHEM J, V317, P487, DOI 10.1042/bj3170487; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Filoteo AG, 1997, J BIOL CHEM, V272, P23741, DOI 10.1074/jbc.272.38.23741; Guerini D, 1999, CALCIUM AS A CELLULAR REGULATOR, P249; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; Horst RL, 1997, J MAMMARY GLAND BIOL, V2, P253, DOI 10.1023/A:1026384421273; Kip SN, 2003, AM J PHYSIOL-RENAL, V284, pF122, DOI 10.1152/ajprenal.00161.2002; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; NEVILLE MC, 1982, J PHYSIOL-LONDON, V323, P497, DOI 10.1113/jphysiol.1982.sp014088; NEVILLE MC, 1979, J PHYSIOL-LONDON, V290, P59, DOI 10.1113/jphysiol.1979.sp012759; NEVILLE MC, 1994, J DAIRY SCI, V77, P1964, DOI 10.3168/jds.S0022-0302(94)77142-3; Okunande GW, 2004, J BIOL CHEM, V279, P33742, DOI 10.1074/jbc.M404628200; Penniston JT, 1997, ANN NY ACAD SCI, V834, P56, DOI 10.1111/j.1749-6632.1997.tb52225.x; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Reinhardt TA, 2004, AM J PHYSIOL-CELL PH, V286, pC164, DOI 10.1152/ajpcell.00065.2003; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; Reinhardt TA, 1999, AM J PHYSIOL-CELL PH, V276, pC796, DOI 10.1152/ajpcell.1999.276.4.C796; Schuh K, 2004, J BIOL CHEM, V279, P28220, DOI 10.1074/jbc.M312599200; Shennan DB, 1998, J MAMMARY GLAND BIOL, V3, P247, DOI 10.1023/A:1018759326200; Shennan DB, 2000, PHYSIOL REV, V80, P925, DOI 10.1152/physrev.2000.80.3.925; Shull GE, 2003, ANN NY ACAD SCI, V986, P453, DOI 10.1111/j.1749-6632.2003.tb07229.x; STINNAKRE MG, 1994, P NATL ACAD SCI USA, V91, P6544, DOI 10.1073/pnas.91.14.6544; Strehler EE, 2004, CURR MOL MED, V4, P323, DOI 10.2174/1566524043360735; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; VIRK SS, 1985, BIOCHEM J, V226, P741, DOI 10.1042/bj2260741; Wuytack F, 2003, PFLUG ARCH EUR J PHY, V446, P148, DOI 10.1007/s00424-003-1011-5; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847	38	104	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42369	42373		10.1074/jbc.M407788200	http://dx.doi.org/10.1074/jbc.M407788200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302868	hybrid			2022-12-25	WOS:000224226400006
J	Kouzmenko, AP; Takeyama, K; Ito, S; Furutani, T; Sawatsubashi, S; Maki, A; Suzuki, E; Kawasaki, Y; Akiyama, T; Tabata, T; Kato, S				Kouzmenko, AP; Takeyama, K; Ito, S; Furutani, T; Sawatsubashi, S; Maki, A; Suzuki, E; Kawasaki, Y; Akiyama, T; Tabata, T; Kato, S			Wnt/beta-catenin and estrogen signaling converge in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; REPLACEMENT THERAPY; ANDROGEN RECEPTOR; NUCLEAR RECEPTOR; DROSOPHILA; ARMADILLO; ESTRADIOL; CANCER; CELLS; TRANSCRIPTION	Wnt and estrogen signaling represent important regulatory pathways, each controlling a wide range of biological processes. While an increasing number of observations suggest potential convergence between these pathways, no direct evidence of their functional interaction has been reported. Using human colon and breast cancer cells, we found that estrogen receptor (ER) alpha- and beta-catenin precipitated within the same immunocomplexes, reciprocally enhanced the transactivation of cognate reporter genes, and were reciprocally recruited to cognate response elements in the promoters of endogenous target genes. Using transgenic Drosophila that ectopically expressed human ERalpha alone or together with metabolically stable beta-catenin/Armadillo mutants, we demonstrated genetic interaction between these signal transducers in vivo. Thus, we present here the first direct evidence of cross-talk between Wnt and estrogen signaling pathways via functional interaction between beta-catenin and ERalpha.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol, SORST, Kawaguchi, Saitama 3320012, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Astellas Pharmaceuticals	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	uskato@mail.ecc.u-tokyo.ac.jp	Eckhardt, Erik/G-1567-2010	Matsuura-Suzuki, Eriko/0000-0002-1485-7959; Sawatsubashi, Shun/0000-0003-3093-8334				Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Cardona-Gomez P, 2004, MOL CELL NEUROSCI, V25, P363, DOI 10.1016/j.mcn.2003.10.008; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Crandall CJ, 1999, J WOMEN HEALTH GEN-B, V8, P1155, DOI 10.1089/jwh.1.1999.8.1155; Creasman WT, 2002, GYNECOL ONCOL, V86, P1, DOI 10.1006/gyno.2001.6499; Freeman M, 2001, EMBO REP, V2, P157, DOI 10.1093/embo-reports/kve019; Greaves S, 1999, GENETICS, V153, P1753; Gunin AG, 2004, EUR J OBSTET GYN R B, V114, P83, DOI 10.1016/j.ejogrb.2003.09.023; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; ITO S, 2004, GENES CELLS; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Pai LM, 1997, DEVELOPMENT, V124, P2255; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Tabata T, 2001, NAT REV GENET, V2, P620, DOI 10.1038/35084577; Takeyama K, 2002, NEURON, V35, P855, DOI 10.1016/S0896-6273(02)00875-9; Tolwinski NS, 2001, DEVELOPMENT, V128, P2107; Tzagarakis-Foster C, 2002, J BIOL CHEM, V277, P44772, DOI 10.1074/jbc.M205355200; Waltzer L, 2001, EMBO J, V20, P137, DOI 10.1093/emboj/20.1.137; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200	32	175	183	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 24	2004	279	39					40255	40258		10.1074/jbc.C400331200	http://dx.doi.org/10.1074/jbc.C400331200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	854PW	15304487	hybrid			2022-12-25	WOS:000223916800003
J	Fricke, I; Mitchell, D; Petersen, F; Bohle, A; Bulfone-Paus, S; Brandau, S				Fricke, I; Mitchell, D; Petersen, F; Bohle, A; Bulfone-Paus, S; Brandau, S			Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells	FASEB JOURNAL			English	Article						platelets; dendritic cells; NK cells; inflammation; BCG	CXC-CHEMOKINE PLATELET-FACTOR-4; DENDRITIC CELLS; IN-VITRO; DISTINCT SUBSETS; RELEASE; ALPHA; NEUTROPHILS; ACTIVATION; EXPRESSION; RESPONSES	Recent evidence suggests that platelets are not only involved in haemostatic processes but also modulate immune responses. As antigen-presenting cells (APC) are of crucial importance for the regulation of immunity, in this study we wanted to define the role of platelet factor 4 (PF-4) as one of the major platelet-derived chemokines on the transition of monocytes into APCs. Our experiments show that within 3 days PF-4 in conjunction with IL-4 induces a rapid differentiation of monocytes into APC. These PFAPC (PF-4/IL-4 differentiated APC) display unique phenotypical and functional characteristics setting them apart from macrophages and conventional dendritic cells. Functional studies revealed that PFAPC preferentially stimulated proliferation of lymphocytes and lytic NK activity while they induced only moderate cytokine responses. Beyond day 3 of differentiation, PFAPC became less immunostimulatory and maintained their capacity to phagocytose particulate material even after LPS-induced maturation. These experiments uncover a previously unknown role for the platelet-derived CXC-chemokine PF-4 in differentiation of human APC. Our data further support the newly discovered function of platelets in immunomodulation and provide new evidence for a rapid transition of monocytes into APC under the influence of inflammatory stimuli.	Res Ctr Borstel, Div Immunotherapy, D-23845 Borstel, Germany; Res Ctr Borstel, Div Immunobiol, D-23845 Borstel, Germany; Res Ctr Borstel, Div Biochem Immunol, D-23845 Borstel, Germany; Helios Agnes KArll Hosp, Bad Schwartau, Germany	Forschungszentrum Borstel; Forschungszentrum Borstel; Forschungszentrum Borstel	Brandau, S (corresponding author), Res Ctr Borstel, Div Immunotherapy, PArkallee 1-40, D-23845 Borstel, Germany.	sbrandau@fz-borstel.de		Fricke, Ingo/0000-0001-7638-3181; Brandau, Sven/0000-0002-2702-4163				Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; BOYUM A, 1964, NATURE, V204, P793, DOI 10.1038/204793a0; Brandt E, 2000, IMMUNOL REV, V177, P204, DOI 10.1034/j.1600-065X.2000.17705.x; BRINDLEY LL, 1983, J CLIN INVEST, V72, P1218, DOI 10.1172/JCI111077; Chang CCJ, 2000, J IMMUNOL, V165, P3584, DOI 10.4049/jimmunol.165.7.3584; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Dauer M, 2003, J IMMUNOL, V170, P4069, DOI 10.4049/jimmunol.170.8.4069; DEUEL TF, 1982, J CLIN INVEST, V69, P1046, DOI 10.1172/JCI110509; Di Pucchio T, 2003, EUR J IMMUNOL, V33, P358; Duperrier K, 2000, J IMMUNOL METHODS, V238, P119, DOI 10.1016/S0022-1759(00)00147-2; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; Ebner S, 2002, J IMMUNOL, V168, P6199, DOI 10.4049/jimmunol.168.12.6199; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Fleischer J, 2002, J IMMUNOL, V169, P770, DOI 10.4049/jimmunol.169.2.770; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GRAGEGRIEBENOW E, 1993, EUR J IMMUNOL, V23, P3126, DOI 10.1002/eji.1830231213; Hart PH, 1996, IMMUNOLOGY, V89, P599, DOI 10.1046/j.1365-2567.1996.d01-779.x; Ho CSK, 2002, BLOOD, V99, P2897, DOI 10.1182/blood.V99.8.2897; Kalia R, 1999, COMPUT SCI ENG, V1, P2; Kim KD, 1999, IMMUNOLOGY, V97, P626; Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623; Lasagni L, 2003, J EXP MED, V197, P1537, DOI 10.1084/jem.20021897; Loskog A, 2002, CANCER GENE THER, V9, P846, DOI 10.1038/sj.cgt.7700507; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Marti F, 2002, J LEUKOCYTE BIOL, V72, P590; Narendran P, 2002, ANN NY ACAD SCI, V958, P170; PERVUSHINA O, IN PRESS J IMMUNOL; Petersen F, 1996, J IMMUNOL, V156, P1954; Pickl WF, 1996, J IMMUNOL, V157, P3850; Pietschmann P, 2000, SCAND J IMMUNOL, V51, P377; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Randolph GJ, 2002, J EXP MED, V196, P517, DOI 10.1084/jem.20011608; Relloso M, 2002, J IMMUNOL, V168, P2634, DOI 10.4049/jimmunol.168.6.2634; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Scheuerer B, 2000, BLOOD, V95, P1158, DOI 10.1182/blood.V95.4.1158.004k31_1158_1166; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Thurnher M, 1997, INT J CANCER, V70, P128; Turpin J, 1986, J Clin Apher, V3, P111, DOI 10.1002/jca.2920030207; Xia CQ, 2003, INT IMMUNOL, V15, P1007, DOI 10.1093/intimm/dxg100; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040	44	43	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1588	+		10.1096/fj.03-1435fje	http://dx.doi.org/10.1096/fj.03-1435fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319366				2022-12-25	WOS:000223554900011
J	Khetchoumian, K; Teletin, M; Mark, M; Lerouge, T; Cervino, M; Oulad-Abdelghani, M; Chambon, P; Losson, R				Khetchoumian, K; Teletin, M; Mark, M; Lerouge, T; Cervino, M; Oulad-Abdelghani, M; Chambon, P; Losson, R			TIF1 delta, a novel HP1-interacting member of the transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; HISTONE H3; CHROMATIN-STRUCTURE; MOLECULAR-MECHANISMS; EPIGENETIC CONTROL; NUCLEAR RECEPTORS; GENOMIC STRUCTURE; REPRESSOR DOMAIN; GENE-EXPRESSION; PHD FINGER	TIF1 (transcriptional intermediary factor 1) proteins are encoded by an expanding family of developmental and physiological control genes that are conserved from flies to man. These proteins are characterized by an N-terminal RING-B box-coiled-coil (RBCC) motif and a C-terminal PHD finger/bromodomain unit, and have been implicated in epigenetic mechanisms of transcriptional repression involving histone modifiers and heterochromatin-binding proteins. We describe here the isolation and functional characterization of a fourth murine TIF1 gene, TIF1delta. The predicted TIF1delta protein displays all the structural hallmarks of a bona fide TIF1 family member and resembles the other TIF1s in that it can exert a deacetylase-dependent silencing effect when tethered to a promoter region. Moreover, like TIF1alpha and TIF1beta, TIF1delta can homodimerize and contains a PXVXL motif necessary and sufficient for HP1 (heterochromatin protein 1) binding. Although TIF1alpha and TIF1beta also bind nuclear receptors and Kruppel-associated boxes specifically and respectively, TIF1delta appears to lack nuclear receptor- and Kruppel-associated box binding activity. Furthermore, TIF1delta is unique among the TIF1 family proteins in that its expression is largely restricted to the testis and confined to haploid elongating spermatids, where it associates preferentially with HP1 isotype gamma (HP1gamma) and forms discrete foci dispersed within the centromeric chromocenter and the surrounding nucleoplasm. Collectively, these data are consistent with specific, nonredundant functions for the TIF1 family members in vivo and suggest a role for TIF1delta in heterochromatin-mediated gene silencing during postmeiotic phases of spermatogenesis.	Coll France, CNRS,INSERM,ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Inst Clin Souris, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Losson, R (corresponding author), Coll France, CNRS,INSERM,ULP, Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Illkirch Graffenstaden, France.	losson@igbmc.u-strasbg.fr	TELETIN, Marius/AAS-2241-2020; TELETIN, Marius/P-6460-2016; abdelghani, mustapha oulad/A-5986-2017	TELETIN, Marius/0000-0002-3286-8125; TELETIN, Marius/0000-0002-3286-8125; abdelghani, mustapha oulad/0000-0002-8381-4397				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; Bloch DB, 1996, J BIOL CHEM, V271, P29198, DOI 10.1074/jbc.271.46.29198; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cammas F, 2002, J CELL SCI, V115, P3439; CAMMAS F, 2002, RECENT RES DEV MOL C, V3, P591; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Dyson MH, 2001, FRONT BIOSCI, V6, pD853, DOI 10.2741/Dyson; Eddy EM, 1998, CURR TOP DEV BIOL, V37, P141; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; GEREMIA R, 1978, EXP CELL RES, V111, P23, DOI 10.1016/0014-4827(78)90232-X; Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Gozani O, 2003, CELL, V114, P99, DOI 10.1016/S0092-8674(03)00480-X; Gunduz M, 2000, CANCER RES, V60, P3143; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Ito T, 1999, GENE DEV, V13, P1529, DOI 10.1101/gad.13.12.1529; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kalkhoven E, 2003, HUM MOL GENET, V12, P441, DOI 10.1093/hmg/ddg039; KIERSZENBAUM AL, 1978, FED PROC, V37, P2512; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kistler WS, 1996, EXP CELL RES, V225, P374, DOI 10.1006/excr.1996.0188; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lewis JD, 2003, BIOCHEM CELL BIOL, V81, P131, DOI 10.1139/o03-045; Li YH, 2002, P NATL ACAD SCI USA, V99, P16462, DOI 10.1073/pnas.162371699; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Malkov M, 1998, BIOL REPROD, V59, P84, DOI 10.1095/biolreprod59.1.84; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Martianov I, 2002, DEVELOPMENT, V129, P945; Minc E, 2000, CYTOGENET CELL GENET, V90, P279, DOI 10.1159/000056789; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Niederreither K, 1999, MECH DEVELOP, V88, P111, DOI 10.1016/S0925-4773(99)00175-6; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Remboutsika E, 1999, J CELL SCI, V112, P1671; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; RUSSELL LD, 1990, HISTOLOGICAL HISOPAT; Sassone-Corsi P, 2002, ENDOCRINOLOGY, V143, P1575, DOI 10.1210/en.143.5.1575; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Steger K, 1999, ANAT EMBRYOL, V199, P471, DOI 10.1007/s004290050245; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; VOM BE, 1996, EMBO J, V15, P110; Wang GZ, 2000, MOL CELL BIOL, V20, P6970, DOI 10.1128/MCB.20.18.6970-6983.2000; Weber P, 2002, DEVELOPMENT, V129, P2329; Winston F, 1999, NAT STRUCT BIOL, V6, P601, DOI 10.1038/10640; Wouters-Tyrou D, 1998, BIOCHIMIE, V80, P117, DOI 10.1016/S0300-9084(98)80018-7; Yan KP, 2004, GENE, V334, P3, DOI 10.1016/j.gene.2004.02.056; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463; Zhou YG, 2002, EMBO J, V21, P4632, DOI 10.1093/emboj/cdf460	80	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48329	48341		10.1074/jbc.M404779200	http://dx.doi.org/10.1074/jbc.M404779200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15322135	hybrid			2022-12-25	WOS:000224957000108
J	Seidel, RD; Amor, JC; Kahn, RA; Prestegard, JH				Seidel, RD; Amor, JC; Kahn, RA; Prestegard, JH			Conformational changes in human Arf1 on nucleotide exchange and deletion of membrane-binding elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; DIPOLAR COUPLINGS; PROTEIN-STRUCTURE; GTP; ACTIVATION; BETA; SPECTROSCOPY; RESONANCE; PEPTIDES; H-1-N-15	Conformational changes associated with nucleotide exchange or truncation of the N-terminal alpha-helix of human Arf1 have been investigated by using forms of easily acquired NMR data, including residual dipolar couplings and amide proton exchange rates. ADP-ribosylation factors (Arfs) are 21-kDa GTPases that regulate aspects of membrane traffic in all eukaryotic cells. An essential component of the biological actions of Arfs is their ability to reversibly bind to membranes, a process that involves exposure of the myristoylated N-terminal amphipathic alpha-helix upon activation and GTP binding. Deletion of this helix results in a protein, termed Delta17Arf1, that has a reduced affinity for GDP and the ability to bind GTP in the absence of lipids or detergents. Previous studies, comparing crystal structures for Arf1.GDP and Delta17Arf1.GTP, identified several regions of structural variation and suggested that these be associated with nucleotide exchange rather than removal of the N-terminal helix. However, separation of conformational changes because of nucleotide binding and N-terminal truncation cannot be addressed in comparing these structures, because both the bound nucleotide and the N terminus differ. Resolving the two effects is important as any structural changes involving the N terminus may represent membrane-mediated conformational adjustments that precede GTP binding. Results from NMR experiments presented here on Arf1.GDP and Delta17Arf1.GDP in solution reveal substantial structural differences that can only be associated with N-terminal truncation.	Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	University System of Georgia; University of Georgia; Emory University	Prestegard, JH (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	jpresteg@ccrc.uga.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM61268, R01 GM061268] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061268] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amor JC, 2002, J BIOMOL NMR, V23, P253, DOI 10.1023/A:1019839607202; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Amor JC, 2001, J BIOL CHEM, V276, P42477, DOI 10.1074/jbc.M106660200; Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8; Chou JJ, 2000, J BIOMOL NMR, V18, P217, DOI 10.1023/A:1026563923774; Clore GM, 2004, J AM CHEM SOC, V126, P2923, DOI 10.1021/ja0386804; Cornilescu G, 1998, J AM CHEM SOC, V120, P6836, DOI 10.1021/ja9812610; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dempsey CE, 2001, PROG NUCL MAG RES SP, V39, P135, DOI 10.1016/S0079-6565(01)00032-2; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FESIK SW, 1988, NATURE, V332, P865, DOI 10.1038/332865a0; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hill K, 2003, J BIOL CHEM, V278, P36032, DOI 10.1074/jbc.M301632200; Hwang TL, 1997, J AM CHEM SOC, V119, P6203, DOI 10.1021/ja970160j; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Lacal JC, 1993, RAS SUPERFAMILY GTPA; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P3804, DOI 10.1021/bi9923050; MacArthur MW, 1996, J MOL BIOL, V264, P1180, DOI 10.1006/jmbi.1996.0705; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Pasqualato S, 2001, EMBO REP, V2, P234, DOI 10.1093/embo-reports/kve043; Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; STONEHOUSE J, 1994, J MAGN RESON SER A, V107, P178, DOI 10.1006/jmra.1994.1066; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Valafar H, 2004, J MAGN RESON, V167, P228, DOI 10.1016/j.jmr.2003.12.012; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wang YX, 1998, J AM CHEM SOC, V120, P7385, DOI 10.1021/ja980862o; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5; Zhu XJ, 2000, J BIOL CHEM, V275, P13465, DOI 10.1074/jbc.275.18.13465	44	21	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48307	48318		10.1074/jbc.M402109200	http://dx.doi.org/10.1074/jbc.M402109200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15308674	hybrid			2022-12-25	WOS:000224957000106
J	Vaithianathan, T; Matthias, K; Bahr, B; Schachner, M; Suppiramaniam, V; Dityatev, A; Steinhauser, C				Vaithianathan, T; Matthias, K; Bahr, B; Schachner, M; Suppiramaniam, V; Dityatev, A; Steinhauser, C			Neural cell adhesion molecule-associated polysialic acid potentiates alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor currents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTORS; RECOGNITION MOLECULES; GLUTAMATE RECEPTORS; LIGAND-BINDING; NMDA RECEPTORS; LOW-AFFINITY; PSA-NCAM; CHANNEL; DESENSITIZATION; GLYCOSYLATION	The highly negatively charged polysialic acid (PSA) is a carbohydrate predominantly carried by the neural cell adhesion molecule (NCAM) in mammals. NCAM and, in particular, PSA play important roles in cellular and synaptic plasticity. Here we investigated whether PSA modulates the activity of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) subtype of glutamate receptors (AMPA-Rs). Single channel recordings of affinity-purified AMPA-Rs reconstituted in lipid bilayers revealed that bacterially derived PSA, called colominic acid, prolonged the open channel time of AMPA-R-mediated currents by severalfold and altered the bursting pattern of the receptor channels but did not modify AMPA-R single channel conductance. This effect was reversible, concentration-dependent, and specific, since monomers of sialic acid and another negatively charged carbohydrate, chondroitin sulfate, did not potentiate single channel AMPA-R currents. Recombinant PSA-NCAM also potentiated currents mediated by reconstituted AMPA-Rs. In pyramidal neurons acutely isolated from the CA1 region of the early postnatal hippocampus, L-glutamate or AMPA (applied in the presence of antagonists blocking voltage-gated Na+ and K+ currents and N-methyl-D-aspartate and metabotropic glutamate receptors) induced inward currents, which were significantly increased by co-application of colominic acid. Chondroitin sulfate did not affect AMPA-R-mediated currents in CA1 neurons. The effect of colominic acid was age-dependent, since in pyramidal neurons from adult hippocampus, colominic acid failed to potentiate glutamate responses. Thus, our study demonstrates age-dependent potentiation of AMPA receptors by PSA via a mechanism probably involving direct PSA-AMPA-R interactions. This mechanism might amplify AMPA-R-mediated signaling in immature cells, thereby affecting their development.	Auburn Univ, Dept Pharmacal Sci, Auburn, AL 36849 USA; Univ Bonn, Dept Neurosurg, D-53105 Bonn, Germany; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	Auburn University System; Auburn University; University of Bonn; University of Connecticut; University of Hamburg; University Medical Center Hamburg-Eppendorf	Suppiramaniam, V (corresponding author), Auburn Univ, Dept Pharmacal Sci, Auburn, AL 36849 USA.	suppivd@auburn.edu; dityatev@zmnh.uni-hamburg.de	Vaithianathan, Thirumalini/ABI-3170-2020; Dityatev, Alexander/A-4034-2008	Dityatev, Alexander/0000-0002-0472-0553; Matthias, Katja/0000-0002-7934-0256				AMBROSINGERSON J, 1993, P NATL ACAD SCI USA, V90, P7903, DOI 10.1073/pnas.90.16.7903; BAHR BA, 1992, J NEUROCHEM, V59, P1979, DOI 10.1111/j.1471-4159.1992.tb11038.x; Bahr BA, 1996, NEUROSCIENCE, V74, P707, DOI 10.1016/0306-4522(96)00133-9; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Becker CG, 1996, J NEUROSCI RES, V45, P143, DOI 10.1002/(SICI)1097-4547(19960715)45:2<143::AID-JNR6>3.0.CO;2-A; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Borges K, 1998, PROG BRAIN RES, V116, P153, DOI 10.1016/S0079-6123(08)60436-7; CORONADO R, 1983, BIOPHYS J, V43, P231, DOI 10.1016/S0006-3495(83)84343-4; Dingledine R, 1999, PHARMACOL REV, V51, P7; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; Endo A, 1998, NEUROSCI LETT, V246, P37, DOI 10.1016/S0304-3940(98)00204-3; FAZELI MS, 1994, NEUROSCI LETT, V169, P77, DOI 10.1016/0304-3940(94)90360-3; Gomperts SN, 2000, J NEUROSCI, V20, P2229; HALL RA, 1992, J NEUROCHEM, V59, P1997; Hall RA, 1996, NEUROSCI LETT, V217, P179, DOI 10.1016/0304-3940(96)12984-0; Hjelmstad GO, 1999, J NEUROPHYSIOL, V81, P3096, DOI 10.1152/jn.1999.81.6.3096; Hoffman KB, 1998, BRAIN RES, V811, P152, DOI 10.1016/S0006-8993(98)00907-X; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Inglis FM, 2002, J NEUROSCI, V22, P8042; KAWAMOTO S, 1995, J NEUROCHEM, V64, P1258; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KISS JZ, 1994, EMBO J, V13, P5284, DOI 10.1002/j.1460-2075.1994.tb06862.x; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Morkve SH, 2002, J PHYSIOL-LONDON, V542, P147, DOI 10.1113/jphysiol.2002.020305; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; PARTIN KM, 1994, MOL PHARMACOL, V46, P129; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Robert A, 2003, J NEUROSCI, V23, P847; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schuster T, 2001, J NEUROBIOL, V49, P142, DOI 10.1002/neu.1071; Seifert G, 2000, NEUROPHARMACOLOGY, V39, P931, DOI 10.1016/S0028-3908(99)00212-9; Seifert G, 2003, MOL CELL NEUROSCI, V22, P248, DOI 10.1016/S1044-7431(03)00039-3; Seki T, 1998, J NEUROSCI, V18, P3757; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; Sinnarajah S, 1999, SYNAPSE, V31, P203; Smith TC, 2000, J NEUROSCI, V20, P2073; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SPRENGEL R, 1993, FEBS LETT, V325, P90, DOI 10.1016/0014-5793(93)81420-5; Standley S, 1998, J NEUROCHEM, V70, P2434; Standley S, 2000, CELL MOL LIFE SCI, V57, P1508, DOI 10.1007/PL00000635; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; SUBRAMANIAM T, 2001, SOC NEUR ABSTR, V27, P310; Suppiramaniam V, 2001, SYNAPSE, V40, P154, DOI 10.1002/syn.1037; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Theodosis DT, 1999, J NEUROSCI, V19, P10228; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; Uryu K, 1999, J COMP NEUROL, V405, P216, DOI 10.1002/(SICI)1096-9861(19990308)405:2<216::AID-CNE6>3.0.CO;2-6; VODYANOY V, 1993, NEUROSCI LETT, V150, P80, DOI 10.1016/0304-3940(93)90113-Y; VODYANOY V, 1989, MOLECULAR ELECTRONICS : BIOSENSORS AND BIOCOMPUTERS, P317; Vutskits L, 2001, EUR J NEUROSCI, V13, P1391, DOI 10.1046/j.0953-816x.2001.01516.x; VYKLICKY L, 1991, NEURON, V7, P971, DOI 10.1016/0896-6273(91)90342-W; Weber M, 2001, J NEUROCHEM, V77, P1108, DOI 10.1046/j.1471-4159.2001.00340.x; WILMSEN U, 1983, PHYSICAL CHEM TRANSM, P479; Xu DS, 2003, NEURON, V39, P513, DOI 10.1016/S0896-6273(03)00463-X	62	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47975	47984		10.1074/jbc.M407138200	http://dx.doi.org/10.1074/jbc.M407138200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15317811	hybrid			2022-12-25	WOS:000224957000068
J	Breuza, L; Halbeisen, R; Jeno, P; Otte, S; Barlowe, C; Hong, WJ; Hauri, HP				Breuza, L; Halbeisen, R; Jeno, P; Otte, S; Barlowe, C; Hong, WJ; Hauri, HP			Proteomics of endoplasmic reticulum-golgi intermediate compartment (ERGIC) membranes from brefeldin A-treated HepG2 cells identifies ERGIC-32, a new cycling protein that interacts with human Erv46	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SECRETORY PATHWAY; CIS-GOLGI; QUALITY-CONTROL; VESICULAR TRANSPORT; BINDING PROTEIN; KDEL RECEPTOR; RETROGRADE TRANSPORT; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; RECYCLING PATHWAY	Cycling proteins play important roles in the organization and function of the early secretory pathway by participating in membrane traffic and selective transport of cargo between the endoplasmic reticulum ( ER), the intermediate compartment ( ERGIC), and the Golgi. To identify new cycling proteins, we have developed a novel procedure for the purification of ERGIC membranes from HepG2 cells treated with brefeldin A, a drug known to accumulate cycling proteins in the ERGIC. Membranes enriched 110-fold over the homogenate for ERGIC-53 were obtained and analyzed by mass spectrometry. Major proteins corresponded to established and putative cargo receptors and components mediating protein maturation and membrane traffic. Among the uncharacterized proteins, a 32-kDa protein termed ERGIC-32 is a novel cycling membrane protein with sequence homology to Erv41p and Erv46p, two proteins enriched in COPII vesicles of yeast. ERGIC-32 localizes to the ERGIC and partially colocalizes with the human homologs of Erv41p and Erv46p, which mainly localize to the cis-Golgi. ERGIC-32 interacts with human Erv46 (hErv46) as revealed by covalent cross-linking and mistargeting experiments, and silencing of ERGIC-32 by small interfering RNAs increases the turnover of hErv46. We propose that ERGIC-32 functions as a modulator of the hErv41-hErv46 complex by stabilizing hErv46. Our novel approach for the isolation of the ERGIC from BFA-treated cells may ultimately lead to the identification of all proteins rapidly cycling early in the secretory pathway.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Biochem, Hanover, NH 03756 USA; Inst Mol & Cell Biol, Singapore 117609, Singapore	University of Basel; Dartmouth College; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hauri, HP (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Hans-Peter.Hauri@unibas.ch	HONG, Wanjin/E-9927-2010	Breuza, Lionel/0000-0002-8075-8625				Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Bachert C, 2001, MOL BIOL CELL, V12, P3152, DOI 10.1091/mbc.12.10.3152; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barrowman J, 2003, J BIOL CHEM, V278, P19878, DOI 10.1074/jbc.M302406200; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bell AW, 2001, J BIOL CHEM, V276, P5152, DOI 10.1074/jbc.M006143200; Bieberich E, 1997, EUR J BIOCHEM, V246, P681, DOI 10.1111/j.1432-1033.1997.t01-1-00681.x; Blum R, 1999, J CELL SCI, V112, P537; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; Duhig T, 1998, GENOMICS, V52, P72, DOI 10.1006/geno.1998.5372; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; Fullekrug J, 1999, J CELL SCI, V112, P2813; Fullekrug J, 1997, FEBS LETT, V404, P75, DOI 10.1016/S0014-5793(97)00097-5; Fullekrug J, 1999, MOL BIOL CELL, V10, P1939, DOI 10.1091/mbc.10.6.1939; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; Hammond AT, 2000, MOL BIOL CELL, V11, P3013, DOI 10.1091/mbc.11.9.3013; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hardt B, 2001, BIOL CHEM, V382, P1039, DOI 10.1515/BC.2001.130; Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713; Hauri HP, 2000, J CELL SCI, V113, P587; Hirosawa M, 1999, DNA Res, V6, P329, DOI 10.1093/dnares/6.5.329; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jenne N, 2002, J BIOL CHEM, V277, P46504, DOI 10.1074/jbc.M206989200; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Klumperman J, 1998, J CELL SCI, V111, P3411; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Lin P, 1998, J CELL BIOL, V141, P1515, DOI 10.1083/jcb.141.7.1515; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; LINSTEDT AD, 1995, P NATL ACAD SCI USA, V92, P5102, DOI 10.1073/pnas.92.11.5102; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nickel W, 2002, J CELL SCI, V115, P3235; Orci L, 2003, P NATL ACAD SCI USA, V100, P4586, DOI 10.1073/pnas.0730885100; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Otte S, 2001, J CELL BIOL, V152, P503, DOI 10.1083/jcb.152.3.503; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; REEVES JE, 1995, MOL MEMBR BIOL, V12, P201, DOI 10.3109/09687689509027508; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; SARASTE J, 1995, J CELL SCI, V108, P1541; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shorter J, 2002, J CELL BIOL, V157, P45, DOI 10.1083/jcb.200112127; Shugrue CA, 1999, J CELL SCI, V112, P4547; SMITH T, 1995, J BIOL CHEM, V270, P18323, DOI 10.1074/jbc.270.31.18323; Spiro MJ, 2001, GLYCOBIOLOGY, V11, P803, DOI 10.1093/glycob/11.10.803; Stephens DJ, 2000, J CELL SCI, V113, P2177; SUBRAMANIAM VN, 1995, J CELL SCI, V108, P2405; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TANG BL, 1995, EUR J CELL BIOL, V68, P199; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	83	87	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47242	47253		10.1074/jbc.M406644200	http://dx.doi.org/10.1074/jbc.M406644200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15308636	hybrid			2022-12-25	WOS:000224832400112
J	Morgan, CP; Skippen, A; Segui, B; Ball, A; Allen-Baume, V; Larijani, B; Murray-Rust, J; McDonald, N; Sapkota, G; Morrice, N; Cockcroft, S				Morgan, CP; Skippen, A; Segui, B; Ball, A; Allen-Baume, V; Larijani, B; Murray-Rust, J; McDonald, N; Sapkota, G; Morrice, N; Cockcroft, S			Phosphorylation of a distinct structural form of phosphatidylinositol transfer protein alpha at Ser(166) by protein kinase C disrupts receptor-mediated phospholipase C signaling by inhibiting delivery of phosphatidylinositol to membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; HL60 CELLS; DEPENDENT PHOSPHORYLATION; BETA; 3-KINASE; ATP; SPHINGOMYELIN; SECRETION; TERMINUS; ISOFORMS	Phosphatidylinositol transfer protein alpha (PITPalpha) participates in the supply of phosphatidylinositol ( PI) required for many cellular events including phospholipase C (PLC) beta and gamma signaling by G-protein-coupled receptors and receptor-tyrosine kinases, respectively. Protein kinase C has been known to modulate PLC signaling by G-protein-coupled receptors and receptor-tyrosine kinases, although the molecular target has not been identified in most instances. In each case phorbol myristate acetate pretreatment of HL60, HeLa, and COS-7 cells abrogated PLC stimulation by the agonists formyl-Met-Leu-Phe, ATP, and epidermal growth factor, respectively. Here we show that phosphorylation of PITPalpha at Ser(166) resulted in inhibition of receptor-stimulated PLC activity. Ser(166) is localized in a small pocket between the 165 - 172 loop and the rest of the protein and was not solvent-accessible in either the PI- or phosphatidylcholine-loaded structures of PITPalpha. To allow phosphorylation at Ser(166), a distinct structural form is postulated, and mutation of Thr(59) to alanine shifted the equilibrium to this form, which could be resolved on native PAGE. The elution profile observed by size exclusion chromatography of phosphorylated PITPalpha from rat brain or in vitro phosphorylated PITPalpha demonstrated that phosphorylated PITPalpha is structurally distinct from the non-phosphorylated form. Phosphorylated PITPalpha was unable to deliver its PI cargo, although it could deliver phosphatidylcholine. We conclude that the PITPalpha structure has to relax to allow access to the Ser(166) site, and this may occur at the membrane surface where PI delivery is required for receptor-mediated PLC signaling.	UCL, Dept Physiol, London WC1E 6JJ, England; Univ London Birkbeck Coll, Sch Crystallog, London WC1E 7HX, England; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Canc Res UK, London Res Inst, Cell Biophys Lab, London WC2A 3PX, England	University of London; University College London; University of London; Birkbeck University London; University of Dundee; Cancer Research UK	Cockcroft, S (corresponding author), UCL, Dept Physiol, London WC1E 6JJ, England.	S.Cockcroft@ucl.ac.uk	Sapkota, Gopal/C-7300-2014; Ségui, Bruno/O-8957-2014; Larijani, Banafshe/H-3909-2015; Cockcroft, Shamshad/F-9480-2011	Sapkota, Gopal/0000-0001-9931-3338; Ségui, Bruno/0000-0002-6119-1889; Larijani, Banafshe/0000-0003-4735-1169; Cockcroft, Shamshad/0000-0002-5731-476X				ALB JG, 1995, P NATL ACAD SCI USA, V92, P8826, DOI 10.1073/pnas.92.19.8826; Alb JG, 2002, MOL BIOL CELL, V13, P739, DOI 10.1091/mbc.01-09-0457; Allen-Baume V, 2002, FEBS LETT, V531, P74, DOI 10.1016/S0014-5793(02)03412-9; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2000, ENDOCR RES, V26, P629, DOI 10.3109/07435800009048583; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; Cockcroft S, 2001, J MEMBRANE BIOL, V180, P187, DOI 10.1007/s002320010069; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DeVries KJ, 1996, EXP CELL RES, V227, P33, DOI 10.1006/excr.1996.0246; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Hamilton BA, 1997, NEURON, V18, P711, DOI 10.1016/S0896-6273(00)80312-8; Hara S, 1997, J BIOL CHEM, V272, P14908, DOI 10.1074/jbc.272.23.14908; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Heitz F, 2002, BBA-PROTEIN STRUCT M, V1597, P1, DOI 10.1016/S0167-4838(02)00273-X; Hsuan J, 2001, GENOME BIOL, V2; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; Kular G, 1997, BIOCHEM J, V325, P299, DOI 10.1042/bj3250299; Larijani B, 2003, CURR BIOL, V13, P78, DOI 10.1016/S0960-9822(02)01395-7; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Litvak V, 2002, CURR BIOL, V12, P1513, DOI 10.1016/S0960-9822(02)01107-7; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Milligan SC, 1997, J CELL BIOL, V139, P351, DOI 10.1083/jcb.139.2.351; MONACO ME, 1986, BIOCHEM J, V236, P171, DOI 10.1042/bj2360171; Monaco ME, 2004, BIOCHEM BIOPH RES CO, V317, P444, DOI 10.1016/j.bbrc.2004.03.054; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Prosser S, 1997, BIOCHEM J, V324, P19, DOI 10.1042/bj3240019; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Schouten A, 2002, EMBO J, V21, P2117, DOI 10.1093/emboj/21.9.2117; Segui B, 2002, BIOCHEM J, V366, P23, DOI 10.1042/BJ20020317; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; STUTCHFIELD J, 1988, BIOCHEM J, V250, P375, DOI 10.1042/bj2500375; Swigart P, 2000, BIOCHEM J, V347, P837, DOI 10.1042/0264-6021:3470837; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; Tilley SJ, 2004, STRUCTURE, V12, P317, DOI 10.1016/j.str.2004.01.013; van Tiel CM, 2002, J BIOL CHEM, V277, P22447, DOI 10.1074/jbc.M201532200; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; Voziyan PA, 1996, BIOCHEMISTRY-US, V35, P12526, DOI 10.1021/bi960562o; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; Yoder MD, 2001, J BIOL CHEM, V276, P9246, DOI 10.1074/jbc.M010131200; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200	54	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47159	47171		10.1074/jbc.M405827200	http://dx.doi.org/10.1074/jbc.M405827200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322105	hybrid			2022-12-25	WOS:000224832400103
J	Seeds, AM; Sandquist, JC; Spana, EP; York, JD				Seeds, AM; Sandquist, JC; Spana, EP; York, JD			A molecular basis for inositol polyphosphate synthesis in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPORT; PHOSPHOLIPASE-C; SACCHAROMYCES-CEREVISIAE; PHOSPHATE MULTIKINASE; HUMAN HOMOLOG; KINASE; 1,4,5-TRISPHOSPHATE; HEXAKISPHOSPHATE; DICTYOSTELIUM; CELLS	Metabolism of inositol 1,4,5-trisphosphate (I( 1,4,5) P-3) results in the production of diverse arrays of inositol polyphosphates (IPs), such as IP4, IP5, IP6, and PP-IP5. Insights into their synthesis in metazoans are reported here through molecular studies in the fruit fly, Drosophila melanogaster. Two I(1,4,5) P-3 kinase gene products are implicated in initiating catabolism of these important IP regulators. We find dmIpk2 is a nucleocytoplasmic 6-/3-kinase that converts I(1,4,5) P-3 to I(1,3,4,5,6) P-5, and harbors 5-kinase activity toward I(1,3,4,6) P-4, and dmIP3K is a 3-kinase that converts I(1,4,5) P-3 to I(1,3,4,5) P-4. To assess their relative roles in the cellular production of IPs we utilized complementation analysis, RNA interference, and overexpression studies. Heterologous expression of dmIpk2, but not dmIP3K, in ipk2 mutant yeast recapitulates phospholipase C-dependent cellular synthesis of IP6. Knockdown of dmIpk2 in Drosophila S2 cells and transgenic flies results in a significant reduction of IP6 levels; whereas depletion of dmIP3K, either alpha or beta isoforms or both, does not decrease IP6 synthesis but instead increases its production, possibly by expanding I( 1,4,5) P3 pools. Similarly, knockdown of an I( 1,4,5) P-3 5-phosphatase results in significant increase in dmIpk2/dmIpk1-dependent IP6 synthesis. IP6 production depends on the I(1,3,4,5,6) P-5 2-kinase activity of dmIpk1 and is increased in transgenic flies overexpressing dmIpk2. Our studies reveal that phosphatase and kinase regulation of I( 1,4,5) P3 metabolic pools directly impinge on higher IP synthesis, and that the major route of IP6 synthesis depends on the activities of dmIpk2 and dmIpk1, but not dmIP3K, thereby challenging the role of IP3K in the genesis of higher IP messengers.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Duke Univ, DCMB Grp, Durham, NC 27708 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University	York, JD (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.	yorkj@duke.edu		Seeds, Andrew/0000-0002-4932-6496	NHLBI NIH HHS [HL-55672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beall EL, 2002, GENETICS, V162, P217; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brearley CA, 1996, BIOCHEM J, V314, P227, DOI 10.1042/bj3140227; Chang SC, 2002, J BIOL CHEM, V277, P43836, DOI 10.1074/jbc.M206134200; COMMUNI D, 1995, CELL SIGNAL, V7, P643, DOI 10.1016/0898-6568(95)00035-N; DRAYER AL, 1994, EMBO J, V13, P1601, DOI 10.1002/j.1460-2075.1994.tb06423.x; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; Feng YC, 2001, P NATL ACAD SCI USA, V98, P875, DOI 10.1073/pnas.021558098; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; Jun KS, 1998, LEARN MEMORY, V5, P317; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Mikoshiba K, 1997, CURR OPIN NEUROBIOL, V7, P339, DOI 10.1016/S0959-4388(97)80061-X; Monnier V, 2002, FREE RADICAL BIO MED, V33, P1250, DOI 10.1016/S0891-5849(02)01019-5; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Pouillon V, 2003, NAT IMMUNOL, V4, P1136, DOI 10.1038/ni980; Royet J, 1998, EMBO J, V17, P7351, DOI 10.1093/emboj/17.24.7351; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Saiardi A, 2001, P NATL ACAD SCI USA, V98, P2306, DOI 10.1073/pnas.041614598; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Shi JR, 2003, PLANT PHYSIOL, V131, P507, DOI 10.1104/pp.014258; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Speed CJ, 1996, EMBO J, V15, P4852, DOI 10.1002/j.1460-2075.1996.tb00866.x; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; Stevenson-Paulik J, 2002, J BIOL CHEM, V277, P42711, DOI 10.1074/jbc.M209112200; Sun Y, 2003, J BIOL CHEM, V278, P43645, DOI 10.1074/jbc.M300674200; VANDIJKEN P, 1995, J BIOL CHEM, V270, P29724; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wen BG, 2004, P NATL ACAD SCI USA, V101, P5604, DOI 10.1073/pnas.0306907101; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1; Xia HJ, 2003, PLANT CELL, V15, P449, DOI 10.1105/tpc.006676; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YORK JD, 2003, HDB CELL SIGNALING, V2, P229	44	53	57	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47222	47232		10.1074/jbc.M408295200	http://dx.doi.org/10.1074/jbc.M408295200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322119	hybrid			2022-12-25	WOS:000224832400110
J	Tombline, G; Bartholomew, LA; Tyndall, GA; Gimi, K; Urbatsch, IL; Senior, AE				Tombline, G; Bartholomew, LA; Tyndall, GA; Gimi, K; Urbatsch, IL; Senior, AE			Properties of P-glycoprotein with mutations in the "catalytic carboxylate" glutamate residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; DISULFIDE CROSS-LINKING; ATP-BINDING; ABC TRANSPORTER; MULTIDRUG-RESISTANCE; CONSERVED WALKER; SER RESIDUES; MECHANISM; SITES; CYCLE	It is known from earlier work that two conserved Glu residues, designated "catalytic carboxylates," are critical for function in P-glycoprotein (Pgp). Here the role of these residues (Glu-552 and Glu-1197 in mouse MDR3 Pgp) was studied further. Mutation E552Q or E1197Q reduced Pgp-ATPase to low but still measurable rates. Two explanations previously offered for effects of these mutations, namely that ADP release is slowed or that a second (drug site-resetting) round of ATP hydrolysis is blocked, were evaluated and appeared unsatisfactory. Thus the study was extended to include E552A, -D, and -K and E1197A, -D, and -K mutants. All reduced ATPase to similar low but measurable rates. Orthovanadate-trapping experiments showed that mutation to Gln, Ala, Asp, or Lys altered characteristics of the transition state but did not eliminate its formation in contrast e. g. with mutation of the analogous catalytic Glu in F-1-ATPase. Retention of ATP as well as ADP was seen in Ala, Asp, and Lys mutants. Mutation E552A in nucleotide binding domain 1 (NBD1) was combined with mutation S528A or S1173A in the LSGGQ sequence of NBD1 or NBD2, respectively. Synergistic effects were seen. E552A/S1173A had extremely low turnover rate for ATPase, while E552A/S528A showed zero or close to zero ATPase. Both showed orthovanadate-independent retention of ATP and ADP. We propose that mutations of the catalytic Glu residues interfere with formation and characteristics of a closed conformation, involving an interdigitated NBD dimer interface, which normally occurs immediately following ATP binding and progresses to the transition state.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NCI NIH HHS [T32CA09363] Funding Source: Medline; NIGMS NIH HHS [GM50156] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMANO T, 1994, FEBS LETT, V348, P93, DOI 10.1016/0014-5793(94)00588-5; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bliss JM, 1996, GLYCOBIOLOGY, V6, P445, DOI 10.1093/glycob/6.4.445; Carrier I, 2003, BIOCHEMISTRY-US, V42, P12875, DOI 10.1021/bi034257w; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Geourjon C, 2001, TRENDS BIOCHEM SCI, V26, P539, DOI 10.1016/S0968-0004(01)01907-7; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nadanaciva S, 2000, BIOCHEMISTRY-US, V39, P9583, DOI 10.1021/bi000941o; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Orelle C, 2003, J BIOL CHEM, V278, P47002, DOI 10.1074/jbc.M308268200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2003, J BIOL CHEM, V278, P23171, DOI 10.1074/jbc.M301957200; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Vigano C, 2002, J BIOL CHEM, V277, P5008, DOI 10.1074/jbc.M107928200	38	58	58	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46518	46526		10.1074/jbc.M408052200	http://dx.doi.org/10.1074/jbc.M408052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326176	hybrid			2022-12-25	WOS:000224832400023
J	Djaman, O; Outten, FW; Imlay, JA				Djaman, O; Outten, FW; Imlay, JA			Repair of oxidized iron-sulfur clusters in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; MANGANESE-SUPEROXIDE-DISMUTASE; DIHYDROXY-ACID DEHYDRATASE; SACCHAROMYCES-CEREVISIAE; CYSTEINE DESULFURASE; NITRIC-OXIDE; IN-VIVO; AZOTOBACTER-VINELANDII; ASSEMBLY PROTEINS; HYDROGEN-PEROXIDE	The [4Fe-4S](2+) clusters of dehydratases are rapidly damaged by univalent oxidants, including hydrogen peroxide, superoxide, and peroxynitrite. The loss of an electron destabilizes the cluster, causing it to release its catalytic iron atom and converting the cluster initially to an inactive [3Fe-4S](1+) form. Continued exposure to oxidants in vitro leads to further iron release. Experiments have shown that these clusters are repaired in vivo. We sought to determine whether repair is mediated by either the Isc or Suf cluster-assembly systems that have been identified in Escherichia coli. We found that all the proteins encoded by the isc operon were critical for de novo assembly, but most of these were unnecessary for cluster repair. IscS, a cysteine desulfurase, appeared to be an exception: although iscS mutants repaired damaged clusters, they did so substantially more slowly than did wild-type cells. Because sulfur mobilization should be required only if clusters degrade beyond the [3Fe-4S](1+) state, we used whole cell EPR to visualize the fate of oxidized enzymes in vivo. Fumarase A was overproduced. Brief exposure of cells to hydrogen peroxide resulted in the appearance of the characteristic [3Fe-4S](1+) signal of the oxidized enzyme. When hydrogen peroxide was then scavenged, the enzyme activity reappeared within minutes, in concert with the disappearance of the EPR signal. Thus it is unclear why IscS is required for efficient repair. The iscS mutants grew poorly, allowing the possibility that metabolic defects indirectly slow the repair process. Our data did indicate that damaged clusters decompose beyond the [3Fe-4S](1+) state in vivo when stress is prolonged. Under the conditions of our experiments, mutants that lacked other repair candidates - Suf proteins, glutathione, and NADPH: ferredoxin reductase - all repaired clusters at normal rates. We conclude that the mechanism of cluster repair is distinct from that of de novo assembly and that this is true because mild oxidative stress does not degrade clusters in vivo to the point of presenting an apoenzyme to the de novo cluster-assembly systems.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	University of Illinois System; University of Illinois Urbana-Champaign; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Imlay, JA (corresponding author), Univ Illinois, Dept Microbiol, 601 S Goodwin, Urbana, IL 61801 USA.	jimlay@uiuc.edu	Matin, AC/A-1315-2007	Matin, AC/0000-0003-4468-980X; Outten, Franklin/0000-0002-9095-0194	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049640, R01GM049640] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49640] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229, DOI DOI 10.1016/S0076-6879(94)33026-3; BIANCHI V, 1995, J BACTERIOL, V177, P4528, DOI 10.1128/jb.177.15.4528-4531.1995; BONGAERTS J, 1995, MOL MICROBIOL, V16, P521, DOI 10.1111/j.1365-2958.1995.tb02416.x; Brown NM, 2002, J BIOL CHEM, V277, P7246, DOI 10.1074/jbc.M110282200; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CRIBBS R, 1964, GENETICS, V49, P95; CSONKA LN, 1980, J BACTERIOL, V143, P529, DOI 10.1128/JB.143.1.529-530.1980; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Ding HG, 1997, P NATL ACAD SCI USA, V94, P8445, DOI 10.1073/pnas.94.16.8445; FLINT D H, 1990, P285; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Flint DH, 1996, J BIOL CHEM, V271, P16068; FRAENKEL DG, 1964, J BIOL CHEM, V239, P2765; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; Gaudu P, 1997, J BIOL CHEM, V272, P5082, DOI 10.1074/jbc.272.8.5082; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; GRUER MJ, 1994, MICROBIOL-SGM, V140, P2531, DOI 10.1099/00221287-140-10-2531; Gruer MJ, 1997, MICROBIOL-UK, V143, P1837, DOI 10.1099/00221287-143-6-1837; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HENSON CP, 1967, J BIOL CHEM, V242, P3833; HENSON JM, 1987, J GEN MICROBIOL, V133, P2631; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Keyer K, 1997, J BIOL CHEM, V272, P27652, DOI 10.1074/jbc.272.44.27652; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; KUO CF, 1987, J BIOL CHEM, V262, P4724; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; LINN S, 1987, J CELL SCI, P289; LIOCHEV SI, 1994, P NATL ACAD SCI USA, V91, P1328, DOI 10.1073/pnas.91.4.1328; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Maringanti S, 1999, J BACTERIOL, V181, P3792, DOI 10.1128/JB.181.12.3792-3802.1999; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MEINHARDT SW, 1989, BIOCHEMISTRY-US, V28, P2153, DOI 10.1021/bi00431a029; MEISTER A, 1985, METHOD ENZYMOL, V113, P327; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; MILLER JH, 1972, EXPT MOL GENETICS, P32; MILLER RE, 1972, J BIOL CHEM, V247, P7407; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Outten FW, 2003, J BIOL CHEM, V278, P45713, DOI 10.1074/jbc.M308004200; Pan N, 2001, MOL MICROBIOL, V39, P1562, DOI 10.1046/j.1365-2958.2001.02343.x; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; RAFTER GW, 1957, METHOD ENZYMOL, V3, P887, DOI 10.1016/S0076-6879(57)03471-0; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Shen J, 1997, MOL MICROBIOL, V26, P223, DOI 10.1046/j.1365-2958.1997.5561923.x; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tang Y, 1999, MICROBIOL-SGM, V145, P3069, DOI 10.1099/00221287-145-11-3069; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; TOUATI D, 1983, J BACTERIOL, V155, P1078, DOI 10.1128/JB.155.3.1078-1087.1983; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Varghese S, 2003, J BACTERIOL, V185, P221, DOI 10.1128/JB.185.1.221-230.2003; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; YANDOVSKAYA V, 2003, SCIENCE, V299, P700; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	82	135	145	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44590	44599		10.1074/jbc.M406487200	http://dx.doi.org/10.1074/jbc.M406487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308657	hybrid			2022-12-25	WOS:000224505600044
J	Lunn, JA; Rozengurt, E				Lunn, JA; Rozengurt, E			Hyperosmotic stress induces rapid focal adhesion kinase phosphorylation at tyrosines 397 and 577 - Role of Src family kinases and Rho family GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IRRADIATION-INDUCED APOPTOSIS; INTACT SWISS 3T3-CELLS; HOG1 MAP KINASE; GROWTH-FACTOR; SIGNALING PATHWAYS; OSMOTIC-STRESS; LYSOPHOSPHATIDIC ACID; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS	Hyperosmotic stress induced by treatment of Swiss 3T3 cells with the non-permeant solutes sucrose or sorbitol, rapidly and robustly stimulated endogenous focal adhesion kinase (FAK) phosphorylation at Tyr-397, the major autophosphorylation site, and at Tyr-577, within the kinase activation loop. Hyperosmotic stress-stimulated FAK phosphorylation at Tyr-397 occurred via a Src-independent pathway, whereas Tyr-577 phosphorylation was completely blocked by exposure to the Src family kinase inhibitor PP-2. Inhibition of p38 MAP kinase or phosphatidylinositol 3-kinases did not prevent FAK phosphorylation stimulated by hyperosmotic stress. Overexpression of N17 RhoA did not reduce hyperosmotic stress-mediated localization of phosphorylated FAK to focal contacts and treatment with the Rho-associated kinase inhibitor Y-27632 did not prevent FAK translocation and tyrosine phosphorylation in response to hyperosmotic stress. Overexpression of N17 Rac only slightly altered the hyperosmotic stress-mediated localization of phosphorylated FAK to focal contacts. In contrast, overexpression of the N17 mutant of Cdc42 disrupted hyperosmotic stress-stimulated FAK Tyr-397 localization to focal contacts. Additionally, treatment of cells with Clostridium difficile toxin B potently inhibited hyperosmotic stress-induced FAK tyrosine phosphorylation. Furthermore, FAK null fibroblasts compared with their FAK containing controls show markedly increased sensitivity, manifest by subsequent apoptosis, to sustained hyperosmotic stress. Our results indicate that FAK plays a fundamental role in protecting cells from hyperosmotic stress, and that the pathway(s) that mediates FAK autophosphorylation at Tyr-397 in response to osmotic stress can be distinguished from the pathways utilized by many other stimuli, including neuropeptides and bioactive lipids (Rho- and Rho-associated kinase-dependent), tyrosine kinase receptor agonists (phosphatidylinositol 3-kinase-dependent), and integrins (Src-dependent).	Univ Calif Los Angeles, David Geffen Sch Med,CURE,Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unite Signal Transduct & Gastrointestinal Canc, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,CURE,Digest Dis Res Ctr, Dept Med,Div Digest Dis, Unite Signal Transduct & Gastrointestinal Canc, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [P50 CA90388, K08CA104039-01] Funding Source: Medline; NIDDK NIH HHS [DK-41301, DK56930, DK 55003] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA104039, P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizawa H, 1999, GENES CELLS, V4, P311, DOI 10.1046/j.1365-2443.1999.00262.x; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; Charlesworth A, 1996, ONCOGENE, V12, P1337; Clerk A, 1997, FEBS LETT, V403, P23, DOI 10.1016/S0014-5793(97)00020-3; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Di Ciano-Oliveira C, 2003, AM J PHYSIOL-CELL PH, V285, pC555, DOI 10.1152/ajpcell.00086.2003; Duzgun SA, 2000, J CELL BIOCHEM, V76, P567, DOI 10.1002/(SICI)1097-4644(20000315)76:4<567::AID-JCB5>3.0.CO;2-W; FLYNN DC, 1992, ONCOGENE, V7, P579; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Guay J, 1997, J CELL SCI, V110, P357; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Jekel J. F., 1996, EPIDEMIOLOGY BIOSTAT; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KING CR, 1989, ONCOGENE, V4, P13; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Linseman DA, 2000, J NEUROCHEM, V74, P2010, DOI 10.1046/j.1471-4159.2000.0742010.x; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Mattison CP, 2000, GENE DEV, V14, P1229; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Paemeleire K, 1999, EXP BRAIN RES, V126, P473, DOI 10.1007/s002210050755; PARK SS, 2004, ONCOGENE; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Reiser V, 2000, NAT CELL BIOL, V2, P620, DOI 10.1038/35023568; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schliess F, 1998, ARCH BIOCHEM BIOPHYS, V351, P35, DOI 10.1006/abbi.1997.0517; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tsuda T, 1997, BIOCHEMISTRY-US, V36, P16328, DOI 10.1021/bi971448o; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	88	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45266	45278		10.1074/jbc.M314132200	http://dx.doi.org/10.1074/jbc.M314132200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302877	hybrid			2022-12-25	WOS:000224505600120
J	Moon, AF; Edavettal, SC; Krahn, JM; Munoz, EM; Negishi, M; Linhardt, RJ; Liu, J; Pedersen, LC				Moon, AF; Edavettal, SC; Krahn, JM; Munoz, EM; Negishi, M; Linhardt, RJ; Liu, J; Pedersen, LC			Structural analysis of the sulfotransferase (3-O-sulfotransferase isoform 3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HERPES-SIMPLEX-VIRUS; HEPARAN-SULFATE; CRYSTAL-STRUCTURE; CRYSTALLOGRAPHY; ANTITHROMBIN; EXPRESSION; PROGRAM; TYPE-1; SUITE	Heparan sulfate (HS) plays essential roles in assisting herpes simplex virus infection and other biological processes. The biosynthesis of HS includes numerous specialized sulfotransferases that generate a variety of sulfated saccharide sequences, conferring the selectivity of biological functions of HS. We report a structural study of human HS 3-O-sulfotransferase isoform 3 (3-OST-3), a key sulfotransferase that transfers a sulfuryl group to a specific glucosamine in HS generating an entry receptor for herpes simplex virus 1. We have obtained the crystal structure of 3-OST-3 at 1.95 Angstrom in a ternary complex with 3'-phosphoadenosine 5'-phosphate and a tetrasaccharide substrate. Mutational analyses were also performed on the residues involved in the binding of the substrate. Residues Gln(255) and Lys(368) are essential for the sulfotransferase activity and lie within hydrogen bonding distances to the carboxyl and sulfo groups of the uronic acid unit. These residues participate in the substrate recognition of 3-OST-3. This structure provides atomic level evidence for delineating the substrate recognition and catalytic mechanism for 3-OST-3.	Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Rensselaer Polytech Inst, Dept Chem & Chem Biol, Troy, NY 12180 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Rensselaer Polytechnic Institute	Liu, J (corresponding author), Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Rm 309,Beard Hall, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Pedersen, Lars/C-6173-2019; Negishi, Masahiko/F-7805-2019	Pedersen, Lars/0000-0002-4488-4077; Negishi, Masahiko/0000-0002-2076-8928	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062244, R01HL052622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL062244, R01 HL052622, HL52622, R01 HL052622-07, R01 HL052622-08, R01 HL062244-05A1, R01 HL062244-06] Funding Source: Medline; NIAID NIH HHS [AI50050, R01 AI050050] Funding Source: Medline; NIGMS NIH HHS [R01 GM038060-16A2, R01 GM038060, R01 GM038060-17] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; Das SK, 2001, CHEM-EUR J, V7, P4821; Edavettal SC, 2004, J BIOL CHEM, V279, P25789, DOI 10.1074/jbc.M401089200; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 2003, BIOCHEM SOC T, V31, P331, DOI 10.1042/BST0310331; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mikhailov D, 1996, BIOCHEM J, V315, P447, DOI 10.1042/bj3150447; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Spear PG, 2003, J VIROL, V77, P10179, DOI 10.1128/JVI.77.19.10179-10185.2003; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200	35	71	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45185	45193		10.1074/jbc.M405013200	http://dx.doi.org/10.1074/jbc.M405013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304505	Green Accepted, Green Submitted, hybrid			2022-12-25	WOS:000224505600112
J	Abid, MR; Schoots, IG; Spokes, KC; Wu, SQ; Mawhinney, C; Aird, WC				Abid, MR; Schoots, IG; Spokes, KC; Wu, SQ; Mawhinney, C; Aird, WC			Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and I kappa B/NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NADPH OXIDASE ACTIVITY; TNF-ALPHA; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; UP-REGULATION; CELL GROWTH; CAENORHABDITIS-ELEGANS; ADHESION MOLECULE-1	The mitochondrial antioxidant manganese superoxide dismutase (Mn-SOD) plays a critical cytoprotective role against oxidative stress. Vascular endothelial growth factor (VEGF) was shown previously to induce expression of Mn-SOD in endothelial cells by a NADPH oxidase-dependent mechanism. The goal of the current study was to determine the transcriptional mechanisms underlying this phenomenon. VEGF resulted in protein kinase C-dependent phosphorylation of IkappaB and subsequent translocation of p65 NF-kappaB into the nucleus. Overexpression of constitutively active IkappaB blocked VEGF stimulation of Mn-SOD. In transient transfection assays, VEGF increased Mn-SOD promoter activity, an effect that was dependent on a second intronic NF-kappaB consensus motif. In contrast, VEGF-mediated induction of Mn-SOD was enhanced by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 and by dominant negative Akt and was decreased by constitutively active Akt. Overexpression of a constitutively active (phosphorylation-resistant) form of FKHRL1 (TM-FKHRL1) resulted in increased Mn-SOD expression, suggesting that the negative effect of PI3K-Akt involves attenuation of forkhead activity. In co-transfection assays, the Mn-SOD promoter was transactivated by TM-FKHRL1. Flavoenzyme inhibitor, diphenyleneiodonium (DPI), and antisense oligonucleotides against p47(phox) (AS-p47(phox)) inhibited VEGF stimulation of IkappaB/NF-kappaB and forkhead phosphorylation, supporting a role for NADPH oxidase activity in both signaling pathways. Like VEGF, hepatocyte growth factor (HGF) activated the PI3K-Akt-forkhead pathway. However, HGF-PI3K-Akt-forkhead signaling was insensitive to diphenyleneiodonium and AS-p47(phox). Moreover, HGF failed to induce phosphorylation of IkappaB/NF-kappaB or nuclear translocation of NF-kappaB and had no effect on Mn-SOD expression. Together, these data suggest that VEGF is uniquely coupled to Mn-SOD expression through growth factor-specific reactive oxygen species (ROS)-sensitive positive (protein kinase C-NF-kappaB) and negative (PI3K-Akt-forkhead) signaling pathways.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Abid, MR (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Mol & Vasc Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.	rabid@bidmc.harvard.edu	Schoots, Ivo/ABB-9840-2020	Schoots, Ivo/0000-0002-9804-0603	NHLBI NIH HHS [HL60585, HL63609, HL36028, HL65216] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063609, P01HL036028, R01HL065216, R01HL060585] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Abid R, 2004, ARTERIOSCL THROM VAS, V24, P294, DOI 10.1161/01.ATV.0000110502.10593.06; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bey EA, 2000, J LIPID RES, V41, P489; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Chen ZQ, 1997, CANCER RES, V57, P2013; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Epperly MW, 2003, EXP HEMATOL, V31, P465, DOI 10.1016/S0301-472X(03)00041-9; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Johnson EN, 2003, J BIOL CHEM, V278, P1686, DOI 10.1074/jbc.M210250200; Keller JN, 1998, J NEUROSCI, V18, P687; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Marumo T, 1999, DIABETES, V48, P1131, DOI 10.2337/diabetes.48.5.1131; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; MORIMOTO A, 1991, BIOCHEM BIOPH RES CO, V179, P1042, DOI 10.1016/0006-291X(91)91924-2; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Rogers RJ, 2000, BIOCHEM J, V347, P233, DOI 10.1042/0264-6021:3470233; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Taniyama Y, 2003, HYPERTENSION, V42, P1075, DOI 10.1161/01.HYP.0000100443.09293.4F; Tjwa M, 2003, CELL TISSUE RES, V314, P5, DOI 10.1007/s00441-003-0776-3; TRAN H, 2003, SCI STKE; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; Yamaoka-Tojo M, 2004, CIRC RES, V95, P276, DOI 10.1161/01.RES.0000136522.58649.60; Yanase S, 2002, MECH AGEING DEV, V123, P1579, DOI 10.1016/S0047-6374(02)00093-3; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909	51	84	89	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44030	44038		10.1074/jbc.M408285200	http://dx.doi.org/10.1074/jbc.M408285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308628	hybrid			2022-12-25	WOS:000224383100082
J	Chen, NY; Leu, SJ; Todorovic, V; Lam, SCT; Lau, LF				Chen, NY; Leu, SJ; Todorovic, V; Lam, SCT; Lau, LF			Identification of a novel integrin alpha(v)beta(3) binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; HUMAN SKIN FIBROBLASTS; HEPARAN-SULFATE PROTEOGLYCANS; PHAGE DISPLAY LIBRARY; C-TERMINAL DOMAIN; INTEGRIN ALPHA(V)BETA(3); ATHEROSCLEROTIC LESIONS; MATRICELLULAR PROTEINS; BREAST-CANCER	CCN1 (CYR61) is a matricellular inducer of angiogenesis essential for successful vascular development. Though devoid of the canonical RGD sequence motif recognized by some integrins, CCN1 binds to, and functions through integrin alpha(v)beta(3) to promote pro-angiogenic activities in activated endothelial cells. In this study we identify a 20-residue sequence, V2 (NCKHQCTCIDGAVGCIPLCP), in domain II of CCN1 as a novel binding site for integrin alpha(v)beta(3). Immobilized synthetic V2 peptide supports alpha(v)beta(3)-mediated cell adhesion; soluble V2 peptide inhibits endothelial cell adhesion to CCN1 and the homologous family members CCN2 (connective tissue growth factor, CTGF) or CCN3 (NOV) but not to collagen. These activities are obliterated by mutation of the aspartate residue in the V2 peptide to alanine. The corresponding D125A mutation in the context of the N-terminal half of CCN1 (domains I and II) greatly diminished direct solid phase binding to purified integrin alpha(v)beta(3) and abolished alpha(v)beta(3)-mediated cell adhesion activity. Likewise, soluble full-length CCN1 with the D125A mutation is defective in binding purified alpha(v)beta(3) and impaired in alpha(v)beta(3)-mediated pro-angiogenic activities in vascular endothelial cells, including stimulation of cell migration and enhancement of DNA synthesis. In contrast, immobilized full-length CCN1-D125A mutant binds alpha(v)beta(3) and supports alpha(v)beta(3)-mediated cell adhesion similar to wild type CCN1. These results indicate that V2 is the primary alpha(v)beta(3) binding site in soluble CCN1, whereas additional cryptic alpha(v)beta(3) binding site(s) in the C-terminal half of CCN1 becomes exposed when the protein is immobilized. Together, these results identify a novel and functionally important binding site for integrin alpha(v)beta(3) and provide a new approach for dissecting alpha(v)beta(3)-specific CCN1 functions both in cultured cells and in the organism.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Todorovic, Viktor/0000-0002-1428-6973; Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA80080, CA46565] Funding Source: Medline; NHLBI NIH HHS [HL41793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041793, R29HL041793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Absenger Y, 2004, MOL HUM REPROD, V10, P399, DOI 10.1093/molehr/gah053; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Ball DK, 1998, BIOL REPROD, V59, P828, DOI 10.1095/biolreprod59.4.828; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Eliceiri BP, 2000, CANCER J, V6, pS245; Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Gilbert RE, 2003, DIABETES CARE, V26, P2632, DOI 10.2337/diacare.26.9.2632; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; GRZESZKIEWICZ TM, 2002, THESIS U ILLINOIS CH; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; McLane MA, 1996, FEBS LETT, V391, P139, DOI 10.1016/0014-5793(96)00716-8; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Roestenberg P, 2004, DIABETES CARE, V27, P1164, DOI 10.2337/diacare.27.5.1164; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Taverna D, 2004, P NATL ACAD SCI USA, V101, P763, DOI 10.1073/pnas.0307289101; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; Wu KJ, 2000, INT J MOL MED, V6, P433; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yamada T, 1996, FEBS LETT, V387, P11, DOI 10.1016/0014-5793(96)00409-7; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	60	102	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44166	44176		10.1074/jbc.M406813200	http://dx.doi.org/10.1074/jbc.M406813200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308622	hybrid			2022-12-25	WOS:000224383100096
J	Deora, AB; Kreitzer, G; Jacovina, AT; Hajjar, KA				Deora, AB; Kreitzer, G; Jacovina, AT; Hajjar, KA			An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; FIBROBLAST-GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; MATRIX INVASION; PROTEIN-KINASE; FACTOR-I; EXPRESSION; RECEPTOR; MODULATION; EXOCYTOSIS	Annexin 2 is a profibrinolytic co-receptor for plasminogen and tissue plasminogen activator that stimulates activation of the major fibrinolysin, plasmin, at cell surfaces. In human subjects, overexpression of annexin 2 in acute promyelocytic leukemia leads to a bleeding diathesis reflective of excessive cell surface annexin 2-dependent generation of plasmin (Menell, J. S., Cesarman, G. M., Jacovina, A. T., McLaughlin, M. A., Lev, E. A., and Hajjar, K. A. ( 1999) N. Engl. J. Med. 340, 994 - 1004). In addition, mice completely deficient in annexin 2 display fibrin accumulation within blood vessels and impaired clearance of injury-induced thrombi ( Ling Q., Jacovina, A. T., Deora, A. B., Febbraio, M., Simantov, R., Silverstein, R. L., Hempstead, B. L., Mark, W., and Hajjar, K. A. ( 2004) J. Clin. Investig. 113, 38 - 48). Here, we show that endothelial cell annexin 2, a protein that lacks a typical signal peptide, translocates from the cytoplasm to the extracytoplasmic plasma membrane in response to brief temperature stress both in vitro and in vivo in the absence of cell death or cell lysis. This regulated response is independent of new protein or mRNA synthesis and does not require the classical endoplasmic reticulum-Golgi pathway. Temperature stress-induced annexin 2 translocation is dependent on both expression of protein p11 (S100A10) and tyrosine phosphorylation of annexin 2 because annexin 2 release is completely eliminated on depletion of p11, inactivation of tyrosine kinase, or mutation of tyrosine 23. Translocation of annexin 2 to the cell surface dramatically increases tissue plasminogen activator-dependent plasminogen activation potential and may represent a novel stress-induced protein secretion pathway.	Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Protein Ctr, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Hajjar, KA (corresponding author), Cornell Univ, Dept Cell & Dev Biol, Weill Med Coll, New York, NY 10021 USA.	khajjar@med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058981, P01HL046403, R01HL042493, T32HL007423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42493, HL 07423, HL 58981, HL 46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Beaton AR, 2002, P NATL ACAD SCI USA, V99, P13154, DOI 10.1073/pnas.192432299; Bellagamba C, 1997, J BIOL CHEM, V272, P3195, DOI 10.1074/jbc.272.6.3195; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brownstein C, 2004, BLOOD, V103, P317, DOI 10.1182/blood-2003-04-1304; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; ERIKSON E, 1980, CELL, V21, P829, DOI 10.1016/0092-8674(80)90446-8; Falcone DJ, 2001, BLOOD, V97, P777, DOI 10.1182/blood.V97.3.777; Gardella S, 2001, BLOOD, V98, P2152, DOI 10.1182/blood.V98.7.2152; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Girard C, 2002, EMBO J, V21, P4439, DOI 10.1093/emboj/cdf469; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAJJAR KA, 1991, J BIOL CHEM, V266, P21962; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; ISACKE CM, 1986, MOL CELL BIOL, V6, P2745, DOI 10.1128/MCB.6.7.2745; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Ishii H, 2001, CIRC RES, V89, P1240, DOI 10.1161/hh2401.101066; Jacovina AT, 2001, J BIOL CHEM, V276, P49350, DOI 10.1074/jbc.M106289200; Katz AB, 1999, J INVEST DERMATOL, V112, P818, DOI 10.1046/j.1523-1747.1999.00572.x; KIANG JG, 1992, AM J PHYSIOL, V263, pC30, DOI 10.1152/ajpcell.1992.263.1.C30; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Krishnan S, 2004, DEV BIOL, V265, P140, DOI 10.1016/j.ydbio.2003.08.026; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Ling Q, 2004, J CLIN INVEST, V113, P38, DOI 10.1172/JCI200419684; LU D, 1993, AM J PHYSIOL, V264, pC715, DOI 10.1152/ajpcell.1993.264.3.C715; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; Marmorstein AD, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P341; Menell JS, 1999, NEW ENGL J MED, V340, P994, DOI 10.1056/NEJM199904013401303; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Okuda M, 1999, J BIOL CHEM, V274, P26803, DOI 10.1074/jbc.274.38.26803; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROCHA V, 1990, BIOCHEM SOC T, V18, P1110, DOI 10.1042/bst0181110; Rubartelli A., 1997, UNUSUAL SECRETORY PA, P87, DOI [10.1007/978-3-662-22581-3_3, DOI 10.1007/978-3-662-22581-3_3]; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; SHARP FR, 1993, STROKE S1, V24, P72; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; THIEL C, 1992, J CELL SCI, V103, P733; Thorey IS, 2001, J BIOL CHEM, V276, P35818, DOI 10.1074/jbc.M104871200; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; XU QB, 1993, ARTERIOSCLER THROMB, V13, P1763, DOI 10.1161/01.ATV.13.12.1763; XU QB, 1994, CIRC RES, V75, P1078, DOI 10.1161/01.RES.75.6.1078; ZHU W, 1994, BIOCHEM BIOPH RES CO, V200, P389, DOI 10.1006/bbrc.1994.1461	57	185	195	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43411	43418		10.1074/jbc.M408078200	http://dx.doi.org/10.1074/jbc.M408078200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302870	hybrid			2022-12-25	WOS:000224383100010
J	Yoshizuka, N; Moriuchi, R; Mori, T; Yamada, K; Hasegawa, S; Maeda, T; Shimada, T; Yamada, Y; Kamihira, S; Tomonaga, M; Katamine, S				Yoshizuka, N; Moriuchi, R; Mori, T; Yamada, K; Hasegawa, S; Maeda, T; Shimada, T; Yamada, Y; Kamihira, S; Tomonaga, M; Katamine, S			An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; NON-HODGKINS-LYMPHOMA; VIRUS TYPE-1 TAX; HTLV-I TAX; LEUKEMIA-VIRUS; PROTEIN-KINASE; HUMAN ONCOGENE; STRUCTURAL SIMILARITIES; EXPRESSION CLONING; HUMAN-LYMPHOCYTES	By screening cDNA expression libraries derived from fresh leukemic cells of adult T-cell leukemia for the potential to transform murine fibroblasts, NIH3T3, we have identified a novel transforming gene, designated Tgat. Expression of Tgat in NIH3T3 resulted in the loss of contact inhibition, increase of saturation density, anchorage-independent growth in a semisolid medium, tumorigenicity in nude mice, and increased invasiveness. Sequence comparison revealed that an alternative RNA splicing of the Trio gene was involved in the generation of Tgat. The Tgat cDNA encoded a protein product consisting of the Rho-guanosine nucleotide exchange factor (GEF) domain of a multifunctional protein, TRIO, and a unique C-terminal 15-amino acid sequence, which were derived from the exons 38-46 of the Trio gene and a novel exon located downstream of its last exon (exon 58), respectively. A Tgat mutant cDNA lacking the C-terminal coding region preserved Rho-GEF activity but lost the transforming potential, indicating an indispensable role of the unique sequence. On the other hand, treatment of Tgat-transformed NIH3T3 cells with Y-27632, a pharmacological inhibitor of Rho-associated kinase, abrogated their transforming phenotypes, suggesting the coinvolvement of Rho-GEF activity. Thus, alternative RNA splicing, resulting in the fusion protein with the Rho-GEF domain and the unique 15 amino acids, is the mechanism generating the novel oncogene, Tgat.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Gen Med, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Lab Med, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Hematol, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University	Moriuchi, R (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	ryozo@net.nagasaki-u.ac.jp	hasegawa, sumitaka/A-4020-2012					ALBINI A, 1987, CANCER RES, V47, P3239; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FUJII M, 1995, ONCOGENE, V11, P7; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; IMADA K, 1995, BLOOD, V86, P2350, DOI 10.1182/blood.V86.6.2350.bloodjournal8662350; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Ohno N, 2001, BLOOD, V98, P1160, DOI 10.1182/blood.V98.4.1160; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Okazaki S, 2001, VIRUS GENES, V23, P123, DOI 10.1023/A:1011840918149; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P128, DOI 10.1200/JCO.1988.6.1.128; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; Suzuki Takeshi, 1997, Leukemia (Basingstoke), V11, P14; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; UTSUNOMIYA A, 1988, CANCER, V61, P824, DOI 10.1002/1097-0142(19880215)61:4<824::AID-CNCR2820610430>3.0.CO;2-6; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Yamada Y, 1997, LEUKEMIA LYMPHOMA, V26, P327, DOI 10.3109/10428199709051782; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	45	43	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43998	44004		10.1074/jbc.M406082200	http://dx.doi.org/10.1074/jbc.M406082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308664	hybrid			2022-12-25	WOS:000224383100078
J	Ohara-Imaizumi, M; Cardozo, AK; Kikuta, T; Eizirik, DL; Nagamatsu, S				Ohara-Imaizumi, M; Cardozo, AK; Kikuta, T; Eizirik, DL; Nagamatsu, S			The cytokine interleukin-1 beta reduces the docking and fusion of insulin granules in pancreatic beta-cells, preferentially decreasing the first phase of exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; 1ST-DEGREE RELATIVES; SECRETORY GRANULES; ISLETS; APOPTOSIS; RELEASE; DYSFUNCTION; SUPPRESSION; EXPRESSION; MICROSCOPY	The prediabetic period in type I diabetes mellitus is characterized by the loss of first phase insulin release. This might be due to islet infiltration mediated by mononuclear cells and local release of cytokines, but the mechanisms involved are unknown. To determine the role of cytokines in insulin exocytosis, we have presently utilized total internal reflection fluorescence microscopy (TIRFM) to image and analyze the dynamic motion of single insulin secretory granules near the plasma membrane in live beta-cells exposed for 24 h to interleukin (IL)-1beta or interferon (IFN)-gamma. Immunohistochemistry observed via TIRFM showed that the number of docked insulin granules was decreased by 60% in beta-cells treated with IL-1beta, while it was not affected by exposure to IFN-gamma. This effect of IL-1beta was paralleled by a 50% reduction in the mRNA and the number of clusters of SNAP-25 in the plasma membrane. TIRF images of single insulin granule motion during a 15-min stimulation by 22 mM glucose in IL-1beta-treated beta-cells showed a marked reduction in the fusion events from previously docked granules during the first phase insulin release. Fusion from newcomers, however, was well preserved during the second phase of insulin release of IL-1beta-treated beta-cells. The present observations indicate that IL-1beta, but not IFN-gamma, has a preferential inhibitory effect on the first phase of glucose-induced insulin release, mostly via an action on previously docked granules. This suggests that beta-cell exposure to immune mediators during the course of insulitis might be responsible for the loss of first phase insulin release.	Kyorin Univ, Dept Biochem, Sch Med, Tokyo 1818611, Japan; Free Univ Brussels, Expt Med Lab, B-1070 Brussels, Belgium	Kyorin University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Nagamatsu, S (corresponding author), Kyorin Univ, Dept Biochem, Sch Med, 6-20-2 Shinkawa, Tokyo 1818611, Japan.	shinya@kyorin-u.ac.jp		Kupper Cardozo, Alessandra/0000-0001-7143-3696				Cardozo AK, 2001, J BIOL CHEM, V276, P48879, DOI 10.1074/jbc.M108658200; Cardozo AK, 2001, DIABETES, V50, P909, DOI 10.2337/diabetes.50.5.909; CHASE HP, 1987, J PEDIATR-US, V111, P807, DOI 10.1016/S0022-3476(87)80192-0; CHEN MC, 1999, DIABETOLOGIA, V39, P875; CONGET I, 1993, DIABETOLOGIA, V36, P358, DOI 10.1007/BF00400241; Gale EAM, 2001, DIABETES, V50, P217, DOI 10.2337/diabetes.50.2.217; Hoorens A, 2001, DIABETES, V50, P551, DOI 10.2337/diabetes.50.3.551; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Imagawa A, 2001, DIABETES, V50, P1269, DOI 10.2337/diabetes.50.6.1269; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Kutlu B, 2003, DIABETES, V52, P2701, DOI 10.2337/diabetes.52.11.2701; Ling ZD, 1998, ENDOCRINOLOGY, V139, P1540, DOI 10.1210/en.139.4.1540; Ling ZD, 2000, DIABETES, V49, P340, DOI 10.2337/diabetes.49.3.340; Mica OI, 2004, BIOCHEM J, V381, P13, DOI 10.1042/BJ20040434; Nagamatsu S, 1996, J BIOL CHEM, V271, P1160, DOI 10.1074/jbc.271.2.1160; Notkins AL, 2002, J BIOL CHEM, V277, P43545, DOI 10.1074/jbc.R200012200; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Ohara-Imaizumi M, 2004, J BIOL CHEM, V279, P8403, DOI 10.1074/jbc.M308954200; OHARAIMAIZUMI M, 2004, IN PRESS DIABETOLOGI; Rizzoli SO, 2004, SCIENCE, V303, P2037, DOI 10.1126/science.1094682; RODER ME, 1994, J CLIN ENDOCR METAB, V79, P1570, DOI 10.1210/jc.79.6.1570; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X; SPINAS GA, 1992, DIABETES CARE, V15, P632, DOI 10.2337/diacare.15.5.632; SRIKANTA S, 1985, NEW ENGL J MED, V313, P461, DOI 10.1056/NEJM198508223130801; SRIKANTA S, 1983, ANN INTERN MED, V99, P320, DOI 10.7326/0003-4819-99-3-320; STRANDELL E, 1990, J CLIN INVEST, V85, P1944, DOI 10.1172/JCI114657; STRANDELL E, 1992, DIABETOLOGIA, V35, P924, DOI 10.1007/BF00401420; VARDI P, 1991, DIABETOLOGIA, V34, P93, DOI 10.1007/BF00500379; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340	31	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41271	41274		10.1074/jbc.C400360200	http://dx.doi.org/10.1074/jbc.C400360200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15319424	hybrid			2022-12-25	WOS:000224075500004
J	Eliseev, RA; VanWinkle, B; Rosier, RN; Gunter, TE				Eliseev, RA; VanWinkle, B; Rosier, RN; Gunter, TE			Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NF kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNEL; OXIDATIVE STRESS; MITOCHONDRIAL; PHOSPHORYLATION; INHIBITION; HEART; CALCIUM; BCL-2; TRANSLOCATION; NUCLEOTIDES	Treatment of various types of cells with the mitochondrial ATP-sensitive K+ channel opener, diazoxide, preconditions cells to subsequent injuries and inhibits apoptosis. The mechanism of such preconditioning is not well understood. We have studied the effect of diazoxide pretreatment on mitochondrial morphology and function in HL60 cells and on susceptibility of these cells to apoptosis. We have found that diazoxide pretreatment inhibited etoposide-induced apoptosis and mitochondrial dysfunction. Diazoxide induced moderate mitochondrial swelling and increase in the cytosolic fraction of mitochondrial intermembrane proteins including cytochrome c without any significant effect on the oxidative phosphorylation function or membrane potential. Possibly as an adaptive response, total protein and mRNA levels of cytochrome c and of the anti-apoptotic Bcl-2 family member, Bcl-xl, increased. These effects coincided with activation of the transcription factors cAMP-response element-binding protein (CREB) and NFkappaB. The gene encoding cytochrome c carries the cAMP-response element (CRE), and the gene encoding Bcl-xl carries both the CRE and NFkappaB response elements. The inability of etoposide to trigger apoptosis in preconditioned cells was most likely because of pro-survival signaling by CREB and NFkappaB, which included up-regulation of cytochrome c and Bcl-xl. All described effects were reversed by a specific mitochondrial ATP-sensitive K+ channel inhibitor, 5-hydroxydecanoate, proving the specificity of the action of diazoxide. Preconditioning was also reversed by a specific NFkappaB inhibitor, SN50, proving the importance of this transcription factor for the phenomenon of preconditioning. CREB and NFkappaB were activated most likely in response to an observed elevation in cytosolic calcium following diazoxide treatment. We, therefore, conclude that diazoxide-mediated preconditioning against apoptosis involves activation of the pro-survival transcription factors CREB and NFkappaB.	Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Musculoskeletal Res Unit, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Gunter, TE (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, Box 712,575 Elmwood Ave, Rochester, NY 14642 USA.	Thomas_Gunter@urmc.rochester.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010041] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES10041] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akao M, 2001, CIRC RES, V88, P1267, DOI 10.1161/hh1201.092094; Andela VB, 2002, BIOCHEM BIOPH RES CO, V297, P237, DOI 10.1016/S0006-291X(02)02141-1; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; Beresewicz A, 2004, CARDIOVASC RES, V63, P118, DOI 10.1016/j.cardiores.2004.02.012; Chen F, 1999, J BIOL CHEM, V274, P35591, DOI 10.1074/jbc.274.50.35591; Eliseev RA, 2003, EXP CELL RES, V289, P275, DOI 10.1016/S0014-4827(03)00278-7; Eliseev RA, 2002, MITOCHONDRION, V1, P361, DOI 10.1016/S1567-7249(01)00039-3; Eliseev RA, 2003, BBA-BIOENERGETICS, V1604, P1, DOI 10.1016/S0005-2728(03)00005-7; Ferranti R, 2003, FEBS LETT, V536, P51, DOI 10.1016/S0014-5793(03)00007-3; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Grabowski DR, 1998, BIOCHEM PHARMACOL, V56, P345, DOI 10.1016/S0006-2952(98)00159-2; GUTNER KK, 1999, CURRENT PROTOCOLS TO; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hanley PJ, 2002, J PHYSIOL-LONDON, V542, P735, DOI 10.1113/jphysiol.2002.023960; Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HIRAYAMA T, 1990, MICROB PATHOGENESIS, V8, P421, DOI 10.1016/0882-4010(90)90029-P; Holmuhamedov EL, 2004, FEBS LETT, V568, P167, DOI 10.1016/j.febslet.2004.05.031; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; Hongpaisan J, 2003, MOL CELL NEUROSCI, V24, P1103, DOI 10.1016/j.mcn.2003.09.003; JENSEN BD, 1986, ARCH BIOCHEM BIOPHYS, V248, P305, DOI 10.1016/0003-9861(86)90427-3; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kopustinskiene DM, 2002, J BIOENERG BIOMEMBR, V34, P49, DOI 10.1023/A:1013870704002; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu D, 2002, J CEREBR BLOOD F MET, V22, P431, DOI 10.1097/00004647-200204000-00007; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Nagy K, 2004, J NEUROSCI RES, V76, P697, DOI 10.1002/jnr.20120; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Shake JG, 2001, ANN THORAC SURG, V72, P1849, DOI 10.1016/S0003-4975(01)03192-7; Teshima Y, 2003, BRAIN RES, V990, P45, DOI 10.1016/S0006-8993(03)03383-3; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Zhao LX, 2003, J NEUROSCI, V23, P4228	37	40	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46748	46754		10.1074/jbc.M406217200	http://dx.doi.org/10.1074/jbc.M406217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326191	hybrid			2022-12-25	WOS:000224832400053
J	Hinsby, AM; Olsen, JV; Mann, M				Hinsby, AM; Olsen, JV; Mann, M			Tyrosine phosphoproteomics of fibroblast growth factor signaling - A role for insulin receptor substrate-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED ACTIVATION; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN INTERACTIONS; POSTTRANSLATIONAL MODIFICATIONS; NEUROTROPHIC RECEPTORS; CELL-DIFFERENTIATION; MASS-SPECTROMETRY; DOCKING PROTEINS; EXCHANGE FACTOR	Signal transduction by receptor tyrosine kinases is initiated by recruitment of a variety of signaling proteins to tyrosine-phosphorylated motifs in the activated receptors. Several signaling pathways are thus activated in parallel, the combination of which decides the cellular response. Here, we present a dual strategy for extensive mapping of tyrosine-phosphorylated proteins and probing of signal-dependent protein interactions of a signaling cascade. The approach relies on labeling of cells with "heavy" and "light" isotopic forms of Arg to distinguish two cell populations. First, tyrosine-phosphorylated proteins from stimulated ("heavy"-labeled) and control samples ("normal"-labeled) are isolated and subjected to high sensitivity Fourier transform ion cyclotron resonance mass spectrometry analysis. Next, phosphopeptides corresponding to tyrosine phosphorylation sites identified during the tyrosine phosphoproteomic analysis are used as baits to isolate phosphospecific protein binding partners, which are subsequently identified by mass spectrometry. We used this approach to identify 28 components of the signaling cascade induced by stimulation with the basic fibroblast growth factor. Insulin receptor substrate-4 was identified as a novel candidate in fibroblast growth factor receptor signaling, and we defined phosphorylation-dependent interactions with other components, such as adaptor protein Grb2, of the signaling cascade. Finally, we present evidence for a complex containing insulin receptor substrate-4 and ShcA in signaling by the fibroblast growth factor receptor.	Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, Odense 5230, Denmark; Univ Copenhagen, Panum Inst 6 1, Prot Lab, DK-2200 Copenhagen, Denmark	University of Southern Denmark; University of Copenhagen	Mann, M (corresponding author), Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, Campusvej 55, Odense 5230, Denmark.	mann@bmb.sdu.dk	Mann, Matthias/A-3454-2013; Olsen, Jesper/ABH-4638-2020; Olsen, Jesper/C-4738-2008	Mann, Matthias/0000-0003-1292-4799; Olsen, Jesper/0000-0002-4747-4938; 				Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dell'Era P, 1999, MOL BIOL CELL, V10, P23, DOI 10.1091/mbc.10.1.23; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; Dunican DJ, 2001, CELL GROWTH DIFFER, V12, P255; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fujioka T, 2001, EUR J BIOCHEM, V268, P4158, DOI 10.1046/j.1432-1327.2001.02327.x; Fujioka T, 2001, EUR J BIOCHEM, V268, P25, DOI 10.1046/j.1432-1327.2001.01831.x; Furge LL, 1999, J BIOL CHEM, V274, P33504, DOI 10.1074/jbc.274.47.33504; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Goodlett DR, 2001, RAPID COMMUN MASS SP, V15, P1214, DOI 10.1002/rcm.362; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Hinsby AM, 2003, MOL CELL PROTEOMICS, V2, P29, DOI 10.1074/mcp.M200075-MCP200; Hresko RC, 2002, J BIOL CHEM, V277, P25233, DOI 10.1074/jbc.M202556200; Hung CH, 1996, P NATL ACAD SCI USA, V93, P10797, DOI 10.1073/pnas.93.20.10797; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KLINT P, 1999, FRONT BIOSCI, V4, P165; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Manabe R, 2002, J CELL SCI, V115, P1497; Mann M, 2003, NAT BIOTECHNOL, V21, P255, DOI 10.1038/nbt0303-255; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P608, DOI 10.1074/mcp.T400003-MCP200; Olsen JV, 2004, MOL CELL PROTEOMICS, V3, P82, DOI 10.1074/mcp.M300103-MCP200; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Ong SE, 2003, J PROTEOME RES, V2, P173, DOI 10.1021/pr0255708; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Pandey A, 2000, P NATL ACAD SCI USA, V97, P179, DOI 10.1073/pnas.97.1.179; Pandey A, 2002, ONCOGENE, V21, P8029, DOI 10.1038/sj.onc.1205988; Pawson T, 2000, GENE DEV, V14, P1027; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Sano H, 2002, J BIOL CHEM, V277, P19439, DOI 10.1074/jbc.M111838200; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yamada M, 1997, J BIOL CHEM, V272, P30334, DOI 10.1074/jbc.272.48.30334; Yan KS, 2002, J BIOL CHEM, V277, P17088, DOI 10.1074/jbc.M107963200; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	77	81	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46438	46447		10.1074/jbc.M404537200	http://dx.doi.org/10.1074/jbc.M404537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316024	hybrid			2022-12-25	WOS:000224832400014
J	Mihindukulasuriya, KA; Zhou, GS; Qin, J; Tan, TH				Mihindukulasuriya, KA; Zhou, GS; Qin, J; Tan, TH			Protein phosphatase 4 interacts with and down-regulates insulin receptor substrate 4 following tumor necrosis factor-alpha stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 4; FACTOR-I RECEPTOR; KAPPA-B KINASE; MEDIATED SIGNAL-TRANSDUCTION; N-TERMINAL KINASE; MICE LACKING; PHOSPHOTYROSINE PROTEIN; MOLECULAR-MECHANISMS; GLUCOSE-HOMEOSTASIS; GROWTH-RETARDATION	Protein phosphatase 4 (PP4; also named PPX or PPP4) is a PP2A-related protein serine/threonine phosphatase with important roles in a variety of cellular processes such as microtubule growth/organization, apoptosis, tumor necrosis factor (TNF)-alpha signaling, and activation of c-Jun N-terminal kinase and NF-kappaB. To further investigate the cellular functions of PP4, we isolated and identified PP4-interacting proteins using a proteomic approach. We found that insulin receptor substrate 4 (IRS-4) interacted with PP4 and that this interaction was enhanced following TNF-alpha stimulation. We also found that PP4, but not PP2A, down-regulated IRS-4 in a phosphatase activity-dependent manner. Pulse-chase analysis revealed that PP4 decreased the half-life of IRS-4 from 4 to 1 h. Moreover, we found that TNF-alpha stimulated a PP4-dependent degradation of IRS-4, as indicated by the blockage of the degradation by a potent PP4 inhibitor ( okadaic acid) and a phosphatase-dead PP4 mutant (PP4-RL). Taken together, our studies indicate that IRS-4 is subject to regulation by TNF-alpha and that PP4 mediates TNF-alpha-induced degradation of IRS-4.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Zhou, GS (corresponding author), Baylor Coll Med, Dept Immunol, 1 Baylor Plaza,M929, Houston, TX 77030 USA.	guisheng@bcm.tmc.edu; ttan@bcm.tmc.edu	Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Mihindukulasuriya, Kathie/0000-0001-9372-3758	NCI NIH HHS [R01-CA87076] Funding Source: Medline; NIAID NIH HHS [T32-AI07495] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007495] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Almind K, 1998, DIABETOLOGIA, V41, P969, DOI 10.1007/s001250051015; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bastians H, 1996, J CELL SCI, V109, P2865; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Broussard SR, 2003, ENDOCRINOLOGY, V144, P2988, DOI 10.1210/en.2003-0087; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Carnegie GK, 2003, J CELL SCI, V116, P1905, DOI 10.1242/jcs.00409; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; de Alvaro C, 2004, J BIOL CHEM, V279, P17070, DOI 10.1074/jbc.M312021200; Dounay AB, 2002, CURR MED CHEM, V9, P1939, DOI 10.2174/0929867023368791; Escribano O, 2003, HEPATOLOGY, V37, P1461, DOI 10.1053/jhep.2003.50245; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Fantin VR, 1999, BIOCHEM BIOPH RES CO, V260, P718, DOI 10.1006/bbrc.1999.0967; Gahr S, 2002, J MOL ENDOCRINOL, V28, P99, DOI 10.1677/jme.0.0280099; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Hastie CJ, 1998, FEBS LETT, V431, P357, DOI 10.1016/S0014-5793(98)00775-3; Hastie CJ, 2000, BIOCHEM J, V347, P845, DOI 10.1042/0264-6021:3470845; Helps NR, 1998, J CELL SCI, V111, P1331; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hu MCT, 2001, GENE, V278, P89, DOI 10.1016/S0378-1119(01)00734-X; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Iwata M, 2001, DIABETES, V50, P1083, DOI 10.2337/diabetes.50.5.1083; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; Karas M, 2001, ENDOCRINOLOGY, V142, P1835, DOI 10.1210/en.142.5.1835; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Krebs DL, 2002, MOL CELL BIOL, V22, P4567, DOI 10.1128/MCB.22.13.4567-4578.2002; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Ling P, 1999, MOL CELL BIOL, V19, P1359; Lingohr MK, 2003, MOL CELL ENDOCRINOL, V209, P17, DOI 10.1016/j.mce.2003.08.003; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Mourtada-Maarabouni M, 2003, CELL DEATH DIFFER, V10, P1016, DOI 10.1038/sj.cdd.4401274; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Qu BH, 1999, J BIOL CHEM, V274, P31179, DOI 10.1074/jbc.274.44.31179; Sano H, 2002, J BIOL CHEM, V277, P19439, DOI 10.1074/jbc.M111838200; Schreyer S, 2003, ENDOCRINOLOGY, V144, P1211, DOI 10.1210/en.2002-220723; Sesti G, 2001, FASEB J, V15, P2099, DOI 10.1096/fj.01-0009rev; Shen WH, 2002, CANCER RES, V62, P4746; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Sumiyoshi E, 2002, J CELL SCI, V115, P1403; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Tsuruzoe K, 2001, MOL CELL BIOL, V21, P26, DOI 10.1128/MCB.21.1.26-38.2001; Urso B, 2003, CELL SIGNAL, V15, P385, DOI 10.1016/S0898-6568(02)00113-4; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wada T, 2001, J AM SOC NEPHROL, V12, P2601, DOI 10.1681/ASN.V12122601; Warne JP, 2003, J ENDOCRINOL, V177, P351, DOI 10.1677/joe.0.1770351; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Yeh PY, 2004, J BIOL CHEM, V279, P26143, DOI 10.1074/jbc.M402362200; Yen HW, 2004, MOL HUM REPROD, V10, P473, DOI 10.1093/molehr/gah066; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200; Zhou LX, 1999, MOL ENDOCRINOL, V13, P505, DOI 10.1210/me.13.3.505	69	36	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46588	46594		10.1074/jbc.M408067200	http://dx.doi.org/10.1074/jbc.M408067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331607	hybrid			2022-12-25	WOS:000224832400032
J	Ahmad, Z; Senior, AE				Ahmad, Z; Senior, AE			Role of beta Asn-243 in the phosphate-binding subdomain of catalytic sites of Escherichia coli F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING; ATP SYNTHESIS; MITOCHONDRIAL ATPASE; FLUOROALUMINATE; F1-ATPASE; SYNTHASE; SUBUNIT; RESIDUE; COOPERATIVITY; INHIBITION	In the catalytic mechanism of ATP synthase, phosphate (P-i) binding and release steps are believed to be correlated to gamma-subunit rotation, and P-i binding is proposed to be prerequisite for binding ADP in the face of high cellular [ATP]/[ADP] ratios. In x-ray structures, residue betaAsn-243 appears centrally located in the P-i-binding subdomain of catalytic sites. Here we studied the role of betaAsn-243 in Escherichia coli ATP synthase by mutagenesis to Ala and Asp. Mutation betaN243A caused 30-fold impairment of F-1-ATPase activity; 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole inhibited this activity less potently than in wild type and P-i protected from inhibition. ADP-fluoroaluminate was more inhibitory than in wild-type, but ADP-fluoroscandium was less inhibitory. betaN243D F-1-ATPase activity was impaired by 1300-fold and was not inhibited by ADP-fluoroaluminate or ADP-fluoroscandium. 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole activated betaN243D F-1-ATPase, and P-i did not affect activation. We conclude that residue betaAsn-243 is not involved in P-i binding directly but is necessary for correct organization of the transition state complex through extensive involvement in hydrogen bonding to neighboring residues. It is also probably involved in orientation of the "attacking water" and of an associated second water.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu		Ahmad, Zulfiqar/0000-0001-7306-8151	NIGMS NIH HHS [R15 GM085771, GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R15GM085771, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad Z, 2004, J BIOL CHEM, V279, P31505, DOI 10.1074/jbc.M404621200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braig K, 2000, STRUCTURE, V8, P567, DOI 10.1016/S0969-2126(00)00145-3; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; Dou C, 1997, BIOCHEMISTRY-US, V36, P3719, DOI 10.1021/bi962353+; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; LUNARDI J, 1988, P NATL ACAD SCI USA, V85, P8958, DOI 10.1073/pnas.85.23.8958; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nadanaciva S, 2000, BIOCHEMISTRY-US, V39, P9583, DOI 10.1021/bi000941o; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P15493, DOI 10.1021/bi9917683; Nadanaciva S, 1999, BIOCHEMISTRY-US, V38, P7670, DOI 10.1021/bi990663x; Nadanaciva S, 1999, J BIOL CHEM, V274, P7052, DOI 10.1074/jbc.274.11.7052; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; PEREZ JA, 1986, FEBS LETT, V198, P113, DOI 10.1016/0014-5793(86)81195-4; RAO R, 1988, J BIOL CHEM, V263, P5569; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SENIOR AE, 1984, ARCH BIOCHEM BIOPHYS, V228, P49, DOI 10.1016/0003-9861(84)90045-6; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; Weber J, 2004, METHOD ENZYMOL, V380, P132; Weber J, 2003, FEBS LETT, V545, P61, DOI 10.1016/S0014-5793(03)00394-6; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210	36	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46057	46064		10.1074/jbc.M407608200	http://dx.doi.org/10.1074/jbc.M407608200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322126	hybrid			2022-12-25	WOS:000224694900091
J	Youn, H; Kerby, RL; Roberts, GP				Youn, H; Kerby, RL; Roberts, GP			Changing the ligand specificity of CooA, a highly specific heme-based CO sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; SENSING TRANSCRIPTIONAL ACTIVATOR; RESONANCE RAMAN-SPECTROSCOPY; CARBON-MONOXIDE; RHODOSPIRILLUM-RUBRUM; OXYGEN SENSOR; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; HISTIDINE 77	The CO-specific heme-based sensor CooA regulates the ability of Rhodospirillum rubrum to grow on CO as an energy source. Only CO triggers the conformational change of CooA essential for the protein to function as a transcriptional activator. A structurally informed mutagenesis, followed by an in vivo screening method, allowed the isolation of a series of novel CooA variants that show very substantial response to imidazole. Compared with wild-type CooA, the ligand selectivity between imidazole and CO had been changed in some variants by roughly three orders of magnitude. Remarkably, different CooA variants also showed the ability to discriminate among imidazole derivatives, strongly implying a mechanism of precise interactions between the affected residues and the various ligands. Although wild-type CooA and imidazole-responsive CooA variants appear to recognize their respective ligands by fundamentally different mechanisms, several lines of evidence suggest that they respond by a similar C-helix repositioning that results in the rearrangement of the DNA-binding domains responsible for specific DNA contact. These results have implications for the molecular basis of both the imidazole responsiveness in the variants and the stringent CO specificity of wild-type CooA.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Roberts, GP (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	groberts@bact.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53228] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1995, SHORT PROTOCOLS MOL, P21; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denninger JW, 2000, BIOCHEMISTRY-US, V39, P4191, DOI 10.1021/bi992332q; Dunham CM, 2003, BIOCHEMISTRY-US, V42, P7701, DOI 10.1021/bi0343370; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Hao B, 2002, BIOCHEMISTRY-US, V41, P12952, DOI 10.1021/bi020144l; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; Kerby RL, 2003, J MOL BIOL, V325, P809, DOI 10.1016/S0022-2836(02)01203-2; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; Olson JS, 1997, J BIOL INORG CHEM, V2, P544, DOI 10.1007/s007750050169; Pal B, 2004, J INORG BIOCHEM, V98, P824, DOI 10.1016/j.jinorgbio.2003.12.007; Reynolds MF, 2000, BIOCHEMISTRY-US, V39, P388, DOI 10.1021/bi991378g; Roberts GP, 2001, PROG NUCLEIC ACID RE, V67, P35, DOI 10.1016/S0079-6603(01)67024-7; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Tezcan FA, 1998, J AM CHEM SOC, V120, P13383, DOI 10.1021/ja982536e; Thorsteinsson MV, 2000, BIOCHEMISTRY-US, V39, P8284, DOI 10.1021/bi000327c; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Waterman M R, 1978, Methods Enzymol, V52, P456; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Youn H, 2003, J BIOL CHEM, V278, P2333, DOI 10.1074/jbc.M210825200; Youn H, 2002, J BIOL CHEM, V277, P33616, DOI 10.1074/jbc.M203684200; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	33	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45744	45752		10.1074/jbc.M404336200	http://dx.doi.org/10.1074/jbc.M404336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326187	hybrid			2022-12-25	WOS:000224694900057
J	Besser, D				Besser, D			Expression of nodal, lefty-A, and lefty-B in undifferentiated human embryonic stem cells requires activation of Smad2/3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESODERM INDUCTION; PRIMITIVE STREAK; MOUSE EMBRYOS; DIFFERENTIATION; WNT; GASTRULATION; PLURIPOTENCY; MAINTENANCE; ACTIVIN	Human embryonic stem cells will remain undifferentiated or undergo differentiation when grown in conditioned or non-conditioned medium, respectively. The factors and signaling events that control the maintenance of the undifferentiated state are not well characterized and their identification is of major importance. Based on the data from global expression analyses, we set out to identify genes and the signaling pathways controlling them that are regulated in the early phase of the differentiation process. This study shows that nodal and the inhibitors of Nodal signaling, lefty-A and lefty-B, are down-regulated very early upon differentiation. High expression of these genes in undifferentiated cells is maintained by activation of the transcription factor Smad2/3, downstream of the activin-linked kinases (ALK) 4/5/7. Treatment of differentiating cells with Activin A leads to activation of Smad2/3 and expression of nodal, lefty-A and lefty-B, while inhibition of ALK4/5/7 by the kinase inhibitor SB-431542 blocks activation of Smad2/3 and expression of these genes in the undifferentiated state. In addition, when cells are maintained undifferentiated by treatment with the GSK3-inhibitor, BIO, high expression of nodal, lefty-A, and lefty-B also requires activation of ALK4/5/7. Conversely, BMP signaling leading to Smad1/5/8 activation via ALK2/3/6 is blocked in undifferentiated cells and becomes activated upon differentiation. Taken together, these observations establish that Smad2/3 is activated in undifferentiated hESCs and required for the expression of genes controlling Nodal signaling. Moreover, there appears to be cross-talk between inhibition of GSK3, a hallmark of Wnt signaling and the Activin/Nodal pathway.	Rockefeller Univ, Lab Mol Vertebrate Embryol, New York, NY 10021 USA	Rockefeller University	Besser, D (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	d.besser@mdc-berlin.de	Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624				Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Hoodless PA, 2001, GENE DEV, V15, P1257, DOI 10.1101/gad.881501; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Ko MSH, 2001, TRENDS BIOTECHNOL, V19, P511, DOI 10.1016/S0167-7799(01)01806-6; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rosler ES, 2004, DEV DYNAM, V229, P259, DOI 10.1002/dvdy.10430; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Sambrook J., 2002, MOL CLONING LAB MANU; Sato N, 2003, DEV BIOL, V260, P404, DOI 10.1016/S0012-1606(03)00256-2; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schohl A, 2002, DEVELOPMENT, V129, P37; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Weinstein M, 1998, P NATL ACAD SCI USA, V95, P9378, DOI 10.1073/pnas.95.16.9378; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zeng XM, 2004, STEM CELLS, V22, P292, DOI 10.1634/stemcells.22-3-292	41	154	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45076	45084		10.1074/jbc.M404979200	http://dx.doi.org/10.1074/jbc.M404979200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308665	hybrid			2022-12-25	WOS:000224505600100
J	Lee, JN; Ye, J				Lee, JN; Ye, J			Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MESSENGER-RNA; CLEAVAGE; SCAP; MEMBRANES; TRANSLATION; DEGRADATION; SREBPS; ATF6	Insig-1 and Insig-2 are closely related proteins of the endoplasmic reticulum (ER) that block proteolytic activation of sterol regulatory element-binding proteins (SREBPs), membrane-bound transcription factors that activate synthesis of cholesterol and fatty acids in animal cells. When cellular cholesterol levels are high, Insig proteins bind to SREBP cleavage-activating protein, retaining it in the ER and preventing it from escorting SREBPs to the site of proteolytic activation in the Golgi complex. Here we report that hypotonic stress reverses the sterol-mediated inhibition of SREBP proteolytic activation by reducing the level of Insig-1 but not Insig-2. The reduction of Insig-1, a protein with a rapid turnover rate, results from a general inhibition of protein synthesis mediated by hypotonic stress. Insig-2 is not affected by hypotonic stress because of its slower turnover rate. Inhibition of protein synthesis by hypotonic shock has not been reported previously. Thapsigargin, an activator of the ER stress response, also inhibits protein synthesis and activates proteolysis of SREBP. Such activation also correlates with the disappearance of Insig-1. The current study demonstrates that animal cells, in response to either hypotonic shock or ER stress, can bypass the cholesterol inhibition of SREBP processing, an effect that is attributable to the rapid turnover of Insig-1.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ye, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	jin.ye@utsouthwestern.edu			NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HASAN MT, 1994, SOMAT CELL MOLEC GEN, V20, P183, DOI 10.1007/BF02254759; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Nohturfft A, 1998, P NATL ACAD SCI USA, V95, P12848, DOI 10.1073/pnas.95.22.12848; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 1998, J BIOL CHEM, V273, P28261, DOI 10.1074/jbc.273.43.28261; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Sever N, 2003, MOL CELL, V11, P25, DOI 10.1016/S1097-2765(02)00822-5; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yabe D, 2002, P NATL ACAD SCI USA, V99, P12753, DOI 10.1073/pnas.162488899; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7	25	156	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45257	45265		10.1074/jbc.M408235200	http://dx.doi.org/10.1074/jbc.M408235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304479	hybrid			2022-12-25	WOS:000224505600119
J	Lanning, CC; Daddona, JL; Ruiz-Velasco, R; Shafer, SH; Williams, CL				Lanning, CC; Daddona, JL; Ruiz-Velasco, R; Shafer, SH; Williams, CL			The Rac1 C-terminal polybasic region regulates the nuclear localization and protein degradation of Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; BINDING; GTPASE; SMGGDS; TRANSLOCATION; DISSOCIATION; ACTIVATION; INTERACTS; MEMBRANE; BOX	We observed evolutionary conservation of canonical nuclear localization signal sequences (K(K/R)X(K/R)) in the C-terminal polybasic regions (PBRs) of some Rac and Rho isoforms. Canonical D-box sequences (RXXL), which target proteins for proteasome-mediated degradation, are also evolutionarily conserved near the PBRs of these small GTPases. We show that the Rac1 PBR (PVKKRKRK) promotes Rac1 nuclear accumulation, whereas the RhoA PBR (RRGKKKSG) keeps RhoA in the cytoplasm. A mutant Rac1 protein named Rac1 (pbrRhoA), in which the RhoA PBR replaces the Rac1 PBR, has greater cytoplasmic localization, enhanced resistance to proteasome-mediated degradation, and higher protein levels than Rac1. Mutating the D-box by substituting alanines at amino acids 174 and 177 significantly increases the protein levels of Rac1 but not Rac1(pbrRhoA). These results suggest that Rac1 (pbrRhoA) is more resistant than Rac1 to proteasome-mediated degradative pathways involving the D-box. The cytoplasmic localization of Rac1(pbrRhoA) provides the most obvious reason for its resistance to proteasome-mediated degradation, because we show that Rac1(pbrRhoA) does not greatly differ from Rac1 in its ability to stimulate membrane ruffling or to interact with SmgGDS and IQGAP1-calmodulin complexes. These findings support the model that nuclear localization signal sequences in the PBR direct Rac1 to the nucleus, where Rac1 participates in signaling pathways that ultimately target it for degradation.	Guthrie Res Inst, Mol Pharmacol Lab, Sayre, PA 18840 USA		Williams, CL (corresponding author), Guthrie Res Inst, Mol Pharmacol Lab, 1 Guthrie Sq, Sayre, PA 18840 USA.	williams_carol@guthrie.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL063921, R01 HL63921, R01 HL63921-03S1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Gandhi PN, 2004, BIOCHEM J, V378, P409, DOI 10.1042/BJ20030979; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Hofemeister H, 2000, MOL BIOL CELL, V11, P3233, DOI 10.1091/mbc.11.9.3233; KAWAMURA M, 1993, BIOCHEM BIOPH RES CO, V190, P832, DOI 10.1006/bbrc.1993.1124; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Lerm M, 2002, INFECT IMMUN, V70, P4053, DOI 10.1128/IAI.70.8.4053-4058.2002; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Pop M, 2004, J BIOL CHEM, V279, P35840, DOI 10.1074/jbc.M404346200; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Ruiz-Velasco R, 2002, J BIOL CHEM, V277, P33081, DOI 10.1074/jbc.M202664200; Senadheera D, 2001, INT J MOL MED, V8, P127; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Vikis HG, 2002, ONCOGENE, V21, P2425, DOI 10.1038/sj.onc.1205306; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Williams CL, 2003, CELL SIGNAL, V15, P1071, DOI 10.1016/S0898-6568(03)00098-6; Yokoo T, 2003, J BIOL CHEM, V278, P52919, DOI 10.1074/jbc.M309334200	28	82	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44197	44210		10.1074/jbc.M404977200	http://dx.doi.org/10.1074/jbc.M404977200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304504	hybrid			2022-12-25	WOS:000224383100099
J	Xiong, HB; Li, HX; Chen, YB; Zhao, J; Unkeless, JC				Xiong, HB; Li, HX; Chen, YB; Zhao, J; Unkeless, JC			Interaction of TRAF6 with MAST205 regulates NF-kappa B activation and MAST205 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RECEPTORS; PROTEIN-KINASE; MEDIATE ACTIVATION; UBIQUITIN LIGASE; GENE-EXPRESSION; MACROPHAGE; INTERLEUKIN-12; DEGRADATION; PROTEASOME; COMPLEX	The binding of immune complexes to macrophage Fcgamma receptor results in a subsequent inhibition of lipopolysaccharide-stimulated interleukin-12 synthesis without affecting the induction of tumor necrosis factor-alpha. RNA interference targeting MAST205, a 205-kDa serine/ threonine kinase, and transfection of dominant negative MAST205 mutants also mimic this type II macrophage phenotype. Our previous epistasis experiments suggested that the position of MAST205 in the TLR4 signal pathway was proximal to the IkappaB kinase complex. We now report that MAST205 forms a complex with TRAF6, resulting in the inhibition of TRAF6 NF-kappaB activation. We have identified a peptide ( residues 218 - 233) from the N terminus of MAST205 that, when coupled to a protein transduction domain, inhibits the lipopolysaccharide-stimulated activation of NF-kappaB, modulates the size of the MAST205 . TRAF6 complex, and inhibits ubiquitination of TRAF6. A dominant negative N-terminal MAST205 deletion mutant also inhibits TRAF6 ubiquitination. The domain required for degradation of MAST205 after Fcgamma receptor activation resides within the N-terminal 261 residues, and degradation is triggered by protein kinase C isoform phosphorylation of Ser/Thr residues. These results suggest that MAST205 functions as a scaffolding protein controlling TRAF6 activity and, therefore, plays an important role in regulating inflammatory responses.	CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol & Biochem, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Unkeless, JC (corresponding author), CUNY Mt Sinai Sch Med, Immunobiol Ctr, 1425 Madison Ave, New York, NY 10029 USA.	jay.unkeless@mssm.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI024322, R01AI024322, R21AI052325] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24322, AI-52325] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahonen CL, 2002, NAT IMMUNOL, V3, P451, DOI 10.1038/ni792; Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101; Anderson CF, 2002, J IMMUNOL, V168, P3697, DOI 10.4049/jimmunol.168.8.3697; Berset G, 2002, MOL CELL BIOL, V22, P4463, DOI 10.1128/MCB.22.13.4463-4476.2002; Breton A, 2000, BIOCHEM BIOPH RES CO, V276, P472, DOI 10.1006/bbrc.2000.3511; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Cheung PCF, 2004, BIOCHEM J, V378, P27, DOI 10.1042/BJ20031794; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gerber JS, 2001, J IMMUNOL, V166, P6861, DOI 10.4049/jimmunol.166.11.6861; Hawiger J, 1999, BLOOD, V94, P1711, DOI 10.1182/blood.V94.5.1711.417k20_1711_1716; Ishitani T, 2003, EMBO J, V22, P6277, DOI 10.1093/emboj/cdg605; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Jin G, 2004, P NATL ACAD SCI USA, V101, P2028, DOI 10.1073/pnas.0307314101; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074-7613(03)00230-9; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lumeng C, 1999, NAT NEUROSCI, V2, P611, DOI 10.1038/10165; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Penrose KJ, 2000, J VIROL, V74, P6031, DOI 10.1128/JVI.74.13.6031-6038.2000; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sanjo H, 2003, MOL CELL BIOL, V23, P1231, DOI 10.1128/MCB.23.4.1231-1238.2003; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Sutterwala FS, 1999, J LEUKOCYTE BIOL, V65, P543, DOI 10.1002/jlb.65.5.543; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; WALDEN PD, 1993, MOL CELL BIOL, V13, P7625, DOI 10.1128/MCB.13.12.7625; Walden PD, 1996, BIOL REPROD, V55, P1039, DOI 10.1095/biolreprod55.5.1039; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; ZHENG L, 1995, J IMMUNOL, V155, P776; Zhou H, 2004, J IMMUNOL, V172, P2559, DOI 10.4049/jimmunol.172.4.2559	45	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43675	43683		10.1074/jbc.M404328200	http://dx.doi.org/10.1074/jbc.M404328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308666	hybrid			2022-12-25	WOS:000224383100041
J	Qiao, M; Shapiro, P; Kumar, R; Passaniti, A				Qiao, M; Shapiro, P; Kumar, R; Passaniti, A			Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; CROSS-CASCADE ACTIVATION; TRANSCRIPTION FACTOR; OSTEOBLAST DIFFERENTIATION; OSTEOCALCIN PROMOTER; BONE SIALOPROTEIN; GENE-EXPRESSION; P21-ACTIVATED KINASES; PROTEIN-KINASES; CBFA1 GENE	Insulin-like growth factor-1 (IGF-1) is an angiogenic and oncogenic factor that activates signal transduction pathways involved in the expression of transcriptional regulators of tumorigenesis. RUNX2, a member of the Ig-loop family of transcription factors is expressed in vascular endothelial cells (EC) and regulates EC migration, invasion, and proliferation. Here we show that IGF-1 and its receptor regulate post-translational changes in RUNX2 to activate DNA binding in proliferating EC. The phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, reduced both basal and IGF-1-stimulated RUNX2 DNA binding activity in the absence of changes in RUNX2 protein as did the overexpression of the phosphatidylinositol 3-phosphate phosphatase, confirming that PI3K signaling mediates RUNX2 activation. IGF-1 increased ERK1/2 activation, which was abrogated by the inhibition of PI3K, thus linking these two pathways in EC. Treatment with U0126, which inhibits ERK1/2 activation, reduced IGF-1-stimulated RUNX2 DNA binding without affecting RUNX2 protein levels. Overexpression of constitutively active MKK1 increased RUNX2 DNA binding and phosphorylation. No additive effects of PI3K or ERK inhibitors on DNA binding were evident. Surprisingly, these IGF-1-mediated effects on RUNX2 were not regulated by Akt phosphorylation, a common downstream target of PI3K, as determined by pharmacological or genetic inhibition. However, an inhibitor of the p21-activated protein kinase-1, glutathione S-transferase-Pak1-( 83 - 149), inhibited both basal and IGF-1-stimulated RUNX2 DNA binding, suggesting that Pak1 mediates IGF-1 signaling to increase RUNX2 activity. These results indicate that the angiogenic growth factor, IGF-1, can regulate RUNX2 DNA binding through sequential activation of the PI3K/Pak1 and ERK1/2 signaling cascade.	Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Pathol,Program Oncol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Biochem & Mol Biol,Program Oncol, Baltimore, MD 21201 USA; Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, Baltimore, MD 21201 USA; Univ Texas, MD Anderson Canc Ctr, Dept Cellular & Mol Oncol, Houston, TX 77030 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; UTMD Anderson Cancer Center	Passaniti, A (corresponding author), Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Pathol,Program Oncol, Bressler Res Bldg 7-021,655 W Baltimore St, Baltimore, MD 21201 USA.	apass001@umaryland.edu			NATIONAL CANCER INSTITUTE [R21CA095350, R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA95350, CA90970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Barnes GL, 2003, CANCER RES, V63, P2631; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Brubaker KD, 2003, PROSTATE, V56, P13, DOI 10.1002/pros.10233; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; COFFIN JD, 1995, MOL BIOL CELL, V6, P1861, DOI 10.1091/mbc.6.12.1861; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dunn SE, 2000, MOL CARCINOGEN, V27, P10, DOI 10.1002/(SICI)1098-2744(200001)27:1<10::AID-MC3>3.0.CO;2-Z; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Geoffroy V, 1998, MAMM GENOME, V9, P54, DOI 10.1007/s003359900679; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Kumar R, 2002, MICROSC RES TECHNIQ, V59, P49, DOI 10.1002/jemt.10176; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lehr JE, 1998, J NATL CANCER I, V90, P118, DOI 10.1093/jnci/90.2.118; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Liang K, 1999, ENDOCRINOLOGY, V140, P5780; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Lopaczynski W, 1999, ACTA BIOCHIM POL, V46, P51, DOI 10.18388/abp.1999_4183; Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002-220072; Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Riminucci M, 2003, CALCIFIED TISSUE INT, V73, P281, DOI 10.1007/s00223-002-2134-y; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Shelton JG, 2004, CELL CYCLE, V3, P372; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676; Strayhorn CL, 1999, J PERIODONTOL, V70, P1345, DOI 10.1902/jop.1999.70.11.1345; Sun LX, 2004, ONCOGENE, V23, P4722, DOI 10.1038/sj.onc.1207589; Sun LX, 2001, CANCER RES, V61, P4994; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Wee HJ, 2002, EMBO REP, V3, P967, DOI 10.1093/embo-reports/kvf193; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Yeung F, 2002, J BIOL CHEM, V277, P2468, DOI 10.1074/jbc.M105947200; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2; Zhang YW, 1997, ONCOGENE, V15, P367, DOI 10.1038/sj.onc.1201352; Zheng QP, 2003, J CELL BIOL, V162, P833, DOI 10.1083/jcb.200211089	61	118	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42709	42718		10.1074/jbc.M404480200	http://dx.doi.org/10.1074/jbc.M404480200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15304489	hybrid			2022-12-25	WOS:000224226400045
J	Croce, R; Morosinotto, T; Ihalainen, JA; Chojnicka, A; Breton, J; Dekker, JP; van Grondelle, R; Bassi, R				Croce, R; Morosinotto, T; Ihalainen, JA; Chojnicka, A; Breton, J; Dekker, JP; van Grondelle, R; Bassi, R			Origin of the 701-nm fluorescence emission of the Lhca2 subunit of higher plant photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; CHLOROPHYLL-PROTEIN COMPLEXES; CRYSTAL-STRUCTURE; MUTATION ANALYSIS; ANTENNA COMPLEX; PIGMENT-BINDING; RECONSTITUTION; LHCII	Photosystem I of higher plants is characterized by red-shifted spectral forms deriving from chlorophyll chromophores. Each of the four Lhca1 to - 4 subunits exhibits a specific fluorescence emission spectrum, peaking at 688, 701, 725, and 733 nm, respectively. Recent analysis revealed the role of chlorophyll-chlorophyll interactions of the red forms in Lhca3 and Lhca4, whereas the basis for the fluorescence emission at 701 nm in Lhca2 is not yet clear. We report a detailed characterization of the Lhca2 subunit using molecular biology, biochemistry, and spectroscopy and show that the 701-nm emission form originates from a broad absorption band at 690 nm. Spectroscopy on recombinant mutant proteins assesses that this band represents the low energy form of an excitonic interaction involving two chlorophyll a molecules bound to sites A5 and B5, the same protein domains previously identified for Lhca3 and Lhca4. The resulting emission is, however, substantially shifted to higher energies. These results are discussed on the basis of the structural information that recently became available from x-ray crystallography (Ben Shem, A., Frolow, F., and Nelson, N. (2003) Nature 426, 630 - 635). We suggest that, within the Lhca subfamily, spectroscopic properties of chromophores are modulated by the strength of the excitonic coupling between the chromophores A5 and B5, thus yielding fluorescence emission spanning a large wavelength interval. It is concluded that the interchromophore distance rather than the transition energy of the individual chromophores or the orientation of transition vectors represents the critical factor in determining the excitonic coupling in Lhca pigment-protein complexes.	ITC, CNR, Ist Biofis, I-38100 Trento, Italy; Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; Univ Aix Marseille 2, LGBP, Fac Sci Luminy, Dept Biol, F-13288 Marseille, France; Vrije Univ Amsterdam, Fac Sci, Div Phys & Astron, NL-1081 HV Amsterdam, Netherlands; CEA, Serv Bioenerget, F-91191 Gif Sur Yvette, France	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Istituto per le Tecnologie della Costruzione (ITC-CNR); University of Verona; UDICE-French Research Universities; Aix-Marseille Universite; Vrije Universiteit Amsterdam; CEA; UDICE-French Research Universities; Universite Paris Saclay	Croce, R (corresponding author), ITC, CNR, Ist Biofis, Via Sommar 18, I-38100 Trento, Italy.	croce@itc.it	Croce, Roberta/HGU-9554-2022; Croce, Roberta/N-4067-2014; Croce, Roberta/ABG-3595-2021; Morosinotto, Tomas/AAC-3188-2019; Croce, Roberta/F-1174-2014	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Morosinotto, Tomas/0000-0002-0803-7591; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Caffarri S, 2004, BIOCHEMISTRY-US, V43, P9467, DOI 10.1021/bi036265i; Castelletti S, 2003, BIOCHEMISTRY-US, V42, P4226, DOI 10.1021/bi027398r; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; den Hartog FTH, 1998, J PHYS CHEM B, V102, P11007; EVANS JR, 1986, PHOTOBIOCH PHOTOBIOP, V10, P135; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; GOBETS B, 1994, BBA-BIOENERGETICS, V1188, P75, DOI 10.1016/0005-2728(94)90024-8; HAWORTH P, 1982, BIOCHIM BIOPHYS ACTA, V682, P152, DOI 10.1016/0005-2728(82)90129-3; HAWORTH P, 1983, BIOCHIM BIOPHYS ACTA, V724, P151, DOI 10.1016/0005-2728(83)90036-1; HAYES JM, 1988, BIOCHIM BIOPHYS ACTA, V932, P287, DOI 10.1016/0005-2728(88)90166-1; Ihalainen JA, 2000, BIOCHEMISTRY-US, V39, P8625, DOI 10.1021/bi0007369; JANSSON S, 1994, BBA-BIOENERGETICS, V1184, P1, DOI 10.1016/0005-2728(94)90148-1; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Morosinotto T, 2003, J BIOL CHEM, V278, P49223, DOI 10.1074/jbc.M309203200; Morosinotto T, 2002, J BIOL CHEM, V277, P36253, DOI 10.1074/jbc.M205062200; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Remelli R, 1999, J BIOL CHEM, V274, P33510, DOI 10.1074/jbc.274.47.33510; Rogl H, 1999, BIOCHEMISTRY-US, V38, P16214, DOI 10.1021/bi990739p; Schmid VHR, 1997, P NATL ACAD SCI USA, V94, P7667, DOI 10.1073/pnas.94.14.7667; Schmid VHR, 2002, J BIOL CHEM, V277, P37307, DOI 10.1074/jbc.M205889200; van Amerongen H, 2001, J PHYS CHEM B, V105, P604, DOI 10.1021/jp0028406; Zhang H, 1997, PLANT PHYSIOL, V115, P1525, DOI 10.1104/pp.115.4.1525	31	36	36	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48543	48549		10.1074/jbc.M408908200	http://dx.doi.org/10.1074/jbc.M408908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15328342	hybrid			2022-12-25	WOS:000225098100009
J	Muller, FL; Liu, YH; Van Remmen, H				Muller, FL; Liu, YH; Van Remmen, H			Complex III releases superoxide to both sides of the inner mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; HYDROGEN-PEROXIDE PRODUCTION; REACTIVE OXYGEN; Q(O) SITE; RESPIRATORY-CHAIN; UBIHYDROQUINONE OXIDATION; NEONATAL LETHALITY; HEART-MITOCHONDRIA; MUTANT MICE; Q-CYCLE	Mechanisms of mitochondrial superoxide formation remain poorly understood despite considerable medical interest in oxidative stress. Superoxide is produced from both Complexes I and III of the electron transport chain, and once in its anionic form it is too strongly charged to readily cross the inner mitochondrial membrane. Thus, superoxide production exhibits a distinct membrane sidedness or "topology." In the present work, using measurements of hydrogen peroxide (Amplex red) as well as superoxide ( modified Cypridina luciferin analog and aconitase), we demonstrate that Complex I-dependent superoxide is exclusively released into the matrix and that no detectable levels escape from intact mitochondria. This finding fits well with the proposed site of electron leak at Complex I, namely the iron-sulfur clusters of the (matrix-protruding) hydrophilic arm. Our data on Complex III show direct extramitochondrial release of superoxide, but measurements of hydrogen peroxide production revealed that this could only account for similar to 50% of the total electron leak even in mitochondria lacking CuZn-superoxide dismutase. We posit that the remaining similar to 50% of the electron leak must be due to superoxide released to the matrix. Measurements of ( mitochondrial matrix) aconitase inhibition, performed in the presence of exogenous superoxide dismutase and catalase, confirmed this hypothesis. Our data indicate that Complex III can release superoxide to both sides of the inner mitochondrial membrane. The locus of superoxide production in Complex III, the ubiquinol oxidation site, is situated immediately next to the intermembrane space. This explains extramitochondrial release of superoxide but raises the question of how superoxide could reach the matrix. We discuss two models explaining this result.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev Studies, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Muller, FL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,MSC 7762, San Antonio, TX 78229 USA.	mullerf@uthscsa.edu		Muller, Florian/0000-0001-7568-2948	NATIONAL INSTITUTE ON AGING [T32AG021890, P01AG014674] Funding Source: NIH RePORTER; NIA NIH HHS [5T3-AG021890-02, P01AG14674] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIKENS J, 1991, J BIOL CHEM, V266, P15091; Barja G, 1999, J BIOENERG BIOMEMBR, V31, P347, DOI 10.1023/A:1005427919188; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BIELSKI BHJ, 1985, J PHYS CHEM REF DATA, V14, P1041, DOI 10.1063/1.555739; BIELSKI BHJ, 1983, J BIOL CHEM, V258, P4759; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHAPPELL JB, 1954, NATURE, V173, P1094, DOI 10.1038/1731094a0; Copin JC, 2000, FREE RADICAL BIO MED, V28, P1571, DOI 10.1016/S0891-5849(00)00280-X; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; de Grey ADNJ, 2000, J ANTI-AGING MED, V3, P25, DOI 10.1089/rej.1.2000.3.25; Ernster L., 1967, METHOD ENZYMOL, V10, P86; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; GUILLIVI C, 1999, REACTIVE OXYGEN SPEC, P77; GUSKOVA RA, 1984, BIOCHIM BIOPHYS ACTA, V778, P579, DOI 10.1016/0005-2736(84)90409-7; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMON HJ, 1987, J BIOENERG BIOMEMBR, V19, P167, DOI 10.1007/BF00762723; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JENSEN PK, 1966, BIOCHIM BIOPHYS ACTA, V122, P157, DOI 10.1016/0926-6593(66)90057-9; KETTLE AJ, 1994, FREE RADICAL BIO MED, V17, P161, DOI 10.1016/0891-5849(94)90111-2; Korshunov SS, 2002, MOL MICROBIOL, V43, P95, DOI 10.1046/j.1365-2958.2002.02719.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Liochev SI, 1999, FREE RADICAL BIO MED, V26, P777; Liu SS, 1999, J BIOENERG BIOMEMBR, V31, P367; Longo VD, 1999, ARCH BIOCHEM BIOPHYS, V365, P131, DOI 10.1006/abbi.1999.1158; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; LOSCHEN G, 1976, RECENT ADV STUDIES C, V7, P3; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Muller F, 2003, FREE RADICAL BIO MED, V35, pS27; Muller F, 2002, BIOCHEMISTRY-US, V41, P7866, DOI 10.1021/bi025581e; Muller F, 2000, J AM AGING ASSOC, V23, P227, DOI 10.1007/s11357-000-0022-9; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; Nakano M, 1998, CELL MOL NEUROBIOL, V18, P565, DOI 10.1023/A:1020257532357; NICHOLLS DG, 2002, BIOENERGETICS, V3, P128; NOHL H, 1990, FREE RADICAL RES COM, V8, P307, DOI 10.3109/10715769009053364; Nohl H, 1996, FREE RADICAL BIO MED, V20, P207, DOI 10.1016/0891-5849(95)02038-1; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Scheffler IE, 1999, MITOCHONDRIA; Sharp RE, 1999, J BIOENERG BIOMEMBR, V31, P225, DOI 10.1023/A:1005467628660; Sipos I, 2003, J NEUROCHEM, V84, P112, DOI 10.1046/j.1471-4159.2003.01513.x; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; TAKAHASHI M, 1988, ARCH BIOCHEM BIOPHYS, V267, P714, DOI 10.1016/0003-9861(88)90080-X; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TAKESHIGE K, 1979, BIOCHEM J, V180, P129, DOI 10.1042/bj1800129; Teranishi K, 1997, ANAL BIOCHEM, V249, P37, DOI 10.1006/abio.1997.2150; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Yano T, 2002, MOL ASPECTS MED, V23, P345, DOI 10.1016/S0098-2997(02)00011-0; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	80	739	758	1	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49064	49073		10.1074/jbc.M407715200	http://dx.doi.org/10.1074/jbc.M407715200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15317809	hybrid			2022-12-25	WOS:000225098100070
J	Pawliczak, R; Logun, C; Madara, P; Lawrence, M; Woszczek, G; Ptasinska, A; Kowalski, ML; Wu, T; Shelhamer, JH				Pawliczak, R; Logun, C; Madara, P; Lawrence, M; Woszczek, G; Ptasinska, A; Kowalski, ML; Wu, T; Shelhamer, JH			Cytosolic phospholipase A(2) group IV alpha but not secreted phospholipase A(2) group IIA, V, or X induces interleukin-8 and cyclooxygenase-2 gene and protein expression through peroxisome proliferator-activated receptors gamma 1 and 2 in human lung cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; EPIDERMAL-GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID MOBILIZATION; PROSTAGLANDIN E-2 PRODUCTION; COX-2 EXPRESSION; PPAR-GAMMA; P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION	It has been reported that interleukin-8 (IL-8) and cyclooxygenase-2 (COX-2) expression is regulated by peroxisome proliferator-activated receptor (PPAR)-gamma synthetic ligands. We have shown previously that cytosolic phospholipase A(2) (cPLA(2)) is able to activate gene expression through PPAR-gamma response elements (Pawliczak, R., Han, C., Huang, X. L., Demetris, A. J., Shelhamer, J. H., and Wu, T. (2002) J. Biol. Chem. 277, 33153 - 33163). In this study we investigated the influence of cPLA(2) and secreted phospholipase A(2) (sPLA(2)) Group IIA, Group V, and Group X on IL-8 and COX-2 expression in human lung epithelial cells (A549 cells). We also studied the results of cPLA(2) activation by epidermal growth factor (EGF) and calcium ionophore (A23187) on IL-8 and COX-2 reporter gene activity, mRNA level, and protein synthesis. cPLA(2) overexpression and activation increased both IL-8 and COX-2 reporter gene activity. Overexpression and activation of Group IIA, Group V, or Group X sPLA(2)s did not increase IL-8 and COX-2 reporter gene activity. Methyl arachidonyl fluorophosphate, a cPLA(2) inhibitor, inhibited the effect of A23187 and of EGF on both IL-8 and COX-2 reporter gene activity, steady state levels of IL-8 and COX-2 mRNA, and IL-8 and COX-2 protein expression. Small inhibitory RNAs directed against PPAR-gamma1 and -gamma2 blunted the effect of A23187 and of EGF on IL-8 and COX-2 protein expression. Moreover small inhibitory RNAs directed against cPLA(2) decreased the effect of A23187 and EGF on IL-8 and COX-2 protein expression. These results demonstrate that cPLA(2) has an influence on IL-8 and COX 2 gene and protein expression at least in part through PPAR-gamma.	NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA; Med Univ Lodz, Dept Allergy & Clin Immunol, PL-92213 Lodz, Poland; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	National Institutes of Health (NIH) - USA; Medical University Lodz; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, Bldg 10,Rm 7D43,9000 Rockville Pike, Bethesda, MD 20892 USA.	jshelhamer@nih.gov	Pawliczak, Rafa/S-2021-2019; Pawliczak, Rafal Tomasz/S-9649-2016; Woszczek, Grzegorz/H-5792-2012	Pawliczak, Rafa/0000-0001-6784-453X; 				Aoki Y, 1998, AM J PHYSIOL-LUNG C, V274, pL1030, DOI 10.1152/ajplung.1998.274.6.L1030; Armoni M, 2003, J BIOL CHEM, V278, P30614, DOI 10.1074/jbc.M304654200; Balboa MA, 2003, J IMMUNOL, V171, P989, DOI 10.4049/jimmunol.171.2.989; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; Balsinde J, 2000, ANN NY ACAD SCI, V905, P11; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Beck S, 2003, J BIOL CHEM, V278, P29799, DOI 10.1074/jbc.M211763200; BENFIELD TL, 1995, RESP MED, V89, P285, DOI 10.1016/0954-6111(95)90089-6; Bradbury DA, 2002, AM J PHYSIOL-LUNG C, V283, pL717, DOI 10.1152/ajplung.00070.2002; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Dennis EA, 2000, AM J RESP CRIT CARE, V161, pS32, DOI 10.1164/ajrccm.161.supplement_1.ltta-7; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dolan-O'Keefe M, 2000, AM J PHYSIOL-LUNG C, V278, pL649, DOI 10.1152/ajplung.2000.278.4.L649; Evans JH, 2003, ADV ENZYME REGUL, V43, P229, DOI 10.1016/S0065-2571(02)00034-1; Fong CY, 2000, AM J PHYSIOL-LUNG C, V279, pL201, DOI 10.1152/ajplung.2000.279.1.L201; Fu YC, 2002, ATHEROSCLEROSIS, V160, P11, DOI 10.1016/S0021-9150(01)00541-X; Ghosh M, 2004, AM J RESP CELL MOL, V30, P91, DOI 10.1165/rcmb.2003-0005OC; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Hegen M, 2003, J EXP MED, V197, P1297, DOI 10.1084/jem.20030016; Hinz B, 2003, BIOCHEM BIOPH RES CO, V302, P415, DOI 10.1016/S0006-291X(03)00195-5; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Huh YH, 2003, J BIOL CHEM, V278, P9691, DOI 10.1074/jbc.M211360200; Ikawa H, 2001, EXP CELL RES, V267, P73, DOI 10.1006/excr.2001.5233; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; Jozkowicz A, 2001, PROSTAG OTH LIPID M, V66, P165, DOI 10.1016/S0090-6980(01)00155-1; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Pang LH, 2003, J IMMUNOL, V170, P1043, DOI 10.4049/jimmunol.170.2.1043; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pawliczak R, 2002, J BIOL CHEM, V277, P33153, DOI 10.1074/jbc.M200246200; Pawliczak R, 2002, AM J RESP CELL MOL, V27, P722, DOI 10.1165/rcmb.2002-0033OC; Rebsamen MC, 2003, J MOL CELL CARDIOL, V35, P81, DOI 10.1016/S0022-2828(02)00281-X; Richter A, 2002, AM J RESP CELL MOL, V27, P85, DOI 10.1165/ajrcmb.27.1.4789; Rodrigues S, 2003, FASEB J, V17, P7, DOI 10.1096/fj.02-0201com; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Subauste MC, 2001, INT IMMUNOPHARMACOL, V1, P1229, DOI 10.1016/S1567-5769(01)00063-7; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Uozumi N, 2002, PROSTAG OTH LIPID M, V68-9, P59, DOI 10.1016/S0090-6980(02)00021-7; Wadhwa S, 2002, BIOCHEM BIOPH RES CO, V297, P46, DOI 10.1016/S0006-291X(02)02124-1; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; Wu T, 1997, AM J PHYSIOL-LUNG C, V273, pL331, DOI 10.1152/ajplung.1997.273.2.L331; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104; Zhao HY, 2003, AM J PHYSIOL-RENAL, V285, pF281, DOI 10.1152/ajprenal.00030.2003	48	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48550	48561		10.1074/jbc.M408926200	http://dx.doi.org/10.1074/jbc.M408926200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15331599	hybrid			2022-12-25	WOS:000225098100010
J	Williamson, AJK; Dibling, BC; Boyne, JR; Selby, P; Burchill, SA				Williamson, AJK; Dibling, BC; Boyne, JR; Selby, P; Burchill, SA			Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38(MAPK) and up-regulation of the death receptor p75(NTR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PRO-INFLAMMATORY CYTOKINES; FAS-INDUCED APOPTOSIS; EWINGS-SARCOMA CELLS; P38 MAP KINASE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; INDUCED PHOSPHORYLATION; NEUROECTODERMAL TUMOR; JNK ACTIVATION	Basic fibroblast growth factor (bFGF) induces cell death in cells of the Ewing's sarcoma family of tumors in vivo and in vitro. In this study we demonstrate that this is dependent on the rapid and sustained activation of p38(MAPK), in contrast to the transient activation of p38(MAPK) associated with bFGF-induced cell proliferation. Stem cell factor-induced survival of TC-32 cells was also associated with transient activation of p38(MAPK). Inhibition of p38(MAPK) by SB202190 and p38(MAPK) small interfering RNA reduces bFGF-induced death in TC-32 cells, consistent with the hypothesis that activation of p38(MAPK) is essential for induction of death by bFGF. This appears to be dependent on sustained activation of p38(MAPK), demonstrated by inhibition of bFGF-induced cell death following addition of SB202190 to TC-32 cells 5 min after exposure to bFGF (20 ng/ml) and activation of p38(MAPK). Prolonged activation of p38(MAPK) is accompanied by a rapid and sustained phosphorylation of Ras and ERK; inhibition of ERK phosphorylation using the MEK-1 inhibitor PD98059 rescued similar to30% of cells from bFGF-induced death suggesting ERK plays a secondary role in the induction of death. This hypothesis is supported by observations in the A673 cell line; bFGF induced sustained activation of ERK and transient activation of p38(MAPK), which was not associated with cell death. These data demonstrate that sustained activation of p38(MAPK) is essential for activation of the death cascade following exposure of Ewing's sarcoma family of tumors cells to bFGF and provide evidence that activation of p38(MAPK) results in an up-regulation of the death receptor p75(NTR).	St James Univ Hosp, Canc Res UK Clin Ctr, Candlelighters Childrens Canc Res Lab, Leeds LS9 7TF, W Yorkshire, England	Cancer Research UK; Saint James's University Hospital; University of Leeds	Burchill, SA (corresponding author), St James Univ Hosp, Canc Res UK Clin Ctr, Candlelighters Childrens Canc Res Lab, Beckett St, Leeds LS9 7TF, W Yorkshire, England.	S.A.Burchill@leeds.ac.uk	Boyne, James/AAU-6616-2021	Boyne, James/0000-0003-1219-6453				Benini S, 2001, CLIN CANCER RES, V7, P1790; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.3.CO;2-S; Chang FM, 2003, INT J ONCOL, V22, P469; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Craxton A, 1998, J IMMUNOL, V161, P3225; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Hu YL, 1999, AM J PHYSIOL-HEART C, V277, pH1593, DOI 10.1152/ajpheart.1999.277.4.H1593; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang C, 2001, CANCER RES, V61, P3062; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kashiwada M, 1996, EUR J IMMUNOL, V26, P1451, DOI 10.1002/eji.1830260708; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Keeton AB, 2002, J BIOL CHEM, V277, P48565, DOI 10.1074/jbc.M207837200; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kovar Heinrich, 1999, Current Opinion in Oncology, V11, P275, DOI 10.1097/00001622-199907000-00007; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Landuzzi L, 2000, AM J PATHOL, V157, P2123, DOI 10.1016/S0002-9440(10)64850-X; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; MARSHALL NJ, 1995, GROWTH REGULAT, V5, P69; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nebl G, 2004, CELL SIGNAL, V16, P235, DOI 10.1016/S0898-6568(03)00133-5; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raucci A, 2004, J BIOL CHEM, V279, P1747, DOI 10.1074/jbc.M310384200; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Sasaki K, 2004, MOL BIOL CELL, V15, P1387, DOI 10.1091/mbc.E03-06-0367; SCHWEIGERER L, 1987, J CLIN INVEST, V80, P1516, DOI 10.1172/JCI113236; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 1998, CANCER RES, V58, P4127; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sturla LM, 2000, CANCER RES, V60, P6160; Sutter AP, 2003, BRIT J CANCER, V89, P564, DOI 10.1038/sj.bjc.6601125; Tabassum A, 2003, INT J CANCER, V105, P47, DOI 10.1002/ijc.11038; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Valladares A, 2000, ENDOCRINOLOGY, V141, P4383, DOI 10.1210/en.141.12.4383; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; Wang WL, 2002, J BIOL CHEM, V277, P21723, DOI 10.1074/jbc.M202224200; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang ZS, 2001, CANCER RES, V61, P7171; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; West DC, 2000, CURR OPIN ONCOL, V12, P323, DOI 10.1097/00001622-200007000-00008; Westwood G, 2002, ONCOGENE, V21, P809, DOI 10.1038/sj.onc.1205128; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	95	38	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47912	47928		10.1074/jbc.M409035200	http://dx.doi.org/10.1074/jbc.M409035200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15310753	hybrid			2022-12-25	WOS:000224957000062
J	Costa-Rodrigues, J; Carvalho, AF; Gouveia, AM; Fransen, M; Sa-Miranda, C; Azevedo, JE				Costa-Rodrigues, J; Carvalho, AF; Gouveia, AM; Fransen, M; Sa-Miranda, C; Azevedo, JE			The N terminus of the peroxisomal cycling receptor, Pex5p, is required for redirecting the peroxisome-associated peroxin back to the cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGETING SIGNAL RECEPTOR; MATRIX PROTEIN IMPORT; HUMAN PTS1 RECEPTOR; SACCHAROMYCES-CEREVISIAE; 3-KETOACYL-COA THIOLASE; BIOGENESIS DISORDERS; YARROWIA-LIPOLYTICA; MEMBRANE-PROTEINS; PICHIA-PASTORIS; LONGER ISOFORM	Most newly synthesized peroxisomal matrix proteins are transported to the organelle by Pex5p, a remarkable multidomain protein involved in an intricate network of transient protein-protein interactions. Presently, our knowledge regarding the structure/function of amino acid residues 118 to the very last residue of mammalian Pex5p is quite vast. Indeed, the cargo-protein receptor domain as well as the binding sites for several peroxins have all been mapped to this region of Pex5p. In contrast, structural/functional data regarding the first 117 amino acid residues of Pex5p are still scarce. Here we show that a truncated Pex5p lacking the first 110 amino acid residues (DeltaN110-Pex5p) displays exactly the peroxisomal import properties of the full-length peroxin implying that this N-terminal domain is involved neither in cargo-protein binding nor in the docking/translocation step of the Pex5p-cargo protein complex at the peroxisomal membrane. However, the ATP-dependent export step of DeltaN110-Pex5p from the peroxisomal membrane is completely blocked, a phenomenon that was also observed for a Pex5p version lacking just the first 17 amino acid residues but not for a truncated protein comprising amino acid residues 1-324 of Pex5p. By exploring the unique properties of DeltaN110-Pex5p, the effect of temperature on the import/export kinetics of Pex5p was characterized. Our data indicate that the export step of Pex5p from the peroxisomal compartment ( in contrast with its insertion into the organelle membrane) is highly dependent on the temperature.	Inst Biol Mol & Celular, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Katholieke Univ Leuven, Fac Geneeskunde, Dept Mol Celbiol, B-3000 Louvain, Belgium; Inst Genet Med Jacinto de Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto; KU Leuven	Azevedo, JE (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	jazevedo@ibme.up.pt	sá Miranda, Maria Clara/K-3920-2013; Fransen, Marc/C-6262-2008; Gouveia, Alexandra/P-3525-2016; Carvalho, Andreia/J-9013-2015; Costa-Rodrigues, João/L-1058-2014; Fransen, Marc/ADL-0723-2022; Azevedo, Jorge E/A-4113-2008	sá Miranda, Maria Clara/0000-0003-0123-5525; Fransen, Marc/0000-0001-9284-1197; Gouveia, Alexandra/0000-0001-8784-4246; Carvalho, Andreia/0000-0001-8781-5680; Azevedo, Jorge E/0000-0001-7714-5302; Costa-Rodrigues, Joao/0000-0003-1375-8067				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Azevedo JE, 2004, CELL BIOCHEM BIOPHYS, V41, P451, DOI 10.1385/CBB:41:3:451; Braverman N, 1998, HUM MOL GENET, V7, P1195, DOI 10.1093/hmg/7.8.1195; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dodt G, 2001, J BIOL CHEM, V276, P41769, DOI 10.1074/jbc.M106932200; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; Einwachter H, 2001, EMBO REP, V2, P1035, DOI 10.1093/embo-reports/kve228; Elgersma Y, 1998, J CELL BIOL, V140, P807, DOI 10.1083/jcb.140.4.807; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AM, 2003, J BIOL CHEM, V278, P4389, DOI 10.1074/jbc.C200650200; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; KAIN KC, 1991, BIOTECHNIQUES, V10, P366; Klein ATJ, 2001, J BIOL CHEM, V276, P15034, DOI 10.1074/jbc.M010776200; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; MIURA S, 1992, J BIOL CHEM, V267, P14405; Nito K, 2002, PLANT CELL PHYSIOL, V43, P355, DOI 10.1093/pcp/pcf057; Oliveira ME, 2003, J BIOL CHEM, V278, P39483, DOI 10.1074/jbc.M305089200; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 1998, J CELL BIOL, V143, P1859; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Rehling P, 2000, J BIOL CHEM, V275, P3593, DOI 10.1074/jbc.275.5.3593; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Salomons FA, 2000, J BIOL CHEM, V275, P12603, DOI 10.1074/jbc.275.17.12603; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Sichting M, 2003, MOL BIOL CELL, V14, P810, DOI 10.1091/mbc.E02-08-0539; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TERLECKY SR, 1995, EMBO J, V14, P3627, DOI 10.1002/j.1460-2075.1995.tb00032.x; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; Urquhart AJ, 2000, J BIOL CHEM, V275, P4127, DOI 10.1074/jbc.275.6.4127; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; Weller S, 2003, ANNU REV GENOM HUM G, V4, P165, DOI 10.1146/annurev.genom.4.070802.110424; Zhang JW, 1996, J CELL BIOL, V132, P325, DOI 10.1083/jcb.132.3.325	51	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46573	46579		10.1074/jbc.M406399200	http://dx.doi.org/10.1074/jbc.M406399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328363	Green Published, hybrid			2022-12-25	WOS:000224832400030
J	Pettigrew, D; Anderson, KL; Billington, J; Cota, E; Simpson, P; Urvil, P; Rabuzin, F; Roversi, P; Nowicki, B; du Merle, L; Le Bouguenec, C; Matthews, S; Lea, SM				Pettigrew, D; Anderson, KL; Billington, J; Cota, E; Simpson, P; Urvil, P; Rabuzin, F; Roversi, P; Nowicki, B; du Merle, L; Le Bouguenec, C; Matthews, S; Lea, SM			High resolution studies of the Afa/Dr adhesin DraE and its interaction with chloramphenicol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; DECAY-ACCELERATING FACTOR; AFA-3 GENE-CLUSTER; AFIMBRIAL-ADHESIN; DIFFUSE ADHERENCE; NUCLEOTIDE-SEQUENCE; HELA-CELLS; DIARRHEA; BINDING; FAMILY	Pathogenic Escherichia coli expressing Afa/Dr adhesins are able to cause both urinary tract and diarrheal infections. The Afa/Dr adhesins confer adherence to epithelial cells via interactions with the human complement regulating protein, decay accelerating factor (DAF or CD55). Two of the Afa/Dr adhesions, AfaE-III and DraE, differ from each other by only three residues but are reported to have several different properties. One such difference is disruption of the interaction between DraE and CD55 by chloramphenicol, whereas binding of AfaE-III to CD55 is unaffected. Here we present a crystal structure of a strand-swapped trimer of wild type DraE. We also present a crystal structure of this trimer in complex with chloramphenicol, as well as NMR data supporting the binding position of chloramphenicol within the crystal. The crystal structure reveals the precise atomic basis for the sensitivity of DraE-CD55 binding to chloramphenicol and demonstrates that in contrast to other chloramphenicol-protein complexes, drug binding is mediated via recognition of the chlorine "tail" rather than via intercalation of the benzene rings into a hydrophobic pocket.	Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, London SW7 2AZ, England; Univ Texas, Med Branch, Dept Obstet & Gynaecol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Oxford; Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Matthews, S (corresponding author), Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, 28 Rue Docteur Roux, F-75724 Paris 15, France.	s.j.matthews@imperial.ac.uk; susan@biop.ox.ac.uk	Cota, Ernesto/A-5292-2009; Roversi, Pietro/AAK-4241-2021; Roversi, Pietro/F-8925-2011; Lea, Susan M/B-7678-2009	Roversi, Pietro/0000-0001-9280-9437; Roversi, Pietro/0000-0001-9280-9437; Lea, Susan M/0000-0001-9287-8053; Simpson, Pete/0000-0002-2679-9303; Matthews, Steve/0000-0003-0676-0927				Anderson KL, 2004, MOL CELL, V15, P647, DOI 10.1016/j.molcel.2004.08.003; Anderson KL, 2004, J BIOMOL NMR, V29, P409, DOI 10.1023/B:JNMR.0000032498.94441.08; BAQUI AH, 1992, J INFECT DIS, V166, P792, DOI 10.1093/infdis/166.4.792; Barnhart MM, 2000, P NATL ACAD SCI USA, V97, P7709, DOI 10.1073/pnas.130183897; Berger CN, 2004, MOL MICROBIOL, V52, P963, DOI 10.1111/j.1365-2958.2004.04033.x; BILGE SS, 1989, J BACTERIOL, V171, P4281, DOI 10.1128/JB.171.8.4281-4289.1989; BLANC E, 2004, IN PRESS ACTA CRYS D, V60; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Carnoy C, 1997, MOL MICROBIOL, V23, P365, DOI 10.1046/j.1365-2958.1997.2231590.x; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; Garcia MI, 1996, MOL MICROBIOL, V19, P683, DOI 10.1046/j.1365-2958.1996.394935.x; GIRON JA, 1991, J INFECT DIS, V163, P507, DOI 10.1093/infdis/163.3.507; Guignot J, 2000, INFECT IMMUN, V68, P3554, DOI 10.1128/IAI.68.6.3554-3563.2000; Hansen JL, 2003, J MOL BIOL, V330, P1061, DOI 10.1016/S0022-2836(03)00668-5; Izard T, 2000, EMBO J, V19, P2690, DOI 10.1093/emboj/19.11.2690; JALLAT C, 1993, J CLIN MICROBIOL, V31, P2031, DOI 10.1128/JCM.31.8.2031-2037.1993; Jouve M, 1997, INFECT IMMUN, V65, P4082, DOI 10.1128/IAI.65.10.4082-4089.1997; Keller R, 2002, INFECT IMMUN, V70, P2681, DOI 10.1128/IAI.70.5.2681-2689.2002; LABIGNEROUSSEL A, 1988, INFECT IMMUN, V56, P640, DOI 10.1128/IAI.56.3.640-648.1988; LABIGNEROUSSEL A, 1985, J BACTERIOL, V162, P1285, DOI 10.1128/JB.162.3.1285-1292.1985; LABIGNEROUSSEL AF, 1984, INFECT IMMUN, V46, P251, DOI 10.1128/IAI.46.1.251-259.1984; Le Bouguenec C, 2001, J CLIN MICROBIOL, V39, P1738, DOI 10.1128/JCM.39.5.1738-1745.2001; Liu YS, 2002, PROTEIN SCI, V11, P371, DOI 10.1110/ps.36602; Lukacik P, 2004, P NATL ACAD SCI USA, V101, P1279, DOI 10.1073/pnas.0307200101; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; NOWICKI B, 1989, INFECT IMMUN, V57, P446, DOI 10.1128/IAI.57.2.446-451.1989; NOWICKI B, 1988, INFECT IMMUN, V56, P1057, DOI 10.1128/IAI.56.5.1057-1060.1988; Sauer FG, 2000, CURR OPIN STRUC BIOL, V10, P548, DOI 10.1016/S0959-440X(00)00129-9; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Sauer FG, 2002, CELL, V111, P543, DOI 10.1016/S0092-8674(02)01050-4; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; SWANSON TN, 1991, INFECT IMMUN, V59, P261, DOI 10.1128/IAI.59.1.261-268.1991; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Van Loy CP, 2002, MOL MICROBIOL, V45, P439; WESTERLUND B, 1989, MOL MICROBIOL, V3, P329, DOI 10.1111/j.1365-2958.1989.tb00178.x; YAMAMOTO T, 1992, J INFECT DIS, V166, P1295, DOI 10.1093/infdis/166.6.1295; Zavialov AV, 2003, CELL, V113, P587, DOI 10.1016/S0092-8674(03)00351-9; Zegers I, 1999, P NATL ACAD SCI USA, V96, P818, DOI 10.1073/pnas.96.3.818	41	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46851	46857		10.1074/jbc.M409284200	http://dx.doi.org/10.1074/jbc.M409284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331605	hybrid			2022-12-25	WOS:000224832400066
J	Arce, JD; Soto, U; van Riggelen, J; Schwarz, E; zur Hausen, H; Rosl, F				Arce, JD; Soto, U; van Riggelen, J; Schwarz, E; zur Hausen, H; Rosl, F			Ectopic expression of nonliganded retinoic acid receptor beta abrogates AP-1 activity by selective degradation of c-Jun in cervical carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASES; CANCER CELLS; X-RECEPTOR; TRANSCRIPTION FACTOR; GROWTH-INHIBITION; ALL-TRANS; IN-VIVO; PROTEASOME INHIBITORS; MEDIATED REPRESSION	Expression of the nuclear retinoic acid receptor beta2 (RARbeta2) gene is often disturbed in cervical carcinoma cells. One important mechanism by which RARbeta2 can exert growth inhibitory function is based on its ability to repress the AP-1 transcription factor in a ligand-dependent manner. Because less is known about the biological effects of RARbeta in the absence of ligand, the corresponding cDNA was stably introduced into HPV18-positive HeLa cervical carcinoma cells. In the present study we describe a novel mechanism by which AP-1 becomes inactivated. Constitutive expression of nonliganded RARbeta abrogated both AP-1 binding affinity and activity by a selective degradation of the c-Jun protein as major dimerization partner, without substitution by other members of the Jun family. Blockage of the proteasomal pathway completely rescued c-Jun and reconstituted the AP-1 function. Moreover, HeLa RARbeta2 clones treated either with tumor necrosis factor-alpha or transfected with a constitutive active upstream mitogen-activated protein kinase (MEKK1Delta) also resulted in c-Jun phosphorylation and restoration of AP-1 affinity and functionality similar to that found in nontransfected parental HeLa cells. These data revealed an important cross-talk between trans-repression of AP-1 and nonliganded RARbeta in human papillomavirus-positive cells. Because AP-1 activity was not irreversibly disturbed, but could be switched on through activation of the Jun N-terminal kinase pathway, a model for the transient activation of AP-1 even in the presence of RARbeta as repressor is suggested.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Virale Transofrmat Mech, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Virale Transofrmat Mech, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@dkfz.de						Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bachmann A, 2002, J VIROL, V76, P280, DOI 10.1128/JVI.76.1.280-291.2002; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BERNARD HU, 1994, ARCH DERMATOL, V130, P210, DOI 10.1001/archderm.130.2.210; Boudjelal M, 2000, CANCER RES, V60, P2247; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CRIPE T P, 1990, New Biologist, V2, P450; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Garrett SH, 2002, TOXICOL LETT, V126, P69, DOI 10.1016/S0378-4274(01)00448-9; Geisen C, 1997, CANCER RES, V57, P1460; Geisen C, 2000, INT J CANCER, V85, P289, DOI 10.1002/(SICI)1097-0215(20000115)85:2<289::AID-IJC22>3.0.CO;2-T; Gianni M, 2003, J BIOL CHEM, V278, P34458, DOI 10.1074/jbc.M304952200; Giannini F, 1997, INT J CANCER, V70, P194; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karamouzis M, 2004, EUR J CANCER, V40, P761, DOI 10.1016/j.ejca.2003.12.002; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; Lee HY, 1998, J BIOL CHEM, V273, P7066, DOI 10.1074/jbc.273.12.7066; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE XH, 1995, EXP CELL RES, V218, P296, DOI 10.1006/excr.1995.1158; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin F, 2000, CANCER RES, V60, P3271; Masaki R, 2000, J NEUROSCI RES, V62, P75, DOI 10.1002/1097-4547(20001001)62:1<75::AID-JNR8>3.0.CO;2-V; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nabhan JF, 2001, MOL BIOCHEM PARASIT, V116, P209, DOI 10.1016/S0166-6851(01)00321-8; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Steinmuller L, 2001, BIOCHEM J, V360, P599, DOI 10.1042/0264-6021:3600599; Suzukawa K, 2002, ONCOGENE, V21, P2181, DOI 10.1038/sj.onc.1205281; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Tate BF, 1996, FASEB J, V10, P1524, DOI 10.1096/fasebj.10.13.8940298; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Weston AD, 2003, J CELL BIOL, V161, P223, DOI 10.1083/jcb.200211117; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu QH, 2002, J BIOL CHEM, V277, P41693, DOI 10.1074/jbc.M207095200; Ye XF, 2003, WORLD J GASTROENTERO, V9, P1915, DOI 10.3748/wjg.v9.i9.1915; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zhou XF, 1999, MOL ENDOCRINOL, V13, P276, DOI 10.1210/me.13.2.276	79	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45408	45416		10.1074/jbc.M401818200	http://dx.doi.org/10.1074/jbc.M401818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308638	hybrid			2022-12-25	WOS:000224694900016
J	Gros-Louis, F; Lariviere, R; Gowing, G; Laurent, S; Camu, W; Bouchard, JP; Meininger, V; Rouleau, GA; Julien, JP				Gros-Louis, F; Lariviere, R; Gowing, G; Laurent, S; Camu, W; Bouchard, JP; Meininger, V; Rouleau, GA; Julien, JP			A frameshift deletion in peripherin gene associated with amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON DISEASE; INTERMEDIATE-FILAMENT PROTEINS; HEAVY NEUROFILAMENT SUBUNIT; SUPEROXIDE-DISMUTASE GENE; SPASTIC PARALYSIS; MOUSE MODEL; NF-M; MUTATION; RAT; ALS	Peripherin is a neuronal intermediate filament associated with inclusion bodies in motor neurons of patients with amyotrophic lateral sclerosis (ALS). A possible peripherin involvement in ALS pathogenesis has been suggested based on studies with transgenic mouse overexpressors and with a toxic splicing variant of the mouse peripherin gene. However, the existence of peripherin gene mutations in human ALS has not yet been documented. Therefore, we screened for sequence variants of the peripherin gene (PRPH) in a cohort of ALS patients including familial and sporadic cases. We identified 18 polymorphic variants of PRPH detected in both ALS and age-matched control populations. Two additional PRPH variants were discovered in ALS cases but not in 380 control individuals. One variant consisted of a nucleotide insertion in intron 8 (PRPHIVS8-36insA), whereas the other one consisted of a 1-bp deletion within exon 1 (PRPH228delC), predicting a truncated peripherin species of 85 amino acids. Remarkably, expression of this frameshift peripherin mutant in SW13 cells resulted in disruption of neurofilament network assembly. These results suggest that PRPH mutations may be responsible for a small percentage of ALS, cases and they provide further support of the view that neurofilament disorganization may contribute to pathogenesis.	Univ Laval, Dept Anat & Physiol, CHU Laval, Ctr Rech, Quebec City, PQ G1V 4G2, Canada; McGill Univ, Ctr Hlth, Montreal Gen Hosp Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Inst Biol, INSERM, V336, Unite Neurol Comportementale, F-34295 Montpellier 5, France; Inst Biol, INSERM, V336, Degenerat Mol Unit, F-34295 Montpellier 5, France; Hop Guy de Chauliac, Clin Motoneurone, Serv Explorat Neurol, F-34295 Montpellier 5, France; Hop La Pitie Salpetriere, Federat Neurol Mazarin, F-75651 Paris 13, France; Ctr Hosp Affilie Univ Quebec, Dept Neurol Sci, Quebec City, PQ G1J 1Z4, Canada	Laval University; McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Julien, JP (corresponding author), Univ Laval, Dept Anat & Physiol, CHU Laval, Ctr Rech, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Jean-Pierre.Julien@crchul.ulaval.ca	camu, william/AAB-4727-2020					Al-Chalabi A, 1999, HUM MOL GENET, V8, P157, DOI 10.1093/hmg/8.2.157; Beaulieu JM, 1999, BIOCHEM CELL BIOL, V77, P41, DOI 10.1139/bcb-77-1-41; Beaulieu JM, 1999, J CELL BIOL, V147, P531, DOI 10.1083/jcb.147.3.531; BRODY BA, 1989, J NEUROSCI, V9, P2391; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; Ching GY, 1999, J CELL SCI, V112, P2233; CORBO M, 1992, J NEUROPATH EXP NEUR, V51, P531, DOI 10.1097/00005072-199209000-00008; De Jonghe P, 2001, ANN NEUROL, V49, P245, DOI 10.1002/1531-8249(20010201)49:2<245::AID-ANA45>3.0.CO;2-A; Devon RS, 2003, CLIN GENET, V64, P210, DOI 10.1034/j.1399-0004.2003.00138.x; ESCURAT M, 1990, J NEUROSCI, V10, P764; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; Gros-Louis F, 2003, ANN NEUROL, V53, P144, DOI 10.1002/ana.10422; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Lariviere RC, 2003, NEUROBIOL DIS, V13, P158, DOI 10.1016/S0969-9961(03)00036-6; Lariviere RC, 2002, J NEUROCHEM, V81, P525, DOI 10.1046/j.1471-4159.2002.00853.x; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962; MIGHELI A, 1993, LAB INVEST, V68, P185; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; PARYSEK LM, 1988, NEURON, V1, P395, DOI 10.1016/0896-6273(88)90189-4; PRAMATAROVA A, 1995, AM J HUM GENET, V56, P592; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Robertson J, 2003, J CELL BIOL, V160, P939, DOI 10.1083/jcb.200205027; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; TANDAN R, 1985, ANN NEUROL, V18, P271, DOI 10.1002/ana.410180302; Tomkins J, 1998, NEUROREPORT, V9, P3967, DOI 10.1097/00001756-199812010-00036; TROY CM, 1990, BRAIN RES, V529, P232, DOI 10.1016/0006-8993(90)90832-V; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zheng YL, 2003, J BIOL CHEM, V278, P24026, DOI 10.1074/jbc.M303079200	35	136	141	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45951	45956		10.1074/jbc.M408139200	http://dx.doi.org/10.1074/jbc.M408139200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322088	hybrid			2022-12-25	WOS:000224694900080
J	Garcia-Campayo, V; Jablonka-Shariff, A; Boime, I				Garcia-Campayo, V; Jablonka-Shariff, A; Boime, I			A single-chain bifunctional gonadotropin analog is secreted from chinese hamster ovary cells as two distinct bioactive species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; ENDOPLASMIC-RETICULUM; BETA-SUBUNIT; STIMULATING-HORMONE; ALPHA-SUBUNIT; CHORIOGONADOTROPIN; GLYCOPROTEIN; SPECIFICITY; COMPLEXES; FUSION	One of the major developments in exploring structure activity relationships of the glycoprotein hormone family was the genetic engineering of single chains comprised of the common alpha subunit and one or more of the hormone-specific beta subunits tandemly arranged. These studies indicate that there is a structural permissiveness in the quaternary relationships between the subunits and biological activity. However, the conformational relationships between the ligand and the receptor are unclear. Bifunctional triple-domain analogs represent an ideal model to address this issue. Does a single molecule possess the ability to simultaneously interact with both specific receptors or are there two functionally distinct species in the chimeric population? Here we show, using a preadsorption protocol comprised of Chinese hamster ovary cells expressing either the luteinizing hormone (LH)/chorionic gonadotropin (CG) or follicle-stimulating hormone (FSH) receptor, that at least two distinct bioactive populations of the dually active triple-domain chimera FSHbeta-CGbeta-alpha are synthesized, each corresponding to a single activity (CG or FSH). Furthermore, we show that these bioactive populations form distinct stable heterodimer-like contacts. That there is not a single biologically active species formed during synthesis of the chimera implies that in vivo the heterodimer exists in multiple conformations and is not a static rigid molecule.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL)	Boime, I (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, 660 S Euclid,Box 8103, St Louis, MO 63110 USA.	IBoime@molecool.wustl.edu		Garcia-Campayo, Javier/0000-0002-3797-4218; Garcia-Campayo, Vicenta/0000-0002-5737-9897				Ben-Menahem D, 1999, BIOCHEMISTRY-US, V38, P15070, DOI 10.1021/bi991510c; BenMenahem D, 1997, J BIOL CHEM, V272, P6827, DOI 10.1074/jbc.272.11.6827; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; Garcia-Campayo V, 2002, ENDOCRINOLOGY, V143, P3773, DOI 10.1210/en.2002-220336; Griffiths G, 1996, PROTOPLASMA, V195, P37, DOI 10.1007/BF01279185; Grossmann M, 1997, J BIOL CHEM, V272, P21312, DOI 10.1074/jbc.272.34.21312; Jackson AM, 1999, MOL ENDOCRINOL, V13, P2175, DOI 10.1210/me.13.12.2175; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kanda M, 1999, MOL ENDOCRINOL, V13, P1873, DOI 10.1210/me.13.11.1873; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; Sato A, 1997, J BIOL CHEM, V272, P18098, DOI 10.1074/jbc.272.29.18098; SITIA R, 1992, MOL BIOL CELL, V3, P1067, DOI 10.1091/mbc.3.10.1067; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Wang YH, 2000, MOL CELL ENDOCRINOL, V170, P67, DOI 10.1016/S0303-7207(00)00331-2	16	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44286	44293		10.1074/jbc.M408386200	http://dx.doi.org/10.1074/jbc.M408386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308629	hybrid			2022-12-25	WOS:000224505600009
J	Lennartsson, J; Shivakrupa, R; Linnekin, D				Lennartsson, J; Shivakrupa, R; Linnekin, D			Synergistic growth of stem cell factor and granulocyte macrophage colony-stimulating factor involves kinase-dependent and -independent contributions from c-Kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY SIGNALING PATHWAYS; GM-CSF; TYROSINE PHOSPHORYLATION; ACTIVATION; ERYTHROPOIETIN; RECEPTOR; LIGAND; SUBUNIT; PROTEIN; LINE	Stem cell factor (SCF) binds and activates the receptor tyrosine kinase c-Kit, and this interaction is critical for normal hematopoiesis. SCF also synergizes with a variety of growth factors, including those binding members of the cytokine receptor superfamily. The mechanisms mediating this synergy remain to be defined. The present study investigates both structural and biochemical cross-talk between c-Kit and the receptor for granulocyte macrophage colony-stimulating factor (GM-CSF). We have found that c-Kit forms a complex with the beta-chain of the GM-CSF receptor, and this interaction involves the first part of the c-Kit kinase domain. Although inhibition of c-Kit kinase activity completely blocked SCF-induced proliferation, there was still greater than additive growth induced by SCF in combination with GM-CSF. In contrast, an inhibitory antibody against the extracellular domain of c-Kit (K-27) completely inhibited growth in response to SCF alone or in combination with GM-CSF. These results support a kinase-independent component of the synergistic growth induced by SCF and GM-CSF that may relate to interaction of these receptors. It is also clear that a significant part of the synergistic growth is dependent of c-Kit kinase activity. Although synergistic increases in phosphorylation of c-Kit and the beta-chain of the GM-CSF receptor were not observed, SCF and GM-CSF in combination prolonged the duration of Erk1/2 phosphorylation in a phosphatidylinositol 3-kinase-dependent manner. Consistent with these findings, phosphatidylinositol 3-kinase is synergistically activated by SCF and GM-CSF together. Hence, c-Kit makes both kinase-independent and - dependent contributions to the proliferative synergy induced by SCF in combination with GM-CSF.	NCI, Basic Res Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lennartsson, J (corresponding author), Biomed Ctr, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	Johan.Lennartsson@LICR.uu.se			DIVISION OF BASIC SCIENCES - NCI [Z01BC010004] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzai N, 2002, BLOOD, V99, P4413, DOI 10.1182/blood.V99.12.4413; ASHMAN LK, 1990, LEUKEMIA RES, V14, P637, DOI 10.1016/0145-2126(90)90019-6; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; Boer AK, 2003, EXP HEMATOL, V31, P512, DOI 10.1016/S0301-472X(03)00075-4; CATLETT JP, 1991, BLOOD, V78, P3186; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Duarte RF, 2000, BLOOD, V96, P3422; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HALLEK M, 1992, J CELL PHYSIOL, V153, P176, DOI 10.1002/jcp.1041530122; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HENDRIE PC, 1991, EXP HEMATOL, V19, P1031; ICHIHARA M, 1995, EMBO J, V14, P939, DOI 10.1002/j.1460-2075.1995.tb07075.x; Jahn T, 2002, BLOOD, V100, p132A; Kamijo T, 1997, LEUKEMIA RES, V21, P1097, DOI 10.1016/S0145-2126(97)00086-6; KISS C, 1993, LEUKEMIA, V7, P235; Lee YH, 2001, BIOCHEM BIOPH RES CO, V280, P675, DOI 10.1006/bbrc.2000.4215; Lee YJ, 2003, BBA-MOL CELL RES, V1593, P219, DOI 10.1016/S0167-4889(02)00392-0; Leslie KB, 1996, BLOOD, V87, P3186, DOI 10.1182/blood.V87.8.3186.bloodjournal8783186; Linnekin D, 1999, INT J BIOCHEM CELL B, V31, P1053, DOI 10.1016/S1357-2725(99)00078-3; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; Muszynski KW, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.150063; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishida K, 2002, BLOOD, V99, P1866, DOI 10.1182/blood.V99.5.1866; OFarrell AM, 1996, BLOOD, V87, P3655, DOI 10.1182/blood.V87.9.3655.bloodjournal8793655; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pearson MA, 1998, GROWTH FACTORS, V15, P293, DOI 10.3109/08977199809017484; Sattler M, 1997, J BIOL CHEM, V272, P10248; Shivakrupa R, 2003, CANCER RES, V63, P4412; Sui XW, 1998, BLOOD, V92, P1142, DOI 10.1182/blood.V92.4.1142.416k42_1142_1149; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Ting HC, 2002, IMMUNOL LETT, V82, P205, DOI 10.1016/S0165-2478(02)00044-5; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	41	25	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44544	44553		10.1074/jbc.M404085200	http://dx.doi.org/10.1074/jbc.M404085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308671	hybrid			2022-12-25	WOS:000224505600039
J	Yoshizaki, H; Ohba, Y; Parrini, MC; Dulyaninova, NG; Bresnick, AR; Mochizuki, N; Matsuda, M				Yoshizaki, H; Ohba, Y; Parrini, MC; Dulyaninova, NG; Bresnick, AR; Mochizuki, N; Matsuda, M			Cell type-specific regulation of RhoA activity during cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT-CHAIN; CLEAVAGE FURROW; P21-ACTIVATED KINASE; MITOTIC SPINDLE; EXCHANGE FACTOR; PHOSPHORYLATION; MGCRACGAP; PROTEINS; GTPASES; CDC42	Rho family GTPases play pivotal roles in cytokinesis. By using probes based on the principle of fluorescence resonance energy transfer (FRET), we have shown that in HeLa cells RhoA activity increases with the progression of cytokinesis. Here we show that in Rat1A cells RhoA activity remained suppressed during most of the cytokinesis. Consistent with this observation, the expression of C3 toxin inhibited cytokinesis in HeLa cells but not in Rat1A cells. Furthermore, the expression of a dominant negative mutant of Ect2, a Rho GEF, or Y-27632, an inhibitor of the Rho-dependent kinase ROCK, inhibited cytokinesis in HeLa cells but not in Rat1A cells. In contrast to the activity of RhoA, the activity of Rac1 was suppressed during cytokinesis and started increasing at the plasma membrane of polar sides before the abscission of the daughter cells in both HeLa and Rat1A cells. This type of Rac1 suppression was shown to be essential for cytokinesis because a constitutively active mutant of Rac1 induced a multinucleated phenotype in both HeLa and Rat1A cells. Moreover, the involvement of MgcRacGAP/CYK-4 in this suppression of Rac1 during cytokinesis was shown by the use of a dominant negative mutant. Because ML-7, an inhibitor of myosin light chain kinase, delayed the cytokinesis of Rat1A cells and because Pak, a Rac1 effector, is known to suppress myosin light chain kinase, the suppression of the Rac1-Pak pathway by MgcRacGAP may play a pivotal role in the cytokinesis of Rat1A cells.	Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan; Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Suita, Osaka 5658565, Japan; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Osaka University; National Cerebral & Cardiovascular Center - Japan; Yeshiva University; Albert Einstein College of Medicine	Matsuda, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Tumor Virol, Suita, Osaka 5650871, Japan.	matsudam@biken.osaka-u.ac.jp	Parrini, Maria Carla/J-5390-2016; Yoshizaki, Hisayoshi/AAL-3421-2021; Ohba, Yusuke/E-7944-2011	Parrini, Maria Carla/0000-0002-7082-9792; Yoshizaki, Hisayoshi/0000-0001-8731-3015; Matsuda, Michiyuki/0000-0002-5876-9969				Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Ban R, 2004, J BIOL CHEM, V279, P16394, DOI 10.1074/jbc.M313257200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Dulyaninova NG, 2004, J CELL SCI, V117, P1481, DOI 10.1242/jcs.00993; Dutartre H, 1996, J CELL SCI, V109, P367; Gerisch G, 2000, CURR OPIN CELL BIOL, V12, P126, DOI 10.1016/S0955-0674(99)00066-6; Glotzer M, 2004, J CELL BIOL, V164, P347, DOI 10.1083/jcb.200310112; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Lee JS, 2004, EXP CELL RES, V293, P275, DOI 10.1016/j.yexcr.2003.10.015; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; Mandato CA, 2000, CELL MOTIL CYTOSKEL, V45, P87, DOI 10.1002/(SICI)1097-0169(200002)45:2<87::AID-CM1>3.0.CO;2-0; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Mishima M, 2003, CURR BIOL, V13, pR589, DOI 10.1016/S0960-9822(03)00521-9; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muris DFR, 2002, EUR J CANCER, V38, P1775, DOI 10.1016/S0959-8049(02)00100-4; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; Poperechnaya A, 2000, J CELL BIOL, V151, P697, DOI 10.1083/jcb.151.3.697; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Rooney RD, 1996, J BIOL CHEM, V271, P21498, DOI 10.1074/jbc.271.35.21498; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Somers WG, 2003, DEV CELL, V4, P29, DOI 10.1016/S1534-5807(02)00402-1; Straight AF, 2003, SCIENCE, V299, P1743, DOI 10.1126/science.1081412; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049	39	100	101	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44756	44762		10.1074/jbc.M402292200	http://dx.doi.org/10.1074/jbc.M402292200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308673	hybrid			2022-12-25	WOS:000224505600064
J	Tiwari, S; Kishan, KVR; Chakrabarti, T; Chakraborti, PK				Tiwari, S; Kishan, KVR; Chakrabarti, T; Chakraborti, PK			Amino acid residues involved in autophosphorylation and phosphotransfer activities are distinct in nucleoside diphosphate kinase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; TRIPHOSPHATE SYNTHESIS; ESCHERICHIA-COLI; ACTIVE-SITE; MYXOCOCCUS-XANTHUS; PROTEINS; CELL; MECHANISM; SEQUENCE; BINDING	Nucleoside diphosphate kinase (NdK) is a ubiquitous enzyme in both prokaryotes and eukaryotes and is primarily involved in the maintenance of cellular nucleotide pools. We have cloned ndk from Mycobacterium tuberculosis strain H37Ra and expressed it in Escherichia coli as a fusion protein with glutathione S-transferase. The purified protein, following thrombin cleavage and gel permeation chromatography, was found to be hexameric with a monomeric unit molecular mass of similar to 16.5 kDa. The protein exhibited nucleotide binding, divalent cation-dependent autophosphorylation, and phosphate transfer ability from nucleoside triphosphate to nucleoside diphosphate. Although UDP inhibited the catalytic activity of the recombinant protein, the classic inhibitors, like cromoglycate, 5'-adenosine 3'-phosphate, and adenosine 3'-phosphate 5'-phosphosulfate, had no effect on the activity. Among three histidine residues in the protein, His-117 was found to be essential for autophosphorylation. However, in subsequent phosphate transfer, we observed that His-53 had a significant contribution. Consistent with this observation, substitution of His-53 with either Ala or Gln affected the ability of the recombinant protein to complement NdK function in Pseudomonas aeruginosa. Furthermore, mutational analysis established critical roles for Tyr-50 and Arg-86 of the M. tuberculosis protein in maintaining phosphotransfer ability.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Chakraborti, PK (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.	pradip@imtech.res.in						Andersen Ase Bengard, 1994, P307; ANOSTARIO M, 1990, ANAL BIOCHEM, V190, P60, DOI 10.1016/0003-2697(90)90133-T; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chaba R, 2002, EUR J BIOCHEM, V269, P1078, DOI 10.1046/j.1432-1033.2002.02778.x; Chakrabarty AM, 1998, MOL MICROBIOL, V28, P875, DOI 10.1046/j.1365-2958.1998.00846.x; Chen YX, 2002, PROTEINS, V47, P556, DOI 10.1002/prot.10113; Chopra P, 2003, EUR J BIOCHEM, V270, P625, DOI 10.1046/j.1432-1033.2003.03402.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Couch R, 2002, BIOTECHNIQUES, V32, P1230, DOI 10.2144/02326bm03; DIVER JM, 1990, ANAL BIOCHEM, V189, P75, DOI 10.1016/0003-2697(90)90046-C; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Gounaris K, 2001, INFECT IMMUN, V69, P3658, DOI 10.1128/IAI.69.6.3658-3662.2001; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Janin J, 2000, J BIOENERG BIOMEMBR, V32, P215, DOI 10.1023/A:1005528811303; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Kowluru A, 2002, BIOCHEM PHARMACOL, V63, P2091, DOI 10.1016/S0006-2952(02)01025-0; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1993, ANAL BIOCHEM, V209, P6, DOI 10.1006/abio.1993.1075; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P237, DOI 10.1023/A:1005532912212; Lascu I, 2000, J BIOENERG BIOMEMBR, V32, P227, DOI 10.1023/A:1005580828141; Lefevre P, 1997, J BACTERIOL, V179, P2900, DOI 10.1128/jb.179.9.2900-2906.1997; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Min K, 2002, PROTEINS, V46, P340, DOI 10.1002/prot.10038; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2707; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; Postel EH, 2002, BIOCHEMISTRY-US, V41, P6330, DOI 10.1021/bi025606+; Postel EH, 2000, J BIOENERG BIOMEMBR, V32, P277, DOI 10.1023/A:1005541114029; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Punj V, 2000, INFECT IMMUN, V68, P4930, DOI 10.1128/IAI.68.9.4930-4937.2000; Sambrook J, 2001, MOL CLONING LAB MANU; Sarin J, 2001, J BIOL CHEM, V276, P44590, DOI 10.1074/jbc.M105401200; Schneider B, 2001, EUR J BIOCHEM, V268, P1964, DOI 10.1046/j.1432-1327.2001.02070.x; Schneider B, 1998, J BIOL CHEM, V273, P28773, DOI 10.1074/jbc.273.44.28773; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; Shankar S, 1997, MOL MICROBIOL, V24, P477, DOI 10.1046/j.1365-2958.1997.3491724.x; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Sundin GW, 1996, MOL MICROBIOL, V20, P965, DOI 10.1111/j.1365-2958.1996.tb02538.x; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; Zaborina O, 1999, MOL MICROBIOL, V31, P1333, DOI 10.1046/j.1365-2958.1999.01240.x	51	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43595	43603		10.1074/jbc.M401704200	http://dx.doi.org/10.1074/jbc.M401704200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302878	hybrid			2022-12-25	WOS:000224383100032
J	Shi, RX; Ong, CN; Shen, HM				Shi, RX; Ong, CN; Shen, HM			Luteolin sensitizes tumor necrosis factor-alpha-induced apoptosis in human tumor cells	ONCOGENE			English	Article						luteolin; TNF alpha; NF-kappa B; JNK; apoptosis	NF-KAPPA-B; ZINC-FINGER PROTEIN; TNF-INDUCED APOPTOSIS; DOMAIN KINASE RIP; DEATH DOMAIN; INDUCED ACTIVATION; TERMINAL KINASE; JNK ACTIVATION; CANCER; INDUCTION	Tumor necrosis factor-alpha (TNFalpha) activates both cell death and cell survival pathways, which render most cancer cells resistant to its cytotoxicity. In this study, we found that pretreatment with luteolin, a plant flavonoid, greatly sensitized TNFalpha-induced apoptotic cell death in a number of human cancer cell lines; including colorectal cancer COLO205, HCT116 cells and cervical cancer HeLa cells. In the search of the molecular mechanisms responsible for the sensitization effect of luteolin, we discovered that luteolin inhibited TNFalpha-induced activation of nuclear transcription factor-kappa B (NF-kappaB), the main survival factor in TNFa signaling. As a result, luteolin suppressed the expression of NF-kappaB-targeted antiapoptotic genes, including A20 and cellular inhibitor of apoptosis protein-1 (c-IAP1). The role of A20 and c-IAP1 was further confirmed by ectopic expression of these two genes, which significantly protected cell death induced by luteolin followed by TNFalpha. In addition, inhibition of NF-kappaB by luteolin led to augmentation and prolongation of c-Jun N-terminal kinase (JNK) activation induced by TNFalpha. Suppression of JNK activation, either by a synthetic JNK inhibitor ( SP600125) or by overexpression of the dominant negative forms of JNK kinase 1 (JNKK1) and JNK kinase 2 (JNKK2), conferred significant protection against apoptotic cell death induced by luteolin and TNFalpha, suggesting that NF-kappaB and JNK are closely associated with the sensitization effect of luteolin. Data from this study reveal a novel function of luteolin and enhance the value of luteolin as an anticancer agent.	Natl Univ Singapore, Fac Med, Dept Community Occupat & Family Med, Singapore 117597, Singapore	National University of Singapore	Shen, HM (corresponding author), Natl Univ Singapore, Fac Med, Dept Community Occupat & Family Med, 16 Med Dr, Singapore 117597, Singapore.	cofshm@nus.edu.sg	Shi, Ranxin/F-9817-2012; SHEN, Han-Ming/B-5942-2011; Shi, Ranxin/E-5934-2012; Ong, Choon Nam/E-8638-2010	SHEN, Han-Ming/0000-0001-7369-5227; 				Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Darzynkiewicz Z, 1998, Hum Cell, V11, P3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Farah M, 2003, AM J PHYSIOL-GASTR L, V285, pG919, DOI 10.1152/ajpgi.00205.2003; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Huang YT, 1999, BRIT J PHARMACOL, V128, P999, DOI 10.1038/sj.bjp.0702879; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kim DM, 2003, CANCER RES, V63, P621; Kim SH, 2003, BIOCHEM PHARMACOL, V66, P955, DOI 10.1016/S0006-2952(03)00465-9; Ko WG, 2002, PHYTOTHER RES, V16, P295, DOI 10.1002/ptr.871; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lademann U, 2001, CELL DEATH DIFFER, V8, P265, DOI 10.1038/sj.cdd.4400805; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mafune K, 1999, CLIN CANCER RES, V5, P4073; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Petak I, 2000, CLIN CANCER RES, V6, P4119; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shen HM, 2000, FREE RADICAL BIO MED, V28, P1115, DOI 10.1016/S0891-5849(00)00206-9; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Ueda H, 2003, BIOL PHARM BULL, V26, P560, DOI 10.1248/bpb.26.560; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; Xagorari A, 2001, J PHARMACOL EXP THER, V296, P181; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V380, P319, DOI 10.1006/abbi.2000.1939; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	55	81	94	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7712	7721		10.1038/sj.onc.1208046	http://dx.doi.org/10.1038/sj.onc.1208046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334063				2022-12-25	WOS:000224306700012
J	Zhu, NX; Gu, LB; Findley, HW; Li, FZ; Zhou, MX				Zhu, NX; Gu, LB; Findley, HW; Li, FZ; Zhou, MX			An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy	ONCOGENE			English	Article						survivin variant; p53; apoptosis; leukemia	PRE-MESSENGER-RNA; ANTI-APOPTOSIS GENE; WILD-TYPE P53; BCL-X; EXPRESSION; IDENTIFICATION; CHECKPOINT; INHIBITOR; INDUCTION; CASPASE-9	Survivin is a unique member of the inhibitor of apoptosis protein family, and its expression is regulated by p53. Recent identification of several functionally divergent survivin variants augments the complexity of survivin action as well as its regulation. Here we report that survivin-2B ( retaining a part of intron 2 as a cryptic exon) is positively regulated by p53, and its overexpression plays a role in sensitizing leukemia cells to chemotherapeutic drug doxorubicin. Doxorubicin treatment activated p53, downregulated survivin and survivin-DeltaEx3 but upregulated survivin-2B in EU-3, an acute lymphocytic leukemia (ALL) cell line with wild-type (wt)-p53 phenotype. In contrast, doxorubicin treatment failed to induce these alterations in EU-6 cells, a mutant-p53 ALL cell line. To specify the role of wt-p53 in regulating survivin and its variants, a temperature-sensitive p53 mutant plasmid p53-143 was transfected into EU-4, a p53-null ALL cell line, to establish a subline EU-4/p53-143. When EU-4/p53-143 cell culture was shifted from 37.5 degreesC to the wt-p53-permissive temperature (32.5 degreesC), the expression of survivin and survivin-DEx3 was decreased whereas survivin-2B expression was increased, confirming the distinct regulatory effect of p53 on survivin and its variants. To clarify the role of survivin-2B in the process of apoptosis, survivin-2B cDNA was cloned into pcDNA3HA vector and transfected into EU-4 cells. Enforced expression of survivin-2B in EU-4 cells inhibited cell growth and sensitized these cells to doxorubicin-induced apoptosis. These results suggest that survivin-2B variant is a proapoptotic factor and its expression is upregulated by p53.	Emory Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol BMT, Atlanta, GA 30322 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Emory University; Roswell Park Cancer Institute	Zhou, MX (corresponding author), Emory Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol BMT, 2040 Ridgewood Dr NE, Atlanta, GA 30322 USA.	mzhou@emory.edu	Li, Fengzhi/GXF-0115-2022		NCI NIH HHS [R01 CA82323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 2000, BLOOD, V96, P1921; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HU H, 2003, ONCOL RES, V13, P429; Islam A, 2000, MED PEDIATR ONCOL, V35, P550, DOI 10.1002/1096-911X(20001201)35:6<550::AID-MPO12>3.0.CO;2-Y; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kato J, 2001, INT J CANCER, V95, P92; Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153; Li FZ, 2003, J CELL PHYSIOL, V197, P8, DOI 10.1002/jcp.10327; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mahotka C, 2002, INT J CANCER, V100, P30, DOI 10.1002/ijc.10450; Maxwell SA, 1999, APOPTOSIS, V4, P109, DOI 10.1023/A:1009618811038; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tu SP, 2003, CANCER RES, V63, P7724; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHOU MX, 1995, BLOOD, V85, P1608, DOI 10.1182/blood.V85.6.1608.bloodjournal8561608; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	31	52	55	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7545	7551		10.1038/sj.onc.1208038	http://dx.doi.org/10.1038/sj.onc.1208038			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334064				2022-12-25	WOS:000224176500011
J	Puri, N; Eller, MS; Byers, HR; Dykstra, S; Kubera, J; Gilchrest, BA				Puri, N; Eller, MS; Byers, HR; Dykstra, S; Kubera, J; Gilchrest, BA			Telomere-based DNA damage responses: a new approach to melanoma	FASEB JOURNAL			English	Article						melanocyte; apoptosis; differentiation; p73; livin/ML-IAP	HUMAN OVARIAN-CANCER; TUMOR-INFILTRATING LYMPHOCYTES; THYMIDINE DINUCLEOTIDES; METASTATIC MELANOMA; CUTANEOUS MELANOMA; HUMAN MELANOCYTES; CELL-CYCLE; APOPTOSIS; MELANOGENESIS; EXPRESSION	Melanoma is the most fatal skin cancer, often highly resistant to chemotherapy. Here we show that treatment with an 11-base DNA oligonucleotide homologous to the telomere 3' overhang sequence (T-oligo) induces apoptosis of several established human melanoma cell lines, including the aggressive MM-AN line, whereas normal human melanocytes exposed to the same or higher T-oligo concentrations show only transient cell cycle arrest, implying that malignant cells are more sensitive to T-oligo effects. When MM-AN cells were briefly exposed to T-oligo in culture and injected into the flank or tail vein of SCID mice, eventual tumor volume and number of metastases were reduced 85-95% compared with control mice. Similarly, T-oligos administered intralesionally or systemically selectively inhibited the growth of previously established MM-AN tumor nodules in the flank and peritoneal cavity by 85 to 90% without detectable toxicity. We previously showed that T-oligos act through ATM, p95/Nbs1, E2F1, p16(INK4A), p53, and the p53 homologue p73 to modulate downstream effectors and now additionally demonstrate striking down-regulation of the inhibitor of apoptosis protein livin/ML-IAP. We suggest that T-oligo mimics a physiologic DNA damage signal that is frequently masked in malignant cells and thereby activates innate cancer prevention responses. T-oligos may provide a novel therapeutic approach to melanoma.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St,J Bldg, Boston, MA 02118 USA.	bgilchre@bu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR050110] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR050110-02] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agami R, 1999, NATURE, V399, P809; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; BYERS HR, 1993, MELANOMA RES, V3, P247; BYERS HR, 1991, AM J PATHOL, V139, P423; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; CHEN C, 1995, CANCER RES, V55, P4230; Couzin J, 2002, SCIENCE, V298, P522, DOI 10.1126/science.298.5593.522; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Eller MS, 2003, FASEB J, V17, P152, DOI 10.1096/fj.02-0197com; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GILCHREST BA, 1984, J INVEST DERMATOL, V83, P370, DOI 10.1111/1523-1747.ep12264638; Glaessl A, 1999, ARCH DERMATOL RES, V291, P81, DOI 10.1007/s004030050387; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Li G, 1998, MELANOMA RES, V8, P17, DOI 10.1097/00008390-199802000-00004; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Maeda T, 1999, MUTAT RES-DNA REPAIR, V433, P137, DOI 10.1016/S0921-8777(98)00071-8; Miracco C, 2000, INT J CANCER, V88, P411, DOI 10.1002/1097-0215(20001101)88:3<411::AID-IJC13>3.3.CO;2-G; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nonoyama S, 1996, Int Rev Immunol, V13, P289, DOI 10.3109/08830189609061753; PaineMurrieta GD, 1997, CANCER CHEMOTH PHARM, V40, P209, DOI 10.1007/s002800050648; Parris CN, 1999, BRIT J CANCER, V79, P47, DOI 10.1038/sj.bjc.6690010; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; RIVOLTINI L, 1995, J IMMUNOL, V154, P2257; Sasaki H, 2000, CANCER RES, V60, P5659; Slingluff CL, 2000, CANCER IMMUNOL IMMUN, V48, P661, DOI 10.1007/s002620050015; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Villa R, 2000, INT J ONCOL, V16, P995; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Yang P, 2000, INT J ONCOL, V17, P913; Zhang H, 2002, INT J ONCOL, V21, P43; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	56	69	74	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1373	1381		10.1096/fj.04-1774com	http://dx.doi.org/10.1096/fj.04-1774com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333580				2022-12-25	WOS:000224243200056
J	McAllister, SD; Hurst, DP; Barnett-Norris, J; Lynch, D; Reggio, PH; Abood, ME				McAllister, SD; Hurst, DP; Barnett-Norris, J; Lynch, D; Reggio, PH; Abood, ME			Structural mimicry in class A G protein-coupled receptor rotamer toggle switches - The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; INDUCED CONFORMATIONAL-CHANGES; TRANSMEMBRANE DOMAINS III; CB1 RECEPTOR; INVERSE AGONISM; CONSTITUTIVE ACTIVATION; PI-INTERACTIONS; IONIC LOCK; RHODOPSIN; SR141716A	In this study, we tested the hypothesis that a CB1 TMH3-4-5-6 aromatic microdomain, which includes F3.25(190), F3.36(201), W5.43(280), and W6.48(357), is centrally involved in CB1 receptor activation, with the F3.36(201)/W6.48(357) interaction key to the maintenance of the CB1-inactive state. We have shown previously that when F3.36(201), W5.43(280), and W6.48(357) are individually mutated to alanine, a significant reduction in ligand binding affinity is observed in the presence of WIN 55,212-2 and SR141716A but not CP55,940 and anandamide. In the work presented here, we report a detailed functional analysis of the F3.36(201) A, F3.25(190) A, W5.43(280) A, and W6.48(357) A mutant receptors in stable cell lines created in HEK cells for agonist-stimulated guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding and GIRK1/4 channel current effects in Xenopus oocytes where the mutant proteins were expressed transiently. The F3.36(201) A mutation showed statistically significant increases in ligand-independent stimulation of GTPgammaS binding versus wild type CB1, although basal levels for the W6.48(357) A mutant were not statistically different from wild type CB1. F3.36(201) A demonstrated a limited activation profile in the presence of multiple agonists. In contrast, enhanced agonist activation was produced by W6.48(357) A. These results suggest that a F3.36(201)/W6.48(357)-specific contact is an important constraint for the CB1-inactive state that may need to break during activation. Modeling studies suggest that the F3.36(201)/W6.48(357) contact can exist in the inactive state of CB1 and be broken in the activated state via a chi(1) rotamer switch (F3.36(201) trans, W6.48(357)g+)-->(F3.36(201)g+, W6.48(357) trans). The F3.36(201)/W6.48(357) interaction therefore may represent a "toggle switch" for activation of CB1.	Calif Pacific Med Ctr Res Inst, Forbes Norris ALS MDA Res Ctr, San Francisco, CA 94115 USA; Kennesaw State Univ, Kennesaw, GA 30144 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University System of Georgia; Kennesaw State University	Abood, ME (corresponding author), Calif Pacific Med Ctr Res Inst, Forbes Norris ALS MDA Res Ctr, 2351 Clay St,Suite 416, San Francisco, CA 94115 USA.	mabood@cooper.cpmc.org		Abood, Mary/0000-0002-1744-2820	NIDA NIH HHS [DA00489, DA03934, DA05274, DA09978] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003934, R01DA009978] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abood ME, 1997, BIOCHEM PHARMACOL, V53, P207, DOI 10.1016/S0006-2952(96)00727-7; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Barnett-Norris J, 2002, J MED CHEM, V45, P3649, DOI 10.1021/jm0200761; Barnett-Norris J, 2002, INT J QUANTUM CHEM, V88, P76, DOI 10.1002/qua.10093; Befort K, 1999, J BIOL CHEM, V274, P18574, DOI 10.1074/jbc.274.26.18574; Blaker M, 2000, MOL PHARMACOL, V58, P399, DOI 10.1124/mol.58.2.399; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; BRAMBLETT RD, 1995, LIFE SCI, V56, P1971, DOI 10.1016/0024-3205(95)00178-9; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Griffin G, 1998, J PHARMACOL EXP THER, V285, P553; Guarnieri F, 1996, J AM CHEM SOC, V118, P5580, DOI 10.1021/ja952745o; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; HOBOHM U, 1994, PROTEIN SCI, V3, P522; HOBOHM U, 1992, PROTEIN SCI, V1, P409; Hulme EC, 1999, EUR J PHARMACOL, V375, P247, DOI 10.1016/S0014-2999(99)00297-6; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; Hurst DP, 2002, MOL PHARMACOL, V62, P1274, DOI 10.1124/mol.62.6.1274; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Kearn CS, 1999, J NEUROCHEM, V72, P2379, DOI 10.1046/j.1471-4159.1999.0722379.x; Kenakin T., 1997, PHARMACOLOGIC ANAL D, Vsecond edition, P137, DOI DOI 10.1097/00007691-198803000-00029; Klein-Seetharaman J, 2004, P NATL ACAD SCI USA, V101, P3409, DOI 10.1073/pnas.0308713101; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; MacLennan SJ, 1998, BRIT J PHARMACOL, V124, P619, DOI 10.1038/sj.bjp.0701915; Mato S, 2002, EUR J PHARMACOL, V443, P43, DOI 10.1016/S0014-2999(02)01575-3; McAllister SD, 2003, J MED CHEM, V46, P5139, DOI 10.1021/jm0302647; McAllister SD, 2002, BIOCHEM PHARMACOL, V63, P2121, DOI 10.1016/S0006-2952(02)01031-6; McAllister SD, 1999, J PHARMACOL EXP THER, V291, P618; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Meschler JP, 2000, BIOCHEM PHARMACOL, V60, P1315, DOI 10.1016/S0006-2952(00)00447-0; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pan XH, 1998, MOL PHARMACOL, V54, P1064, DOI 10.1124/mol.54.6.1064; Reggio PH, 1998, J MED CHEM, V41, P5177, DOI 10.1021/jm9801197; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Tao Q, 1999, MOL PHARMACOL, V55, P605; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2002, INT J QUANTUM CHEM, V88, P65, DOI 10.1002/qua.10078	49	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48024	48037		10.1074/jbc.M406648200	http://dx.doi.org/10.1074/jbc.M406648200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15326174	Green Published, hybrid			2022-12-25	WOS:000224957000074
J	Delevoye, C; Nilges, M; Dautry-Varsat, A; Subtil, A				Delevoye, C; Nilges, M; Dautry-Varsat, A; Subtil, A			Conservation of the biochemical properties of IncA from Chlamydia trachomatis and Chlamydia caviae - Oligomerization of IncA mediates interaction between facing membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCLUSION MEMBRANE; COILED COILS; HOST-CELL; DEVELOPMENTAL CYCLE; MOLECULAR-DYNAMICS; PROTEIN-SYNTHESIS; EPITHELIAL-CELLS; INFECTED-CELLS; FUSION; SECRETION	The developmental cycle of Chlamydiaceae occurs in a membrane compartment called an inclusion. IncA is a member of a family of proteins synthesized and secreted onto the inclusion membrane by bacteria. IncA proteins from different species of Chlamydiaceae show little sequence similarity. We report that the biochemical properties of Chlamydia trachomatis and Chlamydia caviae are conserved. Both proteins self-associate to form multimers. When artificially expressed by the host cell, they localize to the endoplasmic reticulum. Strikingly, heterologous expression of IncA in the endoplasmic reticulum completely inhibits concomitant inclusion development. Using truncated forms of IncA from C. caviae, we show that expression of the C-terminal cytoplasmic domain of the protein at the surface of the endoplasmic reticulum is sufficient to disrupt the bacterial developmental cycle. On the other hand, development of a C. trachomatis strain that does not express IncA is not inhibited by artificial IncA expression, showing that the disruptive effect observed with the wild-type strain requires direct interactions between IncA molecules at the inclusion and on the endoplasmic reticulum. Finally, we modeled IncA tetramers in parallel four helix bundles based on the structure of the SNARE complex, a conserved structure involved in membrane fusion in eukaryotic cells. Both C. trachomatis and C. caviae IncA tetramers were highly stable in this model. In conclusion, we show that the property of IncA proteins to assemble into multimeric structures is conserved between chlamydial species, and we propose that these proteins may have co-evolved with the SNARE machinery for a role in membrane fusion.	Inst Pasteur, CNRS, URA 2582, Unite Biol Interact Cellulaires, F-75015 Paris, France; Inst Pasteur, CNRS, URA 2185, Unite Biol Interact Cellulaires, F-75015 Paris, France; Inst Pasteur, CNRS, URA 2185, Unite Bioinformat Struct, F-75015 Paris, France; Inst Pasteur, CNRS, URA 2582, Unite Bioinformat Struct, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Subtil, A (corresponding author), Inst Pasteur, CNRS, URA 2582, Unite Biol Interact Cellulaires, 25 Rue Docteur Roux, F-75015 Paris, France.	asubtil@pasteur.fr	Subtil, Agathe/C-7464-2017; Nilges, Michael/E-4803-2011	Subtil, Agathe/0000-0002-7481-4846; Nilges, Michael/0000-0002-1451-8092; Delevoye, Cedric/0000-0002-3835-6649				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bannantine JP, 2000, CELL MICROBIOL, V2, P35; Bannantine JP, 1998, INFECT IMMUN, V66, P6017, DOI 10.1128/IAI.66.12.6017-6021.1998; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Boleti H, 1999, J CELL SCI, V112, P1487; Brown WJ, 2002, INFECT IMMUN, V70, P5860, DOI 10.1128/IAI.70.10.5860-5864.2002; Carabeo RA, 2003, P NATL ACAD SCI USA, V100, P6771, DOI 10.1073/pnas.1131289100; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; DAVID V, 1993, J BIOL CHEM, V268, P9585; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fields KA, 2003, MOL MICROBIOL, V48, P671, DOI 10.1046/j.1365-2958.2003.03462.x; Fields KA, 2002, INFECT IMMUN, V70, P3816, DOI 10.1128/IAI.70.7.3816-3823.2002; Fields KA, 2002, ANNU REV CELL DEV BI, V18, P221, DOI 10.1146/annurev.cellbio.18.012502.105845; Grieshaber SS, 2003, J CELL SCI, V116, P3793, DOI 10.1242/jcs.00695; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; Hackstadt T, 1999, CELL MICROBIOL, V1, P119, DOI 10.1046/j.1462-5822.1999.00012.x; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hatch GM, 1998, INFECT IMMUN, V66, P3727, DOI 10.1128/IAI.66.8.3727-3735.1998; Horn M, 2004, SCIENCE, V304, P728, DOI 10.1126/science.1096330; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jahn R, 2002, CURR OPIN CELL BIOL, V14, P488, DOI 10.1016/S0955-0674(02)00356-3; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MATSUMOTO A, 1991, J ELECTRON MICROSC, V40, P356; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; Prozialeck WC, 2002, INFECT IMMUN, V70, P2605, DOI 10.1128/IAI.70.5.2605-2613.2002; Rockey DD, 2002, MICROBES INFECT, V4, P333, DOI 10.1016/S1286-4579(02)01546-0; Rockey DD, 2002, MICROBIOL-SGM, V148, P2497, DOI 10.1099/00221287-148-8-2497; Rockey DD, 1997, MOL MICROBIOL, V24, P217, DOI 10.1046/j.1365-2958.1997.3371700.x; ROCKEY DD, 1995, MOL MICROBIOL, V15, P617, DOI 10.1111/j.1365-2958.1995.tb02371.x; Rzomp KA, 2003, INFECT IMMUN, V71, P5855, DOI 10.1128/IAI.71.10.5855-5870.2003; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Scidmore MA, 2003, INFECT IMMUN, V71, P973, DOI 10.1128/IAI.71.2.973-984.2003; Scidmore MA, 2001, MOL MICROBIOL, V39, P1638, DOI 10.1046/j.1365-2958.2001.02355.x; Scidmore MA, 1996, INFECT IMMUN, V64, P5366, DOI 10.1128/IAI.64.12.5366-5372.1996; Shaw EI, 2000, MOL MICROBIOL, V37, P913, DOI 10.1046/j.1365-2958.2000.02057.x; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Subtil A, 2004, J CELL SCI, V117, P3923, DOI 10.1242/jcs.01247; Subtil A, 2001, MOL MICROBIOL, V39, P792, DOI 10.1046/j.1365-2958.2001.02272.x; Suchland RJ, 2000, INFECT IMMUN, V68, P360, DOI 10.1128/IAI.68.1.360-367.2000; Toh H, 2003, DNA RES, V10, P9, DOI 10.1093/dnares/10.1.9; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Van Ooij C, 1998, INFECT IMMUN, V66, P5364, DOI 10.1128/IAI.66.11.5364-5371.1998; [No title captured]	48	72	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46896	46906		10.1074/jbc.M407227200	http://dx.doi.org/10.1074/jbc.M407227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316015	hybrid			2022-12-25	WOS:000224832400072
J	Delplanque, J; Delpierre, G; Opperdoes, FR; Van Schaftingen, E				Delplanque, J; Delpierre, G; Opperdoes, FR; Van Schaftingen, E			Tissue distribution and evolution of fructosamine 3-kinase and fructosamine 3-kinase-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTES; ADP-RIBOSE; RED-CELLS; HEMOGLOBIN; BINDING; IDENTIFICATION; PURIFICATION; SPECIFICITY; DEGLYCATION; CONVERSION	Fructosamine 3-kinase (FN3K) and FN3K-related protein (FN3K-RP) catalyze the phosphorylation of the Amadori products ribulosamines, psicosamines, and, in the case of FN3K, fructosamines. BLAST searches in chordate genomes revealed two genes encoding proteins homologous to FN3K or FN3K-RP in various mammals and in chicken but only one gene, encoding a protein more similar to FN3K-RP than to FN3K, in fishes and the sea squirt Ciona intestinalis. This suggests that a gene duplication event occurred after the fish radiation and that the FN3K gene evolved more rapidly than the FN3K-RP gene. In agreement with this distribution, only one enzyme, phosphorylating ribulosamines and psicosamines but not fructosamines, was found in the tissues from a fish (Clarias gariepinus), whereas two enzymes with specificities similar to either FN3K or FN3K-RP were found in mouse, rat, and chicken tissues. FN3K is particularly active in brain, heart, kidney, and skeletal muscle. Its activity is also relatively elevated in erythrocytes from man, rat, and mouse but barely detectable in erythrocytes from chicken and pig, which correlates well with the low intracellular concentration of glucose in erythrocytes from these species. This is in keeping with the specific role of FN3K to repair protein damage caused by glucose. FN3K-RP was more evenly distributed in tissues, except for skeletal muscle where its activity was particularly low. This may be related to low activity of the pentose phosphate pathway in this tissue, as suggested by assays of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase. This finding, together with the high affinity of FN3K-RP for ribulosamines, suggests that this enzyme may serve to repair damage caused by the powerful glycating agent, ribose 5-phosphate.	Christian de Duve Inst Cellular Pathol, Physiol Chem Lab, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, Trop Dis Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Christian de Duve Inst Cellular Pathol, Physiol Chem Lab, Ave Hippocrate 75, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020; Opperdoes, Fred/N-9922-2019; Opperdoes, Frederik R/C-8897-2018	Opperdoes, Fred/0000-0003-1984-3764; Opperdoes, Frederik R/0000-0003-1984-3764; Van Schaftingen, Emile/0000-0002-6199-7647				Baynes J W, 1989, Prog Clin Biol Res, V304, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burk DL, 2001, BIOCHEMISTRY-US, V40, P8756, DOI 10.1021/bi010504p; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; Collard F, 2004, BIOCHEM J, V382, P137, DOI 10.1042/BJ20040307; Collard FO, 2003, DIABETES, V52, P2888, DOI 10.2337/diabetes.52.12.2888; Delpierre G, 2000, DIABETES, V49, P1627, DOI 10.2337/diabetes.49.10.1627; Delpierre G, 2004, J BIOL CHEM, V279, P27613, DOI 10.1074/jbc.M402091200; Delpierre G, 2002, BIOCHEM J, V365, P801, DOI 10.1042/BJ20020325; Delpierre G, 2000, BIOCHEM J, V352, P835, DOI 10.1042/0264-6021:3520835; Drabkin DL, 1935, J BIOL CHEM, V112, P51; Fischer D, 1999, PROTEINS, P209; GUIDA L, 1992, BIOCHEM BIOPH RES CO, V188, P402, DOI 10.1016/0006-291X(92)92399-I; HIGGINS PJ, 1982, DIABETES, V31, P743, DOI 10.2337/diabetes.31.9.743; HODGE JE, 1955, ADV CARBOHYD CHEM, V10, P169, DOI 10.1016/S0096-5332(08)60392-6; HOWARD SM, 1965, ARCH BIOCHEM BIOPHYS, V110, P395, DOI 10.1016/0003-9861(65)90140-2; Johnstone RM, 1998, EUR J CELL BIOL, V75, P66, DOI 10.1016/S0171-9335(98)80048-4; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KALCKAR HM, 1947, J BIOL CHEM, V167, P477; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; MARECHAL LR, 1972, J BIOL CHEM, V247, P3223; Ohno S., 1970, EVOLUTION GENE DUPLI; Sharma S D, 2002, J Biochem Mol Biol Biophys, V6, P233; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; ZOCCHI E, 1993, BIOCHEM J, V295, P121, DOI 10.1042/bj2950121	27	46	47	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46606	46613		10.1074/jbc.M407678200	http://dx.doi.org/10.1074/jbc.M407678200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331600	hybrid			2022-12-25	WOS:000224832400034
J	Nishiyama, T; Kii, I; Kudo, A				Nishiyama, T; Kii, I; Kudo, A			Inactivation of Rho/ROCK signaling is crucial for the nuclear accumulation of FKHR and myoblast fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; MYOTONIC-DYSTROPHY KINASE; BINDING PROTEIN-RHO; MYOGENIC DIFFERENTIATION; MOUSE MYOBLASTS; ADHESION MOLECULE; OBLIGATORY ROLE; P115 RHOGEF; N-CADHERIN; RAS	Myoblast fusion is a critical process for the terminal differentiation of skeletal muscle. To elucidate the intracellular mechanisms regulating myoblast fusion, we studied the roles of signaling through the small GTPase Rho and its effector, the Rho-associated kinase ROCK, in myoblast fusion of mouse C2C12 cells. We found that Rho activity, which was high in proliferating myoblasts, decreased during myogenesis. Expression of a constitutively active form of Rho blocked myoblast fusion, but not the earlier steps of differentiation. Consistently, ROCK activity was also decreased in differentiating C2C12 cells, and an active ROCK mutant prevented their fusion. Furthermore, inactivation of ROCK by the specific inhibitor Y-27632 enhanced myoblast fusion, even in cells expressing the active Rho mutant. Thus, the down-regulation of Rho/ROCK signaling is required for myoblast fusion. We also found that Rho/ROCK signaling was required for retaining FKHR, a transcription factor implicated in myoblast fusion, in the cytoplasm and that inactivation of ROCK was essential for the nuclear accumulation of FKHR that took place just before the onset of myoblast fusion. Moreover, ROCK directly phosphorylated FKHR in vitro. We conclude that the inactivation of Rho/ROCK signaling is a prerequisite for FKHR nuclear translocation and myoblast fusion in C2C12 cells, providing evidence for a novel regulatory role of Rho/ROCK signaling in myogenic differentiation.	Tokyo Inst Technol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kudo, A (corresponding author), Tokyo Inst Technol, Dept Biol Informat, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	akudo@bio.titech.ac.jp	KII, Isao/C-4117-2017; Kudo, Akira/C-7340-2015	KII, Isao/0000-0002-6153-6250; Kudo, Akira/0000-0001-6289-3391				Beqaj S, 2002, J CELL BIOL, V156, P893, DOI 10.1083/jcb.200107049; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KNUDSEN KA, 1990, DEV BIOL, V138, P159, DOI 10.1016/0012-1606(90)90185-L; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MEGE RM, 1992, J CELL SCI, V103, P897; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; Meriane M, 2000, MOL BIOL CELL, V11, P2513, DOI 10.1091/mbc.11.8.2513; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; Schwander M, 2003, DEV CELL, V4, P673, DOI 10.1016/S1534-5807(03)00118-7; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Wei L, 2001, DEVELOPMENT, V128, P2953; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; ZESCHNIGK M, 1995, J CELL SCI, V108, P2973	38	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47311	47319		10.1074/jbc.M403546200	http://dx.doi.org/10.1074/jbc.M403546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322110	hybrid			2022-12-25	WOS:000224832400119
J	Anzai, N; Miyazaki, H; Noshiro, R; Khamdang, S; Chairoungdua, A; Shin, HJ; Enomoto, A; Sakamoto, S; Hirata, T; Tomita, K; Kanai, Y; Endou, H				Anzai, N; Miyazaki, H; Noshiro, R; Khamdang, S; Chairoungdua, A; Shin, HJ; Enomoto, A; Sakamoto, S; Hirata, T; Tomita, K; Kanai, Y; Endou, H			The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; IDENTIFICATION; RECEPTOR; KIDNEY; INTERACTS; CHANNEL; FAMILY; EXPRESSION; EXCRETION; MECHANISM	The urate-anion exchanger URAT1 is a member of the organic anion transporter ( OAT) family that regulates blood urate level in humans and is targeted by uricosuric and antiuricosuric agents (Enomoto, A., Kimura, H., Chairoungdua, A., Shigeta, Y., Jutabha, P., Cha, S. H., Hosoyamada, M., Takeda, M., Sekine, T., Igarashi, T., Matsuo, H., Kikuchi, Y., Oda, T., Ichida, K., Hosoya, T., Shimotaka, K., Niwa, T., Kanai, Y., and Endou, H. (2002) Nature 417, 447-452). URAT1 is expressed only in the kidney, where it is thought to participate in tubular urate reabsorption. We found that the multivalent PDZ (PSD-95, Drosophila discs-large protein, Zonula occludens protein 1) domain-containing protein, PDZK1 interacts with URAT1 in a yeast two-hybrid screen. Such an interaction requires the PDZ motif of URAT1 in its extreme intracellular C-terminal region and the first, second, and fourth PDZ domains of PDZK1 as identified by yeast two-hybrid assay, in vitro binding assay and surface plasmon resonance analysis (K-D = 1.97-514 nM). Coimmunoprecipitation studies revealed that the wildtype URAT1, but not its mutant lacking the PDZ-motif, directly interacts with PDZK1. Colocalization of URAT1 and PDZK1 was observed at the apical membrane of renal proximal tubular cells. The association of URAT1 with PDZK1 enhanced urate transport activities in HEK293 cells (1.4-fold), and the deletion of the URAT1 C-terminal PDZ motif abolished this effect. The augmentation of the transport activity was accompanied by a significant increase in the V-max of urate transport via URAT1 and was associated with the increased surface expression level of URAT1 protein from HEK293 cells stably expressing URAT1 transfected with PDZK1. Taken together, the present study indicates the novel role of PDZK1 in regulating the functional activity of URAT1-mediated urate transport in the apical membrane of renal proximal tubules.	Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Mitaka, Tokyo 1818611, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, Kumamoto 8608556, Japan	Kyorin University; Kumamoto University	Endou, H (corresponding author), Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	endouh@kyorin-u.ac.jp	Enomoto, Atsushi/I-7272-2014; ANZAI, NAOHIKO/K-9492-2017	Enomoto, Atsushi/0000-0002-9206-6116; ANZAI, NAOHIKO/0000-0003-0605-0458; Shin, Hojung/0000-0002-1629-9954				Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Bezprozvanny I, 2001, P NATL ACAD SCI USA, V98, P787, DOI 10.1073/pnas.98.3.787; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gisler SM, 2003, KIDNEY INT, V64, P1733, DOI 10.1046/j.1523-1755.2003.00266.x; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Hosoyamada M, 1999, AM J PHYSIOL-RENAL, V276, pF122, DOI 10.1152/ajprenal.1999.276.1.F122; Hosoyamada M, 2004, J AM SOC NEPHROL, V15, P261, DOI 10.1097/01.ASN.0000107560.80107.19; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ichida K, 2004, J AM SOC NEPHROL, V15, P164, DOI 10.1097/01.ASN.0000105320.04395.D0; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kocher O, 1998, LAB INVEST, V78, P117; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; Kocher O, 1999, LAB INVEST, V79, P1161; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Maesaka JK, 1998, AM J KIDNEY DIS, V32, P917, DOI 10.1016/S0272-6386(98)70067-8; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Roch-Ramel F, 1999, NEWS PHYSIOL SCI, V14, P80; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; Sica DA, 2000, KIDNEY, P680; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903	34	138	153	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45942	45950		10.1074/jbc.M406724200	http://dx.doi.org/10.1074/jbc.M406724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15304510	hybrid			2022-12-25	WOS:000224694900079
J	Sefat-e-Khuda; Yoshida, M; Xing, Y; Shimasaki, T; Takeya, M; Kuwahara, K; Sakaguchi, N				Sefat-e-Khuda; Yoshida, M; Xing, Y; Shimasaki, T; Takeya, M; Kuwahara, K; Sakaguchi, N			The Sac3 homologue shd1 is involved in mitotic progression in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN GANP; GERMINAL CENTER; CENTROSOME AMPLIFICATION; SPINDLE; KINASE; MCM3; IDENTIFICATION; LOCALIZATION; KINETOCHORES; EXPRESSION	Saccharomyces Sac3 required for actin assembly was shown to be involved in DNA replication. Here, we studied the function of a mammalian homologue SHD1 in cell cycle progression. SHD1 is localized on centrosomes at interphase and at spindle poles and mitotic spindles, similar to alpha-tubulin, at M phase. RNA interference suppression of endogenous shd1 caused defects in centrosome duplication and spindle formation displaying cells with a single apparent centrosome and down-regulated Mad2 expression, generating increased micronuclei. Conversely, increased expression of SHD1 by DNA transfection with shd1-green fluorescent protein (gfp) vector for a fusion protein of SHD1 and GFP caused abnormalities in centrosome duplication displaying cells with multiple centrosomes and deregulated spindle assembly with up-regulated Mad2 expression until anaphase, generating polyploidy cells. These results demonstrated that shd1 is involved in cell cycle progression, in particular centrosome duplication and a spindle assembly checkpoint function.	Kumamoto Univ, Grad Sch Med Sci, Dept Immunol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto 8608556, Japan; Kumamoto Univ, Inst Resource Dev & Anal, Ctr Resource Anal, Div Isotope Sci, Kumamoto 8600811, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi 3320012, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Sakaguchi, N (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Immunol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	nobusaka@kaiju.medic.kumamoto-u.ac.jp						Abe E, 2000, GENE, V255, P219, DOI 10.1016/S0378-1119(00)00336-X; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Bauer A, 1996, J CELL SCI, V109, P1575; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Kuwahara K, 2000, BLOOD, V95, P2321, DOI 10.1182/blood.V95.7.2321.007k33_2321_2328; Kuwahara K, 2001, P NATL ACAD SCI USA, V98, P10279, DOI 10.1073/pnas.181335698; Kuwata N, 1999, J IMMUNOL, V163, P6355; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Li YM, 2002, GENE DEV, V16, P183, DOI 10.1101/gad.959402; Matuliene J, 2002, MOL BIOL CELL, V13, P1832, DOI 10.1091/mbc.01-10-0504; Rabinovitch PS, 1999, CANCER RES, V59, P5148; SANDBERG AA, 1991, MUTAT RES, V247, P231, DOI 10.1016/0027-5107(91)90019-K; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Straight AF, 1997, CURR BIOL, V7, pR613, DOI 10.1016/S0960-9822(06)00315-0; Takei Y, 1998, J BIOL CHEM, V273, P22177, DOI 10.1074/jbc.273.35.22177; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Varmark H, 2004, J CELL BIOCHEM, V91, P904, DOI 10.1002/jcb.20013; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	26	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46182	46190		10.1074/jbc.M405347200	http://dx.doi.org/10.1074/jbc.M405347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322101	hybrid			2022-12-25	WOS:000224694900105
J	Kadotani, N; Nakayashiki, H; Tosa, Y; Mayama, S				Kadotani, N; Nakayashiki, H; Tosa, Y; Mayama, S			One of the two Dicer-like proteins in the filamentous fungi Magnaporthe oryzae genome is responsible for hairpin RNA-triggered RNA silencing and related small interfering RNA accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MICRORNAS; INITIATION; IDENTIFICATION; BIOSYNTHESIS; DICER-LIKE1; MATURATION; PATHWAYS; CLEAVAGE; GENES	Dicer is a ribonuclease III-like enzyme playing a key role in the RNA silencing pathway. Genome sequencing projects have demonstrated that eukaryotic genomes vary in the numbers of Dicer-like (DCL) proteins from one ( human) to four ( Arabidopsis). Two DCL genes, MDL-1 and - 2 ( Magnaporthe Dicer-like-1 and - 2) have been identified in the genome of the filamentous fungus Magnaporthe oryzae. Here we show that the knockout of MDL-2 drastically impaired gene silencing of enhanced green fluorescence protein by hairpin RNA and reduced related small interfering RNA ( siRNA) accumulation to nondetectable levels. In contrast, mutating the other DCL, MDL-1, exhibited a gene silencing frequency similar to wild type and accumulated siRNA normally. The silencing-deficient phenotype and loss of siRNA accumulation in the mdl-2 mutant was restored by genetic complementation with the wild-type MDL-2 allele. These results indicate that only MDL-2 is responsible for siRNA production, and no functional redundancy exists between MDL-1 and MDL-2 in the RNA silencing pathway in M. oryzae. Our findings contrast with a recent report in the filamentous fungus Neurospora crassa, where two DCL proteins are redundantly involved in the RNA silencing pathway, but are similar to the results obtained in a more distantly related organism, Drosophila melanogaster, where an individual DCL protein has a distinct role in the siRNA/micro-RNA pathways.	Kobe Univ, Fac Agr, Plant Pathol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan	Kobe University	Nakayashiki, H (corresponding author), Kobe Univ, Fac Agr, Plant Pathol Lab, Nada Ku, 1-1 Rokkodaicho, Kobe, Hyogo 6578501, Japan.	hnakaya@kobe-u.ac.jp						Baulcombe D, 2002, CURR BIOL, V12, pR82, DOI 10.1016/S0960-9822(02)00665-6; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Catalanotto C, 2004, MOL CELL BIOL, V24, P2536, DOI 10.1128/MCB.24.6.2536-2545.2004; Couch BC, 2002, MYCOLOGIA, V94, P683, DOI 10.2307/3761719; Dalmay T, 2000, PLANT CELL, V12, P369, DOI 10.1105/tpc.12.3.369; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719; Finnegan EJ, 2003, CURR BIOL, V13, P236, DOI 10.1016/S0960-9822(03)00010-1; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Kadotani N, 2003, MOL PLANT MICROBE IN, V16, P769, DOI 10.1094/MPMI.2003.16.9.769; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; KIMURA N, 1993, J BACTERIOL, V175, P4427, DOI 10.1128/JB.175.14.4427-4435.1993; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Makeyev EV, 2002, MOL CELL, V10, P1417, DOI 10.1016/S1097-2765(02)00780-3; Martin SL, 2002, NUCLEIC ACIDS RES, V30, P121, DOI 10.1093/nar/30.1.121; Nakayashiki H, 1999, GENETICS, V153, P693; Namiki F, 2001, MOL PLANT MICROBE IN, V14, P580, DOI 10.1094/MPMI.2001.14.4.580; Nicolas FE, 2003, EMBO J, V22, P3983, DOI 10.1093/emboj/cdg384; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Schauer SE, 2002, TRENDS PLANT SCI, V7, P487, DOI 10.1016/S1360-1385(02)02355-5; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	35	70	86	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44467	44474		10.1074/jbc.M408259200	http://dx.doi.org/10.1074/jbc.M408259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304480	hybrid			2022-12-25	WOS:000224505600030
J	Lougheed, JC; Chen, RH; Mak, P; Stout, TJ				Lougheed, JC; Chen, RH; Mak, P; Stout, TJ			Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ACTIVATION; GROWTH; COMPLEX; FAMILY; SUBSTRATE; CDC42; HCK; AUTOPHOSPHORYLATION; REFINEMENT	ACK1 is a multidomain non-receptor tyrosine kinase that is an effector of the Cdc42 GTPase. Members of the ACK family have a unique domain ordering and are the only tyrosine kinases known to interact with Cdc42. In contrast with many protein kinases, ACK1 has only a modest increase in activity upon phosphorylation. We have solved the crystal structures of the human ACK1 kinase domain in both the unphosphorylated and phosphorylated states. Comparison of these structures reveals that ACK1 adopts an activated conformation independent of phosphorylation. Furthermore, the unphosphorylated activation loop is structured, and its conformation resembles that seen in activated tyrosine kinases. In addition to the apo structure, complexes are also presented with a non-hydrolyzable nucleotide analog (adenosine 5'-(beta,gamma-methylenetriphosphate)) and with the natural product debromohymenialdisine, a general inhibitor of many protein kinases. Analysis of these structures reveals a typical kinase fold, a pre-organization into the activated conformation, and an unusual substrate-binding cleft.	Exelixis Inc, San Francisco, CA 94083 USA	Exelixis, Inc.	Stout, TJ (corresponding author), Exelixis Inc, 170 Harbor Way,POB 511, San Francisco, CA 94083 USA.	tstout@exelixis.com						ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Ahmed I, 2004, BIOCHEM BIOPH RES CO, V314, P571, DOI 10.1016/j.bbrc.2003.12.137; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brasher BB, 2000, J BIOL CHEM, V275, P35631, DOI 10.1074/jbc.M005401200; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Downward J, 1996, CANCER SURV, V27, P87; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; Hoehn GT, 1996, ONCOGENE, V12, P903; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; HOWLIN B, 1993, J APPL CRYSTALLOGR, V26, P622, DOI 10.1107/S0021889893002729; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ITO M, 1994, GENE, V139, P215; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kato-Stankiewicz J, 2001, BIOCHEM BIOPH RES CO, V284, P470, DOI 10.1006/bbrc.2001.5004; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; LESLIE AGW, 1992, JOINT CCP4 ESF EACBM; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Mayer BJ, 2001, J CELL SCI, V114, P1253; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; MURDUSHOV GN, 1996, P DAR STUD WEEK CLRC, P93; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Oda T, 2001, BIOCHEM BIOPH RES CO, V288, P1078, DOI 10.1006/bbrc.2001.5890; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Saylor P, 1998, BIOCHEMISTRY-US, V37, P17875, DOI 10.1021/bi981775b; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Till JH, 2002, STRUCTURE, V10, P1187, DOI 10.1016/S0969-2126(02)00814-6; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Worby CA, 2002, J BIOL CHEM, V277, P9422, DOI 10.1074/jbc.M110172200; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524; Yang WN, 2001, J BIOL CHEM, V276, P43987, DOI 10.1074/jbc.M104819200; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	50	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44039	44045		10.1074/jbc.M406703200	http://dx.doi.org/10.1074/jbc.M406703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308621	hybrid			2022-12-25	WOS:000224383100083
J	Lundmark, R; Carlsson, SR				Lundmark, R; Carlsson, SR			Regulated membrane recruitment of dynamin-2 mediated by sorting nexin 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; PROTEIN INTERACTIONS; AXONAL GUIDANCE; F-ACTIN; CLATHRIN; BINDING; DOMAIN; ALDOLASE; RECEPTOR; PLASMODIUM	The endocytic proteins sorting nexin 9 (SNX9) and dynamin-2 (Dyn2) assemble in the cytosol as a resting complex, together with a 41-kDa protein. We show here that the complex can be activated for membrane binding of SNX9 and Dyn2 by incubation of cytosol in the presence of ATP. SNX9 was essential for Dyn2 recruitment, whereas the reverse was not the case. RNA interference experiments confirmed that SNX9 functions as a mediator of Dyn2 recruitment to membranes in cells. The 41-kDa component was identified as the glycolytic enzyme aldolase. Aldolase bound with high affinity to a tryptophan-containing acidic sequence in SNX9 located close to its Phox homology domain, thereby blocking the membrane binding activity of SNX9. Phosphorylation of SNX9 released aldolase from the native cytosolic complex and rendered SNX9 competent for membrane binding. The results suggest that SNX9-dependent recruitment of Dyn2 to the membrane is regulated by an interaction between SNX9 and aldolase.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Carlsson, SR (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	sven.carlsson@medkem.umu.se		Carlsson, Sven R/0000-0001-5123-135X				Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Habermann B, 2004, EMBO REP, V5, P250, DOI 10.1038/sj.embor.7400105; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kim H, 1998, BIOCHEMISTRY-US, V37, P4388, DOI 10.1021/bi972233h; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Kusakabe T, 1997, ARCH BIOCHEM BIOPHYS, V344, P184, DOI 10.1006/abbi.1997.0204; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Leprince C, 2003, J CELL SCI, V116, P1937, DOI 10.1242/jcs.00403; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lundmark R, 2003, J BIOL CHEM, V278, P46772, DOI 10.1074/jbc.M307334200; Lundmark R, 2002, BIOCHEM J, V362, P597, DOI 10.1042/0264-6021:3620597; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Miele AE, 2004, NAT STRUCT MOL BIOL, V11, P242, DOI 10.1038/nsmb736; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Schafer DA, 2004, TRAFFIC, V5, P463, DOI 10.1111/j.1600-0854.2004.00199.x; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; STECK TL, 1978, J SUPRAMOL STR CELL, V8, P311, DOI 10.1002/jss.400080309; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Szaszak M, 2002, J BIOL CHEM, V277, P21650, DOI 10.1074/jbc.M200778200; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Volker KW, 1997, ARCH BIOCHEM BIOPHYS, V338, P237, DOI 10.1006/abbi.1996.9819; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Worby CA, 2002, J BIOL CHEM, V277, P9422, DOI 10.1074/jbc.M110172200; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922	43	79	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42694	42702		10.1074/jbc.M407430200	http://dx.doi.org/10.1074/jbc.M407430200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299020	hybrid			2022-12-25	WOS:000224226400043
J	Pike, J; Holmes, D; Kamalati, T; Davies, D; Tolhurst, R; Mazhar, D; Fishpool, S; al-Jehani, R; Waxman, J; Zelent, A; Lemoine, NR; Ali, S; Buluwela, L				Pike, J; Holmes, D; Kamalati, T; Davies, D; Tolhurst, R; Mazhar, D; Fishpool, S; al-Jehani, R; Waxman, J; Zelent, A; Lemoine, NR; Ali, S; Buluwela, L			Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor	ONCOGENE			English	Article						prostate cancer; androgen receptor; PLZF; gene expression	ACID RECEPTOR-ALPHA; DNA-BINDING DOMAIN; HISTONE DEACETYLASE; PROSTATE-CANCER; RAR-ALPHA; NUCLEAR RECEPTORS; PROMYELOCYTIC LEUKEMIA; CELL-LINE; EXPRESSION; ESTROGEN	The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and plays a key role in the development and progression of prostate cancer. Current therapies include the use of antiandrogens aimed at inhibiting the transcriptional activation of AR-regulated genes by AR. Here, we explore a strategy aimed at obtaining silencing of AR-regulated genes, based on the properties of the transcriptional repressor promyelocytic leukamia zinc-finger protein ( PLZF). In order to do this, we have made a fusion protein between PLZF and AR, named PLZF-AR, and show that PLZF-AR is able to bring about silencing of genomically encoded AR-regulated genes and inhibit the androgen-regulated growth of LNCaP prostate cancer cells. Together, our results show that this strategy is able to bring about potent repression of AR-regulated responses and, therefore, could be of value in the development of new therapies for prostate cancer.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England	Imperial College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Du Cane Rd, London W12 0NN, England.	simak.ali@imperial.ac.uk; l.buluwela@imperial.ac.uk	Zelent, Arthur/B-3532-2009; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816; Zelent, Arthur/0000-0002-7968-9888; Holmes, David/0000-0002-4560-3572; Davies, Derek/0000-0002-6977-4181				Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Blankvoort BMG, 2001, ANAL BIOCHEM, V298, P93, DOI 10.1006/abio.2001.5352; Bramlett KS, 2001, MOL CELL ENDOCRINOL, V183, P19, DOI 10.1016/S0303-7207(01)00636-0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Glass CK, 2000, GENE DEV, V14, P121; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heemers H, 2000, BIOCHEM BIOPH RES CO, V269, P209, DOI 10.1006/bbrc.2000.2262; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsieh ML, 1997, CANCER RES, V57, P2651; HUGGINS C, 1967, CANCER RES, V27, P1925; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LABRIE F, 1986, ENDOCR REV, V7, P67, DOI 10.1210/edrv-7-1-67; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu QY, 1996, CANCER RES, V56, P1155; Mabjeesh NJ, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090115; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MONNE M, 1994, CANCER RES, V54, P6344; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	59	10	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7561	7570		10.1038/sj.onc.1208030	http://dx.doi.org/10.1038/sj.onc.1208030			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334066				2022-12-25	WOS:000224176500013
J	Du, ZH; Yu, JH; Chen, YH; Andino, R; James, TL				Du, ZH; Yu, JH; Chen, YH; Andino, R; James, TL			Specific recognition of the C-rich strand of human telomeric DNA and the RNA template of human telomerase by the first KH domain of human poly(C)-binding protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(RC) BINDING-PROTEIN; NUCLEAR RIBONUCLEOPROTEIN-K; 3' UNTRANSLATED REGION; STEM-LOOP IV; MESSENGER-RNA; ERYTHROID-DIFFERENTIATION; POLIOVIRUS RNA; COMPLEX; SEQUENCE; IDENTIFICATION	Poly(C)-binding proteins (PCBPs) constitute a family of nucleic acid-binding proteins that play important roles in a wide spectrum of regulatory mechanisms. The diverse functions of PCBPs are dependent on the ability of the PCBPs to recognize poly(C) sequences with high affinity and specificity. PCBPs contain three copies of KH ( hnRNP K homology) domains, which are responsible for binding nucleic acids. We have determined the NMR structure of the first KH domain (KH1) from PCBP2. The PCBP2 KH1 domain adopts a structure with three alpha-helices packed against one side of a three-stranded antiparallel beta-sheet. Specific binding of PCBP2 KH1 to a number of poly(C) RNA and DNA sequences, including the C-rich strand of the human telomeric DNA repeat, the RNA template region of human telomerase, and regulatory recognition motifs in the poliovirus-1 5'-untranslated region, was established by monitoring chemical shift changes in protein N-15-HSQC spectra. The nucleic acid binding groove was further mapped by chemical shift perturbation upon binding to a six-nucleotide human telomeric DNA. The binding groove is an alpha/beta platform formed by the juxtaposition of two alpha-helices, one beta-strand, and two flanking loops. Whereas there is a groove in common with all of the DNA and RNA binders with a hydrophobic floor accommodating a three-residue stretch of C residues, nuances in recognizing flanking residues are provided by hydrogen bonding partners in the KH domain. Specific interactions of PCBP2 KH1 with telomeric DNA and telomerase RNA suggest that PCBPs may participate in mechanisms involved in the regulation of telomere/telomerase functions.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	James, TL (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,Genentech Hall, San Francisco, CA 94143 USA.	james@picasso.ucsf.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046967] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR-01081] Funding Source: Medline; NIAID NIH HHS [AI46967] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; Baber JL, 1999, J MOL BIOL, V289, P949, DOI 10.1006/jmbi.1999.2818; Bandiera A, 2003, ARCH BIOCHEM BIOPHYS, V409, P305, DOI 10.1016/S0003-9861(02)00413-7; BAX A, 1991, Journal of Biomolecular NMR, V1, P99, DOI 10.1007/BF01874573; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; Blyn LB, 1996, P NATL ACAD SCI USA, V93, P11115, DOI 10.1073/pnas.93.20.11115; Braddock DT, 2002, NATURE, V415, P1051, DOI 10.1038/4151051a; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Cassiday LA, 2002, NUCLEIC ACIDS RES, V30, P4118, DOI 10.1093/nar/gkf512; Chkheidze AN, 1999, MOL CELL BIOL, V19, P4572; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; Dejgaard K, 1996, EUR J BIOCHEM, V241, P425, DOI 10.1111/j.1432-1033.1996.00425.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Du ZH, 2004, BIOCHEMISTRY-US, V43, P5757, DOI 10.1021/bi0363228; Du ZH, 2003, BIOCHEMISTRY-US, V42, P4373, DOI 10.1021/bi027314e; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Ford LP, 2002, ONCOGENE, V21, P580, DOI 10.1038/sj.onc.1205086; Gamarnik AV, 1998, GENE DEV, V12, P2293, DOI 10.1101/gad.12.15.2293; Gamarnik AV, 2000, J VIROL, V74, P2219, DOI 10.1128/JVI.74.5.2219-2226.2000; Gamarnik AV, 1997, RNA, V3, P882; GODDARD TD, 1998, SPARKY 3 0; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Huang C. C., 1996, PAC S BIOCOMPUT, P724, DOI DOI 10.1142/9789814531399; Lacroix L, 2000, NUCLEIC ACIDS RES, V28, P1564, DOI 10.1093/nar/28.7.1564; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Lewis HA, 1999, STRUCTURE, V7, P191, DOI 10.1016/S0969-2126(99)80025-2; Lindquist JN, 2000, NUCLEIC ACIDS RES, V28, P4306, DOI 10.1093/nar/28.21.4306; Liu ZH, 2001, SCIENCE, V294, P1098, DOI 10.1126/science.1064719; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Musco G, 1996, CELL, V85, P237, DOI 10.1016/S0092-8674(00)81100-9; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Parsley TB, 1997, RNA, V3, P1124; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Silvera D, 1999, J BIOL CHEM, V274, P38163, DOI 10.1074/jbc.274.53.38163; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Waggoner SA, 2003, MOL CELL BIOL, V23, P7055, DOI 10.1128/MCB.23.19.7055-7067.2003; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	50	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48126	48134		10.1074/jbc.M405371200	http://dx.doi.org/10.1074/jbc.M405371200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15331611	hybrid			2022-12-25	WOS:000224957000086
J	Dupeyrat, F; Vidaud, C; Lorphelin, A; Berthomieu, C				Dupeyrat, F; Vidaud, C; Lorphelin, A; Berthomieu, C			Long distance charge redistribution upon Cu,Zn-superoxide dismutase reduction - Significance for dismutase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; INFRARED DIFFERENCE SPECTROSCOPY; QUANTITATIVE IR SPECTROPHOTOMETRY; ELECTRON-PARAMAGNETIC-RESONANCE; METAL-BOUND HISTIDINE; WATER H2O SOLUTIONS; PHOTOSYSTEM-II; RAMAN-SPECTRA; 3-DIMENSIONAL STRUCTURE; VIBRATIONAL-SPECTRA	Cu, Zn-superoxide dismutase (Cu, Zn-SOD) is a ubiquitous enzyme with an essential role in antioxidant defense. To better understand structural factors at the origin of the highly efficient superoxide dismutation mechanism, we analyzed the consequence of copper reduction on the electronic properties of the backbone and individual amino acids by using electrochemistry coupled to Fourier transform infrared spectroscopy. Comparison of data recorded with bovine erythrocyte and recombinant chloroplastic Cu, Zn-SOD from Lycopersicon esculentum, expressed as a functional tetramer in Escherichia coli and N-14- or fully N-15-labeled, demonstrated that the infrared changes were dominated by reorganizations of peptide bonds and histidine copper ligands. Two main infrared modes of histidine side chain, markers of metal coordination, were identified by using Cu- and Zn-methylimidazole models: the nu(C4C5) at 1605-1594 cm(-1) or approximate to1586 cm(-1) for Ntau or Npi coordination, and the nu(C(5)Ntau) at approximate to 1113-1088 cm(-1). These modes, also identified in Cu, Zn-SOD by using N-15 labeling, showed that the electronic properties of the histidine Ntau ligands of copper are mostly affected upon copper reduction. A striking conclusion of this work is that peptide groups from loops and beta-sheet largely participate in charge redistribution upon copper reduction, and in contrast, electronic properties of polar and charged amino acids of the superoxide access channel remain unaffected. This is notably shown for the strictly conserved Arg-143 by site-directed mutagenesis on chloroplastic Cu, Zn-SOD. Charge compensation by the peptide backbone and preserved electronic properties of the superoxide access channel and docking site upon copper reduction may be the determinant factors for the high reaction kinetics of superoxide with both reduced and oxidized Cu, Zn-SOD.	Univ Mediterranee, CEA 1000, Commissariat Energie Atom Cadarache, Lab Bioenerget Cellulaire,UMR CNRS CEA Aix Marsei, F-13108 St Paul Les Durance, France; Commissariat Energie Atom Valrho, DSV DIEP, Serv Biochim Postgenom & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France	CEA; UDICE-French Research Universities; Aix-Marseille Universite; CEA	Berthomieu, C (corresponding author), Univ Mediterranee, CEA 1000, Commissariat Energie Atom Cadarache, Lab Bioenerget Cellulaire,UMR CNRS CEA Aix Marsei, Bat 156, F-13108 St Paul Les Durance, France.	catherine.berthomieu@cea.fr	VIDAUD, Claude/AGX-9878-2022; Berthomieu, Catherine/AAX-9559-2021	Berthomieu, Catherine/0000-0001-8784-5396				Ascone I, 1997, BIOCHEM BIOPH RES CO, V241, P119, DOI 10.1006/bbrc.1997.7777; ASHIKAWA I, 1979, BIOPOLYMERS, V18, P1859, DOI 10.1002/bip.1979.360180804; AZAB HA, 1992, INORG CHEM, V31, P4649, DOI 10.1021/ic00048a037; BAILEY DB, 1980, BIOCHEMISTRY-US, V19, P591, DOI 10.1021/bi00544a031; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; BANCI L, 1989, INORG CHEM, V28, P2377, DOI 10.1021/ic00311a024; Banci L, 2002, EUR J BIOCHEM, V269, P1905, DOI 10.1046/j.1432-1033.2002.02840.x; BANCI L, 1988, J AM CHEM SOC, V110, P3629, DOI 10.1021/ja00219a043; BANCI L, 1993, INORG CHEM, V32, P1403, DOI 10.1021/ic00060a014; BANNISTER WH, 1991, FREE RADICAL RES COM, V12-3, P349, DOI 10.3109/10715769109145804; Barth A, 2002, Q REV BIOPHYS, V35, P369, DOI 10.1017/S0033583502003815; Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079-6107(00)00021-3; BERTHOMIEU C, 1992, BIOCHEMISTRY-US, V31, P11460, DOI 10.1021/bi00161a026; Berthomieu C, 2002, BIOCHEMISTRY-US, V41, P10360, DOI 10.1021/bi020344x; Berthomieu C, 2001, BIOCHEMISTRY-US, V40, P4044, DOI 10.1021/bi002236l; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BERTINI I, 1991, EUR J BIOCHEM, V197, P691, DOI 10.1111/j.1432-1033.1991.tb15960.x; BEYER WF, 1987, J BIOL CHEM, V262, P11182; BORDO D, 1994, J MOL BIOL, V238, P366, DOI 10.1006/jmbi.1994.1298; BORSARI M, 1992, BIOELECTROCH BIOENER, V27, P229, DOI 10.1016/0302-4598(92)87046-W; BOWLER C, 1994, CRIT REV PLANT SCI, V13, P199, DOI 10.1080/713608062; BRAIMAN MS, 1999, J PHYS CHEM-US, V103, P1243; Breton J, 2002, BIOCHEMISTRY-US, V41, P11200, DOI 10.1021/bi0262404; CARUGO KD, 1994, FEBS LETT, V349, P93, DOI 10.1016/0014-5793(94)00651-2; CHIRGADZE YN, 1975, BIOPOLYMERS, V14, P679, DOI 10.1002/bip.1975.360140402; DEFREITAS DM, 1990, INORG CHEM, V29, P3512; DEOCRDES ND, 1967, SPECTROCHIM ACTA A, V24, P237; DJINOVIC K, 1992, J MOL BIOL, V225, P791, DOI 10.1016/0022-2836(92)90401-5; DJINOVICCARUGO K, 1994, J MOL BIOL, V240, P179, DOI 10.1006/jmbi.1994.1432; DONG AC, 1995, ARCH BIOCHEM BIOPHYS, V320, P59, DOI 10.1006/abbi.1995.1342; Ellerby LM, 1996, J AM CHEM SOC, V118, P6556, DOI 10.1021/ja953845x; Ferraroni M, 1998, J BIOL INORG CHEM, V3, P411, DOI 10.1007/s007750050251; FIELDEN EM, 1974, BIOCHEM J, V139, P49, DOI 10.1042/bj1390049; FISHER CL, 1994, PROTEINS, V19, P24, DOI 10.1002/prot.340190105; Gallouj H, 1997, J RAMAN SPECTROSC, V28, P909, DOI 10.1002/(SICI)1097-4555(199711)28:11<909::AID-JRS187>3.0.CO;2-X; Ge B, 2003, BIOSENS BIOELECTRON, V18, P295, DOI 10.1016/S0956-5663(02)00174-4; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; HARIS PI, 1992, BIOCHEMISTRY-US, V31, P6279, DOI 10.1021/bi00142a016; Hart PJ, 1999, BIOCHEMISTRY-US, V38, P2167, DOI 10.1021/bi982284u; Hasegawa K, 2000, J PHYS CHEM B, V104, P4253, DOI 10.1021/jp000157d; Hasegawa K, 2002, J PHYS CHEM A, V106, P3377, DOI 10.1021/jp012251f; Hashimoto S, 1998, J RAMAN SPECTROSC, V29, P969, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<969::AID-JRS328>3.3.CO;2-Y; Hienerwadel R, 1995, BIOCHEMISTRY-US, V34, P16288, DOI 10.1021/bi00050a008; HILL HAO, 1985, J ELECTROANAL CHEM, V187, P315; Hough MA, 2003, STRUCTURE, V11, P937, DOI 10.1016/S0969-2126(03)00155-2; Hough MA, 1999, J MOL BIOL, V287, P579, DOI 10.1006/jmbi.1999.2610; KITAGAWA Y, 1991, J BIOCHEM-TOKYO, V109, P477, DOI 10.1093/oxfordjournals.jbchem.a123407; KLUG D, 1972, J BIOL CHEM, V247, P4839; KLUGROTH D, 1973, J AM CHEM SOC, V95, P2786, DOI 10.1021/ja00790a007; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAWRENCE GD, 1979, BIOCHEMISTRY-US, V18, P3045, DOI 10.1021/bi00581a021; Leone M, 1998, BIOCHEMISTRY-US, V37, P4459, DOI 10.1021/bi971878e; MAJOUBE M, 1995, J MOL STRUCT, V344, P21, DOI 10.1016/0022-2860(94)08412-B; MANTELE W, 1993, TRENDS BIOCHEM SCI, V18, P197, DOI 10.1016/0968-0004(93)90186-Q; MARINO M, 1995, PROTEIN ENG, V8, P551, DOI 10.1093/protein/8.6.551; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCCORD JM, 1999, CURRENT PROTOCOLS TO; Miller A.-F., 1997, COMMENTS MOL CELL BI, V9, P1; Miura T, 2000, BIOCHEMISTRY-US, V39, P7024, DOI 10.1021/bi0002479; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Miura T, 1998, J RAMAN SPECTROSC, V29, P41, DOI 10.1002/(SICI)1097-4555(199801)29:1<41::AID-JRS212>3.0.CO;2-R; MOSS D, 1990, EUR J BIOCHEM, V187, P565, DOI 10.1111/j.1432-1033.1990.tb15338.x; Murphy LM, 1997, STRUCTURE, V5, P371, DOI 10.1016/S0969-2126(97)00194-9; Noguchi T, 1999, BIOCHEMISTRY-US, V38, P399, DOI 10.1021/bi982294v; Ogihara NL, 1996, BIOCHEMISTRY-US, V35, P2316, DOI 10.1021/bi951930b; PERLTREVES R, 1988, PLANT MOL BIOL, V11, P609, DOI 10.1007/BF00017461; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Rahmelow K, 1998, ANAL BIOCHEM, V257, P1, DOI 10.1006/abio.1997.2502; REDFORD SM, 1990, J MOL BIOL, V212, P449, DOI 10.1016/0022-2836(90)90323-E; RYPNIEWSKI WR, 1995, J MOL BIOL, V251, P282, DOI 10.1006/jmbi.1995.0434; Sambrook J., 1989, MOL CLONING LAB MANU, V2; STCLAIR CS, 1992, INORG CHEM, V31, P925, DOI 10.1021/ic00031a041; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; SUSI H, 1987, ARCH BIOCHEM BIOPHYS, V258, P465, DOI 10.1016/0003-9861(87)90367-5; SUSI H, 1969, STRUCTURE STABILITY, V2, P575; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; Tian Y, 2002, BBA-GEN SUBJECTS, V1569, P151, DOI 10.1016/S0304-4165(01)00246-X; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1259, DOI 10.1002/bip.360301310; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; VERHAGEN MFJM, 1995, BBA-GEN SUBJECTS, V1244, P99, DOI 10.1016/0304-4165(94)00201-8; Wang DJ, 2000, J AM CHEM SOC, V122, P2193, DOI 10.1021/ja992410x; Wu XQ, 1999, BIOELECTROCH BIOENER, V48, P227, DOI 10.1016/S0302-4598(98)00233-5; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889; Zhao XJ, 1998, INORG CHEM, V37, P5414, DOI 10.1021/ic980705q; Zscherp C, 2001, BIOCHEMISTRY-US, V40, P1875, DOI 10.1021/bi002567y	89	26	26	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48091	48101		10.1074/jbc.M402728200	http://dx.doi.org/10.1074/jbc.M402728200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15328354	hybrid			2022-12-25	WOS:000224957000082
J	Keiper, M; Stope, MB; Szatkowski, D; Bohm, A; Tysack, K; vom Dorp, F; Saur, O; Weernink, PAO; Evellin, S; Jakobs, KH; Schmidt, M				Keiper, M; Stope, MB; Szatkowski, D; Bohm, A; Tysack, K; vom Dorp, F; Saur, O; Weernink, PAO; Evellin, S; Jakobs, KH; Schmidt, M			Epac- and Ca2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-EPSILON; BETA(2)-ADRENERGIC RECEPTOR; CYCLIC-AMP; DEPENDENT ACTIVATION; PARATHYROID-HORMONE; CELL-GROWTH; PROTEIN; CAMP; RAP1; PATHWAY	We have recently reported that two typical G(s)-coupled receptors, the beta(2)-adrenergic receptor and the receptor for prostaglandin E-1, stimulate phospholipase C-epsilon (PLC-epsilon) and increase intracellular Ca2+ concentration ([Ca2+](i)) in HEK-293 cells and N1E-115 neuroblastoma cells, respectively, by a pathway involving Epac1, a cAMP-activated and Rap-specific guanine nucleotide exchange factor (GEF), and the GTPase Rap2B. Here we have demonstrated that these G(s)-coupled receptors use this pathway to activate H-Ras and the extracellular signal-regulated kinases 1 and 2 (ERK1/2). Specifically, agonist activation of the receptors resulted in activation of H-Ras and ERK1/2. The latter action was suppressed by dominant negative H-Ras, but not Rap1A. The receptor actions were independent of protein kinase A but fully mimicked by an Epac-specific cAMP analog as well as by a constitutively active Rap2B mutant. On the other hand, a cAMP-binding-deficient Epac1 mutant, the Rap GTPase-activating proteinII, and a dominant negative Rap2B mutant suppressed receptor- and Epac-mediated activation of H-Ras and ERK1/2. Finally, we have demonstrated that activation of H-Ras and ERK1/2 requires the lipase activity of PLC-epsilon and the subsequent [Ca2+](i) increase, suggesting that H-Ras activation is mediated by a Ca2+-activated GEF. In line with this hypothesis, receptor- mediated activation of H-Ras and ERK1/2 was strongly enhanced by expression of RasGRP1, a Ca2+-regulated Ras-GEF. Collectively, our data indicated that G(s)-coupled receptors can activate H-Ras and subsequently the mitogen-activated protein kinases ERK1/2 by a Ca2+-activated Ras-GEF, possibly RasGRP1, mediated by cAMP-activated Epac proteins, which then lead via Rap2B and PLC-epsilon stimulation to [Ca2+](i) increase.	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany	University of Duisburg Essen	Schmidt, M (corresponding author), Univ Klinikum Essen, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.	martina.schmidt@uni-essen.de						Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Friedman J, 2002, MOL PHARMACOL, V62, P1094, DOI 10.1124/mol.62.5.1094; Fujita T, 2002, J BIOL CHEM, V277, P22191, DOI 10.1074/jbc.M110364200; Gutkind J.S, 2000, SCI STKE; Iacovelli L, 2001, MOL PHARMACOL, V60, P924, DOI 10.1124/mol.60.5.924; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; Lefkowitz RJ, 2002, MOL PHARMACOL, V62, P971, DOI 10.1124/mol.62.5.971; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Lin SL, 2003, J NEUROCHEM, V87, P1076, DOI 10.1046/j.1471-4159.2003.02076.x; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Lorenzo PS, 2001, CANCER RES, V61, P943; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; REBMANN H, 2003, J BIOL CHEM, V278, P38548; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Stope MB, 2004, MOL CELL BIOL, V24, P4664, DOI 10.1128/MCB.24.11.4664-4676.2004; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; vom Dorp F, 2004, CELL SIGNAL, V16, P921, DOI 10.1016/j.cellsig.2004.01.009; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	46	90	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46497	46508		10.1074/jbc.M403604200	http://dx.doi.org/10.1074/jbc.M403604200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15319437	hybrid			2022-12-25	WOS:000224832400021
J	Meyer, PR; Smith, AJ; Matsuura, SE; Scott, WA				Meyer, PR; Smith, AJ; Matsuura, SE; Scott, WA			Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEIC ACID INTERACTIONS; POLYMERASE ACTIVE-SITE; GROOVE-BINDING TRACK; KINETIC-ANALYSIS; DRUG-RESISTANCE; DNA-TEMPLATE; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; NUCLEOSIDE INHIBITORS; SELECTIVE EXCISION	HIV-1 reverse transcriptase can remove chain terminators from blocked DNA ends through a nucleotide-dependent mechanism. We show that the catalytic efficiency of the removal reaction can vary several hundredfold in different sequence contexts and is most strongly affected by the nature of the base pair at the 3'-primer terminus and the six base pairs upstream of it. Similar effects of the upstream sequence were observed with primer-templates terminated with 2', 3'-dideoxy-AMP, 2', 3'-dideoxy-CMP, or 2', 3'-dideoxy-GMP. However, the removal of 2', 3'-dideoxy-TMP or 3'-azido-2', 3'-dideoxy-TMP was much less influenced by upstream primer-template sequence, and the rate of excision of these thymidylate analogues was greater than or equal to that of the other chain-terminating residues in each sequence context tested. These results strongly indicate that the primer terminus and adjacent upstream base pairs interact with reverse transcriptase in a sequence-dependent manner that affects the removal reaction. We conclude that primer-template sequence context is a major factor to consider when evaluating the removal of different chain terminators by HIV-1 reverse transcriptase.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Scott, WA (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.	wscott@med.miami.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039973] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI039973, R01 AI39973, R01 AI039973-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS J, 1993, J BIOL CHEM, V268, P10312; Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000; Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Arion D, 2000, J BIOL CHEM, V275, P9251, DOI 10.1074/jbc.275.13.9251; Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Boyer PL, 2002, J VIROL, V76, P9143, DOI 10.1128/JVI.76.18.9143-9151.2002; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Canard B, 1999, J BIOL CHEM, V274, P35768, DOI 10.1074/jbc.274.50.35768; Chamberlain PP, 2002, J VIROL, V76, P10015, DOI 10.1128/JVI.76.19.10015-10019.2002; CLARK PK, 1990, AIDS RES HUM RETROV, V6, P753, DOI 10.1089/aid.1990.6.753; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Ding JP, 1997, BIOPOLYMERS, V44, P125, DOI 10.1002/(SICI)1097-0282(1997)44:2&lt;125::AID-BIP2&gt;3.0.CO;2-X; Fisher TS, 2003, J VIROL, V77, P5837, DOI 10.1128/JVI.77.10.5837-5845.2003; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; Klarmann GJ, 2000, J BIOL CHEM, V275, P359, DOI 10.1074/jbc.275.1.359; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; Lennerstrand J, 2001, J VIROL, V75, P7202, DOI 10.1128/JVI.75.15.7202-7205.2001; Lennerstrand J, 2001, ANTIMICROB AGENTS CH, V45, P2144, DOI 10.1128/AAC.45.7.2144-2146.2001; Luscombe NM, 2002, J MOL BIOL, V320, P991, DOI 10.1016/S0022-2836(02)00571-5; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; Marchand B, 2003, J BIOL CHEM, V278, P35362, DOI 10.1074/jbc.M304262200; Mas A, 2002, J MOL BIOL, V323, P181, DOI 10.1016/S0022-2836(02)00911-7; Mas A, 2000, EMBO J, V19, P5752, DOI 10.1093/emboj/19.21.5752; Meyer PR, 2003, J VIROL, V77, P3871, DOI 10.1128/JVI.77.6.3871-3877.2003; Meyer PR, 2002, ANTIMICROB AGENTS CH, V46, P1540, DOI 10.1128/AAC.46.5.1540-1545.2002; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2003, J VIROL, V77, P6127, DOI 10.1128/JVI.77.11.6127-6137.2003; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Pop MP, 1996, BIOCHEMISTRY-US, V35, P5054, DOI 10.1021/bi9530292; Ray AS, 2003, BIOCHEMISTRY-US, V42, P8831, DOI 10.1021/bi034435l; REARDON JE, 1990, J BIOL CHEM, V265, P20302; Sarafianos SG, 2003, J BIOL CHEM, V278, P16280, DOI 10.1074/jbc.M212911200; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; TABOR S, 1990, J BIOL CHEM, V265, P8322; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z	47	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45389	45398		10.1074/jbc.M405072200	http://dx.doi.org/10.1074/jbc.M405072200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308646	hybrid			2022-12-25	WOS:000224694900014
J	Raymond, CK; Castle, J; Garrett-Engele, P; Armour, CD; Kan, ZY; Tsinoremas, N; Johnson, JM				Raymond, CK; Castle, J; Garrett-Engele, P; Armour, CD; Kan, ZY; Tsinoremas, N; Johnson, JM			Expression of alternatively spliced sodium channel alpha-subunit genes - Unique splicing patterns are observed in dorsal root ganglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPATHIC PAIN; RAT-BRAIN; MOUSE; NEURONS; MODEL; MICROARRAYS; TRANSCRIPTS; EVOLUTION; CURRENTS; ISOFORMS	Molecular medicine requires the precise definition of drug targets, and tools are now in place to provide genome-wide information on the expression and alternative splicing patterns of any known gene. DNA microarrays were used to monitor transcript levels of the nine well-characterized alpha-subunit sodium channel genes across a broad range of tissues from cynomolgus monkey, a non-human primate model. Alternative splicing of human transcripts for a subset of the genes that are expressed in dorsal root ganglia, SCN8A (Na(v)1.6), SCN9A (Na(v)1.7), and SCN11A (Na(v)1.9) was characterized in detail. Genomic sequence analysis among gene family paralogs and between cross-species orthologs suggested specific alternative splicing events within transcripts of these genes, all of which were experimentally confirmed in human tissues. Quantitative PCR revealed that certain alternative splice events are uniquely expressed in dorsal root ganglia. In addition to characterization of human transcripts, alternatively spliced sodium channel transcripts were monitored in a rat model for neuropathic pain. Consistent down-regulation of all transcripts was observed, as well as significant changes in the splicing patterns of SCN8A and SCN9A.	Rosetta Inpharmat LLC, Seattle, WA 98109 USA	Merck & Company	Raymond, CK (corresponding author), Rosetta Inpharmat LLC, 401 Terry Ave N, Seattle, WA 98109 USA.	christopher_raymond@merck.com						AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; BELCHER SM, 1995, P NATL ACAD SCI USA, V92, P11034, DOI 10.1073/pnas.92.24.11034; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; Castle J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r66; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Dib-Hajj SD, 2002, MOL NEUROBIOL, V26, P235, DOI 10.1385/MN:26:2-3:235; Dib-Hajj SD, 1999, PAIN, V83, P591, DOI 10.1016/S0304-3959(99)00169-4; DibHajj S, 1996, P NATL ACAD SCI USA, V93, P14950, DOI 10.1073/pnas.93.25.14950; Dietrich PS, 1998, J NEUROCHEM, V70, P2262; Goldin AL, 2000, NEURON, V28, P365, DOI 10.1016/S0896-6273(00)00116-1; GUSTAFSON TA, 1993, J BIOL CHEM, V268, P18648; He YDD, 2003, BIOINFORMATICS, V19, P956, DOI 10.1093/bioinformatics/btg126; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KAN Z, P S BIOC, P4204; Kan ZY, 2002, GENOME RES, V12, P1837, DOI 10.1101/gr.764102; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032; Modrek B, 2003, NAT GENET, V34, P177, DOI 10.1038/ng1159; Plummer NW, 1998, GENOMICS, V54, P287, DOI 10.1006/geno.1998.5550; Plummer NW, 1999, GENOMICS, V57, P323, DOI 10.1006/geno.1998.5735; Plummer NW, 1997, J BIOL CHEM, V272, P24008, DOI 10.1074/jbc.272.38.24008; Sangameswaran L, 1997, J BIOL CHEM, V272, P14805, DOI 10.1074/jbc.272.23.14805; SARAO R, 1991, NUCLEIC ACIDS RES, V19, P5673, DOI 10.1093/nar/19.20.5673; SCHALLER KL, 1992, J NEUROSCI, V12, P1370; Sleeper AA, 2000, J NEUROSCI, V20, P7279; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tan JG, 2002, J NEUROSCI, V22, P5300; Thanaraj TA, 2003, NUCLEIC ACIDS RES, V31, P2544, DOI 10.1093/nar/gkg355; Wang H, 2002, NEUROSCIENCE, V114, P529, DOI 10.1016/S0306-4522(02)00341-X; Waxman SG, 2000, J REHABIL RES DEV, V37, P517; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; Zimmer T, 2002, AM J PHYSIOL-HEART C, V282, pH1007, DOI 10.1152/ajpheart.00644.2001; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	35	97	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46234	46241		10.1074/jbc.M406387200	http://dx.doi.org/10.1074/jbc.M406387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302875	Green Submitted, hybrid			2022-12-25	WOS:000224694900110
J	Shechter, D; Ying, CY; Gautier, J				Shechter, D; Ying, CY; Gautier, J			DNA unwinding is an MCM complex-dependent and ATP hydrolysis-dependent process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; ORIGIN RECOGNITION COMPLEX; XENOPUS EGG EXTRACTS; REPLICATION LICENSING SYSTEM; HELICASE ACTIVITY; SCHIZOSACCHAROMYCES-POMBE; PREREPLICATION COMPLEX; BIND CHROMATIN; S-PHASE; INITIATION	Minichromosome maintenance proteins (Mcm) are essential in all eukaryotes and are absolutely required for initiation of DNA replication. The eukaryotic and archaeal Mcm proteins have conserved helicase motifs and exhibit DNA helicase and ATP hydrolysis activities in vitro. Although the Mcm proteins have been proposed to be the replicative helicase, the enzyme that melts the DNA helix at the replication fork, their function during cellular DNA replication elongation is still unclear. Using nucleoplasmic extract (NPE) from Xenopus laevis eggs and six purified polyclonal antibodies generated against each of the Xenopus Mcm proteins, we have demonstrated that Mcm proteins are required during DNA replication and DNA unwinding after initiation of replication. Quantitative depletion of Mcms from the NPE results in normal replication and unwinding, confirming that Mcms are required before pre-replicative complex assembly and dispensable thereafter. Replication and unwinding are inhibited when pooled neutralizing antibodies against the six different Mcm2-7 proteins are added during NPE incubation. Furthermore, replication is blocked by the addition of the Mcm antibodies after an initial period of replication in the NPE, visualized by a pulse of radiolabeled nucleotide at the same time as antibody addition. Addition of the cyclin-dependent kinase 2 inhibitor p21(cip1) specifically blocks origin firing but does not prevent helicase action. When p21(cip1) is added, followed by the non-hydrolyzable analog ATPgammaS to block helicase function, unwinding is inhibited, demonstrating that plasmid unwinding is specifically attributable to an ATP hydrolysis-dependent function. These data support the hypothesis that the Mcm protein complex functions as the replicative helicase.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Hammer Hlth Sci Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, Dept Genet & Dev, New York, NY 10032 USA	Columbia University; Columbia University	Gautier, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, Hammer Hlth Sci Ctr, Rm 1620,701 W 168th St, New York, NY 10032 USA.	jg130@columbia.edu	Gautier, jean/A-2774-2008; Shechter, David/B-4660-2008	Shechter, David/0000-0001-9388-6004	NATIONAL CANCER INSTITUTE [R01CA092245] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2001, EMBO J, V20, P3293, DOI 10.1093/emboj/20.13.3293; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Coue M, 1998, EXP CELL RES, V245, P282, DOI 10.1006/excr.1998.4271; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DEAN FB, 1992, J BIOL CHEM, V267, P14129; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Forsburg SL, 1997, GENETICS, V147, P1025; Harvey KJ, 2003, MOL CELL BIOL, V23, P6769, DOI 10.1128/MCB.23.19.6769-6779.2003; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; KELMAN Z, 1995, CURR BIOL, V5, P1239, DOI 10.1016/S0960-9822(95)00247-8; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Krude T, 1996, J CELL SCI, V109, P309; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lei M, 2001, J CELL SCI, V114, P1447; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Liang DT, 1999, J CELL SCI, V112, P559; MAINE GT, 1984, GENETICS, V106, P365; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; MOIR D, 1982, GENETICS, V100, P547; Neuwald AF, 1999, GENOME RES, V9, P27; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Richter A, 1998, BIOL CHEM, V379, P1181; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; Romanowski P, 1996, P NATL ACAD SCI USA, V93, P10189, DOI 10.1073/pnas.93.19.10189; San Martin C, 1998, STRUCTURE, V6, P501; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Sclafani RA, 2000, J CELL SCI, V113, P2111; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; von Hippel PH, 2003, BIOESSAYS, V25, P1168, DOI 10.1002/bies.10369; Waiter J, 1997, SCIENCE, V275, P993, DOI 10.1126/science.275.5302.993; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; You ZY, 1999, MOL CELL BIOL, V19, P8003; Zou L, 1997, MOL CELL BIOL, V17, P553, DOI 10.1128/MCB.17.2.553	60	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45586	45593		10.1074/jbc.M407772200	http://dx.doi.org/10.1074/jbc.M407772200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326181	hybrid			2022-12-25	WOS:000224694900037
J	Lishko, VK; Podolnikova, NP; Yakubenko, VP; Yakovlev, S; Medved, L; Yadav, SP; Ugarova, TP				Lishko, VK; Podolnikova, NP; Yakubenko, VP; Yakovlev, S; Medved, L; Yadav, SP; Ugarova, TP			Multiple binding sites in fibrinogen for integrin alpha(M)beta(2) (Mac-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-C-DOMAIN; SUBSTRATE-SPECIFICITY; PEPTIDE LIBRARIES; MOLECULAR-BASIS; DNAK CHAPERONE; CD11B CD18; RECOGNITION; SEQUENCE; IDENTIFICATION; ADHESION	The leukocyte integrin alpha(M)beta(2) (Mac-1) is a multiligand receptor that mediates a range of adhesive reactions of leukocytes during the inflammatory response. This integrin binds the coagulation protein fibrinogen providing a key link between thrombosis and inflammation. However, the mechanism by which alpha(M)beta(2) binds fibrinogen remains unknown. Previous studies indicated that a model in which two fibrinogen gammaC domain sequences, P1 (gamma190 - 202) and P2 (gamma377 - 395), serve as the alpha(M)beta(2) binding sites cannot fully account for recognition of fibrinogen by integrin. Here, using surface plasmon resonance, we examined the interaction of the ligand binding alpha(M)I-domain of alpha(M)beta(2) with the D fragment of fibrinogen and showed that this ligand is capable of associating with several alpha(M)I-domain molecules. To localize the alternative alpha(M)I-domain binding sites, we screened peptide libraries covering the complete sequences of the gammaC and betaC domains, comprising the majority of the D fragment structure, for alpha(M)I-domain binding. In addition to the P2 and P1 peptides, the alpha(M)I-domain bound to many other sequences in the gammaC and betaC scans. Similar to P1 and P2, synthetic peptides derived from gammaC and betaC were efficient inhibitors of alpha(M)beta(2)-mediated cell adhesion and were able to directly support adhesion suggesting that they contain identical recognition information. Analyses of recognition specificity using substitutional peptide libraries demonstrated that the alpha(M)I-domain binding depends on basic and hydrophobic residues. These findings establish a new model of alpha(M)beta(2) binding in which the alpha(M)I-domain interacts with multiple sites in fibrinogen and has the potential to recognize numerous sequences. This paradigm may have implications for mechanisms of promiscuity in ligand binding exhibited by integrin alpha(M)beta(2).	Lerner Res Inst, JJ Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Cleveland, OH 44195 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA	Cleveland Clinic Foundation; American Red Cross	Ugarova, TP (corresponding author), Lerner Res Inst, JJ Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Mail Code NB-50, Cleveland, OH 44195 USA.	ugarovt@ccf.org		Medved, Leonid/0000-0002-3665-9849; Yakovlev, Sergiy/0000-0002-2078-5218	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016789] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063199, R01HL056051] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-016789] Funding Source: Medline; NHLBI NIH HHS [HL-56051, HL-63199, R01 HL056051] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; Chavakis T, 2001, FASEB J, V15, P2365, DOI 10.1096/fj.01-0201com; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; Forsyth CB, 2001, J EXP MED, V193, P1123, DOI 10.1084/jem.193.10.1123; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; KISHIMOTO TK, 1999, INFLAMMATION BASIC P, P537; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; Kramer A, 1998, METH MOL B, V87, P25; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; Lishko VK, 2001, BLOOD, V98, P2448, DOI 10.1182/blood.V98.8.2448; Moyano JV, 1997, J BIOL CHEM, V272, P24832, DOI 10.1074/jbc.272.40.24832; Rich RL, 1999, J BIOL CHEM, V274, P26939, DOI 10.1074/jbc.274.38.26939; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Rudiger S, 2000, J MOL BIOL, V304, P245, DOI 10.1006/jmbi.2000.4193; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Spraggon G, 1998, P NATL ACAD SCI USA, V95, P9099, DOI 10.1073/pnas.95.16.9099; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; UGAROVA TP, 1993, J BIOL CHEM, V268, P21080; Ugarova TP, 2003, BIOCHEMISTRY-US, V42, P9365, DOI 10.1021/bi034057k; UGAROVA TP, 1992, J BIOL CHEM, V267, P13687; Ustinov VA, 2002, J BIOL CHEM, V277, P18769, DOI 10.1074/jbc.M110242200; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Yakubenko VP, 2002, J BIOL CHEM, V277, P48635, DOI 10.1074/jbc.M208877200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Yalamanchili P, 2000, J BIOL CHEM, V275, P21877, DOI 10.1074/jbc.M908868199	33	87	88	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44897	44906		10.1074/jbc.M408012200	http://dx.doi.org/10.1074/jbc.M408012200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304494	hybrid			2022-12-25	WOS:000224505600080
J	Shulami, S; Furdui, C; Adir, N; Shoham, Y; Anderson, KS; Baasov, T				Shulami, S; Furdui, C; Adir, N; Shoham, Y; Anderson, KS; Baasov, T			A reciprocal single mutation affects the metal requirement of 3-deoxy-D-manno-2-octulosonate-8-phosphate (KDO8P) synthases from Aquifex pyrophilus and Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONATE 8-PHOSPHATE SYNTHASE; MECHANISM-BASED INHIBITOR; 3-DEOXY-D-ARABINO-HEPTULOSONATE-7-PHOSPHATE SYNTHASE; PHOSPHOENOLPYRUVATE; CATALYSIS; AEOLICUS; SUBSTRATE; ENZYME; ANALOGS; D-ARABINOSE-5-PHOSPHATE	The enzyme 3-deoxy-D-manno-2-octulosonate-8-phosphate (KDO8P) synthase is metal-dependent in one class of organisms and metal-independent in another. We have used a rapid transient kinetic approach combined with site-directed mutagenesis to characterize the role of the metal ion as well as to explore the catalytic mechanisms of the two classes of enzymes. In the metal-dependent Aquifex pyrophilus KDO8P synthase, Cys(11) was replaced by Asn (ApC11N), and in the metal-independent Escherichia coli KDO8P synthase a reciprocal mutation, Asn(26) to Cys, was prepared (EcN26C). The ApC11N mutant retained about 10% of the wild-type maximal activity in the absence of metal ions. Addition of divalent metal ions did not affect the catalytic activity of the mutant enzyme and its catalytic efficiency (k(cat)/K-m) was reduced by only similar to12-fold, implying that the ApC11N KDO8P synthase mutant has become a bone fide metal-independent enzyme. The isolated EcN26C mutant had similar metal content and spectral properties as the metal-dependent wild-type A. pyrophilus KDO8P synthase. EDTA-treated EcN26C retained about 6% of the wild-type activity, and the addition of Mn2+ or Cd2+ stimulated its activity to similar to30% of the wild-type maximal activity. This suggests that EcN26C KDO8P synthase mutant has properties similar to that of metal-dependent KDO8P synthases. The combined data indicate that the metal ion is not directly involved in the chemistry of the KDO8P synthase catalyzed reaction, but has an important structural role in metal-dependent enzymes in maintaining the correct orientation of the substrates and/or reaction intermediate(s) in the enzyme active site.	Technion Israel Inst Technol, Dept Biotechnol & Food Engn, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Yale University	Shoham, Y (corresponding author), Technion Israel Inst Technol, Dept Biotechnol & Food Engn, IL-32000 Haifa, Israel.	chtimor@techunix.technion.ac.il; yshoham@techunix.technion.ac.il	Adir, Noam/ABE-6990-2020; Baasov, Timor/L-5173-2019; Shoham, Yuval/M-4409-2013	Baasov, Timor/0000-0002-1427-2619; Furdui, Cristina M./0000-0003-3771-7999	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM71805, GM61413] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERG DG, 1992, J AM CHEM SOC, V114, P3535, DOI 10.1021/ja00035a058; Asojo O, 2001, BIOCHEMISTRY-US, V40, P6326, DOI 10.1021/bi010339d; BAASOV T, 1989, J BACTERIOL, V171, P6155, DOI 10.1128/jb.171.11.6155-6160.1989; BEDNARSKI MD, 1988, TETRAHEDRON LETT, V29, P427, DOI 10.1016/S0040-4039(00)80113-6; Benenson Y, 1996, BIOORG MED CHEM LETT, V6, P2901, DOI 10.1016/S0960-894X(96)00539-2; Birck MR, 2001, J MOL EVOL, V52, P205, DOI 10.1007/s002390010149; Clements JM, 2002, ANTIMICROB AGENTS CH, V46, P1793, DOI 10.1128/AAC.46.6.1793-1799.2002; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; DOTSON GD, 1993, BIOCHEMISTRY-US, V32, P12392, DOI 10.1021/bi00097a017; Du SC, 1997, J ORG CHEM, V62, P794, DOI 10.1021/jo961929y; Du SC, 1999, BIOORGAN MED CHEM, V7, P2671, DOI 10.1016/S0968-0896(99)00233-3; Duewel HS, 2001, J BIOL CHEM, V276, P8393, DOI 10.1074/jbc.M007884200; Duewel HS, 2000, J BIOL CHEM, V275, P22824, DOI 10.1074/jbc.M000133200; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; HIRSCHBEIN BL, 1982, J ORG CHEM, V47, P3765, DOI 10.1021/jo00140a036; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; Jensen RA, 2002, J MOL EVOL, V54, P416, DOI 10.1007/s00239-001-0031-z; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P61; KIM DH, 1995, J AM CHEM SOC, V117, P1494, DOI 10.1021/ja00110a005; KOHEN A, 1993, BIOORG MED CHEM LETT, V3, P1577, DOI 10.1016/S0960-894X(00)80021-9; KOHEN A, 1992, EUR J BIOCHEM, V208, P443, DOI 10.1111/j.1432-1033.1992.tb17206.x; Krosky DJ, 2002, BBA-PROTEIN STRUCT M, V1594, P297, DOI 10.1016/S0167-4838(01)00319-3; Li ZL, 2003, J AM CHEM SOC, V125, P9938, DOI 10.1021/ja0354768; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; Park OK, 1999, J BACTERIOL, V181, P1636, DOI 10.1128/JB.181.5.1636-1642.1999; Plater AR, 1999, J MOL BIOL, V285, P843, DOI 10.1006/jmbi.1998.2376; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAY PH, 1980, J BACTERIOL, V141, P635, DOI 10.1128/JB.141.2.635-644.1980; Sambrook J., 1989, MOL CLONING, pA1; Sau AK, 2004, J BIOL CHEM, V279, P15787, DOI 10.1074/jbc.M308989200; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Shulami S, 2003, EXTREMOPHILES, V7, P471, DOI 10.1007/s00792-003-0346-3; Wagner T, 2000, J MOL BIOL, V301, P233, DOI 10.1006/jmbi.2000.3956; Walsh CT, 1996, CHEM BIOL, V3, P83, DOI 10.1016/S1074-5521(96)90282-3; Wang J, 2002, J MOL BIOL, V324, P205, DOI 10.1016/S0022-2836(02)01096-3; Wang J, 2001, BIOCHEMISTRY-US, V40, P15676, DOI 10.1021/bi015568e; Wong C.-H., 1994, ENZYMES SYNTHETIC OR, V12, P195	37	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45110	45120		10.1074/jbc.M404561200	http://dx.doi.org/10.1074/jbc.M404561200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308670				2022-12-25	WOS:000224505600104
J	Valles, AM; Beuvin, M; Boyer, B				Valles, AM; Beuvin, M; Boyer, B			Activation of Rac1 by paxillin-Crk-DOCK180 signaling complex is antagonized by Rap1 in migrating NBT-II cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAXILLIN KINASE LINKER; RHO-GTPASES; FOCAL ADHESIONS; BINDING PROTEIN; DORSAL CLOSURE; SH3 DOMAIN; LD4 MOTIF; CRK; DOCK180; IDENTIFICATION	Induction of epithelial cell motility is a fundamental morphogenetic event that is recapitulated during carcinoma metastasis. Random motility of NBT-II carcinoma cells on collagen critically depends on paxillin phosphorylation at Tyr-31 and Tyr-118, the binding sites for the adapter protein CrkII. Two constitutive partners of CrkII are the exchange factors DOCK180 and C3G. CrkII bound to DOCK180 formed a signaling complex with phosphorylated paxillin that was necessary for cell migration as inferred from the inhibition caused by a DOCK180-interfering mutant. DOCK180, which acts predominantly on the Rho family GTPase Rac1, restored cell locomotion in cells expressing Phe-31/118 paxillin mutants deficient in Rac1 GTP-loading, suggesting that formation of paxillin-Crk-DOCK180 signaling complex controls collagen-dependent migration mainly through Rac1 activation. In migrating cells, CrkII constitutive association with C3G was not sufficient to stimulate its GDP/GTP exchange activity toward the Ras family GTPase Rap1. However, when constitutively active RapV12 was overexpressed, it negatively regulated cell motility. Activation of the C3G/Rap1 signaling pathway resulted in down-regulation of the paxillin-CrkDOCK180 complex and reduction of Rac1-GTP, suggesting that Rap1 activation could suppress the Rac1 signaling pathway in epithelial cells.	Ctr Univ, CNRS, UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Valles, AM (corresponding author), Ctr Univ, CNRS, UMR 146, Batiment 110, F-91405 Orsay, France.	ana-maria.valles@curie.u-psud.fr						Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2003, GENETICS, V165, P159; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Braga VMM, 2002, NAT CELL BIOL, V4, pE188, DOI 10.1038/ncb0802-e188; Brown MC, 2002, MOL BIOL CELL, V13, P1550, DOI 10.1091/mbc.02-02-0015; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Edme N, 2002, J CELL SCI, V115, P2591; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Fukui Y, 2001, NATURE, V412, P826, DOI 10.1038/35090591; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kobayashi S, 2001, BIOCHEM J, V354, P73, DOI 10.1042/0264-6021:3540073; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Van Aelst L, 2002, GENE DEV, V16, P1032, DOI 10.1101/gad.978802; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	46	77	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44490	44496		10.1074/jbc.M405144200	http://dx.doi.org/10.1074/jbc.M405144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308668	hybrid			2022-12-25	WOS:000224505600033
J	Zietkiewicz, S; Krzewska, J; Liberek, K				Zietkiewicz, S; Krzewska, J; Liberek, K			Successive and synergistic action of the Hsp70 and Hsp100 chaperones in protein disaggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; NEWLY SYNTHESIZED PROTEINS; ESCHERICHIA-COLI PROTEINS; GREEN FLUORESCENT PROTEIN; ATP-BINDING-SITES; MOLECULAR CHAPERONE; DNAK CHAPERONE; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL HSP78; RNA-POLYMERASE	Proteins belonging to the B-subtype of the Hsp100/Clp chaperone family execute a crucial role in cellular thermotolerance. They cooperate with the Hsp70 chaperones in reactivation of thermally aggregated protein substrates. We investigated the initial events of the disaggregation reaction in real time using denatured, aggregated green fluorescent protein (GFP) as a substrate. Bacterial Hsp70 (DnaK), its co-chaperones (DnaJ and GrpE), and Hsp100 (ClpB) were incubated with aggregated GFP, and the increase in GFP fluorescence was monitored. Incubation of aggregated GFP with DnaK/DnaJ/GrpE but not with ClpB resulted in the rapid initiation of the disaggregation reaction. Under the same conditions a complex between DnaK, DnaJ, and GFP, but not ClpB, was formed as demonstrated by sedimentation analysis and light scattering experiments. Chaperone-dependent disaggregation of chemically denatured aggregated luciferase showed that, similar to GFP disaggregation, incubation with Hsp70 results in the rapid start of the reactivation reaction. For both aggregated GFP and luciferase, incubation with Hsp70 chaperones changes the initial rate but not the overall efficiency or rate of the refolding reaction. Our results clearly demonstrate that the interaction of DnaK and its co-chaperones with aggregated substrate is the rate-limiting reaction at the initial steps of disaggregation.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Liberek, K (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, Kladki 24, PL-80822 Gdansk, Poland.	liberek@biotech.univ.gda.pl	Liberek, Krzysztof/F-5812-2011; Ziętkiewicz, Szymon/L-5259-2014	Zietkiewicz, Szymon/0000-0002-3435-4603; Liberek, Krzysztof/0000-0002-7532-9279; Wolak, Joanna/0000-0003-1068-1770				Banecki B, 1998, BBA-GENE STRUCT EXPR, V1442, P39, DOI 10.1016/S0167-4781(98)00118-3; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Germaniuk A, 2002, J BIOL CHEM, V277, P27801, DOI 10.1074/jbc.M201756200; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; HWANG DS, 1990, J BIOL CHEM, V265, P19244; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; Krzewska J, 2001, J MOL BIOL, V314, P901, DOI 10.1006/jmbi.2001.5190; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; KUCHARCZYK K, 1991, MOL MICROBIOL, V5, P2935, DOI 10.1111/j.1365-2958.1991.tb01853.x; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Makino Y, 1997, J BIOL CHEM, V272, P12468, DOI 10.1074/jbc.272.19.12468; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Mogk A, 2004, CURR BIOL, V14, pR78, DOI 10.1016/j.cub.2003.12.051; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schmitt M, 1996, J CELL BIOL, V134, P1375, DOI 10.1083/jcb.134.6.1375; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WEIZBEZAHN J, 2003, J BIOL CHEM, V278, P32608; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	53	115	116	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44376	44383		10.1074/jbc.M402405200	http://dx.doi.org/10.1074/jbc.M402405200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302880	hybrid			2022-12-25	WOS:000224505600020
J	Morrow, G; Battistini, S; Zhang, P; Tanguay, RM				Morrow, G; Battistini, S; Zhang, P; Tanguay, RM			Decreased lifespan in the absence of expression of the mitochondrial small heat shock protein Hsp22 in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; CAENORHABDITIS-ELEGANS; LONGEVITY; DAF-16; EXTENSION; OVEREXPRESSION; MELANOGASTER; EXTENDS; STRESS; MUTANT	Aging is a well regulated biological process involving oxidative stress and macromolecular damages. Three main pathways have been shown to influence lifespan, the insulin/insulin-like growth factor-1 pathway, the silent regulator pathway, and the target of rapamycin pathway. Among many proteins influencing lifespan, two transcription factors, FOXO and the heat shock factor, have been shown to be involved in the aging process and in small heat shock proteins (sHsps) expression following stress and during lifespan. We have recently shown that overexpressing the mitochondrial Hsp22 increases Drosophila melanogaster lifespan by 32% and resistance to oxidative stress. Here we show that flies that are not expressing this mitochondrial small Hsp22 have a 40% decrease in lifespan. These flies die faster than their matched control and display a decrease of 30% in locomotor activity compared with controls. The absence of Hsp22 also sensitizes flies to mild stress. These data support a key role of sHsps in aging and underline the importance of mitochondrial sHsps in this process.	Univ Laval, Lab Genet Cellulaire & Dev, Dept Med, CREFSIP, Ste Foy, PQ G1K 7P4, Canada; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA	Laval University; University of Connecticut	Tanguay, RM (corresponding author), Univ Laval, Lab Genet Cellulaire & Dev, Dept Med, CREFSIP, Pavillon CE Marchand, Ste Foy, PQ G1K 7P4, Canada.	robert.tanguay@rsvs.ulaval.ca						Anson RM, 2004, AGING CELL, V3, P29, DOI 10.1111/j.1474-9728.2003.00077.x; Barbieri M, 2003, AM J PHYSIOL-ENDOC M, V285, pE1064, DOI 10.1152/ajpendo.00296.2003; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; CARBAJAL ME, 1990, EUR J CELL BIOL, V52, P147; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Harris TE, 2003, SCI STKE, V2003, pr; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Huang AM, 2000, DROSOPHILA PROTOCOLS, P429; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; King V, 1999, DEV BIOL, V207, P107, DOI 10.1006/dbio.1998.9147; KLEMENZ R, 1986, MOL CELL BIOL, V6, P2011, DOI 10.1128/MCB.6.6.2011; Kurapati R, 2000, J GERONTOL A-BIOL, V55, pB552, DOI 10.1093/gerona/55.11.B552; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; MARIN R, 1993, DEV GENET, V14, P69, DOI 10.1002/dvg.1020140109; Mason PB, 1997, J BIOL CHEM, V272, P33227, DOI 10.1074/jbc.272.52.33227; Minois N, 2000, BIOGERONTOLOGY, V1, P15, DOI 10.1023/A:1010085823990; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Morrow G, 2000, J BIOL CHEM, V275, P31204, DOI 10.1074/jbc.M002960200; Morrow G, 2004, FASEB J, V18, P598, DOI 10.1096/fj.03-0860fje; Morrow G, 2003, SEMIN CELL DEV BIOL, V14, P291, DOI 10.1016/j.semcdb.2003.09.023; Munoz MJ, 2003, MECH AGEING DEV, V124, P43, DOI 10.1016/S0047-6374(02)00168-9; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Pletcher SD, 2002, CURR BIOL, V12, P712, DOI 10.1016/S0960-9822(02)00808-4; Quivy JP, 1996, J MOL BIOL, V256, P249, DOI 10.1006/jmbi.1996.0083; Rohde JR, 2003, MOL CELL BIOL, V23, P629, DOI 10.1128/MCB.23.2.629-635.2003; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; Sun JT, 2002, GENETICS, V161, P661; Sun JT, 1999, MOL CELL BIOL, V19, P216; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Timakov B, 2002, GENETICS, V160, P1011; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147	48	106	117	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43382	43385		10.1074/jbc.C400357200	http://dx.doi.org/10.1074/jbc.C400357200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15331597	hybrid			2022-12-25	WOS:000224383100006
J	Stolze, IP; Tian, YM; Appelhoff, RJ; Turley, H; Wykoff, CC; Gleadle, JM; Ratcliffe, PJ				Stolze, IP; Tian, YM; Appelhoff, RJ; Turley, H; Wykoff, CC; Gleadle, JM; Ratcliffe, PJ			Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL HYDROXYLATION/; STRUCTURAL BASIS; MAMMALIAN-CELLS; OXYGEN; HIF-1-ALPHA; EXPRESSION; PROTEIN; VHL; FACTOR-1-ALPHA; FAMILY	Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor that directs a broad range of cellular responses to hypoxia. Recent studies have defined a set of 2-oxoglutarate and Fe(II)-dependent dioxygenases that modify HIF-alpha subunits by prolyl and asparaginyl hydroxylation. These processes potentially provide a dual system of control, down-regulating both HIF-alpha stability and transcriptional activity. Although genetic analyses in both primitive organisms and mammalian cells have demonstrated a critical role for the prolyl hydroxylase pathway in the regulation of HIF, analogous studies have not been performed on the HIF asparaginyl hydroxylase pathway, and its role in directing the expression of endogenous HIF transcriptional targets has not yet been clearly defined. Here we demonstrate, using small interfering RNA-mediated FIH suppression and controlled overexpression by a doxycycline-inducible system, that alterations in FIH expression in both directions have reciprocal effects on the expression of a range of HIF target genes. These effects were observed in normoxic and severely hypoxic cells but not anoxic cells. Evidence for FIH activity in severely hypoxic cells contrasted with results for the prolyl hydroxylase PHD2, suggesting that these enzymes display different oxygen dependence in vivo, with PHD2 requiring higher levels of oxygen for biological activity. Our results demonstrate an important physiological role for FIH in regulating HIF-dependent target genes over a wide range of oxygen tensions and indicate that inhibition of FIH has the potential to augment HIF target gene expression even in severe hypoxia.	Univ Oxford, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Canc Res United Kingdom,Tumor Pathol Grp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; John Radcliffe Hosp, CRUK, Mol Oncol Grp, Weatherall Inst Mol Med, Oxford OX3 9DU, England	University of Oxford; Cancer Research UK; University of Oxford; University of Oxford	Ratcliffe, PJ (corresponding author), Univ Oxford, Henry Wellcome Bldg Genom Med,Roosevelt Dr, Oxford OX3 7BN, England.	pjr@well.ox.ac.uk	Gleadle, Jonathan M/K-4188-2012	Gleadle, Jonathan M/0000-0002-5215-7208; Ratcliffe, Peter/0000-0002-2853-806X				Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200; DEUSCHLE U, 1995, MOL CELL BIOL, V15, P1907; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Linke S, 2004, J BIOL CHEM, V279, P14391, DOI 10.1074/jbc.M313614200; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOCHEM J, V367, P571, DOI 10.1042/BJ20021162; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sowter HM, 2003, CANCER RES, V63, P6130; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wykoff CC, 2000, CANCER RES, V60, P7075; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	34	132	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42719	42725		10.1074/jbc.M406713200	http://dx.doi.org/10.1074/jbc.M406713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302861	hybrid			2022-12-25	WOS:000224226400046
J	Martins, A; Shuman, S				Martins, A; Shuman, S			An RNA ligase from Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHODIESTER BOND FORMATION; CRYSTAL-STRUCTURE; DNA-LIGASE; MUTATIONAL ANALYSIS; FUNCTIONAL DOMAINS; TRYPANOSOMA-BRUCEI; CAPPING ENZYME; U-DELETION; SYNTHETASE; COMPLEX	Although DNA repair pathways have been the focus of much attention, there is an emerging appreciation that distinct pathways exist to maintain or manipulate RNA structure in response to breakage events. Here we identify an RNA ligase (DraRnl) from the radiation-resistant bacterium Deinococcus radiodurans. DraRnl seals 3'-OH/ 5'-PO4 RNA nicks in either a duplex RNA or an RNA: DNA hybrid, but it cannot seal 3'-OH/5'-PO4 DNA nicks. The specificity of DraRnl arises from a requirement for RNA on the 3'-OH side of the nick. DraRnl is a 342-amino acid monomeric protein with a distinctive structure composed of a C-terminal adenylyltransferase domain linked to an N-terminal module that resembles the OB-fold of phenylalanyl-tRNA synthetases. RNA sealing activity was abolished by mutation of the predicted lysine adenylylation site (Lys-165) in the C-terminal domain and was reduced by an order of magnitude by deletion of the N-terminal OB module. Our findings highlight the existence of an RNA repair capacity in bacteria and support the hypothesis that contemporary DNA ligases, RNA ligases, and RNA capping enzymes evolved by the fusion of ancillary effector domains to an ancestral catalytic module involved in RNA repair.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Martins, Alexandra/J-9592-2013	Martins, Alexandra/0000-0003-4322-8497				Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; Blanc V, 1999, J BIOL CHEM, V274, P24289, DOI 10.1074/jbc.274.34.24289; Blondal T, 2003, NUCLEIC ACIDS RES, V31, P7247, DOI 10.1093/nar/gkg914; CHOU FI, 1990, J BACTERIOL, V172, P2029, DOI 10.1128/jb.172.4.2029-2035.1990; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Doherty AJ, 1999, J MOL BIOL, V285, P63, DOI 10.1006/jmbi.1998.2301; EVANS DM, 1985, MUTAT RES, V145, P119, DOI 10.1016/0167-8817(85)90018-5; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Gao GH, 2003, J BIOL CHEM, V278, P27570, DOI 10.1074/jbc.M303317200; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; Graille M, 2004, EMBO J, V23, P1474, DOI 10.1038/sj.emboj.7600162; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 2004, STRUCTURE, V12, P327, DOI 10.1016/j.str.2004.01.011; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Huang CE, 2001, EMBO J, V20, P4694, DOI 10.1093/emboj/20.17.4694; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEIBOWITZ PJ, 1976, PHOTOCHEM PHOTOBIOL, V23, P45; Levin-Zaidman S, 2003, SCIENCE, V299, P254, DOI 10.1126/science.1077865; Liu YQ, 2003, P NATL ACAD SCI USA, V100, P4191, DOI 10.1073/pnas.0630387100; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Martins A, 2004, J BIOL CHEM, V279, P18220, DOI 10.1074/jbc.M313386200; MOSYAK L, 1995, NAT STRUCT BIOL, V2, P537, DOI 10.1038/nsb0795-537; Nandakumar J, 2004, MOL CELL, V16, P211, DOI 10.1016/j.molcel.2004.09.022; Nandakumar J, 2004, J BIOL CHEM, V279, P31337, DOI 10.1074/jbc.M402394200; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Palazzo SS, 2003, MOL BIOCHEM PARASIT, V127, P161, DOI 10.1016/S0166-6851(02)00333-X; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saida F, 2003, NUCLEIC ACIDS RES, V31, P2751, DOI 10.1093/nar/gkg377; Sawaya R, 2003, J BIOL CHEM, V278, P43928, DOI 10.1074/jbc.M307839200; Sawaya R, 2003, BIOCHEMISTRY-US, V42, P8240, DOI 10.1021/bi034396d; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Soelaiman S, 2001, MOL CELL, V8, P1053, DOI 10.1016/S1097-2765(01)00396-3; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Tomita K, 2000, P NATL ACAD SCI USA, V97, P8278, DOI 10.1073/pnas.140213797; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; Wang LK, 2003, J BIOL CHEM, V278, P29454, DOI 10.1074/jbc.M304320200; Worthey EA, 2003, NUCLEIC ACIDS RES, V31, P6392, DOI 10.1093/nar/gkg870; Yang XJ, 2001, NAT STRUCT BIOL, V8, P968, DOI 10.1038/nsb1101-968; Yin SM, 2004, VIROLOGY, V319, P141, DOI 10.1016/j.virol.2003.10.037; Yin SM, 2003, J BIOL CHEM, V278, P17601, DOI 10.1074/jbc.M300817200; Zhang YL, 2003, MOL CELL, V12, P913, DOI 10.1016/S1097-2765(03)00402-7; Zhang YM, 2000, APPL ENVIRON MICROB, V66, P105, DOI 10.1128/AEM.66.1.105-112.2000; Zhu H, 2004, J BIOL CHEM, V279, P26358, DOI 10.1074/jbc.M403200200	55	28	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50654	50661		10.1074/jbc.M407657200	http://dx.doi.org/10.1074/jbc.M407657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15333634	hybrid			2022-12-25	WOS:000225355800005
J	Xin, XN; Mains, RE; Eipper, BA				Xin, XN; Mains, RE; Eipper, BA			Monooxygenase X, a member of the copper-dependent monooxygenase family localized to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-BETA-HYDROXYLASE; ALPHA-AMIDATING MONOOXYGENASE; ADRENAL CHROMAFFIN GRANULES; PEPTIDE AMIDATION; SYNAPTIC VESICLES; MEMBRANE-PROTEIN; DISULFIDE BONDS; QUALITY-CONTROL; CATALYTIC CORE; EXPRESSION	Based on sequence comparisons, MOX ( monooxygenase X), is a member of the copper monooxygenase family that includes dopamine beta-monooxygenase (DBM) and peptidylglycine alpha-hydroxylating monooxygenase (PHM). MOX has all of the residues expected to be critical for copper binding, and its cysteine residues can yield the intramolecular disulfide bond pattern observed in DBM. Although DBM and PHM function within the lumen of the secretory pathway, the published sequence for human MOX lacks a signal sequence, suggesting that it does not enter this compartment. We identified an upstream exon that encodes the signal sequence of human MOX. A retained intron yields minor amounts of transcript encoding MOX without a signal sequence. MOX transcripts are widely expressed, with the highest levels in the salivary gland and ovary and moderate levels in brain, pituitary, and heart. Despite the presence of a signal sequence, exogenous MOX is not secreted, and it localizes throughout the endoplasmic reticulum in both endocrine or nonendocrine cells. Neither appending green fluorescent protein to its C terminus nor deleting the hydrophobic domain near its C terminus facilitates secretion of MOX. MOX is N-glycosylated, is tightly membrane-associated, and forms oligomers that are not disulfide-linked. Based on its sequence and localization, MOX is predicted to hydroxylate a hydrophobic substrate in the endoplasmic reticulum.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Eipper, BA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NIDDK NIH HHS [DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R37DK032949, R56DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BON S, 1991, J NEUROCHEM, V57, P1100, DOI 10.1111/j.1471-4159.1991.tb08267.x; Chambers KJ, 1998, GENE, V218, P111, DOI 10.1016/S0378-1119(98)00344-8; Chen F, 2001, J IMMUNOL, V166, P1771, DOI 10.4049/jimmunol.166.3.1771; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; CUTTITTA F, 1993, ANAT REC, V236, P87, DOI 10.1002/ar.1092360112; Czyzyk TA, 2003, J NEUROSCI RES, V74, P446, DOI 10.1002/jnr.10792; DHARIWAL KR, 1991, J BIOL CHEM, V266, P12908; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; EIPPER BA, 1983, P NATL ACAD SCI-BIOL, V80, P5144, DOI 10.1073/pnas.80.16.5144; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ernsberger U, 2000, MECH DEVELOP, V92, P169, DOI 10.1016/S0925-4773(99)00336-6; FENG ZH, 1992, J BIOL CHEM, V267, P21808; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HOUHOU L, 1995, J BIOL CHEM, V270, P12601, DOI 10.1074/jbc.270.21.12601; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; IKENO T, 1977, MOL CELL BIOCHEM, V18, P117, DOI 10.1007/BF00280277; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Ishida T, 1996, J BIOCHEM, V120, P346; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; KENT UM, 1987, J BIOL CHEM, V262, P8174; Knecht AK, 2001, DEV BIOL, V234, P365, DOI 10.1006/dbio.2001.0275; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; MAY V, 1985, J BIOL CHEM, V260, P6224; McPherson CE, 2002, GENE, V284, P41, DOI 10.1016/S0378-1119(02)00386-4; Meskini RE, 2000, ENDOCRINOLOGY, V141, P3020; Monastirioti M, 1996, J NEUROSCI, V16, P3900; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Oyarce AM, 2000, J BIOL CHEM, V275, P3270, DOI 10.1074/jbc.275.5.3270; Oyarce AM, 1997, FASEB J, V11, pA1061; OYARCE AM, 1995, J CELL SCI, V108, P287; PAIK SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P617, DOI 10.1016/0003-9861(92)90618-7; Partoens P, 1998, J CELL SCI, V111, P681; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; ROBERTSON JG, 1994, BIOCHEMISTRY-US, V33, P11563, DOI 10.1021/bi00204a019; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; Steveson TC, 2001, J BIOL CHEM, V276, P40326, DOI 10.1074/jbc.M011460200; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; SUNDLER R, 1978, J BIOL CHEM, V253, P4175; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Ugarte YV, 2003, EUR J PHARMACOL, V472, P165, DOI 10.1016/S0014-2999(03)01911-3; Vandenbulcke F, 2000, J CELL SCI, V113, P2963; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; YUN HY, 1995, J BIOL CHEM, V270, P15412, DOI 10.1074/jbc.270.25.15412; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200; Zhang JW, 1997, DEV BIOL, V192, P375, DOI 10.1006/dbio.1997.8750	49	36	40	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48159	48167		10.1074/jbc.M407486200	http://dx.doi.org/10.1074/jbc.M407486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337741	hybrid			2022-12-25	WOS:000224957000090
J	Mueckler, M; Roach, W; Makepeace, C				Mueckler, M; Roach, W; Makepeace, C			Transmembrane segment 3 of the Glut1 glucose transporter is an outer helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SCANNING MUTAGENESIS; SUGAR PERMEATION PATHWAY; XENOPUS-OOCYTES; ESCHERICHIA-COLI; ACCESSIBILITY; BINDING; MECHANISM; DOMAINS; FAMILY; HEPG2	A model has been proposed for the structure of the Glut1 glucose transporter based on the results of mutagenesis studies and homology modeling in which eight transmembrane segments form an inner helical bundle surrounded by four outer helices. The role of transmembrane segment 3 in this structural model was investigated using cysteine-scanning mutagenesis in conjunction with the membrane-impermeant, sulfhydryl-specific reagent, p-chloromercuribenzenesulfonate (pCMBS). Twenty-one Glut1 mutants were created from a fully functional, cysteine-less, parental Glut1 molecule by successively changing each residue along transmembrane helix 3 to a cysteine. The single cysteine mutants were then expressed in Xenopus oocytes, and their expression levels, transport activities, and sensitivities to pCMBS were determined. Cysteine substitution at methionine 96 abolished transport activity, whereas substitutions at the other positions resulted in either modest reductions or no significant effect on transport activity. In striking contrast to all other helices that have been examined to date, only one of the 21 helix 3 single-cysteine mutants was inhibited by pCMBS, suggesting that only a small portion of this helix is exposed to the external solvent. This result is consistent with predictions based on our current structural model, in which helix 3 is one of four outer helices that surround the inner helical bundle that comprises the aqueous substrate-binding cavity. An updated two-dimensional model for the orientation of the 12 transmembrane helices and the conformation of the exofacial glucose-binding site of Glut1 is presented that is consistent with existing experimental data.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mike@cellbio.wustl.edu	Mueckler, Mike M/F-6115-2012		NIDDK NIH HHS [DK 43695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNETT JEG, 1973, BIOCHEM J, V131, P211, DOI 10.1042/bj1310211; GARCIA JC, 1992, J BIOL CHEM, V267, P7770; Heinze M, 2004, BIOCHEMISTRY-US, V43, P931, DOI 10.1021/bi030175w; HRESKO RC, 1994, J BIOL CHEM, V269, P32110; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Hruz PW, 2000, BIOCHEMISTRY-US, V39, P9367, DOI 10.1021/bi000821g; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; KELLER K, 1989, J BIOL CHEM, V264, P18884; LOWE AG, 1989, RED BLOOD CELL MEMBR, V11, P597; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; Mueckler M, 2004, J BIOL CHEM, V279, P10494, DOI 10.1074/jbc.M310786200; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1994, J BIOL CHEM, V269, P20533; Mueckler M, 1997, J BIOL CHEM, V272, P30141, DOI 10.1074/jbc.272.48.30141; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Olsowski A, 2000, BIOCHEMISTRY-US, V39, P2469, DOI 10.1021/bi992160x; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; WELLNER M, 1995, FEBS LETT, V370, P19, DOI 10.1016/0014-5793(95)00783-6	25	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46876	46881		10.1074/jbc.M408632200	http://dx.doi.org/10.1074/jbc.M408632200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15308632	hybrid			2022-12-25	WOS:000224832400069
J	Chen, M; Abele, R; Tampe, R				Chen, M; Abele, R; Tampe, R			Functional non-equivalence of ATP-binding cassette signature motifs in the transporter associated with antigen processing (TAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; WALKER-A-SEQUENCE; CLASS-I MOLECULES; NUCLEOTIDE-BINDING; PEPTIDE-BINDING; ABC-TRANSPORTER; DISTINCT FUNCTIONS; P-GLYCOPROTEIN; LSGGQ MOTIF	The transporter associated with antigen processing ( TAP) is a key component of the cellular immune system. As a member of the ATP-binding cassette (ABC) superfamily, TAP hydrolyzes ATP to energize the transport of peptides from the cytosol into the lumen of the endoplasmic reticulum. TAP is composed of TAP1 and TAP2, each containing a transmembrane domain and a nucleotide-binding domain (NBD). Here we investigated the role of the ABC signature motif (C-loop) on the functional non-equivalence of the NBDs, which contain a canonical C-loop (LSGGQ) for TAP1 and a degenerate C-loop (LAAGQ) for TAP2. Mutation of the leucine or glycine ( LSGGQ) in TAP1 fully abolished peptide transport. However, TAP complexes with equivalent mutations in TAP2 still showed residual peptide transport activity. To elucidate the origin of the asymmetry of the NBDs of TAP, we further examined TAP complexes with exchanged C-loops. Strikingly, the chimera with two canonical C-loops showed the highest transport rate whereas the chimera with two degenerate C-loops had the lowest transport rate, demonstrating that the ABC signature motifs control peptide transport efficiency. All single site mutants and chimeras showed similar activities in peptide or ATP binding, implying that these mutations affect the ATPase activity of TAP. In addition, these results prove that the serine of the C-loop is not essential for TAP function but rather coordinates, together with other residues of the C-loop, the ATP hydrolysis in both nucleotide-binding sites.	Univ Frankfurt, Biozentrum, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Biozentrum, Inst Biochem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; ANDROLEWICZ MJ, 1994, IMMUNITY, V1, P7, DOI 10.1016/1074-7613(94)90004-3; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; Bakos E, 1997, BIOCHEM J, V323, P777, DOI 10.1042/bj3230777; Browne BL, 1996, J BACTERIOL, V178, P1712, DOI 10.1128/jb.178.6.1712-1719.1996; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; Daumke O, 2001, EUR J BIOCHEM, V268, P4776, DOI 10.1046/j.1432-1327.2001.02406.x; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Hewitt EW, 2003, EUR J IMMUNOL, V33, P422, DOI 10.1002/immu.200310016; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; Ketchum CJ, 2001, J BIOL CHEM, V276, P29007, DOI 10.1074/jbc.M100810200; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; Saveanu L, 2001, J BIOL CHEM, V276, P22107, DOI 10.1074/jbc.M011221200; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szakacs G, 2001, BIOCHEM J, V356, P71, DOI 10.1042/0264-6021:3560071; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; UEBEL S, 1995, J BIOL CHEM, V270, P18512, DOI 10.1074/jbc.270.31.18512; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065	42	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46073	46081		10.1074/jbc.M404042200	http://dx.doi.org/10.1074/jbc.M404042200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322097	hybrid			2022-12-25	WOS:000224694900093
J	Delon, C; Manifava, M; Wood, E; Thompson, D; Krugmann, S; Pyne, S; Ktistakis, NT				Delon, C; Manifava, M; Wood, E; Thompson, D; Krugmann, S; Pyne, S; Ktistakis, NT			Sphingosine kinase 1 is an intracellular effector of phosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; ADP-RIBOSYLATION FACTOR; PHOSPHOLIPASE-D; DEPENDENT ACTIVATION; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE PHOSPHOHYDROLASE; BINDING; PROTEIN; PHOSPHATIDYLCHOLINE; TRANSLOCATION	Sphingosine kinase 1 (SK1) phosphorylates sphingosine to generate sphingosine 1-phosphate (S1P). Because both substrate and product of the enzyme are potentially important signaling molecules, the regulation of SK1 is of considerable interest. We report that SK1, which is ordinarily a cytosolic enzyme, translocates in vivo and in vitro to membrane compartments enriched in phosphatidic acid (PA), the lipid product of phospholipase D. This translocation depends on direct interaction of SK1 with PA, because recombinant purified enzyme shows strong affinity for pure PA coupled to Affi-Gel. The SK1-PA interaction maps to the C terminus of SK1 and is independent of catalytic activity or of the diacylglycerol kinase-like domain of the enzyme. Thus SK1 constitutes a novel, physiologically relevant PA effector.	Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Strathclyde	Ktistakis, NT (corresponding author), Babraham Inst, Dept Signalling, Cambridge CB2 4AT, England.	nicholas.ktistakis@bbsrc.ac.uk	Pyne, Susan/AAF-5001-2019; Vermeren, Sonja/AAK-7442-2020	Pyne, Susan/0000-0002-6608-9584; Vermeren, Sonja/0000-0002-8460-0884; Delon, Christine/0000-0001-5163-1716				Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Baillie GS, 2002, J BIOL CHEM, V277, P28298, DOI 10.1074/jbc.M108353200; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DINH TT, 1991, CELL REGUL, V2, P299, DOI 10.1091/mbc.2.4.299; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heringdorf DMZ, 2003, FEBS LETT, V554, P443, DOI 10.1016/S0014-5793(03)01219-5; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Ktistakis NT, 2003, BIOCHEM SOC T, V31, P94, DOI 10.1042/bst0310094; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Le Stunff H, 2002, J CELL BIOL, V158, P1039, DOI 10.1083/jcb.200203123; Lim ZY, 2002, J CHEM SOC PERK T 1, P1067, DOI 10.1039/b200585a; LIN PY, 1992, EUR J BIOCHEM, V207, P163, DOI 10.1111/j.1432-1033.1992.tb17033.x; Litosch I, 2000, BIOCHEMISTRY-US, V39, P7736, DOI 10.1021/bi000022y; Lopez-Andreo MJ, 2003, MOL BIOL CELL, V14, P4885, DOI 10.1091/mbc.E03-05-0295; Manifava M, 2001, J BIOL CHEM, V276, P8987, DOI 10.1074/jbc.M010308200; Manifava M, 1999, J BIOL CHEM, V274, P1072, DOI 10.1074/jbc.274.2.1072; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez AJ, 2002, SEMIN IMMUNOL, V14, P49, DOI 10.1006/smim.2001.0341; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Ramos B, 2002, MOL PHARMACOL, V62, P1068, DOI 10.1124/mol.62.5.1068; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; YAMAMOTO I, 1995, BBA-BIOMEMBRANES, V1233, P21, DOI 10.1016/0005-2736(94)00220-J; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1	52	169	173	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44763	44774		10.1074/jbc.M405771200	http://dx.doi.org/10.1074/jbc.M405771200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310762	hybrid			2022-12-25	WOS:000224505600065
J	Ishida, T; Choi, SSY; Kundu, RK; Spin, J; Yamashita, T; Hirata, K; Kojima, Y; Yokoyama, M; Cooper, AD; Quertermous, T				Ishida, T; Choi, SSY; Kundu, RK; Spin, J; Yamashita, T; Hirata, K; Kojima, Y; Yokoyama, M; Cooper, AD; Quertermous, T			Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CELL-DERIVED LIPASE; CHOLESTEROL; GENE; HYPERCHOLESTEROLEMIA; DETERMINANT; CATABOLISM; PROMOTES; LESIONS	Endothelial lipase (EL) expression correlates inversely with circulating high density lipoprotein (HDL) cholesterol levels in genetic mouse models, and human genetic variation in this locus has been linked to differences in HDL cholesterol levels. These data suggest a role for EL in the development of atherosclerotic vascular disease. To investigate this possibility, LIPG-null alleles were bred onto the apoE knockout background, and the homozygous double knockout animals were characterized. Both apoE knockout and double knockout mice had low HDL cholesterol levels when compared with wild-type mice, but the HDL cholesterol levels of the double knockout mice were higher than those of apoE knockout mice. Atherogenic very low density lipoprotein and intermediate density lipoprotein/low density lipoprotein cholesterol levels of the double knockout mice were also greater than those of the apoE knockout animals. Despite this lipid profile, there was a significant similar to 70% decrease in atherosclerotic disease area in double knockout mice on a regular diet. Immunohistochemistry and protein blot studies revealed increased EL expression in the atherosclerotic aortas of the apoE knockout animals. An observed decrease in macrophage content in vessels lacking EL correlated with ex vivo vascular monocyte adhesion assays, suggesting that this protein can modulate monocyte adhesion and infiltration into diseased tissues. These data suggest that EL may have indirect atherogenic actions in vivo through its effect on circulating HDL cholesterol and direct atherogenic actions through vascular wall processes such as monocyte recruitment and cholesterol uptake.	Stanford Univ, Sch Med, Div Cardiovasc Med, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Div Gastroenterol, Donald W Reynolds Cardiovasc Clin Res Ctr, Stanford, CA 94305 USA; Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA	Stanford University; Stanford University; Kobe University; Palo Alto Medical Foundation Research Institute	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Donald W Reynolds Cardiovasc Clin Res Ctr, 300 Pasteur Dr,Falk CVRC, Stanford, CA 94305 USA.	tomq1@stanford.edu		Yamashita, Tomoya/0000-0003-0267-3842; Spin, Joshua/0000-0002-4256-9161; Quertermous, Thomas/0000-0002-7645-9067	NIDDK NIH HHS [DK38318, DK38107] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038318] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Assmann G, 1996, ATHEROSCLEROSIS, V124, pS11, DOI 10.1016/0021-9150(96)05852-2; Azumi H, 2003, CARDIOVASC RES, V58, P647, DOI 10.1016/S0008-6363(03)00287-6; Babaev VR, 1999, J CLIN INVEST, V103, P1697, DOI 10.1172/JCI6117; Broedl UC, 2004, CIRC RES, V94, P1554, DOI 10.1161/01.RES.0000130657.00222.39; BRONZERT TJ, 1977, CLIN CHEM, V23, P2089; Fuki IV, 2003, J BIOL CHEM, V278, P34331, DOI 10.1074/jbc.M302181200; Gauster M, 2004, BIOCHEM J, V382, P75, DOI 10.1042/BJ20031882; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Hirata K, 2000, BIOCHEM BIOPH RES CO, V272, P90, DOI 10.1006/bbrc.2000.2747; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Ishida T, 2003, J CLIN INVEST, V111, P347, DOI [10.1172/JCI200316306, 10.1172/JCI16306]; Jaye M, 1999, NAT GENET, V21, P424, DOI 10.1038/7766; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; Jin WJ, 2002, TRENDS ENDOCRIN MET, V13, P174, DOI 10.1016/S1043-2760(02)00589-1; Ma K, 2003, P NATL ACAD SCI USA, V100, P2748, DOI 10.1073/pnas.0438039100; Maugeais C, 2003, CIRCULATION, V108, P2121, DOI 10.1161/01.CIR.0000092889.24713.DC; McCoy MG, 2002, J LIPID RES, V43, P921; Mezdour H, 1997, J BIOL CHEM, V272, P13570, DOI 10.1074/jbc.272.21.13570; Ozaki M, 2001, HYPERTENSION, V37, P322, DOI 10.1161/01.HYP.37.2.322; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Paradis ME, 2003, J LIPID RES, V44, P1902, DOI 10.1194/jlr.M300118-JLR200; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; SHIMOKAWA Y, 2003, CIRC J S, V67, P220; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Strauss JG, 2002, BIOCHEM J, V368, P69, DOI 10.1042/BJ20020306; Tsao PS, 1998, ARTERIOSCL THROM VAS, V18, P947, DOI 10.1161/01.ATV.18.6.947; Yamakawa-Kobayashi K, 2003, HUM GENET, V113, P311, DOI 10.1007/s00439-003-0985-6; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	31	125	140	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45085	45092		10.1074/jbc.M406360200	http://dx.doi.org/10.1074/jbc.M406360200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304490	hybrid			2022-12-25	WOS:000224505600101
J	McElwee, JJ; Schuster, E; Blanc, E; Thomas, JH; Gems, D				McElwee, JJ; Schuster, E; Blanc, E; Thomas, JH; Gems, D			Shared transcriptional signature in Caenorhabditis elegans dauer larvae and long-lived daf-2 mutants implicates detoxification system in longevity assurance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTENDS LIFE-SPAN; HEAT-SHOCK FACTOR; C-ELEGANS; GENE-EXPRESSION; OXIDATIVE STRESS; INSULIN-RECEPTOR; UDP-GLUCURONOSYLTRANSFERASES; DEVELOPMENTAL VARIANT; FAMILY-MEMBER; FORK HEAD	In the nematode Caenorhabditis elegans, formation of the long-lived dauer larva and adult aging are both controlled by insulin/insulin-like growth factor-1 signaling. Potentially, increased adult life span in daf-2 insulin/ insulin-like growth factor-1 receptor mutants results from mis-expression in the adult of a dauer larva longevity program. By using oligonucleotide microarray analysis, we identified a dauer transcriptional signature in daf-2 mutant adults. By means of a nonbiased statistical approach, we identified gene classes whose expression is altered similarly in dauers and daf-2 mutants, which represent potential determinants of life span. These include known determinants of longevity; the small heat shock protein/alpha-crystallins are up-regulated in both milieus. The cytochrome P450, short-chain dehydrogenase/ reductase, UDP-glucuronosyltransferase, and glutathione S-transferase ( in daf-2 mutants) gene classes were also up-regulated. These four gene classes act together in metabolism and excretion of toxic endobiotic and xenobiotic metabolites. This suggests that diverse toxic lipophilic and electrophilic metabolites, disposed of by phase 1 and phase 2 drug metabolism, may be the major determinants of the molecular damage that causes aging. In addition, we observed downregulation of genes linked to nutrient uptake, including nhx-2 and pep-2. These work together in the uptake of dipeptides in the intestine, implying dietary restriction in daf-2 mutants. Some gene groups up-regulated in dauers and/or daf-2 were enriched for certain promoter elements as follows: the daf-16-binding element, the heat shock-response element, the heat shock-associated sequence, or the hif-1-response element. By contrast, the daf-16-associated element was enriched in genes down-regulated in dauers and daf-2 mutants. Thus, particular promoter elements appear longevity-associated or aging associated.	UCL, Dept Biol, London WC1E 6BT, England; European Bioinformat Inst, Cambridge CB10 1SD, England; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	University of London; University College London; European Molecular Biology Laboratory (EMBL); University of Washington; University of Washington Seattle	Gems, D (corresponding author), UCL, Dept Biol, Gower St, London WC1E 6BT, England.	david.gems@ucl.ac.uk	Blanc, Eric/C-5424-2009	Schuster, Eugene/0000-0001-5076-2810; Gems, David/0000-0002-6653-4676				ANDERSON GL, 1982, CAN J ZOOL, V60, P288, DOI 10.1139/z82-038; Arantes-Oliveira N, 2002, SCIENCE, V295, P502, DOI 10.1126/science.1065768; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; CASSADA RC, 1975, DEV BIOL, V46, P326, DOI 10.1016/0012-1606(75)90109-8; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; DORMAN JB, 1995, GENETICS, V141, P1399; Eneqvist T, 2003, EUR J BIOCHEM, V270, P518, DOI 10.1046/j.1432-1033.2003.03408.x; FRIEDMAN DB, 1988, GENETICS, V118, P75; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 1998, GENETICS, V150, P129; GEMS D, 2004, IN PRESS MECH AGEING; Gerisch B, 2001, DEV CELL, V1, P841, DOI 10.1016/S1534-5807(01)00085-5; Gibson GG, 2001, INTRO DRUG METABOLIS; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hsin H, 1999, NATURE, V399, P362, DOI 10.1038/20694; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jia KL, 2002, DEVELOPMENT, V129, P221; Jones SJM, 2001, GENOME RES, V11, P1346, DOI 10.1101/gr.184401; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; Leiers BR, 2003, FREE RADICAL BIO MED, V34, P1405, DOI 10.1016/S0891-5849(03)00102-3; Lewis JA, 1995, METHOD CELL BIOL, V48, P4; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Mansuy D, 1998, COMP BIOCHEM PHYS C, V121, P5, DOI 10.1016/S0742-8413(98)10026-9; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Meissner B, 2004, J BIOL CHEM, V279, P36739, DOI 10.1074/jbc.M403415200; Menzel R, 2001, ARCH BIOCHEM BIOPHYS, V395, P158, DOI 10.1006/abbi.2001.2568; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nehrke K, 2003, J BIOL CHEM, V278, P44657, DOI 10.1074/jbc.M307351200; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oppermann UCT, 2000, TOXICOLOGY, V144, P71, DOI 10.1016/S0300-483X(99)00192-4; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Riddle DL, 1997, C ELEGANS, P739; RUVOLO V, 1992, DNA CELL BIOL, V11, P111, DOI 10.1089/dna.1992.11.111; Scott BA, 2002, SCIENCE, V296, P2388, DOI 10.1126/science.1072302; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Sulston J., 1988, NEMATODE CAENORHABDI, P587; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Wang J, 2003, DEVELOPMENT, V130, P1621, DOI 10.1242/dev.00363; Wells PG, 2004, DRUG METAB DISPOS, V32, P281, DOI 10.1124/dmd.32.3.281	68	306	320	2	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44533	44543		10.1074/jbc.M406207200	http://dx.doi.org/10.1074/jbc.M406207200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308663	hybrid			2022-12-25	WOS:000224505600038
J	Xing, YN; Lin, W; Jiang, M; Cao, DH; Myers, RV; Bernard, MP; Moyle, WR				Xing, YN; Lin, W; Jiang, M; Cao, DH; Myers, RV; Bernard, MP; Moyle, WR			Use of protein knobs to characterize the position of conserved alpha-subunit regions in lutropin receptor complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; ENDOPLASMIC-RETICULUM; HUMAN CHORIOGONADOTROPIN; LINKED OLIGOSACCHARIDES; STIMULATING-HORMONE; SIGNAL-TRANSDUCTION; BINDING; SPECIFICITY	Efforts to identify the manner in which human choriogonadotropin (hCG) contacts lutropin receptors (LHR) have been stymied by the complex structure of the hormone and the likelihood that it contacts the receptor at multiple sites. During studies of hCG assembly in mammalian cells, we found that addition of a cysteine to the long disordered beta-subunit COOH terminus (betaCT) enabled it to become cross-linked by a disulfide to cysteines that are substituted for residues in loop alpha2 or in the alpha-subunit COOH terminus (alphaCT). This created a "knob" on the alpha-subunit at the location of the cysteine. Knobs of various sizes and charges were useful for probing surfaces of the alpha-subunit thought previously to contact the LHR. Attachment of the betaCT to residues in loop alpha2 facing loops beta1 and beta3 reduced hormone activity only a few fold revealing that this surface does not participate in essential high affinity receptor contacts, a finding inconsistent with our earlier view of the hCG-LHR complex. In contrast, this approach showed that the opposite surface of loop alpha2 appeared to be nearer the receptor interface. Although attachment of knobs to portions of the alphaCT reduced hormone activity substantially, this finding was difficult to interpret. As discussed, this procedure should be adapted readily to other proteins and may facilitate the introduction of fluorophores, enzymes, or other reagents at specific sites on protein surfaces. It may also permit one to cross-link proteins or to obscure specific protein surfaces during the development of "Trojan Horse" therapeutics.	Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Ob Gyn, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Moyle, WR (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Ob Gyn, Piscataway, NJ 08854 USA.	moyle@umdnj.edu			NICHD NIH HHS [HD14907, HD38547] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038547, R37HD014907, R01HD014907] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernard MP, 1998, BIOCHEM J, V335, P611, DOI 10.1042/bj3350611; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; Cosowsky L, 1997, J BIOL CHEM, V272, P3309, DOI 10.1074/jbc.272.6.3309; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; Einstein M, 2001, EXP BIOL MED, V226, P581, DOI 10.1177/153537020122600612; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Grossmann M, 1996, MOL ENDOCRINOL, V10, P769, DOI 10.1210/me.10.6.769; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; Heikoop JC, 1997, NAT BIOTECHNOL, V15, P658, DOI 10.1038/nbt0797-658; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; Li MD, 1998, J ENDOCRINOL, V156, P529, DOI 10.1677/joe.0.1560529; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1987, J BIOL CHEM, V262, P16920; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; Moyle WR, 2004, J BIOL CHEM, V279, P44442, DOI 10.1074/jbc.M406948200; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MOYLE WR, 1975, J BIOL CHEM, V250, P9163; Myers RV, 2000, BBA-GEN SUBJECTS, V1475, P390, DOI 10.1016/S0304-4165(00)00097-0; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIRAM MR, 1985, SCIENCE, V229, P65, DOI 10.1126/science.2990039; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; XIA HY, 1994, ENDOCRINOLOGY, V134, P1768, DOI 10.1210/en.134.4.1768; Xing YN, 2004, J BIOL CHEM, V279, P35437, DOI 10.1074/jbc.M403053200; Xing YN, 2004, J BIOL CHEM, V279, P35458, DOI 10.1074/jbc.M403055200; Xing YN, 2004, J BIOL CHEM, V279, P35426, DOI 10.1074/jbc.M403052200; Xing YN, 2001, J BIOL CHEM, V276, P46953, DOI 10.1074/jbc.M108374200; YOO J, 1991, J BIOL CHEM, V266, P17741	35	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44427	44437		10.1074/jbc.M406931200	http://dx.doi.org/10.1074/jbc.M406931200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304492	hybrid			2022-12-25	WOS:000224505600026
J	Chakravarti, A; Zhai, GG; Zhang, M; Malhotra, R; Latham, DE; Delaney, MA; Robe, P; Nestler, U; Song, QH; Loeffler, J				Chakravarti, A; Zhai, GG; Zhang, M; Malhotra, R; Latham, DE; Delaney, MA; Robe, P; Nestler, U; Song, QH; Loeffler, J			Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms	ONCOGENE			English	Article						Survivin; radiation resistance; primary human glioblastoma	ANTI-APOPTOSIS GENE; MALIGNANT GLIOMA; BRAIN-TUMORS; EXPRESSION; CANCER; PROTEIN; INHIBITOR; PROGNOSIS; PROLIFERATION; NEUROBLASTOMA	The observed radioresistance of human glioblastoma multiforme (GBM) poses a major challenge, which, if overcome, may lead to significant advances in the management of this patient population. There is accumulating evidence from correlative studies that Survivin expression is associated with increased malignant potential of human gliomas. The purpose of this study was to investigate whether Survivin plays a direct role in mediating radiation resistance in primary human glioma cell lines, and, if so, investigating the underlying mechanisms. Our panel of GBM cell lines included two that were relatively radiation resistant (GM20 and GM21) and two that were more radiation sensitive (GM22 and GM23), which demonstrated differential levels of Survivin expression between the two groups. Through the use of adenoviral vectors containing either dominant-negative (pAd-S(T34A)) or wild-type Suvrivin (pAd-S(WT)), we were able to inactivate or overexpress Survivin, respectively. Our findings suggest that Survivin plays a critical role in mediating radiation resistance in primary GBM cells, in part through suppression of apoptotic cell death via a caspase-independent manner. We have identified novel mechanisms by which Survivin may enhance tumor cell survival upon radiation exposure such as regulation of double-strand DNA break repair and tumor cell metabolism, which were most evident in the radiation-resistant cell lines. These differences in Survivin function both in radiation-resistant vs radiation-sensitive cell lines and in the presence vs absence of radiation exposure warrant further investigation and highlight potentially important mechanisms of radiation resistance in these tumors.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA; Univ Giessen, Dept Neurosurg, Giessen, Germany	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Justus Liebig University Giessen	Chakravarti, A (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Founders House,Room 536, Boston, MA 02114 USA.	achakravarti@partners.org	Nestler, Ulf/D-6503-2014; Nestler, Ulf/AHD-3675-2022	Nestler, Ulf/0000-0002-2963-4344; Nestler, Ulf/0000-0002-2963-4344; Malhotra, Rajeev/0000-0003-0120-4630	NCI NIH HHS [KO882163CA] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 2000, BLOOD, V96, P1921; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Cande C, 2002, BIOCHIMIE, V84, P215, DOI 10.1016/S0300-9084(02)01374-3; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.3.CO;2-C; Fortugno P, 2002, J CELL SCI, V115, P575; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Hall E, 2000, RADIOBIOLOGY RADIOLO; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Kajiwara Y, 2003, CANCER-AM CANCER SOC, V97, P1077, DOI 10.1002/cncr.11122; Katoh M, 2003, J NEURO-ONCOL, V64, P71, DOI 10.1007/BF02700022; Kawasaki H, 1998, CANCER RES, V58, P5071; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lang-Rollin ICJ, 2003, J NEUROSCI, V23, P11015; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Lu CD, 1998, CANCER RES, V58, P1808; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; MANGIARDI J, 2001, BRAIN TUMORS, P105; Merlo A, 2003, NEUROSURG REV, V26, P145, DOI 10.1007/s10143-003-0267-8; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Olie RA, 2000, CANCER RES, V60, P2805; Sasaki T, 2002, ACTA NEUROPATHOL, V104, P105, DOI 10.1007/s00401-002-0532-x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324; TAN EC, 1993, J BIOL CHEM, V268, P27291; Tanaka K, 2000, CLIN CANCER RES, V6, P127; WALKER MD, 1978, J NEUROSURG, V49, P333, DOI 10.3171/jns.1978.49.3.0333; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WESTPHAL M, 1990, CULTURE HUMAN BRAIN, V5; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1	38	176	186	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	2004	23	45					7494	7506		10.1038/sj.onc.1208049	http://dx.doi.org/10.1038/sj.onc.1208049			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326475				2022-12-25	WOS:000224176500006
J	Guillet, C; Prod'homme, M; Balage, M; Gachon, P; Giraudet, C; Morin, L; Grizard, J; Boirie, Y				Guillet, C; Prod'homme, M; Balage, M; Gachon, P; Giraudet, C; Morin, L; Grizard, J; Boirie, Y			Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans	FASEB JOURNAL			English	Article						sarcopenia; post-prandial anabolism; insulin; signaling pathways	HUMAN SKELETAL-MUSCLE; AMINO-ACIDS; TRANSLATION INITIATION; INSULIN-RESISTANCE; SYNTHESIS RATES; BODY-FAT; HYPERINSULINEMIA; STIMULATION; LEUCINE; MITOCHONDRIAL	Age-related loss of muscle protein may involve a decreased response to anabolic factors of muscle protein synthesis through dysregulation of translation factors. To verify this hypothesis, we simultaneously investigated muscle protein synthesis and expression of some factors implicated in insulin signal transduction during hyperinsulinemia and hyperaminoacidemia in 6 young (25 +/- 1 year; mean +/- SEM) and 8 elderly subjects (72 +/- 2 year). Incorporation of L-[1-C-13] leucine in muscle proteins ( fractional synthesis rate, FSR) was measured in vastus lateralis, before and during a euglycemic hyperinsulinemic hyperaminoacidemic clamp, together with Western blot analysis of protein kinase B (PKB), mTOR, 4E-BP1, and S6K1 phosphorylation. In basal state, muscle protein FSR was reduced in elderly in comparison with young subjects ( 0.061 +/- 0.004% per hour) vs 0.082 +/- 0.010% per hour, elderly vs. young, P< 0.05). During clamp, muscle protein FSR was stimulated in young (0.119 +/- 0.006% per hour; P< 0.05), but this response was significantly lower in elderly subjects ( 0.084 +/- 0.005% per hour, P< 0.05 vs young subjects). Phosphorylation of PKB, mTOR, and 4E-BP1 were similarly increased by insulin and amino acid in both groups, except for S6K1 phosphorylation, which was not stimulated in elderly subjects. In conclusion, 1) response of muscle protein synthesis to insulin and amino acid is impaired in elderly humans; 2) a defect in S6K1 pathway activation may be responsible for this alteration. This modification is a mechanistic basis of sarcopenia development during aging.	UMR Univ Auvergne, INRA, CRNH,CHU, Unite Metab Prot Energet, Clermont Ferrand, France; INRA, CRNH, Unite Nutr & Metab Prot, Clermont Ferrand, France	CHU Clermont Ferrand; INRAE; INRAE	Boirie, Y (corresponding author), Lab Nutr Humaine, Unite Metab Prot Energet, BP 321,58 Rue Montalembert, F-63009 Clermont Ferrand 1, France.	boirie@clermont.inra.fr						Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; BAILLIE AGS, 1992, AM J PHYSIOL, V262, pE1, DOI 10.1152/ajpendo.1992.262.1.E1; Balage M, 2001, AM J PHYSIOL-ENDOC M, V281, pE565, DOI 10.1152/ajpendo.2001.281.3.E565; BENNET WM, 1990, AM J PHYSIOL, V259, pE185, DOI 10.1152/ajpendo.1990.259.2.E185; BODEN G, 1993, DIABETES CARE, V16, P728, DOI 10.2337/diacare.16.5.728; Boirie Y, 2001, DIABETES, V50, P2652, DOI 10.2337/diabetes.50.12.2652; Bryhni B, 2003, METABOLISM, V52, P850, DOI 10.1016/S0026-0495(03)00100-8; COON PJ, 1992, J CLIN ENDOCR METAB, V75, P1125, DOI 10.1210/jc.75.4.1125; DARDEVET D, 1994, ENDOCRINOLOGY, V134, P1475, DOI 10.1210/en.134.3.1475; Dardevet D, 2002, J NUTR, V132, P95, DOI 10.1093/jn/132.1.95; Dardevet D, 2000, J NUTR, V130, P2630, DOI 10.1093/jn/130.11.2630; Davis TA, 2002, AM J PHYSIOL-ENDOC M, V282, pE880, DOI 10.1152/ajpendo.00517.2001; Greiwe JS, 2001, AM J PHYSIOL-ENDOC M, V281, pE466, DOI 10.1152/ajpendo.2001.281.3.E466; Guillet C, 2004, EXP GERONTOL, V39, P745, DOI 10.1016/j.exger.2004.02.011; Hasten DL, 2000, AM J PHYSIOL-ENDOC M, V278, pE620, DOI 10.1152/ajpendo.2000.278.4.E620; HEYMSFIELD SB, 1990, AM J CLIN NUTR, V52, P214, DOI 10.1093/ajcn/52.2.214; Hillier T, 2000, J CLIN ENDOCR METAB, V85, P4900, DOI 10.1210/jc.85.12.4900; Hillier TA, 1998, AM J PHYSIOL-ENDOC M, V274, pE1067, DOI 10.1152/ajpendo.1998.274.6.E1067; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; Kimball SR, 1997, AM J PHYSIOL-CELL PH, V272, pC754, DOI 10.1152/ajpcell.1997.272.2.C754; Liu ZQ, 2002, J CLIN ENDOCR METAB, V87, P5553, DOI 10.1210/jc.2002-020424; Ljungqvist OH, 1997, AM J PHYSIOL-ENDOC M, V273, pE564, DOI 10.1152/ajpendo.1997.273.3.E564; Long W, 2000, AM J PHYSIOL-ENDOC M, V279, pE301, DOI 10.1152/ajpendo.2000.279.2.E301; MOSONI L, 1995, AM J PHYSIOL-ENDOC M, V268, pE328, DOI 10.1152/ajpendo.1995.268.2.E328; NAIR KS, 1995, J GERONTOL A-BIOL, V50, P107; NEWMAN E, 1994, METABOLISM, V43, P70, DOI 10.1016/0026-0495(94)90159-7; O'Connor PMJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE40, DOI 10.1152/ajpendo.00563.2002; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Rimbert V, 2004, FASEB J, V18, P737, DOI 10.1096/fj.03-1104fje; Roubenoff R, 2000, J Nutr Health Aging, V4, P140; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; Stump CS, 2003, P NATL ACAD SCI USA, V100, P7996, DOI 10.1073/pnas.1332551100; Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896; Vary TC, 1999, AM J PHYSIOL-ENDOC M, V277, pE1077, DOI 10.1152/ajpendo.1999.277.6.E1077; Volpi E, 2003, AM J CLIN NUTR, V78, P250, DOI 10.1093/ajcn/78.2.250; Volpi E, 1998, J CLIN INVEST, V101, P2000, DOI 10.1172/JCI939; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; Volpi E, 2000, J CLIN ENDOCR METAB, V85, P4481, DOI 10.1210/jc.85.12.4481; Volpi E, 1999, AM J PHYSIOL-ENDOC M, V277, pE513, DOI 10.1152/ajpendo.1999.277.3.E513; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; Wolfe RR, 2002, J NUTR, V132, p3219S, DOI 10.1093/jn/131.10.3219S; WOLFSON L, 1995, J GERONTOL A-BIOL, V50, P64	43	307	317	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1586	+		10.1096/fj.03-1341fje	http://dx.doi.org/10.1096/fj.03-1341fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319361	Bronze			2022-12-25	WOS:000223554900002
J	Nukuna, BN; Penn, MS; Anderson, VE; Hazen, SL				Nukuna, BN; Penn, MS; Anderson, VE; Hazen, SL			Latency and substrate binding globally reduce solvent accessibility of plasminogen activator inhibitor type 1 (PAI-1) - An adaptation of PAI-1 conformer crystal structures by hydrogen-deuterium exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER LOOP INSERTION; SERPIN; IDENTIFICATION; FORM; PURIFICATION; PROTEINASE; RESIDUES; COMPLEX; BETA; MUTAGENESIS	Plasminogen activator inhibitor type 1 (PAI-1) plays key regulatory roles in fibrinolysis, cell migration, and tissue remodeling. A regulatory protein without known catalytic activity, PAI-1 modulates plasminogen activators through protein-protein interactions. Although global conformational alterations that occur in PAI-1 determine its regulatory activity, comprehensive assessments of concurrent dynamic, structural, and functional alterations of this critical regulatory protein have not yet been clearly defined. X-ray crystallographic studies have described four distinct PAI-1 conformational states: active, latent, reactive center loop peptide-annealed (RCL-PA), and cleaved mutant. In this study, backbone amide hydrogen-deuterium exchange detected by mass spectrometry was used to characterize dynamic and structural alterations of human PAI-1 (hPAI-1) in relation to its function. hPAI-1 conformers were defined by surface mapping the solvent-accessible sites for strategic secondary structural components of the protein. We observed a global protection from solvent for a majority of peptides in the latent conformer relative to the active conformer. Significant differences were observed in the RCL, helix A, helix D, and sheet 1C, and these regions were markedly more dynamic or solvent-exposed in the active conformation. The RCL-PA form adopts an intermediate conformational state between the active and the latent conformers. Our results demonstrate that the most dynamic regions of PAI-1 ( the RCL, helices D and A, and sheet 5A) are flexible in the transition toward latency. They also show that the dynamic surface structures of the active, latent, and peptide-annealed conformers of PAI-1 are underestimated by theoretical solvent accessibility calculations derived from crystallographic data.	Cleveland Clin Fdn, Dept Cardiovasc Med, Prevent Cardiol Sect, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Prevent Cardiol Sect, 9500 Euclid Ave,C51, Cleveland, OH 44195 USA.	hazens@ccf.org	Anderson, Vernon/W-2673-2019; Hazen, Stanley L/ABD-5845-2021	Anderson, Vernon Emmett/0000-0002-1699-7621	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL077692, HL61878, HL70621, P01 HL076491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077692, P01HL076491, R01HL061878, R01HL070621] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AERTGEERTS K, 1995, PROTEINS, V23, P118, DOI 10.1002/prot.340230114; Aertgeerts K, 1997, J STRUCT BIOL, V118, P236, DOI 10.1006/jsbi.1997.3860; ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; Askari AT, 2003, J EXP MED, V197, P615, DOI 10.1084/jem.20021426; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; Declerck P, 1993, Verh K Acad Geneeskd Belg, V55, P457; DECLERCK PJ, 1992, J BIOL CHEM, V267, P11693; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; Deng YZ, 1999, J AM SOC MASS SPECTR, V10, P675, DOI 10.1016/S1044-0305(99)00038-0; Egelund R, 1998, BIOCHEMISTRY-US, V37, P6375, DOI 10.1021/bi973043+; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Gils A, 1997, FEBS LETT, V415, P192, DOI 10.1016/S0014-5793(97)01122-8; Glueck CJ, 1997, METABOLISM, V46, P1470, DOI 10.1016/S0026-0495(97)90150-5; Gorlatova NV, 2003, J BIOL CHEM, V278, P16329, DOI 10.1074/jbc.M208420200; Hansen M, 2001, EUR J BIOCHEM, V268, P6274, DOI 10.1046/j.0014-2956.2001.02582.x; Huber K, 2001, THROMB RES, V103, pS7, DOI 10.1016/S0049-3848(01)00293-6; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Kirkegaard T, 1999, EUR J BIOCHEM, V263, P577, DOI 10.1046/j.1432-1327.1999.00545.x; Koppel K, 2002, J ACQ IMMUN DEF SYND, V29, P441, DOI 10.1097/00042560-200204150-00003; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Macfelda K, 2002, J MOL CELL CARDIOL, V34, P1681, DOI 10.1006/jmcc.2002.2117; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nar H, 2000, J MOL BIOL, V297, P683, DOI 10.1006/jmbi.2000.3604; Ngo TH, 2002, THROMB HAEMOSTASIS, V88, P288; Nordt TK, 2001, THROMB RES, V103, pS1, DOI 10.1016/S0049-3848(01)00292-4; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; SCHNEIDER TR, 1996, P CCP4 STUD WEEK MAC, P133; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; Sui GC, 1998, BIOCHEM J, V331, P409, DOI 10.1042/bj3310409; Vleugels N, 2000, BBA-PROTEIN STRUCT M, V1476, P20, DOI 10.1016/S0167-4838(99)00224-1; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; Woods VL, 2001, J CELL BIOCHEM, V84, P89, DOI 10.1002/jcb.10069; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1	40	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50132	50141		10.1074/jbc.M407548200	http://dx.doi.org/10.1074/jbc.M407548200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15337743	hybrid			2022-12-25	WOS:000225229500072
J	Donthi, RV; Ye, G; Wu, CD; McClain, DA; Lange, AJ; Epstein, PN				Donthi, RV; Ye, G; Wu, CD; McClain, DA; Lange, AJ; Epstein, PN			Cardiac expression of kinase-deficient 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase inhibits glycolysis, promotes hypertrophy, impairs myocyte function, and reduces insulin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-INFARCTION; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; OVEREXPRESSION; METABOLISM; HEART; METALLOTHIONEIN; LIVER; FRUCTOSE-2,6-BISPHOSPHATE; CARDIOMYOPATHY	Glycolysis is important to cardiac metabolism and reduced glycolysis may contribute to diabetic cardiomyopathy. To understand its role independent of diabetes or hypoxic injury, we modulated glycolysis by cardiac-specific overexpression of kinase-deficient 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (kd-PFK-2). PFK-2 controls the level of fructose 2,6-bisphosphate (Fru-2,6-P-2), an important regulator of glycolysis. Transgenic mice had over 2-fold reduced levels of Fru-2,6-P-2. Heart weight/body weight ratio indicated mild hypertrophy. Sirius red staining for collagen was significantly increased. We observed a 2-fold elevation in glucose 6-phosphate and fructose 6-phosphate levels, whereas fructose 1,6-bisphosphate was reduced 2-fold. Pathways branching off of glycolysis above phosphofructokinase were activated as indicated by over 2-fold elevated UDP-N-acetylglucosamine and glycogen. The kd-PFK-2 transgene significantly inhibited glycolysis in perfused hearts. Insulin stimulation of metabolism and Akt phosphorylation were sharply reduced. In addition, contractility of isolated cardiomyocytes was impaired during basal and hypoxic incubations. The present study shows that cardiac overexpression of kinase-deficient PFK-2 reduces cardiac glycolysis that produced negative consequences to the heart including hypertrophy, fibrosis, and reduced cardiomyocyte function. In addition, metabolic and signaling responses to insulin were significantly decreased.	Univ Louisville, Sch Med, Dept Pediat Diabet Res, Louisville, KY 40202 USA; Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Utah, Div Endocrinol, Salt Lake City, UT 84132 USA	University of Louisville; University of Minnesota System; University of Minnesota Twin Cities; Utah System of Higher Education; University of Utah	Epstein, PN (corresponding author), Univ Louisville, Sch Med, Dept Pediat Diabet Res, 570 S Preston St,Baxter Biomed Bldg,Suite 304, Louisville, KY 40202 USA.	paul.epstein@louisville.edu		Epstein, Paul/0000-0002-7006-8954; McClain, Don/0000-0002-3310-2359	NHLBI NIH HHS [HL62892, HL66778] Funding Source: Medline; NIDDK NIH HHS [DK38354] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062892, R01HL066778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038354, R37DK038354] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; Angyalosi G, 2001, INFECT IMMUN, V69, P5874, DOI 10.1128/IAI.69.9.5874-5882.2001; AVOGARO A, 1999, AM J PHYSIOL, V258, pE606; Barr RL, 2000, J PHARMACOL TOX MET, V43, P141, DOI 10.1016/S1056-8719(00)00096-4; Belke DD, 2000, AM J PHYSIOL-ENDOC M, V279, pE1104, DOI 10.1152/ajpendo.2000.279.5.E1104; Belke DD, 2001, AM J PHYSIOL-ENDOC M, V280, pE420, DOI 10.1152/ajpendo.2001.280.3.E420; BISHOP SP, 1970, AM J PHYSIOL, V218, P153, DOI 10.1152/ajplegacy.1970.218.1.153; Clark RJ, 2003, J BIOL CHEM, V278, P44230, DOI 10.1074/jbc.M303810200; Donthi RV, 2000, CARDIOVASC DRUG THER, V14, P463, DOI 10.1023/A:1007876703644; GALDERISI M, 1991, AM J CARDIOL, V68, P85, DOI 10.1016/0002-9149(91)90716-X; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hue L, 2002, J MOL CELL CARDIOL, V34, P1091, DOI 10.1006/jmcc.2002.2063; Huisamen B, 2001, CARDIOVASC DRUG THER, V15, P445, DOI 10.1023/A:1013358011019; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KHAIDAR A, 1994, CIRCULATION, V90, P479, DOI 10.1161/01.CIR.90.1.479; KURLAND IJ, 1992, J BIOL CHEM, V267, P4416; Liang QR, 2002, CARDIOVASC RES, V53, P423, DOI 10.1016/S0008-6363(01)00495-3; Liang QR, 2002, DIABETES, V51, P174, DOI 10.2337/diabetes.51.1.174; Liang QR, 1999, J PHARMACOL EXP THER, V291, P766; LOWRY OH, 1993, FLEXIBLE SYSTEM ENZY, P111; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Neely J R, 1975, Methods Enzymol, V39, P43; NEWSHOLM EA, 1964, BIOCHEM J, V93, P641, DOI 10.1042/bj0930641; Nielsen JN, 2003, ACTA PHYSIOL SCAND, V178, P309, DOI 10.1046/j.1365-201X.2003.01165.x; *NIH, 1996, NIH PUBL; Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6; Ren J, 1997, AM J PHYSIOL-HEART C, V272, pH148, DOI 10.1152/ajpheart.1997.272.1.H148; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; SHEHADEH A, 1995, CLIN CARDIOL, V18, P301, DOI 10.1002/clc.4960180604; SOLER NG, 1974, LANCET, V1, P475; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; STONE PH, 1989, J AM COLL CARDIOL, V14, P49, DOI 10.1016/0735-1097(89)90053-3; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wu CD, 2004, ENDOCRINOLOGY, V145, P650, DOI 10.1210/en.2003-1290; Wu CD, 2002, DIABETES, V51, pA319; Wu CD, 2001, J CLIN INVEST, V107, P91, DOI 10.1172/JCI11103; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Ye G, 2003, DIABETES, V52, P777, DOI 10.2337/diabetes.52.3.777	44	47	50	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48085	48090		10.1074/jbc.M405510200	http://dx.doi.org/10.1074/jbc.M405510200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15331593	hybrid			2022-12-25	WOS:000224957000081
J	Huang, DM; Hinds, TR; Martinez, SE; Doneanu, C; Beavo, JA				Huang, DM; Hinds, TR; Martinez, SE; Doneanu, C; Beavo, JA			Molecular determinants of cGMP binding to chicken cone photoreceptor phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; GAF DOMAINS; VISUAL TRANSDUCTION; ROD PHOSPHODIESTERASE; GMP; SITES; PROTEINS; RECEPTOR; IDENTIFICATION; PURIFICATION	Structural studies on photoreceptor phosphodiesterases type 6 (PDE6s) have been hampered by an inability to express and purify substantial amounts of enzyme. Here we describe bacterial expression and characterization of the chicken cone PDE6 regulatory GAF-A and GAF-B domains. High affinity cGMP binding was found only for GAF-A as predicted from sequence alignments with the GAF domains of PDE2 and PDE5. A homology model of the GAF-A domain of chicken cone PDE6 based on the crystal structure of mouse PDE2A GAF-B was used to identify residues likely to make contact with cGMP. Alanine mutagenesis of 4 of these residues (F123A, D169A, T172A, and T176A) showed that each was absolutely required for cGMP binding. Three of these residues map to the H4 helical structure of the GAF-A domain indicating this region as a key structural component for cGMP binding. Mutagenesis of another residue, S97A, decreased cGMP binding affinity 5-fold. Finally mutagenesis of Glu-124 indicated that it is responsible for part but not all of the high specificity for cGMP binding to PDE6 GAF-A. Since little data is available on the properties of the chicken cone PDE6 holoenzyme, we also characterized the native PDEs of chicken retina. Two histone-activated PDE6 peaks were separated by ion exchange chromatography and identified by mass spectrometry as cone and rod photoreceptor PDE6s, respectively. Both of these PDEs had cGMP binding and kinetic properties similar to their corresponding bovine photoreceptor PDEs. Moreover the cGMP binding properties of chicken cone PDE6 holoenzyme were very similar to those of the bacterially expressed individual GAF-A or GAF-A/B domains.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Beavo, JA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	beavo@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-44948] Funding Source: Medline; NIDDK NIH HHS [DK-21723] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cook TA, 2000, METHOD ENZYMOL, V315, P597; Corbin JD, 2003, MOL PHARMACOL, V63, P1364, DOI 10.1124/mol.63.6.1364; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; DETERRE P, 1987, BIOCHIMIE, V69, P365, DOI 10.1016/0300-9084(87)90027-7; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; Francis SH, 2002, J BIOL CHEM, V277, P47581, DOI 10.1074/jbc.M206088200; FRANCIS SH, 1990, CYCLIC NUCLEOTIDE PH, V2, P117; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1988, THESIS U WASHINGTON; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hebert MC, 1998, J BIOL CHEM, V273, P5557, DOI 10.1074/jbc.273.10.5557; Helmreich EJM, 1996, BBA-REV BIOMEMBRANES, V1286, P285, DOI 10.1016/S0304-4157(96)00013-5; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HURWITZ RL, 1984, J BIOL CHEM, V259, P8612; Liu L, 2002, CELL SIGNAL, V14, P45, DOI 10.1016/S0898-6568(01)00216-9; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; Morin F, 2001, J NEUROCHEM, V78, P88, DOI 10.1046/j.1471-4159.2001.00407.x; MORRIS VB, 1970, J COMP NEUROL, V140, P359, DOI 10.1002/cne.901400308; MORRIS VB, 1967, J COMP NEUROL, V129, P313, DOI 10.1002/cne.901290404; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PUGH EN, 1986, VISION RES, V26, P1613, DOI 10.1016/0042-6989(86)90051-9; Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SEMPLEROWLAND SL, 1994, EXP EYE RES, V59, P365, DOI 10.1006/exer.1994.1119; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sopory S, 2003, FEBS LETT, V539, P161, DOI 10.1016/S0014-5793(03)00219-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki M, 2002, J BIOL CHEM, V277, P40675, DOI 10.1074/jbc.M203469200; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267	44	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48143	48151		10.1074/jbc.M404338200	http://dx.doi.org/10.1074/jbc.M404338200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15331594	Green Published, Green Submitted, hybrid			2022-12-25	WOS:000224957000088
J	Mackey, ZB; O'Brien, TC; Greenbaum, DC; Blank, RB; McKerrow, JH				Mackey, ZB; O'Brien, TC; Greenbaum, DC; Blank, RB; McKerrow, JH			A cathepsin B-like protease is required for host protein degradation in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEISHMANIA-DONOVANI COMPLEX; MAJOR CYSTEINE PROTEASE; BLOOD-STREAM FORMS; EPOXYSUCCINYL INHIBITORS; EXPRESSION; CHEMOTHERAPY; CLONING; TARGET; CRUZI; CELL	Identification and analysis of Clan CA (papain) cysteine proteases in primitive protozoa and metazoa have suggested that this enzyme family is more diverse and biologically important than originally thought. The protozoan parasite Trypanosoma brucei is the etiological agent of African sleeping sickness. The cysteine protease activity of this organism is a validated drug target as first recognized by the killing of the parasite with the diazomethane inhibitor Z-Phe-Ala-CHN2 (where Z is benzyloxycarbonyl). Whereas the presumed target of this inhibitor was rhodesain (also brucipain, trypanopain), the major cathepsin L-like cysteine protease of T. brucei, genomic analysis has now identified tbcatB, a cathepsin B-like cysteine protease as a possible inhibitor target. The mRNA of tbcatB is more abundantly expressed in the bloodstream versus the procyclic form of the parasite. Induction of RNA interference against rhodesain did not result in an abnormal phenotype in cultured T. brucei. However, induction of RNA interference against tbcatB led to enlargement of the endosome, accumulation of fluorescein isothiocyanate-transferrin, defective cytokinesis after completion of mitosis, and ultimately the death of cultured parasites. Therefore, tbcatB, but not rhodesain, is essential for T. brucei survival in culture and is the most likely target of the diazomethane protease inhibitor Z-Phe-Ala-CHN2 in T. brucei.	Univ Calif San Francisco, Dept Pathol, Trop Dis Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Mackey, ZB (corresponding author), Univ Calif San Francisco, Dept Pathol, Trop Dis Res Unit, 513 Parnassus HSW 501, San Francisco, CA 94143 USA.	zmackey@itsa.ucsf.edu		Mackey, Zachary/0000-0002-4533-0973	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035707] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35707] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Barrett AJ, 2003, BIOL CHEM, V384, P873, DOI 10.1515/BC.2003.098; BART G, 1995, MOL BIOCHEM PARASIT, V73, P271, DOI 10.1016/0166-6851(95)00113-F; Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2; Caffrey CR, 2001, MOL BIOCHEM PARASIT, V118, P61, DOI 10.1016/S0166-6851(01)00368-1; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; HUET G, 1992, BIOCHIM BIOPHYS ACTA, V1138, P213, DOI 10.1016/0925-4439(92)90040-T; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; Lalmanach G, 2002, BIOL CHEM, V383, P739, DOI 10.1515/BC.2002.077; Linke M, 2002, J CELL SCI, V115, P4877, DOI 10.1242/jcs.00184; LONSDALEECCLES JD, 1987, EUR J BIOCHEM, V169, P467, DOI 10.1111/j.1432-1033.1987.tb13634.x; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; McKerrow JH, 1999, INT J PARASITOL, V29, P833, DOI 10.1016/S0020-7519(99)00044-2; McKerrow JH, 1999, BIOORGAN MED CHEM, V7, P639, DOI 10.1016/S0968-0896(99)00008-5; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; Mundodi V, 2002, GENE, V282, P257, DOI 10.1016/S0378-1119(01)00851-4; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nkemngu NJ, 2003, INT J ANTIMICROB AG, V22, P155, DOI 10.1016/S0924-8579(03)00096-7; Nobrega OT, 1998, MOL BIOCHEM PARASIT, V97, P235, DOI 10.1016/S0166-6851(98)00125-X; PAMER EG, 1990, NUCLEIC ACIDS RES, V18, P6141, DOI 10.1093/nar/18.20.6141; ROBERTSON CD, 1990, J GEN MICROBIOL, V136, P921, DOI 10.1099/00221287-136-5-921; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Sakanari JA, 1997, EXP PARASITOL, V85, P63, DOI 10.1006/expr.1996.4116; Scory S, 1999, EXP PARASITOL, V91, P327, DOI 10.1006/expr.1998.4381; Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015; SHAW E, 1988, J BIOL CHEM, V263, P2768; SHI GP, 1992, J BIOL CHEM, V267, P7258; Somanna A, 2002, J BIOL CHEM, V277, P25305, DOI 10.1074/jbc.M203034200; TURK D, 1995, BIOCHEMISTRY-US, V34, P4791, DOI 10.1021/bi00014a037; van den Hoff M J, 1995, Methods Mol Biol, V48, P185; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Ward W, 1997, CELL, V89, P437, DOI 10.1016/S0092-8674(00)80224-X; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	38	86	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48426	48433		10.1074/jbc.M402470200	http://dx.doi.org/10.1074/jbc.M402470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15326171	hybrid			2022-12-25	WOS:000224957000119
J	Campian, JL; Qian, MQ; Gao, XH; Eaton, JW				Campian, JL; Qian, MQ; Gao, XH; Eaton, JW			Oxygen tolerance and coupling of mitochondrial electron transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; FLUOROMETRIC ASSAY; HEME OXYGENASE-1; CELL-DEATH; IN-VIVO; SUPEROXIDE; HYPEROXIA; GENE; UBISEMIQUINONE; METABOLISM	Oxygen is critical to aerobic metabolism, but excessive oxygen (hyperoxia) causes cell injury and death. An oxygen-tolerant strain of HeLa cells, which proliferates even under 80% O-2, termed "HeLa-80," was derived from wild-type HeLa cells ("HeLa-20") by selection for resistance to stepwise increases of oxygen partial pressure. Surprisingly, antioxidant defenses and susceptibility to oxidant-mediated killing do not differ between these two strains of HeLa cells. However, under both 20 and 80% O2, intracellular reactive oxygen species (ROS) production is significantly (similar to2-fold) less in HeLa-80 cells. In both cell lines the source of ROS is evidently mitochondrial. Although HeLa-80 cells consume oxygen at the same rate as HeLa-20 cells, they consume less glucose and produce less lactic acid. Most importantly, the oxygen-tolerant HeLa-80 cells have significantly higher cytochrome c oxidase activity (similar to2-fold), which may act to deplete upstream electron-rich intermediates responsible for ROS generation. Indeed, preferential inhibition of cytochrome c oxidase by treatment with n-methyl protoporphyrin ( which selectively diminishes synthesis of heme a in cytochrome c oxidase) enhances ROS production and abrogates the oxygen tolerance of the HeLa-80 cells. Thus, it appears that the remarkable oxygen tolerance of these cells derives from tighter coupling of the electron transport chain.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, Louisville, KY 40202 USA	University of Louisville	Eaton, JW (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, 580 S Preston St,Baxter Res Bldg 2,Rm 210, Louisville, KY 40202 USA.	EatonRedox@aol.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058882] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58882] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez S, 2003, BIOCHEM BIOPH RES CO, V305, P771, DOI 10.1016/S0006-291X(03)00818-0; Atamna H, 2001, J BIOL CHEM, V276, P48410, DOI 10.1074/jbc.M108362200; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bostek C C, 1989, AANA J, V57, P231; Branicky R, 2000, BIOESSAYS, V22, P48, DOI 10.1002/(SICI)1521-1878(200001)22:1&lt;48::AID-BIES9&gt;3.0.CO;2-F; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Castro L, 2001, NUTRITION, V17, P161, DOI 10.1016/S0899-9007(00)00570-0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; Fuller KM, 2002, ELECTROPHORESIS, V23, P1571, DOI 10.1002/1522-2683(200206)23:11<1571::AID-ELPS1571>3.0.CO;2-3; Gamble JT, 2000, DRUG METAB DISPOS, V28, P373; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Gerschman R, 2001, Nutrition, V17, P162; GLOSTER JA, 1962, CLIN CHIM ACTA, V7, P206, DOI 10.1016/0009-8981(62)90011-6; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Guppy M, 2002, BIOCHEM J, V364, P309, DOI 10.1042/bj3640309; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0; JOENJE H, 1985, LAB INVEST, V52, P420; JOENJE H, 1985, FREE RADIC BIOL MED, V1, P307; Jyonouchi H, 1998, AM J RESP CELL MOL, V19, P426, DOI 10.1165/ajrcmb.19.3.2862m; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0400265101; MA M, 1992, P NATL ACAD SCI USA, V89, P7924, DOI 10.1073/pnas.89.17.7924; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; Mao C, 1999, CRIT CARE MED, V27, P2806, DOI 10.1097/00003246-199912000-00033; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Nikolaychik VV, 1996, J BIOMAT SCI-POLYM E, V7, P881, DOI 10.1163/156856296X00057; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; NORTHWAY WH, 1968, RADIOLOGY, V91, P49, DOI 10.1148/91.1.49; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; PAGE B, 1993, INT J ONCOL, V3, P473; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TANGERAS A, 1986, BIOCHIM BIOPHYS ACTA, V882, P77, DOI 10.1016/0304-4165(86)90058-9; TRINDER P, 1969, J CLIN PATHOL, V22, P158, DOI 10.1136/jcp.22.2.158; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Villani G, 2000, FREE RADICAL BIO MED, V29, P202, DOI 10.1016/S0891-5849(00)00303-8; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Williams AJ, 1998, ANAL BIOCHEM, V259, P176, DOI 10.1006/abio.1998.2624; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; WONG A, 1995, GENETICS, V139, P1247; Zhang JG, 2001, ARCH BIOCHEM BIOPHYS, V393, P87, DOI 10.1006/abbi.2001.2486; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	58	57	58	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46580	46587		10.1074/jbc.M406685200	http://dx.doi.org/10.1074/jbc.M406685200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328348	hybrid			2022-12-25	WOS:000224832400031
J	Guihard, G; Bellot, G; Moreau, C; Pradal, G; Ferry, N; Thomy, R; Fichet, P; Meflah, K; Vallette, FM				Guihard, G; Bellot, G; Moreau, C; Pradal, G; Ferry, N; Thomy, R; Fichet, P; Meflah, K; Vallette, FM			The mitochondrial apoptosis-induced channel (MAC) corresponds to a late apoptotic event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; ADENINE-NUCLEOTIDE TRANSLOCATOR; PEPTIDE-SENSITIVE CHANNEL; BCL-2 FAMILY PROTEINS; INDUCED LIVER-INJURY; OUTER-MEMBRANE; CELL-DEATH; BAX OLIGOMERIZATION	We have investigated the mechanism responsible for mitochondria permeabilization occurring during cell apoptosis. We have developed an in vivo model of apoptotic rat liver. Mitochondria appeared as an homogenous population in control liver. On the contrary, mitochondria varied in size, morphology, and the matrical density in apoptotic liver. Mitochondria were purified from control and apoptotic livers. In control conditions, a single mitochondrial population was identified; whereas three populations of mitochondria were purified from apoptotic liver. Our data show that these apoptotic populations correspond to early, intermediate, and late apoptotic mitochondria, which are characterized by an increasing extent of permeabilization of their outer membrane and a gradual enrichment in oligomerized Bax protein. Remarkably, a new ionic channel was observed in apoptotic but not in control mitochondria. The biophysical and pharmacological properties of this channel are in good agreement with those reported for a previously described mitochondrial apoptosis-induced channel (MAC) (Pavlov, E. V., Priault, M., Pietkiewicz, D., Cheng, E. H., Antonsson, B., Manon, S., Korsmeyer, S. J., Mannella, C. A., and Kinnally, K. W. (2001) J. Cell Biol. 155, 725-731). However, MAC activity was only observed in the late apoptotic mitochondrial population. Thus, our study establishes that MAC activity is related to the overall apoptotic process but corresponds to a late event.	INSERM, Dept Rech Cancerol, UMR601, F-44035 Nantes, France; UFR Med, F-44000 Nantes, France; CIC INSERM 04, UFR Med, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Guihard, G (corresponding author), INSERM, Dept Rech Cancerol, UMR601, 9 Quai Moncousu, F-44035 Nantes, France.	gilles.guihard@nantes.inserm.fr	Vallette, Francois M/K-9047-2015; Vallette, Francois/N-2361-2018	Vallette, Francois M/0000-0002-3296-8572; Vallette, Francois/0000-0003-0802-0519				Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Belzacq AS, 2003, CANCER RES, V63, P541; Borner C, 2004, BBA-MOL CELL RES, V1644, P71, DOI 10.1016/j.bbamcr.2003.11.003; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Epand RF, 2002, BIOCHEM J, V367, P849, DOI 10.1042/BJ20020986; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; FORTE M, 1987, J MEMBRANE BIOL, V99, P65, DOI 10.1007/BF01870622; GOVADZE V, 2004, BIOCHEM J, V378, P213; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guihard G, 2000, FEBS LETT, V476, P234, DOI 10.1016/S0014-5793(00)01752-X; Guo L, 2004, AM J PHYSIOL-CELL PH, V286, pC1109, DOI 10.1152/ajpcell.00183.2003; Henry JP, 1996, J BIOENERG BIOMEMBR, V28, P101, DOI 10.1007/BF02110639; Hille B., 1992, IONIC CHANNELS EXCIT; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lemeshko SV, 2004, MOL CELL BIOCHEM, V256, P127, DOI 10.1023/B:MCBI.0000009864.77216.00; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; MANDEL N, 1977, J BIOL CHEM, V252, P4619; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Martinez-Caballero S, 2004, FEBS LETT, V568, P35, DOI 10.1016/j.febslet.2004.05.006; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Moczydlowski E., 1986, ION CHANNEL RECONSTI, P75; Muro C, 2003, BIOPHYS J, V84, P2981, DOI 10.1016/S0006-3495(03)70024-1; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Pelleschi M, 1997, J MEMBRANE BIOL, V156, P37, DOI 10.1007/s002329900185; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wirth A, 2003, MOL CELL, V12, P261, DOI 10.1016/S1097-2765(03)00283-1; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; ZIZI M, 1994, J BIOL CHEM, V269, P1614	57	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46542	46550		10.1074/jbc.M405153200	http://dx.doi.org/10.1074/jbc.M405153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328340	hybrid			2022-12-25	WOS:000224832400026
J	Ishida, T; Akimitsu, N; Kashioka, T; Hatano, M; Kubota, T; Ogata, Y; Sekimizu, K; Katayama, T				Ishida, T; Akimitsu, N; Kashioka, T; Hatano, M; Kubota, T; Ogata, Y; Sekimizu, K; Katayama, T			DiaA, a novel DnaA-binding protein, ensures the timely initiation of Escherichia coli chromosome replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQA PROTEIN; IN-VITRO; SLIDING CLAMP; ORIGIN; MUTANT; CYCLE; GENE; IDENTIFICATION; COMPLEXES; DOMAINS	The DnaA protein is the initiator of Escherichia coli chromosomal replication. In this study, we identify a novel DnaA-associating protein, DiaA, that is required for the timely initiation of replication during the cell cycle. DiaA promotes the growth of specific temperature-sensitive dnaA mutants and ensures stable minichromosome maintenance, whereas DiaA does not decrease the cellular DnaA content. A diaA::Tn5 mutation suppresses the cold-sensitive growth of an overinitiation type dnaA mutant independently of SeqA, a negative modulator of initiation. Flow cytometry analyses revealed that the timing of replication initiation is disrupted in the diaA mutant cells as well as wild-type cells with pBR322 expressing the diaA gene. Gel filtration and chemical cross-linking experiments showed that purified DiaA forms a stable homodimer. Immunoblotting analysis indicated that a single cell contains about 280 DiaA dimers. DiaA stimulates minichromosome replication in an in vitro system especially when the level of DnaA included is limited. Moreover, specific and direct binding between DnaA and DiaA was observed, which requires a DnaA N-terminal region. DiaA binds to both ATP- and ADP-bound forms of DnaA with a similar affinity. Thus, we conclude that DiaA is a novel DnaA-associating factor that is crucial to ensure the timely initiation of chromosomal replication.	Kyushu Univ, Dept Mol Biol, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Katayama, T (corresponding author), Kyushu Univ, Dept Mol Biol, Grad Sch Pharmaceut Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp		Ogata, Yasuyuki/0000-0003-0316-0109; Katayama, Tsutomu/0000-0001-9994-1684				Bateman A, 1999, TRENDS BIOCHEM SCI, V24, P94, DOI 10.1016/S0968-0004(99)01357-2; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BOYE E, 1989, DNA REPLICATION CELL, P15; Brooke JS, 1996, J BIOL CHEM, V271, P3608; Brooke JS, 1996, J BACTERIOL, V178, P3339, DOI 10.1128/jb.178.11.3339-3341.1996; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Grimwade JE, 2000, MOL MICROBIOL, V35, P835, DOI 10.1046/j.1365-2958.2000.01755.x; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; HELMSTETTER CE, 1996, ESCHERICHIA COLI SAL, P1627; Hiraga S, 2000, GENES CELLS, V5, P327, DOI 10.1046/j.1365-2443.2000.00334.x; KANO Y, 1991, GENE, V103, P25; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; Katayama T, 1997, MOL MICROBIOL, V26, P687, DOI 10.1046/j.1365-2958.1997.5941967.x; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Katayama T, 1997, MOL MICROBIOL, V25, P661, DOI 10.1046/j.1365-2958.1997.5001872.x; Katayama T, 2001, MOL MICROBIOL, V41, P9, DOI 10.1046/j.1365-2958.2001.02483.x; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kornberg A., 1992, DNA REPLICATION; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; Nishida S, 2002, J BIOL CHEM, V277, P14986, DOI 10.1074/jbc.M108303200; Obita T, 2002, BIOCHEM BIOPH RES CO, V299, P42, DOI 10.1016/S0006-291X(02)02590-1; Ryan VT, 2002, MOL MICROBIOL, V46, P113, DOI 10.1046/j.1365-2958.2002.03129.x; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; Seitz H, 2000, MOL MICROBIOL, V37, P1270, DOI 10.1046/j.1365-2958.2000.02096.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; Skarstad K, 1995, METHOD ENZYMOL, V262, P604; Skarstad K, 2000, MOL MICROBIOL, V36, P1319, DOI 10.1046/j.1365-2958.2000.01943.x; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; Sorensen KI, 1996, J BACTERIOL, V178, P1003, DOI 10.1128/jb.178.4.1003-1011.1996; Su'etsugu M, 2004, GENES CELLS, V9, P509, DOI 10.1111/j.1356-9597.2004.00741.x; Su'etsugu M, 2003, GENES CELLS, V8, P731, DOI 10.1046/j.1365-2443.2003.00671.x; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Taghbalout A, 2000, GENES CELLS, V5, P873, DOI 10.1046/j.1365-2443.2000.00380.x; Takata M, 2000, MOL MICROBIOL, V35, P454, DOI 10.1046/j.1365-2958.2000.01722.x; Withers HL, 1998, J BACTERIOL, V180, P1624, DOI 10.1128/JB.180.7.1624-1631.1998; Wold S, 1998, EMBO J, V17, P4158, DOI 10.1093/emboj/17.14.4158; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	52	89	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45546	45555		10.1074/jbc.M402762200	http://dx.doi.org/10.1074/jbc.M402762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326179	hybrid			2022-12-25	WOS:000224694900033
J	Nakamura, K; Kennedy, MA; Baldan, A; Bojanic, DD; Lyons, K; Edwards, PA				Nakamura, K; Kennedy, MA; Baldan, A; Bojanic, DD; Lyons, K; Edwards, PA			Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-WHITE GENE; FARNESOID-X RECEPTOR; ABC-TRANSPORTER; DIETARY-CHOLESTEROL; TANGIER-DISEASE; LOADED MACROPHAGES; ACTIVATED RECEPTOR; MOLECULAR-CLONING; NUCLEAR RECEPTOR; MESSENGER-RNA	The murine Abcg1 gene is reported to consist of 15 exons that encode a single mRNA ( herein referred to as Abcg1-a) and protein. We now demonstrate that (i) the murine gene contains two additional coding exons downstream of exon 1, (ii) transcription involves the use of multiple promoters, and (iii) the RNA undergoes alternative splicing reactions. As a result, three mRNAs are expressed that encode three putative protein isoforms that differ at their amino terminus. ABCG1 transcripts are induced in vivo in multiple tissues in response to the liver X receptor ligand T0901317. Identification and characterization of four liver X receptor response elements in the intron downstream of exon 2 provides a mechanism by which this induction occurs. Importantly, cholesterol efflux to high density lipoprotein was stimulated following transfection of Hek293 cells with plasmids encoding individual ABCG1 isoforms. In situ hybridization studies in embryonic day 11.5-15.5 mouse embryos revealed strong expression of ABCG1 transcripts in the olfactory epithelium, hind brain, eye, and dorsal root ganglia. The relatively high levels of expression in neuronal tissues and the eye suggest that ABCG1-dependent cholesterol efflux may be critical for normal neuronal function in addition to its role in macrophages.	Univ Calif Los Angeles, Dept Med & Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Cell Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	pedwards@mednet.ucla.edu	Kennedy, Michael/M-2578-2019; Kennedy, Michael/ABE-6002-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL068445] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68445, HL30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; AMBUDKAR SV, 1998, ABC TRANSPORTERS BIO, V292, P101; Anisfeld AM, 2003, J BIOL CHEM, V278, P20420, DOI 10.1074/jbc.M302505200; Annilo T, 2001, CYTOGENET CELL GENET, V94, P196, DOI 10.1159/000048816; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Campbell JL, 2001, J NEUROBIOL, V49, P339, DOI 10.1002/neu.10009; Chen HM, 1996, AM J HUM GENET, V59, P66; Childs S, 1994, Important Adv Oncol, P21; Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6; Dean M, 2001, J LIPID RES, V42, P1007; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hoekstra M, 2003, J BIOL CHEM, V278, P25448, DOI 10.1074/jbc.M301189200; Hogan B, 1994, MANIPULATING MOUSE E; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Langmann T, 2000, BBA-GENE STRUCT EXPR, V1494, P175, DOI 10.1016/S0167-4781(00)00215-3; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lorkowski S, 2001, BIOCHEM BIOPH RES CO, V280, P121, DOI 10.1006/bbrc.2000.4089; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Mackenzie SM, 2000, GENETICA, V108, P239, DOI 10.1023/A:1004115718597; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; Oldfield S, 2002, BBA-MOL CELL RES, V1591, P175, DOI 10.1016/S0167-4889(02)00269-0; Oram JF, 2001, J LIPID RES, V42, P1173; PEPLING M, 1990, NUCLEIC ACIDS RES, V18, P1633, DOI 10.1093/nar/18.6.1633; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sanchez-Fernandez R, 2001, J BIOL CHEM, V276, P30231, DOI 10.1074/jbc.M103104200; Savary S, 1996, MAMM GENOME, V7, P673, DOI 10.1007/s003359900203; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; TEARLE RG, 1989, GENETICS, V122, P595; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	54	135	142	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45980	45989		10.1074/jbc.M408652200	http://dx.doi.org/10.1074/jbc.M408652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319426	hybrid			2022-12-25	WOS:000224694900083
J	Qiao, FY; Mi, J; Wilson, JB; Zhi, G; Bucheimer, NR; Jones, NJ; Kupfer, GM				Qiao, FY; Mi, J; Wilson, JB; Zhi, G; Bucheimer, NR; Jones, NJ; Kupfer, GM			Phosphorylation of Fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-D GENE; NUCLEAR ACCUMULATION; HEMATOPOIETIC-CELLS; GAMMA-INTERFERON; COMPLEX; APOPTOSIS; FANCG/XRCC9; EXPRESSION; BINDS; POLYPEPTIDE	Fanconi anemia ( FA) is an autosomal recessive disease of cancer susceptibility. FA cells exhibit a characteristic hypersensitivity to DNA cross-linking agents. The molecular mechanism for the disease is unknown as few of the FA proteins have functional motifs. Several post-translational modifications of the proteins have been described. We and others (Qiao, F., Moss, A., and Kupfer, G. M. (2001) J. Biol. Chem. 276, 23391-23396 and Futaki, M., Watanabe, S., Kajigaya, S., and Liu, J. M. (2001) Biochem. Biophys. Res. Commun. 281, 347-351) have reported that the FANCG protein ( Fanconi complementation group G) is phosphorylated. We show that in an in vitro kinase reaction FANCG is radioactively labeled. Mass spectrometry analysis detected a peptide containing phosphorylation of serine 7. Using PCR-mediated site-directed mutagenesis we mutated serine 7 to alanine. Only wild-type FANCG cDNA fully corrected FA-G mutant cells. We also tested the effect of human wild-type FANCG in Chinese hamster ovary cells in which the FANCG homologue is mutant. Human FANCG complemented these cells, whereas human FANCG(S7A) did not. Unexpectedly, FANCG( S7A) bound to and stabilized the endogenous forms of the FANCA and FANCC proteins in the FA-G cells. FANCG(S7A) aberrantly localized to globules in chromatin and did not abrogate the internuclear bridges seen in the FA-G mutant cells. Phosphorylation of serine 7 in FANCG is functionally important in the FA pathway.	Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	University of Virginia; University of Virginia; University of Liverpool	Kupfer, GM (corresponding author), Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA.	gk9@virginia.edu	Jones, Nigel J/D-1997-2010		NHLBI NIH HHS [HL-063776] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063776] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1997, GENETIC BASIS HUMAN, P317; Blom E, 2004, DNA REPAIR, V3, P77, DOI 10.1016/j.dnarep.2003.09.007; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Christianson TA, 2000, BLOOD, V95, P725, DOI 10.1182/blood.V95.2.725; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DUTRILLAUX B, 1982, HUM GENET, V62, P327, DOI 10.1007/BF00304549; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; Futaki M, 2001, BIOCHEM BIOPH RES CO, V281, P347, DOI 10.1006/bbrc.2001.4359; Garcia-Higuera I, 2000, BLOOD, V96, P3224, DOI 10.1182/blood.V96.9.3224.h8003224_3224_3230; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Haneline LS, 1998, BLOOD, V91, P4092; HEAD DR, 1989, CANCER-AM CANCER SOC, V64, P2199, DOI 10.1002/1097-0142(19891201)64:11<2199::AID-CNCR2820641102>3.0.CO;2-3; Hejna JA, 2000, AM J HUM GENET, V66, P1540, DOI 10.1086/302896; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; KAISER TN, 1982, CYTOMETRY, V2, P291; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Kupfer GM, 1996, BLOOD, V88, P1019; Lamerdin JE, 2004, MUTAGENESIS, V19, P237, DOI 10.1093/mutage/geh019; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Marathi UK, 1996, BLOOD, V88, P2298, DOI 10.1182/blood.V88.6.2298.bloodjournal8862298; McCleland ML, 2003, GENE DEV, V17, P101, DOI 10.1101/gad.1040903; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; MI J, 2004, IN PRESS BLOOD; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Naf D, 1998, MOL CELL BIOL, V18, P5952; Pace P, 2002, EMBO J, V21, P3414, DOI 10.1093/emboj/cdf355; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Qiao FY, 2001, J BIOL CHEM, V276, P23391, DOI 10.1074/jbc.M101855200; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Ridet A, 1997, CANCER RES, V57, P1722; Schroeder MJ, 2004, ANAL CHEM, V76, P3590, DOI 10.1021/ac0497104; Shevchenko A, 2001, ANAL BIOCHEM, V296, P279, DOI 10.1006/abio.2001.5321; STONESIFER KJ, 1987, ACTA CYTOL, V31, P125; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, BLOOD, V100, P2457, DOI 10.1182/blood-2002-03-0860; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thomashevski A, 2004, J BIOL CHEM, V279, P26201, DOI 10.1074/jbc.M400091200; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; van de Vrugt HJ, 2002, GENES CELLS, V7, P333, DOI 10.1046/j.1365-2443.2002.00518.x; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Whitney MA, 1996, BLOOD, V88, P49; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Yagasaki H, 2001, BLOOD, V98, P3650, DOI 10.1182/blood.V98.13.3650; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755	64	36	38	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46035	46045		10.1074/jbc.M408323200	http://dx.doi.org/10.1074/jbc.M408323200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15299017	hybrid			2022-12-25	WOS:000224694900089
J	Rouet-Benzineb, P; Rouyer-Fessard, C; Jarry, A; Avondo, V; Pouzet, C; Yanagisawa, M; Laboisse, C; Laburthe, M; Voisin, T				Rouet-Benzineb, P; Rouyer-Fessard, C; Jarry, A; Avondo, V; Pouzet, C; Yanagisawa, M; Laboisse, C; Laburthe, M; Voisin, T			Orexins acting at native OX1 receptor in colon cancer and neuroblastoma cells or at recombinant OX1 receptor suppress cell growth by inducing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NEUROTENSIN RECEPTOR; PERIPHERAL-TISSUES; ACTIVATION; PATHWAY; LINE; EXPRESSION; BINDING; KINASE; TRANSACTIVATION	Screening of 26 gut peptides for their ability to inhibit growth of human colon cancer HT29-D4 cells grown in 10% fetal calf serum identified orexin-A and orexin-B as anti-growth factors. Upon addition of either orexin (1 muM), suppression of cell growth was total after 24 h and >70% after 48 or 72 h, with an EC50 of 5 nM peptide. Orexins did not alter proliferation but promoted apoptosis as demonstrated by morphological changes in cell shape, DNA fragmentation, chromatin condensation, cytochrome c release into cytosol, and activation of caspase-3 and caspase-7. The serpentine G protein-coupled orexin receptor OX1R but not OX2R was expressed in HT29-D4 cells and mediated orexin-induced Ca2+ transients in HT29-D4 cells. The expression of OX1R and the pro-apoptotic effects of orexins were also indicated in other colon cancer cell lines including Caco-2, SW480, and LoVo but, most interestingly, not in normal colonic epithelial cells. The role of OX1R in mediating apoptosis was further demonstrated by transfecting Chinese hamster ovary cells with OX1R cDNA, which conferred the ability of orexins to promote apoptosis. A neuroblastoma cell line SK-N-MC, which expresses OX1R, also underwent growth suppression and apoptosis upon treatment with orexins. Promotion of apoptosis appears to be an intrinsic property of OX1R regardless of the cell type where it is expressed. In conclusion, orexins, acting at native or recombinant OX1R, are pro-apoptotic peptides. These findings add a new dimension to the biological activities of these neuropeptides, which may have important implications in health and disease, in particular colon cancer.	Univ Paris 07, INSERM, U410, F-75870 Paris 18, France; Univ Paris 07, IFR Claude Bernard 02, F-75870 Paris 18, France; Fac Med, INSERM, U539, F-44035 Nantes, France; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Voisin, T (corresponding author), Univ Paris 07, INSERM, U410, 16 Rue Henri Huchard,BP 416, F-75870 Paris 18, France.	tvoisin@bichat.inserm.fr	voisin, thierry/R-1241-2017; jarry, anne/O-5964-2015; LABURTHE, Marc/C-1875-2012	voisin, thierry/0000-0002-4320-5183; JARRY, Anne/0000-0002-3489-7800				Beuckmann CT, 2002, J MOL MED, V80, P329, DOI 10.1007/s00109-002-0322-x; Biard-Piechaczyk M, 2000, VIROLOGY, V268, P329, DOI 10.1006/viro.1999.0151; BOZOU JC, 1989, BIOCHEM J, V264, P871, DOI 10.1042/bj2640871; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bursch W, 2000, J CELL SCI, V113, P1189; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Carethers JM, 2004, GASTROENTEROLOGY, V126, P394, DOI 10.1053/j.gastro.2003.12.023; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Charrier L, 2002, CANCER RES, V62, P2169; Darker JG, 2001, BIOORG MED CHEM LETT, V11, P737, DOI 10.1016/S0960-894X(01)00043-9; Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dehez S, 2002, CELL GROWTH DIFFER, V13, P375; Dkhissi F, 2003, HUM GENE THER, V14, P997, DOI 10.1089/104303403766682250; FANTINI J, 1986, J CELL SCI, V83, P235; Ferris HA, 1997, J CLIN INVEST, V100, P2530, DOI 10.1172/JCI119795; Fink SP, 2001, CANCER RES, V61, P256; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Johren O, 2001, ENDOCRINOLOGY, V142, P3324, DOI 10.1210/en.142.8.3324; Jones BA, 1997, AM J PHYSIOL-GASTR L, V273, pG1174, DOI 10.1152/ajpgi.1997.273.6.G1174; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Kirchgessner AL, 1999, NEURON, V24, P941, DOI 10.1016/S0896-6273(00)81041-7; LABURTHE M, 1978, P NATL ACAD SCI USA, V75, P2772, DOI 10.1073/pnas.75.6.2772; Langmead CJ, 2004, BRIT J PHARMACOL, V141, P340, DOI 10.1038/sj.bjp.0705610; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Liu JJ, 2002, CARCINOGENESIS, V23, P2087, DOI 10.1093/carcin/23.12.2087; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Lund PE, 2000, J BIOL CHEM, V275, P30806, DOI 10.1074/jbc.M002603200; MAORET JJ, 1994, BIOCHEM BIOPH RES CO, V203, P465, DOI 10.1006/bbrc.1994.2205; Maoret JJ, 1999, INT J CANCER, V80, P448, DOI 10.1002/(SICI)1097-0215(19990129)80:3<448::AID-IJC19>3.0.CO;2-N; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; MURGIA M, 1992, J BIOL CHEM, V267, P10939; Neunlist M, 2003, AM J PHYSIOL-GASTR L, V285, pG1028, DOI 10.1152/ajpgi.00066.2003; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; Okumura T, 2001, BIOCHEM BIOPH RES CO, V280, P976, DOI 10.1006/bbrc.2001.4235; Overeem S, 2002, CURR OPIN NEUROL, V15, P739, DOI 10.1097/00019052-200212000-00013; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Reinmuth N, 2002, LAB INVEST, V82, P1377, DOI 10.1097/01.LAB.0000032411.41603.C2; Remondino A, 2003, CIRC RES, V92, P136, DOI 10.1161/01.RES.0000054624.03539.B4; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Roberts RB, 2002, P NATL ACAD SCI USA, V99, P1521, DOI 10.1073/pnas.032678499; Rovere C, 1998, BIOCHEM BIOPH RES CO, V246, P155, DOI 10.1006/bbrc.1998.8506; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SALOMON R, 1993, AM J PHYSIOL, V264, pE294, DOI 10.1152/ajpendo.1993.264.2.E294; Smart D, 1999, BRIT J PHARMACOL, V128, P1, DOI 10.1038/sj.bjp.0702780; St Pierre DH, 2003, NEWS PHYSIOL SCI, V18, P242; Teijeiro R, 2002, CELL PHYSIOL BIOCHEM, V12, P31, DOI 10.1159/000047824; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; Voisin T, 2000, J PHARMACOL EXP THER, V292, P638; Voisin T, 2003, CELL MOL LIFE SCI, V60, P72, DOI 10.1007/s000180300005; Wieland HA, 2002, EUR J BIOCHEM, V269, P1128, DOI 10.1046/j.0014-2956.2001.02739.x; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	55	83	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45875	45886		10.1074/jbc.M404136200	http://dx.doi.org/10.1074/jbc.M404136200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15310763	hybrid			2022-12-25	WOS:000224694900072
J	Lee, MH; Rapti, M; Murphy, G				Lee, MH; Rapti, M; Murphy, G			Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; ACTIVE DOMAIN; TIMP-1; EPITOPES; (TIMP)-3; FAMILY; TACE	Tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE, ADAM-17) is a zinc-dependent ADAM ((a) under bar (d) under bar isintegrin (a) under bar nd (m) under bar etalloproteinase) metalloproteinase (MP) of the metzincin superfamily. The enzyme regulates the shedding of a variety of cell surface-anchored molecules such as cytokines, growth factors, and receptors. The activities of the MPs are modulated by the endogenous inhibitors, the tissue inhibitor of metalloproteinases (TIMPs). Among the four mammalian TIMPs (TIMP-1 to -4), TACE is selectively inhibited by TIMP-3. The rationale for such selectivity is not fully understood. Here, we examine the molecular basis of TIMP-TACE selectivity using TIMP-2 as the scaffold. By systematically replacing the surface epitopes of TIMP-2 with those of TIMP-3 and a TIMP-1 variant V4S/TIMP-3 AB-loop/V69L/T98L, we created a novel TIMP-2 mutant that exhibits inhibitory potency almost equal to that of the TIMP-3. The affinity of the mutant with TACE is 1.49 nM, a marked improvement in comparison to that of the wild-type protein (K-i 893 nM). The inhibitory pattern of the mutant is typical of that of a slow, tight binding inhibitor. We identify phenylalanine 34, a residue unique to the TIMP-3 AB-loop, as a vital element in TACE association. Mutagenesis carried out on leucine 100 also upholds our previous findings that a leucine on the EF-loop is critical for TACE recognition. Replacement of the residue by other amino acids resulted in a dramatic decrease in binding affinity, although isoleucine (L100I) and methionine (L100M) are still capable of producing the slow, tight binding effect. Our findings here represent a significant advance toward designing tailor-made TIMPs for specific MP targeting.	Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England	University of Cambridge	Murphy, G (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.	gm290@cam.ac.uk						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Kang TB, 2002, J BIOL CHEM, V277, P48514, DOI 10.1074/jbc.M208961200; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; Lee MH, 2004, J BIOL CHEM, V279, P17562, DOI 10.1074/jbc.M312589200; Lee MH, 2003, J BIOL CHEM, V278, P40224, DOI 10.1074/jbc.M305678200; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Maskos K, 2003, MOL BIOTECHNOL, V25, P241, DOI 10.1385/MB:25:3:241; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; Nagase H, 1999, ANN NY ACAD SCI, V878, P1, DOI 10.1111/j.1749-6632.1999.tb07670.x; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stracke JO, 2000, J BIOL CHEM, V275, P14809, DOI 10.1074/jbc.275.20.14809; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200; Williamson RA, 1996, EUR J BIOCHEM, V241, P476, DOI 10.1111/j.1432-1033.1996.00476.x; Zou J, 2004, J BIOL CHEM, V279, P9818, DOI 10.1074/jbc.M309696200	27	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45121	45129		10.1074/jbc.M406611200	http://dx.doi.org/10.1074/jbc.M406611200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308656	hybrid			2022-12-25	WOS:000224505600105
J	Miyazaki, T; Shen, M; Fujikura, D; Tosa, N; Kim, HR; Kon, S; Uede, T; Reed, JC				Miyazaki, T; Shen, M; Fujikura, D; Tosa, N; Kim, HR; Kon, S; Uede, T; Reed, JC			Functional role of death-associated protein 3 (DAP3) in anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL-DEATH; APOPTOSIS; SURVIVAL; PATHWAY; MEDIATOR; IDENTIFICATION; MITOCHONDRIA; INTEGRINS; RECEPTORS; CANCER	Detachment of adherent epithelial cells from the extracellular matrix induces apoptosis, known as anoikis. Integrin stimulation protects cells from anoikis, but the responsible mechanisms are not well known. Here, we demonstrated that a pro-apoptotic GTP-binding protein, DAP3 (death-associated protein 3), is critical for induction of anoikis. Down-regulation of DAP3 expression by antisense oligonucleotides inhibited anoikis. Conversely, overexpression of DAP3 augmented cell death and caspase activation induced by cell detachment. Furthermore, the association of DAP3 with FADD and the activation of caspase-8 were induced by cell detachment. We also showed that DAP3 is phosphorylated by kinase Akt (PKB), and active Akt can nullify apoptosis induction by DAP3. Mutation of a consensus Akt phosphorylation site in DAP3 renders it resistant to suppression by active Akt in cells. Integrin ligation stimulates Akt activation and phosphorylation of DAP3 in intact cells, as well as suppresses the ability of DAP3 overexpression to augment anoikis. Involvement of DAP3 in anoikis signaling demonstrates a novel role for this GTP-binding protein in apoptosis induction caused by cell detachment.	Burnham Inst, La Jolla, CA 92037 USA; Hokkaido Univ, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Sanford Burnham Prebys Medical Discovery Institute; Hokkaido University	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org	Miyazaki, Tadaaki/D-9368-2012; Tosa, Noriko/E-1602-2012; Kon, Shigeyuki/A-3809-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061694] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-61694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Berger T, 2000, J CELL SCI, V113, P3603; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Lawlor MA, 2001, J CELL SCI, V114, P2903; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Miyazaki T, 2002, NAT IMMUNOL, V3, P4, DOI 10.1038/ni0102-4; Miyazaki T, 2001, NAT IMMUNOL, V2, P493, DOI 10.1038/88684; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morgan CJ, 2001, BIOCHEM BIOPH RES CO, V280, P177, DOI 10.1006/bbrc.2000.4119; Mukamel Z, 2004, J BIOL CHEM, V279, P36732, DOI 10.1074/jbc.M400041200; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Suzuki T, 2001, J BIOL CHEM, V276, P33181, DOI 10.1074/jbc.M103236200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553	32	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44667	44672		10.1074/jbc.M408101200	http://dx.doi.org/10.1074/jbc.M408101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302871	hybrid			2022-12-25	WOS:000224505600053
J	Leu, SJ; Chen, NY; Chen, CC; Todorovic, V; Bai, T; Juric, V; Liu, Y; Yan, GQ; Lam, SCT; Lau, LF				Leu, SJ; Chen, NY; Chen, CC; Todorovic, V; Bai, T; Juric, V; Liu, Y; Yan, GQ; Lam, SCT; Lau, LF			Targeted mutagenesis of the angiogenic protein CCN1 (CYR61) - Selective inactivation of integrin alpha(6)beta(1)-heparan sulfate proteoglycan coreceptor-mediated cellular functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; VEIN ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; MATRICELLULAR PROTEINS; TERMINAL DOMAIN; BINDING-SITE; ADHESION; PRODUCT	The matricellular protein CCN1 (CYR61) regulates multiple cellular processes and plays essential roles in embryonic vascular development. A ligand of several integrin receptors, CCN1 acts through integrin alpha(6)beta(1) and heparan sulfate proteoglycans (HSPGs) to promote specific functions in fibroblasts, smooth muscle cells, and endothelial cells. We have previously identified a novel alpha(6)beta(1) binding site, T1, in domain III of CCN1. Here we uncover two novel 16-residue sequences, H1 and H2, in domain IV that can support alpha(6)beta(1)- and HSPGs-dependent cell adhesion, suggesting that these sequences contain closely juxtaposed or overlapping sites for interaction with alpha(6)beta(1) and HSPGs. Furthermore, fibroblast adhesion to the H1 and H2 peptides is sufficient to induce prolonged MAPK activation, whereas adhesion to T1 induces transient MAPK activation. To dissect the roles of these sites in CCN1 function, we have created mutants disrupted in T1, H1, and H2 or in all three sites in the context of full-length CCN1. We show that the T1 and H1/H2 sites are functionally non-equivalent, and disruption of these sites differentially affected cell adhesion, migration, mitogen-activated protein kinase activation, and regulation of gene expression. Disruption of all three sites completely abolished alpha(6)beta(1)- HSPG-mediated cellular activities. All mutants disrupting T1, H1, and H2 fully retain alpha(v)beta(3)-mediated pro-angiogenic activities, indicating that these mutants are biologically active and are defective only in alpha(6)beta(1)- HSPG-mediated functions. Together, these findings identify and dissect the differential roles of the three sites (T1, H1, H2) required for alpha(6)beta(1)- HSPG-dependent CCN1 activities and provide a strategy to investigate these alpha(6)beta(1)-HSPG-specific activities in vivo.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Todorovic, Viktor/0000-0002-1428-6973; Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041793, R01HL041793] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA046565-16, CA46565, CA80080, R01 CA046565] Funding Source: Medline; NHLBI NIH HHS [HL41793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Armstrong LC, 2003, MATRIX BIOL, V22, P63, DOI 10.1016/S0945-053X(03)00005-2; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Ball DK, 1998, BIOL REPROD, V59, P828, DOI 10.1095/biolreprod59.4.828; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Calzada MJ, 2003, J BIOL CHEM, V278, P40679, DOI 10.1074/jbc.M302014200; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2004, J BIOL CHEM, V279, P44166, DOI 10.1074/jbc.M406813200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Fataccioli V, 2002, HUM GENE THER, V13, P1461, DOI 10.1089/10430340260185094; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; Hurvitz JR, 1999, NAT GENET, V23, P94, DOI 10.1038/12699; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Ivkovic S, 2003, DEVELOPMENT, V130, P2779, DOI 10.1242/dev.00505; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Jones DT, 2001, PROTEINS, P127; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; KOSKINEN P, 1990, ONCOGENE, V5, P615; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Mostafavi-Pour Z, 2003, J CELL BIOL, V161, P155, DOI 10.1083/jcb.200210176; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; Schober JM, 2003, J BIOL CHEM, V278, P25808, DOI 10.1074/jbc.M301534200; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; SONNENBERG A, 1990, J CELL SCI, V96, P207; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Wu KJ, 2000, INT J MOL MED, V6, P433; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	53	58	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44177	44187		10.1074/jbc.M407850200	http://dx.doi.org/10.1074/jbc.M407850200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15322081	hybrid			2022-12-25	WOS:000224383100097
J	Taylor, LM; James, A; Schuller, CE; Brce, J; Lock, RB; MacKenzie, KL				Taylor, LM; James, A; Schuller, CE; Brce, J; Lock, RB; MacKenzie, KL			Inactivation of p16(INK4 alpha), with retention of pRB and p53/p21(cip1) function, in human MRC5 fibroblasts that overcome a telomere-independent crisis during immortalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; CYCLIN-DEPENDENT KINASES; LIFE-SPAN; HUMAN-CELLS; SENESCENCE; EXPRESSION; RAS; GROWTH; P53; P16(INK4A)	Recent investigations, including our own, have shown that specific strains of fibroblasts expressing telomerase reverse transcriptase ( hTERT) have an extended lifespan, but are not immortal. We previously demonstrated that hTERT-transduced MRC5 fetal lung fibroblasts (MRC5hTERTs) bypassed senescence but eventually succumbed to a second mortality barrier ( crisis). In the present study, 67 MRC5hTERT clones were established by limiting dilution of a mass culture. Whereas 39/67 clones had an extended lifespan, all 39 extended lifespan clones underwent crisis. 11 of 39 clones escaped crisis and were immortalized. There was no apparent relationship between the fate of clones at crisis and the level of telomerase activity. Telomeres were hyperextended in the majority of the clones analyzed. There was no difference in telomere length of pre-crisis compared with post-crisis and immortal clones, indicating that hyperextended telomeres were conducive for immortalization and confirming that crisis was independent of telomere length. Immortalization of MRC5hTERT cells was associated with repression of the cyclin-dependent kinase inhibitor p16(INK4a) and up-regulation of pRB. However, the regulation of pRB phosphorylation and the response of the p53/p21(cip1/waf1) pathway were normal in immortal cells subject to genotoxic stress. Overexpression of oncogenic ras failed to de-repress p16(INK4a) in immortal cells. Furthermore, expression of ras enforced senescent-like growth arrest in p16(INK4a)-positive, but not p16(INK4a)-negative MRC5hTERT cells. Immortal cells expressing ras formed small, infrequent colonies in soft agarose, but were non-tumorigenic. Overall, these results implicate the inactivation of p16(INK4a) as a critical event for overcoming telomere-independent crisis, immortalizing MRC5 fibroblasts and overcoming ras-induced premature senescence.	Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia	Children's Cancer Institute	MacKenzie, KL (corresponding author), Childrens Canc Inst Australia Med Res, POB 81,High St, Randwick, NSW 2031, Australia.	k.mackenzie@unsw.edu.au	Mackenzie, Karen/F-1310-2011; Lock, Richard/G-4253-2013; MacKenzie, Karen/N-5849-2019	Lock, Richard/0000-0002-3436-9071; James, Alexander/0000-0001-8523-0857; MacKenzie, Karen/0000-0003-2996-1617				Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOND JA, 1994, ONCOGENE, V9, P1885; Bond JA, 1999, MOL CELL BIOL, V19, P3103; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolnikov A, 2003, CANCER GENE THER, V10, P745, DOI 10.1038/sj.cgt.7700603; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; EINHWALD JG, 2002, MOL CELL BIOL, V22, P5157; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; Gorbunova V, 2003, J BIOL CHEM, V278, P7692, DOI 10.1074/jbc.M212944200; Gu XL, 2003, INVEST OPHTH VIS SCI, V44, P3219, DOI 10.1167/ivos.02-0852; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaul SC, 2003, EXP CELL RES, V286, P96, DOI 10.1016/S0014-4827(03)00101-0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; LI Y, 1994, CANCER RES, V54, P6078; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Milyavsky M, 2003, CANCER RES, V63, P7147; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Stein GH, 1999, MOL CELL BIOL, V19, P2109; TAHARA H, 1995, ONCOGENE, V10, P835; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wei S, 1999, CANCER RES, V59, P1539; Wei WY, 2003, MOL CELL BIOL, V23, P2859, DOI 10.1128/MCB.23.8.2859-2870.2003; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	58	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43634	43645		10.1074/jbc.M402388200	http://dx.doi.org/10.1074/jbc.M402388200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308640	hybrid			2022-12-25	WOS:000224383100036
J	Adachi, K; Toyota, M; Sasaki, Y; Yamashita, T; Ishida, S; Ohe-Toyota, M; Maruyama, R; Hinoda, Y; Saito, T; Imai, K; Kudo, R; Tokino, T				Adachi, K; Toyota, M; Sasaki, Y; Yamashita, T; Ishida, S; Ohe-Toyota, M; Maruyama, R; Hinoda, Y; Saito, T; Imai, K; Kudo, R; Tokino, T			Identification of SCN3B as a novel p53-inducible proapoptotic gene	ONCOGENE			English	Article						p53; SCN3B; apoptosis; ER	ADENOVIRUS-MEDIATED TRANSFER; KINASE C-ABL; DNA-DAMAGE; ENDOPLASMIC-RETICULUM; APOPTOTIC RESPONSE; SODIUM-CHANNELS; DIRECT TARGET; CANCER-CELLS; P53; P73	Tumor suppressor p53 is a transcription factor that induces growth arrest and/or apoptosis in response to cellular stress. To identify novel p53-inducible genes, we compared the expression of genes in normal mouse embryo fibroblasts (MEFs) to p53-null cells by cDNA representational difference analysis. We report here that expression of endogenous sodium channel subunit beta 3 (SCN3B) is upregulated in mouse embryonic fibroblasts by DNA damage in a p53-dependent manner. In addition, we found that SCN3B levels are upregulated in human cancer cell lines by DNA damaging agents, as well as by overexpression of p53, but not significantly by p63 or p73. Furthermore, we identified two putative p53-binding sites upstream of the first exon (RE1) and in the third intron (RE2). The p53 protein can directly interact with the putative p53-binding sites in vivo, as assessed by chromatin immunoprecipitation. A reporter gene assay revealed that these two p53-binding sites are functional response elements. The SCN3B protein appears to be localized to the endoplasmic reticulum (ER). Introduction of the SCN3B gene into T98G and Saos2 cells potently suppressed colony formation. Furthermore, we found that adenovirus-mediated transfer of SCN3B induced apoptosis when combined with anticancer agents. The results presented here suggest that SCN3B mediates a p53-dependent apoptotic pathway and may be a candidate for gene therapy combined with anticancer drugs.	Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, Sapporo, Hokkaido 0608556, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Sch Med, Dept Obstet & Gynecol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Yamaguchi Univ, Sch Med, Div Clin Lab, Ube, Yamaguchi 7558505, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Yamaguchi University	Tokino, T (corresponding author), Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Mol Biol,Chuo Ku, S-1,W-17, Sapporo, Hokkaido 0608556, Japan.	tokino@sapmed.ac.jp	Tokino, Takashi/AAI-9887-2021; Sasaki, Yasushi/AAA-3079-2019	Sasaki, Yasushi/0000-0002-3500-8059				Agami R, 1999, NATURE, V399, P809; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Gong JG, 1999, NATURE, V399, P806; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; MIYASHITA T, 1995, CELL, V80, P293; Morgan K, 2000, P NATL ACAD SCI USA, V97, P2308, DOI 10.1073/pnas.030362197; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, CANCER LETT, V94, P1, DOI 10.1016/0304-3835(95)03834-J; Sasaki Y, 2000, J CLIN LAB ANAL, V14, P314, DOI 10.1002/1098-2825(20001212)14:6<314::AID-JCLA11>3.0.CO;2-O; Sasaki Y, 2003, CANCER RES, V63, P8145; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sasaki Y, 2001, GENE THER, V8, P1401, DOI 10.1038/sj.gt.3301538; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	29	51	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7791	7798		10.1038/sj.onc.1208067	http://dx.doi.org/10.1038/sj.onc.1208067			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334053				2022-12-25	WOS:000224331600005
J	Bambou, JC; Giraud, A; Menard, S; Begue, B; Rakotobe, S; Heyman, M; Taddei, FO; Cerf-Bensussan, N; Gaboriau-Routhiau, V				Bambou, JC; Giraud, A; Menard, S; Begue, B; Rakotobe, S; Heyman, M; Taddei, FO; Cerf-Bensussan, N; Gaboriau-Routhiau, V			In vitro and ex vivo activation of the TLR5 signaling pathway in intestinal epithelial cells by a commensal Escherichia coli strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTOR-4; INNATE IMMUNE-RESPONSE; REGULATED EXPRESSION; BACTERIAL FLAGELLIN; GENE-EXPRESSION; LIPOPOLYSACCHARIDE; KC; INTERLEUKIN-8; INFECTION	The capacity of non-pathogenic enteric bacteria to induce a pro-inflammatory response is under debate in terms of its effect on the symbiosis between the mammalian host and its commensal gut microflora. Activation of NF-kappaB and induction of interleukin-8 (IL-8) and CCL-20 by the commensal Escherichia coli strain MG1655 were first studied in vitro in the human intestinal epithelial cell (IECs) lines HT29-19A and Caco-2, transfected or not with plasmids encoding dominant negative Toll-like receptor (TLR) 5 and myeloid differentiation factor-88 (MyD88) adaptor protein. The response of enterocytes in situ was then assessed using murine ileal biopsies mounted in Ussing chambers. Commensal E. coli induced NF-kappaB DNA binding, NF-kappaB transcriptional activity, CCL-20 expression, and IL-8 secretion in the human IEC lines. E. coli MG1655 flagellin was necessary and sufficient to trigger this pro-inflammatory pathway via its interaction with TLR5 and the subsequent recruitment of the adaptor protein MyD88. Following epithelial cell polarization, signaling could be induced by live E. coli and flagellin on the apical side of HT29-19A. The in vivo relevance of our findings was confirmed, because immunohistochemical staining of murine ileum demonstrated expression of TLR5 in the apical part of enterocytes in situ. Furthermore, flagellin added on the mucosal side of murine ileal biopsies mounted in Ussing chambers induced a basolateral production of KC, a functional murine homolog of human IL-8. These findings provide strong evidence that flagellin released by flagellated commensal bacteria in the intestinal lumen can induce a pro-inflammatory response in enterocytes in vivo.	Fac Necker Enfants Malad, INSERM, EMI 0212, F-75015 Paris, France; Fac Necker Enfants Malad, INSERM, U571, F-75015 Paris, France; INRA, Unite Ecol & Physiol Syst Digest, F-78350 Jouy En Josas, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Gaboriau-Routhiau, V (corresponding author), Fac Necker Enfants Malad, INSERM, EMI 0212, 156 Rue Vaugirard, F-75015 Paris, France.	gaboriau@necker.fr	Giraud, Antoine/V-5368-2018; Cerf-Bensussan, nadine/H-9505-2017; Begue, Bernadette/I-2744-2017; GABORIAU-ROUTHIAU, Valérie/H-9493-2017; Menard, Sandrine/ABF-8935-2021; RAKOTOBE, Sabine/H-9535-2017	Giraud, Antoine/0000-0002-8559-5781; Cerf-Bensussan, nadine/0000-0003-0665-1245; Begue, Bernadette/0000-0002-1228-9978; GABORIAU-ROUTHIAU, Valérie/0000-0002-7662-4034; Menard, Sandrine/0000-0001-8867-199X; RAKOTOBE, Sabine/0000-0001-7622-755X; Taddei, Francois/0000-0002-7894-0647				Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Berin MC, 2002, CELL MICROBIOL, V4, P635, DOI 10.1046/j.1462-5822.2002.00218.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Elewaut D, 1999, J IMMUNOL, V163, P1457; FIERER J, 1993, INFECT AGENT DIS, V2, P255; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Haller D, 2003, J BIOL CHEM, V278, P23851, DOI 10.1074/jbc.M300075200; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hecht G, 1999, AM J PHYSIOL-CELL PH, V277, pC351, DOI 10.1152/ajpcell.1999.277.3.C351; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hornef MW, 2003, J EXP MED, V198, P1225, DOI 10.1084/jem.20022194; Huang GTJ, 1996, J CLIN INVEST, V98, P572, DOI 10.1172/JCI118825; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Matysiak-Budnik T, 2003, GASTROENTEROLOGY, V125, P696, DOI 10.1016/S0016-5085(03)01049-7; MUNOZ E, 1994, J VIROL, V68, P8035; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; OHMORI Y, 1995, J IMMUNOL, V155, P3593; OHMORI Y, 1994, J IMMUNOL, V153, P2204; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598; Smith KD, 2004, NAT IMMUNOL, V5, P451, DOI 10.1038/ni0404-451; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Song F, 1999, J IMMUNOL, V162, P2275; Strober W, 1998, ANN NY ACAD SCI, V859, P37, DOI 10.1111/j.1749-6632.1998.tb11109.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Witthoft T, 1998, AM J PHYSIOL-GASTR L, V275, pG564, DOI 10.1152/ajpgi.1998.275.3.G564; Zeng H, 2003, J IMMUNOL, V171, P3668, DOI 10.4049/jimmunol.171.7.3668; Zhou X, 2003, INFECT IMMUN, V71, P2120, DOI 10.1128/IAI.71.4.2120-2129.2003	41	157	165	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42984	42992		10.1074/jbc.M405410200	http://dx.doi.org/10.1074/jbc.M405410200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302888	hybrid, Green Published			2022-12-25	WOS:000224226400079
J	Poulsen, N; Kroger, N				Poulsen, N; Kroger, N			Silica morphogenesis by alternative processing of silaffins in the diatom Thalassiosira pseudonana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE-SEPARATION; BIOSILICA; POLYAMINES; PEPTIDES; PROTEINS	For almost 200 years scientists have been fascinated by the ornate cell walls of the diatoms. These structures are made of amorphous silica, exhibiting species-specific, mostly porous patterns in the nano- to micrometer range. Recently, from the diatom Cylindrotheca fusiformis unusual phosphoproteins ( termed silaffins) and long chain polyamines have been identified and implicated in biosilica formation. However, analysis of the role of silaffins in morphogenesis of species-specific silica structures has so far been hampered by the difficulty of obtaining structural data from these extremely complex proteins. In the present study, the five major silaffins from the diatom Thalassiosira pseudonana (tpSil1H, - 1L, - 2H, - 2L, and - 3) have been isolated, functionally analyzed, and structurally characterized, making use of the recently available genome data from this organism. Surprisingly, the silaffins of T. pseudonana and C. fusiformis share no sequence homology but are similar regarding amino acid composition and posttranslational modifications. Silaffins tpSil1H and - 2H are higher molecular mass isoforms of tpSil1L and - 2L, respectively, generated in vivo by alternative processing of the same precursor polypeptides. Interestingly, only tpSil1H and - 2H but not tpSil1L and - 2L induce the formation of porous silica patterns in vitro, suggesting that the alternative processing event is an important step in morphogenesis of T. pseudonana biosilica.	Univ Regensburg, Lehrstuhl Biochem 1, D-93053 Regensburg, Germany	University of Regensburg	Kroger, N (corresponding author), Univ Regensburg, Lehrstuhl Biochem 1, Univ Str 31, D-93053 Regensburg, Germany.	nils.kroeger@vkl.uni-regensburg.de		Poulsen, Nicole/0000-0002-4533-8860				Bauerlein E, 2000, BIOMINERALIZATION BI; Brunner E, 2004, PHYS CHEM CHEM PHYS, V6, P854, DOI 10.1039/b313261g; BUSS JE, 1983, METHOD ENZYMOL, V99, P7; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; El-Ashry ESH, 2003, CARBOHYD RES, V338, P2265, DOI 10.1016/j.carres.2003.09.002; Fischer H, 1999, J PHYCOL, V35, P113, DOI 10.1046/j.1529-8817.1999.3510113.x; FLEET GWJ, 1988, TETRAHEDRON, V44, P2637, DOI 10.1016/S0040-4020(01)81716-6; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2000, P NATL ACAD SCI USA, V97, P14133, DOI 10.1073/pnas.260496497; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Menzel H, 2003, CHEM COMMUN, P2994, DOI 10.1039/b310201g; Mizutani T, 1998, B CHEM SOC JPN, V71, P2017, DOI 10.1246/bcsj.71.2017; NAKAJIMA T, 1969, SCIENCE, V164, P1400, DOI 10.1126/science.164.3886.1400; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Patwardhan SV, 2001, J INORG ORGANOMET P, V11, P193, DOI 10.1023/A:1015293712319; Poulsen N, 2003, P NATL ACAD SCI USA, V100, P12075, DOI 10.1073/pnas.2035131100; Rodriguez F, 2004, BIOMACROMOLECULES, V5, P261, DOI 10.1021/bm034232c; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIMPSON TL, 1981, SILICON SILICEOUS ST; Sumper M, 2002, SCIENCE, V295, P2430, DOI 10.1126/science.1070026; Sumper M, 2004, J MATER CHEM, V14, P2059, DOI 10.1039/b401028k; Sumper M, 2003, ANGEW CHEM INT EDIT, V42, P5192, DOI 10.1002/anie.200352212; TERHO TT, 1971, ANAL BIOCHEM, V41, P471, DOI 10.1016/0003-2697(71)90167-9; Weir CA, 1999, J ORG CHEM, V64, P1554, DOI 10.1021/jo982009d	25	176	184	7	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42993	42999		10.1074/jbc.M407734200	http://dx.doi.org/10.1074/jbc.M407734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15304518	hybrid			2022-12-25	WOS:000224226400080
J	Chen, CM; Chang, JL; Behringer, RR				Chen, CM; Chang, JL; Behringer, RR			Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts	ONCOGENE			English	Article						ovarian cancer; tumor suppressor; p53; ovary transplantation; hemangiosarcoma	MICE; ANGIOSARCOMA; INDUCTION; SPECTRUM; CANCER; MODEL; GENE	p53 gene alterations correlate highly with advanced ovarian carcinoma in women. In mice, p53 deficiency predominantly results in the formation of lymphomas and sarcomas. However, ovarian epithelial tumors have not been documented in p53 homozygous mutant (p53(-/-)) mice, probably because they die before other tumors can form. To determine whether p53(-/-) ovaries can develop epithelial tumors, they were transplanted into the ovarian bursae of histocompatible wild-type recipient females. The p53(-/-) ovarian grafts formed tumors similar to1 year posttransplantation. The tumor type was angiosarcoma, suggesting that vascular tissues are predisposed to tumor formation in p53(-/-) ovaries. These findings suggest that p53 deficiency alone is not sufficient for ovarian epithelial tumorigenesis in mice. Thus, other genetic lesions are likely required to develop mouse models of human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Armed Forced Taoyuan Gen Hosp, Dept Pathol, Taoyuan, Taiwan	University of Texas System; UTMD Anderson Cancer Center	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rrb@notes.mdacc.tmc.edu		Chen, Chun-Ming/0000-0001-8873-7602	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD030284] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA83639] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; ONCHIT HHS [OC20187] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ONCHIT HHS		Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bast RC, 2000, METH MOLEC MED, V39, P37; Blackburn AC, 2003, CANCER RES, V63, P2364; Chen CM, 2004, GENE DEV, V18, P320, DOI 10.1101/gad.1162204; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jylling A M, 1999, Pathol Oncol Res, V5, P318, DOI 10.1053/paor.1999.0213; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Mohr U., 2001, INT CLASSIFICATION R; Nagy A., 2003, MANIPULATING MOUSE E; Naka N, 1997, INT J CANCER, V71, P952, DOI 10.1002/(SICI)1097-0215(19970611)71:6<952::AID-IJC7>3.3.CO;2-N; Nucci MR, 1998, AM J SURG PATHOL, V22, P620, DOI 10.1097/00000478-199805000-00014; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Platt JS, 1999, GYNECOL ONCOL, V73, P443, DOI 10.1006/gyno.1998.5335; PURDIE CA, 1994, ONCOGENE, V9, P603; Schuijer M, 2003, HUM MUTAT, V21, P285, DOI 10.1002/humu.10181; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TURUSOV V, 1994, IARC SCI PUBLICATION, V111; Venkatachalam Sundaresan, 2002, P247; Zietz C, 1998, AM J PATHOL, V153, P1425, DOI 10.1016/S0002-9440(10)65729-X	22	16	16	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7722	7725		10.1038/sj.onc.1208037	http://dx.doi.org/10.1038/sj.onc.1208037			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334065				2022-12-25	WOS:000224306700013
J	Pandey, M; Patel, S; Gabriel, A				Pandey, M; Patel, S; Gabriel, A			Insights into the role of an active site aspartate in Ty1 reverse transcriptase polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; GDD SEQUENCE MOTIF; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; ACID RESIDUES; IN-VIVO; MECHANISM; MUTATION; MUTAGENESIS; MANGANESE	Long terminal repeat-containing retrotransposons encode reverse transcriptases (RTs) that replicate their RNA into integratable, double-stranded DNA. A mutant version of the RT from Saccharomyces cerevisiae retrotransposon Ty1, in which one of the three active site aspartates has been changed to asparagine (D211N), is still capable of in vitro polymerization, although it is blocked for in vivo transposition. We generated recombinant WT and D211N Ty1 RTs to study RT function and determine specific roles for the Asp(211) residue. Pre-steady-state kinetic analysis of the two enzymes shows that the D211N mutation has minimal effect on nucleotide binding but reduces the k(pol) by similar to230-fold. The mutation reduces binding affinity for both Mn2+ and Mg2+, indicating that the Asp(211) side chain helps create a tight metal binding pocket. Although both enzymes are highly processive and tend to remain bound to their initial substrate, each shows distinctive patterns of pausing, attributable to interactions between metal ions and the active site residue. These results provide insights to specific roles for the Asp(211) residue during polymerization and indicate unusual enzymatic properties that bear on the Ty1 replication pathway.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gabriel, A (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gabriel@cabm.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966, R01GM060534] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60534, GM51966, GM55310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; Bibillo A, 2002, J BIOL CHEM, V277, P34836, DOI 10.1074/jbc.M204345200; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; Bock CW, 1999, J AM CHEM SOC, V121, P7360, DOI 10.1021/ja9906960; Bolton EC, 2002, MOL CELL, V9, P879, DOI 10.1016/S1097-2765(02)00495-1; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dudev T, 2003, J AM CHEM SOC, V125, P3168, DOI 10.1021/ja0209722; GEORGIADIS MM, 1995, STRUCTURE, V3, P879, DOI 10.1016/S0969-2126(01)00223-4; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JABLONSKI SA, 1995, J VIROL, V69, P1532, DOI 10.1128/JVI.69.3.1532-1539.1995; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; Mules EH, 1998, J VIROL, V72, P6490, DOI 10.1128/JVI.72.8.6490-6503.1998; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Peterson-Burch BD, 2002, MOL BIOL EVOL, V19, P1832, DOI 10.1093/oxfordjournals.molbev.a004008; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Sigel H., 1989, ACS SYM SER, V402, P159; Uzun O, 2001, J VIROL, V75, P6337, DOI 10.1128/JVI.75.14.6337-6347.2001; Vazquez AL, 2000, J VIROL, V74, P3888, DOI 10.1128/JVI.74.8.3888-3891.2000; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; Wilhelm M, 2000, BIOCHEM J, V348, P337, DOI 10.1042/0264-6021:3480337; Wrobel JA, 1998, P NATL ACAD SCI USA, V95, P638, DOI 10.1073/pnas.95.2.638; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	38	10	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47840	47848		10.1074/jbc.M406019200	http://dx.doi.org/10.1074/jbc.M406019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15333632	hybrid			2022-12-25	WOS:000224957000053
J	Basset, O; Boittin, FX; Dorchies, OM; Chatton, JY; van Breemen, C; Ruegg, UT				Basset, O; Boittin, FX; Dorchies, OM; Chatton, JY; van Breemen, C; Ruegg, UT			Involvement of inositol 1,4,5-trisphosphate in nicotinic calcium responses in dystrophic myotubes assessed by near-plasma membrane calcium measurement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE CELLS; MDX MOUSE; 2-AMINOETHOXYDIPHENYL BORATE; SARCOPLASMIC-RETICULUM; INSP(3) RECEPTORS; LEAK CHANNELS; CA2+ RELEASE; IN-VIVO; IP3	In skeletal muscle cells, plasma membrane depolarization causes a rapid calcium release from the sarcoplasmic reticulum through ryanodine receptors triggering contraction. In Duchenne muscular dystrophy (DMD), a lethal disease that is caused by the lack of the cytoskeletal protein dystrophin, the cytosolic calcium concentration is known to be increased, and this increase may lead to cell necrosis. Here, we used myotubes derived from control and mdx mice, the murine model of DMD, to study the calcium responses induced by nicotinic acetylcholine receptor stimulation. The photoprotein aequorin was expressed in the cytosol or targeted to the plasma membrane as a fusion protein with the synaptosome-associated protein SNAP-25, thus allowing calcium measurements in a restricted area localized just below the plasma membrane. The carbachol-induced calcium responses were 4.5 times bigger in dystrophic myotubes than in control myotubes. Moreover, in dystrophic myotubes the carbachol-mediated calcium responses measured in the subsarcolemmal area were at least 10 times bigger than in the bulk cytosol. The initial calcium responses were due to calcium influx into the cells followed by a fast refilling/release phase from the sarcoplasmic reticulum. In addition and unexpectedly, the inositol 1,4,5-trisphosphate receptor pathway was involved in these calcium signals only in the dystrophic myotubes. This surprising involvement of this calcium release channel in the excitation-contraction coupling could open new ways for understanding exercise-induced calcium increases and downstream muscle degeneration in mdx mice and, therefore, in DMD.	Univ Lausanne Geneva, Sch Pharm, Pharmacol Lab, CH-1211 Geneva, Switzerland; Univ Lausanne, Dept Physiol, CH-1005 Lausanne, Switzerland; Univ Lausanne, Cellular Imaging Facil, CH-1005 Lausanne, Switzerland; Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1Z1, Canada	University of Geneva; University of Lausanne; University of Lausanne; University of British Columbia	Ruegg, UT (corresponding author), Univ Lausanne Geneva, Sch Pharm, Pharmacol Lab, CH-1211 Geneva, Switzerland.	Urs.Ruegg@pharm.unige.ch	Dorchies, Olivier M/M-8681-2013	Dorchies, Olivier M/0000-0002-6665-7887; RUEGG, Urs/0000-0001-6078-8280; Chatton, Jean-Yves/0000-0002-8911-0315				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; Alvarez J, 2002, CELL CALCIUM, V32, P251, DOI 10.1016/S0143416002001860; Araya R, 2003, J GEN PHYSIOL, V121, P3, DOI 10.1085/jgp.20028671; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Challet C, 2001, J BIOL CHEM, V276, P3791, DOI 10.1074/jbc.M006209200; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; De Luca A, 2003, J PHARMACOL EXP THER, V304, P453, DOI 10.1124/jpet.102.041343; De Smet P, 1999, CELL CALCIUM, V26, P9; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; FABBRIZIO E, 1995, BIOCHEM BIOPH RES CO, V213, P295, DOI 10.1006/bbrc.1995.2129; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; Hou CF, 2004, J PHARMACOL EXP THER, V309, P697, DOI 10.1124/jpet.103.060574; Jaimovich E, 2000, AM J PHYSIOL-CELL PH, V278, pC998, DOI 10.1152/ajpcell.2000.278.5.C998; JANCZEWSKI AM, 1993, AM J PHYSIOL, V265, pH517, DOI 10.1152/ajpheart.1993.265.2.H517; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Launikonis BS, 2003, P NATL ACAD SCI USA, V100, P2941, DOI 10.1073/pnas.0536227100; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; Leijendekker WJ, 1996, BRIT J PHARMACOL, V118, P611, DOI 10.1111/j.1476-5381.1996.tb15445.x; Liberona JL, 1998, MUSCLE NERVE, V21, P902, DOI 10.1002/(SICI)1097-4598(199807)21:7<902::AID-MUS8>3.0.CO;2-A; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Mallouk N, 2000, P NATL ACAD SCI USA, V97, P4950, DOI 10.1073/pnas.97.9.4950; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; McCarter GC, 2000, J MEMBRANE BIOL, V176, P169, DOI 10.1007/s002320001086; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, pS162, DOI 10.1016/S0960-8966(02)00101-3; OBA T, 1992, BIOPHYS J, V63, P1416, DOI 10.1016/S0006-3495(92)81704-6; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; Passaquin AC, 1998, BRIT J PHARMACOL, V124, P1751, DOI 10.1038/sj.bjp.0702036; Peppiatt CM, 2003, CELL CALCIUM, V34, P97, DOI 10.1016/S0143-4160(03)00026-5; Pinset C, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P226; Powell JA, 2001, J CELL SCI, V114, P3673; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Robert V, 2001, J BIOL CHEM, V276, P4647, DOI 10.1074/jbc.M006337200; Ruegg Urs T., 1999, Trends in Pharmacological Sciences, V20, P351, DOI 10.1016/S0165-6147(99)01377-2; SACCO P, 1992, CLIN SCI, V82, P227, DOI 10.1042/cs0820227; Salanova M, 2002, CELL CALCIUM, V32, P193, DOI 10.1016/S0143416002001549; Scriven DRL, 2002, ANN NY ACAD SCI, V976, P488; Talon S, 1999, PFLUG ARCH EUR J PHY, V438, P804, DOI 10.1007/s004240051110; Talon S, 2002, AM J PHYSIOL-REG I, V282, pR1164, DOI 10.1152/ajpregu.00073.2001; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; VERGARA J, 1985, P NATL ACAD SCI USA, V82, P6352, DOI 10.1073/pnas.82.18.6352; Vilquin JT, 1998, MUSCLE NERVE, V21, P567, DOI 10.1002/(SICI)1097-4598(199805)21:5<567::AID-MUS2>3.0.CO;2-6; Yamaguchi N, 1997, BIOCHEM BIOPH RES CO, V240, P772, DOI 10.1006/bbrc.1997.7583	56	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47092	47100		10.1074/jbc.M405054200	http://dx.doi.org/10.1074/jbc.M405054200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322099	hybrid			2022-12-25	WOS:000224832400095
J	Dilova, I; Aronova, S; Chen, JCY; Powers, T				Dilova, I; Aronova, S; Chen, JCY; Powers, T			Tor signaling and nutrient-based signals converge on Mks1p phosphorylation to regulate expression of Rtg1p center dot Rtg3p-dependent target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RTG-DEPENDENT MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; PROTEIN-SYNTHESIS; MASTER REGULATOR; RAPAMYCIN TOR; YEAST; PATHWAY; LOCALIZATION; STARVATION; MECHANISM	The heterodimeric bZip/HLH transcription factors Rtg1p and Rtg3p regulate the expression of a concise set of metabolic genes (termed RTG target genes) required for de novo biosynthesis of glutamate and glutamine. Several components have now been identified that control both the intracellular localization as well as activity of the Rtg1p.Rtg3p complex, yet the precise upstream regulatory signals involved remain unclear. For example, it has been proposed that Rtg1p.Rtg3p activity is repressed by glutamate, acting through the mitochondrial retrograde response pathway or, alternatively, by glutamine, acting through the Tor kinase pathway. Here we demonstrate that RTG target gene regulation is remarkably complex, with glutamate and glutamine as well as ammonia collaborating as potentially distinct signals to regulate RTG target gene expression. We show that both Tor and these nutrient-based signals converge on Mks1p, the immediate upstream inhibitor of Rtg1p.Rtg3p, and that a direct correlation exists between the degree of Mks1p phosphorylation and the extent of RTG target gene repression. Finally, we find that Tor- and glutamine-mediated RTG-target gene repression can be experimentally uncoupled, indicating that glutamine and Tor act, at least in part, independently to inhibit this pathway.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Powers, T (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	tpowers@ucdavis.edu		Chen, CJ/0000-0003-3766-4612				Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Brachmann CB, 1998, YEAST, V14, P115; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guaragnella N, 2003, J BIOL CHEM, V278, P45882, DOI 10.1074/jbc.M309301200; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jia YK, 1997, MOL CELL BIOL, V17, P1110, DOI 10.1128/MCB.17.3.1110; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Liu ZC, 2003, MOL CELL, V12, P401, DOI 10.1016/S1097-2765(03)00285-5; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Rohde JR, 2003, CURR TOP MICROBIOL, V279, P53; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; STRYER L, 1995, BIOCHEMISTRY-US, P505; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; Tate JJ, 2003, J BIOL CHEM, V278, P36924, DOI 10.1074/jbc.M301829200; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	42	67	71	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46527	46535		10.1074/jbc.M409012200	http://dx.doi.org/10.1074/jbc.M409012200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326168	hybrid			2022-12-25	WOS:000224832400024
J	Langdown, J; Johnson, DJD; Baglin, TP; Huntington, JA				Langdown, J; Johnson, DJD; Baglin, TP; Huntington, JA			Allosteric activation of antithrombin critically depends upon hinge region extension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY HEPARIN; ANTICOAGULANT FUNCTION; BASIC RESIDUES; COFACTOR-II; FACTOR XA; MECHANISM; THROMBIN; BINDING; INHIBITION; SERPIN	Antithrombin ( AT) inhibits most of the serine proteases generated in the blood coagulation cascade, but its principal targets are factors IXa, Xa, and thrombin. Heparin binding to AT, via a specific pentasaccharide sequence, alters the conformation of AT in a way that promotes efficient inhibition of factors IXa and Xa, but not of thrombin. The conformational change most likely to be relevant to protease recognition is the expulsion of the N-terminal portion of the reactive center loop ( hinge region) from the main beta-sheet A. Here we investigate the hypothesis that the exosites on the surface of AT are accessible for interaction with a protease only when the hinge region is fully extended, as seen in the related Michaelis complex between heparin cofactor II and thrombin. We engineered a disulfide bond between residues 222 on strand 3A and 381 in the reactive center loop to prevent the extension of the hinge region upon pentasaccharide binding. The disulfide bond did not significantly alter the ability of the variant to bind to heparin or to inhibit thrombin. Although the basal rate of factor Xa inhibition was not affected, that of factor IXa inhibition was reduced to the limit of detection. In addition, the disulfide bond completely abrogated the pentasaccharide accelerated inhibition of factors Xa and IXa. We conclude that AT hinge region extension is the activating conformational change for inhibition of factors IXa and Xa, and propose models for the progressive and activated AT Michaelis complexes with thrombin, factor Xa, and factor IXa.	Univ Cambridge, Thrombosis Res Unit, Div Struct Med, Cambridge Inst Med Res,Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge	Huntington, JA (corresponding author), Univ Cambridge, Thrombosis Res Unit, Div Struct Med, Cambridge Inst Med Res,Dept Haematol, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [R01 HL68629] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068629] Funding Source: NIH RePORTER; MRC [G117/444] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Bedsted T, 2003, BIOCHEMISTRY-US, V42, P8143, DOI 10.1021/bi034363y; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; Garone L, 1996, BIOCHEMISTRY-US, V35, P8881, DOI 10.1021/bi960542m; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; Huntington JA, 2003, J THROMB HAEMOST, V1, P1535, DOI 10.1046/j.1538-7836.2003.00305.x; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Izaguirre G, 2003, J BIOL CHEM, V278, P51433, DOI 10.1074/jbc.M309266200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2004, J BIOL CHEM, V279, P4913, DOI 10.1074/jbc.M311644200; Johnson DJD, 2003, BIOCHEMISTRY-US, V42, P8712, DOI 10.1021/bi034524y; Kojima T, 2002, INT J HEMATOL, V76, P36, DOI 10.1007/BF03165083; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Lindahl U, 1981, BIOCHEM SOC T, V9, P499, DOI 10.1042/bst0090499; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; Mushunje A, 2003, BLOOD, V102, P4028, DOI 10.1182/blood-2003-05-1560; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Riener CK, 2002, ANAL BIOANAL CHEM, V373, P266, DOI 10.1007/s00216-002-1347-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SIE P, 1988, BIOCHIM BIOPHYS ACTA, V966, P188, DOI 10.1016/0304-4165(88)90111-0; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Whisstock JC, 2000, J MOL BIOL, V301, P1287, DOI 10.1006/jmbi.2000.3982; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; Zettlmeissl G, 1988, Behring Inst Mitt, P26	38	26	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47288	47297		10.1074/jbc.M408961200	http://dx.doi.org/10.1074/jbc.M408961200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326167	hybrid			2022-12-25	WOS:000224832400117
J	Pobbati, AV; Razeto, A; Boddener, M; Becker, S; Fasshauer, D				Pobbati, AV; Razeto, A; Boddener, M; Becker, S; Fasshauer, D			Structural basis for the inhibitory role of tomosyn in exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL SNARE COMPLEX; CELL POLARITY; TUMOR SUPPRESSORS; CRYSTAL-STRUCTURE; ELECTRON-DENSITY; PROTEIN; BINDING; FUSION; IDENTIFICATION; DROSOPHILA	Upon Ca2+ influx synaptic vesicles fuse with the plasma membrane and release their neurotransmitter cargo into the synaptic cleft. Key players during this process are the Q-SNAREs syntaxin 1a and SNAP-25 and the R-SNARE synaptobrevin 2. It is thought that these membrane proteins gradually assemble into a tight trans-SNARE complex between vesicular and plasma membrane, ultimately leading to membrane fusion. Tomosyn is a soluble protein of 130 kDa that contains a COOH-terminal R-SNARE motif but lacks a transmembrane anchor. Its R-SNARE motif forms a stable core SNARE complex with syntaxin 1a and SNAP-25. Here we present the crystal structure of this core tomosyn SNARE complex at 2.0-Angstrom resolution. It consists of a four-helical bundle very similar to that of the SNARE complex containing synaptobrevin. Most differences are found on the surface, where they prevented tight binding of complexin. Both complexes form with similar rates as assessed by CD spectroscopy. In addition, synaptobrevin cannot displace the tomosyn helix from the tight complex and vice versa, indicating that both SNARE complexes represent end products. Moreover, data bank searches revealed that the R-SNARE motif of tomosyn is highly conserved throughout all eukaryotic kingdoms. This suggests that the formation of a tight SNARE complex is important for the function of tomosyn.	Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany	Max Planck Society; Max Planck Society	Fasshauer, D (corresponding author), Max Planck Inst Biophys Chem, Dept Neurobiol, Fassberg 11, D-37077 Gottingen, Germany.	dfassha@gwdg.de	Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282				Antonin W, 2002, NAT STRUCT BIOL, V9, P107, DOI 10.1038/nsb746; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bracher A, 2002, J BIOL CHEM, V277, P26517, DOI 10.1074/jbc.M203460200; Chen XC, 2002, NEURON, V33, P397, DOI 10.1016/S0896-6273(02)00583-4; Ernst JA, 2003, J BIOL CHEM, V278, P8630, DOI 10.1074/jbc.M211889200; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 2004, J BIOL CHEM, V279, P7613, DOI 10.1074/jbc.M312064200; Fasshauer D, 2003, BBA-MOL CELL RES, V1641, P87, DOI 10.1016/S0167-4889(03)00090-9; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Hatsuzawa K, 2003, J BIOL CHEM, V278, P31159, DOI 10.1074/jbc.M305500200; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Justice NJ, 2003, NAT CELL BIOL, V5, P273, DOI 10.1038/ncb0403-273; Kagami M, 1998, GENETICS, V149, P1717; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kraut R, 2001, CURR BIOL, V11, P417, DOI 10.1016/S0960-9822(01)00124-5; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Sakisaka T, 2004, J CELL BIOL, V166, P17, DOI 10.1083/jcb.200405002; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Wadskog I, 2004, MOL BIOL CELL, V15, P1436, DOI 10.1091/mbc.E03-02-0114; Widberg CH, 2003, J BIOL CHEM, V278, P35093, DOI 10.1074/jbc.M304261200; Winn MD, 2002, ACTA CRYSTALLOGR D, V58, P1929, DOI 10.1107/S0907444902016116; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yizhar O, 2004, P NATL ACAD SCI USA, V101, P2578, DOI 10.1073/pnas.0308700100; Yokoyama S, 1999, BIOCHEM BIOPH RES CO, V256, P218, DOI 10.1006/bbrc.1999.0300	52	77	85	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47192	47200		10.1074/jbc.M408767200	http://dx.doi.org/10.1074/jbc.M408767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316007	hybrid, Green Published			2022-12-25	WOS:000224832400107
J	Stinnett, LG; Smiley, RD; Hicks, SN; Howell, EE				Stinnett, LG; Smiley, RD; Hicks, SN; Howell, EE			"Catch 222," the effects of symmetry on ligand binding and catalysis in R67 dihydrofolate reductase as determined by mutations at Tyr-69	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE PORE; R-PLASMID R67; ESCHERICHIA-COLI; TERNARY COMPLEX; PROTEIN; INHIBITION; TITRATION; GENE; PH; VITRONECTIN	R67 dihydrofolate reductase (R67 DHFR) catalyzes the transfer of a hydride ion from NADPH to dihydrofolate, generating tetrahydrofolate. The homotetrameric enzyme provides a unique environment for catalysis as both ligands bind within a single active site pore possessing 222 symmetry. Mutation of one active site residue results in concurrent mutation of three additional symmetry-related residues, causing large effects on binding of both ligands as well as catalysis. For example, mutation of symmetry-related tyrosine 69 residues to phenylalanine (Y69F), results in large increases in K-m values for both ligands and a 2-fold rise in the k(cat) value for the reaction (Strader, M. B., Smiley, R. D., Stinnett, L. G., VerBerkmoes, N. C., and Howell, E. E. ( 2001) Biochemistry 40, 11344-11352). To understand the interactions between specific Tyr-69 residues and each ligand, asymmetric Y69F mutants were generated that contain one to four Y69F mutations. A general trend observed from isothermal titration calorimetry and steady-state kinetic studies of these asymmetric mutants is that increasing the number of Y69F mutations results in an increase in the K-d and K-m values. In addition, a comparison of steady-state kinetic values suggests that two Tyr-69 residues in one half of the active site pore are necessary for NADPH to exhibit a wild-type K-m value. A tyrosine 69 to leucine mutant was also generated to approach the type(s) of interaction( s) occurring between Tyr-69 residues and the ligands. These studies suggest that the hydroxyl group of Tyr-69 is important for interactions with NADPH, whereas both the hydroxyl group and hydrophobic ring atoms of the Tyr-69 residues are necessary for proper interactions with dihydrofolate.	Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Howell, EE (corresponding author), Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA.	lzh@utk.edu		Howell, Elizabeth/0000-0001-6157-433X				ABUKHALED M, 1985, BIOCHEM BIOPH RES CO, V130, P1273, DOI 10.1016/0006-291X(85)91752-8; Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; Bradrick TD, 1996, J BIOL CHEM, V271, P28031, DOI 10.1074/jbc.271.45.28031; Brewer CF, 2002, CURR OPIN STRUC BIOL, V12, P616, DOI 10.1016/S0959-440X(02)00364-0; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P1461, DOI 10.1021/bi00220a003; BRITO RMM, 1990, BIOCHEMISTRY-US, V29, P9825, DOI 10.1021/bi00494a011; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Clark ED, 1999, METHOD ENZYMOL, V309, P217; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FERSHT A, 1999, STRUCTURE MECH PROTE, P101; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; Hicks SN, 2004, J BIOL CHEM, V279, P46995, DOI 10.1074/jbc.M404484200; Hicks SN, 2003, BIOCHEMISTRY-US, V42, P10569, DOI 10.1021/bi034643d; Howell EE, 2001, J COMPUT AID MOL DES, V15, P1035, DOI 10.1023/A:1014824725891; Javaud C, 2003, GENETICA, V118, P157, DOI 10.1023/A:1024101625214; Kitov PI, 2003, J AM CHEM SOC, V125, P16271, DOI 10.1021/ja038223n; Kortt AA, 2001, BIOMOL ENG, V18, P95, DOI 10.1016/S1389-0344(01)00090-9; KRAUT J, 1987, BIOL MACROMOL ASSEM, V3, P1; Lazcano A, 1995, Adv Space Res, V15, P345, DOI 10.1016/S0273-1177(99)80106-9; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Li DW, 2001, BIOCHEMISTRY-US, V40, P4242, DOI 10.1021/bi0026425; Loidl G, 1999, P NATL ACAD SCI USA, V96, P5418, DOI 10.1073/pnas.96.10.5418; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; O'Brien PJ, 1999, CHEM BIOL, V6, pR91, DOI 10.1016/S1074-5521(99)80033-7; Park H, 1997, PROTEIN ENG, V10, P1415, DOI 10.1093/protein/10.12.1415; Park HY, 1997, J BIOL CHEM, V272, P2252; Pitcher WH, 2003, BIOCHEMISTRY-US, V42, P11150, DOI 10.1021/bi0349874; POE M, 1973, J BIOL CHEM, V248, P7025; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; Smiley RD, 2002, BIOCHEMISTRY-US, V41, P15664, DOI 10.1021/bi026676j; Sridhar J, 2003, J MED CHEM, V46, P4196, DOI 10.1021/jm0302041; STONE D, 1979, J BIOL CHEM, V254, P857; Strader MB, 2004, BIOCHEMISTRY-US, V43, P7403, DOI 10.1021/bi049646k; Strader MB, 2001, BIOCHEMISTRY-US, V40, P11344, DOI 10.1021/bi0110544; STRADER MB, 1997, GIBCO BRL FOCUS, V19, P24; West FW, 2000, BIOCHEMISTRY-US, V39, P3678, DOI 10.1021/bi992195x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	42	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47003	47009		10.1074/jbc.M404485200	http://dx.doi.org/10.1074/jbc.M404485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15333637	hybrid			2022-12-25	WOS:000224832400084
J	Weitz-Schmidt, G; Welzenbach, K; Dawson, J; Kallen, J				Weitz-Schmidt, G; Welzenbach, K; Dawson, J; Kallen, J			Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives - Molecular basis determined by X-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; INTEGRIN; DOMAIN; ANTAGONISTS; BINDING; ANTI-LFA-1; SIGNALS; LOCKING; TRIAL	The integrin lymphocyte function-associated antigen-1 (LFA-1) (alpha(L)beta(2); CD11a/CD18) plays an important role in leukocyte migration and T cell activation. LFA-1 is inhibited by the cholesterol-lowering drug lovastatin, which binds to an allosteric site of the alpha(L) I domain termed the lovastatin site (L-site). Here we report for the first time the x-ray structures of the LFA-1 I domain complexed with derivatives of lovastatin optimized for LFA-1 inhibition. This analysis identified two new subpockets within the L-site occupied by chemical groups of the statin derivatives but not by lovastatin itself. Occupancy of these L-site subpockets led to distinct conformational changes in LFA-1, which were detectable by an epitope-monitoring assay. We utilized this assay to demonstrate improved LFA-1 inhibition in human blood in vitro and in blood samples from treated animals ex vivo. Moreover, we demonstrate that the novel lovastatin-derived LFA-1 inhibitor LFA878 exhibits potent anti-inflammatory effects in carrageenan-induced rat paw edema. In summary, the findings reported here extend the understanding of LFA-1 inhibition at the molecular level, allow for the identification and design of LFA-1 inhibitors of further enhanced potency, and support the expectation that LFA-1 inhibitors binding to the L-site will be of therapeutic value in treating inflammatory diseases.	Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Novartis	Weitz-Schmidt, G (corresponding author), Novartis Inst Biomed Res, CH-4002 Basel, Switzerland.	gabriele.weitz@pharma.novartis.com; joerg.kallen@pharma.novartis.com		Dawson, Janet/0000-0003-4615-4091				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; BRUENGER AT, 1992, X PLOR VERSION 3 1 S; CavazzanaCalvo M, 1996, BRIT J HAEMATOL, V93, P131, DOI 10.1046/j.1365-2141.1996.4831024.x; Crump MP, 2004, BIOCHEMISTRY-US, V43, P2394, DOI 10.1021/bi035422a; Frenette PS, 2001, NEW ENGL J MED, V345, P1419, DOI 10.1056/NEJM200111083451911; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Last-Barney K, 2001, J AM CHEM SOC, V123, P5643, DOI 10.1021/ja0104249; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Liu G, 2000, J MED CHEM, V43, P4025, DOI 10.1021/jm0002782; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Raggatt LJ, 2002, DRUGS, V62, P2185, DOI 10.2165/00003495-200262150-00002; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wattanasin S, 2003, BIOORG MED CHEM LETT, V13, P499, DOI 10.1016/S0960-894X(02)00991-5; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wekerle H, 2002, NATURE, V420, P39, DOI 10.1038/420039a; Welzenbach K, 2002, J BIOL CHEM, V277, P10590, DOI 10.1074/jbc.M110521200; Willard NR, 2002, CELL MOL LIFE SCI, V59, P1771, DOI 10.1007/PL00012505; Woska JR, 2003, J IMMUNOL METHODS, V277, P101, DOI 10.1016/S0022-1759(03)00176-5; Yang W, 2004, P NATL ACAD SCI USA, V101, P2333, DOI 10.1073/pnas.0307291101; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	32	56	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46764	46771		10.1074/jbc.M407951200	http://dx.doi.org/10.1074/jbc.M407951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15304496	hybrid			2022-12-25	WOS:000224832400055
J	Witt, TL; Stapels, SE; Matherly, LH				Witt, TL; Stapels, SE; Matherly, LH			Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells - Localization of a substrate binding domain to transmembrane domains 7-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT; METHOTREXATE SENSITIVITY; FUNCTIONAL-ROLE; L1210 LEUKEMIA; MECHANISM; PROTEINS; CDNA; IDENTIFICATION; GLYCOSYLATION; TRANSLOCATION	Reduced folates such as 5-methyl tetrahydrofolate and classical antifolates such as methotrexate are actively transported into mammalian cells by the reduced folate carrier (RFC). RFC is characterized by 12 stretches of mostly hydrophobic, alpha-helix-promoting amino acids, internally oriented N and C termini, and a large central linker connecting transmembrane domains (TMDs) 1-6 and 7-12. Previous studies showed that deletion of the majority of the central loop domain between TMDs 6 and 7 abolished transport, but this segment could be replaced with mostly non-homologous sequence from the SLC19A2 thiamine transporter to restore transport function. In this report, we expressed RFC from separate TMD1-6 and TMD7-12 RFC half-molecule constructs, each with a unique epitope tag, in RFC-null K562 cells to restore transport activity. Restored transport exhibited characteristic transport kinetics for methotrexate, a capacity for trans-stimulation by pretreatment with leucovorin, and inhibition by N-hydroxysuccinimide methotrexate, a documented affinity inhibitor of RFC. The TMD1-6 half-molecule migrated on SDS gels as a 38-58 kDa glycosylated species and was converted to 27 kDa by N-glycosidase F or tunicamycin treatments. The 40 kDa TMD7-12 half-molecule was unaffected by these treatments. Using transfected cells expressing both TMDs1-6 and TMDs7-12 as separate polypeptides, the TMD7-12 half-molecule was covalently radiolabeled with N-hydroxysuccinimide [H-3]methotrexate. No radioactivity was incorporated into the TMD1-6 half-molecule. Digestion with endoproteinase GluC decreased the size of the radiolabeled 40 kDa TMD7-12 polypeptide to similar to20 kDa. Our results demonstrate that a functional RFC can be reconstituted with RFC half- molecules and localize a critical substrate binding domain to within TMDs7-12.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Canc Biol Program, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@karmanos.org			NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Cao W, 2004, BIOCHEM J, V378, P201, DOI 10.1042/BJ20031288; Cao W, 2003, BIOCHEM J, V374, P27, DOI 10.1042/BJ20030301; DIXON KH, 1994, J BIOL CHEM, V269, P17; DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; Flintoff WF, 2003, J BIOL CHEM, V278, P40867, DOI 10.1074/jbc.M302102200; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; GOLDMAN ID, 1971, BIOCHIM BIOPHYS ACTA, V233, P624, DOI 10.1016/0005-2736(71)90162-3; Goldsborough R, 2002, POPTRONICS, V3, P17; HARLOW E, 1988, ANTIBODIES LABORATOR, P424; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XY, 2003, BIOCHEM J, V369, P31, DOI 10.1042/BJ20020419; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; MATHERLY LH, 1991, CANCER RES, V51, P3420; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSCOW JA, 1995, CANCER RES, V55, P3790; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Sadlish H, 2002, BIOCHEM J, V364, P777, DOI 10.1042/BJ20011361; Sadlish H, 2002, J BIOL CHEM, V277, P42105, DOI 10.1074/jbc.M206459200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Sharina IG, 2002, BIOCHEM PHARMACOL, V63, P1717, DOI 10.1016/S0006-2952(02)00955-3; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Witt TL, 2002, BBA-BIOMEMBRANES, V1567, P56, DOI 10.1016/S0005-2736(02)00583-7; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Wong SC, 1998, BBA-BIOMEMBRANES, V1375, P6, DOI 10.1016/S0005-2736(98)00118-7; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 2000, CLIN CANCER RES, V6, P3687; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873	48	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46755	46763		10.1074/jbc.M408696200	http://dx.doi.org/10.1074/jbc.M408696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337749	hybrid			2022-12-25	WOS:000224832400054
J	Yamashita, T; Hoashi, Y; Tomisugi, Y; Ishikawa, Y; Uno, T				Yamashita, T; Hoashi, Y; Tomisugi, Y; Ishikawa, Y; Uno, T			The C-helix in CooA rolls upon CO binding to ferrous heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR COOA; O BENDING VIBRATIONS; RESONANCE RAMAN; RHODOSPIRILLUM-RUBRUM; CARBON-MONOXIDE; LIGAND-BINDING; HISTIDINE 77; TARGET DNA; PROTEIN; MYOGLOBIN	CooA is a homodimeric transcriptional activator from Rhodospirillum rubrum containing one heme in each subunit. CO binding to the heme in its sensor domain activates CooA, facilitating the binding to DNA by its DNA-binding domain. The C-helix links the two domains and shapes an interface between the subunits. To probe the nature of CO activation, residues at positions 112 121 on the C-helix were replaced by Asn or Gln and their effects were evaluated by resonance Raman spectroscopy and by the measurements of CO binding affinity. The nu(Fe-CO) stretching Raman line in CO-bound wildtype CooA was up-shifted by 6 cm(-1) in the L116Q, G117N, and L120Q mutants, indicating unequivocally that these residues are close to the bound CO. Residues Leu(116) and Leu(120) from each subunit form contacts with the corresponding residues in the opposite subunit, enabling hydrophobic interactions in the inactive ferrous form. Thus, in the CO-bound activated form, both C-helices appear to roll to direct these residues toward the heme, forming a hydrophobic pocket for the bound CO. The CO affinity is approximately one order of magnitude higher in the L112Q, I115Q, L116Q, G117N, L120Q, and T121N mutants but reduced in A114N mutant. The variation indicates that these residues are close to the heme in the ferrous and/or CO-bound forms and are responsible for CooA activation. A roll-and-slide mechanism is proposed for CO activation of CooA.	Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan	Kumamoto University	Uno, T (corresponding author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto 8620973, Japan.	unot@gpo.kumamoto-u.ac.jp	Uno, Tadayuki/E-1622-2013	Uno, Tadayuki/0000-0003-2056-5781				Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; Aono S, 1999, BIOCHEM BIOPH RES CO, V261, P270, DOI 10.1006/bbrc.1999.1046; Chan MK, 2000, NAT STRUCT BIOL, V7, P822, DOI 10.1038/79559; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Coyle CM, 2003, J BIOL CHEM, V278, P35384, DOI 10.1074/jbc.M301000200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kincaid J.R., 2000, PORPHYRIN HDB, V7, P227; Kumazaki S, 2000, J BIOL CHEM, V275, P38378, DOI 10.1074/jbc.M005533200; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Puranik M, 2004, J BIOL CHEM, V279, P21096, DOI 10.1074/jbc.M400613200; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; SAKAN Y, 1993, BIOCHEMISTRY-US, V32, P5815, DOI 10.1021/bi00073a014; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Thorsteinsson MV, 2001, J BIOL CHEM, V276, P26807, DOI 10.1074/jbc.M102758200; TSUBAKI M, 1982, BIOCHEMISTRY-US, V21, P1132, DOI 10.1021/bi00535a004; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uno T, 2003, BIOCHEMISTRY-US, V42, P10191, DOI 10.1021/bi034569z; UNO T, 1987, J BIOL CHEM, V262, P4549; Uno T, 2001, J AM CHEM SOC, V123, P512, DOI 10.1021/ja002079d; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; Yamashita T, 2004, J BIOL CHEM, V279, P21394, DOI 10.1074/jbc.M400512200; Youn H, 2002, J BIOL CHEM, V277, P33616, DOI 10.1074/jbc.M203684200; Youn H, 2001, J BIOL CHEM, V276, P41603, DOI 10.1074/jbc.M106165200; YU NT, 1983, BIOCHEMISTRY-US, V22, P4534, DOI 10.1021/bi00288a028	41	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47320	47325		10.1074/jbc.M407766200	http://dx.doi.org/10.1074/jbc.M407766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326178	hybrid			2022-12-25	WOS:000224832400120
J	Cheng, RZ; Feng, Q; Argirov, OK; Ortwerth, BJ				Cheng, RZ; Feng, Q; Argirov, OK; Ortwerth, BJ			Structure elucidation of a novel yellow chromophore from human lens protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCT; MAILLARD REACTION; ASCORBIC-ACID; AMINO-ACIDS; CROSS-LINKS; TISSUE PROTEINS; HUMAN CATARACTS; EYE LENS; IDENTIFICATION; CATARACTOGENESIS	We report here the isolation of a novel acid-labile yellow chromophore from the enzymatic digest of human lens proteins and the identification of its chemical structure by liquid chromatography-mass spectrometry, liquid chromatography-tandem mass spectrometry, and H-1, C-13, and two-dimensional NMR. This new chromophore exhibited a UV absorbance maximum at 343 nm and fluorescence at 410 nm when excited at 343 nm. Analysis of the purified compound by reversed-phase HPLC with in-line electrospray ionization mass spectrometry revealed a molecular mass of 370 Da. One- and two-dimensional NMR analyses elucidated the structure to be 1-(5-amino-5-carboxypentyl)-4-(5-amino-5-carboxypentylamino)-3-hydroxy-2,3-dihydropyridinium, a cross-link between the epsilon-amino groups of two lysine residues, and a five-carbon ring. Because this cross-link contains two lysine residues and a dihydropyridinium ring, we assigned it the trivial name of K2P. Quantitative determinations of K2P in individual normal human lens or cataract lens water-soluble and water-insoluble protein digests were made using a high-performance liquid chromatograph equipped with a diode array detector. These measurements revealed a significant enhancement of K2P in cataract lens proteins (613 +/- 362 pmol/mg of water-insoluble sonicate supernatant (WISS) protein or 85 +/- 51 pmol/mg of WS protein) when compared with aged normal human lens proteins (261 +/- 93 pmol/mg of WISS protein or 23 +/- 15 pmol/mg of water-soluble ( WS) protein). These data provide chemical evidence for increased protein cross-linking during aging and cataract development in vivo. This new cross-link may serve as a quantitatively more significant biomarker for assessing the role of lens protein modifications during aging and in the pathogenesis of cataract.	Univ Missouri, Mason Eye Inst E, Columbia, MO 65201 USA	University of Missouri System; University of Missouri Columbia	Cheng, RZ (corresponding author), Univ Missouri, Mason Eye Inst E, 404 Portland St, Columbia, MO 65201 USA.	chengr@health.missouri.edu			NEI NIH HHS [EY07070] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1981, MOL CELLULAR BIOL EY; Argirov OK, 2004, J BIOL CHEM, V279, P6487, DOI 10.1074/jbc.M309090200; BENSCH KG, 1985, P NATL ACAD SCI USA, V82, P7193, DOI 10.1073/pnas.82.21.7193; BEYER WF, 1989, ARCH BIOCHEM BIOPHYS, V271, P149, DOI 10.1016/0003-9861(89)90265-8; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Bova LM, 2001, INVEST OPHTH VIS SCI, V42, P200; BUCKINGHAM RH, 1972, EXP EYE RES, V14, P123, DOI 10.1016/0014-4835(72)90057-7; Cheng RZ, 2003, EXP EYE RES, V77, P313, DOI 10.1016/S0014-4835(03)00131-3; Cheng RZ, 2002, BBA-MOL BASIS DIS, V1587, P65, DOI 10.1016/S0925-4439(02)00069-8; Cheng RZ, 2001, BBA-MOL BASIS DIS, V1537, P14, DOI 10.1016/S0925-4439(01)00051-5; CHIO KS, 1969, BIOCHEMISTRY-US, V8, P2821, DOI 10.1021/bi00835a019; COTLIER E, 1981, CAN J OPHTHALMOL, V16, P113; Frye EB, 1998, J BIOL CHEM, V273, P18714, DOI 10.1074/jbc.273.30.18714; FULHORST H. WILLIAM, 1966, INVEST OPHTHALMOL, V5, P298; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; KAMEI A, 1991, CHEM PHARM BULL, V39, P1272; KURZEL RB, 1973, EXP EYE RES, V17, P65, DOI 10.1016/0014-4835(73)90168-1; LERMAN S, 1976, OPHTHALMIC RES, V8, P335, DOI 10.1159/000264841; LI LK, 1986, CURR EYE RES, V5, P127, DOI 10.3109/02713688609015101; LUTHRA M, 1994, FEBS LETT, V349, P39, DOI 10.1016/0014-5793(94)00635-0; Maillard LC, 1912, CR HEBD ACAD SCI, V154, P66; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; ORTWERTH BJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P10, DOI 10.1016/0167-4838(88)90292-0; ORTWERTH BJ, 1997, VITAMIN C HLTH DIS, P123; PIRIE A, 1968, INVEST OPHTH VISUAL, V7, P634; Reiser KM, 1998, P SOC EXP BIOL MED, V218, P23; SELL DR, 1989, J BIOL CHEM, V264, P21597; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Truscott RJW, 2000, OPHTHALMIC RES, V32, P185, DOI 10.1159/000055612; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANDENBERG TJTP, 1995, INVEST OPHTH VIS SCI, V36, P322; Vazquez S, 2002, J BIOL CHEM, V277, P4867, DOI 10.1074/jbc.M107529200; ZIGMAN S, 1976, EXP EYE RES, V23, P555, DOI 10.1016/0014-4835(76)90163-9	38	41	42	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45441	45449		10.1074/jbc.M405664200	http://dx.doi.org/10.1074/jbc.M405664200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15316021	hybrid			2022-12-25	WOS:000224694900020
J	da-Silva, WS; Bomfim, FM; Galina, A; de Meis, L				da-Silva, WS; Bomfim, FM; Galina, A; de Meis, L			Heat of PPi hydrolysis varies depending on the enzyme used - Yeast and corn vacuolar pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; UNCOUPLED ATPASE ACTIVITY; INORGANIC PYROPHOSPHATASE; H+-PYROPHOSPHATASE; THERMODYNAMIC PARAMETERS; PUMPING PYROPHOSPHATASE; ENERGY TRANSDUCTION; REACTION PATHWAY; WATER; MECHANISM	With yeast-soluble inorganic pyrophosphatase, the heat released during PPi hydrolysis was -6.3 kcal/mol regardless of the KCl concentration in the medium. With the membrane-bound pyrophosphatase of corn vacuoles, the heat released varies between -23.5 and -7.5 kcal/mol depending on the KCl concentration in the medium and whether or not a H+ gradient is formed across the vacuole membranes. The data support the proposal that enzymes are able to handle the energy derived from phosphate compound hydrolysis in such a way as to determine the parcel that is used for work and the fraction that is converted into heat (de Meis, L. (2001) J. Biol. Chem. 276, 25078-25087).	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@bioqmed.ufrj.br	da Silva, Wagner S/A-7835-2008; Galina, Antonio/A-9292-2008	da Silva, Wagner S/0000-0002-0001-0386; 				Arruda AP, 2003, BIOCHEM J, V375, P753, DOI 10.1042/BJ20031015; Baltscheffsky M, 1999, FEBS LETT, V457, P525, DOI 10.1016/S0014-5793(99)00914-X; Barata H, 2002, J BIOL CHEM, V277, P16868, DOI 10.1074/jbc.M200648200; BAYKOV AA, 1990, EUR J BIOCHEM, V194, P879, DOI 10.1111/j.1432-1033.1990.tb19482.x; Baykov AA, 2000, BIOCHEMISTRY-US, V39, P11939, DOI 10.1021/bi000627u; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; Bianconi ML, 2003, J BIOL CHEM, V278, P18709, DOI 10.1074/jbc.M211103200; Boyer PD, 1998, BIOSCIENCE REP, V18, P97, DOI 10.1023/A:1020188311092; COOPERMAN BS, 1982, METHOD ENZYMOL, V87, P526; da-Silva WS, 2003, BIOCHEM BIOPH RES CO, V307, P472, DOI 10.1016/S0006-291X(03)01226-9; Darley CP, 1998, PLANTA, V206, P272, DOI 10.1007/s004250050400; DAVIES JM, 1992, P NATL ACAD SCI USA, V89, P11701, DOI 10.1073/pnas.89.24.11701; DAVIES JM, 1991, FEBS LETT, V278, P66, DOI 10.1016/0014-5793(91)80085-H; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 2002, J MEMBRANE BIOL, V188, P1, DOI 10.1007/s00232-001-0171-5; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1984, J BIOL CHEM, V259, P6090; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1985, BIOCHEMISTRY-US, V24, P7783, DOI 10.1021/bi00347a042; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; FACANHA AR, 1995, PLANT PHYSIOL, V108, P241, DOI 10.1104/pp.108.1.241; Facanha AR, 1998, PLANT PHYSIOL, V116, P1487, DOI 10.1104/pp.116.4.1487; Fiske CH, 1925, J BIOL CHEM, V66, P375; FLODGAARD H, 1974, J BIOL CHEM, V249, P3465; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; GEORGE P, 1970, BIOCHIM BIOPHYS ACTA, V223, P1, DOI 10.1016/0005-2728(70)90126-X; GING NS, 1954, J AM CHEM SOC, V76, P2087, DOI 10.1021/ja01637a015; GORDONWEEKS R, 1977, PLANT PHYSIOL, V114, P901; Halonen P, 2002, BIOCHEMISTRY-US, V41, P12025, DOI 10.1021/bi026018z; HAYES DM, 1978, J AM CHEM SOC, V100, P4331, DOI 10.1021/ja00482a002; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; JANSON CA, 1979, J BIOL CHEM, V254, P3743; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maeshima M, 2000, BBA-BIOMEMBRANES, V1465, P37, DOI 10.1016/S0005-2736(00)00130-9; Maeshima M, 1999, PLANT CELL PHYSIOL, V40, P439, DOI 10.1093/oxfordjournals.pcp.a029560; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; Obermeyer G, 1996, BBA-BIOMEMBRANES, V1284, P203, DOI 10.1016/S0005-2736(96)00130-7; OHLMEYER P, 1952, ARCH BIOCHEM BIOPHYS, V36, P411, DOI 10.1016/0003-9861(52)90426-8; Pohjanjoki P, 2001, J BIOL CHEM, V276, P434, DOI 10.1074/jbc.M007360200; Reis M, 2002, MOL MEMBR BIOL, V19, P301, DOI 10.1080/09687680210166217; Reis M, 2001, J BIOL CHEM, V276, P42793, DOI 10.1074/jbc.M107625200; ROMERO PJ, 1989, J BIOL CHEM, V264, P7869; ROS R, 1995, J BIOL CHEM, V270, P4368, DOI 10.1074/jbc.270.9.4368; SATO MH, 1994, J BIOL CHEM, V269, P6725; SPRINGS B, 1981, BIOCHEMISTRY-US, V20, P6384, DOI 10.1021/bi00525a016; Suzuki Y, 1999, PHYTOCHEMISTRY, V50, P535, DOI 10.1016/S0031-9422(98)00554-8; Szoke A, 2003, FEBS LETT, V553, P18, DOI 10.1016/S0014-5793(03)01008-1; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	52	9	10	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45613	45617		10.1074/jbc.M408866200	http://dx.doi.org/10.1074/jbc.M408866200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322117	hybrid			2022-12-25	WOS:000224694900040
J	Daltrop, O; Ferguson, SJ				Daltrop, O; Ferguson, SJ			In vitro studies on thioether bond formation between Hydrogenobacter thermophilus apocytochrome c(552) with metalloprotoporphyrin derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROME; PROTOPORPHYRIN-IX; EMISSION-SPECTRA; B-TYPE; HEME; HEMOGLOBINS; PEROXIDASE; BIOGENESIS; ABSORPTION; MATURATION	Previously, in vitro formation of thioether bonds between Hydrogenobacter thermophilus apocytochrome c(552) and Fe-protoporphyrin IX has been demonstrated (Daltrop, O., Allen, J. W. A., Willis, A. C., and Ferguson, S. J. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7872-7876). Now we report studies on the reaction between the metalloderivatives Zn-, Co-, and Mn-protoporphyrin IX and the cysteine thiols of H. thermophilus apocytochrome c(552). All of these metalloporphyrins were capable of forming a "b-type cytochrome" state in which the hydrophobic prosthetic group is bound non-covalently. Zn(II)-protoporphyrin IX attached to the polypeptide covalently in the presence of either dithiothreitol or tri(2-carboxyethyl) phosphine to keep the thiol moieties reduced. These data show that the chemical nature of the thiol-reducing agent does not interfere with the thioether bond-forming mechanism. Mn-porphyrin could only react with the protein in the divalent state of the metal ion. Co-porphyrin did not react with the cysteine thiols of the apocytochrome in either oxidation state of the metal. In the absence of a metal (i.e. protoporphyrin IX itself), no reactivity toward apocytochrome is observed. These results have significant implications for the chemical requirements for thioether bond formation of heme vinyl groups to cysteine thiols and also have potential applications in de novo design of metalloproteins.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Daltrop, O (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	oliver.daltrop@bioch.ox.ac.uk; stuart.ferguson@bioch.ox.ac.uk			Biotechnology and Biological Sciences Research Council [B19947] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Allen JWA, 2003, J BIOL CHEM, V278, P52075, DOI 10.1074/jbc.M307196200; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; Daltrop O, 2003, J BIOL CHEM, V278, P24308, DOI 10.1074/jbc.M301967200; Daltrop O, 2003, J BIOL CHEM, V278, P4404, DOI 10.1074/jbc.M211124200; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DICKINSON LC, 1975, BIOCHEMISTRY-US, V14, P3526, DOI 10.1021/bi00687a003; DICKINSON LC, 1977, J BIOL CHEM, V252, P6156; FALK JE, 1965, PORPHYRINS METALLOPO, V2; FISHER WR, 1973, J BIOL CHEM, V248, P3188; Gruenke LD, 1997, BIOCHEMISTRY-US, V36, P7114, DOI 10.1021/bi970407p; Kang XS, 1999, BIOCHEMISTRY-US, V38, P15944, DOI 10.1021/bi9919089; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1460, DOI 10.1021/bi00704a022; Nocek JM, 1997, J AM CHEM SOC, V119, P2146, DOI 10.1021/ja9630811; Qian CM, 2003, J BIOL INORG CHEM, V8, P394, DOI 10.1007/s00775-002-0428-1; RIDSDALE S, 1973, J BIOL CHEM, V248, P771; Rosenblatt MM, 2003, P NATL ACAD SCI USA, V100, P13140, DOI 10.1073/pnas.2231273100; Sanders C, 2000, BBA-BIOENERGETICS, V1459, P131, DOI 10.1016/S0005-2728(00)00122-5; SEBRING ED, 1970, J BIOL CHEM, V245, P5395; Tomlinson EJ, 2000, P NATL ACAD SCI USA, V97, P5156, DOI 10.1073/pnas.090089397; Tomlinson EJ, 2000, J BIOL CHEM, V275, P32530, DOI 10.1074/jbc.M004022200; VANDERKOOI JM, 1975, EUR J BIOCHEM, V60, P199, DOI 10.1111/j.1432-1033.1975.tb20992.x; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c; Wain R, 2004, J BIOL CHEM, V279, P15177, DOI 10.1074/jbc.M311869200; Wain R, 2001, J BIOL CHEM, V276, P45813, DOI 10.1074/jbc.M107572200; YONETANI T, 1969, J BIOL CHEM, V244, P4580; YONETANI T, 1968, J BIOL CHEM, V243, P3996; YONETANI T, 1974, J BIOL CHEM, V249, P682	31	24	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45347	45353		10.1074/jbc.M408637200	http://dx.doi.org/10.1074/jbc.M408637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326165	hybrid			2022-12-25	WOS:000224694900009
J	Koon, HW; Zhao, DZ; Na, X; Moyer, MP; Pothoulakis, C				Koon, HW; Zhao, DZ; Na, X; Moyer, MP; Pothoulakis, C			Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-DIFFICILE TOXIN; NF-KAPPA-B; EGF RECEPTOR TRANSACTIVATION; COLONIC EPITHELIAL-CELLS; HUMAN ASTROCYTOMA-CELLS; NEUROKININ-1 RECEPTOR; HB-EGF; GENE-EXPRESSION; NK-1 RECEPTOR; TUMOR-GROWTH	Substance P (SP) participates in acute intestinal inflammation via binding to the G-protein-coupled neurokinin-1 receptor (NK-1R) and release of proinflammatory cytokines from colonic epithelial cells. SP also stimulates cell proliferation, a critical event in tissue healing during chronic colitis, via transactivation of the epidermal growth factor (EGF) receptor (EGFR) and activation of mitogen-activated protein kinase (MAPK). Here we examined the mechanism by which SP induces EGFR and MAPK activation. We used non-transformed human NCM460 colonocytes stably transfected with the human NK-1R (NCM460-NK-1R cells) as well as untransfected U373 MG cells expressing high levels of endogenous NK-1R. Exposure of both cell lines to SP (10(-7) M) stimulated EGFR activation (1 min) followed by extracellular signal-regulated protein kinase (ERK1/2) activation (2-5 min). SP-induced ERK1/2 activation was blocked by pretreatment with the metalloproteinase inhibitor Batimastat/GM6001, the EGFR phosphorylation inhibitor AG1478, and the tumor necrosis factor-alpha-converting enzyme (TACE) inhibitor TAPI-1. Pretreatment with antibodies against potential EGFR ligands suggested that transforming growth factor-alpha (TGFalpha), but not the other EGFR ligands EGF, heparin-binding EGF, or amphiregulin, mediates SP-induced EGFR transactivation. SP stimulated TGFalpha release into the extracellular space that was measurable within 2 min, and this release was inhibited by metalloproteinase inhibitors and the TACE inhibitor TAPI-1. SP also induced MAPK-mediated cell proliferation that was inhibited by TACE, matrix metalloproteinase (MMP), EGFR, and MEK1 inhibitors. Thus, in human colonocytes, NK-1R-induced EGFR and MAPK activation and cell proliferation involve matrix metalloproteinases (most likely TACE) and the release of TGFalpha. These signaling mechanisms may be involved in the protective effects of NK-1R in chronic colitis.	Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Sch Med, Gastrointestinal Neuropeptide Ctr, Boston, MA 02215 USA; INCELL Corp, San Antonio, TX 78249 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pothoulakis, C (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Gastroenterol,Sch Med, Gastrointestinal Neuropeptide Ctr, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	cpothoul@bidmc.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047343] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 47343] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Sarraj A, 2002, NEUROSCI LETT, V332, P111, DOI 10.1016/S0304-3940(02)00939-4; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Azzolina A, 2003, BBA-MOL CELL RES, V1643, P75, DOI 10.1016/j.bbamcr.2003.09.003; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; BOST KL, 1995, ADV EXP MED BIOL, V373, P219; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 1997, P NATL ACAD SCI USA, V94, P4788, DOI 10.1073/pnas.94.9.4788; Castagliuolo I, 2002, BRIT J PHARMACOL, V136, P271, DOI 10.1038/sj.bjp.0704697; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; COSTA M, 1982, CIBA F SYMP, V91, P129; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Derocq JM, 1996, FEBS LETT, V399, P321, DOI 10.1016/S0014-5793(96)01346-4; Fiebich BL, 2000, J IMMUNOL, V165, P5606, DOI 10.4049/jimmunol.165.10.5606; Friess H, 2003, LAB INVEST, V83, P731, DOI 10.1097/01.LAB.0000067499.57309.F6; FRUCHT H, 1992, CANCER RES, V52, P1114; GOLDIN E, 1989, DIGEST DIS SCI, V34, P754, DOI 10.1007/BF01540348; Goode T, 2003, J CELL PHYSIOL, V197, P30, DOI 10.1002/jcp.10234; Hinkle CL, 2003, BIOCHEMISTRY-US, V42, P2127, DOI 10.1021/bi026709v; Holzer P, 1997, PHARMACOL THERAPEUT, V73, P173, DOI 10.1016/S0163-7258(96)00195-7; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; Kirkwood KS, 2001, AM J PHYSIOL-GASTR L, V281, pG544, DOI 10.1152/ajpgi.2001.281.2.G544; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Lieb K, 1996, J NEUROIMMUNOL, V67, P77; Lieb K, 1997, J IMMUNOL, V159, P4952; Luo WH, 1996, CANCER RES, V56, P4983; MAGGI CA, 1990, ARCH INT PHARMACOD T, V303, P157; Mantyh CR, 1996, GASTROENTEROLOGY, V111, P1272, DOI 10.1053/gast.1996.v111.pm8898641; Mantyh CR, 1996, DIGEST DIS SCI, V41, P614, DOI 10.1007/BF02282350; Mantyh PW, 2002, J CLIN PSYCHIAT, V63, P6; Modjtahedi H, 1998, INT J CANCER, V75, P310, DOI 10.1002/(SICI)1097-0215(19980119)75:2<310::AID-IJC22>3.0.CO;2-F; Palma C, 1999, BRIT J CANCER, V79, P236, DOI 10.1038/sj.bjc.6690039; Pothoulakis C, 1998, AM J PHYSIOL-GASTR L, V275, pG68, DOI 10.1152/ajpgi.1998.275.1.G68; POTHOULAKIS C, 1994, P NATL ACAD SCI USA, V91, P947, DOI 10.1073/pnas.91.3.947; PRADIER L, 1993, J NEUROCHEM, V61, P1850, DOI 10.1111/j.1471-4159.1993.tb09826.x; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAMESH G, 1995, INT J CANCER, V62, P492, DOI 10.1002/ijc.2910620422; Renzi D, 2000, AM J PATHOL, V157, P1511, DOI 10.1016/S0002-9440(10)64789-X; Riegler M, 1999, AM J PHYSIOL-GASTR L, V276, pG1473, DOI 10.1152/ajpgi.1999.276.6.G1473; ROLLANDY I, 1989, NEUROPEPTIDES, V13, P175, DOI 10.1016/0143-4179(89)90089-9; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Simeonidis S, 2003, P NATL ACAD SCI USA, V100, P2957, DOI 10.1073/pnas.0530112100; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; Sitohy B, 2002, ACTA ONCOL, V41, P543; Stucchi AF, 2000, AM J PHYSIOL-GASTR L, V279, pG1298, DOI 10.1152/ajpgi.2000.279.6.G1298; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Weinstock JV, 2003, J IMMUNOL, V171, P3762, DOI 10.4049/jimmunol.171.7.3762; Yang CM, 2002, CELL SIGNAL, V14, P913, DOI 10.1016/S0898-6568(02)00039-6; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zhao DZ, 2002, BIOCHEM J, V368, P665, DOI 10.1042/BJ20020950	55	101	103	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45519	45527		10.1074/jbc.M408523200	http://dx.doi.org/10.1074/jbc.M408523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319441	hybrid			2022-12-25	WOS:000224694900030
J	Lim, SY; Jang, JH; Na, HK; Lu, SC; Rahman, I; Surh, YJ				Lim, SY; Jang, JH; Na, HK; Lu, SC; Rahman, I; Surh, YJ			15-deoxy-Delta(12,14)-prostaglandin J(2) protects against nitrosative PC12 cell death through up-regulation of intracellular glutathione synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; CYCLOPENTENONE PROSTAGLANDINS; ALZHEIMERS-DISEASE; PPAR-GAMMA; GLUTAMYLCYSTEINE SYNTHETASE; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; GENE-EXPRESSION	Nitrosative stress with subsequent inflammatory cell death has been associated with many neurodegenerative disorders. Expression of inducible nitric-oxide synthase and production of nitric oxide (NO) have been frequently elevated in many inflammatory disorders. NO can rapidly react with superoxide anion, producing more reactive peroxynitrite. In the present study, exposure of rat pheochromocytoma (PC12) cells to the peroxynitrite donor 3-morpholinosydnonimine hydrochloride (SIN-1) induced apoptosis, which accompanied depletion of intracellular glutathione (GSH), c-Jun N-terminal kinase activation, mitochondrial membrane depolarization, the cleavage of poly(ADP-ribose) polymerase, and DNA fragmentation. During SIN-1-induced apoptotic cell death, expression of inducible cyclooxy-genase (COX-2), and peroxisome proliferator-activated receptor-gamma (PPARgamma) was elevated. SIN-1 treatment resulted in elevated production of 15-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), an endogenous PPARgamma activator. Preincubation with 15d-PGJ(2) rendered PC12 cells resistant to nitrosative stress induced by SIN-1.15d-PGJ(2) fortified an intracellular GSH pool through up-regulation of glutamylcysteine ligase, thereby preventing cells from SIN-1-induced GSH depletion. The above findings suggest that 15d-PGJ(2) may act as a survival mediator capable of augmenting cellular thiol antioxidant capacity through up-regulation of the intracellular GSH synthesis in response to the nitrosative insult.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Univ So Calif, Keck Sch Med, Res Ctr Liver Dis, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA; Univ Rochester, Med Ctr, Div Lung Biol & Dis, Dept Environm Med, Rochester, NY 14642 USA	Seoul National University (SNU); University of Southern California; University of Rochester	Surh, YJ (corresponding author), Seoul Natl Univ, Coll Pharm, Shinlim Dong, Seoul 151742, South Korea.	surh@plaza.snu.ac.kr	Lu, Shelly/AAH-5937-2021	Lu, Shelly/0000-0003-2128-5407	NIDDK NIH HHS [DK45334] Funding Source: Medline; NIEHS NIH HHS [ES01247] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045334, R29DK045334, R01DK045334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; Asanuma Masato, 2003, Nihon Shinkei Seishin Yakurigaku Zasshi, V23, P111; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3; Boyd CS, 2002, BIOL CHEM, V383, P411, DOI 10.1515/BC.2002.045; Breitner JCS, 1996, NEUROBIOL AGING, V17, P789; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brune B, 1997, J BIOL CHEM, V272, P7253, DOI 10.1074/jbc.272.11.7253; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Colville-Nash PR, 2000, PROSTAG OTH LIPID M, V62, P33, DOI 10.1016/S0090-6980(00)00074-5; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Emi M, 2004, BIOCHEM PHARMACOL, V67, P1259, DOI 10.1016/j.bcp.2003.10.037; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hubatsch I, 2002, CHEM RES TOXICOL, V15, P1114, DOI 10.1021/tx020027r; Itoh K, 2004, MOL CELL BIOL, V24, P36, DOI 10.1128/MCB.24.1.36-45.2004; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; Kang CD, 1998, NEUROSCI LETT, V256, P37, DOI 10.1016/S0304-3940(98)00751-4; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Levonen AL, 2001, ARTERIOSCL THROM VAS, V21, P1846, DOI 10.1161/hq1101.098488; Luth HJ, 2002, BRAIN RES, V953, P135, DOI 10.1016/S0006-8993(02)03280-8; McGeer EG, 1998, EXP GERONTOL, V33, P371, DOI 10.1016/S0531-5565(98)00013-8; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Na HK, 2003, BIOCHEM PHARMACOL, V66, P1381, DOI 10.1016/S0006-2952(03)00488-X; Nogawa S, 1997, J NEUROSCI, V17, P2746; Perez-Sala D, 2002, ANN NY ACAD SCI, V973, P533, DOI 10.1111/j.1749-6632.2002.tb04695.x; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Reuter BK, 1996, J CLIN INVEST, V98, P2076, DOI 10.1172/JCI119013; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Szabo C, 1996, FEBS LETT, V381, P82, DOI 10.1016/0014-5793(96)00087-7; Taba Y, 2003, AM J PHYSIOL-HEART C, V285, pH38, DOI 10.1152/ajpheart.01037.2002; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Tian L, 1997, ARCH BIOCHEM BIOPHYS, V342, P126, DOI 10.1006/abbi.1997.9997; Uchida K, 2000, MECH AGEING DEV, V116, P135, DOI 10.1016/S0047-6374(00)00129-9; Von Knethen A, 2001, FASEB J, V15, P535, DOI 10.1096/fj.00-0187com; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447	48	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46263	46270		10.1074/jbc.M406555200	http://dx.doi.org/10.1074/jbc.M406555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319433	hybrid			2022-12-25	WOS:000224694900113
J	Eriksson, KK; Vago, R; Calanca, V; Galli, C; Paganetti, P; Molinari, M				Eriksson, KK; Vago, R; Calanca, V; Galli, C; Paganetti, P; Molinari, M			EDEM contributes to maintenance of protein folding efficiency and secretory capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-CELL DIFFERENTIATION; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; MISFOLDED GLYCOPROTEINS; ALZHEIMERS-DISEASE; MESSENGER-RNA; B-CELLS; ER; OLIGOSACCHARIDE; DEGRADATION	A stringent quality control process selects misfolded polypeptides generated in the endoplasmic reticulum (ER) for ER-associated degradation (ERAD). Here we assessed the maintenance of efficient glycoprotein folding in cells with defective ERAD caused by lack of adaptation of the intralumenal level of ER degradation-enhancing alpha-mannosidase-like protein ( EDEM) to an increase in the ER cargo load. When these cells were converted into factories for production of high levels of human beta-secretase, maturation of this N-glycosylated aspartic protease progressed as in wild-type cells initially to gradually become less efficient. Up-regulation of EDEM to strengthen the ERAD machinery ( but not up-regulation of calnexin to reinforce the folding machinery) was instrumental in maintaining folding efficiency and secretory capacity. Our data underscore the important role that the degradation machinery plays in maintaining a functional folding environment in the ER.	Inst Biomed Res, CH-6500 Bellinzona, Switzerland; Ist Sci San Raffaele, Dept Biol & Tech Res, I-20132 Milan, Italy; Novartis Pharma AG, Neurosci Res, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Universita della Svizzera Italiana; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Novartis	Molinari, M (corresponding author), Inst Biomed Res, CH-6500 Bellinzona, Switzerland.	maurizio.molinari@irb.unisi.ch	Paganetti, Paolo/AAF-8039-2020; Molinari, Maurizio/N-2587-2019; Vago, Riccardo/K-3256-2018	Molinari, Maurizio/0000-0002-7636-5829; Vago, Riccardo/0000-0002-3781-6770; Paganetti, Paolo/0000-0003-1896-6324				Braakman I, 2001, EMBO REP, V2, P666, DOI 10.1093/embo-reports/kve162; Cabral CM, 2002, MOL BIOL CELL, V13, P2639, DOI 10.1091/mbc.E02-02-0068; Cabral CM, 2001, TRENDS BIOCHEM SCI, V26, P619, DOI 10.1016/S0968-0004(01)01942-9; CLAUSS IM, 1993, DEV DYNAM, V197, P146, DOI 10.1002/aja.1001970207; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Gass JN, 2004, TRENDS IMMUNOL, V25, P17, DOI 10.1016/j.it.2003.11.004; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Hampton RY, 2003, DEV CELL, V4, P144, DOI 10.1016/S1534-5807(03)00032-7; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hosokawa N, 2003, J BIOL CHEM, V278, P26287, DOI 10.1074/jbc.M303395200; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Kopito RR, 2000, NAT CELL BIOL, V2, pE207, DOI 10.1038/35041139; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Ma YJ, 2003, NAT IMMUNOL, V4, P310, DOI 10.1038/ni0403-310; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 2002, J CELL BIOL, V158, P247, DOI 10.1083/jcb.200204122; Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181; Parodi AJ, 2000, BIOCHEM J, V348, P1, DOI 10.1042/0264-6021:3480001; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Reimold AM, 2000, GENE DEV, V14, P152; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; Tremblay LO, 1999, GLYCOBIOLOGY, V9, P1073, DOI 10.1093/glycob/9.10.1073; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Trombetta ES, 2003, GLYCOBIOLOGY, V13, p77R, DOI 10.1093/glycob/cwg075; Vallee F, 2000, J BIOL CHEM, V275, P41287, DOI 10.1074/jbc.M006927200; van Anken E, 2003, IMMUNITY, V18, P243, DOI 10.1016/S1074-7613(03)00024-4; Wang T, 2003, NAT STRUCT BIOL, V10, P319, DOI 10.1038/nsb0503-319; Wu Y, 2003, P NATL ACAD SCI USA, V100, P8229, DOI 10.1073/pnas.1430537100; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4	44	33	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44600	44605		10.1074/jbc.M407972200	http://dx.doi.org/10.1074/jbc.M407972200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308654	hybrid			2022-12-25	WOS:000224505600045
J	Garzon, R; Soriano, SF; Rodriguez-Frade, JM; Gomez, L; de Ana, AM; Sanchez-Gomez, M; Martinez, C; Mellado, M				Garzon, R; Soriano, SF; Rodriguez-Frade, JM; Gomez, L; de Ana, AM; Sanchez-Gomez, M; Martinez, C; Mellado, M			CXCR4-mediated suppressor of cytokine signaling up-regulation inactivates growth hormone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; STEM-CELL MOBILIZATION; MONOCLONAL-ANTIBODIES; BINDING; SDF-1; GH; RESPONSES; PROTEINS; IMMUNE; CHEMOATTRACTANT	Coordinated action between cytokines and chemokines is required for effective endocrine and immune responses. Proteins of both families promote receptor oligomerization, activation of the Janus kinase (JAK)/ STAT pathway, and transcription of many genes, including the suppressor of cytokine signaling ( SOCS) family. In this study, we show that chemokine-mediated SOCS1 and SOCS3 up-regulation modulates the signaling and function associated to a cytokine receptor, both in vitro and in vivo. The effect is mediated by SOCS binding to JAK2 and to the cytokine receptor, which blocks subsequent signaling events. The data reinforce the premise of cytokine-chemokine cross-talk, which helps contribute to modulating individual responses and in defining the functional plasticity of the immune system.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Nacl Colombia, Dept Chem, Lab Hormones, Bogota, Colombia	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Universidad Nacional de Colombia	Mellado, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco, E-28049 Madrid, Spain.	mmellado@cnb.uam.es	Garzon, Ruth/F-3341-2016; Mellado, Mario/M-9893-2014; Frade, Jose Miguel Rodriguez/K-4266-2014	Garzon, Ruth/0000-0003-4035-9002; Mellado, Mario/0000-0001-6325-1630; Frade, Jose Miguel Rodriguez/0000-0002-7753-1462; Sanchez-Gomez, Myriam/0000-0002-9481-7534				Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Aller MA, 2004, EXP BIOL MED, V229, P170, DOI 10.1177/153537020422900206; BANG P, 1991, ACTA ENDOCRINOL-COP, V124, P620, DOI 10.1530/acta.0.1240620; Beauloye V, 1999, AM J PHYSIOL-ENDOC M, V277, pE308, DOI 10.1152/ajpendo.1999.277.2.E308; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Carlo-Stella C, 2004, EXP HEMATOL, V32, P171, DOI 10.1016/j.exphem.2003.11.007; CHAPPEL S, 2002, CYTOKINE REFERENCE, P251; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Gagnerault MC, 1996, ENDOCRINOLOGY, V137, P1719, DOI 10.1210/en.137.5.1719; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gonzalo JA, 1996, J IMMUNOL, V157, P3298; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Jeay S, 2002, MOL CELL ENDOCRINOL, V188, P1, DOI 10.1016/S0303-7207(02)00014-X; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Kopchick JJ, 2000, MOL GENET METAB, V71, P293, DOI 10.1006/mgme.2000.3068; Le Roith D, 2001, TRENDS ENDOCRIN MET, V12, P48; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; MARTIN JL, 1999, IGF SYSTEM MOL BIOL, P227; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Mellado M, 1996, J CLIN ENDOCR METAB, V81, P1613, DOI 10.1210/jc.81.4.1613; MERIMEE TJ, 1991, J CLIN ENDOCR METAB, V73, P1031, DOI 10.1210/jcem-73-5-1031; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Olney RC, 2003, MED PEDIATR ONCOL, V41, P228, DOI 10.1002/mpo.10342; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; REINEROVA M, 1991, NEOPLASMA, V38, P175; Richter HE, 2003, J MOL ENDOCRINOL, V30, P139, DOI 10.1677/jme.0.0300139; Rudling M, 1999, GROWTH HORM IGF RES, V9, P1, DOI 10.1016/S1096-6374(99)80002-1; Soriano SF, 2002, J EXP MED, V196, P311, DOI 10.1084/jem.20012041; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tian ZG, 1998, STEM CELLS, V16, P193, DOI 10.1002/stem.160193; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wald O, 2004, EUR J IMMUNOL, V34, P1164, DOI 10.1002/eji.200324441; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Youn BS, 2000, IMMUNOL REV, V177, P150, DOI 10.1034/j.1600-065X.2000.17701.x; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	54	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44460	44466		10.1074/jbc.M408010200	http://dx.doi.org/10.1074/jbc.M408010200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304476	hybrid			2022-12-25	WOS:000224505600029
J	Johnson, D; Montpetit, ML; Stocker, PJ; Bennett, ES				Johnson, D; Montpetit, ML; Stocker, PJ; Bennett, ES			The sialic acid component of the beta(1) subunit modulates voltage-gated sodium channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1 SUBUNIT; GENERALIZED EPILEPSY; FEBRILE SEIZURES; SKELETAL-MUSCLE; MOLECULAR DETERMINANTS; EXTRACELLULAR DOMAIN; STATE INACTIVATION; MESSENGER-RNA; ALPHA-SUBUNIT; RAT-BRAIN	Voltage-gated sodium channels (Na-v) are responsible for initiation and propagation of nerve, skeletal muscle, and cardiac action potentials. Na-v are composed of a pore-forming alpha subunit and often one to several modulating beta subunits. Previous work showed that terminal sialic acid residues attached to alpha subunits affect channel gating. Here we show that the fully sialylated beta(1) subunit induces a uniform, hyperpolarizing shift in steady state and kinetic gating of the cardiac and two neuronal alpha subunit isoforms. Under conditions of reduced sialylation, the beta(1)-induced gating effect was eliminated. Consistent with this, mutation of beta(1) N-glycosylation sites abolished all effects of beta(1) on channel gating. Data also suggest an interaction between the cis effect of alpha sialic acids and the trans effect of beta(1) sialic acids on channel gating. Thus, beta(1) sialic acids had no effect on the gating of the heavily glycosylated skeletal muscle alpha subunit. However, when glycosylation of the skeletal muscle alpha subunit was reduced through chimeragenesis such that alpha sialic acids did not impact gating, beta(1) sialic acids caused a significant hyperpolarizing shift in channel gating. Together, the data indicate that beta(1) N-linked sialic acids can modulate Na-v gating through an apparent saturating electrostatic mechanism. A model is proposed in which a spectrum of differentially sialylated Na-v can directly modulate channel gating, thereby impacting cardiac, skeletal muscle, and neuronal excitability.	Univ S Florida, Coll Med, Dept Physiol & Biophys, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Program Neurosci, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Bennett, ES (corresponding author), Univ S Florida, Coll Med, Dept Physiol & Biophys, MDC 8, Tampa, FL 33612 USA.	esbennet@hsc.usf.edu						Abriel H, 2001, CIRC RES, V88, P740, DOI 10.1161/hh0701.089668; Bennett E, 1997, J GEN PHYSIOL, V109, P327, DOI 10.1085/jgp.109.3.327; Bennett ES, 2002, J PHYSIOL-LONDON, V538, P675, DOI 10.1113/jphysiol.2001.013285; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; COHEN SA, 1993, CIRC RES, V73, P735, DOI 10.1161/01.RES.73.4.735; Cummins TR, 2001, J NEUROSCI, V21, P5952, DOI 10.1523/JNEUROSCI.21-16-05952.2001; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Hille B, 2001, ION CHANNELS EXCITAB, P646; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; Isom LL, 2001, NEUROSCIENTIST, V7, P42, DOI 10.1177/107385840100700108; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Makita N, 1996, J NEUROSCI, V16, P7117; Malhotra JD, 2001, CIRCULATION, V103, P1303; Marban E, 1998, J PHYSIOL-LONDON, V508, P647, DOI 10.1111/j.1469-7793.1998.647bp.x; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; McCormick KA, 1999, J BIOL CHEM, V274, P32638, DOI 10.1074/jbc.274.46.32638; McCormick KA, 1998, J BIOL CHEM, V273, P3954, DOI 10.1074/jbc.273.7.3954; McEwen DP, 2004, J BIOL CHEM, V279, P16044, DOI 10.1074/jbc.M400856200; Meadows L, 2001, J NEUROCHEM, V76, P1871, DOI 10.1046/j.1471-4159.2001.00192.x; Meadows LS, 2002, J NEUROSCI, V22, P10699; Meadows LS, 2002, NEUROSCIENCE, V114, P745, DOI 10.1016/S0306-4522(02)00242-7; MESSNER DJ, 1985, J BIOL CHEM, V260, P597; MILLER JA, 1983, BIOCHEMISTRY-US, V22, P462, DOI 10.1021/bi00271a032; Qu Y, 2001, MOL CELL NEUROSCI, V18, P570, DOI 10.1006/mcne.2001.1039; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; ROBERTS RH, 1987, J BIOL CHEM, V262, P2298; Sashihara S, 1996, J NEUROSCI, V16, P702; Sashihara S, 1995, MOL BRAIN RES, V34, P239, DOI 10.1016/0169-328X(95)00168-R; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; Shah BS, 2001, J PHYSIOL-LONDON, V534, P763, DOI 10.1111/j.1469-7793.2001.t01-1-00763.x; Smith MR, 1998, J NEUROSCI, V18, P6093; Smith RD, 1998, J NEUROSCI, V18, P811; Spampanato J, 2003, NEUROSCIENCE, V116, P37, DOI 10.1016/S0306-4522(02)00698-X; Splawski I, 2002, SCIENCE, V297, P1333, DOI 10.1126/science.1073569; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STANLEY P, 1985, MOL CELL BIOL, V5, P923, DOI 10.1128/MCB.5.5.923; SUTKOWSKI EM, 1990, J BIOL CHEM, V265, P12393; Tyrrell L, 2001, J NEUROSCI, V21, P9629, DOI 10.1523/JNEUROSCI.21-24-09629.2001; Vijayaragavan K, 2001, J NEUROSCI, V21, P7909, DOI 10.1523/JNEUROSCI.21-20-07909.2001; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; YANG JS, 1993, NEURON, V11, P915, DOI 10.1016/0896-6273(93)90121-7; Zhang Y, 1999, J MEMBRANE BIOL, V171, P195, DOI 10.1007/s002329900571; Zimmer T, 2002, J GEN PHYSIOL, V120, P887, DOI 10.1085/jgp.20028703; ZONA C, 1990, PROC R SOC SER B-BIO, V239, P119, DOI 10.1098/rspb.1990.0011	49	83	85	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44303	44310		10.1074/jbc.M408900200	http://dx.doi.org/10.1074/jbc.M408900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316006	hybrid			2022-12-25	WOS:000224505600011
J	Liu, H; Shaw, CK; Reineke, EL; Liu, Y; Kao, HY				Liu, H; Shaw, CK; Reineke, EL; Liu, Y; Kao, HY			Retinoid X receptor alpha (RXR alpha) helix 12 plays an inhibitory role in the recruitment of the p160 co-activators by unliganded RXR alpha/retinoic acid receptor alpha heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; THYROID-HORMONE; DETERMINANTS; COMPLEX; TRANSCRIPTION; SPECIFICITY; REPRESSION	Retinoid X receptor (RXR)/retinoic acid receptor (RAR) heterodimers control gene expression through recruitment of co-repressors or co-activators, depending on their hormone binding status. We show that the helix 12 of RXRalpha and RARalpha is critical for recruitment of the co-regulators and transcriptional regulation by RXRalpha, RARalpha, and RXRalpha/RARalpha. LG268, an RXR-specific agonist, was able to promote co-activator association with the heterodimers, but was unable to dissociate co-repressors. Reconstitution experiments in yeast demonstrated that LG268 was capable of activating transcription by RXRalpha/RARalpha through recruitment of the coactivator. We hypothesize that the inability to release co-repressors from RXRalpha/RARalpha is responsible for the inability of LG268 to activate RXRalpha/RARalpha heterodimers in mammalian cells. Deletion of RARalpha helix 12 (RXRalpha/RARalpha Delta403) abolished both hormone-dependent dissociation from co-repressors and hormone-dependent association with co-activators. Deletion of RXRalpha helix 12 (RXRalpha Delta443/RARalpha) resulted in a higher binding affinity for co-repressors. Unexpectedly, RXRalpha Delta443/RARalpha also gained hormone-independent co-activator binding activity. Moreover, LG268 became an antagonist to RXRalpha Delta443/RARalpha heterodimers. These data suggest that the helix 12 of RXRalpha plays an inhibitory role in the recruitment of co-activators by unliganded RXRalpha/RARalpha.	Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Res Inst,Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ctr Comprehens Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; University Hospitals of Cleveland	Kao, HY (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Res Inst,Dept Biochem, Cleveland, OH 44106 USA.	hxk43@po.cwru.edu						Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Castillo AI, 2004, MOL CELL BIOL, V24, P502, DOI 10.1128/MCB.24.2.502-513.2004; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; Ghosh JC, 2002, P NATL ACAD SCI USA, V99, P5842, DOI 10.1073/pnas.092043399; Glass CK, 2000, GENE DEV, V14, P121; Greschik I, 2003, CURR TOP MED CHEM, V3, P1573, DOI 10.2174/1568026033451736; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Kao HY, 2003, J BIOL CHEM, V278, P7366, DOI 10.1074/jbc.M207569200; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; Lee G, 2002, J BIOL CHEM, V277, P19649, DOI 10.1074/jbc.M200743200; LEFEBVRE B, 1995, BIOCHEMISTRY-US, V34, P5477, DOI 10.1021/bi00016a019; Li DS, 2002, MOL CELL BIOL, V22, P5782, DOI 10.1128/MCB.22.16.5782-5792.2002; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 1999, MOL CELL BIOL, V19, P6448	30	7	7	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45208	45218		10.1074/jbc.M408033200	http://dx.doi.org/10.1074/jbc.M408033200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310754	hybrid			2022-12-25	WOS:000224505600114
J	Odenthal, U; Haehn, S; Tunggal, P; Merkl, B; Schomburg, D; Frie, C; Paulsson, M; Smyth, N				Odenthal, U; Haehn, S; Tunggal, P; Merkl, B; Schomburg, D; Frie, C; Paulsson, M; Smyth, N			Molecular analysis of laminin N-terminal domains mediating self-interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; EPIDERMOLYSIS-BULLOSA; SHORT ARM; CHAIN; EXPRESSION; BINDING; POLYMERIZATION; GLYCOPROTEIN; INHIBITION; MUTATIONS	The ability of laminins to self-polymerize is crucial for the formation of basement membranes. Development of this polymerized network has profound effects upon tissue architecture as well as on the intracellular organization and differentiation of neighboring cells. The laminin N-terminal (LN) domains have been shown to mediate this interaction and studies using proteolytic fragments derived from laminin-1 led to the theory that network assembly depends on the formation of a heterotrimeric complex between LN domains derived from alpha, beta, and gamma chains in different laminin molecules with homologous interactions being insignificant. The laminin family consists of 15 known isoforms formed from five alpha, three beta, and three gamma chains, of which some are truncated and lack the N-terminal LN domain. To address whether the model of heterotrimeric complex formation is applicable to laminin isoforms other than laminin-1, eight LN domains found in the laminin protein family were recombinantly expressed and tested in three different assays for homologous and heterologous interactions. The results showed that the lack of homologous interactions is an exception, with such interactions being seen for LN domains derived from all alpha chains and from the beta(2) and beta(3) subunits. The gamma chain-derived LN domains showed a far more limited binding repertoire, particularly in the case of the gamma(3) chain, which is found present in a range of non-basement membrane locations. Further, whereas the interactions depended upon Ca2+ ions, with EDTA reversibly abrogating binding, EDTA-induced conformational changes were not reversible. Together these results demonstrate that the assembly model proposed on the basis of laminin-1 may be a simplification, with the assembly of naturally occurring laminin networks being far more complex and highly dependent upon which laminin isoforms are present.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med, D-50931 Cologne, Germany; Univ Cologne, Fac Math & Nat Sci, Inst Biochem, D-50674 Cologne, Germany	University of Cologne; University of Cologne; University of Cologne	Smyth, N (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	Neil.Smyth@uni-koeln.de		Smyth, Neil/0000-0002-3734-2149; Schomburg, Dietmar/0000-0002-3354-822X				BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Colognato H, 1999, CURR BIOL, V9, P1327, DOI 10.1016/S0960-9822(00)80056-1; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; De Arcangelis A, 1996, J CELL BIOL, V133, P417, DOI 10.1083/jcb.133.2.417; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Garbe JHO, 2002, BIOCHEM J, V362, P213, DOI 10.1042/0264-6021:3620213; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Koch M, 2000, J CELL BIOL, V151, P221, DOI 10.1083/jcb.151.2.221; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Libby RT, 1999, J NEUROSCI, V19, P9399; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MAURER P, 1996, LAMININS, P27; Mellerio JE, 1998, BRIT J DERMATOL, V139, P325; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Nakano A, 2002, HUM GENET, V110, P41, DOI 10.1007/s00439-001-0630-1; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1985, EMBO J, V4, P309, DOI 10.1002/j.1460-2075.1985.tb03630.x; Pulkkinen L, 1998, LAB INVEST, V78, P859; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; Schuger L, 1998, INT J DEV BIOL, V42, P217; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Smyth N, 2000, METH MOL B, V139, P49; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; TIMPL R, 1979, J BIOL CHEM, V254, P9933; Tsiper MV, 2002, J CELL SCI, V115, P1005; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Yang Y, 1998, DEVELOPMENT, V125, P2621; Yin Y, 2002, MOL CELL NEUROSCI, V19, P344, DOI 10.1006/mcne.2001.1089; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	41	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44504	44512		10.1074/jbc.M402455200	http://dx.doi.org/10.1074/jbc.M402455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310759	hybrid			2022-12-25	WOS:000224505600035
J	Fujimura, T; Esteban, R				Fujimura, T; Esteban, R			The bipartite 3 '-cis-acting signal for replication is required for formation of a ribonucleoprotein complex in vivo between the viral genome and its RNA polymerase in yeast 23 S RNA virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; 23 S RNA; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; ANTIVIRAL SYSTEM; POLIOVIRUS RNA; SELF-CLEAVAGE; 20-S RNA; YEAST; SEQUENCES	23 S RNA narnavirus is a persistent positive strand RNA virus found in Saccharomyces cerevisiae. The viral genome (2.9 kb) encodes only its RNA-dependent RNA polymerase, p104, and forms a ribonucleoprotein complex with p104 in vivo. Previously we succeeded in generating 23 S RNA virus in yeast from an expression vector containing the entire viral cDNA sequence. Using this system, we have recently identified a bipartite 3' cis-acting signal for replication. The signal consists of a stretch of four cytidines (Cs) at the 3' end and a mismatched pair of purines in a stem-loop structure that partially overlaps the terminal four Cs. Although the 3' terminal and penultimate Cs are not essential for virus launching, the generated viruses efficiently recovered these terminal nucleotides. In this work, we expressed RNA transcripts containing the entire 23 S RNA genome but incapable of generating the virus because of the presence of non-viral extra sequences at the 3' ends. These transcripts could form complexes with p104 in vivo, and a detailed analysis indicated that the mismatched pair of purines as well as the third and fourth Cs from the viral 3' end was essential for this complex-forming activity. Given that 23 S RNA virus does not have genes for capsid proteins, the binding of p104 to the viral 3' end, in addition to the efficient 3' terminal repair, may play a crucial role in virus persistence by protecting and maintaining the correct viral 3' end in vivo.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Esteban, R (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Avda Campo Charro S-N, Salamanca 37007, Spain.	mrosa@gugu.usal.es	Hu, Ruogu/B-2203-2008; Fujimura, Tsutomu/K-5807-2014; Esteban, Rosa/K-4356-2014	Fujimura, Tsutomu/0000-0002-9457-6769; Esteban, Rosa/0000-0001-6804-7209				ADAMS A, 1975, P NATL ACAD SCI USA, V72, P1477, DOI 10.1073/pnas.72.4.1477; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Area E, 2004, P NATL ACAD SCI USA, V101, P308, DOI 10.1073/pnas.0307127101; Barton DJ, 2001, EMBO J, V20, P1439, DOI 10.1093/emboj/20.6.1439; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; Brown JT, 2000, RNA, V6, P449, DOI 10.1017/S1355838200991787; Caston JR, 1997, J CELL BIOL, V138, P975, DOI 10.1083/jcb.138.5.975; CHENG RH, 1994, J MOL BIOL, V244, P255, DOI 10.1006/jmbi.1994.1726; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Esteban R, 2003, P NATL ACAD SCI USA, V100, P2568, DOI 10.1073/pnas.0530167100; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; Fujimura T, 2004, J BIOL CHEM, V279, P13215, DOI 10.1074/jbc.M313797200; GarciaCuellar MP, 1997, RNA, V3, P27; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; Herold J, 2001, MOL CELL, V7, P581, DOI 10.1016/S1097-2765(01)00205-2; HOWLEY PM, 1983, AM J PATHOL, V113, P413; ICHO T, 1989, J BIOL CHEM, V264, P6716; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KADOWAKI K, 1971, J BACTERIOL, V105, P826, DOI 10.1128/JB.105.3.826-830.1971; Klumpp K, 1997, EMBO J, V16, P1248, DOI 10.1093/emboj/16.6.1248; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Perrotta AT, 1996, NUCLEIC ACIDS RES, V24, P1314, DOI 10.1093/nar/24.7.1314; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Schwartz M, 2002, MOL CELL, V9, P505, DOI 10.1016/S1097-2765(02)00474-4; Searfoss AW, 2000, P NATL ACAD SCI USA, V97, P9133, DOI 10.1073/pnas.97.16.9133; Solorzano A, 2000, J BIOL CHEM, V275, P26428, DOI 10.1074/jbc.M002281200; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; Wickner R. B, 2001, FIELDS VIROLOGY, V1, P629; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; WICKNER RB, 1980, CELL, V21, P217, DOI 10.1016/0092-8674(80)90129-4; WICKNER RB, 2000, VIRUS TAXONOMY, P651; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	44	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44219	44228		10.1074/jbc.M408530200	http://dx.doi.org/10.1074/jbc.M408530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308662	hybrid			2022-12-25	WOS:000224383100101
J	Tedford, HW; Gilles, N; Menez, A; Doering, CJ; Zamponi, GW; King, GF				Tedford, HW; Gilles, N; Menez, A; Doering, CJ; Zamponi, GW; King, GF			Scanning mutagenesis of omega-atracotoxin-Hv1a reveals a spatially restricted epitope that confers selective activity against insect calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN GVIA; FUNNEL-WEB SPIDERS; SMALL-MOLECULE; FUNCTIONAL ASSAY; III MIMETICS; DROSOPHILA; NEUROTOXIN; TOXIN; BLOCKER; ANALOGS	We constructed a complete panel of alanine mutants of the insect-specific calcium channel blocker omega-atracotoxin-Hv1a. Lethality assays using these mutant toxins identified three spatially contiguous residues, Pro(10), Asn(27), and Arg(35), that are critical for insecticidal activity against flies (Musca domestica) and crickets (Acheta domestica). Competitive binding assays using radiolabeled omega-atracotoxin-Hv1a and neuronal membranes prepared from the heads of American cockroaches (Periplaneta americana) confirmed the importance of these three residues for binding of the toxin to target calcium channels presumably expressed in the insect membranes. At concentrations up to 10 muM, omega-atracotoxin-Hv1a had no effect on heterologously expressed rat Ca(v)2.1, Ca(v)2.2, and Ca(v)1.2 calcium channels, consistent with the previously reported insect selectivity of the toxin. 30 muM omega-atracotoxin-Hv1a inhibited rat Ca-v currents by 10-34%, depending on the channel subtype, and this low level of inhibition was essentially unchanged when Asn(27) and Arg(35), which appears to be critical for interaction of the toxin with insect Ca-v channels, were both mutated to alanine. We propose that the spatially contiguous epitope formed by Pro(10), Asn(27), and Arg(35) confers specific binding to insect Ca-v channels and is largely responsible for the remarkable phyletic selectivity of omega-atracotoxin-Hv1a. This epitope provides a structural template for rational design of chemical insecticides that selectively target insect Ca-v channels.	Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, Farmington, CT 06032 USA; CEA, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada	University of Connecticut; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Calgary	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Mol Microbial & Struct Biol, 263 Farmington Ave, Farmington, CT 06032 USA.	glenn@psel.uchc.edu	King, Glenn F/J-5059-2012	King, Glenn F/0000-0002-2308-2200; Zamponi, Gerald W./0000-0002-0644-9066	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI051791] Funding Source: NIH RePORTER; NIAID NIH HHS [1-R41-AI51791] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Atkinson RK., 1998, Patent No. 5763568; Baell JB, 2001, J COMPUT AID MOL DES, V15, P1119, DOI 10.1023/A:1015930031890; Baell JB, 2002, J COMPUT AID MOL DES, V16, P245, DOI 10.1023/A:1016310602813; Bloomquist JR, 2003, INVERTEBR NEUROSCI, V5, P45, DOI 10.1007/s10158-003-0027-z; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brogdon WG, 1998, EMERG INFECT DIS, V4, P605, DOI 10.3201/eid0404.980410; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cohen L, 2004, J BIOL CHEM, V279, P8206, DOI 10.1074/jbc.M307531200; Copping LG, 2000, PEST MANAG SCI, V56, P651, DOI 10.1002/1526-4998(200008)56:8<651::AID-PS201>3.0.CO;2-U; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; Eberl DF, 1998, GENETICS, V148, P1159; EITAN M, 1990, BIOCHEMISTRY-US, V29, P5941, DOI 10.1021/bi00477a009; Favreau P, 2001, BIOCHEMISTRY-US, V40, P14567, DOI 10.1021/bi002871r; Fletcher JI, 1997, NAT STRUCT BIOL, V4, P559, DOI 10.1038/nsb0797-559; Flinn JP, 1999, EUR J BIOCHEM, V262, P447, DOI 10.1046/j.1432-1327.1999.00383.x; Gadek TR, 2003, BIOCHEM PHARMACOL, V65, P1, DOI 10.1016/S0006-2952(02)01479-X; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; Hall L. M., 1995, Molecular action of insecticides on ion channels., P162; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hoopengardner B, 2003, SCIENCE, V301, P832, DOI 10.1126/science.1086763; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Kawasaki F, 2002, J NEUROSCI, V22, P5856; KIM JI, 1994, J BIOL CHEM, V269, P23876; KIM JI, 1995, BIOCHEM BIOPH RES CO, V206, P449, DOI 10.1006/bbrc.1995.1063; King GF, 2002, J TOXICOL-TOXIN REV, V21, P359, DOI 10.1081/TXR-120014409; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Lew MJ, 1997, J BIOL CHEM, V272, P12014, DOI 10.1074/jbc.272.18.12014; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Maggio F, 2002, J BIOL CHEM, V277, P22806, DOI 10.1074/jbc.M202297200; Maggio F, 2002, TOXICON, V40, P1355, DOI 10.1016/S0041-0101(02)00154-X; MAGGIO F, 2004, IN PRESS COMPREHENSI; Menzler S, 2000, BIOORG MED CHEM LETT, V10, P345, DOI 10.1016/S0960-894X(99)00699-X; Muegge I, 2002, CHEM-EUR J, V8, P1976, DOI 10.1002/1521-3765(20020503)8:9<1976::AID-CHEM1976>3.0.CO;2-K; NADASDI L, 1995, BIOCHEMISTRY-US, V34, P8076, DOI 10.1021/bi00025a013; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Smith LA, 1998, GENETICS, V149, P1407; SOLLOD BL, 2004, IN PRESS PEPTIDES; Tedford HW, 2004, TOXICON, V43, P601, DOI 10.1016/j.toxicon.2004.02.010; Tedford HW, 2001, J BIOL CHEM, V276, P26568, DOI 10.1074/jbc.M102199200; Wang XH, 1999, EUR J BIOCHEM, V264, P488, DOI 10.1046/j.1432-1327.1999.00646.x; Wicher D, 1997, J NEUROPHYSIOL, V77, P186, DOI 10.1152/jn.1997.77.1.186; Zamponi GW, 2004, NEURON, V41, P3, DOI 10.1016/S0896-6273(03)00846-8; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810	49	56	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44133	44140		10.1074/jbc.M404006200	http://dx.doi.org/10.1074/jbc.M404006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308644	hybrid			2022-12-25	WOS:000224383100093
J	Wang, DJ; Park, JS; Chu, JSF; Krakowski, A; Luo, KX; Chen, DJ; Li, S				Wang, DJ; Park, JS; Chu, JSF; Krakowski, A; Luo, KX; Chen, DJ; Li, S			Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta 1 stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-DIMENSIONAL GEL-ELECTROPHORESIS; TGF-BETA; ACTIN EXPRESSION; STROMAL CELLS; IN-VIVO; DIFFERENTIATION; GELSOLIN	Bone marrow mesenchymal stem cells (MSCs) can differentiate into different types of cells and have tremendous potential for cell therapy and tissue engineering. Transforming growth factor beta1 (TGF-beta) plays an important role in cell differentiation and vascular remodeling. We showed that TGF-beta induced cell morphology change and an increase in actin fibers in MSCs. To determine the global effects of TGF-beta on MSCs, we employed a proteomic strategy to analyze the effect of TGF-beta on the human MSC proteome. By using two-dimensional gel electrophoresis and electrospray ionization coupled to quadrupole/time-of-flight tandem mass spectrometers, we have generated a proteome reference map of MSCs, and we identified similar to30 proteins with an increase or decrease in expression or phosphorylation in response to TGF-beta. The proteins regulated by TGF-beta included cytoskeletal proteins, matrix synthesis proteins, membrane proteins, metabolic enzymes, etc. TGF-beta increased the expression of smooth muscle alpha-actin and decreased the expression of gelsolin. Overexpression of gelsolin inhibited TGF-beta-induced assembly of smooth muscle alpha-actin; on the other hand, knocking down gelsolin expression enhanced the assembly of alpha-actin and actin filaments without significantly affecting alpha-actin expression. These results suggest that TGF-beta coordinates the increase of alpha-actin and the decrease of gelsolin to promote MSC differentiation. This study demonstrates that proteomic tools are valuable in studying stem cell differentiation and elucidating the underlying molecular mechanisms.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Wang, DJ (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 84-171, Berkeley, CA 94720 USA.	djwang@lbl.gov; songli@socrates.berkeley.edu		Krakowski, Ari/0000-0003-0554-1669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL079419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; ARPIN M, 1994, J CELL BIOL, V127, P1995, DOI 10.1083/jcb.127.6.1995; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Caplan AI, 2001, TRENDS MOL MED, V7, P259, DOI 10.1016/S1471-4914(01)02016-0; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; FATH KR, 1995, CURR BIOL, V5, P591, DOI 10.1016/S0960-9822(95)00117-5; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GALMICHE MC, 1993, BLOOD, V82, P66, DOI 10.1182/blood.V82.1.66.bloodjournal82166; GLENNEY JR, 1981, J BIOL CHEM, V256, P9283; Gojo S, 2003, EXP CELL RES, V288, P51, DOI 10.1016/S0014-4827(03)00132-0; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hirschi KK, 2002, ANN NY ACAD SCI, V961, P223, DOI 10.1111/j.1749-6632.2002.tb03090.x; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858; Kinner B, 2002, EXP CELL RES, V278, P72, DOI 10.1006/excr.2002.5561; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; LANDRY J, 1992, J BIOL CHEM, V267, P794; Lilley KS, 2002, CURR OPIN CHEM BIOL, V6, P46, DOI 10.1016/S1367-5931(01)00275-7; Liu Y, 2003, J BIOL CHEM, V278, P48004, DOI 10.1074/jbc.M301902200; MacCoss MJ, 2001, CURR OPIN CLIN NUTR, V4, P369, DOI 10.1097/00075197-200109000-00006; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Miao H, 2002, FASEB J, V16, pA464; Mo WJ, 2002, CURR OPIN CHEM BIOL, V6, P666, DOI 10.1016/S1367-5931(02)00379-4; Moustakas A, 2001, J CELL SCI, V114, P4359; Patterson SD, 2003, NAT GENET, V33, P311, DOI 10.1038/ng1106; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rabilloud T, 2002, PROTEOMICS, V2, P3, DOI 10.1002/1615-9861(200201)2:1<3::AID-PROT3>3.3.CO;2-I; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Srinivas PR, 2002, CLIN CHEM, V48, P1160; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; Topper JN, 2000, TRENDS CARDIOVAS MED, V10, P132, DOI 10.1016/S1050-1738(00)00061-X; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212; Witzmann FA, 2002, AM J PHYSIOL-GASTR L, V282, pG735, DOI 10.1152/ajpgi.00510.2001; Yarmush ML, 2002, ANNU REV BIOMED ENG, V4, P349, DOI 10.1146/annurev.bioeng.4.020702.153443	42	201	222	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43725	43734		10.1074/jbc.M407368200	http://dx.doi.org/10.1074/jbc.M407368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302865	hybrid			2022-12-25	WOS:000224383100047
J	Ohashi, Y; Ueda, M; Kawase, T; Kawakami, Y; Toda, M				Ohashi, Y; Ueda, M; Kawase, T; Kawakami, Y; Toda, M			Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning	ONCOGENE			English	Article						glioma; RLGS; RFX1; methylation; epigenetics	HUMAN PROSTATE-CANCER; DNA-BINDING; CPG ISLANDS; EXPRESSION; METHYLATION; PROTEIN; HYPERMETHYLATION; INACTIVATION; PROGRESSION; SEQUENCES	To identify the CpG islands differentially methylated in human glioma, we performed restriction landmark genomic scanning with a CpG methylation-sensitive enzyme. We found 12 spots, the intensity of which was entirely lost or decreased in both the human glioma tissues examined as compared with that in matched normal lymphocytes, indicating aberrant methylation of these CpG islands in gliomas. The expression of RFX1, one of the genes associated with the methylated CpG islands, was frequently decreased in human glioma cell lines and tissues. We also demonstrated that the isolated CpG island located in the seventh intron of the RFX1 gene had enhancer activity and was hypermethylated in all of the glioma tissues and cell lines analysed, but not in normal brains or lymphocytes. Treatment of glioma cells with a demethylating agent, 5-azacytidine, resulted in the expression of RFX1, indicating that the silencing of the RFX1 gene may be attributable to its methylation. RFX1 has been implicated in transcriptional downregulation of the proto-oncogene c-myc. By expression of the RFX1 gene, the cellular proliferative activity of glioma cells was suppressed. Taken together, these results suggest that the RFX1 gene may be epigenetically silenced in human gliomas and involved in glioma tumorigenesis.	Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo, Japan; Keio Univ, Sch Med, Dept Surg, Tokyo 160, Japan; Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University; Keio University	Toda, M (corresponding author), Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	todam@sc.itc.keio.ac.jp	Kawakami, Yutaka/E-7429-2013; Toda, Masahiro/L-2268-2013; nakamura, asuka/S-7235-2016	Kawakami, Yutaka/0000-0003-4836-2855; 				BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; Chen L, 2000, J BIOL CHEM, V275, P32227, DOI 10.1074/jbc.M002645200; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Emery P, 1996, NUCLEIC ACIDS RES, V24, P803, DOI 10.1093/nar/24.5.803; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FULTS D, 1992, CANCER RES, V52, P674; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HUMPHREY PA, 1988, CANCER RES, V48, P2231; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maegawa S, 2001, MOL CARCINOGEN, V31, P1, DOI 10.1002/mc.1034; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Melki JR, 1999, CANCER RES, V59, P3730; Nakamura M, 2001, LAB INVEST, V81, P77, DOI 10.1038/labinvest.3780213; Rasheed B K, 1999, Curr Opin Oncol, V11, P162; Saito Y, 2001, HEPATOLOGY, V33, P561, DOI 10.1053/jhep.2001.22507; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SIEGRIST CA, 1993, MOL CELL BIOL, V13, P6375, DOI 10.1128/MCB.13.10.6375; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Yamada KM, 2001, J CELL SCI, V114, P2375; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	28	25	33	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7772	7779		10.1038/sj.onc.1208058	http://dx.doi.org/10.1038/sj.onc.1208058			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334059				2022-12-25	WOS:000224331600003
J	Singh, V; Miranda, TB; Jiang, W; Frankel, A; Roemer, ME; Robb, VA; Gutmann, DH; Herschman, HR; Clarke, S; Newsham, IF				Singh, V; Miranda, TB; Jiang, W; Frankel, A; Roemer, ME; Robb, VA; Gutmann, DH; Herschman, HR; Clarke, S; Newsham, IF			DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo	ONCOGENE			English	Article						PRMT3; DAL-1/4.1B; tumor suppressor; protein methylation	N-METHYLTRANSFERASE; SUBCELLULAR-LOCALIZATION; BINDING; DOMAIN; SPECIFICITY; GROWTH; CD44; TRANSCRIPTION; MEMBRANE; RECEPTOR	DAL-1 (differentially expressed in adenocarcinoma of the lung)/4.1B is a tumor suppress-or gene on human chromosome 18p11.3 whose expression is lost in >50% of primary non-small-cell lung carcinomas. Based on sequence similarity, DAL-1/4.1B has been assigned to the Protein 4.1 superfamily whose members interact with plasma membrane proteins through their N-terminal FERM (4.1/Ezrin/Radixin/Moesin) domain, and cytoskeletal components via their C-terminal SAB (spectrin-actin binding) region. Using the DAL-1/4.1B FERM domain as bait for yeast two-hybrid interaction cloning, we identified protein arginine N-methyltransferase 3 (PRMT3) as a specific DAL-1/4.1B-interacting protein. PRMT3 catalyses the post-translational transfer of methyl groups from S-adenosyl-L-methionine to arginine residues of proteins. Coimmunoprecipitation experiments using lung and breast cancer cell lines confirmed this interaction in mammalian cells in vivo. In vitro binding assays demonstrated that this was an interaction occurring via the C-terminal catalytic core domain of PRMT3. DAL-1/4.1B was determined not to be a substrate for PRMT3-mediated methylation but its presence inhibits the in vitro methylation of a glycine-rich and arginine-rich methyl-accepting protein, GST (glutathione-S-transferase-GAR (glycine- and arginine-rich), which contains 14 'RGG' consensus methylation sites. In addition, induced expression of DAL-1/4.1B in MCF-7 breast cancer cells showed that the DAL-1/4.1B protein significantly inhibits PRMT3 methylation of cellular substrates. These findings suggest that modulation of post-translational methylation may be an important mechanism through which DAL-1/ 4.1B affects tumor cell growth.	Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Doreen Hermelin Lab Mol Oncogenet, Detroit, MI 48202 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Henry Ford Health System; Henry Ford Hospital; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Washington University (WUSTL); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Newsham, IF (corresponding author), Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, David & Doreen Hermelin Lab Mol Oncogenet, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	irene@bogler.net		Gutmann, David/0000-0002-3127-5045	NCI NIH HHS [F32-CA-097816-01, CA77030] Funding Source: Medline; NIGMS NIH HHS [GM26020, T32 GM07185] Funding Source: Medline; NINDS NIH HHS [NS41520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA097816] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, T32GM007185, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bachand F, 2004, EMBO J, V23, P2641, DOI 10.1038/sj.emboj.7600265; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Berthet C, 2002, GENES CELLS, V7, P29, DOI 10.1046/j.1356-9597.2001.00497.x; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kittiniyom K, 2001, BREAST CANCER RES, V3, P192, DOI 10.1186/bcr294; KUMAR A, 1986, J BIOL CHEM, V261, P1266; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Robb VA, 2004, ONCOGENE, V23, P3589, DOI 10.1038/sj.onc.1207445; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; Trofatter J A, 1993, Cell, V75, P826; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu TX, 2002, BIOCHEM J, V365, P783, DOI 10.1042/BJ20020060	45	85	104	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7761	7771		10.1038/sj.onc.1208057	http://dx.doi.org/10.1038/sj.onc.1208057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334060	Bronze			2022-12-25	WOS:000224331600002
J	Wang, J; Feng, XH; Schwartz, RJ				Wang, J; Feng, XH; Schwartz, RJ			SUMO-1 modification activated GATA4-dependent cardiogenic gene activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; TRANSCRIPTION FACTORS; PROTEIN INHIBITOR; E3 LIGASE; GATA-4; PIASY; CONJUGATION; SUMOYLATION; EXPRESSION; RECEPTOR	Sumoylation, an important posttranslational modification process, is involved in regulating bioactivities of diverse proteins. GATA4, a cardiac-enriched dual zinc finger transcription factor, plays a critical role in regulating cardiac-specified genes. Here, we demonstrated that GATA4 is sumoylated by small ubiquitin-like modifier-1 (SUMO-1), which resulted in enhanced GATA4 transcriptional activity. We further revealed that lysine 366 of GATA4 constituted a major sumyolation site. Conversion of lysine 366 to arginine 366 resulted in reduced GATA4 nuclear occupation, suggesting that SUMO modification may also modulate GATA4 nuclear localization. In GATA4 sumoylation, PIAS1 served as an E3 ligase and positively modulated GATA4 transactivation via its RING finger domain. In the presence of SUMO-1 and/or PIAS1, GATA4 triggered the activation of cardiogenic genes in pluripotent 10T1/2 fibroblast. GATA4 was identified as a SUMO-1-targeted transcription factor and together with PIAS1 was shown to be a potent regulator of cardiac gene activity.	Baylor Coll Med, Dept Mol & Cellular Biol, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Ctr Cardiovasc Dev, Div Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Ctr Cardiovasc Dev, Rm 145E,1 Baylor Plaza, Houston, TX 77030 USA.	Schwartz@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49953] Funding Source: Medline; NIGMS NIH HHS [R01 GM63773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Chen WY, 2004, J BIOL CHEM, V279, P38730, DOI 10.1074/jbc.M405006200; Chun TH, 2003, CIRC RES, V92, P1201, DOI 10.1161/01.RES.0000076893.70898.36; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Collavin L, 2004, P NATL ACAD SCI USA, V101, P8870, DOI 10.1073/pnas.0308605101; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Imoto S, 2004, BIOCHEM BIOPH RES CO, V319, P275, DOI 10.1016/j.bbrc.2004.04.161; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Komatsu T, 2004, MOL ENDOCRINOL, V18, P2451, DOI 10.1210/me.2004-0173; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Liang M, 2004, J BIOL CHEM, V279, P22857, DOI 10.1074/jbc.M401554200; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Matsuzaki K, 2003, BIOCHEM BIOPH RES CO, V306, P32, DOI 10.1016/S0006-291X(03)00910-0; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2002, CELL CYCLE, V1, P243, DOI 10.4161/cc.1.4.131; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Narita N, 1997, DEV BIOL, V189, P270, DOI 10.1006/dbio.1997.8684; Nemer G, 2001, ANN MED, V33, P604, DOI 10.3109/07853890109002106; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wong KA, 2004, MOL CELL BIOL, V24, P5577, DOI 10.1128/MCB.24.12.5577-5586.2004; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200	55	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49091	49098		10.1074/jbc.M407494200	http://dx.doi.org/10.1074/jbc.M407494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15337742	hybrid			2022-12-25	WOS:000225098100073
J	Yang, X; Chang, YJ; Lin, SW; Walsh, PN				Yang, X; Chang, YJ; Lin, SW; Walsh, PN			Identification of residues Asn(89), Ile(90), and Val(107) of the factor IXa second epidermal growth factor domain that are essential for the assembly of the factor X-activating complex on activated platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-IX; FACTOR-VIIIA; PROTEASE DOMAIN; BINDING-SITE; HIGH-AFFINITY; COFACTOR; SURFACE; LOOP; CONFORMATION; STIMULATION	Activated platelets promote intrinsic factor X-activating complex assembly by presenting high affinity, saturable binding sites for factor IXa mediated by two disulfide-constrained loop structures (loop 1, Cys(88)-Cys(99); loop 2, Cys(95)-Cys(109)) within the second epidermal growth factor (EGF2) domain. To identify amino acids essential for factor X activation complex assembly, recombinant factor IXa point mutants in loop 1 (N89A, I90A, K91A, and R94A) and loop 2 (D104A, N105A, and V107A) were prepared. All seven mutants were similar to the native factor IXa by SDS-PAGE, active site titration, and content of gamma-carboxyglutamic acid residues. Kinetic constants obtained by either titrating factor X or factor VIIIa on SFLLRN-activated platelets or phospholipid vesicles revealed near normal values of K-m(app) and K-d(app)FVIIIa for all mutants, indicating normal substrate and cofactor binding. In a factor Xa generation assay in the presence of activated platelets and cofactor factor VIIIa, compared with native factor IXa (K-d(app)FIXa similar to 1.1 nM, V-max similar to 12 nM min(-1)), N89A displayed an increase of similar to20-fold in K-d(app)FIXa and a decrease of similar to20-fold in V-max; I90A had an increase of similar to5-fold in K-d(app)FIXa and similar to10-fold decrease in V-max; and V107A had an increase of similar to3-fold in K-d(app)FIXa and similar to4-fold decrease in V-max. We conclude that residues Asn(89), Ile(90), and Val(107) within loops 1 and 2 (Cys(88)-Cys(109)) of the EGF2 domain of factor IXa are essential for normal interactions with the platelet surface and for the assembly of the factor X-activating complex on activated platelets.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Natl Chung Kung Univ, Dept Biochem, Tainan 701, Taiwan; Natl Taiwan Univ Hosp, Grad Inst Med Technol, Dept Lab Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Cheng Kung University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Biochem, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@temple.edu	Yang, Xia V/F-6911-2011	LIN, SHU-WHA/0000-0001-6748-5581; Chang, Yu-Jia/0000-0003-3978-3244	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL046213, R01HL070683] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46213, HL64943, HL74154, HL70683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1992, SEMIN THROMB HEMOST, V18, P311, DOI 10.1055/s-2007-1002570; Ahmad SS, 1998, BIOCHEMISTRY-US, V37, P1671, DOI 10.1021/bi971591h; AHMAD SS, 1994, BIOCHEMISTRY-US, V33, P12048, DOI 10.1021/bi00206a006; AHMAD SS, 1989, J BIOL CHEM, V264, P20012; AHMAD SS, 1992, J BIOL CHEM, V267, P8571; AHMAD SS, 1994, FASEB J, V8, pA1375; Ahmad SS, 1998, BLOOD, V92, p352A; Ahmad SS, 2003, J THROMB HAEMOST, V1, P48, DOI 10.1046/j.1538-7836.2003.00020.x; AHMAD SS, 1989, J BIOL CHEM, V264, P3244; AHMAD SS, 1990, J BIOL CHEM, V265, P20907; AHMAD SS, 1995, BIOCHEM J, V310, P427, DOI 10.1042/bj3100427; AHMAD SS, 1994, TRENDS CARDIOVAS MED, V4, P271, DOI 10.1016/1050-1738(94)90031-0; Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; BAJAJ SP, 1992, P NATL ACAD SCI USA, V89, P152, DOI 10.1073/pnas.89.1.152; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; Blostein MD, 2003, J BIOL CHEM, V278, P31297, DOI 10.1074/jbc.M302840200; Celie PHN, 2002, J BIOL CHEM, V277, P20214, DOI 10.1074/jbc.M108446200; Chang YJ, 2002, J BIOL CHEM, V277, P25393, DOI 10.1074/jbc.M105432200; Christophe OD, 1998, J BIOL CHEM, V273, P222, DOI 10.1074/jbc.273.1.222; HAMAGUCHI N, 1994, BLOOD, V84, P1837, DOI 10.1182/blood.V84.6.1837.bloodjournal8461837; Kolkman JA, 2000, BIOCHEM J, V350, P701, DOI 10.1042/0264-6021:3500701; Kolkman JA, 1999, J BIOL CHEM, V274, P29087, DOI 10.1074/jbc.274.41.29087; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; Monroe DM, 1998, BLOOD COAGUL FIBRIN, V9, pS15; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; Persson KEM, 2002, J BIOL CHEM, V277, P35616, DOI 10.1074/jbc.M205930200; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; RAWALASHEIKH R, 1992, BLOOD, V79, P398; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Wilkinson FH, 2002, J BIOL CHEM, V277, P5734, DOI 10.1074/jbc.M107753200; Wilkinson FH, 2002, J BIOL CHEM, V277, P5725, DOI 10.1074/jbc.M107027200; WINER BJ, 1991, STAT PRINCIPLES EXPT, P158; Wong MY, 1999, BIOCHEMISTRY-US, V38, P8948, DOI 10.1021/bi982835g; Yan SB, 1996, J MOL RECOGNIT, V9, P211; YANG X, 2003, J THROMB HAEMOST S, V1, P198	41	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46400	46405		10.1074/jbc.M406552200	http://dx.doi.org/10.1074/jbc.M406552200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328360	hybrid			2022-12-25	WOS:000224832400009
J	Amini, S; Saunders, M; Kelley, K; Khalili, K; Sawaya, BE				Amini, S; Saunders, M; Kelley, K; Khalili, K; Sawaya, BE			Interplay between HIV-1 Vpr and Sp1 modulates p21(WAF1) gene expression in human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSCRIPTION FACTOR SP1; TUMOR-SUPPRESSOR PROTEIN; ELEMENT-BINDING PROTEIN; LONG TERMINAL REPEAT; KRUPPEL-LIKE FACTOR; GROWTH-FACTOR-BETA; CELL-CYCLE; SYNERGISTIC ACTIVATION; FUNCTIONAL INTERACTION	The Vpr (viral protein R) of human immunodeficiency virus, type 1, which is expressed during the late stage of the viral infection, has received special attention because of its ability to control transcription of the human immunodeficiency virus, type 1, long terminal repeat and to influence cell cycle progression. Here we demonstrate that Vpr has the ability to regulate transcription of the cyclin-dependent kinase inhibitor, p21(WAF1) (p21), one of the key regulators of the cell cycle, in human astrocytic cells. The results from transcription assays demonstrated that Vpr augments promoter activity of p21 through the GC-rich region located between nucleotides -84 and -74 with respect to the + 1 transcription start site. Activation of p21 by Vpr required cooperativity of Sp1, which binds to the DNA sequence spanning -84 to -74. Results from bandshift assay revealed an increased level of Sp1 DNA binding activity in the presence of Vpr. Furthermore, Vpr was able to associate with Sp1 via the zinc finger domain located in the C-terminal region of Sp1. Functional studies revealed that the cooperativity between Vpr and Sp1 requires the zinc finger domain at the C terminus and the glutamine-rich domain at the N terminus of Sp1. Expression of p53 further enhanced the level of Vpr-Sp1-mediated transcription activation of p21 through the sequence spanning -84 to -74 and increased the DNA binding activity of Sp1 in the presence of Vpr. Results from glutathione S-transferase pull-down assay showed the association of Vpr with p53 in extracts containing Sp1. Altogether, the outcome of our functional and binding studies suggested that the physical interaction of Vpr with Sp1 and p53 could modulate transcriptional activity of p21.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Sawaya, BE (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St 015-96, Philadelphia, PA 19122 USA.	sawaya@temple.edu			NINDS NIH HHS [R01 NS040673-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040673] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amini S, 2002, ONCOGENE, V21, P5797, DOI 10.1038/sj.onc.1205754; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Chang YC, 2001, MOL CELL BIOL, V21, P1121, DOI 10.1128/MCB.21.4.1121-1131.2001; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dovat S, 2002, GENE DEV, V16, P2985, DOI 10.1101/gad.1040502; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Hasleton MD, 2003, BIOCHEM J, V373, P925, DOI 10.1042/BJ20030388; Hilton TL, 2003, J BIOL CHEM, V278, P12992, DOI 10.1074/jbc.M300412200; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; JEANG KT, 1993, J VIROL, V67, P6224, DOI 10.1128/JVI.67.10.6224-6233.1993; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim BJ, 2002, CARCINOGENESIS, V23, P1411, DOI 10.1093/carcin/23.9.1411; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Lu XH, 2003, CELL CYCLE, V2, P59, DOI 10.4161/cc.2.1.273; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN JM, 1993, FEBS LETT, V331, P141, DOI 10.1016/0014-5793(93)80313-J; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wang Z, 2000, CANCER RES, V60, P5376; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Zhang XL, 2003, J BIOL CHEM, V278, P21474, DOI 10.1074/jbc.M212098200; Zhou YH, 2002, CANCER INVEST, V20, P348, DOI 10.1081/CNV-120001180; Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003	59	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46046	46056		10.1074/jbc.M403792200	http://dx.doi.org/10.1074/jbc.M403792200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15302882	hybrid			2022-12-25	WOS:000224694900090
J	Sonnenschein, K; de Groot, H; Kirsch, M				Sonnenschein, K; de Groot, H; Kirsch, M			Formation of S-nitrosothiols from regiospecific reaction of thiols with N-nitrosotryptophan derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; NITROXYL ANION; SERUM-ALBUMIN; PEROXYNITRITE; NITROSATION; ENDOTHELIUM; TRYPTOPHAN; ACID; GLUTATHIONE; CHEMISTRY	S-nitrosothiols transport nitric oxide in vivo, and so-called transnitrosation reactions (i.e. the transfer of the nitroso function from nitrosothiol to thiolate) are believed to be involved in this process. In the present study we examined the N-nitrosotryptophan derivative-dependent nitrosation of thiols, a hitherto ignored possibility for the formation of S-nitrosothiols. The corresponding products were identified by N-15-NMR spectrometry. The fact that the reaction proceeded under hypoxic conditions as well as in non-aqueous solution strongly indicated the occurrence of a transnitrosation reaction. Interestingly, S-nitrosothiols could only very slowly transnitrosate N-terminal-blocked tryptophan derivatives like melatonin in non-aqueous solution but did not induce such a reaction in water. The indole moiety of the N-nitrosotryptophan derivatives was fully restituted during the reaction with thiols, as demonstrated by both capillary zone electrophoresis and fluorescence spectroscopy. A determination of the Arrhenius parameters demonstrated that the corresponding rate constants were comparable with the ones known for the transfer of the nitroso function from nitrosothiol to thiolate. Thus, N-nitrosotryptophan-dependent nitrosation of thiols may occur in vivo and might offer the possibility of developing a new class of vasodilative drugs.	Univ Klinikum, Inst Physiol Chem, D-45122 Essen, Germany	University of Duisburg Essen	Kirsch, M (corresponding author), Univ Klinikum, Inst Physiol Chem, Hufelandstr 55, D-45122 Essen, Germany.	michael.kirsch@uni-essen.de						Alvarez B, 1996, CHEM RES TOXICOL, V9, P390, DOI 10.1021/tx950133b; AUKRUST P, 1995, BLOOD, V86, P1383, DOI 10.1182/blood.V86.4.1383.bloodjournal8641383; Blanchard-Fillion B, 2001, FREE RADICAL RES, V35, P857, DOI 10.1080/10715760100301351; BONNETT R, 1974, J CHEM SOC P1, V1, P962; Butler AR, 1997, ANAL BIOCHEM, V249, P1; COTTRELL JE, 1978, NEW ENGL J MED, V298, P809, DOI 10.1056/NEJM197804132981502; CZAPSKI G, 1995, FREE RADICAL BIO MED, V19, P785, DOI 10.1016/0891-5849(95)00081-8; Forman HJ, 2004, AM J PHYSIOL-CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gross SS, 2001, NATURE, V409, P577, DOI 10.1038/35054661; GuardiolaLemaitre B, 1997, J BIOL RHYTHM, V12, P697, DOI 10.1177/074873049701200627; Guo HY, 2003, JPN HEART J, V44, P865, DOI 10.1536/jhj.44.865; Harohalli K, 2002, J BIOMED SCI, V9, P47, DOI 10.1007/BF02256578; HEYNS K, 1952, H-S Z PHYSIOL CHEM, V290, P171; Holliman BJ, 1997, SOUTHERN MED J, V90, P451, DOI 10.1097/00007611-199704000-00020; Holmes AJ, 2000, J CHEM SOC PERK T 2, P1639, DOI 10.1039/b004028m; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; Kirsch M, 1998, J BIOL CHEM, V273, P12716, DOI 10.1074/jbc.273.21.12716; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kirsch M, 2002, J BIOL CHEM, V277, P13379, DOI 10.1074/jbc.M108079200; Kirsch M, 2003, J BIOL CHEM, V278, P11931, DOI 10.1074/jbc.M300237200; LIJINSKY W, 1970, TETRAHEDRON, V26, P5137, DOI 10.1016/S0040-4020(01)93166-7; MACALLISTER RJ, 1995, J PHARMACOL EXP THER, V273, P154; Magri F, 2004, J PINEAL RES, V36, P256, DOI 10.1111/j.1600-079X.2004.00125.x; MEYER TA, 1982, J CHEM SOC PERK T 2, P1383, DOI 10.1039/p29820001383; MONCADA S, 1991, PHARMACOL REV, V43, P109; Mutschler E, 1995, DRUG ACTIONS BASIC P; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; Ohshima H, 1999, FREE RADICAL BIO MED, V26, P1305, DOI 10.1016/S0891-5849(98)00327-X; Padmaja S, 1996, REDOX REP, V2, P173, DOI 10.1080/13510002.1996.11747045; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P181, DOI 10.1111/j.1476-5381.1987.tb11310.x; Rodriguez J, 2003, P NATL ACAD SCI USA, V100, P336, DOI 10.1073/pnas.0234600100; RUBANYI GM, 1991, J CELL BIOCHEM, V46, P27, DOI 10.1002/jcb.240460106; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; SEDDON WA, 1973, CAN J CHEM, V51, P1123, DOI 10.1139/v73-166; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 2004, CIRC RES, V94, P414, DOI 10.1161/01.RES.0000122071.55721.BC; Szacilowski K, 2001, PROG REACT KINET MEC, V26, P1; Vaananen AJ, 2003, FREE RADICAL RES, V37, P381, DOI 10.1080/1071576031000061011; VENITT S, 1980, CARCINOGENESIS, V1, P523, DOI 10.1093/carcin/1.6.523; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	48	41	41	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45433	45440		10.1074/jbc.M405987200	http://dx.doi.org/10.1074/jbc.M405987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308658	hybrid			2022-12-25	WOS:000224694900019
J	Zhong, XY; Shen, YX; Ballar, P; Apostolou, A; Agami, R; Fang, SY				Zhong, XY; Shen, YX; Ballar, P; Apostolou, A; Agami, R; Fang, SY			AAA ATPase p97/valosin-containing protein interacts with gp78, a ubiquitin ligase for endoplasmic reticulum-associated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; ER-ASSOCIATED DEGRADATION; CELL-RECEPTOR SUBUNITS; MEMBRANE-FUSION; RETRO-TRANSLOCATION; MEDIATED PROTEOLYSIS; TRANSCRIPTION FACTOR; QUALITY-CONTROL; CUE DOMAIN; HUMAN HRD1	Endoplasmic reticulum-associated degradation (ERAD) is a protein quality control mechanism that eliminates unwanted proteins from the endoplasmic reticulum (ER) through a ubiquitin-dependent proteasomal degradation pathway. gp78 is a previously described ER membrane-anchored ubiquitin ligase (E3) involved in ubiquitination of ER proteins. AAA ATPase (ATPase associated with various cellular activities) p97/valosin-containing protein (VCP) subsequently dislodges the ubiquitinated proteins from the ER and chaperones them to the cytosol, where they undergo proteasomal degradation. We now report that gp78 physically interacts with p97/VCP and enhances p97/VCP-polyubiquitin association. The enhanced association correlates with decreases in ER stress-induced accumulation of polyubiquitinated proteins. This effect is abolished when the p97/VCP-interacting domain of gp78 is removed. Further, using ERAD substrate CD3delta, gp78 consistently enhances p97/VCP-CD3delta binding and facilitates CD3delta degradation. Moreover, inhibition of endogenous gp78 expression by RNA interference markedly increases the levels of total polyubiquitinated proteins, including CD3delta, and abrogates VCP-CD3delta interactions. The gp78 mutant with deletion of its p97/VCP-interacting domain fails to increase CD3delta degradation and leads to accumulation of polyubiquitinated CD3delta, suggesting a failure in delivering ubiquitinated CD3delta for degradation. These data suggest that gp78-p97/VCP interaction may represent one way of coupling ubiquitination with retrotranslocation and degradation of ERAD substrates.	Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, Baltimore, MD 21201 USA; Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands	University System of Maryland; University of Maryland Baltimore; Netherlands Cancer Institute	Fang, SY (corresponding author), Univ Maryland, Ctr Med Biotechnol, Inst Biotechnol, UMBI Bldg,M359,725 W Lombard St, Baltimore, MD 21201 USA.	fangs@umbi.umd.edu	agami, reuven/GOG-8289-2022; Fang, Shengyun/H-3802-2011; Kirmizibayrak, Petek Ballar/Y-6869-2018	Kirmizibayrak, Petek Ballar/0000-0002-6189-1818; Shen, Yuxian/0000-0002-0916-0743; Fang, Shengyun/0000-0001-7280-5463; Agami, Reuven/0000-0002-2848-2473	NIGMS NIH HHS [R01 GM69967-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao K, 2004, CELL CYCLE, V3, P422; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Elkabetz Y, 2004, J BIOL CHEM, V279, P3980, DOI 10.1074/jbc.M309938200; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hartmann-Petersen R, 2004, CURR BIOL, V14, P824, DOI 10.1016/j.cub.2004.04.029; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Kikkert M, 2004, J BIOL CHEM, V279, P3525, DOI 10.1074/jbc.M307453200; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Maurizi Michael R., 2001, EMBO Reports, V2, P980, DOI 10.1093/embo-reports/kve229; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Nadav E, 2003, BIOCHEM BIOPH RES CO, V303, P91, DOI 10.1016/S0006-291X(03)00279-1; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Silletti S, 1997, Pathol Oncol Res, V3, P230, DOI 10.1007/BF02899927; Taxis C, 2003, J BIOL CHEM, V278, P35903, DOI 10.1074/jbc.M301080200; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Wang Q, 2004, J STRUCT BIOL, V146, P44, DOI 10.1016/j.jsb.2003.11.014; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	50	166	173	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45676	45684		10.1074/jbc.M409034200	http://dx.doi.org/10.1074/jbc.M409034200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15331598	hybrid			2022-12-25	WOS:000224694900048
J	Viladevall, L; Serrano, R; Ruiz, A; Domenech, G; Giraldo, J; Barcelo, A; Arino, J				Viladevall, L; Serrano, R; Ruiz, A; Domenech, G; Giraldo, J; Barcelo, A; Arino, J			Characterization of the calcium-mediated response to alkaline stress in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; CA2+ INFLUX; YEAST; CALCINEURIN; PROTEIN; HOMOLOG; TOLERANCE; PATHWAY	Exposure of the yeast Saccharomyces cerevisiae to alkaline stress resulted in adaptive changes that involved remodeling the gene expression. Recent evidence suggested that the calcium-activated protein phosphatase calcineurin could play a role in alkaline stress signaling. By using an aequorin luminescence reporter, we showed that alkaline stress resulted in a sharp and transient rise in cytoplasmic calcium. This increase was largely abolished by addition of EGTA to the medium or in cells lacking Mid1 or Cch1, components of the high affinity cell membrane calcium channel. Under these circumstances, the alkaline response of different calcineurin-sensitive transcriptional promoters was also blocked. Therefore, exposure to alkali resulted in entry of calcium from the external medium, and this triggered a calcineurin-mediated response. The involvement of calcineurin and Crz1/Tcn1, the transcription factor activated by the phosphatase, in the transcriptional response triggered by alkalinization has been globally assessed by DNA microarray analysis in a time course experiment using calcineurin-deficient (cnb1) and crz1 mutants. We found that exposure to pH 8.0 increased at least 2-fold the mRNA levels of 266 genes. In many cases (60%) the response was rather early ( peak after 10 min). The transcriptional response of 27 induced genes (10%) was reduced or fully abolished in cnb1 cells. In general, the response of crz1 mutants was similar to that of calcineurin-deficient cells. By analysis of a systematic deletion library, we found 48 genes whose mutation resulted in increased sensitivity to the calcineurin inhibitor FK506. Twenty of these mutations (42%) also provoked alkaline pH sensitivity. In conclusion, our results demonstrated that calcium signaling and calcineurin activation represented a significant component of the yeast response to environmental alkalinization.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Grp Modelitzacio Estruct & Func Sistemes Biol, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Unit Bioestadist, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Serv DNA Microxips & Sequenciacio, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona; Autonomous University of Barcelona	Arino, J (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Fac Vet, E-08193 Barcelona, Spain.	Joaquin.Arino@uab.es	Giraldo, Jesus/F-9881-2011; Ruiz, Amparo/AAZ-2317-2021; Arino, Joaquin/D-3756-2011; barcelo, anna/K-2383-2014	Giraldo, Jesus/0000-0001-7082-4695; Ruiz, Amparo/0000-0002-3947-4540; Arino, Joaquin/0000-0002-6774-2987; Arino Carmona, Joaquin/0000-0002-0390-4270				Adams A, 1997, METHODS YEAST GENETI; ALBEROLA TM, 2004, IN PRESS INT MICROBI; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Birchwood CJ, 2001, J BIOL CHEM, V276, P11712, DOI 10.1074/jbc.M010221200; Bonilla M, 2003, MOL BIOL CELL, V14, P4296, DOI 10.1091/mbc.E03-02-0113; Cabiscol E, 2002, J BIOL CHEM, V277, P44531, DOI 10.1074/jbc.M206525200; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Courchesne WE, 2003, MOL MICROBIOL, V47, P223, DOI 10.1046/j.1365-2958.2003.03291.x; Cui XQ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-210; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Ezaki B, 1998, FEMS MICROBIOL LETT, V159, P99, DOI 10.1016/S0378-1097(97)00554-5; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Garcia R, 2004, J BIOL CHEM, V279, P15183, DOI 10.1074/jbc.M312954200; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gorlach J, 2000, EMBO J, V19, P3618, DOI 10.1093/emboj/19.14.3618; HALACHMI D, 1989, FEBS LETT, V256, P55, DOI 10.1016/0014-5793(89)81717-X; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hilioti Z, 2004, TOP CURR GENET, V5, P73; Hilioti Z, 2004, GENE DEV, V18, P35, DOI 10.1101/gad.1159204; Hilioti Z, 2003, BIOCHEM BIOPH RES CO, V311, P1089, DOI 10.1016/S0006-291X(03)01515-8; IIDA H, 1990, J BIOL CHEM, V265, P13391; Issel-Tarver L, 2002, METHOD ENZYMOL, V350, P329, DOI 10.1016/S0076-6879(02)50972-1; Kafadar KA, 2003, GENE DEV, V17, P2698, DOI 10.1101/gad.1140603; Kapteyn JC, 2001, MOL MICROBIOL, V39, P469, DOI 10.1046/j.1365-2958.2001.02242.x; Kingsbury TJ, 2000, GENE DEV, V14, P1595; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lamb TM, 2003, MOL CELL BIOL, V23, P677, DOI 10.1128/MCB.23.2.677-686.2003; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Mewes HW, 2000, NUCLEIC ACIDS RES, V28, P37, DOI 10.1093/nar/28.1.37; Monteiro G, 2002, FREE RADICAL BIO MED, V32, P278, DOI 10.1016/S0891-5849(01)00801-2; Muller EM, 2003, J BIOL CHEM, V278, P38461, DOI 10.1074/jbc.M304089200; Muller EM, 2001, GENETICS, V159, P1527; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Rodrigues-Pousada CA, 2004, FEBS LETT, V567, P80, DOI 10.1016/j.febslet.2004.03.119; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	56	158	166	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43614	43624		10.1074/jbc.M403606200	http://dx.doi.org/10.1074/jbc.M403606200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299026	hybrid			2022-12-25	WOS:000224383100034
J	Huang, CL; Liu, DG; Masuya, D; Kameyama, K; Nakashima, T; Yokomise, H; Ueno, M; Miyake, M				Huang, CL; Liu, DG; Masuya, D; Kameyama, K; Nakashima, T; Yokomise, H; Ueno, M; Miyake, M			MRP-1/CD9 gene transduction downregulates Wnt signal pathways	ONCOGENE			English	Article						MRP-1/CD9; Wnt; microarray; real-time PCR	ENDOTHELIAL GROWTH-FACTOR; CELL MOTILITY; BREAST-CANCER; UP-REGULATION; CYCLIN D1; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; MATRIX METALLOPROTEINASE-26; EPITHELIAL ORIGIN; COLON-CARCINOMA	Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/ CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/ CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.	Kagawa Univ, Fac Med, Dept Surg 2, Miki, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Pathol & Host Def, Kagawa 7610793, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Osaka 5308480, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 5308480, Japan	Kagawa University; Kagawa University; Kitano Hospital; Kitano Hospital	Huang, CL (corresponding author), Kagawa Univ, Fac Med, Dept Surg 2, 1750-1, Miki, Kagawa 7610793, Japan.	chuang@kms.ac.jp						Adachi M, 1998, J CLIN ONCOL, V16, P1060, DOI 10.1200/JCO.1998.16.3.1060; Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dale TC, 1998, BIOCHEM J, V329, P209; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Desnoyers L, 2001, J BIOL CHEM, V276, P47599, DOI 10.1074/jbc.M108339200; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Katoh M, 2003, INT J MOL MED, V12, P811; Katoh M, 2003, INT J ONCOL, V22, P209; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kleer CG, 2002, ONCOGENE, V21, P3172, DOI 10.1038/sj.onc.1205462; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; Mine S, 2003, EXP CELL RES, V288, P189, DOI 10.1016/S0014-4827(03)00184-8; MITCHELL CE, 1995, ANAL BIOCHEM, V224, P148, DOI 10.1006/abio.1995.1020; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyazaki YJ, 2002, ONCOGENE, V21, P798, DOI 10.1038/sj.onc.1205126; Mori M, 1998, CLIN CANCER RES, V4, P1507; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Saitoh T, 2002, INT J MOL MED, V9, P515; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uria JA, 2000, CANCER RES, V60, P4745; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Xie D, 2001, CANCER RES, V61, P8917; Xu LF, 2000, GENE DEV, V14, P585; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhang XB, 2001, CANCER RES, V61, P6050	50	57	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	2004	23	45					7475	7483		10.1038/sj.onc.1208063	http://dx.doi.org/10.1038/sj.onc.1208063			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334057				2022-12-25	WOS:000224176500004
J	Lipkow, K; Buisine, N; Chalmers, R				Lipkow, K; Buisine, N; Chalmers, R			Promiscuous target interactions in the mariner transposon Himar1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC COMPLEX; SLEEPING-BEAUTY; SITE SELECTION; DNA; ELEMENT; PROTEINS; CATALYSIS; EXCHANGE; CAPTURE; PATTERN	We have previously characterized the early intermediates of mariner transposition. Here we characterize the target interactions that occur later in the reaction. We find that, in contrast to the early transposition intermediates, the strand transfer complex is extremely stable and difficult to disassemble. Transposase is tightly bound to the transposon ends constraining rotation of the DNA at the single strand gaps in the target site flanking the element on either side. We also find that although the cleavage step requires Mg2+ or Mn2+ as cofactor, the strand transfer step is also supported by Ca2+, suggesting that the structure of the active site changes between cleavage and insertion. Finally, we show that, in contrast to the bacterial cut and paste transposons, mariner target interactions are promiscuous and can take place either before or after cleavage of the flanking DNA. This is similar to the behavior of the V(D) J system, which is believed to be derived from an ancestral eukaryotic transposon. We discuss the implications of promiscuous target interactions for promoting local transposition and whether this is an adaptation to facilitate the invasion of a genome following horizontal transfer to a new host species.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Chalmers, R (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.			chalmers, ronald/0000-0002-1395-7173				Akerley BJ, 2002, METHOD ENZYMOL, V358, P100; BANCROFT I, 1993, GENETICS, V134, P1221; Barry EG, 2004, GENETICS, V166, P823, DOI 10.1534/genetics.166.2.823; Buisine N, 2002, FEBS LETT, V522, P52, DOI 10.1016/S0014-5793(02)02882-X; Craig Nancy L., 2002, P423; Crellin P, 2004, MOL CELL, V13, P537, DOI 10.1016/S1097-2765(04)00052-8; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Dawson A, 2003, MOL CELL, V11, P225, DOI 10.1016/S1097-2765(02)00798-0; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; ENGELS WR, 1994, SCIENCE, V263, P1623, DOI 10.1126/science.8128250; Fischer SEJ, 2003, GENETICS, V164, P127; HANIFORD DB, 2002, MOBILE DNA, V2, P457; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Horie K, 2003, MOL CELL BIOL, V23, P9189, DOI 10.1128/MCB.23.24.9189-9207.2003; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lee GS, 2004, CELL, V117, P171, DOI 10.1016/S0092-8674(04)00301-0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Lipkow K, 2004, MOL CELL BIOL, V24, P8301, DOI 10.1128/MCB.24.18.8301-8311.2004; Loot C, 2002, EMBO J, V21, P4172, DOI 10.1093/emboj/cdf403; Machida C, 1997, P NATL ACAD SCI USA, V94, P8675, DOI 10.1073/pnas.94.16.8675; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; Montgomery DC., 2017, DESIGN ANAL EXPT, V9th edn; MURPHY LD, 1994, BBA-GENE STRUCT EXPR, V1219, P277, DOI 10.1016/0167-4781(94)90049-3; Neiditch MB, 2001, MOL CELL BIOL, V21, P4302, DOI 10.1128/MCB.21.13.4302-4310.2001; Plasterk RHA, 1999, TRENDS GENET, V15, P326, DOI 10.1016/S0168-9525(99)01777-1; Pribil PA, 2003, J MOL BIOL, V330, P247, DOI 10.1016/S0022-2836(03)00588-6; REZNIKOFF WS, 2002, MOBILE DNA, V2, P403; ROBERTSON HM, 1995, MOL BIOL EVOL, V12, P850; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; Sewitz S, 2003, NUCLEIC ACIDS RES, V31, P5868, DOI 10.1093/nar/gkg797; TOWER J, 1993, GENETICS, V133, P347; Vigdal TJ, 2002, J MOL BIOL, V323, P441, DOI 10.1016/S0022-2836(02)00991-9	36	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48569	48575		10.1074/jbc.M408759200	http://dx.doi.org/10.1074/jbc.M408759200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15333635	hybrid			2022-12-25	WOS:000225098100012
J	Zimmermann, K; Ritter, E; Bartl, FJ; Hofmann, KP; Heck, M				Zimmermann, K; Ritter, E; Bartl, FJ; Hofmann, KP; Heck, M			Interaction with transducin depletes metarhodopsin III - A regulated retinal storage in visual signal transduction?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; META-III; PHOTORECEPTOR CELLS; BOVINE RHODOPSIN; LIGHT-SCATTERING; DISK MEMBRANE; BINDING; MECHANISM; KINETICS; RECEPTOR	In the phototransduction pathway of rhodopsin, the metarhodopsin (Meta) III retinal storage form arises from the active G-protein binding Meta II by a slow spontaneous reaction through the Meta I precursor or by light absorption and photoisomerization, respectively. Meta III is a side product of the Meta II decay path and holds its retinal in the original binding site, with the Schiff base bond to the apoprotein reprotonated as in the dark ground state. It thus keeps the retinal away from the regeneration pathway in which the photolyzed all-trans-retinal is released. This study was motivated by our recent observation that Meta III remains stable for hours in membranes devoid of regulatory proteins, whereas it decays much more rapidly in situ. We have now explored the possibility of regulated formation and decay of Meta III, using intrinsic opsin tryptophan fluorescence and UV-visible and Fourier transform infrared spectroscopy. We find that a rapid return of Meta III into the regeneration pathway is triggered by the G-protein transducin (G(t)). Depletion of the retinal storage is initiated by a novel direct bimolecular interaction of G(t) with Meta III, which was previously considered inactive. G(t) thereby induces the transition of Meta III into Meta II, so that the retinylidene bond to the apoprotein can be hydrolyzed, and the retinal can participate again in the normal retinoid cycle. Beyond the potential significance for retinoid metabolism, this may provide the first example of a G-protein-catalyzed conversion of a receptor.	Charite Univ Med Berlin, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Humboldt Univ, Zentrum Biophys & Bioinformat, D-10015 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Heck, M (corresponding author), Charite Univ Med Berlin, Inst Med Phys & Biophys, Campus Charite Mitte,Schumannstr 20-21, D-10098 Berlin, Germany.	martin.heck@charite.de						ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; BAUMANN C, 1973, J PHYSIOL-LONDON, V235, P761, DOI 10.1113/jphysiol.1973.sp010415; BIRGE RR, 1988, BIOPHYS J, V53, P367, DOI 10.1016/S0006-3495(88)83114-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; DeGrip W. J., 2000, HDB BIOL PHYS, P1, DOI 10.1016/s1383- 8121(00)80004- 4; DONNER KO, 1975, VISION RES, V15, P985, DOI 10.1016/0042-6989(75)90241-2; EBREY TG, 1968, VISION RES, V8, P965, DOI 10.1016/0042-6989(68)90071-0; EMEIS D, 1981, FEBS LETT, V136, P201, DOI 10.1016/0014-5793(81)80618-7; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Heck M, 2003, VISION RES, V43, P3003, DOI 10.1016/j.visres.2003.08.011; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Hofmann K. P., 2000, HDB BIOL PHYSICS, P91, DOI 10.1016/s1383-8121(00)80006-8; HOFMANN KP, 1986, PHOTOBIOCH PHOTOBIOP, V13, P309; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; Kolesnikov AV, 2003, VISUAL NEUROSCI, V20, P249, DOI 10.1017/S0952523803203047; KUHN H, 1982, METHOD ENZYMOL, V81, P556; Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; Ritter E, 2004, J BIOL CHEM, V279, P48102, DOI 10.1074/jbc.M406857200; SCHMID R, 1982, NONFORMAL KINETICS, P17; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Spudich JL, 2000, ANNU REV CELL DEV BI, V16, P365, DOI 10.1146/annurev.cellbio.16.1.365; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2004, BIOCHEMISTRY-US, V43, P9457, DOI 10.1021/bi049337u; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216	43	24	24	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48112	48119		10.1074/jbc.M406856200	http://dx.doi.org/10.1074/jbc.M406856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15322130	hybrid			2022-12-25	WOS:000224957000084
J	Im, SH; Hueber, A; Monticelli, S; Kang, KH; Rao, A				Im, SH; Hueber, A; Monticelli, S; Kang, KH; Rao, A			Chromatin-level regulation of the IL10 gene in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLATION; INTERFERON-GAMMA; IN-VIVO; INTERLEUKIN-10; TRANSCRIPTION; DIFFERENTIATION; ACTIVATION; ENHANCER; RECEPTOR; EXPRESSION	The immunoregulatory cytokine interleukin 10 (IL-10) modulates the function of diverse immune and non-immune cells. Here, we examine the chromatin structural changes associated with IL10 gene transcription by naive and differentiated murine T cells. Naive T cells lack DNase I hypersensitive (HS) sites in the vicinity of the IL10 gene, whereas differentiated T cells display a strong 3' constitutive HS site as well as several inducible sites. The majority of HS sites map to regions that are strongly conserved in sequence between mouse and human genomes. In committed Th1 cells, the mechanism of IL10 gene silencing is associated with the development of repressive histone modifications near the IL10 promoter and also near intronic hypersensitive regions of the IL10 gene. Our results constitute the first report of chromatin structural differences within the IL10 gene in differentiated Th1 and Th2 cells and emphasize the surprising diversity of mechanisms used to regulate cytokine gene expression at the chromatin level.	Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Gwangju Institute of Science & Technology (GIST); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Im, SH (corresponding author), Gwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	imsh@gist.ac.kr	Kang, Kyuho/AAK-1628-2020; Im, Sin-Hyeog/AAM-9586-2021; Monticelli, Silvia/ABE-7054-2020; Im, Sin-Hyeog/E-6811-2013	Kang, Kyuho/0000-0003-3448-5336; Im, Sin-Hyeog/0000-0002-3173-1856; Im, Sin-Hyeog/0000-0002-3173-1856; Hueber, Axel/0000-0001-6454-1234; Monticelli, Silvia/0000-0002-5909-8802	NATIONAL CANCER INSTITUTE [R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048213] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA42471] Funding Source: Medline; NIAID NIH HHS [R01-AI48213] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Hernandez-Munain C, 1998, MOL CELL BIOL, V18, P3223, DOI 10.1128/MCB.18.6.3223; JAIN JN, 1993, J IMMUNOL, V151, P837; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Lee DU, 2004, J BIOL CHEM, V279, P4802, DOI 10.1074/jbc.M307904200; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Mayor C, 2000, BIOINFORMATICS, V16, P1046, DOI 10.1093/bioinformatics/16.11.1046; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Salazar-Onfray F, 1999, MED ONCOL, V16, P86, DOI 10.1007/BF02785841; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; Wang DZ, 1995, ANN NY ACAD SCI, V766, P182, DOI 10.1111/j.1749-6632.1995.tb26661.x; ZDANOV A, 1995, STRUCTURE, V3, P591, DOI 10.1016/S0969-2126(01)00193-9	24	88	91	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46818	46825		10.1074/jbc.M401722200	http://dx.doi.org/10.1074/jbc.M401722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15319439	hybrid			2022-12-25	WOS:000224832400062
J	Narayanan, R; Sepulveda, VAT; Falzon, M; Weigel, NL				Narayanan, R; Sepulveda, VAT; Falzon, M; Weigel, NL			The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RETINOID-X-RECEPTOR; LIGAND-INDEPENDENT ACTIVATION; RAT OSTEOSARCOMA CELLS; 1,25-DIHYDROXYVITAMIN D-3; PROGESTERONE-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PHOSPHORYLATION SITE; ANDROGEN RECEPTOR; HORMONE-RECEPTOR	The actions of the active metabolite of 1,25-(OH)(2)D-3 ( 1,25- D) are mediated primarily by the vitamin D receptor (VDR), a member of the nuclear receptor family of ligand-activated transcription factors. Although their ligands cause transcriptional activation, many of the ligands also rapidly activate cellular signaling pathways through mechanisms that have not been fully elucidated. We find that 1,25- D causes a rapid, but sustained activation of ERK ( extracellular signal-regulated kinase) in bone cell lines. However, the effect of ERK activation on VDR transcriptional activity was cell line-specific. Inhibition of ERK activation by the MEK inhibitor, U0126, stimulated VDR activity in MC3T3-E1 cells, but inhibited the activity in MG-63 cells as well as in HeLa cells. VDR is not a known target of ERK. We found that the ERK target responsible for reduced VDR activity in MC3T3-E1 cells is RXRalpha. MC3T3-E1 cells express lower levels of RXRbeta and RXRgamma than either HeLa or MG-63 cells. Although overexpression of RXRalpha in MC3T3-E1 cells increased VDR activity, U0126 further enhanced the activity. In contrast, overexpression of RXRgamma stimulated VDR activity but abrogated the stimulation by U0126. Thus, although 1,25- D treatment activates ERK in many cell types, subsequently inducing changes independent of VDR, the effects of treatment with 1,25- D on the transcriptional activity of VDR are RXR isoform-specific. In cells in which RXRalpha is the VDR partner, the transcriptional activation of VDR by 1,25- D is attenuated by the concomitant activation of ERK. In cells utilizing RXRgamma, ERK activation enhances VDR transcriptional activity.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	nweigel@bcm.tmc.edu						Adachi S, 2002, HEPATOLOGY, V35, P332, DOI 10.1053/jhep.2002.31164; ARBOUR NC, 1993, MOL ENDOCRINOL, V7, P1307, DOI 10.1210/me.7.10.1307; Barsony J, 2002, VITAM HORM, V65, P345, DOI 10.1016/S0083-6729(02)65071-X; Bastien J, 2002, J BIOL CHEM, V277, P28683, DOI 10.1074/jbc.M203623200; Bettoun DJ, 2003, MOL ENDOCRINOL, V17, P2320, DOI 10.1210/me.2003-0148; Blutt SE, 2000, CANCER RES, V60, P779; Blutt SE, 1997, ENDOCRINOLOGY, V138, P1491, DOI 10.1210/en.138.4.1491; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; BOWERS GN, 1966, CLIN CHEM, V12, P70; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; Brown SA, 2003, OSTEOPOROSIS INT, V14, P442, DOI 10.1007/s00198-002-1331-x; Chae HJ, 2002, IMMUNOPHARM IMMUNOT, V24, P31, DOI 10.1081/IPH-120003401; Chattopadhyay N, 2003, AM J PHYSIOL-ENDOC M, V284, pE219, DOI 10.1152/ajpendo.00247.2002; Chen DB, 2004, ENDOCRINOLOGY, V145, P113, DOI 10.1210/en.2003-0547; Christakos S, 2003, J CELL BIOCHEM, V88, P695, DOI 10.1002/jcb.10423; Danilenko M, 2003, CANCER RES, V63, P1325; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; Deluca HF, 1997, OSTEOPOROSIS INT, V7, P24, DOI 10.1007/BF03194338; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukagawa M, 2002, NEPHRON, V92, P41, DOI 10.1159/000065376; Gianni M, 2003, J BIOL CHEM, V278, P34458, DOI 10.1074/jbc.M304952200; Gniadecki R, 1996, J INVEST DERMATOL, V106, P1212, DOI 10.1111/1523-1747.ep12348498; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Haussler MR, 1997, J ENDOCRINOL, V154, pS57; HIURA K, 1991, ENDOCRINOLOGY, V128, P1630, DOI 10.1210/endo-128-3-1630; Hsieh JC, 1998, J CELL BIOCHEM, V70, P94, DOI 10.1002/(SICI)1097-4644(19980701)70:1<94::AID-JCB10>3.3.CO;2-Q; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JONES BB, 1991, MOL ENDOCRINOL, V5, P1137, DOI 10.1210/mend-5-8-1137; JURUTKA PW, 1993, BIOCHEMISTRY-US, V32, P8184, DOI 10.1021/bi00083a019; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; Kabasawa Y, 2003, DNA CELL BIOL, V22, P541, DOI 10.1089/104454903322405428; KUROKI Y, 1995, J CELL PHYSIOL, V164, P459, DOI 10.1002/jcp.1041640303; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee HY, 2000, J BIOL CHEM, V275, P32193, DOI 10.1074/jbc.M005490200; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Liu YY, 2000, MOL ENDOCRINOL, V14, P1776, DOI 10.1210/me.14.11.1776; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Mahonen A, 1998, J CELL BIOCHEM, V68, P151, DOI 10.1002/(SICI)1097-4644(19980201)68:2<151::AID-JCB2>3.0.CO;2-U; Narayanan R, 2002, BONE, V31, P381, DOI 10.1016/S8756-3282(02)00836-0; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; Oda Y, 2003, MOL ENDOCRINOL, V17, P2329, DOI 10.1210/me.2003-0063; OZONO K, 1991, J BONE MINER RES, V6, P1021; Prufer K, 2002, MOL ENDOCRINOL, V16, P961, DOI 10.1210/me.16.5.961; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Schroeder Neil J., 2003, Nephron, V94, pp62, DOI 10.1159/000072519; Solomon C, 1999, J CLIN INVEST, V103, P1729, DOI 10.1172/JCI6871; Solomon C, 1998, J BIOL CHEM, V273, P17573, DOI 10.1074/jbc.273.28.17573; SONE T, 1990, J BIOL CHEM, V265, P21997; Song XD, 1998, ENDOCRINOLOGY, V139, P457, DOI 10.1210/en.139.2.457; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tryfonidou MA, 2002, J NUTR, V132, P2644, DOI 10.1093/jn/132.9.2644; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Wali RK, 2003, J CELL BIOCHEM, V88, P794, DOI 10.1002/jcb.10432; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Zagar Y, 2004, J BIOL CHEM, V279, P2403, DOI 10.1074/jbc.M309132200; Zanello LP, 2004, P NATL ACAD SCI USA, V101, P1589, DOI 10.1073/pnas.0305802101; Zenmyo M, 2001, HUM PATHOL, V32, P410, DOI 10.1053/hupa.2001.23524; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577	67	47	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47298	47310		10.1074/jbc.M404101200	http://dx.doi.org/10.1074/jbc.M404101200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331595	hybrid			2022-12-25	WOS:000224832400118
J	Tsuboi, T; McMahon, HT; Rutter, GA				Tsuboi, T; McMahon, HT; Rutter, GA			Mechanisms of dense core vesicle recapture following "kiss and run" ("cavicapture") exocytosis in insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; GREEN FLUORESCENT PROTEIN; EVANESCENT-WAVE MICROSCOPY; PLASMINOGEN-ACTIVATOR; SYNAPTIC VESICLES; ENDOCRINE-CELLS; NEUROMUSCULAR-JUNCTION; GRANULE EXOCYTOSIS; RAPID ENDOCYTOSIS; CHROMAFFIN CELLS	The molecular mechanisms underlying "kiss and run" or "cavicapture" exocytosis of dense core secretory vesicles are presently unclear. Although dynamin-1 has previously been implicated in the recapture process in neurons, the recruitment of this fission protein to a single exocytosing vesicle has not been examined in real time during peptide release from pancreatic beta-cells. Imaged simultaneously in clonal insulin-secreting cells by dual color total internal reflection fluorescence microscopy, monomeric red fluorescent protein (mRFP)tagged neuropeptide Y and green fluorescent protein (GFP)-tagged synaptotagmin-1 or synaptobrevin-2 rapidly diffused from sites of exocytosis, whereas the vesicle membrane protein phogrin and tissue plasminogen activator (tPA) were retained, consistent with fusion pore closure. Vesicle recovery frequently involved the recruitment of enhanced GFP-tagged dynamin-1, and GTPase-defective dynamin-1(K44E) increased the dwell time of tPA-mRFP at the plasma membrane. By contrast, recruitment of GFP chimeras of clathrin, epsin, and amphiphysin was not observed. Expression of dynamin-1( K535A), mutated in the pleckstrin homology domain, caused the apparent full fusion of vesicles, as reported by the additional release of tPA-mRFP (15-nm diameter) and enhanced GFP-tagged phogrin. We conclude that re-uptake of vesicles after peptide release by cavicapture corresponds to a novel form of endocytosis in which dynamin-1 stabilizes and eventually closes the fusion pore, with no requirement for "classical" endocytosis for retreat from the plasma membrane.	Univ Bristol, Henry Wellcome Labs Instegrated Cell Signalling, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Bristol; University of Bristol; MRC Laboratory Molecular Biology	Rutter, GA (corresponding author), Univ Bristol, Henry Wellcome Labs Instegrated Cell Signalling, Univ Walk, Bristol BS8 1TD, Avon, England.	g.a.rutter@bristol.ac.uk	TSUBOI, Takashi/AAD-7976-2019	TSUBOI, Takashi/0000-0001-8290-2021; Rutter, Guy/0000-0001-6360-0343				Artalejo CR, 2002, P NATL ACAD SCI USA, V99, P6358, DOI 10.1073/pnas.082658499; Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cui L, 1996, J BIOL CHEM, V271, P24817, DOI 10.1074/jbc.271.40.24817; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Di Paolo G, 2002, NEURON, V33, P789, DOI 10.1016/S0896-6273(02)00601-3; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; Higgins MK, 2002, TRENDS BIOCHEM SCI, V27, P257, DOI 10.1016/S0968-0004(02)02089-3; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Huttner WB, 2002, TRENDS CELL BIOL, V12, P155, DOI 10.1016/S0962-8924(02)02252-3; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; KOENIG JH, 1989, J NEUROSCI, V9, P3844; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Lochner JE, 1998, MOL BIOL CELL, V9, P2463, DOI 10.1091/mbc.9.9.2463; Ma L, 2004, P NATL ACAD SCI USA, V101, P9266, DOI 10.1073/pnas.0403201101; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Molinete M, 2000, DIABETOLOGIA, V43, P1157, DOI 10.1007/s001250051507; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; ORCI L, 1973, SCIENCE, V179, P82, DOI 10.1126/science.179.4068.82; Ort T, 2000, EUR J CELL BIOL, V79, P621, DOI 10.1078/0171-9335-00095; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; Pouli AE, 1998, BIOCHEM J, V331, P669, DOI 10.1042/bj3310669; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Rutter GA, 2004, NEUROREPORT, V15, P79, DOI 10.1097/00001756-200401190-00016; Saeki K, 2002, DIABETES, V51, P1842, DOI 10.2337/diabetes.51.6.1842; Silver RB, 2001, BIOL BULL-US, V201, P263, DOI 10.2307/1543356; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Taraska JW, 2004, P NATL ACAD SCI USA, V101, P8780, DOI 10.1073/pnas.0401316101; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; TERAKAWA S, 1997, BIOIMAGES, V5, P24; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2003, CURR BIOL, V13, P563, DOI 10.1016/S0960-9822(03)00176-3; Tsuboi T, 2002, BIOPHYS J, V83, P172, DOI 10.1016/S0006-3495(02)75159-X; Tsuboi T, 2002, J BIOL CHEM, V277, P15957, DOI 10.1074/jbc.C200051200; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Valtorta F, 2001, TRENDS CELL BIOL, V11, P324, DOI 10.1016/S0962-8924(01)02058-X; Varadi A, 2003, BIOCHEM BIOPH RES CO, V311, P272, DOI 10.1016/j.bbrc.2003.09.208; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; Zenisek D, 2002, NEURON, V35, P1085, DOI 10.1016/S0896-6273(02)00896-6	57	149	154	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47115	47124		10.1074/jbc.M408179200	http://dx.doi.org/10.1074/jbc.M408179200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331588	hybrid			2022-12-25	WOS:000224832400098
J	Benjamin, JM; Torke, SJ; Demeler, B; McGarry, TJ				Benjamin, JM; Torke, SJ; Demeler, B; McGarry, TJ			Geminin has dimerization, Cdt1-binding, and destruction domains that are required for biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; INHIBITION	Geminin is an unstable regulatory protein that affects both cell division and cell differentiation. Geminin inhibits a second round of DNA synthesis during S and G(2) phase by binding the essential replication protein Cdt1. Geminin is also required for entry into mitosis, either by preventing replication abnormalities or by down-regulating the checkpoint kinase Chk1. Geminin overexpression during embryonic development induces ectopic neural tissue, inhibits eye formation, and perturbs the segmental patterning of the embryo. In order to define the structural and functional domains of the geminin protein, we generated over 40 missense and deletion mutations and tested their phenotypes in biological and biochemical assays. We find that geminin self-associates through the coiled-coil domain to form dimers and that dimerization is required for activity. Geminin contains a typical bipartite nuclear localization signal that is also required for its destruction during mitosis. Nondegradable mutants of geminin interfere with DNA replication in succeeding cell cycles. Geminin's Cdt1-binding domain lies immediately adjacent to the dimerization domain and overlaps it. We constructed two nonbinding mutants in this domain and found that they neither inhibited replication nor permitted entry into mitosis, indicating that this domain is necessary for both activities. We identified several missense mutations in geminin's Cdt1 binding domain that were deficient in their ability to inhibit replication yet were still able to allow mitotic entry, suggesting that these are separate functions of geminin.	Northwestern Univ, Feinberg Sch Med, Dept Med, Div Cardiol, Chicago, IL 60611 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	Northwestern University; Feinberg School of Medicine; University of Texas System; University of Texas Health San Antonio	McGarry, TJ (corresponding author), Tarry 15-759,303 E Chicago Ave, Chicago, IL 60611 USA.	t-mcgarry@northwestern.edu		Demeler, Borries/0000-0002-2414-9518				Cohn E., 1943, PROTEINS AMINO ACIDS, P157; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Demeler B, 1998, BIOPHYS J, V74, P444, DOI 10.1016/S0006-3495(98)77802-6; Dingwall C, 1998, CURR BIOL, V8, pR922, DOI 10.1016/S0960-9822(98)00010-4; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HILL DE, 1989, CURRENT PROTOCOLS MO; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P164; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Russell TR, 2004, BIOCHEMISTRY-US, V43, P1580, DOI 10.1021/bi035578a; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309	20	38	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45957	45968		10.1074/jbc.M407726200	http://dx.doi.org/10.1074/jbc.M407726200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308655	hybrid			2022-12-25	WOS:000224694900081
J	Cabello, P; Pino, C; Olmo-Mira, MF; Castillo, F; Roldan, MD; Moreno-Vivian, C				Cabello, P; Pino, C; Olmo-Mira, MF; Castillo, F; Roldan, MD; Moreno-Vivian, C			Hydroxylamine assimilation by Rhodobacter capsulatus E1F1 - Requirement of the hcp gene (hybrid cluster protein) located in the nitrate assimilation nas gene region for hydroxylamine reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-VULGARIS HILDENBOROUGH; 6FE-6S PRISMANE-CLUSTER; X-RAY STRUCTURES; DESULFURICANS ATCC-27774; PHOTOTROPHIC BACTERIUM; SPECTROSCOPIC EVIDENCE; NADH-OXIDOREDUCTASE; NITRITE REDUCTASE; ANGSTROM; IRON	Rhodobacter capsulatus E1F1 grows phototrophically with nitrate as nitrogen source. Using primers designed for conserved motifs in bacterial assimilatory nitrate reductases, a 450-bp DNA was amplified by PCR and used for the screening of a genomic library. A cosmid carrying an insert with four SalI fragments of 2.8, 4.1, 4.5, and 5.8 kb was isolated, and DNA sequencing revealed that it contains a nitrate assimilation (nas) gene region, including the hcp gene coding for a hybrid cluster protein (HCP). Expression of hcp is probably regulated by a nitrite-sensitive repressor encoded by the adjacent nsrR gene. A His(6)-HCP was overproduced in Escherichia coli and purified. HCP contained about 6 iron and 4 labile sulfide atoms per molecule, in agreement with the presence of both [2Fe-2S] and [4Fe-2S-2O] clusters, and showed hydroxylamine reductase activity, forming ammonia in vitro with methyl viologen as reductant. The apparent K-m values for NH2OH and methyl viologen were 1 mM and 7 muM, respectively, at the pH and temperature optima (9.3 and 40 degreesC). The activity was oxygen-sensitive and was inhibited by sulfide and iron reagents. R. capsulatus E1F1 grew phototrophically, but not heterotrophically, with 1 mM NH2OH as nitrogen source, and up to 10 mM NH2OH was taken up by anaerobic resting cells. Ammonium was transiently accumulated in the media, and its assimilation was prevented by L-methionine-D, L-sulfoximine, a glutamine synthetase inhibitor. In addition, hydroxylamine- or nitrite-grown cells showed the higher hydroxylamine reductase activities. However, R. capsulatus B10S, a strain lacking the whole hcp-nas region, did not grow with 1 mM NH2OH. Also, E. coli cells overproducing HCP tolerate hydroxylamine better during anaerobic growth. These results suggest that HCP is involved in assimilation of NH2OH, a toxic product that could be formed during nitrate assimilation, probably in the nitrite reduction step.	Univ Cordoba, Dept Bioquim & Biol Mol, Edificio Severo Ochoa, E-14071 Cordoba, Spain; Univ Cordoba, Dept Biol Vegetal, Area Fisiol Vegetal, Edificio Celestino Mutis, E-14071 Cordoba, Spain	Universidad de Cordoba; Universidad de Cordoba	Moreno-Vivian, C (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Edificio Severo Ochoa, 1a Planta,Campus Univ Rabanales, E-14071 Cordoba, Spain.	bb1movic@uco.es	Roldán Ruiz, María Dolores/K-4370-2014; Moreno, Conrado/K-3976-2014; Cabello, Purificación/K-2805-2014	Roldán Ruiz, María Dolores/0000-0001-7173-8641; 				Angove HC, 2002, J BIOL CHEM, V277, P23374, DOI 10.1074/jbc.M200495200; Aragao D, 2003, J BIOL INORG CHEM, V8, P540, DOI 10.1007/s00775-003-0443-x; Arendsen AF, 1998, J BIOL INORG CHEM, V3, P81, DOI 10.1007/s007750050210; ARNOLD W, 1988, GENE, V70, P171, DOI 10.1016/0378-1119(88)90115-1; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BEAUMONT HJE, 2003, COST ACT 856 M EC AS, P13; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beliaev Alex S., 2002, OMICS A Journal of Integrative Biology, V6, P39, DOI 10.1089/15362310252780834; Blasco R, 1997, FEBS LETT, V414, P45, DOI 10.1016/S0014-5793(97)00968-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Briolat V, 2002, J BACTERIOL, V184, P2333, DOI 10.1128/JB.184.9.2333-2343.2002; Cooper SJ, 2000, BIOCHEMISTRY-US, V39, P15044, DOI 10.1021/bi001483m; Dominy CN, 1997, MICROBIOL-UK, V143, P3123, DOI 10.1099/00221287-143-10-3123; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Einsle O, 2002, J AM CHEM SOC, V124, P11737, DOI 10.1021/ja0206487; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; Haselkorn R, 2001, PHOTOSYNTH RES, V70, P43, DOI 10.1023/A:1013883807771; Heo J, 2002, J BACTERIOL, V184, P5894, DOI 10.1128/JB.184.21.5894-5897.2002; Keon RG, 1997, ARCH MICROBIOL, V167, P376, DOI 10.1007/s002030050458; Kim CC, 2003, INFECT IMMUN, V71, P3196, DOI 10.1128/IAI.71.6.3196-3205.2003; KORPELA TK, 1981, ANAL BIOCHEM, V110, P251, DOI 10.1016/0003-2697(81)90143-3; Krockel M, 1998, EUR J BIOCHEM, V251, P454, DOI 10.1046/j.1432-1327.1998.2510454.x; Kuznetsova S, 2004, BIOCHEMISTRY-US, V43, P510, DOI 10.1021/bi035662q; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; Lopez-Lozano A, 2002, FEMS MICROBIOL ECOL, V41, P151, DOI 10.1111/j.1574-6941.2002.tb00976.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macedo S, 2002, J BIOL INORG CHEM, V7, P514, DOI 10.1007/s00775-001-0326-y; MARTINEZLUQUE M, 1991, ARCH MICROBIOL, V155, P149; MORENO-VIVIAN C, 1982, Photosynthesis Research, V3, P313, DOI 10.1007/BF00034112; Moreno-Vivian C, 1999, J BACTERIOL, V181, P6573; MORENOVIVIAN C, 1994, FEMS MICROBIOL LETT, V115, P279, DOI 10.1111/j.1574-6968.1994.tb06651.x; MORENOVIVIAN C, 1986, FEMS MICROBIOL LETT, V34, P105, DOI 10.1111/j.1574-6968.1986.tb01358.x; MORENOVIVIAN C, 1992, EUR J BIOCHEM, V204, P531, DOI 10.1111/j.1432-1033.1992.tb16664.x; MOURA I, 1992, J BIOL CHEM, V267, P4489; Nilsson UA, 2002, FREE RADICAL RES, V36, P677, DOI 10.1080/10715760290029128; Pereira AS, 1999, BIOCHEM BIOPH RES CO, V260, P209, DOI 10.1006/bbrc.1999.0748; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P705, DOI 10.1111/j.1432-1033.1992.tb16977.x; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P697, DOI 10.1111/j.1432-1033.1992.tb16976.x; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; Richardson DJ, 2001, CELL MOL LIFE SCI, V58, P165, DOI 10.1007/PL00000845; Rudolf M, 2002, BIOCHEM SOC T, V30, P649, DOI 10.1042/BST0300649; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SOLORZANO L, 1969, LIMNOL OCEANOGR, V14, P799, DOI 10.4319/lo.1969.14.5.0799; STOKKERMANS JPWG, 1992, EUR J BIOCHEM, V208, P435, DOI 10.1111/j.1432-1033.1992.tb17205.x; van den Berg WAM, 2000, EUR J BIOCHEM, V267, P666, DOI 10.1046/j.1432-1327.2000.01032.x; VANDENBERG WAM, 1994, BBA-PROTEIN STRUCT M, V1206, P240, DOI 10.1016/0167-4838(94)90214-3; WEAVER PF, 1975, ARCH MICROBIOL, V105, P207, DOI 10.1007/BF00447139; Wolfe MT, 2002, J BACTERIOL, V184, P5898, DOI 10.1128/JB.184.21.5898-5902.2002	50	55	59	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45485	45494		10.1074/jbc.M404417200	http://dx.doi.org/10.1074/jbc.M404417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322098	hybrid			2022-12-25	WOS:000224694900026
J	Dyachok, O; Gylfe, E				Dyachok, O; Gylfe, E			Ca2+-induced Ca2+ release via inositol 1,4,5-trisphosphate receptors is amplified by protein kinase A and triggers exocytosis in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCAGON-LIKE PEPTIDE-1; ISLET HORMONE-SECRETION; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; INSULIN-RELEASE; B-CELLS; 2-AMINOETHOXYDIPHENYL BORATE; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTORS; CYTOPLASMIC CA-2+	Hormones, such as glucagon and glucagon-like peptide-1, potently amplify nutrient stimulated insulin secretion by raising cAMP. We have studied how cAMP affects Ca2+-induced Ca2+ release (CICR) in pancreatic beta-cells from mice and rats and the role of CICR in secretion. CICR was observed as pronounced Ca2+ spikes on top of glucose-or depolarization-dependent rise of the cytoplasmic Ca2+ concentration ([Ca2+](i)). cAMP-elevating agents strongly promoted CICR. This effect involved sensitization of the receptors underlying CICR, because many cells exhibited the characteristic Ca2+ spiking at low or even in the absence of depolarization-dependent elevation of [Ca2+](i). The cAMP effect was mimicked by a specific activator of protein kinase A in cells unresponsive to activators of cAMP-regulated guanine nucleotide exchange factor. Ryanodine pretreatment, which abolishes CICR mediated by ryanodine receptors, did not prevent CICR. Moreover, a high concentration of caffeine, known to activate ryanodine receptors independently of Ca2+, failed to mobilize intracellular Ca2+. On the contrary, a high caffeine concentration abolished CICR by interfering with inositol 1,4,5-trisphosphate receptors (IP(3)Rs). Therefore, the cell-permeable IP3R antagonist 2-aminoethoxydiphenyl borate blocked the cAMP-promoted CICR. Individual CICR events in pancreatic beta-cells were followed by [Ca2+](i) spikes in neighboring human erythroleukemia cells, used to report secretory events in the beta-cells. The results indicate that protein kinase A-mediated promotion of CICR via IP3Rs is part of the mechanism by which cAMP amplifies insulin release.	Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden; Natl T Shevchenko Univ Kiev, Dept Biophys, Kiev, Ukraine	Uppsala University; Ministry of Education & Science of Ukraine; Taras Shevchenko National University Kiev	Gylfe, E (corresponding author), Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden.	erik.gylfe@medcellbiol.uu.se	Dyachok, Oleg/B-5935-2017	Gylfe, Erik/0000-0002-8414-2107				Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Akbar GK, 1996, J RECEPT SIGNAL TR R, V16, P209, DOI 10.3109/10799899609039949; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; Arredouani A, 2002, DIABETES, V51, P3245, DOI 10.2337/diabetes.51.11.3245; Ashby MC, 2002, J CELL BIOL, V158, P283, DOI 10.1083/jcb.200112025; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Beauvois MC, 2004, J PHYSIOL-LONDON, V559, P141, DOI 10.1113/jphysiol.2004.067454; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERTS A, 1995, BIOCHEM BIOPH RES CO, V208, P644, DOI 10.1006/bbrc.1995.1387; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Bruton JD, 2002, FASEB J, V16, P301, DOI 10.1096/fj.02-0481fje; Cancela JM, 2002, DIABETES, V51, pS349, DOI 10.2337/diabetes.51.2007.S349; Dyachok O, 2004, CELL CALCIUM, V36, P1, DOI 10.1016/j.ceca.2003.11.004; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; FABIATO A, 1979, NATURE, V281, P146, DOI 10.1038/281146a0; Fujimoto K, 2002, J BIOL CHEM, V277, P50497, DOI 10.1074/jbc.M210146200; GRAPENGIESSER E, 1988, BIOCHEM BIOPH RES CO, V151, P1299, DOI 10.1016/S0006-291X(88)80503-5; GRAPENGIESSER E, 1991, J BIOL CHEM, V266, P12207; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; Gromada J, 1997, PFLUG ARCH EUR J PHY, V434, P515, DOI 10.1007/s004240050431; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYLFE E, 1991, PFLUG ARCH EUR J PHY, V419, P639, DOI 10.1007/BF00370308; HAHN HJ, 1974, J BIOL CHEM, V249, P5275; HELLMAN B, 1959, ACTA ENDOCRINOL-COP, V32, P92; HELLMAN B, 1965, ANN NY ACAD SCI, V131, P541, DOI 10.1111/j.1749-6632.1965.tb34819.x; HELLMAN B, 1986, BIOCHEM INT, V13, P383; Holst Jens Juul, 2004, Expert Opin Emerg Drugs, V9, P155, DOI 10.1517/14728214.9.1.155; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Johnson JD, 2004, FASEB J, V18, P878, DOI 10.1096/fj.03-1280fje; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; LEITNER JW, 1975, ENDOCRINOLOGY, V96, P662; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Liu YJ, 1999, ENDOCRINOLOGY, V140, P5524, DOI 10.1210/en.140.12.5524; Liu YJ, 1996, ARCH BIOCHEM BIOPHYS, V334, P295, DOI 10.1006/abbi.1996.0458; Liu YJ, 1998, J PHYSIOL-LONDON, V508, P471, DOI 10.1111/j.1469-7793.1998.471bq.x; LUND PE, 1994, N-S ARCH PHARMACOL, V349, P503, DOI 10.1007/BF00169140; Lundquist I, 2003, AM J PHYSIOL-ENDOC M, V285, pE1055, DOI 10.1152/ajpendo.00498.2002; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MONTAGUE W, 1971, BIOCHEM J, V122, P115, DOI 10.1042/bj1220115; Roderick HL, 2003, CURR BIOL, V13, pR425, DOI 10.1016/S0960-9822(03)00358-0; Shariatmadari R, 2001, PFLUG ARCH EUR J PHY, V442, P312, DOI 10.1007/s004240000513; SITSAPESAN R, 1990, J PHYSIOL-LONDON, V423, P425, DOI 10.1113/jphysiol.1990.sp018031; Solovyova N, 2002, EMBO J, V21, P622, DOI 10.1093/emboj/21.4.622; SYKES JA, 1959, P SOC EXP BIOL MED, V100, P125, DOI 10.3181/00379727-100-24546; Tengholm A, 2001, J PHYSIOL-LONDON, V530, P533, DOI 10.1111/j.1469-7793.2001.0533k.x; Tengholm A, 1999, J BIOL CHEM, V274, P36883, DOI 10.1074/jbc.274.52.36883; TOESCU EC, 1992, J BIOL CHEM, V267, P23467; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190	59	80	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45455	45461		10.1074/jbc.M407673200	http://dx.doi.org/10.1074/jbc.M407673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15316011	hybrid, Green Published			2022-12-25	WOS:000224694900022
J	Nakatani, Y; Kaneto, H; Kawamori, D; Hatazaki, M; Miyatsuka, T; Matsuoka, T; Kajimoto, Y; Matsuhisa, M; Yamasaki, Y; Hori, M				Nakatani, Y; Kaneto, H; Kawamori, D; Hatazaki, M; Miyatsuka, T; Matsuoka, T; Kajimoto, Y; Matsuhisa, M; Yamasaki, Y; Hori, M			Modulation of the JNK pathway in liver affects insulin resistance status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED SIGNALING PATHWAYS; PANCREATIC BETA-CELLS; OXIDATIVE STRESS; PROTEIN-KINASE; MEDIATED SUPPRESSION; GLUCOSE; SECRETION; PREVENTION; OBESITY; DAMAGE	The c-Jun N-terminal kinase (JNK) pathway is known to be activated under diabetic conditions and to possibly be involved in the progression of insulin resistance. In this study, we examined the effects of modulation of the JNK pathway in liver on insulin resistance and glucose tolerance. Overexpression of dominant-negative type JNK in the liver of obese diabetic mice dramatically improved insulin resistance and markedly decreased blood glucose levels. Conversely, expression of wild type JNK in the liver of normal mice decreased insulin sensitivity. The phosphorylation state of crucial molecules for insulin signaling was altered upon modification of the JNK pathway. Furthermore, suppression of the JNK pathway resulted in a dramatic decrease in the expression levels of the key gluconeogenic enzymes, and endogenous hepatic glucose production was also greatly reduced. Similar effects were observed in high fat, high sucrose diet-induced diabetic mice. Taken together, these findings suggest that suppression of the JNK pathway in liver exerts greatly beneficial effects on insulin resistance status and glucose tolerance in both genetic and dietary models of diabetes.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan	Osaka University	Kaneto, H (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneto@medone.med.osaka-u.ac.jp						Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Evans JL, 2002, ENDOCR REV, V23, P599, DOI 10.1210/er.2001-0039; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ihara Y, 1999, DIABETES, V48, P927, DOI 10.2337/diabetes.48.4.927; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Leinonen J, 1997, FEBS LETT, V417, P150, DOI 10.1016/S0014-5793(97)01273-8; Liu WL, 2000, AM J PHYSIOL-ENDOC M, V279, pE782, DOI 10.1152/ajpendo.2000.279.4.E782; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Purves T, 2001, FASEB J, V15, P2508, DOI 10.1096/fj.01-0253hyp; ROBERTSON RP, 1992, J CLIN INVEST, V90, P320, DOI 10.1172/JCI115865; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; Sakai K, 2003, BIOCHEM BIOPH RES CO, V300, P216, DOI 10.1016/S0006-291X(02)02832-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258	36	179	192	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45803	45809		10.1074/jbc.M406963200	http://dx.doi.org/10.1074/jbc.M406963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15331609	hybrid			2022-12-25	WOS:000224694900064
J	Barnes, BJ; Richards, J; Mancl, M; Hanash, S; Beretta, L; Pitha, PM				Barnes, BJ; Richards, J; Mancl, M; Hanash, S; Beretta, L; Pitha, PM			Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-7; NF-KAPPA-B; GENE-EXPRESSION; TRANSCRIPTION FACTORS; ALPHA GENES; IN-VIVO; SIGNALING PATHWAY; VIRUS-INFECTION; DENDRITIC CELLS; HOST-DEFENSE	The interferon regulatory factors (IRF) are transcriptional mediators of cellular response to viral invasion that play a critical role in the innate antiviral defense. Two of these factors, IRF-5 and IRF-7, play a critical role in the induction of interferon (IFNA) genes in infected cells; they are expressed constitutively in monocytes, B cells, and precursors of dendritic cells (pDC2) that are high producers of interferon alpha, and their expression can be further stimulated by type I interferon. The goal of the present study was to identify and analyze expression of cellular genes that are modulated by IRF-5 and IRF-7 during the innate response to viral infection. The transcription profiles of infected BJAB cells overexpressing IRF-5 or IRF-7 were determined by using oligonucleotide arrays with probe sets representing about 6800 human genes. This analysis shows that IRF-5 and IRF-7 activate a broad profile of heterologous genes encoding not only antiviral, inflammatory, and pro-apoptotic proteins but also proteins of other functional categories. The number of IRF-5- and IRF-7-modulated genes was significantly higher in infected than in uninfected cells, and the transcription signature was predominantly positive. Although IRF-5 and IRF-7 stimulated a large number of common genes, a distinct functional profile was associated with each of these IRFs. The noted difference was a broad antiviral and early inflammatory transcriptional profile in infected BJAB/IRF-5 cells, whereas the IRF-7-induced transcripts were enriched for the group of mitochondrial genes and genes affecting the DNA structure. Taken together, these data indicate that IRF-5 and IRF-7 act primarily as transcriptional activators and that IRF-5 and IRF-7-induced innate antiviral response results in a broad alteration of the transcriptional profile of cellular genes.	Univ Michigan, Sidney Kimmel Comprehens Canc Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University	Pitha, PM (corresponding author), CAnc Res Bldg,1650 Orleans St, Baltimore, MD 21231 USA.	parowe@jhmi.edu		Laura, Beretta/0000-0002-2054-684X	NCI NIH HHS [T32 CA88784, R01CA 19737-19A1] Funding Source: Medline; NIAID NIH HHS [AI054537-01] Funding Source: Medline; NIAMS NIH HHS [P30 AR48310] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA088784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054537] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agnew LL, 2003, AIDS, V17, P1985, DOI 10.1097/00002030-200309050-00019; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2003, J BIOL CHEM, V278, P16630, DOI 10.1074/jbc.M212609200; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Braun SE, 2000, J IMMUNOL, V164, P4025, DOI 10.4049/jimmunol.164.8.4025; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; Buckova D, 2002, ALLERGY, V57, P446; Chapple JP, 2000, HUM MOL GENET, V9, P1919, DOI 10.1093/hmg/9.13.1919; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Eskildsen S, 2003, NUCLEIC ACIDS RES, V31, P3166, DOI 10.1093/nar/gkg427; Esposito C, 2003, BIOCHEM J, V370, P205, DOI 10.1042/BJ20021390; Febbraio MA, 2002, BIOCHEM BIOPH RES CO, V296, P1264, DOI 10.1016/S0006-291X(02)02079-X; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hillinger S, 2003, J IMMUNOL, V171, P6457, DOI 10.4049/jimmunol.171.12.6457; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Lapidot T, 2001, ANN NY ACAD SCI, V938, P83, DOI 10.1111/j.1749-6632.2001.tb03577.x; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lu RQ, 2002, J BIOL CHEM, V277, P16592, DOI 10.1074/jbc.M111440200; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Oglesbee MJ, 2002, VIRAL IMMUNOL, V15, P399, DOI 10.1089/088282402760312296; OKUMURA K, 1995, GENOMICS, V27, P377, DOI 10.1006/geno.1995.1062; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; RAJ NBK, 1983, P NATL ACAD SCI-BIOL, V80, P3923, DOI 10.1073/pnas.80.13.3923; Sawada S, 2003, J BIOL CHEM, V278, P26323, DOI 10.1074/jbc.C300210200; Seewald MJ, 2003, MOL CELL BIOL, V23, P8124, DOI 10.1128/MCB.23.22.8124-8136.2003; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shigeta M, 2003, J CELL BIOL, V163, P165, DOI 10.1083/jcb.200301075; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; Walter BL, 2002, J VIROL, V76, P12008, DOI 10.1128/JVI.76.23.12008-12022.2002; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101	74	178	190	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45194	45207		10.1074/jbc.M400726200	http://dx.doi.org/10.1074/jbc.M400726200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308637	hybrid			2022-12-25	WOS:000224505600113
J	Kiefer, HLB; Hanley, TM; Marcello, JE; Karthik, AG; Viglianti, GA				Kiefer, HLB; Hanley, TM; Marcello, JE; Karthik, AG; Viglianti, GA			Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter - Uncoupling of histone acetylation and chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; THYROID-HORMONE RECEPTOR; LIGATION-MEDIATED PCR; CREB-BINDING-PROTEIN; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; PHORBOL ESTER; CO-REPRESSOR; HIV-1 TAT	All-trans retinoic acid (RA) represses HIV-1 transcription and replication in cultured monocytic cells and in primary monocyte-derived macrophages. Here we examine the role of histone acetylation and chromatin remodeling in RA-mediated repression. RA pretreatment of latently infected U1 promonocytes inhibits HIV-1 expression in response to the histone deacetylase ( HDAC) inhibitor, trichostatin A (TSA). TSA is thought to activate HIV-1 transcription by inducing histone hyperacetylation within a regulatory nucleosome, nuc-1, positioned immediately downstream from the transcription start site. Acetylation of nuc-1 is thought to be a critical step in activation that precedes nuc-1 remodeling and, subsequently, transcriptional initiation. Here we demonstrate that TSA treatment induces H3 and H4 hyperacetylation and nuc-1 remodeling. Although RA pretreatment inhibits nuc-1 remodeling and HIV-1 transcription, it has no effect on histone acetylation. This suggests that acetylation and remodeling are not obligatorily coupled. We also show that growth of U1 cells in retinoid-deficient medium induces nuc-1 remodeling and HIV-1 expression but does not induce histone hyperacetylation. These findings suggest that remodeling, not histone hyperacetylation, is the limiting step in transcriptional activation in these cells. Together, these data suggest that RA signaling maintains the chromatin structure of the HIV-1 promoter in a transcriptionally non-permissive state that may contribute to the establishment of latency in monocyte/macrophages.	Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA	Boston University	Viglianti, GA (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA.	gviglian@bu.edu	Hanley, Timothy/AAG-7547-2020	Hanley, Timothy/0000-0002-6253-6850; Viglianti, Gregory/0000-0002-0244-8293	NHLBI NIH HHS [HL57882] Funding Source: Medline; NIAID NIH HHS [AI49098] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049098] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Brown XQ, 2002, AIDS RES HUM RETROV, V18, P649, DOI 10.1089/088922202760019347; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COUTSOUDIS A, 1995, AM J PUBLIC HEALTH, V85, P1076, DOI 10.2105/AJPH.85.8_Pt_1.1076; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Fawzi W, 2003, CLIN INFECT DIS, V37, pS112, DOI 10.1086/375882; Fawzi WW, 2000, J PEDIATR-US, V137, P660, DOI 10.1067/mpd.2000.110136; Fawzi WW, 1999, PEDIATR INFECT DIS J, V18, P127, DOI 10.1097/00006454-199902000-00009; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; Hanley TM, 2004, J VIROL, V78, P2819, DOI 10.1128/JVI.78.6.2819-2830.2004; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Henderson A, 2004, MOL CELL BIOL, V24, P389, DOI 10.1128/MCB.24.1.389-397.2004; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Hsia SCV, 2002, MOL CELL BIOL, V22, P4043, DOI 10.1128/MCB.22.12.4043-4052.2002; KARTER DL, 1995, J ACQ IMMUN DEF SYND, V8, P199; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Maciaszek JW, 1998, J VIROL, V72, P5862, DOI 10.1128/JVI.72.7.5862-5869.1998; MACIASZEK JW, 1994, J VIROL, V68, P6598, DOI 10.1128/JVI.68.10.6598-6604.1994; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Melikian G, 2001, NUTRITION, V17, P567, DOI 10.1016/S0899-9007(01)00567-6; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; Neely KE, 2002, MOL GENET METAB, V76, P1, DOI 10.1016/S1096-7192(02)00014-8; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; POLI G, 1992, P NATL ACAD SCI USA, V89, P2689, DOI 10.1073/pnas.89.7.2689; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; SEMBA RD, 1995, J INFECT DIS, V171, P1196, DOI 10.1093/infdis/171.5.1196; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; TOWERS G, 1995, AIDS, V9, P129, DOI 10.1097/00002030-199509020-00003; TURPIN JA, 1992, J IMMUNOL, V148, P2539; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; Villamor E, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e6; Villamor E, 2000, J INFECT DIS, V182, pS122, DOI 10.1086/315921; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; YAMAGUCHI K, 1994, AIDS, V8, P1675, DOI 10.1097/00002030-199412000-00006	49	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43604	43613		10.1074/jbc.M408069200	http://dx.doi.org/10.1074/jbc.M408069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15299018	hybrid			2022-12-25	WOS:000224383100033
J	Pirko, I; Ciric, B; Gamez, J; Bieber, AJ; Warrington, AE; Johnson, AJ; Hanson, DP; Pease, LR; Macura, SI; Rodriguez, M				Pirko, I; Ciric, B; Gamez, J; Bieber, AJ; Warrington, AE; Johnson, AJ; Hanson, DP; Pease, LR; Macura, SI; Rodriguez, M			A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS	FASEB JOURNAL			English	Article						Theiler's murine encephalitis virus; demyelination; in vivo small animal MRI; antibody-mediated remyelination	NERVOUS-SYSTEM REMYELINATION; MONOCLONAL AUTOANTIBODY; MULTIPLE; OLIGODENDROCYTES; MECHANISM; PROGRESS; REPAIR; PDGF	The human monoclonal antibody rHIgM22 enhances remyelination following spinal cord demyelination in a virus-induced murine model of multiple sclerosis. Using three-dimensional T2-weighted in vivo spinal cord magnetic resonance imaging (MRI), we have therefore assessed the extent of spinal cord demyelination, before and after 5 weeks of treatment with rHIgM22, to determine whether antibody enhanced remyelination can be detected by MRI. A significant decrease was seen in T2 high signal lesion volume following antibody treatment. Histologic examination of the spinal cord tissue reveals that this decrease in lesion volume correlates with antibody promoted remyelination. To show that rHIgM22 enters the spinal cord and colocalizes with demyelinating lesions, we used ultrasmall superparamagnetic iron oxide particle ( USPIO)labeled antibodies. This may be considered as additional evidence to the hypothesis that rHIgM22 promotes remyelination by local effects in the lesions, likely by binding to CNS cells. The reduction in high signal T2-weighted lesion volume may be an important outcome measure in future clinical trials in humans.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biomed Imaging Resource, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, NMR Core Facil, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	rodriguez@mayo.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Rodriguez, Moses/0000-0001-6328-6497				Asakura K, 1996, J NEUROSCI RES, V43, P273, DOI 10.1002/(SICI)1097-4547(19960201)43:3<273::AID-JNR2>3.0.CO;2-G; Asakura K, 1996, J NEUROIMMUNOL, V65, P11, DOI 10.1016/0165-5728(95)00175-1; Asakura K, 1998, MULT SCLER, V4, P217, DOI 10.1177/135245859800400324; Asakura K, 1998, J NEUROSCI, V18, P7700; Barkhof F, 1997, MULT SCLER, V3, P129, DOI 10.1177/135245859700300212; Bieber A, 2000, Mult Scler, V6 Suppl 2, pS1; Bieber A, 2000, MULT SCLER S2, V6, pS33; Bieber AJ, 2003, ANN NEUROL, V53, P680, DOI 10.1002/ana.10578; Bieber AJ, 2002, GLIA, V37, P241, DOI 10.1002/glia.10033; Bieber AJ, 2001, TRENDS NEUROSCI, V24, pS39, DOI 10.1016/S0166-2236(00)01991-3; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Bruck W, 2003, J NEUROL SCI, V206, P181, DOI 10.1016/s0022-510x(02)00191-0; Ciric B, 2004, J NEUROIMMUNOL, V146, P153, DOI 10.1016/j.jneuroim.2003.11.002; Ciric B, 2001, BLOOD, V97, P321, DOI 10.1182/blood.V97.1.321; Deloire-Grassin MSA, 2000, J NEUROL SCI, V178, P10, DOI 10.1016/S0022-510X(00)00331-2; Duncan ID, 1996, NEUROPATH APPL NEURO, V22, P87, DOI 10.1111/j.1365-2990.1996.tb00852.x; DUNCAN ID, 1992, DEV NEUROSCI-BASEL, V14, P114, DOI 10.1159/000111655; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Howe CL, 2004, NEUROBIOL DIS, V15, P120, DOI 10.1016/j.nbd.2003.09.002; Lassmann H, 1997, MULT SCLER J, V3, P133, DOI 10.1177/135245859700300213; MCKINNON RD, 1993, GLIA, V7, P245, DOI 10.1002/glia.440070308; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; Miller DH, 1998, BRAIN, V121, P3, DOI 10.1093/brain/121.1.3; Miller DJ, 1997, J NEUROIMMUNOL, V75, P204, DOI 10.1016/S0165-5728(97)00027-1; Mitsunaga Y, 2002, FASEB J, V16, P1325, DOI 10.1096/fj.01-0994fje; Moore GRW, 2000, NEUROLOGY, V55, P1506, DOI 10.1212/WNL.55.10.1506; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; Pavelko KD, 1998, J NEUROSCI, V18, P2498; Pirko I, 2003, CROAT MED J, V44, P463; Pirko I, 2004, FASEB J, V18, P179, DOI 10.1096/fj.02-1124fje; Soldan MMP, 2003, MOL CELL NEUROSCI, V22, P14, DOI 10.1016/S1044-7431(02)00018-0; 't Hart BA, 1998, AM J PATHOL, V153, P649, DOI 10.1016/S0002-9440(10)65606-4; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820; Warrington AE, 2001, J ALLERGY CLIN IMMUN, V108, pS121, DOI 10.1067/mai.2001.118301	35	77	87	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1577	+		10.1096/fj.04-2026fje	http://dx.doi.org/10.1096/fj.04-2026fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319372				2022-12-25	WOS:000223554900007
J	Morgan, MJ; Woltering, JM; Rieden, PMJID; Durston, AJ; Thiery, JP				Morgan, MJ; Woltering, JM; Rieden, PMJID; Durston, AJ; Thiery, JP			YY1 regulates the neural crest-associated slug gene in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SLUG; EMBRYONIC-DEVELOPMENT; MESSENGER-RNA; INDUCTION; PROTEIN; EXPRESSION; BINDING; SNAIL; DROSOPHILA; LOCALIZATION	slug gene expression is associated with the specification and migration of neural crest cells in the African clawed frog Xenopus laevis. We provide evidence that the protein Ying-Yang 1 (YY1) regulates the slug gene expression both indirectly and directly, via a YY1 cis-element in the slug promoter, during Xenopus development. The ability of the YY1 to bind this YY1 cis-element was confirmed by electromobility shift assays and reporter assays. YY1 was detected in the nuclei of ectodermal cells contemporaneously with the process of neural crest specification. The injection of anti-YY1 morpholino, which targeted both YY1alpha and YY1beta gene products, depleted YY1 expression below 20% and was lethal at gastrulation. Sublethal depletion of YY1 reduced the length of the anterior-posterior axis and severely inhibited the expression of the neural marker Nrp1 and of the slug gene. Overexpression of YY1 or mutation of the YY1 cis-element reduced the restricted spatial expression of the slug reporter gene in the neural ectoderm border and provoked its expression in the nonneural ectoderm. Chromatin immunoprecipitation indicated that endogenous YY1 interacts directly with the YY1 cis-element of the endogenous slug gene and with the slug gene reporter sequence injected into embryos. The results suggest that YY1 is essential for Xenopus development; is necessary for neural ectoderm differentiation, a prerequisite for neural crest specification; and restricts which cells can form neural crest mesenchyme through directly blocking slug gene activity.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Morgan, MJ (corresponding author), Inst Curie, CNRS, UMR 144, 26 Rue Ulm, F-75248 Paris 05, France.	matthew.morgan@curie.fr	Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020; Woltering, Joost/0000-0002-2630-6572				Atchison L, 2003, EMBO J, V22, P1347, DOI 10.1093/emboj/cdg124; Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; BUSSE U, 1993, MECH DEVELOP, V40, P63, DOI 10.1016/0925-4773(93)90088-F; Carl TF, 1999, DEV BIOL, V213, P101, DOI 10.1006/dbio.1999.9320; Deardorff MA, 2001, DEVELOPMENT, V128, P3655; del Barrio MG, 2002, DEVELOPMENT, V129, P1583; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Ficzycz A, 2002, J BIOL CHEM, V277, P8382, DOI 10.1074/jbc.M110304200; Ficzycz A, 2001, J BIOL CHEM, V276, P22819, DOI 10.1074/jbc.M011188200; Gilthorpe J, 2002, DEVELOPMENT, V129, P3887; GIRTON JR, 1994, DEV BIOL, V161, P393, DOI 10.1006/dbio.1994.1040; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Jiang RL, 1998, BBA-GENE STRUCT EXPR, V1443, P251, DOI 10.1016/S0167-4781(98)00225-5; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Kwon HJ, 2003, BIOCHEM BIOPH RES CO, V306, P1008, DOI 10.1016/S0006-291X(03)01071-4; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Latinkic BV, 2004, DEVELOPMENT, V131, P669, DOI 10.1242/dev.00953; LEIBOVICI M, 1992, J CELL SCI, V102, P63; Luo T, 2002, DEV BIOL, V245, P136, DOI 10.1006/dbio.2002.0621; Mahmoudi T, 2003, NUCLEIC ACIDS RES, V31, P4147, DOI 10.1093/nar/gkg479; Mancilla A, 1996, DEV BIOL, V177, P580, DOI 10.1006/dbio.1996.0187; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; Mayor R, 1999, CURR TOP DEV BIOL, V43, P85; MAYOR R, 1993, DEVELOPMENT, V119, P661; MAYOR R, 1995, DEVELOPMENT, V121, P767; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; NIEUWKOOP PD, 1967, NORMAL TABLE XENOPUS, P162; Omichinski JG, 1997, NAT STRUCT BIOL, V4, P122, DOI 10.1038/nsb0297-122; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; Saka Y, 2001, DEV BIOL, V229, P307, DOI 10.1006/dbio.2000.0101; Satijn DPE, 2001, MOL CELL BIOL, V21, P1360, DOI 10.1128/MCB.21.4.1360-1369.2001; Savagner P, 1998, DEV DYNAM, V213, P182, DOI 10.1002/(SICI)1097-0177(199810)213:2<182::AID-AJA3>3.0.CO;2-C; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Sive H., 2000, EARLY DEV XENOPUS LA, P91; Stegmann K, 1999, MUTAT RES-GENOMICS, V406, P63, DOI 10.1016/S1383-5726(99)00002-3; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Vallin J, 2001, J BIOL CHEM, V276, P30350, DOI 10.1074/jbc.M103167200; Veenstra GJC, 1998, CELL DEATH DIFFER, V5, P774, DOI 10.1038/sj.cdd.4400416; Villanueva S, 2002, DEV BIOL, V241, P289, DOI 10.1006/dbio.2001.0485; Wilson PA, 1997, DEVELOPMENT, V124, P3177	46	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46826	46834		10.1074/jbc.M406140200	http://dx.doi.org/10.1074/jbc.M406140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326190	hybrid			2022-12-25	WOS:000224832400063
J	Sawhney, RS; Cookson, MM; Sharma, B; Hauser, J; Brattain, MG				Sawhney, RS; Cookson, MM; Sharma, B; Hauser, J; Brattain, MG			Autocrine transforming growth factor alpha regulates cell adhesion by multiple signaling via specific phosphorylation sites of p70S6 kinase in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; S6 KINASE; MAMMALIAN-CELLS; INTEGRIN; DISRUPTION; P70(S6K); REVEALS; TARGET; ALPHA-2-BETA-1; SENSITIVITY	Recently, we showed that autocrine transforming growth factor alpha (TGFalpha) controls the epidermal growth factor receptor (EGFR)-mediated basal expression of integrin alpha(2), cell adhesion and motility in highly progressed HCT116 colon cancer cells. We also reported that the expression of basal integrin alpha(2) and its biological effects are critically controlled by the constitutive activation of the ERK/MAPK pathway (Sawhney, R. S., Sharma, B., Humphrey, L. E., and Brattain, M. G. ( 2003) J. Biol. Chem. 278, 19861 - 19869). In the present report, we further examine the downstream signaling mechanisms underlying EGFR/ ERK signaling and integrin alpha(2) function in HCT116 cells. Selective MEK inhibitors attenuated TGFalpha-mediated basal activation of p70S6K (S6K) specifically at Thr-389, indicating that this S6K site is downstream of ERK/MAPK signaling. Cells were treated with the selective protein kinase C (PKC) inhibitor bisindolylmaleimide to determine the role of PKC in S6K activation. The Thr-421 and Ser-424 phosphorylation sites of S6K were specifically inhibited by bisindolylmaleimide, which also blocked integrin alpha(2) expression, cell adhesion, and motility. These data establish a novel cell motility function of S6K via PKC activation in a cancer cell. In addition, we examined whether mammalian target of rapamycin signaling controls S6K activation. Rapamycin inhibited constitutive S6K phosphorylation specifically at Thr-389, Thr-421, and Ser-424 sites. The assignment of these phosphorylation sites on S6K to biological functions was unequivocally confirmed by transfection of cells with specific single phosphorylation site dominant negative mutants. These experiments show for the first time that autocrine TGFalpha regulates cell adhesion function by multiple signaling pathways via specific phosphorylation sites of S6K in cancer cells.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Sawhney, RS (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Calton St, Buffalo, NY 14263 USA.	rajinder.sawhney@roswellpark.org; michael.brattain@roswellpark.org		Sharma, Bhavya/0000-0003-4388-5702	NCI NIH HHS [CA34432, CA16056, CA54807, CA50457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA034432, R01CA054807, R01CA050457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasubramanian S, 2003, J BIOL CHEM, V278, P42214, DOI 10.1074/jbc.M303428200; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Fukazawa H, 2000, CANCER RES, V60, P2104; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Klekotka PA, 2001, J BIOL CHEM, V276, P9503, DOI 10.1074/jbc.M006286200; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; Lindberg LE, 2002, MOL BIOL CELL, V13, P2894, DOI 10.1091/mbc.E02-02-0064; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; Paine E, 2000, J BIOL CHEM, V275, P11284, DOI 10.1074/jbc.275.15.11284; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pellegatta F, 1998, J BIOL CHEM, V273, P27768, DOI 10.1074/jbc.273.43.27768; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; RAY LB, 1988, J BIOL CHEM, V263, P12721; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Sawhney RS, 2003, J BIOL CHEM, V278, P19861, DOI 10.1074/jbc.M213162200; Sawhney RS, 2002, J BIOL CHEM, V277, P75, DOI 10.1074/jbc.M103268200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Yang CQ, 2003, CANCER RES, V63, P8312; ZUTTER MM, 1990, AM J PATHOL, V137, P113; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	35	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47379	47390		10.1074/jbc.M402031200	http://dx.doi.org/10.1074/jbc.M402031200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15304500	hybrid			2022-12-25	WOS:000224832400127
J	Wuller, S; Wiesner, B; Loffler, A; Furkert, J; Krause, G; Hermosilla, R; Schaefer, M; Schulein, R; Rosenthal, W; Oksche, A				Wuller, S; Wiesner, B; Loffler, A; Furkert, J; Krause, G; Hermosilla, R; Schaefer, M; Schulein, R; Rosenthal, W; Oksche, A			Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V-2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; V2 RECEPTOR; PHARMACOLOGICAL RESCUE; AVPR2 MUTATIONS; MOLECULAR-BASIS; RHODOPSIN; IDENTIFICATION; HETERODIMERS; TEMPLATE; GENE	Some membrane-permeable antagonists restore cell surface expression of misfolded receptors retained in the endoplasmic reticulum ( ER) and are therefore termed pharmacochaperones. Whether pharmacochaperones increase protein stability, thereby preventing rapid degradation, or assist folding via direct receptor interactions or interfere with quality control components remains elusive. We now show that the cell surface expression and function ( binding of the agonist) of the mainly ER-retained wild-type murine vasopressin V-2 receptor GFP fusion protein (mV(2)R.GFP) is restored by the vasopressin receptor antagonists SR49059 and SR121463B with EC50 values similar to their K-D values. This effect was preserved when protein synthesis was abolished. In addition, SR121463B rescued eight mutant human V(2)Rs (hV(2)Rs, three are responsible for nephrogenic diabetes insipidus) characterized by amino acid exchanges at the C-terminal end of transmembrane helix TM I and TM VII. In contrast, mutants with amino acid exchanges at the interface of TM II and IV were not rescued by either antagonist. The mechanisms involved in successful rescue of cell surface delivery are explained in a three-dimensional homology model of the antagonist-bound hV(2)R.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Rhein Westfal TH Aachen Klinikum, Kinderklin, D-52074 Aachen, Germany; Charite Univ Med Berlin, Inst Pharmakol, D-14195 Berlin, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Oksche, A (corresponding author), Thielallee 67-73, D-14195 Berlin, Germany.	alexander.oksche@medizin.fu-berlin.de	Oksche, Alexander/M-6678-2019	Oksche, Alexander/0000-0003-4592-1770				Ala Y, 1998, J AM SOC NEPHROL, V9, P1861; Amiri H, 2003, CELL CALCIUM, V33, P463, DOI 10.1016/S0143-4160(03)00061-7; Arthus MF, 2000, J AM SOC NEPHROL, V11, P1044, DOI 10.1681/ASN.V1161044; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BICHET DG, 1994, AM J HUM GENET, V55, P278; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; CASE DA, 1998, AMBER 5 0; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gregan B, 2004, J BIOL CHEM, V279, P27679, DOI 10.1074/jbc.M403601200; Hermosilla R, 2001, MOL PHARMACOL, V60, P1031, DOI 10.1124/mol.60.5.1031; Issaeva N, 2003, P NATL ACAD SCI USA, V100, P13303, DOI 10.1073/pnas.1835733100; Janovick JA, 2002, J CLIN ENDOCR METAB, V87, P3255, DOI 10.1210/jc.87.7.3255; Krause G, 2000, MOL PHARMACOL, V57, P232; Maric K, 1998, AM J PHYSIOL-RENAL, V275, pF796, DOI 10.1152/ajprenal.1998.275.5.F796; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Oksche A, 1998, FEBS LETT, V424, P57, DOI 10.1016/S0014-5793(98)00140-9; Oksche A, 2002, MOL ENDOCRINOL, V16, P799, DOI 10.1210/me.16.4.799; Oksche A, 1998, J MOL MED, V76, P326, DOI 10.1007/s001090050224; Oksche A, 1996, MOL PHARMACOL, V50, P820; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; Saliba RS, 2002, J CELL SCI, V115, P2907; Schulein R, 2000, FEBS LETT, V466, P101, DOI 10.1016/S0014-5793(99)01764-0; Tahtaoui C, 2003, J BIOL CHEM, V278, P40010, DOI 10.1074/jbc.M301128200; Tan CM, 2003, J BIOL CHEM, V278, P35678, DOI 10.1074/jbc.M301888200; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; YUASA H, 1994, J CLIN ENDOCR METAB, V79, P361, DOI 10.1210/jc.79.2.361	30	113	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47254	47263		10.1074/jbc.M408154200	http://dx.doi.org/10.1074/jbc.M408154200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15319430	hybrid			2022-12-25	WOS:000224832400113
J	Zhou, GF; Golden, T; Aragon, IV; Honkanen, RE				Zhou, GF; Golden, T; Aragon, IV; Honkanen, RE			Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; INDUCIBLE FACTOR 1-ALPHA; SERINE/THREONINE PHOSPHATASE; GROWTH ARREST; HIF-ALPHA; P53; PP5; IDENTIFICATION; TRANSDUCTION; ASK1	Mitogen-activated protein kinase (MAPK) signaling cascades are multifunctional signaling networks that influence cell growth, differentiation, apoptosis, and cellular responses to stress. Since the activation/propagation of MAPK signaling requires the sequential phosphorylation of many downstream proteins, the phosphatases that dephosphorylate MAPKs represent critical elements in the control of MAPK-signaling networks. Here we show that hypoxia induces a transient increase in the activity of apoptosis signal-regulating kinase 1 (ASK-1), a MAPKKK that responds to oxidative stress by triggering cascades leading to the phosphorylation/activation of c-Jun N-terminal kinases (JNK) and p38-MAPK. Hypoxia-induced ASK-1/MKK-4/JNK signaling is suppressed by serine/threonine protein phosphatase type 5 (PP5), which acts to turn off ASK-1/MKK-4/JNK signaling via two mechanisms. First, in a rapid response hypoxia facilitates the association of endogenous PP5 with ASK-1. PP5 binds to the C-terminal domain of ASK-1, and studies with siRNA targeting PP5 indicate that PP5 acts to suppress the phosphorylation of MKK4 (Thr-261), JNK (Thr-183/Tyr-185), and c-Jun (Ser-63) without affecting the activating phosphorylation of p38 MAPK (Thr-180/ Tyr-182), p44/p42MAPK/ERK1/2 (Thr-202/Tyr-204), or c-Jun protein levels. If hypoxia is prolonged, the expression of PP5 is increased due to the activation of a transcriptional activator, which was identified as hypoxia-inducible factor-1. Together, these studies indicate that PP5 plays an important role in the survival of cells in a low oxygen environment by suppressing a hypoxia-induced ASK-1/MKK4/JNK signaling cascade that promotes an apoptotic response.	Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, Mobile, AL 36688 USA	University of South Alabama	Honkanen, RE (corresponding author), Univ S Alabama, Coll Med, Dept Biochem & Mol Biol, MSB 2430, Mobile, AL 36688 USA.	honkanen@sungcg.usouthal.edu			NCI NIH HHS [R01 CA060750, CA-605750] Funding Source: Medline; NHLBI NIH HHS [HLB-59154] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060750] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cohen P T, 1996, Adv Pharmacol, V36, P67; Gleadle JM, 1998, MOL MED TODAY, V4, P122, DOI 10.1016/S1357-4310(97)01198-2; Golden T, 2004, CANCER LETT, V215, P95, DOI 10.1016/j.canlet.2004.03.027; Golden TA, 2003, METHOD ENZYMOL, V366, P372; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Huang SL, 2004, J BIOL CHEM, V279, P36490, DOI 10.1074/jbc.M401208200; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Lubert EJ, 2001, J BIOL CHEM, V276, P38582, DOI 10.1074/jbc.M106906200; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Seta KA, 2004, J APPL PHYSIOL, V96, P765, DOI 10.1152/japplphysiol.00836.2003; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Swingle MR, 2004, J BIOL CHEM, V279, P33992, DOI 10.1074/jbc.M402855200; Theodosiou A, 2002, GENOME BIOL, V3; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Urban G, 2003, J BIOL CHEM, V278, P9747, DOI 10.1074/jbc.M210993200; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Zhang QG, 2002, NEUROSCI LETT, V329, P232, DOI 10.1016/S0304-3940(02)00650-X; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	56	97	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46595	46605		10.1074/jbc.M408320200	http://dx.doi.org/10.1074/jbc.M408320200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328343	hybrid			2022-12-25	WOS:000224832400033
J	May, MJ; Larsen, SE; Shim, JH; Madge, LA; Ghosh, S				May, MJ; Larsen, SE; Shim, JH; Madge, LA; Ghosh, S			A novel ubiquitin-like domain in I kappa B kinase beta is required for functional activity of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; IKK-ALPHA; MICE LACKING; DNA-REPAIR; NEMO/IKK-GAMMA; ACTIVATION; SUBUNIT; PROTEIN; PHOSPHORYLATION; COMPLEX	Activation of NF-kappaB requires two highly related kinases named IKKalpha and IKKbeta that share identity in the nature and positioning of their structural domains. Despite their similarity, the kinases are functionally divergent, and we therefore sought to identify any structural features specific for IKKalpha or IKKbeta. We performed bioinformatics analysis, and we identified a region resembling a ubiquitin-like domain (UBL) that exists only in IKKbeta and that we named the UBL-like domain (ULD). Deletion of the ULD rendered IKKbeta catalytically inactive and unable to induce NF-kappaB activity, and overexpression of only the ULD dose-dependently inhibited tumor necrosis factor-alpha-induced NF-kappaB activity. The ULD could not be functionally replaced within IKKbeta by ubiquitin or the corresponding region of IKKalpha, whereas deletion of the equivalent section of IKKalpha did not affect its catalytic activity against IkappaBalpha or its activation by NF-kappaB-inducing kinase. We identified five residues conserved among the larger family of UBL-containing proteins and IKKbeta, and alanine scanning revealed that the leucine at position 353 (Leu(353)) is absolutely critical for IKKbeta-induced NF-kappaB activation. Most intriguingly, the L353A mutant was catalytically active but, unlike wildtype IKKbeta, formed a stable complex with the NF-kappaB p65 subunit. Our findings therefore establish the ULD as a critical functional domain specific for IKKbeta that might play a role in dissociating IKKbeta from p65.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; University of Pennsylvania; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 310 Cedar St, New Haven, CT 06520 USA.	sankar.ghosh@yale.edu		May, Michael/0000-0002-2485-3716; Shim, Jae-Hyuck/0000-0002-4947-3293	NIAID NIH HHS [R37-AI33443] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brower CS, 1999, J BIOL CHEM, V274, P13629, DOI 10.1074/jbc.274.19.13629; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Eskildsen S, 2003, NUCLEIC ACIDS RES, V31, P3166, DOI 10.1093/nar/gkg427; Fujiwara K, 2004, J BIOL CHEM, V279, P4760, DOI 10.1074/jbc.M309448200; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hartmann R, 1998, NUCLEIC ACIDS RES, V26, P4121, DOI 10.1093/nar/26.18.4121; Hartmann-Petersen R, 2004, SEMIN CELL DEV BIOL, V15, P247, DOI 10.1016/j.semcdb.2003.12.006; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Mueller TD, 2003, EMBO J, V22, P4634, DOI 10.1093/emboj/cdg467; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Ryu KS, 2003, J BIOL CHEM, V278, P36621, DOI 10.1074/jbc.M304628200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	55	48	49	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45528	45539		10.1074/jbc.M408579200	http://dx.doi.org/10.1074/jbc.M408579200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319427	hybrid			2022-12-25	WOS:000224694900031
J	Dai, T; Abou-Rjaily, GA; Al-Share, QY; Yang, Y; Fernstrom, MA; DeAngelis, AM; Lee, AD; Sweetman, L; Amato, A; Pasquali, M; Lopaschuk, GD; Erickson, SK; Najjar, SM				Dai, T; Abou-Rjaily, GA; Al-Share, QY; Yang, Y; Fernstrom, MA; DeAngelis, AM; Lee, AD; Sweetman, L; Amato, A; Pasquali, M; Lopaschuk, GD; Erickson, SK; Najjar, SM			Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACIDS; L-CARNITINE; RECEPTOR; GLUCOSE; RESISTANCE; ENDOCYTOSIS; INHIBITION; CLEARANCE; PP120; INCREASES	Inactivation of CEACAM1 in L-SACC1 mice by a dominant-negative transgene in liver impairs insulin clearance and increases serum free fatty acid (FFA) levels, resulting in insulin resistance. The contribution of elevated FFAs in the pathogenesis of insulin resistance is herein investigated. Treatment of L-SACC1 female mice with carnitine restored plasma FFA content. Concomitantly, it normalized insulin levels without directly regulating receptor-mediated insulin internalization and prevented glucose tolerance in these mice. Similarly, treatment with nicotinic acid, a lipolysis inhibitor, restored insulin-stimulated receptor uptake in L-SACC1 mice. Taken together, these data suggest that chronic elevation in plasma FFAs levels contributes to the regulation of insulin metabolism and action in L-SACC1 mice.	Med Coll Ohio, Dept Pharmacol & Therapeut, Toledo, OH 43614 USA; Med Coll Ohio, Dept Phys Therapy, Toledo, OH 43614 USA; Baylor Univ, Med Ctr, Inst Metab Dis, Dallas, TX 75246 USA; Sigma Tau Res Inc, Gaithersburg, MD 20877 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Alberta, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Baylor University; Baylor University Medical Center; Utah System of Higher Education; University of Utah; University of Alberta; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Najjar, SM (corresponding author), Med Coll Ohio, Dept Pharmacol & Therapeut, 3035 Arlington Ave,HSci Bldg,Rm 270, Toledo, OH 43614 USA.	snajjar@mco.edu	Najjar, Sonia M/GXW-2217-2022	Al-Share, Qusai/0000-0002-2306-6198	NIDDK NIH HHS [DK 57497, DK 54254] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057497, R01DK054254] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; Baldeweg SE, 2000, EUR J CLIN INVEST, V30, P45; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V3, P1238; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BOSELLO O, 1990, ANN NUTR METAB, V34, P359, DOI 10.1159/000177610; BRADY LJ, 1986, METABOLISM, V35, P555, DOI 10.1016/0026-0495(86)90015-6; Charles MA, 1997, DIABETOLOGIA, V40, P1101, DOI 10.1007/s001250050793; Choice CV, 1998, J BIOL CHEM, V273, P22194, DOI 10.1074/jbc.273.35.22194; Clouet P, 1996, BBA-LIPID LIPID MET, V1299, P191, DOI 10.1016/0005-2760(95)00206-5; Erickson SK, 2003, J LIPID RES, V44, P1001, DOI 10.1194/jlr.M200489-JLR200; Escobar O, 1999, AM J MED SCI, V317, P282, DOI 10.1097/00000441-199905000-00003; Fisher SJ, 2003, J CLIN INVEST, V111, P463, DOI 10.1172/JCI16426; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; GROOP LC, 1991, J CLIN INVEST, V87, P83, DOI 10.1172/JCI115005; HENNES MMI, 1990, INT J OBESITY, V14, P831; Hennigar RA, 1998, BBA-LIPID LIPID MET, V1392, P85, DOI 10.1016/S0005-2760(98)00023-X; HOKLAND BM, 1988, BIOCHIM BIOPHYS ACTA, V961, P234, DOI 10.1016/0005-2760(88)90118-X; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; KING MT, 1985, ANAL BIOCHEM, V146, P173, DOI 10.1016/0003-2697(85)90412-9; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; Koopmans SJ, 1999, METABOLISM, V48, P330, DOI 10.1016/S0026-0495(99)90081-1; Leiter EH, 1997, DIABETES REV, V5, P131; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; MACCARI F, 1987, LIPIDS, V22, P1005, DOI 10.1007/BF02536440; MAEBASHI M, 1978, LANCET, V2, P805; MALTESE WA, 1981, BIOCHIM BIOPHYS ACTA, V663, P645, DOI 10.1016/0005-2760(81)90075-8; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; Parks EJ, 2001, J NUTR, V131, p2772S, DOI 10.1093/jn/131.10.2772S; PEIRIS AN, 1986, J CLIN INVEST, V78, P1648, DOI 10.1172/JCI112758; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; Rashed MS, 1997, CLIN CHEM, V43, P1129; Robinson C, 1998, AM J PHYSIOL-ENDOC M, V274, pE737, DOI 10.1152/ajpendo.1998.274.4.E737; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Semenkovich CF, 1997, PROG LIPID RES, V36, P43, DOI 10.1016/S0163-7827(97)00003-9; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; SVEDBERG J, 1991, J CLIN INVEST, V88, P2054, DOI 10.1172/JCI115534; TANAKA K, 1980, CLIN CHEM, V26, P1847; Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824; Zammit VA, 2002, ANN NY ACAD SCI, V967, P52	45	18	18	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45155	45161		10.1074/jbc.M404764200	http://dx.doi.org/10.1074/jbc.M404764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316023	hybrid			2022-12-25	WOS:000224505600109
J	Ibrahim, FBM; Pang, SJ; Melendez, AJ				Ibrahim, FBM; Pang, SJ; Melendez, AJ			Anaphylatoxin signaling in human neutrophils - A key role for sphingosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; N-METHYL DERIVATIVES; LEUKEMIC HL-60 CELLS; TRANSENDOTHELIAL MIGRATION; IN-VITRO; RECEPTOR; C5A; INDUCTION; SPHINGOSINE-1-PHOSPHATE; INTERLEUKIN-1	Anaphylatoxins activate immune cells to trigger the release of proinflammatory mediators that can lead to the pathology of several immune-inflammatory diseases. However, the intracellular signaling pathways triggered by anaphylatoxins are not well understood. Here we report for the first time that sphingosine kinase (SPHK) plays a key role in C5a-triggered signaling, leading to physiological responses of human neutrophils. We demonstrate that C5a rapidly stimulates SPHK activity in neutrophils and differentiated HL-60 cells. Using the SPHK inhibitor N,N-dimethylsphingosine (DMS), we show that inhibition of SPHK abolishes the Ca2+ release from internal stores without inhibiting phospholipase C or protein kinase C activation triggered by C5a but has no effect on calcium signals triggered by other stimuli (FcgammaRII). We also show that DMS inhibits degranulation, activation of the NADPH oxidase, and chemotaxis triggered by C5a. Moreover, an antisense oligonucleotide against SPHK1, in neutrophil-differentiated HL-60 cells, had similar inhibitory properties as DMS, suggesting that the SPHK utilized by C5a is SPHK1. Our data indicate that C5a stimulation decreases cellular sphingosine levels and increases the formation of sphingosine-1-phosphate. Exogenously added sphingosine has a dual effect on C5a-stimulated oxidative burst: it has a priming effect at lower concentrations but a dose-dependent inhibitory effect at higher concentrations; however, C5a-triggered protein kinase C activity was only reduced at high concentration of sphingosine. In contrast, C5a-triggered Ca2+ signals, chemotaxis, and degranulation were not affected by sphingosine at all. Exogenous sphingosine-1-phosphate, by itself, did not induce degranulation or chemotaxis, but it did marginally induce Ca2+ signals and oxidative burst and had a priming effect, enhancing all the C5a-triggered responses. Taken together, these results suggest that SPHK plays an important role in the immune-inflammatory pathologies triggered by anaphylatoxins in human neutrophils and point out SPHK as a potential therapeutic target for the treatment of diseases associated with neutrophil hyperactivation.	Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore	National University of Singapore	Melendez, AJ (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, 2 Med Dr,MD 01-05, Singapore 117597, Singapore.	phsmraj@nus.edu.sg						Alemany R, 1999, J BIOL CHEM, V274, P3994, DOI 10.1074/jbc.274.7.3994; AREND WP, 1989, J IMMUNOL, V142, P173; Bless NM, 1998, AM J PATHOL, V153, P1113, DOI 10.1016/S0002-9440(10)65655-6; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; CAVAILLON JM, 1990, EUR J IMMUNOL, V20, P253, DOI 10.1002/eji.1830200204; Choi OH, 1996, NATURE, V380, P634; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DeVries ME, 1999, SEMIN IMMUNOL, V11, P95, DOI 10.1006/smim.1999.0165; DiScipio RG, 1999, J IMMUNOL, V162, P1127; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HARKIN DG, 1994, CELL BIOL INT, V18, P177, DOI 10.1006/cbir.1994.1059; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; Heller T, 1999, J IMMUNOL, V163, P985; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; KELLER HU, 1983, CELL MOTIL CYTOSKEL, V3, P47, DOI 10.1002/cm.970030105; KHAN WA, 1990, BIOCHEM BIOPH RES CO, V172, P683, DOI 10.1016/0006-291X(90)90728-6; KIMURA S, 1992, BIOCHEM PHARMACOL, V44, P1585; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Matsumoto K, 1999, CLIN EXP IMMUNOL, V117, P361, DOI 10.1046/j.1365-2249.1999.00975.x; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Mohr M, 1998, EUR J CLIN INVEST, V28, P227; Niwa M, 1999, LIFE SCI, V66, P245, DOI 10.1016/S0024-3205(99)00587-1; OHTA H, 1995, CANCER RES, V55, P691; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; OKUSAWA S, 1987, J IMMUNOL, V139, P2635; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pellas TC, 1998, J IMMUNOL, V160, P5616; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; Short A, 1999, BRIT J PHARMACOL, V126, P551, DOI 10.1038/sj.bjp.0702338; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; SMITH WB, 1991, IMMUNOLOGY, V72, P65; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651	44	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44802	44811		10.1074/jbc.M403977200	http://dx.doi.org/10.1074/jbc.M403977200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302883	hybrid			2022-12-25	WOS:000224505600069
J	Mareeva, T; Lebedeva, T; Anikeeva, N; Manser, T; Sykulev, Y				Mareeva, T; Lebedeva, T; Anikeeva, N; Manser, T; Sykulev, Y			Antibody specific for the peptide center dot major histocompatibility complex - Is it T cell receptor-like?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RECOMBINANT ANTIBODIES; PROTEIN-PROTEIN INTERACTIONS; POSITIVE SELECTION; RESTRICTED SPECIFICITY; MONOCLONAL-ANTIBODY; BINDING-SITES; HIGH-AFFINITY; MHC; ANTIGEN; RECOGNITION	Antibodies recognizing peptide bound to a major histocompatability complex (MHC) protein usually have a higher affinity for the composite peptide.MHC (pMHC) ligand than T cell receptors (TCR) with the same specificity. Because the solvent-accessible peptide area constitutes only a small portion of the contacting pMHC surface, we hypothesized that the contribution of the MHC moiety to the TCR-pMHC complex stability is limited, ensuring a small increment of the binding energy delivered by the peptide to be distinguishable by the TCR or the peptide-specific antibody. This suggests that the gain in affinity of the antibody-pMHC interaction can be achieved through an increase in the on-rate without a significant change in the off-rate of the interaction. To test the hypothesis, we have analyzed the binding of an ovalbumin peptide (pOV8) and its variants associated with soluble H-2K(b) protein to the 25-D1.16 monoclonal antibody and compared it with the binding of the same pMHC complexes to the OT-1 TCR. This comparison revealed a substantially higher on-rate of the antibody-pMHC interaction compared with the TCR-pMHC interaction. In contrast, both the antibody and the TCR-pMHC complexes exhibited comparably fast off-rates. Sequencing of the 25-D1.16 V-H and V-L genes showed that they have very few somatic mutations and those occur mainly in framework regions. We propose that the above features constitute a signature of the recognition of MHC-bound peptide antigens by TCR and TCR-like antibodies, which could explain why the latter are rarely produced in vivo.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Sykulev, Y (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Bluemle Life Sci Bldg 650, Philadelphia, PA 19107 USA.	ysykulev@lac.jci.tju.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039966, R01AI043254, R21AI043254] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43254, AI39966] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHARONI R, 1991, NATURE, V351, P147, DOI 10.1038/351147a0; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; ALRAMADI BK, 1995, J IMMUNOL, V155, P662; Andersen PS, 1996, P NATL ACAD SCI USA, V93, P1820, DOI 10.1073/pnas.93.5.1820; Anikeeva N, 2003, J IMMUNOL METHODS, V277, P75, DOI 10.1016/S0022-1759(03)00179-0; Anikeeva N, 2003, BIOCHEMISTRY-US, V42, P4709, DOI 10.1021/bi026864+; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; Biddison WE, 2003, J IMMUNOL, V171, P3064, DOI 10.4049/jimmunol.171.6.3064; Boniface JJ, 1999, P NATL ACAD SCI USA, V96, P11446, DOI 10.1073/pnas.96.20.11446; BRUNMARK A, 1998, MHC, V2, P53; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; Cohen CJ, 2003, J MOL RECOGNIT, V16, P324, DOI 10.1002/jmr.640; Denkberg G, 2002, P NATL ACAD SCI USA, V99, P9421, DOI 10.1073/pnas.132285699; EISENBERG D, 1979, PHYS CHEM APPL LIFE, P242; England P, 1997, BIOCHEMISTRY-US, V36, P164, DOI 10.1021/bi961419y; FOOTE J, 1991, NATURE, V352, P530, DOI 10.1038/352530a0; Gakamsky DM, 2004, P NATL ACAD SCI USA, V101, P9063, DOI 10.1073/pnas.0402840101; Garcia KC, 2001, P NATL ACAD SCI USA, V98, P6818, DOI 10.1073/pnas.111161198; Hogquist KA, 1997, IMMUNITY, V6, P389, DOI 10.1016/S1074-7613(00)80282-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Holler PD, 2003, NAT IMMUNOL, V4, P55, DOI 10.1038/ni863; Holler PD, 2001, J EXP MED, V194, P1043, DOI 10.1084/jem.194.8.1043; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; Kabat EA, 1991, SEQUENCES PROTEINS I; Lee PUY, 2000, J EXP MED, V191, P1355, DOI 10.1084/jem.191.8.1355; Lev A, 2002, CANCER RES, V62, P3184; Manning TC, 1999, IMMUNOL TODAY, V20, P417, DOI 10.1016/S0167-5699(99)01508-X; Manning TC, 1998, IMMUNITY, V8, P413, DOI 10.1016/S1074-7613(00)80547-6; Markvicheva EA, 2000, APPL BIOCHEM BIOTECH, V88, P145, DOI 10.1385/ABAB:88:1-3:145; Morea V, 1998, J MOL BIOL, V275, P269, DOI 10.1006/jmbi.1997.1442; Mozdzanowski J, 1998, ANAL BIOCHEM, V260, P183, DOI 10.1006/abio.1998.2690; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Robinson RA, 1996, J IMMUNOL, V156, P4266; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Schreiber G, 2002, CURR OPIN STRUC BIOL, V12, P41, DOI 10.1016/S0959-440X(02)00287-7; Shusta EV, 2000, NAT BIOTECHNOL, V18, P754, DOI 10.1038/77325; Sinha N, 2002, BIOPHYS J, V83, P2946, DOI 10.1016/S0006-3495(02)75302-2; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; Udaka K, 1996, J IMMUNOL, V157, P670; Wang ZC, 2002, J IMMUNOL, V169, P3146, DOI 10.4049/jimmunol.169.6.3146; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Zarutskie JA, 2001, P NATL ACAD SCI USA, V98, P12450, DOI 10.1073/pnas.211439398; Zhang C, 1999, PROTEINS, V34, P255, DOI 10.1002/(SICI)1097-0134(19990201)34:2<255::AID-PROT10>3.3.CO;2-F; Zhu YR, 2003, J MOL BIOL, V326, P1157, DOI 10.1016/S0022-2836(02)01437-7	52	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44243	44249		10.1074/jbc.M407021200	http://dx.doi.org/10.1074/jbc.M407021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302863	hybrid			2022-12-25	WOS:000224505600004
J	Ruiz, FA; Lea, CR; Oldfield, E; Docampo, R				Ruiz, FA; Lea, CR; Oldfield, E; Docampo, R			Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-PUMPING PYROPHOSPHATASE; TRYPANOSOMA-CRUZI; INORGANIC POLYPHOSPHATE; CALCIUM-PUMP; CA2+ POOLS; INTRACELLULAR STORES; SEROTONIN STORAGE; BODIES; ATPASES; CELLS	Inorganic polyphosphate (polyP) has been identified and measured in human platelets. Millimolar levels (in terms of Pi residues) of short chain polyP were found. The presence of polyP of similar to70-75 phosphate units was identified by P-31 NMR and by urea-polyacrylamide gel electrophoresis of platelet extracts. An analysis of human platelet dense granules, purified using metrizamide gradient centrifugation, indicated that polyP was preferentially located in these organelles. This was confirmed by visualization of polyP in the dense granules using 4',6-diamidino-2-phenylindole and by its release together with pyrophosphate and serotonin upon thrombin stimulation of intact platelets. Dense granules were also shown to contain large amounts of calcium and potassium and both bafilomycin A(1)-sensitive ATPase and pyrophosphatase activities. In agreement with these results, when human platelets were loaded with the fluorescent calcium indicator Fura-2 acetoxymethyl ester to measure their intracellular Ca2+ concentration ([Ca2+](i)), they were shown to possess a significant amount of Ca2+ stored in an acidic compartment. This was indicated by the following: 1) the increase in [Ca2+](i) induced by nigericin, monensin, or the weak base, NH4Cl, in the nominal absence of extracellular Ca-2 and 2) the effect of ionomycin, which could not take Ca2+ out of acidic organelles and was more effective after alkalinization of this compartment by the previous addition of nigericin, monensin, or NH4Cl. All of these characteristics of the platelet dense granules, together with their known acidity and high density (both by weight and by electron microscopy), are similar to those of acidocalcisomes (volutin granules, polyP bodies) of bacteria and unicellular eukaryotes. The results suggest that acidocalcisomes have been conserved during evolution from bacteria to humans.	Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Coll Vet Med, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA.	rodoc@uiuc.edu	Ruiz, Felix A./B-1032-2008	Ruiz, Felix A./0000-0003-0748-5015	NIAID NIH HHS [AI23259] Funding Source: Medline; NIGMS NIH HHS [GM50694] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN RA, 1980, CAN J MICROBIOL, V26, P912, DOI 10.1139/m80-158; AUTHI KS, 1993, BIOCHEM J, V294, P119, DOI 10.1042/bj2940119; BOULLIN DJ, 1972, BRIT J PHARMACOL, V45, P83, DOI 10.1111/j.1476-5381.1972.tb09579.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRASS LF, 1985, J BIOL CHEM, V260, P5172; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1104, P188, DOI 10.1016/0005-2736(92)90149-G; BRUNE B, 1991, J BIOL CHEM, V266, P19232; BULL BS, 1966, BLOOD-J HEMATOL, V28, P901, DOI 10.1182/blood.V28.6.901.901; CARTY SE, 1981, J BIOL CHEM, V256, P1244; COSTA JL, 1982, BIOCHEM PHARMACOL, V31, P3215, DOI 10.1016/0006-2952(82)90552-4; COSTA JL, 1977, J PHYSIOL-LONDON, V264, P297, DOI 10.1113/jphysiol.1977.sp011669; COSTA JL, 1974, SCIENCE, V183, P537, DOI 10.1126/science.183.4124.537; DEAN GE, 1984, J BIOL CHEM, V259, P9569; DOCAMPO R, 1995, BIOCHEM J, V310, P1005, DOI 10.1042/bj3101005; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; ENGELENDER S, 1995, J BIOL CHEM, V270, P21050, DOI 10.1074/jbc.270.36.21050; FUKAMI MH, 1978, J CELL BIOL, V77, P389, DOI 10.1083/jcb.77.2.389; FUKAMI MH, 1980, BIOCHEM J, V192, P99, DOI 10.1042/bj1920099; HOLMSEN H, 1979, ANNU REV MED, V30, P119, DOI 10.1146/annurev.me.30.020179.001003; Jensen Thomas E., 1993, P7; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Kornberg A, 1999, ANNU REV BIOCHEM, V68, P89, DOI 10.1146/annurev.biochem.68.1.89; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; Lemercier G, 2004, J BIOL CHEM, V279, P3420, DOI 10.1074/jbc.M309974200; LIU CM, 1978, J BIOL CHEM, V253, P5892; Lu HG, 1998, MOL CELL BIOL, V18, P2309, DOI 10.1128/MCB.18.4.2309; Lu HG, 1997, J BIOL CHEM, V272, P9464, DOI 10.1074/jbc.272.14.9464; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; McNicol A, 1999, THROMB RES, V95, P1, DOI 10.1016/S0049-3848(99)00015-8; Merzendorfer H, 1997, J EXP BIOL, V200, P225; Meyer A., 1904, BOT Z, V62, P113; Moreno B, 2000, J BIOL CHEM, V275, P28356, DOI 10.1074/jbc.M003893200; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; PAPP B, 1992, BIOCHEM J, V288, P297, DOI 10.1042/bj2880297; POPOV EG, 1987, THROMB RES, V47, P639, DOI 10.1016/0049-3848(87)90102-2; RENDU F, 1982, BRIT J HAEMATOL, V52, P241, DOI 10.1111/j.1365-2141.1982.tb03886.x; Rodrigues CO, 1999, MOL CELL BIOL, V19, P7712; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Seufferheld M, 2003, J BIOL CHEM, V278, P29971, DOI 10.1074/jbc.M304548200; Shiba T, 2003, J BIOL CHEM, V278, P26788, DOI 10.1074/jbc.M303468200; SKAER RJ, 1976, J CELL SCI, V20, P441; SKAER RJ, 1981, BRIT J HAEMATOL, V49, P435, DOI 10.1111/j.1365-2141.1981.tb07246.x; Sun B, 2000, J BIOMED SCI, V7, P35; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUNODA Y, 1991, EXP CELL RES, V193, P356, DOI 10.1016/0014-4827(91)90107-6; Turetta L, 2002, CELL CALCIUM, V31, P235, DOI 10.1016/S0143-4160(02)00052-0; Van Wazer J. R., 1987, PHOSPHORUS NMR BIOL, P1; WHITE JG, 1969, BLOOD-J HEMATOL, V33, P598, DOI 10.1182/blood.V33.4.598.598; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153	53	308	319	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44250	44257		10.1074/jbc.M406261200	http://dx.doi.org/10.1074/jbc.M406261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308650	hybrid			2022-12-25	WOS:000224505600005
J	Somasundaram, T; Bhat, SP				Somasundaram, T; Bhat, SP			Developmentally dictated expression of heat shock factors: Exclusive expression of HSF4 in the postnatal lens and its specific interaction with alpha B-crystallin heat shock promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; BINDING; PROTEIN; ACTIVATION; CATARACT; ELEMENT; STRESS; DIFFERENTIATION; PHOSPHORYLATION	The molecular cascade of stress response in higher eukaryotes commences in the cytoplasm with the trimerization of the heat shock factor 1 (HSF1), followed by its transport to the nucleus, where it binds to the heat shock element leading to the activation of transcription from the down-stream gene(s). This well-established paradigm has been mostly studied in cultured cells. The developmental and tissue-specific control of the heat shock transcription factors (HSFs) and their interactions with heat shock promoters remain unexplored. We report here that in the rat lens, among the three mammalian HSFs, expression of HSF1 and HSF2 is largely fetal, whereas the expression of HSF4 is predominantly postnatal. Similar pattern of expression of HSF1 and HSF4 is seen in fetal and adult human lenses. This stage-specific inverse relationship between the expression of HSF1/2 and HSF4 suggests tissue-specific management of stress depending on the presence or absence of specific HSF(s). In addition to real-time PCR and immunoblotting, gel mobility shift assays, coupled with specific antibodies and HSE probes, derived from three different heat shock promoters, establish that there is no HSF1 or HSF2 binding activity in the postnatal lens nuclear extracts. Using this unique, developmentally modulated in vivo system, we demonstrate 1) specific patterns of HSF4 binding to heat shock elements derived from alphaB-crystallin, Hsp70, and Hsp82 promoters and 2) that it is HSF4 and not HSF1 or HSF2 that interacts with the canonical heat shock element of the alphaB-crystallin gene.	Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bhat, SP (corresponding author), Univ Calif Los Angeles, Sch Med, Brain Res Inst, 100 Stein Plaza,Rm BH-623, Los Angeles, CA 90095 USA.	bhat@jsei.ucla.edu		Bhat, Suraj P/0000-0003-4707-5870				Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; Bhat SP, 2003, PROG DRUG RES, V60, P205; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bu L, 2002, NAT GENET, V31, P276, DOI 10.1038/ng921; COLLIER NC, 1986, EXP EYE RES, V43, P103, DOI 10.1016/S0014-4835(86)80049-5; DEJONG WW, 1986, J CELL BIOL, V102, P104, DOI 10.1083/jcb.102.1.104; Frejtag W, 2001, J BIOL CHEM, V276, P14685, DOI 10.1074/jbc.M009224200; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; Head MW, 1996, J CELL SCI, V109, P1029; HEIKKILA JJ, 1993, DEV GENET, V14, P1, DOI 10.1002/dvg.1020140102; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Kallio M, 2002, EMBO J, V21, P2591, DOI 10.1093/emboj/21.11.2591; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; Manuel M, 2002, EUR J BIOCHEM, V269, P2527, DOI 10.1046/j.1432-1033.2002.02917.x; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; Morimoto R. I., 1996, STRESS INDUCIBLE CEL; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NAGINENI CN, 1992, EXP EYE RES, V54, P193, DOI 10.1016/S0014-4835(05)80208-8; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Sadamitsu C, 2001, J BIOCHEM, V129, P813, DOI 10.1093/oxfordjournals.jbchem.a002924; Somasundaram T, 2000, J BIOL CHEM, V275, P17154, DOI 10.1074/jbc.M000304200; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SRINIVASAN AN, 1994, DNA CELL BIOL, V13, P651, DOI 10.1089/dna.1994.13.651; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Trinklein ND, 2004, CELL STRESS CHAPERON, V9, P21, DOI 10.1379/1466-1268(2004)009<0021:TRABOH>2.0.CO;2; Walsh David, 1999, Environmental Medicine (Nagoya), V43, P79; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zhao WL, 2004, BLOOD, V103, P695, DOI 10.1182/blood-2003-06-1901; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752	36	67	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44497	44503		10.1074/jbc.M405813200	http://dx.doi.org/10.1074/jbc.M405813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308659	hybrid			2022-12-25	WOS:000224505600034
J	Vasilcanu, D; Girnita, A; Girnita, L; Vasilcanu, R; Axelson, M; Larsson, O				Vasilcanu, D; Girnita, A; Girnita, L; Vasilcanu, R; Axelson, M; Larsson, O			The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway	ONCOGENE			English	Article						IGF-1R; Akt; apoptosis; dominant-negative mutants	IGF-I; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; CELL-DEATH; CANCER; AUTOPHOSPHORYLATION; MITOGENESIS; EXPRESSION; MELANOMA; ANTIBODY; DOMAIN	The insulin-like growth factor-1 receptor (IGF-1R) is crucial for many functions in neoplastic cells, for example, antiapoptosis. Recently, we demonstrated that the cyclolignan PPP efficiently inhibited phosphorylation of IGF-1R without interfering with insulin receptor activity. PPP preferentially reduced phosphorylated Akt, as compared to phosphorylated Erk1/2, and caused apoptosis. Now, we aimed to investigate how PPP inhibits the IGF-1R tyrosine kinase (IGF-1RTK) and the PI3K/Akt apoptotic pathway. Using a baculovirus driven IGF-1RTK we found that PPP interfered with tyrosine phosphorylation in the activation loop of the kinase domain. Specifically, it blocked phosphorylation of tyrosine (Y) 1136, while sparing the two others (Y1131 and Y1135). To explore the impact of inhibition of Y1136 on Akt phosphorylation we transfected P6 cells (overexpressing IGF-1R) and malignant melanoma cells with different IGF-1R mutants, including Y1136F (tyrosine replaced by phenylalanine). Y1136F was found to strongly decrease IGF-1 stimulated phosphorylation of Akt. Conversely, Akt phosphorylation was weakly affected in the Y1131F transfectant. Taken together, our data suggest that the preferential inhibition of phosphorylated Akt, after PPP treatment, may be due to specific inhibition of Y1136. PPP was proven not to interfere directly with Akt or any of its downstream molecules in the apoptotic pathway.	Karolinska Hosp, CCK, Div Cellular & Mol Tumor Pathol, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Hosp, CCK, Div Cellular & Mol Tumor Pathol, Dept Pathol & Oncol, R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Girnita, Leonard/0000-0003-0280-9500; 				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Cann AD, 1998, BIOCHEMISTRY-US, V37, P11289, DOI 10.1021/bi9809122; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kanter-Lewensohn L, 2000, MOL CELL ENDOCRINOL, V165, P131, DOI 10.1016/S0303-7207(00)00253-7; KATO H, 1993, J BIOL CHEM, V268, P2655; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Roith D, 1999, ISR MED ASSOC J, V1, P25; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LI SW, 1994, J BIOL CHEM, V269, P32558; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Yam A, 2001, J BIOL CHEM, V276, P24409, DOI 10.1074/jbc.M102358200; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	38	126	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7854	7862		10.1038/sj.onc.1208065	http://dx.doi.org/10.1038/sj.onc.1208065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334055				2022-12-25	WOS:000224331600011
J	Nakajima, H; Nagaso, H; Kakui, N; Ishikawa, M; Hiranuma, T; Hoshiko, S				Nakajima, H; Nagaso, H; Kakui, N; Ishikawa, M; Hiranuma, T; Hoshiko, S			Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappa B-dependent gene expression in primary cultured mouse glial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE POLYMERASE; ASTROCYTE-ENRICHED CULTURES; DNA-BINDING; TRANSCRIPTION FACTOR; NITRIC-OXIDE; ENDOTOXIC-SHOCK; MIXED GLIA; RAT-BRAIN; ACTIVATION; SYNTHETASE	Synthesis of ADP-ribose polymers catalyzed by poly( ADP-ribose) polymerase-1 (PARP-1) has been implicated in transcriptional regulation. Recent studies with PARP-1 null mice and PARP-1 inhibitors have also demonstrated that PARP-1 has an essential role in nuclear factor-kappaB (NF-kappaB)-dependent gene expression induced by various inflammatory stimuli. In this study, we used primary cultured mouse glial cells to investigate the role of poly( ADP-ribosyl) ation by PARP-1 in NF-kappaB-dependent gene expression. PARP-1 inhibitors and the antisense RNA for PARP-1 mRNA suppressed lipopolysaccharide (LPS)-induced expression of tumor necrosis factor-alpha and inducible nitric-oxide synthase, suggesting that PARP-1 activity has a critical role in synthesis. Western blotting with anti-poly( ADP-ribose) antibody revealed that PARP-1 itself was mainly poly( ADP-ribosyl) ated in glial cells, i.e. automodified PARP-1 (AM-PARP). The amounts of AM-PARP were not affected by LPS treatment, but were decreased by PARP-1 inhibitors. Electrophoretic mobility shift assay revealed that PARP-1 inhibitors and the antisense RNA for PARP-1 mRNA reduced the LPS-induced DNA binding of NF-kappaB. Non-modified PARP-1 also reduced the DNA binding of NF-kappaB via its physical association with NF-kappaB, whereas AM-PARP had no effect. On the other hand, enhancement of the automodification of PARP-1 by the addition of NAD(+), its substrate, promoted the DNA binding of NF-kappaB. Furthermore, in in vitro transcription assay, the addition of AM-PARP or NAD(+) to nuclear extracts promoted NF-kappaB p50-dependent transcription. These results indicate that automodification of PARP-1 positively up-regulates formation of the NF-kappaB . DNA complex and enhances transcriptional activation. Therefore, AM-PARP may be critical for the NF-kappaB-dependent gene expression of some inflammatory mediators in glial cells.	Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2228567, Japan	Meiji Holdings Co., Ltd.	Nakajima, H (corresponding author), Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, 760 Moro Oka Cho, Yokohama, Kanagawa 2228567, Japan.	hidemitsu_nakajima@meiji.co.jp		Nakajima, Hidemitsu/0000-0002-0441-1929				Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2002, BRIT J PHARMACOL, V137, P761, DOI 10.1038/sj.bjp.0704934; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; FERRO AM, 1982, J BIOL CHEM, V257, P15990; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hasko G, 2002, MOL MED, V8, P283, DOI 10.1007/BF03402154; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hassa PO, 2003, J BIOL CHEM, V278, P45145, DOI 10.1074/jbc.M307957200; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; Kong LY, 1997, NEUROCHEM INT, V30, P491, DOI 10.1016/S0197-0186(96)00086-1; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LUKASIUK K, 1995, NEUROCHEM INT, V26, P173, DOI 10.1016/0197-0186(94)00121-A; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; NAKAJIMA K, 1989, BIOMED RES-TOKYO, V10, P411; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; OGATA N, 1981, J BIOL CHEM, V256, P4135; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; TANUMA S, 1982, J BIOL CHEM, V257, P6565; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375	50	85	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42774	42786		10.1074/jbc.M407923200	http://dx.doi.org/10.1074/jbc.M407923200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15302869	hybrid			2022-12-25	WOS:000224226400053
J	Guo, Y; Smith, K; Petris, MJ				Guo, Y; Smith, K; Petris, MJ			Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter - Requirement for the extracellular methionine-rich clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFUR-CONTAINING NUCLEOPHILES; CANCER CELL-LINES; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; OVARIAN-CANCER; STIMULATED ENDOCYTOSIS; PLASMA-MEMBRANE; DISEASE PROTEIN; EXPORT PUMP; RESISTANCE	Cisplatin is a highly effective cancer chemotherapy agent. However, acquired resistance currently limits the clinical utility of this drug. The human high affinity copper importer, hCtr1, and its yeast and murine orthologues have been shown to mediate the uptake of cisplatin. This transporter is located at the plasma membrane under low copper conditions, and excess copper concentrations stimulate its endocytosis and degradation. In this study we further examined the link between cisplatin and hCtr1 by examining whether cisplatin can also stimulate the endocytosis and degradation of hCtr1. The steady-state location of hCtr1 and its endocytosis from the plasma membrane were not altered by cisplatin treatment. Unexpectedly, cisplatin treatment of a cell line expressing hCtr1 revealed the time- and concentration-dependent appearance of a stable hCtr1 multimeric complex, consistent with a homotrimer, which was not observed following copper treatment of these same cells. Mutagenesis studies identified two methionine-rich clusters in the extracellular amino-terminal region of hCtr1 that were required for stabilization of the hCtr1 multimer by cisplatin, suggesting that these sequences bind cisplatin and form cross-links between hCtr1 polypeptides. Treatment with the metal chelator dimethyldithiocarbamate disassembled the hCtr1 multimer following cisplatin exposure, suggesting that platinum was an integral component of this complex. These studies provide the first evidence for a direct interaction between cisplatin and the hCtr1 protein and establish that cisplatin and copper have distinct biochemical consequences on this transporter.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.	petrism@missouri.edu		Fulcher, Yan/0000-0002-7060-3523	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK066333, R01DK066333] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK66333] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORCH RF, 1979, P NATL ACAD SCI USA, V76, P6611, DOI 10.1073/pnas.76.12.6611; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DEDON PC, 1987, BIOCHEM PHARMACOL, V36, P1955, DOI 10.1016/0006-2952(87)90494-1; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GONIAS SL, 1981, J BIOL CHEM, V256, P2478; GONIAS SL, 1984, CANCER RES, V44, P5764; Guo Y, 2004, J BIOL CHEM, V279, P17428, DOI 10.1074/jbc.M401493200; HIDAKA S, 1995, J APPL TOXICOL, V15, P267, DOI 10.1002/jat.2550150407; Holford J, 2000, EUR J CANCER, V36, P1984, DOI 10.1016/S0959-8049(00)00192-1; HOLZER AK, 2004, IN PRESS MOL PHARM; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Ivanov AI, 1998, J BIOL CHEM, V273, P14721, DOI 10.1074/jbc.273.24.14721; Katano K, 2002, CANCER RES, V62, P6559; Katano K, 2003, MOL PHARMACOL, V64, P466, DOI 10.1124/mol.64.2.466; Klomp AEM, 2003, BIOCHEM J, V370, P881, DOI 10.1042/BJ20021128; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Komatsu M, 2000, CANCER RES, V60, P1312; KUROKAWA H, 1995, BIOCHEM BIOPH RES CO, V216, P258, DOI 10.1006/bbrc.1995.2618; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lin XJ, 2002, MOL PHARMACOL, V62, P1154, DOI 10.1124/mol.62.5.1154; MONTINE TJ, 1990, BIOCHEM PHARMACOL, V39, P1751, DOI 10.1016/0006-2952(90)90121-Z; OGURI S, 1988, J CLIN PHARMACOL, V28, P208, DOI 10.1002/j.1552-4604.1988.tb03134.x; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Panteix G, 2002, ANTICANCER RES, V22, P1329; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Petris MJ, 2004, PFLUG ARCH EUR J PHY, V447, P752, DOI 10.1007/s00424-003-1092-1; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; Safaei R, 2004, CANCER CHEMOTH PHARM, V53, P239, DOI 10.1007/s00280-003-0736-3; Samimi G, 2004, MOL PHARMACOL, V66, P25, DOI 10.1124/mol.66.1.25; Samimi G, 2004, CLIN CANCER RES, V10, P4661, DOI 10.1158/1078-0432.CCR-04-0137; STONE PJ, 1974, NATURE, V251, P736, DOI 10.1038/251736a0; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2003, J BIOL CHEM, V278, P48210, DOI 10.1074/jbc.M309820200; ZWELLING LA, 1979, MUTAT RES, V67, P271, DOI 10.1016/0165-1218(79)90021-1	43	61	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46393	46399		10.1074/jbc.M407777200	http://dx.doi.org/10.1074/jbc.M407777200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15326162	hybrid			2022-12-25	WOS:000224832400008
J	Ribeiro-Neto, F; Leon, A; Urbani-Brocard, J; Lou, LG; Nyska, A; Altschuler, DL				Ribeiro-Neto, F; Leon, A; Urbani-Brocard, J; Lou, LG; Nyska, A; Altschuler, DL			cAMP-dependent oncogenic action of Rap1b in the thyroid gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; CYCLIC-AMP; BINDING PROTEINS; CELL-ADHESION; GROWTH; RAS; ACTIVATION; GTPASE; GENE; INHIBITION	cAMP signaling leads to activation and phosphorylation of Rap1b. Using cellular models where cAMP stimulates cell proliferation, we have demonstrated that cAMP-mediated activation, as well as phosphorylation of Rap1b, is critical for cAMP stimulation of DNA synthesis. To determine whether Rap1b stimulates mitogenesis in vivo, we have constructed a transgenic mouse where a constitutively active G12V-Rap1b, flanked by Cre recombinase LoxP sites, is followed by the dominant negative S17N mutant. Employing this novel mouse model, we have switched, in a tissue-specific ( thyroid) and temporally controlled manner, the expression of Rap1b from a stimulatory to an inhibitory form. These experiments provide conclusive evidence that Rap1b is oncogenic in the thyroid in ways linked to transduction of the cAMP mitogenic signal.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; NIEHS, NIH, Res Triangle Pk, NC 27709 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Altschuler, DL (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, 200 Lothrop St, Pittsburgh, PA 15261 USA.	altschul@server.pharm.pitt.edu		Brocard, Julie/0000-0001-9345-5191	NIDDK NIH HHS [DK063069] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063069] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Apicelli AJ, 2003, GLIA, V42, P225, DOI 10.1002/glia.10214; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2003, BIOCHEM SOC T, V31, P83, DOI 10.1042/bst0310083; Brocard J, 1997, P NATL ACAD SCI USA, V94, P14559, DOI 10.1073/pnas.94.26.14559; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Gerard AC, 2003, J ENDOCRINOL, V177, P269, DOI 10.1677/joe.0.1770269; Hochbaum D, 2003, J BIOL CHEM, V278, P33738, DOI 10.1074/jbc.M305208200; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLAINER LM, 1962, J BIOL CHEM, V237, P1239; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Largaespada DA, 2003, CANCER CELL, V4, P3, DOI 10.1016/S1535-6108(03)00171-5; Ledent C, 1997, ENDOCRINOLOGY, V138, P369, DOI 10.1210/en.138.1.369; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Ledent C, 1996, EXP CLIN ENDOCR DIAB, V104, P43, DOI 10.1055/s-0029-1211683; Maillet M, 2003, NAT CELL BIOL, V5, P633, DOI 10.1038/ncb1007; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PRICE LS, 2004, J BIOL CHEM; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; SANTELLI G, 1993, CANCER RES, V53, P5523; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; SELYE H, 1961, SCIENCE, V133, P44, DOI 10.1126/science.133.3445.44; SIHIDA D, 2003, CANC CELLS, V4, P55; Singh L, 2003, J VIROL, V77, P1614, DOI 10.1128/JVI.77.2.1614-1620.2003; SNYDER PJ, 1972, J CLIN INVEST, V51, P2077, DOI 10.1172/JCI107014; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; THOMAS GA, 1991, BRIT J CANCER, V63, P213, DOI 10.1038/bjc.1991.51; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WYNFORDTHOMAS D, 1982, ACTA ENDOCRINOL-COP, V101, P210, DOI 10.1530/acta.0.1010210; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zeiger MA, 1997, ENDOCRINOLOGY, V138, P3133, DOI 10.1210/en.138.8.3133; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	55	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46868	46875		10.1074/jbc.M406858200	http://dx.doi.org/10.1074/jbc.M406858200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331589	hybrid			2022-12-25	WOS:000224832400068
J	Trencia, A; Fiory, F; Maitan, MA; Vito, P; Barbagallo, APM; Perfetti, A; Miele, C; Ungaro, P; Oriente, F; Cilenti, L; Zervos, AS; Formisano, P; Beguinot, F				Trencia, A; Fiory, F; Maitan, MA; Vito, P; Barbagallo, APM; Perfetti, A; Miele, C; Ungaro, P; Oriente, F; Cilenti, L; Zervos, AS; Formisano, P; Beguinot, F			Omi/HtrA2 promotes cell death by binding and degrading the anti-apoptotic protein ped/pea-15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; GLUCOSE-TRANSPORT; STRUCTURAL BASIS; XIAP; MITOCHONDRIA; INHIBITOR; PEA-15; SMAC/DIABLO; EXPRESSION; INTERACTS	ped/pea-15 is a ubiquitously expressed 15-kDa protein featuring a broad anti-apoptotic function. In a yeast two-hybrid screen, the pro-apoptotic Omi/HtrA2 mitochondrial serine protease was identified as a specific interactor of the ped/pea-15 death effector domain. Omi/HtrA2 also bound recombinant ped/pea-15 in vitro and co-precipitated with ped/pea-15 in 293 and HeLa cell extracts. In these cells, the binding of Omi/HtrA2 to ped/pea-15 was induced by UVC exposure and followed the mitochondrial release of Omi/HtrA2 into the cytoplasm. Upon UVC exposure, cellular ped/pea-15 protein expression levels decreased. This effect was prevented by the ucf-101 specific inhibitor of the Omi/HtrA2 proteolytic activity, in a dose-dependent fashion. In vitro incubation of ped/pea-15 with Omi/HtrA2 resulted in ped/pea-15 degradation. In intact cells, the inhibitory action of ped/pea-15 on UVC-induced apoptosis progressively declined at increasing Omi/HtrA2 expression. This further effect of Omi/HtrA2 was also inhibited by ucf-101. In addition, ped/pea-15 expression blocked Omi/HtrA2 co-precipitation with the caspase inhibitor protein XIAP and caspase 3 activation. Thus, in part, apoptosis following Omi/HtrA2 mitochondrial release is mediated by reduction in ped/pea-15 cellular levels. The ability of Omi/HtrA2 to relieve XIAP inhibition on caspases is modulated by the relative levels of Omi/HtrA2 and ped/pea-15.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Univ Naples Federico II, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Studi Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Sannio; State University System of Florida; University of Central Florida	Beguinot, F (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Sergio Pansini 5, I-80131 Naples, Italy.	beguino@unina.it	vito, pasquale/ABF-5505-2020; Formisano, Pietro/J-4237-2018; ORIENTE, Francesco/J-6652-2018	Formisano, Pietro/0000-0001-7020-6870; vito, pasquale/0000-0002-5721-7716; ORIENTE, Francesco/0000-0003-4375-4526	Telethon [E.0896] Funding Source: Medline	Telethon(Fondazione Telethon)		Cilenti L, 2003, J BIOL CHEM, V278, P11489, DOI 10.1074/jbc.M212819200; Condorelli G, 2001, DIABETES, V50, P1244, DOI 10.2337/diabetes.50.6.1244; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; GATEAU O, 1978, EUR J BIOCHEM, V88, P613, DOI 10.1111/j.1432-1033.1978.tb12488.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Hao CH, 2001, CANCER RES, V61, P1162; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kitsberg D, 1999, J NEUROSCI, V19, P8244; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trencia A, 2003, MOL CELL BIOL, V23, P4511, DOI 10.1128/MCB.23.13.4511-4521.2003; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903	35	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46566	46572		10.1074/jbc.M406317200	http://dx.doi.org/10.1074/jbc.M406317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328349	Green Published, hybrid			2022-12-25	WOS:000224832400029
J	Bhasin, N; Carl, P; Harper, S; Feng, G; Lu, H; Speicher, DW; Discher, DE				Bhasin, N; Carl, P; Harper, S; Feng, G; Lu, H; Speicher, DW; Discher, DE			Chemistry on a single protein, vascular cell adhesion molecule-1, during forced unfolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BONDS; DYNAMICS; TRIS(2-CARBOXYETHYL)PHOSPHINE; DITHIOTHREITOL; EXPRESSION; MICROSCOPY; INTEGRIN; DOMAINS; DNA	Proteins of many types experience tensile forces in their normal function, and vascular cell adhesion molecule-1 (VCAM-1) is typical in this. VCAM has seven Ig domains, and each has a disulfide bond (-S-S-) buried in its core that covalently stabilizes about half of each domain against unfolding. VCAM is extended here by single molecule atomic force microscopy in the presence or absence of reducing agents. In the absence of reducing agent, a sawtooth pattern of forced unfolding reveals an average period and total length consistent with disulfide locations in VCAM. With increasing reducing agent, accessible disulfides are specifically reduced ( to SH); the average period for unfolding increases up to saturation together with additional metrics of unfolding. Steered molecular dynamics simulations of unfolding indeed show that the core disulfide bond is solvent-exposed in the very earliest stages of protein extension. Michaelis-Menten kinetics emerge with reduction catalyzed by force (tau(reduction) similar to 10(-4) s). The results establish single molecule reduction, one bond at a time, and show that mechanical forces can play a key role in modulating the redox state of cell adhesion proteins that are invariably stressed in cell adhesion.	Univ Penn, Dept Chem & Biomol Engn, Syst Biol & Polymer Engn Lab, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Syst Biol Program, Philadelphia, PA 19104 USA; Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA	University of Pennsylvania; The Wistar Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Discher, DE (corresponding author), Univ Penn, Dept Chem & Biomol Engn, Syst Biol & Polymer Engn Lab, Philadelphia, PA 19104 USA.	discher@seas.upenn.edu		discher, dennis/0000-0001-6163-2229; Lu, Hui/0000-0001-8347-0830	PHS HHS [R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Al-Maawali S, 2001, J PHYS CHEM B, V105, P3965, DOI 10.1021/jp0037246; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bustanji Y, 2002, ANGEW CHEM INT EDIT, V41, P1546, DOI 10.1002/1521-3773(20020503)41:9<1546::AID-ANIE1546>3.0.CO;2-U; Carl P, 2001, P NATL ACAD SCI USA, V98, P1565, DOI 10.1073/pnas.031409698; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; EVANS E, 1991, BIOPHYS J, V59, P849, DOI 10.1016/S0006-3495(91)82297-4; Getz EB, 1999, ANAL BIOCHEM, V273, P73, DOI 10.1006/abio.1999.4203; Gozu M, 2003, J BIOCHEM, V133, P731, DOI 10.1093/jb/mvg094; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KIKUCHI H, 1986, BIOCHEMISTRY-US, V25, P2009, DOI 10.1021/bi00356a026; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; Law R, 2003, BIOPHYS J, V84, P533, DOI 10.1016/S0006-3495(03)74872-3; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Lu H, 1999, PROTEINS, V35, P453, DOI 10.1002/(SICI)1097-0134(19990601)35:4<453::AID-PROT9>3.3.CO;2-D; Marko JF, 1995, MACROMOLECULES, V28, P8759, DOI 10.1021/ma00130a008; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; NELSON N, 1996, J SUPERCOMPUTING APP, V10, P251; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; REIF M, 1998, PHYS REV LETT, V81, P4764; REIF M, 1997, SCIENCE, V276, P1109; REIF M, 1999, J MOL BIOL, V286, P553; Rouzina I, 2001, BIOPHYS J, V80, P882, DOI 10.1016/S0006-3495(01)76067-5; Sahaf B, 2003, P NATL ACAD SCI USA, V100, P4001, DOI 10.1073/pnas.2628032100; Shao JY, 1999, BIOPHYS J, V77, P587, DOI 10.1016/S0006-3495(99)76915-8; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; WALLACE TJ, 1964, J AM CHEM SOC, V86, P4099, DOI 10.1021/ja01073a039; WU CY, 1995, J CELL SCI, V108, P821; Zlatanova J, 2003, J BIOL CHEM, V278, P23213, DOI 10.1074/jbc.R300007200	34	41	42	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45865	45874		10.1074/jbc.M404103200	http://dx.doi.org/10.1074/jbc.M404103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308645	hybrid			2022-12-25	WOS:000224694900071
J	Griffiths, GJ; Koh, MY; Brunton, VG; Cawthorne, C; Reeves, NA; Greaves, M; Tilby, MJ; Pearson, DG; Ottley, CJ; Workman, P; Frame, MC; Dive, C				Griffiths, GJ; Koh, MY; Brunton, VG; Cawthorne, C; Reeves, NA; Greaves, M; Tilby, MJ; Pearson, DG; Ottley, CJ; Workman, P; Frame, MC; Dive, C			Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-x(L) and increases oxaliplatin- and Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-KINASE; V-SRC; COLORECTAL-CANCER; ADENOCARCINOMA CELLS; STAT3 ACTIVATION; PHOSPHORYLATION; TRANSFORMATION; INHIBITION; GROWTH; DEATH	Tumor resistance to current drugs prevents curative treatment of human colon cancer. A pressing need for effective, tumor-specific chemotherapies exists. The non-receptor-tyrosine kinase c-Src is overexpressed in >70% of human colon cancers and represents a tractable drug target. KM12L4A human metastatic colon cancer cells were stably transfected with two distinct kinase-defective mutants of c-src. Their response to oxaliplatin, to SN38, the active metabolite of irinotecan ( drugs active in colon cancer), and to activation of the death receptor Fas was compared with vector control cells in terms of cell cycle arrest and apoptosis. Both kinase-defective forms of c-Src co-sensitized cells to apoptosis induced by oxaliplatin and Fas activation but not by SN38. Cells harboring kinase-defective forms of c-Src carrying function blocking point mutations in SH3 or SH2 domains were similarly sensitive to oxaliplatin, suggesting that reduction in kinase activity and not a Src SH2-SH3 scaffold function was responsible for the observed altered sensitivity. Oxaliplatin-induced apoptosis, potentiated by kinase-defective c-Src mutants, was dependent on activation of caspase 8 and associated with Bid cleavage. Each of the stable cell lines in which kinase-defective mutants of c-Src were expressed had reduced levels of Bcl-x(L). However, inhibition of c-Src kinase activity by PP2 in vector control cells did not alter the oxaliplatin response over 72 h nor did it reduce Bcl-x(L) levels. The data suggest that longer term suppression of Src kinase activity may be required to lower Bcl-x(L) levels and sensitize colon cancer cells to oxaliplatin-induced apoptosis.	Paterson Inst Canc Res, Cellular & Mol Pharmacol Grp, Manchester M20 4BX, Lancs, England; Canc Res UK Paterson Inst Canc Res, Manchester, Lancs, England; Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M20 4BX, Lancs, England; Canc Res UK Beatson Inst, Glasgow GG1 1BD, Lanark, Scotland; Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Durham, Dept Geol Sci, Durham DH1 3HP, England; Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England	Paterson Institute for Cancer Research; Cancer Research UK; University of Manchester; Beatson Institute; Newcastle University - UK; Durham University; Cancer Research UK; University of London; Institute of Cancer Research - UK	Dive, C (corresponding author), Paterson Inst Canc Res, Cellular & Mol Pharmacol Grp, Winslow Rd, Manchester M20 4BX, Lancs, England.	cdive@picr.man.ac.uk	Cawthorne, Christopher/AAC-1018-2022; Cawthorne, Christopher J/Q-5512-2018; Pearson, Graham/AAN-5507-2020	Cawthorne, Christopher/0000-0002-5975-0354; Cawthorne, Christopher J/0000-0002-5975-0354; Dive, Caroline/0000-0002-1726-8850; Koh, Mei Yee/0000-0002-3241-7316				Afar DEH, 1996, MOL CELL BIOL, V16, P3465; Avizienyte E, 2004, MOL BIOL CELL, V15, P2794, DOI 10.1091/mbc.E03-12-0879; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cam WR, 2001, CANCER, V92, P61, DOI 10.1002/1097-0142(20010701)92:1<61::AID-CNCR1292>3.0.CO;2-D; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Cartwright C, 1998, GASTROENTEROLOGY, V114, P1335, DOI 10.1016/S0016-5085(98)70443-3; Chen G, 1997, ONCOGENE, V15, P1643, DOI 10.1038/sj.onc.1201347; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X; Falcone A, 2002, J CLIN ONCOL, V20, P4006, DOI 10.1200/JCO.2002.12.075; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Jones RJ, 2002, BRIT J CANCER, V87, P1128, DOI 10.1038/sj.bjc.6600594; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Masumoto N, 1999, INT J CANCER, V80, P731, DOI 10.1002/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; MORIKAWA K, 1988, CANCER RES, V48, P1943; NAKAZAKI M, 1983, J CHEM SOC CHEM COMM, P787, DOI 10.1039/c39830000787; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RECHHIA R, 2004, BONE NY, V34, P65; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tillman DM, 1999, CLIN CANCER RES, V5, P425; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; Wils J, 2001, ANN ONCOL, V12, P13, DOI 10.1023/A:1008357725209; Workman P, 2002, TRENDS MOL MED, V8, pS1, DOI 10.1016/S1471-4914(02)02319-5; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	47	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46113	46121		10.1074/jbc.M408550200	http://dx.doi.org/10.1074/jbc.M408550200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326164	hybrid			2022-12-25	WOS:000224694900097
J	Liu, Y; Su, WD; Thompson, EA; Leitges, M; Murray, NR; Fields, AP				Liu, Y; Su, WD; Thompson, EA; Leitges, M; Murray, NR; Fields, AP			Protein kinase C beta II regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABERRANT CRYPT FOCI; CARCINOGENESIS; CANCER; ACID; GENE; PROLIFERATION; STIMULATION; ACTIVATION; PROMOTER; INSULIN	Protein kinase C betaII (PKCbetaII) is induced early during colon carcinogenesis. Transgenic mice expressing elevated PKCbetaII in the colonic epithelium (transgenic PKCbetaII mice) exhibit hyperproliferation and enhanced colon carcinogenesis. Here we demonstrate that nullizygous PKCbeta (PKCbetaKO) mice are highly resistant to azoxymethane (AOM)-induced preneoplastic lesions, aberrant crypt foci. However, reexpression of PKCbetaII in the colon of PKCbetaKO mice by transgenesis restores susceptibility to AOM-induced colon carcinogenesis. Expression of human PKCbetaII in rat intestinal epithelial (RIE) cells induces expression of endogenous rat PKCbetaII mRNA and protein. Induction of PKCbetaII is dependent upon catalytically active PKCbetaII and does not appear to involve changes in alternative splicing of the PKCbeta gene. Two human PKCbeta promoter constructs are activated by expression of PKCbetaII in RIE cells. Both PKCbeta promoter activity and PKCbetaII mRNA levels are inhibited by the MEK1 and -2 inhibitor U0126, but not the Cox-2 inhibitor celecoxib in RIE/PKCbetaII cells. PKCbeta promoter activity correlates directly with expression of endogenous PKCbetaII mRNA and protein in HT29 and HCT116 human colon cancer cell lines. PKCbeta promoter activity and PKCbetaII mRNA expression in HCT116 cells are inhibited by the selective PKCbeta inhibitor LY317615 and by U0126, demonstrating autoregulation of PKCbetaII expression. Transgenic PKCbetaII mice exhibit specific induction of endogenous PKCbetaII, but not its splice variant PKCbetaII, in the colonic epithelium in vivo. Taken together, our results demonstrate that 1) expression of PKCbetaII in the colonic epithelium is both necessary and sufficient to confer susceptibility to AOM-induced colon carcinogenesis in transgenic mice, 2) PKCbetaII regulates its own expression in RIE and human colon cancer cells in vitro and in the colonic epithelium in vivo, and 3) PKCbetaII autoregulation is mediated through a MEK-dependent signaling pathway in RIE/PKCbetaII and HCT116 colon cancer cells.	Mayo Clin, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	Mayo Clinic; Max Planck Society	Fields, AP (corresponding author), Mayo Clin, Ctr Comprehens Canc, Griffin Canc Res Bldg,Room 312,4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995	NCI NIH HHS [CA81436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUM CL, 1990, CANCER RES, V50, P3915; BIRD RP, 1995, CANCER LETT, V93, P55, DOI 10.1016/0304-3835(95)03788-X; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; Calvert PM, 2002, ANN INTERN MED, V137, P603, DOI 10.7326/0003-4819-137-7-200210010-00012; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; CRAVEN PA, 1992, CANCER RES, V52, P2216; CRAVEN PA, 1988, GASTROENTEROLOGY, V95, P676, DOI 10.1016/S0016-5085(88)80014-3; CRAVEN PA, 1987, J CLIN INVEST, V79, P532, DOI 10.1172/JCI112844; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Gustafson WC, 2004, J BIOL CHEM, V279, P9400, DOI 10.1074/jbc.M312840200; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; MAGNUSON BA, 1993, CANCER RES, V53, P4499; Murray NR, 2002, J CELL BIOL, V157, P915, DOI 10.1083/jcb.200201127; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; MURRAY NR, 1997, ROLE PROTEIN KINASE, P97; OBEID LM, 1992, J BIOL CHEM, V267, P20804; OBEID LM, 1990, J BIOL CHEM, V265, P2370; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; SIMON TC, 1993, J BIOL CHEM, V268, P18345; Teicher BA, 2002, CANCER CHEMOTH PHARM, V49, P69, DOI 10.1007/s00280-001-0386-2; Yu WS, 2003, J BIOL CHEM, V278, P11167, DOI 10.1074/jbc.M211424200; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	26	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45556	45563		10.1074/jbc.M407701200	http://dx.doi.org/10.1074/jbc.M407701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322124	hybrid			2022-12-25	WOS:000224694900034
J	Stork, O; Zhdanov, A; Kudersky, A; Yoshikawa, T; Obata, K; Pape, HC				Stork, O; Zhdanov, A; Kudersky, A; Yoshikawa, T; Obata, K; Pape, HC			Neuronal functions of the novel serine/threonine kinase Ndr2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MEMORY CONSOLIDATION; FEAR MEMORY; AMYGDALA; ACTIVATION; INDUCE; GROWTH; GENES	We have identified a novel member of the Ndr subfamily of serine/threonine protein kinases, Ndr2, as a gene product that is induced in the mouse amygdala during fear memory consolidation and examined a possible function of this kinase in neural differentiation. Expression of Ndr2 mRNA was detected in various cortical and subcortical brain regions, as well as non-neuronal tissues. Its expression in the amygdala was increased 6 h after Pavlovian fear conditioning training and returned to control levels within 24 h. To study intracellular localization and functions of Ndr2, EGFP::Ndr2 fusion proteins were expressed in rat pheochromocytoma (PC12) cells and acutely isolated cortical neurons, thereby revealing an association of Ndr2 with the actin cytoskeleton in somata, neurites and filopodia, in spines and at sites of cell contact. Co-precipitation and pull-down experiments support this finding. Evidence for an involvement of Ndr2 in actin-mediated cellular functions further comes from the observation of decreased cell spreading and changes in neurite outgrowth that were associated with protein serine phosphorylation in transfected PC12 cells. Together, our data suggest that Ndr2 is an interesting candidate gene for the regulation of structural processes in differentiating and mature neuronal cells.	Univ Magdeburg, Inst Physiol, D-39120 Magdeburg, Germany; RIKEN, Brain Sci Inst, Lab Mol Psychiat, Wako, Saitama 3510198, Japan; Natl Inst Physiol Sci, Neurochem Lab, Okazaki, Aichi 4448585, Japan	Otto von Guericke University; RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Stork, O (corresponding author), Univ Magdeburg, Inst Physiol, D-39120 Magdeburg, Germany.	oliver.stork@medizin.uni-magdeburg.de	Yoshikawa, Takeo/F-9599-2019	Zhdanov, Alexander/0000-0001-5787-2035; Stork, Oliver/0000-0003-4285-7507				Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Geinisman Y, 2001, J NEUROSCI, V21, P5568, DOI 10.1523/JNEUROSCI.21-15-05568.2001; Geng W, 2000, GENETICS, V156, P1817; Goslin K., 1998, CULTURING NERVE CELL, P339; Huang CM, 1996, J NEUROCHEM, V67, P530; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Lamprecht R, 2002, NEURON, V36, P727, DOI 10.1016/S0896-6273(02)01047-4; Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Mikkelsen SE, 2001, J NEUROCHEM, V79, P767, DOI 10.1046/j.1471-4159.2001.00605.x; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Moita MAP, 2002, NAT NEUROSCI, V5, P837, DOI 10.1038/nn901; O'Malley A, 1998, NEUROSCIENCE, V87, P607, DOI 10.1016/S0306-4522(98)00178-X; OHTA Y, 1987, FEBS LETT, V222, P305, DOI 10.1016/0014-5793(87)80391-5; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schafe GE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-18-j0003.2000; Schafe GE, 2000, J NEUROSCI, V20, P8177; SELINFREUND RH, 1990, J CELL BIOL, V111, P2021, DOI 10.1083/jcb.111.5.2021; Stegert MR, 2004, J BIOL CHEM, V279, P23806, DOI 10.1074/jbc.M402472200; Stork O, 2002, CELL TISSUE RES, V310, P271, DOI 10.1007/s00441-002-0656-2; Stork O, 2001, LEARN MEMORY, V8, P209, DOI 10.1101/lm.39401; Tamaskovic R, 2003, FEBS LETT, V546, P73, DOI 10.1016/S0014-5793(03)00474-5; Yoshikawa T, 1997, AM J MED GENET, V74, P140, DOI 10.1002/(SICI)1096-8628(19970418)74:2<140::AID-AJMG5>3.0.CO;2-Y; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	29	42	44	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45773	45781		10.1074/jbc.M403552200	http://dx.doi.org/10.1074/jbc.M403552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15308672	hybrid			2022-12-25	WOS:000224694900061
J	Wegele, R; Tasler, R; Zeng, YH; Rivera, M; Frankenberg-Dinkel, N				Wegele, R; Tasler, R; Zeng, YH; Rivera, M; Frankenberg-Dinkel, N			The heme oxygenase(s)-phytochrome system of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPIN FERRIHEME PROTEINS; CORYNEBACTERIUM-DIPHTHERIAE; CRYSTAL-STRUCTURE; OXIDATIVE CLEAVAGE; ESCHERICHIA-COLI; IRON SOURCES; ACTIVE-SITE; OXYGENASE; EXPRESSION; COMPLEX	For many pathogenic bacteria like Pseudomonas aeruginosa heme is an essential source of iron. After uptake, the heme molecule is degraded by heme oxygenases to yield iron, carbon monoxide, and biliverdin. The heme oxygenase PigA is only induced under iron-limiting conditions and produces the unusual biliverdin isomers IXbeta and IXdelta. The gene for a second putative heme oxygenase in P. aeruginosa, bphO, occurs in an operon with the gene bphP encoding a bacterial phytochrome. Here we provide biochemical evidence that bphO encodes for a second heme oxygenase in P. aeruginosa. HPLC, H-1, and C-13 NMR studies indicate that BphO is a "classic" heme oxygenase in that it produces biliverdin IXdelta. The data also suggest that the overall fold of BphO is likely to be the same as that reported for other alpha-hydroxylating heme oxygenases. Recombinant BphO was shown to prefer ferredoxins or ascorbate as a source of reducing equivalents in vitro and the rate-limiting step for the oxidation of heme to biliverdin is the release of product. In eukaryotes, the release of biliverdin is driven by biliverdin reductase, the subsequent enzyme in heme catabolism. Because P. aeruginosa lacks a biliverdin reductase homologue, data are presented indicating an involvement of the bacterial phytochrome BphP in biliverdin release from BphO and possibly from PigA.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Univ Kansas, Dept Chem, Lawrence, KS 66045 USA	Braunschweig University of Technology; University of Kansas	Frankenberg-Dinkel, N (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.	n.frankenberg@tu-bs.de	Frankenberg-Dinkel, Nicole/C-1058-2011	Frankenberg-Dinkel, Nicole/0000-0002-7757-6839	NIGMS NIH HHS [GM 50503] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050503, R01GM050503] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arora A, 2002, CURR SCI INDIA, V82, P1227; Avila L, 2003, J AM CHEM SOC, V125, P4103, DOI 10.1021/ja029311v; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bertini I, 1999, J BIOL INORG CHEM, V4, P515, DOI 10.1007/s007750050337; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONNETT R, 1973, J CHEM SOC PERK T 1, P881, DOI 10.1039/p19730000881; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunce RA, 1997, J LABELLED COMPD RAD, V39, P669, DOI 10.1002/(SICI)1099-1344(199708)39:8<669::AID-JLCR17>3.0.CO;2-B; Caignan GA, 2002, J AM CHEM SOC, V124, P14879, DOI 10.1021/ja0274960; Cornejo J, 1998, PLANT J, V15, P99, DOI 10.1046/j.1365-313X.1998.00186.x; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Friedman J, 2004, BIOCHEMISTRY-US, V43, P5239, DOI 10.1021/bi049687g; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorst CM, 1998, J AM CHEM SOC, V120, P8875, DOI 10.1021/ja9815475; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; Hirotsu S, 2004, J BIOL CHEM, V279, P11937, DOI 10.1074/jbc.M311631200; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; LAMAR GN, 1981, J BIOL CHEM, V256, P6075; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; LANKHORST PP, 1983, NUCLEIC ACIDS RES, V11, P2839, DOI 10.1093/nar/11.9.2839; Li YM, 2002, J BIOL CHEM, V277, P33018, DOI 10.1074/jbc.M204216200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Migita CT, 2003, EUR J BIOCHEM, V270, P687, DOI 10.1046/j.1432-1033.2003.03421.x; Muramoto T, 2002, PLANT PHYSIOL, V130, P1958, DOI 10.1104/pp.008128; Muramoto T, 1999, PLANT CELL, V11, P335, DOI 10.1105/tpc.11.3.335; PATT SL, 1972, J CHEM PHYS, V56, P3182, DOI 10.1063/1.1677669; Ratliff M, 2001, J BACTERIOL, V183, P6394, DOI 10.1128/JB.183.21.6394-6403.2001; Rivera M, 2004, ANAL BIOANAL CHEM, V378, P1464, DOI 10.1007/s00216-003-2340-0; RIVERA M, 1995, ANAL BIOCHEM, V230, P295, DOI 10.1006/abio.1995.1477; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Shokhirev NV, 1998, J BIOL INORG CHEM, V3, P581, DOI 10.1007/s007750050271; Skaar EP, 2004, J BIOL CHEM, V279, P436, DOI 10.1074/jbc.M307952200; SKERRA A, 1994, GENE, V151, P131, DOI 10.1016/0378-1119(94)90643-2; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; TERRY MJ, 1991, J BIOL CHEM, V266, P22215; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; WARREN MJ, 1990, TRENDS BIOCHEM SCI, V15, P426; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; Wilks A, 2002, ANTIOXID REDOX SIGN, V4, P603, DOI 10.1089/15230860260220102; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; Zeng YH, 2004, BIOCHEMISTRY-US, V43, P5222, DOI 10.1021/bi035970o; ZHANG X, 2004, EUR J BIOCH; Zhu WM, 2000, J BACTERIOL, V182, P439, DOI 10.1128/JB.182.2.439-447.2000	49	82	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45791	45802		10.1074/jbc.M408303200	http://dx.doi.org/10.1074/jbc.M408303200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15310749	Green Published, hybrid			2022-12-25	WOS:000224694900063
J	Huang, J; Chen, J; Chesla, SE; Yago, T; Mehta, P; McEver, RP; Zhu, C; Long, M				Huang, J; Chen, J; Chesla, SE; Yago, T; Mehta, P; McEver, RP; Zhu, C; Long, M			Quantifying the effects of molecular orientation and length on two-dimensional receptor-ligand binding kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; P-SELECTIN; CELL-ADHESION; CONCURRENT BINDING; MEMBRANE; FLOW; NEUTROPHILS; FIBRONECTIN; AFFINITY; IDENTIFICATION	Surface presentation of adhesion receptors influences cell adhesion, although the mechanisms underlying these effects are not well understood. We used a micropipette adhesion frequency assay to quantify how the molecular orientation and length of adhesion receptors on the cell membrane affected two-dimensional kinetic rates of interactions with surface ligands. Interactions of P-selectin, E-selectin, and CD16A with their respective ligands or antibody were used to demonstrate such effects. Randomizing the orientation of the adhesion receptor or lowering its ligand- and antibody-binding domain above the cell membrane lowered two-dimensional affinities of the molecular interactions by reducing the forward rates but not the reverse rates. In contrast, the soluble antibody bound with similar three-dimensional affinities to cell-bound P-selectin constructs regardless of their orientation and length. These results demonstrate that the orientation and length of an adhesion receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding.	Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA; Chinese Acad Sci, Inst Mech, Natl Micrograv Lab, Beijing 100080, Peoples R China; Georgia Inst Technol, Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University System of Georgia; Georgia Institute of Technology; Chinese Academy of Sciences; Institute of Mechanics, CAS; University System of Georgia; Georgia Institute of Technology; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhu, C (corresponding author), Georgia Inst Technol, George W Woodruff Sch Mech Engn, Atlanta, GA 30332 USA.	cheng.zhu@me.gatech.edu; mlong@imech.ac.cn	Huang, Jun/E-8472-2010; Zhu, Cheng/A-5724-2011		FOGARTY INTERNATIONAL CENTER [R03TW005774] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038282, R29AI038282, R01AI044902, R21AI044902] Funding Source: NIH RePORTER; FIC NIH HHS [TW 05774-01] Funding Source: Medline; NHLBI NIH HHS [HL 65631] Funding Source: Medline; NIAID NIH HHS [AI38282, AI 44902] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAN PY, 1992, MOL BIOL CELL, V3, P157, DOI 10.1091/mbc.3.2.157; Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Dwir O, 2000, J BIOL CHEM, V275, P18682, DOI 10.1074/jbc.M001103200; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Keselowsky BG, 2003, J BIOMED MATER RES A, V66A, P247, DOI 10.1002/jbm.a.10537; KOFLER R, 1977, J IMMUNOL METHODS, V16, P201, DOI 10.1016/0022-1759(77)90198-3; LI SH, 1994, J BIOL CHEM, V269, P4431; Long M, 2001, ANN BIOMED ENG, V29, P935, DOI 10.1114/1.1415529; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Michael KE, 2003, LANGMUIR, V19, P8033, DOI 10.1021/la034810a; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Patel KD, 1995, J CELL BIOL, V131, P1893, DOI 10.1083/jcb.131.6.1893; PATEL KD, 1995, J CLIN INVEST, V96, P1887, DOI 10.1172/JCI118234; Riper JW, 1998, BIOPHYS J, V74, P492, DOI 10.1016/S0006-3495(98)77807-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200; Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Zhu C, 2000, BIOPHYS J, V79, P1850, DOI 10.1016/S0006-3495(00)76434-4	34	92	100	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44915	44923		10.1074/jbc.M407039200	http://dx.doi.org/10.1074/jbc.M407039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299021	hybrid			2022-12-25	WOS:000224505600082
J	Jones, EMC; Roti, ECR; Wang, JL; Delfosse, SA; Robertson, GA				Jones, EMC; Roti, ECR; Wang, JL; Delfosse, SA; Robertson, GA			Cardiac I-Kr channels minimally comprise hERG 1a and 1b subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; POTASSIUM CHANNEL; ION-CHANNEL; K+ CHANNEL; PROTEIN TRAFFICKING; HUMAN HEART; PAS DOMAIN; EXPRESSION; RECTIFIER; MUTATIONS	Previous studies suggest native cardiac I-Kr channels are composed of alpha subunits encoded solely by the 1a transcript of the ERG1 gene. Using isoform-specific ERG1 antibodies, we have new evidence that subunits encoded by an alternate transcript, ERG1b, are also expressed in rat, canine, and human heart. The ERG1a and -1b subunits associate in vivo where they localize to the T tubules of ventricular myocytes. These data indicate native ventricular I-Kr channels are heteromers containing two alpha subunit types, ERG1a and -1b. The hERG1b-specific exon thus represents a novel target to screen for mutations causing type 2 long QT syndrome. These findings also suggest phenotypic analyses of existing type 2 long QT syndrome mutations, especially those exclusive to the hERG1a amino terminus, should be carried out in systems expressing both subunits.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Robertson, GA (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	Robertson@physiology.wisc.edu		Robertson, Gail/0000-0003-4694-5790	NHLBI NIH HHS [R32 HL07936, R01 HL68868] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007936, R01HL068868] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brette F, 2003, CIRC RES, V92, P1182, DOI 10.1161/01.RES.0000074908.17214.FD; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; CRAIG R, 1976, PROC R SOC SER B-BIO, V192, P451, DOI 10.1098/rspb.1976.0023; Crociani O, 2003, J BIOL CHEM, V278, P2947, DOI 10.1074/jbc.M210789200; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Delisle BP, 2003, J BIOL CHEM, V278, P35749, DOI 10.1074/jbc.M305787200; Finley MR, 2002, AM J PHYSIOL-HEART C, V283, pH126, DOI 10.1152/ajpheart.00622.2001; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Harris SP, 2002, CIRC RES, V90, P594, DOI 10.1161/01.RES.0000012222.70819.64; He JQ, 2001, CARDIOVASC RES, V49, P298, DOI 10.1016/S0008-6363(00)00256-X; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Larsen LA, 2001, CLIN CHEM, V47, P1390; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; Paulussen A, 2002, J BIOL CHEM, V277, P48610, DOI 10.1074/jbc.M206569200; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Rasmussen HB, 2004, AM J PHYSIOL-HEART C, V286, pH1300, DOI 10.1152/ajpheart.00344.2003; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	25	147	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44690	44694		10.1074/jbc.M408344200	http://dx.doi.org/10.1074/jbc.M408344200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304481	hybrid			2022-12-25	WOS:000224505600056
J	Li, YF; Prinz, WA				Li, YF; Prinz, WA			ATP-binding cassette (ABC) transporters mediate nonvesicular, raft-modulated sterol movement from the plasma membrane to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CHOLESTEROL TRANSPORT; SACCHAROMYCES-CEREVISIAE; CELL-SURFACE; TANGIER-DISEASE; BREFELDIN-A; GOLGI PROTEINS; DOMAINS RAFTS; LIPID RAFTS; YEAST; MUTATIONS	Little is known about the mechanisms of intracellular sterol transport or how cells maintain the high sterol concentration of the plasma membrane (PM). Here we demonstrate that two inducible ATP-binding cassette (ABC) transporters (Aus1p and Pdr11p) mediate nonvesicular movement of PM sterol to the endoplasmic reticulum (ER) in Saccharomyces cerevisiae. This transport facilitates exogenous sterol uptake, which we find requires steryl ester synthesis in the ER. Surprisingly, while expression of Aus1p and Pdr11p significantly increases sterol movement from PM to ER, it does not alter intracellular sterol distribution. Thus, ER sterol is likely rapidly returned to the PM when it is not esterified in the ER. We show that the propensity of PM sterols to be moved to the ER is largely determined by their affinity for sterol sphingolipid-enriched microdomains (rafts). Our findings suggest that raft association is a primary determinant of sterol accumulation in the PM and that Aus1p and Pdr11p facilitate sterol uptake by increasing the cycling of sterol between the PM and ER.	NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Prinz, WA (corresponding author), NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA.	wprinz@helix.nih.gov		LI, YIFU/0000-0002-7077-7689	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK060004, ZIADK060004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507; Chang A, 2002, METHOD ENZYMOL, V351, P339; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Hamilton JA, 2003, CURR OPIN LIPIDOL, V14, P263, DOI 10.1097/00041433-200306000-00006; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Knight BL, 2004, BIOCHEM SOC T, V32, P124, DOI 10.1042/BST0320124; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; Prinz W, 2002, SEMIN CELL DEV BIOL, V13, P197, DOI 10.1016/S1084-9521(02)00048-4; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; URBANI L, 1990, J BIOL CHEM, V265, P1919; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Wilcox LJ, 2002, J BIOL CHEM, V277, P32466, DOI 10.1074/jbc.M204707200; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993; Zweytick D, 2000, EUR J BIOCHEM, V267, P1075, DOI 10.1046/j.1432-1327.2000.01103.x	44	112	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45226	45234		10.1074/jbc.M407600200	http://dx.doi.org/10.1074/jbc.M407600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316012	hybrid			2022-12-25	WOS:000224505600116
J	Sugawara, H; Kuzunoki, M; Kurisu, G; Fujimoto, T; Aoyagi, H; Hatakeyama, T				Sugawara, H; Kuzunoki, M; Kurisu, G; Fujimoto, T; Aoyagi, H; Hatakeyama, T			Characteristic recognition of N-acetylgalactosamine by an invertebrate C-lype lectin, CEL-I, revealed by X-ray crystallographic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUCUMARIA-ECHINATA; CRYSTAL-STRUCTURE; BINDING PROTEIN; STRUCTURAL BASIS; PROGRAM; DOMAINS; HOLOTHUROIDEA; ANGSTROM; SEQUENCE; CDNA	CEL-I is a C-type lectin, purified from the sea cucumber Cucumaria echinata, that shows a high specificity for N-acetylgalactosamine ( GalNAc). We determined the crystal structures of CEL-I and its complex with GalNAc at 2.0 and 1.7 Angstrom resolution, respectively. CEL-I forms a disulfide-linked homodimer and contains two intramolecular disulfide bonds, although it lacks one intramolecular disulfide bond that is widely conserved among various C-type carbohydrate recognition domains (CRDs). Although the sequence similarity of CEL-I with other C-type CRDs is low, the overall folding of CEL-I was quite similar to those of other C-type CRDs. The structure of the complex with GalNAc revealed that the basic recognition mode of GalNAc was very similar to that for the GalNAc-binding mutant of the mannose-binding protein. However, the acetamido group of GalNAc appeared to be recognized more strongly by the combination of hydrogen bonds to Arg(115) and van der Waals interaction with Gln(70). Mutational analyses, in which Gln(70) and/or Arg(115) were replaced by alanine, confirmed that these residues contributed to GalNAc recognition in a cooperative manner.	Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; Osaka Univ, Res Ctr Stuct & Funct Proteom, Inst Prot Res, Suita, Osaka 5650871, Japan; RIKEN Plant Sci Ctr, Lab Commun Mech, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Nagasaki University; Osaka University; RIKEN	Hatakeyama, T (corresponding author), Nagasaki Univ, Fac Engn, Dept Appl Chem, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	thata@net.nagasaki-u.ac.jp	KURISU, GENJI/ABA-5960-2020; KURISU, GENJI/AAD-7109-2022	KURISU, GENJI/0000-0002-5354-0807; KURISU, GENJI/0000-0002-5354-0807; Hatakeyama, Tomomitsu/0000-0002-9505-1980				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; Brunger AT, 1997, METHOD ENZYMOL, V277, P366, DOI 10.1016/S0076-6879(97)77021-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HATAKEYAMA T, 1995, J BIOL CHEM, V270, P3560, DOI 10.1074/jbc.270.8.3560; HATAKEYAMA T, 1994, J BIOCHEM, V116, P209, DOI 10.1093/oxfordjournals.jbchem.a124495; Hatakeyama T, 2002, BIOSCI BIOTECH BIOCH, V66, P157, DOI 10.1271/bbb.66.157; Hatakeyama T, 2004, J BIOCHEM, V135, P101, DOI 10.1093/jb/mvh012; Hatakeyama T, 2002, ACTA CRYSTALLOGR D, V58, P143, DOI 10.1107/S0907444901017358; Hatakeyama T, 1996, J BIOL CHEM, V271, P16915, DOI 10.1074/jbc.271.28.16915; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; Kakiuchi M, 2002, GLYCOBIOLOGY, V12, P85, DOI 10.1093/glycob/12.2.85; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; Kolatkar AR, 1998, J BIOL CHEM, V273, P19502, DOI 10.1074/jbc.273.31.19502; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizuno H, 1999, J MOL BIOL, V289, P103, DOI 10.1006/jmbi.1999.2756; Mizuno H, 1997, NAT STRUCT BIOL, V4, P438, DOI 10.1038/nsb0697-438; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakano M, 1999, BBA-PROTEIN STRUCT M, V1435, P167, DOI 10.1016/S0167-4838(99)00212-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Oda T, 1997, J BIOCHEM, V121, P560; Oda T, 1999, J BIOCHEM, V125, P713, DOI 10.1093/oxfordjournals.jbchem.a022341; Poget SF, 1999, J MOL BIOL, V290, P867, DOI 10.1006/jmbi.1999.2910; SOMERS WS, 2000, EMBO J, V19, P467; Swaminathan GJ, 2001, J BIOL CHEM, V276, P26197, DOI 10.1074/jbc.M100848200; Uchida T, 2004, J BIOL CHEM, V279, P37133, DOI 10.1074/jbc.M404065200; Walker JR, 2004, BIOCHEMISTRY-US, V43, P3783, DOI 10.1021/bi035871a; WATANABE N, 1995, REV SCI INSTRUM, V66, P1824, DOI 10.1063/1.1145795; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	49	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45219	45225		10.1074/jbc.M408840200	http://dx.doi.org/10.1074/jbc.M408840200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15319425	hybrid			2022-12-25	WOS:000224505600115
J	Tang, ZZ; Liang, MC; Lu, SQ; Yu, DJ; Yu, CY; Yue, DT; Soong, TW				Tang, ZZ; Liang, MC; Lu, SQ; Yu, DJ; Yu, CY; Yue, DT; Soong, TW			Transcript scanning reveals novel and extensive splice variations in human L-type voltage-gated calcium channel, Ca(v)1.2 alpha(1) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VASCULAR SMOOTH-MUSCLE; DEPENDENT K+ CHANNEL; CA2+ CHANNEL; MOLECULAR DIVERSITY; FUNCTIONAL EXPRESSION; CA2+-DEPENDENT INACTIVATION; GATING KINETICS; CURRENT-DENSITY; N-TERMINUS	The L-type (Ca(v)1.2) voltage-gated calcium channels play critical roles in membrane excitability, gene expression, and muscle contraction. The generation of splice variants by the alternative splicing of the pore-forming Ca(v)1.2 alpha(1)-subunit (alpha(1)1.2) may thereby provide potent means to enrich functional diversity. To date, however, no comprehensive scan of alpha(1)1.2 splice variation has been performed, particularly in the human context. Here we have undertaken such a screen, exploiting recently developed "transcript scanning" methods to probe the human gene. The degree of variation turns out to be surprisingly large; 19 of the 55 exons comprising the human alpha(1)1.2 gene were subjected to alternative splicing. Two of these are previously unrecognized exons and two others were not known to be spliced. Comparisons of fetal and adult heart and brain uncovered a large IVS3-S4 variability resulting from combinatorial utilization of exons 31-33. Electrophysiological characterization of such IVS3-S4 variation revealed unmistakable shifts in the voltage dependence of activation, according to an interesting correlation between increased IVS3-S4 linker length and activation at more depolarized potentials. Steady-state inactivation profiles remained unaltered. This systematic portrait of splice variation furnishes a reference library for comprehending combinatorial arrangements of Ca(v)1.2 splice exons, especially as they impact development, physiology, and disease.	Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore; Natl Inst Neurosci, Singapore 308433, Singapore; Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National University of Singapore; National Neuroscience Institute (NNI); Johns Hopkins University; Johns Hopkins University	Soong, TW (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, Blk Md9,2 Med Dr, Singapore 117597, Singapore.	phsstw@nus.edu.sg	Tuluc, Petronel/C-2527-2011	Soong, Tuck Wah/0000-0002-0876-0325; Liang, Mui Cheng/0000-0003-1208-0733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052307] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL52307-10] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abernethy DR, 2002, J PHARMACOL EXP THER, V300, P724, DOI 10.1124/jpet.300.3.724; Alseikhan BA, 2002, P NATL ACAD SCI USA, V99, P17185, DOI 10.1073/pnas.262372999; Bell TJ, 2004, NEURON, V41, P127, DOI 10.1016/S0896-6273(03)00801-8; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; Bielefeldt K, 1999, J LAB CLIN MED, V133, P469, DOI 10.1016/S0022-2143(99)90024-0; Blumenstein Y, 2002, J BIOL CHEM, V277, P3419, DOI 10.1074/jbc.C100642200; Bonci A, 1998, J NEUROSCI, V18, P6693; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chaudhuri D, 2004, J NEUROSCI, V24, P6334, DOI 10.1523/JNEUROSCI.1712-04.2004; Dai BS, 2002, BIOCHEM BIOPH RES CO, V296, P429, DOI 10.1016/S0006-291X(02)00894-X; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Erickson MG, 2003, NEURON, V39, P97, DOI 10.1016/S0896-6273(03)00395-7; Fearon IM, 2000, CIRC RES, V87, P537, DOI 10.1161/01.RES.87.7.537; FERON O, 1994, EUR J BIOCHEM, V222, P195, DOI 10.1111/j.1432-1033.1994.tb18857.x; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gerzanich V, 2003, CIRC RES, V93, P805, DOI 10.1161/01.RES.0000097872.69043.A0; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Hans M, 1999, BIOPHYS J, V76, P1384, DOI 10.1016/S0006-3495(99)77300-5; Ivanina T, 2000, J BIOL CHEM, V275, P39846, DOI 10.1074/jbc.M005881200; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; Lacinova L, 2000, PFLUG ARCH EUR J PHY, V440, P50, DOI 10.1007/s004240051021; Lin ZX, 1999, J NEUROSCI, V19, P5322; Lin ZX, 1997, NEURON, V18, P153, DOI 10.1016/S0896-6273(01)80054-4; Lipscombe D, 2002, MOL NEUROBIOL, V26, P21, DOI 10.1385/MN:26:1:021; MA WJ, 1992, J BIOL CHEM, V267, P22728; McRory JE, 2004, J NEUROSCI, V24, P1707, DOI 10.1523/JNEUROSCI.4846-03.2004; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Mittman S, 1999, NEUROSCI LETT, V274, P143, DOI 10.1016/S0304-3940(99)00716-8; Neves G, 2004, NAT GENET, V36, P240, DOI 10.1038/ng1299; Pang L, 2003, FEBS LETT, V546, P349, DOI 10.1016/S0014-5793(03)00629-X; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Raghib A, 2001, J NEUROSCI, V21, P8495, DOI 10.1523/JNEUROSCI.21-21-08495.2001; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Soong TW, 2002, J NEUROSCI, V22, P10142; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	61	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44335	44343		10.1074/jbc.M407023200	http://dx.doi.org/10.1074/jbc.M407023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15299022	hybrid			2022-12-25	WOS:000224505600015
J	Martinelli, S; Urosevic, M; Daryadel, A; Oberholzer, PA; Baumann, C; Fey, MF; Dummer, R; Simon, HU; Yousefi, S				Martinelli, S; Urosevic, M; Daryadel, A; Oberholzer, PA; Baumann, C; Fey, MF; Dummer, R; Simon, HU; Yousefi, S			Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; HUMAN BONE-MARROW; TYROSINE PHOSPHORYLATION; EXPRESSION PATTERNS; APOPTOSIS; GAMMA; ALPHA; INFLAMMATION; RESPONSES; CYTOKINE	Interferons (IFNs) are cytokines that possess potent anti-viral and immunoregulatory activities. In contrast, their potential role(s) in anti-bacterial defense and neutrophil activation mechanisms is less well explored. By comparing gene expression patterns between immature and mature human neutrophils, we obtained evidence that intracellular proteases and other anti-bacterial proteins are produced at earlier stages of maturation, whereas the genes for receptors and signaling molecules required for the release of these effector molecules are preferentially induced during terminal differentiation. For instance, mature neutrophils strongly expressed genes that increase their responses to type I and type II IFNs. Interestingly, granulocyte/macrophage colony-stimulating factor was identified as a repressor of IFN signaling components and consequently of IFN-responsive genes. Both IFN-alpha and IFN-gamma induced strong tyrosine phosphorylation of STAT1 in mature but not in immature neutrophils. Functional in vitro studies suggested that IFNs act as priming factors on mature neutrophils, allowing the formation of extracellular traps upon subsequent stimulation with complement factor 5a (C5a). In contrast, both IFN-alpha and IFN-gamma had only little capacity to prime immature cells in this system. Moreover, both IFNs did not have significant anti-proliferative effects on immature neutrophils. These data contribute to our understanding regarding changes of gene expression during neutrophil differentiation and IFN-mediated anti-bacterial defense mechanisms.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Zurich, Dept Dermatol, CH-8091 Zurich, Switzerland; Univ Bern, Inselspital, Inst Med Oncol, CH-3010 Bern, Switzerland	University of Bern; University of Zurich; University of Bern; University Hospital of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-7410-2020; Yousefi, Shida/L-9689-2016	Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305				Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Anderlini P, 1996, BLOOD, V88, P2819, DOI 10.1182/blood.V88.8.2819.bloodjournal8882819; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; Baumann R, 2003, FASEB J, V17, P2221, DOI 10.1096/fj.03-0110com; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; BROUDY VC, 1987, J IMMUNOL, V139, P464; CLUITMANS FHM, 1995, BLOOD, V85, P2038, DOI 10.1182/blood.V85.8.2038.bloodjournal8582038; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DIAMOND RD, 1991, J CLIN INVEST, V87, P711, DOI 10.1172/JCI115050; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ellis CN, 1999, CLIN IMMUNOL, V92, P49, DOI 10.1006/clim.1999.4731; GANSER A, 1989, BLOOD, V73, P31; Gaviria JM, 1999, J INFECT DIS, V179, P1038, DOI 10.1086/314679; Itoh K, 1998, BLOOD, V92, P1432, DOI 10.1182/blood.V92.4.1432.416k13_1432_1441; KAWAKAMI M, 1990, BLOOD, V76, P1962; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Nold M, 2003, BIOCHEM PHARMACOL, V66, P505, DOI 10.1016/S0006-2952(03)00294-6; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; ROILIDES E, 1993, INFECT IMMUN, V61, P1185, DOI 10.1128/IAI.61.4.1185-1193.1993; Schlaak JF, 2002, J BIOL CHEM, V277, P49428, DOI 10.1074/jbc.M205571200; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Taniguchi T, 2001, NAT REV MOL CELL BIO, V2, P378, DOI 10.1038/35073080; TERSTAPPEN LWMM, 1990, LEUKEMIA, V4, P657; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499; Willers J, 2001, J INVEST DERMATOL, V116, P874, DOI 10.1046/j.1523-1747.2001.01339.x; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	37	206	212	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44123	44132		10.1074/jbc.M405883200	http://dx.doi.org/10.1074/jbc.M405883200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302890	hybrid			2022-12-25	WOS:000224383100092
J	Turelli, P; Vianin, S; Trono, D				Turelli, P; Vianin, S; Trono, D			The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE TRANSCRIPTION; MOBILE ELEMENTS; ENZYME APOBEC3G; VIF PROTEIN; HIV-1 VIF; DNA; REPLICATION; DEGRADATION; MECHANISM	APOBEC3G ( apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G) is an innate intracellular antiretroviral factor that can inhibit viral retroelements such as retroviruses and hepadnaviruses. However, it is unknown whether it can act on non-viral substrates. Retrotransposons are transposable elements that cumulatively account for about one third of the human genome. They are commonly classified in long terminal repeat (LTR) retrotransposons, which are strongly homologous to retroviruses, and non-LTR retrotransposons also known as L1 elements or LINE-1 ( long interspersed nucleotide element-1) elements. Most of the L1 elements are defective and only a small number are very active in vivo, but they are responsible for nearby all of the retrotransposition in the human population. The cloning of active human L1 elements has allowed the development of tissue culture-based assays for measuring their retrotransposition potential. We used such an assay to demonstrate that APOBEC3G, which impairs the replication of exogenous retroelements, does not affect the replication of endogenous L1 retrotransposons.	Univ Geneva, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland; Univ Geneva, Frontiers Genet Res Program, CH-1211 Geneva 4, Switzerland	University of Geneva; University of Geneva	Trono, D (corresponding author), CMU, Dept Microbiol & Mol Med, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Didier.Trono@medecine.unige.ch						Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Cost GJ, 2002, EMBO J, V21, P5899, DOI 10.1093/emboj/cdf592; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kazazian HH, 1998, CURR OPIN GENET DEV, V8, P343, DOI 10.1016/S0959-437X(98)80092-0; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Meischl C, 2000, EUR J HUM GENET, V8, P697, DOI 10.1038/sj.ejhg.5200523; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Ostertag EM, 2000, NUCLEIC ACIDS RES, V28, P1418, DOI 10.1093/nar/28.6.1418; Prak ETL, 2000, NAT REV GENET, V1, P134; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; Schwahn U, 1998, NAT GENET, V19, P327, DOI 10.1038/1214; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Suminaga R, 2000, J HUM GENET, V45, P331, DOI 10.1007/s100380070003; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	24	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43371	43373		10.1074/jbc.C400334200	http://dx.doi.org/10.1074/jbc.C400334200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15322092	hybrid			2022-12-25	WOS:000224383100003
J	Wu, LJ; Duan, B; Mei, YD; Gao, J; Chen, JG; Zhuo, M; Xu, L; Wu, MA; Xu, TL				Wu, LJ; Duan, B; Mei, YD; Gao, J; Chen, JG; Zhuo, M; Xu, L; Wu, MA; Xu, TL			Characterization of acid-sensing ion channels in dorsal horn neurons of rat spinal cord	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; ROOT GANGLION-CELLS; CAENORHABDITIS-ELEGANS; HIPPOCAMPAL-NEURONS; ACTIVATED CURRENTS; PAIN; H+; EXPRESSION	Acid-sensing ion channels (ASICs) are ligand-gated cation channels activated by extracellular protons. In periphery, they contribute to sensory transmission, including that of nociception and pain. Here we characterized ASIC-like currents in dorsal horn neurons of the rat spinal cord and their functional modulation in pathological conditions. Reverse transcriptase-nested PCR and Western blotting showed that three ASIC isoforms, ASIC1a, ASIC2a, and ASIC2b, are expressed at a high level in dorsal horn neurons. Electrophysiological and pharmacological properties of the proton-gated currents suggest that homomeric ASIC1a and/or heteromeric ASIC1a + 2b channels are responsible for the proton-induced currents in the majority of dorsal horn neurons. Acidification-induced action potentials in these neurons were compatible in a pH-dependent manner with the pH dependence of ASIC-like current. Furthermore, peripheral complete Freund's adjuvant-induced inflammation resulted in increased expression of both ASIC1a and ASIC2a in dorsal horn. These results support the idea that the ASICs of dorsal horn neurons participate in central sensory transmission/modulation under physiological conditions and may play important roles in inflammation-related persistent pain.	Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China; Huazhong Univ Sci & Technol, Dept Pharmacol, Tongji Med Coll, Wuhan 430030, Peoples R China; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada; Chinese Acad Sci, Lab Learning & Memory, Kunming Inst Zool, Kunming 650223, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Huazhong University of Science & Technology; University of Toronto; Chinese Academy of Sciences; Kunming Institute of Zoology	Xu, TL (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	tlxu@ion.ac.cn	Mei, Yide/M-4468-2013; Wu, Long-Jun/E-2684-2012; Xu, Lin/T-5531-2017; Wu, Long-Jun/AAK-7113-2020; Zhuo, Min/A-2072-2008	Xu, Lin/0000-0002-2710-3507; Wu, Long-Jun/0000-0001-8019-3380; Zhuo, Min/0000-0001-9062-3241; Wu, Mian/0000-0002-2714-0500				AKAIKE N, 1990, J NEUROPHYSIOL, V63, P805, DOI 10.1152/jn.1990.63.4.805; Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Askwith CC, 2004, J BIOL CHEM, V279, P18296, DOI 10.1074/jbc.M312145200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; CHVATAL A, 1988, PHYSIOL BOHEMOSLOV, V37, P203; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Grunder S, 2000, NEUROREPORT, V11, P1607; Hesselager M, 2004, J BIOL CHEM, V279, P11006, DOI 10.1074/jbc.M313507200; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Li YF, 2003, J PHYSIOL-LONDON, V552, P73, DOI 10.1113/jphysiol.2003.047324; Li YX, 1997, DEV BRAIN RES, V102, P261, DOI 10.1016/S0165-3806(97)00102-8; Lin WH, 2002, J NEUROPHYSIOL, V88, P133, DOI 10.1152/jn.2002.88.1.133; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Mamet J, 2002, J NEUROSCI, V22, P10662; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; RANDIC M, 1993, J NEUROSCI, V13, P5228, DOI 10.1523/JNEUROSCI.13-12-05228.1993; Reeh P W, 2001, Curr Opin Pharmacol, V1, P45, DOI 10.1016/S1471-4892(01)00014-5; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Scholz J, 2002, NAT NEUROSCI, V5, P1062, DOI 10.1038/nn942; Ugawa S, 2003, J NEUROSCI, V23, P3616; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; Wu LJ, 2001, J NEUROSCI METH, V108, P199, DOI 10.1016/S0165-0270(01)00404-6; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zhuo M, 2002, DRUG DISCOV TODAY, V7, P259, DOI 10.1016/S1359-6446(01)02138-9	47	141	149	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43716	43724		10.1074/jbc.M403557200	http://dx.doi.org/10.1074/jbc.M403557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302881	hybrid			2022-12-25	WOS:000224383100046
J	An, SG; Musier-Forsyth, K				An, SG; Musier-Forsyth, K			Trans-editing of Cys-tRNA(Pro) by Haemophilus influenzae YbaK protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; RIBONUCLEIC-ACID SYNTHETASE; ESCHERICHIA-COLI; INSERTION DOMAIN; IN-VITRO; AMINOACYLATION; ISOLEUCINE; SELECTION; TRNA(PRO); CYSTEINE	Prolyl-tRNA synthetases (ProRSs) from all three domains of life have been shown to misactivate cysteine and to mischarge cysteine onto tRNA(Pro). Although most bacterial ProRSs possess an amino acid editing domain that deacylates mischarged Ala-tRNA(Pro), editing of Cys-tRNA(Pro) has not been demonstrated and a double-sieve mechanism of editing does not appear to be sufficient to eliminate all misacylated tRNA(Pro) species from the cell. It was recently shown that a ProRS paralog, the YbaK protein from Haemophilus influenzae, which is homologous to the ProRS editing domain, is capable of weakly deacylating Ala-tRNA(Pro). This function appears to be redundant with that of its corresponding ProRS, which contains a canonical bacterial editing domain. In the present study, we test the specificity of editing by H. influenzae YbaK and show that it efficiently edits Cys-tRNA(Pro) and that a conserved Lys residue is essential for this activity. These findings represent the first example of an editing domain paralog possessing altered specificity and suggest that similar autonomous editing domains could act upon different mischarged tRNAs thus providing cells with enhanced proofreading potential. This work also suggests a novel mechanism of editing wherein a third sieve is used to clear CystRNA(Pro) in at least some organisms.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Musier-Forsyth, K (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.	musier@chem.umn.edu	An, Songon/A-6714-2009	An, Songon/0000-0003-2189-7374				Ahel I, 2003, P NATL ACAD SCI USA, V100, P15422, DOI 10.1073/pnas.2136934100; Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; Ambrogelly A, 2002, J BIOL CHEM, V277, P34749, DOI 10.1074/jbc.M206929200; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Beebe K, 2004, P NATL ACAD SCI USA, V101, P5958, DOI 10.1073/pnas.0401530101; Beebe K, 2003, EMBO J, V22, P668, DOI 10.1093/emboj/cdg065; Beuning PJ, 2000, P NATL ACAD SCI USA, V97, P8916, DOI 10.1073/pnas.97.16.8916; Beuning PJ, 2001, J BIOL CHEM, V276, P30779, DOI 10.1074/jbc.M104761200; Beuning PJ, 1997, J AM CHEM SOC, V119, P8397, DOI 10.1021/ja971020c; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen JF, 2000, BIOCHEMISTRY-US, V39, P6726, DOI 10.1021/bi000108r; Dock-Bregeon AC, 2000, CELL, V103, P877, DOI 10.1016/S0092-8674(00)00191-4; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH S, 1986, NUCLEIC ACIDS RES, V14, P7529, DOI 10.1093/nar/14.19.7529; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P1, DOI 10.1021/bi00672a001; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FREIST W, 1989, BIOCHEMISTRY-US, V28, P6787, DOI 10.1021/bi00443a001; Freist W, 1998, J THEOR BIOL, V193, P19, DOI 10.1006/jtbi.1998.0672; Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Kamtekar S, 2003, P NATL ACAD SCI USA, V100, P1673, DOI 10.1073/pnas.0437911100; Korencic D, 2004, P NATL ACAD SCI USA, V101, P10260, DOI 10.1073/pnas.0403926101; LAUGHREA M, 1982, EXP GERONTOL, V17, P305, DOI 10.1016/0531-5565(82)90020-1; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; Lipman RSA, 2002, J MOL BIOL, V315, P943, DOI 10.1006/jmbi.2001.5297; Lipman RSA, 2002, J MOL BIOL, V316, P421, DOI 10.1006/jmbi.2001.5373; LIU HJ, 1995, NUCLEIC ACIDS RES, V23, P165, DOI 10.1093/nar/23.1.165; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; ORGEL LE, 1963, P NATL ACAD SCI USA, V49, P517, DOI 10.1073/pnas.49.4.517; Sankaranarayanan R, 2000, NAT STRUCT BIOL, V7, P461; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolf YI, 1999, GENOME RES, V9, P689; Wong FC, 2003, J BIOL CHEM, V278, P52857, DOI 10.1074/jbc.M309627200; Wong FC, 2002, BIOCHEMISTRY-US, V41, P7108, DOI 10.1021/bi012178j; Zhang H, 2000, PROTEINS, V40, P86, DOI 10.1002/(SICI)1097-0134(20000701)40:1<86::AID-PROT100>3.0.CO;2-Y	42	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42359	42362		10.1074/jbc.C400304200	http://dx.doi.org/10.1074/jbc.C400304200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15322138	hybrid			2022-12-25	WOS:000224226400004
J	Melendez, J; Turner, C; Avraham, H; Steinberg, SF; Schaefer, E; Sussman, MA				Melendez, J; Turner, C; Avraham, H; Steinberg, SF; Schaefer, E; Sussman, MA			Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-COUPLED RECEPTORS; N-TERMINAL KINASE; TYROSINE KINASE; PYK2 AUTOPHOSPHORYLATION; VENTRICULAR MYOCYTES; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; BETA-CATENIN; IN-VITRO	Altered cellular adhesion and apoptotic signaling in cardiac remodeling requires coordinated regulation of multiple constituent proteins that comprise cytoskeletal focal adhesions. One such protein activated by cardiac remodeling is related adhesion focal tyrosine kinase ( RAFTK, also known as pyk2). Adenoviral-mediated expression of RAFTK in neonatal rat cardiomyocytes involves concurrent increases in phosphorylation of Src, c-Jun N-terminal kinase, and p38 leading to characteristic apoptotic changes including cleavage of poly( ADP-ribose) polymerase, caspase-3 activation, and increased DNA laddering. DNA laddering was decreased by mutation of the Tyr(402) Src-binding site in RAFTK, suggesting a central role for Src activity in apoptotic cell death that was confirmed by adenoviral-mediated Src expression. Multiple apoptotic signaling cascades are recruited by RAFTK as demonstrated by prevention of apoptosis using caspase-3 inhibitor IV (caspase-3 specific inhibitor), PP2 (Src-specific kinase inhibitor), or Csk ( cellular negative regulator for Src), as well as dominant negative constructs for p38beta or MKP-1. These RAFTK-mediated phenotypic characteristics are prevented by concurrent expression of wildtype or a phosphorylation-deficient paxillin mutated at Tyr(31) and Tyr(118). Wild-type or mutant paxillin protein accumulation in the cytoplasm has no overt effect upon cell structure, but paxillin accumulation prevents losses of myofibril organization as well as focal adhesion kinase, vinculin, and paxillin protein levels mediated by RAFTK. Apoptotic signaling cascade inhibition by paxillin indicates interruption of signaling proximal to but downstream of RAFTK activity. Chronic RAFTK activation in cardiac remodeling may represent a maladaptive reactive response that can be modulated by paxillin, opening up novel possibilities for inhibition of cardiomyocyte apoptosis and structural degeneration in heart failure.	San Diego State Univ, Inst Heart, San Diego, CA 92182 USA; Childrens Hosp Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Biosource Int, Hopkinton, MA 01748 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Columbia University; California State University System; San Diego State University	Sussman, MA (corresponding author), San Diego State Univ, Inst Heart, 5500 Campanile Dr, San Diego, CA 92182 USA.	sussman@heart.sdsu.edu	; Sussman, Mark/H-2284-2014	Avraham, Hava/0000-0002-7545-3640; Sussman, Mark/0000-0002-0104-4799; Melendez Rojel, Jaime/0000-0003-4711-864X	NIGMS NIH HHS [R01 GM047607] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Bayer AL, 2002, AM J PHYSIOL-HEART C, V283, pH695, DOI 10.1152/ajpheart.00021.2002; Bayer AL, 2001, J MOL CELL CARDIOL, V33, P1017, DOI 10.1006/jmcc.2001.1369; BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chay KO, 2002, J BIOL CHEM, V277, P14521, DOI 10.1074/jbc.M111639200; CLERK A, 1994, J BIOL CHEM, V269, P32848; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Du QS, 2001, J CELL SCI, V114, P2977; Goldspink DF, 2003, EXP PHYSIOL, V88, P447, DOI 10.1113/eph8802549; Grgurevich S, 1999, BIOCHEM BIOPH RES CO, V256, P668, DOI 10.1006/bbrc.1999.0398; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Harrington EO, 2001, AM J PHYSIOL-LUNG C, V280, pL342, DOI 10.1152/ajplung.2001.280.2.L342; Hazeki K, 2003, EUR J IMMUNOL, V33, P740, DOI 10.1002/eji.200323375; Kang PM, 2003, TRENDS MOL MED, V9, P177, DOI 10.1016/S1471-4914(03)00025-X; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V290, P1470, DOI 10.1006/bbrc.2002.6350; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kook S, 2000, CELL BIOCHEM FUNCT, V18, P1; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; Lavastre V, 2002, J TOXICOL ENV HEAL A, V65, P1013, DOI 10.1080/00984100290071270; Lesay A, 2001, NEUROREPORT, V12, P2111, DOI 10.1097/00001756-200107200-00014; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Liu ZY, 1997, J CLIN INVEST, V99, P1798, DOI 10.1172/JCI119344; McShan GD, 2002, INT J ONCOL, V21, P197; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; Missbach M, 1999, BONE, V24, P437, DOI 10.1016/S8756-3282(99)00020-4; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; Mucha DR, 2003, AM J PHYSIOL-HEART C, V284, pH994, DOI 10.1152/ajpheart.00862.2002; Mukhopadhyay D, 1998, CANCER RES, V58, P1278; Nieminen AL, 2003, INT REV CYTOL, V224, P29, DOI 10.1016/S0074-7696(05)24002-0; Ogata Y, 2003, HYPERTENSION, V41, P1156, DOI 10.1161/01.HYP.0000064342.30653.24; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Plank DM, 2003, AM J PHYSIOL-HEART C, V285, pH305, DOI 10.1152/ajpheart.00425.2002; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; ROCIC P, 2001, AM J PHYSIOL, V280, pE90; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sabri A, 2003, J BIOL CHEM, V278, P23944, DOI 10.1074/jbc.M302718200; Shim SR, 2001, BIOCHEM BIOPH RES CO, V286, P601, DOI 10.1006/bbrc.2001.5441; Song LS, 2002, CIRC RES, V90, P174, DOI 10.1161/hh0202.103230; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093; Tobe K, 1996, MOL CELL BIOL, V16, P4765; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 2000, J CELL SCI, V113, P4139; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200	65	46	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53516	53523		10.1074/jbc.M408475200	http://dx.doi.org/10.1074/jbc.M408475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15322113	hybrid			2022-12-25	WOS:000225680600087
J	Nall, TA; Chappell, KJ; Stoermer, MJ; Fang, NX; Tyndall, JDA; Young, PR; Fairlie, DP				Nall, TA; Chappell, KJ; Stoermer, MJ; Fang, NX; Tyndall, JDA; Young, PR; Fairlie, DP			Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR RECOGNITION; STRUCTURAL-ANALYSIS; SERINE-PROTEASE; INHIBITORS; PEPTIDE; SITE; NS2B; CONFORMATION; PROTEINASE; CLEAVAGE	West Nile Virus (WNV) is a mosquito-borne flavivirus with a rapidly expanding global distribution. Infection causes severe neurological disease and fatalities in both human and animal hosts. The West Nile viral protease (NS2B-NS3) is essential for post-translational processing in host-infected cells of a viral polypeptide precursor into structural and functional viral proteins, and its inhibition could represent a potential treatment for viral infections. This article describes the design, expression, and enzymatic characterization of a catalytically active recombinant WNV protease, consisting of a 40-residue component of cofactor NS2B tethered via a noncleavable nonapeptide (G(4)SG(4)) to the N-terminal 184 residues of NS3. A chromogenic assay using synthetic para-nitroanilide (pNA) hexapeptide substrates was used to identify optimal enzyme-processing conditions (pH 9.5, I < 0.1 M, 30% glycerol, 1 mM CHAPS), preferred substrate cleavage sites, and the first competitive inhibitor (Ac-FASGKR- H, IC50 similar to 1 mu M). A putative three-dimensional structure of WNV protease, created through homology modeling based on the crystal structures of Dengue-2 and Hepatitis C NS3 viral proteases, provides some valuable insights for structure-based design of potent and selective inhibitors of WNV protease.	Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland	Fairlie, DP (corresponding author), Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.	d.fairlie@imb.uq.edu.au	Stoermer, Martin J/E-2317-2012; tyndall, joel/C-2803-2008; Fairlie, David P/F-8865-2014; Young, Paul R/A-6176-2010	Stoermer, Martin J/0000-0003-3445-2104; tyndall, joel/0000-0003-0783-1635; Fairlie, David P/0000-0002-7856-8566; Young, Paul R/0000-0002-2040-5190				Abbenante G, 2000, LETT PEPT SCI, V7, P347, DOI 10.1023/A:1013016323676; Amberg SM, 1999, J VIROL, V73, P8083, DOI 10.1128/JVI.73.10.8083-8094.1999; Arakaki TL, 2002, PROTEIN EXPRES PURIF, V25, P241, DOI 10.1016/S1046-5928(02)00005-0; Brinkworth RI, 1999, J GEN VIROL, V80, P1167, DOI 10.1099/0022-1317-80-5-1167; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Buckley A, 2003, J GEN VIROL, V84, P2807, DOI 10.1099/vir.0.19341-0; Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7; Clum S, 1997, J BIOL CHEM, V272, P30715, DOI 10.1074/jbc.272.49.30715; Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t; FALGOUT B, 1993, J VIROL, V67, P2034, DOI 10.1128/JVI.67.4.2034-2042.1993; Glenn MP, 2002, MINI-REV MED CHEM, V2, P433, DOI 10.2174/1389557023405747; Gulick RM, 2003, CLIN MICROBIOL INFEC, V9, P186, DOI 10.1046/j.1469-0691.2003.00570.x; Gussio R, 1996, J MED CHEM, V39, P1645, DOI 10.1021/jm9508088; Hayes CG, 2001, ANN NY ACAD SCI, V951, P25; Hicks RP, 2003, BIOPOLYMERS, V68, P459, DOI 10.1002/bip.10325; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m; Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; LOUGHLIN WA, 2004, IN PRESS CHEM REV; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Murthy HMK, 1999, J BIOL CHEM, V274, P5573, DOI 10.1074/jbc.274.9.5573; RUTENBER E, 1993, J BIOL CHEM, V268, P15343; SCHULTZ RM, 1989, J BIOL CHEM, V264, P1497; Siev DV, 2000, ORG LETT, V2, P19, DOI 10.1021/ol991161e; Stocks CE, 1998, J VIROL, V72, P2141, DOI 10.1128/JVI.72.3.2141-2149.1998; Teo KF, 1997, J GEN VIROL, V78, P337, DOI 10.1099/0022-1317-78-2-337; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyndall JDA, 1999, J MOL RECOGNIT, V12, P363, DOI 10.1002/(SICI)1099-1352(199911/12)12:6<363::AID-JMR478>3.0.CO;2-M; Wuthrich K, 1986, NMR PROTEINS NUCL AC	32	97	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48535	48542		10.1074/jbc.M406810200	http://dx.doi.org/10.1074/jbc.M406810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15322074	hybrid			2022-12-25	WOS:000225098100008
J	Kim, CS; Hwang, CK; Choi, HS; Song, KY; Law, PY; Wei, LN; Loh, HH				Kim, CS; Hwang, CK; Choi, HS; Song, KY; Law, PY; Wei, LN; Loh, HH			Neuron-restrictive silencer factor (NRSF) functions as a repressor in neuronal cells to regulate the mu opioid receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL GENE; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; ADHESION MOLECULE; RNA-POLYMERASE; MESSENGER-RNA; TARGET GENES; DNA-BINDING; IN-VIVO; EXPRESSION	The mu opioid receptor (MOR) is expressed in the central nervous system and specific cell lines with varying expression levels perhaps playing important roles. One of the neuronal-specific transcription regulators, neuron-restrictive silencer factor ( NRSF), has been shown to repress the expression of neuron-specific genes in non-neuronal cells. However, we showed here that the neuron-restrictive silencer element (NRSE) of MOR functions as a critical regulator to repress the MOR gene expression in specific neuronal cells depending on NRSF expression level. Using co-transfection studies, we showed that the NRSE of the MOR promoter is functional in NRSF-positive cells (NS20Y and HeLa) but not in NRSF-negative cells (PC12). NRSF binds to the NRSE of the MOR gene in a sequence-specific manner confirmed by supershift and chromatin immunoprecipitation assays, respectively. The suppression of NRSF activity with either trichostatin A or a dominant-negative NRSF induced MOR promoter activity and transcription of the MOR gene. When the NRSF was disrupted in NS20Y and HeLa cells using small interfering RNA, the transcription of the endogenous target MOR gene increased significantly. This provides direct evidence the role of NRSF in the cells and also indicates that NRSF expression is regulated by post-translational modification in neuronal NMB cells. Our data suggested that NRSF can function as a repressor of MOR transcription in specific cells, via a mechanism dependent on the MOR NRSE.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kim, CS (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St Se, Minneapolis, MN 55455 USA.	kimxx313@umn.edu		Song, Kyu Young/0000-0001-7313-514X	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R37DA001583, R01DA000564, K05DA070554, R01DA011190, K02DA013926, R01DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00564, DA01583, DA11190, K05-DA70554, DA13926, DA11806] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bessis A, 1997, P NATL ACAD SCI USA, V94, P5906, DOI 10.1073/pnas.94.11.5906; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DELFS JM, 1994, J NEUROCHEM, V63, P777; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Donze O, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e46; Garcia-Sanchez R, 2003, BBA-GEN SUBJECTS, V1620, P39, DOI 10.1016/S0304-4165(02)00505-6; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hwang CK, 2003, J BIOL CHEM, V278, P3742, DOI 10.1074/jbc.M208780200; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; Kallunki P, 1997, J CELL BIOL, V138, P1343, DOI 10.1083/jcb.138.6.1343; KEMP DM, 2003, J BIOL CHEM; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Ko JL, 1998, J BIOL CHEM, V273, P27678, DOI 10.1074/jbc.273.42.27678; Ko JL, 2001, J BIOL CHEM, V276, P788, DOI 10.1074/jbc.M004279200; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; Kojima T, 2001, MOL BRAIN RES, V90, P174, DOI 10.1016/S0169-328X(01)00107-3; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; Kuwahara K, 2001, MOL CELL BIOL, V21, P2085, DOI 10.1128/MCB.21.6.2085-2097.2001; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Mieda M, 1997, J BIOL CHEM, V272, P5854, DOI 10.1074/jbc.272.9.5854; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Olson GA, 1997, PEPTIDES, V18, P1651, DOI 10.1016/S0196-9781(97)00264-7; Palm K, 1999, MOL BRAIN RES, V72, P30, DOI 10.1016/S0169-328X(99)00196-5; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Pan YX, 2002, GENE, V295, P97, DOI 10.1016/S0378-1119(02)00825-9; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Seth KA, 2001, J BIOL CHEM, V276, P13917, DOI 10.1074/jbc.M007745200; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; TapiaRamirez J, 1997, P NATL ACAD SCI USA, V94, P1177, DOI 10.1073/pnas.94.4.1177; Vries RGJ, 2001, EMBO J, V20, P6095, DOI 10.1093/emboj/20.21.6095; WOODRUFFPAK DS, 1988, LIFE-SPAN DEV BEHAV, V9, P1; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	48	75	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46464	46473		10.1074/jbc.M403633200	http://dx.doi.org/10.1074/jbc.M403633200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322094	hybrid			2022-12-25	WOS:000224832400017
J	Lopez-Llano, J; Maldonado, S; Bueno, M; Lostao, A; Angeles-Jimenez, M; Lillo, MP; Sancho, J				Lopez-Llano, J; Maldonado, S; Bueno, M; Lostao, A; Angeles-Jimenez, M; Lillo, MP; Sancho, J			The long and short flavodoxins - I. The role of the differentiating loop in apoflavodoxin structure and FMN binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; ESCHERICHIA-COLI; ANABAENA APOFLAVODOXIN; FOLDING MECHANISM; MOLTEN GLOBULE; STABILIZATION; STABILITY; REDUCTASE; ACTIVATION; ENERGETICS	Flavodoxins are well known one-domain alpha/beta electron-transfer proteins that, according to the presence or absence of a similar to20-residue loop splitting the fifth beta-strand of the central beta-sheet, have been classified in two groups: long and short-chain flavodoxins, respectively. Although the flavodoxins have been extensively used as models to study electron transfer, ligand binding, protein stability and folding issues, the role of the loop has not been investigated. We have constructed two shortened versions of the long-chain Anabaena flavodoxin in which the split beta-strand has been spliced to remove the original loop. The two variants have been carefully analyzed using various spectroscopic and hydrodynamic criteria, and one of them is clearly well folded, indicating that the long loop is a peripheral element of the structure of long flavodoxins. However, the removal of the loop ( which is not in contact with the cofactor in the native structure) markedly decreases the affinity of the apoflavodoxin-FMN complex. This seems related to the fact that, in long flavodoxins, the adjacent tyrosine-bearing FMN binding loop ( which is longer and thus more flexible than in short flavodoxins) is stabilized in its competent conformation by interactions with the excised loop. The modest role played by the long loop of long flavodoxins in the structure of these proteins ( and in its conformational stability, see Lopez-Llano, J., Maldonado, S., Jain, S., Lostao, A., Godoy-Ruiz, R., Sanchez-Ruiz, Cortijo, M., Fernandez-Recio, J., and Sancho, J. ( 2004) J. Biol. Chem. 279, 47184 - 47191) opens the possibility that its conservation in so many species is related to a functional role yet to be discovered. In this respect, we discuss the possibility that the long loop is involved in the recognition of some flavodoxin partners. In addition, we report on a structural feature of flavodoxins that could indicate that the short flavodoxins derive from the long ones.	Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain; Univ Zaragoza, Biocomputat & Complex Syst Phys Inst, Zaragoza, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain	University of Zaragoza; University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Sancho, J (corresponding author), Univ Zaragoza, Fac Ciencias, Dept Bioquim & Biol Mol & Celular, E-50009 Zaragoza, Spain.	jsancho@unizar.es	Lillo, M. Pilar/O-2556-2013; Bueno, Marta/GXM-7181-2022; Lostao, Anabel/P-8693-2015; Sancho, javier/AAA-1225-2019; Jimenez, M. Angeles/C-7193-2008	Lillo, M. Pilar/0000-0001-8582-4591; Bueno, Marta/0000-0001-7140-9899; Lostao, Anabel/0000-0001-7460-5916; Sancho, javier/0000-0002-2879-9200; Jimenez, M. Angeles/0000-0001-6835-5850				AMANN E, 1998, GENE, V69, P310; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; BLASCHKOWSKI HP, 1982, EUR J BIOCHEM, V123, P563; Casaus JL, 2002, J BIOL CHEM, V277, P22338, DOI 10.1074/jbc.M112258200; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DONZEL B, 1974, J AM CHEM SOC, V96, P801, DOI 10.1021/ja00810a027; Fernandez-Recio J, 1999, J MOL BIOL, V290, P319, DOI 10.1006/jmbi.1999.2863; Fernandez-Recio J, 2001, BIOCHEMISTRY-US, V40, P15234, DOI 10.1021/bi010216t; FILLAT MF, 1988, ARCH MICROBIOL, V150, P160, DOI 10.1007/BF00425156; FILLAT MF, 1991, BIOCHEM J, V280, P187, DOI 10.1042/bj2800187; FITZGERALD MP, 1980, BIOCHEM J, V192, P665, DOI 10.1042/bj1920665; Genzor CG, 1996, NAT STRUCT BIOL, V3, P329, DOI 10.1038/nsb0496-329; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Irun MP, 2001, J MOL BIOL, V306, P877, DOI 10.1006/jmbi.2001.4436; Irun MP, 2001, PROTEIN ENG, V14, P173, DOI 10.1093/protein/14.3.173; Langdon GM, 2001, PROTEINS, V43, P476, DOI 10.1002/prot.1059; Lillo MP, 2002, BIOCHEMISTRY-US, V41, P12436, DOI 10.1021/bi0261793; Lopez-Llano J, 2004, J BIOL CHEM, V279, P47184, DOI 10.1074/jbc.M405791200; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; Lostao A, 2003, J BIOL CHEM, V278, P24053, DOI 10.1074/jbc.M301049200; Lostao A, 2000, J BIOL CHEM, V275, P9518, DOI 10.1074/jbc.275.13.9518; LUDWIG ML, 1969, J BIOL CHEM, V244, P6047; LUDWIG ML, 1992, CHEM BIOCH FLAVOENZY, V3, P427; Maldonado S, 2002, PROTEIN SCI, V11, P1260, DOI 10.1110/ps.2980102; Maldonado S, 1998, BIOCHIMIE, V80, P813, DOI 10.1016/S0300-9084(00)88876-8; Maldonado S, 1998, BIOCHEMISTRY-US, V37, P10589, DOI 10.1021/bi980368x; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; OSBORNE C, 1991, J BACTERIOL, V173, P1729, DOI 10.1128/jb.173.5.1729-1737.1991; PECK HD, 1982, PHILOS T R SOC B, V298, P443, DOI 10.1098/rstb.1982.0091; RAO ST, 1992, PROTEIN SCI, V1, P1413, DOI 10.1002/pro.5560011103; Sanyal I, 1996, ARCH BIOCHEM BIOPHYS, V326, P48, DOI 10.1006/abbi.1996.0045; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; SMILLIE RM, 1965, BIOCHEM BIOPH RES CO, V20, P621, DOI 10.1016/0006-291X(65)90445-6; SMITH WW, 1983, J MOL BIOL, V165, P737, DOI 10.1016/S0022-2836(83)80277-0; WATENPAUGH KD, 1972, P NATL ACAD SCI USA, V69, P3185, DOI 10.1073/pnas.69.11.3185	37	33	34	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47177	47183		10.1074/jbc.M405792200	http://dx.doi.org/10.1074/jbc.M405792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15317816	hybrid, Green Submitted, Green Published			2022-12-25	WOS:000224832400105
J	Rideout, HJ; Dietrich, P; Wang, QH; Dauer, WT; Stefanis, L				Rideout, HJ; Dietrich, P; Wang, QH; Dauer, WT; Stefanis, L			alpha-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; CORTICAL-NEURONS; DEATH; MUTANT; PROTEIN; OVEREXPRESSION; APOPTOSIS; PARKIN; CELLS; NEURODEGENERATION	Proteasomal dysfunction may underlie certain neurodegenerative conditions such as Parkinson disease. We have shown that pharmacological inhibition of the proteasome in cultured neuronal cells leads to apoptotic death and formation of cytoplasmic ubiquitinated inclusions. These inclusions stain for alpha-synuclein and assume a fibrillar structure, as assessed by thioflavine S staining, and therefore resemble Lewy bodies. alpha-Synuclein is thought to be a central component of Lewy bodies. Whether alpha-synuclein is required for inclusion formation or apoptotic death has not been formally assessed. The present study examines whether alpha-synuclein deficiency in neurons alters their sensitivity to proteasomal inhibition-induced apoptosis or inclusion formation. Cortical neurons derived from alpha-synuclein-null mice showed a similar sensitivity to death induced by the proteasomal inhibitor lactacystin compared with neurons derived from wild-type mice. Furthermore, the absence of alpha-synuclein did not influence the percentage of lactacystin-treated neurons harboring cytoplasmic ubiquitinated inclusions or alter the solubility of such inclusions. In contrast, however, ubiquitinated inclusions in alpha-synuclein-deficient neurons lacked amyloid-like fibrillization, as determined by thioflavine S staining. This indicates that although alpha-synuclein deficiency does not affect the formation of ubiquitinated inclusions, it does significantly alter their structure. The lack of effect on survival in alpha-synuclein knock-out cultures further suggests that the fibrillar nature of the inclusions does not contribute to neuronal degeneration in this model.	Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Acad Athens, Fdn Biomed Res, Neurobiol Lab, Athens 11527, Greece	Columbia University; Columbia University; Academy of Athens	Rideout, HJ (corresponding author), Columbia Univ, Dept Neurol, Black Bldg,Rm 326,650 W 168th St, New York, NY 10032 USA.	HR227@columbia.edu	Stefanis, Leonidas/AAD-7192-2019	Dauer, William/0000-0003-1775-7504				Baba M, 1998, AM J PATHOL, V152, P879; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Dietrich P, 2003, MOL CELL NEUROSCI, V24, P430, DOI 10.1016/S1044-7431(03)00201-X; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang-Rollin I, 2003, HISTOL HISTOPATHOL, V18, P509, DOI 10.14670/HH-18.509; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lindersson E, 2004, J BIOL CHEM, V279, P12924, DOI 10.1074/jbc.M306390200; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Morris EJ, 1996, J CELL BIOL, V134, P757, DOI 10.1083/jcb.134.3.757; Neumann M, 2002, J CLIN INVEST, V110, P1429, DOI 10.1172/JC1200215777; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rideout HJ, 2003, J NEUROSCI, V23, P1237, DOI 10.1523/JNEUROSCI.23-04-01237.2003; Rideout HJ, 2003, J NEUROCHEM, V84, P803, DOI 10.1046/j.1471-4159.2003.01574.x; Rideout HJ, 2002, MOL CELL NEUROSCI, V21, P223, DOI 10.1006/mcne.2002.1173; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stefanis L, 1999, J NEUROSCI, V19, P6235; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tofaris GK, 2003, J BIOL CHEM, V278, P44405, DOI 10.1074/jbc.M308041200; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; Vekrellis K, 2004, MOL NEUROBIOL, V30, P1, DOI 10.1385/MN:30:1:001; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	47	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46915	46920		10.1074/jbc.M405146200	http://dx.doi.org/10.1074/jbc.M405146200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322100	hybrid			2022-12-25	WOS:000224832400074
J	Wu, JV; Krouse, ME; Rustagi, A; Joo, NS; Wine, JJ				Wu, JV; Krouse, ME; Rustagi, A; Joo, NS; Wine, JJ			An inwardly rectifying potassium channel in apical membrane of Calu-3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; HUMAN AIRWAY CELLS; PH SENSITIVITY; POSSIBLE INVOLVEMENT; EPITHELIAL-CELLS; ANION SECRETION; KIR4.1 CHANNELS; CONDUCTANCE; EXPRESSION; CFTR	Patch clamp methods and reverse transcription-polymerase chain reaction (RT-PCR) were used to characterize an apical K+ channel in Calu-3 cells, a widely used model of human airway gland serous cells. In cell-attached and excised apical membrane patches, we found an inwardly rectifying K+ channel (Kir). The permeability ratio was P-Na/P-K = 0.058. In 30 patches with both cystic fibrosis transmembrane conductance regulator and Kir present, we observed 79 cystic fibrosis transmembrane conductance regulator and 58 Kir channels. The average chord conductance was 24.4 +/- 0.5 pS (n = 11), between 0 and -200 mV, and was 9.6 +/- 0.7 pS (n = 8), between 0 and 50 mV; these magnitudes and their ratio of similar to2.5 are most similar to values for rectifying K+ channels of the Kir4.x subfamilies. We attempted to amplify transcripts for Kir4.1, Kir4.2, and Kir5.1; of these only Kir4.2 was present in Calu-3 lysates. The channel was only weakly activated by ATP and was relatively insensitive to internal pH. External Cs+ and Ba2+ blocked the channel with K-d values in the millimolar range. Quantitative modeling of Cl- secreting epithelia suggests that secretion rates will be highest and luminal K+ will rise to 16-28 mM if 11-25% of the total cellular K+ conductance is placed in the apical membrane ( Cook, D. I., and Young, J.A. (1989) J. Membr. Biol. 110, 139-146). Thus, we hypothesize that the K+ channel described here optimizes the rate of secretion and is involved in K+ recycling for the recently proposed apical H+-K+-ATPase in Calu-3 cells.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA	Stanford University	Wine, JJ (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Rm 450,Bldg 420,Main Quad, Stanford, CA 94305 USA.	wine@stanford.edu		Rustagi, Arjun/0000-0002-6921-1012	NIDDK NIH HHS [DK-51817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhandari S, 2001, KIDNEY BLOOD PRESS R, V24, P142, DOI 10.1159/000054221; Bichet D, 2003, NAT REV NEUROSCI, V4, P957, DOI 10.1038/nrn1244; Bradley KK, 1999, J PHYSIOL-LONDON, V515, P639, DOI 10.1111/j.1469-7793.1999.639ab.x; COOK DI, 1989, J MEMBRANE BIOL, V110, P139, DOI 10.1007/BF01869469; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; Cowley EA, 2002, J PHYSIOL-LONDON, V538, P747, DOI 10.1113/jphysiol.2001.013300; Cuthbert AW, 2003, BRIT J PHARMACOL, V140, P81, DOI 10.1038/sj.bjp.0705403; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Dewson G, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-22; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FINDLAY I, 1986, PFLUG ARCH EUR J PHY, V407, P238, DOI 10.1007/BF00580683; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; Hayashi M, 2003, J PHYSIOL-LONDON, V547, P255, DOI 10.1113/jphysiol.2002.035857; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; Irokawa T, 2004, AM J PHYSIOL-LUNG C, V287, pL784, DOI 10.1152/ajplung.00124.2004; Klein H, 1999, J MEMBRANE BIOL, V167, P43, DOI 10.1007/s002329900470; Krapivinsky G, 1998, NEURON, V20, P995, DOI 10.1016/S0896-6273(00)80480-8; KROUSE ME, 2004, IN PRESS AM J PHYSL, V287; Kusaka S, 1999, J PHYSIOL-LONDON, V520, P373, DOI 10.1111/j.1469-7793.1999.00373.x; Lee MC, 1998, AM J PHYSIOL-LUNG C, V274, pL450, DOI 10.1152/ajplung.1998.274.3.L450; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; Lourdel S, 2002, J PHYSIOL-LONDON, V538, P391, DOI 10.1113/jphysiol.2001.012961; McNicholas CM, 1996, AM J PHYSIOL-RENAL, V271, pF275, DOI 10.1152/ajprenal.1996.271.2.F275; Moon S, 1997, AM J PHYSIOL-LUNG C, V273, pL1208, DOI 10.1152/ajplung.1997.273.6.L1208; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Pearson WL, 1999, J PHYSIOL-LONDON, V514, P639, DOI 10.1111/j.1469-7793.1999.639ad.x; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Shuck ME, 1997, J BIOL CHEM, V272, P586; SILVA P, 1977, AM J PHYSIOL, V233, pF298, DOI 10.1152/ajprenal.1977.233.4.F298; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; Tare M, 1998, J PHYSIOL-LONDON, V506, P303, DOI 10.1111/j.1469-7793.1998.303bw.x; Thiery E, 2000, MECH DEVELOP, V95, P313, DOI 10.1016/S0925-4773(00)00364-6; Thompson GA, 2000, J PHYSIOL-LONDON, V526, P231, DOI 10.1111/j.1469-7793.2000.00231.x; Topert C, 1998, J NEUROSCI, V18, P4096; Trapp S, 2003, EMBO J, V22, P2903, DOI 10.1093/emboj/cdg282; WANG WH, 1991, J GEN PHYSIOL, V98, P35, DOI 10.1085/jgp.98.1.35; Xu HX, 2000, J PHYSIOL-LONDON, V528, P267, DOI 10.1111/j.1469-7793.2000.00267.x; Xu HX, 2000, AM J PHYSIOL-CELL PH, V279, pC1464, DOI 10.1152/ajpcell.2000.279.5.C1464; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x	46	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46558	46565		10.1074/jbc.M406058200	http://dx.doi.org/10.1074/jbc.M406058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328350	hybrid			2022-12-25	WOS:000224832400028
J	Tanimoto, Y; Yokozeki, M; Hiura, K; Matsumoto, K; Nakanishi, H; Matsumoto, T; Marie, PJ; Moriyama, K				Tanimoto, Y; Yokozeki, M; Hiura, K; Matsumoto, K; Nakanishi, H; Matsumoto, T; Marie, PJ; Moriyama, K			A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW CELLS; CROUZON-SYNDROME; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS; COLLAGEN-SYNTHESIS; BIRTH PREVALENCE; CALVARIAL BONE; SKULL VAULT; GENE CAUSE; IN-VIVO	Apert syndrome is an autosomal dominant disease characterized by craniosynostosis and bony syndactyly associated with point mutations (S252W and P253R) in the fibroblast growth factor receptor ( FGFR) 2 that cause FGFR2 activation. Here we investigated the role of the S252W mutation of FGFR2 on osteoblastic differentiation. Osteoblastic cells derived from digital bone in two Apert patients with the S252W mutation showed more prominent alkaline phosphatase activity, osteocalcin and osteopontin mRNA expression, and mineralized nodule formation compared with the control osteoblastic cells derived from two independent non-syndromic polydactyly patients. Stable clones of the human MG63 osteosarcoma cells (MG63-Ap and MG63-IIIc) overexpressing a splice variant form of FGFR2 with or without the S252W mutation (FGFR2IIIcS252W and FGFR2IIIc) showed a higher RUNX2 mRNA expression than parental MG63 cells. Furthermore MG63-Ap exhibited a higher osteopontin mRNA expression than did MG63-IIIc. The enhanced osteoblastic marker gene expression and mineralized nodule formation of the MG63-Ap was inhibited by the conditioned medium from the COS-1 cells overexpressing the soluble FGFR2IIIcS252W. Furthermore the FGF2-induced osteogenic response in the mouse calvarial organ culture system was blocked by the soluble FGFR2IIIcS252W. These results show that the S252W mutation in the FGFR2 gene enhances the osteoblast phenotype in human osteoblasts and that a soluble FGFR2 with the S252W mutation controls osteoblast differentiation induced by the S252W mutation through a dominant negative effect on FGFR2 signaling in Apert syndrome.	Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Orthodont & Dentofacial Orthoped, Tokushima 7708504, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Plast & Reconstruct Surg, Tokushima 7708503, Japan; Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan; Hop Lariboisiere, INSERM, U606, Lab Osteoblast Biol & Pathol, F-75475 Paris, France	Tokushima University; Tokushima University; Tokushima University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Moriyama, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Orthodont & Dentofacial Orthoped, 3-18-15 Kuramoto Cho, Tokushima 7708504, Japan.	moriyama@dent.tokushima-u.ac.jp	Moriyama, Keiji/AAC-3193-2019	Moriyama, Keiji/0000-0003-0580-4510				Aikawa T, 2001, J BIOL CHEM, V276, P29347, DOI 10.1074/jbc.M101859200; Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; Arman E, 1999, P NATL ACAD SCI USA, V96, P11895, DOI 10.1073/pnas.96.21.11895; CANALIS E, 1988, J CLIN INVEST, V81, P1572, DOI 10.1172/JCI113490; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; COHEN MM, 1992, AM J MED GENET, V42, P655, DOI 10.1002/ajmg.1320420505; COHEN MM, 1992, INT J ORAL MAX SURG, V21, P107, DOI 10.1016/S0901-5027(05)80544-2; Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Eswarakumar VP, 2002, DEVELOPMENT, V129, P3783; Fragale A, 1999, AM J PATHOL, V154, P1465, DOI 10.1016/S0002-9440(10)65401-6; FRANCESCHI RT, 1988, J BIOL CHEM, V263, P18938; FRANCESCHI RT, 1990, J BONE MINER RES, V5, P1157; Goldfarb Mitchell, 1996, Cytokine and Growth Factor Reviews, V7, P311, DOI 10.1016/S1359-6101(96)00039-1; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Greenwald JA, 2001, AM J PATHOL, V158, P441, DOI 10.1016/S0002-9440(10)63987-9; Hanneken A, 2001, FEBS LETT, V489, P176, DOI 10.1016/S0014-5793(00)02409-1; HARPER JW, 1993, CELL, V75, P805; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Iseki S, 1999, DEVELOPMENT, V126, P5611; Iseki S, 1997, DEVELOPMENT, V124, P3375; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200; Kim HJ, 1998, DEVELOPMENT, V125, P1241; Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lomri A, 1998, J CLIN INVEST, V101, P1310; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; Matsumoto K, 2002, SCAND J PLAST RECONS, V36, P368, DOI 10.1080/028443102321096375; Matsumoto K, 1998, PLAST RECONSTR SURG, V101, P307, DOI 10.1097/00006534-199802000-00007; MCCARTHY TL, 1989, ENDOCRINOLOGY, V125, P2118, DOI 10.1210/endo-125-4-2118; Moloney DM, 1996, NAT GENET, V13, P48, DOI 10.1038/ng0596-48; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; NOFF D, 1989, FEBS LETT, V250, P619, DOI 10.1016/0014-5793(89)80808-7; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; Oldridge M, 1997, HUM MOL GENET, V6, P137, DOI 10.1093/hmg/6.1.137; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; PARK WJ, 1995, AM J HUM GENET, V57, P321; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PITARU S, 1993, J BONE MINER RES, V8, P919; Przylepa KA, 1996, NAT GENET, V13, P492, DOI 10.1038/ng0896-492; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; Rice DPC, 2000, DEVELOPMENT, V127, P1845; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; Ryhanen S, 1998, J CELL BIOCHEM, V70, P414, DOI 10.1002/(SICI)1097-4644(19980901)70:3<414::AID-JCB14>3.0.CO;2-K; Sarkar S, 2001, DEVELOPMENT, V128, P2143; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Slaney SF, 1996, AM J HUM GENET, V58, P923; Tajima Y, 1998, P NATL ACAD SCI USA, V95, P11903, DOI 10.1073/pnas.95.20.11903; von Gernet S, 2000, CLIN GENET, V57, P137, DOI 10.1034/j.1399-0004.2000.570208.x; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xu XL, 1998, DEVELOPMENT, V125, P753; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536; Zhou YX, 2000, HUM MOL GENET, V9, P2001, DOI 10.1093/hmg/9.13.2001	61	57	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45926	45934		10.1074/jbc.M404824200	http://dx.doi.org/10.1074/jbc.M404824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15310757	hybrid			2022-12-25	WOS:000224694900077
J	Yamaguchi, H; Wang, HG				Yamaguchi, H; Wang, HG			CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH RECEPTOR-5; GENE-EXPRESSION; ACTIVATION; ER; CASPASE-12; P53; IDENTIFICATION; MITOCHONDRIA; APO2L/TRAIL; KILLER/DR5	It has been shown that excess stress to the endoplasmic reticulum ( ER) triggers apoptosis, but the mechanisms underlying these processes remain unclear. We and others have reported previously that DR5 expression is up-regulated in thapsigargin (THG)-treated human cancer cells. Here, we provide evidence that CHOP is involved in THG up-regulation of DR5, which is a critical step for ER stress-induced apoptosis in human cancer cells. In human colon cancer HCT116 cells, knockdown of DR5 by siRNA blocked THG-induced Bax conformational change along with caspase-3 activation and cell death. Moreover, inhibition of CHOP expression attenuated DR5 up-regulation and apoptosis induced by THG, whereas ectopic expression of DR5 restored the sensitivity of CHOP siRNA-transfected cells to THG-induced apoptosis. In addition to HCT116 cells, inhibition of CHOP or DR5 induction also attenuated THG-induced cell death in other cancer cell lines including LNCaP, A2780S, and DU145, indicating that CHOP and DR5 are critical for ER stress-mediated apoptosis in human carcinoma cells. Furthermore, we identified a potential CHOP-binding site in the 5'-flanking region of the DR5 gene. Mutation of this site abrogated the enhanced reporter activity in response to THG treatment. Together, our findings suggest that CHOP regulates ER stress-induced apoptosis, at least in part, through enhancing DR5 expression in some types of human cancer cells.	Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol,Coll Med, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Yamaguchi, H (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol,Coll Med, 12902 Magnolia Dr, Tampa, FL 33612 USA.	YamaguH@moffitt.usf.edu; WangHG@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA82197] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082197] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; TSUTSUMI S, 2004, CELL DEATH DIFFER; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XD, 2001, GENE DEV, V15, P2922; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 1999, BIOCHEM J, V340, P767, DOI 10.1042/0264-6021:3400767; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	33	621	642	0	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45495	45502		10.1074/jbc.M406933200	http://dx.doi.org/10.1074/jbc.M406933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322075	hybrid			2022-12-25	WOS:000224694900027
J	Alves, ID; Ciano, KA; Boguslavski, V; Varga, E; Salamon, Z; Yamamura, HI; Hruby, VJ; Tollin, G				Alves, ID; Ciano, KA; Boguslavski, V; Varga, E; Salamon, Z; Yamamura, HI; Hruby, VJ; Tollin, G			Selectivity, cooperativity, and reciprocity in the interactions between the delta-opioid receptor, its ligands, and G-proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WAVE-GUIDE RESONANCE; LIPID-BILAYER-MEMBRANES; COUPLED RECEPTORS; PLASMON RESONANCE; CRYSTAL-STRUCTURE; BINDING; SPECTROSCOPY; SYSTEM; REQUIREMENTS; ACTIVATION	A better understanding of signal transduction mechanisms is of critical importance. Methodologies that allow studies to be done while receptors are incorporated into lipid bilayers are advantageous. One such technique is plasmon-waveguide resonance (PWR) spectroscopy, which can follow changes in conformation accompanying protein-ligand, protein-protein, and protein-lipid interactions occurring in G-protein-coupled receptors in real time with high sensitivity and without the need for molecular labeling. Here we investigated several aspects of human delta-opioid receptor (hDOR)-G-protein interactions: 1) the effect of different types of agonists on the interaction with individual G-protein subtypes; 2) the affinities of the separate G-protein alpha and betagamma subunits to different ligand-occupied states of the receptor; and 3) the effect of the presence of the G-protein on the interactions of the ligand with the receptor. To accomplish this we have incorporated the receptor into a solid supported lipid bilayer in the presence of ligand or G-protein and monitored the PWR spectral changes induced by the reciprocal G-protein or ligand interactions. We found a high degree of selectivity in the interactions of different agonist-bound states of the receptor with the different G-protein subtypes. This has important implications for agonist-directed trafficking and selective drug design. Studies with the separated alpha and betagamma subunits show that cooperativity exists in these interactions. The high affinities of the separated subunits to the receptor point to the possibility of independent promotion of specific signaling events. The presence of G-proteins increased the affinity of agonists to the hDOR, and caused faster binding kinetics and different ligand-induced conformational changes. Because ligand also influences G-protein binding, reciprocity exists between these two binding processes.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona; University of Arizona	Tollin, G (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1306 E Univ Blvd,Old Chem Bldg, Tucson, AZ 85721 USA.	gtollin@u.arizona.edu	Alves, Isabel D/R-9613-2016	Alves, Isabel D/0000-0003-3193-2436	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA013449, P01DA006284] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06284, DA13449] Funding Source: Medline; NIGMS NIH HHS [GM59630] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alves ID, 2004, MOL PHARMACOL, V65, P1248, DOI 10.1124/mol.65.5.1248; Alves ID, 2003, J BIOL CHEM, V278, P48890, DOI 10.1074/jbc.M306866200; Bieri C, 1999, NAT BIOTECHNOL, V17, P1105, DOI 10.1038/15090; Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026; Devanathan S, 2004, BIOCHEMISTRY-US, V43, P3280, DOI 10.1021/bi035825a; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Hermans E, 2003, PHARMACOL THERAPEUT, V99, P25, DOI 10.1016/S0163-7258(03)00051-2; Hosohata K, 2000, EUR J PHARMACOL, V392, pR9, DOI 10.1016/S0014-2999(00)00132-1; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; Liao SB, 1997, BIOORG MED CHEM LETT, V7, P3049, DOI 10.1016/S0960-894X(97)10145-7; MISICKA A, 1991, BIOCHEM BIOPH RES CO, V180, P1290, DOI 10.1016/S0006-291X(05)81335-X; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; Okura T, 2000, EUR J PHARMACOL, V387, pR11, DOI 10.1016/S0014-2999(99)00761-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; PRATHER PL, 1994, MOL PHARMACOL, V45, P997; PRATHER PL, 1994, J BIOL CHEM, V269, P21293; RODBELL M, 1971, J BIOL CHEM, V246, P1877; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; Salamon Z, 2000, BIOPHYS J, V79, P2463, DOI 10.1016/S0006-3495(00)76489-7; Salamon Z, 1997, BIOPHYS J, V73, P2791, DOI 10.1016/S0006-3495(97)78308-5; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; Salamon Z, 1998, BIOPHYS J, V75, P1874, DOI 10.1016/S0006-3495(98)77628-3; Salamon Z, 2001, BIOPHYS J, V80, P1557, DOI 10.1016/S0006-3495(01)76128-0; SALAMON Z, 1999, ENCY SPECTROSCOPY SP, V3, P2311; SALAMON Z, 1999, ENCY SPECTROSCOPY SP, V3, P2294; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0	32	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44673	44682		10.1074/jbc.M404713200	http://dx.doi.org/10.1074/jbc.M404713200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15317820	hybrid			2022-12-25	WOS:000224505600054
J	Harris, FM; Brecht, WJ; Xu, Q; Mahley, RW; Huang, YD				Harris, FM; Brecht, WJ; Xu, Q; Mahley, RW; Huang, YD			Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase - Modulation by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; SPORADIC ALZHEIMERS-DISEASE; SYNAPTICALLY-RELEASED ZINC; METHYL-D-ASPARTATE; P70 S6 KINASE; PROTEIN-KINASE; UP-REGULATION; HIPPOCAMPAL-NEURONS; NEUROFIBRILLARY PATHOLOGY; NEUROFILAMENT PROTEIN	Although apolipoprotein (apo) E4 is present in amyloid plaques and neurofibrillary tangles, its pathogenic role in Alzheimer's disease (AD) is unclear. Neuronal expression of apoE4 or apoE4 fragments in transgenic mice increases tau phosphorylation. To identify the kinase responsible for the increase, we studied transgenic mice expressing human apoE3 or apoE4 in neurons under the control of the neuron-specific enolase promoter. Brain levels of phosphorylated tau (p-tau) and phosphorylated (active) extracellular signal-regulated kinase (p-Erk) increased with age in both groups but were considerably higher in the apoE4 mice. Other candidate kinases, including glycogen synthase kinase 3beta and cyclin-dependent kinase-5 and its activators p25 and p35, were not significantly altered. The increases in p-Erk and p-tau were highest in the hippocampus, intermediate in the cortex, and lowest in the cerebellum. In the hippocampus, p-Erk and p-tau accumulated in the hilus and CA3 region of the dentate gyrus, where high levels of zinc are found along mossy fibers. In Neuro-2a cells stably expressing apoE3 or apoE4, treatment with ZnCl2 generated 2-fold more p-Erk and 3-fold more p-tau in the apoE4-expressing cells. Phosphorylation of Erk and tau was reduced by preincubation with the Erk pathway inhibitor U0126. Thus, increased tau phosphorylation in apoE4 transgenic mice was associated with Erk activation and could be modified by zinc, suggesting that apoE4 and zinc act in concert to contribute to the pathogenesis of AD.	Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Huang, YD (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, POB 419100, San Francisco, CA 94141 USA.	yhuang@gladstone.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG022074] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL37063] Funding Source: Medline; NIA NIH HHS [P01 AG022074] Funding Source: Medline; NINDS NIH HHS [R21 NS046465] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; An WL, 2003, AM J PATHOL, V163, P591, DOI 10.1016/S0002-9440(10)63687-5; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Bales KR, 1999, P NATL ACAD SCI USA, V96, P15233, DOI 10.1073/pnas.96.26.15233; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Brownlees J, 1997, NEUROREPORT, V8, P3251, DOI 10.1097/00001756-199710200-00013; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Buttini M, 2000, NEUROSCIENCE, V97, P207, DOI 10.1016/S0306-4522(00)00069-5; Buttini M, 2002, J NEUROSCI, V22, P10539; Buttini M, 1999, J NEUROSCI, V19, P4867; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CROWTHER RA, 1993, CURR OPIN STRUC BIOL, V3, P202, DOI 10.1016/S0959-440X(05)80153-8; CSERMELY P, 1988, J BIOL CHEM, V263, P6487; Danscher G, 1997, J NEUROSCI METH, V76, P53, DOI 10.1016/S0165-0270(97)00079-4; Deibel MA, 1996, J NEUROL SCI, V143, P137, DOI 10.1016/S0022-510X(96)00203-1; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Ferrer I, 2001, BRAIN PATHOL, V11, P144; FIORE RS, 1993, NEUROSCIENCE, V55, P463, DOI 10.1016/0306-4522(93)90516-I; FORSYTHE ID, 1988, J NEUROSCI, V8, P3733; Goedert M, 1991, Curr Opin Neurobiol, V1, P441, DOI 10.1016/0959-4388(91)90067-H; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; Gonzalez C, 1999, EUR J CLIN INVEST, V29, P637; Grbovic OM, 2003, J BIOL CHEM, V278, P31261, DOI 10.1074/jbc.M304122200; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Harris FM, 2004, J BIOL CHEM, V279, P3862, DOI 10.1074/jbc.M309475200; Harris FM, 2003, P NATL ACAD SCI USA, V100, P10966, DOI 10.1073/pnas.1434398100; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Huang YD, 2004, J MOL NEUROSCI, V23, P189, DOI 10.1385/JMN:23:3:189; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HYMAN BT, 1994, AM J PATHOL, V144, P565; HYMAN BT, 1994, NEUROSCI LETT, V166, P113, DOI 10.1016/0304-3940(94)90853-2; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; Ji ZS, 2002, J BIOL CHEM, V277, P21821, DOI 10.1074/jbc.M112109200; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Korneyev AY, 1998, NEUROCHEM RES, V23, P1539, DOI 10.1023/A:1020980004539; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LEDESMA MD, 1992, FEBS LETT, V308, P218, DOI 10.1016/0014-5793(92)81278-T; Lee G, 2004, J NEUROSCI, V24, P2304, DOI 10.1523/JNEUROSCI.4162-03.2004; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LEGENDRE P, 1990, J PHYSIOL-LONDON, V429, P429, DOI 10.1113/jphysiol.1990.sp018266; Lengyel I, 2000, J NEUROCHEM, V75, P594, DOI 10.1046/j.1471-4159.2000.0750594.x; Ljungberg MC, 2002, NEUROREPORT, V13, P867, DOI 10.1097/00001756-200205070-00026; Lovell MA, 1998, J NEUROL SCI, V158, P47, DOI 10.1016/S0022-510X(98)00092-6; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; Manzerra P, 2001, P NATL ACAD SCI USA, V98, P11055, DOI 10.1073/pnas.191353598; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moir RD, 1999, BIOCHEMISTRY-US, V38, P4595, DOI 10.1021/bi982437d; MURAKAMI K, 1987, J BIOL CHEM, V262, P13902; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Pei JJ, 2002, MOL BRAIN RES, V109, P45, DOI 10.1016/S0169-328X(02)00488-6; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2002, J NEUROSCI, V22, P5204, DOI 10.1523/JNEUROSCI.22-12-05204.2002; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1994, CURR NEUROL, V14, P111; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Seo SR, 2001, J NEUROCHEM, V78, P600, DOI 10.1046/j.1471-4159.2001.00438.x; SMITH MA, 1995, J NEUROCHEM, V64, P2660; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Tesseur I, 2000, AM J PATHOL, V157, P1495, DOI 10.1016/S0002-9440(10)64788-8; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; TROJANOWSKI JQ, 1993, BRAIN RES, V618, P333, DOI 10.1016/0006-8993(93)91286-2; VICKERS JC, 1994, NEUROSCIENCE, V62, P1, DOI 10.1016/0306-4522(94)90310-7; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; WEINBERGER RP, 1991, J NEUROCHEM, V57, P605, DOI 10.1111/j.1471-4159.1991.tb03791.x; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	98	112	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44795	44801		10.1074/jbc.M408127200	http://dx.doi.org/10.1074/jbc.M408127200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322121	hybrid			2022-12-25	WOS:000224505600068
J	Wharton, W				Wharton, W			Repression of G(0)/G(1) traverse in human fibroblasts exposed to low levels of ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; GROWTH-FACTOR; G(1) ARREST; P53; INHIBITION; CHECKPOINT; PROTEIN; EXPRESSION; ASSOCIATION	Quiescent cultures of human fibroblasts were exposed to levels of ionizing radiation sufficient to induce a transient growth delay, while causing only small decreases in long term clonogenicity. Following the mitogenic stimulation of damaged cells, cyclin D-associated kinase activity was induced to levels equivalent to those seen in control cultures. In addition, late G(0)/G(1) E2F-dependent transcriptional and translational activity was observed in restimulated irradiated cells. However, cells became arrested prior to entry into S phase in a manner that paralleled the repression of cdk2-associated kinase activity. Cyclin A/cdk2-associated kinase activity was repressed in a biphasic manner following the irradiation of logarithmically growing cells. The initial rapid decline in activity to levels similar to 50% of those observed in control cultures occurred prior to increases in cellular levels of p21(Cip1) protein, was not blocked by the addition of cycloheximide, and was not accompanied by alterations in cdk2 phosphotyrosine content. The subsequent repression to undetectable levels was coincident with the induction of p21(Cip1) and was dependent on de novo protein synthesis. Only a subpopulation of cyclin A complexes were associated with p21(Cip1) regardless of the magnitude of the repression of catalytic activity, although all cyclin A-cdk2-p21(Cip1) complexes were inactive. These data suggest that temporally and functionally distinct mechanisms mediate the repression of cyclin-cdk activity in damaged cells. In addition, we present evidence that irradiated cells are competent to traverse S phase and arrest in G(2) in the complete absence of cdk2-associated kinase activity.	Univ New Mexico, Dept Internal Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Wharton, W (corresponding author), Univ New Mexico, Dept Internal Med, Hlth Sci Ctr, MSC10 5550, Albuquerque, NM 87131 USA.	wwharton@salud.unm.edu						Adkins JN, 2000, BIOCHEMISTRY-US, V39, P13925, DOI 10.1021/bi001524e; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; BAE IS, 1995, CANCER RES, V55, P2387; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CORNFORTH MN, 1987, RADIAT RES, V111, P385, DOI 10.2307/3576926; DAnna JA, 1997, RADIAT RES, V148, P260, DOI 10.2307/3579611; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Gray N, 1999, CURR MED CHEM, V6, P859; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hwang A, 1998, RADIAT RES, V150, pS52, DOI 10.2307/3579808; KASTAN MB, 1991, CANCER RES, V51, P6304; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Savell J, 2004, MOL CANCER THER, V3, P205; Savell J, 2001, RADIAT RES, V155, P554, DOI 10.1667/0033-7587(2001)155[0554:PGAIIH]2.0.CO;2; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Syljuasen RG, 1999, CANCER RES, V59, P1008; TSAI LH, 1993, ONCOGENE, V8, P1593; TSTSU O, 2003, CANC CELLS, V3, P233; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WHARTON W, 1995, CANCER RES, V55, P5069; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YAMADA M, 1961, P NATL ACAD SCI USA, V47, P1181, DOI 10.1073/pnas.47.8.1181; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	48	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43667	43674		10.1074/jbc.M407959200	http://dx.doi.org/10.1074/jbc.M407959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304475	hybrid			2022-12-25	WOS:000224383100040
J	Degl'Innocenti, D; Arighi, E; Popsueva, A; Sangregorio, R; Alberti, L; Rizzetti, MG; Ferrario, C; Sariola, H; Pierotti, MA; Borrello, MG				Degl'Innocenti, D; Arighi, E; Popsueva, A; Sangregorio, R; Alberti, L; Rizzetti, MG; Ferrario, C; Sariola, H; Pierotti, MA; Borrello, MG			Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching	ONCOGENE			English	Article						RET isoforms; Tyr1062; cell branching; cell scattering; cell transformation	RECEPTOR TYROSINE KINASE; URETERAL BUD DEVELOPMENT; ENTERIC NERVOUS-SYSTEM; NEUROTROPHIC FACTOR; C-RET; TRANSFORMING ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; DOCKING SITE; GDNF FAMILY; AUTOPHOSPHORYLATION SITES	The receptor tyrosine kinase RET is alternatively spliced to yield two main isoforms, RET9 and RET51, which differ in their carboxyl terminal. Activated RET induces different biological responses such as morphological transformation, neurite outgrowth, proliferation, cell migration and branching. The two isoforms have been suggested to have separate intracellular signaling pathways and different roles in mouse development. Here we show that both isoforms are able to induce cell scattering of SK-N-MC neuroepithelioma cell line and branching tubule formation in MDCK cell line. However, the Y1062F mutation, which abrogates the transforming activity of both activated RET isoforms in NIH3T3 cells, does not abolish scattering and branching morphogenesis of RET51, whereas impairs these biological effects of RET9. The GDNF-induced biological effects of RET51 are inhibited by the simultaneous abrogation of both Tyr1062 and Tyr1096 docking sites. Thus, Tyr1096 may substitute the functions of Tyr1062. GRB2 is the only known adaptor protein binding to Tyr1096. Dominant-negative GRB2 expressed in MDCK cells together with RET9 or RET51 significantly reduces branching. Therefore, GRB2 is necessary for RET-mediated branching of MDCK cells.	Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, I-20133 Milan, Italy; Univ Helsinki, Biomedicum Helsinki, Inst Biomed, FIN-0014 Helsinki, Finland; Univ Helsinki, Cent Hosp, HUCH Diagnost Dept Pathol, FIN-00290 Helsinki, Finland; FIRC, Inst Mol Oncol IFOM, I-20139 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; IFOM - FIRC Institute of Molecular Oncology	Borrello, MG (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Res Unit 3, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; mariagrazia.borrello@istitutotumori.mi.it	Borrello, Maria Grazia/C-3161-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Borrello, Maria Grazia/0000-0002-6854-2848; Pierotti, Marco Alessandro/0000-0002-7431-8332				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Andreozzi F, 2003, ONCOGENE, V22, P2942, DOI 10.1038/sj.onc.1206475; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 2002, BIOCHEM BIOPH RES CO, V296, P515, DOI 10.1016/S0006-291X(02)00886-0; Borrello MG, 1995, ONCOGENE, V11, P2419; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Carter MT, 2001, CYTOGENET CELL GENET, V95, P169, DOI 10.1159/000059341; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; De Vita G, 2000, CANCER RES, V60, P3727; Durbec PL, 1996, DEVELOPMENT, V122, P349; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, J NEURO-ONCOL, V55, P51, DOI 10.1023/A:1012946812930; Hennige AM, 2000, MOL CELL ENDOCRINOL, V167, P69, DOI 10.1016/S0303-7207(00)00283-5; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Iwashita T, 2001, GASTROENTEROLOGY, V121, P24, DOI 10.1053/gast.2001.25515; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; KAWAMOTO Y, 2004, J BIOL CHEM     0106; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lanzi C, 2000, INT J CANCER, V85, P384, DOI 10.1002/(SICI)1097-0215(20000201)85:3<384::AID-IJC15>3.3.CO;2-P; Lee DCW, 2002, ONCOGENE, V21, P5582, DOI 10.1038/sj.onc.1205741; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Mograbi B, 2001, MOL CELL BIOL, V21, P6719, DOI 10.1128/MCB.21.20.6719-6730.2001; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuchardt A, 1996, DEVELOPMENT, V122, P1919; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Srinivas S, 1999, DEVELOPMENT, V126, P1375; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tang MJ, 1998, J CELL BIOL, V142, P1337, DOI 10.1083/jcb.142.5.1337; Taraviras S, 1999, CURR OPIN GENET DEV, V9, P321, DOI 10.1016/S0959-437X(99)80048-3; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; TSUZUKI T, 1995, ONCOGENE, V10, P191; vanPuijenbroek AAFL, 1997, ONCOGENE, V14, P1147, DOI 10.1038/sj.onc.1200911; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	60	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7297	7309		10.1038/sj.onc.1207862	http://dx.doi.org/10.1038/sj.onc.1207862			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326489				2022-12-25	WOS:000224021400001
J	Wang, FD; Kim, BE; Petris, MJ; Eide, DJ				Wang, FD; Kim, BE; Petris, MJ; Eide, DJ			The mammalian Zip5 protein is a zinc transporter that localizes to the basolateral surface of polarized cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACRODERMATITIS-ENTEROPATHICA; FUNCTIONAL EXPRESSION; METAL TRANSPORTER; UPTAKE SYSTEM; GENE ENCODES; ABSORPTION; FAMILY; METALLOTHIONEIN; IDENTIFICATION; TRAFFICKING	The mouse and human Zip5 proteins are members of the ZIP family of metal ion transporters. In this study, we present evidence that mouse Zip5 is a zinc uptake transporter that is specific for Zn(II) over other potential metal ion substrates. We also show that, unlike many other mammalian ZIP proteins, the endocytic removal of mZip5 from the plasma membrane is not triggered by zinc treatment. Thus, the activity of mZip5 does not appear to be down-regulated by zinc repletion. Zip5 expression is restricted to many tissues important for zinc homeostasis, including the intestine, pancreas, liver, and kidney. Zip5 is similar in sequence to the Zip4 protein, which is involved in the uptake of dietary zinc. Co-expression of Zip4 and Zip5 in the intestine led to the hypothesis that these proteins play overlapping roles in the uptake of dietary zinc across the apical membrane of intestinal enterocytes. Surprisingly, however, we found that mZip5 localizes specifically to the basolateral membrane of polarized Madin-Darby canine kidney cells. These observations suggest that Zip5 plays a novel role in polarized cells by carrying out serosal-to-mucosal zinc transport. Furthermore, given its expression in tissues important to zinc homeostasis, we propose that Zip5 plays a central role in controlling organismal zinc status.	Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Wisconsin, Dept Nutr Sci, 340B Nutr Sci,1415 Linden Dr, Madison, WI 53706 USA.	eide@nutrisci.wisc.edu	Wang, Fudi/L-7888-2018	Wang, Fudi/0000-0001-8730-0003	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056285] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50181] Funding Source: Medline; NIGMS NIH HHS [GM56285] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES PM, 1973, P ROY SOC MED, V66, P327, DOI 10.1177/003591577306600411; Begum NA, 2002, GENOMICS, V80, P630, DOI 10.1006/geno.2002.7000; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Cousins RJ, 2000, J NUTR, V130, p1384S, DOI 10.1093/jn/130.5.1384S; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; Franklin RB, 2003, J INORG BIOCHEM, V96, P435, DOI 10.1016/S0162-0134(03)00249-6; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; Grider A, 1998, BIOL TRACE ELEM RES, V61, P1, DOI 10.1007/BF02784035; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; King JC, 2000, J NUTR, V130, p1360S, DOI 10.1093/jn/130.5.1360S; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Krebs NF, 2000, J NUTR, V130, p1374S, DOI 10.1093/jn/130.5.1374S; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Kury Sebastien, 2003, Hum Mutat, V22, P337, DOI 10.1002/humu.9178; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; LOMBECK I, 1975, LANCET, V1, P855; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MESSER HH, 1982, J NUTR, V112, P652, DOI 10.1093/jn/112.4.652; NELDNER KH, 1975, NEW ENGL J MED, V292, P879, DOI 10.1056/NEJM197504242921702; RICHARDS MP, 1975, BIOCHEM BIOPH RES CO, V64, P1215, DOI 10.1016/0006-291X(75)90822-0; Taylor KM, 2004, BIOCHEM J, V377, P131, DOI 10.1042/BJ20031183; Taylor KM, 2003, BBA-BIOMEMBRANES, V1611, P16, DOI 10.1016/S0005-2736(03)00048-8; VAZQUEZ F, 1995, BIOL TRACE ELEM RES, V50, P109, DOI 10.1007/BF02789413; Vert G, 2002, PLANT CELL, V14, P1223, DOI 10.1105/tpc.001388; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Wang FD, 2004, HUM MOL GENET, V13, P563, DOI 10.1093/hmg/ddh049; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; WEISMANN K, 1979, BRIT J DERMATOL, V101, P573, DOI 10.1111/j.1365-2133.1979.tb11889.x; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	35	119	126	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51433	51441		10.1074/jbc.M408361200	http://dx.doi.org/10.1074/jbc.M408361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15322118	hybrid			2022-12-25	WOS:000225355800095
J	Zhu, Y; Inouye, M				Zhu, Y; Inouye, M			The HAMP linker in histidine kinase dimeric receptors is critical for symmetric transmembrane signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS RECEPTOR; SINGLE CYTOPLASMIC DOMAIN; ESCHERICHIA-COLI; ASPARTATE CHEMORECEPTOR; LIGAND-BINDING; PHOSPHATASE-ACTIVITIES; ENVZ; MODEL; PROTEINS; REGION	The HAMP linker, a common structural element between a sensor and a transmitter module in various sensor proteins, plays an essential role in signal transduction. Here, by in vivo complementation experiments with Tar-EnvZ hybrid receptor mutants in which the HAMP linker forms a heterodimer with Tar and EnvZ-type subunits, we found that mutations at one linker only affect the function of EnvZ in the same subunit. However, the same mutations affect the EnvZ function of both subunits when only a Tar or EnvZ-type HAMP linker is used. These results suggest that intersubunit interactions in the HAMP linker normally mediate signal transduction through both subunits in a sensor dimer, whereas the signal is asymmetrically transduced through the linker in a heterodimer. This is the first demonstration that two HAMP linkers in a sensor dimer are functionally coupled for normal signal transduction; however, this functional coupling can be reduced when the HAMP linkers lose their symmetric nature.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.	inouye@rwja.umdnj.edu			NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleman JA, 2003, J BACTERIOL, V185, P4872, DOI 10.1128/JB.185.16.4872-4882.2003; Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Feng XH, 1997, J BACTERIOL, V179, P6714, DOI 10.1128/jb.179.21.6714-6720.1997; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KIM SH, 1992, COLD SPRING HARB SYM, V57, P17, DOI 10.1101/SQB.1992.057.01.004; KRIKOS A, 1985, P NATL ACAD SCI USA, V82, P1326, DOI 10.1073/pnas.82.5.1326; Kristich CJ, 2003, MOL MICROBIOL, V47, P1353, DOI 10.1046/j.1365-2958.2003.03375.x; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; WAUKAU J, 1992, J BACTERIOL, V174, P1522, DOI 10.1128/jb.174.5.1522-1527.1992; Weerasuriya S, 1998, J BACTERIOL, V180, P914, DOI 10.1128/JB.180.4.914-920.1998; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; YANG Y, 1993, J MOL BIOL, V232, P493, DOI 10.1006/jmbi.1993.1405; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057; YEH JI, 1993, J BIOL CHEM, V268, P9787; Zhang YH, 1999, P NATL ACAD SCI USA, V96, P939, DOI 10.1073/pnas.96.3.939; Zhu Y, 2003, J BIOL CHEM, V278, P22812, DOI 10.1074/jbc.M300916200; Zhu Y, 2002, MOL MICROBIOL, V45, P653, DOI 10.1046/j.1365-2958.2002.03061.x	33	17	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48152	48158		10.1074/jbc.M401024200	http://dx.doi.org/10.1074/jbc.M401024200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15316026	hybrid			2022-12-25	WOS:000224957000089
J	Browner, NC; Dey, NB; Boch, KD; Lincoln, TM				Browner, NC; Dey, NB; Boch, KD; Lincoln, TM			Regulation of cGMP-dependent protein kinase expression by soluble guanylyl cyclase in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCES NEOINTIMA FORMATION; NITRIC-OXIDE RECEPTOR; ACTIVITY REQUIRES; DOWN-REGULATION; GENE-TRANSFER; SUBUNIT; NO; DESENSITIZATION; PROLIFERATION; INHIBITION	Vascular smooth muscle cells (VSMC) undergo many phenotypic changes when placed in culture. Several studies have shown that the levels of expression of soluble guanylyl cyclase (sGC) or cGMP-dependent protein kinase (PKG) are altered in cultured VSMC. In this study the mechanisms involved in the coordinated expression of sGC and PKG were examined. Pro-inflammatory cytokines that increase the expression of type II NO synthase (inducible NO synthase, or iNOS) decreased PKG expression in freshly isolated, non-passaged bovine aortic SMC. However, in several passaged VSMC lines (i.e. bovine aortic SMC, human aortic SMC, and A7r5 cells), PKG protein expression was not suppressed by cytokines or NO. sGC was highly expressed in non-passaged bovine aortic SMC but not in passaged cell lines. Restoration of expression of sGC to passaged bovine SMC using adenovirus encoding the alpha(1) and beta(1) subunits of sGC restored the capacity of the cells to increase cGMP in response to NO. Furthermore, treatment of these sGC-transduced cells with NO donors for 48 h resulted in decreased PKG protein expression. In contrast, passaged rat aortic SMC expressed high levels of NO-responsive sGC but demonstrated reduced expression of PKG. Adenovirus-mediated expression of the PKG catalytically active domain in rat aortic SMC caused a reduction in the expression of sGC in these cells. These results suggest that there is a mechanism for the coordinated expression of sGC and PKG in VSMC and that prolonged activation of sGC down-regulates PKG expression. Likewise, the loss of PKG expression appears to increase sGC expression. These effects may be an adaptive mechanism allowing growth and survival of VSMC in vitro.	Univ S Alabama, Dept Physiol, Mobile, AL 36688 USA; Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Hartford, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiovasc Div, Charlestown, MA 02129 USA; Univ Hartford, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA	University of South Alabama; University of Alabama System; University of Alabama Birmingham; Harvard University; Massachusetts General Hospital; University of Hartford; Harvard University; Massachusetts General Hospital; University of Hartford	Lincoln, TM (corresponding author), Univ S Alabama, Dept Physiol, Med Sci Bldg,Rm 3024, Mobile, AL 36688 USA.	tlincoln@usouthal.edu			NHLBI NIH HHS [HL66164, R01 HL053426, R01 HL066164, HL53426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053426, R01HL066164] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PG, 2000, ARTERIOSCL THROM VAS, V20, P2192, DOI 10.1161/01.ATV.20.10.2192; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; BUECHLER WA, 1991, BIOCHEM BIOPH RES CO, V174, P351, DOI 10.1016/0006-291X(91)90527-E; Chen LH, 2000, CIRC RES, V86, P520, DOI 10.1161/01.RES.86.5.520; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; de Frutos S, 2003, BBA-MOL CELL RES, V1643, P105, DOI 10.1016/j.bbamcr.2003.10.003; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dey NB, 1998, CIRC RES, V82, P139; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; HARTENECK C, 1990, FEBS LETT, V272, P221, DOI 10.1016/0014-5793(90)80489-6; Jeremy JY, 1999, CARDIOVASC RES, V43, P580, DOI 10.1016/S0008-6363(99)00171-6; Kloss S, 2004, MOL PHARMACOL, V65, P1440, DOI 10.1124/mol.65.6.1440; Kloss S, 2000, HYPERTENSION, V35, P43; KOESLING D, 1988, FEBS LETT, V239, P29, DOI 10.1016/0014-5793(88)80539-8; Murad F, 1997, CIRCULATION, V95, P1101; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; Ruetten H, 1999, CIRC RES, V85, P534, DOI 10.1161/01.RES.85.6.534; Sarkar R, 1996, CIRC RES, V78, P225, DOI 10.1161/01.RES.78.2.225; Schlossmann J, 2003, ANN MED, V35, P21, DOI 10.1080/07853890310004093; Sinnaeve P, 2002, CIRCULATION, V105, P2911, DOI 10.1161/01.CIR.0000018169.59205.CA; Sinnaeve P, 2001, CIRC RES, V88, P103, DOI 10.1161/01.RES.88.1.103; Smith JK, 2000, J BIOL CHEM, V275, P154, DOI 10.1074/jbc.275.1.154; Takata M, 2001, AM J PHYSIOL-LUNG C, V280, pL272, DOI 10.1152/ajplung.2001.280.2.L272; UJIIE K, 1994, J PHARMACOL EXP THER, V270, P761; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Wolfsgruber W, 2003, P NATL ACAD SCI USA, V100, P13519, DOI 10.1073/pnas.1936024100; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; Yamashita T, 2000, HYPERTENSION, V36, P97, DOI 10.1161/01.HYP.36.1.97	38	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46631	46636		10.1074/jbc.M408518200	http://dx.doi.org/10.1074/jbc.M408518200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337747	hybrid			2022-12-25	WOS:000224832400037
J	Hobson, JP; Netzel-Arnett, S; Szabo, R; Rehault, SM; Church, FC; Strickland, DK; Lawrence, DA; Antalis, TM; Bugge, TH				Hobson, JP; Netzel-Arnett, S; Szabo, R; Rehault, SM; Church, FC; Strickland, DK; Lawrence, DA; Antalis, TM; Bugge, TH			Mouse DESC1 is located within a cluster of seven DESC1-like genes and encodes a type II transmembrane serine protease that forms serpin inhibitory complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELLS EXPRESS; C INHIBITOR; PLASMINOGEN-ACTIVATOR; MICE DEFICIENT; HUMAN-LIVER; HEPSIN; CLONING; CANCER; MATRIPTASE; CARCINOMA	We report the identification and functional analysis of a type II transmembrane serine protease encoded by the mouse differentially expressed in squamous cell carcinoma ( DESC) 1 gene, and the definition of a cluster of seven homologous DESC1-like genes within a 0.5-Mb region of mouse chromosome 5E1. This locus is syntenic to a region of human chromosome 4q13.3 containing the human orthologues of four of the mouse DESC1-like genes. Bioinformatic analysis indicated that all seven DESC1-like genes encode functional proteases. Direct cDNA cloning showed that mouse DESC1 encodes a multidomain serine protease with an N-terminal signal anchor, a SEA ( sea urchin sperm protein, enterokinase, and agrin) domain, and a C-terminal serine protease domain. The mouse DESC1 mRNA was present in epidermal, oral, and male reproductive tissues and directed the translation of a membrane-associated 60-kDa N-glycosylated protein with type II topology. Mouse DESC1 was synthesized in insect cells as a zymogen that could be activated by exposure to trypsin. The purified activated DESC1 hydrolyzed synthetic peptide substrates, showing a preference for Arg in the P-1 position. DESC1 proteolytic activity was abolished by generic inhibitors of serine proteases but not by other classes of protease inhibitors. Most interestingly, DESC1 formed stable inhibitory complexes with both plasminogen activator inhibitor-1 and protein C inhibitor that are expressed in the same tissues with DESC1, suggesting that type II transmembrane serine proteases may be novel targets for serpin inhibition. Together, these data show that mouse DESC1 encodes a functional cell surface serine protease that may have important functions in the epidermis, oral, and reproductive epithelium.	NIDCR, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Physiol, Rockville, MD 20855 USA; Univ Maryland, Sch Med, Dept Surg, Rockville, MD 20855 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Carolina; University of North Carolina Chapel Hill	Bugge, TH (corresponding author), NIDCR, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Rm 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	REHAULT-GODBERT, Sophie/Y-3890-2019	Rehault-Godbert, Sophie/0000-0003-2800-3417; Lawrence, Daniel/0000-0003-3126-1935	NATIONAL CANCER INSTITUTE [R01CA098369, R56CA098369] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, R01HL055374, R01HL050710, R01HL032656, P01HL054710, T32HL007698, R01HL055747, R29HL050710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NCI NIH HHS [CA098369] Funding Source: Medline; NHLBI NIH HHS [HL007698, HL32656, HL50710, HL50784, HL54710, HL55374, HL55747, HL-06350] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Ben-Yosef T, 2001, J MED GENET, V38, P396, DOI 10.1136/jmg.38.6.396; Cal S, 2003, P NATL ACAD SCI USA, V100, P9185, DOI 10.1073/pnas.1633392100; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; EGGERMONT E, 1971, Acta Gastro-Enterologica Belgica, V34, P655; Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; Glasscock LN, 2003, BBA-PROTEINS PROTEOM, V1649, P106, DOI 10.1016/S1570-9639(03)00164-X; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; Hansen IA, 2004, ENDOCRINOLOGY, V145, P1898, DOI 10.1210/en.2003-0930; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hooper JD, 2003, BIOCHEM J, V373, P689, DOI 10.1042/BJ20030390; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; Kim DR, 2001, BBA-GENE STRUCT EXPR, V1518, P204, DOI 10.1016/S0167-4781(01)00184-1; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009-8981(99)00224-7; Lang JC, 2001, BRIT J CANCER, V84, P237, DOI 10.1054/bjoc.2000.1586; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin BY, 1999, CANCER RES, V59, P4180; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2003, J CELL BIOL, V163, P901, DOI 10.1083/jcb.200304161; Luo J, 2001, CANCER RES, V61, P4683; LYONS JG, 1991, BIOCHEMISTRY-US, V30, P1449, DOI 10.1021/bi00220a001; Magee JA, 2001, CANCER RES, V61, P5692; MAROUX S, 1971, J BIOL CHEM, V246, P5031; Masmoudi S, 2001, HUM MUTAT, V18, P101, DOI 10.1002/humu.1159; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Netzel-Arnett S, 2002, J BIOL CHEM, V277, P45154, DOI 10.1074/jbc.M206354200; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Palmieri D, 2002, J BIOL CHEM, V277, P40950, DOI 10.1074/jbc.M202333200; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; Rutgeerts L, 1976, Tijdschr Gastroenterol, V19, P231; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanimoto H, 2001, TUMOR BIOL, V22, P104, DOI 10.1159/000050604; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Uhrin P, 2000, J CLIN INVEST, V106, P1531, DOI 10.1172/JCI10768; Underwood LJ, 2000, BBA-MOL BASIS DIS, V1502, P337, DOI 10.1016/S0925-4439(00)00058-2; Vaarala MH, 2001, J PATHOL, V193, P134, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; Wallrapp C, 2000, CANCER RES, V60, P2602; Welsh JB, 2001, CANCER RES, V61, P5974; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Yamaguchi N, 2002, J BIOL CHEM, V277, P6806, DOI 10.1074/jbc.M103645200; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yoshinaga Sumiko, 1998, Journal of Medical Investigation, V45, P77; Yu IS, 2000, THROMB HAEMOSTASIS, V84, P865, DOI 10.1055/s-0037-1614129; Yuan X, 1998, AM J PHYSIOL-GASTR L, V274, pG342, DOI 10.1152/ajpgi.1998.274.2.G342	62	41	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46981	46994		10.1074/jbc.M403299200	http://dx.doi.org/10.1074/jbc.M403299200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15328353	hybrid			2022-12-25	WOS:000224832400082
J	Bergman, A; Laudon, H; Winblad, B; Lundkvist, J; Naslund, J				Bergman, A; Laudon, H; Winblad, B; Lundkvist, J; Naslund, J			The extreme C terminus of presenilin 1 is essential for gamma-secretase complex assembly and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; ALZHEIMERS-DISEASE; BETA-APP; NICASTRIN; PEN-2; NOTCH; CLEAVAGE; APH-1	The gamma-secretase complex catalyzes the cleavage of the amyloid precursor protein in its transmembrane domain resulting in the formation of the amyloid beta-peptide and the cytoplasmic APP intracellular domain. The active gamma-secretase complex is composed of at least four subunits: presenilin (PS), nicastrin, Aph-1, and Pen-2, where the presence of all components is critically required for gamma-cleavage to occur. The PS proteins are themselves subjected to endoproteolytic cleavage resulting in the generation of an N-terminal and a C-terminal fragment that remain stably associated as a heterodimer. Here we investigated the effects of modifications on the C terminus of PS1 on PS1 endoproteolysis, gamma-secretase complex assembly, and activity in cells devoid of endogenous PS. We report that certain mutations and, in particular, deletions of the PS1 C terminus decrease gamma-secretase activity, PS1 endoproteolysis, and gamma-secretase complex formation. We demonstrate that the N- and C-terminal PS1 fragments can associate with each other in mutants having C-terminal truncations that cause loss of interaction with nicastrin and Aph-1. In addition, we show that the C-terminal fragment of PS1 alone can mediate interaction with nicastrin and Aph-1 in PS null cells expressing only the C-terminal fragment of PS1. Taken together, these data suggest that the PS1 N- and C-terminal fragment intermolecular interactions are independent of an association with nicastrin and Aph-1, and that nicastrin and Aph-1 interact with the C-terminal part of PS1 in the absence of an association with full-length PS1 or the N- terminal fragment.	Karolinska Inst, Novum, Dept Neurotec, Sect Expt Geriatr, S-14157 Huddinge, Sweden; Med Nobel Inst, Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Naslund, J (corresponding author), Karolinska Inst, Novum, Dept Neurotec, Sect Expt Geriatr, Kaspac Pl 5, S-14157 Huddinge, Sweden.	jan.naslund@neurotec.ki.se	Laudon, Hjalmar/J-3074-2013	Laudon, Hjalmar/0000-0001-6058-1466				Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Bergman A, 2004, J BIOL CHEM, V279, P16744, DOI 10.1074/jbc.M313999200; Bergman A, 2003, EXP CELL RES, V287, P1, DOI 10.1016/S0014-4827(03)00117-4; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Buxbaum JD, 1998, NAT MED, V4, P1177, DOI 10.1038/2673; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fraering PC, 2004, BIOCHEMISTRY-US, V43, P323, DOI 10.1021/bi035748j; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Laudon H, 2004, J NEUROCHEM, V89, P44, DOI 10.1046/j.1471-4159.2003.02298.x; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leissring MA, 2000, P NATL ACAD SCI USA, V97, P8590, DOI 10.1073/pnas.97.15.8590; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	38	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45564	45572		10.1074/jbc.M407717200	http://dx.doi.org/10.1074/jbc.M407717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322123	hybrid			2022-12-25	WOS:000224694900035
J	Ghiso, J; Shayo, M; Calero, M; Ng, D; Tomidokoro, Y; Gandy, S; Rostagno, A; Frangione, B				Ghiso, J; Shayo, M; Calero, M; Ng, D; Tomidokoro, Y; Gandy, S; Rostagno, A; Frangione, B			Systemic catabolism of Alzheimer's A beta 40 and A beta 42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PEPTIDE; INSULIN-DEGRADING ENZYME; BLOOD-BRAIN-BARRIER; TISSUE PLASMINOGEN-ACTIVATOR; RECEPTOR-MEDIATED TRANSPORT; RETINOL-BINDING-PROTEIN; LONG-TERM POTENTIATION; CEREBROSPINAL-FLUID; COMPLEX RECEPTOR; OXIDATIVE STRESS	To better understand the physiologic excretion and/or catabolism of circulating peripheral amyloid beta (Abeta), we labeled human Abeta40 (monomeric, with predominant unordered structure) and Abeta42 (mixture of monomers and oligomers in similar to50:50 ratio, rich in beta-sheet conformation) with either (NaI)-I-125 or I-125-tyramine cellobiose, also known as the cell-trapping ligand procedure, testing their blood clearance and organ uptake in B6SJLF1/J mice. Irrespective of the labeling protocol, the peptide conformation, and the degree of oligomerization, both Abeta40 and Abeta42 showed a short half-life of 2.5-3.0 min. The liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide uptake, followed by the kidney. In vivo, hepatocytes captured >90% of the radiolabeled peptides which, after endocytosis, were preferentially catabolized and excreted into the bile. Biliary excretion of intact as well as partially degraded Abeta species became obviously relevant at doses above 10 mug. The use of biotin-labeled Abeta allowed the visualization of the interaction with HepG2 cells in culture, whereas competitive inhibition experiments with unlabeled Abeta demonstrated the specificity of the binding. The capability of the liver to uptake, catabolize, and excrete large doses of Abeta, several orders of magnitude above its physiologic concentration, may explain not only the femtomolar plasma levels of Abeta but the little fluctuation observed with age and disease stages.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Dept Psychiat, New York, NY 10016 USA; Inst Salud Carlos III, Dept Microbiol, Madrid 28220, Spain; Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA	New York University; New York University; Instituto de Salud Carlos III; Jefferson University	Ghiso, J (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave,TH-432, New York, NY 10016 USA.	ghisoj01@popmail.med.nyu.edu	Calero, Miguel/H-5691-2015; Rostagno, Agueda/A-5801-2008	Calero, Miguel/0000-0001-5366-3324; Rostagno, Agueda/0000-0002-6817-2074	NIA NIH HHS [AG05891, AG08721, AG10491] Funding Source: Medline; NINDS NIH HHS [NS38777] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, P01AG010491, R01AG008721, R37AG005891] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABE K, 1990, J BIOCHEM-TOKYO, V108, P726, DOI 10.1093/oxfordjournals.jbchem.a123272; Authier F, 1996, CLIN INVEST MED, V19, P149; BALTZ ML, 1985, CLIN EXP IMMUNOL, V59, P235; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barnham KJ, 2003, J BIOL CHEM, V278, P42959, DOI 10.1074/jbc.M305494200; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; BOLAND K, 1995, J BIOL CHEM, V270, P28022; Butterfield DA, 2004, NEUROBIOL AGING, V25, P563, DOI 10.1016/j.neurobiolaging.2003.12.027; Calero M, 1999, BIOCHEM J, V344, P375, DOI 10.1042/0264-6021:3440375; Carson JA, 2002, J NEUROCHEM, V81, P1, DOI 10.1046/j.1471-4159.2002.00855.x; DIXON FJ, 1952, J EXP MED, V96, P313, DOI 10.1084/jem.96.4.313; Farris W, 2004, AM J PATHOL, V164, P1425, DOI 10.1016/S0002-9440(10)63229-4; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; FUCHS HE, 1985, BLOOD, V65, P539; GhersiEgea JF, 1996, J NEUROCHEM, V67, P880; Ghiso J, 1997, FEBS LETT, V408, P105, DOI 10.1016/S0014-5793(97)00400-6; Ghiso J, 2002, ADV DRUG DELIVER REV, V54, P1539, DOI 10.1016/S0169-409X(02)00149-7; GHISO J, 1992, BIOCHEM J, V288, P1053, DOI 10.1042/bj2881053; GJOEN T, 1987, J BIOL CHEM, V262, P10926; GLASS CK, 1983, J BIOL CHEM, V258, P7161; Haass C, 2001, NAT NEUROSCI, V4, P859, DOI 10.1038/nn0901-859; Holtzman DM, 2002, ADV DRUG DELIVER REV, V54, P1603, DOI 10.1016/S0169-409X(02)00158-8; Hone E, 2003, J ALZHEIMERS DIS, V5, P1, DOI 10.3233/JAD-2003-5101; HUTCHINSON WL, 1994, J CLIN INVEST, V94, P1390, DOI 10.1172/JCI117474; HYSING J, 1986, BIOCHIM BIOPHYS ACTA, V887, P42, DOI 10.1016/0167-4889(86)90120-5; IZZO JL, 1975, INSULIN, P195; JOSLIN G, 1991, J BIOL CHEM, V266, P21897; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; Maekawa H, 1996, J BIOL CHEM, V271, P18604, DOI 10.1074/jbc.271.31.18604; MAKOVER A, 1988, J BIOL CHEM, V263, P8598; MALABA L, 1995, J BIOL CHEM, V270, P15686, DOI 10.1074/jbc.270.26.15686; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; Matter ML, 1998, J CELL BIOL, V141, P1019, DOI 10.1083/jcb.141.4.1019; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Morelli L, 2002, NEUROCHEM RES, V27, P1387, DOI 10.1023/A:1021679817756; NASTRAND J, 1994, P NATL ACAD SCI USA, V91, P8378; NOLTE MS, 2004, BASIC CLIN PHARM, P693; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PERLMUTTER DH, 1994, PEDIATR RES, V36, P271, DOI 10.1203/00006450-199409000-00001; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; Poduslo JF, 1997, NEUROBIOL DIS, V4, P27, DOI 10.1006/nbdi.1997.0132; Poduslo JF, 1999, NEUROBIOL DIS, V6, P190, DOI 10.1006/nbdi.1999.0238; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Roher AE, 2000, BBA-MOL BASIS DIS, V1502, P31, DOI 10.1016/S0925-4439(00)00030-2; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Seglen P., 1993, METHODS TOXICOL, P231; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sigurdsson EM, 2002, NEUROBIOL AGING, V23, P1001, DOI 10.1016/S0197-4580(02)00124-0; Sigurdsson EM, 2002, DRUG DEVELOP RES, V56, P135, DOI 10.1002/ddr.10068; Small D H, 1998, Amyloid, V5, P301, DOI 10.3109/13506129809007304; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wijmenga C, 2004, P NUTR SOC, V63, P31, DOI 10.1079/PNS2003316; Zlokovic BV, 2002, ADV DRUG DELIVER REV, V54, P1553, DOI 10.1016/S0169-409X(02)00150-3; Zlokovic BV, 1996, P NATL ACAD SCI USA, V93, P4229, DOI 10.1073/pnas.93.9.4229	73	145	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45897	45908		10.1074/jbc.M407668200	http://dx.doi.org/10.1074/jbc.M407668200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322125	hybrid			2022-12-25	WOS:000224694900074
J	Nagiec, MJ; Lei, B; Parker, SK; Vasil, ML; Matsumoto, M; Ireland, RM; Beres, SB; Hoe, NP; Musser, JM				Nagiec, MJ; Lei, B; Parker, SK; Vasil, ML; Matsumoto, M; Ireland, RM; Beres, SB; Hoe, NP; Musser, JM			Analysis of a novel prophage-encoded Group A Streptococcus extracellular phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SEROTYPE M3 STRAIN; MECHANISM; ONTARIO; VENOM	Group A Streptococcus ( GAS) is an important human pathogen that causes many types of infections, including pharyngitis and severe invasive diseases. We recently sequenced the genome of a serotype M3 strain and identified a prophage-encoded secreted phospholipase A(2) designated SlaA. To study SlaA structure-activity relationships, 20 site-specific mutants were constructed by alanine-replacement mutagenesis and purified to apparent homogeneity. Enzymatic activity was greatly reduced by alanine replacement of amino acid residues previously described as crucial in the catalytic mechanism of secreted phospholipase A(2). Similarly, substitution of five residues in an inferred Ca2+-binding loop and three residues in the inferred active site region resulted in loss of activity of 76.5% or greater relative to the wild-type enzyme. Analysis of enzyme substrate specificity confirmed SlaA as a phospholipase A(2), with activity against multiple phospholipid head groups and acyl chains located at the sn-2 position. PCR analysis of 1,189 GAS strains representing 48 M protein serotypes commonly causing human infections identified the slaA gene in 129 strains of nine serotypes (M1, M2, M3, M4, M6, M22, M28, M75, and st3757). Expression of SlaA by strains of these serotypes was confirmed by Western immunoblot. SlaA production increased rapidly and substantially on co-culture with Detroit 562 human pharyngeal epithelial cells. Together, these data provide new information about a novel extracellular enzyme that participates in GAS-human interactions.	Baylor Coll Med, Dept Pathol, Ctr Human Bacterial Pathogenesis Res, Houston, TX 77030 USA; NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Univ Colorado, Hlth Sci Ctr, Dept Microbiol, Denver, CO 80262 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Musser, JM (corresponding author), Baylor Coll Med, Dept Pathol, Ctr Human Bacterial Pathogenesis Res, 1 Baylor Plaza, Houston, TX 77030 USA.	musser@bcm.tmc.edu		Lei, Benfang Lei/0000-0001-8133-6021				Banks DJ, 2004, J INFECT DIS, V190, P727, DOI 10.1086/422697; Banks DJ, 2003, INFECT IMMUN, V71, P7079, DOI 10.1128/IAI.71.12.7079-7086.2003; Banks DJ, 2002, TRENDS MICROBIOL, V10, P515, DOI 10.1016/S0966-842X(02)02461-7; BANKS DJ, 2004, BACTERIOPHAGES BACTE; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Deems RA, 2000, ANAL BIOCHEM, V287, P1, DOI 10.1006/abio.2000.4766; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; Hoe N, 1999, EMERG INFECT DIS, V5, P254, DOI 10.3201/eid0502.990210; KAPUR V, 1994, MICROB PATHOGENESIS, V16, P443, DOI 10.1006/mpat.1994.1044; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Li ZY, 2003, J INFECT DIS, V188, P1587, DOI 10.1086/379050; Lukomski S, 2000, INFECT IMMUN, V68, P535, DOI 10.1128/IAI.68.2.535-542.2000; Moses AE, 2003, J CLIN MICROBIOL, V41, P4655, DOI 10.1128/JCM.41.10.4655-4659.2003; Muller MP, 2003, ARCH INTERN MED, V163, P467, DOI 10.1001/archinte.163.4.467; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; MUSSER JM, 1993, J INFECT DIS, V167, P337, DOI 10.1093/infdis/167.2.337; MUSSER JM, 1991, P NATL ACAD SCI USA, V88, P2668, DOI 10.1073/pnas.88.7.2668; Musser JM, 1998, BIOMED RES REP, P185; Nakagawa I, 2003, GENOME RES, V13, P1042, DOI 10.1101/gr.1096703; O'Brien KL, 2002, CLIN INFECT DIS, V35, P268, DOI 10.1086/341409; PEARSON JA, 1993, BIOCHIM BIOPHYS ACTA, V1161, P223, DOI 10.1016/0167-4838(93)90217-F; REYNOLDS LJ, 1992, ANAL BIOCHEM, V204, P190, DOI 10.1016/0003-2697(92)90160-9; Schmitz FJ, 2003, J INFECT DIS, V188, P1578, DOI 10.1086/379230; Scott D L, 1994, Adv Inorg Biochem, V10, P139; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Sharkawy A, 2002, CLIN INFECT DIS, V34, P454, DOI 10.1086/338466; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; Soragni E, 2001, EMBO J, V20, P5079, DOI 10.1093/emboj/20.18.5079; Steiner RA, 2001, ACTA CRYSTALLOGR D, V57, P516, DOI 10.1107/S0907444901002530; Sugiyama M, 2002, J BIOL CHEM, V277, P20051, DOI 10.1074/jbc.M200264200; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787	36	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45909	45918		10.1074/jbc.M405434200	http://dx.doi.org/10.1074/jbc.M405434200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15304506	hybrid			2022-12-25	WOS:000224694900075
J	Bhalla, S; Ozalp, C; Fang, SS; Xiang, LJ; Kemper, K				Bhalla, S; Ozalp, C; Fang, SS; Xiang, LJ; Kemper, K			Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1 alpha - Functional implications in hepatic cholesterol and glucose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; NEGATIVE FEEDBACK-REGULATION; BILE-ACID HOMEOSTASIS; GAMMA COACTIVATOR-1-ALPHA; GENE-EXPRESSION; TRANSCRIPTIONAL COACTIVATOR; 1-ALPHA PGC-1-ALPHA; FACTOR 4-ALPHA; GLUCONEOGENESIS	Previous studies show that feedback inhibition of bile acid production by bile acids is mediated by multiple mechanisms, including activation of pregnane X receptor (PXR). Consistent with these studies, the antibiotic rifampicin, a ligand for human PXR, reduces hepatic bile acid levels in cholestasis patients. To delineate the mechanisms underlying PXR-mediated suppression of bile acid biosynthesis, we examined the functional cross-talk between human PXR and HNF-4, a key hepatic activator of genes involved in bile acid biosynthesis including the cholesterol 7-alpha hydroxylase (CYP7A1) and sterol 12-alpha hydroxylase (CYP8B1) genes. Treatment with rifampicin resulted in repression of endogenous human CYP7A1 expression in HepG2 cells that was reversed by PXR small interfering RNA. The coactivator PGC-1 enhanced transcriptional activity of HNF-4, and this enhancement was suppressed by rifampicin-activated PXR. Endogenous PGC-1 from mouse liver extracts bound to PXR, and recombinant PGC-1 directly interacted with both PXR and HNF-4 in vitro. Rifampicin-dependent interaction of PXR with PGC-1 was shown in cells by coimmunoprecipitation, and intranuclear localization studies using confocal microscopy provided further evidence for this interaction. In chromatin immunoprecipitation studies, rifampicin treatment did not inhibit HNF-4 binding to the native promoters of CYP7A1 and CYP8B1 but resulted in dissociation of PGC-1 and concomitant gene repression. Most interestingly, these rifampicin effects were also observed in the phosphoenolpyruvate carboxykinase gene that contains a functional HNF-4-binding site and is central to hepatic gluconeogenesis. Our study suggests that ligand-activated PXR interferes with HNF-4 signaling by targeting the common coactivator PGC-1, which underlies physiologically relevant inhibitory cross-talk between drug metabolism and cholesterol/glucose metabolism.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Kemper, K (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.	jongsook@uiuc.edu	Özalp, Veli/B-2940-2009	Özalp, Veli/0000-0002-7659-5990				Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Goodwin B, 2003, P NATL ACAD SCI USA, V100, P223, DOI 10.1073/pnas.0237082100; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Herzog B, 2004, MOL ENDOCRINOL, V18, P807, DOI 10.1210/mg.2003-0384; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Hofmann AF, 2002, GUT, V51, P756, DOI 10.1136/gut.51.5.756; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Kawana K, 2003, MOL PHARMACOL, V63, P524, DOI 10.1124/mol.63.3.524; Kemper JK, 2004, MOL CELL BIOL, V24, P7707, DOI 10.1128/MCB.24.17.7707-7719.2004; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 2002, J LIPID RES, V43, P359; Ktistaki E, 1997, SCIENCE, V277, P109, DOI 10.1126/science.277.5322.109; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Min GS, 2002, J BIOL CHEM, V277, P34626, DOI 10.1074/jbc.M205239200; Min GS, 2002, J BIOL CHEM, V277, P26356, DOI 10.1074/jbc.M200051200; Monsalve M, 2000, MOL CELL, V6, P307, DOI 10.1016/S1097-2765(00)00031-9; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiraki T, 2003, J BIOL CHEM, V278, P11344, DOI 10.1074/jbc.M212859200; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Tirona RG, 2003, NAT MED, V9, P220, DOI 10.1038/nm815; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104	48	180	189	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45139	45147		10.1074/jbc.M405423200	http://dx.doi.org/10.1074/jbc.M405423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322103	hybrid			2022-12-25	WOS:000224505600107
J	Kanei-Ishii, C; Nomura, T; Tanikawa, J; Ichikawa-Iwata, E; Ishii, S				Kanei-Ishii, C; Nomura, T; Tanikawa, J; Ichikawa-Iwata, E; Ishii, S			Differential sensitivity of v-Myb and c-Myb to Wnt-1-induced protein degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC ACTIVATION; TERMINAL TRUNCATION; CELLULAR PROGENITOR; GENE; TRANSFORMATION; CELLS; PROTOONCOGENE; APOPTOSIS	Recently we have shown that the c-myb proto-oncogene product (c-Myb) is degraded in response to Wnt-1 signaling via the pathway involving TAK1 ( transforming growth factor-beta-activated kinase), HIPK2 (homeodomain-interacting protein kinase 2), and NLK (Nemo-like kinase). NLK and HIPK2 bind directly to c-Myb, which results in the phosphorylation of c-Myb at multiple sites, followed by its ubiquitination and proteasome-dependent degradation. The v-myb gene carried by avian myeloblastosis virus has a transforming capacity, but the c- myb proto-oncogene does not. Here, we report that two characteristics of v-Myb make it relatively resistant to Wnt-1-induced protein degradation. First, HIPK2 binds with a lower affinity to the DNA-binding domain of v-Myb than to that of c-Myb. The mutations of three hydrophobic amino acids on the surface of the DNA-binding domain in v-Myb decrease the affinity to HIPK2. Second, a loss of multiple NLK phosphorylation sites by truncation of the C-terminal region of c- Myb increases its stability. Among 15 putative NLK phosphorylation sites in mouse c- Myb, the phosphorylation sites in the C-terminal region are more critical than other sites for Wnt-1-induced protein degradation. The relative resistance of v-Myb to Wnt-1-induced degradation may explain, at least in part, the differential transforming capacity of v-Myb versus c- Myb.	RIKEN Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Ishii, S (corresponding author), RIKEN Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Kanei-Ishii C, 2004, GENE DEV, V18, P816, DOI 10.1101/gad.1170604; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Nomura T, 2004, J BIOL CHEM, V279, P16715, DOI 10.1074/jbc.M313069200; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	32	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44582	44589		10.1074/jbc.M407831200	http://dx.doi.org/10.1074/jbc.M407831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308626	hybrid			2022-12-25	WOS:000224505600043
J	Liang, JJ; Oelkers, P; Guo, CY; Chu, PC; Dixon, JL; Ginsberg, HN; Sturley, SL				Liang, JJ; Oelkers, P; Guo, CY; Chu, PC; Dixon, JL; Ginsberg, HN; Sturley, SL			Overexpression of human diacylglycerol acyltransferase 1, Acyl-CoA : cholesterol acyltransferase 1, or Acyl-CoA : cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE APO-B; HEP G2 CELLS; INTRACELLULAR DEGRADATION; HUMAN LIVER; INHIBITION; COENZYME; DECREASES; ACAT; EXPRESSION; VLDL	The relative importance of each core lipid in the assembly and secretion of very low density lipoproteins ( VLDL) has been of interest over the past decade. The isolation of genes encoding diacylglycerol acyltransferase (DGAT) and acyl-CoA: cholesterol acyltransferases ( ACAT1 and ACAT2) provided the opportunity to investigate the effects of isolated increases in triglycerides (TG) or cholesteryl esters (CE) on apolipoprotein B ( apoB) lipoprotein biogenesis. Overexpression of human DGAT1 in rat hepatoma McA-RH7777 cells resulted in increased synthesis, cellular accumulation, and secretion of TG. These effects were associated with decreased intracellular degradation and increased secretion of newly synthesized apoB as VLDL. Similarly, overexpression of human ACAT1 or ACAT2 in McA-RH7777 cells resulted in increased synthesis, cellular accumulation, and secretion of CE. This led to decreased intracellular degradation and increased secretion of VLDL apoB. Overexpression of ACAT2 had a significantly greater impact upon assembly and secretion of VLDL from liver cells than did overexpression of ACAT1. The addition of oleic acid (OA) to media resulted in a further increase in VLDL secretion from cells expressing DGAT1, ACAT1, or ACAT2. VLDL secreted from DGAT1-expressing cells incubated in OA had a higher TG: CE ratio than VLDL secreted from ACAT1- and ACAT2-expressing cells treated with OA. These studies indicate that increasing DGAT1, ACAT1, or ACAT2 expression in McA-RH7777 cells stimulates the assembly and secretion of VLDL from liver cells and that the core composition of the secreted VLDL reflects the enzymatic activity that is elevated.	Columbia Univ, Dept Med, Med Ctr, New York, NY 10032 USA; Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10032 USA; Columbia Univ, Inst Human Nutr, Med Ctr, New York, NY 10032 USA; Univ Missouri, Dalton Cardiovasc Res Ctr, Columbia, MO USA	Columbia University; Columbia University; Columbia University; University of Missouri System; University of Missouri Columbia	Ginsberg, HN (corresponding author), Columbia Univ, Dept Med, Med Ctr, 630 W 168th St, New York, NY 10032 USA.	hng1@columbia.edu; sls37@columbia.edu		Oelkers, Peter/0000-0002-2421-472X	NHLBI NIH HHS [T32HL07343, HL 55368, HL-47586] Funding Source: Medline; NIDDK NIH HHS [DK54320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047586, R01HL047586, T32HL007343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; ARAD Y, 1990, J LIPID RES, V31, P567; ARBEENY CM, 1992, J LIPID RES, V33, P843; Avramoglu RK, 1995, J LIPID RES, V36, P2513; Azuma Y, 1999, JPN J PHARMACOL, V79, P151, DOI 10.1254/jjp.79.151; Benoist F, 1996, ARTERIOSCL THROM VAS, V16, P1229, DOI 10.1161/01.ATV.16.10.1229; BOREN J, 1994, J BIOL CHEM, V269, P25879; Borradaile NM, 2002, J LIPID RES, V43, P1544, DOI 10.1194/jlr.M200115-JLR200; Bouvier-Nave P, 2000, EUR J BIOCHEM, V267, P85, DOI 10.1046/j.1432-1327.2000.00961.x; Buhman KF, 2000, BBA-MOL CELL BIOL L, V1529, P142, DOI 10.1016/S1388-1981(00)00144-X; Buhman KK, 2000, NAT MED, V6, P1341, DOI 10.1038/82153; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Burnett JR, 1999, CLIN CHIM ACTA, V286, P231, DOI 10.1016/S0009-8981(99)00104-7; Burnett JR, 1997, ARTERIOSCL THROM VAS, V17, P2589, DOI 10.1161/01.ATV.17.11.2589; Burnett JR, 1998, BBA-LIPID LIPID MET, V1393, P63, DOI 10.1016/S0005-2760(98)00059-9; Burnett JR, 1999, J LIPID RES, V40, P1317; CARR TP, 1995, J LIPID RES, V36, P25; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chang CCY, 2000, J BIOL CHEM, V275, P28083; Chang TY, 2001, J LIPID RES, V42, P1933; Chen HC, 2002, J CLIN INVEST, V109, P175, DOI 10.1172/JCI0213880; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; GINSBERG HN, 1994, MED CLIN N AM, V78, P1; Graham A, 1996, BBA-LIPID LIPID MET, V1302, P46, DOI 10.1016/0005-2760(96)00030-6; Homan R, 1998, J CHROMATOGR B, V708, P21, DOI 10.1016/S0378-4347(97)00651-8; Joyce CW, 2000, MOL BIOL CELL, V11, P3675, DOI 10.1091/mbc.11.11.3675; Khelef N, 1998, J BIOL CHEM, V273, P11218, DOI 10.1074/jbc.273.18.11218; Lee O, 1998, J LIPID RES, V39, P1722; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Musanti R, 1996, J LIPID RES, V37, P1; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; Olofsson SO, 2000, TRENDS CARDIOVAS MED, V10, P338, DOI 10.1016/S1050-1738(01)00071-8; Ooyen C, 1997, ATHEROSCLEROSIS, V130, P143, DOI 10.1016/S0021-9150(96)06060-1; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; Seo T, 2001, BIOCHEMISTRY-US, V40, P4756, DOI 10.1021/bi0022947; SLAYBACK JRB, 1977, ANAL BIOCHEM, V83, P372, DOI 10.1016/0003-2697(77)90046-X; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Spady DK, 2000, J BIOL CHEM, V275, P27005; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Taghibiglou C, 2002, BIOCHEM PHARMACOL, V63, P349, DOI 10.1016/S0006-2952(01)00918-2; TANAKA M, 1993, J BIOL CHEM, V268, P12713; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; Wilcox LJ, 2001, J LIPID RES, V42, P725; Willner EL, 2003, P NATL ACAD SCI USA, V100, P1262, DOI 10.1073/pnas.0336398100; WU XJ, 1994, J LIPID RES, V35, P1200; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yao ZM, 1997, J LIPID RES, V38, P1937; Zhang ZJ, 1999, ARTERIOSCL THROM VAS, V19, P743, DOI 10.1161/01.ATV.19.3.743; Zhu DM, 2002, ATHEROSCLEROSIS, V164, P221, DOI 10.1016/S0021-9150(02)00060-6	62	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44938	44944		10.1074/jbc.M408507200	http://dx.doi.org/10.1074/jbc.M408507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15308631	hybrid			2022-12-25	WOS:000224505600085
J	Regelsberger, G; Laaha, U; Dietmann, D; Ruker, F; Canini, A; Grilli-Caiola, M; Furtmuller, PG; Jakopitsch, C; Peschek, GA; Obinger, C				Regelsberger, G; Laaha, U; Dietmann, D; Ruker, F; Canini, A; Grilli-Caiola, M; Furtmuller, PG; Jakopitsch, C; Peschek, GA; Obinger, C			The iron superoxide dismutase from the filamentous cyanobacterium Nostoc PCC 7120 - Localization, overexpression, and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION STRUCTURE; WATER-WATER CYCLE; BLUE-GREEN-ALGA; NITROGEN-FIXATION; PURIFICATION; MANGANESE; PROTEINS; HETEROCYSTS; MEMBRANES; OXIDASE	The nitrogen-fixing filamentous cyanobacterium Nostoc PCC 7120 (formerly named Anabaena PCC 7120) possesses two genes for superoxide dismutase, a unique membrane-associated manganese superoxide dismutase (MnSOD) and a soluble iron superoxide dismutase (FeSOD). A phylogenetic analysis of FeSODs shows that cyanobacterial enzymes form a well separated cluster with filamentous species found in one subcluster and unicellular species in the other. Activity staining, inhibition patterns, and immunogold labeling show that FeSOD is localized in the cytosol of vegetative cells and heterocysts (nitrogenase containing specialized cells formed during nitrogen-limiting conditions). The recombinant Nostoc FeSOD is a homodimeric, acidic enzyme exhibiting the characteristic iron peak at 350 nm in its ferric state, an almost 100% occupancy of iron per subunit, a specific activity using the ferricytochrome assay of (2040 +/- 90) units mg(-1) at pH 7.8, and a dissociation constant K-d of the azide-FeSOD complex of 2.1 mM. Using stopped flow spectroscopy it was shown that the decay of superoxide in the presence of various FeSOD concentrations is first-order in enzyme concentration allowing the calculation of the catalytic rate constants, which increase with decreasing pH: 5.3 x 10(9) M-1 s(-1) (pH 7) to 4.8 x 10(6) M-1 s(-1) (pH 10). FeSOD and MnSOD complement each other to keep the superoxide level low in Nostoc PCC 7120, which is discussed with respect to the fact that Nostoc PCC 7120 exhibits oxygenic photosynthesis and oxygen-dependent respiration within a single prokaryotic cell and also has the ability to form differentiated cells under nitrogen-limiting conditions.	Univ Nat Resources & Appl Life Sci, BOKU, Metalloprot Res Grp,Div Biochem, Dept Chem, A-1190 Vienna, Austria; Univ Nat Resources & Appl Life Sci, BOKU, Dept Biotechnol, A-1190 Vienna, Austria; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Vienna, Mol Bioenerget Grp, Inst Phys Chem, A-1090 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Rome Tor Vergata; University of Vienna	Obinger, C (corresponding author), Univ Nat Resources & Appl Life Sci, BOKU, Metalloprot Res Grp,Div Biochem, Dept Chem, Muthgasse 18, A-1190 Vienna, Austria.	christian.obinger@boku.ac.at	Obinger, Christian/AAV-3173-2021; Furtmüller, Paul G./Y-5819-2018	Furtmüller, Paul G./0000-0002-1199-2469; Obinger, Christian/0000-0002-7133-3430; Canini, Antonella/0000-0003-1132-8899; Regelsberger, Gunther/0000-0002-3233-1491; Rueker, Florian/0000-0001-7639-2686; Jakopitsch, Christa/0000-0002-5855-2057				ASADA K, 1975, J BIOL CHEM, V250, P2801; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Asada K, 2000, PHILOS T ROY SOC B, V355, P1419, DOI 10.1098/rstb.2000.0703; Atzenhofer W, 2002, J MOL BIOL, V321, P479, DOI 10.1016/S0022-2836(02)00624-1; BAGCHI SN, 1991, Z NATURFORSCH C, V46, P407; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; Berman-Frank I, 2001, SCIENCE, V294, P1534, DOI 10.1126/science.1064082; BEYER WF, 1987, BIOCHEMISTRY-US, V26, P1251, DOI 10.1021/bi00379a008; Bohme H, 1998, TRENDS PLANT SCI, V3, P346, DOI 10.1016/S1360-1385(98)01290-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULL C, 1985, J AM CHEM SOC, V107, P3295, DOI 10.1021/ja00297a040; CAMPBELL WS, 1995, J BACTERIOL, V177, P964, DOI 10.1128/jb.177.4.964-972.1995; CANINI A, 1992, PLANTA, V187, P438, DOI 10.1007/BF00199961; Chadd HE, 1996, FEMS MICROBIOL LETT, V138, P161, DOI 10.1111/j.1574-6968.1996.tb08150.x; FAY P, 1992, MICROBIOL REV, V56, P340, DOI 10.1128/MMBR.56.2.340-373.1992; FEE JA, 1986, J BIOL CHEM, V261, P3000; Flint DH, 1996, CHEM REV, V96, P2315, DOI 10.1021/cr950041r; GALLAGHER SR, 1995, CURRENT PROTOCOLS PR; Golden JW, 1998, CURR OPIN MICROBIOL, V1, P623, DOI 10.1016/S1369-5274(98)80106-9; HENRY LEA, 1978, BIOCHEM J, V174, P373, DOI 10.1042/bj1740373; Hunsucker SW, 2004, BIOCHEM BIOPH RES CO, V317, P1121, DOI 10.1016/j.bbrc.2004.03.173; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kerfeld CA, 2003, J BIOL INORG CHEM, V8, P707, DOI 10.1007/s00775-003-0469-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li T, 2002, J BACTERIOL, V184, P5096, DOI 10.1128/JB.184.18.5096-5103.2002; Maunsbach AB, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P249; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MILLER AF, 2001, HDB METALLOPROTEINS, V2, P668; Miyake C, 2003, ADV PHOTO RESPIRAT, V14, P183; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; OKADA S, 1979, FEBS LETT, V103, P106, DOI 10.1016/0014-5793(79)81260-0; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Peschek GA, 2004, PHYSIOL PLANTARUM, V120, P358, DOI 10.1111/j.1399-3054.2004.00274.x; PESCHEK GA, 1989, BIOCHEMISTRY-US, V28, P3057, DOI 10.1021/bi00433a048; Regelsberger G, 2002, J BIOL CHEM, V277, P43615, DOI 10.1074/jbc.M207691200; Regelsberger G, 2002, PLANT PHYSIOL BIOCH, V40, P479, DOI 10.1016/S0981-9428(02)01405-5; RILEY DP, 1991, ANAL BIOCHEM, V196, P344, DOI 10.1016/0003-2697(91)90476-A; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLYKHOUSE TO, 1976, J BIOL CHEM, V251, P5472; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vargas MA, 1998, J PHYCOL, V34, P812, DOI 10.1046/j.1529-8817.1998.340812.x; WALSBY A E, 1985, Proceedings of the Royal Society of London Series B Biological Sciences, V226, P345, DOI 10.1098/rspb.1985.0099; WASTYN M, 1988, BIOCHIM BIOPHYS ACTA, V935, P217, DOI 10.1016/0005-2728(88)90218-6; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Youn HD, 1996, BIOCHEM J, V318, P889, DOI 10.1042/bj3180889	46	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44384	44393		10.1074/jbc.M406254200	http://dx.doi.org/10.1074/jbc.M406254200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15302891	hybrid			2022-12-25	WOS:000224505600021
J	Hibino, H; Fujita, A; Iwai, K; Yamada, M; Kurachi, Y				Hibino, H; Fujita, A; Iwai, K; Yamada, M; Kurachi, Y			Differential assembly of inwardly rectifying K+ channel subunits, Kir4.1 and Kir5.1, in brain astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPACE SURROUNDING PHOTORECEPTORS; LIGHT-DEPENDENT HYDRATION; POTASSIUM CHANNEL; EXTRACELLULAR-SPACE; GLIAL-CELLS; BASOLATERAL MEMBRANE; GLYCOPROTEIN COMPLEX; ALPHA-SYNTROPHIN; WATER TRANSPORT; K-AB-2 KIR4.1	The inwardly rectifying K+ channel subunit Kir5.1 is expressed abundantly in the brain, but its precise distribution and function are still largely unknown. Because Kir5.1 is co-expressed with Kir4.1 in retinal glial Muller cells, we have compared the biochemical and immunological properties of Kir5.1 and Kir4.1 in the mouse brain. Immunoprecipitation experiments suggested that brain expressed at least two subsets of Kir channels, heteromeric Kir4.1/5.1 and homomeric Kir4.1. Immunolabeling using specific antibodies showed that channels comprising Kir4.1 and Kir5.1 subunits were assembled in a region-specific fashion. Heteromeric Kir4.1/5.1 was identified in the neocortex and in the glomeruli of the olfactory bulb. Homomeric Kir4.1 was confined to the hippocampus and the thalamus. Homomeric Kir5.1 was not identified. Kir4.1/5.1 and Kir4.1 expression appeared to occur only in astrocytes, specifically in the membrane domains facing the pia mater and blood vessels or in the processes surrounding synapses. Both Kir4.1/5.1 and Kir4.1 could be associated with PDZ domain-containing syntrophins, which might be involved in the subcellular targeting of these astrocyte Kir channels. Because heteromeric Kir4.1/5.1 and homomeric Kir4.1 have distinct ion channel properties (Tanemoto, M., Kittaka, N., Inanobe, A., and Kurachi, Y. (2000) J. Physiol. (Lond.) 525, 587-592 and Tucker, S. J., Imbrici, P., Salvatore, L., D'Adamo, M. C., and Pessia, M. (2000) J. Biol. Chem. 275, 16404-16407), it is plausible that these channels play differential physiological roles in the K+-buffering action of brain astrocytes in a region-specific manner.	Osaka Univ, Grad Sch Med, Dept Pharmacol 2, Suita, Osaka 5650871, Japan; Osaka Prefecture Univ, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Osaka 5998531, Japan	Osaka University; Osaka Metropolitan University	Kurachi, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Pharmacol 2, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	ykurachi@pharma2.med.osaka-u.ac.jp						Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Anderson CM, 2000, GLIA, V32, P1; Blaustein MP, 2002, ANN NY ACAD SCI, V976, P356; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; Boussouf A, 1997, GLIA, V19, P74, DOI 10.1002/(SICI)1098-1136(199701)19:1<74::AID-GLIA8>3.0.CO;2-A; Claudepierre T, 2000, J CELL SCI, V113, P3409; Connors NC, 2004, J BIOL CHEM, V279, P28387, DOI 10.1074/jbc.M402604200; Connors NC, 2002, J NEUROSCI, V22, P4321, DOI 10.1523/JNEUROSCI.22-11-04321.2002; Derst C, 2001, FEBS LETT, V491, P305, DOI 10.1016/S0014-5793(01)02202-5; DIETZEL I, 1980, EXP BRAIN RES, V40, P432; DOUGLAS R, 1998, NEOCORTEX SYNAPTIC O, P459; Giffard RG, 2000, J NEUROSCI, V20, P1001, DOI 10.1523/JNEUROSCI.20-03-01001.2000; Gosset P, 1997, GENOMICS, V44, P237, DOI 10.1006/geno.1997.4865; Guadagno E, 2004, GLIA, V47, P138, DOI 10.1002/glia.20039; Hibino H, 1997, J NEUROSCI, V17, P4711; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; Hibino H, 2004, EUR J NEUROSCI, V19, P76, DOI 10.1111/j.1460-9568.2004.03092.x; Hibino H, 2003, P NATL ACAD SCI USA, V100, P307, DOI 10.1073/pnas.0136791100; Hibino H, 2000, EMBO J, V19, P78, DOI 10.1093/emboj/19.1.78; Higashi K, 2001, AM J PHYSIOL-CELL PH, V281, pC922, DOI 10.1152/ajpcell.2001.281.3.C922; Holthoff K, 1996, J NEUROSCI, V16, P2740, DOI 10.1523/jneurosci.16-08-02740.1996; Horio Y, 1997, J BIOL CHEM, V272, P12885, DOI 10.1074/jbc.272.20.12885; Ishii M, 1997, J NEUROSCI, V17, P7725; Ishii M, 2003, AM J PHYSIOL-CELL PH, V285, pC260, DOI 10.1152/ajpcell.00560.2002; Ito M, 1996, FEBS LETT, V388, P11, DOI 10.1016/0014-5793(96)00502-9; Konstas AA, 2003, AM J PHYSIOL-CELL PH, V284, pC910, DOI 10.1152/ajpcell.00479.2002; Kuffer S. W., 1966, Ergebnisse der Physiologie, V57, P1; LI JD, 1994, VISUAL NEUROSCI, V11, P743, DOI 10.1017/S0952523800003047; LI JD, 1994, INVEST OPHTH VIS SCI, V35, P2700; Li LY, 2001, GLIA, V33, P57, DOI 10.1002/1098-1136(20010101)33:1<57::AID-GLIA1006>3.0.CO;2-0; Lourdel S, 2002, J PHYSIOL-LONDON, V538, P391, DOI 10.1113/jphysiol.2001.012961; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; Moukhles H, 2001, J NEUROCHEM, V78, P824, DOI 10.1046/j.1471-4159.2001.00466.x; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; NEGOESCU A, 1994, J HISTOCHEM CYTOCHEM, V42, P433, DOI 10.1177/42.3.7508473; NETTER FH, 1983, CIBA COLLECTION MED, P131; Newman EA, 1999, GLIA, V26, P302, DOI 10.1002/(SICI)1098-1136(199906)26:4<302::AID-GLIA4>3.0.CO;2-A; NEWMAN EA, 1984, NATURE, V309, P155, DOI 10.1038/309155a0; Newman EA, 1996, J NEUROSCI, V16, P159; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; Pearson WL, 1999, J PHYSIOL-LONDON, V514, P639, DOI 10.1111/j.1469-7793.1999.639ad.x; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; Poopalasundaram S, 2000, GLIA, V30, P362, DOI 10.1002/(SICI)1098-1136(200006)30:4<362::AID-GLIA50>3.0.CO;2-4; RANSOM BR, 1985, J NEUROSCI, V5, P532; Schmitt BM, 2000, J NEUROSCI, V20, P6839, DOI 10.1523/JNEUROSCI.20-18-06839.2000; SHEPHERD GM, 1998, OLFACTORY BULB, P159; Shuck ME, 1997, J BIOL CHEM, V272, P586; SVOBODA J, 1991, BRAIN RES, V560, P216, DOI 10.1016/0006-8993(91)91235-S; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; Tanemoto M, 2002, NEURON, V34, P387, DOI 10.1016/S0896-6273(02)00675-X; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; Tucker SJ, 2000, J BIOL CHEM, V275, P16404, DOI 10.1074/jbc.C000127200; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Yang ZJ, 2000, J GEN PHYSIOL, V116, P33, DOI 10.1085/jgp.116.1.33; Zaccaria ML, 2001, NEUROSCIENCE, V104, P311, DOI 10.1016/S0306-4522(01)00092-6	58	128	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					44065	44073		10.1074/jbc.M405985200	http://dx.doi.org/10.1074/jbc.M405985200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15310750	hybrid			2022-12-25	WOS:000224383100086
J	Chang, WZ; Rewari, A; Centrella, M; McCarthy, TL				Chang, WZ; Rewari, A; Centrella, M; McCarthy, TL			Fos-related antigen 2 controls protein kinase A-induced CCAAT/enhancer-binding protein beta expression in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT BONE; GROWTH-FACTOR-BETA; DELTA-GENE-EXPRESSION; JUN-RELATED GENES; TRANSCRIPTION FACTOR; C/EBP-BETA; CELL-CULTURES; DEOXYRIBONUCLEIC-ACID; SIGNAL-TRANSDUCTION; COLLAGEN-SYNTHESIS	Transcription factor CCAAT/enhancer-binding protein beta (C/EBPbeta) plays an important role in hormone-dependent gene expression. In osteoblasts C/EBPbeta can increase insulin-like growth factor I (IGF-I) transcription following treatment with hormones that activate protein kinase A, but little is known as yet about the expression of C/EBPbeta itself in these cells. We initially showed that prostaglandin E-2 (PGE(2)) rapidly enhances C/EBPbeta mRNA and protein expression, and in this study we identified a 3'-proximal region of the C/EBPbeta promoter containing a 541-bp upstream sequence that could account for this effect. PGE(2)-dependent activation of C/EBPbeta was blocked by expression of a mutated regulatory subunit of protein kinase A or by mutation of two previously identified cAMP-sensitive cis-acting regulatory elements within the promoter between bp -111 and -61. Nuclear protein binding to these elements was induced by PGE(2), required new protein synthesis, and was sensitive to antibody to the transcription factor termed Fos-related antigen 2 (Fra-2). Fra-2 cDNA generated from rat osteoblasts by reverse transcriptase PCR was 95% homologous to human Fra-2, and PGE(2) rapidly induced Fra-2 mRNA and protein expression. Consistent with these findings, over-expression of Fra-2 significantly increased C/EBPbeta promoter activity in PGE(2)-induced osteoblasts, whereas expression of Fra-2 lacking its activation domain had a dominant negative inhibitory effect. Together, these results reveal a significant, hormone-dependent role for Fra-2 in osteoblast function, both directly, through its ability to increase new C/EBPbeta gene expression, and indirectly, through downstream C/EBP sensitive genes.	Yale Univ, Sch Med, Dept Surg, Sect Plast Surg, New Haven, CT 06520 USA	Yale University	McCarthy, TL (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Plast Surg, POB 208041, New Haven, CT 06520 USA.	thomas.mccarthy@yale.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039201, R01AR039201] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056310] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39201] Funding Source: Medline; NIDDK NIH HHS [DK56310] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; Buck M, 2003, HEPATOLOGY, V37, P731, DOI 10.1053/jhep.2003.50155; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Carpenter TO, 1998, ENDOCRINOLOGY, V139, P35, DOI 10.1210/en.139.1.35; CARRASCO D, 1995, ONCOGENE, V10, P1069; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; Centrella M, 1996, ANN NY ACAD SCI, V785, P224, DOI 10.1111/j.1749-6632.1996.tb56267.x; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; Franceschi RT, 2003, CONNECT TISSUE RES, V44, P109, DOI 10.1080/03008200390152188; Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; Granet C, 2002, CELL SIGNAL, V14, P679, DOI 10.1016/S0898-6568(02)00008-6; GRUDA MC, 1994, ONCOGENE, V9, P2537; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Harrison JR, 2000, J BONE MINER RES, V15, P1138, DOI 10.1359/jbmr.2000.15.6.1138; Ji CH, 1999, ENDOCRINOLOGY, V140, P4564, DOI 10.1210/en.140.10.4564; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Ji CH, 2003, MOL ENDOCRINOL, V17, P1834, DOI 10.1210/me.2002-0235; Ji CH, 1998, J CELL BIOCHEM, V69, P353, DOI 10.1002/(SICI)1097-4644(19980601)69:3<353::AID-JCB12>3.3.CO;2-W; Karsenty G, 2000, SEMIN CELL DEV BIOL, V11, P343, DOI 10.1006/scdb.2000.0188; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lewinson D, 2003, J HISTOCHEM CYTOCHEM, V51, P1161, DOI 10.1177/002215540305100906; MCCABE LR, 1995, EXP CELL RES, V218, P255, DOI 10.1006/excr.1995.1154; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCarthy TL, 2000, ENDOCRINOLOGY, V141, P127, DOI 10.1210/en.141.1.127; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; McCarthy TL, 2000, J BIOL CHEM, V275, P21746, DOI 10.1074/jbc.M002291200; McCarthy TL, 2003, J BIOL CHEM, V278, P43121, DOI 10.1074/jbc.M306531200; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SCHILLING AF, 2003, J BONE MIN RES S2, V18, pS3; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Smith M, 2001, MOL CELL BIOL, V21, P3704, DOI 10.1128/MCB.21.11.3704-3713.2001; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Tanabe A, 2000, BIOL PHARM BULL, V23, P1424, DOI 10.1248/bpb.23.1424; Tierney EP, 2003, PHYSIOL GENOMICS, V16, P47, DOI 10.1152/physiolgenomics.00066.2003; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Varghese S, 2000, ENDOCRINOLOGY, V141, P2185, DOI 10.1210/en.141.6.2185; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yamada T, 1997, J BIOCHEM-TOKYO, V121, P731; Yamada T, 1998, BIOCHEM BIOPH RES CO, V242, P88, DOI 10.1006/bbrc.1997.7915; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A	61	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					42438	42444		10.1074/jbc.M405549200	http://dx.doi.org/10.1074/jbc.M405549200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15299028	hybrid			2022-12-25	WOS:000224226400014
J	Morelli, C; Garofalo, C; Sisci, D; del Rincon, S; Cascio, S; Tu, X; Vecchione, A; Sauter, ER; Miller, WH; Surmacz, E				Morelli, C; Garofalo, C; Sisci, D; del Rincon, S; Cascio, S; Tu, X; Vecchione, A; Sauter, ER; Miller, WH; Surmacz, E			Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters	ONCOGENE			English	Article						breast cancer; estrogen receptor alpha; nuclear insulin receptor substrate 1; insulin-like growth factor; estrogen-responsive elements	HUMAN BREAST-CANCER; FACTOR-I RECEPTOR; IRS-SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL-3-OH KINASE; CELL-LINE; T-ANTIGEN; IGF-I; GROWTH; EXPRESSION; TRANSLOCATION	Insulin receptor substrate 1 (IRS-1) is a major signaling molecule activated by the insulin and insulin-like growth factor I receptors. Recent data obtained in different cell models suggested that in addition to its conventional role as a cytoplasmic signal transducer, IRS-1 has a function in the nuclear compartment. However, the role of nuclear IRS-1 in breast cancer has never been addressed. Here we report that in estrogen receptor alpha (ERalpha)- positive MCF-7 cells, (1) a fraction of IRS-1 was translocated to the nucleus upon 17-beta-estradiol (E2) treatment; ( 2) E2-dependent nuclear translocation of IRS-1 was blocked with the antiestrogen ICI 182,780; ( 3) nuclear IRS-1 colocalized and co-precipitated with ERalpha; (4) the IRS-1: ERalpha complex was recruited to the E2-sensitive pS2 gene promoter. Notably, IRS-1 interaction with the pS2 promoter did not occur in ERalpha-negative MDA-MB-231 cells, but was observed in MDA-MB-231 cells retransfected with ERalpha. Transcription reporter assays with E2-sensitive promoters suggested that the presence of IRS-1 inhibits ERalpha activity at estrogen-responsive element-containing DNA. In summary, our data suggested that nuclear IRS-1 interacts with ERalpha and that this interaction might influence ERalpha transcriptional activity.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Postgrad Sch Clin Pathol, I-87036 Cosenza, Italy; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ, Canada; Univ Palermo, Dept Oncol, Sect Mol Oncol, Palermo, Italy; Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO 65212 USA	Jefferson University; University of Calabria; Lady Davis Institute; McGill University; University of Palermo; University of Missouri System; University of Missouri Columbia	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.	eva.surmacz@jefferson.edu	Garofalo, Cecilia/B-3834-2017; /AAD-9701-2019; Morelli, Catia/AAE-1886-2019	Garofalo, Cecilia/0000-0001-5334-8930; /0000-0001-6577-1541; Morelli, Catia/0000-0002-9407-0805; Cascio, Sandra/0000-0003-4234-0508; Vecchione, Andrea/0000-0002-5497-6856	NATIONAL CANCER INSTITUTE [R21CA087391] Funding Source: NIH RePORTER; NCI NIH HHS [CA87391] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando S, 1998, BIOCHEM BIOPH RES CO, V253, P315, DOI 10.1006/bbrc.1998.9330; Bartucci M, 2001, CANCER RES, V61, P6747; Boylan JM, 2002, ENDOCRINOLOGY, V143, P4178, DOI 10.1210/en.2002-220321; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Guvakova MA, 1997, CANCER RES, V57, P2606; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Maggiolini M, 2001, MOL PHARMACOL, V60, P595; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Morelli C, 2003, ONCOGENE, V22, P4007, DOI 10.1038/sj.onc.1206436; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Salerno M, 1999, INT J CANCER, V81, P299; Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F; Sciacca L, 2003, ENDOCRINOLOGY, V144, P2650, DOI 10.1210/en.2002-0136; Seol KC, 2003, BIOCHEM BIOPH RES CO, V306, P898, DOI 10.1016/S0006-291X(03)01046-5; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Sun HZ, 2003, MOL ENDOCRINOL, V17, P472, DOI 10.1210/me.2002-0276; Sun M, 2001, CANCER RES, V61, P5985; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Tu X, 2002, J BIOL CHEM, V277, P44357, DOI 10.1074/jbc.M208001200; Vladusic EA, 2000, ONCOL REP, V7, P157; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	34	75	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7517	7526		10.1038/sj.onc.1208014	http://dx.doi.org/10.1038/sj.onc.1208014			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15318176				2022-12-25	WOS:000224176500008
J	Sengupta, S; Kiziltepe, T; Sasisekharan, R				Sengupta, S; Kiziltepe, T; Sasisekharan, R			A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules	FASEB JOURNAL			English	Article						angiogenesis; tumor model; growth factors; extracellular matrix	GROWTH FACTOR/SCATTER FACTOR; ENDOTHELIAL-CELLS; HEPARAN-SULFATE; REGULATORY ROLE; TUMOR-GROWTH; IN-VITRO; ANGIOGENESIS; CANCER; DIFFERENTIATION; COCULTURE	We have developed a simple yet sensitive dual color fluorescence-based technique for dissecting the tumor-neovascularization relationship and evaluated the susceptibility of each component to therapeutic interventions. Green fluorescent protein (GFP)-expressing melanoma cells were cocultured with endothelial cells on different three-dimensional (3-D) matrices and exposed to multiple growth factors and molecules with established anti-angiogenic or anticancer activities. Cells were fixed and stained with propidium iodide, imaged using a confocal microscope, and stereologically analyzed. Three-dimensionality of the system was tested by depth-coding and pseudocolor 3-D reconstruction in the z-axis. Selective ablation of the tumor cells was affected by the anthracycline antibiotic doxorubicin. Treatment with vascular endothelial growth factor ( VEGF) and hepatocyte growth factor (HGF) promoted the neovascular responses on matrigel and collagen-1 matrices. VEGF-induced angiogenesis was inhibited after treatment with combretastatin and thalidomide. In contrast, HGF exerted a protective effect against these antiangiogenics in a matrigel matrix. However, this effect was lost when the matrix was substituted with collagen, suggesting that the extracellular matrix impinges on cellular function, possibly through an Akt-mediated mechanism. The VEGF-receptor antagonist PTK787 also selectively ablated the VEGF-induced angiogenic effect without inhibiting the HGF-induced response, demonstrating the sensitivity of the system to detect modulation of distinct signal cascades. The current model encompasses the possibility of studying tumor-angiogenesis- matrix interaction on the same platform, expanding the rapid screening of novel molecules in a simulated clinicopathological setting.	MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Biol Engn Div, 16-560,77 Massachusetts Ave, Cambridge, MA 02139 USA.	rams@MIT.edu						Dutt K, 2003, TISSUE ENG, V9, P893, DOI 10.1089/107632703322495547; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; Griffioen AW, 2000, PHARMACOL REV, V52, P237; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; Johnson NA, 2004, FASEB J, V18, P188, DOI 10.1096/fj.03-0097fje; Khodarev NN, 2003, J CELL SCI, V116, P1013, DOI 10.1242/jcs.00281; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Longo N, 2001, BLOOD, V98, P3717, DOI 10.1182/blood.V98.13.3717; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Masiero L, 1997, Angiogenesis, V1, P23, DOI 10.1023/A:1018301031580; NEHLS V, 1995, HISTOCHEM CELL BIOL, V104, P459, DOI 10.1007/BF01464336; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Sengupta S, 2003, CANCER RES, V63, P8351; Sengupta S, 2003, CIRCULATION, V107, P2955, DOI 10.1161/01.CIR.0000077501.19266.E5; Sengupta S, 2003, BRIT J PHARMACOL, V139, P219, DOI 10.1038/sj.bjp.0705216; Sengupta S, 2003, ARTERIOSCL THROM VAS, V23, P69, DOI 10.1161/01.ATV.0000048701.86621.D0; Shekhar MPV, 2001, CANCER RES, V61, P1320; St Croix B, 2000, SCIENCE, V289, P1197; Tozer GM, 2002, INT J EXP PATHOL, V83, P21, DOI 10.1046/j.1365-2613.2002.00211.x; Wood JM, 2000, CANCER RES, V60, P2178; Yu JL, 2002, DIFFERENTIATION, V70, P599, DOI 10.1046/j.1432-0436.2002.700913.x; 2003, ANGIOGENESIS INHIBIT	24	8	10	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1565	+		10.1096/fj.04-1934fje	http://dx.doi.org/10.1096/fj.04-1934fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15333517				2022-12-25	WOS:000223554900001
J	Li, P; Wohland, T; Ho, B; Ding, JL				Li, P; Wohland, T; Ho, B; Ding, JL			Perturbation of lipopolysaccharide (LPS) micelles by Sushi 3 (S3) antimicrobial peptide - The importance of an intermolecular disulfide bond in S3 dimer for binding, disruption, and neutralization of LPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; FACTOR-C; HORSESHOE-CRAB; MECHANISM; ENDOTOXIN; PROTEINS; REMOVAL	S3 peptide, derived from the Sushi 3 domain of Factor C, which is the lipopolysaccharide (LPS)-sensitive serine protease of the horseshoe crab coagulation cascade, was shown previously to harbor antimicrobial activity against Gram-negative bacteria. However, the mechanism of action remains poorly understood at the molecular level. Here we demonstrate that the intermolecular disulfide bonding of S3 resulting in S3 dimers is indispensable for its interaction with LPS. The binding properties of the S3 monomer and dimer to LPS were analyzed by several approaches including enzyme-linked immunosorbent assay (ELISA)-based assay, surface plasmon resonance, and fluorescence correlation spectroscopy (FCS). It is evident that the S3 dimer exhibits stronger binding to LPS, demonstrating 50% LPS-neutralizing capability at a concentration of 1 muM. Circular dichroism spectrometry revealed that the S3 peptide undergoes conformational change in the presence of a disulfide bridge, transitioning from a random coil to beta-sheet structure. Using a fluorescence correlation spectroscopy monitoring system, we describe a novel approach for examining the mechanism of peptide interaction with LPS in the native environment. The strategy shows that intermolecular disulfide bonding of S3 into dimers plays a critical role in its propensity to disrupt LPS micelles and consequently neutralize LPS activity. S3 dimers display detergent-like properties in disrupting LPS micelles. Considering intermolecular disulfide bonds as an important parameter in the structure-activity relationship, this insight provides clues for the future design of improved LPS-binding and - neutralizing peptides.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Ding, JL (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14,Sci Dr 4, Singapore 117543, Singapore.	dbsdjl@nus.edu.sg	Wohland, Thorsten/H-8285-2012; Ding, Jeak/H-8057-2012; WOHLAND, THORSTEN/R-6404-2019	Wohland, Thorsten/0000-0002-0148-4321; 				Aurell CA, 1998, BIOCHEM BIOPH RES CO, V253, P119, DOI 10.1006/bbrc.1998.9773; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Breithaupt H, 1999, NAT BIOTECHNOL, V17, P1165, DOI 10.1038/70705; Ding Jeak L., 1995, Molecular Marine Biology and Biotechnology, V4, P90; Ding JL, 2001, J CHROMATOGR B, V759, P237, DOI 10.1016/S0378-4347(01)00227-4; DING JL, 1993, BIOCHIM BIOPHYS ACTA, V1202, P149, DOI 10.1016/0167-4838(93)90076-4; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; Frecer V, 2000, BBA-BIOMEMBRANES, V1466, P87, DOI 10.1016/S0005-2736(00)00174-7; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; Gidalevitz D, 2003, P NATL ACAD SCI USA, V100, P6302, DOI 10.1073/pnas.0934731100; HO B, 1983, Microbios Letters, V24, P81; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Krichevsky O, 2002, REP PROG PHYS, V65, P251, DOI 10.1088/0034-4885/65/2/203; Lai JR, 2002, BIOCHEMISTRY-US, V41, P12835, DOI 10.1021/bi026127d; Meseth U, 1999, BIOPHYS J, V76, P1619, DOI 10.1016/S0006-3495(99)77321-2; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Neumann L, 2002, CHEMBIOCHEM, V3, P993, DOI 10.1002/1439-7633(20021004)3:10<993::AID-CBIC993>3.0.CO;2-Y; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; Petsch D, 2000, J BIOTECHNOL, V76, P97, DOI 10.1016/S0168-1656(99)00185-6; Situ H, 2003, BIOCHEM J, V375, P175, DOI 10.1042/BJ20030779; Tam JP, 2002, J BIOL CHEM, V277, P50450, DOI 10.1074/jbc.M208429200; Tan NS, 2000, FASEB J, V14, P859, DOI 10.1096/fasebj.14.7.859; Tan NS, 2000, FASEB J, V14, P1801, DOI 10.1096/fj.99-0866com; Thomas CJ, 2001, J BIOL CHEM, V276, P35701, DOI 10.1074/jbc.M011319200; Wang J, 2002, J BIOL CHEM, V277, P36363, DOI 10.1074/jbc.M202837200; Wohland T, 1999, BIOCHEMISTRY-US, V38, P8671, DOI 10.1021/bi990366s; Wohland T, 2001, SPRINGER SERIES CHEM, V67, P195; Wohland T, 2001, BIOPHYS J, V80, P2987, DOI 10.1016/S0006-3495(01)76264-9; Wu ZB, 2003, P NATL ACAD SCI USA, V100, P8880, DOI 10.1073/pnas.1533186100; Yau YH, 2001, ANTIMICROB AGENTS CH, V45, P2820, DOI 10.1128/AAC.45.10.2820-2825.2001; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	37	64	64	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50150	50156		10.1074/jbc.M405606200	http://dx.doi.org/10.1074/jbc.M405606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15328339	hybrid			2022-12-25	WOS:000225229500074
J	Shiozawa, K; Maita, N; Tomii, K; Seto, A; Goda, N; Akiyama, Y; Shimizu, T; Shirakawa, M; Hiroaki, H				Shiozawa, K; Maita, N; Tomii, K; Seto, A; Goda, N; Akiyama, Y; Shimizu, T; Shirakawa, M; Hiroaki, H			Structure of the N-terminal domain of PEX1 AAA-ATPase - Characterization of a putative adaptor-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VALOSIN-CONTAINING PROTEIN; PEROXISOME BIOGENESIS; MEMBRANE-FUSION; ENDOPLASMIC-RETICULUM; ZELLWEGER-SYNDROME; CRYSTAL-STRUCTURE; LIPID-METABOLISM; COMMON-CAUSE; NSF; FAMILY	Peroxisomes are responsible for several pathways in primary metabolism, including beta-oxidation and lipid biosynthesis. PEX1 and PEX6 are hexameric AAA-type ATPases, both of which are indispensable in targeting over 50 peroxisomal resident proteins from the cytosol to the peroxisomes. Although the tandem AAA-ATPase domains in the central region of PEX1 and PEX6 are highly similar, the N-terminal sequences are unique. To better understand the distinct molecular function of these two proteins, we analyzed the unique N-terminal domain (NTD) of PEX1. Extensive computational analysis revealed weak similarity (< 10% identity) of PEX1 NTD to the N-terminal domains of other membrane-related type II AAA-ATPases, such as VCP (p97) and NSF. We have determined the crystal structure of mouse PEX1 NTD at 2.05-angstrom resolution, which clearly demonstrated that the domain belongs to the double-psi-barrel fold family found in the other AAA-ATPases. The N-domains of both VCP and NSF are structural neighbors of PEX1 NTD with a 2.7- and 2.1-angstrom root mean square deviation of backbone atoms, respectively. Our findings suggest that the supradomain architecture, which is composed of a single N-terminal domain followed by tandem AAA domains, is a common feature of organellar membrane-associating AAA-ATPases. We propose that PEX1 functions as a protein unfoldase in peroxisomal biogenesis, using its N-terminal putative adaptor-binding domain.	Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan; Japan Biol Informat Consortium, Chuo Ku, Tokyo 1040032, Japan; Natl Inst Adv Ind Sci & Technol, Computat Biol Res Ctr, Koto Ku, Tokyo 1350064, Japan	Yokohama City University; National Institute of Advanced Industrial Science & Technology (AIST)	Hiroaki, H (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-20 Suehiro, Kanagawa 2300045, Japan.	hiroakih@tsurumi.ykohama-cu.ac.jp	Tomii, Kentaro/B-1135-2017; HIROAKI, HIDEKAZU/N-1658-2019; Tomii, Kentaro/AAK-6940-2021; Maita, Nobuo/J-1443-2012; Hiroaki, Hidekazu/G-9564-2012; Akiyama, Yutaka/D-2048-2015	Tomii, Kentaro/0000-0002-4567-4768; HIROAKI, HIDEKAZU/0000-0003-1621-5893; Tomii, Kentaro/0000-0002-4567-4768; Maita, Nobuo/0000-0003-2260-5783; Akiyama, Yutaka/0000-0003-2863-8703				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beyer A, 1997, PROTEIN SCI, V6, P2043; Birschmann I, 2003, MOL BIOL CELL, V14, P2226, DOI 10.1091/mbc.E02-11-0752; BREITKREUTZ BJ, 2003, GENOME BIOL, V4; Brown LA, 2003, J CELL MOL MED, V7, P388, DOI 10.1111/j.1582-4934.2003.tb00241.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; *COLL COMP PROJ 4, 1999, ACTA CRYSTALLOGR D, V50, P760; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; de Bakker PIW, 2001, BIOINFORMATICS, V17, P748, DOI 10.1093/bioinformatics/17.8.748; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Eckert JH, 2003, J CELL SCI, V116, P3623, DOI 10.1242/jcs.00678; Elazar Z, 2003, BBA-MOL CELL RES, V1641, P145, DOI 10.1016/S0167-4889(03)00086-7; Faber KN, 1998, MOL CELL BIOL, V18, P936, DOI 10.1128/MCB.18.2.936; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Frohlich KU, 2001, J CELL SCI, V114, P1601; Fujiki Y, 2000, CELL BIOCHEM BIOPHYS, V32, P155, DOI 10.1385/CBB:32:1-3:155; Gartner J, 2000, EUR J PEDIATR, V159, pS236, DOI 10.1007/PL00014410; Geisbrecht BV, 1998, P NATL ACAD SCI USA, V95, P8630, DOI 10.1073/pnas.95.15.8630; Geuze HJ, 2003, MOL BIOL CELL, V14, P2900, DOI 10.1091/mbc.E02-11-0734; Goda N, 2004, PROTEIN SCI, V13, P652, DOI 10.1110/ps.03439004; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horsnell WGC, 2002, BIOCHEMISTRY-US, V41, P5230, DOI 10.1021/bi0160359; Huyton T, 2003, J STRUCT BIOL, V144, P337, DOI 10.1016/j.jsb.2003.10.007; Imamura A, 1998, HUM MOL GENET, V7, P2089, DOI 10.1093/hmg/7.13.2089; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kiel JAKW, 1999, YEAST, V15, P1059, DOI 10.1002/(SICI)1097-0061(199908)15:11<1059::AID-YEA434>3.0.CO;2-I; Kiel JAKW, 2000, APPL MICROBIOL BIOT, V54, P238, DOI 10.1007/s002530000378; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kunau WH, 1998, CURR OPIN MICROBIOL, V1, P232, DOI 10.1016/S1369-5274(98)80016-7; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Matsumoto N, 2003, NAT CELL BIOL, V5, P454, DOI 10.1038/ncb982; Matsumoto N, 2001, J HUM GENET, V46, P273, DOI 10.1007/s100380170078; Maxwell MA, 2002, HUM MUTAT, V20, P342, DOI 10.1002/humu.10128; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Mizuguchi K, 1999, STRUCT FOLD DES, V7, pR215, DOI 10.1016/S0969-2126(99)80169-5; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Portsteffen H, 1997, NAT GENET, V17, P449, DOI 10.1038/ng1297-449; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Reuber BE, 1997, NAT GENET, V17, P445, DOI 10.1038/ng1297-445; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shiozawa K, 2004, ACTA CRYSTALLOGR D, V60, P2098, DOI 10.1107/S090744490402428X; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stebbings LA, 2004, NUCLEIC ACIDS RES, V32, pD203, DOI 10.1093/nar/gkh027; Suyama M, 2003, BIOINFORMATICS, V19, P673, DOI 10.1093/bioinformatics/btg031; Tamura S, 1998, BIOCHEM BIOPH RES CO, V245, P883, DOI 10.1006/bbrc.1998.8522; Tamura S, 1998, P NATL ACAD SCI USA, V95, P4350, DOI 10.1073/pnas.95.8.4350; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Titorenko VI, 2000, J CELL BIOL, V150, P881, DOI 10.1083/jcb.150.4.881; Tomii K, 2004, BIOINFORMATICS, V20, P594, DOI 10.1093/bioinformatics/btg474; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Vogel C, 2004, CURR OPIN STRUC BIOL, V14, P208, DOI 10.1016/j.sbi.2004.03.011; Vogel C, 2004, J MOL BIOL, V336, P809, DOI 10.1016/j.jmb.2003.12.026; Wanders RJA, 2000, BIOCHEM SOC T, V28, P141, DOI 10.1042/bst0280141; Wanders RJA, 2000, CELL BIOCHEM BIOPHYS, V32, P89, DOI 10.1385/CBB:32:1-3:89; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; Whiteheart SW, 2004, J STRUCT BIOL, V146, P32, DOI 10.1016/j.jsb.2003.09.015; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; Wojcik C, 2004, J CELL SCI, V117, P281, DOI 10.1242/jcs.00841; Woodman PG, 1997, BBA-MOL CELL RES, V1357, P155, DOI 10.1016/S0167-4889(97)00039-6; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656; Yu RC, 1999, MOL CELL, V4, P97, DOI 10.1016/S1097-2765(00)80191-4; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	83	59	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50060	50068		10.1074/jbc.M407837200	http://dx.doi.org/10.1074/jbc.M407837200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15328346	hybrid			2022-12-25	WOS:000225229500064
J	Kihara, A; Igarashi, Y				Kihara, A; Igarashi, Y			FVT-1 is a mammalian 3-ketodihydrosphingosine reductase with an active site that faces the cytosolic side of the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT TRANSLOCATION T(2-18)(P11-Q21); SERINE PALMITOYLTRANSFERASE ACTIVITY; SHORT-CHAIN DEHYDROGENASES; SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID SYNTHESIS; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; GLUCOSYLCERAMIDE SYNTHESIS; 3-DIMENSIONAL STRUCTURE; ALCOHOL-DEHYDROGENASE; FOLLICULAR LYMPHOMA	Sphingolipids are essential membrane components of eukaryotic cells. Their synthesis is initiated with the condensation of L-serine with palmitoyl-CoA, producing 3-ketodihydrosphingosine (KDS), followed by a reduction to dihydrosphingosine by KDS reductase. Until now, only yeast TSC10 has been identified as a KDS reductase gene. Here, we provide evidence that the human FVT-1 (hFVT-1) and mouse FVT-1 (mFVT-1) are functional mammalian KDS reductases. The forced expression of hFVT-1 or mFVT-1 in TSC10-null yeast cells suppressed growth defects, and hFVT-1 overproduced in cultured cells exhibited KDS reductase activity in vitro. Moreover, purified recombinant hFVT-1 protein exhibited NADPH-dependent KDS reductase activity. The identification of the FVT-1 genes enabled us to characterize the mammalian KDS reductase at the molecular level. Northern blot analyses demonstrated that both hFVT-1 and mFVT-1 mRNAs are ubiquitously expressed, suggesting that FVT-1 is a major KDS reductase. We also found the presence of hFVT-1 variants, which were differentially expressed among tissues. Immunofluorescence microscopic analysis revealed that hFVT-1 is localized at the endoplasmic reticulum. Moreover, a proteinase K digestion assay revealed that the large hydrophilic domain of hFVT-1, which contains putative active site residues, faces the cytosol. These results suggest that KDS is converted to dihydrosphingosine in the cytosolic side of the endoplasmic reticulum membrane. Moreover, the topology studies provide insight into the spatial organization of the sphingolipid biosynthetic pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Igarashi, Y (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				ALBALAT R, 1992, FEBS LETT, V308, P235; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; BERTHEAS MF, 1991, BRIT J HAEMATOL, V78, P132, DOI 10.1111/j.1365-2141.1991.tb04400.x; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; ENSOR CM, 1991, BIOCHEM BIOPH RES CO, V176, P840, DOI 10.1016/S0006-291X(05)80262-1; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Huitema K, 2004, EMBO J, V23, P33, DOI 10.1038/sj.emboj.7600034; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kihara A, 2003, GENES CELLS, V8, P525, DOI 10.1046/j.1365-2443.2003.00653.x; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kihara A, 2002, J BIOL CHEM, V277, P30048, DOI 10.1074/jbc.M203385200; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MCKINLEYMCKEE JS, 1991, BIOCHEM INT, V25, P879; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NOTHWEHR SF, 1990, BIOESSAYS, V12, P479, DOI 10.1002/bies.950121005; OBEID J, 1992, BIOCHEM BIOPH RES CO, V188, P222, DOI 10.1016/0006-291X(92)92373-6; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; RIMOKH R, 1993, BLOOD, V81, P136; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sims KJ, 2004, BIOCHEM CELL BIOL, V82, P45, DOI 10.1139/o03-086; Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Yamaoka S, 2004, J BIOL CHEM, V279, P18688, DOI 10.1074/jbc.M401205200; Yasuda S, 2003, J BIOL CHEM, V278, P4176, DOI 10.1074/jbc.M209602200; ZHAO C, 1994, J BIOL CHEM, V269, P21480	50	66	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49243	49250		10.1074/jbc.M405915200	http://dx.doi.org/10.1074/jbc.M405915200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15328338	hybrid			2022-12-25	WOS:000225098100091
J	Blein, S; Ginham, R; Uhrin, D; Smith, BO; Soares, DC; Veltel, S; McIlhinney, RAJ; White, JH; Barlow, PN				Blein, S; Ginham, R; Uhrin, D; Smith, BO; Soares, DC; Veltel, S; McIlhinney, RAJ; White, JH; Barlow, PN			Structural analysis of the complement control protein (CCP) modules of GABA(B) receptor 1a - Only one of the two CCP modules is compactly folded	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-13/N-15-ENRICHED PROTEINS; IMPROVED SENSITIVITY; SECONDARY STRUCTURE; DISORDERED PROTEIN; GENOMIC STRUCTURE; SPLICE VARIANTS; PICHIA-PASTORIS; NMR EXPERIMENTS; B RECEPTOR; EXPRESSION	The gamma-aminobutyric acid type B (GABA(B)) receptor is a heterodimeric G-protein-coupled receptor. In humans, three splice variants of the GABA(B) receptor 1 (R1) subunit differ in having one, both, or neither of two putative complement control protein (CCP) modules at the extracellular N terminus, prior to the GABA-binding domain. The in vivo function of these predicted modules remains to be discovered, but a likely association with extracellular matrix proteins is intriguing. The portion of the GABA(B) R1a variant encompassing both of its CCP module-like sequences has been expressed, as have the sequences corresponding to each individual module. Each putative CCP module exhibits the expected pattern of disulfide formation. However, the second module (CCP2) is more compactly folded than the first, and the three-dimensional structure of this more C-terminal module (expressed alone) was solved on the basis of NMR-derived nuclear Overhauser effects. This revealed a strong similarity to previously determined CCP module structures in the regulators of complement activation. The N-terminal module (CCP1) displayed conformational heterogeneity under a wide range of conditions whether expressed alone or together with CCP2. Several lines of evidence indicated the presence of native disorder in CCP1, despite the fact that recombinant CCP1 contributes to binding to the extracellular matrix protein fibulin-2. Thus, we have shown that the two CCP modules of GABA(B) R1a have strikingly different structural properties, reflecting their different functions.	Univ Edinburgh, Edinburgh Prot Interact Ctr, Edinburgh EH9 3JJ, Midlothian, Scotland; MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; GlaxoSmithKline Med Res Ctr, Pathway Discovery Genom & Proteom Sci, Stevenage SG1 2NY, Herts, England	University of Edinburgh; GlaxoSmithKline	Barlow, PN (corresponding author), Univ Edinburgh, Edinburgh Prot Interact Ctr, Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Soares, Dinesh C/A-4425-2012; Smith, Brian O/J-1899-2015; Smith, Brian/AAJ-9393-2020; Barlow, Paul N/G-2853-2011	Soares, Dinesh C/0000-0001-7557-0495; Smith, Brian O/0000-0003-3363-4168; Smith, Brian/0000-0003-3363-4168; Veltel, Stefan/0000-0002-4925-3776				Aitio H, 2000, J MAGN RESON, V143, P391, DOI 10.1006/jmre.1999.2010; Bettler B, 1998, CURR OPIN NEUROBIOL, V8, P345, DOI 10.1016/S0959-4388(98)80059-7; Blein S, 2000, CELL MOL LIFE SCI, V57, P635, DOI 10.1007/PL00000725; Bowery NG, 2002, PHARMACOL REV, V54, P247, DOI 10.1124/pr.54.2.247; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calver AR, 2000, NEUROSCIENCE, V100, P155, DOI 10.1016/S0306-4522(00)00262-1; Calver AR, 2002, NEUROSIGNALS, V11, P299, DOI 10.1159/000068257; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; GINHAM R, 2002, FENS ABSTR, V1; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Hawrot E, 1998, FEBS LETT, V432, P103, DOI 10.1016/S0014-5793(98)00794-7; HEIDEN W, 1993, J COMPUT CHEM, V14, P246, DOI 10.1002/jcc.540140212; Henderson CE, 2001, J MOL BIOL, V307, P323, DOI 10.1006/jmbi.2000.4477; Herbst R, 1997, MOL BRAIN RES, V44, P309, DOI 10.1016/S0169-328X(96)00274-4; IMOTO T, 1997, PROTEIN FUNCTION PRA, P279; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; Kirkitadze MD, 1999, BIOCHEMISTRY-US, V38, P7019, DOI 10.1021/bi982453a; Kirkitadze MD, 1998, J VIROL, V72, P10066, DOI 10.1128/JVI.72.12.10066-10072.1998; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; MALLIN RL, 2003, THESIS U EDINBURGH; Martin SC, 2001, GENE, V278, P63, DOI 10.1016/S0378-1119(01)00678-3; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; MOLNAR E, 1994, J NEUROCHEM, V63, P683; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Leary JM, 2004, PROTEIN SCI, V13, P1238, DOI 10.1110/ps.03582704; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Privalov P L, 1986, Methods Enzymol, V131, P4; Rees S, 1996, BIOTECHNIQUES, V20, P102; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Romero, 1997, Genome Inform Ser Workshop Genome Inform, V8, P110; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Saghatelyan AK, 2003, MOL CELL NEUROSCI, V24, P271, DOI 10.1016/S1044-7431(03)00163-5; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schwarz DA, 2000, J BIOL CHEM, V275, P32174, DOI 10.1074/jbc.M005333200; Shatsky M, 2002, LECT NOTES COMPUT SC, V2452, P235; SHIMIZUNISHIKAWA K, 1995, BIOCHEM BIOPH RES CO, V216, P382, DOI 10.1006/bbrc.1995.2635; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WANG AC, 1994, J MAGN RESON SER B, V105, P196, DOI 10.1006/jmrb.1994.1123; WHITE CE, 1994, STRUCTURE, V2, P1003, DOI 10.1016/S0969-2126(94)00103-0; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; White JH, 2000, P NATL ACAD SCI USA, V97, P13967, DOI 10.1073/pnas.240452197; WHITE JH, 2002, FENS ABSTR, V1; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; Yuan XM, 1998, PROTEIN SCI, V7, P2127, DOI 10.1002/pro.5560071009; [No title captured]	75	51	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48292	48306		10.1074/jbc.M406540200	http://dx.doi.org/10.1074/jbc.M406540200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15304491	Green Submitted, hybrid			2022-12-25	WOS:000224957000105
J	Green, AR; Aiston, S; Greenberg, CC; Freeman, S; Poucher, SM; Brady, MJ; Agius, L				Green, AR; Aiston, S; Greenberg, CC; Freeman, S; Poucher, SM; Brady, MJ; Agius, L			The glycogenic action of protein targeting to glycogen in hepatocytes involves multiple mechanisms including phosphorylase inactivation and glycogen synthase translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HEXOKINASE I; INSULIN; GLUCOSE-6-PHOSPHATE; SUBUNITS; GLUCOSE; PTG; PHOSPHATASE-1; LIVER; OVEREXPRESSION	Expression of the glycogen-targeting protein PTG promotes glycogen synthase activation and glycogen storage in various cell types. In this study, we tested the contribution of phosphorylase inactivation to the glycogenic action of PTG in hepatocytes by using a selective inhibitor of phosphorylase (CP-91149) that causes dephosphorylation of phosphorylase a and sequential activation of glycogen synthase. Similar to CP-91194, graded expression of PTG caused a concentration-dependent inactivation of phosphorylase and activation of glycogen synthase. The latter was partially counteracted by the expression of muscle phosphorylase and was not additive with the activation by CP-91149, indicating that it is in part secondary to the inactivation of phosphorylase. PTG expression caused greater stimulation of glycogen synthesis and translocation of glycogen synthase than CP-91149, and the translocation of synthase could not be explained by accumulation of glycogen, supporting an additional role for glycogen synthase translocation in the glycogenic action of PTG. The effects of PTG expression on glycogen synthase and glycogen synthesis were additive with the effects of glucokinase expression, confirming the complementary roles of depletion of phosphorylase a (a negative modulator) and elevated glucose 6-phosphate (a positive modulator) in potentiating the activation of glycogen synthase. PTG expression mimicked the inactivation of phosphorylase caused by high glucose and counteracted the activation caused by glucagon. The latter suggests a possible additional role for PTG on phosphorylase kinase inactivation.	Newcastle Univ, Dept Diabet, Sch Clin Med Sci, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Chicago, Dept Med, Chicago, IL 60637 USA; AstraZeneca, Macclesfield SK10 4TG, Cheshire, England	Newcastle University - UK; University of Chicago; AstraZeneca	Agius, L (corresponding author), Newcastle Univ, Dept Diabet, Sch Clin Med Sci, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Loranne.Agius@ncl.ac.uk						AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; Aiston S, 2004, BIOCHEM J, V377, P195, DOI 10.1042/BJ20031191; Aiston S, 2003, EUR J BIOCHEM, V270, P2773, DOI 10.1046/j.1432-1033.2003.03648.x; Aiston S, 2003, DIABETES, V52, P1333, DOI 10.2337/diabetes.52.6.1333; Aiston S, 2001, J BIOL CHEM, V276, P23858, DOI 10.1074/jbc.M101454200; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; Armstrong CG, 1997, FEBS LETT, V418, P210, DOI 10.1016/S0014-5793(97)01385-9; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bergans N, 2000, DIABETES, V49, P1419, DOI 10.2337/diabetes.49.9.1419; Berman HK, 1998, J BIOL CHEM, V273, P26421, DOI 10.1074/jbc.273.41.26421; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Browne GJ, 2001, BIOCHEM J, V360, P449, DOI 10.1042/0264-6021:3600449; Crosson SM, 2003, J CLIN INVEST, V111, P1423, DOI 10.1172/JCI200317975; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V288, P497, DOI 10.1042/bj2880497; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; Guinovart JJ, 1997, BIOCHEM SOC T, V25, P157, DOI 10.1042/bst0250157; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Latsis T, 2002, BIOCHEM J, V368, P309, DOI 10.1042/BJ20021070; Martin WH, 1998, P NATL ACAD SCI USA, V95, P1776, DOI 10.1073/pnas.95.4.1776; Munro S, 2002, DIABETES, V51, P591, DOI 10.2337/diabetes.51.3.591; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Orlicky DJ, 2001, J LIPID RES, V42, P460; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078	33	20	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46474	46482		10.1074/jbc.M405660200	http://dx.doi.org/10.1074/jbc.M405660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322104	hybrid			2022-12-25	WOS:000224832400018
J	Hicks, SN; Smiley, RD; Stinnett, LG; Minor, KH; Howell, EE				Hicks, SN; Smiley, RD; Stinnett, LG; Minor, KH; Howell, EE			Role of Lys-32 residues in R67 dihydrofolate reductase probed by asymmetric mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE PORE; ESCHERICHIA-COLI; TERNARY COMPLEX; HOST-GUEST; BINDING; PROTEIN; LIGAND; CONFORMATION; CATALYSIS; ENZYME	R67 dihydrofolate reductase ( R67 DHFR) is a novel protein encoded by an R-plasmid that confers resistance to the antibiotic, trimethoprim. This homotetrameric enzyme possesses 222 symmetry, which imposes numerous constraints on the single active site pore, including a "one-site-fits-both" strategy for binding its ligands, dihydrofolate (DHF) and NADPH. Previous studies uncovered salt effects on binding and catalysis ( Hicks, S. N., Smiley, R. D., Hamilton, J. B., and Howell, E. E. ( 2003) Biochemistry 42, 10569-10578), however the one or more residues that participate in ionic contacts with the negatively charged tail of DHF as well as the phosphate groups in NADPH were not identified. Several studies predict that Lys-32 residues were involved, however mutations at this residue destabilize the R67 DHFR homotetramer. To study the role of Lys-32 in binding and catalysis, asymmetric K32M mutations have been utilized. To create asymmetry, individual mutations were added to a tandem array of four in-frame gene copies. These studies show one K32M mutation is tolerated quite well, whereas addition of two mutations has variable effects. Two double mutants, K32M: 1 + 2 and K32M: 1 + 4, which place the mutations on opposite sides of the pore, reduce k(cat). However a third double mutant, K32M: 1 + 3, that places two mutations on the same half pore, enhances k(cat) 4- to 5-fold compared with the parent enzyme, albeit at the expense of weaker binding of ligands. Because the k(cat)/K-m values for this double mutant series are similar, these mutations appear to have uncovered some degree of non-productive binding. This non-productive binding mode likely arises from formation of an ionic interaction that must be broken to allow access to the transition state. The K32M:1 + 3 mutant data suggest this interaction is an ionic interaction between Lys-32 and the charged tail of dihydrofolate. This unusual catalytic scenario arises from the 222 symmetry imposed on the single active site pore.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Howell, EE (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA.	lzh@utk.edu		Howell, Elizabeth/0000-0001-6157-433X				BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; Bagnol L, 2003, ORG LETT, V5, P5055, DOI 10.1021/ol036052l; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; Bradrick TD, 1996, J BIOL CHEM, V271, P28031, DOI 10.1074/jbc.271.45.28031; BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P1461, DOI 10.1021/bi00220a003; BRITO RMM, 1990, BIOCHEMISTRY-US, V29, P9825, DOI 10.1021/bi00494a011; Chong LT, 1998, PROTEIN SCI, V7, P206, DOI 10.1002/pro.5560070122; Clark ED, 1999, METHOD ENZYMOL, V309, P217; Dougherty RC, 2003, BIOPHYS CHEM, V105, P269, DOI 10.1016/S0301-4622(03)00077-2; DUNN SMJ, 1990, BIOCHEMISTRY-US, V29, P8569, DOI 10.1021/bi00489a010; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FERSHT A, 1999, STRUCTURE MECH PROTE, P109; GAREL L, 1993, J AM CHEM SOC, V115, P11652, DOI 10.1021/ja00077a096; HAMILTON JB, 1997, THESIS U TENNESSEE K; Harder S, 2002, CHEM-EUR J, V8, P1991, DOI 10.1002/1521-3765(20020503)8:9<1991::AID-CHEM1991>3.0.CO;2-9; Hicks SN, 2003, BIOCHEMISTRY-US, V42, P10569, DOI 10.1021/bi034643d; HORECKER BL, 1948, J BIOL CHEM, V175, P385; Houk KN, 2003, ANGEW CHEM INT EDIT, V42, P4872, DOI 10.1002/anie.200200565; Howell EE, 2001, J COMPUT AID MOL DES, V15, P1035, DOI 10.1023/A:1014824725891; HOWELL EE, 1987, BIOCHEMISTRY-US, V26, P8591, DOI 10.1021/bi00400a015; JENSEN DE, 1976, J BIOL CHEM, V251, P7198; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; Li DW, 2001, BIOCHEMISTRY-US, V40, P4242, DOI 10.1021/bi0026425; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; Park C, 2001, J AM CHEM SOC, V123, P11472, DOI 10.1021/ja0164834; Park H, 1997, PROTEIN ENG, V10, P1415, DOI 10.1093/protein/10.12.1415; Pitcher WH, 2003, BIOCHEMISTRY-US, V42, P11150, DOI 10.1021/bi0349874; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; Roca M, 2003, J AM CHEM SOC, V125, P7726, DOI 10.1021/ja0299497; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SCHNEIDER HJ, 1991, J AM CHEM SOC, V113, P1996, DOI 10.1021/ja00006a020; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SHOICHET BK, 1993, PROTEIN ENG, V6, P723, DOI 10.1093/protein/6.7.723; Smiley RD, 2002, BIOCHEMISTRY-US, V41, P15664, DOI 10.1021/bi026676j; Stinnett LG, 2004, J BIOL CHEM, V279, P47003, DOI 10.1074/jbc.M404485200; Strader MB, 2004, BIOCHEMISTRY-US, V43, P7403, DOI 10.1021/bi049646k; Strader MB, 2001, BIOCHEMISTRY-US, V40, P11344, DOI 10.1021/bi0110544; STRADER MB, 1997, GIBCO BRL FOCUS, V19, P24; UMEZURIKE GM, 1987, BIOCHEM J, V241, P455, DOI 10.1042/bj2410455; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; West FW, 2000, BIOCHEMISTRY-US, V39, P3678, DOI 10.1021/bi992195x; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; ZHUANG P, 1993, J BIOL CHEM, V268, P22672	46	14	14	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46995	47002		10.1074/jbc.M404484200	http://dx.doi.org/10.1074/jbc.M404484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15333636	hybrid			2022-12-25	WOS:000224832400083
J	Kristan, K; Podlesek, Z; Hojnik, V; Gutierrez-Aguirre, I; Guncar, G; Turk, D; Gonzalez-Manas, JM; Lakey, JH; Macek, P; Anderluh, G				Kristan, K; Podlesek, Z; Hojnik, V; Gutierrez-Aguirre, I; Guncar, G; Turk, D; Gonzalez-Manas, JM; Lakey, JH; Macek, P; Anderluh, G			Pore formation by equinatoxin, a eukaryotic pore-forming toxin, requires a flexible N-terminal region and a stable beta-sandwich	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMONE STICHODACTYLA-HELIANTHUS; CHOLESTEROL-DEPENDENT CYTOLYSIN; PROTEIN STICHOLYSIN II; MODEL LIPID-MEMBRANES; SEA-ANEMONE; DISULFIDE BONDS; MOLTEN-GLOBULE; ACTINIA-EQUINA; COMMON FOLD; COLICIN-A	Actinoporins are eukaryotic pore-forming proteins that create 2-nm pores in natural and model lipid membranes by the self-association of four monomers. The regions that undergo conformational change and form part of the transmembrane pore are currently being defined. It was shown recently that the N-terminal region (residues 10-28) of equinatoxin, an actinoporin from Actinia equina, participates in building of the final pore wall. Assuming that the pore is formed solely by a polypeptide chain, other parts of the toxin should constitute the conductive channel and here we searched for these regions by disulfide scanning mutagenesis. Only double cysteine mutants where the N-terminal segment 1-30 was attached to the beta-sandwich exhibited reduced hemolytic activity upon disulfide formation, showing that other parts of equinatoxin, particularly the beta-sandwich and importantly the C-terminal alpha-helix, do not undergo large conformational rearrangements during the pore formation. The role of the beta-sandwich stability was independently assessed via destabilization of a part of its hydrophobic core by mutations of the buried Trp(117). These mutants were considerably less stable than the wild-type but exhibited similar or slightly lower permeabilizing activity. Collectively these results show that a flexible N-terminal region and stable beta-sandwich are pre-requisite for proper pore formation by the actinoporin family.	Univ Ljubljana, Dept Biol, Biotech Fac, Ljubljana 1000, Slovenia; Univ Basque Country, Unidad Biophys, CSIC UPV EHU, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain; Univ Ljubljana, Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia; Newcastle Univ, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Ljubljana; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; University of Ljubljana; Newcastle University - UK	Anderluh, G (corresponding author), Univ Ljubljana, Dept Biol, Biotech Fac, Vecna Pot 111, Ljubljana 1000, Slovenia.	gregor.anderluh@bf.uni-lj.si	Maček, Peter/Y-9877-2019; Anderluh, Gregor/C-6905-2014; Maček, Peter/U-4662-2017	Maček, Peter/0000-0001-6470-7759; Anderluh, Gregor/0000-0002-9916-8465; Maček, Peter/0000-0001-6470-7759; Gutierrez Aguirre, Ion/0000-0002-8348-8616; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982; Turk, Dusan/0000-0003-0205-6609; Guncar, Gregor/0000-0003-4500-6951				Anderluh G, 2003, STRUCTURE, V11, P1312, DOI 10.1016/j.str.2003.10.007; Anderluh G, 2003, J BIOL CHEM, V278, P45216, DOI 10.1074/jbc.M305916200; Anderluh G, 1999, EUR J BIOCHEM, V263, P128, DOI 10.1046/j.1432-1327.1999.00477.x; Anderluh G, 1996, BIOCHEM BIOPH RES CO, V220, P437, DOI 10.1006/bbrc.1996.0391; Anderluh G, 2000, J MEMBRANE BIOL, V173, P47, DOI 10.1007/s002320001006; Anderluh G, 2002, TOXICON, V40, P111, DOI 10.1016/S0041-0101(01)00191-X; Athanasiadis A, 2001, STRUCTURE, V9, P341, DOI 10.1016/S0969-2126(01)00592-5; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Bonev BB, 2003, BIOPHYS J, V84, P2382, DOI 10.1016/S0006-3495(03)75044-9; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Duche D, 1996, J BIOL CHEM, V271, P15401, DOI 10.1074/jbc.271.26.15401; DUCHE D, 1994, J BIOL CHEM, V269, P6332; Fridd SL, 2002, BIOCHEMISTRY-US, V41, P1579, DOI 10.1021/bi015633k; Goni FM, 2002, MOL MEMBR BIOL, V19, P237, DOI 10.1080/0968768021000035078; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hinds MG, 2002, J MOL BIOL, V315, P1219, DOI 10.1006/jmbi.2001.5321; Hong Q, 2002, J BIOL CHEM, V277, P41916, DOI 10.1074/jbc.M204625200; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Kawate T, 2003, PROTEIN SCI, V12, P997, DOI 10.1110/ps.0231203; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lakey JH, 2001, CURR TOP MICROBIOL, V257, P131; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MACEK P, 1995, EUR J BIOCHEM, V234, P329, DOI 10.1111/j.1432-1033.1995.329_c.x; Malovrh P, 2000, BIOCHEM J, V346, P223, DOI 10.1042/0264-6021:3460223; Malovrh P, 2003, J BIOL CHEM, V278, P22678, DOI 10.1074/jbc.M300622200; Mancheno JM, 2003, STRUCTURE, V11, P1319, DOI 10.1016/j.str.2003.09.019; Mancheno JM, 2001, BBA-PROTEIN STRUCT M, V1545, P122, DOI 10.1016/S0167-4838(00)00269-7; Menestrina G, 1999, BIOCHEM BIOPH RES CO, V254, P174, DOI 10.1006/bbrc.1998.9898; MENESTRINA G, 2003, PROE FORMING PEPTIDE; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; Poklar N, 1999, BIOCHEMISTRY-US, V38, P14999, DOI 10.1021/bi9916022; Poklar N, 1997, BIOCHEMISTRY-US, V36, P14345, DOI 10.1021/bi971719v; Ramachandran R, 2002, NAT STRUCT BIOL, V9, P823, DOI 10.1038/nsb855; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Tejuca M, 2001, J MEMBRANE BIOL, V183, P125, DOI 10.1007/s00232-001-0060-y; Tejuca M, 1996, BIOCHEMISTRY-US, V35, P14947, DOI 10.1021/bi960787z; Turk D., 1992, THESIS TU MUNCHEN GE; Valcarcel CA, 2001, BIOPHYS J, V80, P2761, DOI 10.1016/S0006-3495(01)76244-3; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X	56	95	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46509	46517		10.1074/jbc.M406193200	http://dx.doi.org/10.1074/jbc.M406193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15322132	hybrid			2022-12-25	WOS:000224832400022
J	Takazaki, R; Shishido, Y; Iwamoto, R; Mekada, E				Takazaki, R; Shishido, Y; Iwamoto, R; Mekada, E			Suppression of the biological activities of the epidermal growth factor (EGF)-like domain by the heparin-binding domain of heparin-binding EGF-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; FACTOR HB-EGF; CRYSTAL-STRUCTURE; MEMBRANE-PROTEIN; SULFATE PROTEOGLYCANS; CELLS; COMPLEX; JUXTACRINE; GENE; SITE	Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family of growth factors that has a high affinity for heparin and heparan sulfate. While interactions with heparin are thought to modulate the biological activity of HB-EGF, the precise role of the heparin-binding domain has remained unclear. We analyzed the activity of wild-type HB-EGF and a mutant form lacking the heparin-binding domain (DeltaHB) in the presence or absence of heparin. The activity of the EGF-like domain of HB-EGF was determined by measuring binding to diphtheria toxin (DT) as well as the growth factor activity in EGF receptor-expressing cells. The binding affinity of DeltaHB for DT was much higher than that of wild-type HB-EGF in the absence of heparin. The binding affinity of HB-EGF for DT was increased by addition of exogenous heparin and reached the level close to the affinity of DeltaHB, whereas that of DeltaHB was not affected. Moreover, the growth factor activity of DeltaHB was much higher than that of wild-type HB-EGF in the absence of heparin but was not affected by addition of exogenous heparin, whereas HB-EGF had increased growth factor activity with added heparin. These results indicate that the heparin-binding domain suppresses the activity of the EGF-like domain of HB-EGF and that association of heparin with HB-EGF via this domain removes the suppressive effect. Thus, we conclude that the heparin-binding domain serves as a negative regulator of this growth factor.	Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, Suita, Osaka 5650871, Japan	Osaka University	Iwamoto, R (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	riwamoto@biken.osaka-u.ac.jp		Mekada, Eisuke/0000-0001-8858-4781				Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; DAS SK, 1994, DEVELOPMENT, V120, P1071; Davis-Fleischer KM, 2001, GROWTH FACTORS, V19, P127, DOI 10.3109/08977190109001081; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Mitamura T, 1997, J BIOL CHEM, V272, P27084, DOI 10.1074/jbc.272.43.27084; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; RAPRAEGER AC, 1995, CHEM BIOL, V2, P645, DOI 10.1016/1074-5521(95)90025-X; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHISHIDO Y, 1995, J BIOL CHEM, V270, P29578, DOI 10.1074/jbc.270.49.29578; Takemura T, 2001, J AM SOC NEPHROL, V12, P964, DOI 10.1681/ASN.V125964; THOMPSON SA, 1994, J BIOL CHEM, V269, P2541; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; UCHIDA T, 1973, J BIOL CHEM, V248, P3838; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	49	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47335	47343		10.1074/jbc.M408556200	http://dx.doi.org/10.1074/jbc.M408556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15331606	hybrid			2022-12-25	WOS:000224832400122
J	Baglia, FA; Gailani, D; Lopez, JA; Walsh, PN				Baglia, FA; Gailani, D; Lopez, JA; Walsh, PN			Identification of a binding site for glycoprotein Ib alpha in the Apple 3 domain of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRACTED ARTICLE. SEE; MOLECULAR-WEIGHT KININOGEN; COAGULATION FACTOR-XI; PG 29067; FACTOR-IX; ACTIVATED PLATELETS; AMINO-ACIDS; HEAVY-CHAIN; THROMBIN; PROTHROMBIN	Factor XI (FXI) is a homodimeric plasma zymogen that is cleaved at two internal Arg(369)-Ile(370) bonds by thrombin, factor XIIa, or factor XIa. FXI circulates as a complex with the glycoprotein high molecular weight kininogen (HK). FXI binds to specific sites (K-d = similar to 10 nM, B-max = similar to1,500/platelet) on the surface of stimulated platelets, where it is efficiently activated by thrombin. The FXI Apple 3 (A3) domain mediates binding to platelets in the presence of HK and zinc ions (Zn2+) or prothrombin and calcium ions. The platelet glycoprotein (GP) Ib-IX-V complex is the receptor for FXI (Baglia, F. A., Badellino, K. O., Li, C. Q., Lopez, J. A., and Walsh, P. N. (2002) J. Biol. Chem. 277, 1662-1668). Using surface plasmon resonance, we determined that FXI binds specifically to glycocalicin, the extracellular domain of GPIbalpha, in a Zn2+-dependent fashion (K-d = similar to52 nM). We now show that recombinant FXI A3 domain inhibits FXI inbinding to glycocalicin in the presence of Zn2+, whereas the recombinant FXI A1, A2, or A4 domains have no effect. Experiments with full-length recombinant FXI mutants show that, in the presence of Zn2+, glycocalicin binds FXI at a heparin-binding site in A3 (Lys(252) and Lys(253)) and not by amino acids previously shown to be required for platelet binding (Ser(248), Arg(250), Lys(255), Phe(260), and Gln(263)). However, binding in the presence of HK and Zn2+ requires Ser(248), Arg(250), Lys(255), Phe(260), and GLn(263) and not Lys(252) and Lys(253). Thus, binding of FXI to GPIbalpha is mediated by amino acids in the A3 domain in the presence or absence of HK. This interaction is important for the initiation of the consolidation phase of blood coagulation and the generation of thrombin at sites of platelet thrombus formation.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Vanderbilt University; Vanderbilt University; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837, R01HL070683, R01HL046213, P50HL065967, P01HL064943, P01HL074124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58837, HL46213, HL64943, HL70683, P50 HL65967, HL74124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200; Baglia FA, 2003, BLOOD, V102, p129A; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Baglia FA, 2003, J BIOL CHEM, V278, P21744, DOI 10.1074/jbc.M212991200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354; BRUNNEE T, 1993, BLOOD, V81, P580; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715; Sun MF, 2001, BLOOD, V98, P125, DOI 10.1182/blood.V98.1.125; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	34	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45470	45476		10.1074/jbc.M406727200	http://dx.doi.org/10.1074/jbc.M406727200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15317813	hybrid			2022-12-25	WOS:000224694900024
J	Bryan, B; Kumar, V; Stafford, LJ; Cai, Y; Wu, GY; Liu, MY				Bryan, B; Kumar, V; Stafford, LJ; Cai, Y; Wu, GY; Liu, MY			GEFT, a Rho family guanine nucleotide exchange factor, regulates neurite outgrowth and dendritic spine formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IN-VIVO; PC12 CELLS; AXON GUIDANCE; NMDA RECEPTOR; SMALL GTPASES; ACTIVATION; GROWTH; NEURONS; CDC42	The Rho family of small GTPases controls a wide range of cellular processes in eukaryotic cells, such as normal cell growth, proliferation, differentiation, gene regulation, actin cytoskeletal organization, cell fate determination, and neurite outgrowth. The activation of Rho-GTPases requires the exchange of GDP for GTP, a process catalyzed by the Dbl family of guanine nucleotide exchange factors. We demonstrate that a newly identified guanine nucleotide exchange factor, GEFT, is widely expressed in the brain and highly concentrated in the hippocampus, and the Purkinje and granular cells of the cerebellum. Exogenous expression of GEFT promotes dendrite outgrowth in hippocampal neurons, resulting in spines with larger size as compared with control spines. In neuroblastoma cells, GEFT promotes the active GTP-bound state of Rac1, Cdc42, and RhoA and increases neurite outgrowth primarily via Rac1. Furthermore, we demonstrated that PAK1 and PAK5, both downstream effectors of Rac1/Cdc42, are necessary for GEFT-induced neurite outgrowth. AP-1 and NF-kappaB, two transcriptional factors involved in neurite outgrowth and survival, were up-regulated in GEFT-expressing cells. Together, our data suggest that GEFT enhances dendritic spine formation and neurite outgrowth in primary neurons and neuroblastoma cells, respectively, through the activation of Rac/Cdc42-PAK signaling pathways.	Texas A&M Univ Syst Hlth Sci Ctr, Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ Syst Hlth Sci Ctr, Dept Med Biochem & Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Baylor College of Medicine	Liu, MY (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Alkek Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@tamu.edu		Liu, Mingyao/0000-0001-7339-5048				Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bateman J, 2000, NEURON, V26, P93, DOI 10.1016/S0896-6273(00)81141-1; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bonhoeffer T, 2002, NEURON, V35, P1019, DOI 10.1016/S0896-6273(02)00906-6; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Dunaevsky A, 2003, TRENDS NEUROSCI, V26, P155, DOI 10.1016/S0166-2236(03)00028-6; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fiala JC, 1998, J NEUROSCI, V18, P8900; Foehr ED, 2000, J NEUROSCI, V20, P7556; Guo XG, 2003, J BIOL CHEM, V278, P13207, DOI 10.1074/jbc.M208896200; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kenney AM, 1998, J NEUROSCI, V18, P1318; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Liu D, 2000, ONCOGENE, V19, P5964, DOI 10.1038/sj.onc.1203992; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Lutz S, 2004, N-S ARCH PHARMACOL, V369, P540, DOI 10.1007/s00210-004-0926-5; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; May V, 2002, J NEUROSCI, V22, P6980; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; O'Kane EM, 2003, MOL BRAIN RES, V114, P1, DOI 10.1016/S0169-328X(03)00121-9; O'Kane EM, 2003, J NEUROCHEM, V87, P1309, DOI 10.1046/j.1471-4159.2003.02102.x; Park HT, 2002, BIOESSAYS, V24, P821, DOI 10.1002/bies.10141; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Scott EK, 2003, J NEUROSCI, V23, P3118; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; Sin WC, 2002, NATURE, V419, P475, DOI 10.1038/nature00987; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Souchet M, 2002, J CELL SCI, V115, P629; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu YM, 2001, J NEUROSCI, V21, P2630, DOI 10.1523/JNEUROSCI.21-08-02630.2001; Xia ZG, 1996, J NEUROSCI, V16, P5425	56	69	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45824	45832		10.1074/jbc.M406216200	http://dx.doi.org/10.1074/jbc.M406216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322108	hybrid			2022-12-25	WOS:000224694900067
J	Kneass, ZT; Marchase, RB				Kneass, ZT; Marchase, RB			Neutrophils exhibit rapid agonist-induced increases in protein-associated O-GlcNAc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; ACTIVATED HUMAN-NEUTROPHILS; INSULIN-RESISTANCE; CYTOSOLIC PROTEINS; RESPIRATORY BURST; POSTTRANSLATIONAL MODIFICATION; NUCLEOCYTOPLASMIC PROTEINS; CYTOPLASMIC GLYCOSYLATION; TETRATRICOPEPTIDE REPEATS; SIGNAL-TRANSDUCTION	A variety of cytoplasmic and nuclear proteins can be modified on serine and threonine residues by O-linked beta-N-acetylglucosamine (O-GlcNAc), although the effects of this modification on protein and cellular functions are not completely defined. The sugar donor for the O-GlcNAc transferase that catalyzes this post-translational modification is UDP-N-acetylglucosamine (UDPGlcNAc), a product of the hexosamine biosynthesis pathway (HBP). Here, the dynamics of the O-GlcNAc modification are examined in the physiological context of agonist-induced signal transduction using neutrophils. Formylated Met-Leu-Phe (fMLF) is shown to stimulate a rapid and transient increase in protein O-GlcNAcylation in both immunoblot and immunofluorescence imaging assays using O-GlcNAc-specific antibodies. In high performance liquid chromatography analyses of HBP metabolic activity, short term exposure to an exogenous substrate of the HBP, glucosamine (GlcNH(2)), leads to increased GlcNH(2) 6-phosphate and then UDP-GlcNAc levels. The GlcNH(2) treatments also increase O-GlcNAcylation and augment the aforementioned fMLF-associated increase. In functional assays, GlcNH(2) pre-treatment selectively augments fMLF-induced chemotaxis but has little effect on respiratory burst activity. Furthermore, augmenting levels of O-GlcNAc in the absence of agonist is sufficient to stimulate chemotaxis. These data demonstrate that neutrophils possess a functionally significant O-GlcNAcylation pathway that is robustly induced by stimulation with agonist. We propose that O-GlcNAcylation plays an important role in rapid and dynamic neutrophil signal transduction, especially with respect to chemotaxis.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Marchase, RB (corresponding author), Univ Alabama, Dept Cell Biol, 1918 Univ Blvd,MCLM 690, Birmingham, AL 35294 USA.	marchase@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055647] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK55647] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PC, 1984, BLOOD, V64, P883; ANDREWS PC, 1983, BLOOD, V61, P333; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; CALDWELL SE, 1988, J IMMUNOL, V140, P3560; Chen QD, 2003, J IMMUNOL, V170, P5302, DOI 10.4049/jimmunol.170.10.5302; CHOU TY, 1995, P NATL ACAD SCI USA, V92, P4417, DOI 10.1073/pnas.92.10.4417; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Ding M, 1996, J BIOL CHEM, V271, P12555, DOI 10.1074/jbc.271.21.12555; Downey GP, 1998, J IMMUNOL, V160, P434; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; Frevert CW, 1998, J IMMUNOL METHODS, V213, P41, DOI 10.1016/S0022-1759(98)00016-7; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Griffith LS, 1999, EUR J BIOCHEM, V262, P824, DOI 10.1046/j.1432-1327.1999.00439.x; GRIFFITH LS, 1995, J NEUROSCI RES, V41, P270, DOI 10.1002/jnr.490410214; HALLET MB, 1997, MOL IONIC SIGNALING; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; HART GW, 1995, ADV EXP MED BIOL, V376, P115; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Hiromura M, 2003, J BIOL CHEM, V278, P14046, DOI 10.1074/jbc.M300789200; HOLT GD, 1987, J BIOL CHEM, V262, P14847; Iyer SPN, 2003, BIOCHEMISTRY-US, V42, P2493, DOI 10.1021/bi020685a; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Konrad RJ, 2002, BIOCHEM BIOPH RES CO, V293, P207, DOI 10.1016/S0006-291X(02)00200-0; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; MARSHALL S, 2004, J BIOL CHEM, P824; McClain DA, 2002, J DIABETES COMPLICAT, V16, P72, DOI 10.1016/S1056-8727(01)00188-X; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; Parker GJ, 2003, J BIOL CHEM, V278, P10022, DOI 10.1074/jbc.M207787200; ROBINSON KA, 1995, DIABETES, V44, P1438, DOI 10.2337/diabetes.44.12.1438; Slawson C, 2001, BBA-MOL BASIS DIS, V1537, P147, DOI 10.1016/S0925-4439(01)00067-9; Traynor AJ, 1996, J MED CHEM, V39, P2894, DOI 10.1021/jm960175c; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006; Walgren JLE, 2003, AM J PHYSIOL-ENDOC M, V284, pE424, DOI 10.1152/ajpendo.00382.2002; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Wells L, 2003, FEBS LETT, V546, P154, DOI 10.1016/S0014-5793(03)00641-0; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Yao PJ, 1998, J NEUROSCI, V18, P2399; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zu YL, 1998, J IMMUNOL, V160, P1982	54	51	51	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45759	45765		10.1074/jbc.M407911200	http://dx.doi.org/10.1074/jbc.M407911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322139	hybrid			2022-12-25	WOS:000224694900059
J	Kotake, T; Yamaguchi, D; Ohzono, H; Hojo, S; Kaneko, S; Ishida, HK; Tsumuraya, Y				Kotake, T; Yamaguchi, D; Ohzono, H; Hojo, S; Kaneko, S; Ishida, HK; Tsumuraya, Y			UDP-sugar pyrophosphorylase with broad substrate specificity toward various monosaccharide 1-phosphates from pea sprouts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE PYROPHOSPHORYLASE; L-ARABINOSE; ENZYMATIC-SYNTHESIS; POTATO-TUBER; CDNA CLONING; D-XYLOSE; PURIFICATION; ARABIDOPSIS; PLANTS; BIOSYNTHESIS	UDP-sugars, activated forms of monosaccharides, are synthesized through de novo and salvage pathways and serve as substrates for the synthesis of polysaccharides, glycolipids, and glycoproteins in higher plants. A UDP-sugar pyrophosphorylase, designated PsUSP, was purified about 1,200-fold from pea ( Pisum sativum L.) sprouts by conventional chromatography. The apparent molecular mass of the purified PsUSP was 67,000 Da. The enzyme catalyzed the formation of UDP-Glc, UDP-Gal, UDP-glucuronic acid, UDP-L-arabinose, and UDP-xylose from respective monosaccharide 1-phosphates in the presence of UTP as a co-substrate, indicating that the enzyme has broad substrate specificity toward monosaccharide 1-phosphates. Maximum activity of the enzyme occurred at pH 6.5-7.5, and at 45 degreesC in the presence of 2 mM Mg2+. The apparent K-m values for Glc 1-phosphate and L-arabinose 1-phosphate were 0.34 and 0.96 mM, respectively. PsUSP cDNA was cloned by reverse transcriptase-PCR. PsUSP appears to encode a protein with a molecular mass of 66,040 Da ( 600 amino acids) and possesses a uridine-binding site, which has also been found in a human UDP-N-acetylhexosamine pyrophosphorylase. Phylogenetic analysis revealed that PsUSP can be categorized in a group together with homologues from Arabidopsis and rice, which is distinct from the UDP-Glc and UDP-N-acetylhexosamine pyrophosphorylase groups. Recombinant PsUSP expressed in Escherichia coli catalyzed the formation of UDP-sugars from monosaccharide 1-phosphates and UTP with efficiency similar to that of the native enzyme. These results indicate that the enzyme is a novel type of UDP-sugar pyrophosphorylase, which catalyzes the formation of various UDP-sugars at the end of salvage pathways in higher plants.	Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, Saitama 3388570, Japan; Natl Food Res Inst, Biol Funct Div, Tsukuba, Ibaraki 3058642, Japan; Noguchi Inst, Itabashi Ku, Tokyo 1730003, Japan	Saitama University; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Kotake, T (corresponding author), Saitama Univ, Fac Sci, Dept Biochem & Mol Biol, Sakura Ku, 255 Shimo Okubo, Saitama 3388570, Japan.	kotake@molbiol.saitama-u.ac.jp	Tsumuraya, Yoichi/C-7903-2012; KOTAKE, TOSHIHISA/F-1117-2011	KOTAKE, TOSHIHISA/0000-0002-1110-5006				ASPINALL GO, 1972, CAN J BIOCHEM CELL B, V50, P574, DOI 10.1139/o72-079; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burget EG, 1999, PLANT PHYSIOL, V121, P383, DOI 10.1104/pp.121.2.383; DOBLIN MS, 2003, PLANT CELL WALL ANN, V8, P183; DOLEZAL O, 1991, PLANT PHYSIOL, V96, P1255, DOI 10.1104/pp.96.4.1255; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Ernst C, 2003, J ORG CHEM, V68, P5780, DOI 10.1021/jo034379u; Feingold DS, 1980, BIOCH PLANTS, V3, P101, DOI [10.1016/B978-0-12-675403-2.50010-7, DOI 10.1016/B978-0-12-675403-2.50010-7]; GINSBURG V, 1956, P NATL ACAD SCI USA, V42, P333, DOI 10.1073/pnas.42.6.333; GUSTAFSON LG, 1972, J BIOL CHEM, V247, P1387; Harper AD, 2002, PLANT PHYSIOL, V130, P2188, DOI 10.1104/pp.009654; KATSUBE T, 1990, J BIOCHEM-TOKYO, V108, P321, DOI 10.1093/oxfordjournals.jbchem.a123200; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kim JS, 1999, BIOTECHNOL APPL BIOC, V29, P11; Kobayashi M, 2002, PLANT CELL PHYSIOL, V43, P1259, DOI 10.1093/pcp/pcf157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACDONALD DK, 1962, J ORG CHEM, V27, P1107, DOI 10.1021/jo01050a552; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; O'Neill MA, 2001, SCIENCE, V294, P846, DOI 10.1126/science.1062319; Pauly M, 2000, ANAL BIOCHEM, V278, P69, DOI 10.1006/abio.1999.4411; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Reiter WD, 2001, PLANT MOL BIOL, V47, P95, DOI 10.1023/A:1010671129803; ROSEMAN S, 1961, J AM CHEM SOC, V83, P659, DOI 10.1021/ja01464a035; RUDICK VL, 1974, J BIOL CHEM, V249, P7832; SOWOKINOS JR, 1993, PLANT PHYSIOL, V101, P1073, DOI 10.1104/pp.101.3.1073; TUBOI KK, 1969, J BIOL CHEM, V244, P1008; Wang-Gillam A, 2000, J BIOL CHEM, V275, P1433, DOI 10.1074/jbc.275.2.1433; YAMAMOTO R, 1988, PLANT PHYSIOL, V86, P1223, DOI 10.1104/pp.86.4.1223	30	99	102	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45728	45736		10.1074/jbc.M408716200	http://dx.doi.org/10.1074/jbc.M408716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326166	hybrid			2022-12-25	WOS:000224694900055
J	Whittier, JE; Xiong, YJ; Rechsteiner, MC; Squier, TC				Whittier, JE; Xiong, YJ; Rechsteiner, MC; Squier, TC			Hsp90 enhances degradation of oxidized calmodulin by the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; 20S PROTEASOME; OXIDATIVE INACTIVATION; DEPENDENT ACTIVATION; HYDROGEN-PEROXIDE; 26S PROTEASOME; S PROTEASOME; HEAT-SHOCK-PROTEIN-90; COMPLEX; BINDING	The 20 S proteasome has been suggested to play a critical role in mediating the degradation of abnormal proteins under conditions of oxidative stress and has been found in tight association with the molecular chaperone Hsp90. To elucidate the role of Hsp90 in promoting the degradation of oxidized calmodulin (CaMox), we have purified red blood cell 20 S proteasomes free of Hsp90 and assessed their ability to degrade CaMox in the absence or presence of Hsp90. Purified 20 S proteasome does not degrade CaMox unless Hsp90 is added. CaMox degradation is sensitive to both proteasome and Hsp90-specific inhibitors and is further enhanced in the presence of 2 mM ATP. Irrespective of the presence of Hsp90, we find that unoxidized CaM is not significantly degraded. Direct binding measurements demonstrate that Hsp90 selectively associates with CaMox; essentially no binding is observed between Hsp90 and unoxidized CaM. These results indicate that Hsp90 in association with the 20 S proteasome can selectively associate with oxidized and partially unfolded CaM to promote degradation by the proteasome.	Pacific NW Natl Lab, Div Biol Sci, Cell Biol & Biochem Grp, Richland, WA 99352 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	United States Department of Energy (DOE); Pacific Northwest National Laboratory; Utah System of Higher Education; University of Utah	Squier, TC (corresponding author), Pacific NW Natl Lab, Div Biol Sci, Cell Biol & Biochem Grp, POB 999,Mail Stop P7-53, Richland, WA 99352 USA.	thomas.squier@pnl.gov	Xiong, Yijia/C-1341-2011		NATIONAL INSTITUTE ON AGING [R01AG017996] Funding Source: NIH RePORTER; NIA NIH HHS [AG17996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balog EM, 2003, J BIOL CHEM, V278, P15615, DOI 10.1074/jbc.M209180200; Bartlett RK, 2003, BIOCHEMISTRY-US, V42, P3231, DOI 10.1021/bi026956z; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Boudeau J, 2003, BIOCHEM J, V370, P849, DOI 10.1042/BJ20021813; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Conconi M, 1999, ARCH BIOCHEM BIOPHYS, V362, P325, DOI 10.1006/abbi.1998.1037; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Eleuteri AM, 2002, PROTEINS, V48, P169, DOI 10.1002/prot.10101; Ferrington DA, 2001, J BIOL CHEM, V276, P937, DOI 10.1074/jbc.M005356200; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 2000, ANN NY ACAD SCI, V908, P143; Gao J, 1998, BIOPHYS J, V74, P1115, DOI 10.1016/S0006-3495(98)77830-0; Gao J, 1998, BIOCHEMISTRY-US, V37, P9536, DOI 10.1021/bi9803877; Gao J, 2001, BIOPHYS J, V80, P1791, DOI 10.1016/S0006-3495(01)76149-8; Garnier C, 2002, BIOCHEMISTRY-US, V41, P11770, DOI 10.1021/bi025650p; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Goasduff T, 2000, ARCH BIOCHEM BIOPHYS, V379, P321, DOI 10.1006/abbi.2000.1870; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Groll M, 2003, INT J BIOCHEM CELL B, V35, P606, DOI 10.1016/S1357-2725(02)00390-4; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; HASTINGS RH, 1992, J APPL PHYSIOL, V73, P1310, DOI 10.1152/jappl.1992.73.4.1310; Hendil KB, 1998, BIOCHEM J, V332, P749, DOI 10.1042/bj3320749; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; Hill CP, 2002, CURR TOP MICROBIOL, V268, P73; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Husom AD, 2004, ARCH BIOCHEM BIOPHYS, V421, P67, DOI 10.1016/j.abb.2003.10.010; Imai J, 2003, EMBO J, V22, P3557, DOI 10.1093/emboj/cdg349; Imamura T, 1998, J BIOL CHEM, V273, P11183, DOI 10.1074/jbc.273.18.11183; Ishii T, 1999, J IMMUNOL, V162, P1303; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; Kisselev AF, 2000, J BIOL CHEM, V275, P14831, DOI 10.1074/jbc.275.20.14831; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu XH, 2001, ARCH BIOCHEM BIOPHYS, V387, P163, DOI 10.1006/abbi.2001.2270; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Marcu MG, 2003, CURR CANCER DRUG TAR, V3, P343, DOI 10.2174/1568009033481804; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matayoshi E, 2001, SPRINGER SERIES CHEM, V65, P84; Maupin-Furlow JA, 1998, J BACTERIOL, V180, P1480, DOI 10.1128/JB.180.6.1480-1487.1998; Minami Y, 2000, J BIOL CHEM, V275, P9055, DOI 10.1074/jbc.275.12.9055; Montel V, 1999, BIOCHEM MOL BIOL INT, V47, P465; Montgomery HJ, 2003, BIOCHEMISTRY-US, V42, P7759, DOI 10.1021/bi027097h; Nardai G, 2002, EXP GERONTOL, V37, P1257, DOI 10.1016/S0531-5565(02)00134-1; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Osmulski PA, 2002, BIOCHEMISTRY-US, V41, P7047, DOI 10.1021/bi0159130; Osmulski PK, 2000, J BIOL CHEM, V275, P13171, DOI 10.1074/jbc.C901035199; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Rechsteiner M, 2000, BIOCHEM J, V345, P1, DOI 10.1042/0264-6021:3450001; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; Roe SM, 2004, CELL, V116, P87, DOI 10.1016/S0092-8674(03)01027-4; SCHWILLE P, 2004, SINGLE MOL TECHNIQUE; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Shringarpure R, 2002, FREE RADICAL BIO MED, V32, P1084, DOI 10.1016/S0891-5849(02)00824-9; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Sreedhar AS, 2004, FEBS LETT, V562, P11; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WAGNER BJ, 1995, ARCH BIOCHEM BIOPHYS, V323, P455, DOI 10.1006/abbi.1995.0067; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; Yin D, 2000, CHEM RES TOXICOL, V13, P103, DOI 10.1021/tx990142a; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	76	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46135	46142		10.1074/jbc.M406048200	http://dx.doi.org/10.1074/jbc.M406048200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15319444	hybrid			2022-12-25	WOS:000224694900100
J	Yin, L; Huang, L; Kufe, D				Yin, L; Huang, L; Kufe, D			MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED ANTIGEN; GROWTH-FACTOR RECEPTOR; BETA-CATENIN; CELL-CYCLE; C-SRC; PROTEIN; PATHWAY; DOMAIN; DF3; GENE	The MUC1 transforming protein is aberrantly overexpressed by most human carcinomas. Recent studies demonstrated that MUC1 confers a protective function against oxidative stress-induced apoptosis; however, the mechanisms responsible for this response are not known. The present work demonstrates that MUC1 regulates FKHRL1/FOXO3a, a member of the forkhead family of transcription factors that induces oxidant scavenging and DNA repair. We show that MUC1 attenuates activation of the phosphoinositide 3-kinase --> phosphoAkt/PKB pathway in HCT116 colon carcinoma cells and thereby decreases FOXO3a phosphorylation. MUC1 is expressed as an N-terminal ectodomain that is tethered to the cell surface by a C-terminal transmembrane subunit. The results demonstrate that the MUC1 cytoplasmic domain is sufficient to induce FOXO3a activation and attenuation of oxidative stress. We also demonstrate that stable down-regulation of endogenous MUC1 in ZR75-1 breast cancer cells inactivates FOXO3a, increases intracellular oxidant levels, and sensitizes cells to H2O2-induced necrosis. These findings indicate that MUC1 regulates the FOXO3a signaling pathway in a survival response to oxidative stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu			NCI NIH HHS [CA98628, CA97098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA098628] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BRUNET A, 1999, CELL, V17, P1959; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Huang L, 2003, CANCER BIOL THER, V2, P702; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2003, MOL CANCER RES, V1, P765; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; MERLO GR, 1989, CANCER RES, V49, P6966; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Raina D, 2004, J BIOL CHEM, V279, P20607, DOI 10.1074/jbc.M310538200; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yin L, 2003, J BIOL CHEM, V278, P35458, DOI 10.1074/jbc.M301987200	30	83	95	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45721	45727		10.1074/jbc.M408027200	http://dx.doi.org/10.1074/jbc.M408027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15322085	hybrid			2022-12-25	WOS:000224694900054
J	Fujii, I; Yasuoka, Y; Tsai, HF; Chang, YC; Kwon-Chung, KJ; Ebizuka, Y				Fujii, I; Yasuoka, Y; Tsai, HF; Chang, YC; Kwon-Chung, KJ; Ebizuka, Y			Hydrolytic polyketide shortening by Ayg1p, a novel enzyme involved in fungal melanin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HYDROLASE; SYNTHASE; DEGRADATION; GENES; MECHANISM; ACID; IDENTIFICATION; PENTAKETIDE; EXPRESSION	The pentaketide 1,3,6,8-tetrahydroxynaphthalene (T4HN) is a key precursor of 1,8-dihydroxynaphthalenemelanin, an important virulence factor in pathogenic fungi, where T4HN is believed to be the direct product of pentaketide synthases. We showed recently the involvement of a novel protein, Ayg1p, in the formation of T4HN from the heptaketide precursor YWA1 in Aspergillus fumigatus. To investigate the mechanism of its enzymatic function, Ayg1p was purified from an Aspergillus oryzae strain that overexpressed the ayg1 gene. The Ayg1p converted the naphthopyrone YWA1 to T4HN with a release of the acetoacetic acid. Although Ayg1p does not show significant homology with known enzymes, a serine protease-type hydrolytic motif is present in its sequence, and serine-specific inhibitors strongly inhibited the activity. To identify its catalytic residues, site-directed Ayg1p mutants were expressed in Escherichia coli, and their enzyme activities were examined. The single substitution mutations S257A, D352A, and H380A resulted in a complete loss of enzyme activity in Ayg1p. These results indicated that the catalytic triad Asp(352)-His(380)-Ser(257) constituted the active-site of Ayg1p. From a Dixon plot analysis, 2-acetyl-1,3,6,8-tetrahydroxynaphthalene was found to be a strong mixed-type inhibitor, suggesting the involvement of an acyl-enzyme intermediate. These studies support the mechanism in which the Ser(257) at the active site functions as a nucleophile to attack the YWA1 side-chain 1'-carbonyl and cleave the carbon-carbon bond between the naphthalene ring and the side chain. Acetoacetic acid is subsequently released from the Ser(257)-O-acetoacetylated Ayg1p by hydrolysis. An enzyme with activity similar to Ayg1p in melanin biosynthesis has not been reported in any other organism.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA	University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fujii, I (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	ifujii@mol.f.u-tokyo.ac.jp						Aoki H, 1996, J FERMENT BIOENG, V81, P187, DOI 10.1016/0922-338X(96)82207-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANCILLA DA, 1992, J CHROMATOGR, V627, P1, DOI 10.1016/0021-9673(92)87181-7; DIAZ E, 1995, J BIOL CHEM, V270, P6403, DOI 10.1074/jbc.270.11.6403; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; Fujii I, 2000, BIOCHEMISTRY-US, V39, P8853, DOI 10.1021/bi000644j; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Grogan G, 2002, J MOL CATAL B-ENZYM, V19, P73, DOI 10.1016/S1381-1177(02)00153-4; Grogan G, 2001, J BIOL CHEM, V276, P12565, DOI 10.1074/jbc.M011538200; Habe H, 1996, APPL ENVIRON MICROB, V62, P4471, DOI 10.1128/AEM.62.12.4471-4477.1996; HARPER JW, 1985, BIOCHEMISTRY-US, V24, P1831, DOI 10.1021/bi00329a005; Jaspers MCM, 2001, J BACTERIOL, V183, P270, DOI 10.1128/JB.183-1.270-279.2001; KWONCHUNG KJ, 1992, MED MYCOL, P201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam WWY, 1997, BIOCHEMISTRY-US, V36, P12242, DOI 10.1021/bi971115r; MENN FM, 1991, GENE, V104, P91, DOI 10.1016/0378-1119(91)90470-V; Momany C, 2004, BIOCHEMISTRY-US, V43, P1193, DOI 10.1021/bi035744e; Nandhagopal N, 2001, J MOL BIOL, V309, P1139, DOI 10.1006/jmbi.2001.4737; OHAGEN D, 1991, POLYKETIDE METABOLIT; Timm DE, 1999, STRUCTURE, V7, P1023, DOI 10.1016/S0969-2126(99)80170-1; Tsai HF, 1999, J BACTERIOL, V181, P6469, DOI 10.1128/JB.181.20.6469-6477.1999; Tsai HF, 1997, MOL MICROBIOL, V26, P175, DOI 10.1046/j.1365-2958.1997.5681921.x; Tsai HF, 2001, J BIOL CHEM, V276, P29292, DOI 10.1074/jbc.M101998200; WASHBURN RG, 1996, MYCOTA, V6, P147; Watanabe A, 1999, TETRAHEDRON LETT, V40, P91, DOI 10.1016/S0040-4039(98)80027-0; Watanabe A, 2000, FEMS MICROBIOL LETT, V192, P39, DOI 10.1111/j.1574-6968.2000.tb09356.x; Watanabe A, 2002, TETRAHEDRON LETT, V43, P843, DOI 10.1016/S0040-4039(01)02251-1; WHEELER MH, 1988, CURRENT TOPICS MED M, V2; Whittingham JL, 2003, J BIOL CHEM, V278, P1744, DOI 10.1074/jbc.M211188200; Yamada A, 1998, APPL ENVIRON MICROB, V64, P2006	31	72	78	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44613	44620		10.1074/jbc.M406758200	http://dx.doi.org/10.1074/jbc.M406758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310761	hybrid			2022-12-25	WOS:000224505600047
J	Koybasi, S; Senkal, CE; Sundararaj, K; Spassieva, S; Bielawski, J; Osta, W; Day, TA; Jiang, JC; Jazwinski, SM; Hannun, YA; Obeid, LM; Ogretmen, B				Koybasi, S; Senkal, CE; Sundararaj, K; Spassieva, S; Bielawski, J; Osta, W; Day, TA; Jiang, JC; Jazwinski, SM; Hannun, YA; Obeid, LM; Ogretmen, B			Defects in cell growth regulation by C-18 : 0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; TELOMERASE ACTIVITY; ENDOGENOUS CERAMIDE; INDUCED APOPTOSIS; LAG1; YEAST; INHIBITION; GENERATION; ACTIVATION; CANCER	In this study, endogenous long chain ceramides were measured in 32 human head and neck squamous cell carcinoma (HNSCC) and 10 nonsquamous head and neck carcinoma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/mass spectroscopy. Interestingly, only one specific ceramide, C-18:0-ceramide, was selectively down-regulated in the majority of HNSCC tumor tissues. On the other hand, in nonsquamous tumor tissues, this selectivity for C-18-ceramide was not detected. These data suggested the hypotheses that decreased levels of C-18-ceramide might impart a growth advantage to HNSCC cells and that increased generation of C-18-ceramide may be involved in the inhibition of growth. These roles were examined by reconstitution of C-18-ceramide at physiologically relevant concentrations in UM-SCC-22A cells ( squamous cell carcinoma of hypopharynx) via overexpression of mammalian upstream regulator of growth and differentiation factor 1 (mUOG1), a mouse homologue of longevity assurance gene 1 (mLAG1), which has been shown to specifically induce the generation of C-18-ceramide. Liquid chromatography/mass spectroscopy analysis showed that overexpression of the mLAG1/mUOG1 resulted in increased levels of only C-18:0-ceramide by similar to2-fold, i.e. concentrations similar to those of normal head and neck tissues. Importantly, increased generation of C-18-ceramide by mLAG1/mUOG1 inhibited cell growth (similar to70-80%), which mechanistically involved the modulation of telomerase activity and induction of apoptotic cell death by mitochondrial dysfunction. In conclusion, this study demonstrates, for the first time, a biological role for LAG1 and C-18-ceramide in the regulation of growth of HNSCC.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Abant Izzet Baysal Univ, Izzet Baysal Med Fac, Dept Otolaryngol, Bolu, Turkey	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Abant Izzet Baysal University	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	ogretmen@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [R01CA088932, P01CA097132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG006168, R37AG006168, R01AG016583] Funding Source: NIH RePORTER; NCI NIH HHS [CA-88932, CA-097132] Funding Source: Medline; NIA NIH HHS [AG06168, AG-16583] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; Dong G, 2001, CANCER RES, V61, P5911; Fabricius EM, 2002, ANAL CELL PATHOL, V24, P25, DOI 10.1155/2002/452527; Gleich Lyon L, 2002, Cancer Control, V9, P369; Guillas I, 2003, J BIOL CHEM, V278, P37083, DOI 10.1074/jbc.M307554200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Her C, 2001, AM FAM PHYSICIAN, V63, P1776; Jazwinski SM, 2002, INT J BIOCHEM CELL B, V34, P1491, DOI 10.1016/S1357-2725(02)00044-4; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kraveka JM, 2003, ARCH BIOCHEM BIOPHYS, V419, P110, DOI 10.1016/j.abb.2003.08.034; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Liao CT, 2004, HEAD NECK-J SCI SPEC, V26, P504, DOI 10.1002/hed.20007; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Mehta S, 2000, CANCER CHEMOTH PHARM, V46, P85, DOI 10.1007/s002800000140; Nguyen DC, 2003, INT J ONCOL, V22, P1285; Obeid Lina M, 2003, Sci Aging Knowledge Environ, V2003, pPE27, DOI 10.1126/sageke.2003.39.pe27; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Patel MM, 2002, HEAD NECK-J SCI SPEC, V24, P1060, DOI 10.1002/hed.10169; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Pettus BJ, 2004, RAPID COMMUN MASS SP, V18, P577, DOI 10.1002/rcm.1373; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Sullards MC, 2003, CELL MOL BIOL, V49, P789; Sullards MC, 2000, METHOD ENZYMOL, V312, P32; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Yu HP, 2004, J SURG ONCOL, V86, P99, DOI 10.1002/jso.20050	34	165	176	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44311	44319		10.1074/jbc.M406920200	http://dx.doi.org/10.1074/jbc.M406920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15317812	hybrid			2022-12-25	WOS:000224505600012
J	Ehlers, I; Horke, S; Reumann, K; Rang, A; Grosse, F; Will, H; Heise, T				Ehlers, I; Horke, S; Reumann, K; Rang, A; Grosse, F; Will, H; Heise, T			Functional characterization of the interaction between human La and hepatitis B virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED TRANSLATION; CYTOTOXIC T-LYMPHOCYTES; ALBUMIN MESSENGER-RNA; INTERFERON-ALPHA; GENE-EXPRESSION; ENDORIBONUCLEASE ACTIVITY; 3'-UNTRANSLATED REGION; RIBONUCLEASE-ACTIVITY; BINDING PROTEINS; TRANSGENIC MICE	The La protein is a multifunctional RNA-binding protein and has also been suggested to be involved in the stabilization of hepatitis B virus (HBV) RNA. Here we demonstrate that antibodies against the human La protein specifically precipitate HBV RNA from HBV ribonucleoprotein-containing mammalian cell extracts, providing evidence for the association between human La and HBV RNA. Moreover, we report that the turnover of HBV RNA depends on structural features and less on the primary sequence of the La-binding site on the viral RNA. In addition we show that the interaction between human La and HBV RNA in vitro is modulated by accessory factor(s) in a phosphorylation-dependent manner. Taken together these data indicate that both structural features, the composition of La/HBV ribonucleoprotein particles as well as interacting cellular factors, are critical determinants in the regulation of the stability of the HBV RNA.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20206 Hamburg, Germany; Biochem Abt, Inst Mol Biotechnol, D-07745 Jena, Germany	Heinrich Pette Institute; University of Hamburg	Heise, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Postfac 201652,Martinistr 52, D-20206 Hamburg, Germany.	heise@hpi.uni-hamburg.de						Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; BACHMANN M, 1989, J GEN VIROL, V70, P881, DOI 10.1099/0022-1317-70-4-881; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chernokalskaya E, 1997, NUCLEIC ACIDS RES, V25, P735, DOI 10.1093/nar/25.4.735; Chisari FV, 1997, J CLIN INVEST, V99, P1472, DOI 10.1172/JCI119308; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; GUIDOTTI LG, 1994, P NATL ACAD SCI USA, V91, P3764, DOI 10.1073/pnas.91.9.3764; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Heise T, 2001, J VIROL, V75, P6874, DOI 10.1128/JVI.75.15.6874-6883.2001; Heise T, 1999, J VIROL, V73, P474, DOI 10.1128/JVI.73.1.474-481.1999; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Heise T, 1998, BIOL CHEM, V379, P875, DOI 10.1515/bchm.1998.379.7.875; Heise TD, 2000, CHRONIC HEPATITIS NE, P23; Horke S, 2002, J BIOL CHEM, V277, P34949, DOI 10.1074/jbc.M201911200; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Jensen TH, 2003, MOL CELL, V11, P1129, DOI 10.1016/S1097-2765(03)00191-6; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Klocker U, 2000, J VIROL, V74, P5525, DOI 10.1128/JVI.74.12.5525-5533.2000; Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; MALTER JS, 1991, J BIOL CHEM, V266, P3167; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Rang A, 1999, J HEPATOL, V31, P791, DOI 10.1016/S0168-8278(99)80279-7; Rang A, 2000, NUCLEIC ACIDS RES, V28, P1120, DOI 10.1093/nar/28.5.1120; Rang A, 2002, J BIOL CHEM, V277, P7645, DOI 10.1074/jbc.C100729200; Robek MD, 2004, P NATL ACAD SCI USA, V101, P1743, DOI 10.1073/pnas.0308340100; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Schultz U, 1999, J VIROL, V73, P5459, DOI 10.1128/JVI.73.7.5459-5465.1999; Schultz UA, 1999, J VIROL, V73, P3162, DOI 10.1128/JVI.73.4.3162-3168.1999; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SELLS MA, 1987, P NATL ACAD SCI USA, V84, P1005, DOI 10.1073/pnas.84.4.1005; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim J, 2002, MOL CELLS, V14, P323; Shimazaki T, 2002, HEPATOLOGY, V35, P199, DOI 10.1053/jhep.2002.30202; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Wang ZR, 2000, EMBO J, V19, P295, DOI 10.1093/emboj/19.2.295; Wieland SF, 2003, J VIROL, V77, P1227, DOI 10.1128/JVI.77.2.1227-1236.2003	53	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43437	43447		10.1074/jbc.M402227200	http://dx.doi.org/10.1074/jbc.M402227200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15302879	hybrid			2022-12-25	WOS:000224383100013
J	Pesesse, X; Choi, K; Zhang, T; Shears, SB				Pesesse, X; Choi, K; Zhang, T; Shears, SB			Signaling by higher inositol Polyphosphates - Synthesis of bisdiphosphoinositol tetrakisphosphate ("InsP(8)") is selectively activated by hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; HEXAKISPHOSPHATE; PYROPHOSPHATES; INTEGRITY; PATHWAY; KINASES; MAPK; DICTYOSTELIUM; APOPTOSIS; RESPONSES	Evidence has accumulated that inositol pyrophosphates ( diphosphoinositol pentakisphosphate (PP-InsP(5)) and bisdiphosphoinositol tetrakisphosphate ([PP](2)-InsP(4))) are intracellular signals that regulate many cellular processes including endocytosis, vesicle trafficking, apoptosis, and DNA repair. Yet, in contrast to the situation with all other second messengers, no one studying multicellular organisms has previously described a stimulus that acutely and specifically elevates cellular levels of PP-InsP(5) or [PP](2)-InsP(4). We now show up to 25-fold elevations in [PP](2)-InsP(4) levels in animal cells. Importantly, this does not involve classical agonists. Instead, we show that this [PP](2)-InsP(4) response is a novel consequence of the activation of ERK1/2 and p38MAPalpha/beta kinases by hyperosmotic stress. JNK did not participate in regulating [PP](2)-InsP(4) levels. Identification of [PP](2)-InsP(4) as a sensor of hyperosmotic stress opens up a new area of research for studies into the cellular activities of higher inositol phosphates.	NIEHS, Inositide Signaling Grp, NIH, DHSS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Shears, SB (corresponding author), NIEHS, Inositide Signaling Grp, NIH, DHSS, POB 12233, Res Triangle Pk, NC 27709 USA.	shears@niehs.nih.gov	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046, ZIAES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bagowski CP, 2003, CURR BIOL, V13, P315, DOI 10.1016/S0960-9822(03)00083-6; Chiasson JL, 2003, CAN MED ASSOC J, V168, P859; Couchman JR, 2002, J BIOL CHEM, V277, P49296, DOI 10.1074/jbc.M209679200; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Harrison JC, 2004, J BIOL CHEM, V279, P2616, DOI 10.1074/jbc.M306110200; Haussinger D, 1996, BIOCHEM J, V313, P697; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; Hua LV, 2003, BIOCHEM J, V373, P81, DOI 10.1042/BJ20030142; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Kultz D, 2001, COMP BIOCHEM PHYS A, V130, P421, DOI 10.1016/S1095-6433(01)00440-8; Laussmann T, 2000, EUR J BIOCHEM, V267, P2447, DOI 10.1046/j.1432-1327.2000.01264.x; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	29	57	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43378	43381		10.1074/jbc.C400286200	http://dx.doi.org/10.1074/jbc.C400286200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15316027	hybrid			2022-12-25	WOS:000224383100005
J	Sauane, M; Gopalkrishnan, RV; Choo, HT; Gupta, P; Lebedeva, IV; Yacoub, A; Dent, P; Fisher, PB				Sauane, M; Gopalkrishnan, RV; Choo, HT; Gupta, P; Lebedeva, IV; Yacoub, A; Dent, P; Fisher, PB			Mechanistic aspects of mda-7/IL-24 cancer cell selectivity analysed via a bacterial fusion protein	ONCOGENE			English	Article						cancer gene therapy; GST-MDA-7/IL-24; apoptosis; breast cancer; radiotherapy	DIFFERENTIATION-ASSOCIATED GENE; APOPTOSIS INDUCING CYTOKINE; GLUTATHIONE-S-TRANSFERASE; HUMAN-MELANOMA CELLS; PANCREATIC-CANCER; MDA-7 IL-24; SUPPRESSOR GENE; IN-VITRO; GROWTH; PATHWAYS	The human mda-7/IL-24 gene product is normally expressed in melanocytes and certain lymphocyte populations. Loss of expression, a distinctive feature of many tumor suppressor genes, has been documented at RNA and protein levels in association with melanoma progression both in vitro as well as in human tumor-derived material. The MDA-7/IL-24 protein undergoes post-translational processing, including removal of an amino-terminal 48-residue signal peptide and extensive glycosylation prior to its secretion by producing cells. Its inherent cytokine properties have been documented in multiple reports, which have identified and characterized its cognate receptors and activation of the JAK/STAT signaling pathway following ligand/receptor docking. A notable and incompletely understood property of MDA-7/IL-24 is its ability to induce apoptosis in transformed cells, while having marginal growth suppressive effects on normal primary or immortalized cell lines. MDA-7/IL-24 has been delivered to cells, tumor xenografts and patients in clinical trials via a nonreplicating adenovirus (Ad.mda-7). Studies utilizing eukaryotically expressed and purified MDA-7/ IL-24 protein from several sources have recapitulated some of the molecule's reported properties including receptor binding and JAK/STAT activation. Here, we report the properties and characteristics of a bacterially expressed and purified GST-MDA-7 fusion protein. These studies reveal that GST-MDA-7 retains its cancer-selective apoptosis-inducing properties, thereby providing a new reagent that will assist in de. ning the mechanism of action of this novel cytokine. In addition, retention of tumor-specific activity of GST-MDA-7 suggests that this protein may also have therapeutic applications.	Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY 10027 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ, Coll Phys & Surg, Dept Neurosurg, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Urol, Med Ctr,Herbert Irving Comprehens Canc Ctr, New York, NY USA	Columbia University; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr,Herbert Irving Comprehens Canc Ctr, BB-1501,630 W 16th St, New York, NY 10027 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA097318, R01CA088906, R01CA098172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA097318, CA098172, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLASZKOWSKY L, 1998, FRONT BIOSCI, V3, P214; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chada S, 2001, CANCER GENE THER, V8, pS3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lorenz M, 2000, EUR J CANCER, V36, P957, DOI 10.1016/S0959-8049(00)00073-3; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9; Namiki S, 2003, BIOCHEM BIOPH RES CO, V305, P592, DOI 10.1016/S0006-291X(03)00807-6; NEMUNITAIS J, 2003, CANCER GENE THER, V10, pS106; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; PESTKA S, 2003, ENCY HORMONES, P507; Ramesh R, 2003, CANCER RES, V63, P5105; Regine William F., 1998, Frontiers in Bioscience, V3, pE186; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2004, CANCER RES, V64, P2988, DOI 10.1158/0008-5472.CAN-04-0200; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sieger KA, 2004, MOL THER, V9, P355, DOI 10.1016/j.ymthe.2003.11.014; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097-0045(20000201)42:2<88::AID-PROS2>3.0.CO;2-P; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, MOL CANCER THER, V2, P623; YACOUB A, 2004, IN PRESS CANC BIOL T; Zhan Y, 2001, GENE, V281, P1, DOI 10.1016/S0378-1119(01)00797-1	46	54	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7679	7690		10.1038/sj.onc.1207958	http://dx.doi.org/10.1038/sj.onc.1207958			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334067				2022-12-25	WOS:000224306700009
J	Wang, YS; Ju, W; Liu, LD; Fam, S; D'Souza, S; Taghibiglou, C; Salter, M; Wang, YT				Wang, YS; Ju, W; Liu, LD; Fam, S; D'Souza, S; Taghibiglou, C; Salter, M; Wang, YT			alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor (AMPAR) endocytosis is essential for N-methyl-D-aspartate-induced neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC-TRANSMISSION; CELL-DEATH; INTERNALIZATION; PLASTICITY; PATHWAYS; TRAFFICKING; LTD; AKT	Excessive activation of the N-methyl-D-aspartate subtype glutamate receptor (NMDAR) is thought to be involved in mediating programmed cell death (apoptosis) in numerous central nervous diseases. However, the underlying mechanisms remain unknown. We report here that stimulation of NMDARs activates intracellular signaling cascades leading to apoptosis and facilitates clathrin-dependent endocytosis of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptors (AMPARs). Both broad spectrum inhibitors of clathrin-dependent endocytotic processes and a specific inhibitor of AMPAR endocytosis selectively inhibit NMDA-induced apoptosis without affecting apoptosis produced by staurosporine. These results demonstrate that clathrin-dependent endocytosis of AMPARs is an essential step in NMDAR-mediated neuronal apoptosis. Our study not only identifies a previously unsuspected step in NMDA-induced apoptosis but also demonstrates that AMPAR endocytosis, in addition to attenuating synaptic strength as previously demonstrated in models of synaptic plasticity, may play a critical role in mediating other important intracellular pathways.	Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 2B5, Canada; Univ British Columbia, Dept Med, Vancouver Hosp & Hlth Sci Ctr, Vancouver, BC V6T 2B5, Canada; Univ Toronto, Programme Brain & Behav, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Def R&D Canada, Med Therapy Grp, Chem Biol Def Sect, Medicine Hat, AB T1A 8K6, Canada	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Defence Research & Development Canada	Wang, YT (corresponding author), Univ British Columbia, Brain Res Ctr, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.	ytwang@interchange.ubc.ca	Wang, Yu Tian/A-4729-2008; Wang, Yu Tian/J-8255-2015; Taghibiglou, Changiz/H-4590-2019	Liu, Lidong/0000-0002-7026-690X				Ahmadian G, 2004, EMBO J, V23, P1040, DOI 10.1038/sj.emboj.7600126; Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Coffer PJ, 1998, BIOCHEM J, V335, P1; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Graham SH, 2001, J CEREBR BLOOD F MET, V21, P99, DOI 10.1097/00004647-200102000-00001; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Man HY, 2000, CELL MOL LIFE SCI, V57, P1526, DOI 10.1007/PL00000637; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Marks B, 1998, CURR BIOL, V8, P740, DOI 10.1016/S0960-9822(98)70297-0; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nicotera P, 1999, J CEREBR BLOOD F MET, V19, P583, DOI 10.1097/00004647-199906000-00001; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 2000, NEURON, V25, P635, DOI 10.1016/S0896-6273(00)81066-1; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3	29	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 1	2004	279	40					41267	41270		10.1074/jbc.C400199200	http://dx.doi.org/10.1074/jbc.C400199200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	856WG	15319422	hybrid			2022-12-25	WOS:000224075500003
J	Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; Laurent-Puig, P; Zucman-Rossi, J				Rebouissou, S; Rosty, C; Lecuru, F; Boisselier, S; Bui, H; Le Frere-Belfa, MA; Sastre, X; Laurent-Puig, P; Zucman-Rossi, J			Mutation of TCF1 encoding hepatocyte nuclear factor 1 alpha in gynecological cancer	ONCOGENE			English	Article						endometrial cancer; ovarian cancer; breast cancer; hepatocyte nuclear factor 1; HNF1 alpha; gene mutation; liver cell adenoma; microsatellite instability; MSI-H	DNA-BINDING; POU DOMAIN; GENE; INACTIVATION; HNF-1-ALPHA; EXPRESSION; PROMOTER; LF-B1; YOUNG; PCR	TCF1 ( transcription factor 1) encoding hepatocyte nuclear factor 1alpha (HNF1alpha) is mutated in 50% of liver cell adenomas, a benign tumor closely associated with oral contraceptive use. These genetic alterations inactivate both alleles, leading to the absence of wild-type HNF1alpha expression in liver cell adenomas. To search for a role of HNF1alpha in other hormone-related neoplasias, we screened for HNF1alpha mutations in a series of 36 endometrial carcinomas, 29 breast carcinomas and 20 ovarian epithelial tumors. HNF1alpha mutations were identified in 4/ 36 (11%) of endometrial tumors. No mutation was found in ovarian and breast tumors. HNF1alpha mutations were somatic in all cases, monoallelic in three cases and biallelic in one case. These results suggest that HNF1alpha may contribute to endometrial carcinogenesis through complete HNF1alpha inactivation like in liver cell adenoma or by haploinsufficiency like in MSI-H colorectal cancer.	INSERM, U434, F-75010 Paris, France; Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, F-75010 Paris, France; Inst Curie, Serv Anatomopathol, F-75005 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Gynecol Serv, F-75015 Paris, France; Assistance Publ Hop Paris, Hop Europeen Georges Pompidou, Serv Anatomopathol, F-75015 Paris, France; INSERM, U490, Mol Toxicol Lab, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Foundation Jean Dausset-CEPH; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Zucman-Rossi, J (corresponding author), INSERM, U434, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; laurent-puig, pierre/B-2226-2013; Rosty, Christophe/F-1796-2010; Rebouissou, Sandra/O-5938-2017; zucman-rossi, Jessica/B-5098-2009; j, zucman-rossi/AAV-3594-2021	Laurent-Puig, Pierre/0000-0001-8475-5459; laurent-puig, pierre/0000-0001-8475-5459; Rebouissou, Sandra/0000-0003-0188-2271; zucman-rossi, Jessica/0000-0002-5687-0334; j, zucman-rossi/0000-0002-5687-0334; Rosty, Christophe/0000-0001-7671-2651				Aguanno A, 1996, J BIOL CHEM, V271, P4528; Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Bacq Y, 2003, GASTROENTEROLOGY, V125, P1470, DOI 10.1016/j.gastro.2003.07.012; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Bluteau O, 1999, BIOTECHNIQUES, V27, P1100, DOI 10.2144/99276bm01; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Bluteau O, 1999, GASTROEN CLIN BIOL, V23, P1225; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; Ellard S, 2000, HUM MUTAT, V16, P377, DOI 10.1002/1098-1004(200011)16:5<377::AID-HUMU1>3.0.CO;2-2; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HENDERSON BE, 1988, CANCER RES, V48, P246; Ishii Y, 2000, MOL PHARMACOL, V57, P940; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Laurent-Puig P, 2003, GASTROENTEROLOGY, V124, P1311, DOI 10.1016/S0016-5085(03)00268-3; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	19	19	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7588	7592		10.1038/sj.onc.1207989	http://dx.doi.org/10.1038/sj.onc.1207989			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326484				2022-12-25	WOS:000224176500016
J	De Felice, FG; Vieira, MNN; Saraiva, LM; Figueroa-Villar, JD; Garcia-Abreu, J; Liu, R; Chang, L; Klein, WL; Ferreira, ST				De Felice, FG; Vieira, MNN; Saraiva, LM; Figueroa-Villar, JD; Garcia-Abreu, J; Liu, R; Chang, L; Klein, WL; Ferreira, ST			Targeting the neurotoxic species in Alzheimer's disease: inhibitors of A beta oligomerization	FASEB JOURNAL			English	Article						amyloid; oligomers; neuroprotection; small molecule inhibitors	LONG-TERM POTENTIATION; REVERSIBLE MEMORY LOSS; FIBRILS IN-VITRO; AMYLOID-BETA; NERVOUS-SYSTEM; PROTEIN; MODEL; NEURODEGENERATION; IMMUNIZATION; AGGREGATION	In the past two decades, a large body of evidence has established a causative role for the beta-amyloid peptide (Abeta) in Alzheimer's disease (AD). However, recent debate has focused on whether amyloid fibrils or soluble oligomers of Abeta are the main neurotoxic species that contribute to neurodegeneration and dementia. Considerable early evidence has indicated that amyloid fibrils are toxic, but some recent studies support the notion that Abeta oligomers are the primary neurotoxins. While this crucial aspect of AD pathogenesis remains controversial, effective therapeutic strategies should ideally target both oligomeric and fibrillar species of Abeta. Here, we describe the anti-amyloidogenic and neuroprotective actions of some di- and tri-substituted aromatic compounds. Inhibition of the formation of soluble Abeta oligomers was monitored using a specific antibody-based assay that discriminates between Abeta oligomers and monomers. Thioflavin T and electron microscopy were used to screen for inhibitors of fibril formation. Taken together, these results led to the identification of compounds that more effectively block Abeta oligomerization than fibrillization. It is significant that such compounds completely blocked the neurotoxicity of Abeta to rat hippocampal neurons in culture. These findings provide a basis for the development of novel small molecule Abeta inhibitors with potential applications in AD.	Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Anat, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil; Inst Mil Engn, Dept Quim Organ, Rio De Janeiro, Brazil; Northwestern Univ, Dept Neurobiol & Physiol, Cognit Neurol & Alzheimers Dis Ctr, Inst Neurosci, Evanston, IL USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Instituto Militar de Engenharia (IME); Northwestern University	De Felice, FG (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21944590 Rio De Janeiro, Brazil.	felice@bioqmed.ufrj.br; ferreira@bioqmed.ufrj.br	De Felice, Fernanda G/M-1074-2017; Abreu, Jose G/G-6159-2010; Ferreira, Sergio/AAZ-1576-2020; Saraiva, Ligia M/H-8537-2012; Abreu, Jose G/ABB-1199-2021	Abreu, Jose G/0000-0002-9875-7786; Ferreira, Sergio/0000-0001-7160-9866; Saraiva, Ligia M/0000-0002-0675-129X; Abreu, Jose G/0000-0002-1363-1755				Birmingham K, 2002, NAT MED, V8, P199, DOI 10.1038/nm0302-199b; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chang L, 2003, J MOL NEUROSCI, V20, P305, DOI 10.1385/JMN:20:3:305; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; De Felice FG, 2002, CELL MOL NEUROBIOL, V22, P545, DOI 10.1023/A:1021832302524; DICKSON DW, 1995, NEUROBIOL AGING, V16, P285, DOI 10.1016/0197-4580(95)00013-5; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Gazit E, 2002, FASEB J, V16, P77, DOI 10.1096/fj.01-0442hyp; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Grace EA, 2002, NEUROSCIENCE, V114, P265, DOI 10.1016/S0306-4522(02)00241-5; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KIM HJ, 2003, FASEB J, V17, P118; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lin SJ, 2004, BIOORG MED CHEM LETT, V14, P1173, DOI 10.1016/j.bmcl.2003.12.086; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Raghu P, 2002, ARCH BIOCHEM BIOPHYS, V400, P43, DOI 10.1006/abbi.2002.2779; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2002, BIOCHEM SOC T, V30, P552, DOI 10.1042/BST0300552; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	42	157	175	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1366	1372		10.1096/fj.04-1764com	http://dx.doi.org/10.1096/fj.04-1764com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15333579				2022-12-25	WOS:000224243200055
J	Lee, LYL; Liang, XW; Hook, M; Brown, EL				Lee, LYL; Liang, XW; Hook, M; Brown, EL			Identification and characterization of the C3 binding domain of the Staphylococcus aureus extracellular fibrinogen-binding protein (Efb)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT REGULATORY PROTEIN; CHEMOTAXIS INHIBITORY PROTEIN; PANTON-VALENTINE LEUKOCIDIN; COMPLETE GENOME SEQUENCE; METHICILLIN-RESISTANT; FACTOR-H; PLATELET-AGGREGATION; BORRELIA-BURGDORFERI; LEISHMANIA-MEXICANA; SECONDARY STRUCTURE	The secreted Staphylococcus aureus extracellular fibrinogen-binding protein (Efb) is a virulence factor that binds to both the complement component C3b and fibrinogen. Our laboratory previously reported that by binding to C3b, Efb inhibited complement activation and blocked opsonophagocytosis. We have now located the Efb binding domain in C3b to the C3d fragment and determined a disassociation constant (K-d) of 0.24 muM for the Efb-C3d binding using intrinsic fluorescence quenching assays. Using truncated, recombinant forms of Efb, we also demonstrate that the C3b binding region of Efb is located within the C terminus, in contrast to the fibrinogen binding domains that are located at the N-terminal end of the protein. Enzyme-linked immunosorbent assay-type binding assays demonstrated that recombinant Efb could bind to both C3b and fibrinogen simultaneously, forming a trimolecular complex and that the C-terminal region of Efb could inhibit complement activity in vitro. In addition, secondary structure analysis using circular dichroism spectroscopy revealed that the C-terminal, C3b binding region of Efb is composed primarily of alpha-helices, suggesting that this domain of Efb represents a novel type of C3b-binding protein.	Texas A&M Univ Syst, Hlth Sci Ctr, Ctr Extracellular Matrix Biol, Albert B Alkek Inst Biosci & Technol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Brown, EL (corresponding author), Wyle Labs Bioastronaut Team, Human Adaptat & Countermeasures, Whyle HAC W1,1290 Hercules Dr,120,Off 408, Houston, TX 77058 USA.	ebrown@wylehou.com		Liang, Xiaowen/0000-0002-6174-2951				Boackle SA, 2003, BIOMED PHARMACOTHER, V57, P269, DOI 10.1016/S0753-3322(03)00084-2; Boackle Susan A, 2003, Curr Dir Autoimmun, V6, P154; BODEN MK, 1992, MICROB PATHOGENESIS, V12, P289, DOI 10.1016/0882-4010(92)90047-R; BODEN MK, 1994, MOL MICROBIOL, V12, P599, DOI 10.1111/j.1365-2958.1994.tb01046.x; BODEN MK, 1989, INFECT IMMUN, V57, P2358; Botto M, 1993, Int Rev Immunol, V10, P37, DOI 10.3109/08830189309051170; Chavakis T, 2002, NAT MED, V8, P687, DOI 10.1038/nm728; CHINA B, 1993, INFECT IMMUN, V61, P3129, DOI 10.1128/IAI.61.8.3129-3136.1993; Cunnion KM, 2003, INFECT IMMUN, V71, P656, DOI 10.1128/IAI.71.2.656-662.2003; Cunnion KM, 2001, INFECT IMMUN, V69, P6796, DOI 10.1128/IAI.69.11.6796-6803.2001; de Haas CJC, 2004, J EXP MED, V199, P687, DOI 10.1084/jem.20031636; Dobson DE, 2003, J BIOL CHEM, V278, P15523, DOI 10.1074/jbc.M301568200; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; Haas KM, 2004, J IMMUNOL, V172, P5833, DOI 10.4049/jimmunol.172.10.5833; Hall AV, 1998, J CLIN PATHOL, V51, P215, DOI 10.1136/jcp.51.3.215; HALL RT, 1993, INFECT IMMUN, V61, P1829, DOI 10.1128/IAI.61.5.1829-1834.1993; HAVILAND DL, 1999, ENCY MOL BIOL, P525; Heilmann C, 2002, J INFECT DIS, V186, P32, DOI 10.1086/341081; HIGH AS, 1993, J GEN MICROBIOL, V139, P1715, DOI 10.1099/00221287-139-8-1715; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; HONG YQ, 1992, CLIN IMMUNOL IMMUNOP, V62, P133, DOI 10.1016/0090-1229(92)90065-V; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; KIM HS, 1978, AM J CLIN PATHOL, V70, P18; Kirschfink M, 2001, IMMUNOL REV, V180, P177, DOI 10.1034/j.1600-065X.2001.1800116.x; KISSANE JM, 1997, PATHOLOGY INFECT DIS, V1, P805; Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2; LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; Lee LYL, 2004, J INFECT DIS, V190, P571, DOI 10.1086/422259; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Lubinski JM, 1998, J VIROL, V72, P8257, DOI 10.1128/JVI.72.10.8257-8263.1998; Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9; Martinez-Aguilar G, 2003, PEDIATR INFECT DIS J, V22, P593, DOI 10.1097/00006454-200307000-00006; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V57, P31, DOI 10.1016/0166-6851(93)90241-O; Meri T, 2002, INFECT IMMUN, V70, P5185, DOI 10.1128/IAI.70.9.5185-5192.2002; Mueller-Ortiz SL, 2001, INFECT IMMUN, V69, P7501, DOI 10.1128/IAI.69.12.7501-7511.2001; Na'was T, 1998, J CLIN MICROBIOL, V36, P414; Naimi TS, 2001, CLIN INFECT DIS, V33, P990, DOI 10.1086/322693; Nimmo GR, 2000, J CLIN MICROBIOL, V38, P3926, DOI 10.1128/JCM.38.11.3926-3931.2000; Norris KA, 1996, MICROB PATHOGENESIS, V21, P235, DOI 10.1006/mpat.1996.0058; NORRIS KA, 1991, J IMMUNOL, V147, P2240; Okuma K, 2002, J CLIN MICROBIOL, V40, P4289, DOI 10.1128/JCM.40.11.4289-4294.2002; Palma M, 1996, INFECT IMMUN, V64, P5284, DOI 10.1128/IAI.64.12.5284-5289.1996; Palma M, 1998, J BIOL CHEM, V273, P13177, DOI 10.1074/jbc.273.21.13177; Palma M, 2001, J BIOL CHEM, V276, P31691, DOI 10.1074/jbc.M104554200; PANCOSKA P, 1992, BIOCHEMISTRY-US, V31, P10250, DOI 10.1021/bi00157a011; Pandiripally V, 2002, INFECT IMMUN, V70, P6206, DOI 10.1128/IAI.70.11.6206-6214.2002; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PELEG D, 1992, PEDIATR INFECT DIS J, V11, P401, DOI 10.1097/00006454-199205000-00011; Perkins SJ, 2002, BIOCHEM SOC T, V30, P996, DOI 10.1042/bst0300996; Perkins SJ, 2002, J MOL BIOL, V316, P217, DOI 10.1006/jmbi.2001.5337; Petros S, 1998, INTENS CARE MED, V24, P189, DOI 10.1007/s001340050544; Postma B, 2004, J IMMUNOL, V172, P6994, DOI 10.4049/jimmunol.172.11.6994; Prodinger WM, 1999, FUNDAMENTAL IMMUNOLO, P967; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Rost B, 1996, METHOD ENZYMOL, V266, P525; Rost B, 1997, PROTEINS, P192; RUSSELL DG, 1987, EUR J BIOCHEM, V164, P213, DOI 10.1111/j.1432-1033.1987.tb11013.x; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; Sattler CA, 2002, PEDIATR INFECT DIS J, V21, P910, DOI 10.1097/00006454-200210000-00005; SCHLESINGER LS, 1990, J CLIN INVEST, V85, P1304, DOI 10.1172/JCI114568; Shannon O, 2004, THROMB HAEMOSTASIS, V91, P779, DOI 10.1160/TH03-05-0287; SOPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stevens MP, 2004, J CLIN MICROBIOL, V42, P2501, DOI 10.1128/JCM.42.6.2501-2507.2004; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Tacconelli E, 1998, NEW ENGL J MED, V339, P2026; Totan Mehmet, 2002, Indian Journal of Pediatrics, V69, P625, DOI 10.1007/BF02722692; Wade D, 1998, BIOCHEM BIOPH RES CO, V248, P690, DOI 10.1006/bbrc.1998.9028; WASTFELT MKB, 1995, J CLIN MICROBIOL, V33, P2347; WILKINSON BJ, 1979, INFECT IMMUN, V26, P1159, DOI 10.1128/IAI.26.3.1159-1163.1979; Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971	77	100	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50710	50716		10.1074/jbc.M408570200	http://dx.doi.org/10.1074/jbc.M408570200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15337748	hybrid			2022-12-25	WOS:000225355800012
J	Paling, NRD; Wheadon, H; Bone, HK; Welham, MJ				Paling, NRD; Wheadon, H; Bone, HK; Welham, MJ			Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; PLURIPOTENTIAL CELLS; MOUSE EMBRYOS; ES CELLS; DIFFERENTIATION; EXPRESSION; STAT3	The maintenance of murine embryonic stem (ES) cell self-renewal is regulated by leukemia inhibitory factor (LIF)-dependent activation of signal transducer and activator of transcription 3 (STAT3) and LIF-independent mechanisms including Nanog, BMP2/4, and Wnt signaling. Here we demonstrate a previously undescribed role for phosphoinositide 3-kinases (PI3Ks) in regulation of murine ES cell self-renewal. Treatment with the reversible PI3K inhibitor, LY294002, or more specific inhibition of class I-A PI3K via regulated expression of dominant negative Deltap85, led to a reduction in the ability of LIF to maintain self-renewal, with cells concomitantly adopting a differentiated morphology. Inhibition of PI3Ks reduced basal and LIF-stimulated phosphorylation of PKB/Akt, GSK3alpha/beta, and S6 proteins. Importantly, LY294002 and Deltap85 expression had no effect on LIF-induced phosphorylation of STAT3 at Tyr(705), but did augment LIF-induced phosphorylation of ERKs in both short and long term incubations. Subsequently, we demonstrate that inhibition of MAP-Erk kinases (MEKs) reverses the effects of PI3K inhibition on self-renewal in a time- and dose-dependent manner, suggesting that the elevated ERK activity observed upon PI3K inhibition contributes to the functional response we observe. Surprisingly, upon long term inhibition of PI3Ks we observed a reduction in phosphorylation of beta-catenin, the target of GSK-3 action in the canonical Wnt pathway, although no consistent alterations in cytosolic levels of beta-catenin were observed, indicating this pathway is not playing a major role downstream of PI3Ks. Our studies support a role for PI3Ks in regulation of self-renewal and increase our understanding of the molecular signaling components involved in regulation of stem cell fate.	Univ Bath, Ctr Regenerat Med, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England	University of Bath	Welham, MJ (corresponding author), Univ Bath, Ctr Regenerat Med, Dept Pharm & Pharmacol, Claverton Down, Bath BA2 7AY, Avon, England.	M.J.Welham@bath.ac.uk		Paling, Nicholas/0000-0002-6358-1119; Wheadon, Helen/0000-0001-9902-3170				Anneren C, 2004, J BIOL CHEM, V279, P31590, DOI 10.1074/jbc.M403547200; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Boeuf H, 2001, J BIOL CHEM, V276, P46204, DOI 10.1074/jbc.M106718200; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Dani C, 1998, DEV BIOL, V203, P149, DOI 10.1006/dbio.1998.9026; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Ernst M, 1996, J BIOL CHEM, V271, P30136, DOI 10.1074/jbc.271.47.30136; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Hallmann D, 2003, J BIOL CHEM, V278, P5099, DOI 10.1074/jbc.M208451200; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Nemetz C, 1998, DIFFERENTIATION, V62, P213, DOI 10.1046/j.1432-0436.1998.6250213.x; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Qi XX, 2004, P NATL ACAD SCI USA, V101, P6027, DOI 10.1073/pnas.0401367101; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Runyan CE, 2004, J BIOL CHEM, V279, P2632, DOI 10.1074/jbc.M310412200; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Scutt A, 1999, CALCIFIED TISSUE INT, V64, P69, DOI 10.1007/s002239900581; SMITH AG, 1987, DEV BIOL, V121, P1, DOI 10.1016/0012-1606(87)90132-1; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	50	330	392	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48063	48070		10.1074/jbc.M406467200	http://dx.doi.org/10.1074/jbc.M406467200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15328362	hybrid			2022-12-25	WOS:000224957000078
J	Anter, E; Thomas, SR; Schulz, E; Shapira, OM; Vita, JA; Keaney, JF				Anter, E; Thomas, SR; Schulz, E; Shapira, OM; Vita, JA; Keaney, JF			Activation of endothelial nitric-oxide synthase by the p38 MAPK in response to black tea polyphenols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; HYDROGEN-PEROXIDE; AKT; PHOSPHORYLATION; CORONARY; CONSUMPTION; CYTOPROTECTION; DYSFUNCTION; METABOLISM; FLAVONOIDS	Black tea improves endothelial function in patients with coronary artery disease. We sought to determine the responsible components of black tea and elucidate the underlying cell signaling mechanisms. We exposed porcine aortic endothelial cells to components of black tea and found that the polyphenol fraction acutely enhanced nitric oxide bioactivity. This effect involved endothelial nitric-oxide synthase ( eNOS) phosphorylation at Ser-1177 and dephosphorylation at Thr-495, consistent with increased eNOS activity. These effects were calcium-dependent, as removal of extracellular calcium prevented eNOS phosphorylation at Ser-1177, whereas inhibition of intracellular calcium mobilization with TMB-8 blunted Thr-495 dephosphorylation. Black tea polyphenol-induced eNOS activation appeared dependent upon the phosphatidylinositol 3-kinase-Akt pathway, as it was significantly inhibited by LY294002 and a dominant negative Akt, respectively. Pharmacological inhibition of p38 mitogen-activated protein kinase ( p38 MAPK) with either SB202190 or SB203580 as well as overexpression of a dominant negative p38 MAPKalpha attenuated both eNOS activation and phosphorylation changes in response to black tea polyphenols. Inhibition of p38 MAPKalpha also blunted Akt activation in response to black tea polyphenols, suggesting that p38alpha MAPK is upstream of Akt in this pathway. Finally, a constitutively active mutant of MKK6bE, an upstream kinase for p38 MAPK, enhanced both the basal and stimulated activity of Akt, leading to increased eNOS activity. Taken together, these data identify the p38 MAPK as an upstream component of Akt-mediated eNOS activation.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Mem Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Cardiothorac Surg, Boston, MA 02118 USA	Boston University; Boston University; Boston University	Keaney, JF (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,Rm W507, Boston, MA 02118 USA.	jkeaney@bu.edu		Keaney, John/0000-0002-0866-1837; Vita, Joseph/0000-0001-5607-1797	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758, P01HL060886, K02HL067206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68758, HL60886, HL67206] Funding Source: Medline; NIDDK NIH HHS [DK55656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Boullier A, 2001, ANN NY ACAD SCI, V947, P214; Cai H, 2003, MOL PHARMACOL, V63, P325, DOI 10.1124/mol.63.2.325; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duffy SJ, 2003, CURR OPIN LIPIDOL, V14, P21, DOI 10.1097/00041433-200302000-00005; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Halliwell B, 2000, IUBMB LIFE, V50, P251, DOI 10.1080/15216540051080930; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393; Lieberman EH, 1996, AM J CARDIOL, V78, P1210, DOI 10.1016/S0002-9149(96)00597-8; Lin MI, 2003, J BIOL CHEM, V278, P44719, DOI 10.1074/jbc.M302836200; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mineo C, 2003, J BIOL CHEM, V278, P9142, DOI 10.1074/jbc.M211394200; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Princen HMG, 1998, ARTERIOSCL THROM VAS, V18, P833, DOI 10.1161/01.ATV.18.5.833; ROBAK J, 1988, BIOCHEM PHARMACOL, V37, P837, DOI 10.1016/0006-2952(88)90169-4; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; van Acker FAA, 2000, FEBS LETT, V473, P145, DOI 10.1016/S0014-5793(00)01517-9; Vita JA, 2003, J NUTR, V133, p3293S, DOI 10.1093/jn/133.10.3293S; Wallerath T, 2002, CIRCULATION, V106, P1652, DOI 10.1161/01.CIR.0000029925.18593.5C; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Widlansky ME, 2003, J AM COLL CARDIOL, V42, P1149, DOI 10.1016/S0735-1097(03)00994-X	38	116	126	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46637	46643		10.1074/jbc.M405547200	http://dx.doi.org/10.1074/jbc.M405547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15333638	hybrid			2022-12-25	WOS:000224832400038
J	Dai, JX; Punchihewa, C; Mistry, P; Ooi, AT; Yang, DZ				Dai, JX; Punchihewa, C; Mistry, P; Ooi, AT; Yang, DZ			Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; CRYSTAL-STRUCTURE; TOPOISOMERASE-I; ANTITUMOR-ACTIVITY; COMPLEX; BINDING; REVEALS; POISON; DACA; AP-1	The new bisphenazine anticancer drug MLN944 is a novel cytotoxic agent with exceptional anti-tumor activity against a range of human and murine tumor models both in vitro and in vivo. MLN944 has recently entered Phase I clinical trials. Despite the structural similarity with its parent monophenazine carboxamide and acridine carboxamide anticancer compounds, MLN944 appears to work by a distinct mechanism of inhibiting DNA transcription rather than the expected mechanism of topoisomerase I and II inhibition. Here we present the first NMR structure of MLN944 complexed with d(ATG-CAT) 2 DNA duplex, demonstrating a novel binding mode in which the two phenazine rings bis-intercalate at the 5'-TpG site, with the carboxamide amino linker lying in the major groove of DNA. The MLN944 molecule adopts a significantly unexpected conformation and side chain orientation in the DNA complex, with the N10 on the phenazine ring protonated at pH 7. The phenazine chromophore of MLN944 is very well stacked with the flanking DNA base pairs using the parallel base-stacking intercalation binding mode. The DNA sequence specificity and the groove recognition of MLN944 binding is determined by several site-specific hydrogen bond interactions with the central G: C base pair as well as the favorable stacking interactions with the 5'-flanking thymine. The specific binding site of MLN944 is known to be recognized by a number of important transcription factors. Our electrophoretic gel mobility shift assay results demonstrated that the c-Jun DNA binding to the AP-1 site is significantly inhibited by MLN944 in a dose-dependent manner. Thus, the exceptional biological activity of MLN944 may be due to its novel DNA binding mode leading to a unique mechanism of action.	Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; Xenova Ltd, Slough SL1 4NL, Berks, England; Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA	University of Arizona; Arizona Center Cancer Care; University of Arizona	Yang, DZ (corresponding author), Univ Arizona, Coll Pharm, 1703 E Mabel St, Tucson, AZ 85721 USA.	yangd@pharmacy.arizona.edu	Dai, Jixun/C-8275-2011; Dai, Jixun/B-5075-2009; Yang, Danzhou/B-6228-2012; YANG, Dan/HHD-2733-2022	Yang, Danzhou/0000-0001-7489-7111	NATIONAL CANCER INSTITUTE [K01CA083886] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016659] Funding Source: NIH RePORTER; NCI NIH HHS [1K01 CA83886-01] Funding Source: Medline; NCRR NIH HHS [1S10 RR16659-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams A, 1999, BIOCHEMISTRY-US, V38, P9221, DOI 10.1021/bi990352m; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Blackman RK, 2003, CLIN CANCER RES, V9, p6075S; Blomquist P, 1999, NUCLEIC ACIDS RES, V27, P517, DOI 10.1093/nar/27.2.517; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Byers SA, 2003, CLIN CANCER RES, V9, p6078S; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Dornberger U, 1998, J MOL BIOL, V284, P1453, DOI 10.1006/jmbi.1998.2261; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; EGLI M, 1995, P NATL ACAD SCI USA, V92, P180, DOI 10.1073/pnas.92.1.180; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Finlay GJ, 1996, EUR J CANCER, V32A, P708, DOI 10.1016/0959-8049(95)00604-4; FREATHY C, 2003, P AM ASS CANC RES, V44; Gallego J, 1999, BIOCHEMISTRY-US, V38, P15104, DOI 10.1021/bi9915869; Gamage SA, 2001, J MED CHEM, V44, P1407, DOI 10.1021/jm0003283; GAO Q, 1991, P NATL ACAD SCI USA, V88, P2422, DOI 10.1073/pnas.88.6.2422; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GORIN AA, 1995, J MOL BIOL, V247, P34, DOI 10.1006/jmbi.1994.0120; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; KAMITORI S, 1992, J MOL BIOL, V225, P445, DOI 10.1016/0022-2836(92)90931-9; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KELLER W, 1995, J MOL BIOL, V254, P657, DOI 10.1006/jmbi.1995.0645; Kielkopf CL, 2000, NAT STRUCT BIOL, V7, P117; Mistry P, 2002, ANTI-CANCER DRUG, V13, P15, DOI 10.1097/00001813-200201000-00002; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PALMER BD, 1988, J MED CHEM, V31, P707, DOI 10.1021/jm00399a003; Sappal DS, 2004, MOL CANCER THER, V3, P47; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart AJ, 2001, ANTI-CANCER DRUG, V12, P359, DOI 10.1097/00001813-200104000-00009; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; Todd AK, 1999, J MED CHEM, V42, P536, DOI 10.1021/jm980479u; Vicker N, 2002, J MED CHEM, V45, P721, DOI 10.1021/jm010329a; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; Yang DZ, 1998, J AM CHEM SOC, V120, P2979, DOI 10.1021/ja973433j; YANG DZ, 1994, BIOCHEMISTRY-US, V33, P6595, DOI 10.1021/bi00187a029	37	65	65	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					46096	46103		10.1074/jbc.M404053200	http://dx.doi.org/10.1074/jbc.M404053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15317822	hybrid			2022-12-25	WOS:000224694900095
J	Furdui, C; Zhou, L; Woodard, RW; Anderson, KS				Furdui, C; Zhou, L; Woodard, RW; Anderson, KS			Insights into the mechanism of 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (Phe) from Escherichia coli using a transient kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONATE-8-PHOSPHATE SYNTHASE; 8-PHOSPHATE SYNTHASE; PHENYLALANINE; PURIFICATION; CATALYSIS; ENZYME; PHOSPHOENOLPYRUVATE; INHIBITION; CYSTEINES; PATHWAY	Escherichia coli phenylalanine-sensitive 3-deoxy-arabinoheptulosonate 7-phosphate synthase (DAHP synthase) catalyzes the net aldol condensation of phosphoenolpyruvate and erythrose 4-phosphate to form 3-deoxy-D-arabino-heptulosonate 7-phosphate and inorganic phosphate. For the first time, the presteady-state kinetic analysis of the Phe-sensitive DAHP synthase from E. coli is reported. The steady-state and presteady-state kinetic parameters of the DAHP synthase reconstituted with Mn(II), Cu(II), and Zn(II) were compared. These studies showed the following: 1) product release is rate-limiting for all of the three metal ions studied under physiologically relevant conditions; 2) concentration of the active sites of the metal-containing DAHP synthase is increasing from Mn-(30%) to Zn-(52%) and to Cu-DAHP synthase (88%); 3) rate constant for product formation is higher in Mn- (130-200 s(-1)) than Cu- (55 s(-1)) and Zn- DAHP synthase (6.8 s(-1)); and 4) steady-state rate (rate constant for product release) is higher for the Mn(70 s(-1)) than for Cu- (5.6 s(-1)) and Zn- DAHP synthase (1.8 s(-1)). In addition, an examination of the reaction kinetics at lower pH reveals that for Cu- DAHP synthase, product release is no longer rate-limiting, whereas the Mn- and Zn- DAHP synthase show a slower rate of product formation, suggesting that the intermediate formation becomes rate-limiting in product formation. Also, a deuterium-isotope effect on the burst rate constant of product formation for Mn- DAHP synthase was observed at pH 6.0. This supports the hypothesis that the role of metal ion in E. coli DAHP synthase is to position the amino acids with the appropriate geometry required to coordinate and activate the water molecule.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Michigan, Dept Med Chem & Chem, Ann Arbor, MI 48109 USA	Yale University; University of Michigan System; University of Michigan	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu		Furdui, Cristina M./0000-0003-3771-7999; Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069, GM 61413, GM 71085] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061413, R01GM071085, R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAASOV T, 1989, J BACTERIOL, V171, P6155, DOI 10.1128/jb.171.11.6155-6160.1989; BRACHER M, 1977, BIOCHIM BIOPHYS ACTA, V485, P446, DOI 10.1016/0005-2744(77)90180-2; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; da Silva Frausto, 1993, BIOL CHEM ELEMENTS; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; GANSON RJ, 1988, ARCH BIOCHEM BIOPHYS, V260, P85, DOI 10.1016/0003-9861(88)90427-4; GORLACH J, 1994, PLANTA, V193, P216, DOI 10.1007/BF00192533; Harding MM, 2001, ACTA CRYSTALLOGR D, V57, P401, DOI 10.1107/S0907444900019168; HEDSTROM L, 1988, BIOCHEM BIOPH RES CO, V157, P816, DOI 10.1016/S0006-291X(88)80322-X; Howe DL, 2003, BIOCHEMISTRY-US, V42, P4843, DOI 10.1021/bi026553z; Howe DL, 2000, J BIOL CHEM, V275, P40258, DOI 10.1074/jbc.M003585200; Jordan PA, 2001, BIOCHEMISTRY-US, V40, P8387, DOI 10.1021/bi010238f; Li ZL, 2003, J AM CHEM SOC, V125, P9938, DOI 10.1021/ja0354768; Liang PH, 1998, BIOCHEMISTRY-US, V37, P16390, DOI 10.1021/bi981374w; PARAVICINI G, 1989, EUR J BIOCHEM, V186, P361, DOI 10.1111/j.1432-1033.1989.tb15217.x; Park OK, 1999, J BACTERIOL, V181, P1636, DOI 10.1128/JB.181.5.1636-1642.1999; Pasternak A, 2001, PROTEIN SCI, V10, P958, DOI 10.1110/ps.52101; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAY JM, 1991, J BACTERIOL, V173, P1894, DOI 10.1128/jb.173.6.1894-1901.1991; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Shumilin IA, 2003, BIOCHEMISTRY-US, V42, P3766, DOI 10.1021/bi027257p; STAUB M, 1969, BIOCHIM BIOPHYS ACTA, V178, P599, DOI 10.1016/0005-2744(69)90228-9; STEPHENS CM, 1992, J BIOL CHEM, V267, P5762; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Sundaram AK, 1998, FEBS LETT, V441, P195, DOI 10.1016/S0014-5793(98)01545-2; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; Wu J, 2003, J BIOL CHEM, V278, P27525, DOI 10.1074/jbc.M304631200	27	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45618	45625		10.1074/jbc.M404753200	http://dx.doi.org/10.1074/jbc.M404753200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326172	hybrid			2022-12-25	WOS:000224694900041
J	Vercammen, D; van de Cotte, B; De Jaeger, G; Eeckhout, D; Casteels, P; Vandepoele, K; Vandenberghe, I; Van Beeumen, J; Inze, D; Van Breusegem, F				Vercammen, D; van de Cotte, B; De Jaeger, G; Eeckhout, D; Casteels, P; Vandepoele, K; Vandenberghe, I; Van Beeumen, J; Inze, D; Van Breusegem, F			Type II metacaspases Atmc4 and Atmc9 of Arabidopsis thaliana cleave substrates after arginine and lysine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CASPASE-LIKE ACTIVITY; CRYSTAL-STRUCTURE; TOBACCO CELLS; ACTIVATION; APOPTOSIS; INVOLVEMENT; PROTEIN; IDENTIFICATION; PURIFICATION	Nine potential caspase counterparts, designated metacaspases, were identified in the Arabidopsis thaliana genome. Sequence analysis revealed two types of metacaspases, one with ( type I) and one without ( type II) a proline- or glutamine-rich N-terminal extension, possibly representing a prodomain. Production of recombinant Arabidopsis type II metacaspases in Escherichia coli resulted in cysteine-dependent autocatalytic processing of the proform into large and small subunits, in analogy to animal caspases. A detailed biochemical characterization with a broad range of synthetic oligopeptides and several protease inhibitors of purified recombinant proteins of both metacaspase 4 and 9 showed that both metacaspases are arginine/lysine-specific cysteine proteases and did not cleave caspase-specific synthetic substrates. These findings suggest that type II metacaspases are not directly responsible for earlier reported caspase-like activities in plants.	State Univ Ghent VIB, Dept Plant Syst Biol, B-9052 Ghent, Belgium; Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University	Inze, D (corresponding author), State Univ Ghent VIB, Dept Plant Syst Biol, Technol Pk 927, B-9052 Ghent, Belgium.	dirk.inze@psb.ugent.be	Van Breusegem, Frank/AAJ-2647-2020; Inzé, Dirk/AAW-6381-2021; Van Breusegem, Frank/Y-2999-2019; Vandepoele, Klaas/E-7514-2010; Vercammen, Dominique/A-4237-2008	Van Breusegem, Frank/0000-0002-3147-0860; Inzé, Dirk/0000-0002-3217-8407; Vandepoele, Klaas/0000-0003-4790-2725; De Jaeger, Geert/0000-0001-6558-5669; Eeckhout, Dominique/0000-0001-5770-7670				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bozhkov PV, 2004, CELL DEATH DIFFER, V11, P175, DOI 10.1038/sj.cdd.4401330; Buckner B, 2000, PHYSIOL PLANTARUM, V108, P231, DOI 10.1034/j.1399-3054.2000.108003231.x; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Coffeen WC, 2004, PLANT CELL, V16, P857, DOI 10.1105/tpc.017947; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Danon A, 1998, FEBS LETT, V437, P131, DOI 10.1016/S0014-5793(98)01208-3; Dat JF, 2003, PLANT J, V33, P621, DOI 10.1046/j.1365-313X.2003.01655.x; De Jong AJ, 2000, PLANTA, V211, P656, DOI 10.1007/s004250000341; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eichinger A, 1999, EMBO J, V18, P5453, DOI 10.1093/emboj/18.20.5453; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Fukuda H, 2000, PLANT MOL BIOL, V44, P245, DOI 10.1023/A:1026532223173; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hoeberichts FA, 2003, PLANTA, V217, P517, DOI 10.1007/s00425-003-1049-9; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Katsuhara M, 1997, PLANT CELL PHYSIOL, V38, P1091, DOI 10.1093/oxfordjournals.pcp.a029277; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Korthout HAAJ, 2000, FEBS LETT, V475, P139, DOI 10.1016/S0014-5793(00)01643-4; Kratsch HA, 2000, PLANT CELL ENVIRON, V23, P337, DOI 10.1046/j.1365-3040.2000.00560.x; Lockshin RA, 2002, CURR OPIN CELL BIOL, V14, P727, DOI 10.1016/S0955-0674(02)00383-6; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Mikolajczyk J, 2003, J BIOL CHEM, V278, P10458, DOI 10.1074/jbc.M210564200; Minami A, 1995, PLANT CELL PHYSIOL, V36, P1599; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; O'Brien IEW, 1998, EXP CELL RES, V241, P46, DOI 10.1006/excr.1998.4036; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Pugin A, 1997, PLANT CELL, V9, P2077, DOI 10.1105/tpc.9.11.2077; Qiao J, 2002, PLANT CELL PHYSIOL, V43, P992, DOI 10.1093/pcp/pcf122; Raes Jeroen, 2003, Journal of Structural and Functional Genomics, V3, P117, DOI 10.1023/A:1022666020026; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rogl H, 1998, FEBS LETT, V432, P21, DOI 10.1016/S0014-5793(98)00825-4; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Schiex T., 2001, LNCS, P111, DOI [10.1007/3-540-45727-5_10, DOI 10.1007/3-540-45727-5_10]; Simillion C, 2002, P NATL ACAD SCI USA, V99, P13627, DOI 10.1073/pnas.212522399; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; Szallies A, 2002, FEBS LETT, V517, P144, DOI 10.1016/S0014-5793(02)02608-X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; Wu T.D., 1995, P 3 INT C INT SYST M, P402	52	253	276	0	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45329	45336		10.1074/jbc.M406329200	http://dx.doi.org/10.1074/jbc.M406329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326173	hybrid			2022-12-25	WOS:000224694900007
J	Wang, JQ; Kon, J; Mogi, C; Tobo, M; Damirin, A; Sato, K; Komachi, M; Malchinkhuu, E; Murata, N; Kimura, T; Kuwabara, A; Wakamatsu, K; Koizumi, H; Uede, T; Tsujimoto, G; Kurose, H; Sato, T; Harada, A; Misawa, N; Tomura, H; Okajima, F				Wang, JQ; Kon, J; Mogi, C; Tobo, M; Damirin, A; Sato, K; Komachi, M; Malchinkhuu, E; Murata, N; Kimura, T; Kuwabara, A; Wakamatsu, K; Koizumi, H; Uede, T; Tsujimoto, G; Kurose, H; Sato, T; Harada, A; Misawa, N; Tomura, H; Okajima, F			TDAG8 is a proton-sensing and psychosine-sensitive G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH-ASSOCIATED GENE; SIGNALING PATHWAYS; CELLS; ACTIVATION; SPHINGOSYLPHOSPHORYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE; IDENTIFICATION; ANTAGONIST; APOPTOSIS; ADENOSINE	T cell death-associated gene 8 (TDAG8) has been reported to be a receptor for psychosine. Ovarian cancer G-protein-coupled receptor 1 (OGR1) and GPR4, G-protein-coupled receptors (GPCRs) closely related to TDAG8, however, have recently been identified as proton-sensing or extracellular pH-responsive GPCRs that stimulate inositol phosphate and cAMP production, respectively. In the present study, we examined whether TDAG8 senses extracellular pH change. In the several cell types that were transfected with TDAG8 cDNA, cAMP was markedly accumulated in response to neutral to acidic extracellular pH, with a peak response at approximately pH 7.0-6.5. The pH effect was inhibited by copper ions and was reduced or lost in cells expressing mutated TDAG8 in which histidine residues were changed to phenylalanine. In the membrane fractions prepared from TDAG8-transfected cells, guanosine 5'-O-(3-thiotriphosphate) binding activity and adenylyl cyclase activity were remarkably stimulated in response to neutral and acidic pH. The concentration-dependent effect of extracellular protons on cAMP accumulation was shifted to the right in the presence of psychosine. The inhibitory psychosine effect was also observed for pH-dependent actions in OGR1- and GPR4-expressing cells but not for prostaglandin E-2- and sphingosine 1-phosphate-induced actions in any pH in native and sphingosine 1-phosphate receptor-expressing cells. Glucosylsphingosine and sphingosylphosphorylcholine similarly inhibited the pH-dependent action, although to a lesser extent. Psychosine-sensitive and pH-dependent cAMP accumulation was also observed in mouse thymocytes. We concluded that TDAG8 is one of the proton-sensing GPCRs coupling to adenylyl cyclase and psychosine, and its related lysosphingolipids behave as if they were antagonists against protein-sensing receptors, including TDAG8, GPR4, and OGR1.	Gunma Univ, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan; Gunma Univ, Dept Cell Biol, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan; Gunma Univ, Dept Biochem & Chem Engn, Fac Engn, Kiryu, Gumma 3768515, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Hokkaido Univ, Div Mol Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Kyoto Univ, Dept Genom Drug Discovery Sci, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan; Kyushu Univ, Dept Pharmacol & Toxicol, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan	Gunma University; Gunma University; Gunma University; Kirin Brewery Company Limited; Hokkaido University; Kyoto University; Kyushu University	Okajima, F (corresponding author), Gunma Univ, Lab Signal Transduct, Maebashi, Gumma 3718512, Japan.	fokajima@showa.gunma-u.ac.jp	Malchinkhuu, Enkhzol/AAH-4600-2019; Wakamatsu, Kaori/AAQ-9690-2020	Wakamatsu, Kaori/0000-0003-1412-5691; Malchinkhuu, Enkhzol/0000-0003-0744-079X; Sato, Koichi/0000-0001-7694-4014; Misawa, Norihiko/0000-0003-1373-0769				Apasov S, 2000, BLOOD, V95, P3859; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; Cussac D, 2004, EUR J PHARMACOL, V485, P111, DOI 10.1016/j.ejphar.2003.11.077; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kuribayashi F, 2002, EMBO J, V21, P6312, DOI 10.1093/emboj/cdf642; Kyaw H, 1998, DNA CELL BIOL, V17, P493, DOI 10.1089/dna.1998.17.493; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; PATINO JAG, 2000, J IMMUNOL, V164, P1689; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Tomura H, 1997, J BIOL CHEM, V272, P23130, DOI 10.1074/jbc.272.37.23130; Tosa N, 2003, INT IMMUNOL, V15, P741, DOI 10.1093/intimm/dxg070; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamada T, 2004, J BIOL CHEM, V279, P6595, DOI 10.1074/jbc.M308133200; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	18	173	185	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45626	45633		10.1074/jbc.M406966200	http://dx.doi.org/10.1074/jbc.M406966200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15326175	hybrid			2022-12-25	WOS:000224694900042
J	Ma, LN; Vaz, FM; Gu, ZM; Wanders, RJA; Greenberg, ML				Ma, LN; Vaz, FM; Gu, ZM; Wanders, RJA; Greenberg, ML			The human TAZ gene complements mitochondrial dysfunction in the Yeast taz1 Delta mutant - Implications for Barth syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARDIOSKELETAL MYOPATHY; SACCHAROMYCES-CEREVISIAE; CARDIOLIPIN METABOLISM; ZELLWEGER-SYNDROME; RESPIRATORY-CHAIN; HUMAN-LIVER; DEFICIENCY; ACID; FIBROBLASTS; DISEASE	Barth syndrome is a genetic disorder that is caused by different mutations in the TAZ gene G4.5. The yeast gene TAZ1 is highly homologous to human TAZ, and the taz1Delta mutant has phospholipid defects similar to those observed in Barth syndrome cells, including aberrant cardiolipin species and decreased cardiolipin levels. Subcellular fractionation studies revealed that Taz1p is localized exclusively in mitochondria, which supports the theory that tafazzins are involved in cardiolipin remodeling. Because cardiolipin plays an important role in respiratory function, we measured the energy transformation and osmotic properties of isolated mitochondria from the taz1Delta mutant. Energy coupling in taz1Delta mitochondria was dependent on the rate of oxidative phosphorylation, as coupling was diminished when NADH was used as a respiratory substrate but was unaffected when ethanol was the substrate. Membrane stability was compromised in taz1Delta mitochondria exposed to increased temperature and hypotonic conditions. Mitochondria from taz1Delta also displayed decreased swelling in response to ATP, which induces the yeast mitochondrial unspecific channel, and to alamethicin, a membrane-disrupting agent. Coupling was measured in taz1Delta cells containing different splice variants of the human TAZ gene. Only the variant that restores wild type cardiolipin synthesis (lacking exon 5) restored coupling in hypotonic conditions and at elevated temperature. These findings may shed light on the mitochondrial deficiencies observed in Barth syndrome.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Univ Amsterdam, Dept Clin Chem, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Dept Pediat, NL-1100 DE Amsterdam, Netherlands	Wayne State University; University of Amsterdam; University of Amsterdam	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	MLGREEN@sun.science.wayne.edu		Vaz, Frederic/0000-0002-9048-1041	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5; Barth PG, 1996, J INHERIT METAB DIS, V19, P157, DOI 10.1007/BF01799418; Barth PG, 1999, J INHERIT METAB DIS, V22, P555, DOI 10.1023/A:1005568609936; CHRISTODOULOU J, 1994, AM J MED GENET, V50, P255, DOI 10.1002/ajmg.1320500309; DAdamo P, 1997, AM J HUM GENET, V61, P862, DOI 10.1086/514886; FRANZUSOFF A, 1991, P662; Gu ZM, 2004, MOL MICROBIOL, V51, P149, DOI 10.1046/j.1365-2958.2003.03802.x; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; HUNTER FE, 1967, METHOD ENZYMOL, V10, P689; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Koshkin V, 2002, BIOCHEM J, V364, P317, DOI 10.1042/bj3640317; Koshkin V, 2000, BIOCHEM J, V347, P687, DOI 10.1042/0264-6021:3470687; LEHNINGER AL, 1964, MITOCHONDRION, P180; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Lowenstein JM, 1969, METHOD ENZYMOL, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Manon S, 1999, BBA-BIOENERGETICS, V1410, P85, DOI 10.1016/S0005-2728(98)00178-9; Neuwald AF, 1997, CURR BIOL, V7, pR465; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176; Valianpour F, 2004, CLIN CHEM, V50, P403, DOI 10.1373/clinchem.2003.027169; Valianpour F, 2003, J LIPID RES, V44, P560, DOI 10.1194/jlr.M200217-JLR200; Vaz FM, 2003, J BIOL CHEM, V278, P43089, DOI 10.1074/jbc.M305956200; Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952; WANDERS RJA, 1986, CLIN CHIM ACTA, V159, P1, DOI 10.1016/0009-8981(86)90160-9; WANDERS RJA, 1994, BBA-MOL BASIS DIS, V1227, P177, DOI 10.1016/0925-4439(94)90092-2; Xu Y, 2003, J BIOL CHEM, V278, P51380, DOI 10.1074/jbc.M307382200	28	84	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44394	44399		10.1074/jbc.M405479200	http://dx.doi.org/10.1074/jbc.M405479200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15304507	hybrid			2022-12-25	WOS:000224505600022
J	Duan, CJ; Li, MH; Rui, LY				Duan, CJ; Li, MH; Rui, LY			SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE B; MULTIFACTORIAL MOUSE MODEL; MEDIATED DEGRADATION; SIGNALING PATHWAYS; GROWTH-FACTOR; MICE LACKING; OBESE GENE; IDENTIFICATION; RESISTANCE; MECHANISM	Leptin regulates energy homeostasis primarily by binding and activating its long form receptor (LRb). Deficiency of either leptin or LRb causes morbid obesity. Leptin stimulates LRb-associated JAK2, thus initiating multiple pathways including the Stat3 and phosphatidylinositol ( PI) 3-kinase pathways that mediate leptin biological actions. Here we report that SH2-B, a JAK2-interacting protein, promotes activation of the PI 3-kinase pathway by recruiting insulin receptor substrate 1 (IRS1) and IRS2 in response to leptin. SH2-B directly bound, via its PH and SH2 domain, to both IRS1 and IRS2 both in vitro and in intact cells and mediated formation of a JAK2/SH2-B/IRS1 or IRS2 tertiary complex. Consequently, SH2-B dramatically enhanced leptin-stimulated tyrosine phosphorylation of IRS1 and IRS2 in HEK293 cells stably expressing LRb, thus promoting association of IRS1 and IRS2 with the p85 regulatory subunit of PI 3-kinase and phosphorylation and activation of Akt. SH2-B mutants with lower affinity for IRS1 and IRS2 exhibited reduced ability to promote association of JAK2 with IRS1, tyrosine phosphorylation of IRS1, and association of IRS1 with p85 in response to leptin. Moreover, deletion of the SH2-B gene impaired leptin-stimulated tyrosine phosphorylation of endogenous IRS1 in mouse embryonic fibroblasts (MEF), which was reversed by reintroduction of SH2-B. Similarly, SH2-B promoted growth hormone-stimulated tyrosine phosphorylation of IRS1 in both HEK293 and MEF cells. Our data suggest that SH2-B is a novel mediator of the PI 3-kinase pathway in response to leptin or other hormones and cytokines that activate JAK2.	Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Rui, LY (corresponding author), Univ Michigan, Sch Med, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.	ruily@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020542, R01DK065122] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065122, R01 DK 065122, NIH5P60 DK20542, R01 DK065122-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderwald C, 2002, MOL ENDOCRINOL, V16, P1612, DOI 10.1210/me.16.7.1612; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Burks DJ, 2000, NATURE, V407, P377, DOI 10.1038/35030105; Carvalheira JBC, 2003, BIOL CHEM, V384, P151, DOI 10.1515/BC.2003.016; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Cui YX, 2004, MOL CELL BIOL, V24, P258, DOI 10.1128/MCB.24.1.258-269.2004; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Huang W, 2004, J BIOL CHEM, V279, P21695, DOI 10.1074/jbc.M401546200; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kurzer JH, 2004, MOL CELL BIOL, V24, P4557, DOI 10.1128/MCB.24.10.4557-4570.2004; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 2000, J BIOL CHEM, V275, P2885, DOI 10.1074/jbc.275.4.2885; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suzuki R, 2004, J BIOL CHEM, V279, P25039, DOI 10.1074/jbc.M311956200; Tajmir P, 2004, ENDOCRINOLOGY, V145, P1550, DOI 10.1210/en.2003-1128; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vecchione C, 2002, DIABETES, V51, P168, DOI 10.2337/diabetes.51.1.168; WARDEN CH, 1993, J CLIN INVEST, V92, P773, DOI 10.1172/JCI116649; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Yousaf N, 2001, J BIOL CHEM, V276, P40940, DOI 10.1074/jbc.M104191200; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	48	136	141	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43684	43691		10.1074/jbc.M408495200	http://dx.doi.org/10.1074/jbc.M408495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15316008	Green Accepted, hybrid			2022-12-25	WOS:000224383100042
J	Segall, L; Scanzano, R; Kaunisto, MA; Wessman, M; Palotie, A; Gargus, JJ; Blostein, R				Segall, L; Scanzano, R; Kaunisto, MA; Wessman, M; Palotie, A; Gargus, JJ; Blostein, R			Kinetic alterations due to a missense mutation in the Na,K-ATPase alpha 2 subunit cause familial hemiplegic migraine type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; EXTRACELLULAR K+; AMINO-ACIDS; NA+/K+-PUMP; RAT; ISOFORMS; ATPASE; CA2+-ATPASE; HIPPOCAMPUS	A number of missense mutations in the ATP1A2 gene, which encodes the Na, K-ATPase alpha2 subunit, have been identified in familial hemiplegic migraine with aura. Loss of function and haploinsufficiency have been the suggested mechanisms in mutants for which functional analysis has been reported. This paper describes a kinetic analysis of mutant T345A, recently identified in a detailed genetic analysis of a large Finnish family (Kaunisto, M. A., Harno, H., Vanmolkot, K. R., Gargus, J. J., Sun, G., Hamalainen, E., Liukkonen, E., Kallela, M., van den Maagdenberg, A. M., Frants, R. R., Farkkila, M., Palotie, A., and Wessman, M. ( 2004) Neurogenetics 5, 141 146). Introducing T345A into the conserved rat alpha2 enzyme does not alter cell growth or catalytic turnover but causes a substantial decrease in apparent K+ affinity (2-fold increase in K0.5(K+)). In view of the location of Thr-345 in the cytoplasmic stalk domain adjacent to transmembrane segment 4, the 2-fold increase in K0.5(K+) is probably due to T345A replacement altering K+ occlusion/deocclusion. Faster K+ deocclusion of the mutant via the E-2(K) + ATP --> E-1 . ATP + K+ partial reaction is evidenced in (i) a marked increase (300%) in K+ stimulation of Na-ATPase at micromolar ATP, (ii) a 4-fold decrease in K-ATP, and (iii) only a modest increase (similar to 3-fold) in I-50 for vanadate, which was used as a probe of the steady state E-1/E-2 conformational equilibrium. We suggest that the decreased apparent K+ affinity is the basis for a reduced rate of extracellular K+ removal, which delays the recovery phase of nerve impulse transmission in the central nervous system and, thereby, the clinical picture of migraine with aura. This is the first demonstration of a mutation that leads to a disease associated with a kinetically altered but fully functional Na, K-ATPase, refining the molecular mechanism of pathogenesis in familial hemiplegic migraine.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Sect Human Genet, Dept Pediat, Irvine, CA 92697 USA; Biomedicum Helsinki, Helsinki 00029, Finland; Univ Helsinki, Dept Clin Chem, Helsinki 00029, Finland; Univ Helsinki, Finnish Genome Ctr, Helsinki 900957008, Finland; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA	McGill University; McGill University; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Helsinki; University of Helsinki; University of Helsinki; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Blostein, R (corresponding author), Montreal Gen Hosp, Res Inst, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	Rhoda.Blostein@mcgill.ca		Kaunisto, Mari/0000-0002-6946-9195	NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS37675-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037675] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; Blostein R, 1999, J BIOL CHEM, V274, P18374, DOI 10.1074/jbc.274.26.18374; Crambert G, 2000, J BIOL CHEM, V275, P1976, DOI 10.1074/jbc.275.3.1976; D'Ambrosio R, 2002, J NEUROPHYSIOL, V87, P87, DOI 10.1152/jn.00240.2001; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Estevez M, 2004, HUM GENET, V114, P225, DOI 10.1007/s00439-003-1055-9; Horisberger JD, 2002, J PHYSIOL-LONDON, V539, P669, DOI 10.1113/jphysiol.2001.013201; James PF, 1999, MOL CELL, V3, P555, DOI 10.1016/S1097-2765(00)80349-4; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; Jorgensen PL, 2003, ANNU REV PHYSIOL, V65, P817, DOI 10.1146/annurev.physiol.65.092101.142558; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kaunisto MA, 2004, NEUROGENETICS, V5, P141, DOI 10.1007/s10048-004-0178-z; Keryanov S, 2002, GENE, V292, P151, DOI 10.1016/S0378-1119(02)00647-9; KURKATROTT K, 2004, NEUROLOGY, V62, P1857; LANE LK, 1993, J BIOL CHEM, V268, P17930; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Moseley AE, 1996, INVEST OPHTH VIS SCI, V37, P1502; Moseley AE, 2003, J BIOL CHEM, V278, P5317, DOI 10.1074/jbc.M211315200; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; Ransom CB, 2000, J PHYSIOL-LONDON, V522, P427, DOI 10.1111/j.1469-7793.2000.00427.x; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; Segall L, 2001, J BIOL CHEM, V276, P31535, DOI 10.1074/jbc.M103720200; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Vanmolkot KRJ, 2003, ANN NEUROL, V54, P360, DOI 10.1002/ana.10674; Wetzel RK, 2001, INVEST OPHTH VIS SCI, V42, P763; Xiong ZQ, 2000, DEV BRAIN RES, V122, P113, DOI 10.1016/S0165-3806(00)00057-2	35	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43692	43696		10.1074/jbc.M407471200	http://dx.doi.org/10.1074/jbc.M407471200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15308625	hybrid			2022-12-25	WOS:000224383100043
J	Klemba, M; Gluzman, I; Goldberg, DE				Klemba, M; Gluzman, I; Goldberg, DE			A Plasmodium falciparum dipeptidyl aminopeptidase I participates in vacuolar hemoglobin degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITES; PEPTIDASE-I; CYSTEINE PROTEASE; HOST ERYTHROCYTE; GENOME SEQUENCE; AMINO-ACIDS; M1 FAMILY; INHIBITION; EXPRESSION; TRAFFICKING	Intraerythrocytic growth of the human malaria parasite Plasmodium falciparum requires the catabolism of large amounts of host cell hemoglobin. Endoproteolytic digestion of hemoglobin to short oligopeptides occurs in an acidic organelle called the food vacuole. How amino acids are generated from these peptides is not well understood. To gain insight into this process, we have studied a plasmodial ortholog of the lysosomal exopeptidase cathepsin C. The plasmodial enzyme dipeptidyl aminopeptidase 1 (DPAP1) was enriched from parasite extract by two different approaches and was shown to possess hydrolytic activity against fluorogenic dipeptide substrates. To localize DPAP1 we created a transgenic parasite line expressing a chromosomally encoded DPAP1-green fluorescent protein fusion. Green fluorescent protein fluorescence was observed in the food vacuole of live transgenic parasites, and anti-DPAP1 antibody labeled the food vacuole in parasite cryosections. Together these data implicate DPAP1 in the generation of dipeptides from hemoglobin-derived oligopeptides. To assess the significance of DPAP1, we attempted to ablate DPAP1 activity from blood stage parasites by truncating the chromosomal DPAP1-coding sequence. The inability to disrupt the coding sequence indicates that DPAP1 is important for asexual proliferation. The proenzyme form of DPAP1 was found to accumulate in the parasitophorous vacuole of mature parasites. This observation suggests a trafficking route for DPAP1 through the parasitophorous vacuole to the food vacuole.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu			NIAID NIH HHS [AI41418] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Adisa A, 2003, J BIOL CHEM, V278, P6532, DOI 10.1074/jbc.M207039200; Adkison AM, 2002, J CLIN INVEST, V109, P363, DOI 10.1172/JCI13462; AIKAWA M, 1966, J CELL BIOL, V28, P355, DOI 10.1083/jcb.28.2.355; Allary M, 2002, PARASITOLOGY, V125, P1, DOI 10.1017/S0031182002001828; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Bennett TN, 2004, MOL BIOCHEM PARASIT, V133, P99, DOI 10.1016/j.molbiopara.2003.09.008; BENTING J, 1994, BIOCHEM J, V300, P821, DOI 10.1042/bj3000821; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; CALLAHAN PX, 1972, FED PROC, V31, P1105; Cigic B, 1998, BBA-PROTEIN STRUCT M, V1382, P143, DOI 10.1016/S0167-4838(97)00173-8; Crabb BS, 1997, MOL BIOCHEM PARASIT, V90, P131, DOI 10.1016/S0166-6851(97)00143-6; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; DLUZEWSKI AR, 1984, T ROY SOC TROP MED H, V78, P622, DOI 10.1016/0035-9203(84)90221-9; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Florent I, 1998, MOL BIOCHEM PARASIT, V97, P149, DOI 10.1016/S0166-6851(98)00143-1; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gavigan CS, 2001, MOL BIOCHEM PARASIT, V117, P37, DOI 10.1016/S0166-6851(01)00327-9; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; HUI GSN, 1988, MOL BIOCHEM PARASIT, V29, P283, DOI 10.1016/0166-6851(88)90083-7; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P192; Klemba M, 2004, J CELL BIOL, V164, P47, DOI 10.1083/jcb200307147; Kolakovich KA, 1997, MOL BIOCHEM PARASIT, V87, P123, DOI 10.1016/S0166-6851(97)00062-5; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; Krugliak M, 2002, MOL BIOCHEM PARASIT, V119, P249, DOI 10.1016/S0166-6851(01)00427-3; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lew VL, 2004, BLOOD CELL MOL DIS, V32, P353, DOI 10.1016/j.bcmd.2004.01.006; Lew VL, 2003, BLOOD, V101, P4189, DOI 10.1182/blood-2002-08-2654; Li H, 2002, PARASITOL INT, V51, P343, DOI 10.1016/S1383-5769(02)00042-9; Lopez-Estrano C, 2003, P NATL ACAD SCI USA, V100, P12402, DOI 10.1073/pnas.2133080100; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Olsen JG, 2001, FEBS LETT, V506, P201, DOI 10.1016/S0014-5793(01)02911-8; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Przyborski JM, 2003, MOL BIOCHEM PARASIT, V132, P17, DOI 10.1016/S0166-6851(03)00212-3; RABILLOUD T, 1992, ELECTROPHORESIS, V13, P429, DOI 10.1002/elps.1150130190; ROSENTHAL PJ, 1995, EXP PARASITOL, V80, P272, DOI 10.1006/expr.1995.1033; Rosenthal PJ, 1998, EMERG INFECT DIS, V4, P49, DOI 10.3201/eid0401.980107; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; SHERMAN IW, 1969, MIL MED, V134, P954; Sijwali PS, 2004, P NATL ACAD SCI USA, V101, P4384, DOI 10.1073/pnas.0307720101; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; STANLEY HA, 1989, MOL BIOCHEM PARASIT, V36, P139, DOI 10.1016/0166-6851(89)90186-2; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Thamotharan M, 1997, J BIOL CHEM, V272, P11786, DOI 10.1074/jbc.272.18.11786; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Turk D, 2001, EMBO J, V20, P6570, DOI 10.1093/emboj/20.23.6570; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Wickert H, 2003, EUR J CELL BIOL, V82, P271, DOI 10.1078/0171-9335-00319; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Wickham ME, 2003, J BIOL CHEM, V278, P37658, DOI 10.1074/jbc.M305252200; Wolters PJ, 2001, J BIOL CHEM, V276, P18551, DOI 10.1074/jbc.M100223200; Wu YM, 2003, GENOME RES, V13, P601, DOI 10.1101/gr.913403; Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130; Wyatt DM, 2002, FEBS LETT, V513, P159, DOI 10.1016/S0014-5793(02)02241-X	62	141	145	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 8	2004	279	41					43000	43007		10.1074/jbc.M408123200	http://dx.doi.org/10.1074/jbc.M408123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	858XQ	15304495	hybrid			2022-12-25	WOS:000224226400081
J	Gourdier, I; Crabbe, L; Andreau, K; Pau, B; Kroemer, G				Gourdier, I; Crabbe, L; Andreau, K; Pau, B; Kroemer, G			Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA	ONCOGENE			English	Article						oxaliplatin; p53; Bak; Bax; cytoplasts	IN-VITRO; BAX; CISPLATIN; CANCER; P53; CHEMOTHERAPY; PHARMACOLOGY; RESISTANCE; PROTEIN; ABSENCE	We previously established a model of acquired oxaliplatin resistance derived from the HCT116 oxaliplatin-sensitive cell line (HCT116S) and consisting in two resistant clones (HCT116R1, HCT116R2) and their total or partial revertants (HCT116Rev1 and HCT116Rev2, respectively). Using this cellular model, we explored the contribution of mitochondrial apoptosis and nuclear DNA to oxaliplatin-mediated apoptosis induction and oxaliplatin resistance. We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsi(m)). In addition, we observed that p53 only contributed marginally to oxaliplatin-induced cytotoxicity and was not involved in oxaliplatin resistance. Moreover and surprisingly, depletion of the nucleus in HCT116S cells did not abolish the oxaliplatin-induced DeltaPsi(m) loss indicative of imminent apoptosis. Enucleation abolished the oxaliplatin resistance of HCT116R1 cells, while HCT116R2 cytoplasts conserved their resistant phenotype. Altogether, these data demonstrate that oxaliplatin exerts its cytotoxic effects by inducing mitochondrial apoptosis and that these effects can be initiated by interacting on other cellular structures than nuclear DNA. Resistance to oxaliplatin may imply both nuclear and cytoplasmic compartments.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Pasteur, Paris, France; CNRS, UMR 5160, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Crabbé, Laure/P-8955-2014	KROEMER, Guido/0000-0002-9334-4405; Crabbé, Laure/0000-0001-7764-3600; Andreau, Karine/0000-0002-9773-0733				Boulikas T, 2003, ONCOL REP, V10, P1663; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Castedo M, 1996, J IMMUNOL, V157, P512; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; ElAkawi Z, 1996, CANCER LETT, V105, P5, DOI 10.1016/0304-3835(96)04245-0; Fink D, 1997, CANCER RES, V57, P1841; Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hector S, 2001, CANCER CHEMOTH PHARM, V48, P398, DOI 10.1007/s002800100363; Ibrahim A, 2004, ONCOLOGIST, V9, P8, DOI 10.1634/theoncologist.9-1-8; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Kollmannsberger C, 2004, J CLIN ONCOL, V22, P108, DOI 10.1200/JCO.2004.06.068; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mishima M, 2002, EUR J CANCER, V38, P1405, DOI 10.1016/S0959-8049(02)00096-5; Misset JL, 2000, CRIT REV ONCOL HEMAT, V35, P75, DOI 10.1016/S1040-8428(00)00070-6; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Raymond E, 2002, MOL CANCER THER, V1, P227; Reardon JT, 1999, CANCER RES, V59, P3968; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Vekris A, 2004, CANCER RES, V64, P356, DOI 10.1158/0008-5472.CAN-03-2258; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920; WOYNAROWSKI JM, 1998, MOL PHARM, V54, P1998; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	31	57	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7449	7457		10.1038/sj.onc.1208047	http://dx.doi.org/10.1038/sj.onc.1208047			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334062				2022-12-25	WOS:000224176500001
J	Crean, JK; Furlong, F; Finlay, D; Mitchell, D; Conway, B; Brady, HR; Godson, C; Martin, F				Crean, JK; Furlong, F; Finlay, D; Mitchell, D; Conway, B; Brady, HR; Godson, C; Martin, F			Connective tissue growth factor [CTGF]/CCN2 stimulates mesangial cell migration through integrated dissolution of focal adhesion complexes and activation of cell polarization	FASEB JOURNAL			English	Article						protein kinase C zeta; Rho; focal adhesion kinase; SHP-2; actin disassembly	TYROSINE-PHOSPHATASE SHP-2; PROTEIN-KINASE-C; VASCULAR ENDOTHELIAL-CELLS; FACTOR INDUCES APOPTOSIS; IN-VITRO; CDC42; RHO; EXPRESSION; FAMILY; FAK	Connective tissue growth factor [CTGF]/CCN2 is a prototypic member of the CCN family of regulatory proteins. CTGF expression is up-regulated in a number of fibrotic diseases, including diabetic nephropathy, where it is believed to act as a downstream mediator of TGF-function; however, the exact mechanisms whereby CTGF mediates its effects remain unclear. Here, we describe the role of CTGF in cell migration and actin disassembly in human mesangial cells, a primary target in the development of renal glomerulosclerosis. The addition of CTGF to primary mesangial cells induced cell migration and cytoskeletal rearrangement but had no effect on cell proliferation. Cytoskeletal rearrangement was associated with a loss of focal adhesions, involving tyrosine dephosphorylation of focal adhesion kinase and paxillin, increased activity of the protein tyrosine phosphatase SHP-2, with a concomitant decrease in RhoA and Rac1 activity. Conversely, Cdc42 activity was increased by CTGF. These functional responses were associated with the phosphorylation and translocation of protein kinase C-zeta to the leading edge of migrating cells. Inhibition of CTGF-induced protein kinase C-zeta activity with a myristolated PKC-zeta inhibitor prevented cell migration. Moreover, transient transfection of human mesangial cells with a PKC-zeta kinase inactive mutant ( dominant negative) expression vector also led to a decrease in CTGF-induced migration compared with wild-type. Furthermore, CTGF stimulated phosphorylation and activation of GSK-3beta. These data highlight for the first time an integrated mechanism whereby CTGF regulates cell migration through facilitative actin cytoskeleton disassembly, which is mediated by dephosphorylation of focal adhesion kinase and paxillin, loss of RhoA activity, activation of Cdc42, and phosphorylation of PKC-zeta and GSK-3beta. These changes indicate that the initial stages of CTGF mediated mesangial cell migration are similar to those involved in the process of cell polarization. These findings begin to shed mechanistic light on the renal diabetic milieu, where increased CTGF expression in the glomerulus contributes to cellular dysfunction.	Univ Coll Dublin, Mater Misericordiae Hosp, Dept Med & Therapeut, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Univ Coll Dublin, Mater Misericordiae Hosp, Dept Pharmacol, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Dublin Mol Med Ctr, Dublin 4, Ireland; Queens Univ Belfast, Inst Clin Sci, Dept Med, Belfast, Antrim, North Ireland	Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Trinity College Dublin; University College Dublin; Queens University Belfast	Crean, JK (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Med & Therapeut, Dublin 4, Ireland.	john.crean@ucd.ie		/0000-0002-4337-6177; Furlong, Fiona/0000-0002-9206-2297; Godson, Catherine/0000-0003-0655-1041				Babic AM, 1999, MOL CELL BIOL, V19, P2958; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; Blom IE, 2001, NEPHROL DIAL TRANSPL, V16, P1139, DOI 10.1093/ndt/16.6.1139; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRADY HR, 1992, KIDNEY INT, V42, P480, DOI 10.1038/ki.1992.312; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brill S, 1996, MOL CELL BIOL, V16, P4869; Cary LA, 1996, J CELL SCI, V109, P1787; Chen BH, 2002, J BIOL CHEM, V277, P33857, DOI 10.1074/jbc.M204429200; Cortes P, 2000, KIDNEY INT, V58, P2452, DOI 10.1046/j.1523-1755.2000.00428.x; Cortes P, 2002, CLIN EXP PHARMACOL P, V29, P149, DOI 10.1046/j.1440-1681.2002.03615.x; Crean JKG, 2002, J BIOL CHEM, V277, P44187, DOI 10.1074/jbc.M203715200; Dlugosz JA, 2002, AM J PHYSIOL-RENAL, V282, pF151, DOI 10.1152/ajprenal.0055.2001; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Harwood A, 2003, NAT CELL BIOL, V5, P275, DOI 10.1038/ncb0403-275; Hishikawa K, 2000, EUR J PHARMACOL, V392, P19, DOI 10.1016/S0014-2999(00)00115-1; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; ILLC D, 1995, NATURE, V377, P539; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kubota S, 2000, FEBS LETT, V474, P58, DOI 10.1016/S0014-5793(00)01573-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; MacGillivray M, 2003, J BIOL CHEM, V278, P27190, DOI 10.1074/jbc.M213083200; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nishida T, 1998, BIOCHEM BIOPH RES CO, V247, P905, DOI 10.1006/bbrc.1998.8895; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Roberts LA, 2003, J CELL PHYSIOL, V196, P196, DOI 10.1002/jcp.10303; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Standaert ML, 1999, J BIOL CHEM, V274, P14074, DOI 10.1074/jbc.274.20.14074; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Tzima E, 2003, J BIOL CHEM, V278, P31020, DOI 10.1074/jbc.M301179200; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whiteside CI, 2002, AM J PHYSIOL-RENAL, V282, pF975, DOI 10.1152/ajprenal.00014.2002; Yano KJ, 1999, ENDOCRINOLOGY, V140, P4622, DOI 10.1210/en.140.10.4622; Yokoi H, 2001, AM J KIDNEY DIS, V38, pS134, DOI 10.1053/ajkd.2001.27422; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; ZHOU XP, 1995, LAB INVEST, V73, P372	60	65	70	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1541	+		10.1096/fj.04-1546fje	http://dx.doi.org/10.1096/fj.04-1546fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319369				2022-12-25	WOS:000223554900014
J	La, P; Silva, AC; Hou, ZY; Wang, HR; Schnepp, RW; Yan, N; Shi, YG; Hua, XX				La, P; Silva, AC; Hou, ZY; Wang, HR; Schnepp, RW; Yan, N; Shi, YG; Hua, XX			Direct binding of DNA by tumor suppressor menin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOCRINE NEOPLASIA TYPE-1; CHROMOSOME-ABNORMALITIES; PROTEINS; INTERACTS; GENE; PRODUCT; BRCA1; TRANSCRIPTION; LYMPHOCYTES; INHIBITION	Menin is a tumor suppressor that is mutated in patients with multiple endocrine neoplasia type I (MEN1), an inherited tumor-prone syndrome. Because there is no obvious conserved structural domain in menin that suggests a biochemical function, little is known as to how menin suppresses tumorigenisis. Although menin interacts with a variety of nuclear proteins including transcription factors, it is unknown whether menin itself can directly bind DNA. Here we show that menin directly binds to double-stranded DNA. It also binds a variety of DNA structures, including Y-structures, branched structures, and 4-way junction structures. The COOH terminus of menin mediates binding to DNA, but MEN1 disease-derived mutations in the COOH terminus abolish the ability of menin to bind DNA. Importantly, these MEN1 disease-related menin mutants also fail to repress cell proliferation as well as cell cycle progression at the G(2)/M phase. Furthermore, detailed mutagenesis studies indicate that positively charged residues in two nuclear localization signals mediate direct DNA binding as well as repression of cell proliferation. Collectively, these results demonstrate, for the first time, a novel biochemical activity of menin, binding to DNA, and link its DNA binding to the regulation of cell proliferation.	Drexel Univ, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Drexel Univ, Signal Transduct Program, Philadelphia, PA 19104 USA; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Drexel University; Princeton University	Hua, XX (corresponding author), Drexel Univ, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	huax@mail.med.upenn.edu		Shi, Yigong/0000-0003-2030-168X	NATIONAL CANCER INSTITUTE [R01CA113962, R01CA100912] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100912, R01 CA113962-01, R01 CA113962, R01 CA100912-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal SK, 1999, CELL, V96, P143, DOI 10.1016/S0092-8674(00)80967-8; Annab LA, 2000, BREAST CANCER RES, V2, P139, DOI 10.1186/bcr45; Bertolino P, 2003, MECH DEVELOP, V120, P549, DOI 10.1016/S0925-4773(03)00039-X; Constantinou A, 2001, CELL, V104, P259, DOI 10.1016/S0092-8674(01)00210-0; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Gadhavi PL, 2001, BIOCHEM BIOPH RES CO, V281, P520, DOI 10.1006/bbrc.2001.4375; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Hessman O, 2001, J CLIN ENDOCR METAB, V86, P1355, DOI 10.1210/jc.86.3.1355; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Itakura Y, 2000, BIOMED PHARMACOTHER, V54, p187S, DOI 10.1016/S0753-3322(00)80041-4; Jin SH, 2003, CANCER RES, V63, P4204; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KERN SE, 1991, ONCOGENE, V6, P131; Kim H, 2003, CANCER RES, V63, P6135; Kim YS, 1999, ONCOGENE, V18, P5936, DOI 10.1038/sj.onc.1203005; La P, 2004, ENDOCRINOLOGY, V145, P3443, DOI 10.1210/en.2004-0124; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Marx SJ, 1999, RECENT PROG HORM RES, V54, P397; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Pannett AAJ, 1999, ENDOCR-RELAT CANCER, V6, P449, DOI 10.1677/erc.0.0060449; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Poisson A, 2003, CANCER LETT, V189, P1, DOI 10.1016/S0304-3835(02)00509-8; Ratineau C, 2004, J BIOL CHEM, V279, P24477, DOI 10.1074/jbc.M401835200; Sambrook J, 2001, MOL CLONING LAB MANU; Sayo Y, 2002, ENDOCRINOLOGY, V143, P2437, DOI 10.1210/en.143.6.2437; SCAPPATICCI S, 1992, CANCER GENET CYTOGEN, V63, P17, DOI 10.1016/0165-4608(92)90057-F; SCAPPATICCI S, 1991, CANCER GENET CYTOGEN, V52, P85, DOI 10.1016/0165-4608(91)90057-2; Schnepp RW, 2004, CANCER RES, V64, P6791, DOI 10.1158/0008-5472.CAN-04-0724; Schnepp RW, 2004, J BIOL CHEM, V279, P10685, DOI 10.1074/jbc.M308073200; Schussheim DH, 2001, TRENDS ENDOCRIN MET, V12, P173, DOI 10.1016/S1043-2760(00)00372-6; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; STEINMEYER K, 1988, ONCOGENE, V3, P501; Sukhodolets KE, 2003, MOL CELL BIOL, V23, P493, DOI 10.1128/MCB.23.2.493-509.2003; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	44	60	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49045	49054		10.1074/jbc.M409358200	http://dx.doi.org/10.1074/jbc.M409358200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15331604	Green Accepted, hybrid			2022-12-25	WOS:000225098100068
J	Numao, S; Damager, I; Li, CM; Wrodnigg, TM; Begum, A; Overall, CM; Brayer, GD; Withers, SG				Numao, S; Damager, I; Li, CM; Wrodnigg, TM; Begum, A; Overall, CM; Brayer, GD; Withers, SG			In situ extension as an approach for identifying novel alpha-amylase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; ANGSTROM RESOLUTION; GLYCOSYL HYDROLASES; STRUCTURAL-ANALYSIS; CYCLODEXTRIN GLYCOSYLTRANSFERASE; CARBOHYDRATE-ABSORPTION; 2.2-ANGSTROM RESOLUTION; GLYCOSIDASE MECHANISMS; ANALOG INHIBITOR; ACARBOSE	A new approach for the discovery and subsequent structural elucidation of oligosaccharide-based inhibitors of alpha-amylases based upon autoglucosylation of known alpha-glucosidase inhibitors is presented. This concept, highly analogous to what is hypothesized to occur with acarbose, is demonstrated with the known alpha-glucosidase inhibitor, D-gluconohydroximino-1,5-lactam. This was transformed from an inhibitor of human pancreatic alpha-amylase with a K-i value of 18 mM to a trisaccharide analogue with a K-i value of 25 muM. The three-dimensional structure of this complex was determined by x-ray crystallography and represents the first such structure determined with this class of inhibitors in any alpha-glycosidase. This approach to the discovery and structural analysis of amylase inhibitors should be generally applicable to other endoglucosidases and readily adaptable to a high throughput format.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca		Numao, Shin/0000-0002-6204-7117				Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; Bailey CJ, 1998, CHEM IND-LONDON, P53; Brayer GD, 2000, BIOCHEMISTRY-US, V39, P4778, DOI 10.1021/bi9921182; BRAYER GD, 1995, PROTEIN SCI, V4, P1730, DOI 10.1002/pro.5560040908; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; FLEET GWJ, 1990, TETRAHEDRON LETT, V31, P409, DOI 10.1016/S0040-4039(00)94568-4; HAYASHI M, 1984, CHEM LETT, P1747, DOI 10.1246/cl.1984.1747; Heightman TD, 1999, ANGEW CHEM INT EDIT, V38, P750, DOI 10.1002/(SICI)1521-3773(19990315)38:6<750::AID-ANIE750>3.0.CO;2-6; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hoos R, 1997, CARBOHYD RES, V298, P291, DOI 10.1016/S0008-6215(96)00320-5; HOOS R, 1993, HELV CHIM ACTA, V76, P2666, DOI 10.1002/hlca.19930760723; JENKINS DJA, 1981, DIABETES, V30, P951, DOI 10.2337/diabetes.30.11.951; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; LEATHERBARROW RJ, 1998, GRAFIT 4 0 21; MACHIUS M, 1995, J MOL BIOL, V246, P545, DOI 10.1006/jmbi.1994.0106; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; MEYER BH, 1984, S AFR MED J, V66, P222; Mosi R, 1998, BIOCHEMISTRY-US, V37, P17192, DOI 10.1021/bi981109a; Notenboom V, 2000, BIOCHEMISTRY-US, V39, P11553, DOI 10.1021/bi0010625; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Ramasubbu N, 1996, ACTA CRYSTALLOGR D, V52, P435, DOI 10.1107/S0907444995014119; Rydberg EH, 1999, PROTEIN SCI, V8, P635; Rydberg EH, 2002, BIOCHEMISTRY-US, V41, P4492, DOI 10.1021/bi011821z; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Takada M, 1999, J CARBOHYD CHEM, V18, P149, DOI 10.1080/07328309908543988; Takada M, 1998, J BIOCHEM-TOKYO, V123, P508; TAO BY, 1989, BIOCHIM BIOPHYS ACTA, V995, P214, DOI 10.1016/0167-4838(89)90038-1; TAYLOR RH, 1982, DIABETES CARE, V5, P92, DOI 10.2337/diacare.5.2.92; Uchida R, 1999, CHEM PHARM BULL, V47, P187; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Yoon SH, 2003, CARBOHYD RES, V338, P1969, DOI 10.1016/S0008-6215(03)00293-3; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	39	16	16	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48282	48291		10.1074/jbc.M406804200	http://dx.doi.org/10.1074/jbc.M406804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15304511	hybrid			2022-12-25	WOS:000224957000104
J	Beddoe, T; Bushell, SR; Perugini, MA; Lithgow, T; Mulhern, TD; Bottomley, SP; Rossjohn, J				Beddoe, T; Bushell, SR; Perugini, MA; Lithgow, T; Mulhern, TD; Bottomley, SP; Rossjohn, J			A biophysical analysis of the tetratricopeptide repeat-rich mitochondrial import receptor, Tom70, reveals an elongated monomer that is inherently flexible, unstable, and unfolds via a multistate pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; SIGNAL ANCHOR SEQUENCE; YEAST MITOCHONDRIA; ADP/ATP CARRIER; TPR; BINDING; MAS70P; DOMAIN; MOTIF; PREPROTEINS	Proteins destined for all submitochondrial compartments are translocated across the outer mitochondrial membrane by the TOM (translocase of the outer membrane) complex, which consists of a number of specialized receptor subunits that bind mitochondrial precursor proteins for delivery into the translocation channel. One receptor, Tom70, binds large, hydrophobic mitochondrial precursors. The current model of Tom70-mediated import involves multiple dimers of the receptor recognizing a single molecule of substrate. Here we show via a battery of biophysical and spectroscopic techniques that the cytosolic domain of Tom70 is an elongated monomer. Thermal and urea-induced denaturation revealed that the receptor, which unfolds via a multistate pathway, is a relatively unstable molecule undergoing major conformational change at physiological temperatures. The data suggest that the malleability of the monomeric Tom70 receptor is an important factor in mitochondrial import.	Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia; Monash Univ, Protein Crystallog Unit, ARC Ctr Struct & Functional Microbial Genom, Clayton, Vic 3800, Australia; Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia	Monash University; Monash University; University of Melbourne	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia.	Stephen.Bottomley@med.monash.edu.Au; Jamie.Rossjohn@med.monash.edu.au	Mulhern, Terrence/A-1206-2007; Lithgow, Trevor J/H-5925-2017; Beddoe, Travis/F-3415-2014; Rossjohn, Jamie/F-9032-2013	Lithgow, Trevor J/0000-0002-0102-7884; Beddoe, Travis/0000-0003-4550-2277; Rossjohn, Jamie/0000-0002-2020-7522; Bushell, Simon/0000-0001-5477-6777; Mulhern, Terrence/0000-0002-1609-7498				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; BARRICK D, 1993, BIOCHEMISTRY-US, V32, P3790, DOI 10.1021/bi00065a035; BEDDOE T, 2003, R GRIMWADE SCH BIOCH, P161; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Brix J, 2000, J MOL BIOL, V303, P479, DOI 10.1006/jmbi.2000.4120; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Koehler CM, 2000, MOL CELL BIOL, V20, P1187, DOI 10.1128/MCB.20.4.1187-1193.2000; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; Main ERG, 2003, STRUCTURE, V11, P497, DOI 10.1016/S0969-2126(03)00076-5; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; Mosavi LK, 2002, P NATL ACAD SCI USA, V99, P16029, DOI 10.1073/pnas.252537899; Mosavi LK, 2002, J MOL BIOL, V320, P165, DOI 10.1016/S0022-2836(02)00441-2; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PFANNER N, 1987, J BIOL CHEM, V262, P7528; RIEZMAN H, 1983, EMBO J, V2, P2161, DOI 10.1002/j.1460-2075.1983.tb01717.x; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; Stumpp MT, 2003, J MOL BIOL, V332, P471, DOI 10.1016/S0022-2836(03)00897-0; Tang KS, 1999, J MOL BIOL, V285, P1869, DOI 10.1006/jmbi.1998.2420; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Waizenegger T, 2003, J BIOL CHEM, V278, P42064, DOI 10.1074/jbc.M305736200; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhang B, 2000, J MOL BIOL, V299, P1121, DOI 10.1006/jmbi.2000.3803; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	42	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46448	46454		10.1074/jbc.M405639200	http://dx.doi.org/10.1074/jbc.M405639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316022	hybrid			2022-12-25	WOS:000224832400015
J	Ye, JZS; Donigian, JR; van Overbeek, M; Loayza, D; Luo, Y; Krutchinsky, AN; Chait, BT; de Lange, T				Ye, JZS; Donigian, JR; van Overbeek, M; Loayza, D; Luo, Y; Krutchinsky, AN; Chait, BT; de Lange, T			TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; LENGTH REGULATOR; PROTEIN; IDENTIFICATION; TANKYRASE-1; POT1; ELONGATION; DOMAIN; IRAP	Human telomeres contain two related telomeric DNA-binding proteins, TRF1 and TRF2. The TRF1 complex contains the TRF1 interacting partner, TIN2, as well as PIP1 and POT1 and regulates telomere-length homeostasis. The TRF2 complex is primarily involved in telomere protection and contains the TRF2 interacting partner human ( h) Rap1 as well as several factors involved in the DNA damage response. A prior report showed that conditional deletion of murine TRF1 reduced the presence of TRF2 on telomeres. Here we showed that TRF2 is also lost from human telomeres upon TRF1 depletion with small interfering RNA prompting a search for the connection between the TRF1 and TRF2 complexes. Using mass spectrometry and co-immunoprecipitation, we found that TRF1, TIN2, PIP1, and POT1 are associated with the TRF2-hRap1 complex. Gel filtration identified a TRF2 complex containing TIN2 and POT1 but not TRF1 indicating that TRF1 is not required for this interaction. Co-immunoprecipitation, Far-Western assays, and two-hybrid assays showed that TIN2, but not POT1 or PIP1, interacts directly with TRF2. Furthermore, TIN2 was found to bind TRF1 and TRF2 simultaneously, showing that TIN2 can link these telomeric proteins. This connection appeared to stabilize TRF2 on the telomeres as the treatment of cells with TIN2 small interfering RNA resulted in a decreased presence of TRF2 and hRap1 at chromosome ends. The TIN2-mediated cooperative binding of TRF1 and TRF2 to telomeres has important implications for the mechanism of telomere length regulation and protection.	Rockefeller Univ, Cell Biol & Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Rockefeller University; Memorial Sloan Kettering Cancer Center	de Lange, T (corresponding author), Rockefeller Univ, Cell Biol & Genet Lab, Box 159,1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NATIONAL CANCER INSTITUTE [K08CA093604] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NCI NIH HHS [K08CA93604] Funding Source: Medline; NCRR NIH HHS [RR00862] Funding Source: Medline; NIGMS NIH HHS [GM49069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Chiang YJ, 2004, MOL CELL BIOL, V24, P6631, DOI 10.1128/mcb.24.15.6631-6634.2004; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7; Cook BD, 2002, MOL CELL BIOL, V22, P332, DOI 10.1128/MCB.22.1.332-342.2002; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Iwano T, 2004, J BIOL CHEM, V279, P1442, DOI 10.1074/jbc.M309138200; Kameoka S, 2004, EMBO J, V23, P1782, DOI 10.1038/sj.emboj.7600187; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2003, MOL CELL BIOL, V23, P6533, DOI 10.1128/MCB.23.18.6533-6541.2003; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Kishi S, 2001, J BIOL CHEM, V276, P29282, DOI 10.1074/jbc.M011534200; Krutchinsky AN, 2000, J AM SOC MASS SPECTR, V11, P493, DOI 10.1016/S1044-0305(00)00114-8; Krutchinsky AN, 2001, ANAL CHEM, V73, P5066, DOI 10.1021/ac010682o; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; LILLARDWETHEREL.K, 2004, HUM MOL GENET; LIU D, 2004, NAT CELL BIOL; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Mattern KA, 2004, MOL CELL BIOL, V24, P5587, DOI 10.1128/MCB.24.12.5587-5594.2004; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Opresko PL, 2004, MOL CELL, V14, P763, DOI 10.1016/j.molcel.2004.05.023; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Sbodio JI, 2002, J BIOL CHEM, V277, P31887, DOI 10.1074/jbc.M203916200; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Ye JZS, 2004, NAT GENET, V36, P618, DOI 10.1038/ng1360; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	48	241	261	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47264	47271		10.1074/jbc.M409047200	http://dx.doi.org/10.1074/jbc.M409047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15316005	hybrid			2022-12-25	WOS:000224832400114
J	Landrier, JF; Thomas, C; Grober, J; Duez, H; Percevault, F; Souidi, M; Linard, C; Staels, B; Besnard, P				Landrier, JF; Thomas, C; Grober, J; Duez, H; Percevault, F; Souidi, M; Linard, C; Staels, B; Besnard, P			Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN C-III; COA REDUCTASE INHIBITOR; PPAR-ALPHA; TRANSCRIPTIONAL ACTIVITIES; ADIPOCYTE DIFFERENTIATION; TRIGLYCERIDE SECRETION; CHOLESTEROL-SYNTHESIS; APO B-100; ATORVASTATIN; MICE	Statins are drugs widely used in humans to treat hypercholesterolemia. Statins act by inhibiting cholesterol synthesis resulting in the activation of the transcription factor sterol-responsive element-binding protein-2 that controls the expression of genes involved in cholesterol homeostasis. Statin therapy also decreases plasma triglyceride and non-esterified fatty acid levels, but the mechanism behind this effect remains more elusive. Liver fatty acid-binding protein (L-FABP) plays a role in the influx of long-chain fatty acids into hepatocytes. Here we show that L-FABP is a target for statins. In rat hepatocytes, simvastatin treatment induced L-FABP mRNA levels in a dose-dependent manner. Moreover, L-FABP promoter activity was induced by statin treatment. Progressive 5'-deletion analysis revealed that the peroxisome proliferator-activated receptor (PPAR)-responsive element located at position -67/-55 was responsible for the statin-mediated transactivation of the rat L-FABP promoter. Moreover, treatment with simvastatin and the PPARalpha agonist Wy14,649 resulted in a synergistic induction of L-FABP expression (mRNA and protein) in rat Fao hepatoma cells. This effect was also observed in vivo in wild-type mice but not in PPARalpha-null animals demonstrating the direct implication of PPARalpha in L-FABP regulation by statin treatment. Statin treatment resulted in a rise in PPARalpha mRNA levels both in vitro and in vivo and activated the mouse PPARalpha promoter in a reporter assay. Altogether, these data demonstrate that L-FABP expression is up-regulated by statins through a mechanism involving PPARalpha. Moreover, PPARalpha might be a statin target gene. These effects might contribute to the triglyceride/non-esterified fatty acid-lowering properties of statins.	Univ Bourgogne 1, Ecole Natl Super Biol Appl Nutr & Alimentat, UMR 5170,CNRS,Ctr Europeen Sci Gout, Inst Natl Rech Agron, F-21000 Dijon, France; Univ Lille 2, UR 545, INSERM, F-59019 Lille, France; Univ Lille 2, Fac Pharm, Lille, France; Inst Radioprotect & Surete Nucl, Inst Radioprotect, Dept Radioprotect Homme, F-92262 Fontenay Aux Roses, France	INRAE; Institut Agro; AgroSup Dijon; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille	Besnard, P (corresponding author), Univ Bourgogne 1, Ecole Natl Super Biol Appl Nutr & Alimentat, UMR 5170,CNRS,Ctr Europeen Sci Gout, Inst Natl Rech Agron, 1 Esplanade Erasme, F-21000 Dijon, France.	pbesnard@u-bourgogne.fr	Thomas, charles/C-7130-2019; percevault, frederic/K-1836-2015; Duez, Helene/M-7609-2017; Landrier, Jean-Francois/AAH-2757-2019; Staels, Bart/N-9497-2016; Duez, Helene/AAC-3217-2019	Thomas, charles/0000-0001-9998-6698; Landrier, Jean-Francois/0000-0002-8690-8014; Staels, Bart/0000-0002-3784-1503; Duez, Helene/0000-0002-4130-7987				Akiyama TE, 2000, J BIOL CHEM, V275, P27117; Bays H, 2003, EXPERT OPIN PHARMACO, V4, P1901, DOI 10.1517/14656566.4.11.1901; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Egawa T, 2003, LIPIDS, V38, P519, DOI 10.1007/s11745-003-1093-x; Erol E, 2003, FASEB J, V17, P347, DOI 10.1096/fj.03-0330fje; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Funatsu T, 2002, EUR J PHARMACOL, V455, P161, DOI 10.1016/S0014-2999(02)02611-0; Funatsu T, 2002, BBA-MOL CELL BIOL L, V1580, P161, DOI 10.1016/S1388-1981(01)00201-3; Funatsu T, 2001, ATHEROSCLEROSIS, V157, P107, DOI 10.1016/S0021-9150(00)00714-0; Gaw A, 2003, CARDIOVASC DRUG THER, V17, P53, DOI 10.1023/A:1024207925670; Ginsberg HN, 1998, AM J CARDIOL, V81, p32B, DOI 10.1016/S0002-9149(98)00035-6; Gotto A M Jr, 1999, Circulation, V99, pE1; GUZMAN M, 1993, LIPIDS, V28, P1087, DOI 10.1007/BF02537075; Haubenwallner S, 1995, J LIPID RES, V36, P2541; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Mahley RW, 1999, J LIPID RES, V40, P1; Makar RSJ, 1998, J LIPID RES, V39, P1647; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; MeunierDurmort C, 1996, BIOCHEM J, V319, P483, DOI 10.1042/bj3190483; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Poirier H, 1997, FEBS LETT, V412, P480, DOI 10.1016/S0014-5793(97)00830-2; Raal FJ, 2000, ATHEROSCLEROSIS, V150, P421, DOI 10.1016/S0021-9150(99)00435-9; Roglans N, 2002, J PHARMACOL EXP THER, V302, P232, DOI 10.1124/jpet.302.1.232; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Schaefer JR, 1999, ATHEROSCLEROSIS, V144, P177, DOI 10.1016/S0021-9150(99)00053-2; Schoonjans K, 1999, FEBS LETT, V452, P160, DOI 10.1016/S0014-5793(99)00632-8; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Sniderman AD, 2000, ATHEROSCLEROSIS, V148, P215, DOI 10.1016/S0021-9150(99)00282-8; Sposito AC, 2003, ATHEROSCLEROSIS, V166, P311, DOI 10.1016/S0021-9150(02)00334-9; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Takemoto M, 2001, ARTERIOSCL THROM VAS, V21, P1712, DOI 10.1161/hq1101.098486; Torra IP, 2003, MOL ENDOCRINOL, V17, P259, DOI 10.1210/me.2002-0120; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; Wagner AM, 2003, J CLIN ENDOCR METAB, V88, P3212, DOI 10.1210/jc.2003-030153; Wierzbicki AS, 2003, PHARMACOL THERAPEUT, V99, P95, DOI 10.1016/S0163-7258(03)00055-X; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Xydakis AM, 2002, AM J CARDIOL, V90, p21K; Yamamoto K, 1999, LIFE SCI, V65, P1493, DOI 10.1016/S0024-3205(99)00390-2	53	80	91	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45512	45518		10.1074/jbc.M407461200	http://dx.doi.org/10.1074/jbc.M407461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15337740	hybrid			2022-12-25	WOS:000224694900029
J	Li, QJ; Dashwood, RH				Li, QJ; Dashwood, RH			Activator protein 2 alpha associates with adenomatous polyposis coli/beta-catenin and inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR AP-2; EPITHELIAL-CELLS; DNA-BINDING; NEGATIVE REGULATION; COLON-CANCER; GROWTH; GENE; APC; EXPRESSION; AP-2-ALPHA	In most human colorectal cancers, mutations in the adenomatous polyposis coli gene (APC) or CTNNB1 constitutively activate the beta-catenin/T-cell factor (TCF)/lymphoid enhancer factor (LEF) signaling pathway. Here, we show that the transcription factor activator protein (AP)-2alpha inhibited a beta-catenin/TCF-responsive reporter in human embryonic kidney 293 cells and in two human colorectal cancer lines, despite the fact that beta-catenin and TCF-4 protein levels were unchanged in the nucleus. Co-immunoprecipitation studies revealed that AP-2alpha formed a complex with APC and beta-catenin and that AP-2alpha disrupted beta-catenin/TCF-4 interactions in the nucleus. Thus, AP-2alpha.APC.beta-catenin complex formation appears to suppress beta-catenin transactivation by shifting the pool of nuclear beta-catenin toward an inactive form, having reduced binding to TCF/LEF transcription factors. Glutathione S-transferase pull-down assays showed that AP-2alpha physically associated with APC rather than with beta-catenin, and the AP-2alpha binding site was identified in the N terminus of APC, involving both the heptad and armadillo repeat domains, whereas the APC binding site in AP-2alpha was in the basic region of the C-terminal DNA binding domain. These findings provide the first evidence for a specific interaction between the tumor suppressor protein APC and the transcription factor AP-2alpha, and they suggest a link between the Wnt signaling pathway and various other pathways of development and differentiation associated with AP-2alpha.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Dashwood, RH (corresponding author), Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA.	Rod.Dashwood@oregonstate.edu	Dashwood, Roderick H/E-9090-2011; Dashwood, Roderick/AAF-2025-2020	Li, Qingjie/0000-0003-1405-7000	NATIONAL CANCER INSTITUTE [R01CA065525, P01CA090890, R01CA080176, R29CA065525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA090890-01A29001, P01 CA090890-05, R01 CA065525-06A1, R01 CA080176-04, R01 CA065525-09, R01 CA080176-05, CA65525, CA80176, CA90890, R01 CA065525, R29 CA065525, P01 CA090890-05S1, R01 CA080176-03, P01 CA090890, R01 CA065525-07, R01 CA080176-02, P01 CA090890-01A20003, R01 CA065525-08, R01 CA080176] Funding Source: Medline; NIEHS NIH HHS [P30 ES00210, P30 ES000210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al-Fageeh M, 2004, ONCOGENE, V23, P4839, DOI 10.1038/sj.onc.1207634; Batsche E, 1999, ONCOGENE, V18, P5662, DOI 10.1038/sj.onc.1202927; Batsche E, 1998, MOL CELL BIOL, V18, P3647, DOI 10.1128/MCB.18.7.3647; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; EKLOF SK, 2001, EMBO J, V20, P6203; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; Gee JMW, 1999, J PATHOL, V189, P514, DOI 10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9; Graham NA, 2004, J BIOL CHEM, V279, P23517, DOI 10.1074/jbc.M314055200; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Huang ZM, 2004, J BONE MINER RES, V19, P245, DOI 10.1359/jbmr.2004.19.2.245; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Imhof A, 1999, MOL CELL BIOL, V19, P194; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Karjalainen JM, 1998, J CLIN ONCOL, V16, P3584, DOI 10.1200/JCO.1998.16.11.3584; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mori N, 1996, CANCER RES, V56, P779; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Nath N, 2003, P NATL ACAD SCI USA, V100, P12584, DOI 10.1073/pnas.2134840100; Polakis P, 2000, GENE DEV, V14, P1837; Ropponen KM, 2001, J CLIN PATHOL, V54, P533, DOI 10.1136/jcp.54.7.533; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Roth C, 2000, GENOMICS, V63, P384, DOI 10.1006/geno.1999.6084; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Sparks AB, 1998, CANCER RES, V58, P1130; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Wajapeyee N, 2003, J BIOL CHEM, V278, P52093, DOI 10.1074/jbc.M305624200; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	44	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45669	45675		10.1074/jbc.M405025200	http://dx.doi.org/10.1074/jbc.M405025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15331612	Green Accepted, hybrid			2022-12-25	WOS:000224694900047
J	de Vitry, C; Ouyang, YX; Finazzi, G; Wollman, FA; Kallas, T				de Vitry, C; Ouyang, YX; Finazzi, G; Wollman, FA; Kallas, T			The chloroplast Rieske iron-sulfur protein - At the crossroad of electron transport and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME B(6)F COMPLEX; PETA MESSENGER-RNA; CHLAMYDOMONAS-REINHARDTII; STATE TRANSITIONS; PHOTOSYSTEM-II; BC(1) COMPLEX; SULFOQUINOVOSYL DIACYLGLYCEROL; DOMAIN MOVEMENT; Q-CYCLE; DIRECTED MUTAGENESIS	We have addressed the functional and structural roles of three domains of the chloroplast Rieske iron-sulfur protein; that is, the flexible hinge that connects the transmembrane helix to the soluble cluster-bearing domain, the N-terminal stromal protruding domain, and the transmembrane helix. To this aim mutants were generated in the green alga Chlamydomonas reinhardtii. Their capacities to assemble the cytochrome b(6)f complex, perform plastoquinol oxidation, and signal redox-induced activation of the light-harvesting complex II kinase during state transition were tested in vivo. Deletion of one residue and extensions of up to five residues in the flexible hinge had no significant effect on complex accumulation or electron transfer efficiency. Deletion of three residues (Delta3G) dramatically decreased reaction rates by a factor of similar to 10. These data indicate that the chloroplast iron-sulfur protein-linking domain is much more flexible than that of its counterpart in mitochondria. Despite greatly slowed catalysis in the Delta3G mutant, there was no apparent delay in light-harvesting complex II kinase activation or state transitions. This indicates that conformational changes occurring in the Rieske protein did not represent a limiting step for kinase activation within the time scale tested. No phenotype could be associated with mutations in the N-terminal stromal-exposed domain. In contrast, the N17V mutation in the Rieske protein transmembrane helix resulted in a large decrease in the cytochrome f synthesis rate. This reveals that the Rieske protein transmembrane helix plays an active role in assembly-mediated control of cytochrome f synthesis. We propose a structural model to interpret this phenomenon based on the C. reinhardtii cytochrome b(6)f structure.	Inst Biol Physicochim, CNRS, UPR 1261, F-75005 Paris, France; Univ Wisconsin, Dept Biol & Microbiol, Oshkosh, WI 54901 USA	Centre National de la Recherche Scientifique (CNRS); University of Wisconsin System	de Vitry, C (corresponding author), Inst Biol Physicochim, CNRS, UPR 1261, 13 Rue Pierre & Marie Curie, F-75005 Paris, France.	catherine.devitry@ibpc.fr						ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; Aoki M, 2004, EUR J BIOCHEM, V271, P685, DOI 10.1111/j.1432-1033.2003.03970.x; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BREYTON C, 1994, J BIOL CHEM, V269, P7597; Breyton C, 2000, BBA-BIOENERGETICS, V1459, P467, DOI 10.1016/S0005-2728(00)00185-7; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; Choquet Y, 1998, P NATL ACAD SCI USA, V95, P4380, DOI 10.1073/pnas.95.8.4380; Choquet Y, 2003, PLANT CELL, V15, P1443, DOI 10.1105/tpc.011692; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; Darrouzet E, 2001, TRENDS BIOCHEM SCI, V26, P445, DOI 10.1016/S0968-0004(01)01897-7; de Vitry C, 2004, BIOCHEMISTRY-US, V43, P3956, DOI 10.1021/bi036093p; de Vitry C, 1999, PLANT CELL, V11, P2031, DOI 10.1105/tpc.11.10.2031; DELEPELAIRE P, 1985, BIOCHIM BIOPHYS ACTA, V809, P277, DOI 10.1016/0005-2728(85)90071-4; Depege N, 2003, SCIENCE, V299, P1572, DOI 10.1126/science.1081397; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; DREPPER F, 1993, BIOCHEMISTRY-US, V32, P11915, DOI 10.1021/bi00095a022; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; Finazzi G, 2003, EMBO J, V22, P807, DOI 10.1093/emboj/cdg081; Finazzi G, 2001, J BIOL CHEM, V276, P9770, DOI 10.1074/jbc.M010092200; Fleischmann MM, 1999, J BIOL CHEM, V274, P30987, DOI 10.1074/jbc.274.43.30987; Hamel P, 2000, J BIOL CHEM, V275, P17072, DOI 10.1074/jbc.M001468200; Heimann S, 2000, BIOCHEMISTRY-US, V39, P2692, DOI 10.1021/bi9921992; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOLIOT P, 1994, P NATL ACAD SCI USA, V91, P1034, DOI 10.1073/pnas.91.3.1034; KROPAT J, 1995, MOL GEN GENET, V248, P727, DOI 10.1007/BF02191713; KURAS R, 1994, EMBO J, V13, P1019, DOI 10.1002/j.1460-2075.1994.tb06350.x; Kurisu G, 2003, SCIENCE, V302, P1009, DOI 10.1126/science.1090165; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; Majeran W, 2000, PLANT CELL, V12, P137; Majeran W., 2002, THESIS I NATL AGRONO; Minoda A, 2003, FEBS LETT, V553, P109, DOI 10.1016/S0014-5793(03)00981-5; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; Riekhof WR, 2003, PLANT PHYSIOL, V133, P864, DOI 10.1104/pp.103.029249; SATO N, 1995, EUR J BIOCHEM, V234, P16, DOI 10.1111/j.1432-1033.1995.016_c.x; Sato N, 2003, PLANTA, V217, P245, DOI 10.1007/s00425-003-0992-9; Schoepp B, 1999, FEBS LETT, V450, P245, DOI 10.1016/S0014-5793(99)00511-6; SELAK MA, 1982, FEBS LETT, V150, P286, DOI 10.1016/0014-5793(82)80753-9; Soriano GM, 2002, J BIOL CHEM, V277, P41865, DOI 10.1074/jbc.M205772200; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; Takahashi Y, 1996, EMBO J, V15, P3498, DOI 10.1002/j.1460-2075.1996.tb00718.x; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; Wostrikoff K, 2001, GENETICS, V159, P119; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yan JS, 2003, J BIOL CHEM, V278, P20925, DOI 10.1074/jbc.M212616200; Yu B, 2003, PLANT J, V36, P762, DOI 10.1046/j.1365-313X.2003.01918.x; Yu B, 2002, P NATL ACAD SCI USA, V99, P5732, DOI 10.1073/pnas.082696499; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zito F, 1999, EMBO J, V18, P2961, DOI 10.1093/emboj/18.11.2961; Zito F, 2002, J BIOL CHEM, V277, P12446, DOI 10.1074/jbc.M110914200	56	46	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44621	44627		10.1074/jbc.M406955200	http://dx.doi.org/10.1074/jbc.M406955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15316016	hybrid			2022-12-25	WOS:000224505600048
J	Hao, LY; Strong, MA; Greider, CW				Hao, LY; Strong, MA; Greider, CW			Phosphorylation of H2AX at short telomeres in T cells and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; SACCHAROMYCES-CEREVISIAE; DYSFUNCTIONAL TELOMERES; MAMMALIAN TELOMERES; IONIZING-RADIATION; LACKING TELOMERASE; LENGTH; YEAST; MOUSE; END	Eukaryotic cells undergo arrest and enter apoptosis in response to short telomeres. T cells from late generation mTR(-/-) mice that lack telomerase show increased apoptosis when stimulated to enter the cell cycle. The increased apoptosis was not inhibited by colcemid, indicating that the response did not result from breakage of dicentric chromosomes at mitosis. The damage response protein gamma-H2AX localized to telomeres in metaphases from T cells and fibroblasts from mTR(-/-) cells with short telomeres. These data suggest that the major mechanism for induction of apoptosis in late generation mTR(-/-) cells is independent of chromosome segregation and that loss of telomere function through progressive telomere shortening in the absence of telomerase leads to recognition of telomeres as DNA breaks.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Grad Program Human Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, 617 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	cgreider@jhmi.edu		Strong, Margaret/0000-0002-0055-6573	NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA16519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, DNA REPAIR; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; CELESTE A, 2003, NAT CELL BIOL; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Enomoto S, 2002, MOL BIOL CELL, V13, P2626, DOI 10.1091/mbc.02-02-0012; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Hemann MT, 2001, MOL BIOL CELL, V12, P2023, DOI 10.1091/mbc.12.7.2023; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Ijpma AS, 2003, MOL BIOL CELL, V14, P987, DOI 10.1091/mbc.02-04-0057; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; Meeker AK, 2002, CANCER RES, V62, P6405; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Qi L, 2003, CANCER RES, V63, P8188; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Riha K, 2002, EMBO J, V21, P2819, DOI 10.1093/emboj/21.11.2819; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; Ritchie KB, 1999, MOL CELL BIOL, V19, P6065; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	48	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					45148	45154		10.1074/jbc.M403924200	http://dx.doi.org/10.1074/jbc.M403924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15322096	hybrid			2022-12-25	WOS:000224505600108
J	Qu, ZX; Qing, GL; Rabson, A; Xiao, GT				Qu, ZX; Qing, GL; Rabson, A; Xiao, GT			Tax deregulation of NF-kappa B2 p100 processing involves both beta-TrCP-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA IKK-ALPHA; HTLV-I; MEDIATED ACTIVATION; MICE DEFICIENT; BZIP PROTEINS; P50 SUBUNIT; DNA-BINDING; KINASE IKK; GENE	Processing of the nf-kappab2 gene product p100 to generate p52 is a tightly regulated event, consistent with the fact that the processing product, p52, is hardly detected in most cell types, including T cells, although the precursor p100 is expressed abundantly in these cells. However, in T cells transformed by the human T-cell leukemia virus type I (HTLV-I), p100 processing is very active, resulting in high level expression of p52. Because overproduction of p52 is associated with lymphoid hyperplasia and transformation, deregulation of p100 processing may be part of the oncogenic mechanism of HTLV-I. We demonstrated previously that HTLV-I Tax oncoprotein is a potent inducer of p100 processing through specific targeting of IKKalpha via IKKgamma to p100 to trigger p100 phosphorylation and ubiquitination. In this study, we further show that Tax-mediated recruitment of IKKalpha to p100 requires serines 866 and 870 of p100, shown to be essential for inducible processing of p100. Upon interaction with p100, activated IKKalpha phosphorylates both Nand C-terminal serines of p100 ( serines 99, 108, 115, 123 and 872), serving as a critical step in Tax-induced p100 processing. Using a genetic approach, we find that beta-transducin repeat-containing protein, a component of the SCF ubiquitin ligase complex, previously shown to be required for physiological p100 processing mediated by nuclear factor-kappaB-inducing kinase, is only partially involved in Tax-induced processing of p100. These results indicate that both beta-transducin repeat-containing protein-dependent and - independent mechanisms contribute to Tax-deregulated p100 processing, further suggesting the involvement of different mechanisms in cellular and viral pathways of p100 processing.	Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08855 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Xiao, GT (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, Nelson Biol Labs, 604 Allison Rd, Piscataway, NJ 08854 USA.	xiao@biology.rutgers.edu						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BERAUD C, 1994, MOL CELL BIOL, V14, P1374, DOI 10.1128/MCB.14.2.1374; Betts JC, 1996, MOL CELL BIOL, V16, P6363; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LANOIX J, 1994, ONCOGENE, V9, P841; Liao GX, 2003, ONCOGENE, V22, P4868, DOI 10.1038/sj.onc.1206761; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sun SC, 2003, CANCER METAST REV, V22, P405, DOI 10.1023/A:1023733231406; THAKUR S, 1994, ONCOGENE, V9, P2335; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; ZHANG JD, 1994, ONCOGENE, V9, P1931; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	53	38	41	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44563	44572		10.1074/jbc.M403689200	http://dx.doi.org/10.1074/jbc.M403689200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15310758	hybrid			2022-12-25	WOS:000224505600041
J	Beher, D; Clarke, EE; Wrigley, JDJ; Martin, ACL; Nadin, A; Churcher, I; Shearman, MS				Beher, D; Clarke, EE; Wrigley, JDJ; Martin, ACL; Nadin, A; Churcher, I; Shearman, MS			Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site - Evidence for an allosteric mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; BETA-APP; INTRAMEMBRANE CLEAVAGE; THYMOCYTE DEVELOPMENT; TRANSMEMBRANE DOMAIN; MISSENSE MUTATIONS; INHIBITOR BINDING; ACTIVE-SITE	gamma-Secretase is a multi-component enzyme complex that performs an intramembranous cleavage, releasing amyloid-beta (Abeta) peptides from processing intermediates of the beta-amyloid precursor protein. Because Abeta peptides are thought to be causative for Alzheimer's disease, inhibiting gamma-secretase represents a potential treatment for this neurodegenerative condition. Whereas inhibitors directed at the active center of gamma-secretase inhibit the cleavage of all its substrates, certain non-steroidal anti-inflammatory drugs ( NSAIDs) have been shown to selectively reduce the production of the more amyloidogenic Abeta( 1 - 42) peptide without inhibiting alternative cleavages. In contrast to the majority of previous studies, however, we demonstrate that in cell-free systems the mode of action of selected NSAIDs and their derivatives, depending on the concentrations used, can either be classified as modulatory or inhibitory. At modulatory concentrations, a selective and, with respect to the substrate, noncompetitive inhibition of Abeta( 1 - 42) production was observed. At inhibitory concentrations, on the other hand, biochemical readouts reminiscent of a nonselective gamma-secretase inhibition were obtained. When these compounds were analyzed for their ability to displace a radiolabeled, transition-state analog inhibitor from solubilized enzyme, noncompetitive antagonism was observed. The allosteric nature of radioligand displacement suggests that NSAID-like inhibitors change the conformation of the gamma-secretase enzyme complex by binding to a novel site, which is discrete from the binding site for transition-state analogs and therefore distinct from the catalytic center. Consequently, drug discovery efforts aimed at this site may identify novel allosteric inhibitors that could benefit from a wider window for inhibition of gamma (42)-cleavage over alternative cleavages in the beta-amyloid precursor protein and, more importantly, alternative substrates.	Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Dept Mol & Cellular Neurosci, Harlow CM20 2QR, Essex, England	Merck & Company	Beher, D (corresponding author), Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Dept Mol & Cellular Neurosci, Terlings Pk,Eastwick Rd, Harlow CM20 2QR, Essex, England.	dirk_beher@merck.com		Beher, Dirk/0000-0001-8005-5359				Beher D, 2003, BIOCHEMISTRY-US, V42, P8133, DOI 10.1021/bi034045z; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Eriksen JL, 2003, J CLIN INVEST, V112, P440, DOI 10.1172/JCI200318162; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; HAASS C, 1992, NATURE, V359, P325; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Harrison T, 2003, PROGR MED CHEM, V41, P99, DOI 10.1016/S0079-6468(02)41003-X; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Lewis HD, 2003, BIOCHEMISTRY-US, V42, P7580, DOI 10.1021/bi034310g; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 2002, P NATL ACAD SCI USA, V99, P1365, DOI 10.1073/pnas.032395699; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Nadin A, 2001, TETRAHEDRON, V57, P1861, DOI 10.1016/S0040-4020(00)01167-4; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Takahashi Y, 2003, J BIOL CHEM, V278, P18664, DOI 10.1074/jbc.M301619200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tian GC, 2003, J BIOL CHEM, V278, P28968, DOI 10.1074/jbc.M300905200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weggen S, 2003, J BIOL CHEM, V278, P30748, DOI 10.1074/jbc.M304824200; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Weggen S, 2003, J BIOL CHEM, V278, P31831, DOI 10.1074/jbc.M303592200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wrigley JDJ, 2004, J NEUROCHEM, V90, P1312, DOI 10.1111/j.1471-4159.2004.02596.x; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhou Y, 2003, SCIENCE, V302, P1215, DOI 10.1126/science.1090154	48	166	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43419	43426		10.1074/jbc.M404937200	http://dx.doi.org/10.1074/jbc.M404937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15304503	hybrid			2022-12-25	WOS:000224383100011
J	Makridakis, N; Akalu, A; Reichardt, JKV				Makridakis, N; Akalu, A; Reichardt, JKV			Identification and characterization of somatic steroid 5 alpha-reductase (SRD5A2) mutations in human prostate cancer tissue	ONCOGENE			English	Article						somatic mutations; androgen metabolism; prostate cancer; steroid 5 alpha-reductase; pharmacogenetics	ANDROGEN RECEPTOR GENE; AMPLIFICATION; SUBSTITUTION; PROGRESSION; FINASTERIDE; INHIBITOR; CARCINOMA	Prostate cancer is a very common disease in industrialized countries and it is known to be androgen-dependent. The human SRD5A2 gene encodes the prostatic ( or type II) steroid 5alpha-reductase, which catalyses the irreversible conversion of testosterone to dihydrotestosterone (DHT), the most active androgen in the prostate. We have sequenced the entire protein-coding region of this locus in 30 microdissected prostate adenocarcinomas. We identified a total of 17 de novo amino-acid substitutions in 13 of these tumors. We also identified six additional silent substitutions. In total, 18 out of 30 (60%) of the tumors examined had de novo somatic substitutions in the prostatic steroid 5alpha-reductase-coding region. We also characterized all of the SRD5A2 missense substitutions biochemically and pharmacologically, using three 5alpha-reductase inhibitors, including. nasteride. The biochemical parameters of the distinct 5alpha-reductase missense substitutions varied substantially. We note that two out of the three recurrent SRD5A2 missense substitutions increased 5alpha-reductase in vitro activity, while the third one is essentially neutral. These findings are consistent with a role for increased DHT levels in the prostate through increased activity of the SRD5A2 locus in prostate cancer progression, in a subset of patients. Our pharmacologic studies also reveal substantial variability for each 5alpha-reductase inhibitor. These data, therefore, should be taken into account in both prevention as well as therapeutic trials of prostate cancer utilizing 5alpha-reductase inhibitors.	Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Reichardt, JKV (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, 2250 Alcazar St,IGM240, Los Angeles, CA 90089 USA.	reichard@usc.edu		Reichardt, Juergen/0000-0001-6458-2773				Akalu A, 1999, J UROLOGY, V161, P1355, DOI 10.1016/S0022-5347(01)61683-5; Akalu A, 1999, GENET ANAL-BIOMOL E, V15, P229, DOI 10.1016/S1050-3862(99)00050-9; BROTHMAN AR, 1990, CANCER RES, V50, P3795; Cheng Earl, 1993, P57; di Salle E, 1998, J STEROID BIOCHEM, V64, P179, DOI 10.1016/S0960-0760(97)00158-1; Frye S V, 1998, Pharm Biotechnol, V11, P393; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Luo J, 2003, PROSTATE, V57, P134, DOI 10.1002/pros.10284; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; Makridakis N, 1997, CANCER RES, V57, P1020; Makridakis NM, 2000, PHARMACOGENETICS, V10, P407, DOI 10.1097/00008571-200007000-00004; Makridakis NM, 1999, LANCET, V354, P975, DOI 10.1016/S0140-6736(98)11282-5; Nelson DL, 2000, LEHNINGER PRINCIPLES, P257; Ross RK, 1998, CANCER RES, V58, P4497; SCHRODER FH, 1992, PROSTATE, P129; Stoner E, 1996, PROSTATE, P82; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WIGLEY WC, 1994, BIOCHEMISTRY-US, V33, P1265, DOI 10.1021/bi00171a029	22	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7399	7405		10.1038/sj.onc.1207922	http://dx.doi.org/10.1038/sj.onc.1207922			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15326487				2022-12-25	WOS:000224021400010
J	Leinninger, GM; Backus, C; Uhler, MD; Lentz, SI; Feldman, EL				Leinninger, GM; Backus, C; Uhler, MD; Lentz, SI; Feldman, EL			Phosphatidylinositol 3-kinase and Akt effectors mediate insulin-like growth factor-I neuroprotection in dorsal root ganglia neurons	FASEB JOURNAL			English	Article						insulin-like growth factor; dorsal root ganglia neurons; apoptosis; glucose; CREB; FKHR	PROTEIN-KINASE; SKELETAL-MUSCLE; APOPTOSIS; PHOSPHORYLATION; DEATH; EXPRESSION; RECEPTOR; SURVIVAL; GLUCOSE; BCL-2	Insulin-like growth factor-I (IGF-I) protects neurons of the peripheral nervous system from apoptosis, but the underlying signaling pathways are not well understood. We studied IGF-I mediated signaling in embryonic dorsal root ganglia (DRG) neurons. DRG neurons express IGF-I receptors (IGF-IR), and IGF-I activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. High glucose exposure induces apoptosis, which is inhibited by IGF-I through the PI3K/Akt pathway. IGF-I stimulation of the PI3K/Akt pathway phosphorylates three known Akt effectors: the survival transcription factor cyclic AMP response element binding protein ( CREB) and the pro-apoptotic effector proteins glycogen synthase kinase-3 (GSK-3) and forkhead ( FKHR). IGF-I regulates survival at the nuclear level through accumulation of phospho-Akt in DRG neuronal nuclei, increased CREB-mediated transcription, and nuclear exclusion of FKHR. High glucose increases expression of the pro-apoptotic Bcl protein Bim ( a transcriptional target of FKHR). However, IGF-I does not regulate Bim or anti-apoptotic Bcl-xL protein expression levels, which suggests that IGF-I neuroprotection is not through regulation of their expression. High glucose also induces loss of the initiator caspase-9 and increases caspase-3 cleavage, effects blocked by IGF-I. These data suggest that IGF-I prevents apoptosis in DRG neurons by regulating PI3K/Akt pathway effectors, including GSK-3, CREB, and FKHR, and by blocking caspase activation.	Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Mental Hlth Res Inst, Ann Arbor, MI USA; Univ Michigan, MDRTC morphol & Image Anal Core, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol 4414, Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Lentz, Stephen/0000-0003-1686-7998; Feldman, Eva/0000-0002-9162-2694	NHGRI NIH HHS [HG02367] Funding Source: Medline; NIDDK NIH HHS [DK063340] Funding Source: Medline; NINDS NIH HHS [NS38849, NS43023, NS36778] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002367] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK063340] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036778, F31NS043023, R01NS038849] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EICHLER ME, 1989, BRAIN RES, V482, P340, DOI 10.1016/0006-8993(89)91197-9; Federici M, 1998, DIABETES, V47, P87, DOI 10.2337/diabetes.47.1.87; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gao WQ, 1999, J NEUROBIOL, V39, P142, DOI 10.1002/(SICI)1097-4695(199904)39:1<142::AID-NEU11>3.0.CO;2-H; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Hetman M, 2000, J NEUROSCI, V20, P2567; Jones DM, 2003, J NEUROCHEM, V86, P1116, DOI 10.1046/j.1471-4159.2003.01925.x; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KORINKOVA P, 1976, ACTA HISTOCHEM, V56, P47; Leinninger GM, 2003, MED INTELL UNIT, P158; LEWIS ME, 1993, EXP NEUROL, V124, P73, DOI 10.1006/exnr.1993.1177; Linseman DA, 2002, J NEUROSCI, V22, P9287; Lonze BE, 2002, NEURON, V34, P371, DOI 10.1016/S0896-6273(02)00686-4; Mayfield J, 1998, AM FAM PHYSICIAN, V58, P1355; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McDonald ES, 2002, NEUROBIOL DIS, V9, P220, DOI 10.1006/nbdi.2001.0468; Medina-Kauwe LK, 2001, GENE THER, V8, P1753, DOI 10.1038/sj.gt.3301583; MU XJ, 1993, J NEUROSCI, V13, P4029; Parrizas M, 1997, J BIOL CHEM, V272, P154; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Rabinovsky ED, 2002, FASEB J, V16, P53, DOI 10.1096/fj.02-0183fje; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Russell JW, 2002, FASEB J, V16, P1738, DOI 10.1096/fj.01-1027com; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; Walton M, 1999, J NEUROCHEM, V73, P1836; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225	40	133	139	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1544	+		10.1096/fj.04-1581fje	http://dx.doi.org/10.1096/fj.04-1581fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319368	Green Submitted			2022-12-25	WOS:000223554900013
J	Saxena, NK; Titus, MA; Ding, XK; Floyd, J; Srinivasan, S; Sitaraman, SV; Anania, FA				Saxena, NK; Titus, MA; Ding, XK; Floyd, J; Srinivasan, S; Sitaraman, SV; Anania, FA			Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation	FASEB JOURNAL			English	Article						nonalcoholic steohepatitis (NASH); liver fibrosis; proliferation; MAP kinase; PI-3 kinase	SIGNALING PATHWAYS; LIVER FIBROSIS; GROWTH-FACTOR; RECEPTOR; EXPRESSION; PROLIFERATION; ACTIVATION; RAT; FIBROGENESIS; SURVIVAL	A key feature in the molecular pathogenesis of liver fibrosis requires maintenance of the activated hepatic stellate cell (HSC) phenotype by both proliferation and inhibition of apoptosis. We provide evidence that leptin is a potent HSC mitogen and dramatically inhibits stellate cell apoptosis. Leptin proved to be as potent an HSC mitogen as platelet-derived growth factor ( PDGF) as assessed by bromodeoxyuridine ( BrdU) incorporation in isolated primary HSCs; data using fluorescent propidium iodide ( PI) uptake revealed that leptin, like PDGF, increased HSC populations in the S- and G(2)/M-phases of the cell cycle. Leptin resulted in a robust increase in cyclin D1 expression. Using the chemical inhibitor of Janus kinase 2 (Jak2) activity, AG 490, and overexpression of the suppressor of cytokine signaling 3 (SOCS-3), we show that blockade of leptin receptor (Ob-Rb) phosphorylation blocks leptin-induced HSC proliferation. Leptin-associated phosphorylation of both extracellular regulated kinase (p44/p42, Erk) and Akt is also prohibited. Further, the PI-3 kinase inhibitor LY294002 and MAPK inhibitor PD98059 were found to significantly reduce leptin-induced HSC proliferation, thereby indicating that leptin induced HSC proliferation is Akt- and Erk-dependent. Akt was also protective against HSC apoptosis. Leptin abolished both cycloheximide-induced and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, demonstrated by reduced caspase-3 activity, HSC-TUNEL staining, and DNA fragmentation. We conclude that leptin acts as a direct hepatic stellate cell survival agonist. Importantly, we have demonstrated that leptin-induced HSC proliferation and survival by Ob-Rb phosphorylation are both Erk- and Akt- dependent.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Univ Maryland, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA	Emory University; University System of Maryland; University of Maryland Baltimore	Anania, FA (corresponding author), Room 248,615 Michael St, Atlanta, GA 30322 USA.	fanania@emory.edu	Srinivasan, Shanthi/A-6133-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062092, R03DK064644, K08DK002802, R56DK062092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA012933] Funding Source: NIH RePORTER; NIAAA NIH HHS [R21 AA012933-01, R21 AA012933, AA 12933] Funding Source: Medline; NIDDK NIH HHS [R01 DK062092-03, DK 064644, K08 DK002802, R01 DK062092, R03 DK064644, DK 062092, R56 DK062092, DK 022802] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Alessenko AV, 1997, FEBS LETT, V416, P113, DOI 10.1016/S0014-5793(97)01161-7; ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burysek L, 2002, J BIOL CHEM, V277, P33509, DOI 10.1074/jbc.M201941200; CASINI A, 1993, GASTROENTEROLOGY, V105, P245, DOI 10.1016/0016-5085(93)90033-9; Contos MJ, 2002, ADV ANAT PATHOL, V9, P37, DOI 10.1097/00125480-200201000-00005; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Diehl AM, 1999, SEMIN LIVER DIS, V19, P221, DOI 10.1055/s-2007-1007111; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gores GJ, 2001, HEPATOLOGY, V34, P3, DOI 10.1053/jhep.2001.25173; Honda H, 2002, HEPATOLOGY, V36, P12, DOI 10.1053/jhep.2002.33684; Ikejima K, 2002, GASTROENTEROLOGY, V122, P1399, DOI 10.1053/gast.2002.32995; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kloek C, 2002, J BIOL CHEM, V277, P41547, DOI 10.1074/jbc.M205148200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leclercq IA, 2002, J HEPATOL, V37, P206, DOI 10.1016/S0168-8278(02)00102-2; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Myers MG, 2004, RECENT PROG HORM RES, V59, P287, DOI 10.1210/rp.59.1.287; Ormerod MG, 1998, LEUKEMIA, V12, P1013, DOI 10.1038/sj.leu.2401061; Pinzani M, 1996, AM J PATHOL, V148, P785; Potter JJ, 1998, BIOCHEM BIOPH RES CO, V244, P178, DOI 10.1006/bbrc.1997.8193; Saile B, 1997, AM J PATHOL, V151, P1265; SAXENA NK, 2002, J HEPATOL, V37, P206; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Taimr P, 2003, HEPATOLOGY, V37, P87, DOI 10.1053/jhep.2003.50002; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Trim N, 2000, AM J PATHOL, V156, P1235, DOI 10.1016/S0002-9440(10)64994-2; Vecchione C, 2002, DIABETES, V51, P168, DOI 10.2337/diabetes.51.1.168; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	51	171	192	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2004	18	11					1612	+		10.1096/fj.04-1847fje	http://dx.doi.org/10.1096/fj.04-1847fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	849QN	15319373	Green Accepted			2022-12-25	WOS:000223554900008
